PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	OLIVERA, A; BUCKLEY, NE; SPIEGEL, S				OLIVERA, A; BUCKLEY, NE; SPIEGEL, S			SPHINGOMYELINASE AND CELL-PERMEABLE CERAMIDE ANALOGS STIMULATE CELLULAR PROLIFERATION IN QUIESCENT SWISS-3T3 FIBROBLASTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; GROWTH-FACTOR RECEPTOR; EPIDERMOID CARCINOMA-CELLS; NECROSIS-FACTOR-ALPHA; LEUKEMIA HL-60 CELLS; GOLGI-APPARATUS; SIGNAL TRANSDUCTION; PLASMA-MEMBRANE; PHORBOL ESTERS; NEUTRAL SPHINGOMYELINASE	Sphingomyelin or the products derived from its metabolism may constitute a signaling system involved in a variety of cellular processes. The activation of a plasma membrane neutral sphingomyelinase, which catalyzes the first step in sphingomyelin turnover, has been suggested to play an important role in cellular differentiation. We have studied the effect of exogenous staphyloccocal sphingomyelinase on DNA synthesis and on the composition of membrane sphingolipids in quiescent Swiss 3T3 fibroblasts. Sphingomyelinase stimulated proliferation of Swiss 3T3 cells and potentiated the mitogenic action of other growth factors, such as insulin, epidermal growth factor, and bombesin. Treatment with sphingomyelinase produced a significant decrease in sphingomyelin accompanied by a corresponding increase in ceramide levels. No significant increases were detected in the levels of products derived from ceramide, i.e. ceramide 1-phosphate, sphingosine, or sphingosine 1-phosphate. To further investigate the role of ceramide in cellular proliferation, we studied the effect of cell-permeable analogs of ceramide on DNA synthesis in quiescent Swiss 3T3 cells. Both N-hexanoylsphingosine and N-acetylsphingosine at low concentrations stimulated [H-3]thymidine incorporation and acted synergistically with a wide variety of growth factors known to induce proliferation of quiescent Swiss 3T3 fibroblasts. Similar effects were observed with bovine brain ceramides. These results suggest that ceramide may be involved in the regulation of cellular proliferation.	GEORGE WASHINGTON UNIV,MED CTR,DEPT BIOCHEM & MOLEC BIOL,357 BASIC SCI BLDG,3900 RESERVOIR RD NW,WASHINGTON,DC 20037	George Washington University	SPIEGEL, S (corresponding author), GEORGE WASHINGTON UNIV,MED CTR,DEPT BIOCHEM & MOLEC BIOL,357 BASIC SCI BLDG,3900 RESERVOIR RD NW,WASHINGTON,DC 20037, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM039718] Funding Source: NIH RePORTER; NIGMS NIH HHS [1R 29 GM 39718] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAJJALIEH SM, 1989, J BIOL CHEM, V264, P14354; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BILLAH MM, 1990, BIOCHEM J, V269, P281, DOI 10.1042/bj2690281; BUEHRER BM, 1992, J BIOL CHEM, V267, P3154; CHATTERJEE S, 1989, J BIOL CHEM, V264, P12554; DAS DVM, 1984, BIOCHIM BIOPHYS ACTA, V777, P339; DAVIS RJ, 1988, J BIOL CHEM, V263, P5373; DENNIS EA, 1991, FASEB J, V5, P2068, DOI 10.1096/fasebj.5.7.1901288; DESAI NN, 1991, BIOCHEM BIOPH RES CO, V178, P1378; DRESSLER KA, 1990, J BIOL CHEM, V265, P14917; DRESSLER KA, 1991, J BIOL CHEM, V266, P11522; DRESSLER KA, 1992, SCIENCE, V255, P1715, DOI 10.1126/science.1313189; EXTON JH, 1990, J BIOL CHEM, V265, P1; FAUCHER M, 1988, J BIOL CHEM, V263, P5319; FUTERMAN AH, 1990, J BIOL CHEM, V265, P8650; GOLDKORN T, 1991, J BIOL CHEM, V266, P16092; HAKOMORI SI, 1990, J BIOL CHEM, V265, P18713; HANNUN YA, 1986, J BIOL CHEM, V261, P2604; HANNUN YA, 1989, SCIENCE, V243, P500, DOI 10.1126/science.2643164; HUBSCHER G., 1960, JOUR LIPID RES, V1, P433; IGARASHI Y, 1990, BIOCHEMISTRY-US, V29, P3644; JEFFERSON AB, 1988, J BIOL CHEM, V263, P15241; KIM MY, 1991, J BIOL CHEM, V266, P484; KOLESNICK RN, 1989, J BIOL CHEM, V264, P7617; KOLESNICK RN, 1991, PROG LIPID RES, V30, P1, DOI 10.1016/0163-7827(91)90005-P; KOLESNICK RN, 1987, J BIOL CHEM, V262, P16759; KOVAL M, 1991, BIOCHIM BIOPHYS ACTA, V1082, P113, DOI 10.1016/0005-2760(91)90184-J; KOVAL M, 1990, J CELL BIOL, V111, P429, DOI 10.1083/jcb.111.2.429; KOVAL M, 1989, J CELL BIOL, V108, P2169, DOI 10.1083/jcb.108.6.2169; KRISHNAMURTHI S, 1989, BIOCHIM BIOPHYS ACTA, V1010, P258, DOI 10.1016/0167-4889(89)90170-5; LIPSKY NG, 1985, SCIENCE, V228, P745, DOI 10.1126/science.2581316; MATHIAS S, 1991, P NATL ACAD SCI USA, V88, P10009, DOI 10.1073/pnas.88.22.10009; MERRILL AH, 1990, BIOCHIM BIOPHYS ACTA, V1044, P1, DOI 10.1016/0005-2760(90)90211-F; MERRILL AH, 1991, J BIOENERG BIOMEMBR, V23, P83; MERRILL AH, 1989, BIOCHIM BIOPHYS ACTA, V1010, P131, DOI 10.1016/0167-4889(89)90152-3; MURRAY DK, 1979, ENDOCRINOLOGY, V105, P774, DOI 10.1210/endo-105-3-774; NELSON DH, 1982, J CLIN ENDOCR METAB, V54, P292, DOI 10.1210/jcem-54-2-292; NELSON DH, 1986, BIOCHEM BIOPH RES CO, V138, P463, DOI 10.1016/0006-291X(86)90303-7; NELSON DH, 1982, P NATL ACAD SCI-BIOL, V79, P6690, DOI 10.1073/pnas.79.21.6690; OKAZAKI T, 1989, J BIOL CHEM, V264, P19076; OKAZAKI T, 1990, J BIOL CHEM, V265, P15823; PAGANO RE, 1985, SCIENCE, V229, P1051, DOI 10.1126/science.4035344; PAGANO RE, 1991, J CELL BIOL, V113, P1267, DOI 10.1083/jcb.113.6.1267; PAGANO RE, 1988, TRENDS BIOCHEM SCI, V13, P202, DOI 10.1016/0968-0004(88)90082-5; PREISS JE, 1987, METHOD ENZYMOL, V141, P294; Pushkarev M Iu, 1991, Biokhimiia, V56, P903; RAMACHANDRAN CK, 1990, BIOCHEM BIOPH RES CO, V167, P607, DOI 10.1016/0006-291X(90)92068-B; ROZENGURT E, 1986, SCIENCE, V234, P161, DOI 10.1126/science.3018928; SCHNEIDER EG, 1973, J BIOL CHEM, V248, P3739; SPENCE MW, 1990, BIOCHEM J, V268, P719, DOI 10.1042/bj2680719; SPIEGEL S, 1989, J BIOL CHEM, V264, P16512; SPIEGEL S, 1988, EXP CELL RES, V177, P414, DOI 10.1016/0014-4827(88)90474-0; STEVENS VL, 1989, CANCER RES, V49, P3229; VANVELDHOVEN PP, 1987, ANAL BIOCHEM, V161, P45, DOI 10.1016/0003-2697(87)90649-X; VANVELDHOVEN PP, 1989, J LIPID RES, V30, P611; VANVELDHOVEN PP, 1989, ANAL BIOCHEM, V183, P177, DOI 10.1016/0003-2697(89)90186-3; WILSON E, 1988, J BIOL CHEM, V263, P9304; WINICOV I, 1988, J BIOL CHEM, V263, P12179; ZHANG H, 1990, J BIOL CHEM, V265, P76; ZHANG H, 1991, J CELL BIOL, V114, P155, DOI 10.1083/jcb.114.1.155; ZHANG H, 1990, J BIOL CHEM, V265, P21309	61	116	117	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1992	267	36					26121	26127						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KD073	1464623				2022-12-25	WOS:A1992KD07300080
J	HUANG, S; DEUTSCHER, MP				HUANG, S; DEUTSCHER, MP			SEQUENCE AND TRANSCRIPTIONAL ANALYSIS OF THE ESCHERICHIA-COLI RNT GENE ENCODING RNASE-T	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROMOTER SEQUENCES; END-TURNOVER; CODON USAGE; PROTEIN; OPERON; HELICASE; CLONING; INITIATION; CELLS	The Escherichia coli rnt gene encoding the enzyme RNase T, which is responsible for the end-turnover of tRNA, was cloned on a 1.5-kilobase DNA fragment. When placed in pUC18 and pUC19 vectors this fragment led to approximately a 40-fold overexpression of RNase T activity. The cloned fragment was sequenced and was found to contain an open reading frame sufficient to encode a protein of 215 amino acids with a molecular weight of 23,521, which is close to the subunit molecular weight of RNase T; the fragment also contains a second incomplete open reading frame with some sequence similarity to RNA helicases. The derived sequence of RNase T showed no similarity to any of the other E. coli exoribonucleases sequenced to date. Primer extension analysis and deletion of part of the upstream region were used to identify the transcription start point and the promoter of the rnt gene. Northern and primer extension analysis revealed that the rnt message also included the second open reading frame, suggesting that rnt is part of an operon.	UNIV CONNECTICUT,CTR HLTH,DEPT BIOCHEM,FARMINGTON,CT 06030	University of Connecticut					NIGMS NIH HHS [GM16317] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AIBA H, 1981, J BIOL CHEM, V256, P1905; BYSTROM AS, 1983, EMBO J, V2, P899, DOI 10.1002/j.1460-2075.1983.tb01519.x; CASE LM, 1989, J BACTERIOL, V171, P5736, DOI 10.1128/jb.171.10.5736-5737.1989; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; DEUTSCHER MP, 1985, P NATL ACAD SCI USA, V82, P6427, DOI 10.1073/pnas.82.19.6427; DEUTSCHER MP, 1984, P NATL ACAD SCI-BIOL, V81, P4290, DOI 10.1073/pnas.81.14.4290; DEUTSCHER MP, 1985, J BIOL CHEM, V260, P7067; DEUTSCHER MP, 1983, ENZYMES NUCLEIC ACID, V2, P160; DOOLITTLE RF, 1986, URFS ORFS, P55; DORER DR, 1990, NUCLEIC ACIDS RES, V18, P5489, DOI 10.1093/nar/18.18.5489; FORD MJ, 1988, NATURE, V332, P736, DOI 10.1038/332736a0; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GOLD L, 1987, ESCHERICHIA COLI SAL, P1302; HARLEY CB, 1987, NUCLEIC ACIDS RES, V15, P2343, DOI 10.1093/nar/15.5.2343; HOHN B, 1980, GENE, V11, P291, DOI 10.1016/0378-1119(80)90069-4; IGGO RD, 1991, MOL CELL BIOL, V11, P1326, DOI 10.1128/MCB.11.3.1326; IKEMURA T, 1982, COLD SPRING HARB SYM, V47, P1087, DOI 10.1101/SQB.1983.047.01.123; KALMAN M, 1991, NEW BIOL, V3, P886; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LUPSKI JR, 1989, BIOESSAYS, V10, P152, DOI 10.1002/bies.950100504; MULLIGAN ME, 1984, NUCLEIC ACIDS RES, V12, P789, DOI 10.1093/nar/12.1Part2.789; PADMANABHA KP, 1991, J BACTERIOL, V173, P1376, DOI 10.1128/jb.173.4.1376-1381.1991; POULSEN P, 1984, EMBO J, V3, P1783, DOI 10.1002/j.1460-2075.1984.tb02046.x; REGNIER P, 1986, J MOL BIOL, V187, P23, DOI 10.1016/0022-2836(86)90403-1; Sambrook J, 1989, MOL CLONING LABORATO; WADA K, 1991, NUCLEIC ACIDS RES, V19, P1981, DOI 10.1093/nar/19.suppl.1981; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; ZHANG J, 1988, NUCLEIC ACIDS RES, V16, P6265, DOI 10.1093/nar/16.14.6265	30	23	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1992	267	35					25609	25613						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KB603	1460056				2022-12-25	WOS:A1992KB60300104
J	LOVE, JD; MINTON, KW				LOVE, JD; MINTON, KW			ULTRAVIOLET-INDUCED DIMERIZATION OF NONADJACENT PYRIMIDINES IN POLY[D(A-T)]	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-HELIX FORMATION; DNA-BINDING-PROTEIN; ESCHERICHIA-COLI; THERMODYNAMICS; PHOTOREACTIVITY; SPECIFICITY; MECHANISM; COMPLEXES; SEQUENCES; MN-2+	The DNA photoproduct responsible for the ultraviolet (UV) light-induced -1 frameshift mutation remains unknown. We recently identified a UV photoproduct consisting of a cyclobutane dimer occurring between non-adjacent thymine residues in the same strand, [GRAPHICS] and proposed that replication across this unrepaired photoproduct might result in a - 1 frameshift mutation since the intervening base is extrahelical. Until now this novel photoproduct has only been identified in single-stranded DNA polymers and does not occur in UV-irradiated double-stranded polymers due to conformational restraint. This observation suggested that this photoproduct could only occur in vivo in chromosomal sites that were single-stranded. In the current work the cis-syn dithymine cyclobutane dimer has been identified in the self-complementary polymer poly[d(A-T)] when UV irradiated in solution conditions (concentrated manganese chloride or 60% ethanol plus trace salts) wherein this polymer remains double-stranded but the double-helix is partially destabilized. Taken together, the current findings suggest that dipyrimidine photoproducts between non-adjacent residues on the same strand could occur in vivo in double-stranded, but partially destabilized, DNA.	UNIFORMED SERV UNIV HLTH SCI,FE HEBERT SCH MED,DEPT PATHOL,BETHESDA,MD 20814	Uniformed Services University of the Health Sciences - USA								ABOULELA F, 1985, NUCLEIC ACIDS RES, V13, P4811, DOI 10.1093/nar/13.13.4811; ALBERGO DD, 1981, BIOCHEMISTRY-US, V20, P1413, DOI 10.1021/bi00509a002; ARMSTRONG JD, 1990, P NATL ACAD SCI USA, V87, P9005, DOI 10.1073/pnas.87.22.9005; ARNOLD FH, 1987, BIOCHEMISTRY-US, V26, P4068, DOI 10.1021/bi00387a049; ATTRI AK, 1986, ANAL BIOCHEM, V159, P88, DOI 10.1016/0003-2697(86)90311-8; BENHUR E, 1968, BIOCHIM BIOPHYS ACTA, V166, P9, DOI 10.1016/0005-2787(68)90485-1; BOSE SN, 1984, NUCLEIC ACIDS RES, V12, P7903, DOI 10.1093/nar/12.20.7903; BRASH DE, 1991, P NATL ACAD SCI USA, V88, P10124, DOI 10.1073/pnas.88.22.10124; BROWN DM, 1985, BIOCHEMISTRY-US, V24, P1676, DOI 10.1021/bi00328a016; EICHHORN GL, 1968, J AM CHEM SOC, V90, P7323, DOI 10.1021/ja01028a024; GLASSMAN TA, 1971, BIOCHEMISTRY-US, V10, P843; GRANOT J, 1982, BIOPOLYMERS, V21, P873, DOI 10.1002/bip.360210502; GRAY DM, 1980, NUCLEIC ACIDS RES, V8, P3695, DOI 10.1093/nar/8.16.3695; HOSSZU JL, 1967, BIOCHEM BIOPH RES CO, V29, P327, DOI 10.1016/0006-291X(67)90457-3; KIRKEGAARD K, 1983, P NATL ACAD SCI-BIOL, V80, P2544, DOI 10.1073/pnas.80.9.2544; Kornberg A., 1980, DNA REPLICATION; KRAWIEC S, 1990, MICROBIOL REV, V54, P502, DOI 10.1128/MMBR.54.4.502-539.1990; KUMAR S, 1987, PHOTOCHEM PHOTOBIOL, V45, P571, DOI 10.1111/j.1751-1097.1987.tb07382.x; KUNTZ GPP, 1972, BIOCHEMISTRY-US, V11, P538, DOI 10.1021/bi00754a009; LEE CH, 1981, P NATL ACAD SCI-BIOL, V78, P2838, DOI 10.1073/pnas.78.5.2838; LEVINSON G, 1987, MOL BIOL EVOL, V4, P203; LOVE JD, 1986, J BIOL CHEM, V261, P51; LUCK G, 1972, EUR J BIOCHEM, V29, P523; MCDONELL MW, 1977, J MOL BIOL, V110, P119, DOI 10.1016/S0022-2836(77)80102-2; MEYER RR, 1990, MICROBIOL REV, V54, P342, DOI 10.1128/MMBR.54.4.342-380.1990; MILLER JH, 1985, J MOL BIOL, V182, P45, DOI 10.1016/0022-2836(85)90026-9; MOROWITZ HJ, 1950, SCIENCE, V111, P229; NGUYEN HT, 1989, J MOL BIOL, V210, P869, DOI 10.1016/0022-2836(89)90114-9; NGUYEN HT, 1988, J MOL BIOL, V200, P681, DOI 10.1016/0022-2836(88)90480-9; PATRICK MH, 1976, PHOTOCHEM PHOTOBIOL, V24, P507, DOI 10.1111/j.1751-1097.1976.tb06867.x; Patrick MH., 1976, PHOTOCHEM PHOTOBIOL, V2, P35, DOI [10.1016/B978-0-12-734602-1.50008-3, DOI 10.1016/B978-0-12-734602-1.50008-3]; POHL FM, 1976, NATURE, V260, P365, DOI 10.1038/260365a0; SETLOW RB, 1964, BIOCHIM BIOPHYS ACTA, V91, P446, DOI 10.1016/0926-6550(64)90075-1; STREISINGER G, 1966, COLD SPRING HARB SYM, V31, P77, DOI 10.1101/SQB.1966.031.01.014; VANDESANDE JH, 1982, EMBO J, V1, P777, DOI 10.1002/j.1460-2075.1982.tb01247.x; VARGHESE AJ, 1967, SCIENCE, V156, P955, DOI 10.1126/science.156.3777.955; VORLICKOVA M, 1985, J BIOMOL STRUCT DYN, V3, P67, DOI 10.1080/07391102.1985.10508399; VORLICKOVA M, 1982, NUCLEIC ACIDS RES, V10, P6969, DOI 10.1093/nar/10.21.6969; WANG SY, 1967, BIOCHEM BIOPH RES CO, V29, P543, DOI 10.1016/0006-291X(67)90519-0; WILLIAMS KR, 1983, J BIOL CHEM, V258, P3346	40	11	11	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1992	267	35					24953	24959						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KB603	1460000				2022-12-25	WOS:A1992KB60300010
J	ROITELMAN, J; SIMONI, RD				ROITELMAN, J; SIMONI, RD			DISTINCT STEROL AND NONSTEROL SIGNALS FOR THE REGULATED DEGRADATION OF 3-HYDROXY-3-METHYLGLUTARYL-COA REDUCTASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COENZYME-A REDUCTASE; LOW-DENSITY-LIPOPROTEIN; HAMSTER OVARY CELLS; RECEPTOR GENE-EXPRESSION; MEMBRANE-BOUND DOMAIN; ENDOPLASMIC-RETICULUM; PROTEIN-DEGRADATION; GROWTH-FACTOR; ORNITHINE DECARBOXYLASE; ENHANCED DEGRADATION	The in vivo turnover rate of the endoplasmic reticulum protein 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, the rate-limiting enzyme in the mevalonate (MVA) pathway, is accelerated when excess MVA or sterols are added to the growth medium of cells. As we have shown recently (Roitelman, J., Bar-Nun, S., Inoue, S., and Simoni, R. D. (1991) J. Biol. Chem. 266, 16085-16091), perturbation of cellular Ca2+ homeostasis abrogates the MVA-accelerated degradation of HMG-CoA reductase and HMGal. Here we show that, in contrast, the sterol-accelerated degradation of HMG-CoA reductase is unaffected by Ca2+ perturbation achieved either by Ca2+ ionophore or by inhibitors of the endoplasmic reticulum Ca2+-ATPase. The differential effects of Ca2+ perturbation can be attributed neither to global alteration in protein synthesis nor to inhibition of MVA conversion to sterols. Yet, such manipulations markedly reduce the incorporation of MVA into cellular macromolecules, including prenylated proteins. Furthermore, we directly demonstrate that MVA gives rise to at least two distinct signals, one that is essential to support the effect of sterols and another that operates independently of sterols. Our results indicate that the cellular signals operating in the MVA-accelerated turnover of HMG-CoA reductase are distinct from those involved in the sterol-regulated degradation. A working model for the degradation pathway is proposed.			ROITELMAN, J (corresponding author), STANFORD UNIV,DEPT BIOL SCI,STANFORD,CA 94305, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL026502] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL26502] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AUWERX JH, 1989, MOL CELL BIOL, V9, P2298, DOI 10.1128/MCB.9.6.2298; AUWERX JH, 1989, P NATL ACAD SCI USA, V86, P1133, DOI 10.1073/pnas.86.4.1133; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BLOCK LH, 1991, P NATL ACAD SCI USA, V88, P9041, DOI 10.1073/pnas.88.20.9041; BONIFACINO J S, 1991, Current Opinion in Cell Biology, V3, P592, DOI 10.1016/0955-0674(91)90028-W; BRADFUTE DL, 1992, J BIOL CHEM, V267, P18308; BROSTROM CO, 1990, ANNU REV PHYSIOL, V52, P577; CHANG TY, 1981, J BIOL CHEM, V256, P6174; CHEN HW, 1982, BIOCHIM BIOPHYS ACTA, V712, P484, DOI 10.1016/0005-2760(82)90275-2; CHIANG HL, 1991, NATURE, V350, P313, DOI 10.1038/350313a0; CHUN KT, 1990, J BIOL CHEM, V265, P22004; CHUN KT, 1992, J BIOL CHEM, V267, P4236; CROOK RB, 1978, BIOCHEM J, V176, P47, DOI 10.1042/bj1760047; CUTHBERT JA, 1990, J LIPID RES, V31, P2067; DESGRANGES C, 1991, BIOCHEM PHARMACOL, V41, P1045, DOI 10.1016/0006-2952(91)90213-O; FAUST J, 1987, J BIOL CHEM, V262, P1996; FREIKOPF A, 1976, BIOCHEM BIOPH RES CO, V72, P1195, DOI 10.1016/S0006-291X(76)80257-4; GIL G, 1985, CELL, V41, P249, DOI 10.1016/0092-8674(85)90078-9; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; HAAS AL, 1985, J BIOL CHEM, V260, P2464; HAVEL CM, 1992, ARCH BIOCHEM BIOPHYS, V294, P639, DOI 10.1016/0003-9861(92)90736-G; HERSHKO A, 1991, TRENDS BIOCHEM SCI, V16, P265, DOI 10.1016/0968-0004(91)90101-Z; HIDAKA Y, 1991, J BIOL CHEM, V266, P13171; HOLTTA E, 1986, J BIOL CHEM, V261, P9502; HORIE M, 1990, J BIOL CHEM, V265, P18075; INOUE S, 1992, J BIOL CHEM, V267, P9080; INOUE S, 1991, J BIOL CHEM, V266, P13311; JINGAMI H, 1987, J CELL BIOL, V104, P1693, DOI 10.1083/jcb.104.6.1693; JOLY A, 1991, J BIOL CHEM, V266, P13495; KASS GEN, 1989, J BIOL CHEM, V264, P15192; KLAUSNER RD, 1990, CELL, V62, P611, DOI 10.1016/0092-8674(90)90104-M; KOJIMA I, 1988, J BIOL CHEM, V263, P16561; KOJIMA I, 1990, G PROTEINS, P503; KULKA RG, 1989, RBC-CELL BIOL REV, V21, P321; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAPETINA EG, 1987, P NATL ACAD SCI USA, V84, P2261, DOI 10.1073/pnas.84.8.2261; LISCUM L, 1985, J BIOL CHEM, V260, P522; MAZZONE T, 1989, J BIOL CHEM, V264, P1787; MAZZONE T, 1989, J BIOL CHEM, V264, P15529; MOSLEY ST, 1983, J BIOL CHEM, V258, P3875; MURAKAMI Y, 1985, BIOCHEM J, V225, P689, DOI 10.1042/bj2250689; MURAKAMI Y, 1992, BIOCHEM J, V283, P661, DOI 10.1042/bj2830661; NAKANISHI M, 1988, J BIOL CHEM, V263, P8929; NISHIMOTO I, 1987, J BIOL CHEM, V262, P12120; OLENDER EH, 1992, J BIOL CHEM, V267, P4223; PANINI SR, 1989, J BIOL CHEM, V264, P11044; PANINI SR, 1992, J BIOL CHEM, V267, P12647; PIANSMITH MCM, 1988, ENDOCRINOLOGY, V123, P1984, DOI 10.1210/endo-123-4-1984; PUTNEY JW, 1986, CELL CALCIUM, V7, P1, DOI 10.1016/0143-4160(86)90026-6; RECHSTEINER M, 1991, CELL, V66, P615, DOI 10.1016/0092-8674(91)90104-7; REISS Y, 1992, J BIOL CHEM, V267, P6403; REISS Y, 1990, CELL, V62, P81, DOI 10.1016/0092-8674(90)90242-7; ROITELMAN J, 1992, J CELL BIOL, V117, P959, DOI 10.1083/jcb.117.5.959; ROITELMAN J, 1991, J BIOL CHEM, V266, P16085; ROTH M, 1991, P NATL ACAD SCI USA, V88, P1888, DOI 10.1073/pnas.88.5.1888; SIPERSTEIN MD, 1984, J LIPID RES, V25, P1462; SKALNIK DG, 1988, J BIOL CHEM, V263, P6836; STADTMAN ER, 1990, BIOCHEMISTRY-US, V29, P6323, DOI 10.1021/bi00479a001; STAFFORD FJ, 1991, J CELL BIOL, V115, P1225, DOI 10.1083/jcb.115.5.1225; TANAKA RD, 1986, J LIPID RES, V27, P261; THASTRUP O, 1990, AGENTS ACTIONS, V29, P8, DOI 10.1007/BF01964706; VARSHAVSKY A, 1992, CELL, V69, P725, DOI 10.1016/0092-8674(92)90285-K; WILEMAN T, 1991, CELL REGUL, V2, P753, DOI 10.1091/mbc.2.9.753; WILKIN DJ, 1992, J BIOL CHEM, V267, P2831; WILKIN DJ, 1990, J BIOL CHEM, V265, P4607; ZAMMIT VA, 1991, BIOCHEM J, V279, P377, DOI 10.1042/bj2790377; ZAMMIT VA, 1990, BIOCHEM J, V269, P373, DOI 10.1042/bj2690373	67	96	99	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1992	267	35					25264	25273						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KB603	1460026				2022-12-25	WOS:A1992KB60300055
J	HERZBERG, O				HERZBERG, O			AN ATOMIC MODEL FOR PROTEIN-PROTEIN PHOSPHORYL GROUP TRANSFER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOTRANSFERASE SYSTEM; MACROMOLECULAR STRUCTURES; REFINEMENT; DYNAMICS; PROGRAM; ENZYME; DOMAIN	The high resolution crystal structures of two interacting proteins from the phosphoenolpyruvate:sugar phosphotransferase system, the histidine-containing phosphocarrier protein (HPr) and the IIA domain of glucose permease (IIA(Glc)) from Bacillus subtilis, provide the basis for modeling the transient binary complex formed during the phosphoryl group transfer. The complementarity of the interacting surfaces implies that no major conformational transition is required. The negatively charged phosphoryl group is buried in the interface, suggesting a key role for electrostatic interactions. It is proposed that the phosphoryl transfer is triggered by a switch between two salt bridges involving Arg-17 of the HPr. The first, prior to phosphoryl group transfer, is intramolecular, with the phosphorylated His-15. The second, during the transfer, is intermolecular, with 2 aspartate residues associated with the active site of IIA(Glc). Such alternating ion pairs may be mechanistically important in other protein-protein phosphotransfer reactions.			HERZBERG, O (corresponding author), UNIV MARYLAND,MARYLAND BIOTECHNOL INST,CTR ADV RES BIOTECHNOL,SHADY GROVE CAMPUS,ROCKVILLE,MD 20850, USA.			Herzberg, Osnat/0000-0003-2823-7627				BARFORD D, 1991, J MOL BIOL, V218, P233, DOI 10.1016/0022-2836(91)90887-C; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; COHEN P, 1988, PROC R SOC SER B-BIO, V234, P115, DOI 10.1098/rspb.1988.0040; CONNOLLY ML, 1983, SCIENCE, V221, P709, DOI 10.1126/science.6879170; DAVIES DR, 1990, ANNU REV BIOCHEM, V59, P439, DOI 10.1146/annurev.bi.59.070190.002255; HENDRICKSON WA, 1980, BIOMOLECULAR STRUCTU, V1, P43; HERZBERG O, 1992, P NATL ACAD SCI USA, V89, P2499, DOI 10.1073/pnas.89.6.2499; HURLEY JH, 1990, J BIOL CHEM, V265, P3599; JANIN J, 1990, J BIOL CHEM, V265, P16027; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; KNOWLES JR, 1980, ANNU REV BIOCHEM, V49, P877, DOI 10.1146/annurev.bi.49.070180.004305; Krebs EG, 1986, ENZYMES, V17, P3, DOI 10.1016/S1874-6047(08)60426-6; LIAO DI, 1991, BIOCHEMISTRY-US, V30, P9583, DOI 10.1021/bi00104a004; MEADOW ND, 1990, ANNU REV BIOCHEM, V59, P497, DOI 10.1146/annurev.biochem.59.1.497; SAIER MH, 1990, RES MICROBIOL, V141, P1033, DOI 10.1016/0923-2508(90)90077-4; SPRANG SR, 1988, NATURE, V336, P215, DOI 10.1038/336215a0; STOCK JB, 1990, NATURE, V344, P395, DOI 10.1038/344395a0; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489, DOI 10.1107/S0108767387099124; WORTHYLAKE D, 1991, P NATL ACAD SCI USA, V88, P10382, DOI 10.1073/pnas.88.23.10382; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303	22	51	51	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1992	267	34					24819	24823						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KA263	1447219				2022-12-25	WOS:A1992KA26300099
J	SHACHAR, I; AMITAY, R; RABINOVICH, E; HAIMOVICH, J; BARNUN, S				SHACHAR, I; AMITAY, R; RABINOVICH, E; HAIMOVICH, J; BARNUN, S			POLYMERIZATION OF SECRETORY IGM IN LYMPHOCYTES-B IS PREVENTED BY A PRIOR TARGETING TO A DEGRADATION PATHWAY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN DISULFIDE-ISOMERASE; EXOCRINE PANCREATIC-CELLS; CULTURED RAT HEPATOCYTES; IMMUNOGLOBULIN-J-CHAIN; ENDOPLASMIC-RETICULUM; INTRACELLULAR-TRANSPORT; GOLGI-COMPLEX; BREFELDIN-A; BINDING-PROTEIN; LIGHT-CHAIN	B lymphocytes express on their surface a membrane form of IgM (mIgM), and synthesize but fail to secrete a secretory form of IgM (sIgM). Plasma cells shift to the exclusive synthesis and efficient secretion of sIgM. The sIgM in B cells differs from that in plasma cells in its pattern of assembly: in plasma cells, monomers of sIgM are assembled into polymers and only polymers are secreted; in B lymphocytes, monomeric sIgM is neither polymerized nor secreted and is degraded intracellularly. In this article we blocked the export of proteins from the endoplasmic reticulum at low temperatures or with energy poisons or brefeldin A, and localized the different assembly steps of mIgM and sIgM in the 38C B lymphocytes and of sIgM in the 38C-derived sIgM-secreting D2 hybridoma. In both cell lines, sIgM assembly into monomers was not affected, whereas polymerization of sIgM in D2 cells and monomer formation of mIgM in 38C cells were strongly inhibited. Moreover, probing with specific lectins revealed galactosylated monomers and polymers in D2 cells and galactosylated hemimer and monomers only of mIgM in 38C cells. In addition, when Golgi functions were hampered with Tris base, monomerization of mIgM and polymerization of sIgM were attenuated. These results indicate that polymerization of sIgM in D2 cells and monomerization of mIgM in 38C cells are post-endoplasmic reticulum events, occurring in or beyond the trans-Golgi galactosylation compartment. Since only polymers are secreted from D2 cells and only monomeric mIgM is displayed on the surface of 38C cells, partially assembled molecules may traverse the secretory pathway yet are restricted from the cell surface. Furthermore, monomeric sIgM in 38C cells is never galactosylated, thus it is degraded prior to the galactosylation compartment. We conclude that targeting of sIgM to degradation in 38C cells precedes its assembly site into polymers in D2 cells. This implies that degradation of sIgM does not result from the incompetence of 38C cells to polymerize. Rather, assembly of sIgM into polymers and their subsequent secretion are prevented in B lymphocytes by preceding targeting of monomeric sIgM to degradation.	TEL AVIV UNIV,GEORGE S WISE FAC LIFE SCI,DEPT BIOCHEM,IL-69978 TEL AVIV,ISRAEL; TEL AVIV UNIV,SACKLER SCH MED,DEPT HUMAN MICROBIOL,IL-69978 TEL AVIV,ISRAEL	Tel Aviv University; Tel Aviv University; Sackler Faculty of Medicine								ALBERINI CM, 1990, NATURE, V347, P485, DOI 10.1038/347485a0; AMITAY R, 1991, J BIOL CHEM, V266, P12568; BALCH WE, 1986, J BIOL CHEM, V261, P4681; BAUSKIN AR, 1991, CELL, V66, P685, DOI 10.1016/0092-8674(91)90114-E; BERGMAN Y, 1978, EUR J IMMUNOL, V8, P876, DOI 10.1002/eji.1830081210; BLACKMAN MA, 1986, CELL, V47, P609, DOI 10.1016/0092-8674(86)90625-2; BOLE DG, 1986, J CELL BIOL, V102, P1558, DOI 10.1083/jcb.102.5.1558; BRENCKLE R, 1980, ARCH BIOCHEM BIOPHYS, V201, P160, DOI 10.1016/0003-9861(80)90499-3; CALAME KL, 1985, ANNU REV IMMUNOL, V3, P159, DOI 10.1146/annurev.iy.03.040185.001111; CATTANEO A, 1987, EMBO J, V6, P2753, DOI 10.1002/j.1460-2075.1987.tb02569.x; DAHMS NM, 1986, J BIOL CHEM, V261, P3186; DAVIS AC, 1989, MOL IMMUNOL, V26, P147, DOI 10.1016/0161-5890(89)90096-5; DAVIS AC, 1988, EUR J IMMUNOL, V18, P1001, DOI 10.1002/eji.1830180705; DEGRELLA RF, 1982, J BIOL CHEM, V257, P4256; DUL JL, 1990, P NATL ACAD SCI USA, V87, P8135, DOI 10.1073/pnas.87.20.8135; DULIS BH, 1983, J BIOL CHEM, V258, P2181; ESHHAR Z, 1979, J IMMUNOL, V122, P2430; FREEDMAN RB, 1984, TRENDS BIOCHEM SCI, V9, P438, DOI 10.1016/0968-0004(84)90152-X; FUJIWARA T, 1988, J BIOL CHEM, V263, P18545; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; HAAS IG, 1983, NATURE, V306, P387, DOI 10.1038/306387a0; HAWKES R, 1982, ANAL BIOCHEM, V119, P142, DOI 10.1016/0003-2697(82)90677-7; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; KEHRY M, 1980, CELL, V21, P393, DOI 10.1016/0092-8674(80)90476-6; KLAUSNER RD, 1990, CELL, V62, P611, DOI 10.1016/0092-8674(90)90104-M; KOSHLAND ME, 1985, ANNU REV IMMUNOL, V3, P425; MISUMI Y, 1986, J BIOL CHEM, V261, P1398; NICOLSON GL, 1974, BIOCHEMISTRY-US, V13, P196, DOI 10.1021/bi00698a029; ODA K, 1988, J BIOL CHEM, V263, P12576; ORCI L, 1991, CELL, V64, P1183; PARKHOUSE RM, 1971, BIOCHEM J, V123, P635, DOI 10.1042/bj1230635; PELHAM HRB, 1989, ANNU REV CELL BIOL, V5, P1, DOI 10.1146/annurev.cb.05.110189.000245; REEKE GN, 1974, ANN NY ACAD SCI, V234, P369, DOI 10.1111/j.1749-6632.1974.tb53049.x; ROGERS J, 1980, CELL, V20, P303, DOI 10.1016/0092-8674(80)90616-9; ROSE JK, 1988, ANNU REV CELL BIOL, V4, P257, DOI 10.1146/annurev.cellbio.4.1.257; SARASTE J, 1984, CELL, V38, P535, DOI 10.1016/0092-8674(84)90508-7; SARASTE J, 1986, P NATL ACAD SCI USA, V83, P6425, DOI 10.1073/pnas.83.17.6425; SCHUY W, 1986, EMBO J, V5, P2831, DOI 10.1002/j.1460-2075.1986.tb04576.x; SIDMAN C, 1981, CELL, V23, P379, DOI 10.1016/0092-8674(81)90133-1; SITIA R, 1988, MOL IMMUNOL, V25, P189, DOI 10.1016/0161-5890(88)90067-3; SITIA R, 1987, EMBO J, V6, P3969, DOI 10.1002/j.1460-2075.1987.tb02739.x; SITIA R, 1990, CELL, V60, P781, DOI 10.1016/0092-8674(90)90092-S; TARTAKOFF A, 1979, J CELL BIOL, V83, P284, DOI 10.1083/jcb.83.2.284; TARTAKOFF AM, 1983, CELL, V32, P1026, DOI 10.1016/0092-8674(83)90286-6; TARTAKOFF AM, 1986, EMBO J, V5, P1477, DOI 10.1002/j.1460-2075.1986.tb04385.x; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WORMALD MR, 1991, EUR J BIOCHEM, V198, P131, DOI 10.1111/j.1432-1033.1991.tb15995.x; YOSHIMORI T, 1990, J BIOL CHEM, V265, P15984; YOST CS, 1983, CELL, V34, P759	49	25	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1992	267	34					24241	24247						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KA263	1447174				2022-12-25	WOS:A1992KA26300018
J	KOSAKA, M; IWAI, SA; NISHINA, Y; SUMI, T; NISHIMUNE, Y				KOSAKA, M; IWAI, SA; NISHINA, Y; SUMI, T; NISHIMUNE, Y			C-MYC AND P53 GENE-EXPRESSION IN THE DIFFERENTIATION OF TEMPERATURE-SENSITIVE MUTANTS OF TERATOCARCINOMA F9 CELLS	ONCOGENE			English	Article							EMBRYONAL CARCINOMA-CELLS; INCUBATION TEMPERATURES; RETINOIC ACID; DNA-SYNTHESIS; STEM-CELLS; TRANSFORMATION; INDUCTION; GROWTH; SUPPRESSOR; INHIBITORS	We have previously reported the isolation of several temperature-sensitive (ts) mutants of F9 cells. Further investigations showed that some mutants were induced to differentiate at non-permissive temperature of cell growth, accompanied by changes in the expression of various genes, whereas others were not. During the differentiation induced by shifting up to the nonpermissive temperature, a rapid and transient decrease in both c-myc and p53 mRNA levels and rapid induction of c-jun mRNA were observed. These changes were specific in differentiation-inducible mutants and were not observed in a non-inducible mutant. In both types of mutants, the level of c-myc mRNA decreased in association with growth retardation at the non-permissive temperature. The p53 mRNA, however, showed specific increase in the differentiation-inducible ts mutants. These observations suggest distinct roles for p53 and c-myc from proliferation to differentiation in teratocarcinoma stem cells.	OSAKA UNIV,FAC DENT,MICROBIAL DIS RES INST,SUITA,OSAKA 565,JAPAN; OSAKA UNIV,FAC DENT,DEPT ORAL SURG 2,SUITA,OSAKA 565,JAPAN	Osaka University; Osaka University			KOSAKA, Mitsuko/B-1603-2011; Nishina, Yuta/AHB-6194-2022	KOSAKA, Mitsuko/0000-0001-6146-5184; Nishina, Yuta/0000-0002-4958-1753				CAMPISI J, 1984, CELL, V36, P241, DOI 10.1016/0092-8674(84)90217-4; CHANDRASEKARAN K, 1982, J CELL PHYSIOL, V113, P134, DOI 10.1002/jcp.1041130122; DONY C, 1985, NATURE, V317, P636, DOI 10.1038/317636a0; DUPREY P, 1985, P NATL ACAD SCI USA, V82, P8535, DOI 10.1073/pnas.82.24.8535; ELIYAHU D, 1985, NATURE, V316, P158, DOI 10.1038/316158a0; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HINDS P, 1989, J VIROL, V63, P739, DOI 10.1128/JVI.63.2.739-746.1989; KATO K, 1990, MOL CELL BIOL, V10, P486, DOI 10.1128/MCB.10.2.486; KLEINMAN HK, 1987, DEV BIOL, V122, P373, DOI 10.1016/0012-1606(87)90302-2; KOSAKA M, 1991, EXP CELL RES, V192, P46, DOI 10.1016/0014-4827(91)90155-N; KURKINEN M, 1983, NUCLEIC ACIDS RES, V11, P6199, DOI 10.1093/nar/11.18.6199; LACHMAN HM, 1984, NATURE, V310, P592, DOI 10.1038/310592a0; LAMB AJ, 1986, MOL CELL BIOL, V6, P1385; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; Maniatis T., 1982, MOL CLONING; MORITA T, 1988, GENE, V68, P109; NISHIMUNE Y, 1989, BIOCHEM BIOPH RES CO, V163, P1290; NISHIMUNE Y, 1983, EXP CELL RES, V146, P439, DOI 10.1016/0014-4827(83)90147-7; NISHIMUNE Y, 1989, BIOCHEM BIOPH RES CO, V165, P65, DOI 10.1016/0006-291X(89)91034-6; RYSECK RP, 1988, NATURE, V334, P535, DOI 10.1038/334535a0; SABBAG KR, 1989, DEVELOPMENT, V106, P195; SASAKI M, 1987, P NATL ACAD SCI USA, V84, P935, DOI 10.1073/pnas.84.4.935; SEJERSEN T, 1985, EXP CELL RES, V160, P19, DOI 10.1016/0014-4827(85)90232-0; SHERMAN MI, 1985, CIBA F SYMP, V113, P42; STRICKLAND S, 1978, CELL, V15, P393, DOI 10.1016/0092-8674(78)90008-9; WANG SY, 1983, P NATL ACAD SCI-BIOL, V80, P5880, DOI 10.1073/pnas.80.19.5880; WESTIN EH, 1982, P NATL ACAD SCI-BIOL, V79, P2490, DOI 10.1073/pnas.79.8.2490; YANG-YEN H-F, 1990, New Biologist, V2, P351	31	8	8	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1992	7	12					2455	2460						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KA856	1461650				2022-12-25	WOS:A1992KA85600010
J	PORTIER, M; MOLES, JP; MAZARS, GR; JEANTEUR, P; BATAILLE, R; KLEIN, B; THEILLET, C				PORTIER, M; MOLES, JP; MAZARS, GR; JEANTEUR, P; BATAILLE, R; KLEIN, B; THEILLET, C			P53 AND RAS GENE-MUTATIONS IN MULTIPLE-MYELOMA	ONCOGENE			English	Note							CHRONIC MYELOGENOUS LEUKEMIA; CHRONIC LYMPHOCYTIC-LEUKEMIA; HUMAN LYMPHOID MALIGNANCIES; TUMOR SUPPRESSOR GENE; C-MYC; N-RAS; ONCOGENE MUTATIONS; POINT MUTATION; CELL-LINES; EXPRESSION	We analysed genomic DNA from 30 patients with multiple myeloma (MM), searching for alterations in the p53 and RAS genes by a combination of polymerase chain reaction and single-strand conformation polymorphism techniques. Mutations in the p53 gene were observed in 20% (6 out of 30) of the patients, and were located in conserved sequence blocks within exons 5 and 7. These were single-nucleotide substitutions and consisted predominantly (4/6) of G:C to A:T transitions. Of the six patients with a mutated p53 gene, four were in the terminal phase of the disease. RAS gene mutations were found more frequently since they occurred in 47% (14 out of 30) of the patients. Mutations consisted of single-nucleotide substitutions, located in codons 12, 13 and 61 of either K- or N-RAS, to the exclusion of H-RAS. Moreover, one patient bore two simultaneous mutations, affecting simultaneously the K- and the N-RAS genes. RAS gene mutations were more frequently observed in patients with fulminating disease (10/15, 67%) than in patients with less aggressive forms of the disease (4/15, 26%). We also analysed genomic DNAs from 10 human myeloma cell lines, of which two bore mutations affecting codon 12 of the K-RAS gene, and one codon 12 of the N-RAS gene. The first two cell lines were obtained from freshly explanted tumor cells in which we observed identical mutations. Results presented here show that activating mutations in the RAS genes are, in MM, more frequent than those affecting the p53 gene and suggest that both events are related to terminal phases of the disease.	UNIV MONTPELLIER 2,GENET MOLEC LAB,CNRS,URA 1191,PL EUGENE BATAILLON,F-34095 MONTPELLIER,FRANCE; INSERM,U IMMUNOPATHOL MALADIES TUMORALES & AUTOIMMUNES 291,F-34090 MONTPELLIER,FRANCE; HOP ST ELOI,CTR GUI DE CHAULIAC,F-34059 MONTPELLIER,FRANCE	Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; Universite de Montpellier; CHU de Montpellier			Molès, Jean-Pierre/M-2286-2017; Theillet, Charles/O-7634-2018	Molès, Jean-Pierre/0000-0002-6863-6350; Theillet, Charles/0000-0001-5555-2759				BAKKUS MHC, 1990, ONCOGENE, V5, P1359; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BOS JL, 1989, CANCER RES, V49, P4682; BROWETT PJ, 1989, ONCOGENE, V4, P1029; CHENG J, 1990, MOL CELL BIOL, V10, P5502, DOI 10.1128/MCB.10.10.5502; ERNST TJ, 1988, BLOOD, V72, P1163; FEINSTEIN E, 1991, P NATL ACAD SCI USA, V88, P6293, DOI 10.1073/pnas.88.14.6293; GAIDANO G, 1991, P NATL ACAD SCI USA, V88, P5413, DOI 10.1073/pnas.88.12.5413; GREIL R, 1991, BLOOD, V78, P180; HOLLIDAY R, 1989, TRENDS GENET, V5, P42, DOI 10.1016/0168-9525(89)90020-6; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; KLEIN B, 1989, BLOOD, V73, P517; LEMAISTRE A, 1989, BLOOD, V73, P889; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; Maniatis T, 1989, DECONTAMINATION DILU; MAZARS GR, 1992, ONCOGENE, V7, P1015; NERI A, 1989, J EXP MED, V170, P1715, DOI 10.1084/jem.170.5.1715; NERI A, 1988, P NATL ACAD SCI USA, V85, P9268, DOI 10.1073/pnas.85.23.9268; PALUMBO AP, 1989, CANCER RES, V49, P4701; PAQUETTE RL, 1990, ONCOGENE, V5, P1659; PETTERSSON M, 1992, BLOOD, V79, P495; RADICH JP, 1990, BLOOD, V76, P801; RIDEOUT WM, 1990, SCIENCE, V249, P1288, DOI 10.1126/science.1697983; SAWADA M, 1989, NUCLEIC ACIDS RES, V17, P8867, DOI 10.1093/nar/17.21.8867; SELVANAYAGAM P, 1988, BLOOD, V71, P30; SIDRANSKY D, 1992, NATURE, V355, P846, DOI 10.1038/355846a0; SLINGERLAND JM, 1991, BLOOD, V77, P1500; WRIGHT PA, 1991, ONCOGENE, V6, P1693	28	151	154	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1992	7	12					2539	2543						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KA856	1461658				2022-12-25	WOS:A1992KA85600022
J	MONNING, U; KONIG, G; BANATI, RB; MECHLER, H; CZECH, C; GEHRMANN, J; SCHREITERGASSER, U; MASTERS, CL; BEYREUTHER, K				MONNING, U; KONIG, G; BANATI, RB; MECHLER, H; CZECH, C; GEHRMANN, J; SCHREITERGASSER, U; MASTERS, CL; BEYREUTHER, K			ALZHEIMER BETA-A4-AMYLOID PROTEIN-PRECURSOR IN IMMUNOCOMPETENT CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-AMYLOID PROTEIN; NEXIN-II; NERVOUS-SYSTEM; SECRETED FORM; IMMUNE-SYSTEM; DISEASE; MACROPHAGES; ADHESION; EXPRESSION; MICROGLIA	The mechanism of proteolytic breakdown of the betaA4-amyloid protein precursor (APP) has attracted much attention because of its relevance for Alzheimer's disease. Apart from the pathological role of APP in the amyloidogenesis, many efforts have been made to identify the functional significance of this widely expressed protein in various biological processes. Employing biochemical techniques, we demonstrate that APP is involved in the initiation of the immune response. Upon stimulation, it is expressed by the major functional types of T-lymphocytes, i.e. CD4+ and CD8+ cells. As was demonstrated for the CD4+ lymphoid cell line H9, APP is predominantly secreted. The remaining COOH-terminal fragments generated upon secretion were highly unstable. Of the APP produced by immunocompetent cells, considerable amounts were shown to be leukocyte-derived APP (L-APP). In addition, we were able to identify the KPI-containing L-APP isoform, L-APP733, as the major expressed L-APP isoform in immunocompetent cells, including rat microglial cells and astrocytes. The L-APP expression pattern of these cells showed high similarity. These findings seem to be indicative of an important function of APP within the immune system. Therefore, APP may be involved in various immunopathogenic conditions of the periphery and in the central nervous system.	MAX PLANCK INST PSYCHIAT,DEPT NEUROMORPHOL,W-8033 MARTINSRIED,GERMANY; CTR MENTAL HLTH,W-6700 MANNHEIM,GERMANY; UNIV MELBOURNE,DEPT PATHOL,PARKVILLE,VIC 3052,AUSTRALIA	Max Planck Society; University of Melbourne	MONNING, U (corresponding author), UNIV HEIDELBERG,CTR MOLEC BIOL HEIDELBERG,NEUENHEIMER FELD 282,W-6900 HEIDELBERG,GERMANY.			Czech, Christian/0000-0001-7746-0134				BANATI RB, 1991, J NEUROSCI RES, V30, P593, DOI 10.1002/jnr.490300402; BANATI RB, 1991, NEUROPATH APPL NEURO, V17, P223, DOI 10.1111/j.1365-2990.1991.tb00718.x; BAUER J, 1991, FEBS LETT, V282, P335, DOI 10.1016/0014-5793(91)80508-Z; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P31; BREEN KC, 1991, J NEUROSCI RES, V28, P90, DOI 10.1002/jnr.490280109; BUDKA H, 1989, ACTA NEUROPATHOL, V77, P225, DOI 10.1007/BF00687573; BUSH AI, 1990, J BIOL CHEM, V265, P15977; CHEN M, 1991, NEUROSCI LETT, V125, P223, DOI 10.1016/0304-3940(91)90034-Q; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; ESCH FS, 1990, SCIENCE, V248, P1122, DOI 10.1126/science.2111583; ESTUS S, 1992, SCIENCE, V255, P726, DOI 10.1126/science.1738846; Frei K., 1989, NEUROIMMUNE NETWORKS, P127; GAUDERNACK G, 1986, J IMMUNOL METHODS, V90, P179, DOI 10.1016/0022-1759(86)90074-8; GOLDE TE, 1992, SCIENCE, V255, P728, DOI 10.1126/science.1738847; HAASS C, 1991, J NEUROSCI, V11, P3783; INNOCENTI GM, 1983, DEV BRAIN RES, V11, P39, DOI 10.1016/0165-3806(83)90200-6; KAMETANI F, 1990, J NEUROL SCI, V97, P43, DOI 10.1016/0022-510X(90)90097-7; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KITAGUCHI N, 1988, NATURE, V331, P530, DOI 10.1038/331530a0; KLIER FG, 1990, BRAIN RES, V515, P336, DOI 10.1016/0006-8993(90)90619-M; KONIG G, 1992, J BIOL CHEM, V267, P10804; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MASTERS CL, 1985, P NATL ACAD SCI USA, V82, P4245, DOI 10.1073/pnas.82.12.4245; Masters CL, 1991, BRAIN PATHOL, V1, P226, DOI 10.1111/j.1750-3639.1991.tb00665.x; MCGEER PL, 1991, CAN J NEUROL SCI, V18, P376, DOI 10.1017/S0317167100032479; MCGEER PL, 1988, ACTA NEUROPATHOL, V76, P550, DOI 10.1007/BF00689592; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; MESSING J, 1983, METHOD ENZYMOL, V101, P20; MONNING U, 1990, FEBS LETT, V277, P261, DOI 10.1016/0014-5793(90)80861-C; MULLERHILL B, 1989, ANNU REV BIOCHEM, V58, P287; NARINDRASORASAK S, 1991, J BIOL CHEM, V266, P12878; OLTERSDORF T, 1989, NATURE, V341, P144, DOI 10.1038/341144a0; PALMERT MR, 1989, P NATL ACAD SCI USA, V86, P6338, DOI 10.1073/pnas.86.16.6338; PERRY VH, 1988, TRENDS NEUROSCI, V11, P273, DOI 10.1016/0166-2236(88)90110-5; PODLISNY MB, 1990, BIOCHEM BIOPH RES CO, V167, P1094, DOI 10.1016/0006-291X(90)90635-Z; PONTE P, 1988, NATURE, V331, P525, DOI 10.1038/331525a0; POPOVIC M, 1984, SCIENCE, V224, P497, DOI 10.1126/science.6200935; RUMBLE B, 1989, NEW ENGL J MED, V320, P1446, DOI 10.1056/NEJM198906013202203; SAITOH T, 1989, CELL, V58, P615, DOI 10.1016/0092-8674(89)90096-2; SCHUBERT D, 1989, NEURON, V3, P689, DOI 10.1016/0896-6273(89)90237-7; SELKOE DJ, 1991, NEURON, V6, P487, DOI 10.1016/0896-6273(91)90052-2; SHIVERS BD, 1988, EMBO J, V7, P1365, DOI 10.1002/j.1460-2075.1988.tb02952.x; SIMAN R, 1989, NEURON, V3, P275, DOI 10.1016/0896-6273(89)90252-3; SISODIA SS, 1990, SCIENCE, V248, P492, DOI 10.1126/science.1691865; SMITH RP, 1990, SCIENCE, V248, P1126, DOI 10.1126/science.2111585; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; TANZI RE, 1988, NATURE, V331, P528, DOI 10.1038/331528a0; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VANNOSTRAND WE, 1990, SCIENCE, V248, P745, DOI 10.1126/science.2110384; VANNOSTRAND WE, 1989, NATURE, V341, P546; WECKERLE H, 1986, TRENDS NEUROSCI, V9, P271; WEIDEMANN A, 1989, CELL, V57, P115, DOI 10.1016/0092-8674(89)90177-3; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; WISNIEWSKI HM, 1989, CAN J NEUROL SCI, V16, P535, DOI 10.1017/S0317167100029887	54	85	86	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1992	267	33					23950	23956						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JZ239	1429732				2022-12-25	WOS:A1992JZ23900078
J	WENG, QP; ELDER, J; JACOBSON, GR				WENG, QP; ELDER, J; JACOBSON, GR			SITE-SPECIFIC MUTAGENESIS OF RESIDUES IN THE ESCHERICHIA-COLI MANNITOL PERMEASE THAT HAVE BEEN SUGGESTED TO BE IMPORTANT FOR ITS PHOSPHORYLATION AND CHEMORECEPTION FUNCTIONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PHOSPHOTRANSFERASE SYSTEM; C-TERMINAL DOMAIN; ENZYME-II; BACTERIAL PHOSPHOENOLPYRUVATE; SALMONELLA-TYPHIMURIUM; STEREOCHEMICAL COURSE; PHENOTYPIC SELECTION; TRANSPORT; PROTEIN; SEQUENCE	The Escherichia coli mannitol permease is an integral membrane protein that catalyzes the concomitant transport and phosphorylation Of D-mannitol and also acts as the chemoreceptor for chemotaxis of E. coli to this hexitol. At least 4 aminoacyl residues in this protein have been suggested to be important in these activities: His- 195, His-256, Cys-384, and His-554. Previous evidence has implicated His-554 and Cys-384 as residues that are covalently phosphorylated, in sequence, as intermediates in phosphotransfer to mannitol. We have constructed a number of site-specific mutants of the mannitol permease at these positions. The properties of proteins in which His-554 or Cys-384 has been changed are consistent with their essential roles in phosphorylation. We also used these mutants to show that intermolecular phosphotransfer between His-554 and Cys-384 can occur in vivo in membrane-bound heterodimers consisting of different mutant subunits. The properties of proteins with mutations at position 195 suggest an important role for this residue involving hydrogen bonding, while His-256 performs no significant function in the mannitol permease. Finally, the phosphorylation and chemoreception activities for each mutant protein were each roughly in the same proportion to these activities in the wild-type protein, showing that these functions of the mannitol permease are tightly coupled under normal physiological conditions.	BOSTON UNIV,DEPT BIOL,5 CUMMINGTON ST,BOSTON,MA 02215	Boston University					NIGMS NIH HHS [GM28226] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028226] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ATKINSON MR, 1960, COMP BIOCHEM, V2, P1; BEGLEY GS, 1982, BIOCHEMISTRY-US, V21, P5552, DOI 10.1021/bi00265a026; BOLIVAR F, 1977, GENE, V2, P95, DOI 10.1016/0378-1119(77)90000-2; BOURRET RB, 1991, ANNU REV BIOCHEM, V60, P401, DOI 10.1146/annurev.bi.60.070191.002153; BRAMLEY HF, 1987, P NATL ACAD SCI USA, V84, P4777, DOI 10.1073/pnas.84.14.4777; ERNI B, 1986, BIOCHEMISTRY-US, V25, P305, DOI 10.1021/bi00350a004; GRISAFI PL, 1989, J BACTERIOL, V171, P2719, DOI 10.1128/jb.171.5.2719-2727.1989; GRUBL G, 1990, J BACTERIOL, V172, P5871; JACOBSON GR, 1983, J BIOL CHEM, V258, P748; JACOBSON GR, 1979, J BIOL CHEM, V254, P249; JACOBSON GR, 1992, RES MICROBIOL, V143, P113, DOI 10.1016/0923-2508(92)90040-U; JACOBSON GR, 1989, FEMS MICROBIOL REV, V63, P25; Krebs EG, 1986, ENZYMES, V17, P3, DOI 10.1016/S1874-6047(08)60426-6; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE CA, 1983, J BIOL CHEM, V258, P761; LENGELER JW, 1989, FEMS MICROBIOL REV, V63, P81; LEONARD JE, 1981, J BACTERIOL, V145, P1106, DOI 10.1128/JB.145.2.1106-1109.1981; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MANDEL M, 1970, J MOL BIOL, V53, P159, DOI 10.1016/0022-2836(70)90051-3; Maniatis T., 1982, MOL CLONING; MEADOW ND, 1990, ANNU REV BIOCHEM, V59, P497, DOI 10.1146/annurev.biochem.59.1.497; MUELLER EG, 1990, BIOCHEMISTRY-US, V29, P6892, DOI 10.1021/bi00481a019; PAS HH, 1988, BIOCHEMISTRY-US, V27, P5835, DOI 10.1021/bi00416a002; PAS HH, 1991, J BIOL CHEM, V266, P6690; ROBILLARD GT, 1988, BIOCHIM BIOPHYS ACTA, V947, P493, DOI 10.1016/0304-4157(88)90005-6; ROBILLARD GT, 1987, BIOCHEMISTRY-US, V26, P5796, DOI 10.1021/bi00392a032; ROOSSIEN FF, 1983, BIOCHIM BIOPHYS ACTA, V760, P185, DOI 10.1016/0304-4165(83)90141-1; ROOSSIEN FF, 1984, BIOCHEMISTRY-US, V23, P5682, DOI 10.1021/bi00319a003; SAIER MH, 1989, MICROBIOL REV, V53, P109, DOI 10.1128/MMBR.53.1.109-120.1989; SAIER MH, 1988, FASEB J, V2, P199, DOI 10.1096/fasebj.2.3.2832233; STEPHAN MM, 1989, BIOCHEMISTRY-US, V28, P7941, DOI 10.1021/bi00445a058; STEPHAN MM, 1986, BIOCHEMISTRY-US, V25, P8230, DOI 10.1021/bi00373a016; SUGIYAMA JE, 1991, P NATL ACAD SCI USA, V88, P9603, DOI 10.1073/pnas.88.21.9603; SUTCLIFFE JG, 1979, COLD SPRING HARB SYM, V43, P77, DOI 10.1101/SQB.1979.043.01.013; VANWEEGHEL RP, 1991, BIOCHEMISTRY-US, V30, P1774, DOI 10.1021/bi00221a007; VANWEEGHEL RP, 1991, BIOCHEMISTRY-US, V30, P1768, DOI 10.1021/bi00221a006; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; WAYGOOD EB, 1984, J CELL BIOCHEM, V25, P139, DOI 10.1002/jcb.240250304; WHITE DW, 1990, J BACTERIOL, V172, P1509, DOI 10.1128/jb.172.3.1509-1515.1990	41	33	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1992	267	27					19529	19535						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JP593	1527071				2022-12-25	WOS:A1992JP59300077
J	WESS, J; MAGGIO, R; PALMER, JR; VOGEL, Z				WESS, J; MAGGIO, R; PALMER, JR; VOGEL, Z			ROLE OF CONSERVED THREONINE AND TYROSINE RESIDUES IN ACETYLCHOLINE BINDING AND MUSCARINIC RECEPTOR ACTIVATION - A STUDY WITH M3-MUSCARINIC-RECEPTOR POINT MUTANTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC-RECEPTOR; SITE-DIRECTED MUTAGENESIS; ANTAGONIST BINDING; LIGAND-BINDING; IDENTIFICATION; EXPRESSION; SUBTYPES; AGONIST; PROTEIN; CLONING	Structure-function relationship studies of the m3 muscarinic acetylcholine receptor have recently identified a series of threonine and tyrosine residues (all located within the hydrophobic receptor core) that are critically involved in acetylcholine binding (Wess, J., Gdula, D., and Brann, M. R. (1991) EMBO J. 10, 3729-3734). To gain further insight into the functional roles of these amino acids, the agonist binding properties of six rat m3 muscarinic receptor point mutants, in which the critical threonine and tyrosine residues had been individually replaced by alanine and phenylalanine, respectively, were studied in greater detail following their transient expression in COS-7 cells. The binding profiles of a series of acetylcholine derivatives suggest that the altered threonine and tyrosine residues are primarily involved in the interaction of the acetylcholine ester moiety with the receptor protein. The two m3 receptor point mutants, Thr234 --> Ala and Tyr506 --> Phe, which showed the most pronounced decreases in acetylcholine binding affinities (approximately 40-60-fold as compared with the wild-type receptor), were stably expressed in CHO cells for further functional analysis. Both mutant receptors were found to be severely impaired in their ability to stimulate agonist-dependent phosphatidylinositol hydrolysis. Consistent with this observation, acetylcholine binding to the two mutant receptors was not significantly affected by addition of the GTP analog Gpp(NH)p (5-'guanylyl imidodiphosphate). Our data suggest that Thr234 and Tyr506 (located within transmembrane domains V and VI, respectively), which are conserved among all muscarinic receptors (m1-m5), may play an important role in agonist-induced muscarinic receptor activation.	UPJOHN CO,DEPT MEDICINAL CHEM RES,KALAMAZOO,MI 49001	Pfizer	WESS, J (corresponding author), NINCDS,MOLEC BIOL LAB,BLDG 36,RM 3D-02,BETHESDA,MD 20892, USA.		maggio, Roberto/Q-2032-2015	Maggio, Roberto/0000-0003-4436-2356				BERRIDGE MJ, 1983, BIOCHEM J, V212, P473, DOI 10.1042/bj2120473; BONNER TI, 1987, SCIENCE, V237, P527, DOI 10.1126/science.3037705; BONNER TI, 1988, NEURON, V1, P403, DOI 10.1016/0896-6273(88)90190-0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUCKLEY NJ, 1989, MOL PHARMACOL, V35, P469; CANNON JG, 1981, BURGERS MED CHEM, P339; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; CURTIS CAM, 1989, J BIOL CHEM, V264, P489; DENNIS M, 1988, BIOCHEMISTRY-US, V27, P2346, DOI 10.1021/bi00407a016; DIXON RAF, 1987, EMBO J, V6, P3269, DOI 10.1002/j.1460-2075.1987.tb02645.x; DIXON RAF, 1987, NATURE, V326, P73, DOI 10.1038/326073a0; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; DORJE F, 1991, J PHARMACOL EXP THER, V256, P727; DOUGHERTY DA, 1990, SCIENCE, V250, P1558, DOI 10.1126/science.2274786; FINDLAY JBC, 1986, BIOCHEM J, V238, P625, DOI 10.1042/bj2380625; FRASER CM, 1989, MOL PHARMACOL, V36, P840; FRIEDMAN HARRIS L., 1967, MED RES SER MONOGR, V1, P79; GALZI JL, 1990, J BIOL CHEM, V265, P10430; HULME EC, 1990, ANNU REV PHARMACOL, V30, P633, DOI 10.1146/annurev.pa.30.040190.003221; HULME EC, 1991, BIOCHEM SOC T, V19, P133, DOI 10.1042/bst0190133; JONES SVP, 1992, IN PRESS MOL BIOL RE; KUBO T, 1988, FEBS LETT, V241, P119, DOI 10.1016/0014-5793(88)81043-3; KUBO T, 1986, NATURE, V323, P411, DOI 10.1038/323411a0; KURTENBACH E, 1990, J BIOL CHEM, V265, P13702; LECHLEITER J, 1990, EMBO J, V9, P4381, DOI 10.1002/j.1460-2075.1990.tb07888.x; NATHANSON NM, 1987, ANNU REV NEUROSCI, V10, P195, DOI 10.1146/annurev.ne.10.030187.001211; PERALTA EG, 1987, EMBO J, V6, P3923, DOI 10.1002/j.1460-2075.1987.tb02733.x; STRADER CD, 1991, J BIOL CHEM, V266, P5; STRADER CD, 1988, J BIOL CHEM, V263, P10267; STRADER CD, 1989, J BIOL CHEM, V264, P13572; SUSSMAN JL, 1991, SCIENCE, V253, P872, DOI 10.1126/science.1678899; THANEIWYSS P, 1983, HELV CHIM ACTA, V66, P2198, DOI 10.1002/hlca.19830660731; WESS J, 1989, FEBS LETT, V258, P133, DOI 10.1016/0014-5793(89)81633-3; WESS J, 1990, MOL PHARMACOL, V38, P517; WESS J, 1991, EMBO J, V10, P3729, DOI 10.1002/j.1460-2075.1991.tb04941.x	37	86	91	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1992	267	27					19313	19319						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JP593	1527051				2022-12-25	WOS:A1992JP59300046
J	GULICK, AM; GOIHL, AL; FAHL, WE				GULICK, AM; GOIHL, AL; FAHL, WE			STRUCTURAL STUDIES ON HUMAN GLUTATHIONE-S-TRANSFERASE-PI - FAMILY OF NATIVE-SPECIFIC MONOCLONAL-ANTIBODIES USED TO BLOCK CATALYSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; MAMMALIAN-CELLS; DRUG-RESISTANCE; PROTEINS; EXPRESSION; EPITOPES; GENE; SITE; STEP; YA	The glutathione S-transferases are a family of related detoxification enzymes that have been shown to conjugate numerous electrophiles to the common cellular thiol glutathione. We have generated a panel of monoclonal antibodies against the human pi-class isozyme of this enzyme, and, in this report, we characterize the binding of these antibodies to the glutathione S-transferase antigen. Of the 10 monoclonal antibodies that we have isolated, 7 are able to recognize the native form of the enzyme while the remaining 3 are only able to bind to glutathione S-transferase-pi in assays that partially denature the antigen, such as an enzyme-linked immunosorbent assay or a Western blot. We synthesized seven partial protein fragments and asked whether the monoclonal antibodies could bind to these fragments in an immunoprecipitation reaction. The antibodies that can bind the native form of the enzyme all bind to the carboxyl-terminal domain of the protein. Two antibodies are able to inhibit the glutathione S-transferase-catalyzed reaction noncompetitively against glutathione. Incubation of a 10-fold molar excess of either antibody over enzyme can inhibit the reaction by 50%. We have also used the same protein fragments of glutathione S-transferase-pi to show that amino acids 1-77 retain the capacity to bind glutathione in a glutathione-agarose binding assay.	UNIV WISCONSIN,MCARDLE LAB CANC RES,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison				Gulick, Andrew/0000-0003-4238-7453	NCI NIH HHS [P01-CA22484, P30-CA07175] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA007175, P01CA022484] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AISO S, 1989, J HISTOCHEM CYTOCHEM, V37, P1247, DOI 10.1177/37.8.2754254; ARMSTRONG RN, 1987, CRC CR REV BIOCH MOL, V22, P39, DOI 10.3109/10409238709082547; BOARD PG, 1991, BIOCHEM J, V275, P171, DOI 10.1042/bj2750171; BRONDYK WH, 1991, ONCOGENE, V6, P1269; CHAKRABARTI R, 1989, J BIOL CHEM, V264, P15494; COOPER HM, CURRENT PROTOCOLS MO; DESTGOTH SF, 1980, J IMMUNOL METHODS, V35, P4; EVANGELISTA M, 1991, BIOCHIM BIOPHYS ACTA, V1074, P214, DOI 10.1016/0304-4165(91)90064-N; FRIGUET B, 1984, MOL IMMUNOL, V21, P673, DOI 10.1016/0161-5890(84)90053-1; FRIGUET B, 1989, PROTEIN STRUCTURE PR, P287; GOLDBERG ME, 1991, TRENDS BIOCHEM SCI, V16, P358, DOI 10.1016/0968-0004(91)90148-O; HABIG WH, 1974, J BIOL CHEM, V249, P7130; HARLOW E, 1988, ANTIBODIES LABORATOR; HOESCH RM, 1989, J BIOL CHEM, V264, P17712; HOSODA K, 1990, HYBRIDOMA, V9, P133, DOI 10.1089/hyb.1990.9.133; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; KANTOR RRS, 1991, INT J CANCER, V47, P193, DOI 10.1002/ijc.2910470206; KHYSEANDERSON J, 1984, J BIOCHEM BIOPH METH, V10, P203; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAVER WG, 1990, CELL, V61, P553, DOI 10.1016/0092-8674(90)90464-P; LESLEY SA, 1991, J BIOL CHEM, V266, P2632; MANNERVIK B, 1988, CRC CR REV BIOCH MOL, V23, P283, DOI 10.3109/10409238809088226; MANOHARAN TH, 1987, J BIOL CHEM, V262, P3739; MANOHARAN TH, 1992, J BIOL CHEM, V267, P18940; MIRVISH SS, 1991, CANCER RES, V51, P1059; MORROW CS, 1990, CANCER CELL-MON REV, V2, P15; MOSCOW JA, 1989, MOL PHARMACOL, V36, P22; NAKAGAWA K, 1990, J BIOL CHEM, V265, P4296; PUCHALSKI RB, 1990, P NATL ACAD SCI USA, V87, P2443, DOI 10.1073/pnas.87.7.2443; REINEMER P, 1991, EMBO J, V10, P1997, DOI 10.1002/j.1460-2075.1991.tb07729.x; Sambrook J, 1989, MOL CLONING LABORATO; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TAHIR MK, 1986, J BIOL CHEM, V261, P1048; TSUJI H, 1990, J BIOL CHEM, V265, P16064; WAXMAN DJ, 1990, CANCER RES, V50, P6449; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7	36	13	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1992	267	26					18946	18952						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JN502	1527022				2022-12-25	WOS:A1992JN50200104
J	SHENOY, BC; XIE, Y; PARK, VL; KUMAR, GK; BEEGEN, H; WOOD, HG; SAMOLS, D				SHENOY, BC; XIE, Y; PARK, VL; KUMAR, GK; BEEGEN, H; WOOD, HG; SAMOLS, D			THE IMPORTANCE OF METHIONINE RESIDUES FOR THE CATALYSIS OF THE BIOTIN ENZYME, TRANSCARBOXYLASE - ANALYSIS BY SITE-DIRECTED MUTAGENESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEPTIDES	Almost all biotin enzymes contain the conserved tetrapeptide Ala-Met-Bct-Met (Bct, N(epsilon)-biotinyl-L-lysine). In the 1.3 S biotinyl subunit of transcarboxylase (TC), this sequence is present between positions 87 and 90. The conserved nature of these amino acids implies a critical role in the function of biotin enzymes. In order to examine the role of these conserved amino acids, point mutations in the gene encoding the 1.3 S subunit have been made by site-directed mutagenesis to generate A87G, M88L, M90L, M88T, M88C, M88A, and a double mutant A87M, M88A in the 1.3 S subunit. TC, a multisubunit enzyme containing 12 S, 5 S, and 1.3 S subunits, catalyzes the transfer of a carboxyl group from methylmalonyl-CoA to pyruvate (overall reaction). TC can be dissociated into individual subunits and also reconstituted by assembling isolated subunits to a fully active form. The mutants of the 1.3 S subunit have been reconstituted with native 5 S and 12 S subunits from Propionibacterium shermanii. The effects of mutations on the activity of TC were compared with that of TC-1.3 S wild type (WT) prepared in a similar manner. The results show that any substitution of a residue in the conserved tetrapeptide causes impairment of the rate of TC activity. Comparison of gel filtration profiles, sodium dodecyl sulfate-polyacrylamide gel electrophoresis and electron micrographs of the TC assembled with mutant 1.3 S and with wild type 1.3 S subunits showed that the impairment of the overall activity was not due to a failure of the subunits to assemble into complexes. Steady state kinetic analysis using the mutant 1.3 S subunits indicated that the K(m) for methylmalonyl-CoA or pyruvate did not change significantly indicating that the binding of substrates is not altered. However, the k(cat), values were significantly lower for mutants at positions 87 and 88 than for those at position 90. The replacement of methionine at position 88 either by hydrophobic or hydrophilic residues significantly altered the activity in the overall reaction, while similar substitution at position 90 did not dramatically alter the k(cat). These results suggest that Ala-87 and Met-88 are catalytically critical in the conserved tetrapeptide.	CASE WESTERN RESERVE UNIV,SCH MED,DEPT BIOCHEM,10900 EUCLID AVE,CLEVELAND,OH 44106	Case Western Reserve University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040786] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 40786] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAHLER C, 1981, BIOCHEM INT, V3, P349; CRAFT DV, 1985, BIOCHEMISTRY-US, V24, P2471, DOI 10.1021/bi00331a012; ELLIOTT JI, 1978, ARCH BIOCHEM BIOPHYS, V190, P351, DOI 10.1016/0003-9861(78)90285-0; GREEN NM, 1972, J BIOL CHEM, V247, P6284; HENNESSEY JP, 1982, BIOCHEMISTRY-US, V21, P642, DOI 10.1021/bi00533a007; KONDO H, 1984, INT J PEPT PROT RES, V23, P559; LAYNE E, 1957, METHOD ENZYMOL, V3, P447, DOI 10.1016/S0076-6879(57)03413-8; MURTIF VL, 1985, P NATL ACAD SCI USA, V82, P5617, DOI 10.1073/pnas.82.17.5617; NORTHROP DB, 1969, J BIOL CHEM, V244, P5808; RYLATT DB, 1977, ARCH BIOCHEM BIOPHYS, V183, P113, DOI 10.1016/0003-9861(77)90425-8; SAMOLS D, 1988, J BIOL CHEM, V263, P6461; SHENOY BC, 1988, FASEB J, V2, P2505, DOI 10.1096/fasebj.2.9.3131174; TAKAI T, 1987, FEBS LETT, V272, P98; WARBURG O, 1941, BIOCHEM Z, V310, P394; Wood H G, 1976, CRC Crit Rev Biochem, V4, P47, DOI 10.3109/10409237609102558; Wood H. G., 1969, METHOD ENZYMOL, V8, P215; WOOD HG, 1977, ANNU REV BIOCHEM, V46, P385, DOI 10.1146/annurev.bi.46.070177.002125; WOOD HG, 1986, ANN NY ACAD SCI, V447, P1; WRIGLEY NG, 1977, J BIOL CHEM, V252, P1500	19	30	32	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1992	267	26					18407	18412						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JN502	1526981				2022-12-25	WOS:A1992JN50200029
J	TSYGANKOV, AY; BROKER, BM; FARGNOLI, J; LEDBETTER, JA; BOLEN, JB				TSYGANKOV, AY; BROKER, BM; FARGNOLI, J; LEDBETTER, JA; BOLEN, JB			ACTIVATION OF TYROSINE KINASE P60FYN FOLLOWING T-CELL ANTIGEN RECEPTOR CROSS-LINKING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							SIGNAL TRANSDUCTION; PHOSPHORYLATION; STIMULATION	Activation of T cells by specific antigens in the context of major histocompatibility complex encoded proteins is mediated by the T cell antigen receptor (TcR), consisting of a variable (Ti) and an invariant (CD3) subunits. Tyrosine phosphorylation is considered to be one of the earliest steps in TcR-mediated signal transduction. There are indications that the p60fyn protein tyrosine kinase is involved in signaling via TcR. However, enzymatic activation of the Src-related tyrosine kinases upon TcR triggering has not been shown yet, therefore the identity of TcR-activated tyrosine kinase(s) remains unclear. We demonstrate that cross-linking of CD3 activates p60fyn and induces tyrosine phosphorylation of cellular proteins in human T cells (resting peripheral T cells, a helper T cell clone, a helper T cell clone immortalized with Herpesvirus saimiri, and a leukemic T cell line). Activation of p60fyn was fast, and its maximum (2-4-fold activation as compared with the basal activity) was followed by a decline. The amount of p60fyn in the cells remained unchanged. None of the other T cell Src-related tyrosine kinases was activated after cross-linking of CD3. Activation of p60fyn was induced by anti-CD3, but not by anti-CD4, anti-CD2, or anti-CD28. The activation was correlated with an increase of the phosphotyrosine content of p60fyn. These studies provide direct proof for the functional association between p60fyn and the TcR.	MAX PLANCK SOC,RHEUMATOL IMMUNOL RES UNIT,W-8520 ERLANGEN,GERMANY; BRISTOL MYERS SQUIBB PHARMACEUT,RES INST,SEATTLE,WA 98121	Max Planck Society; Bristol-Myers Squibb	TSYGANKOV, AY (corresponding author), BRISTOL MYERS SQUIBB PHARMACEUT,RES INST,DEPT MOLEC BIOL,SIGNAL TRANSDUCT LAB,PRINCETON,NJ 08543, USA.		Bröker, Barbara M/O-4850-2015; Tsygankov, Alexander Y/K-6205-2017	Bröker, Barbara M/0000-0002-5020-8542; 				BEYERS AD, 1992, P NATL ACAD SCI USA, V89, P2945, DOI 10.1073/pnas.89.7.2945; BIESINGER B, 1992, P NATL ACAD SCI USA, V89, P3116, DOI 10.1073/pnas.89.7.3116; CHAN AC, 1991, P NATL ACAD SCI USA, V88, P9166, DOI 10.1073/pnas.88.20.9166; COOKE MP, 1991, CELL, V65, P281, DOI 10.1016/0092-8674(91)90162-R; Exley M, 1991, Semin Immunol, V3, P283; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; GASSMANN M, 1992, EUR J IMMUNOL, V22, P283, DOI 10.1002/eji.1830220142; JUNE CH, 1990, J IMMUNOL, V144, P1591; JUNE CH, 1990, P NATL ACAD SCI USA, V87, P7722, DOI 10.1073/pnas.87.19.7722; KASHISHIAN A, 1992, EMBO J, V11, P1373, DOI 10.1002/j.1460-2075.1992.tb05182.x; KLAUSNER RD, 1991, CELL, V64, P875, DOI 10.1016/0092-8674(91)90310-U; LEDBETTER JA, 1988, EUR J IMMUNOL, V18, P525, DOI 10.1002/eji.1830180406; MOEBIUS U, 1989, LEUKOCYTE TYPING, V4, P314; MUSTELIN T, 1990, SCIENCE, V247, P1584, DOI 10.1126/science.2138816; REEDIJK M, 1992, EMBO J, V11, P1365, DOI 10.1002/j.1460-2075.1992.tb05181.x; ROTIN D, 1992, J BIOL CHEM, V267, P9678; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; SANCHO J, 1992, J IMMUNOL, V148, P1315; Siegel J N, 1991, Semin Immunol, V3, P325; THOMPSON PA, 1992, ONCOGENE, V7, P719; TSYGANKOV AY, 1992, CELL IMMUNOL, V140, P97, DOI 10.1016/0008-8749(92)90179-S; VANDENBERGHE P, 1992, J EXP MED, V175, P951, DOI 10.1084/jem.175.4.951; VEILLETTE A, 1988, MOL CELL BIOL, V8, P4353, DOI 10.1128/MCB.8.10.4353; Weiss A, 1991, Semin Immunol, V3, P313	24	150	150	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1992	267	26					18259	18262						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JN502	1526965				2022-12-25	WOS:A1992JN50200003
J	CRAWFORD, JM; RANSIL, BJ; NARCISO, JP; GOLLAN, JL				CRAWFORD, JM; RANSIL, BJ; NARCISO, JP; GOLLAN, JL			HEPATIC-MICROSOMAL BILIRUBIN UDP-GLUCURONOSYLTRANSFERASE - THE KINETICS OF BILIRUBIN MONOGLUCURONIDE AND DIGLUCURONIDE SYNTHESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							URIDINE-DIPHOSPHATE GLUCURONYLTRANSFERASE; HUMAN-SERUM-ALBUMIN; RAT-LIVER; ENDOPLASMIC-RETICULUM; RADIATION-INACTIVATION; MESSENGER-RNA; BINDING; MEMBRANE; CDNA; ACID	Hepatic biotransformation of bilirubin to the hydrophilic species bilirubin mono- (BMG) and diglucuronide (BDG) by microsomal bilirubin UDP-glucuronosyltransferase (GT) is a prerequisite for its physiologic excretion into bile. The reaction mechanism of bilirubin-GT and the access of bilirubin and BMG (the intermediate substrate) to the active site of bilirubin-GT are undefined. Highly purified [C-14]bilirubin and [H-3]BMG were coincubated with rat liver microsomes, and the initial rates of radiolabeled bilirubin glucuronide synthesis were measured. Although these substrates differ markedly in their hydrophilicity, no significant differences were observed in [C-14]- and [H-3]BDG rates of formation from equimolar [C-14]bilirubin and [H-3]BMG, in the absence or presence of soluble binding proteins (albumin and hepatic cytosol). In further kinetic studies, [C-14]bilirubin and [H-3]BMG exhibited mutually competitive inhibition of [H-3]- and [C-14]BDG synthesis, respectively, and [H-3]BMG also inhibited [C-14]BMG formation. Finally, unlabeled BMG and BDG inhibited the glucuronidation of [C-14]bilirubin, with all three pigments yielding virtual Michaelis-Menten dissociation constants in the 10-20-mu-M range. These findings indicate that: 1) bilirubin-GT follows Michaelis-Menten kinetics for both bilirubin and BMG glucuronidation over the range of substrate concentrations employed; 2) the findings are consistent with a single active site for the enzymatic synthesis of both BMG and BDG; 3) bilirubin, BMG, and BDG bind competitively to this active site with comparable affinities; and 4) access of both bilirubin and BMG substrates to the enzymatic active site is reduced by soluble binding proteins.	BRIGHAM & WOMENS HOSP, DEPT MED, BOSTON, MA 02115 USA; BETH ISRAEL HOSP, THORNDIKE LAB, BOSTON, MA 02215 USA; HARVARD UNIV, HARVARD DIGEST DIS CTR, BOSTON, MA 02115 USA; BETH ISRAEL HOSP, CHARLES A DANA RES INST, BOSTON, MA 02215 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School	CRAWFORD, JM (corresponding author), BRIGHAM & WOMENS HOSP, DEPT PATHOL, 75 FRANCIS ST, BOSTON, MA 02115 USA.				NIADDK NIH HHS [AM-07502] Funding Source: Medline; NIDDK NIH HHS [DK-36887, DK-39512] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK036887, R29DK039512, R01DK039512] Funding Source: NIH RePORTER	NIADDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADACHI S, 1985, ARCH BIOCHEM BIOPHYS, V241, P486, DOI 10.1016/0003-9861(85)90574-0; ADACHI Y, 1990, CLIN BIOCHEM, V2, P247; ARION WJ, 1989, METHOD ENZYMOL, V174, P58; BLACK M, 1970, CLIN CHIM ACTA, V29, P27, DOI 10.1016/0009-8981(70)90216-0; BLANCKAERT N, 1979, P NATL ACAD SCI USA, V76, P2037, DOI 10.1073/pnas.76.4.2037; BONNETT R, 1978, PROC R SOC SER B-BIO, V202, P249, DOI 10.1098/rspb.1978.0066; BONNETT R, 1976, NATURE, V262, P326, DOI 10.1038/262326a0; BRODERSEN R, 1979, J BIOL CHEM, V254, P2364; Brodersen R, 1986, BILE PIGMENTS JAUNDI, P157; BURCHELL B, 1989, PHARMACOL THERAPEUT, V43, P261, DOI 10.1016/0163-7258(89)90122-8; BURCHELL B, 1987, BIOCHEM SOC T, V15, P581, DOI 10.1042/bst0150581; CAREY MC, 1986, BILE PIGMENTS JAUNDI, P81; CESTARO B, 1983, ITAL J BIOCHEM, V32, P318; CHOWDHURY NR, 1986, HEPATOLOGY, V6, P123, DOI 10.1002/hep.1840060124; COHEN S, 1990, BIOCHEM J, V270, P325, DOI 10.1042/bj2700325; CRAWFORD JM, 1987, J CLIN INVEST, V79, P1172, DOI 10.1172/JCI112934; CRAWFORD JM, 1988, AM J PHYSIOL, V255, pG121, DOI 10.1152/ajpgi.1988.255.1.G121; CRAWFORD JM, 1991, FALK SYMP, V57, P151; CUYPERS HTM, 1983, BIOCHIM BIOPHYS ACTA, V758, P135, DOI 10.1016/0304-4165(83)90294-5; ERIKSEN EF, 1981, J BIOL CHEM, V256, P4269; FEVERY J, 1977, BIOCHEM J, V164, P737, DOI 10.1042/bj1640737; FEVERY J, 1985, J HEPATOL, V1, P437, DOI 10.1016/S0168-8278(85)80781-9; FEVERY J, 1972, J CLIN INVEST, V51, P2482, DOI 10.1172/JCI107062; FOURNELGIGLEUX S, 1989, EUR J BIOCHEM, V183, P653, DOI 10.1111/j.1432-1033.1989.tb21095.x; FREEDLAND RA, 1991, INT J BIOCHEM, V23, P867, DOI 10.1016/0020-711X(91)90073-V; Gollan JL, 1985, LIVER BILIARY DISEAS, P301; GORDON ER, 1983, J BIOL CHEM, V258, P5028; GORDON ER, 1984, J BIOL CHEM, V259, P5500; HAUSER SC, 1984, J BIOL CHEM, V259, P4527; HAUSER SC, 1986, GASTROENTEROLOGY, V91, P287, DOI 10.1016/0016-5085(86)90559-7; HAUSER SC, 1986, GASTROENTEROLOGY, V90, P1732; HAUSER SC, 1988, BIOCHIM BIOPHYS ACTA, V967, P149, DOI 10.1016/0304-4165(88)90004-9; HAYWARD D, 1986, BIOCHIM BIOPHYS ACTA, V860, P149, DOI 10.1016/0005-2736(86)90509-2; HEIRWEGH KP, 1972, BIOCHEM J, V129, P605, DOI 10.1042/bj1290605; HSIEH YZ, 1988, J AM CHEM SOC, V110, P62, DOI 10.1021/ja00209a009; ILLING HP, 1976, BIOCHIM BIOPHYS ACTA, V429, P768; IYANAGI T, 1986, J BIOL CHEM, V261, P5607; JACKSON MR, 1987, BIOCHEM J, V242, P581, DOI 10.1042/bj2420581; JACOBSEN J, 1969, FEBS LETT, V5, P112, DOI 10.1016/0014-5793(69)80307-8; JANSEN PLM, 1975, BIOCHIM BIOPHYS ACTA, V391, P28, DOI 10.1016/0005-2744(75)90149-7; JANSEN PLM, 1992, HEPATOLOGY, V15, P532, DOI 10.1002/hep.1840150328; KIMURA T, 1987, EUR J BIOCHEM, V168, P515, DOI 10.1111/j.1432-1033.1987.tb13448.x; LAUFF JJ, 1982, CLIN CHEM, V28, P629; LEONARD M, 1989, J BIOL CHEM, V264, P5648; LIGHTNER DA, 1988, J BIOL CHEM, V263, P16669; LIGHTNER DA, 1988, ARCH BIOCHEM BIOPHYS, V262, P543, DOI 10.1016/0003-9861(88)90406-7; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MACKENZIE PI, 1986, J BIOL CHEM, V261, P6119; MACKENZIE PI, 1990, J BIOL CHEM, V265, P3432; McDonagh A. F., 1979, PORPHYRINS, VVI; MCDONAGH AF, 1985, PEDIATRICS, V75, P443; MCDONAGH AF, 1984, J CLIN INVEST, V74, P763, DOI 10.1172/JCI111492; MCDONAGH AF, 1991, FALK SYMP, V57, P47; MCINTYRE JC, 1991, BIOCHEMISTRY-US, V30, P11819, DOI 10.1021/bi00115a012; MOROI Y, 1985, B CHEM SOC JPN, V58, P1426, DOI 10.1246/bcsj.58.1426; MURACA M, 1983, CLIN CHEM, V29, P1767; NOY N, 1992, BIOPHYS CHEM, V42, P177, DOI 10.1016/0301-4622(92)85007-Q; OSTROW JD, 1988, J LIPID RES, V29, P335; PETERS WHM, 1984, J BIOL CHEM, V259, P1701; PILLOT T, 1991, FALK SYMP, V57, P161; RITTER JK, 1991, J BIOL CHEM, V266, P1043; ROYCHOWDHURY J, 1991, J BIOL CHEM, V266, P18294; Segel I.H., 1975, ENZYME KINETICS BEHA, Vsecond, P100; SMITH DJ, 1987, J HEPATOL, V4, P1, DOI 10.1016/S0168-8278(87)80002-8; SOMMERER U, 1988, HEPATOLOGY, V8, P116, DOI 10.1002/hep.1840080123; SPIVAK W, 1985, BOCH J, V225, P797; STOLZ A, 1989, ANNU REV PHYSIOL, V51, P161, DOI 10.1146/annurev.ph.51.030189.001113; TEPHLY TR, 1990, TRENDS PHARMACOL SCI, V11, P276, DOI 10.1016/0165-6147(90)90008-V; TIPPING E, 1979, BIOCHEM J, V180, P327, DOI 10.1042/bj1800327; TIRIBELLI C, 1990, HEPATOLOGY, V11, P303, DOI 10.1002/hep.1840110222; VANDERJAGT DL, 1981, FEBS LETT, V136, P319, DOI 10.1016/0014-5793(81)80644-8; VANSTAPEL F, 1989, BIOCHEM J, V259, P659, DOI 10.1042/bj2590659; VANSTAPEL F, 1988, ARCH BIOCHEM BIOPHYS, V263, P216, DOI 10.1016/0003-9861(88)90630-3; VANSTAPEL F, 1987, J BIOL CHEM, V262, P4616; VANSTAPEL F, 1987, BIOCHEMISTRY-US, V26, P6074, DOI 10.1021/bi00393a020; VERMEIR M, 1984, BIOCHEM J, V223, P455, DOI 10.1042/bj2230455; VESSEY DA, 1989, J BIOL CHEM, V264, P6334; WEISS JS, 1983, NEW ENGL J MED, V309, P147, DOI 10.1056/NEJM198307213090305; WHITMER DI, 1987, BIOCHEM J, V244, P41, DOI 10.1042/bj2440041; WHITMER DI, 1986, J BIOL CHEM, V261, P7170; WHITMER DI, 1984, J BIOL CHEM, V59, P11969; WOOSTER R, 1991, BIOCHEM J, V278, P465, DOI 10.1042/bj2780465; ZAKIM D, 1988, J BIOL CHEM, V263, P5164; ZAKIM D, 1990, BIOCHEMISTRY-US, V29, P2003, DOI 10.1021/bi00460a007; ZUCKER SD, 1992, BIOCHEMISTRY-US, V31, P3184, DOI 10.1021/bi00127a020	85	31	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	1992	267	24					16943	16950						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JL053	1512236				2022-12-25	WOS:A1992JL05300036
J	ROSALES, C; BROWN, EJ				ROSALES, C; BROWN, EJ			SIGNAL TRANSDUCTION BY NEUTROPHIL IMMUNOGLOBULIN-G FC-RECEPTORS - DISSOCIATION OF INTRACYTOPLASMIC CALCIUM-CONCENTRATION RISE FROM INOSITOL 1,4,5-TRISPHOSPHATE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATED HUMAN-NEUTROPHILS; CYTOSOLIC FREE CALCIUM; RESPIRATORY BURST; PHOSPHOLIPASE-A2 ACTIVITY; TRISPHOSPHATE RECEPTOR; GAMMA RECEPTORS; TUMOR PROMOTER; SMOOTH-MUSCLE; CA-2+; PHAGOCYTOSIS	The signal transduction mechanisms involved in the regulation of phagocytosis are largely unknown. We have recently shown that in neutrophils, when IgG-mediated phagocytosis is stimulated by formyl-methionyl-leucyl-phenyl-alanine (fMLP), the enhanced ingestion is dependent on the increase in [Ca2+]i which results from ligation of Fc receptors by the IgG-coated target (Rosales, C., and Brown, E. (1991) J. Immunol. 146, 3937-3944). Now, we have studied the mechanism by which this rise in [Ca2+]i occurs. Aggregated IgG, the monoclonal antibody 3G8 (which recognizes Fc receptor type III), and insoluble immune complexes caused an increase in [Ca2+]i. The rise in [Ca2+]i induced by Fc receptor ligation was resistant to pertussis toxin. In contrast, fMLP induced a rise in [Ca2+]i which was inhibited by pertussis toxin. fMLP-induced [Ca2+]i was accompanied by an accumulation of inositol 1,4,5-trisphosphate (IP3) which peaked by 15 s, and which was also abolished by pertussis toxin. IP3 accumulation after aggregated IgG, 3G8, or insoluble immune complexes was much less than after fMLP. Unlike [Ca2+]i rise induced by Fc receptor ligation, this small increase in IP3 was inhibited by pertussis toxin. These data demonstrated that the [Ca2+]i increase induced by Fc receptor ligation is not mediated by IP3. Immediate pretreatment of human polymorphonuclear neutrophils with optimal doses of fMLP also reduced subsequent increase in [Ca2+]i rise from thapsigargin, a sesquiterpene lactone tumor promoter that releases intracellular Ca2+ from IP3-sensitive stores without IP3 turnover. Similarly, to its effects on thapsigargin, fMLP inhibited the [Ca2+]i rise upon subsequent immune complex binding. Pretreatment of cells with immune complexes also prevented subsequent [Ca2+]i rise from thapsigargin and fMLP. These data demonstrate that IgG Fc receptor ligation and fMLP activation of human polymorphonuclear neutrophils use distinct signal transduction mechanisms to release Ca2+ from the same thapsigargin-sensitive intracellular pool. In contrast to fMLP, signal transduction for increased [Ca2+]i after Fc receptor stimulation does not involve a pertussis toxin-sensitive G protein, and is independent of IP3.	WASHINGTON UNIV,SCH MED,DIV INFECT DIS,ST LOUIS,MO 63110	Washington University (WUSTL)			ROSALES, CARLOS/AAA-5206-2019	ROSALES, CARLOS/0000-0003-2568-5723	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038330] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 38330] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON CL, 1990, J EXP MED, V171, P1333, DOI 10.1084/jem.171.4.1333; ANDERSON CL, 1986, IMMUNOL TODAY, V7, P264, DOI 10.1016/0167-5699(86)90007-1; BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.bi.56.070187.001111; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; CHADWICK CC, 1990, P NATL ACAD SCI USA, V87, P2132, DOI 10.1073/pnas.87.6.2132; CHOW SC, 1990, J BIOL CHEM, V265, P902; FERRIS CD, 1989, NATURE, V342, P87, DOI 10.1038/342087a0; FURUICHI T, 1989, NATURE, V342, P32, DOI 10.1038/342032a0; GHOSH TK, 1989, NATURE, V340, P236, DOI 10.1038/340236a0; GRESHAM HD, 1987, J IMMUNOL, V139, P4159; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HIBBS ML, 1988, P NATL ACAD SCI USA, V85, P2240, DOI 10.1073/pnas.85.7.2240; HUIZINGA TWJ, 1989, J IMMUNOL, V142, P2365; HUIZINGA TWJ, 1990, J IMMUNOL, V144, P1432; HUIZINGA TWJ, 1988, NATURE, V333, P667, DOI 10.1038/333667a0; HURN BA, 1980, METHOD ENZYMOL, V74, P104; IRVINE RF, 1986, BIOCHEM J, V240, P917, DOI 10.1042/bj2400917; KADIRI C, 1989, J CELL BIOCHEM, V40, P157, DOI 10.1002/jcb.240400204; KIMBERLY RP, 1990, J EXP MED, V171, P1239, DOI 10.1084/jem.171.4.1239; KINET JP, 1989, CELL, V57, P351, DOI 10.1016/0092-8674(89)90910-0; KORCHAK HM, 1988, J BIOL CHEM, V263, P11090; LANIER LL, 1988, J IMMUNOL, V141, P3478; LEW DP, 1985, NATURE, V315, P509, DOI 10.1038/315509a0; MAEDA N, 1990, EMBO J, V9, P61, DOI 10.1002/j.1460-2075.1990.tb08080.x; MARKS AR, 1990, J BIOL CHEM, V265, P20719; MARKS PW, 1990, J CELL BIOL, V110, P43, DOI 10.1083/jcb.110.1.43; MELDOLESI J, 1990, BIOCHIM BIOPHYS ACTA, V1055, P130, DOI 10.1016/0167-4889(90)90113-R; MELLMAN I, 1988, CURR OPIN IMMUNOL, V1, P16, DOI 10.1016/0952-7915(88)90046-5; MERRITT JE, 1989, J BIOL CHEM, V264, P1522; NITTA T, 1984, J LEUKOCYTE BIOL, V36, P493, DOI 10.1002/jlb.36.4.493; PAWLOWSKI NA, 1983, J EXP MED, V158, P393, DOI 10.1084/jem.158.2.393; PEREZ HD, 1987, BIOCHEM BIOPH RES CO, V145, P976, DOI 10.1016/0006-291X(87)91061-8; PRENTKI M, 1984, J BIOL CHEM, V259, P3777; PUTNEY JW, 1989, FASEB J, V3, P1899, DOI 10.1096/fasebj.3.8.2542110; ROSALES C, 1991, J IMMUNOL, V146, P3937; ROSSI F, 1985, FEBS LETT, V181, P253, DOI 10.1016/0014-5793(85)80270-2; SMITH CD, 1985, J BIOL CHEM, V260, P5875; SNYDERMAN R, 1988, INFLAMMATION BASIC P, P309; STUART SG, 1987, J EXP MED, V166, P1668, DOI 10.1084/jem.166.6.1668; SUPATTAPONE S, 1988, J BIOL CHEM, V263, P1530; SUZUKI T, 1982, P NATL ACAD SCI-BIOL, V79, P591, DOI 10.1073/pnas.79.2.591; TAKEMURA H, 1989, J BIOL CHEM, V264, P12266; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; UNKELESS JC, 1989, CURR OPIN IMMUNOL, V2, P63, DOI 10.1016/0952-7915(89)90098-8; UNKELESS JC, 1988, ANNU REV IMMUNOL, V6, P251, DOI 10.1146/annurev.iy.06.040188.001343; UNKELESS JC, 1988, INFLAMMATION BASIC P, P343; YOUNG JDE, 1984, P NATL ACAD SCI-BIOL, V81, P5430, DOI 10.1073/pnas.81.17.5430	47	89	90	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1992	267	8					5265	5271						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HH747	1531982				2022-12-25	WOS:A1992HH74700043
J	PEREZ, C; MICHELET, B; FERRANT, V; BOGAERTS, P; BOUTRY, M				PEREZ, C; MICHELET, B; FERRANT, V; BOGAERTS, P; BOUTRY, M			DIFFERENTIAL EXPRESSION WITHIN A 3-GENE SUBFAMILY ENCODING A PLASMA-MEMBRANE H+-ATPASE IN NICOTIANA-PLUMBAGINIFOLIA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARABIDOPSIS-THALIANA; MOLECULAR-CLONING; GLUTAMINE-SYNTHETASE; HIGHER-PLANTS; 3RD ISOFORM; SEQUENCE; GENE; TRANSLATION; PROTEIN; PUMP	Genomic and cDNA clones for the three members of a gene subfamily (pma) encoding a plasma membrane H+-translocating ATPase in Nicotiana plumbaginifolia were isolated and sequenced. They are between 95 and 96% identical at the deduced amino acid sequence level. Sequence comparisons with the corresponding tomato genes (Ewing, N. N., Wimmers, L. E., Meyer, D. J., Chetelat, R. T., and Bennett, A. B. (1990) Plant Physiol. 94, 1874-1881) indicate that divergence among the three N. plumbaginifolia pma genes occurred before the development of the Solanaceae family. Here, determination of pma1 transcription initiation sites reveals several 5' boundaries located 266 to 120 nucleotides upstream from the plasma membrane H+-ATPase translation initiation codon. The 5'-untranlated region contains a small open reading frame, 9 residues long. pma3 has a single, 264-nucleotide long 5' leader containing a 5-residue open reading frame. The latter is completely conserved in a corresponding tomato gene. These features suggest the possibility of translational regulation of plant pma genes. S1 nuclease protection assays on total cellular RNA isolated from different organs reveals that all three genes are expressed in leaf, stem, flower, and root tissues, albeit at different levels according to the organ and gene. The different genes for the plant H+-translocating ATPase are thus subject to differential regulation of transcription, possibly related to specific aspects of enzyme function.	CATHOLIC UNIV LOUVAIN,UNITE BIOCHIM PHYSIOL,PL CROIX SUD 2-20,B-1348 LOUVAIN,BELGIUM	Universite Catholique Louvain			Decroocq, Veronique/M-1059-2016	Decroocq, Veronique/0000-0001-6745-6350; Boutry, Marc/0000-0002-2315-6900				BARNES WM, 1983, METHOD ENZYMOL, V101, P98; BIGGIN MD, 1983, P NATL ACAD SCI-BIOL, V80, P3963, DOI 10.1073/pnas.80.13.3963; BOUTRY M, 1989, BIOCHEM BIOPH RES CO, V162, P567, DOI 10.1016/0006-291X(89)92348-6; BOUTRY M, 1985, EMBO J, V4, P2159, DOI 10.1002/j.1460-2075.1985.tb03910.x; BOWMAN BJ, 1986, J MEMBRANE BIOL, V94, P83, DOI 10.1007/BF01871190; BRISKIN DP, 1982, P NATL ACAD SCI-BIOL, V79, P6922, DOI 10.1073/pnas.79.22.6922; BURK SE, 1989, J BIOL CHEM, V264, P18561; CLEMENT JD, 1986, PLANT SCI, V5, P43; EWING NN, 1990, PLANT PHYSIOL, V94, P1874, DOI 10.1104/pp.94.4.1874; GREEB J, 1989, J BIOL CHEM, V264, P18569; HARPER JF, 1990, J BIOL CHEM, V265, P13601; HARPER JF, 1989, P NATL ACAD SCI USA, V86, P1234, DOI 10.1073/pnas.86.4.1234; HARTINGS H, 1989, EMBO J, V8, P2795, DOI 10.1002/j.1460-2075.1989.tb08425.x; JACKSON IJ, 1991, NUCLEIC ACIDS RES, V19, P3795; JAMES PH, 1989, BIOCHEMISTRY-US, V28, P4253, DOI 10.1021/bi00436a020; JOSHI CP, 1987, NUCLEIC ACIDS RES, V15, P6643, DOI 10.1093/nar/15.16.6643; KATINAKIS P, 1985, P NATL ACAD SCI USA, V82, P4157, DOI 10.1073/pnas.82.12.4157; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; Maniatis T., 1982, MOL CLONING; MARRE E, 1985, J BIOENERG BIOMEMBR, V17, P1, DOI 10.1007/BF00744985; MICHELET B, 1989, PLANT MEMBRANE TRANS, P455; MURASHIGE T, 1962, PHYSIOL PLANTARUM, V15, P473, DOI 10.1111/j.1399-3054.1962.tb08052.x; ORLOWSKI J, 1988, J BIOL CHEM, V263, P17817; PALMGREN MG, 1990, J BIOL CHEM, V265, P13423; PARDO JM, 1989, J BIOL CHEM, V264, P8557; PEDERSEN PL, 1987, TRENDS BIOCHEM SCI, V12, P146, DOI 10.1016/0968-0004(87)90071-5; PORTILLO F, 1989, FEBS LETT, V247, P381, DOI 10.1016/0014-5793(89)81375-4; SCHALLER GE, 1988, PLANT PHYSIOL, V86, P512, DOI 10.1104/pp.86.2.512; SCHMIDT RJ, 1990, P NATL ACAD SCI USA, V87, P46, DOI 10.1073/pnas.87.1.46; SERRANO R, 1989, ANNU REV PLANT PHYS, V40, P61; SINGH K, 1990, PLANT CELL, V2, P891, DOI 10.1105/tpc.2.9.891; SNUSTAD DP, 1988, GENETICS, V120, P1111; SUSSMAN MR, 1989, PLANT CELL, V1, P953, DOI 10.1105/tpc.1.10.953; TINGEY SV, 1987, PLANT PHYSIOL, V84, P366, DOI 10.1104/pp.84.2.366	35	72	77	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 15	1992	267	2					1204	1211						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY960	1530935				2022-12-25	WOS:A1992GY96000082
J	TAKAMI, N; ODA, K; IKEHARA, Y				TAKAMI, N; ODA, K; IKEHARA, Y			ABERRANT PROCESSING OF ALKALINE-PHOSPHATASE PRECURSOR CAUSED BY BLOCKING THE SYNTHESIS OF GLYCOSYLPHOSPHATIDYLINOSITOL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VARIANT SURFACE GLYCOPROTEINS; PHOSPHATIDYLINOSITOL MEMBRANE ANCHOR; CLEAVAGE ATTACHMENT SITE; PHOSPHOLIPASE-C; HUMAN CHORIOCARCINOMA; THY-1 GLYCOPROTEIN; CARBOXYL TERMINUS; LYMPHOMA-CELLS; YEAST GENE; BIOSYNTHESIS	Alkaline phosphatase is anchored to the membrane via glycosylphosphatidylinositol (GPI). Mannose residues of the GPI glycan are suggested to be derived from dolichol-P-mannose. In the present study we examined the effect of 2-fluoro-2-deoxy-D-glucose (F-Glc), an inhibitor of dolichol-P-mannose synthesis, on the biosynthesis and processing of alkaline phosphatase in JEG-3 cells. In control cells, a proform precursor (64.5 kDa) with a hydrophobic peptide domain at the COOH terminus was immediately processed into an intermediate form (63 kDa) by proteolytic removal of the COOH-terminal extension and replacement with the GPI anchor, and then to a mature form (66 kDa) by terminal glycosylation of its N-linked oligosaccharides. In contrast, when cells were treated with F-Glc (1 mM), the protein was synthesized as a proform of 61 kDa. The reduction in its molecular mass was mostly due to the inhibition in maturation of N-linked oligosaccharides by F-Glc. The 61-kDa proform identified by antibodies to the COOH-terminal peptide was detectable even at 3 h after the synthesis, and was gradually processed to doublet forms of 58-59 kDa which were finally secreted into the medium. None of these forms were labeled with [H-3]ethanolamine and [H-3] stearic acid, components of the GPI anchor, and expressed on the cell surface as a membrane-bound form. Taken together, these results suggest that the inhibition of the GPI synthesis causes a prolonged accumulation of the proform, which is then gradually processed into secretory forms by proteolytic removal of the COOH-terminal hydrophobic peptide.	FUKUOKA UNIV,SCH MED,DEPT BIOCHEM,JONAN KU,FUKUOKA 81401,JAPAN; FUKUOKA UNIV,SCH MED,RADIOISOTOPE LAB,FUKUOKA 81401,JAPAN	Fukuoka University; Fukuoka University								BAILEY CA, 1988, ANAL BIOCHEM, V170, P532, DOI 10.1016/0003-2697(88)90669-0; BAILEY CA, 1989, P NATL ACAD SCI USA, V86, P22, DOI 10.1073/pnas.86.1.22; BANGS JD, 1986, J CELL BIOL, V103, P253; BERGER J, 1988, J BIOL CHEM, V263, P10016; CARAS IW, 1987, SCIENCE, V238, P1280, DOI 10.1126/science.2446389; CHAPMAN A, 1980, J BIOL CHEM, V255, P4441; CONZELMANN A, 1986, EMBO J, V5, P3291, DOI 10.1002/j.1460-2075.1986.tb04642.x; CONZELMANN A, 1987, BIOCHEM J, V246, P605, DOI 10.1042/bj2460605; CROSS GAM, 1990, ANNU REV CELL BIOL, V6, P1, DOI 10.1146/annurev.cb.06.110190.000245; DATEMA R, 1980, EUR J BIOCHEM, V110, P355, DOI 10.1111/j.1432-1033.1980.tb04875.x; DEGASPERI R, 1990, SCIENCE, V250, P988, DOI 10.1126/science.1978413; DOERING TL, 1989, J BIOL CHEM, V264, P11168; DOERING TL, 1990, J BIOL CHEM, V265, P611; FATEMI SH, 1987, J BIOL CHEM, V262, P4728; FATEMI SH, 1986, CELL, V46, P653, DOI 10.1016/0092-8674(86)90340-5; FERGUSON MAJ, 1986, J BIOL CHEM, V261, P356; FERGUSON MAJ, 1988, SCIENCE, V239, P753, DOI 10.1126/science.3340856; FERGUSON MAJ, 1988, ANNU REV BIOCHEM, V57, P285; GREEN N, 1982, CELL, V28, P477, DOI 10.1016/0092-8674(82)90202-1; HOMANS SW, 1988, NATURE, V333, P269, DOI 10.1038/333269a0; IKEZAWA H, 1976, BIOCHIM BIOPHYS ACTA, V450, P154; ITO F, 1984, J BIOL CHEM, V259, P2526; KODUKULA K, 1991, J BIOL CHEM, V266, P4464; KOHLER PO, 1971, J CLIN ENDOCR METAB, V32, P683, DOI 10.1210/jcem-32-5-683; KOMINAMI T, 1985, BIOCHEM J, V227, P183, DOI 10.1042/bj2270183; KRAKOW JL, 1986, J BIOL CHEM, V261, P2147; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LODISH HF, 1988, J BIOL CHEM, V263, P2107; LOW MG, 1977, BIOCHEM J, V167, P281, DOI 10.1042/bj1670281; LOW MG, 1987, BIOCHEM J, V244, P1; MASTERSON WJ, 1989, CELL, V56, P793, DOI 10.1016/0092-8674(89)90684-3; MAYOR S, 1990, J BIOL CHEM, V265, P6164; MENON AK, 1988, J BIOL CHEM, V263, P1970; MENON AK, 1990, J BIOL CHEM, V265, P9033; MENON AK, 1990, EMBO J, V9, P4249, DOI 10.1002/j.1460-2075.1990.tb07873.x; MICANOVIC R, 1988, P NATL ACAD SCI USA, V85, P1398, DOI 10.1073/pnas.85.5.1398; MICANOVIC R, 1990, P NATL ACAD SCI USA, V87, P157, DOI 10.1073/pnas.87.1.157; MICANOVIC R, 1990, P NATL ACAD SCI USA, V87, P7939, DOI 10.1073/pnas.87.20.7939; MISUMI Y, 1986, J BIOL CHEM, V261, P1398; MORGAN P, 1991, J BIOL CHEM, V266, P1250; OGATA S, 1988, J BIOL CHEM, V263, P10489; ORLEAN P, 1988, J BIOL CHEM, V263, P17499; PLUMMER TH, 1984, J BIOL CHEM, V259, P700; ROBERTS WL, 1988, J BIOL CHEM, V263, P18766; SCHWARZ RT, 1989, BIOCHEM SOC T, V17, P746, DOI 10.1042/bst0170746; TAKAMI N, 1990, EUR J BIOCHEM, V194, P805, DOI 10.1111/j.1432-1033.1990.tb19473.x; TAKAMI N, 1988, J BIOL CHEM, V263, P3016; TATE SS, 1974, J BIOL CHEM, V249, P7593; TROWBRIDGE IS, 1979, CELL, V17, P503, DOI 10.1016/0092-8674(79)90258-7; WATANABE S, 1989, J BIOL CHEM, V264, P12611	50	32	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 15	1992	267	2					1042	1047						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY960	1530933				2022-12-25	WOS:A1992GY96000059
J	LIN, XH; WANG, ZY; GU, LJ; DEUEL, TF				LIN, XH; WANG, ZY; GU, LJ; DEUEL, TF			FUNCTIONAL-ANALYSIS OF THE HUMAN PLATELET-DERIVED GROWTH-FACTOR A-CHAIN PROMOTER REGION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERUM RESPONSE ELEMENT; MEDIATES TRANSCRIPTIONAL RESPONSE; SYNERGISTIC ACTIVATION; REGULATORY ELEMENTS; GENE-EXPRESSION; BINDING-FACTOR; CELL-GROWTH; FACTOR-BETA; FACTOR SP1; IDENTIFICATION	The platelet-derived growth factor (PDGF) A-chain gene is a developmentally regulated gene that is expressed in high levels in a limited number of normal and transformed cell lines and in cells stimulated by cytokines, including PDGF itself. We have now analyzed potential regulatory elements in 3.6 kilobase pairs (kb) of the 5'-flanking sequences of the human PDGF A-chain gene using reporter gene constructs and transient transfection analyses. The region between base pairs (bp) -618 and +392 (relative to the transcription initiation site) is sufficient for optimal promoter activity. A highly G + C region containing three contiguous Spl binding sites between bp -150 and -33 contributes over 80% of promotor activity. DNase I footprinting analyses indicates that Sp1 binds to and protects over 57 bp of this G + C region. A functional serum response element is located within bp -477 and -468 and positively regulates induction of PDGF A by PDGF. A negative regulatory (silencer) element is located from -1.9 to -0.9 kb. The results suggest that the major constitutive expression of the PDGF A-chain gene requires a highly G + C-rich region containing three Sp1 binding sites and that induction of the PDGF A-chain gene by PDGF is mediated by a SRE located at bp -477 to -468.	WASHINGTON UNIV, DEPT MED, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, DEPT BIOCHEM MOLEC BIOPHYS, ST LOUIS, MO 63110 USA; JEWISH HOSP ST LOUIS, ST LOUIS, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL); Barnes-Jewish Hospital					NATIONAL CANCER INSTITUTE [P01CA049712] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL014147, R37HL031102, R01HL031102] Funding Source: NIH RePORTER; NCI NIH HHS [CA49712] Funding Source: Medline; NHLBI NIH HHS [HL14147, HL31102] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSON GM, 1991, MOL CELL BIOL, V11, P1935, DOI 10.1128/MCB.11.4.1935; ARAKI E, 1991, J BIOL CHEM, V266, P3944; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; CAREY M, 1990, NATURE, V345, P361, DOI 10.1038/345361a0; CHRISTY B, 1989, MOL CELL BIOL, V9, P4889, DOI 10.1128/MCB.9.11.4889; COUREY AJ, 1989, CELL, V59, P827, DOI 10.1016/0092-8674(89)90606-5; DEUEL TF, 1987, ANNU REV CELL BIOL, V3, P443, DOI 10.1146/annurev.cb.03.110187.002303; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; GAY CG, 1990, J BIOL CHEM, V265, P3284; GIDONI D, 1985, SCIENCE, V230, P511, DOI 10.1126/science.2996137; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRAHAM R, 1991, SCIENCE, V251, P189, DOI 10.1126/science.1898992; HELDIN CH, 1990, CELL REGUL, V1, P555, DOI 10.1091/mbc.1.8.555; HERBOMEL P, 1984, CELL, V39, P653, DOI 10.1016/0092-8674(84)90472-0; HERSCHMAN HR, 1989, TRENDS BIOCHEM SCI, V14, P455, DOI 10.1016/0968-0004(89)90105-9; KAGEYAMA R, 1989, CELL, V59, P815, DOI 10.1016/0092-8674(89)90605-3; KAWAMOTO T, 1988, MOL CELL BIOL, V8, P267, DOI 10.1128/MCB.8.1.267; KOZMIK Z, 1990, NUCLEIC ACIDS RES, V18, P2198, DOI 10.1093/nar/18.8.2198; LI R, 1991, CELL, V65, P493, DOI 10.1016/0092-8674(91)90467-D; LIN YS, 1990, NATURE, V345, P359, DOI 10.1038/345359a0; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MAJACK RA, 1990, J CELL BIOL, V111, P239, DOI 10.1083/jcb.111.1.239; MAKELA TP, 1987, MOL CELL BIOL, V7, P3656; NISTER M, 1988, CANCER RES, V48, P3910; NORMAN C, 1988, CELL, V55, P989, DOI 10.1016/0092-8674(88)90244-9; ORITA S, 1989, GENE, V75, P13; PAULSSON Y, 1987, NATURE, V328, P715, DOI 10.1038/328715a0; RAINES EW, 1989, SCIENCE, V243, P393, DOI 10.1126/science.2783498; RAUSCHER FJ, 1990, SCIENCE, V250, P1259, DOI 10.1126/science.2244209; RORSMAN F, 1988, MOL CELL BIOL, V8, P571, DOI 10.1128/MCB.8.2.571; ROSENTHAL N, 1987, METHOD ENZYMOL, V152, P704; ROSS R, 1986, CELL, V46, P155, DOI 10.1016/0092-8674(86)90733-6; SHAW PE, 1989, CELL, V56, P563, DOI 10.1016/0092-8674(89)90579-5; TAKIMOTO Y, 1991, P NATL ACAD SCI USA, V88, P1686, DOI 10.1073/pnas.88.5.1686; TREISMAN R, 1986, CELL, V46, P567, DOI 10.1016/0092-8674(86)90882-2; YEH HJ, 1991, CELL, V64, P209, DOI 10.1016/0092-8674(91)90222-K	37	43	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	1992	267	35					25614	25619						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KB603	1460057				2022-12-25	WOS:A1992KB60300105
J	SATOH, T; MINAMI, Y; KONO, T; YAMADA, K; KAWAHARA, A; TANIGUCHI, T; KAZIRO, Y				SATOH, T; MINAMI, Y; KONO, T; YAMADA, K; KAWAHARA, A; TANIGUCHI, T; KAZIRO, Y			INTERLEUKIN 2-INDUCED ACTIVATION OF RAS REQUIRES 2 DOMAINS OF INTERLEUKIN-2 RECEPTOR-BETA SUBUNIT, THE ESSENTIAL REGION FOR GROWTH-STIMULATION AND LCK-BINDING DOMAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-CELL ACTIVATION; C-FOS GENE; PROTO-ONCOGENE; TYROSINE PHOSPHORYLATION; PHOSPHATIDYLINOSITOL 3-KINASE; TRANSCRIPTIONAL ACTIVATION; SIGNAL-TRANSDUCTION; IL-2 RECEPTOR; MYC ONCOGENE; CHAIN GENE	Interleukin 2 (IL-2) can stimulate the proliferation of various kinds of T-cell lines. The receptor for IL-2 is composed of at least two subunits (alpha and beta), of which beta subunit plays the major role in transducing growth signals into the cells. A nonreceptor-type tyrosine kinase, Lck, is associated with IL-2 receptor beta subunit, and the binding of IL-2 to its receptor induces the activation of Lck. On the other hand, it has been shown that stimulation of T-cells with IL-2 causes rapid activation of Ras protein. In this paper, we describe that both of the two regions in IL-2 receptor beta subunit, the indispensable region for the induction of cell growth (serine-rich region) and the binding region of Lck protein (acidic region), are required for the activation of Ras. These two regions are also required for tyrosine phosphorylation of an 85-kDa cellular protein (p85) and the accumulation of fos and jun mRNAs. This observation suggests also that the activation of a receptor-associated tyrosine kinase in response to IL-2-stimulation is primarily responsible for subsequent activation of the pathway through Ras to Fos and Jun.	DNAX RES INST MOLEC & CELLULAR BIOL INC,901 CALIF AVE,PALO ALTO,CA 94304; OSAKA UNIV,INST MOLEC & CELLULAR BIOL,SUITA,OSAKA 565,JAPAN	Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.; Osaka University			Satoh, Takaya/K-2628-2014					AUGUSTINE JA, 1991, MOL CELL BIOL, V11, P4431, DOI 10.1128/MCB.11.9.4431; BURGERING BMT, 1991, EMBO J, V10, P1103, DOI 10.1002/j.1460-2075.1991.tb08050.x; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; DURONIO V, 1992, P NATL ACAD SCI USA, V89, P1587, DOI 10.1073/pnas.89.5.1587; GIBBS JB, 1990, J BIOL CHEM, V265, P20437; GRAVES JD, 1992, J IMMUNOL, V148, P2417; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HARADA H, 1990, CELL, V63, P303, DOI 10.1016/0092-8674(90)90163-9; HATAKEYAMA M, 1989, CELL, V59, P837, DOI 10.1016/0092-8674(89)90607-7; HATAKEYAMA M, 1991, SCIENCE, V252, P1523, DOI 10.1126/science.2047859; HATAKEYAMA M, 1992, P NATL ACAD SCI USA, V89, P2022, DOI 10.1073/pnas.89.6.2022; HATAKEYAMA M, 1989, SCIENCE, V244, P551, DOI 10.1126/science.2785715; HSI ED, 1989, J BIOL CHEM, V264, P10836; IMLER JL, 1988, NATURE, V332, P275, DOI 10.1038/332275a0; IZQUIERDO M, 1992, EUR J IMMUNOL, V22, P817, DOI 10.1002/eji.1830220328; KAZIRO Y, 1991, ANNU REV BIOCHEM, V60, P349, DOI 10.1146/annurev.bi.60.070191.002025; KRUIJER W, 1985, P NATL ACAD SCI USA, V82, P7330, DOI 10.1073/pnas.82.21.7330; KRUIJER W, 1984, NATURE, V312, P711, DOI 10.1038/312711a0; LI BQ, 1992, SCIENCE, V256, P1456, DOI 10.1126/science.1604323; MERIDA I, 1991, J IMMUNOL, V147, P2202; MILLS GB, 1990, J BIOL CHEM, V265, P3561; MULDER KM, 1992, J BIOL CHEM, V267, P5029; MULLER R, 1984, NATURE, V312, P716, DOI 10.1038/312716a0; MUROYA K, 1992, ONCOGENE, V7, P277; NAKAFUKU M, 1992, J BIOL CHEM, V267, P19448; QUANTIN B, 1988, NATURE, V334, P538, DOI 10.1038/334538a0; Qui MS, 1991, NEURON, V7, P937, DOI [DOI 10.1016/0896-6273(91)90339-2, 10.1016/0896-6273(91)90339-2]; RAUSCHER FJ, 1988, GENE DEV, V2, P1687, DOI 10.1101/gad.2.12b.1687; REMILLARD B, 1991, J BIOL CHEM, V266, P14167; RYSECK RP, 1988, NATURE, V334, P535, DOI 10.1038/334535a0; SATOH T, 1992, J BIOL CHEM, V267, P2537; Satoh T, 1992, Semin Cancer Biol, V3, P169; SATOH T, 1990, P NATL ACAD SCI USA, V87, P5993, DOI 10.1073/pnas.87.15.5993; SATOH T, 1991, P NATL ACAD SCI USA, V88, P3314, DOI 10.1073/pnas.88.8.3314; SATOH T, 1990, P NATL ACAD SCI USA, V87, P7926, DOI 10.1073/pnas.87.20.7926; SCHONTHAL A, 1988, CELL, V54, P325, DOI 10.1016/0092-8674(88)90195-X; SHIBUYA H, 1990, NUCLEIC ACIDS RES, V18, P3697, DOI 10.1093/nar/18.13.3697; SHIBUYA H, 1992, CELL, V70, P57, DOI 10.1016/0092-8674(92)90533-I; STACEY DW, 1987, MOL CELL BIOL, V7, P523, DOI 10.1128/MCB.7.1.523; STANTON LW, 1983, NATURE, V303, P401, DOI 10.1038/303401a0; TORIGOE T, 1992, P NATL ACAD SCI USA, V89, P2674, DOI 10.1073/pnas.89.7.2674; TORTI M, 1992, J BIOL CHEM, V267, P8293; TURNER B, 1991, P NATL ACAD SCI USA, V88, P1227, DOI 10.1073/pnas.88.4.1227; WANG HM, 1989, EMBO J, V8, P3677, DOI 10.1002/j.1460-2075.1989.tb08542.x; WANG JYJ, 1985, MOL CELL BIOL, V5, P3640, DOI 10.1128/MCB.5.12.3640; WU BY, 1989, J BIOL CHEM, V264, P9000; YAMAGUCHIIWAI Y, 1990, P NATL ACAD SCI USA, V87, P8670, DOI 10.1073/pnas.87.21.8670	48	90	91	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1992	267	35					25423	25427						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KB603	1460037				2022-12-25	WOS:A1992KB60300078
J	LEE, FJS; MOSS, J; VAUGHAN, M				LEE, FJS; MOSS, J; VAUGHAN, M			HUMAN AND GIARDIA ADP-RIBOSYLATION FACTORS (ARFS) COMPLEMENT ARF FUNCTION IN SACCHAROMYCES-CEREVISIAE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-BINDING-PROTEINS; CHOLERA-TOXIN; ADENYLATE-CYCLASE; GENE DISRUPTION; MESSENGER-RNA; YEAST; GTP; EXPRESSION; ACTIVATORS; SEQUENCES	ADP-ribosylation factors (ARFs) are approximately 20-kDa guanine nucleotide-binding proteins that stimulate the ADP-ribosyltransferase activity of cholera toxin in vitro. ARFs are highly conserved, ubiquitously expressed in eukaryotic cells and appear to be involved in vesicular protein transport. The two yeast ARFs are >60% identical to mammalian ARFs and are essential for cell viability (Stearns, T., Kahn, R. A., Botstein, D., and Hoyt, M. A. (1990) Mol. Cell. Biol. 10, 6690-6699). Although the two yeast ARF proteins are 96% identical in amino acid sequence, the yeast ARF1 gene is constitutively expressed, whereas the ARF2 gene is repressed by glucose. Human ARF5 and ARF6 and a Giardia ARF differ substantially in size and amino acid identity from other mammalian and eukaryotic ARFs but will, as befits their designation, activate cholera toxin. Expression of human ARF5, ARF6, or Giardia ARF cDNA rescued the lethal yeast ARF double mutant (arf1, arf2). Strains rescued by human ARF5, ARF6, or Giardia ARF grew much more slowly than wild-type yeast or strains rescued with yeast ARF1. We infer from the impaired growth of these rescued strains that the homologous ARFs may have specific targeting information that does not interact effectively or efficiently with the yeast protein membrane trafficking system.			LEE, FJS (corresponding author), NHLBI,CELLULAR METAB LAB,RM 5N-307,BLDG 10,BETHESDA,MD 20892, USA.			LEE, FANG-JEN/0000-0002-2167-2426				ALANI E, 1987, GENETICS, V116, P541, DOI 10.1534/genetics.112.541.test; BOBAK DA, 1989, P NATL ACAD SCI USA, V86, P6101, DOI 10.1073/pnas.86.16.6101; BOBAK DA, 1990, ADP RIBOSYLATING TOX, P439; BOEKE JD, 1984, MOL GEN GENET, V197, P345, DOI 10.1007/BF00330984; CHAVRIER P, 1990, CELL, V62, P317, DOI 10.1016/0092-8674(90)90369-P; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KAHN RA, 1984, J BIOL CHEM, V259, P6228; KAHN RA, 1988, J BIOL CHEM, V263, P8282; KAHN RA, 1991, J BIOL CHEM, V266, P2602; LEE FJS, 1989, J BACTERIOL, V171, P5795, DOI 10.1128/jb.171.11.5795-5802.1989; LEE FJS, 1992, BIOTECHNIQUES, V12, P677; LEE FJS, IN PRESS BIOTECHNIQU; Maniatis T., 1982, MOL CLONING; MONACO L, 1990, P NATL ACAD SCI USA, V87, P2206, DOI 10.1073/pnas.87.6.2206; MURTAGH JJ, 1992, J BIOL CHEM, V267, P9654; NEFF NF, 1983, CELL, V33, P211, DOI 10.1016/0092-8674(83)90350-1; PRICE SR, 1988, P NATL ACAD SCI USA, V85, P5488, DOI 10.1073/pnas.85.15.5488; PRICE SR, 1992, J BIOL CHEM, V267, P17766; REINER DS, 1990, EUR J CELL BIOL, V53, P142; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SERAFINI T, 1991, CELL, V67, P239, DOI 10.1016/0092-8674(91)90176-Y; SEWELL JL, 1988, P NATL ACAD SCI USA, V85, P4620, DOI 10.1073/pnas.85.13.4620; Sherman F., 1986, METHODS YEAST GENETI; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STEARNS T, 1990, MOL CELL BIOL, V10, P6690, DOI 10.1128/MCB.10.12.6690; STEARNS T, 1990, P NATL ACAD SCI USA, V87, P1238, DOI 10.1073/pnas.87.3.1238; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; TRECO DA, 1990, CURRENT PROTOCOL MOL; TSAI SC, 1988, J BIOL CHEM, V263, P1768; TSAI SC, 1991, J BIOL CHEM, V266, P8213; TSUCHIYA M, 1989, BIOCHEMISTRY-US, V28, P9668, DOI 10.1021/bi00451a019; TSUCHIYA M, 1991, J BIOL CHEM, V266, P2772	33	35	36	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1992	267	34					24441	24445						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KA263	1447192				2022-12-25	WOS:A1992KA26300048
J	CASES, S; DAUTRY, F				CASES, S; DAUTRY, F			INACTIVATION OF THE MURINE N-RAS GENE BY GENE TARGETING	ONCOGENE			English	Note							EMBRYONIC STEM-CELLS; HOMOLOGOUS RECOMBINATION; SIGNAL TRANSDUCTION; MUTATION; MICE; ORGANIZATION; EXPRESSION; PROTEIN; GROWTH; LOCUS	The mammalian ras genes have been implicated in the genesis of a wide variety of tumors. Although it is likely that they play an essential role in signal transduction, their specific function is still unknown. To initiate a genetic analysis of the ras genes in mammals we inactivated the N-ras gene in murine embryonic stem cells by gene targeting. The frequency of integration at the N-ras locus of our targeting vector being low (of the order of 1/5000 transfectants), we used a positive/negative selection followed by an analysis of individual colonies in order to minimize the in vitro manipulation of the embryonic stem cells. Using this approach, we isolated two clones of ES cells with one inactivated N-ras allele. These cells have no distinctive phenotype either in vitro or in vivo in chimeric mice.	INST GUSTAVE ROUSSY,ONCOL MOLEC LAB,CNRS,UA 1158,F-94805 VILLEJUIF,FRANCE	Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy								BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BONFINI L, 1992, SCIENCE, V255, P603, DOI 10.1126/science.1736363; BOS JL, 1989, CANCER RES, V49, P4682; CAPECCHI MR, 1989, SCIENCE, V244, P1288, DOI 10.1126/science.2660260; CHANG HY, 1987, ONCOGENE RES, V1, P129; CHARDIN P, 1991, CANCER CELL-MON REV, V3, P117; CHAVRIER P, 1990, CELL, V62, P317, DOI 10.1016/0092-8674(90)90369-P; CHESA PG, 1987, P NATL ACAD SCI USA, V84, P3234, DOI 10.1073/pnas.84.10.3234; DECHIARA TM, 1990, NATURE, V345, P78, DOI 10.1038/345078a0; EPSTEIN DJ, 1991, CELL, V67, P767, DOI 10.1016/0092-8674(91)90071-6; GORVEL JP, 1991, CELL, V64, P915, DOI 10.1016/0092-8674(91)90316-Q; GOULD B, 1988, CELL, V53, P753; HALL A, 1985, NUCLEIC ACIDS RES, V13, P5255, DOI 10.1093/nar/13.14.5255; HILL RE, 1991, NATURE, V354, P522, DOI 10.1038/354522a0; JEFFERS M, 1990, NUCLEIC ACIDS RES, V18, P4891; JOYNER AL, 1989, NATURE, V338, P153, DOI 10.1038/338153a0; KATAOKA T, 1984, CELL, V37, P437, DOI 10.1016/0092-8674(84)90374-X; KIM HS, 1988, NUCLEIC ACIDS RES, V16, P8887, DOI 10.1093/nar/16.18.8887; LEON J, 1987, MOL CELL BIOL, V7, P1535, DOI 10.1128/MCB.7.4.1535; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MIZUNO T, 1991, P NATL ACAD SCI USA, V88, P6442, DOI 10.1073/pnas.88.15.6442; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; NICOLAIEW N, 1991, ONCOGENE, V6, P721; RUBIN GM, 1991, TRENDS GENET, V7, P372, DOI 10.1016/0168-9525(91)90258-R; SCHORLE H, 1991, NATURE, V352, P621, DOI 10.1038/352621a0; STERNBERG PW, 1991, TRENDS GENET, V7, P366, DOI 10.1016/0168-9525(91)90257-Q; SZEBERENYI J, 1990, MOL CELL BIOL, V10, P5324, DOI 10.1128/MCB.10.10.5324; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; WITTINGHOFER A, 1991, TRENDS BIOCHEM SCI, V16, P382, DOI 10.1016/0968-0004(91)90156-P; ZIJLSTRA M, 1989, NATURE, V342, P435, DOI 10.1038/342435a0	30	5	5	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1992	7	12					2525	2528						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KA856	1461656				2022-12-25	WOS:A1992KA85600019
J	PAULES, RS; RESNICK, J; KASENALLY, AB; ERNST, MK; DONOVAN, P; VANDEWOUDE, GF				PAULES, RS; RESNICK, J; KASENALLY, AB; ERNST, MK; DONOVAN, P; VANDEWOUDE, GF			CHARACTERIZATION OF ACTIVATED AND NORMAL MOUSE MOS GENE IN MURINE 3T3 CELLS	ONCOGENE			English	Article							PROTO-ONCOGENE PRODUCT; MEIOTIC MATURATION; SARCOMA-VIRUS; M-PHASE; DEVELOPMENTAL REGULATION; OOCYTE MATURATION; XENOPUS OOCYTES; CDC2 PROTEIN; GERM-CELLS; MEIOSIS-II	We have characterized the mouse Mos proto-oncogene product, pp39Mos in murine fibroblasts. When expressed in NIH3T3 cells under the influence of the long terminal repeat regulatory element from Moloney murine sarcoma virus [NIH(pTS-1) cells], the Mos protein was present in low levels and had a half-life of about 30 min. In extracts from NIH(pTS-1) cells, we detected additional forms of Mos protein that apparently arose from internal initiation codons (p24Mos and p29Mos) or from upstream non-AUG initiation codons (p42Mos and p44Mos). The Mos protein was found to exist in these cells as a phosphoprotein, pp39Mos, and, when immunoprecipitated with an antiserum specific for the Mos N-terminus [anti-Mos(6-24)], had autophosphorylating kinase activity. We found that anti-Mos(6-24) also detected non-Mos protein kinase activity and non-Mos phosphoproteins in addition to p39Mos. We present evidence, on both the RNA and protein levels, that non-transformed mouse 3T3 cells do not express endogenous Mos.	ST MARYS HOSP,SCH MED,LUDWIG INST CANC RES,LONDON W2 1PG,ENGLAND; NCI,FREDERICK CANC RES & DEV CTR,BASIC RES PROGRAM,ABL,FREDERICK,MD 21702	Imperial College London; Ludwig Institute for Cancer Research; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	PAULES, RS (corresponding author), NIEHS,MAMMALIAN MOLEC GENET GRP,POB 12233,RES TRIANGLE PK,NC 27709, USA.			Paules, Richard S/0000-0001-9106-7486	OFFICE OF THE DIRECTOR, NCI [N01CO074101] Funding Source: NIH RePORTER; NCI NIH HHS [N01-CO-74101] Funding Source: Medline	OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BLAIR DG, 1986, CELL, V46, P785, DOI 10.1016/0092-8674(86)90354-5; BLAIR DG, 1981, SCIENCE, V212, P941, DOI 10.1126/science.7233190; DAAR I, 1991, SCIENCE, V253, P74, DOI 10.1126/science.1829549; DAAR I, 1991, J CELL BIOL, V114, P329, DOI 10.1083/jcb.114.2.329; DRAETTA G, 1989, CELL, V56, P829, DOI 10.1016/0092-8674(89)90687-9; DUNPHY WG, 1988, CELL, V54, P423, DOI 10.1016/0092-8674(88)90205-X; FRANKEL AE, 1976, P NATL ACAD SCI USA, V73, P3705, DOI 10.1073/pnas.73.10.3705; GAUTIER J, 1988, CELL, V54, P433, DOI 10.1016/0092-8674(88)90206-1; GOLDMAN DS, 1987, P NATL ACAD SCI USA, V84, P4509, DOI 10.1073/pnas.84.13.4509; HERZOG NK, 1989, ONCOGENE, V4, P1307; HERZOG NK, 1988, ONCOGENE, V3, P225; JONES M, 1980, P NATL ACAD SCI-BIOL, V77, P2651, DOI 10.1073/pnas.77.5.2651; KANKI JP, 1991, P NATL ACAD SCI USA, V88, P5794, DOI 10.1073/pnas.88.13.5794; KESHET E, 1988, ONCOGENE, V2, P235; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEIBOVITCH SA, 1990, ONCOGENE, V5, P1149; LEIBOVITCH SA, 1991, ONCOGENE, V6, P1617; MASUI Y, 1971, J EXP ZOOL, V177, P129, DOI 10.1002/jez.1401770202; MAXWELL SA, 1985, J VIROL, V55, P874, DOI 10.1128/JVI.55.3.874-876.1985; MAXWELL SA, 1985, VIROLOGY, V143, P321, DOI 10.1016/0042-6822(85)90119-9; MEIJER L, 1989, EMBO J, V8, P2275, DOI 10.1002/j.1460-2075.1989.tb08353.x; MELCHERS F, 1985, P NATL ACAD SCI USA, V82, P7681, DOI 10.1073/pnas.82.22.7681; MUTTER GL, 1987, P NATL ACAD SCI USA, V84, P5301, DOI 10.1073/pnas.84.15.5301; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; OKEEFE SJ, 1989, P NATL ACAD SCI USA, V86, P7038, DOI 10.1073/pnas.86.18.7038; OSKARSSON M, 1980, SCIENCE, V207, P1222, DOI 10.1126/science.6243788; PAPKOFF J, 1982, CELL, V29, P417, DOI 10.1016/0092-8674(82)90158-1; PAPKOFF J, 1981, CELL, V27, P109, DOI 10.1016/0092-8674(81)90365-2; PAULES RS, 1989, P NATL ACAD SCI USA, V86, P5395, DOI 10.1073/pnas.86.14.5395; PAULES RS, 1988, ONCOGENE, V3, P59; PLATT EJ, 1986, ANAL BIOCHEM, V156, P126, DOI 10.1016/0003-2697(86)90163-6; PROPST F, 1985, NATURE, V315, P516, DOI 10.1038/315516a0; PROPST F, 1987, MOL CELL BIOL, V7, P1629, DOI 10.1128/MCB.7.5.1629; SAGATA N, 1989, NATURE, V342, P512, DOI 10.1038/342512a0; SAGATA N, 1989, SCIENCE, V245, P643, DOI 10.1126/science.2474853; SAGATA N, 1988, NATURE, V335, P519, DOI 10.1038/335519a0; SCHMIDT M, 1988, MOL CELL BIOL, V8, P923, DOI 10.1128/MCB.8.2.923; SCHULZ N, 1992, CANCER RES, V52, P450; SINGH B, 1987, J VIROL, V61, P3625, DOI 10.1128/JVI.61.11.3625-3629.1987; Stein Gary S., 1989, P133; TOBEY RA, 1988, EXP CELL RES, V179, P400, DOI 10.1016/0014-4827(88)90279-0; VANDEWOUDE GF, 1980, COLD SPRING HARB SYM, V44, P735, DOI 10.1101/SQB.1980.044.01.079; WASSERMAN WJ, 1978, J CELL BIOL, V78, P15; WATANABE N, 1989, NATURE, V342, P505, DOI 10.1038/342505a0; YEW N, 1991, MOL CELL BIOL, V11, P604, DOI 10.1128/MCB.11.2.604; YEW N, 1992, NATURE, V355, P649, DOI 10.1038/355649a0; ZHAO X, 1990, ONCOGENE, V5, P1727; ZHAO X, 1991, ONCOGENE, V6, P43; ZHOU R, 1991, CELL GROWTH DIFFER, V2, P257; ZHOU RP, 1991, SCIENCE, V251, P671, DOI 10.1126/science.1825142; ZINN K, 1983, CELL, V34, P856	51	18	18	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1992	7	12					2489	2498						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KA856	1461652				2022-12-25	WOS:A1992KA85600014
J	POSCH, KC; BURNS, RD; NAPOLI, JL				POSCH, KC; BURNS, RD; NAPOLI, JL			BIOSYNTHESIS OF ALL-TRANS-RETINOIC ACID FROM RETINAL - RECOGNITION OF RETINAL BOUND TO CELLULAR RETINOL BINDING-PROTEIN (TYPE-I) AS SUBSTRATE BY A PURIFIED CYTOSOLIC DEHYDROGENASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER MICROSOMES; ALDEHYDE DEHYDROGENASES; ESCHERICHIA-COLI; ESTERIFICATION; HYDROLYSIS; TISSUES; HYDROLASES; REDUCTION; PALMITATE; ISOZYMES	An NAD-dependent rat liver cytosolic dehydrogenase accepted as substrate retinal generated in situ by microsomes from retinol bound to excess CRBP (cellular retinol binding protein, type I). This activity, which was not retained by anion-exchange chromatography at pH 9.15, was designated P1. P1 activity increased 2.5-fold, with no statistically significant change in its K or Hill coefficient, in liver cytosol from rats fed a retinoid-deficient diet. Orally dosed retinoic acid partially suppressed the increase. Activities chromatographically similar to hepatic P1 were observed in cytosols from rat kidney and testes. P1, purified from rat liver cytosol, had a pI of approximately 8.3, migrated as a tetramer (214 kDa) on a Sephadex G-200 column, and had a subunit molecular mass of 55 kDa by sodium dodecyl sulfate-polyacrylamide gel electrophoresis. With free retinal it catalyzed a maximum rate of retinoic acid synthesis of 265 nmol/min/mg of protein and exhibited allosteric kinetics with a K of 0.76 +/- 0.35 muM and a Hill coefficient of 1.5 +/- 0.13 (mean +/- S.D., n = 4). Substrate inhibition was noted with retinal concentrations greater than 6 gm. The purified enzyme not only recognized retinal generated by microsomes as substrate, but also recognized retinal bound to CRBP. The rates of retinoic acid synthesis from CRBP-retinal, with a series of increasing apoCRBP concentrations, exceeded the rates that would be supported by the free retinal present. The CRBP-retinal complex exhibited allosteric kinetics (K, 0.13 muM; Hill coefficient, 1.75; averages of duplicates) in the presence of excess apoCRBP (the ratio total CRBP/total retinal at each concentration of retinal was 2). This enzyme is likely to play a significant role in retinoic acid synthesis in vivo, because it participates in the synthesis of retinoic acid from a physiologically occurring form of retinol (holoCRBP), reflects retinoid status, and is distributed in extrahepatic tissues in addition to liver. These results also suggest a novel role for CRBP in retinoid metabolism, facilitating the conversion of retinal into retinoic acid.	SUNY BUFFALO,SCH MED & BIOMED SCI,DEPT BIOCHEM,140 FARBER HALL,3435 MAIN ST,BUFFALO,NY 14214	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK036870] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK36870] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BASHOR MM, 1973, P NATL ACAD SCI USA, V70, P3483, DOI 10.1073/pnas.70.12.3483; BIERI JG, 1977, J NUTR, V107, P1340; BOERMAN MHEM, 1991, J BIOL CHEM, V266, P22273; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAO QN, 1989, BIOCHEM PHARMACOL, V38, P77, DOI 10.1016/0006-2952(89)90152-4; CLARKE SD, 1989, FASEB J, V3, P2480, DOI 10.1096/fasebj.3.13.2680704; FEX G, 1987, BIOCHIM BIOPHYS ACTA, V901, P255, DOI 10.1016/0005-2736(87)90122-2; GOEDDE HW, 1987, ENZYME, V37, P29, DOI 10.1159/000469239; HARRISON EH, 1989, J BIOL CHEM, V264, P17142; Hempel J., 1990, ENZYMOLOGY MOL BIOL, V3, P1, DOI [10.1007/978-1-4684-5901-2_1, DOI 10.1007/978-1-4684-5901-2_1]; KAKKAD BP, 1988, J BIOL CHEM, V263, P12916; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Leatherbarrow R.J, 1987, ENZFITTER NONLINEAR; LEE MO, 1991, BIOCHEM PHARMACOL, V42, P1279, DOI 10.1016/0006-2952(91)90266-8; LEVIN MS, 1988, J BIOL CHEM, V263, P17715; LI E, 1991, J BIOL CHEM, V266, P3622; Lotan R, 1988, Prog Clin Biol Res, V259, P261; MACDONALD PN, 1987, J BIOL CHEM, V262, P10550; NAPOLI JL, 1986, METHOD ENZYMOL, V123, P112, DOI 10.1016/S0076-6879(86)23015-3; NAPOLI JL, 1987, ARCH BIOCHEM BIOPHYS, V255, P95, DOI 10.1016/0003-9861(87)90298-0; NAPOLI JL, 1992, BIOCHIM BIOPHYS ACTA, V1120, P183, DOI 10.1016/0167-4838(92)90267-H; NAPOLI JL, 1990, BIOCHIM BIOPHYS ACTA, V1034, P228, DOI 10.1016/0304-4165(90)90081-7; NAPOLI JL, 1990, METHOD ENZYMOL, V189, P470; NAPOLI JL, 1989, ARCH BIOCHEM BIOPHYS, V274, P192, DOI 10.1016/0003-9861(89)90430-X; NAPOLI JL, 1981, BIOCHIM BIOPHYS ACTA, V666, P165, DOI 10.1016/0005-2760(81)90102-8; NOY N, 1990, BIOCHEMISTRY-US, V29, P3878, DOI 10.1021/bi00468a012; ONG DE, 1982, J BIOL CHEM, V257, P13385; ONG DE, 1988, J BIOL CHEM, V263, P5789; OTTONELLO S, 1987, J BIOL CHEM, V262, P3975; POSCH KC, 1991, BIOCHEMISTRY-US, V30, P6224, DOI 10.1021/bi00239a021; POSCH KC, 1992, BIOCHEM PHARMACOL, V43, P2296; POSCH KC, 1989, ARCH BIOCHEM BIOPHYS, V274, P171, DOI 10.1016/0003-9861(89)90428-1; REEVES PG, 1989, J NUTR, V119, P1081, DOI 10.1093/jn/119.8.1081; ROSS AC, 1982, J BIOL CHEM, V257, P2453; ROUT UK, 1985, COMP BIOCHEM PHYS B, V81, P647, DOI 10.1016/0305-0491(85)90380-3; RUBERTE E, 1991, DEVELOPMENT, V111, P45; SAARI JC, 1982, BIOCHIM BIOPHYS ACTA, V716, P266, DOI 10.1016/0304-4165(82)90277-X; SUMMERBELL D, 1990, TRENDS NEUROSCI, V13, P142, DOI 10.1016/0166-2236(90)90006-V; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2; YOST RW, 1988, J BIOL CHEM, V263, P18693	40	122	125	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1992	267	27					19676	19682						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JP593	1527087				2022-12-25	WOS:A1992JP59300098
J	WEISS, SJ; FISHER, PA				WEISS, SJ; FISHER, PA			INTERACTION OF DROSOPHILA DNA-POLYMERASE ALPHA HOLOENZYME WITH SYNTHETIC TEMPLATE-PRIMERS CONTAINING MISMATCHED PRIMER BASES OR PROPANODEOXYGUANOSINE ADDUCTS AT VARIOUS POSITIONS IN TEMPLATE AND PRIMER REGIONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENZYMOLOGICAL CHARACTERIZATION; 1,N2-PROPANODEOXYGUANOSINE ADDUCTS; ABASIC SITES; CALF THYMUS; KB-CELLS; BINDING; RECOGNITION; OLIGODEOXYNUCLEOTIDES; MELANOGASTER; MECHANISM	We studied recognition and binding of synthetic template-primers by Drosophila DNA polymerase-alpha (pol-alpha) holoenzyme. The template-primers used contained either mismatched base pairs at various positions in the primer region or exocyclic propanodeoxyguanosine (PdG) adducts at various positions in both template and primer.pol-alpha requires primer-terminal complementarity of greater than or equal to 4 base pairs for efficient binding and incorporation. When a mismatched base pair is at the -4 position relative to the 3'-primer terminus, minimal but detectable binding occurs. This is consistent with the ability of pol-alpha to incorporate a single nucleotide on a template-primer containing a mismatch at this position, but at a rate of only 7% relative to incorporation on a perfectly matched template-primer. No binding or incorporation (less than 1% of incorporation on a perfectly matched template-primer) was evident when a mismatched base pair was at the -3 position or closer, relative to the 3'-primer terminus. Similar results were obtained when PdG was placed at various positions in the primer region. When a PdG residue was located in the template region (+3 position relative to the 3'-primer terminus), single-nucleotide incorporation was stimulated 3-4-fold. These observations suggest that there are intrinsic aspects to the mechanism of nucleotide incorporation by pol a which ensure the fidelity of DNA synthesis by this enzyme and may provide novel insights into the fundamental mechanism of polymerase translocation along templates.	SUNY STONY BROOK,HLTH SCI CTR,DEPT PHARMACOL SCI,STONY BROOK,NY 11794	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook					NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P01ES004068] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035943] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES04068] Funding Source: Medline; NIGMS NIH HHS [GM35943] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEN DJ, 1989, BIOCHEMISTRY-US, V28, P4601, DOI 10.1021/bi00437a014; ALLIS CD, 1977, DEV BIOL, V56, P372, DOI 10.1016/0012-1606(77)90277-9; BASU AK, 1988, CHEM RES TOXICOL, V1, P1, DOI 10.1021/tx00001a001; CHUNG FL, 1984, CANCER RES, V44, P990; FISHER PA, 1979, J BIOL CHEM, V254, P1040; FISHER PA, 1981, BIOCHEMISTRY-US, V20, P4570, DOI 10.1021/bi00519a009; FISHER PA, 1981, BIOCHEMISTRY-US, V20, P4560, DOI 10.1021/bi00519a008; FISHER PA, 1979, J BIOL CHEM, V254, P1033; FISHER PA, 1979, J BIOL CHEM, V254, P6128; FISHER PA, 1981, J BIOL CHEM, V256, P133; KAGUNI LS, 1983, P NATL ACAD SCI-BIOL, V80, P2221, DOI 10.1073/pnas.80.8.2221; KOUCHAKDJIAN M, 1989, BIOCHEMISTRY-US, V28, P5647, DOI 10.1021/bi00439a047; Maniatis T., 1982, MOL CLONING; Maxam A M, 1980, Methods Enzymol, V65, P499; NG L, 1989, J BIOL CHEM, V264, P13018; NG L, 1991, J BIOL CHEM, V266, P11699; RECKMANN B, 1983, NUCLEIC ACIDS RES, V11, P7251, DOI 10.1093/nar/11.20.7251; SHAPIRO R, 1969, ANN NY ACAD SCI, V163, P624, DOI 10.1111/j.1749-6632.1969.tb24881.x; Singer B., 1986, IARC SCI PUBLICATION, V70; TAKESHITA M, 1987, J BIOL CHEM, V262, P10171; WONG SW, 1986, J BIOL CHEM, V261, P7958	21	21	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1992	267	26					18520	18526						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JN502	1526988				2022-12-25	WOS:A1992JN50200045
J	CHISHOLM, O; STAPLETON, P; SYMONDS, G				CHISHOLM, O; STAPLETON, P; SYMONDS, G			CONSTITUTIVE EXPRESSION OF EXOGENOUS MYC IN MYELOMONOCYTIC CELLS - ACQUISITION OF A MORE TRANSFORMED PHENOTYPE AND INHIBITION OF DIFFERENTIATION INDUCTION	ONCOGENE			English	Article							INDUCED TERMINAL DIFFERENTIATION; HUMAN MONOCYTIC DIFFERENTIATION; PROMYELOCYTIC LEUKEMIA-CELLS; MURINE ERYTHROLEUKEMIA-CELLS; COLONY-STIMULATING FACTORS; ONCOGENE-C-MYC; V-MYC; PROTO-ONCOGENE; MYELOID-LEUKEMIA; MULTISTEP CARCINOGENESIS	The effects of deregulated expression of the human c-myc and MC29 v-myc oncogenes have been examined in a murine myelomonocytic cell line J774 (c-myc) and in a variety of myelomonocytic cell lines of different degrees of maturity generated from primary hematopoietic tissue (v-myc). Introduction of a Moloney murine leukemia virus long terminal repeat (LTR) c-myc construct into J774 cells resulted in constitutive expression of the exogenous myc gene and a concomitant increase in the degree of transformation and tumorigenicity of the cells. In addition, constitutive expression of exogenous inhibited induced differentiation of these cells by a variety of treatments including addition to the medium of lipopolysaccharide (LPS) or the phorbol ester 12-O-tetradecanoyl phorbol 13-acetate (TPA) as well as complete withdrawal of serum from the medium. The degree, of increased transformation, tumorigenicity and inhibition of terminal differentiation was dependent upon the level of exogenous myc expression. For the v-myc-generated myelomonocytic cell lines, introduction of v-myc resulted in a high degree of transformation and, irrespective of the differentiation status of the cells, a block of induced differentiation. These results indicate that the level of constitutive myc expression can affect the transformed phenotype, tumorigenicity and differentiation inducibility of myelomonocytic cells.	CHILDRENS MED RES FDN, LEUKEMIA RES & VIRAL PATHOL UNIT, CAMPERDOWN, NSW 2050, AUSTRALIA; RW JOHNSON PHARMACEUT RES INST SYDNEY, EDGECLIFF, NSW 2027, AUSTRALIA	Children's Medical Research Institute - Australia			Chisholm, Orin/L-4206-2016	Chisholm, Orin/0000-0002-9749-4160				ALITALO K, 1986, ADV CANCER RES, V47, P235, DOI 10.1016/S0065-230X(08)60201-8; ALITALO K, 1983, P NATL ACAD SCI-BIOL, V80, P1707, DOI 10.1073/pnas.80.6.1707; BACON TA, 1991, ONCOGENE RES, V6, P21; BAUMBACH WR, 1987, MOL CELL BIOL, V7, P664, DOI 10.1128/MCB.7.2.664; BERLINGIERI MT, 1988, MOL CELL BIOL, V8, P2261, DOI 10.1128/MCB.8.5.2261; BIRCHENALLROBERTS MC, 1989, ONCOGENE, V4, P731; BLOOM BR, 1978, FED PROC, V37, P2765; BONHAM L, 1991, ONCOGENE, V6, P1073; BONHAM L, 1992, IN PRESS ONCOGENE; BRIGHTMAN BK, 1986, J VIROL, V60, P68, DOI 10.1128/JVI.60.1.68-81.1986; CHANEY WG, 1986, SOMAT CELL MOLEC GEN, V12, P237, DOI 10.1007/BF01570782; CHISHOLM O, 1988, NUCLEIC ACIDS RES, V16, P2352, DOI 10.1093/nar/16.5.2352; CHISHOLM O, 1992, INT J CANCER, V51, P149, DOI 10.1002/ijc.2910510126; Clark G., 1981, STAINING PROCEDURES; CLARK SC, 1987, SCIENCE, V236, P1229, DOI 10.1126/science.3296190; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; COLLINS S, 1982, NATURE, V298, P679, DOI 10.1038/298679a0; COLLINS SJ, 1978, P NATL ACAD SCI USA, V75, P2458, DOI 10.1073/pnas.75.5.2458; COPPOLA JA, 1989, MOL CELL BIOL, V9, P1714, DOI 10.1128/MCB.9.4.1714; CORY S, 1987, ONCOGENE RES, V1, P61; DEXTER TM, 1979, NATURE, V277, P471, DOI 10.1038/277471a0; DMITROVSKY E, 1986, NATURE, V322, P748, DOI 10.1038/322748a0; EINAT M, 1985, NATURE, V313, P597, DOI 10.1038/313597a0; ERBA HP, 1988, MOL CELL BIOL, V8, P1775, DOI 10.1128/MCB.8.4.1775; FALCONE G, 1987, EXP CELL RES, V168, P273, DOI 10.1016/0014-4827(87)90435-6; FILMUS J, 1985, CANCER RES, V45, P822; FREYTAG SO, 1988, MOL CELL BIOL, V8, P1614, DOI 10.1128/MCB.8.4.1614; GONDA TJ, 1984, NATURE, V310, P249, DOI 10.1038/310249a0; GREEN SM, 1989, ONCOGENE, V4, P737; HOFFMANLIEBERMANN B, 1991, MOL CELL BIOL, V11, P2375, DOI 10.1128/MCB.11.5.2375; HOLT JT, 1988, MOL CELL BIOL, V8, P963, DOI 10.1128/MCB.8.2.963; ICHIKAWA Y, 1966, P NATL ACAD SCI USA, V56, P488, DOI 10.1073/pnas.56.2.488; JAFFE BD, 1988, ONCOGENE, V2, P167; JUNGI TW, 1986, IMMUNOLOGY, V58, P131; KAWAI S, 1984, MOL CELL BIOL, V4, P1172, DOI 10.1128/MCB.4.6.1172; KELEKAR A, 1986, MOL CELL BIOL, V6, P7, DOI 10.1128/MCB.6.1.7; KOEFFLER HP, 1983, BLOOD, V62, P709; KOREN HS, 1975, J IMMUNOL, V114, P894; LAND H, 1983, SCIENCE, V222, P771, DOI 10.1126/science.6356358; LARSSON LG, 1988, P NATL ACAD SCI USA, V85, P2638, DOI 10.1073/pnas.85.8.2638; LIEBERMANN DA, 1989, ONCOGENE, V4, P583; LOTEM J, 1977, J CELL PHYSIOL, V92, P97, DOI 10.1002/jcp.1040920112; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; MARTIN P, 1986, EMBO J, V5, P1529, DOI 10.1002/j.1460-2075.1986.tb04393.x; MARTINSSON T, 1988, ONCOGENE, V3, P437; MATSUHASHI C, 1981, MEN EKI GAKU JIKKEN; MCCAIRNS E, 1983, MOL CELL BIOCHEM, V56, P165; METCALF D, 1989, NATURE, V339, P27, DOI 10.1038/339027a0; METCALF D, 1986, BLOOD, V67, P257; Metcalf D, 1984, CLONAL CULTURE HEMOP; MITCHELL RL, 1985, CELL, V40, P209, DOI 10.1016/0092-8674(85)90324-1; MULLER R, 1984, NATURE, V312, P716, DOI 10.1038/312716a0; NEPVEU A, 1987, GENE DEV, V1, P938, DOI 10.1101/gad.1.9.938; OHNO H, 1988, CANCER RES, V48, P4959; PFEIFER S, 1980, INT J CANCER, V25, P235, DOI 10.1002/ijc.2910250211; PROCHOWNIK EV, 1986, NATURE, V322, P848, DOI 10.1038/322848a0; PROCHOWNIK EV, 1988, MOL CELL BIOL, V8, P3683, DOI 10.1128/MCB.8.9.3683; RABBITTS TH, 1985, TRENDS GENET, V1, P327, DOI 10.1016/0168-9525(85)90127-1; RALPH P, 1975, J IMMUNOL, V114, P898; RALPH P, 1977, CANCER RES, V37, P546; RAPP UR, 1985, NATURE, V317, P434, DOI 10.1038/317434a0; REITSMA PH, 1983, NATURE, V306, P492, DOI 10.1038/306492a0; ROTHBERG PG, 1984, MOL CELL BIOL, V4, P1096, DOI 10.1128/MCB.4.6.1096; ROVERA G, 1979, P NATL ACAD SCI USA, V76, P2779, DOI 10.1073/pnas.76.6.2779; SACHS L, 1987, SCIENCE, V238, P1374, DOI 10.1126/science.3317831; SACHS L, 1978, NATURE, V274, P535, DOI 10.1038/274535a0; SARIBAN E, 1985, NATURE, V316, P64, DOI 10.1038/316064a0; SCHNEIDER MD, 1987, MOL CELL BIOL, V7, P1973, DOI 10.1128/MCB.7.5.1973; SEGAL S, 1988, MOL IMMUNOL, V25, P1129, DOI 10.1016/0161-5890(88)90147-2; SHIROKI K, 1986, MOL CELL BIOL, V6, P4379, DOI 10.1128/MCB.6.12.4379; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; STAPLETON P, 1991, ONCOGENE, V6, P807; STEWART CC, 1984, MONONUCLEAR PHAGOCYT; SYMONDS G, 1982, EMBO J, V1, P1343, DOI 10.1002/j.1460-2075.1982.tb01320.x; SYMONDS G, 1989, ONCOGENE, V4, P285; SYMONDS G, 1986, MOL CELL BIOL, V6, P1796, DOI 10.1128/MCB.6.5.1796; VENTURA MA, 1987, EXP CELL RES, V170, P290, DOI 10.1016/0014-4827(87)90307-7; WARNER NL, 1969, J NATL CANCER I, V43, P963; WEINBERG RA, 1989, CANCER RES, V49, P3713; WESTIN EH, 1982, P NATL ACAD SCI-BIOL, V79, P2490, DOI 10.1073/pnas.79.8.2490; WICKSTROM EL, 1988, P NATL ACAD SCI USA, V85, P1028, DOI 10.1073/pnas.85.4.1028; YOKOTA J, 1986, SCIENCE, V231, P261, DOI 10.1126/science.3941898; ZERLIN M, 1987, ONCOGENE, V1, P19	83	20	20	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	1992	7	9					1827	1836						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JJ376	1501891				2022-12-25	WOS:A1992JJ37600019
J	HISABORI, T; MUNEYUKI, E; ODAKA, M; YOKOYAMA, K; MOCHIZUKI, K; YOSHIDA, M				HISABORI, T; MUNEYUKI, E; ODAKA, M; YOKOYAMA, K; MOCHIZUKI, K; YOSHIDA, M			SINGLE SITE HYDROLYSIS OF 2',3'-O-(2,4,6-TRINITROPHENYL)-ATP BY THE F1-ATPASE FROM THE THERMOPHYLIC BACTERIUM PS3 IS ACCELERATED BY THE CHASE-ADDITION OF EXCESS ATP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL ADENOSINE-TRIPHOSPHATASE; ESCHERICHIA-COLI F1-ATPASE; NUCLEOTIDE-BINDING-SITES; ISOLATED BETA-SUBUNIT; COUPLING FACTOR-I; CATALYTIC SITES; OXYGEN-EXCHANGE; ADP-BINDING; 5'-TRIPHOSPHATE; COOPERATIVITY	The interaction of 2',3'-O-(2,4,6-trinitrophenyl)adenosine 5'-triphosphate (TNP-ATP) and TNP-ADP to F1-ATPase from a thermophilic bacterium PS3 (TF1) was investigated. When TNP-ADP or TNP-ATP was added to the isolated alpha or beta-subunit of TF1, characteristic difference spectra were generated for each subunit. Difference spectra generated on addition of these analogs to TF1 resembled those observed for the beta-subunit, indicating TNP analogs bind to the beta-subunits in the molecule of TF1. Results of equilibrium dialysis showed that TNP-ADP binds to a single high affinity site on TF1 in the presence of Mg2+ with a dissociation constant of 2.2 nM. When TNP-ATP was added to TF1 in a substoichiometric molar ratio, it rapidly bound to TF1 and was slowly hydrolyzed. The hydrolysis proceeded nearly to completion without showing stable equilibrium between bound species of TNP-ATP and TNP-ADP. Similar to beef heart mitochondrial F1, this hydrolysis was greatly accelerated by the chase-addition of 100-mu-M ATP. However, the hydrolyzed product, TNP-ADP, remained bound on the beta-subunit even after the chase.	YOKOHAMA CITY UNIV,DEPT CHEM,YOKOHAMA 236,JAPAN; TOKYO INST TECHNOL,RESOURCES UTILIZAT RES LAB,YOKOHAMA,KANAGAWA 227,JAPAN; TOKYO INST TECHNOL,DEPT LIFE SCI,YOKOHAMA,KANAGAWA 227,JAPAN	Yokohama City University; Tokyo Institute of Technology; Tokyo Institute of Technology	HISABORI, T (corresponding author), YOKOHAMA CITY UNIV,DEPT BIOL,YOKOHAMA 236,JAPAN.		Odaka, Masafumi/C-2378-2013; Hisabori, Toru/E-5205-2014	Yokoyama, Ken/0000-0002-6813-1096; Hisabori, Toru/0000-0003-2046-0277				ALSHAWI MK, 1989, J BIOL CHEM, V264, P15376; CATTERALL AW, 1973, J BIOL CHEM, V248, P7427; CHIBA T, 1981, PLANT CELL PHYSIOL, V22, P551; CROSS RL, 1982, J BIOL CHEM, V257, P2101; CZARNECKI JJ, 1983, EUR J BIOCHEM, V136, P19, DOI 10.1111/j.1432-1033.1983.tb07699.x; DUNN SD, 1980, J BIOL CHEM, V255, P113; ESCH FS, 1979, J BIOL CHEM, V254, P740; FROMME P, 1990, BIOCHIM BIOPHYS ACTA, V1020, P187, DOI 10.1016/0005-2728(90)90050-E; FROMME P, 1990, BIOCHIM BIOPHYS ACTA, V1016, P29, DOI 10.1016/0005-2728(90)90003-M; FUTAI M, 1983, MICROBIOL REV, V47, P285, DOI 10.1128/MMBR.47.3.285-312.1983; GRESSER MJ, 1982, J BIOL CHEM, V257, P2030; GRUBMEYER C, 1981, J BIOL CHEM, V256, P3728; GRUBMEYER C, 1982, J BIOL CHEM, V257, P2092; GRUBMEYER C, 1981, J BIOL CHEM, V256, P3718; HATEFI Y, 1985, ANNU REV BIOCHEM, V54, P1015, DOI 10.1146/annurev.bi.54.070185.005055; HIRATSUKA T, 1973, BIOCHIM BIOPHYS ACTA, V320, P635, DOI 10.1016/0304-4165(73)90143-8; HISABORI T, 1986, J BIOCHEM-TOKYO, V100, P663, DOI 10.1093/oxfordjournals.jbchem.a121758; HISABORI T, 1984, PLANT CELL PHYSIOL, V25, P483; HUTTON RL, 1979, J BIOL CHEM, V254, P9990; ISSARTEL JP, 1984, BIOCHEMISTRY-US, V23, P6591, DOI 10.1021/bi00321a048; KASHO VN, 1989, BIOCHEMISTRY-US, V28, P6949, DOI 10.1021/bi00443a026; KOHLBRENNER WE, 1983, J BIOL CHEM, V258, P881; LUBBEN M, 1984, EUR J BIOCHEM, V143, P483, DOI 10.1111/j.1432-1033.1984.tb08396.x; MCCARTY RE, 1979, ANNU REV PLANT PHYS, V30, P79, DOI 10.1146/annurev.pp.30.060179.000455; MIWA K, 1989, J BIOCHEM-TOKYO, V106, P679, DOI 10.1093/oxfordjournals.jbchem.a122916; MOCZYDLOWSKI EG, 1981, J BIOL CHEM, V256, P2346; MUNEYUKI E, 1991, BIOCHIM BIOPHYS ACTA, V1058, P304, DOI 10.1016/S0005-2728(05)80251-8; NOUMI T, 1986, J BIOL CHEM, V261, P9196; OHTA S, 1980, J BIOCHEM-TOKYO, V87, P1609, DOI 10.1093/oxfordjournals.jbchem.a132904; OHTSUBO M, 1987, BIOCHEM BIOPH RES CO, V146, P705, DOI 10.1016/0006-291X(87)90586-9; RAO R, 1988, J BIOL CHEM, V263, P5569; ROGNER M, 1986, BIOCHIM BIOPHYS ACTA, V849, P121, DOI 10.1016/0005-2728(86)90103-9; SENIOR AE, 1983, J MEMBRANE BIOL, V73, P105, DOI 10.1007/BF01870434; TANAKA M, 1980, PLANT CELL PHYSIOL, V21, P1585, DOI 10.1093/pcp/21.8.1585; VOGEL PD, 1991, J BIOL CHEM, V266, P6101; WATANABE T, 1982, J BIOL CHEM, V257, P1510; WILLIAMS N, 1982, J BIOL CHEM, V257, P2834; WOOD JM, 1987, J BIOL CHEM, V262, P2180; YOHDA M, 1987, J BIOCHEM-TOKYO, V102, P875, DOI 10.1093/oxfordjournals.jbchem.a122128; YOSHIDA M, 1975, J BIOL CHEM, V250, P7910	40	46	46	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1992	267	7					4551	4556						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HF642	1531655				2022-12-25	WOS:A1992HF64200043
J	SHOREIBAH, MG; HINDSGAUL, O; PIERCE, M				SHOREIBAH, MG; HINDSGAUL, O; PIERCE, M			PURIFICATION AND CHARACTERIZATION OF RAT-KIDNEY UDP-N-ACETYLGLUCOSAMINE - ALPHA-6-D-MANNOSIDE BETA-1,6-N-ACETYLGLUCOSAMINYLTRANSFERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASPARAGINE-LINKED OLIGOSACCHARIDES; GAL-BETA-1->3(4)GLCNAC ALPHA-2->3 SIALYLTRANSFERASE; BETA-GALACTOSIDE ALPHA-2,6-SIALYLTRANSFERASE; 2 FUCOSYL-TRANSFERASE; SUB-MAXILLARY GLANDS; HAMSTER OVARY CELLS; PIG GASTRIC-MUCOSA; GLYCOPROTEIN-SYNTHESIS; MEMBRANE-GLYCOPROTEINS; BOVINE COLOSTRUM	In order to investigate the molecular mechanism of the specific increase of UDP-N-acetylglucosamine:alpha-6-D-mannoside beta-1,6-N-acetylglucosaminyltransferase (GlcNAcT-V, EC 2.4.1.155) activity after viral or oncogenic transformation, we have purified the enzyme from a Triton X-100 extract of rat kidney acetone powder. GlcNAcT-V was purified by sequential affinity chromatography using first UDP-hexanolamine-agarose and then a synthetic oligosaccharide inhibitor-agarose column. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis of the purified enzyme revealed two major bands at apparent molecular masses of 69 and 75 kDa. The enzyme was recovered in a 26% final yield with a 450,000-fold increase in specific activity to a V(max) of 18.8-mu-mol/(mg.min). Enzyme activity was stabilized and enhanced by the addition of 20% glycerol, 0.5 mg/ml IgG, and 0.2 M NaCl. The optimal ranges of pH and Triton X-100 concentrations for enzyme activity were 6.5-7.0 and 1.0-1.5%, respectively. The divalent cations, Mn2+, Ca2+, and Mg2+, were each found to have a negligible (< 10%) effect on activity; moreover, the enzyme was fully active in the presence of 20 mM EDTA. The K(m) value of the purified enzyme toward a synthetic trisaccharide acceptor was 90-mu-M, and the K(i) value toward a synthetic active site inhibitor was 140-mu-M.	UNIV GEORGIA,COMPLEX CARBOHYDRATE RES CTR,ATHENS,GA 30602; UNIV ALBERTA,DEPT CHEM,EDMONTON T6G 2G2,ALBERTA,CANADA	University System of Georgia; University of Georgia; University of Alberta	SHOREIBAH, MG (corresponding author), UNIV GEORGIA,DEPT BIOCHEM,ATHENS,GA 30602, USA.				NATIONAL CANCER INSTITUTE [R01CA035377, R01CA050542] Funding Source: NIH RePORTER; NCI NIH HHS [CA50542, CA35377] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARANGO J, 1988, J CELL BIOCHEM, V37, P225, DOI 10.1002/jcb.240370209; BARKER R, 1972, J BIOL CHEM, V247, P7135; BENDIAK B, 1987, J BIOL CHEM, V262, P5784; BENDIAK B, 1987, J BIOL CHEM, V262, P5775; BEYER TA, 1980, J BIOL CHEM, V255, P5364; BEYER TA, 1980, J BIOL CHEM, V255, P5373; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROCKHAUS M, 1981, J BIOL CHEM, V256, P3223; BROCKHAUSEN I, 1986, EUR J BIOCHEM, V157, P463, DOI 10.1111/j.1432-1033.1986.tb09690.x; BROCKHAUSEN I, 1987, GLYCOCONJUGATES, V1, pE35; CASTRONOVO V, 1989, J NATL CANCER I, V81, P212, DOI 10.1093/jnci/81.3.212; CHANEY W, 1908, J CELL BIOL, V109, P2089; CRAWLEY SC, 1990, ANAL BIOCHEM, V185, P112, DOI 10.1016/0003-2697(90)90264-A; CUMMINGS RD, 1982, J BIOL CHEM, V257, P13421; CUMMINGS RD, 1984, J BIOL CHEM, V259, P6253; DEKORTE D, 1987, CANCER RES, V47, P1841; DENNIS JW, 1989, ONCOGENE, V4, P853; DENNIS JW, 1989, CANCER RES, V49, P945; DENNIS JW, 1987, SCIENCE, V236, P582, DOI 10.1126/science.2953071; DUBOIS M, 1956, ANAL CHEM, V28, P350, DOI 10.1021/ac60111a017; FEIZI T, 1985, TRENDS BIOCHEM SCI, V10, P24, DOI 10.1016/0968-0004(85)90012-X; FUKUSHIMA K, 1984, CANCER RES, V44, P5279; GLEESON PA, 1983, J BIOL CHEM, V258, P6162; HAKOMORI S, 1984, J BIOL CHEM, V259, P4672; HARPAZ N, 1980, J BIOL CHEM, V255, P4885; HARPAZ N, 1980, J BIOL CHEM, V255, P4894; HIRAIZUMI S, 1990, ARCH BIOCHEM BIOPHYS, V280, P9, DOI 10.1016/0003-9861(90)90511-V; HOLMES EH, 1987, J BIOL CHEM, V262, P15649; HUNT LA, 1985, BIOCHEM J, V229, P441, DOI 10.1042/bj2290441; KOENDERMAN AHL, 1987, FEBS LETT, V222, P42, DOI 10.1016/0014-5793(87)80188-6; Kornfeld R., 1980, BIOCH GLYCOPROTEINS, P1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE EU, 1989, J BIOL CHEM, V264, P13848; LEE N, 1990, J BIOL CHEM, V265, P20476; LEGENDRE N, 1988, BIOTECHNIQUES, V6, P154; LEGENDRE N, 1990, Biotechniques, V9, P788; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; NARASIMHAN S, 1977, J BIOL CHEM, V252, P3926; NISHIKAWA Y, 1988, J BIOL CHEM, V263, P8270; OPPENHEIMER CL, 1981, J BIOL CHEM, V256, P799; OPPENHEIMER CL, 1981, J BIOL CHEM, V256, P1477; PALCIC MM, 1990, J BIOL CHEM, V265, P6759; PALCIC MM, 1988, GLYCOCONJUGATE J, V5, P49, DOI 10.1007/BF01048331; PAULSON JC, 1987, BIOCHEM SOC T, V15, P618, DOI 10.1042/bst0150618; PAULSON JC, 1977, J BIOL CHEM, V252, P2356; PAULSON JC, 1977, J BIOL CHEM, V252, P2363; PAULSON JC, 1989, J BIOL CHEM, V264, P10931; PIERCE M, 1987, BIOCHEM BIOPH RES CO, V146, P679, DOI 10.1016/0006-291X(87)90582-1; PIERCE M, 1986, J BIOL CHEM, V261, P772; PINTO BM, 1983, CARBOHYD RES, V124, P313, DOI 10.1016/0008-6215(83)88466-3; ROTH J, 1985, CELL, V43, P287, DOI 10.1016/0092-8674(85)90034-0; SADLER JE, 1979, J BIOL CHEM, V254, P4434; SADLER JE, 1979, J BIOL CHEM, V254, P5934; SADLER JE, 1982, METHOD ENZYMOL, V83, P458; SANTER UV, 1984, CANCER RES, V44, P3730; SCHACHTER H, 1983, CAN J BIOCHEM CELL B, V61, P1049, DOI 10.1139/o83-134; SHAPER NL, 1988, J BIOL CHEM, V263, P10420; SRIVASTAVA OP, 1988, CARBOHYD RES, V179, P137, DOI 10.1016/0008-6215(88)84115-6; STANFORD DR, 1986, INT J CANCER, V37, P435, DOI 10.1002/ijc.2910370316; STULTS NL, 1989, ANAL BIOCHEM, V180, P114, DOI 10.1016/0003-2697(89)90097-3; VANDENEIJNDEN DH, 1988, J BIOL CHEM, V263, P12461; WEINSTEIN J, 1982, J BIOL CHEM, V257, P13845; WEINSTEIN J, 1987, J BIOL CHEM, V262, P17735; WEINSTEIN J, 1982, J BIOL CHEM, V257, P13835; YAMASHITA K, 1985, J BIOL CHEM, V260, P3963; YAMASHITA K, 1984, J BIOL CHEM, V259, P834; YOUSEFI S, 1991, J BIOL CHEM, V266, P1772	67	71	75	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 15	1992	267	5					2920	2927						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HD154	1531335				2022-12-25	WOS:A1992HD15400019
J	YEM, AW; EPPS, DE; MATHEWS, WR; GUIDO, DM; RICHARD, KA; STAITE, ND; DEIBEL, MR				YEM, AW; EPPS, DE; MATHEWS, WR; GUIDO, DM; RICHARD, KA; STAITE, ND; DEIBEL, MR			SITE-SPECIFIC CHEMICAL MODIFICATION OF INTERLEUKIN-1-BETA BY ACRYLODAN AT CYSTEINE-8 AND LYSINE-103	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECOMBINANT HUMAN INTERLEUKIN-1-BETA; SPECTRAL PROPERTIES; CRYSTAL-STRUCTURE; PURIFICATION; RESOLUTION; SEQUENCE; RESIDUES; PROTEIN	Acrylodan, which normally modifies cysteine residues, was employed to derivatize recombinant interleukin-1-beta (rIL-1-beta) under native conditions, using a reagent:protein ratio of 3:1. Two major covalent protein/acrylodan adducts were generated and subsequently purified by DEAE TSK 5PW ion exchange chromatography. Peptide mapping and mass spectrometry were used to locate the probe on the modified proteins. Both modified proteins carried one molecule of acrylodan each, one at Cys-8 and the other at Lys-103. Neither Cys-71 nor any of the other 13 lysine residues of rIL-1-beta was modified. Cysteine 71 is inaccessible to acrylodan, but the unusual specificity for Lys-103 could be caused by the location of that residue at the bottom of a hydrophobic pocket which might specifically bind the reagent. No double-labeled protein was detected, indicating that the introduction of the label at either site interferes with the labeling at the other. Both acrylodan-modified proteins exhibited (bioactivity in the thymocyte proliferation assay at a level equivalent to that of the unmodified control protein (1.7 x 10(7) units/mg), which shows that the modification of either the Cys-8 or Lys-103 position with acrylodan does not interfere with the cellular bioactivities of the respective proteins. Furthermore, receptor binding assays yielded a K(d) = 32.0 +/- 4.8 pM for the Lys-103-labeled protein, K(d) = 69.5 +/- 12.7 pM for the unmodified protein, and K(d) = 75.0 +/- 11.6 pM for the Cys-8-labeled protein. Thus, Cys-8 or Lys-103 modification of rIL-1-beta by acrylodan also does not interfere with the ability of the molecule to bind to its receptor. The slightly higher affinity of the Lys-103-labeled protein for the receptor suggests that the positive charge on this residue in the native molecule may interfere with IL-1 receptor binding. The two fluorescent labeled IL-1 proteins described herein should provide interesting probes for the study of IL-1/IL-1 receptor interactions.	UPJOHN CO,UPJOHN LABS,301 HENRIETTA ST,KALAMAZOO,MI 49001	Pfizer								AURON PE, 1984, P NATL ACAD SCI-BIOL, V81, P7907, DOI 10.1073/pnas.81.24.7907; BIEMANN K, 1988, BIOMED ENVIRON MASS, V16, P99, DOI 10.1002/bms.1200160119; BORASCHI D, 1989, Biotherapy (Dordrecht), V1, P377, DOI 10.1007/BF02171014; CARTER DB, 1988, PROTEINS, V3, P121, DOI 10.1002/prot.340030207; CLORE GM, 1991, BIOCHEMISTRY-US, V30, P2315, DOI 10.1021/bi00223a005; DUSZYNSKI J, 1988, BIOCHEMISTRY-US, V27, P6288, DOI 10.1021/bi00417a014; EPPS DE, 1992, J BIOL CHEM, V267, P3129; FINZEL BC, 1989, J MOL BIOL, V209, P779, DOI 10.1016/0022-2836(89)90606-2; KAMOGASHIRA T, 1988, BIOCHEM BIOPH RES CO, V150, P1106, DOI 10.1016/0006-291X(88)90743-7; LEHRER SS, 1988, BIOCHEMISTRY-US, V27, P5899, DOI 10.1021/bi00416a012; MARCH CJ, 1985, NATURE, V315, P641, DOI 10.1038/315641a0; MEYERS CA, 1987, J BIOL CHEM, V262, P11176; MIZEL SB, 1978, J IMMUNOL, V120, P1497; OPPENHEIM JJ, 1986, IMMUNOL TODAY, V7, P45, DOI 10.1016/0167-5699(86)90124-6; PRENDERGAST FG, 1983, J BIOL CHEM, V258, P7541; PRIESTLE JP, 1988, EMBO J, V7, P339, DOI 10.1002/j.1460-2075.1988.tb02818.x; SPEZIALE SC, 1989, LYMPHOKINE RES, V8, P1; WINGFIELD P, 1989, EUR J BIOCHEM, V179, P565, DOI 10.1111/j.1432-1033.1989.tb14584.x; WINGFIELD P, 1986, EUR J BIOCHEM, V160, P491, DOI 10.1111/j.1432-1033.1986.tb10066.x; YEM AW, 1988, LYMPHOKINE RES, V7, P85; YEM AW, 1989, J BIOL CHEM, V264, P17691	21	29	32	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 15	1992	267	5					3122	3128						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HD154	1531337				2022-12-25	WOS:A1992HD15400048
J	BETTLER, B; TEXIDO, G; RAGGINI, S; RUEGG, D; HOFSTETTER, H				BETTLER, B; TEXIDO, G; RAGGINI, S; RUEGG, D; HOFSTETTER, H			IMMUNOGLOBULIN-E-BINDING SITE IN FC-EPSILON RECEPTOR (FC-EPSILON-RII CD23) IDENTIFIED BY HOMOLOG-SCANNING MUTAGENESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-AFFINITY RECEPTOR; MOLECULAR-STRUCTURE; ANIMAL LECTINS; ADHESION MOLECULES; IGE RECEPTOR; SOLUBLE CD23; EXPRESSION; CDNA; SEQUENCE; FC-EPSILON-RII/CD23	The IgE-binding site of the human low-affinity receptor for IgE (Fc(epsilon)RII/CD23) has previously been mapped to the extracellular domain between amino acid residues 160 and 287. We now have investigated which conformational epitope within this domain specifies the receptor-ligand interaction. The analysis of homolog-scanning mutants expressed in mammalian cells demonstrates that amino acid side chains that affect IgE binding are located in two discontinuous segments, between residues 165-190 and 224-256. The overall structure of the chimeric binding domains, as probed with 11 conformation-sensitive monoclonal antibodies, is generally not distorted, except by replacement of residues 165-183. In this region, disruption of binding function appears to be caused by global conformational constraints on the binding site. Substitution and deletion mutants demonstrate that six out of eight extracellular cysteines, Cys163, Cys174, Cys191, cys259, Cys273, and Cys282, are necessary for IgE binding and are most likely involved in intramolecular disulfide bridges. We show that the Fc(epsilon)RII domain delineated by Cys163 and Cys282 encodes all the structural information required to form the IgE-binding site.	SALK INST BIOL STUDIES, MOLEC NEUROBIOL LAB, SAN DIEGO, CA 92186 USA; CIBA GEIGY LTD, TAKARAZUKA 665, JAPAN	Salk Institute	BETTLER, B (corresponding author), CIBA GEIGY AG, DEPT BIOTECHNOL, DIV PHARMACEUT, CH-4002 BASEL, SWITZERLAND.		bettler, bernhard/AAO-8018-2020	Bettler, Bernhard/0000-0003-0842-8207				BETTLER B, 1989, P NATL ACAD SCI USA, V86, P7566, DOI 10.1073/pnas.86.19.7566; BETTLER B, 1989, P NATL ACAD SCI USA, V86, P7118, DOI 10.1073/pnas.86.18.7118; BRANDLEY BK, 1990, CELL, V63, P861, DOI 10.1016/0092-8674(90)90487-Y; CAPRON A, 1987, SCIENCE, V238, P1065, DOI 10.1126/science.3317823; CONRAD DH, 1990, ANNU REV IMMUNOL, V8, P623, DOI 10.1146/annurev.immunol.8.1.623; COOMBE DR, 1989, IMMUNOL TODAY, V10, P289, DOI 10.1016/0167-5699(89)90083-2; CUNNINGHAM BC, 1989, SCIENCE, V243, P1330, DOI 10.1126/science.2466339; CUNNINGHAM BC, 1989, SCIENCE, V244, P1081, DOI 10.1126/science.2471267; DELESPESSE G, 1991, ADV IMMUNOL, V49, P149; DELESPESSE G, 1989, IMMUNOL TODAY, V10, P159, DOI 10.1016/0167-5699(89)90173-4; DRICKAMER K, 1988, J BIOL CHEM, V263, P9557; FUHLENDORFF J, 1987, BIOCHEMISTRY-US, V26, P6757, DOI 10.1021/bi00395a027; GIGA Y, 1987, J BIOL CHEM, V262, P6197; GIORDA R, 1990, SCIENCE, V249, P1298, DOI 10.1126/science.2399464; GOLLNICK SO, 1990, J IMMUNOL, V144, P1974; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; IKUTA K, 1987, P NATL ACAD SCI USA, V84, P819, DOI 10.1073/pnas.84.3.819; KEHRY MR, 1989, P NATL ACAD SCI USA, V86, P7556, DOI 10.1073/pnas.86.19.7556; KIKUTANI H, 1986, CELL, V47, P657, DOI 10.1016/0092-8674(86)90508-8; LUDIN C, 1987, EMBO J, V6, P109, DOI 10.1002/j.1460-2075.1987.tb04726.x; MOSSALAYI MD, 1990, BLOOD, V75, P1924; MOSSALAYI MD, 1990, J EXP MED, V171, P959, DOI 10.1084/jem.171.3.959; MURAMOTO K, 1990, BIOCHIM BIOPHYS ACTA, V1039, P52, DOI 10.1016/0167-4838(90)90225-5; OSBORN L, 1990, CELL, V62, P3, DOI 10.1016/0092-8674(90)90230-C; PATTHY L, 1988, J MOL BIOL, V202, P689, DOI 10.1016/0022-2836(88)90550-5; RUSK CM, 1988, J IMMUNOL, V140, P2249; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SPIESS M, 1985, P NATL ACAD SCI USA, V82, P6465, DOI 10.1073/pnas.82.19.6465; STOOLMAN LM, 1989, CELL, V56, P907, DOI 10.1016/0092-8674(89)90620-X; SUTER U, 1987, NUCLEIC ACIDS RES, V15, P7295, DOI 10.1093/nar/15.18.7295; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; VERCELLI D, 1989, NATURE, V338, P649, DOI 10.1038/338649a0	32	38	47	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	1992	267	1					185	191						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY439	1530929				2022-12-25	WOS:A1992GY43900034
J	ARUNACHALAM, U; MASSEY, V; VAIDYANATHAN, CS				ARUNACHALAM, U; MASSEY, V; VAIDYANATHAN, CS			P-HYDROXYPHENYLACETATE-3-HYDROXYLASE - A 2-PROTEIN COMPONENT ENZYME	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PARA-HYDROXYBENZOATE HYDROXYLASE; 4-HYDROXYPHENYLACETIC ACID; TRICHOSPORON-CUTANEUM; PHENOL HYDROXYLASE; PURIFICATION; FLAVOPROTEIN; DEGRADATION; CATABOLISM; PATHWAY	p-Hydroxyphenylacetate-3-hydroxylase, an inducible enzyme isolated from the soil bacterium Pseudomonas putida, catalyzes the conversion of p-hydroxyphenylacetate to 3,4-dihydroxyphenylacetate. The enzyme requires two protein components: a flavoprotein and a colorless protein referred to as the coupling protein. The flavoprotein alone in the presence of p-hydroxyphenylacetate and substrate analogs catalyzes the wasteful oxidation of NADH with the stoichiometric generation of H2O2. A 1:1 complex of the flavoprotein and coupling protein is required for stoichiometric product formation. Such complex formation also eliminates the nonproductive NADH oxidase activity of the flavoprotein. A new assay measuring the product formation activity of the enzyme was developed using homoprotocatechuate-2,3-dioxygenase, as monitoring the oxidation of NADH was not sufficient to demonstrate enzyme activity. The coupling protein does not seem to have any redox center in it. Thus, this 2-component flavin hydroxylase resembles the other aromatic hydroxylases in that the only redox chromophore present is FAD.	UNIV MICHIGAN,SCH MED,DEPT BIOL CHEM,ANN ARBOR,MI 48109; INDIAN INST SCI,DEPT BIOCHEM,BANGALORE 560012,KARNATAKA,INDIA	University of Michigan System; University of Michigan; Indian Institute of Science (IISC) - Bangalore	MASSEY, V (corresponding author), UNIV MICHIGAN,SCH MED,DEPT BIOL CHEM,ANN ARBOR,MI 48109, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM011106, R37GM011106] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-11106] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADACHI K, 1964, BIOCHIM BIOPHYS ACTA, V93, P483, DOI 10.1016/0304-4165(64)90332-0; ARUNACHALAM U, 1991, THESIS INDIAN I SCI, P114; BARBOUR MG, 1981, J BACTERIOL, V147, P844, DOI 10.1128/JB.147.3.844-850.1981; Brumby P.E., 1967, METHOD ENZYMOL, V10, P463, DOI DOI 10.1016/0076-6879(67)10078-5; COOPER RA, 1980, J BACTERIOL, V143, P302, DOI 10.1128/JB.143.1.302-306.1980; CUSKEY SM, 1988, J BACTERIOL, V176, P393; DEVI NA, 1975, J BACTERIOL, V122, P866, DOI 10.1128/JB.122.3.866-873.1975; HARELAND WA, 1975, J BACTERIOL, V121, P272, DOI 10.1128/JB.121.1.272-285.1975; HOWELL LG, 1970, BIOCHEM BIOPH RES CO, V40, P887, DOI 10.1016/0006-291X(70)90986-1; HOWELL LG, 1972, J BIOL CHEM, V247, P4340; MASSEY V, 1978, BIOCHEMISTRY-US, V17, P9, DOI 10.1021/bi00594a002; MASSEY V, 1991, FLAVINS AND FLAVOPROTEINS 1990, P59; NEUJAHR HY, 1973, EUR J BIOCHEM, V35, P386, DOI 10.1111/j.1432-1033.1973.tb02851.x; ORVILLE AM, 1989, J BIOL CHEM, V264, P8791; POWLOWSKI JB, 1987, J BIOL CHEM, V262, P69; RAJU SG, 1988, BIOCHEM BIOPH RES CO, V154, P537, DOI 10.1016/0006-291X(88)90173-8; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SPARNINS VL, 1978, J BACTERIOL, V136, P449, DOI 10.1128/JB.136.1.449-451.1978; SPARNINS VL, 1974, J BACTERIOL, V120, P159, DOI 10.1128/JB.120.1.159-167.1974; SPARNINS VL, 1976, J BACTERIOL, V127, P362, DOI 10.1128/JB.127.1.362-366.1976; STRICKLAND S, 1973, J BIOL CHEM, V248, P2944; TAYLOR MG, 1990, J BIOL CHEM, V265, P13687; WHITESTEVENS RH, 1972, J BIOL CHEM, V247, P2358	23	57	57	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1992	267	36					25848	25855						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KD073	1464599				2022-12-25	WOS:A1992KD07300042
J	NICHOLSON, AC; HAJJAR, DP				NICHOLSON, AC; HAJJAR, DP			TRANSFORMING GROWTH-FACTOR-BETA UP-REGULATES LOW-DENSITY-LIPOPROTEIN RECEPTOR-MEDIATED CHOLESTEROL-METABOLISM IN VASCULAR SMOOTH-MUSCLE CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARACHIDONIC-ACID; ENDOTHELIAL-CELLS; PROSTAGLANDIN-E2 SYNTHESIS; PROSTACYCLIN PRODUCTION; ESTER ACCUMULATION; HUMAN-FIBROBLASTS; GENE-EXPRESSION; MESSENGER-RNA; MACROPHAGES; STIMULATION	The effects of transforming growth factor-beta (TGF-beta) on low density lipoprotein (LDL) receptor-mediated cholesterol metabolism were evaluated in vascular smooth muscle cells. TGF-beta significantly increased the binding, uptake, and degradation of I-125-LDL. This increase was paralleled by an increase in LDL receptor mRNA steady state levels and an increase in cholesterol esterification. The increase in LDL cholesterol metabolism was independent of proliferation. LDL receptor expression in response to TGF-beta was not affected by coincubation with an antibody against platelet-derived growth factor or by cyclooxygenase inhibitors in arterial smooth muscle cells, suggesting that TGF-beta's effect was not mediated through platelet-derived growth factor or prostaglandins, as demonstrated in other cell systems. However, coincubation with pertussis toxin abrogated the effect of TGF-beta on LDL receptor expression, suggesting that a pertussis toxin-sensitive G-protein may be involved in the signal transduction pathway. These results are discussed in terms of their potential effects on cellular cholesterol trafficking.	CORNELL UNIV, MED CTR, COLL MED, DEPT BIOCHEM, 1300 YORK AVE, NEW YORK, NY 10021 USA; CORNELL UNIV, MED CTR, COLL MED, DEPT PATHOL, NEW YORK, NY 10021 USA	Cornell University; Cornell University	HAJJAR, DP (corresponding author), CORNELL UNIV, MED CTR, COLL MED, DEPT BIOCHEM, 1300 YORK AVE, NEW YORK, NY 10021 USA.				NATIONAL CENTER FOR RESEARCH RESOURCES [K01RR000085] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL046403] Funding Source: NIH RePORTER; NCRR NIH HHS [RR00085] Funding Source: Medline; NHLBI NIH HHS [HL-46403] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANTONELLIORLIDGE A, 1989, P NATL ACAD SCI USA, V86, P4544, DOI 10.1073/pnas.86.12.4544; ASSOIAN RK, 1986, J CELL BIOL, V102, P1217, DOI 10.1083/jcb.102.4.1217; AUWERX JH, 1989, MOL CELL BIOL, V9, P2298, DOI 10.1128/MCB.9.6.2298; AUWERX JH, 1989, P NATL ACAD SCI USA, V86, P1133, DOI 10.1073/pnas.86.4.1133; BATTEGAY EJ, 1990, CELL, V63, P515, DOI 10.1016/0092-8674(90)90448-N; BILHEIMER DW, 1972, BIOCHIM BIOPHYS ACTA, V260, P212, DOI 10.1016/0005-2760(72)90034-3; BJORKERUD S, 1991, ARTERIOSCLER THROMB, V11, P892, DOI 10.1161/01.ATV.11.4.892; BREVIARIO F, 1990, ARTERIOSCLEROSIS, V10, P129, DOI 10.1161/01.ATV.10.1.129; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; BROWN MS, 1980, J BIOL CHEM, V255, P9344; CHAIT A, 1980, P NATL ACAD SCI-BIOL, V77, P4084, DOI 10.1073/pnas.77.7.4084; CHAIT A, 1988, BIOCHIM BIOPHYS ACTA, V960, P183, DOI 10.1016/0005-2760(88)90063-X; CHEN JK, 1988, IN VITRO CELL DEV B, V24, P199; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COUGHLIN SR, 1981, P NATL ACAD SCI-BIOL, V78, P7134, DOI 10.1073/pnas.78.11.7134; DANIEL TO, 1987, J BIOL CHEM, V262, P11893; DAVIES PF, 1982, BIOCHIM BIOPHYS ACTA, V712, P26, DOI 10.1016/0005-2760(82)90080-7; FALCONE DJ, 1984, J CELL BIOL, V99, P1266, DOI 10.1083/jcb.99.4.1266; FOGELMAN AM, 1988, J CELL SCI, P135; GOERIG M, 1988, J BIOL CHEM, V263, P19384; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; GOLDSTEIN JL, 1977, J CLIN INVEST, V59, P1196, DOI 10.1172/JCI108744; GOLDSTEIN JL, 1980, J BIOL CHEM, V255, P1839; HABENICHT AJR, 1985, J CLIN INVEST, V75, P1381, DOI 10.1172/JCI111839; HABENICHT AJR, 1981, J BIOL CHEM, V256, P2329; HABENICHT AJR, 1980, J BIOL CHEM, V255, P5134; HABENICHT AJR, 1990, NATURE, V345, P634, DOI 10.1038/345634a0; HAJJAR DP, 1984, ENZYME, V32, P218, DOI 10.1159/000469481; HAJJAR DP, 1980, AM J PATHOL, V100, P683; HAJJAR DP, 1982, J CLIN INVEST, V70, P479, DOI 10.1172/JCI110639; HAJJAR DP, 1987, J BIOL CHEM, V262, P6976; HAJJAR DP, 1983, J LIPID RES, V24, P1176; HAJJAR DP, 1983, J BIOL CHEM, V258, P192; HALEY NJ, 1980, J LIPID RES, V21, P961; HANNAN RL, 1988, GROWTH FACTORS, V1, P1; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; HORI T, 1989, EXP CELL RES, V185, P41, DOI 10.1016/0014-4827(89)90035-9; HOWE PH, 1990, J CELL PHYSIOL, V142, P39, DOI 10.1002/jcp.1041420106; HOWE PH, 1989, CANCER RES, V49, P6024; ISHIKAWA TT, 1974, J LIPID RES, V15, P286; KAVANAUGH WM, 1988, J BIOL CHEM, V263, P8470; KORN JH, 1983, J CLIN INVEST, V71, P1240, DOI 10.1172/JCI110873; LEOF EB, 1986, P NATL ACAD SCI USA, V83, P2453, DOI 10.1073/pnas.83.8.2453; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LYONS RM, 1988, J CELL BIOL, V106, P1659, DOI 10.1083/jcb.106.5.1659; MAJACK RA, 1990, J CELL BIOL, V111, P239, DOI 10.1083/jcb.111.1.239; MAJESKY MW, 1991, J CLIN INVEST, V88, P904, DOI 10.1172/JCI115393; MARSHALL PJ, 1985, ANAL BIOCHEM, V145, P192, DOI 10.1016/0003-2697(85)90347-1; MAZZONE T, 1990, J BIOL CHEM, V265, P5145; MAZZONE T, 1989, J BIOL CHEM, V264, P1787; MERWIN JR, 1991, AM J PATHOL, V138, P37; MIDDLETON B, 1992, BIOCHEM BIOPH RES CO, V182, P830, DOI 10.1016/0006-291X(92)91807-3; POMERANTZ KB, 1984, CIRC RES, V54, P554, DOI 10.1161/01.RES.54.5.554; RAPPOLEE DA, 1988, SCIENCE, V241, P708, DOI 10.1126/science.3041594; RISTIMAKI A, 1990, ARTERIOSCLEROSIS, V10, P653, DOI 10.1161/01.ATV.10.4.653; SATO Y, 1989, J CELL BIOL, V109, P309, DOI 10.1083/jcb.109.1.309; SINZINGER H, 1985, BRIT J RADIOL, V58, P1023, DOI 10.1259/0007-1285-58-694-1023; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; TASHJIAN AH, 1985, P NATL ACAD SCI USA, V82, P4535, DOI 10.1073/pnas.82.13.4535; TSUNAWAKI S, 1988, NATURE, V334, P260, DOI 10.1038/334260a0; VINCENT JE, 1990, BIOCHIM BIOPHYS ACTA, V1042, P255, DOI 10.1016/0005-2760(90)90017-R; WAKEFIELD LM, 1988, J BIOL CHEM, V263, P7646; WITTE LD, 1982, J BIOL CHEM, V257, P5392	63	56	56	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 25	1992	267	36					25982	25987						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KD073	1464611				2022-12-25	WOS:A1992KD07300060
J	GLENNON, MC; BIRD, GS; TAKEMURA, H; THASTRUP, O; LESLIE, BA; PUTNEY, JW				GLENNON, MC; BIRD, GS; TAKEMURA, H; THASTRUP, O; LESLIE, BA; PUTNEY, JW			INSITU IMAGING OF AGONIST-SENSITIVE CALCIUM POOLS IN AR4-2J PANCREATOMA CELLS - EVIDENCE FOR AN AGONIST AND INOSITOL 1,4,5-TRISPHOSPHATE-SENSITIVE CALCIUM POOL IN OR CLOSELY ASSOCIATED WITH THE NUCLEAR-ENVELOPE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; ENDOPLASMIC-RETICULUM; 3-KINASE ACTIVITY; PHOSPHOLIPASE-C; PLASMA-MEMBRANE; ACINAR-CELLS; LIVER NUCLEI; CA-2+ POOL; FURA-2; MITOCHONDRIA	The activation of phospholipase C by hormones and neurotransmitters activates a complex combination of Ca2+ release and accumulation by intracellular organelles. Previously, we demonstrated that, in some cell types, the fluorescent Ca2+ indicator, fura-2, can be loaded into intracellular, agonist-sensitive Ca2+ pools (Glennon, M. C., Bird, G. St. J., Kwan, C.-Y., and Putney, J. W., Jr. (1992) J. Biol. Chem. 267, 8230-8233). In the current study, we have attempted to exploit this phenomenon by employing digital fluorescence imaging of compartmentalized fura-2 to investigate the localization and function of the major intracellular sites of Ca2+ regulation in AR4-2J pancreatoma cells. By judicious use of a surface receptor agonist together with the Ca2+-ATPase inhibitor, thapsigargin, cellular regions were identified whose behavior indicates that they contain the sites of agonist- and inositol 1,4,5-trisphosphate-mediated intracellular Ca2+ release. These regions were located throughout the cell and may include the nuclear envelope. They were distinct in locus and behavior from two other regions, which counterstained with fluorescent markers for nuclei and mitochondria. Fura-2 in mitochondrial regions reported low resting levels of [Ca2+], and revealed that organelles in these regions accumulate and retain Ca2+ after agonist activation. These findings demonstrate that fluorescent Ca2+ indicators can be employed to directly monitor changes in [Ca2+] in the major Ca2+-regulating organelles, and provide the first in situ visualization and localization of the major sites of Ca2+ regulation in cells.	NIEHS, CELLULAR & MOLEC PHARMACOL, CALCIUM REGULAT SECT, POB 12233, RES TRIANGLE PK, NC 27709 USA; UNIV COPENHAGEN HOSP, RIGSHOSP, DEPT CLIN CHEM, DK-2100 COPENHAGEN, DENMARK; UNIV COPENHAGEN HOSP, RIGSHOSP, THROMBOSIS GRP, DK-2100 COPENHAGEN, DENMARK	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); Rigshospitalet; University of Copenhagen; Rigshospitalet; University of Copenhagen			Bird, Gary/AAI-8186-2021; Putney, James W/F-7247-2019	Bird, Gary/0000-0003-1389-8748; Putney, James W/0000-0002-3379-4789				BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BIRD GS, 1991, NATURE, V352, P162, DOI 10.1038/352162a0; BIRD GS, 1992, CELL CALCIUM, V13, P49, DOI 10.1016/0143-4160(92)90029-R; BIRD GSJ, 1991, BIOCHEM J, V273, P541, DOI 10.1042/bj2730541; BURGESS GM, 1991, J BIOL CHEM, V266, P4772; CHACON E, 1992, BIOCHEM J, V281, P871, DOI 10.1042/bj2810871; CONNOR JA, 1988, BRAIN RES BULL, V21, P353, DOI 10.1016/0361-9230(88)90147-5; DENTON RM, 1985, AM J PHYSIOL, V249, pE543, DOI 10.1152/ajpendo.1985.249.6.E543; DIVECHA N, 1991, EMBO J, V10, P3207, DOI 10.1002/j.1460-2075.1991.tb04883.x; DIVIRGILIO F, 1988, J IMMUNOL, V140, P915; DIVIRGILIO F, 1990, CELL CALCIUM, V11, P57, DOI 10.1016/0143-4160(90)90059-4; GLENNON MC, 1992, J BIOL CHEM, V267, P8230; GOLDMAN WF, 1989, CIRC RES, V64, P1019, DOI 10.1161/01.RES.64.5.1019; GUNTER TE, 1988, AM J PHYSIOL, V255, pC304, DOI 10.1152/ajpcell.1988.255.3.C304; HORSTMAN DA, 1988, J BIOL CHEM, V263, P15297; JOHNSON LV, 1980, P NATL ACAD SCI-BIOL, V77, P990, DOI 10.1073/pnas.77.2.990; KIMURA Y, 1990, COMP BIOCHEM PHYS B, V97, P527, DOI 10.1016/0305-0491(90)90154-L; KOCH GLE, 1990, BIOESSAYS, V12, P527, DOI 10.1002/bies.950121105; KRAUSEKH, 1991, FEBS LETT, V285, P225; KWAN CY, 1990, J BIOL CHEM, V265, P678; LANINI L, 1992, J BIOL CHEM, V267, P11548; LOESSBERG PA, 1991, J BIOL CHEM, V266, P1363; LYTTON J, 1991, J BIOL CHEM, V266, P17067; MALVIYA AN, 1990, P NATL ACAD SCI USA, V87, P9270, DOI 10.1073/pnas.87.23.9270; MCCORMACK JG, 1989, BIOCHIM BIOPHYS ACTA, V973, P420, DOI 10.1016/S0005-2728(89)80384-6; MELDOLESI J, 1988, TRENDS NEUROSCI, V11, P449, DOI 10.1016/0166-2236(88)90197-X; MENNITI FS, 1991, MOL PHARMACOL, V40, P727; MIYATA H, 1991, AM J PHYSIOL, V261, pH1123, DOI 10.1152/ajpheart.1991.261.4.H1123; NAIRN RC, 1980, CLIN EXP IMMUNOL, V39, P1; NICOTERA P, 1990, P NATL ACAD SCI USA, V87, P6858, DOI 10.1073/pnas.87.17.6858; PAROD RJ, 1980, AM J PHYSIOL, V239, pG99, DOI 10.1152/ajpgi.1980.239.2.G99; POGGIOLI J, 1982, PFLUG ARCH EUR J PHY, V392, P239, DOI 10.1007/BF00584303; RASMUSSEN H, 1985, CALCIUM BIOL SYSTEMS, P13; ROSS CA, 1989, NATURE, V339, P468, DOI 10.1038/339468a0; ROSSIER MF, 1991, TRENDS NEUROSCI, V14, P310, DOI 10.1016/0166-2236(91)90143-I; SCANLON M, 1987, J BIOL CHEM, V262, P6308; SOMLYO AP, 1985, NATURE, V314, P622, DOI 10.1038/314622a0; STEINBERG SF, 1987, AM J PHYSIOL, V253, pC744, DOI 10.1152/ajpcell.1987.253.5.C744; STOLZE H, 1980, AM J PHYSIOL, V238, pG338, DOI 10.1152/ajpgi.1980.238.4.G338; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; THASTRUP O, 1990, AGENTS ACTIONS, V29, P8, DOI 10.1007/BF01964706; TSIEN RY, 1989, ANNU REV NEUROSCI, V12, P227, DOI 10.1146/annurev.neuro.12.1.227; WIER WG, 1987, SCIENCE, V235, P325, DOI 10.1126/science.3798114; WILLIAMS DA, 1990, CELL CALCIUM, V11, P55, DOI 10.1016/0143-4160(90)90058-3; WILLIAMS DA, 1985, NATURE, V318, P558, DOI 10.1038/318558a0; WOMACK MD, 1985, J NEUROSCI, V5, P3370	46	42	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	1992	267	35					25568	25575						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KB603	1460052				2022-12-25	WOS:A1992KB60300098
J	LYTLE, C; XU, JC; BIEMESDERFER, D; HAAS, M; FORBUSH, B				LYTLE, C; XU, JC; BIEMESDERFER, D; HAAS, M; FORBUSH, B			THE NA-K-CL COTRANSPORT PROTEIN OF SHARK RECTAL GLAND .1. DEVELOPMENT OF MONOCLONAL-ANTIBODIES, IMMUNOAFFINITY PURIFICATION, AND PARTIAL BIOCHEMICAL-CHARACTERIZATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							H-3 BUMETANIDE BINDING; DOGFISH SQUALUS-ACANTHIAS; EHRLICH ASCITES-CELLS; DUCK RED-CELLS; POLYACRYLAMIDE GELS; LOOP DIURETICS; CO-TRANSPORT; DOG KIDNEY; CYCLIC-AMP; MECHANISM	The Na-K-Cl cotransporter mediates the coupled transport of Na, K, and Cl across the plasma membrane of many animal cell membranes. It is inhibited by loop diuretics such as furosemide, bumetanide, and benzmetanide. We have developed a panel of monoclonal antibodies directed against the 195-kDa shark rectal gland Na-K-Cl cotransport protein. Four representative antibodies (J3, J4, J7, and J25), each of which recognizes a discrete structural domain, were selected for detailed characterization. When a radiolabeled loop diuretic is bound to the cotransporter prior to solubilization, each antibody immunoprecipitates the same diuretic-protein complex. Of the four antibodies, J4 favors the native protein over the denatured one and does not bind well to proteolytic fragments; in contrast, J7 recognizes the cotransporter only after it has been solubilized. J3, J7, and J25 each recognize a unique ensemble of proteolytic fragments of the 195-kDa protein; analysis of the patterns of recognition has yielded a tentative assignment of the approximate location of the epitopes within the peptide. When the cotransport protein is treated with N-glycanase to remove N-linked oligosaccharides, its apparent mass decreases to approximately 135 kDa. The deglycosylated form is recognized by each of the antibodies except J25; this suggests that the J25 epitope is within the oligosaccharide component or in a peptide domain whose folding is disturbed by carbohydrate removal. An immunoaffinity matrix constructed with the J4 antibody permits single-step purification of the 195-kDa protein; other proteins copurify with the large glycoprotein, but none of these appear to be subunits of a stoichiometric complex. The amino acid sequence of four fragments of the 195-kDa cotransport protein is reported. Immunofluorescence and immunoelectron microscopy demonstrates, in agreement with physiological evidence, that the 195-kDa protein is distributed along the basolateral membrane and excluded from the apical membrane of the rectal gland secretory cell.	YALE UNIV, SCH MED, DEPT INTERNAL MED, NEW HAVEN, CT 06510 USA; MT DESERT ISL BIOL LAB, SALSBURY COVE, ME 04672 USA	Yale University; Mount Desert Island Biological Laboratory	LYTLE, C (corresponding author), YALE UNIV, SCH MED, DEPT CELLULAR & MOLEC PHYSIOL, 333 CEDAR ST, NEW HAVEN, CT 06510 USA.			Lytle, Christian/0000-0001-5442-1546	NIDDK NIH HHS [DK17433] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK017433] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADORANTE JS, 1990, J GEN PHYSIOL, V96, P1153, DOI 10.1085/jgp.96.6.1153; BIEMESDERFER D, 1992, AM J PHYSIOL, V262, pF55, DOI 10.1152/ajprenal.1992.262.1.F55; BULGER RE, 1963, ANAT REC, V147, P95, DOI 10.1002/ar.1091470108; DUNHAM PB, 1990, P NATL ACAD SCI USA, V87, P6828, DOI 10.1073/pnas.87.17.6828; EPSTEIN FH, 1985, ANN NY ACAD SCI, V456, P187, DOI 10.1111/j.1749-6632.1985.tb14864.x; FEIT PW, 1988, J MEMBRANE BIOL, V103, P135, DOI 10.1007/BF01870944; FORBUSH B, 1992, AM J PHYSIOL, V262, pC1000, DOI 10.1152/ajpcell.1992.262.4.C1000; FORBUSH B, 1988, BIOPHYS J, V53, pA222; FORBUSH B, 1983, J BIOL CHEM, V258, P1787; Forbush B., 1989, BIOPHYS J, V55, p422a; FRANKLIN CC, 1989, J BIOL CHEM, V264, P6667; GECK P, 1986, J MEMBRANE BIOL, V91, P97, DOI 10.1007/BF01925787; GREGER R, 1984, PFLUG ARCH EUR J PHY, V402, P376, DOI 10.1007/BF00583938; GREGER R, 1985, PFLUG ARCH EUR J PHY, V403, P446, DOI 10.1007/BF00589260; GREGER R, 1984, PFLUG ARCH EUR J PHY, V402, P63, DOI 10.1007/BF00584833; GREGER R, 1983, KLIN WOCHENSCHR, V61, P1019, DOI 10.1007/BF01537500; HAAS M, 1986, J BIOL CHEM, V261, P8434; HAAS M, 1985, J GEN PHYSIOL, V85, P649, DOI 10.1085/jgp.85.5.649; HAAS M, 1990, AM J PHYSIOL, V259, pC557, DOI 10.1152/ajpcell.1990.259.4.C557; HAAS M, 1989, ANNU REV PHYSIOL, V51, P443, DOI 10.1146/annurev.physiol.51.1.443; HAAS M, 1991, AM J PHYSIOL, V260, pC791, DOI 10.1152/ajpcell.1991.260.4.C791; HAAS M, 1987, KIDNEY INT, V32, pS134; HAAS M, 1987, AM J PHYSIOL, V253, pC243, DOI 10.1152/ajpcell.1987.253.2.C243; HEGDE RS, 1992, J MEMBRANE BIOL, V126, P27; HUNKAPILLER MW, 1983, METHOD ENZYMOL, V91, P227; KENNETT RH, 1980, MONOCLONAL ANTIBODIE; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LYTLE C, 1990, J GEN PHYSIOL, V96, pA44; LYTLE C, 1992, AM J PHYSIOL, V262, pC1009, DOI 10.1152/ajpcell.1992.262.4.C1009; LYTLE C, 1992, J BIOL CHEM, V267, P25438; MCCLEAN W, 1973, HISTOCHEM CYTOCHEM, V22, P1077; NELSON WJ, 1989, J CELL BIOL, V108, P893, DOI 10.1083/jcb.108.3.893; NEUHOFF V, 1988, ELECTROPHORESIS, V9, P255, DOI 10.1002/elps.1150090603; ODONNELL ME, 1989, J BIOL CHEM, V264, P20326; OGRADY SM, 1987, AM J PHYSIOL, V253, pC177, DOI 10.1152/ajpcell.1987.253.2.C177; PALFREY HC, 1980, AM J PHYSIOL, V238, pC139, DOI 10.1152/ajpcell.1980.238.3.C139; PEWITT EB, 1990, J BIOL CHEM, V265, P14364; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHNEIDER C, 1982, J BIOL CHEM, V257, P766; SHAPIRO M, 1991, J CLIN INVEST, V87, P1903, DOI 10.1172/JCI115215; SILVA P, 1984, J COMP PHYSIOL, V154, P139, DOI 10.1007/BF00684137; SILVA P, 1977, AM J PHYSIOL, V233, pF298, DOI 10.1152/ajprenal.1977.233.4.F298; TAKEYASU K, 1988, J BIOL CHEM, V263, P4347; TOKUYASU KT, 1989, HISTOCHEM J, V21, P163, DOI 10.1007/BF01007491; TOKUYASU KT, 1986, J MICROSC-OXFORD, V143, P139, DOI 10.1111/j.1365-2818.1986.tb02772.x	45	92	93	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	1992	267	35					25428	25437						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KB603	1460038				2022-12-25	WOS:A1992KB60300079
J	BURKE, J; PETTITT, JM; SCHACHTER, H; SARKAR, M; GLEESON, PA				BURKE, J; PETTITT, JM; SCHACHTER, H; SARKAR, M; GLEESON, PA			THE TRANSMEMBRANE AND FLANKING SEQUENCES OF BETA-1,2-N-ACETYLGLUCOSAMINYLTRANSFERASE-I SPECIFY MEDIAL-GOLGI LOCALIZATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-SPANNING DOMAIN; BREFELDIN-A CAUSES; ENDOPLASMIC-RETICULUM; RETENTION SIGNAL; IMMUNOELECTRON MICROSCOPY; MONOCLONAL-ANTIBODIES; SECRETORY PROTEINS; ESCHERICHIA-COLI; COMPLEX; APPARATUS	UDP-GlcNAc:alpha3-D-mannoside beta1,2-N-acetylglucosaminyltransferase I (GnTI) is an N(in)/C(out) (type II) membrane protein, localized in the medial-Golgi, that initiates the conversion of high mannose N-glycans to complex N-glycans. Anti-rabbit GnTI antibodies were generated using a purified, enzymatically active, bacterial recombinant fusion protein as immunogen. Rabbit GnTI was effectively retained in the Golgi complex of transfected COS-1 cells and murine L cells, as assessed by indirect immunofluorescence using the species-specific anti-GnTI antibodies; no surface expression of rabbit GnTI could be detected in the transfected cells. Rabbit GnTI, stably expressed in murine L cells, was localized by immunoperoxidase electron microscopy to the medial-cisternae of the Golgi stack. The role of the transmembrane domain of GnTI in Golgi localization was examined by generation of a hybrid construct containing the amino-terminal 31 amino acids of GnTI, corresponding to the 25-residue transmembrane (signal/anchor) domain and flanking hydrophilic sequences, fused with ovalbumin; this ovalbumin/GnTI hybrid molecule was retained in the Golgi complex of transfected COS cells and stably transfected murine L cells. No surface expression of ovalbumin/GnTI was detected. In contrast, ovalbumin fused to the equivalent domains of the human transferrin receptor, a type II cell-surface protein, was efficiently expressed on the cell surface of transfected cells. The ovalbumin/GnTI hybrid molecules in the transfected L cells were N-glycosylated, indicating an N(in)/C(out) membrane orientation, and were localized by immunoperoxidase electron microscopy to one or two cisternae of the medial-Golgi (90% of stained Golgi profiles showed medial-cisternae staining). These results show that a signal contained within the transmembrane domain and flanking residues of GnTI specifies medial-Golgi localization.	MONASH UNIV,ALFRED HOSP,SCH MED,DEPT PATHOL & IMMUNOL,COMMERCIAL RD,MELBOURNE,VIC 3181,AUSTRALIA; HOSP SICK CHILDREN,RES INST,TORONTO M5G 1X8,ONTARIO,CANADA	Florey Institute of Neuroscience & Mental Health; Monash University; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)				Gleeson, Paul/0000-0002-5336-6503				AOKI D, 1992, P NATL ACAD SCI USA, V89, P4319, DOI 10.1073/pnas.89.10.4319; BELTZER JP, 1991, J BIOL CHEM, V266, P973; BIRD P, 1987, J CELL BIOL, V105, P2905, DOI 10.1083/jcb.105.6.2905; CHEGE NW, 1990, J CELL BIOL, V111, P893, DOI 10.1083/jcb.111.3.893; COLLEY KJ, 1989, J BIOL CHEM, V264, P17619; COLLEY KJ, 1992, J BIOL CHEM, V267, P7784; DUNPHY WG, 1985, CELL, V40, P463, DOI 10.1016/0092-8674(85)90161-8; FARQUHAR MG, 1985, ANNU REV CELL BIOL, V1, P447, DOI 10.1146/annurev.cb.01.110185.002311; FUJIWARA T, 1988, J BIOL CHEM, V263, P18545; GABATHULER R, 1990, J CELL BIOL, V111, P1803, DOI 10.1083/jcb.111.5.1803; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GLABE CG, 1980, J BIOL CHEM, V255, P9236; GRAHAM RC, 1966, J HISTOCHEM CYTOCHEM, V14, P291, DOI 10.1177/14.4.291; GRIFFITHS G, 1986, SCIENCE, V234, P438, DOI 10.1126/science.2945253; JACKSON MR, 1990, EMBO J, V9, P3153, DOI 10.1002/j.1460-2075.1990.tb07513.x; KOOY J, 1992, J BIOL CHEM, V267, P20255; KOOY J, 1991, IMMUNOLOGY, V72, P418; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KUMAR R, 1990, P NATL ACAD SCI USA, V87, P9948, DOI 10.1073/pnas.87.24.9948; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; LIPSKY NG, 1985, SCIENCE, V228, P745, DOI 10.1126/science.2581316; Machamer C E, 1991, Trends Cell Biol, V1, P141, DOI 10.1016/0962-8924(91)90001-P; MACHAMER CE, 1990, P NATL ACAD SCI USA, V87, P6944, DOI 10.1073/pnas.87.18.6944; MCCARTHY K, 1963, LANCET, V2, P593; MEEK RL, 1982, J BIOL CHEM, V257, P2245; MELLMAN I, 1992, CELL, V68, P829, DOI 10.1016/0092-8674(92)90027-A; MOORE MW, 1988, CELL, V54, P777, DOI 10.1016/S0092-8674(88)91043-4; MULLIGAN RC, 1981, P NATL ACAD SCI-BIOL, V78, P2072, DOI 10.1073/pnas.78.4.2072; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; MUNRO S, 1991, EMBO J, V10, P3577, DOI 10.1002/j.1460-2075.1991.tb04924.x; NILSSON T, 1991, EMBO J, V10, P3567, DOI 10.1002/j.1460-2075.1991.tb04923.x; PAGANO RE, 1989, J CELL BIOL, V109, P2067, DOI 10.1083/jcb.109.5.2067; PAULSON JC, 1989, J BIOL CHEM, V264, P17615; PELHAM HRB, 1990, TRENDS BIOCHEM SCI, V15, P483, DOI 10.1016/0968-0004(90)90303-S; PELHAM HRB, 1991, CELL, V67, P449, DOI 10.1016/0092-8674(91)90517-3; REAVES B, 1992, J CELL BIOL, V116, P85, DOI 10.1083/jcb.116.1.85; ROSE JK, 1988, ANNU REV CELL BIOL, V4, P257, DOI 10.1146/annurev.cellbio.4.1.257; ROTH J, 1985, CELL, V43, P287, DOI 10.1016/0092-8674(85)90034-0; ROTH J, 1982, J CELL BIOL, V92, P223; ROTHMAN JE, 1992, NATURE, V355, P409, DOI 10.1038/355409a0; RUSSO RN, 1992, J BIOL CHEM, V267, P9241; Sambrook J, 1989, MOL CLONING LABORATO; SARKAR M, 1991, P NATL ACAD SCI USA, V88, P234, DOI 10.1073/pnas.88.1.234; SARKAR M, 1990, GLYCOCONJUGATE J, V7, P380; Schachter H, 1991, CURR OPIN STRUC BIOL, V1, P755, DOI 10.1016/0959-440X(91)90175-S; SCHNEIDER C, 1982, J BIOL CHEM, V257, P8516; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SUGANUMA T, 1991, J HISTOCHEM CYTOCHEM, V39, P299, DOI 10.1177/39.3.1899684; SWIFT AM, 1991, J CELL BIOL, V115, P19, DOI 10.1083/jcb.115.1.19; TAATJES DJ, 1988, J BIOL CHEM, V263, P6302; TANG BL, 1992, J BIOL CHEM, V267, P10122; TASSIN AM, 1985, J CELL BIOL, V101, P630, DOI 10.1083/jcb.101.2.630; TEASDALE RD, 1992, J BIOL CHEM, V267, P4084; ULRICH JT, 1986, J BIOL CHEM, V261, P7975; VISCHER P, 1981, EUR J BIOCHEM, V117, P275, DOI 10.1111/j.1432-1033.1981.tb06334.x; WASSLER M, 1987, BIOCHEM J, V247, P407, DOI 10.1042/bj2470407; WONG SH, 1992, J CELL BIOL, V117, P245, DOI 10.1083/jcb.117.2.245; WOOD SA, 1991, CELL, V67, P591, DOI 10.1016/0092-8674(91)90533-5; ZAMBONI L, 1967, J CELL BIOL, V35, P148	59	80	86	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1992	267	34					24433	24440						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KA263	1447191				2022-12-25	WOS:A1992KA26300047
J	DAS, KC; MISRA, HP				DAS, KC; MISRA, HP			ANTIARRHYTHMIC AGENTS - SCAVENGERS OF HYDROXYL RADICALS AND INHIBITORS OF NADPH-DEPENDENT LIPID-PEROXIDATION IN BOVINE LUNG MICROSOMES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REPERFUSION-INDUCED ARRHYTHMIAS; MYOCARDIAL ISCHEMIA REPERFUSION; SINGLET OXYGEN; RAT-HEART; HYDROGEN-PEROXIDE; FERRIC COMPLEXES; LIVER-MICROSOMES; INJURY; GENERATION; SUPEROXIDE	Antiarrhythmic drugs, e.g. lidocaine, quinidine, and procainamide have been suggested as a means of reducing myocardial damage. The mode of action of these drugs have been attributed to their "membrane-stabilizing" properties. However, as tissue ischemia reperfusion is reported to generate toxic species of oxygen, we investigated the oxygen radical scavenging properties of these drugs and their effect on NADPH-dependent lipid peroxidation. These antiarrhythmic drugs are found to be ineffective as superoxide radical scavengers but are potent scavengers of hydroxyl radical with rate constants of 1.8 x 10(10) M-1 s-1, 1.61 x 10(10) M-1 s-1, and 1.45 x 10(10) M-1 s-1 for quinidine, lidocaine and procainamide, respectively, as determined by deoxyribose assay. In EPR study, using 5,5-dimethyl-1-pyrroline N-oxide (DMPO) as a spin trap, lidocaine, quinidine, and procainamide caused a dose-dependent inhibition of DMPO-OH adduct formation. These drugs also caused a dose-dependent inhibition of NADPH-dependent lipid peroxidation when lung microsomes were incubated with NADPH in presence of Fe3+-ADP. We propose that the antiarrhythmic agents exert their beneficial effects, in part, by their ability to scavenge toxic species of oxygen and by reducing membrane lipid peroxidation.	VIRGINIA POLYTECH INST & STATE UNIV,VIRGINIA MARYLAND REG COLL VET MED,DEPT BIOMED SCI,BLACKSBURG,VA 24060	Virginia Polytechnic Institute & State University					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL042009] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL42009] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AKANMU D, 1991, ARCH BIOCHEM BIOPHYS, V288, P10, DOI 10.1016/0003-9861(91)90158-F; ARROYO CM, 1987, FEBS LETT, V221, P101, DOI 10.1016/0014-5793(87)80360-5; BERNHEIM F, 1948, J BIOL CHEM, V174, P257; BERNIER M, 1986, CIRC RES, V58, P331, DOI 10.1161/01.RES.58.3.331; BOVERIS A, 1972, BIOCHEM J, V128, P617, DOI 10.1042/bj1280617; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURNEY RG, 1974, AM HEART J, V88, P765, DOI 10.1016/0002-8703(74)90287-7; BURTON RM, 1955, METHOD ENZYMOL, V3, P246; COHEN G, 1978, PHOTOCHEM PHOTOBIOL, V28, P669, DOI 10.1111/j.1751-1097.1978.tb06993.x; COHEN G, 1980, ARCH BIOCHEM BIOPHYS, V199, P438, DOI 10.1016/0003-9861(80)90300-8; DAS KC, 1992, IN PRESS MOL CELL BI; FENTON HJ, 1895, P CHEM SOC LOND, V9, P113; FREEMAN BA, 1986, ROLE OXYGEN RADICALS, P201; GAUDUEL Y, 1984, J MOL CELL CARDIOL, V16, P459, DOI 10.1016/S0022-2828(84)80617-3; GUARNIERI C, 1980, J MOL CELL CARDIOL, V12, P797, DOI 10.1016/0022-2828(80)90081-4; HALLIWELL B, 1987, ANAL BIOCHEM, V165, P215, DOI 10.1016/0003-2697(87)90222-3; HARTENSTEIN J, 1986, CARDIOVASCULAR DRUGS, P331; INTERIAN A, 1991, J AM COLL CARDIOL, V17, P1581, DOI 10.1016/0735-1097(91)90651-O; KAKO KJ, 1987, J MOL CELL CARDIOL, V19, P209, DOI 10.1016/S0022-2828(87)80563-1; KENNEDY TP, 1989, J CLIN INVEST, V83, P1326, DOI 10.1172/JCI114019; KING MM, 1975, J BIOL CHEM, V250, P6496; KRONBRUST DJ, 1980, MOL PHARMACOL, V17, P400; KUKIELKA E, 1989, ARCH BIOCHEM BIOPHYS, V275, P540, DOI 10.1016/0003-9861(89)90400-1; LAI CS, 1978, ARCH BIOCHEM BIOPHYS, V190, P27, DOI 10.1016/0003-9861(78)90250-3; LAI CS, 1977, BIOCHEM BIOPH RES CO, V78, P51, DOI 10.1016/0006-291X(77)91220-7; MAK IT, 1988, CIRC RES, V63, P262, DOI 10.1161/01.RES.63.1.262; MANNING AS, 1984, CIRC RES, V55, P545, DOI 10.1161/01.RES.55.4.545; MARTIN D, 1986, PHYSL OXYGEN RADICAL, P131; MCCORD JM, 1968, J BIOL CHEM, V243, P5753; MCCORD JM, 1985, NEW ENGL J MED, V312, P159; MEERSON FZ, 1982, BASIC RES CARDIOL, V77, P465, DOI 10.1007/BF01907940; MISRA BR, 1990, J BIOL CHEM, V265, P15371; MISRA HP, 1984, CIRCULATION, V70, P260; MISRA HP, 1981, J BIOL CHEM, V256, P9994; MISRA HP, 1972, J BIOL CHEM, V247, P6960; MOORHOUSE CP, 1987, FEBS LETT, V213, P23; NETA P, 1968, ADV CHEM SER, P222; PHILLIPS AH, 1962, J BIOL CHEM, V237, P2652; PUNTARULO S, 1988, ARCH BIOCHEM BIOPHYS, V264, P482, DOI 10.1016/0003-9861(88)90313-X; RAO PS, 1983, MYOCARDIAL INJURY, P341; SCHAUB RG, 1977, J THORAC CARDIOV SUR, V74, P571; SHLAFER M, 1982, J THORAC CARDIOV SUR, V83, P830; STELZNER TJ, 1987, J APPL PHYSIOL, V63, P1877, DOI 10.1152/jappl.1987.63.5.1877; SVINGEN BA, 1978, PHOTOCHEM PHOTOBIOL, V28, P803, DOI 10.1111/j.1751-1097.1978.tb07022.x; SVINGEN BA, 1980, MOL BASIS ENV TOXICI, P69; THURMAN RG, 1972, EUR J BIOCHEM, V25, P420, DOI 10.1111/j.1432-1033.1972.tb01711.x; UNDROVINAS AI, 1990, AM J PHYSIOL, V259, pH1609, DOI 10.1152/ajpheart.1990.259.5.H1609; WEISS JJ, 1964, NATURE, V203, P183; WILLS ED, 1969, BIOCHEM J, V113, P315, DOI 10.1042/bj1130315; WOODWARD B, 1985, J MOL CELL CARDIOL, V17, P485, DOI 10.1016/S0022-2828(85)80053-5; YAMAMOTO Y, 1988, LIPID PEROXIDATION B, P32; ZANG LY, 1990, PHOTOCHEM PHOTOBIOL, V52, P677, DOI 10.1111/j.1751-1097.1990.tb08666.x; ZWEIER JL, 1987, P NATL ACAD SCI USA, V84, P1404, DOI 10.1073/pnas.84.5.1404	53	39	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1992	267	27					19172	19178						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JP593	1527038				2022-12-25	WOS:A1992JP59300027
J	JENG, ST; GARDNER, JF; GUMPORT, RI				JENG, ST; GARDNER, JF; GUMPORT, RI			TRANSCRIPTION TERMINATION INVITRO BY BACTERIOPHAGE-T7 RNA-POLYMERASE - THE ROLE OF SEQUENCE ELEMENTS WITHIN AND SURROUNDING A P-INDEPENDENT TRANSCRIPTION TERMINATOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; THREONINE OPERON; STABLE RNA; STEM-LOOP; DNA; T7; ATTENUATOR; EFFICIENCY; REGION; ELONGATION	Rho-independent transcription terminators in Escherichia coli contain a dG + dC-rich dyad-symmetrical structure that encodes an RNA hairpin structure and an adjacent, downstream dA + dT-rich region which encodes uridines at the 3'-end of the transcript. In the threonine (thr) attenuator, there are at least six sequence segments in the DNA that might affect termination: the sequence upstream of the attenuator, the deoxythymidine-rich stretch immediately preceding the G + C-rich region, the G + C-rich region itself and its hairpin loop-encoding region, the deoxyadenosine tract following the G + C-rich region, and the following downstream sequence. Our previous studies (Jeng, S.-T., Gardner, J. F., and Gumport, R. I. (1990) J. Biol. Chem. 265, 3823-3830) indicate that both the stability and sequence of the RNA hairpin formed by the G + C-rich region and the length of the uridine tract encoded by the deoxyadenosine stretch influence the termination of T7 RNA polymerase in vitro. In this report, we demonstrate that the template deoxythymidine run upstream of the G + C-rich region, the loop-encoding segment, and the sequences upstream and downstream of the thr attenuator also affect termination. These results indicate that: 1) a deoxythymidine tract is not absolutely required for termination, but increasing the number of deoxythymidines from one to nine base pairs causes T7 RNA polymerase to terminate more efficiently; 2) a template with the natural loop sequence reversed results in a higher termination efficiency than one encoded by the the wild-type attenuator; 3) the termination of T7 RNA polymerase is affected by sequences both proximal and distal to the thr attenuator.	UNIV ILLINOIS,DEPT BIOCHEM,415 ROGER ADAMS LAB,1209 W CALIF ST,URBANA,IL 61801; UNIV ILLINOIS,DEPT MICROBIOL,URBANA,IL 61801; UNIV ILLINOIS,COLL MED,URBANA,IL 61801; UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign; University of California System; University of California San Francisco				Jeng, Shih-Tong/0000-0002-3522-2792	NIGMS NIH HHS [GM 28717] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028717] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANTAO VP, 1991, NUCLEIC ACIDS RES, V19, P5901, DOI 10.1093/nar/19.21.5901; BREMER V, 1984, NUCLEIC ACIDS RES, V12, P4411; BRENDEL V, 1986, J BIOMOL STRUCT DYN, V3, P705, DOI 10.1080/07391102.1986.10508457; BURTON WS, 1989, THESIS U ILLINOIS UR; CARAFA YD, 1990, J MOL BIOL, V216, P835, DOI 10.1016/S0022-2836(99)80005-9; CARTER AD, 1981, J VIROL, V37, P636, DOI 10.1128/JVI.37.2.636-642.1981; CHEN LJ, 1988, NUCLEIC ACIDS RES, V16, P8411, DOI 10.1093/nar/16.17.8411; CHENG SWC, 1991, SCIENCE, V254, P1205, DOI 10.1126/science.1835546; CHRISTIANSEN J, 1988, NUCLEIC ACIDS RES, V16, P7457, DOI 10.1093/nar/16.15.7457; DUNN JJ, 1983, J MOL BIOL, V166, P477, DOI 10.1016/S0022-2836(83)80282-4; FARNHAM PJ, 1982, P NATL ACAD SCI-BIOL, V79, P998, DOI 10.1073/pnas.79.4.998; FARNHAM PJ, 1980, CELL, V20, P739, DOI 10.1016/0092-8674(80)90320-7; GARDNER JF, 1982, J BIOL CHEM, V257, P3896; GOLIGER JA, 1989, J MOL BIOL, V205, P331, DOI 10.1016/0022-2836(89)90344-6; GROEBE DR, 1988, NUCLEIC ACIDS RES, V16, P11725, DOI 10.1093/nar/16.24.11725; JENG ST, 1990, J BIOL CHEM, V265, P3823; KIEFER M, 1977, J VIROL, V22, P548, DOI 10.1128/JVI.22.2.548-552.1977; LEE DN, 1990, J BIOL CHEM, V265, P15145; LYNN SP, 1987, J MOL BIOL, V194, P59, DOI 10.1016/0022-2836(87)90715-7; LYNN SP, 1988, J BIOL CHEM, V263, P472; LYNN SP, 1985, J MOL BIOL, V183, P529, DOI 10.1016/0022-2836(85)90169-X; MARTIN FH, 1980, NUCLEIC ACIDS RES, V8, P2295, DOI 10.1093/nar/8.10.2295; MCALLISTER WT, 1977, VIROLOGY, V82, P288, DOI 10.1016/0042-6822(77)90004-6; MEAD DA, 1986, PROTEIN ENG, V1, P67, DOI 10.1093/protein/1.1.67; MILLETTE RL, 1970, COLD SPRING HARB SYM, V35, P135, DOI 10.1101/SQB.1970.035.01.020; PLATT T, 1986, ANNU REV BIOCHEM, V55, P339, DOI 10.1146/annurev.bi.55.070186.002011; REYNOLDS R, 1992, J MOL BIOL, V224, P53, DOI 10.1016/0022-2836(92)90575-5; REYNOLDS R, 1992, J MOL BIOL, V224, P31, DOI 10.1016/0022-2836(92)90574-4; SOUSA R, 1992, J MOL BIOL, V224, P319, DOI 10.1016/0022-2836(92)90997-X; STUDIER FW, 1972, SCIENCE, V176, P367, DOI 10.1126/science.176.4033.367; SURRATT CK, 1991, P NATL ACAD SCI USA, V88, P7983, DOI 10.1073/pnas.88.18.7983; TELESNITSKY A, 1989, BIOCHEMISTRY-US, V28, P5210, DOI 10.1021/bi00438a044; TELESNITSKY APW, 1989, J MOL BIOL, V205, P315, DOI 10.1016/0022-2836(89)90343-4; TUERK C, 1988, P NATL ACAD SCI USA, V85, P1364, DOI 10.1073/pnas.85.5.1364; VONHIPPEL PH, 1991, P NATL ACAD SCI USA, V88, P2307, DOI 10.1073/pnas.88.6.2307; VONHIPPEL PH, 1992, SCIENCE, V255, P809, DOI 10.1126/science.1536005; WRIGHT JJ, 1992, EMBO J, V11, P1957, DOI 10.1002/j.1460-2075.1992.tb05249.x; YAGER TD, 1991, BIOCHEMISTRY-US, V30, P1097, DOI 10.1021/bi00218a032; YAGER TD, 1987, ESCHERICHIA COLI SAL, V2, P1241; YANG MT, 1989, J BIOL CHEM, V266, P2634	40	32	33	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1992	267	27					19306	19312						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JP593	1527050				2022-12-25	WOS:A1992JP59300045
J	HASHIRAMOTO, M; KADOWAKI, T; CLARK, AE; MURAOKA, A; MOMOMURA, K; SAKURA, H; TOBE, K; AKANUMA, Y; YAZAKI, Y; HOLMAN, GD; KASUGA, M				HASHIRAMOTO, M; KADOWAKI, T; CLARK, AE; MURAOKA, A; MOMOMURA, K; SAKURA, H; TOBE, K; AKANUMA, Y; YAZAKI, Y; HOLMAN, GD; KASUGA, M			SITE-DIRECTED MUTAGENESIS OF GLUT1 IN HELIX-7 RESIDUE-282 RESULTS IN PERTURBATION OF EXOFACIAL LIGAND-BINDING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ERYTHROCYTE GLUCOSE TRANSPORTER; CYTOCHALASIN-B; SUGAR-TRANSPORT; PROTEOLYTIC DISSECTION; HEXOSE TRANSPORTER; CELL-SURFACE; PROTEINS; SEQUENCE; CARRIER; GENE	The structure-function relationship of the HepG2/erythrocyte-type glucose transporter (GLUT1) has been studied by in vitro site-directed mutagenesis. Chinese hamster ovary clones in which glucose transporters were transfected were shown by Western blotting with a GLUT1 anti-COOH-terminal peptide antibody to have expression levels of Gln282 --> Leu, Asn288 --> Ile, and Asn317 --> Ile mutations that were comparable with the wild type. All three mutant GLUT1 clones had high 2-deoxy-D-glucose transport activity compared with a nontransfected clone, suggesting that these residues are not absolutely required for the transport function. We have examined the possibility that the inner and outer portions of the transport pathway are structurally separate by measuring the interaction of the mutant transporters with the inside site-specific ligand cytochalasin B and the outside site-specific ligand 2-N-4-(1-azi-2,2,2-trifluoroethyl)benzoyl-1,3-bis(D-mannos-4-yloxy)-2-propylamine (ATB-BMPA). All three mutant GLUT1 clones showed high levels of cytochalasin B labeling, and the N288I and N317I mutants showed high levels of ATB-BMPA labeling. In contrast to the transport and cytochalasin B labeling results, the transmembrane helix 7 Gln282 --> Leu mutant was labeled by ATB-BMPA to a level that was only 5% of the level observed in the wild type. We have confirmed that this mutant was defective in the outer site by comparing the inhibition of wild-type and mutant 2-deoxy-D-glucose transport by the outside site-specific ligand 4,6-O-ethylidene-D-glucose. 4,6-O-Ethylidene-D-glucose inhibited wild-type transport with a K(i) of almost-equal-to 12 mM, but this was increased to >120 mM in the Gln282 --> Leu mutant. Thus, of the 3 residues mutated in this study, only glutamine 282 substitution causes a major perturbation in function, and this is a specific and striking reduction in the affinity for the outside site-specific ligands ATB-BMPA and 4,6-O-ethylidene-D-glucose.	ASAHI LIFE FDN,INST DIABET CARE & RES,CHIYODA KU,TOKYO 100,JAPAN; UNIV TOKYO,FAC MED,DEPT INTERNAL MED 3,BUNKYO KU,TOKYO 113,JAPAN; UNIV BATH,BATH BA2 7AY,AVON,ENGLAND	Asahi Life Foundation; University of Tokyo; University of Bath	HASHIRAMOTO, M (corresponding author), KOBE UNIV,SCH MED,DEPT INTERNAL MED 2,7-5-1 KUSUNOKI CHO,CHUO KU,KOBE 650,JAPAN.			Holman, Geoffrey/0000-0001-7045-1358				BALDWIN SA, 1989, ANNU REV PHYSIOL, V51, P459, DOI 10.1146/annurev.physiol.51.1.459; BARNELL WO, 1990, J BACTERIOL, V172, P7227, DOI 10.1128/jb.172.12.7227-7240.1990; BARNETT JEG, 1973, BIOCHEM J, V131, P211, DOI 10.1042/bj1310211; BASKETTER DA, 1978, J PHYSIOL-LONDON, V278, P389, DOI 10.1113/jphysiol.1978.sp012311; CAIRNS BR, 1989, P NATL ACAD SCI USA, V86, P7682, DOI 10.1073/pnas.86.20.7682; CAIRNS MT, 1987, BIOCHIM BIOPHYS ACTA, V905, P295, DOI 10.1016/0005-2736(87)90458-5; CALDERHEAD DM, 1988, J BIOL CHEM, V263, P12171; CELENZA JL, 1988, P NATL ACAD SCI USA, V85, P2130, DOI 10.1073/pnas.85.7.2130; CHANG YD, 1988, J BIOL CHEM, V263, P16696; CLARK AE, 1990, BIOCHEM J, V269, P615, DOI 10.1042/bj2690615; DAVIES A, 1987, J BIOL CHEM, V262, P9347; DAVIES AF, 1991, OCT M MOL BAS BIOL M; DEVES R, 1978, BIOCHIM BIOPHYS ACTA, V510, P339, DOI 10.1016/0005-2736(78)90034-2; GIBBS AF, 1988, BIOCHEM J, V256, P421, DOI 10.1042/bj2560421; GORGA FR, 1981, BIOCHEMISTRY-US, V20, P5108, DOI 10.1021/bi00521a003; GOULD GW, 1990, TRENDS BIOCHEM SCI, V15, P18, DOI 10.1016/0968-0004(90)90125-U; HARRISON SA, 1990, J BIOL CHEM, V265, P5793; HASEGAWA K, 1990, BIOCHIM BIOPHYS ACTA, V1051, P221, DOI 10.1016/0167-4889(90)90126-X; HOLMAN GD, 1981, BIOCHIM BIOPHYS ACTA, V646, P382, DOI 10.1016/0005-2736(81)90306-0; HOLMAN GD, 1987, BIOCHIM BIOPHYS ACTA, V897, P395, DOI 10.1016/0005-2736(87)90437-8; HOLMAN GD, 1982, BIOCHIM BIOPHYS ACTA, V655, P78; KABACK HR, 1990, TRENDS BIOCHEM SCI, V15, P309; KARIM AR, 1987, BIOCHIM BIOPHYS ACTA, V902, P402, DOI 10.1016/0005-2736(87)90208-2; KATAGIRI H, 1991, J BIOL CHEM, V266, P7769; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAIDEN MCJ, 1987, NATURE, V325, P641, DOI 10.1038/325641a0; MAIDEN MCJ, 1988, J BIOL CHEM, V263, P8003; MAY JM, 1989, J MEMBRANE BIOL, V108, P227, DOI 10.1007/BF01871737; MUECKLER M, 1985, SCIENCE, V229, P941, DOI 10.1126/science.3839598; OKA Y, 1990, NATURE, V345, P550, DOI 10.1038/345550a0; OKA Y, 1988, J BIOL CHEM, V263, P13432; QUIOCHO FA, 1986, ANNU REV BIOCHEM, V55, P287, DOI 10.1146/annurev.bi.55.070186.001443; SAUER N, 1990, EMBO J, V9, P3045, DOI 10.1002/j.1460-2075.1990.tb07500.x; SAUER N, 1989, FEBS LETT, V259, P43, DOI 10.1016/0014-5793(89)81489-9; SZKUTNICKA K, 1989, J BACTERIOL, V171, P4486, DOI 10.1128/JB.171.8.4486-4493.1989; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WADZINSKI BE, 1990, BIOCHEM J, V272, P151, DOI 10.1042/bj2720151; WALMSLEY AR, 1987, BIOCHIM BIOPHYS ACTA, V901, P229, DOI 10.1016/0005-2736(87)90119-2; ZHANG CC, 1989, MOL MICROBIOL, V3, P1221, DOI 10.1111/j.1365-2958.1989.tb00272.x	40	87	88	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1992	267	25					17502	17507						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JM223	1517202				2022-12-25	WOS:A1992JM22300007
J	CROOKE, E; CASTUMA, CE; KORNBERG, A				CROOKE, E; CASTUMA, CE; KORNBERG, A			THE CHROMOSOME ORIGIN OF ESCHERICHIA-COLI STABILIZES DNAA PROTEIN DURING REJUVENATION BY PHOSPHOLIPIDS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REPLICATION ORIGIN; ENZYMATIC REPLICATION; INITIATION PROTEIN; ACTIVATION; SEQUENCE; INVITRO	DnaA protein (the initiator protein) binds and clusters at the four DnaA boxes of the Escherichia coli chromosomal origin (oriC) to promote the strand opening for DNA replication. DnaA protein activity depends on the tight binding of ATP; the ADP form of DnaA protein, generated by hydrolysis of the bound ATP, is inactive. Rejuvenation of ADP-DnaA protein, by replacement with ATP, is catalyzed by acidic phospholipids in a highly fluid bilayer. We find that interaction of DnaA protein with oriC DNA is needed to stabilize DnaA protein during this rejuvenation process. Whereas DnaA protein bound to oriC DNA responds to phospholipids, free DnaA protein is inactivated by phospholipids and then fails to bind oriC. Furthermore, oriC DNA facilitates the high affinity binding of ATP to DnaA protein during treatment with phospholipids. A significant portion of the DnaA protein associated with oriC DNA can be replaced by the ADP form of the protein, suggesting that all of the DnaA protein bound to oriC DNA need not be rejuvenated between rounds of replication.			CROOKE, E (corresponding author), STANFORD UNIV,MED CTR,SCH MED,DEPT BIOCHEM,STANFORD,CA 94305, USA.				FIC NIH HHS [5 FO5 TWO4347] Funding Source: Medline; FOGARTY INTERNATIONAL CENTER [F05TW004347] Funding Source: NIH RePORTER	FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC))		BAKER TA, 1988, CELL, V55, P113, DOI 10.1016/0092-8674(88)90014-1; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BRAMHILL D, 1988, CELL, V52, P743, DOI 10.1016/0092-8674(88)90412-6; CHEN PS, 1956, ANAL CHEM, V28, P1756, DOI 10.1021/ac60119a033; FULLER RS, 1984, CELL, V38, P889, DOI 10.1016/0092-8674(84)90284-8; FULLER RS, 1983, P NATL ACAD SCI-BIOL, V80, P5817, DOI 10.1073/pnas.80.19.5817; JACOB F, 1963, COLD SPRING HARB SYM, V28, P329, DOI 10.1101/SQB.1963.028.01.048; KAGAWA Y, 1971, J BIOL CHEM, V246, P5477; KAGUNI JM, 1982, NATURE, V296, P623, DOI 10.1038/296623a0; Kornberg A., 1992, DNA REPLICATION; OKA A, 1982, GENE, V19, P59; OKA A, 1984, J MOL BIOL, V176, P443, DOI 10.1016/0022-2836(84)90171-2; SEKIMIZU K, 1988, J BIOL CHEM, V263, P7131; SEKIMIZU K, 1988, J BIOL CHEM, V263, P7136; SEKIMIZU K, 1987, CELL, V50, P259, DOI 10.1016/0092-8674(87)90221-2; SEKIMIZU K, 1988, J BIOL CHEM, V263, P7124; VANDERENDE A, 1985, P NATL ACAD SCI USA, V82, P3954; VONMEYENBURG K, 1987, ESCHERICHIA COLI SAL, V2, P1555; YUNG BYM, 1990, J BIOL CHEM, V265, P1282; YUNG BYM, 1988, P NATL ACAD SCI USA, V85, P7202, DOI 10.1073/pnas.85.19.7202; YUNG BYM, 1989, J BIOL CHEM, V264, P6146; ZYSKIND JW, 1983, P NATL ACAD SCI-BIOL, V80, P1164, DOI 10.1073/pnas.80.5.1164	22	80	80	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1992	267	24					16779	16782						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JL053	1512219				2022-12-25	WOS:A1992JL05300009
J	BUSK, M; PYTELA, R; SHEPPARD, D				BUSK, M; PYTELA, R; SHEPPARD, D			CHARACTERIZATION OF THE INTEGRIN-ALPHA-V-BETA-6 AS A FIBRONECTIN-BINDING PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARG-GLY-ASP; INTEGRIN BETA-SUBUNIT; AMINO-ACID SEQUENCE; ALPHA-V SUBUNIT; VITRONECTIN RECEPTOR; ADHESION RECEPTORS; CELL-ATTACHMENT; MONOCLONAL-ANTIBODIES; EXTRACELLULAR-MATRIX; CATION REGULATION	Integrins are a complex family of divalent cation-dependent cell adhesion receptors composed of one a and one beta-subunit noncovalently bound to one another. A subset of integrins contains the alpha-v subunit in association with one of several beta-subunits (e.g. beta-3, beta-5, beta-1). We have recently identified a novel integrin beta-subunit, beta-6, that is present in a number of epithelial cell lines. Using a polyclonal antibody raised against the carboxyl-terminal peptide of beta-6, we have now identified the integrin heterodimer, alpha-v-beta-6, on the surface of two human carcinoma cell lines. Using affinity chromatography of lysates from the pancreatic carcinoma cell line, FG-2, we demonstrate that alpha-v-beta-6 binds to fibronectin, but not to vitronectin or collagen I. In contrast, the alpha-v-beta-5 integrin, which is also expressed on FG-2 cells, binds exclusively to vitronectin. Immobilized collagen I does not interact with alpha-v integrins, but binds beta-1-containing integrins. Both alpha-v-beta-6 and alpha-v-beta-5 are eluted from their respective immobilized ligands by a hexapeptide containing the sequence Arg-Gly-Asp (RGD). RGD is highly effective in the presence of Ca2+, somewhat less effective in Mg2+, and virtually inactive in Mn2+. These results suggest that alpha-v-beta-6 functions as an RGD-dependent fibronectin receptor in FG-2 carcinoma cells. In agreement with this notion, cell adhesion assays show that FG-2 cell attachment to fibronectin is only partially inhibited by anti-beta-1 integrin antibodies, implying that other fibronectin receptors may be involved. Taken together with recent reports on the vitronectin receptor function of alpha-v-beta-5, our results suggest that the previously described carcinoma cell integrin, alpha-v-beta-x (Cheresh, D. A., Smith, J. W., Cooper, H. M., and Quaranta, V. (1989) Cell 57, 59-69), is a mixture of at least two different receptors: alpha-v-beta-5, mediating adhesion to vitronectin, and alpha-v-beta-6, mediating adhesion to fibronectin.	UNIV CALIF SAN FRANCISCO,CTR OCCUPAT & ENVIRONM HLTH,CARDIOVASC RES INST,CTR LUNG BIOL,BOX 0854,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT PHARMACOL,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco					NATIONAL CANCER INSTITUTE [R01CA053250] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL019155] Funding Source: NIH RePORTER; NCI NIH HHS [CA53250] Funding Source: Medline; NHLBI NIH HHS [HL19155, HL/A133259] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARGRAVES WS, 1987, J CELL BIOL, V105, P1183, DOI 10.1083/jcb.105.3.1183; BODARY SC, 1990, J BIOL CHEM, V265, P5938; BOSSY B, 1990, BIOCHEMISTRY-US, V29, P10191, DOI 10.1021/bi00496a006; CHARO IF, 1990, J CELL BIOL, V111, P2795, DOI 10.1083/jcb.111.6.2795; CHERESH DA, 1989, CELL, V57, P59, DOI 10.1016/0092-8674(89)90172-4; CHERESH DA, 1987, J BIOL CHEM, V262, P17703; DRANSFIELD I, 1989, EMBO J, V8, P3759, DOI 10.1002/j.1460-2075.1989.tb08552.x; EDWARDS JG, 1987, J CELL SCI, V87, P657; EDWARDS JG, 1988, J CELL SCI, V89, P507; ELICES MJ, 1991, J CELL BIOL, V112, P169, DOI 10.1083/jcb.112.1.169; ENGVALL E, 1977, INT J CANCER, V20, P1, DOI 10.1002/ijc.2910200102; FUJIMURA K, 1983, J BIOL CHEM, V258, P247; GAILIT J, 1988, J BIOL CHEM, V263, P12927; GINSBERG MH, 1986, J CLIN INVEST, V78, P1103, DOI 10.1172/JCI112667; HALL DE, 1987, J CELL BIOL, V104, P623, DOI 10.1083/jcb.104.3.623; HAUTANEN A, 1989, J BIOL CHEM, V264, P1437; HEMLER ME, 1987, J BIOL CHEM, V262, P3300; HEMLER ME, 1990, ANNU REV IMMUNOL, V8, P365, DOI 10.1146/annurev.iy.08.040190.002053; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; KIRCHHOFER D, 1990, J BIOL CHEM, V265, P615; KIRCHHOFER D, 1991, J BIOL CHEM, V266, P4471; KIRCHHOFER D, 1990, J BIOL CHEM, V265, P18525; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOFTUS JC, 1990, SCIENCE, V249, P915, DOI 10.1126/science.2392682; MCDONALD JA, 1989, AM J PHYSIOL, V257, pL331, DOI 10.1152/ajplung.1989.257.6.L331; MOYLE M, 1991, J BIOL CHEM, V266, P19650; PIERSCHBACHER MD, 1984, NATURE, V309, P30, DOI 10.1038/309030a0; PIERSCHBACHER MD, 1981, CELL, V26, P259, DOI 10.1016/0092-8674(81)90308-1; PYTELA R, 1985, P NATL ACAD SCI USA, V82, P5766, DOI 10.1073/pnas.82.17.5766; PYTELA R, 1985, CELL, V40, P191, DOI 10.1016/0092-8674(85)90322-8; PYTELA R, 1987, METHOD ENZYMOL, V144, P475; PYTELA R, 1986, SCIENCE, V231, P1559, DOI 10.1126/science.2420006; RAMASWAMY H, 1990, EMBO J, V9, P1561, DOI 10.1002/j.1460-2075.1990.tb08275.x; RUOSLAHTI E, 1986, CELL, V44, P517, DOI 10.1016/0092-8674(86)90259-X; RUOSLAHTI E, 1981, J BIOL CHEM, V256, P7277; RUOSLAHTI E, 1991, J CLIN INVEST, V87, P1, DOI 10.1172/JCI114957; RUOSLAHTI E, 1989, CANCER CELL-MON REV, V1, P119; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; SHEPPARD D, 1990, J BIOL CHEM, V265, P11502; SMITH JW, 1990, J BIOL CHEM, V265, P11008; STAATZ WD, 1989, J CELL BIOL, V108, P1917, DOI 10.1083/jcb.108.5.1917; SUZUKI S, 1987, J BIOL CHEM, V262, P14080; SUZUKI S, 1990, P NATL ACAD SCI USA, V87, P5354, DOI 10.1073/pnas.87.14.5354; VOGEL BE, 1990, J BIOL CHEM, V265, P5934; WAYNER EA, 1988, J CELL BIOL, V107, P1881, DOI 10.1083/jcb.107.5.1881; WAYNER EA, 1991, J CELL BIOL, V113, P919, DOI 10.1083/jcb.113.4.919; WAYNER EA, 1987, J CELL BIOL, V105, P1873, DOI 10.1083/jcb.105.4.1873; WERB Z, 1989, J CELL BIOL, V109, P877, DOI 10.1083/jcb.109.2.877; YATOHGO T, 1988, CELL STRUCT FUNCT, V13, P281, DOI 10.1247/csf1975.13.281	49	276	293	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1992	267	9					5790	5796						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HK318	1532572				2022-12-25	WOS:A1992HK31800014
J	GU, J; NISHIKAWA, A; FUJII, S; GASA, S; TANIGUCHI, N				GU, J; NISHIKAWA, A; FUJII, S; GASA, S; TANIGUCHI, N			BIOSYNTHESIS OF BLOOD GROUP-I AND I-ANTIGENS IN RAT-TISSUES - IDENTIFICATION OF A NOVEL BETA-1-6-N-ACETYLGLUCOSAMINYLTRANSFERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-ACETYLGLUCOSAMINYLTRANSFERASE-III; HUMAN-ERYTHROCYTES; HUMAN-SERUM; GLYCOSPHINGOLIPIDS; OLIGOSACCHARIDES; GLYCOPROTEINS; MUCIN; POLYLACTOSAMINOGLYCANS; HEPATOMA	The beta-galactoside beta-1-6- and beta-1-3-N-acetylglucosaminyltransferases (beta-1-6GnT and beta-1-3GnT) that synthesize blood group I and i antigens were identified in rat tissues, using pyridylaminated lacto-N-neotetraose (Gal-beta-1-4GlcNAc-beta-1-3Gal-beta-1-4Glc-PA) as an acceptor. The products of the transferase reactions were separated on high performance liquid chromatography. The products of the transferase reactions were identified by H-1 NMR as [GRAPHICS] and GlcNAc-beta-1-3Gal-beta-1-4GlcNAc-beta-1-3Gal-beta-1-4Glc-PA. The product for beta-1-6GnT was also identified by methylation analysis. Kinetic experiments were carried out using rat serum for beta-3GnT and partially purified enzyme from rat intestine for beta-1-6GnT. Beta-1-3GnT has a pH optimum of 7.5 and requires Mn2+ for optimal activity. Beta-1-6GnT has a pH optimum of 7.0 and does not require Mn2+. Studies on the substrate specificity of each enzyme indicated that the preferred substrate for beta-1-3GnT had the general structure Gal-beta-1-4GlcNAc-OR and, for beta-1-6GnT, Gal-beta-1-4GlcNAc-beta-1-3Gal-OR where R = sugar. This is the first demonstration that the beta-1-6GnT acts on an internal galactose of lacto-N-neotetraose and paragloboside, and the enzyme appears to be a novel enzyme in terms of substrate specificity.	OSAKA UNIV, SCH MED, DEPT BIOCHEM, 2-2 YAMADAOKA, SUITA, OSAKA 565, JAPAN; KANSAI MED UNIV, CHEM LAB, HIRAKATA, OSAKA 573, JAPAN; HOKKAIDO UNIV, SCH MED, INST CANC, BIOCHEM LAB, SAPPORO, HOKKAIDO 060, JAPAN	Osaka University; Kansai Medical University; Hokkaido University			Nishikawa, Atsushi/E-6766-2013; Taniguchi, Naoyuki/A-7086-2016; Taniguchi, Naoyuki/I-4182-2014	Nishikawa, Atsushi/0000-0003-4325-1160; Taniguchi, Naoyuki/0000-0001-5889-5968				BASU M, 1984, J BIOL CHEM, V259, P2557; BLANKEN WM, 1982, EUR J BIOCHEM, V127, P547, DOI 10.1111/j.1432-1033.1982.tb06906.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; FUJII S, 1990, J BIOL CHEM, V265, P6009; FUKUDA M, 1984, J BIOL CHEM, V259, P8260; FUKUDA MN, 1979, J BIOL CHEM, V254, P5458; HAKOMORI SI, 1981, SEMIN HEMATOL, V18, P39; HASE S, 1984, J BIOCHEM-TOKYO, V95, P197, DOI 10.1093/oxfordjournals.jbchem.a134585; KOENDERMAN AHL, 1987, EUR J BIOCHEM, V166, P199, DOI 10.1111/j.1432-1033.1987.tb13502.x; KOSCIELAK J, 1979, EUR J BIOCHEM, V96, P331, DOI 10.1111/j.1432-1033.1979.tb13044.x; MAKITA A, 1964, J BIOCHEM-TOKYO, V55, P269, DOI 10.1093/oxfordjournals.jbchem.a127880; NISHIKAWA A, 1988, BIOCHEM BIOPH RES CO, V152, P107, DOI 10.1016/S0006-291X(88)80686-7; NISHIKAWA A, 1990, BIOCHIM BIOPHYS ACTA, V1035, P313, DOI 10.1016/0304-4165(90)90094-D; NISHIKAWA A, 1988, ANAL BIOCHEM, V170, P349, DOI 10.1016/0003-2697(88)90641-0; PILLER F, 1983, J BIOL CHEM, V258, P2293; PILLER F, 1984, J BIOL CHEM, V259, P3385; SLOMIANY BL, 1984, J BIOL CHEM, V259, P2863; STELLNER K, 1973, ARCH BIOCHEM BIOPHYS, V155, P464, DOI 10.1016/0003-9861(73)90138-0; TANIGUCHI N, 1989, METHOD ENZYMOL, V179, P397; VANDENEIJNDEN DH, 1988, J BIOL CHEM, V263, P12461; VANDENEIJNDEN DH, 1983, J BIOL CHEM, V258, P3435; WILLIAMS D, 1980, J BIOL CHEM, V255, P1247; YATES AD, 1983, CARBOHYD RES, V120, P251, DOI 10.1016/0008-6215(83)88020-3; YAZAWA S, 1986, CARBOHYD RES, V149, P241, DOI 10.1016/S0008-6215(00)90381-1; ZIELENSKI J, 1983, FEBS LETT, V158, P164, DOI 10.1016/0014-5793(83)80700-5	25	41	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 15	1992	267	5					2994	2999						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HD154	1531336				2022-12-25	WOS:A1992HD15400030
J	GRECO, A; PIEROTTI, MA; BONGARZONE, I; PAGLIARDINI, S; LANZI, C; DELLAPORTA, G				GRECO, A; PIEROTTI, MA; BONGARZONE, I; PAGLIARDINI, S; LANZI, C; DELLAPORTA, G			TRK-T1 IS A NOVEL ONCOGENE FORMED BY THE FUSION OF TPR AND TRK GENES IN HUMAN PAPILLARY THYROID CARCINOMAS	ONCOGENE			English	Article							TYROSINE KINASE DOMAIN; PROTO-ONCOGENE; BIOCHEMICAL-CHARACTERIZATION; ACTIVATION; PROTOONCOGENE; SEQUENCES; RECOMBINATION; PROTEINS; MECHANISM; DNA	We have recently reported the frequent activation of the TRK oncogene in human papillary thyroid carcinoma. In this paper we describe the isolation and characterization of one of the thyroid TRK oncogenes, designated TRK-T1. A 1746-bp-long cDNA was isolated from a library derived from a primary transformant. The cDNA was able to induce foci in NIH3T3 cells. Sequence analysis revealed that TRK-T1 is created by an intrachromosomal rearrangement that juxtaposes the 5' end of the TPR gene to the TRK tyrosine kinase domain. The resulting hybrid mRNA contains 598 nucleotides of the TPR gene and 1148 nucleotides of the TRK proto-oncogene. TRK-T1 mRNA encodes a protein of 55 kDa reacting with antibodies against the carboxy terminus of the proto-TRK protein. We show also the involvement of TPR in the generation of another TRK-T oncogene.	IST NAZL TUMORI,DIV EXPTL ONCOL B,I-20133 MILAN,ITALY	Fondazione IRCCS Istituto Nazionale Tumori Milan	GRECO, A (corresponding author), IST NAZL TUMORI,DIV EXPTL ONCOL A,VIA G VENEZIAN 1,I-20133 MILAN,ITALY.		Pierotti, Marco Alessandro/AAC-4728-2022; Lanzi, Cinzia/J-6539-2016; Bongarzone, Italia/B-9544-2017; Greco, Angela/C-1953-2017	Pierotti, Marco Alessandro/0000-0002-7431-8332; Lanzi, Cinzia/0000-0002-4480-9413; Bongarzone, Italia/0000-0003-2530-9170; Greco, Angela/0000-0003-2994-0349				BONGARZONE I, 1989, ONCOGENE, V4, P1457; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; CAPETANAKI Y, 1990, ONCOGENE, V5, P645; CHAN AML, 1987, ONCOGENE, V1, P229; COULIER F, 1990, MOL CELL BIOL, V10, P4202, DOI 10.1128/MCB.10.8.4202; COULIER F, 1989, MOL CELL BIOL, V9, P15, DOI 10.1128/MCB.9.1.15; DEAN M, 1987, MOL CELL BIOL, V7, P921, DOI 10.1128/MCB.7.2.921; GRIECO M, 1990, CELL, V60, P557, DOI 10.1016/0092-8674(90)90659-3; HEMPSTEAD BL, 1991, NATURE, V350, P678, DOI 10.1038/350678a0; Huynh TV, 1985, DNA CLONING TECHNIQU, V1, P49; ISHIKAWA F, 1987, MOL CELL BIOL, V7, P1226, DOI 10.1128/MCB.7.3.1226; KING WSH, 1988, ONCOGENE, V2, P617; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KOZMA SC, 1988, EMBO J, V7, P147, DOI 10.1002/j.1460-2075.1988.tb02794.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Maniatis T., 1982, MOL CLONING; MARTINZANCA D, 1989, MOL CELL BIOL, V9, P24, DOI 10.1128/MCB.9.1.24; MARTINZANCA D, 1986, NATURE, V319, P743, DOI 10.1038/319743a0; MARTINZANCA D, 1990, GENE DEV, V4, P683, DOI 10.1101/gad.4.5.683; MIOZZO M, 1990, ONCOGENE, V5, P1411; MITRA G, 1987, P NATL ACAD SCI USA, V84, P6707, DOI 10.1073/pnas.84.19.6707; MORRIS CM, 1991, ONCOGENE, V6, P1093; NALDINI L, 1991, ONCOGENE, V6, P501; OSKAM R, 1988, P NATL ACAD SCI USA, V85, P2964, DOI 10.1073/pnas.85.9.2964; PARK M, 1986, CELL, V45, P895, DOI 10.1016/0092-8674(86)90564-7; PARK M, 1987, P NATL ACAD SCI USA, V84, P6379, DOI 10.1073/pnas.84.18.6379; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WONG GG, 1985, SCIENCE, V228, P810, DOI 10.1126/science.3923623; ZIEMIECKI A, 1990, EMBO J, V9, P191, DOI 10.1002/j.1460-2075.1990.tb08095.x	31	205	227	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1992	7	2					237	242						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HG982	1532241				2022-12-25	WOS:A1992HG98200005
J	HOUCK, KA; LEUNG, DW; ROWLAND, AM; WINER, J; FERRARA, N				HOUCK, KA; LEUNG, DW; ROWLAND, AM; WINER, J; FERRARA, N			DUAL REGULATION OF VASCULAR ENDOTHELIAL GROWTH-FACTOR BIOAVAILABILITY BY GENETIC AND PROTEOLYTIC MECHANISMS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERMEABILITY FACTOR; EXTRACELLULAR-MATRIX; CELLS; PURIFICATION; PROTEIN; MITOGEN; IDENTIFICATION; ANGIOGENESIS; DEGRADATION; EXPRESSION	The vascular endothelial growth factor (VEGF) family encompasses four polypeptides that result from alternative splicing of mRNA. We have previously demonstrated differences in the secretion pattern of these polypeptides. Stable cell lines expressing VEGFs were established in human embryonic kidney CEN4 cells. VEGF121, the shortest form, was secreted and freely soluble in tissue culture medium. VEG189 was secreted, but was almost entirely bound to the cell surface or extracellular matrix. VEGF165 displayed an intermediary behavior. Suramin induced the release of VEGF189, permitting its characterization as a more basic protein with higher affinity for heparin than VEGF165 or VEGF121, but with similar endothelial cell mitogenic activity. Heparin, heparan sulfate, and heparinase all induced the release of VEGF165 and VEGF165 suggesting heparin-containing proteoglycans as candidate VEGF-binding sites. Finally, VEGF165 and VEGF189 were released from their bound states by treatment with plasmin. The released 34-kDa dimeric species are active as endothelial cell mitogens and as vascular permeability agents. We conclude that the bioavailability of VEGF may be regulated at the genetic level by alternative splicing that determines whether VEGF will be soluble or incorporated into a biological reservoir and also through proteolysis following plasminogen activation.	GENENTECH INC, DEPT CARDIOVASC RES, S SAN FRANCISCO, CA 94080 USA; GENENTECH INC, DEPT MOLEC BIOL, S SAN FRANCISCO, CA 94080 USA; GENENTECH INC, DEPT MED & ANALYT CHEM, S SAN FRANCISCO, CA 94080 USA	Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding; Genentech	FERRARA, N (corresponding author), GENENTECH INC, DEPT CARDIOVASC RES, S SAN FRANCISCO, CA 94080 USA.		Houck, Keith/G-8654-2014	Houck, Keith/0000-0002-0055-2249				ANDREASON GL, 1988, BIOTECHNIQUES, V6, P650; BAHSKIN P, 1992, J CELL PHYSL, V151, P126; BECKMANN MP, 1988, SCIENCE, V241, P1346, DOI 10.1126/science.2842868; BERSE B, 1992, MOL BIOL CELL, V3, P211, DOI 10.1091/mbc.3.2.211; BETSHOLTZ C, 1986, P NATL ACAD SCI USA, V83, P6440, DOI 10.1073/pnas.83.17.6440; BRUNNER G, 1991, J CELL BIOL, V114, P1275, DOI 10.1083/jcb.114.6.1275; CACHIANES G, 1992, IN PRESS TECHNIQUE; CHAN AML, 1991, SCIENCE, V254, P1382, DOI 10.1126/science.1720571; CONNOLLY DT, 1989, J BIOL CHEM, V264, P20017; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; Ferrara N, 1991, Growth Factors, V5, P141, DOI 10.3109/08977199109000278; FERRARA N, 1989, BIOCHEM BIOPH RES CO, V161, P851, DOI 10.1016/0006-291X(89)92678-8; FERRARA N, 1992, ENDOCR REV, V13, P18, DOI 10.1210/er.13.1.18; FERRARA N, 1991, NEUROENDOCRINE PERSP, V9, P127; FERRARA N, 1991, METHOD ENZYMOL, V198, P391; GITAYGOREN H, 1992, J BIOL CHEM, V267, P6093; GOSPODAROWICZ D, 1984, P NATL ACAD SCI-BIOL, V81, P6963, DOI 10.1073/pnas.81.22.6963; GOSPODAROWICZ D, 1986, J CELL PHYSIOL, V128, P475, DOI 10.1002/jcp.1041280317; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; HOUCK KA, 1991, MOL ENDOCRINOL, V5, P1806, DOI 10.1210/mend-5-12-1806; JAKEMAN LB, 1992, J CLIN INVEST, V89, P244, DOI 10.1172/JCI115568; KECK PJ, 1989, SCIENCE, V246, P1309, DOI 10.1126/science.2479987; Kim KJ, 1992, GROWTH FACTORS, V7, P53, DOI 10.3109/08977199209023937; KLAGSBRUN M, 1991, ANNU REV PHYSIOL, V53, P217, DOI 10.1146/annurev.physiol.53.1.217; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; LI YS, 1990, SCIENCE, V250, P1690, DOI 10.1126/science.2270483; MIGNATTI P, 1989, J CELL BIOL, V108, P671, DOI 10.1083/jcb.108.2.671; MIKI T, 1992, P NATL ACAD SCI USA, V89, P246, DOI 10.1073/pnas.89.1.246; MILES AA, 1952, J PHYSIOL-LONDON, V118, P228, DOI 10.1113/jphysiol.1952.sp004789; MOSCATELLI D, 1986, P NATL ACAD SCI USA, V83, P2091, DOI 10.1073/pnas.83.7.2091; NAKANE PK, 1974, J HISTOCHEM CYTOCHEM, V22, P1084, DOI 10.1177/22.12.1084; OLANDER JV, 1991, BIOCHEM BIOPH RES CO, V175, P68, DOI 10.1016/S0006-291X(05)81201-X; OSSOWSKI L, 1975, PROTEASES BIOL CONTR, P901; OSTMAN A, 1991, CELL REGUL, V2, P503, DOI 10.1091/mbc.2.7.503; PAPKOFF J, 1989, MOL CELL BIOL, V9, P3377, DOI 10.1128/MCB.9.8.3377; PEPPER MS, 1991, BIOCHEM BIOPH RES CO, V181, P902, DOI 10.1016/0006-291X(91)91276-I; PEPPER MS, 1990, J CELL BIOL, V111, P743, DOI 10.1083/jcb.111.2.743; PHILLIPS HS, 1990, ENDOCRINOLOGY, V127, P965, DOI 10.1210/endo-127-2-965; PLOUET J, 1989, EMBO J, V8, P3801, DOI 10.1002/j.1460-2075.1989.tb08557.x; PRESTRELSKI SJ, 1992, ARCH BIOCHEM BIOPHYS, V293, P314, DOI 10.1016/0003-9861(92)90401-H; ROBERRTS R, 1992, NATURE, V332, P376; RUOSLAHTI E, 1991, CELL, V64, P867, DOI 10.1016/0092-8674(91)90308-L; SAKSELA O, 1990, J CELL BIOL, V110, P767, DOI 10.1083/jcb.110.3.767; SAKSELA O, 1988, J CELL BIOL, V107, P743, DOI 10.1083/jcb.107.2.743; Savona C, 1991, GROWTH FACTORS, V5, DOI 10.3109/08977199109000291; STANLEY E, 1991, MOL CELL BIOL, V11, P3399, DOI 10.1128/MCB.11.7.3399; SU W, 1991, P NATL ACAD SCI USA, V88, P10870, DOI 10.1073/pnas.88.23.10870; TISCHER E, 1991, J BIOL CHEM, V266, P11947; TSUBOI R, 1990, J CELL BIOL, V110, P511, DOI 10.1083/jcb.110.2.511; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VLODAVSKY I, 1991, J CELL BIOCHEM, V45, P167, DOI 10.1002/jcb.240450208; VLODAVSKY I, 1987, P NATL ACAD SCI USA, V84, P2292, DOI 10.1073/pnas.84.8.2292; WERB Z, 1980, J EXP MED, V152, P1340, DOI 10.1084/jem.152.5.1340; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W; ZARNEGAR R, 1989, CANCER RES, V49, P3314	55	953	1007	1	47	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 25	1992	267	36					26031	26037						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KD073	1464614				2022-12-25	WOS:A1992KD07300067
J	PAUCEK, P; MIRONOVA, G; MAHDI, F; BEAVIS, AD; WOLDEGIORGIS, G; GARLID, KD				PAUCEK, P; MIRONOVA, G; MAHDI, F; BEAVIS, AD; WOLDEGIORGIS, G; GARLID, KD			RECONSTITUTION AND PARTIAL-PURIFICATION OF THE GLIBENCLAMIDE-SENSITIVE, ATP-DEPENDENT K+-CHANNEL FROM RAT-LIVER AND BEEF-HEART MITOCHONDRIA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSULIN-SECRETING CELLS; SULFONYLUREA RECEPTOR; POTASSIUM CHANNELS; NA+/H+ ANTIPORTER; MG++ FLUX; TRANSPORT; PROTEIN; CONTRACTION; MEMBRANES	The transport properties of mitochondria are such that net potassium flux across the inner membrane determines mitochondrial volume. It has been known that K+ uptake is mediated by diffusive leak driven by the high electrical membrane potential maintained by redox-driven, electrogenic proton ejection and that regulated K+ efflux is mediated by an 82-kDa inner membrane K+/H+ antiporter. There is also long-standing suggestive evidence for the existence of an inner membrane protein designed to catalyze electrophoretic K+ uptake into mitochondria. We report reconstitution of a highly purified inner membrane protein fraction from rat liver and beef heart mitochondria that catalyzes electrophoretic K+ flux in liposomes and channel activity in planar lipid bilayers. The unit conductance of the channel at saturating [K+] is about 30 pS. Reconstituted K+ flux is inhibited with high affinity by ATP and ADP in the presence of divalent cations and by glibenclamide in the absence of divalent cations. The mitochondrial ATP-dependent K+ channel is selective for K+, with a K(m) of 32 mm, and does not transport Na+. K+ transport depends on voltage in a manner consistent with a channel activity that is not voltage-regulated. Thus, the mitochondrial ATP-dependent K+ channel exhibits properties that are remarkably similar to those of the ATP-dependent K+ channels of plasma membranes.	MED COLL OHIO, DEPT PHARMACOL, TOLEDO, OH 43699 USA; CZECHOSLOVAK ACAD SCI, INST PHYSIOL, CS-14220 PRAGUE, CZECHOSLOVAKIA; RUSSIAN ACAD SCI, INST BIOL PHYS, PUSHCHINO 142292, USSR	Czech Academy of Sciences; Russian Academy of Sciences; Pushchino Scientific Center for Biological Research (PSCBI) of the Russian Academy of Sciences; Institute of Cell Biophysics RAS	GARLID, KD (corresponding author), MED COLL OHIO, DEPT PHARMACOL, TOLEDO, OH 43699 USA.		Mironova, Galina D/Y-3702-2019	Mironova, Galina D/0000-0001-7432-0902; Garlid, Keith/0000-0002-6777-1235	NHLBI NIH HHS [HL 43810, HL 36573] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL036573] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AGUILARBRYAN L, 1990, J BIOL CHEM, V265, P8218; ASHCROFT FM, 1988, ANNU REV NEUROSCI, V11, P97, DOI 10.1146/annurev.neuro.11.1.97; BEAVIS AD, 1985, J BIOL CHEM, V260, P3424; BERNARDI P, 1989, J BIOL CHEM, V264, P18902; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOGUCKA K, 1979, FEBS LETT, V100, P301, DOI 10.1016/0014-5793(79)80356-7; BRIERLEY GP, 1977, J BIOL CHEM, V252, P7932; BRIERLEY GP, 1973, ARCH BIOCHEM BIOPHYS, V159, P742, DOI 10.1016/0003-9861(73)90515-8; BRIERLEY GP, 1978, MOL BIOL MEMBRANES, P295; BROWN GC, 1986, BIOCHEM J, V234, P75, DOI 10.1042/bj2340075; COSTA G, 1991, BIOCHEM BIOPH RES CO, V175, P305, DOI 10.1016/S0006-291X(05)81235-5; DAVIES NW, 1991, J BIOENERG BIOMEMBR, V23, P509, DOI 10.1007/BF00785809; DEWEILLE JR, 1992, J BIOL CHEM, V267, P4557; DIWAN JJ, 1986, J BIOENERG BIOMEMBR, V18, P123, DOI 10.1007/BF00743481; DIWAN JJ, 1990, FEBS LETT, V273, P215, DOI 10.1016/0014-5793(90)81088-6; DIWAN JJ, 1988, BIOCHEM BIOPH RES CO, V153, P224, DOI 10.1016/S0006-291X(88)81212-9; DIWAN JJ, 1988, J BIOENERG BIOMEMBR, V20, P261, DOI 10.1007/BF00768398; DIWAN JJ, 1980, J BIOENERG BIOMEMBR, V12, P205, DOI 10.1007/BF00744684; DUNNE MJ, 1991, BIOCHIM BIOPHYS ACTA, V1071, P67, DOI 10.1016/0304-4157(91)90012-L; FEDOTCHEVA NL, 1984, CRYOBIOL CRYOMED, V15, P50; GAMBLE JL, 1957, J BIOL CHEM, V228, P955; GARLID KD, 1989, BIOCHIM BIOPHYS ACTA, V976, P109, DOI 10.1016/S0005-2728(89)80219-1; GARLID KD, 1980, J BIOL CHEM, V255, P1273; GARLID KD, 1991, J BIOL CHEM, V266, P6518; GARLID KD, 1988, INTEGRATION MITOCHON, P257; GAUTHIER LM, 1979, BIOCHEM BIOPH RES CO, V87, P1072, DOI 10.1016/S0006-291X(79)80017-0; GUI G, 1991, J MOL CELL CARDIOL, V23, pS78; HARA A, 1978, ANAL BIOCHEM, V90, P420, DOI 10.1016/0003-2697(78)90046-5; HEGAZY MG, 1991, BIOPHYS J, V59, P596; HOWLAND JL, 1974, NATURE, V251, P724, DOI 10.1038/251724a0; INOUE I, 1991, NATURE, V352, P244, DOI 10.1038/352244a0; JEZEK P, 1990, J BIOL CHEM, V265, P10522; KAPLAN RS, 1985, ANAL BIOCHEM, V150, P97, DOI 10.1016/0003-2697(85)90445-2; KRAMER W, 1988, FEBS LETT, V229, P355, DOI 10.1016/0014-5793(88)81155-4; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAYNE E, 1957, METHOD ENZYMOL, V3, P447, DOI 10.1016/S0076-6879(57)03413-8; LI XQ, 1990, J BIOL CHEM, V265, P15316; MARTIN WH, 1984, J BIOL CHEM, V259, P2062; MIRONOVA GD, 1981, BIOFIZIKA+, V26, P451; Mitchell P, 1966, CHEMIOSMOTIC COUPLIN; MUELLER PAUL, 1964, RECENT PROGR SURFACE SCI, V1, P379; MURTHY KK, 1990, NUCLEIC ACIDS RES, V18, P4933, DOI 10.1093/nar/18.16.4933; NIKI I, 1991, BIOCHEM J, V277, P619, DOI 10.1042/bj2770619; PALIWAL R, 1992, BIOCHEMISTRY-US, V31, P2223, DOI 10.1021/bi00123a003; PAUCEK P, 1992, Biophysical Journal, V61, pA378; RORSMAN P, 1990, POTASSIUM CHANNELS S, P96; SAMMONS DW, 1981, ELECTROPHORESIS, V2, P135, DOI 10.1002/elps.1150020303; SCHMIDANTOMARCHI H, 1987, J BIOL CHEM, V262, P15840; SCOTT RL, 1961, J BIOL CHEM, V236, P570; STURGESS NC, 1985, LANCET, V2, P474; THIERS RE, 1960, J BIOL CHEM, V235, P2130; WEISS JN, 1989, J GEN PHYSIOL, V94, P911, DOI 10.1085/jgp.94.5.911; WEISS JN, 1992, J PHYSIOL-LONDON, V447, P649, DOI 10.1113/jphysiol.1992.sp019022; ZINCHENKO V P, 1982, Biokhimiya, V47, P1839	54	322	330	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 25	1992	267	36					26062	26069						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KD073	1464617				2022-12-25	WOS:A1992KD07300072
J	WILLNOW, TE; GOLDSTEIN, JL; ORTH, K; BROWN, MS; HERZ, J				WILLNOW, TE; GOLDSTEIN, JL; ORTH, K; BROWN, MS; HERZ, J			LOW-DENSITY-LIPOPROTEIN RECEPTOR-RELATED PROTEIN AND GP330 BIND SIMILAR LIGANDS, INCLUDING PLASMINOGEN ACTIVATOR-INHIBITOR COMPLEXES AND LACTOFERRIN, AN INHIBITOR OF CHYLOMICRON REMNANT CLEARANCE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEYMANN NEPHRITIS ANTIGEN; PERFUSED-RAT-LIVER; ALPHA-2-MACROGLOBULIN RECEPTOR; APOLIPOPROTEIN-E; LDL-RECEPTOR; MONOCLONAL-ANTIBODIES; MEDIATED ENDOCYTOSIS; CULTURED-CELLS; HIGH-AFFINITY; LOCALIZATION	The low density lipoprotein receptor-related protein/alpha2-macroglobulin receptor (LRP) and gp330, two members of the low density lipoprotein receptor gene family, share a multitude of cysteine-rich repeats. LRP has been shown to act as an endocytosis-mediating receptor for several ligands, including protease-anti-protease complexes and plasma lipoproteins. The former include alpha2-macroglobulin-protease complexes and plasminogen activator inhibitor-activator complexes. The latter include chylomicron remnant-like particles designated beta-very low density lipoproteins (beta-VLDL) complexed with apoprotein E or lipoprotein lipase. The binding specificity of gp330 is unknown. In the current studies we show that gp330 from rat kidney membranes binds several of these ligands on nitrocellulose blots. We also show that both LRP and gp330 bind an additional ligand, bovine lactoferrin, which is known to inhibit the hepatic clearance of chylomicron remnants. Lactoferrin blocked the LRP-dependent stimulation of cholesteryl ester synthesis in cultured human fibroblasts elicited by apoprotein E-beta-VLDL or lipoprotein lipase-beta-VLDL complexes. Cross-competition experiments in fibroblasts showed that the multiple ligands recognize at least three distinct, but partially overlapping sites on the LRP molecule. Binding of all ligands to LRP and gp330 was inhibited by the 39-kDa protein, which co-purifies with the two receptors, suggesting that the 39-kDa protein is a universal regulator of ligand binding to both receptors. The correlation of the inhibitory effects of lactoferrin in vivo and in vitro support the notion that LRP functions as a chylomicron remnant receptor in liver. LRP and gp330 share a multiplicity of binding sites, and both may function as endocytosis-mediating receptors for a large number of ligands in different organs.	UNIV TEXAS,SW MED CTR,DEPT BIOCHEM,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	WILLNOW, TE (corresponding author), UNIV TEXAS,SW MED CTR,DEPT MOLEC GENET,DALLAS,TX 75235, USA.		Orth, Kim/AAV-4421-2021	Orth, Kim/0000-0002-0678-7620; Willnow, Thomas/0000-0001-9515-7921	NHLBI NIH HHS [HL 20948] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL020948] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BEISIEGEL U, 1991, P NATL ACAD SCI USA, V88, P8342, DOI 10.1073/pnas.88.19.8342; BENSADOUN A, 1991, ANNU REV NUTR, V11, P217, DOI 10.1146/annurev.nu.11.070191.001245; BROWN MS, 1991, CURR OPIN LIPIDOL, V2, P65; BU GJ, 1992, P NATL ACAD SCI USA, V89, P7427, DOI 10.1073/pnas.89.16.7427; CHATELET F, 1986, AM J PATHOL, V122, P512; EHRLICH HJ, 1991, BIOCHEMISTRY-US, V30, P1021, DOI 10.1021/bi00218a020; FELTS JM, 1975, BIOCHEM BIOPH RES CO, V66, P1467, DOI 10.1016/0006-291X(75)90524-0; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; FURUKAWA T, 1990, J BIOCHEM-TOKYO, V108, P297, DOI 10.1093/oxfordjournals.jbchem.a123197; Goldstein J.L., 1989, METABOLIC BASIS INHE, P1215; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; GOLDSTEIN JL, 1985, ANNU REV CELL BIOL, V1, P1, DOI 10.1146/annurev.cb.01.110185.000245; HERZ J, 1988, EMBO J, V7, P4119, DOI 10.1002/j.1460-2075.1988.tb03306.x; HERZ J, 1991, J BIOL CHEM, V266, P21232; HERZ J, 1990, J BIOL CHEM, V265, P21355; HERZ J, 1992, IN PRESS CELL; HOBBS HH, 1987, NEW ENGL J MED, V317, P734, DOI 10.1056/NEJM198709173171204; HUETTINGER M, 1988, CLIN BIOCHEM, V21, P87, DOI 10.1016/S0009-9120(88)80093-6; HUSSAIN MM, 1991, J BIOL CHEM, V266, P13936; KANALAS JJ, 1991, J BIOL CHEM, V266, P10825; KERJASCHKI D, 1983, J EXP MED, V157, P667, DOI 10.1084/jem.157.2.667; KOUNNAS MZ, 1992, J BIOL CHEM, V267, P12420; KOWAL RC, 1989, P NATL ACAD SCI USA, V86, P5810, DOI 10.1073/pnas.86.15.5810; KOWAL RC, 1990, J BIOL CHEM, V265, P10771; KRISTENSEN T, 1990, FEBS LETT, V276, P151, DOI 10.1016/0014-5793(90)80530-V; LISCUM L, 1992, J LIPID RES, V33, P1239; MAHLEY RW, 1983, BIOCHIM BIOPHYS ACTA, V737, P197, DOI 10.1016/0304-4157(83)90001-1; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; MOESTRUP SK, 1991, J BIOL CHEM, V266, P14011; NYKJAER A, 1992, J BIOL CHEM, V267, P14543; ORTH K, 1992, P NATL ACAD SCI USA, V89, P7422, DOI 10.1073/pnas.89.16.7422; PASTAN IH, 1981, SCIENCE, V214, P504, DOI 10.1126/science.6170111; RAYCHOWDHURY R, 1989, SCIENCE, V244, P1163, DOI 10.1126/science.2786251; RUSSELL DW, 1989, J BIOL CHEM, V264, P21682; SOTTRUPJENSEN L, 1983, ANN NY ACAD SCI, V421, P41, DOI 10.1111/j.1749-6632.1983.tb18091.x; SOTTRUPJENSEN L, 1989, J BIOL CHEM, V264, P11539; STRICKLAND DK, 1991, J BIOL CHEM, V266, P13364; STRICKLAND DK, 1990, J BIOL CHEM, V265, P17401; VANDIJK MCM, 1992, EUR J BIOCHEM, V205, P775, DOI 10.1111/j.1432-1033.1992.tb16842.x; VANDIJK MCM, 1991, BIOCHEM J, V279, P863, DOI 10.1042/bj2790863; VOGEL T, 1985, P NATL ACAD SCI USA, V82, P8696, DOI 10.1073/pnas.82.24.8696; WEISGRABER KH, 1990, J BIOL CHEM, V265, P22453; WILLIAMS SE, 1992, J BIOL CHEM, V267, P9035; WINDLER E, 1985, J LIPID RES, V26, P556; WING LR, 1991, J LAB CLIN MED, V117, P109; YAMAMOTO T, 1984, CELL, V39, P27, DOI 10.1016/0092-8674(84)90188-0	46	437	447	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1992	267	36					26172	26180						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KD073	1464627				2022-12-25	WOS:A1992KD07300087
J	MAEMURA, K; FUKUDA, M				MAEMURA, K; FUKUDA, M			POLY-N-ACETYLLACTOSAMINYL O-GLYCANS ATTACHED TO LEUKOSIALIN - THE PRESENCE OF SIALYL LEX STRUCTURES IN O-GLYCANS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LINKED OLIGOSACCHARIDES; HUMAN-GRANULOCYTES; CELL-ADHESION; BIOSYNTHESIS; GLYCOPROTEINS; CARBOHYDRATE; LACTOSAMINOGLYCAN; GLYCOSYLATION; PURIFICATION; GLYCOLIPIDS	Poly-N-acetyllactosamine extension has been found in O-glycans in addition to N-glycans and glycosphingolipids. Attempts were made in HL-60 and K562 cells to determine the amount of poly-N-acetyllactosaminyl O-glycans in the major sialoglycoprotein, leukosialin. Leukosialin was immunoprecipitated from [H-3]glucosamine-labeled HL-60 and K562 cells. Glycopeptides were prepared by Pronase digestion, and O-glycan-containing glycopeptides were isolated by affinity chromatography using Jacalin-agarose. The glycopeptides bound to Jacalin-agarose and those unbound were treated with alkaline borohydride, and the released O-glycans were fractionated by Bio-Gel P-4 filtration. Sequential glycosidase digestion of the O-glycans, with or without pretreatment by fucosidase or neuraminidase, revealed the following conclusions. 1) Leukosialin from HL-60 cells contains about 1-2 poly-N-acetyllactosaminyl O-glycan chains/molecule. 2) About 50% of these poly-N-acetyllactosaminyl O-glycans contain sialyl Le(x) termini, NeuNAcalpha2-->3Galbeta1-->4(Fucalpha1-->3)GlcNAcbeta1-->R. The amount of sialyl Le(x) structure in leukosialin is roughly equivalent to that on cell surfaces of HL-60 cells. 3) Leukosialin from K562 cells, on the other hand, contains no detectable amount of poly-N-acetyllactosaminyl O-glycans. 4) The presence of poly-N-acetyllactosamine in O-glycans is dependent on the core 2 beta1,6-N-acetylglucosaminyl transferase. 5) Jacalin-agarose binds to sialylated small oligosaccharides such as NeuNAcalpha2-->3Galbeta1-->3(NeuNAcalpha2-->6) GalNAc but not the hexasaccharide NeuNAcalpha2-->3Galbeta1-->3(NeuNAcalpha2-->3Galbeta1-->4GlcNAcbeta1-->6) GalNAc. These results indicate that the formation of polylactosaminyl O-glycans and sialyl Le(x) structure in O-glycans is dependent on the core 2 formation.			MAEMURA, K (corresponding author), LA JOLLA CANC RES FDN,CANC RES CTR,LA JOLLA,CA 92037, USA.				NATIONAL CANCER INSTITUTE [R01CA033895, R01CA048737] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA33895, CA48737] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BEYER TA, 1979, J BIOL CHEM, V254, P2531; BIERHUIZEN MFA, 1992, P NATL ACAD SCI USA, V89, P9326, DOI 10.1073/pnas.89.19.9326; CARLSSON SR, 1986, J BIOL CHEM, V261, P2787; CARLSSON SR, 1986, J BIOL CHEM, V261, P2779; CYSTER JG, 1991, EMBO J, V10, P893, DOI 10.1002/j.1460-2075.1991.tb08022.x; DELL A, 1987, ADV CARBOHYD CHEM BI, V45, P19, DOI 10.1016/S0065-2318(08)60136-5; FEIZI T, 1985, NATURE, V314, P53, DOI 10.1038/314053a0; FUKUDA M, 1991, Glycobiology, V1, P347, DOI 10.1093/glycob/1.4.347; FUKUDA M, 1985, Biochimica et Biophysica Acta, V780, P119; FUKUDA M, 1986, J BIOL CHEM, V261, P2796; FUKUDA M, 1984, J BIOL CHEM, V259, P925; FUKUDA M, 1984, BIOL GLYCOPROTEINS, P183; FUKUDA MN, 1981, J BIOL CHEM, V256, P3900; FUKUDA MN, 1985, J BIOL CHEM, V260, P1067; FUKUSHIMA K, 1984, CANCER RES, V44, P5279; GLASGOW LR, 1977, J BIOL CHEM, V252, P8615; HANISCH FG, 1989, J BIOL CHEM, V264, P872; HIGGINS EA, 1991, J BIOL CHEM, V266, P6280; HO MK, 1983, J BIOL CHEM, V258, P636; HORTIN GL, 1990, ANAL BIOCHEM, V191, P262, DOI 10.1016/0003-2697(90)90217-W; KOJIMA N, 1992, BIOCHEM BIOPH RES CO, V182, P1288, DOI 10.1016/0006-291X(92)91872-N; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARSEN E, 1990, CELL, V63, P467, DOI 10.1016/0092-8674(90)90443-I; LAWRENCE MB, 1991, CELL, V65, P859, DOI 10.1016/0092-8674(91)90393-D; LEE N, 1990, J BIOL CHEM, V265, P20476; LEE YC, 1972, J BIOL CHEM, V247, P5733; LEY K, 1991, BLOOD, V77, P2553; LOWE JB, 1990, CELL, V63, P475, DOI 10.1016/0092-8674(90)90444-J; MEINDL P, 1969, H-S Z PHYSIOL CHEM, V350, P1088, DOI 10.1515/bchm2.1969.350.2.1088; PAULSON JC, 1977, J BIOL CHEM, V252, P2363; PAULSON JC, 1982, J BIOL CHEM, V257, P2734; PHILLIPS ML, 1990, SCIENCE, V250, P1130, DOI 10.1126/science.1701274; PILLER F, 1988, J BIOL CHEM, V263, P15146; SAITOH O, 1992, CANCER RES, V267, P5700; SANO M, 1992, J BIOL CHEM, V267, P1522; Schachter H, 1992, GLYCOCONJUGATES COMP, P263; SPOONCER E, 1984, J BIOL CHEM, V259, P4792; SYMINGTON FW, 1985, J IMMUNOL, V134, P2498; WALZ G, 1990, SCIENCE, V250, P1132, DOI 10.1126/science.1701275; YOUSEFI S, 1991, J BIOL CHEM, V266, P1772	40	171	185	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1992	267	34					24379	24386						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KA263	1447188				2022-12-25	WOS:A1992KA26300039
J	BENVENISTY, N; ORNITZ, DM; BENNETT, GL; SAHAGAN, BG; KUO, A; CARDIFF, RD; LEDER, P				BENVENISTY, N; ORNITZ, DM; BENNETT, GL; SAHAGAN, BG; KUO, A; CARDIFF, RD; LEDER, P			BRAIN-TUMORS AND LYMPHOMAS IN TRANSGENIC MICE THAT CARRY HTLV-I LTR/C-MYC AND IG/TAX GENES	ONCOGENE			English	Article							CELL LEUKEMIA-VIRUS; E-MU-MYC; T-CELL; B-CELL; TAX GENE; EXPRESSION; TUMORS; HYBRIDIZATION; RNA; TRANSFORMATION	The human T-cell leukemia virus type 1 (HTLV-I) is associated with adult CD4+ T-cell leukemia (ATL) and tropical spastic paraparesis (TSP). In as much as only a small percentage of individuals infected with HTLV-I develop either disease, we set out to model a genetic partner for this virus in an effort to understand and possibly reproduce its pathophysiology. To this end we have developed a binary set of transgenic mice, one bearing the relatively inactive HTLV-I long terminal repeat (LTR) positioned to drive the c-myc oncogene and another bearing a fusion transgene consisting of the immunoglobulin promoter/enhancer driving the gene for the HTLV-I transcription activator, tax. Alone, the tax construct, though expressed in the thymus, spleen, lung and brain, has no deleterious effect. Alone, the HTLV-I LTR/c-myc construct is expressed at very low levels in lymphoid cells and occasionally induces lymphomas in older animals. When these two transgenic lines are mated, bigenic offspring harboring both transgenes exhibit dramatic tumor formation. As in the human, these animals develop CD4+ T-cell lymphomas, but they also develop central nervous system tumors by 25-90 days of age. The syndrome, which is 100% penetrant and lethal, provides an animal model for adult T-cell lymphoma and a source of cultured cells of neurogenic origin.	UNIV CALIF DAVIS, SCH MED, DEPT PATHOL, DAVIS, CA 95616 USA	University of California System; University of California Davis	BENVENISTY, N (corresponding author), HARVARD UNIV, SCH MED, HOWARD HUGHES MED INST, 25 SHATTUCK ST, BOSTON, MA 02115 USA.			Ornitz, David/0000-0003-1592-7629				ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; BRINSTER RL, 1984, CELL, V37, P367, DOI 10.1016/0092-8674(84)90367-2; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DURNAM DM, 1983, ANAL BIOCHEM, V131, P385, DOI 10.1016/0003-2697(83)90188-4; FURUTA Y, 1989, J VIROL, V63, P3185, DOI 10.1128/JVI.63.7.3185-3189.1989; GESSAIN A, 1985, LANCET, V2, P407; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GREEN JE, 1989, NATURE, V341, P72, DOI 10.1038/341072a0; HAUPT Y, 1991, CELL, V65, P753, DOI 10.1016/0092-8674(91)90383-A; HINRICHS SH, 1987, SCIENCE, V237, P1340, DOI 10.1126/science.2888191; ITO Y, 1985, CURR TOP MICROBIOL, V115, P99; IWAKURA Y, 1991, SCIENCE, V253, P1026, DOI 10.1126/science.1887217; JULIEN JP, 1986, MOL BRAIN RES, V1, P243, DOI 10.1016/0169-328X(86)90030-6; KOIZUMI T, 1989, INT J CANCER, V44, P701, DOI 10.1002/ijc.2910440425; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MENGLEGAW L, 1987, EMBO J, V6, P1959, DOI 10.1002/j.1460-2075.1987.tb02458.x; NAKAHIRA K, 1990, J BIOL CHEM, V265, P19786; NERENBERG M, 1987, SCIENCE, V237, P1324, DOI 10.1126/science.2888190; NERENBERG MI, 1991, J VIROL, V65, P3349, DOI 10.1128/JVI.65.6.3349-3353.1991; PIGOTT T J D, 1990, British Journal of Neurosurgery, V4, P287, DOI 10.3109/02688699008992738; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; POTTER H, 1984, P NATL ACAD SCI-BIOL, V81, P7161, DOI 10.1073/pnas.81.22.7161; SCHMIDT EV, 1988, P NATL ACAD SCI USA, V85, P6047, DOI 10.1073/pnas.85.16.6047; SEIKI M, 1983, P NATL ACAD SCI-BIOL, V80, P3618, DOI 10.1073/pnas.80.12.3618; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; SODROSKI JG, 1984, SCIENCE, V225, P381, DOI 10.1126/science.6330891; STEWART TA, 1984, CELL, V38, P627, DOI 10.1016/0092-8674(84)90257-5; STRASSER A, 1990, NATURE, V348, P331, DOI 10.1038/348331a0; TANAKA A, 1990, P NATL ACAD SCI USA, V87, P1071, DOI 10.1073/pnas.87.3.1071; TEPPER RI, 1990, CELL, V62, P457, DOI 10.1016/0092-8674(90)90011-3; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; VANLOHUIZEN M, 1991, CELL, V65, P737, DOI 10.1016/0092-8674(91)90382-9; VERBEEK S, 1991, MOL CELL BIOL, V11, P1176, DOI 10.1128/MCB.11.2.1176; WILKINSON DG, 1987, DEVELOPMENT, V99, P493; XU YL, 1990, J BIOL CHEM, V265, P20285; ZELLER R, 1987, GENE DEV, V1, P693, DOI 10.1101/gad.1.7.693	36	58	59	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	1992	7	12					2399	2405						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KA856	1461648				2022-12-25	WOS:A1992KA85600004
J	DUTHU, A; DEBUIRE, B; ROMANO, J; EHRHART, JC; FISCELLA, M; MAY, E; APPELLA, E; MAY, P				DUTHU, A; DEBUIRE, B; ROMANO, J; EHRHART, JC; FISCELLA, M; MAY, E; APPELLA, E; MAY, P			P53 MUTATIONS IN RAJI CELLS - CHARACTERIZATION AND LOCALIZATION RELATIVE TO OTHER BURKITTS LYMPHOMAS	ONCOGENE			English	Article							CELLULAR TUMOR-ANTIGEN; CDNA CLONE; SUPPRESSOR GENE; ONCOGENE; TRANSFORMATION; EXPRESSION; PROTEIN; LINES; DNA; IMMORTALIZATION	The nuclear phosphoprotein p53 is an important regulator of cell proliferation in normal cells. Interestingly, the gene encoding p53 has usually undergone mutations in a wide range of tumor types. Recent studies of the p53 gene in Burkitt's lymphomas have demonstrated that mutations are extremely common, and in fact it is rare that both alleles of the p53 gene in these tumors are not inactivated by mutation or deletion. We present here genetic data regarding the status of the p53 gene in the Burkitt lymphoma cell line, Raji. As is typical for this type of tumor, both alleles have undergone point mutations. Further, statistical analysis of available data from a large number of Burkitt's lymphomas indicates an apparent tumor-specific distribution of p53 mutations. The possibility that specific mutations of the p53 gene may be important for different tumor types is discussed.	CNRS,UPR 275,BP 8,F-94801 VILLEJUIF,FRANCE; NCI,CELL BIOL LAB,BETHESDA,MD 20892	Centre National de la Recherche Scientifique (CNRS); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)								ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BARTEK J, 1990, ONCOGENE, V5, P893; CHENG J, 1990, MOL CELL BIOL, V10, P5502, DOI 10.1128/MCB.10.10.5502; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DEFROMENTEL CC, 1992, GENE CHROMOSOME CANC, V4, P1; DEPPERT W, 1990, ONCOGENE, V5, P1701; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; EPSTEIN MA, 1986, EPSTEIN BARR VIRUS; FARRELL PJ, 1991, EMBO J, V10, P2879, DOI 10.1002/j.1460-2075.1991.tb07837.x; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; GAIDANO G, 1991, P NATL ACAD SCI USA, V88, P5413, DOI 10.1073/pnas.88.12.5413; HARLOW E, 1985, MOL CELL BIOL, V5, P1601, DOI 10.1128/MCB.5.7.1601; HATFULL G, 1988, VIROLOGY, V164, P334, DOI 10.1016/0042-6822(88)90546-6; HIROSE M, 1983, JPN J CANCER RES, V74, P106; HOLLSTEIN MC, 1991, CANCER RES, V51, P402; ISOBE M, 1986, NATURE, V320, P84, DOI 10.1038/320084a0; JENKINS JR, 1984, NATURE, V312, P651, DOI 10.1038/312651a0; KASTAN MB, 1991, CANCER RES, V51, P6304; KLEIN G, 1985, IMMUNOL TODAY, V6, P208, DOI 10.1016/0167-5699(85)90036-2; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; LAVIGUEUR A, 1989, MOL CELL BIOL, V9, P3892; LEVINE AJ, 1990, BIOCHIM BIOPHYS ACTA, V1032, P119, DOI 10.1016/0304-419X(90)90015-S; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; MASUDA H, 1987, P NATL ACAD SCI USA, V84, P7716, DOI 10.1073/pnas.84.21.7716; MATLASHEWSKI G, 1984, EMBO J, V3, P3257, DOI 10.1002/j.1460-2075.1984.tb02287.x; MCBRIDE OW, 1986, P NATL ACAD SCI USA, V83, P130, DOI 10.1073/pnas.83.1.130; MERCER WE, 1982, P NATL ACAD SCI USA, V79, P309; MUNROE DG, 1990, MOL CELL BIOL, V10, P3307, DOI 10.1128/MCB.10.7.3307; PARADA LF, 1984, NATURE, V312, P649, DOI 10.1038/312649a0; POLACK A, 1984, VIROLOGY, V133, P146, DOI 10.1016/0042-6822(84)90433-1; PULVERTA.RJ, 1965, J CLIN PATHOL, V18, P261, DOI 10.1136/jcp.18.3.261; ROMANO JW, 1989, ONCOGENE, V4, P1483; ROVINSKI B, 1988, ONCOGENE, V2, P445; Sambrook J, 1989, MOL CLONING LABORATO; SHOHAT O, 1987, ONCOGENE, V1, P277; SOUSSI T, 1987, ONCOGENE, V1, P71; SOUSSI T, 1990, ONCOGENE, V5, P945; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; WIMAN KG, 1991, ONCOGENE, V6, P1633; ZAKUTHOURI R, 1985, EMBO J, V4, P1251, DOI 10.1002/j.1460-2075.1985.tb03768.x	43	57	59	1	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1992	7	11					2161	2167						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JW665	1437144				2022-12-25	WOS:A1992JW66500008
J	GOLUBIC, M; ROUDEBUSH, M; DOBROWOLSKI, S; WOLFMAN, A; STACEY, DW				GOLUBIC, M; ROUDEBUSH, M; DOBROWOLSKI, S; WOLFMAN, A; STACEY, DW			CATALYTIC PROPERTIES, TISSUE AND INTRACELLULAR-DISTRIBUTION OF NEUROFIBROMIN	ONCOGENE			English	Article							GTPASE-ACTIVATING PROTEIN; TYPE-1 GENE-PRODUCT; RAS GTPASE; IDENTIFICATION; SEQUENCE; DOMAIN; LIPIDS; GAP; MUTANTS; LOCUS	The neurofibromatosis type 1 (NF1) gene encodes a protein, neurofibromin, that shows homology with members of the GTPase-activating protein (GAP) family. To study neurofibromin, rabbit polyclonal antisera were raised against two synthetic peptides. These antisera immunoprecipitated a specific protein of about 240 kDa in lysates of adult murine and rat tissues both in the soluble (S100) and to a lesser degree in the particulate (P100) fractions. The neurofibromin immunoprecipitated from the lysates of several murine organs stimulated the intrinsic GTPase activity of p21 c-Ha-ras protein. Based on immunoblotting, immunoprecipitation and GTPase assays, neurofibromin appears to be at least 10-fold more abundant in the brain than in the other murine organs. The GTPase-stimulatory activity of full-length neurofibromin, like the catalytic GAP-related domain, is inhibited by arachidonic acid and the detergent dodecyl maltoside, while phosphatidic acid, containing arachidonic and stearic acid, is non-inhibitory. Immunofluorescence analysis with anti-neurofibromin sera in NIH3T3 cells suggests that at least some of the cellular protein associates with cytoplasmic structures that are distinct from actin or tubulin filaments.	CLEVELAND CLIN FDN,DEPT VASC CELL BIOL,CLEVELAND,OH 44195	Cleveland Clinic Foundation	GOLUBIC, M (corresponding author), CLEVELAND CLIN FDN,DEPT MOLEC BIOL,9500 EUCLID AVE,NC1 150,CLEVELAND,OH 44195, USA.			Roudebush, Margaret/0000-0001-9005-3672	NATIONAL CANCER INSTITUTE [R01CA048662] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM041220] Funding Source: NIH RePORTER; NCI NIH HHS [CA48662, CA53436] Funding Source: Medline; NIGMS NIH HHS [GM41220] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BALLESTER R, 1990, CELL, V63, P851, DOI 10.1016/0092-8674(90)90151-4; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BOLLAG G, 1991, NATURE, V351, P576, DOI 10.1038/351576a0; BUCHBERG AM, 1990, NATURE, V347, P291, DOI 10.1038/347291a0; CAWTHON RM, 1990, CELL, V62, P193, DOI 10.1016/0092-8674(90)90253-B; Cohen B H, 1989, Oncology (Williston Park), V3, P23; DASTON MM, 1992, NEURON, V8, P415, DOI 10.1016/0896-6273(92)90270-N; DECLUE JE, 1991, P NATL ACAD SCI USA, V88, P9914, DOI 10.1073/pnas.88.22.9914; GOLUBIC M, 1991, EMBO J, V10, P2897, DOI 10.1002/j.1460-2075.1991.tb07839.x; GUTMANN DH, 1991, P NATL ACAD SCI USA, V88, P9658, DOI 10.1073/pnas.88.21.9658; HAN JW, 1991, SCIENCE, V252, P576, DOI 10.1126/science.1902323; HARLOW E, 1988, ANTIBODIES LABORATOR, P309; HATTORI S, 1992, ONCOGENE, V7, P481; HATTORI S, 1991, BIOCHEM BIOPH RES CO, V177, P83, DOI 10.1016/0006-291X(91)91951-8; LOWY DR, 1991, TRENDS GENET, V7, P346, DOI 10.1016/0168-9525(91)90253-M; MARCHUK DA, 1991, GENOMICS, V11, P931, DOI 10.1016/0888-7543(91)90017-9; MARTIN GA, 1990, CELL, V63, P843, DOI 10.1016/0092-8674(90)90150-D; NISHI T, 1991, ONCOGENE, V6, P1555; OSBORN M, 1977, CELL, V12, P561, DOI 10.1016/0092-8674(77)90257-4; RICCARDI VM, 1981, NEW ENGL J MED, V305, P1617, DOI 10.1056/NEJM198112313052704; SANTOS E, 1989, FASEB J, V3, P2151, DOI 10.1096/fasebj.3.10.2666231; SERTH J, 1991, EMBO J, V10, P1325, DOI 10.1002/j.1460-2075.1991.tb07651.x; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; TSAI MH, 1991, MOL CELL BIOL, V11, P2785, DOI 10.1128/MCB.11.5.2785; TSAI MH, 1989, SCIENCE, V243, P522, DOI 10.1126/science.2536192; VANREGENMORTEL MHV, 1988, SYNTHETIC POLYPEPTID, P104; VISKOCHIL D, 1990, CELL, V62, P187, DOI 10.1016/0092-8674(90)90252-A; WALLACE MR, 1990, SCIENCE, V249, P181, DOI 10.1126/science.2134734; WALLACE MR, 1991, NATURE, V353, P864, DOI 10.1038/353864a0; XU GF, 1990, CELL, V63, P835, DOI 10.1016/0092-8674(90)90149-9; YU CL, 1990, MOL CELL BIOL, V10, P6683, DOI 10.1128/MCB.10.12.6683; YU CL, 1988, CELL, V52, P63, DOI 10.1016/0092-8674(88)90531-4	33	59	59	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1992	7	11					2151	2159						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JW665	1437143				2022-12-25	WOS:A1992JW66500007
J	KARNISKI, LP				KARNISKI, LP			HG2+ AND CU+ ARE IONOPHORES, MEDIATING CL-/OH- EXCHANGE IN LIPOSOMES AND RABBIT RENAL BRUSH-BORDER MEMBRANES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROXIMAL TUBULE; MERCURIC-CHLORIDE; INORGANIC MERCURY; LIPID-MEMBRANES; TRANSPORT; CELLS; MITOCHONDRIAL; MECHANISMS; ABSORPTION; VESICLES	Organometals, including organomercurials, are capable of mediating Cl-/OH- exchange across lipid membranes by forming neutral ion pairs. In this study, the ability of inorganic metals to catalyze Cl-/OH- exchange was examined. In the presence of an inwardly directed chloride gradient, HgCl2 at concentrations as low as 30 nM resulted in quenching of acridine orange fluorescence in liposomes, indicating liposomal acidification. In the presence of the reducing agent, ascorbate, CuSO4 at concentrations as low as 0.6 muM also mediated chloride-dependent liposomal acidification. Copper in the absence of ascorbate, iron (with or without ascorbate), cobalt, cadmium, zinc, nickel, and lead were without an effect. Cl-36 efflux from rabbit renal brush border membrane vesicles was also markedly stimulated by micromolar concentrations of mercury or copper plus ascorbate. Vesicle integrity was not altered by the concentrations of mercury or copper employed in these studies. In the absence of ascorbate, CuCl stimulated chloride efflux only under anaerobic conditions, confirming that it is the reduced form of copper (Cu+) that mediates chloride transport across the membrane. In the presence of mercury or reduced copper, an inside alkaline pH gradient stimulated the uphill accumulation of Cl-36 and Br-82, respectively, confirming Cl-/OH- exchange. Studies in liposomes and brush border membranes demonstrate that this is an electroneutral process. These results show that He2+ and Cu+ are capable of acting as ionophores, mediating electroneutral Cl-/OH- exchange in liposomes and brush border membrane vesicles. This effect could contribute to the toxicity of these two metals.	UNIV IOWA,IOWA CITY,IA 52242	University of Iowa	KARNISKI, LP (corresponding author), VET AFFAIRS MED CTR,DEPT INTERNAL MED,EPITHELIAL TRANSPORT LAB,IOWA CITY,IA 52242, USA.							ANTONENKO YN, 1990, J MEMBRANE BIOL, V113, P109, DOI 10.1007/BF01872884; ARONSON PS, 1978, J MEMBRANE BIOL, V42, P81098; BERRY CA, 1989, KIDNEY INT, V36, P403, DOI 10.1038/ki.1989.209; BIENVENUE E, 1984, CHEM-BIOL INTERACT, V48, P91, DOI 10.1016/0009-2797(84)90009-7; BOGUCKA K, 1979, FEBS LETT, V100, P301, DOI 10.1016/0014-5793(79)80356-7; CLARKSON TW, 1990, NEW ENGL J MED, V323, P1137, DOI 10.1056/NEJM199010183231610; COTTON FA, 1988, ADV INORG CHEM RAD, P758; DAWSON AP, 1974, BIOCHEM J, V138, P349, DOI 10.1042/bj1380349; ENDO T, 1988, PHARMACOL TOXICOL, V63, P361, DOI 10.1111/j.1600-0773.1988.tb00969.x; FERREIRA KT, 1970, BIOCHIM BIOPHYS ACTA, V203, P555; GUTKNECHT J, 1981, J MEMBRANE BIOL, V61, P61, DOI 10.1007/BF01870753; HAGER A, 1987, Z NATURFORSCH C, V42, P1116; HARRIS ED, 1991, P SOC EXP BIOL MED, V196, P130, DOI 10.3181/00379727-196-43171B; HOLLAND PC, 1972, BIOCHEM J, V129, P39, DOI 10.1042/bj1290039; HUNTER OF, 1967, J PHYSL, V189, P445; KARNISKI LP, 1987, AM J PHYSIOL, V253, pF513, DOI 10.1152/ajprenal.1987.253.3.F513; KARNISKI LP, 1989, J MEMBRANE BIOL, V112, P59, DOI 10.1007/BF01871164; KOEFOEDJOHNSEN V, 1958, ACTA PHYSIOL SCAND, V42, P298, DOI 10.1111/j.1748-1716.1958.tb01563.x; KONE BC, 1990, J MEMBRANE BIOL, V113, P1, DOI 10.1007/BF01869600; LIPKOWITZ MS, 1989, AM J PHYSIOL, V256, pF18, DOI 10.1152/ajprenal.1989.256.1.F18; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAHNENSMITH RL, 1985, J BIOL CHEM, V260, P2586; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; SELWYN MJ, 1970, EUR J BIOCHEM, V14, P120, DOI 10.1111/j.1432-1033.1970.tb00268.x; SELWYN MJ, 1972, BIOCHEM J, V130, P65; SMITH AM, 1976, CRITICAL STABILITY C, V4, P1; SMITH MW, 1987, BIOCHIM BIOPHYS ACTA, V931, P130, DOI 10.1016/0167-4889(87)90199-6; SMITH MW, 1991, P NATL ACAD SCI USA, V88, P4926, DOI 10.1073/pnas.88.11.4926; STADTMAN ER, 1991, J BIOL CHEM, V266, P2005; WALSHE JM, 1984, SEMIN LIVER DIS, V4, P252, DOI 10.1055/s-2008-1041775; WATLING AS, 1970, FEBS LETT, V10, P139, DOI 10.1016/0014-5793(70)80437-9; WEINBERG JM, 1982, J BIOL CHEM, V257, P60; WIETH JO, 1979, J GEN PHYSIOL, V73, P765, DOI 10.1085/jgp.73.6.765	33	37	39	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1992	267	27					19218	19225						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JP593	1527045				2022-12-25	WOS:A1992JP59300034
J	MA, L; SPREMULLI, LL				MA, L; SPREMULLI, LL			IMMUNOLOGICAL CHARACTERIZATION OF THE COMPLEX FORMS OF CHLOROPLAST TRANSLATIONAL INITIATION FACTOR-II FROM EUGLENA-GRACILIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-II; PROTEIN-SYNTHESIS; MESSENGER-RNA; ESCHERICHIA-COLI; PURIFICATION; IDENTIFICATION; MITOCHONDRIA; SUBUNITS	Euglena gracilis chloroplast translational initiation factor 2 (IF-2chl) occurs in several complex forms ranging in molecular mass from 200 to 800 kDa. Subunits of 97 to >200 kDa have been observed in these preparations. Two monoclonal antibodies were prepared against the 97-kDa subunits of IF-2chl. Both of these antibodies recognize all of the higher molecular mass forms of this factor, suggesting that these subunits are closely related. Gel filtration chromatography indicates that the higher molecular mass subunits of IF-2chl are present in the higher molecular mass complexes, whereas the smaller subunits are present in the 200-400 kDa forms of IF-2chl. Probing extracts of light-induced and dark-grown cells with the antibodies indicates that the light induction of this chloroplast factor results from the synthesis of new polypeptide rather than from the activation of an inactive precursor form of the protein. Both the higher and lower molecular mass subunits of IF-2chl are present in 30 S initiation complexes as indicated by Western analysis. The binding of IF-2chl to chloroplast 30 S ribosomal subunits requires the presence of GTP, but does not require fMet-tRNA, messenger RNA, or other initiation factors. Neither polyclonal nor monoclonal antibodies against E. gracilis IF-2chl cross-react with Escherichia coli IF-2 or with animal mitochondrial IF-2.	UNIV N CAROLINA, DEPT CHEM, CHAPEL HILL, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill			Ma, Lan/B-9295-2009	Ma, Lan/0000-0001-9034-5472	NIGMS NIH HHS [GM24963] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM024963] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CARTER PB, 1986, VET CLIN N AM-SMALL, V16, P1171, DOI 10.1016/S0195-5616(86)50135-2; CHAN RL, 1990, EMBO J, V9, P333, DOI 10.1002/j.1460-2075.1990.tb08115.x; GOLD JC, 1985, J BIOL CHEM, V260, P4897; GRAVES MC, 1983, ARCH BIOCHEM BIOPHYS, V222, P192, DOI 10.1016/0003-9861(83)90516-7; GUALERZI CO, 1990, BIOCHEMISTRY-US, V29, P5881, DOI 10.1021/bi00477a001; HERSHEY JWB, 1977, ARCH BIOCHEM BIOPHYS, V182, P626, DOI 10.1016/0003-9861(77)90543-4; HEUKESHOVEN J, 1985, ELECTROPHORESIS, V6, P103, DOI 10.1002/elps.1150060302; HOULNE G, 1988, MOL GEN GENET, V213, P479, DOI 10.1007/BF00339619; KAY AC, 1976, BIOCHIMIE, V58, P183, DOI 10.1016/S0300-9084(76)80369-0; KAY AC, 1972, BIOCHIMIE, V54, P1281, DOI 10.1016/S0300-9084(72)80069-5; KIMBALL SR, 1987, J BIOL CHEM, V262, P2220; KRAUS BL, 1986, PLANT PHYSL BETHESDA, V88, P993; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIAO HX, 1991, J BIOL CHEM, V266, P20714; LIAO HX, 1990, J BIOL CHEM, V265, P13618; LLOYD MA, 1980, J BIOL CHEM, V255, P1189; MA L, 1990, J BIOL CHEM, V265, P13560; MOLDAVE K, 1985, ANNU REV BIOCHEM, V54, P1109, DOI 10.1146/annurev.biochem.54.1.1109; MONTANDON PE, 1990, NUCLEIC ACIDS RES, V18, P75, DOI 10.1093/nar/18.1.75; OTTER T, 1987, ANAL BIOCHEM, V162, P370, DOI 10.1016/0003-2697(87)90406-4; PAIN VM, 1986, BIOCHEM J, V235, P625, DOI 10.1042/bj2350625; PON CL, 1985, J BIOL CHEM, V260, P8918; RIKIN A, 1988, P NATL ACAD SCI USA, V85, P5117, DOI 10.1073/pnas.85.14.5117; SCHANTZ ML, 1989, NUCLEIC ACIDS RES, V17, P6727, DOI 10.1093/nar/17.16.6727; SHARIF AL, 1989, EUR J BIOCHEM, V184, P353, DOI 10.1111/j.1432-1033.1989.tb15026.x; SHAZAND K, 1990, J BACTERIOL, V172, P2675, DOI 10.1128/jb.172.5.2675-2687.1990; SMEEKENS S, 1990, TRENDS BIOCHEM SCI, V15, P73, DOI 10.1016/0968-0004(90)90180-J; SPREMULLI LL, 1977, ARCH BIOCHEM BIOPHYS, V178, P565, DOI 10.1016/0003-9861(77)90227-2	28	7	7	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	1992	267	26					18356	18360						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JN502	1526976				2022-12-25	WOS:A1992JN50200020
J	WANG, LX; YERRAM, NR; KADUCE, TL; SPECTOR, AA				WANG, LX; YERRAM, NR; KADUCE, TL; SPECTOR, AA			MYRISTIC ACID UTILIZATION IN CHINESE-HAMSTER OVARY CELLS AND PEROXISOME-DEFICIENT MUTANTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN N-MYRISTOYLATION; FATTY-ACID; BETA-OXIDATION; LAURIC ACID; ARACHIDONIC-ACID; GLYCOSYL-PHOSPHATIDYLINOSITOL; PLASMALOGEN BIOSYNTHESIS; PROTEOLIPID PROTEIN; OMEGA-HYDROXYLATION; ACYLATED PROTEINS	Chinese hamster ovary (CHO) cells convert [9,10-H-3]myristic acid ([H-3]14:0) to several lipid-soluble, radioactive metabolites that are released into the medium. The main products are lauric (12:0) and decanoic (10:0) acids. Some of the 12:0 formed also is retained in cell lipids. Similar metabolites are not synthesized from palmitic (16:0), oleic (18:1), or arachidonic (20:4) acids, and the addition of these fatty acids does not reduce the conversion of [H-3]14:0 to 12:0. Two peroxisome-deficient CHO cell lines do not convert [H-3] 14:0 to any polar metabolites, but, they elongate, desaturate, and incorporate [H-3]14:0 into intracellular lipids and proteins normally. While BC3H1 muscle cells convert some [H-3]14:0 to 12:0, they also produce at least nine lipid-soluble polar products from [H-3]12:0. These findings suggest that a previously unrecognized function of myristic acid is to serve as a substrate for the synthesis of 12:0, which can be either secreted into the medium or converted to other oxidized metabolites. The absence of this peroxisomal oxidation pathway, however, does not interfere with other aspects of myristic acid metabolism, including protein myristoylation.	UNIV IOWA,DEPT BIOCHEM,4-550 BSB,IOWA CITY,IA 52242	University of Iowa			Spector, Arthur/AAG-9860-2020		NIDDK NIH HHS [DK 28516] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK028516] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALEXSON SEH, 1984, BIOCHIM BIOPHYS ACTA, V796, P1, DOI 10.1016/0005-2760(84)90231-5; ASHBROOK JD, 1975, J BIOL CHEM, V250, P2333; BIZZOZERO OA, 1986, J NEUROCHEM, V46, P630, DOI 10.1111/j.1471-4159.1986.tb13013.x; BODDUPALLI SS, 1990, J BIOL CHEM, V265, P4233; CHRISTENSEN E, 1989, BIOCHIM BIOPHYS ACTA, V1004, P187, DOI 10.1016/0005-2760(89)90267-1; CROSS GAM, 1990, ANNU REV CELL BIOL, V6, P1, DOI 10.1146/annurev.cb.06.110190.000245; DOERING TL, 1990, J BIOL CHEM, V265, P611; GORDON JA, 1991, BIOCHIM BIOPHYS ACTA, V1085, P21, DOI 10.1016/0005-2760(91)90227-9; GORDON JI, 1991, J BIOL CHEM, V266, P8647; GORDON JI, 1990, CLIN RES, V38, P517; HAYASHI H, 1989, ARCH BIOCHEM BIOPHYS, V274, P582, DOI 10.1016/0003-9861(89)90473-6; IMAOKA S, 1989, BIOCHEM INT, V18, P731; JAMES G, 1990, BIOCHEMISTRY-US, V29, P2623, DOI 10.1021/bi00463a001; KADUCE TL, 1989, J BIOL CHEM, V264, P6823; KONDRUP J, 1985, BIOCHIM BIOPHYS ACTA, V835, P147, DOI 10.1016/0005-2760(85)90041-4; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEES MB, 1972, ANAL BIOCHEM, V47, P184, DOI 10.1016/0003-2697(72)90291-6; LEIGHTON F, 1989, J BIOL CHEM, V264, P10347; LOW MG, 1988, SCIENCE, V239, P268, DOI 10.1126/science.3276003; MCGEE R, 1975, J BIOL CHEM, V250, P5419; MIRANDA CL, 1990, BIOCHEM BIOPH RES CO, V171, P537, DOI 10.1016/0006-291X(90)91179-V; MORRISON WR, 1964, J LIPID RES, V5, P600; MOSER HW, 1987, DEV NEUROSCI-BASEL, V9, P1, DOI 10.1159/000111604; MUERHOFF AS, 1989, J BIOL CHEM, V264, P749; ROMERO G, 1988, SCIENCE, V240, P509, DOI 10.1126/science.3282305; SALTIEL AR, 1987, J BIOL CHEM, V262, P1116; SCHRAKAMP G, 1988, J LIPID RES, V29, P325; SPECTOR AA, 1972, J LIPID RES, V13, P445; STREET JM, 1990, BIOCHEM J, V269, P671, DOI 10.1042/bj2690671; TAKEDA A, 1990, SCIENCE, V250, P676, DOI 10.1126/science.2146743; TANAKA S, 1990, BIOCHIM BIOPHYS ACTA, V1043, P177, DOI 10.1016/0005-2760(90)90293-7; WANDERS RJA, 1988, J NEUROL SCI, V88, P1, DOI 10.1016/0022-510X(88)90203-1; WANG LX, 1991, J BIOL CHEM, V266, P13883; WILCOX CA, 1987, BIOCHEMISTRY-US, V26, P1029, DOI 10.1021/bi00378a008; YERRAM NR, 1989, LIPIDS, V24, P594, DOI 10.1007/BF02535075; ZOELLER RA, 1986, P NATL ACAD SCI USA, V83, P5170, DOI 10.1073/pnas.83.14.5170	36	8	8	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1992	267	26					18983	18990						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JN502	1527024				2022-12-25	WOS:A1992JN50200109
J	SALMIVIRTA, M; HEINO, J; JALKANEN, M				SALMIVIRTA, M; HEINO, J; JALKANEN, M			BASIC FIBROBLAST GROWTH FACTOR-SYNDECAN COMPLEX AT CELL-SURFACE OR IMMOBILIZED TO MATRIX PROMOTES CELL-GROWTH	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMARY EPITHELIAL-CELLS; MESENCHYMAL INTERACTIONS; HEPARAN-SULFATE; MEMBRANE PROTEOGLYCAN; MOLECULAR-CLONING; RECEPTOR SYSTEM; EXPRESSION; FIBRONECTIN; BINDING; ECTODOMAIN	Promotion of cell growth and differentiation by growth factors during early development and organ formation are both temporally and spatially very precise. Syndecan is a well characterized integral membrane proteoglycan that binds several extracellular matrix components via its heparan sulfate chains and is therefore suggested to participate in cell regulation. Syndecan-like molecules, as low affinity receptors for heparin-binding growth factors, have been recently suggested to also regulate growth factor activity. Heparin/heparan sulfate interaction is required before, e.g. basic fibroblast growth factor (bFGF) can associate with its high affinity cell surface receptors and trigger signal transduction. In this paper we show that syndecan, but not free heparan sulfate chains, can simultaneously bind both bFGF and extracellular matrix molecules. Moreover, increased DNA synthesis of 3T3 cells was observed when the 3T3 cells were exposed to beads coated with the fibronectin-syndecan-bFGF complex, indicating that bFGF remains biologically active even when immobilized to matrix via the heparan sulfate chains of syndecan. Finally, when bFGF was bound to the surface of another cell type (epithelial), co-culture with 3T3 cells stimulated 3T3 cell growth. Therefore, we suggest that syndecan-like molecules may determine sites of growth factor action at cell-matrix and cell-cell interfaces.	UNIV TURKU, DEPT MED BIOCHEM, KIINAMYLLYNK 10, SF-20520 TURKU 52, FINLAND; TURKU CTR BIOTECHNOL, SF-20521 TURKU, FINLAND	University of Turku; University of Turku					NIDCR NIH HHS [DE 09399-01] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE009399] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ANDRES JL, 1992, J BIOL CHEM, V267, P5927; BERNFIELD M, 1992, IN PRESS ANN REV CEL; BOUTIN EL, 1991, DEV BIOL, V148, P63, DOI 10.1016/0012-1606(91)90317-V; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; CAREY DJ, 1992, J CELL BIOL, V117, P191, DOI 10.1083/jcb.117.1.191; DAVID G, 1990, J CELL BIOL, V111, P3165, DOI 10.1083/jcb.111.6.3165; ELENIUS K, 1992, J BIOL CHEM, V267, P6435; FINCH PW, 1989, SCIENCE, V245, P752, DOI 10.1126/science.2475908; Heath JK, 1991, CURR OPIN CELL BIOL, V3, P935, DOI 10.1016/0955-0674(91)90110-K; INGBER DE, 1990, P NATL ACAD SCI USA, V87, P3579, DOI 10.1073/pnas.87.9.3579; INKI P, 1991, AM J PATHOL, V139, P1333; JALKANEN M, 1987, J CELL BIOL, V105, P3087, DOI 10.1083/jcb.105.6.3087; JALKANEN M, 1992, RECEPTORS EXTRACELLU, P1; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; KLAGSBRUN M, 1991, CELL, V67, P229, DOI 10.1016/0092-8674(91)90173-V; KODA JE, 1985, J BIOL CHEM, V260, P8157; KOJIMA T, 1992, J BIOL CHEM, V267, P4870; LEPPA S, 1992, P NATL ACAD SCI USA, V89, P932, DOI 10.1073/pnas.89.3.932; LOPEZCASILLAS F, 1991, CELL, V67, P785, DOI 10.1016/0092-8674(91)90073-8; LORIES V, 1992, J BIOL CHEM, V267, P1116; RAPRAEGER A, 1985, J BIOL CHEM, V260, P4103; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; RASMUSSEN S, 1988, J CELL BIOL, V107, P1959, DOI 10.1083/jcb.107.5.1959; RIFKIN DB, 1989, J CELL BIOL, V109, P1, DOI 10.1083/jcb.109.1.1; SALMIVIRTA M, 1991, J BIOL CHEM, V266, P7733; SALMIVIRTA M, 1992, EXP CELL RES, V200, P444, DOI 10.1016/0014-4827(92)90194-D; SANDERSON RD, 1988, P NATL ACAD SCI USA, V85, P9562, DOI 10.1073/pnas.85.24.9562; SAUNDERS S, 1988, J CELL BIOL, V106, P423, DOI 10.1083/jcb.106.2.423; SAUNDERS S, 1989, J CELL BIOL, V108, P1547, DOI 10.1083/jcb.108.4.1547; SCHWARTZ MA, 1991, P NATL ACAD SCI USA, V88, P7849, DOI 10.1073/pnas.88.17.7849; SUN XJ, 1989, J BIOL CHEM, V264, P11288; VAAHTOKARI A, 1991, DEVELOPMENT, V113, P985; VAINIO S, 1989, DEV BIOL, V134, P382, DOI 10.1016/0012-1606(89)90110-3; VAINIO S, 1991, DEV BIOL, V147, P322, DOI 10.1016/0012-1606(91)90290-J; VAINIO S, 1992, IN PRESS DEV BIOL; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W	36	80	84	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 5	1992	267	25					17606	17610						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JM223	1517210				2022-12-25	WOS:A1992JM22300022
J	MARRIOTT, SJ; TRINH, D; BRADY, JN				MARRIOTT, SJ; TRINH, D; BRADY, JN			ACTIVATION OF INTERLEUKIN-2 RECEPTOR-ALPHA EXPRESSION BY EXTRACELLULAR HTLV-I TAX1 PROTEIN - A POTENTIAL ROLE IN HTLV-I PATHOGENESIS	ONCOGENE			English	Article							T-CELL LEUKEMIA; VIRUS TYPE-I; TROPICAL SPASTIC PARAPARESIS; PERIPHERAL-BLOOD LYMPHOCYTES; GROWTH-FACTOR RECEPTOR; MONOCLONAL-ANTIBODIES; GENE-EXPRESSION; IL-2 RECEPTOR; TAT GENE; TRANSFORMATION	The Tax1 protein of human T cell leukemia/lymphoma virus type I (HTLV-1) has been shown to stimulate the proliferation of human lymphocytes. Here we report that lymphocyte proliferation can be induced at extracellular Tax1 concentrations as low as 25 pM. The proliferative response induced by extracellular Tax1 is accompanied by an activation of endogenous interleukin-2 receptor alpha-chain (IL-2R-alpha) expression in human lymphocytes. Functional activation of IL-2R-alpha expression in peripheral blood lymphocytes treated with Tax1 was demonstrated using an [I-125]IL-2-binding assay. In addition, an enzyme-linked immunosorbent assay demonstrated that soluble IL-2R-alpha in the medium of IL-2- and Tax1-treated cells was over 13-fold greater than in the medium of control treated cells. Overexpression of IL-2R-alpha is a common clinical feature of some patients with adult T-cell leukemia (ATL) and tropical spastic paraparesis/HTLV-I-associated myopathy (TSP/HAM). The ability of extracellular Tax1 protein to activate expression of IL-2R-alpha in both infected and uninfected lymphocytes may contribute to the abnormal lymphocyte proliferation observed in both ATL and TSP/HAM.	NIH,MOLEC VIROL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA	MARRIOTT, SJ (corresponding author), BAYLOR COLL MED,DIV MOLEC VIROL,HOUSTON,TX 77030, USA.							ARYA SK, 1984, SCIENCE, V225, P1086; Ausubel FM., 1988, CURRENT PROTOCOLS MO; BALLARD DW, 1988, SCIENCE, V241, P1652, DOI 10.1126/science.2843985; CANN AJ, 1988, ONCOGENE, V3, P123; COATES SR, 1990, J CLIN MICROBIOL, V28, P1139, DOI 10.1128/JCM.28.6.1139-1142.1990; COSMAN D, 1984, NATURE, V312, P768, DOI 10.1038/312768a0; CROSS SL, 1987, CELL, V49, P47, DOI 10.1016/0092-8674(87)90754-9; DEPPER JM, 1984, J IMMUNOL, V133, P1691; DOI T, 1989, EMBO J, V8, P1953, DOI 10.1002/j.1460-2075.1989.tb03600.x; FELBER BK, 1985, SCIENCE, V229, P675, DOI 10.1126/science.2992082; GESSAIN A, 1985, LANCET, V2, P407; GIAM CZ, 1988, P NATL ACAD SCI USA, V83, P7192; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRASSMANN R, 1989, P NATL ACAD SCI USA, V86, P3351, DOI 10.1073/pnas.86.9.3351; HATTORI T, 1981, BLOOD, V58, P645; HINRICHS SH, 1987, SCIENCE, V237, P1340, DOI 10.1126/science.2888191; HINUMA Y, 1981, P NATL ACAD SCI-BIOL, V78, P6476, DOI 10.1073/pnas.78.10.6476; INOUE J, 1986, EMBO J, V5, P2883, DOI 10.1002/j.1460-2075.1986.tb04583.x; ITOYAMA Y, 1988, NEUROLOGY, V38, P816, DOI 10.1212/WNL.38.5.816; JACOBSON S, 1990, NATURE, V348, P245, DOI 10.1038/348245a0; JACOBSON S, 1988, NATURE, V331, P540, DOI 10.1038/331540a0; JEANG KT, 1990, SCIENCE, V247, P1082, DOI 10.1126/science.2309119; KASHIWAGI S, 1990, J INFECT DIS, V161, P426, DOI 10.1093/infdis/161.3.426; LEUNG K, 1988, NATURE, V333, P776, DOI 10.1038/333776a0; LINDHOLM P F, 1990, New Biologist, V2, P1034; LINDHOLM PF, 1992, J VIROL, V66, P1294, DOI 10.1128/JVI.66.3.1294-1302.1992; MARRIOTT SJ, 1991, NEW BIOL, V3, P678; NERENBERG M, 1987, SCIENCE, V237, P1324, DOI 10.1126/science.2888190; OSAME M, 1986, LANCET, V1, P1031; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; PONTE P, 1984, NUCLEIC ACIDS RES, V12, P1687, DOI 10.1093/nar/12.3.1687; POZZATTI R, 1990, MOL CELL BIOL, V10, P413, DOI 10.1128/MCB.10.1.413; RUBIN LA, 1985, J IMMUNOL, V135, P3172; RUDKIN BB, 1989, EMBO J, V8, P3319, DOI 10.1002/j.1460-2075.1989.tb08493.x; SIEKEVITZ M, 1987, P NATL ACAD SCI USA, V84, P5389, DOI 10.1073/pnas.84.15.5389; SODROSKI JG, 1984, SCIENCE, V225, P381, DOI 10.1126/science.6330891; STERN JB, 1986, SCIENCE, V233, P203, DOI 10.1126/science.3523754; TANAKA A, 1990, P NATL ACAD SCI USA, V87, P1071, DOI 10.1073/pnas.87.3.1071; TENDLER CL, 1990, P NATL ACAD SCI USA, V87, P5218, DOI 10.1073/pnas.87.13.5218; UCHIYAMA T, 1985, J CLIN INVEST, V76, P446, DOI 10.1172/JCI111992; UCHIYAMA T, 1977, BLOOD, V50, P481, DOI 10.1182/blood.V50.3.481.481; WALDMANN TA, 1986, SCIENCE, V232, P727, DOI 10.1126/science.3008337; WALDMANN TA, 1991, SCIENCE, V252, P1657, DOI 10.1126/science.2047874; YODOI J, 1983, BLOOD, V62, P509; YOSHIDA M, 1984, P NATL ACAD SCI-BIOL, V81, P2534, DOI 10.1073/pnas.81.8.2534	45	46	47	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1992	7	9					1749	1755						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JJ376	1501887				2022-12-25	WOS:A1992JJ37600011
J	DUFFY, EJ; PARKER, ET; MUTUCUMARANA, VP; JOHNSON, AE; LOLLAR, P				DUFFY, EJ; PARKER, ET; MUTUCUMARANA, VP; JOHNSON, AE; LOLLAR, P			BINDING OF FACTOR-VIIIA AND FACTOR-VIII TO FACTOR-IXA ON PHOSPHOLIPID-VESICLES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PORCINE FACTOR-VIII; FACTOR-X ACTIVATION; ACTIVE-SITE; PROTHROMBINASE COMPLEX; VONWILLEBRAND-FACTOR; MONOCLONAL-ANTIBODIES; SUBUNIT STRUCTURE; PROTEIN-C; THROMBIN; THROMBOMODULIN	The activation of factor X by factor IXa (fIXa) in the presence of phosphatidylcholine-phosphatidylserine (PCPS) vesicles is markedly accelerated by thrombin-activated factor VIII (fVIIIa). The interaction between highly purified fVIIIa and fIXa in this complex was studied fluorometrically at 25-degrees-C by using a derivative of D-phenylalanyl-prolyl-arginyl-fIXa which was modified at the active site with fluorescein-5-maleimide (Fl-M-FPR-fIXa). Titration of Fl-M-FPR-fIXa with fVIIIa at fixed PCPS resulted in a large, saturable increase in anisotropy (DELTA-r = 0.09). The titration data were fit to a model assuming a reversible equilibrium between fVIIIa and fIXa, resulting in an apparent dissociation constant of 2 nM and a stoichiometry of 1 mol of fVIIIa/mol of Fl-M-FPR-fIXa. The initial velocity of factor X activation was measured under identical conditions except that active fIXa and factor X were included, which yielded binding parameters similar to those determined fluorometrically. Thus, the fluorescence method accurately reflects complex formation between fVIIIa and fIXa on the phospholipid surface, and the fVIIIa-fIXa interaction is not influenced by the presence of the substrate, factor X. Addition of fVIII to Fl-M-FPR-fIXa and PCPS produced a small, saturable increase in anisotropy (DELTA-r = 0.03), followed by a larger increase (DELTA-r = 0.07) upon addition of thrombin to activate fVIII. Thus, fVIII binds fIXa, but proteolytic modification of fVIII must occur before the complete fVIIIa-dependent structural change in the active site of fIXa, as reflected in the anisotropy change, occurs.	EMORY UNIV,DEPT MED,DIV HEMATOL ONCOL,DRAWER AJ,1003 WOODRUFF MEM BLDG,ATLANTA,GA 30322; UNIV OKLAHOMA,DEPT CHEM & BIOCHEM,NORMAN,OK 73019	Emory University; University of Oklahoma System; University of Oklahoma - Norman			Johnson, Arthur E/G-3457-2012		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL040921, R01HL032934] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL40921, R01 HL 32934] Funding Source: Medline; PHS HHS [R01 46215] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ANDERSSON LO, 1981, BIOCHEM J, V200, P161, DOI 10.1042/bj2000161; ANDERSSON LO, 1986, P NATL ACAD SCI USA, V83, P2979, DOI 10.1073/pnas.83.9.2979; BARENHOLZ Y, 1977, BIOCHEMISTRY-US, V16, P2806, DOI 10.1021/bi00631a035; Bevington P. R., 1969, DATA REDUCTION ERROR; BOCK PE, 1988, BIOCHEMISTRY-US, V27, P6633, DOI 10.1021/bi00417a063; CHASE T, 1970, METHOD ENZYMOL, V19, P20; CHURCH WR, 1984, P NATL ACAD SCI-BIOL, V81, P6934, DOI 10.1073/pnas.81.22.6934; COOPER HA, 1975, J CLIN INVEST, V56, P751, DOI 10.1172/JCI108146; DAVIE EW, 1987, HEMOSTASIS THROMBOSI, P242; DUFFY EJ, 1992, J BIOL CHEM, V267, P7821; EATON D, 1986, BIOCHEMISTRY-US, V25, P505, DOI 10.1021/bi00350a035; FASS DN, 1982, BLOOD, V59, P594; FAY PJ, 1991, J BIOL CHEM, V266, P8957; FAY PJ, 1986, BIOCHIM BIOPHYS ACTA, V871, P268, DOI 10.1016/0167-4838(86)90208-6; FAY PJ, 1987, BIOCHIM BIOPHYS ACTA, V952, P181; FULCHER CA, 1983, BLOOD, V61, P807; GILBERT GE, 1990, J BIOL CHEM, V265, P815; GREEN GDJ, 1979, ANAL BIOCHEM, V93, P223, DOI 10.1016/S0003-2697(79)80070-6; HEMKER HC, 1967, NATURE, V215, P1201, DOI 10.1038/2151201a0; HILLEUBANKS DC, 1989, P NATL ACAD SCI USA, V86, P6508, DOI 10.1073/pnas.86.17.6508; HULTIN MB, 1981, BLOOD, V57, P476; HULTIN MB, 1982, J CLIN INVEST, V69, P950, DOI 10.1172/JCI110534; HUSTEN EJ, 1987, J BIOL CHEM, V262, P12953; KOEDAM JA, 1990, EUR J BIOCHEM, V189, P229, DOI 10.1111/j.1432-1033.1990.tb15481.x; KRISHNASWAMY S, 1990, J BIOL CHEM, V265, P3807; LAJMANOVICH A, 1981, BIOCHIM BIOPHYS ACTA, V678, P12; LAKOWICZ JR, 1983, PRINCIPLES FLUORESCE, P112; LOLLAR P, 1990, J BIOL CHEM, V265, P1688; LOLLAR P, 1985, BIOCHEMISTRY-US, V24, P8056, DOI 10.1021/bi00348a033; LOLLAR P, 1988, J BIOL CHEM, V263, P10451; LOLLAR P, 1984, ARCH BIOCHEM BIOPHYS, V233, P438, DOI 10.1016/0003-9861(84)90465-X; LOLLAR P, 1984, BLOOD, V63, P1303; LOLLAR P, 1989, BIOCHEMISTRY-US, V28, P666, DOI 10.1021/bi00428a038; LOLLAR P, 1988, BLOOD, V71, P137; LOLLAR P, 1991, J BIOL CHEM, V266, P12481; LU RL, 1989, J BIOL CHEM, V264, P12956; MANN KG, 1988, ANNU REV BIOCHEM, V57, P915, DOI 10.1146/annurev.bi.57.070188.004411; MCGEE MP, 1991, J BIOL CHEM, V266, P8079; MUTUCUMARANA VP, 1992, J BIOL CHEM, V267, P17012; NESHEIM ME, 1981, J BIOL CHEM, V256, P6537; NEUENSCHWANDER P, 1988, BLOOD, V72, P1761; RAPAPORT SI, 1963, BLOOD, V21, P221, DOI 10.1182/blood.V21.2.221.221; ROSING J, 1980, J BIOL CHEM, V255, P274; ROSING J, 1985, BLOOD, V65, P619; ROTBLAT F, 1985, BIOCHEMISTRY-US, V24, P4294, DOI 10.1021/bi00337a007; STERN DM, 1985, J BIOL CHEM, V260, P6717; TOOLE JJ, 1984, NATURE, V312, P342, DOI 10.1038/312342a0; VANDIEIJEN G, 1981, J BIOL CHEM, V256, P3433; VANDIEIJEN G, 1985, THROMB HAEMOSTASIS, V53, P396; VEHAR GA, 1984, NATURE, V312, P337, DOI 10.1038/312337a0; VEHAR GA, 1980, BIOCHEMISTRY-US, V19, P401, DOI 10.1021/bi00544a001; YE J, 1991, J BIOL CHEM, V266, P23016; 1976, J BIOL CHEM, V251, P6879	53	88	88	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1992	267	24					17006	17011						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JL053	1512239				2022-12-25	WOS:A1992JL05300045
J	PROSTKO, CR; BROSTROM, MA; MALARA, EM; BROSTROM, CO				PROSTKO, CR; BROSTROM, MA; MALARA, EM; BROSTROM, CO			PHOSPHORYLATION OF EUKARYOTIC INITIATION FACTOR-(EIF)-2-ALPHA AND INHIBITION OF EIF-2B IN GH3 PITUITARY-CELLS BY PERTURBANTS OF EARLY PROTEIN PROCESSING THAT INDUCE GRP78	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							INTRACELLULAR SEQUESTERED CALCIUM; NUCLEOTIDE-EXCHANGE FACTOR; ELONGATION FACTOR-II; HEAT-SHOCK PROTEIN; ENDOPLASMIC-RETICULUM; SECRETORY PROTEINS; TRANSLATIONAL INITIATION; RAT-LIVER; PHYSIOLOGICAL STRESSES; CHRONIC DEPRIVATION	Agents that mobilize sequestered intracellular Ca2+, including ionophore A23187, EGTA, thapsigargin, and Cbz-Gly-Phe-NH2 (where Cbz is benzyloxycarbonyl), or mild reducing agents, such as dithiothreitol, disrupt early protein processing in the endoplasmic reticulum (ER), inhibit translational initiation, and trigger the induction of GRP78, an ER resident protein. Inhibition of translational initiation in response to acute treatment (15-30 min) of intact GH3 pituitary cells with each of these agents was accompanied by an average 5-fold increase in the amount of phosphorylated eukaryotic initiation factor (eIF) 2-alpha and a 50% reduction in eIF-2B activity. With continued exposure to A23187 (3 h) rates of amino acid incorporation partially recovered, eIF-2-alpha became dephosphorylated, and the inhibition of eIF-2B activity was abolished. These chronic effects were blocked by actinomycin D. Accumulating evidence that the ER may regulate rates of translational initiation through a signaling system altering the activity of eIF-2 is discussed.	UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,DEPT PHARMACOL,PISCATAWAY,NJ 08854	Rutgers State University New Brunswick; Rutgers State University Medical Center					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK035393] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 35393] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BRAAKMAN I, 1992, NATURE, V356, P260, DOI 10.1038/356260a0; BROSTROM CO, 1989, J BIOL CHEM, V264, P1644; BROSTROM CO, 1983, J BIOL CHEM, V258, P4390; BROSTROM CO, 1990, ANNU REV PHYSIOL, V52, P577; BROSTROM MA, 1991, J BIOL CHEM, V266, P7037; BROSTROM MA, 1990, J BIOL CHEM, V265, P20539; BROSTROM MA, 1992, IN PRESS NUTRIENT GE; CHIN KV, 1987, J BIOL CHEM, V262, P16509; CHIN KV, 1988, INT J BIOCHEM, V20, P1313, DOI 10.1016/0020-711X(88)90236-4; DUNCAN R, 1985, J BIOL CHEM, V260, P5493; DUNCAN RF, 1987, ARCH BIOCHEM BIOPHYS, V256, P651, DOI 10.1016/0003-9861(87)90622-9; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; KIMBALL SR, 1990, J BIOL CHEM, V265, P16794; KIMBALL SR, 1991, J BIOL CHEM, V266, P1969; KUZNETSOV G, 1992, J BIOL CHEM, V267, P3932; LODISH HF, 1990, J BIOL CHEM, V265, P10893; MATTS RL, 1989, J BIOL CHEM, V264, P15542; MENAYA J, 1988, BIOCHEM J, V254, P773, DOI 10.1042/bj2540773; NAIRN AC, 1987, J BIOL CHEM, V262, P17299; NGUYEN TH, 1991, P NATL ACAD SCI USA, V88, P1565, DOI 10.1073/pnas.88.4.1565; PROSTKO CR, 1991, J BIOL CHEM, V266, P19790; PROUD CG, 1992, CURR TOP CELL REGUL, V32, P243; REDPATH NT, 1989, BIOCHEM J, V262, P69, DOI 10.1042/bj2620069; ROSE DW, 1989, J BIOL CHEM, V264, P6239; ROTMAN EI, 1992, BIOCHEM J, V282, P487, DOI 10.1042/bj2820487; ROWLANDS AG, 1988, J BIOL CHEM, V263, P5526; ROWLANDS AG, 1988, EUR J BIOCHEM, V175, P93, DOI 10.1111/j.1432-1033.1988.tb14170.x; RYAZANOV A G, 1990, New Biologist, V2, P843; SAFER B, 1983, CELL, V33, P7, DOI 10.1016/0092-8674(83)90326-4; SAMBROOK JF, 1990, CELL, V61, P197, DOI 10.1016/0092-8674(90)90798-J; SANDERS SL, 1992, CELL, V69, P353, DOI 10.1016/0092-8674(92)90415-9; SCORSONE KA, 1987, J BIOL CHEM, V262, P14538; THASTRUP O, 1990, AGENTS ACTIONS, V29, P8, DOI 10.1007/BF01964706; VOGEL JP, 1990, J CELL BIOL, V110, P1885, DOI 10.1083/jcb.110.6.1885; WILEMAN T, 1991, J BIOL CHEM, V266, P4500; WONG WL, 1991, INT J BIOCHEM, V23, P605	36	115	116	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1992	267	24					16751	16754						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JL053	1512215				2022-12-25	WOS:A1992JL05300002
J	BAO, ZZ; MUSCHLER, J; HORWITZ, AF				BAO, ZZ; MUSCHLER, J; HORWITZ, AF			LBL, A NOVEL, DEVELOPMENTALLY REGULATED, LAMININ-BINDING LECTIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASEMENT-MEMBRANE COMPONENTS; HEPARIN-BINDING; PLATELET THROMBOSPONDIN; ENDOGENOUS LECTIN; ELASTIN RECEPTOR; SKELETAL-MUSCLE; CELLS; PROTEIN; ADHESION; FIBRONECTIN	A 190/220-kDa complex found in integrin preparations was purified, and monoclonal antibodies were raised against it. The immunoaffinity-purified complex appears to be a trimer of very similar or identical 70-kDa subunits. It is a novel extracellular matrix molecule as determined by its subunit composition, N-terminal amino acid sequence, and in vivo localization. It is distributed widely in basement membranes including those from muscle, nerve, and kidney. It is also present in connective tissue regions such as perineurium and perimysium. It has the unusual property that it is initially expressed very late in avian development near the time of hatching. This protein is found to copurified with integrin because it binds to the carbohydrate support in Sepharose. Hemagglutination assays with mono- and disaccharides show that it functions as a lectin with galactoside-binding specificity. This protein is also found to bind strongly and specifically to laminin at a site distinct from its lectin activity, but does not bind to fibronectin or type IV collagen. The protein appears to be conserved and is a common contaminant of many laminin preparations. We call this novel protein "LBL" for laminin-binding lectin.	UNIV ILLINOIS,DEPT CELL & STRUCT BIOL,505 S GOODWIN AVE,506 MORRILL HALL,URBANA,IL 61801	University of Illinois System; University of Illinois Urbana-Champaign				Muschler, John/0000-0001-9916-5937	PHS HHS [23244] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AUMAILLEY M, 1987, J BIOL CHEM, V262, P11532; BARONDES SH, 1984, SCIENCE, V223, P1258; BEYER EC, 1979, J CELL BIOL, V82, P565, DOI 10.1083/jcb.82.2.565; BEYER EC, 1982, J CELL BIOL, V92, P28, DOI 10.1083/jcb.92.1.28; BOZYCZKO D, 1989, EXP CELL RES, V183, P72, DOI 10.1016/0014-4827(89)90419-9; CARLIN BE, 1983, J BIOL CHEM, V258, P7729; CERI H, 1979, J SUPRAMOL STR CELL, V11, P61, DOI 10.1002/jss.400110107; CHARONIS AS, 1988, J CELL BIOL, V107, P1253, DOI 10.1083/jcb.107.3.1253; CHIQUETEHRISMANN R, 1986, CELL, V47, P131, DOI 10.1016/0092-8674(86)90374-0; DIXIT VM, 1984, J BIOL CHEM, V259, P100; DZIADEK M, 1985, DEV BIOL, V111, P372, DOI 10.1016/0012-1606(85)90491-9; EHRIG K, 1990, P NATL ACAD SCI USA, V87, P3264, DOI 10.1073/pnas.87.9.3264; FUJIWARA S, 1988, BIOCHEM J, V252, P453, DOI 10.1042/bj2520453; FUJIWARA S, 1984, EUR J BIOCHEM, V143, P145, DOI 10.1111/j.1432-1033.1984.tb08353.x; Gallagher JT, 1989, CURR OPIN CELL BIOL, V1, P1201, DOI 10.1016/S0955-0674(89)80072-9; HAYMAN EG, 1982, J CELL BIOL, V95, P20, DOI 10.1083/jcb.95.1.20; HINEK A, 1988, SCIENCE, V239, P1539, DOI 10.1126/science.2832941; HOGAN BLM, 1980, DEV BIOL, V80, P289, DOI 10.1016/0012-1606(80)90405-4; HUNTER DD, 1989, NATURE, V338, P229, DOI 10.1038/338229a0; HYNES RO, 1990, FIBRONECTINS, P84; KOUZIKOLIAKOS K, 1989, J BIOL CHEM, V264, P17971; LAWLER JW, 1981, THROMB RES, V22, P267, DOI 10.1016/0049-3848(81)90119-5; LEE RT, 1990, J BIOL CHEM, V265, P7864; LIAO NS, 1989, EXP CELL RES, V181, P348, DOI 10.1016/0014-4827(89)90093-1; LIS N., 1972, METHODS ENZIMOL, V28, P360, DOI [10.1016/0076-6879(72)28046-6., DOI 10.1016/0076-6879(72)28046-6]; LUNSTRUM GP, 1991, J CELL BIOL, V113, P963, DOI 10.1083/jcb.113.4.963; MARTIN GR, 1987, ANNU REV CELL BIOL, V3, P57, DOI 10.1146/annurev.cellbio.3.1.57; Mayne R, 1987, STRUCTURE FUNCTION C, P317; MECHAM RP, 1991, J CELL BIOL, V113, P187, DOI 10.1083/jcb.113.1.187; MECHAM RP, 1989, J BIOL CHEM, V264, P16652; MILLER F, 1972, IMMUNOCHEMISTRY, V9, P217, DOI 10.1016/0019-2791(72)90087-0; Montreuil J, 1980, Adv Carbohydr Chem Biochem, V37, P157; NEFF NT, 1982, J CELL BIOL, V95, P654, DOI 10.1083/jcb.95.2.654; PAULSSON M, 1987, EUR J BIOCHEM, V166, P11, DOI 10.1111/j.1432-1033.1987.tb13476.x; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; RUOSLAHTI E, 1988, ANNU REV BIOCHEM, V57, P375, DOI 10.1146/annurev.bi.57.070188.002111; SAUNDERS S, 1988, J CELL BIOL, V106, P423, DOI 10.1083/jcb.106.2.423; SHARON N, 1989, SCIENCE, V246, P227, DOI 10.1126/science.2552581; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; TSILIBARY EC, 1988, J BIOL CHEM, V263, P19112; WOO HJ, 1990, J BIOL CHEM, V265, P7097; WOODLEY DT, 1983, BIOCHIM BIOPHYS ACTA, V761, P278, DOI 10.1016/0304-4165(83)90077-6; YURCHENCO PD, 1985, J BIOL CHEM, V260, P7636; ZHOU Q, 1990, ARCH BIOCHEM BIOPHYS, V281, P27, DOI 10.1016/0003-9861(90)90408-Q	45	10	10	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1992	267	7					4974	4980						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HF642	1531660				2022-12-25	WOS:A1992HF64200101
J	LINDER, S; POPOWICZ, P; SVENSSON, C; MARSHALL, H; BONDESSON, M; AKUSJARVI, G				LINDER, S; POPOWICZ, P; SVENSSON, C; MARSHALL, H; BONDESSON, M; AKUSJARVI, G			ENHANCED INVASIVE PROPERTIES OF RAT EMBRYO FIBROBLASTS TRANSFORMED BY ADENOVIRUS E1A MUTANTS WITH DELETIONS IN THE CARBOXY-TERMINAL EXON	ONCOGENE			English	Article							TOXIC LYMPHOCYTES-T; REGULATORY FUNCTIONS; CELL-TRANSFORMATION; TUMOR-CELLS; EXPRESSION; ONCOGENE; GENE; REGION; METASTASIS; PROTEIN	E1A genes deficient in the carboxy-terminal exon can cooperate with activated ras oncogenes to induce transformation of rat embryo fibroblasts. However, the resulting transformed foci show a distinct appearance characterized by a decreased adhesion of the cells to the substrate. Here, we demonstrate that cell lines derived from foci showing the variant morphology are defective in down-regulation of stromelysin 1 metalloprotease expression and show an increased invasive propensity compared with cells transformed by wild-type E1A. The altered focus morphology, the high invasive propensity and the elevated stromelysin 1 expression were abrogated by glucocorticoid treatment. Our results show that E1A functions necessary for transformation and inhibition of invasive properties may be separated, and indicate that a 23 amino acid serine/threonine-rich region within the E1A carboxy-terminal exon is required for efficient repression of metalloprotease expression in transformed cells.	KAROLINSKA INST & HOSP, RADIUMHEMMET, DEPT ONCOL, DIV EXPTL ONCOL, S-10401 STOCKHOLM, SWEDEN; KAROLINSKA INST, DEPT MICROBIAL GENET, S-10401 STOCKHOLM 60, SWEDEN	Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet			Bondesson, Maria/H-3027-2012	Bondesson, Maria/0000-0001-6358-5788				ALBINI A, 1987, CANCER RES, V47, P3239; COOK JL, 1986, P NATL ACAD SCI USA, V83, P6965, DOI 10.1073/pnas.83.18.6965; DEAR TN, 1990, MOL ASPECTS MED, V11, P243, DOI 10.1016/0098-2997(90)90005-M; EDMONDS M, 1969, J BIOL CHEM, V244, P1314; FRISCH SM, 1990, ONCOGENE, V5, P75; GOLDFARB M, 1982, NATURE, V296, P404, DOI 10.1038/296404a0; GOPAS J, 1989, ADV CANCER RES, V53, P89; KAST WM, 1989, CELL, V59, P603, DOI 10.1016/0092-8674(89)90006-8; KIMELMAN D, 1985, J VIROL, V53, P399, DOI 10.1128/JVI.53.2.399-409.1985; KUPPUSWAMY MN, 1987, VIROLOGY, V159, P31, DOI 10.1016/0042-6822(87)90344-8; LILLIE JW, 1987, CELL, V50, P1091, DOI 10.1016/0092-8674(87)90175-9; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; LIOTTA LA, 1980, NATURE, V284, P67, DOI 10.1038/284067a0; MARTENS I, 1990, EXP CELL RES, V187, P143, DOI 10.1016/0014-4827(90)90128-W; MATRISIAN LM, 1986, MOL CELL BIOL, V6, P1679, DOI 10.1128/MCB.6.5.1679; OFFRINGA R, 1990, CELL, V62, P527, DOI 10.1016/0092-8674(90)90017-9; OFFRINGA R, 1988, NUCLEIC ACIDS RES, V16, P10973, DOI 10.1093/nar/16.23.10973; POZZATTI R, 1986, SCIENCE, V232, P223, DOI 10.1126/science.3456644; POZZATTI R, 1988, MOL CELL BIOL, V8, P2984, DOI 10.1128/MCB.8.7.2984; ROSENGARD AM, 1989, NATURE, V342, P177, DOI 10.1038/342177a0; SAWADA Y, 1985, VIROLOGY, V147, P413, DOI 10.1016/0042-6822(85)90143-6; SCHNEIDER JF, 1987, EMBO J, V6, P2053, DOI 10.1002/j.1460-2075.1987.tb02470.x; SHIH C, 1982, CELL, V29, P161, DOI 10.1016/0092-8674(82)90100-3; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; SUBRAMANIAN T, 1989, ONCOGENE, V4, P415; SVENSSON C, 1991, VIROLOGY, V182, P553, DOI 10.1016/0042-6822(91)90596-4; SVENSSON C, 1983, J MOL BIOL, V165, P475, DOI 10.1016/S0022-2836(83)80214-9; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; TIMMERS HTM, 1988, ONCOGENE RES, V3, P67; TREMBLAY ML, 1988, J BIOL CHEM, V263, P6375; ULFENDAHL PJ, 1987, EMBO J, V6, P2037, DOI 10.1002/j.1460-2075.1987.tb02468.x; URBANELLI D, 1989, VIROLOGY, V173, P607, DOI 10.1016/0042-6822(89)90572-2; VANDAM H, 1989, ONCOGENE, V4, P1207; VELCICH A, 1988, MOL CELL BIOL, V8, P2177, DOI 10.1128/MCB.8.5.2177; WHYTE P, 1988, J VIROL, V62, P257, DOI 10.1128/JVI.62.1.257-265.1988; WIGLER M, 1979, P NATL ACAD SCI USA, V76, P1373, DOI 10.1073/pnas.76.3.1373; ZERLER B, 1986, MOL CELL BIOL, V6, P887, DOI 10.1128/MCB.6.3.887	37	34	34	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	1992	7	3					439	443						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HK005	1532246				2022-12-25	WOS:A1992HK00500006
J	CHAPMAN, ER; ESTEP, RP; STORM, DR				CHAPMAN, ER; ESTEP, RP; STORM, DR			PALMITYLATION OF NEUROMODULIN (GAP-43) IS NOT REQUIRED FOR PHOSPHORYLATION BY PROTEIN-KINASE-C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALMODULIN-BINDING-PROTEIN; GROWTH-ASSOCIATED PROTEIN; AXONALLY TRANSPORTED PROTEINS; LONG-TERM POTENTIATION; ADULT-RAT BRAIN; NEURITE OUTGROWTH; PHORBOL ESTER; B-50 GAP-43; POLYPHOSPHOINOSITIDE METABOLISM; SUBCELLULAR FRACTION	Neuromodulin (also designated GAP-43, B-50, and F-1) is a prominent protein kinase C substrate attached to the membranes of neuronal growth cones during development and to presynaptic membranes in discrete subsets of adult synapses. In this study, we have examined the relationship between the attachment of neuromodulin to membranes and its phosphorylation by protein kinase C. To address this issue, we have compared wild-type and mutant neuromodulins expressed in cells that normally lack the protein. Wild-type neuromodulin expressed in Chinese hamster ovary cells was associated with membranes, incorporated [H-3]palmitic acid, and was phosphorylated in response to phorbol ester treatment. Substitution of serine 41, the in vitro protein kinase C site, abolished the phorbol ester response, indicating that serine 41 serves as the sole protein kinase C phosphorylation site in vivo. Substitution of the putative fatty acylation sites, cysteines 3 and 4, abolished membrane association as well as [H-3]palmitic acid labeling of neuromodulin. Fatty acylation therefore appears to serve as the mechanism for anchoring neuromodulin to membranes. Surprisingly, the soluble cysteine substitution mutant was phosphorylated by protein kinase C at a rate indistinguishable from that of the wild-type protein. Therefore, membrane association may not be required for the phosphorylation of neuromodulin by protein kinase C.			CHAPMAN, ER (corresponding author), UNIV WASHINGTON,DEPT PHARMACOL,SEATTLE,WA 98195, USA.			Chapman, Edwin/0000-0001-9787-8140	NHLBI NIH HHS [HL-23606] Funding Source: Medline; NIGMS NIH HHS [GM-07270, GM-33708] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL023606] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007270, R01GM033708] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKERS R, 1987, J NEUROSCI, V7, P3977; AKERS RF, 1985, BRAIN RES, V334, P147, DOI 10.1016/0006-8993(85)90576-1; AKITA Y, 1990, J BIOL CHEM, V265, P354; ALBERT KA, 1986, P NATL ACAD SCI USA, V83, P2822, DOI 10.1073/pnas.83.9.2822; ALEXANDER KA, 1987, J BIOL CHEM, V262, P6108; ALEXANDER KA, 1988, J BIOL CHEM, V263, P7544; ALLSOPP TE, 1989, J NEUROSCI, V9, P13; APEL ED, 1991, J BIOL CHEM, V266, P10544; APEL ED, 1990, BIOCHEMISTRY-US, V29, P2330, DOI 10.1021/bi00461a017; AU DC, 1989, BIOCHEMISTRY-US, V28, P8142, DOI 10.1021/bi00446a027; Ausubel FM, 1987, CURRENT PROTOCOLS MO, V1-5; BAUDIER J, 1989, J BIOL CHEM, V264, P1824; BAUDIER J, 1991, J BIOL CHEM, V266, P229; BELL RM, 1986, CELL, V45, P631, DOI 10.1016/0092-8674(86)90774-9; BENOWITZ LI, 1988, J NEUROSCI, V8, P339; BUSS JE, 1986, J VIROL, V58, P468, DOI 10.1128/JVI.58.2.468-474.1986; CHAKRAVARTHY BR, 1989, BIOCHEM BIOPH RES CO, V160, P340, DOI 10.1016/0006-291X(89)91661-6; CHAPMAN ER, 1991, J BIOL CHEM, V266, P207; CIMLER BM, 1985, J BIOL CHEM, V260, P784; COGGINS PJ, 1989, J NEUROCHEM, V53, P1895, DOI 10.1111/j.1471-4159.1989.tb09259.x; DEGRAAN PNE, 1988, NEUROSCI RES COMMUN, V3, P175; DEGRAAN PNE, 1989, J NEUROCHEM, V52, P17; DEKKER LV, 1989, NATURE, V342, P74, DOI 10.1038/342074a0; GIRARD PR, 1990, J NEUROCHEM, V54, P300, DOI 10.1111/j.1471-4159.1990.tb13315.x; GISPEN WH, 1985, BRAIN RES, V328, P381, DOI 10.1016/0006-8993(85)91054-6; GORGELS TGMF, 1989, J NEUROSCI, V9, P3861; GRAFF JM, 1989, SCIENCE, V246, P503, DOI 10.1126/science.2814478; GRAFF JM, 1989, J BIOL CHEM, V264, P21818; HALL FL, 1988, J BIOL CHEM, V263, P4460; HOUBRE D, 1991, J BIOL CHEM, V266, P7121; HSU L, 1984, CANCER RES, V44, P4607; LABATE ME, 1989, NEURON, V3, P299, DOI 10.1016/0896-6273(89)90254-7; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARRIVEE DC, 1987, J NEUROCHEM, V49, P1747, DOI 10.1111/j.1471-4159.1987.tb02432.x; LIU YC, 1991, NEURON, V6, P411, DOI 10.1016/0896-6273(91)90249-Y; LIU YC, 1990, TRENDS PHARMACOL SCI, V11, P107; LOVINGER DM, 1986, BRAIN RES, V399, P205, DOI 10.1016/0006-8993(86)91510-6; Maniatis T., 1982, MOL CLONING; MASURE HR, 1986, BIOCHEMISTRY-US, V25, P7553, DOI 10.1021/bi00371a044; MATTSON MP, 1988, J NEUROSCI RES, V21, P447, DOI 10.1002/jnr.490210236; MEIRI KF, 1986, P NATL ACAD SCI USA, V83, P3537, DOI 10.1073/pnas.83.10.3537; MEIRI KF, 1988, J NEUROSCI, V8, P2571; MEIRI KF, 1991, J CELL BIOL, V112, P991, DOI 10.1083/jcb.112.5.991; MEIRI KF, 1990, J NEUROSCI, V10, P256; MOSS DJ, 1990, J NEUROCHEM, V54, P729, DOI 10.1111/j.1471-4159.1990.tb02312.x; MURPHY K M M, 1983, Science (Washington D C), V222, P1036, DOI 10.1126/science.6316499; NELSON RB, 1989, J NEUROSCI, V9, P381; NIELANDER HB, 1990, J NEUROCHEM, V55, P1442, DOI 10.1111/j.1471-4159.1990.tb03159.x; PERRONEBIZZOZERO NI, 1989, J NEUROCHEM, V52, P1149, DOI 10.1111/j.1471-4159.1989.tb01860.x; PERSAUD SJ, 1989, FEBS LETT, V245, P80, DOI 10.1016/0014-5793(89)80196-6; PHILLIPS WA, 1989, J BIOL CHEM, V264, P8361; PISANO MR, 1988, BIOCHEM BIOPH RES CO, V155, P1207, DOI 10.1016/S0006-291X(88)81268-3; REPRESA A, 1990, J NEUROSCI, V10, P3782, DOI 10.1523/JNEUROSCI.10-12-03782.1990; ROUTTENBERG A, 1985, BEHAV NEURAL BIOL, V43, P3, DOI 10.1016/S0163-1047(85)91426-8; SEED B, 1987, NATURE, V329, P840, DOI 10.1038/329840a0; SKENE JHP, 1986, SCIENCE, V233, P783, DOI 10.1126/science.3738509; SKENE JHP, 1989, J CELL BIOL, V108, P613, DOI 10.1083/jcb.108.2.613; SKENE JHP, 1981, J CELL BIOL, V89, P86, DOI 10.1083/jcb.89.1.86; SKENE JHP, 1981, J CELL BIOL, V89, P96, DOI 10.1083/jcb.89.1.96; SPENCER SA, 1991, NEUR ABSTR, V17, P52515; SPINELLI W, 1982, CANCER RES, V42, P5067; STRITTMATTER SM, 1990, NATURE, V344, P836, DOI 10.1038/344836a0; STUMPO DJ, 1989, P NATL ACAD SCI USA, V86, P4012, DOI 10.1073/pnas.86.11.4012; VANDONGEN CJ, 1985, BIOCHEM BIOPH RES CO, V128, P1219, DOI 10.1016/0006-291X(85)91070-8; VANDOREN K, 1984, J VIROL, V50, P606, DOI 10.1128/JVI.50.2.606-614.1984; VANHOOFF COM, 1988, J NEUROSCI, V8, P1789; Woodgett JR., 1987, CELL MEMBRANES, P215, DOI [10.1007/978-1-4613-1915-3_6, DOI 10.1007/978-1-4613-1915-3_6]; ZUBER MX, 1989, SCIENCE, V244, P1193, DOI 10.1126/science.2658062; ZUBER MX, 1989, NATURE, V341, P345, DOI 10.1038/341345a0; ZWIERS H, 1985, J NEUROCHEM, V44, P1083, DOI 10.1111/j.1471-4159.1985.tb08728.x	70	27	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1992	267	35					25233	25238						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KB603	1460023				2022-12-25	WOS:A1992KB60300050
J	LIU, W; HANSEN, JN				LIU, W; HANSEN, JN			ENHANCEMENT OF THE CHEMICAL AND ANTIMICROBIAL PROPERTIES OF SUBTILIN BY SITE-DIRECTED MUTAGENESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEPTIDE ANTIBIOTIC NISIN; ARTIFICIAL MEMBRANES; PROTEIN; BACTERIAL; MODE; EXPRESSION; PRECURSOR; MECHANISM; LIPOSOMES	Subtilin and nisin are gene-encoded antibiotic peptides that are ribosomally synthesized by Bacillus subtilis and Lactococcus lactis, respectively. Gene-encoded antibiotics are unique in that their structures can be manipulated by mutagenesis of their structural genes. Although subtilin and nisin share considerable structural homology, subtilin has a greater tendency than nisin to undergo spontaneous inactivation. This inactivation is accompanied by chemical modification of the dehydroalanine at position 5 (DHA5) with a kinetic first-order t1/2 of 0.8 days. It was hypothesized that the R group carboxyl of Glu4 in subtilin participates in the chemical modification of the adjacent DHA5. Noting that nisin has Ile at position 4, site-directed mutagenesis was used to change Glu4 of subtilin to Ile, in order to eliminate this carboxyl-group participation. The DHA5 of this mutant subtilin (E4I-subtilin) underwent modification with a t1/2 of 48 days, which is 57-fold slower than natural subtilin, and the rate of loss of biological activity dropped by a like amount. These results suggest that an intact DHA5 is critical for subtilin activity against bacterial spore outgrowth. A double mutant of subtilin, in which the DHA5 residue of E4I-subtilin was mutated to Ala was devoid of detectable inhibition against spore outgrowth. The specific activity of E4I-subtilin was 3-4-fold higher than natural subtilin, suggesting that an increase in the hydrophobicity of the N-terminal end of the molecule enhances activity. These are the first mutants of subtilin that have been reported, and E4I-subtilin is the first example of any lantibiotic whose properties have been improved by mutagenesis. In order to carry out the mutagenesis, a host-vector pair was constructed that permits a deletion replacement in which the natural subtilin gene is replaced by the mutant gene at the normal location in the chromosome. This maintains normal gene dosage and regulatory responses, as well as eliminates ambiguities caused by expression of the normal and mutant genes in the same cell.	UNIV MARYLAND, DEPT CHEM & BIOCHEM, COLL PK, MD 20742 USA	University System of Maryland; University of Maryland College Park					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R55AI024454, R01AI024454] Funding Source: NIH RePORTER; NIAID NIH HHS [AI24454] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BANERJEE S, 1988, J BIOL CHEM, V263, P9508; BIERBAUM G, 1989, FEMS MICROBIOL LETT, V58, P223, DOI 10.1016/S0378-1097(97)00526-0; BOTT KF, 1967, J BACTERIOL, V94, P562, DOI 10.1128/JB.94.3.562-570.1967; BROADBENT JR, 1989, J DAIRY SCI, V72, P3342, DOI 10.3168/jds.S0022-0302(89)79496-0; BRON S, 1990, MOL BIOL METHODS BAC, P75; BRUICE TC, 1992, P NATL ACAD SCI USA, V89, P1700, DOI 10.1073/pnas.89.5.1700; BUCHMAN GW, 1988, J BIOL CHEM, V263, P16260; CHUNG YJ, 1992, J BACTERIOL, V174, P1417, DOI 10.1128/jb.174.4.1417-1422.1992; CHUNG YJ, 1992, J BACTERIOL, V174, P6699, DOI 10.1128/JB.174.20.6699-6702.1992; DEVOS WM, 1991, NISIN NOVEL LANTIBIO, P457; FEENEY RE, 1948, ARCH BIOCHEM, V17, P435; GAO FH, 1991, APPL ENVIRON MICROB, V57, P2164, DOI 10.1128/AEM.57.8.2164-2170.1991; GEIER GE, 1979, J BIOL CHEM, V254, P1408; GROSS E, 1971, J AM CHEM SOC, V93, P4634, DOI 10.1021/ja00747a073; GROSS E, 1973, H-S Z PHYSIOL CHEM, V354, P810; GROSS E, 1978, ANTIBIOTICS ISOLATIO, P415; Gross E, 1975, PEPTIDES CHEM STRUCT, P31; Hansen JN, 1991, NISIN NOVEL LANTIBIO, P287; HANSEN JN, 1989, J FOOD SAFETY, V10, P121; HAWKINS G, 1990, THESIS U MARYLAND CO; HEDGE PJ, 1985, NATURE, V318, P478, DOI 10.1038/318478a0; Hurst A., 1981, ADV APPL MICROBIOL, V27, P85, DOI [10.1016/s0065-2164(08)70342-3, DOI 10.1016/S0065-2164(08)70342-3, 10.1016/S0065-2164(08)70342-3]; INGRAM L, 1970, BIOCHIM BIOPHYS ACTA, V224, P263, DOI 10.1016/0005-2787(70)90642-8; INGRAM LC, 1969, BIOCHIM BIOPHYS ACTA, V184, P216, DOI 10.1016/0304-4165(69)90121-4; Jansen E. F., 1944, ARCH BIOCHEM, V4, P297; JAY JM, 1983, FOOD MICROBIOL, V8, P117; KELLNER R, 1988, EUR J BIOCHEM, V177, P53, DOI 10.1111/j.1432-1033.1988.tb14344.x; KELLNER R, 1989, ANGEW CHEM INT EDIT, V28, P616, DOI 10.1002/anie.198906161; KORDEL M, 1988, J BACTERIOL, V170, P84, DOI 10.1128/jb.170.1.84-88.1988; KORDEL M, 1989, FEBS LETT, V244, P99, DOI 10.1016/0014-5793(89)81171-8; KUIPERS OP, 1991, NISIN NOVEL LANTIBIO, P250; LIU W, 1991, J BACTERIOL, V173, P7387, DOI 10.1128/jb.173.22.7387-7390.1991; LIU W, 1990, APPL ENVIRON MICROB, V56, P2551, DOI 10.1128/AEM.56.8.2551-2558.1990; Maniatis T., 1982, MOL CLONING; Mattick ATR, 1944, NATURE, V154, P551, DOI 10.1038/154551a0; MORRIS SL, 1984, J BIOL CHEM, V259, P3590; Rogers LA, 1928, J BACTERIOL, V16, P321, DOI 10.1128/JB.16.5.321-325.1928; RUHR E, 1985, ANTIMICROB AGENTS CH, V27, P841, DOI 10.1128/AAC.27.5.841; SAHL HG, 1985, MICROBIOL SCI, V2, P212; SCHULLER F, 1989, EUR J BIOCHEM, V182, P181, DOI 10.1111/j.1432-1033.1989.tb14815.x; SEARS P M, 1991, Journal of Dairy Science, V74, P203; STEEN M, 1992, THESIS U MARYLAND CO; WILSON GA, 1968, J BACTERIOL, V95, P1439, DOI 10.1128/JB.95.4.1439-1449.1968; YOUNG FE, 1974, HDB GENETICS, V1, P69	44	93	103	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	1992	267	35					25078	25085						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KB603	1460009				2022-12-25	WOS:A1992KB60300028
J	MUDERHWA, JM; BROCKMAN, HL				MUDERHWA, JM; BROCKMAN, HL			LATERAL LIPID DISTRIBUTION IS A MAJOR REGULATOR OF LIPASE ACTIVITY - IMPLICATIONS FOR LIPID-MEDIATED SIGNAL TRANSDUCTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC CHOLESTEROL ESTERASE; PROTEIN-KINASE-C; CARBOXYLESTER LIPASE; FATTY-ACIDS; GEOTRICHUM-CANDIDUM; SURFACE PHASES; BILE-SALTS; STATE; PHOSPHOLIPASE-A2; DIACYLGLYCEROL	Pancreatic carboxylester lipase catalyzes the exchange of O-18 between water and 13,16-cis,cis-docosadienoic acid (DA) in monolayers at the argon-buffer interface (Muderhwa, J. M., Schmid, P. C., and Brockman, H. L. (1992) Biochemistry 31, 141). In mixed monolayers of O-18, O-18-DA and 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC), both the extent and mechanism of O-18 exchange show characteristics of a critical transition in the range of 0.5-0.6 mol fraction of DA (Muderhwa, J. M., and Brockman, H. L. (1992) Biochemistry 31, 149). To determine if the regulatory behavior exhibited on this type of surface is limited to members of the carboxylester lipase gene family (cholinesterases), comparable experiments were performed with a genetically and functionally unrelated lipase, pancreatic colipase-dependent lipase (PL). PL readily catalyzed the exchange of O-18 between water and the carboxyl group of DA with enzyme at either monolayer or catalytic levels in the fatty acid-buffer interface. The oxygen exchange reaction obeyed a random, sequential mechanism, indicating that the dissociation of the enzyme.DA complex is much faster than the rate-limiting step in the overall exchange process. Kinetic analysis of oxygen exchange in pure DA monolayers showed a first-order dependence on interfacial PL and DA concentrations from which k(cat)/K(m) values were calculated. The oxygen exchange reaction proceeded with a rate constant of 16 x 10(-2) cm2 pmol-1 s-1, a value comparable to that for hydrolysis of the ester substrate, 1,3-dioleoylglycerol. With a monolayer of PL adsorbed to the interfacial phase, k(cat)/K(m) for oxygen exchange was about 600-fold lower than the value obtained with catalytic levels of adsorbed enzyme, indicating a possible restriction of substrate diffusion in the protein-covered fatty acid monolayer. With constant bulk PL concentration and mixed lipid monolayers containing DA and the non-substrate lipid, POPC, the extent of oxygen exchange increased abruptly as the abundance of DA in the interface was increased from 0.5 to 0.6 mol fraction. Concomitant with this critical transition was a change in the apparent mechanism of oxygen exchange from coupled to random, sequential. For both the extent of oxygen exchange and its mechanism shift, the critical transition was independent of the lipid packing density, i.e. surface pressure, of the interface. These results show that PL responds similarly to carboxylester lipase with respect to changes in interfacial lipid mole fraction in DA-POPC surfaces. This strengthens the hypothesis that lateral lipid distribution in a phospholipid-substrate surface puts substantial constraints on lipase adsorption to the interface, the in-plane accessibility of substrate to adsorbed lipases, and, possibly, the "interfacial activation" of lipases. The apparent dominance of surface structure as a regulator of lipases suggests that the lateral distribution of fatty acids and diacylglycerols in cell membranes could play an important role in lipid-mediated signal transduction.	UNIV MINNESOTA,HORMEL INST,801 16TH AVE NE,AUSTIN,MN 55912	University of Minnesota System					NHLBI NIH HHS [HL49180] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AHKONG QF, 1973, BIOCHEM J, V136, P147, DOI 10.1042/bj1360147; ALLAN D, 1978, NATURE, V276, P289, DOI 10.1038/276289a0; BERNBACK S, 1990, J CLIN INVEST, V85, P1221, DOI 10.1172/JCI114556; BHAT SG, 1982, BIOCHEMISTRY-US, V21, P1547, DOI 10.1021/bi00536a013; BHAT SG, 1981, J BIOL CHEM, V256, P3017; BITTMAN R, 1986, BIOCHIM BIOPHYS ACTA, V863, P115, DOI 10.1016/0005-2736(86)90393-7; BROCKMAN HL, 1991, GBF MONOGR SER, V16, P95; Brockman HL, 1984, LIPASES, P1; BRZOZOWSKI AM, 1991, NATURE, V351, P491, DOI 10.1038/351491a0; BURGER KNJ, 1991, BIOCHIM BIOPHYS ACTA, V1068, P249, DOI 10.1016/0005-2736(91)90216-U; Cullis P.R., 1985, PHOSPHOLIPIDS CELLUL, P1; CUNNINGHAM BA, 1989, BIOCHEMISTRY-US, V28, P32, DOI 10.1021/bi00427a006; DAS S, 1986, BIOCHEMISTRY-US, V25, P2882, DOI 10.1021/bi00358a022; DAWSON RMC, 1984, BIOCHEM BIOPH RES CO, V125, P836, DOI 10.1016/0006-291X(84)90615-6; DEREWENDA U, 1992, BIOCHEMISTRY-US, V31, P1532, DOI 10.1021/bi00120a034; ESSAM JW, 1980, REP PROG PHYS, V43, P833, DOI 10.1088/0034-4885/43/7/001; GARNER CW, 1970, BIOCHEM BIOPH RES CO, V39, P672, DOI 10.1016/0006-291X(70)90258-5; GAWLINSKI ET, 1981, J PHYS A-MATH GEN, V14, pL291, DOI 10.1088/0305-4470/14/8/007; GOMEZFERNANDEZ JC, 1990, PROG CLIN BIOL RES, V343, P53; HIDE WA, 1992, J LIPID RES, V33, P167; HOSHEN J, 1976, PHYS REV B, V14, P3438, DOI 10.1103/PhysRevB.14.3438; IRVINE RF, 1982, BIOCHEM J, V204, P3, DOI 10.1042/bj2040003; KISSEL JA, 1989, BIOCHIM BIOPHYS ACTA, V1006, P227, DOI 10.1016/0005-2760(89)90201-4; KOYNOVA RD, 1987, BIOCHIM BIOPHYS ACTA, V903, P186, DOI 10.1016/0005-2736(87)90168-4; KREJCI E, 1991, P NATL ACAD SCI USA, V88, P6647, DOI 10.1073/pnas.88.15.6647; KUWAE T, 1990, J BIOL CHEM, V265, P5002; LACHOWIEZ RM, 1988, FEBS LETT, V234, P195, DOI 10.1016/0014-5793(88)81332-2; LINDSTROM MB, 1988, BIOCHIM BIOPHYS ACTA, V959, P178, DOI 10.1016/0005-2760(88)90029-X; MOMSEN WE, 1978, J LIPID RES, V19, P1032; MUDERHWA JM, 1990, J BIOL CHEM, V265, P19644; MUDERHWA JM, 1992, BIOCHEMISTRY-US, V31, P149, DOI 10.1021/bi00116a022; MUDERHWA JM, 1992, BIOCHEMISTRY-US, V31, P141, DOI 10.1021/bi00116a021; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; PEIRONI G, 1979, J BIOL CHEM, V254, P10090; PIERONI G, 1990, ADV COLLOID INTERFAC, V32, P341, DOI 10.1016/0001-8686(90)80023-S; Rudd E.A., 1984, P185; SCHMID PC, 1988, CHEM PHYS LIPIDS, V46, P165, DOI 10.1016/0009-3084(88)90018-7; SCHRAG JD, 1991, NATURE, V351, P761, DOI 10.1038/351761a0; SCOTT DL, 1990, SCIENCE, V250, P1541, DOI 10.1126/science.2274785; SEN A, 1991, BIOCHEMISTRY-US, V30, P4516, DOI 10.1021/bi00232a021; SHIMADA Y, 1990, J BIOCHEM-TOKYO, V107, P703, DOI 10.1093/oxfordjournals.jbchem.a123112; SHINOMURA T, 1991, P NATL ACAD SCI USA, V88, P5149, DOI 10.1073/pnas.88.12.5149; SMABY JM, 1984, BIOCHEMISTRY-US, V23, P3312, DOI 10.1021/bi00309a030; SMABY JM, 1985, BIOPHYS J, V48, P701, DOI 10.1016/S0006-3495(85)83828-5; SMABY JM, 1992, LANGMUIR, V8, P563, DOI 10.1021/la00038a042; STAUFFER D, 1985, INTRO PERCOLATION TH, P15; Stauffer D., 1985, INTRO PERCOLATION TH, P1; THUREN T, 1988, FEBS LETT, V229, P95, DOI 10.1016/0014-5793(88)80805-6; TSUJITA T, 1987, BIOCHEMISTRY-US, V26, P8430, DOI 10.1021/bi00399a060; TSUJITA T, 1987, BIOCHEMISTRY-US, V26, P8423, DOI 10.1021/bi00399a059; TSUJITA T, 1989, J BIOL CHEM, V264, P8612; Verger R, 1980, Methods Enzymol, V64, P340; VERGER R, 1969, BIOCHIM BIOPHYS ACTA, V188, P272, DOI 10.1016/0005-2795(69)90075-0; VERGER R, 1976, ANNU REV BIOPHYS BIO, V5, P77, DOI 10.1146/annurev.bb.05.060176.000453; WINKLER FK, 1990, NATURE, V343, P771, DOI 10.1038/343771a0	55	92	92	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1992	267	34					24184	24192						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KA263	1447168				2022-12-25	WOS:A1992KA26300010
J	BLOMHOFF, HK; SMELAND, EB; ERIKSTEIN, B; RASMUSSEN, AM; SKREDE, B; SKJONSBERG, C; BLOMHOFF, R				BLOMHOFF, HK; SMELAND, EB; ERIKSTEIN, B; RASMUSSEN, AM; SKREDE, B; SKJONSBERG, C; BLOMHOFF, R			VITAMIN-A IS A KEY REGULATOR FOR CELL-GROWTH, CYTOKINE PRODUCTION, AND DIFFERENTIATION IN NORMAL B-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DENSITY-LIPOPROTEIN-RECEPTOR; RETINOIC ACID; LYMPHOCYTES-B; IMMUNE-RESPONSE; DEPLETED RATS; BETA-CAROTENE; CYCLIC-AMP; HUMANS; POLYSACCHARIDE; PROLIFERATION	In the present paper we demonstrate that retinol-retinol-binding protein and chylomicron remnant retinyl esters in concentrations normally found in human plasma inhibit growth of normal human B lymphocytes. Physiological concentrations of retinoic acid (about 30 nM) were less active than physiological concentrations of retinol (about 3 muM). Pharmacological concentrations of retinol and retinoic acid were more active than the concentrations normally found in plasma. Retinol (3 muM) inhibited anti-IgM-mediated DNA synthesis as measured by [H-3]thymidine uptake at 72 h by 78%. Furthermore, we found that the cells were blocked in the mid-G1 phase of the cell cycle. Thus, neither MYC up-regulation measured at 3 h nor the expression of the early activation antigen 4F2 was reduced by retinol, whereas the late activation markers transferrin receptor expression and actinomycin (D staining at 48 h of stimulation) were markedly inhibited. Retinol reduced the interleukin 6 production induced by anti-IgM and interleukin 4 after 48 h, whereas the induction of interleukin 6 and tumor necrosis factor by O-tetradecanoylphorbol-13-acetate and ionomycin was less affected. We also noted that the retinoids reduced the formation of plaque-forming cells (i.e. Ig synthesis). These data imply that vitamin A present in human plasma is a normal modulator of B cell function.	UNIV OSLO,INST NUTR RES,N-0316 OSLO,NORWAY	University of Oslo	BLOMHOFF, HK (corresponding author), NORWEGIAN RADIUM HOSP,INST CANC RES,DEPT PATHOL,IMMUNOL LAB,N-0310 OSLO,NORWAY.		Smeland, Erlend/AAO-3214-2020					BLOMHOFF HK, 1987, J CELL PHYSIOL, V131, P426, DOI 10.1002/jcp.1041310315; BLOMHOFF R, 1990, SCIENCE, V250, P399, DOI 10.1126/science.2218545; BLOMHOFF R, 1990, J INTERN MED, V228, P207, DOI 10.1111/j.1365-2796.1990.tb00219.x; BOHMER RM, 1981, CYTOMETRY, V2, P31, DOI 10.1002/cyto.990020107; BOSMA M, 1988, J CELL PHYSIOL, V135, P317, DOI 10.1002/jcp.1041350220; BUCK J, 1990, J EXP MED, V171, P1613, DOI 10.1084/jem.171.5.1613; EGELAND T, 1988, SCAND J IMMUNOL, V27, P439, DOI 10.1111/j.1365-3083.1988.tb02369.x; FINDLEY HW, 1984, EXP HEMATOL, V12, P768; FRIEDMAN A, 1989, BRIT J NUTR, V62, P439, DOI 10.1079/BJN19890044; FRIEDMAN A, 1991, J NUTR, V121, P395, DOI 10.1093/jn/121.3.395; FUNDERUD S, 1990, EUR J IMMUNOL, V20, P201, DOI 10.1002/eji.1830200129; GJOEN T, 1987, J BIOL CHEM, V262, P10926; GODAL T, 1983, CLIN EXP IMMUNOL, V54, P756; HOLTE H, 1988, EUR J IMMUNOL, V18, P1359, DOI 10.1002/eji.1830180909; ISRAEL H, 1991, CLIN IMMUNOL IMMUNOP, V59, P417, DOI 10.1016/0090-1229(91)90037-B; JETTEN AM, 1984, FED PROC, V43, P134; KRISHAN A, 1975, J CELL BIOL, V66, P188, DOI 10.1083/jcb.66.1.188; LANG RA, 1990, IMMUNOL TODAY, V11, P244, DOI 10.1016/0167-5699(90)90098-T; LARGMAN C, 1989, BLOOD, V74, P99; LOTAN R, 1980, BIOCHIM BIOPHYS ACTA, V605, P33, DOI 10.1016/0304-419X(80)90021-9; MARX JL, 1988, SCIENCE, V239, P975, DOI 10.1126/science.3422766; PASATIEMPO AMG, 1990, FASEB J, V4, P2518, DOI 10.1096/fasebj.4.8.2110538; PASATIEMPO AMG, 1991, J NUTR, V121, P556, DOI 10.1093/jn/121.4.556; PRABHALA RH, 1991, CANCER, V67, P1556, DOI 10.1002/1097-0142(19910315)67:6<1556::AID-CNCR2820670616>3.0.CO;2-O; Roberts A.B., 1984, RETINOIDS, V2, P210; SIDELL N, 1991, J IMMUNOL, V146, P3809; SIDELL N, 1984, CELL IMMUNOL, V88, P374, DOI 10.1016/0008-8749(84)90170-9; SKJONSBERG C, 1991, BLOOD, V77, P2445; SMELAND E, 1985, P NATL ACAD SCI USA, V82, P6255, DOI 10.1073/pnas.82.18.6255; SMELAND EB, 1989, J EXP MED, V170, P1463, DOI 10.1084/jem.170.4.1463; STOKKE T, 1988, CANCER RES, V48, P6708; WATHNE KO, 1989, BIOCHEM J, V257, P239, DOI 10.1042/bj2570239; WATSON RR, 1991, AM J CLIN NUTR, V53, P90, DOI 10.1093/ajcn/53.1.90; WONG GG, 1988, IMMUNOL TODAY, V9, P137, DOI 10.1016/0167-5699(88)91200-5	34	99	100	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1992	267	33					23988	23992						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JZ239	1429735				2022-12-25	WOS:A1992JZ23900083
J	ASANO, T; TAKATA, K; KATAGIRI, H; TSUKUDA, K; LIN, JL; ISHIHARA, H; INUKAI, K; HIRANO, H; YAZAKI, Y; OKA, Y				ASANO, T; TAKATA, K; KATAGIRI, H; TSUKUDA, K; LIN, JL; ISHIHARA, H; INUKAI, K; HIRANO, H; YAZAKI, Y; OKA, Y			DOMAINS RESPONSIBLE FOR THE DIFFERENTIAL TARGETING OF GLUCOSE TRANSPORTER ISOFORMS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA-MEMBRANE; INSULIN; BRAIN; TISSUE; CELLS; TRANSLOCATION; PROTEINS; SIGNAL; GLUT4	Facilitative glucose transporter isoforms, GLUT1 and GLUT4, have different intracellular distributions despite their very similar structure. In insulin-responsive tissues such as adipose tissues and muscle, GLUT4 protein resides mainly in the intracellular region in a basal condition and is translocated to the plasma membrane upon stimulation of insulin. In contrast, GLUT1 protein was distributed about equally between plasma membranes and low density microsomal membranes in 3T3-L1 adipocytes. Furthermore, GLUT1 and GLUT4 were reported to be differentially targeted to the plasma membrane and intracellular region, respectively, when expressed in Chinese hamster ovary cells and HepG2 cells. To elucidate the differential intracellular targeting mechanisms, several chimeric glucose transporters in which portions of GLUT4 are replaced with corresponding portions of GLUT1 have been stably expressed in Chinese hamster ovary cells. Immunofluorescence and immunoelectron microscopy as well as measurement of glucose transport activity revealed that two domains of GLUT4, which are not the NH2- or COOH-terminal domain, determine its targeting to the intracellular vesicles. The first domain contains the consensus sequence of the leucine zipper structure, suggesting that a dimer-forming structure of the glucose transporter might be required for its proper targeting. The other domain contains 28 amino acids, nine of which are different between GLUT1 and GLUT4. Immunoelectron microscopy revealed that the chimeric transporters containing both of these two domains of GLUT1, only the first domain of GLUT1, and none of the domains, exhibited a different cellular distribution with approximately 65, 30, and 15% of the transporters apparently on the plasma membrane, respectively. The addition of insulin did not alter the apparent cellular distributions of these chimeric transporters. These domains would be specifically recognized by intracellular targeting mechanisms in Chinese hamster ovary cells.	KYORIN UNIV,SCH MED,DEPT ANAT,MITAKA,TOKYO 181,JAPAN	Kyorin University	ASANO, T (corresponding author), UNIV TOKYO,FAC MED,DEPT INTERNAL MED 3,TOKYO 113,JAPAN.							ASANO T, 1989, J BIOL CHEM, V264, P3416; ASANO T, 1988, BIOCHEM BIOPH RES CO, V154, P1204, DOI 10.1016/0006-291X(88)90268-9; BELL GI, 1990, DIABETES CARE, V13, P198, DOI 10.2337/diacare.13.3.198; BETZ AL, 1986, ANNU REV PHYSIOL, V48, P241; COMPTON T, 1989, P NATL ACAD SCI USA, V86, P4112, DOI 10.1073/pnas.86.11.4112; CUSHMAN SW, 1980, J BIOL CHEM, V255, P4758; HANEY PM, 1991, J CELL BIOL, V114, P689, DOI 10.1083/jcb.114.4.689; HARRISON SA, 1990, J BIOL CHEM, V265, P20106; JAMES DE, 1988, NATURE, V333, P183, DOI 10.1038/333183a0; KASANICKI MA, 1990, DIABETES CARE, V13, P219, DOI 10.2337/diacare.13.3.219; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LIN JL, 1991, DIABETOLOGIA, V34, P477, DOI 10.1007/BF00403283; MUECKLER M, 1986, CELL, V44, P629, DOI 10.1016/0092-8674(86)90272-2; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; OKA Y, 1990, NATURE, V345, P550, DOI 10.1038/345550a0; OKA Y, 1988, J BIOL CHEM, V263, P13432; OKA Y, 1984, J BIOL CHEM, V259, P8125; PESSINO A, 1991, J BIOL CHEM, V266, P20213; PIPER RC, 1992, J CELL BIOL, V117, P729, DOI 10.1083/jcb.117.4.729; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHIBASAKI Y, 1992, BIOCHEM J, V281, P829, DOI 10.1042/bj2810829; SIMPSON IA, 1986, ANNU REV BIOCHEM, V55, P1059, DOI 10.1146/annurev.biochem.55.1.1059; SUZUKI K, 1980, P NATL ACAD SCI-BIOL, V77, P2542, DOI 10.1073/pnas.77.5.2542; TAKATA K, 1990, BIOCHEM BIOPH RES CO, V173, P67, DOI 10.1016/S0006-291X(05)81022-8; TAKATA K, 1990, ACTA HISTOCHEM CYTOC, V23, P679, DOI 10.1267/ahc.23.679; WEILAND M, 1990, BIOCHEM J, V270, P331, DOI 10.1042/bj2700331; WHITE MK, 1989, NATURE, V340, P103, DOI 10.1038/340103b0; ZORANO A, 1989, J BIOL CHEM, V264, P12358	28	92	95	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1992	267	27					19636	19641						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JP593	1527083				2022-12-25	WOS:A1992JP59300092
J	JENSEN, LM; ZHANG, Y; SHOOTER, EM				JENSEN, LM; ZHANG, Y; SHOOTER, EM			STEADY-STATE POLYPEPTIDE MODULATIONS ASSOCIATED WITH NERVE GROWTH-FACTOR (NGF)-INDUCED TERMINAL DIFFERENTIATION AND NGF DEPRIVATION-INDUCED APOPTOSIS IN HUMAN NEUROBLASTOMA-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EMBRYO SPINAL-CORD; RETROGRADE AXONAL-TRANSPORT; RAT PHEOCHROMOCYTOMA CELLS; DORSAL-ROOT-GANGLIA; SENSORY NEURONS; CHICK-EMBRYO; PROTEIN-SYNTHESIS; MESSENGER-RNA; SYMPATHETIC NEURONS; QUANTITATIVE INVITRO	Human neuroblastoma SH-SY5Y cells differentiate terminally in culture upon exposure to nerve growth factor (NGF) for 4-5 weeks. The neuronal phenotypic properties acquired in response to prolonged NGF treatment include morphological differentiation, cessation of mitotic activity, neuronal marker expression, increased membrane electrical potentials, and a survival dependence upon NGF for trophic support (Jensen, L. M. (1987) Dev. Biol. 120,56-64). Thus, differentiated cultures survive indefinitely in the continued presence of NGF, however, withdrawal of NGF from differentiated cultures effects the loss of cellular viability within 3-6 days. Here, we show that death of differentiated SH-SY5Y cells caused by NGF deprivation is characteristic of apoptosis. To compare the differentiation promoting and the neurotrophic properties of NGF, whole SH-SY5Y cell extracts were analyzed by two-dimensional polyacrylamide gel electrophoresis using isoelectric focusing and nonequilibrium pH gradient electrophoresis gels in the first dimension. Steady-state levels of polypeptides extracted from whole-cell lysates of naive (untreated) cells, terminally differentiated cells, and NGF-deprived differentiated cells were compared. Over 1,000 spots from each were analyzed using computer-aided spot matching and densitometry. We noted 25 polypeptides that decreased during differentiation, including 15 that decreased by a factor of 10 or more. The levels of five polypeptides were induced from very low or undetectable levels in naive cells. Withdrawal of NGF from terminally differentiated cells produced alterations in steady-state protein patterns substantially distinct-from those occurring during differentiation. While levels of most proteins do not appear affected early after NGF withdrawal, others rapidly return to levels comparable with those of the naive state and some changes occurring with differentiation are enhanced further upon NGF withdrawal. Three polypeptides were regulated uniquely by NGF withdrawal, including two that were induced, on average, 20- and 28-fold and another that was depressed more than 7-fold after NGF deprivation, before cell death. These data indicate that NGF elicits both constitutive and nonconstitutive changes in gene expression and suggest that the differentiation promoting and the neurotrophic properties of NGF correlate with the regulation of different gene products.	UNIV CALIF SAN FRANCISCO,DEPT NEUROL SURG,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco	JENSEN, LM (corresponding author), STANFORD UNIV,MED CTR,SCH MED,DEPT NEUROBIOL,STANFORD,CA 94305, USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS004270] Funding Source: NIH RePORTER; NINDS NIH HHS [NS 04270, NS 07158] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANGELETTI PU, 1971, J ULTRA MOL STRUCT R, V36, P24, DOI 10.1016/S0022-5320(71)80086-2; ARENDS MJ, 1990, AM J PATHOL, V136, P593; BARDE YA, 1980, P NATL ACAD SCI-BIOL, V77, P1199, DOI 10.1073/pnas.77.2.1199; BARDE YA, 1989, NEURON, V2, P1525, DOI 10.1016/0896-6273(89)90040-8; BIEDLER JL, 1973, CANCER RES, V33, P2643; BOYDSTON WR, 1979, BRAIN RES, V178, P403, DOI 10.1016/0006-8993(79)90702-9; BRADSHAW RA, 1985, MEDIATORS CELL GROWT, P87; BURSTEIN DE, 1978, P NATL ACAD SCI USA, V75, P6059, DOI 10.1073/pnas.75.12.6059; CARR VM, 1978, J COMP NEUROL, V182, P741; CATSICAS S, 1987, P NATL ACAD SCI USA, V84, P8165, DOI 10.1073/pnas.84.22.8165; CHO KO, 1989, MOL CELL BIOL, V9, P135, DOI 10.1128/MCB.9.1.135; CHUWANG IW, 1978, J COMP NEUROL, V177, P59, DOI 10.1002/cne.901770106; CHUWANG IW, 1978, J COMP NEUROL, V177, P33, DOI 10.1002/cne.901770105; CLARKE PGH, 1990, ANAT EMBRYOL, V181, P195, DOI 10.1007/bf00174615; CLARKE PGH, 1976, J COMP NEUROL, V167, P125, DOI 10.1002/cne.901670202; CLARKE PGH, 1989, J COMP NEUROL, V283, P438, DOI 10.1002/cne.902830311; COLLINS F, 1988, DEV BRAIN RES, V39, P111, DOI 10.1016/0165-3806(88)90072-7; COWAN WM, 1984, SCIENCE, V225, P1258, DOI 10.1126/science.6474175; Crompton T, 1991, GROWTH FACTORS, V4, P109, DOI 10.3109/08977199109000262; DAVIES AM, 1986, NATURE, V319, P497, DOI 10.1038/319497a0; DAVIES AM, 1987, NATURE, V326, P353, DOI 10.1038/326353a0; DAVIES AM, 1990, ANNU REV NEUROSCI, V13, P61, DOI 10.1146/annurev.neuro.13.1.61; EDGAR D, 1981, NATURE, V289, P294, DOI 10.1038/289294a0; ERNSBERGER U, 1988, DEV BIOL, V126, P420, DOI 10.1016/0012-1606(88)90151-0; FEINSTEIN SC, 1985, P NATL ACAD SCI USA, V82, P5761, DOI 10.1073/pnas.82.17.5761; GARRELS JI, 1983, METHOD ENZYMOL, V100, P411; GARRELS JI, 1989, J BIOL CHEM, V264, P5299; GARRELS JI, 1979, J BIOL CHEM, V254, P7978; GORIN PD, 1979, P NATL ACAD SCI USA, V76, P5382, DOI 10.1073/pnas.76.10.5382; GORIN PD, 1980, DEV BIOL, V80, P313, DOI 10.1016/0012-1606(80)90407-8; GREENE LA, 1983, J CELL BIOL, V96, P76, DOI 10.1083/jcb.96.1.76; GREENE LA, 1977, DEV BIOL, V58, P96, DOI 10.1016/0012-1606(77)90076-8; GREENE LA, 1977, DEV BIOL, V58, P106, DOI 10.1016/0012-1606(77)90077-X; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; HAMBURGER V, 1958, AM J ANAT, V102, P365, DOI 10.1002/aja.1001020303; HAMBURGER V, 1982, NEUROSCI COMMENT, V1, P39; HEFTI F, 1986, J NEUROSCI, V6, P2155; HENDERSON S, 1991, CELL, V65, P1107, DOI 10.1016/0092-8674(91)90007-L; HENDRY IA, 1974, BRAIN RES, V68, P103, DOI 10.1016/0006-8993(74)90536-8; HEUMANN R, 1984, EMBO J, V3, P3183, DOI 10.1002/j.1460-2075.1984.tb02277.x; HOLLYDAY M, 1976, J COMP NEUROL, V170, P311, DOI 10.1002/cne.901700304; JENSEN L, 1988, MOL CELL BIOL, V8, P3964, DOI 10.1128/MCB.8.9.3964; JENSEN LM, 1987, DEV BIOL, V120, P56, DOI 10.1016/0012-1606(87)90103-5; JOHNSON EM, 1980, SCIENCE, V210, P916, DOI 10.1126/science.7192014; KERR JFR, 1991, APOPTOSIS MOL BASIS, P5; KNUSEL B, 1991, P NATL ACAD SCI USA, V88, P961, DOI 10.1073/pnas.88.3.961; KYPRIANOU N, 1990, CANCER RES, V50, P3748; LANCEJONES C, 1982, DEV BRAIN RES, V4, P473, DOI 10.1016/0165-3806(82)90192-4; LEONARD DGB, 1988, J CELL BIOL, V106, P181, DOI 10.1083/jcb.106.1.181; LEVIMONTALCINI R, 1968, PHYSIOL REV, V48, P534, DOI 10.1152/physrev.1968.48.3.534; LOCKSHIN RA, 1969, J INSECT PHYSIOL, V15, P1505, DOI 10.1016/0022-1910(69)90172-3; MAISONPIERRE PC, 1990, NEURON, V5, P501, DOI 10.1016/0896-6273(90)90089-X; MARTIN DP, 1988, J CELL BIOL, V106, P829, DOI 10.1083/jcb.106.3.829; MILBRANDT J, 1986, P NATL ACAD SCI USA, V83, P4789, DOI 10.1073/pnas.83.13.4789; NARAYANAN CH, 1978, J EMBRYOL EXP MORPH, V44, P53; NUNEZ G, 1990, J IMMUNOL, V144, P3602; OPPENHEIM RW, 1985, TRENDS NEUROSCI, V8, P487, DOI 10.1016/0166-2236(85)90175-4; OPPENHEIM RW, 1977, BRAIN RES, V125, P154, DOI 10.1016/0006-8993(77)90367-5; OPPENHEIM RW, 1982, J COMP NEUROL, V210, P174, DOI 10.1002/cne.902100208; PEREZPOLO JR, 1979, DEV BIOL, V71, P341, DOI 10.1016/0012-1606(79)90174-X; PILAR G, 1976, J CELL BIOL, V68, P339, DOI 10.1083/jcb.68.2.339; PRASAD KN, 1975, BIOL REV, V50, P129, DOI 10.1111/j.1469-185X.1975.tb01055.x; PRATT RM, 1976, DEV BIOL, V54, P135, DOI 10.1016/0012-1606(76)90292-X; ROGERS LA, 1973, J COMP NEUROL, V147, P291, DOI 10.1002/cne.901470302; ROHRER H, 1988, DEV BIOL, V128, P240, DOI 10.1016/0012-1606(88)90286-2; SADEE W, 1987, CANCER RES, V47, P5207; SCHWAB ME, 1975, CELL TISSUE RES, V158, P543; SCHWAB ME, 1979, BRAIN RES, V168, P473, DOI 10.1016/0006-8993(79)90303-2; SCHWEICHEL JU, 1973, TERATOLOGY, V7, P253, DOI 10.1002/tera.1420070306; SCOTT SA, 1990, J NEUROBIOL, V21, P630, DOI 10.1002/neu.480210410; SHELTON DL, 1984, P NATL ACAD SCI-BIOL, V81, P7951, DOI 10.1073/pnas.81.24.7951; TATA JR, 1966, DEV BIOL, V13, P77, DOI 10.1016/0012-1606(66)90050-9; THOENEN H, 1987, CIBA F SYMP, V126, P82; TIERCY JM, 1986, J CELL BIOL, V103, P2367, DOI 10.1083/jcb.103.6.2367; WILLIAMS LR, 1986, P NATL ACAD SCI USA, V83, P9231, DOI 10.1073/pnas.83.23.9231; WU BY, 1989, J BIOL CHEM, V264, P9000; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0	78	42	44	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1992	267	27					19325	19333						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JP593	1527053				2022-12-25	WOS:A1992JP59300048
J	MATZKE, EA; STEPHENSON, LJ; BROOKER, RJ				MATZKE, EA; STEPHENSON, LJ; BROOKER, RJ			FUNCTIONAL-ROLE OF ARGININE-302 WITHIN THE LACTOSE PERMEASE OF ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LAC PERMEASE; CARRIER PROTEIN; DIRECTED MUTAGENESIS; ENHANCED RECOGNITION; TRANSPORT MALTOSE; PLASMID DNA; MUTANTS; MEMBRANE; PROTON; RECONSTITUTION	Within the lactose permease, an arginine residue is found on a transmembrane segment at position 302. Based upon the effects of mutations at or in the vicinity of Arg-302, this residue has been implicated to be involved with H+ and/or sugar recognition. To further elucidate the role of this residue, we have substituted Arg-302 with serine, histidine, and leucine via site-directed mutagenesis. All three of these substitutions result in an impaired ability to transport galactosides as evidenced by their poor growth on minimal plates supplemented with lactose or melibiose. Furthermore, in vitro transport assays revealed substantial alterations in the kinetic constants for downhill lactose transport. The wild-type strain exhibited a K(m) for lactose transport of 0.30 mM and a V(max) of 267 nmol of lactose/min.mg of protein. The Ser-302, His-302, and Leu-302 were observed to have K(m) values of 0.18, 2.3, and 2.8 mM, and V(max) values of 11.6, 56.4, and 22.0 nmol of lactose/min.mg of protein, respectively. In uphill transport assays, all three mutants were unable to accumulate beta-methyl-D-thiogalactoside. However, both the Ser-302 and His-302 mutants were able to accumulate lactose against a concentration gradient. During H+ transport assays, all three mutants were shown to transport H+ in conjunction with thiodigalactoside. In addition, the Ser-302 and His-302 strains exhibited small alkalinizations upon the addition of lactose. However, for the Leu-302 mutant, the addition of lactose did not result in a significant level of H+ transport. Finally, experiments were conducted which were aimed at measuring the ability of the mutant permeases to catalyze an H+ leak. In this regard, a comparison was made between the wild-type and mutant strains concerning their steady state pH gradient and their rates of H+ influx following oxygen pulses. The results of these experiments suggest that mutations at position 302 cause a sugar-dependent H+ leak.	UNIV MINNESOTA,DEPT GENET & CELL BIOL,ST PAUL,MN 55108; UNIV MINNESOTA,INST ADV STUDIES BIOL PROC TECHNOL,ST PAUL,MN 55108	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities					NIAID NIH HHS [AI24204] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI024204] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; BROOKER RJ, 1990, RES MICROBIOL, V141, P309, DOI 10.1016/0923-2508(90)90004-A; BROOKER RJ, 1985, P NATL ACAD SCI USA, V82, P3959, DOI 10.1073/pnas.82.12.3959; BROOKER RJ, 1985, J BIOL CHEM, V260, P6181; BROOKER RJ, 1990, J BIOL CHEM, V265, P4155; BROOKER RJ, 1991, J BIOL CHEM, V266, P4131; BROOKER RJ, 1989, J BIOL CHEM, V262, P8135; BUCHEL DE, 1980, NATURE, V283, P541, DOI 10.1038/283541a0; CALAMIA J, 1990, P NATL ACAD SCI USA, V87, P4937, DOI 10.1073/pnas.87.13.4937; CARRASCO N, 1989, BIOCHEMISTRY-US, V28, P2533, DOI 10.1021/bi00432a028; COHEN GN, 1956, ANN IN PASTEUR PARIS, V91, P683; COLLINS JC, 1989, J BIOL CHEM, V264, P14698; CRANE RK, 1977, REV PHYSIOL BIOCH P, V78, P99, DOI 10.1007/BFb0027722; FASMAN GD, 1989, PREDICTION PROTEIN S, P232; FELLE H, 1980, BIOCHEMISTRY-US, V19, P3585, DOI 10.1021/bi00556a026; FOSTER DL, 1983, J BIOL CHEM, V258, P31; FRANCO PJ, 1989, J BIOL CHEM, V264, P15988; FRANCO PJ, 1991, J BIOL CHEM, V266, P6693; GRAM CD, 1992, J BIOL CHEM, V267, P3841; HINKLE PC, 1990, BIOCHEMISTRY-US, V29, P10989, DOI 10.1021/bi00501a017; KASHKET ER, 1969, BIOCHIM BIOPHYS ACTA, V193, P212, DOI 10.1016/0005-2736(69)90074-1; KING SC, 1991, BIOCHIM BIOPHYS ACTA, V1062, P177, DOI 10.1016/0005-2736(91)90390-T; KING SC, 1990, J BIOL CHEM, V265, P9645; KING SC, 1990, J BIOL CHEM, V265, P9638; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; Mandel M, 1970, J MOL BIOL, V53, P154; MARKGRAF M, 1985, MOL GEN GENET, V198, P473, DOI 10.1007/BF00332941; MENICK DR, 1987, BIOCHEMISTRY-US, V26, P1132, DOI 10.1021/bi00378a022; MENICK DR, 1987, BIOCHEMISTRY-US, V26, P6638, DOI 10.1021/bi00395a012; Miller J. H., 1972, EXPT MOL GENETICS, P433; Mitchell P., 1963, BIOCHEM SOC SYMP, V22, P142; NEWMAN MJ, 1981, J BIOL CHEM, V256, P1804; NEWMAN MJ, 1980, J BIOL CHEM, V255, P583; OTTO H, 1990, P NATL ACAD SCI USA, V87, P1018, DOI 10.1073/pnas.87.3.1018; PUTTNER IB, 1986, BIOCHEMISTRY-US, V25, P4483; QUIOCHO FA, 1986, ANNU REV BIOCHEM, V55, P287, DOI 10.1146/annurev.bi.55.070186.001443; RICKENBERG HV, 1956, ANN I PASTEUR PARIS, V91, P829; ROEPE PD, 1990, RES MICROBIOL, V141, P290, DOI 10.1016/0923-2508(90)90003-9; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHUMAN HA, 1979, J BACTERIOL, V137, P365, DOI 10.1128/JB.137.1.365-373.1979; TEATHER RM, 1978, MOL GEN GENET, V159, P239, DOI 10.1007/BF00268260; TEATHER RM, 1980, EUR J BIOCHEM, V108, P223, DOI 10.1111/j.1432-1033.1980.tb04715.x; WEST IC, 1973, BIOCHEM J, V132, P587, DOI 10.1042/bj1320587; WRIGHT JK, 1983, FEBS LETT, V162, P11; WRIGHT JK, 1986, BIOCHIM BIOPHYS ACTA, V855, P391; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; ZOLLER MJ, 1983, METHOD ENZYMOL, V100, P468	48	28	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1992	267	27					19095	19100						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JP593	1527034				2022-12-25	WOS:A1992JP59300016
J	SCHMIDT, A; YOSHIDA, K; BUDDECKE, E				SCHMIDT, A; YOSHIDA, K; BUDDECKE, E			THE ANTIPROLIFERATIVE ACTIVITY OF ARTERIAL HEPARAN-SULFATE RESIDES IN DOMAINS ENRICHED WITH 2-O-SULFATED URONIC-ACID RESIDUES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; PERFORMANCE LIQUID-CHROMATOGRAPHY; IDURONATE 2-SULFATE RESIDUES; PROTEOHEPARAN SULFATE; UNSATURATED DISACCHARIDES; STRUCTURAL DETERMINANTS; PROLIFERATION; GROWTH; ATHEROSCLEROSIS; PROTEOGLYCANS	Heparan sulfate isolated from bovine arterial tissue by a multistep purification procedure or from arterial tissue proteoheparan sulfate by beta-elimination exhibits antiproliferative activity toward arterial smooth muscle cells when added to subconfluent cell cultures in a concentration of 50-100 mug/ml medium. Enzymatic disintegration of heparan sulfate by heparitinases I and II and isolation of the resulting oligosaccharides indicate that the antiproliferative activity of the heparan sulfate molecule resides in a sulfate-rich octa/decasaccharide domain which is separated by longer sequences of sulfate-free or sulfate-poor N-acetylglucosamine containing disaccharide units. The octa/decasaccharide fraction has a 3-4-fold higher antiproliferative activity than the native heparan sulfate molecule and contains 45% of a disulfated disaccharide which consists of 2-O-sulfated uronic acid and N-sulfated glucosamine (UA(2S)-GlcNS and 12% of a trisulfated disaccharide (UA(2S)-GlcNS(6S). A sulfate-rich hexasaccharide fraction containing 14% of the disulfated disaccharide but 18% of the trisulfated disaccharide has negligible antiproliferative activity. The results indicate the presence of specific structural determinants in the arterial heparan sulfate molecule which may have the function of an endogenous inhibitor of arterial smooth muscle cell growth.	SEIKAGAKU CORP, TOKYO RES INST, TOKYO 189, JAPAN	Seikagaku Corporation	SCHMIDT, A (corresponding author), UNIV MUNSTER, INST ARTERIOSCLEROSIS RES, WALDEYERSTR 15, W-4400 MUNSTER, GERMANY.							BENITZ WE, 1990, AM J RESP CELL MOL, V2, P13, DOI 10.1165/ajrcmb/2.1.13; BITTER T, 1962, ANAL BIOCHEM, V4, P330, DOI 10.1016/0003-2697(62)90095-7; CASTELLOT JJ, 1986, J CELL BIOL, V102, P1979, DOI 10.1083/jcb.102.5.1979; CASTELLOT JJ, 1985, J CELL PHYSIOL, V124, P21, DOI 10.1002/jcp.1041240105; CASTELLOT JJ, 1981, J CELL BIOL, V90, P372, DOI 10.1083/jcb.90.2.372; CLOWES AW, 1977, NATURE, V265, P625, DOI 10.1038/265625a0; CONRAD HE, 1989, ANN NY ACAD SCI, V556, P18; DODGSON KS, 1962, BIOCHEM J, V84, P106, DOI 10.1042/bj0840106; FEDARKO NS, 1986, J CELL BIOL, V102, P587, DOI 10.1083/jcb.102.2.587; FRITZE LMS, 1985, J CELL BIOL, V100, P1041, DOI 10.1083/jcb.100.4.1041; GALLAGHER JT, 1986, BIOCHEM J, V236, P313, DOI 10.1042/bj2360313; GUYTON JR, 1980, CIRC RES, V46, P625, DOI 10.1161/01.RES.46.5.625; HOLLMANN J, 1989, ARTERIOSCLEROSIS, V9, P154, DOI 10.1161/01.ATV.9.2.154; HOOVER RL, 1980, CIRC RES, V47, P578, DOI 10.1161/01.RES.47.4.578; KARNOVSKY MJ, 1989, ANN NY ACAD SCI, V556, P268; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; KUSCHE M, 1991, J BIOL CHEM, V266, P7400; LINDAHL U, 1987, BIOL PROTEOGLYCANS, P59; LINHARDT RJ, 1990, BIOCHEMISTRY-US, V29, P2611, DOI 10.1021/bi00462a026; MARCUM JA, 1984, J CLIN INVEST, V74, P341, DOI 10.1172/JCI111429; MARCUM JA, 1984, BIOCHEMISTRY-US, V23, P1730, DOI 10.1021/bi00303a023; OTOTANI N, 1979, J BIOCHEM-TOKYO, V85, P1383; ROSS R, 1986, NEW ENGL J MED, V314, P488, DOI 10.1056/NEJM198602203140806; SCHMIDT A, 1985, EUR J BIOCHEM, V153, P269, DOI 10.1111/j.1432-1033.1985.tb09297.x; SCHMIDT A, 1988, EUR J BIOCHEM, V173, P661, DOI 10.1111/j.1432-1033.1988.tb14049.x; SCHMIDT A, 1988, EXP CELL RES, V178, P242, DOI 10.1016/0014-4827(88)90395-3; SCHMIDT A, 1990, EXP CELL RES, V189, P269, DOI 10.1016/0014-4827(90)90246-7; TURNBULL JE, 1990, BIOCHEM J, V265, P715, DOI 10.1042/bj2650715; TURNBULL JE, 1991, BIOCHEM J, V277, P297, DOI 10.1042/bj2770297; TURNBULL JE, 1991, BIOCHEM J, V273, P553, DOI 10.1042/bj2730553; USOV AI, 1971, CARBOHYD RES, V18, P336, DOI 10.1016/S0008-6215(00)80360-2; von Figura K, 1973, Eur J Biochem, V40, P89; WRIGHT TC, 1989, J BIOL CHEM, V264, P1534; YOSHIDA K, 1989, ANAL BIOCHEM, V177, P327, DOI 10.1016/0003-2697(89)90061-4	34	54	60	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 25	1992	267	27					19242	19247						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JP593	1527046				2022-12-25	WOS:A1992JP59300037
J	STALLWOOD, D; BRUGGER, CH; BAGGENSTOSS, BA; STEMMER, PM; SHIRAGA, H; LANDERS, DF; PAUL, S				STALLWOOD, D; BRUGGER, CH; BAGGENSTOSS, BA; STEMMER, PM; SHIRAGA, H; LANDERS, DF; PAUL, S			IDENTITY OF A MEMBRANE-BOUND VASOACTIVE INTESTINAL PEPTIDE-BINDING PROTEIN WITH CALMODULIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COVALENT CROSS-LINKING; LIGHT CHAIN KINASE; CELL-LINE; EPITHELIAL-CELLS; POLYPEPTIDE VIP; CEREBRAL-CORTEX; CALCIUM; RECEPTORS; GLUCAGON; GROWTH	A vasoactive intestinal peptide (VIP)-binding protein purified from guinea pig lung membranes (p18) was digested with trypsin, and the amino acid sequence of the peptide fragments was determined. The sequence of six tryptic fragments of p18 was identical with subsequences present in mammalian calmodulin. Authentic porcine brain calmodulin and p18 co-migrated on an sodium dodecyl sulfate-electrophoresis gel and displayed identical chromatographic behavior on a reverse phase high performance liquid chromatography column. The VIP-binding properties of p18 and calmodulin were indistinguishable. Both proteins displayed saturable and apparent high affinity binding of VIP, evidenced by potent inhibition of complexation with [Tyr10-I-125]VIP by unlabeled VIP (IC50 = 6.0-8.1 nM). Rat growth hormone releasing factor and a C terminally extended form of VIP ([Leu17]VIP-GKR) also displayed potent inhibition of the binding (IC50 = 6.4 and 4 nm, respectively). These neuropeptides are potential modulators of calmodulin function.	UNIV NEBRASKA, MED CTR, DEPT ANESTHESIA, 600 S 42ND ST, OMAHA, NE 68198 USA; UNIV NEBRASKA, MED CTR, DEPT BIOCHEM, OMAHA, NE 68198 USA; UNIV NEBRASKA, MED CTR, DEPT INTERNAL MED, OMAHA, NE 68198 USA	University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center			Shiraga, Hiroyuki/I-9565-2015	Stemmer, Paul/0000-0003-3315-9846	NHLBI NIH HHS [HL02217, HL44126, HL40348] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL044126, K04HL002217, R01HL040348] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AMIRANOFF B, 1980, BIOCHEM BIOPH RES CO, V96, P463, DOI 10.1016/0006-291X(80)91237-1; ANDREASEN TJ, 1983, BIOCHEMISTRY-US, V22, P4615, DOI 10.1021/bi00289a001; AQUARON R, 1990, CELL MOL BIOL, V36, P85; BABU YS, 1988, J MOL BIOL, V204, P191, DOI 10.1016/0022-2836(88)90608-0; BRUGGER CH, 1991, J BIOL CHEM, V266, P18358; CHEUNG WY, 1980, SCIENCE, V207, P19, DOI 10.1126/science.6243188; COUVINEAU A, 1985, J CLIN ENDOCR METAB, V61, P50, DOI 10.1210/jcem-61-1-50; COUVINEAU A, 1990, J BIOL CHEM, V265, P13386; COUVINEAU A, 1986, J NEUROCHEM, V47, P1461; COX JA, 1985, J BIOL CHEM, V260, P2527; CROUCH TH, 1980, BIOCHEMISTRY-US, V19, P3692, DOI 10.1021/bi00557a009; FORNIER S, 1988, J NEUROCHEM, V51, P1599; FOURNIER A, 1984, PEPTIDES, V5, P169, DOI 10.1016/0196-9781(84)90202-X; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GRAB DJ, 1979, J BIOL CHEM, V254, P8690; HAIECH J, 1981, BIOCHEMISTRY-US, V20, P3890, DOI 10.1021/bi00516a035; HEJBLUM G, 1988, CANCER RES, V48, P6201; HONEGGER J, 1991, ENDOCRINOLOGY, V129, P11, DOI 10.1210/endo-129-1-11; HOOPER JE, 1984, J BIOL CHEM, V259, P148; IZZO RS, 1991, REGUL PEPTIDES, V33, P21, DOI 10.1016/0167-0115(91)90011-5; KILHOFFER MC, 1988, J BIOL CHEM, V263, P17023; KLEVIT RE, 1985, BIOCHEMISTRY-US, V24, P8152, DOI 10.1021/bi00348a047; LUKAS TJ, 1986, BIOCHEMISTRY-US, V25, P1458, DOI 10.1021/bi00354a041; MALENCIK DA, 1982, BIOCHEMISTRY-US, V21, P3480, DOI 10.1021/bi00257a035; MALENCIK DA, 1983, BIOCHEMISTRY-US, V22, P995; MALHOTRA RK, 1988, J BIOL CHEM, V263, P2123; MARIE JC, 1986, PEPTIDES, V7, P129, DOI 10.1016/0196-9781(86)90175-0; MARTIN JM, 1989, EUR J BIOCHEM, V180, P435, DOI 10.1111/j.1432-1033.1989.tb14665.x; MCDOWELL L, 1985, BIOCHEMISTRY-US, V24, P2979, DOI 10.1021/bi00333a026; MEANS AR, 1991, PHARMACOL THERAPEUT, V50, P255, DOI 10.1016/0163-7258(91)90017-G; MOREL G, 1991, ENDOCRINOLOGY, V129, P1497, DOI 10.1210/endo-129-3-1497; MUCHMORE DC, 1986, BIOCHEM BIOPH RES CO, V137, P1068; MUTT V, 1988, ANN NY ACAD SCI, V527, P1; NGUYEN TD, 1986, BIOCHEMISTRY-US, V25, P361, DOI 10.1021/bi00350a013; NISHIMURA TS, 1991, J BIOCHEM-TOKYO, V110, P333; OETTLING G, 1990, CANCER LETT, V50, P203, DOI 10.1016/0304-3835(90)90266-Z; OMARY MB, 1987, SCIENCE, V238, P1578, DOI 10.1126/science.2825352; PATTHI S, 1987, J BIOL CHEM, V262, P15740; PAUL S, 1989, SCIENCE, V244, P1158, DOI 10.1126/science.2727702; PENNYPACKER KR, 1988, J NEUROCHEM, V50, P1648, DOI 10.1111/j.1471-4159.1988.tb03055.x; ROBINSON RM, 1982, BIOPOLYMERS, V21, P1217, DOI 10.1002/bip.360210615; ROSSELIN G, 1986, PEPTIDES, V7, P89, DOI 10.1016/0196-9781(86)90170-1; SAID SI, 1984, PEPTIDES, V5, P143, DOI 10.1016/0196-9781(84)90197-9; SAID SI, 1987, AM REV RESPIR DIS, V136, pS52, DOI 10.1164/ajrccm/136.6_Pt_2.S52; SCHOLAR EM, 1991, CANCER, V67, P1561, DOI 10.1002/1097-0142(19910315)67:6<1561::AID-CNCR2820670617>3.0.CO;2-Z; SIMONCSITS A, 1988, EUR J BIOCHEM, V178, P343, DOI 10.1111/j.1432-1033.1988.tb14456.x; SREEDHARAN SP, 1991, P NATL ACAD SCI USA, V88, P4986, DOI 10.1073/pnas.88.11.4986; STONE KL, 1989, TECHNIQUES PROTEIN C, P377; TANNER MJA, 1979, CURR TOP MEMBR TRANS, V12, P1; TESHIMA Y, 1978, J CYCLIC NUCL PROT, V4, P219; TSAGARAKIS S, 1990, J MOL ENDOCRINOL, V7, P71; VANELDIK LJ, 1983, J BIOL CHEM, V258, P4539; WOOD CL, 1985, J BIOL CHEM, V260, P1243; ZORN NE, 1990, BIOCHEM PHARMACOL, V40, P2689, DOI 10.1016/0006-2952(90)90588-C; ZYSK JR, 1986, J BIOL CHEM, V261, P6781	55	21	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 25	1992	267	27					19617	19621						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JP593	1527080				2022-12-25	WOS:A1992JP59300089
J	ZHANG, WY; INOUYE, M; WU, HC				ZHANG, WY; INOUYE, M; WU, HC			NEITHER LIPID MODIFICATION NOR PROCESSING OF PROLIPOPROTEIN IS ESSENTIAL FOR THE FORMATION OF MUREIN-BOUND LIPOPROTEIN IN ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OUTER-MEMBRANE LIPOPROTEIN; CLEAVAGE SITE; CYTOPLASMIC MEMBRANE; PEPTIDOGLYCAN LAYER; PRO-LIPOPROTEIN; SIGNAL SEQUENCE; HYBRID PROTEIN; CELL-WALL; MECHANISM; EXPORT	The relationship between the modification and processing of prolipoprotein and the formation of murein-bound lipoprotein has been investigated using Escherichia coli mutants altered in the signal sequence of prolipoprotein and an E. coli strain producing OmpF-Lpp hybrid protein. The glyceride-modified prolipoprotein in mutant lppT20 and in globomycin-treated wild-type strain were covalently attached to the peptidoglycan. Likewise, the unmodified prolipoproteins in mutants lppL20, lppV20, and lppG21 were attached to the peptidoglycan. The OmpF-Lpp hybrid protein that is processed but not modified with lipid due to the absence of the cysteine-containing modification site in the hybrid protein was also covalently linked to the peptidoglycan. These results indicate that neither lipid modification nor the processing of prolipoprotein is essential for the formation of murein-bound lipoprotein in E. coli. In contrast, introduction of a charged amino acid residue such as Asp or Arg at the 14th position of prolipoprotein affected not only the lipid modification and processing of the mutant prolipoprotein but also the formation of murein-bound lipoprotein. Replacement of the Gly14 with Glu or Lys partially affected the lipid modification and processing of prolipoprotein; the peptidoglycan of the lppEl4 and lppK14 mutants contained a reduced amount of mature lipoprotein but no mutant prolipoprotein. In addition, lpp mutants A20I23I24 and A20I23K24 were found to be defective in both lipid modification/processing of prolipoprotein and the formation of murein-bound lipoprotein. The defective formation of murein-bound lipoprotein in the latter mutants may be related to an alteration in the secondary structure at the modification/processing site of the mutant prolipoproteins.	UNIFORMED SERV UNIV HLTH SCI,DEPT MICROBIOL,BETHESDA,MD 20814; UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,DEPT BIOCHEM,PISCATAWAY,NJ 08854	Uniformed Services University of the Health Sciences - USA; Rutgers State University New Brunswick; Rutgers State University Medical Center					NIGMS NIH HHS [GM28811] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028811] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRAUN V, 1970, EUR J BIOCHEM, V14, P387, DOI 10.1111/j.1432-1033.1970.tb00301.x; BRAUN V, 1975, BIOCHIM BIOPHYS ACTA, V415, P335, DOI 10.1016/0304-4157(75)90013-1; CHOI DS, 1987, J BIOCHEM, V102, P975, DOI 10.1093/oxfordjournals.jbchem.a122174; CHOI DS, 1986, J BIOL CHEM, V261, P8953; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; GENNITY J, 1990, J BIOENERG BIOMEMBR, V22, P233, DOI 10.1007/BF00763167; GIAM CZ, 1984, EUR J BIOCHEM, V141, P331, DOI 10.1111/j.1432-1033.1984.tb08196.x; ICHIHARA S, 1982, J BIOL CHEM, V257, P495; INOUYE M, 1972, J BIOL CHEM, V247, P8154; INOUYE S, 1983, EMBO J, V2, P87, DOI 10.1002/j.1460-2075.1983.tb01386.x; INOUYE S, 1977, P NATL ACAD SCI USA, V74, P1004, DOI 10.1073/pnas.74.3.1004; INOUYE S, 1986, J BIOL CHEM, V261, P970; INUKAI M, 1978, J ANTIBIOT, V31, P1203, DOI 10.7164/antibiotics.31.1203; INUKAI M, 1979, J BACTERIOL, V140, P1098, DOI 10.1128/JB.140.3.1098-1101.1979; ITO K, 1980, J BIOL CHEM, V255, P2123; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LI P, 1988, P NATL ACAD SCI USA, V85, P7685, DOI 10.1073/pnas.85.20.7685; LIN JJC, 1978, P NATL ACAD SCI USA, V75, P4891, DOI 10.1073/pnas.75.10.4891; LIN JJC, 1980, J BACTERIOL, V141, P550, DOI 10.1128/JB.141.2.550-557.1980; LIN JJC, 1980, FEBS LETT, V109, P50, DOI 10.1016/0014-5793(80)81309-3; MASUI Y, 1982, EXPT MANIPULATION GE, P15; NAKAMURA K, 1982, Journal of Molecular and Applied Genetics, V1, P289; POLLITT S, 1986, J BIOL CHEM, V261, P1835; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SUMMERS RG, 1989, J BIOL CHEM, V264, P20082; TOKUNAGA M, 1982, P NATL ACAD SCI-BIOL, V79, P2255, DOI 10.1073/pnas.79.7.2255; TSURUOKA T, 1984, J BACTERIOL, V160, P889, DOI 10.1128/JB.160.3.889-894.1984; YU F, 1984, J BIOL CHEM, V259, P6013	29	10	10	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1992	267	27					19631	19635						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JP593	1527082				2022-12-25	WOS:A1992JP59300091
J	CARR, FE; KASEEM, LL; WONG, NCW				CARR, FE; KASEEM, LL; WONG, NCW			THYROID-HORMONE INHIBITS THYROTROPIN GENE-EXPRESSION VIA A POSITION-INDEPENDENT NEGATIVE L-TRIIODOTHYRONINE-RESPONSIVE ELEMENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-SUBUNIT GENE; RECEPTOR INTERACTION; PROMOTER ACTIVITY; NUCLEAR-PROTEIN; BINDING-SITE; TRANSCRIPTION; CELLS; 3,5,3'-TRIIODOTHYRONINE; IDENTIFICATION; ACTIVATION	We have previously identified a 57-bp DNA fragment encompassing exon 1 of the beta-subunit gene of rat thyrotropin (rTSH-beta) that mediates the negative response to L-triiodothyronine (T3). To determine the specific motif that confers this negative regulation, we tested the T3 sensitivity of various segments of this 57-bp gene fragment in transiently transfected pituitary tumor cells, GH3. The suppressive effects were mediated by a 17-bp motif (+11/+27, CGCCAGTGCAAAGTAAG) located at the 3' end of exon 1. The inhibitory effects mediated by the sequence were evident when a single copy of the motif was inserted 125 bp upstream or 11 bp downstream of the transcriptional start site. These findings indicate that the suppressive effect of T3 is an intrinsic property of the T3-responsive element and not dependent on position relative to the promoter. The T3 receptor (T3R) extracted from GH3 cells or expressed in vitro bound specifically to this sequence. Specific mutations introduced into this region result in a selective loss of nuclear protein binding and a corresponding loss of T3 sensitivity. Additional studies showed that the 17-bp sequence was not responsive to T3 in COS cells which lack endogenous T3R. Cotransfection of a T3R restored the T3 responsiveness of the TSH-beta motif. In summary, we have identified an element in the rTSH-beta gene that mediates negative regulation by T3 and binds to the T3R.	UNIV CALGARY,DEPT MED,CALGARY T2N 4N1,ALBERTA,CANADA; UNIV CALGARY,DEPT MED BIOCHEM,CALGARY T2N 4N1,ALBERTA,CANADA	University of Calgary; University of Calgary	CARR, FE (corresponding author), WALTER REED ARMY MED CTR,DEPT CLIN INVEST,KYLE METAB UNIT,RES LABS,WASHINGTON,DC 20307, USA.							BANIAHMAD A, 1990, CELL, V61, P505, DOI 10.1016/0092-8674(90)90532-J; BEEBE JS, 1991, MOL ENDOCRINOL, V5, P85, DOI 10.1210/mend-5-1-85; BRENT GA, 1991, MOL ENDOCRINOL, V5, P542, DOI 10.1210/mend-5-4-542; BRENT GA, 1989, MOL ENDOCRINOL, V3, P1996, DOI 10.1210/mend-3-12-1996; BURNSIDE J, 1989, J BIOL CHEM, V264, P6886; CARR FE, 1989, MOL ENDOCRINOL, V3, P717, DOI 10.1210/mend-3-4-717; CARR FE, 1988, MOL ENDOCRINOL, V2, P667, DOI 10.1210/mend-2-8-667; CARR FE, 1989, MOL ENDOCRINOL, V3, P709, DOI 10.1210/mend-3-4-709; CARR FE, 1987, J BIOL CHEM, V262, P981; CHATTERJEE VKK, 1989, P NATL ACAD SCI USA, V86, P9114, DOI 10.1073/pnas.86.23.9114; DARLING DS, 1989, MOL ENDOCRINOL, V3, P1359, DOI 10.1210/mend-3-9-1359; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FLUG F, 1987, J BIOL CHEM, V262, P6373; GLASS CK, 1987, NATURE, V329, P738, DOI 10.1038/329738a0; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GREEN S, 1988, TRENDS GENET, V4, P309, DOI 10.1016/0168-9525(88)90108-4; IZUMO S, 1988, NATURE, V334, P539, DOI 10.1038/334539a0; KOENIG RJ, 1987, P NATL ACAD SCI USA, V84, P5670, DOI 10.1073/pnas.84.16.5670; LAZAR MA, 1990, MOL ENDOCRINOL, V4, P1627, DOI 10.1210/mend-4-11-1627; LEVINE M, 1989, CELL, V59, P405, DOI 10.1016/0092-8674(89)90024-X; LOPATA MA, 1984, NUCLEIC ACIDS RES, V12, P5707, DOI 10.1093/nar/12.14.5707; ODONNELL AL, 1991, MOL ENDOCRINOL, V5, P94, DOI 10.1210/mend-5-1-94; PETTY KJ, 1990, J BIOL CHEM, V265, P7395; SAMUELS HH, 1988, J CLIN INVEST, V81, P957, DOI 10.1172/JCI113449; TSIKA RW, 1990, P NATL ACAD SCI USA, V87, P379, DOI 10.1073/pnas.87.1.379; WIGHT PA, 1988, MOL ENDOCRINOL, V2, P536, DOI 10.1210/mend-2-6-536; WONDISFORD FE, 1989, J BIOL CHEM, V264, P14601; WONG NCW, 1990, J BIOL CHEM, V265, P8775; WONG NCW, 1986, J BIOL CHEM, V261, P387; WOOD WM, 1989, J BIOL CHEM, V264, P14840; ZILZ ND, 1990, J BIOL CHEM, V265, P8136	32	55	55	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1992	267	26					18689	18694						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JN502	1527000				2022-12-25	WOS:A1992JN50200068
J	DUVICK, JP; ROOD, T; RAO, AG; MARSHAK, DR				DUVICK, JP; ROOD, T; RAO, AG; MARSHAK, DR			PURIFICATION AND CHARACTERIZATION OF A NOVEL ANTIMICROBIAL PEPTIDE FROM MAIZE (ZEA-MAYS L) KERNELS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYACRYLAMIDE-GEL ELECTROPHORESIS; ANTIBACTERIAL PEPTIDES; PROTEINS; PUROTHIONINS; MEMBRANE; FAMILY; RANGE; NP-5; CDNA; CORN	Several small, acid-soluble, basic peptides with antimicrobial properties have been isolated from maize (inbred B73) kernels. One of these peptides (MBP-1) has been purified to homogeneity and characterized. The peptide has a molecular weight of 4127.08 as determined by plasma desorption mass spectroscopy, has no free cysteines, and is predominantly alpha-helical as determined by circular dichroism. The primary sequence of the peptide (33 residues) has been determined by Edman degradation and shows no homology to the thionins, a group of cysteine-rich peptides found in some cereals including wheat, barley, and sorghum, as well as several dicot species. Like the thionins, however, MBP-1 has been found to have antimicrobial properties in vitro. MBP-1 inhibits spore germination or hyphal elongation of several plant pathogenic fungi, including two seed pathogens of maize (Fusarium moniliforme Sheld. and Fusarium graminearum (Gibberella zeae (Schw.) Petsch)), and several bacteria, including a bacterial pathogen of maize (Clavibacter michiganense ssp. nebraskense). A synthetic MBP-1 peptide, air-oxidized and purified by reverse phase chromatography, was equally antifungal as compared with the naturally occurring peptide.	COLD SPRING HARBOR LAB, COLD SPRING HARBOR, NY 11724 USA	Cold Spring Harbor Laboratory	DUVICK, JP (corresponding author), PIONEER HI-BRED INT INC, 7250 NW 62ND AVE, JOHNSTON, IA 50131 USA.							ANDERSON BL, 1983, ANAL BIOCHEM, V132, P365, DOI 10.1016/0003-2697(83)90022-2; APEL K, 1990, PHYSIOL PLANTARUM, V80, P315, DOI 10.1111/j.1399-3054.1990.tb04413.x; BACH AC, 1987, BIOCHEMISTRY-US, V26, P4389, DOI 10.1021/bi00388a030; BERKOWITZ BA, 1990, BIOCHEM PHARMACOL, V39, P625, DOI 10.1016/0006-2952(90)90138-B; BLOCH C, 1991, FEBS LETT, V279, P101, DOI 10.1016/0014-5793(91)80261-Z; BOHLMANN H, 1991, ANNU REV PLANT PHYS, V42, P227, DOI 10.1146/annurev.pp.42.060191.001303; CAMMUE BPA, 1992, J BIOL CHEM, V267, P2228; CARBONERO P, 1980, J AGR FOOD CHEM, V28, P399, DOI 10.1021/jf60228a018; CASTRO VROE, 1989, TOXICON, V27, P511, DOI 10.1016/0041-0101(89)90112-8; CHRISTENSEN B, 1988, P NATL ACAD SCI USA, V85, P5072, DOI 10.1073/pnas.85.14.5072; DIAMOND G, 1991, P NATL ACAD SCI USA, V88, P3952, DOI 10.1073/pnas.88.9.3952; FIELDS C G, 1991, Peptide Research, V4, P95; Garcia-Olmedo F., 1987, OXFORD SURVEYS PLANT, V4, P275; GARCIAOLMEDA H, 1989, OXFORD SURV PLANT MO, V6, P31; GREENFIE.N, 1969, BIOCHEMISTRY-US, V8, P4108, DOI 10.1021/bi00838a031; HERNANDE.C, 1974, APPL MICROBIOL, V28, P165, DOI 10.1191/0309132504ph479oa; HILL CP, 1991, SCIENCE, V251, P1481, DOI 10.1126/science.2006422; HUYNH QK, 1992, J BIOL CHEM, V267, P6635; JONES BL, 1980, J AGR FOOD CHEM, V28, P904, DOI 10.1021/jf60231a008; KINI RM, 1989, INT J PEPT PROT RES, V34, P277; KOBAYASHI Y, 1991, NEUROCHEM INT, V18, P525, DOI 10.1016/0197-0186(91)90151-3; KRONMAN MJ, 1971, PHOTOCHEM PHOTOBIOL, V14, P113, DOI 10.1111/j.1751-1097.1971.tb06157.x; LEGENDRE N, 1988, BIOTECHNIQUES, V6, P154; LEHRER RI, 1991, CELL, V64, P229, DOI 10.1016/0092-8674(91)90632-9; LEHRER RI, 1990, ASM NEWS, V56, P315; LOH YP, 1985, J BIOL CHEM, V260, P7194; MAINS RE, 1984, ENDOCRINOLOGY, V114, P1522, DOI 10.1210/endo-114-5-1522; MARSHAK DR, 1990, CURRENT RES PROTEIN, P127; NAISBITT GH, 1988, PLANT PHYSIOL, V88, P770, DOI 10.1104/pp.88.3.770; NEUCERE JN, 1991, MYCOPATHOLOGIA, V113, P103, DOI 10.1007/BF00442418; NIMMO CC, 1974, J SCI FOOD AGR, V25, P607, DOI 10.1002/jsfa.2740250603; PARDI A, 1988, J MOL BIOL, V201, P625, DOI 10.1016/0022-2836(88)90643-2; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; RAIKHEL NV, 1987, P NATL ACAD SCI USA, V84, P6745, DOI 10.1073/pnas.84.19.6745; RIDDLES PW, 1983, METHOD ENZYMOL, V91, P49; Roberts W K, 1988, Ann N Y Acad Sci, V544, P141, DOI 10.1111/j.1749-6632.1988.tb40397.x; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SELSTED ME, 1984, INFECT IMMUN, V45, P150, DOI 10.1128/IAI.45.1.150-154.1984; SHURTLEFF MC, 1980, COMPENDIUM CORN DISE; SMART MG, 1990, PHYTOPATHOLOGY, V80, P1287, DOI 10.1094/Phyto-80-1287; Spande T.F., 1967, DETERMINATION TRYPTO, P498; STEINER H, 1988, BIOCHIM BIOPHYS ACTA, V939, P260, DOI 10.1016/0005-2736(88)90069-7; TEETER MM, 1981, BIOCHEMISTRY-US, V20, P5437, DOI 10.1021/bi00522a013; VIGERS AJ, 1991, MOL PLANT MICROBE IN, V4, P315, DOI 10.1094/MPMI-4-315; WALL J, 1987, ADV CEREAL SCI TECHN, V2, P135; Wilson C. M., 1987, Corn: chemistry and technology., P273	46	144	165	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	1992	267	26					18814	18820						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JN502	1527010				2022-12-25	WOS:A1992JN50200086
J	KRAMER, W; WESS, G; SCHUBERT, G; BICKEL, M; GIRBIG, F; GUTJAHR, U; KOWALEWSKI, S; BARINGHAUS, KH; ENHSEN, A; GLOMBIK, H; MULLNER, S; NECKERMANN, G; SCHULZ, S; PETZINGER, E				KRAMER, W; WESS, G; SCHUBERT, G; BICKEL, M; GIRBIG, F; GUTJAHR, U; KOWALEWSKI, S; BARINGHAUS, KH; ENHSEN, A; GLOMBIK, H; MULLNER, S; NECKERMANN, G; SCHULZ, S; PETZINGER, E			LIVER-SPECIFIC DRUG TARGETING BY COUPLING TO BILE-ACIDS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SALT-BINDING POLYPEPTIDES; BORDER MEMBRANE-VESICLES; ISOLATED RAT HEPATOCYTES; BETA-LACTAM ANTIBIOTICS; TRANSPORT-SYSTEM; SMALL-INTESTINE; PHALLOIDIN; PROTEINS; IDENTIFICATION; CELLS	Bile acids are selectively taken up from portal blood into the liver by specific transport systems in the hepatocyte plasma membrane. Therefore, studies were performed to evaluate the potential of bile acids as shuttles to deliver drugs specifically to the liver. The alkylating cytostatic drug chlorambucil and the fluorescent prolyl-4-hydroxylase inhibitor 4-nitrobenzo-2-oxa-1,3-diazol-beta-Ala-Phe-5-oxaproline-Gly were covalently linked via an amide bond to 7-alpha,12-alpha,-dihydroxy-3-beta-(omega-aminoalkoxy)-5-beta-cholan-24-oic acid. The chlorambucil-bile acid conjugates S 2521, S 2539, S 2567, and S 2576 inhibited Na+-dependent [H-3]taurocholate uptake in a concentration-dependent manner both into isolated rat hepatocytes and rabbit ileal brush border membrane vesicles, whereas the parent drug chlorambucil showed no significant inhibitory effect. The chlorambucil-bile acid conjugates were able to prevent photoaffinity labeling of bile acid binding proteins in rat hepatocytes by the photolabile [H-3]7,7-azo derivative of taurocholic acid indicating their bile acid character. The chlorambucil-bile acid conjugate S 2577 was able to alkylate proteins demonstrating the drug character conserved in the hybrid-molecules. Liver perfusion experiments revealed a secretion profile of the chlorambucil-bile acid conjugate S 2576 into bile very similar to taurocholate compared to chlorambucil which is predominantly excreted by the kidney. 4-Nitrobenzo-2-oxa-1,3-diazol-beta-Ala-Phe-5-oxaproline-Gly-t-butylester S 4404), a fluorescent peptide inhibitor of prolyl-4-hydroxylase, was not transported in intact form from portal blood into bile in contrast to its bile acid conjugate S 3744; about 25% of the peptide-bile acid conjugate S 3744 was secreted in intact form into bile within 40 min compared with less than 4% of the parent oxaprolylpeptide S 4404. In conclusion, these studies reveal that modified bile acid molecules can be used as "Trojan horses" to deliver a drug molecule specifically into the liver and the biliary system. This offers important pharmacological options for the development of liver-specific drugs.	HOECHST AG,W-6230 FRANKFURT,GERMANY; UNIV GIESSEN,INST PHARMACOL & TOXIKOL,W-6300 GIESSEN,GERMANY	Sanofi-Aventis; Justus Liebig University Giessen								ABBERGER H, 1981, BILE ACIDS LIPIDS, P233; ABBERGER H, 1983, BILE ACIDS CHOLESTER, P77; ALDINI R, 1982, J LIPID RES, V23, P1167; ANWER MS, 1985, AM J PHYSIOL, V249, pG479, DOI 10.1152/ajpgi.1985.249.4.G479; ANWER MS, 1976, H-S Z PHYSIOL CHEM, V357, P1477, DOI 10.1515/bchm2.1976.357.2.1477; BERRY MN, 1969, J CELL BIOL, V43, P506, DOI 10.1083/jcb.43.3.506; BURCKHARDT G, 1983, J BIOL CHEM, V258, P3618; BURCKHARDT G, 1987, BIOCHEM BIOPH RES CO, V143, P1018, DOI 10.1016/0006-291X(87)90353-6; BURCKHARDT G, 1984, Pfluegers Archiv European Journal of Physiology, V400, pR29; BURCKHARDT G, 1989, HEPATIC TRANSPORT OR, P297; BUSCHER HP, 1985, ENTEROHEPATIC CIRCUL, P243; BUSCHER HP, 1986, RECEPTOR MEDIATED UP, P189; CLEMENT B, 1991, J HEPATOL, V13, pS41, DOI 10.1016/0168-8278(91)90007-X; FALLON JB, 1989, OCCUP MED, V4, P49; FRICKER G, 1987, BIOL CHEM H-S, V368, P1143, DOI 10.1515/bchm3.1987.368.2.1143; FRIMMER M, 1987, TOXICOL LETT, V35, P169, DOI 10.1016/0378-4274(87)90204-9; GUNZLER V, 1988, J BIOL CHEM, V263, P19498; HARDISON WGM, 1991, HEPATOLOGY, V13, P68, DOI 10.1002/hep.1840130111; HILL BT, 1971, BRIT J CANCER, V25, P831, DOI 10.1038/bjc.1971.96; KRAMER W, 1982, EUR J BIOCHEM, V129, P13, DOI 10.1111/j.1432-1033.1982.tb07015.x; KRAMER W, 1990, J CHROMATOGR, V521, P199, DOI 10.1016/0021-9673(90)85044-V; KRAMER W, 1988, BIOCHEM PHARMACOL, V37, P2427, DOI 10.1016/0006-2952(88)90370-X; KRAMER W, 1989, J LIPID RES, V30, P1281; KRAMER W, 1983, J LIPID RES, V24, P910; KRAMER W, 1983, J BIOL CHEM, V258, P3623; KRAMER W, 1982, H-S Z PHYSIOL CHEM, V363, P901; KRAMER W, 1980, H-S Z PHYSIOL CHEM, V361, P1307; KRAMER W, 1988, BIOCHIM BIOPHYS ACTA, V943, P288, DOI 10.1016/0005-2736(88)90560-3; KRAMER W, 1979, EUR J BIOCHEM, V102, P1, DOI 10.1111/j.1432-1033.1979.tb06257.x; KRAMER W, 1981, THESIS U FREIBURG, P1; LACK L, 1967, BIOCHIM BIOPHYS ACTA, V135, P1065, DOI 10.1016/0005-2736(67)90078-8; LACK L, 1979, ENVIRON HEALTH PERSP, V33, P79, DOI 10.2307/3429075; LIN MC, 1988, J MEMBRANE BIOL, V106, P1, DOI 10.1007/BF01871762; LIN MC, 1990, J BIOL CHEM, V265, P14986; LOCHS H, 1986, J BIOL CHEM, V261, P4976; MATERN S, 1979, REV PHYSL BIOCH PHAR, V85, P126; PETZINGER E, 1981, N-S ARCH PHARMACOL, V316, P345, DOI 10.1007/BF00501368; PETZINGER E, 1976, N-S ARCH PHARMACOL, V295, P211, DOI 10.1007/BF00505088; PETZINGER E, 1980, ARCH TOXICOL, V44, P127, DOI 10.1007/BF00303189; PETZINGER E, 1989, AM J PHYSIOL, V256, pG78, DOI 10.1152/ajpgi.1989.256.1.G78; PETZINGER E, 1986, BILE ACIDS LIVER, P111; RUETZ S, 1987, J BIOL CHEM, V262, P11324; SCHWARZ LR, 1975, EUR J BIOCHEM, V55, P617, DOI 10.1111/j.1432-1033.1975.tb02199.x; VLAHCEVIC ZR, 1990, HEPATOLOGY TXB LIVER, P341; VONDIPPE P, 1983, J BIOL CHEM, V258, P8896; WESS G, 1992, TETRAHEDRON LETT, V33, P195, DOI 10.1016/0040-4039(92)88048-A; WIELAND T, 1984, P NATL ACAD SCI-BIOL, V81, P5232, DOI 10.1073/pnas.81.16.5232; WILSON FA, 1976, AM J PHYSIOL, V241, P683; ZIEGLER K, 1982, N-S ARCH PHARMACOL, V319, P254, DOI 10.1007/BF00495875; ZIEGLER K, 1984, BIOCHIM BIOPHYS ACTA, V773, P11, DOI 10.1016/0005-2736(84)90545-5; ZIEGLER K, 1982, N-S ARCH PHARMACOL, V319, P249, DOI 10.1007/BF00495874	51	139	167	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1992	267	26					18598	18604						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JN502	1526993				2022-12-25	WOS:A1992JN50200055
J	MARIC, SC; CROZAT, A; JANNE, OA				MARIC, SC; CROZAT, A; JANNE, OA			STRUCTURE AND ORGANIZATION OF THE HUMAN S-ADENOSYLMETHIONINE DECARBOXYLASE GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERASE CHAIN-REACTION; ESCHERICHIA-COLI; MESSENGER-RNA; PROENZYME FORM; RAT-LIVER; DNA; SEQUENCES; PURIFICATION; INITIATOR; SPERMATOGENESIS	Genomic clones for the S-adenosylmethionine (AdoMet) decarboxylase gene were isolated from a human chromosome 6 DNA library. In addition, polymerase chain reaction and specific primers were used to amplify fragments from chromosomal DNA covering exonic regions not found in the screening of DNA libraries with AdoMet decarboxylase cDNA. The gene encompasses at least 22 kilobases of chromosome 6 DNA and comprises nine exons and eight introns, in contrast to the corresponding rat gene that has only eight exons (Pulkka, A., Ihalainen, R., Aatsinki, J., and Pajunen, A. (1991) FEBS Lett. 291, 289-295). Exon-intron junctions in the human and rat AdoMet decarboxylase genes were in identical positions except that exons 6 and 7 of the human gene formed a single exon in the rat gene. Alu-like sequences are present in four introns and the 5'-flanking region of the human gene. The promoter region contains a TATA box adjacent to the cap site; in addition, DNA elements for binding of transcription factors AP-1, AP-2, CREB, SP-1, and multiple steroid receptors are present between position -3,158 and the transcription start site. Two AdoMet decarboxylase promoter-reporter gene constructs with about 170 and 1,500 nucleotides of the 5'-flanking DNA were used in transient expression studies. AdoMet decarboxylase promoter was capable of driving reporter gene expression, but it was less active than the murine ornithine decarboxylase promoter. There are at least three potential polyadenylation signals at the 3'-end of the gene, and utilization of the first two results in the formation of the 2.0- and 3.6-kilobase AdoMet decarboxylase mRNA species present in human tissues and cell lines. AdoMet decarboxylase gene-related sequences were also present in a human X chromosome-specific DNA library. Partial nucleotide sequencing of this DNA revealed a lack of introns present in the gene located on chromosome 6, suggesting that the locus on the X chromosome contains a processed AdoMet decarboxylase pseudogene.	UNIV HELSINKI,DEPT PHYSIOL,SILTAVUORENPENGER 20 J,SF-00170 HELSINKI 17,FINLAND; ROCKEFELLER UNIV,NEW YORK,NY 10021; POPULAT COUNCIL,NEW YORK,NY 10021	University of Helsinki; Rockefeller University; Population Council					NICHD NIH HHS [HD13541] Funding Source: Medline	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ANTON DL, 1987, J BIOL CHEM, V262, P2817; AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; Ausubel F. M., 1988, CURRENT PROTOCOLS MO; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; CHEN EY, 1985, DNA-J MOLEC CELL BIO, V4, P165, DOI 10.1089/dna.1985.4.165; CROZAT A, 1992, ENDOCRINOLOGY, V130, P1131, DOI 10.1210/en.130.3.1131; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; EASTMAN A, 1987, BIOTECHNIQUES, V5, P731; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P3, DOI 10.1093/nar/20.1.3; GROSSBERGER D, 1987, NUCLEIC ACIDS RES, V15, P6737, DOI 10.1093/nar/15.16.6737; GROSSCHEDL R, 1980, P NATL ACAD SCI-BIOL, V77, P1432, DOI 10.1073/pnas.77.3.1432; GUTHRIE C, 1991, SCIENCE, V253, P157, DOI 10.1126/science.1853200; HEBY O, 1990, TRENDS BIOCHEM SCI, V15, P153, DOI 10.1016/0968-0004(90)90216-X; HICKOK NJ, 1987, DNA-J MOLEC CELL BIO, V6, P179, DOI 10.1089/dna.1987.6.179; JANNE J, 1991, ANN MED, V23, P241, DOI 10.3109/07853899109148056; KASHIWAGI K, 1990, J BIOL CHEM, V265, P22321; MACH M, 1986, J BIOL CHEM, V261, P1697; Maniatis T, 1989, DECONTAMINATION DILU; NELSON DL, 1989, P NATL ACAD SCI USA, V86, P6686, DOI 10.1073/pnas.86.17.6686; NEUMANN JR, 1987, BIOTECHNIQUES, V5, P444; PAJUNEN A, 1988, J BIOL CHEM, V263, P17040; PALVIMO JJ, 1991, NUCLEIC ACIDS RES, V19, P3921, DOI 10.1093/nar/19.14.3921; PEGG AE, 1988, CANCER RES, V48, P759; POSO H, 1982, BIOCHEMISTRY-US, V21, P3116, DOI 10.1021/bi00256a013; PULKKA A, 1990, GENE, V86, P193, DOI 10.1016/0378-1119(90)90279-Z; PULKKA A, 1991, FEBS LETT, V291, P289, DOI 10.1016/0014-5793(91)81304-Q; RADFORD DM, 1988, CYTOGENET CELL GENET, V49, P285, DOI 10.1159/000132679; RECHSTEINER M, 1987, TRENDS BIOCHEM SCI, V12, P390; ROBINSON MO, 1991, NUCLEIC ACIDS RES, V19, P1557, DOI 10.1093/nar/19.7.1557; ROSENTHAL N, 1987, METHOD ENZYMOL, V152, P704; ROY AL, 1991, NATURE, V354, P245, DOI 10.1038/354245a0; SHIRAHATA A, 1985, J BIOL CHEM, V260, P9583; SINGERSAM J, 1990, NUCLEIC ACIDS RES, V18, P1255, DOI 10.1093/nar/18.5.1255; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; SMALE ST, 1990, P NATL ACAD SCI USA, V87, P4509, DOI 10.1073/pnas.87.12.4509; STANLEY BA, 1991, J BIOL CHEM, V266, P18502; STANLEY BA, 1989, J BIOL CHEM, V264, P21073; TABOR CW, 1984, ANNU REV BIOCHEM, V53, P749, DOI 10.1146/annurev.bi.53.070184.003533; TABOR CW, 1987, J BIOL CHEM, V262, P16037; TABOR CW, 1986, P NATL ACAD SCI USA, V83, P6040, DOI 10.1073/pnas.83.16.6040; WICKNER RB, 1970, J BIOL CHEM, V245, P2132	41	44	44	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1992	267	26					18915	18923						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JN502	1527020				2022-12-25	WOS:A1992JN50200100
J	YAMAUCHI, T; CHOI, SY; OKADA, H; YOHDA, M; KUMAGAI, H; ESAKI, N; SODA, K				YAMAUCHI, T; CHOI, SY; OKADA, H; YOHDA, M; KUMAGAI, H; ESAKI, N; SODA, K			PROPERTIES OF ASPARTATE RACEMASE, A PYRIDOXAL 5'-PHOSPHATE-INDEPENDENT AMINO-ACID RACEMASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROLINE RACEMASE; ESCHERICHIA-COLI; FRACTIONATION FACTORS; HYDROXYPROLINE 2-EPIMERASE; PEDIOCOCCUS-PENTOSACEUS; GLUTAMATE RACEMASE; ENZYME CATALYSIS; ACTIVE-SITE; 2 FORMS; ENERGETICS	Aspartate racemase from Streptococcus thermophilus contains no pyridoxal 5'-phosphate or other cofactors such as FAD, NAD+, and metal ions. It was affected by neither carbonyl reagents such as hydroxylamine nor sodium borohydride but was strongly inhibited by iodoacetamide and other thiol reagents. Aspartate, cysteate, and cysteine sulfinate were the only substrates. The K(m) values for L- and D-aspartate were 35 and 8.7 mm, respectively. The enzyme catalyzed the exchange of alpha-hydrogen of the substrate with the solvent hydrogen. Racemization of L-aspartate in (H2O)-H-2 showed an overshooting in the optical rotation of aspartate before the substrate was fully racemized. This shows that the removal of alpha-hydrogen of the substrate is at least partially rate-determining. When L- or D-aspartate was incubated with aspartate racemase in tritiated water, tritium was incorporated preferentially into the product enantiomer. The results strongly suggest that aspartate racemase contains two hydrogen acceptors.	KYOTO UNIV,INST CHEM RES,UJI,KYOTO 611,JAPAN; ASAHI GLASS CO LTD,RES INST,KANAGAWA KU,YOKOHAMA,KANAGAWA 221,JAPAN	Kyoto University; AGC Inc			Yohda, Masafumi/A-5149-2013	Yohda, Masafumi/0000-0001-8307-9671				ALBERY WJ, 1987, J THEOR BIOL, V124, P173, DOI 10.1016/S0022-5193(87)80260-6; ALBERY WJ, 1987, J THEOR BIOL, V124, P137, DOI 10.1016/S0022-5193(87)80259-X; ALBERY WJ, 1986, BIOCHEMISTRY-US, V25, P2572, DOI 10.1021/bi00357a043; Bada J.L, 1985, CHEM BIOCH AMINO ACI, P399; BELASCO JG, 1986, BIOCHEMISTRY-US, V25, P2552, DOI 10.1021/bi00357a040; BELASCO JG, 1986, BIOCHEMISTRY-US, V25, P2558, DOI 10.1021/bi00357a041; BELASCO JG, 1986, BIOCHEMISTRY-US, V25, P2564, DOI 10.1021/bi00357a042; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARDINALE GJ, 1968, BIOCHEMISTRY-US, V7, P3970, DOI 10.1021/bi00851a026; CLELAND WW, 1977, ISOTOPE EFFECTS ENZY, P252; FINLAY TH, 1970, J BIOL CHEM, V245, P5248; FISHER LM, 1986, BIOCHEMISTRY-US, V25, P2529, DOI 10.1021/bi00357a037; FISHER LM, 1986, BIOCHEMISTRY-US, V25, P2538, DOI 10.1021/bi00357a038; FISHER LM, 1986, BIOCHEMISTRY-US, V25, P2543, DOI 10.1021/bi00357a039; HIGGINS W, 1989, EUR J BIOCHEM, V186, P137, DOI 10.1111/j.1432-1033.1989.tb15187.x; KURAMITSU S, 1990, BIOCHEMISTRY-US, V29, P5469, DOI 10.1021/bi00475a010; LAMONT HC, 1972, J BIOL CHEM, V247, P5103; NAKAJIMA N, 1988, AGR BIOL CHEM TOKYO, V52, P3099, DOI 10.1080/00021369.1988.10869187; NAKAJIMA N, 1986, AGR BIOL CHEM TOKYO, V50, P2823, DOI 10.1080/00021369.1986.10867827; OKADA H, 1991, BIOCHIM BIOPHYS ACTA, V1078, P377, DOI 10.1016/0167-4838(91)90159-W; RAMASWAMY SG, 1984, J BIOL CHEM, V259, P249; RUDNICK G, 1975, BIOCHEMISTRY-US, V14, P4515, DOI 10.1021/bi00691a028; SNELL EE, 1970, ENZYMES, V2, P353; WISEMAN JS, 1984, J BIOL CHEM, V259, P8907; YOHDA M, 1991, BIOCHIM BIOPHYS ACTA, V1089, P234, DOI 10.1016/0167-4781(91)90013-C	25	76	76	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1992	267	26					18361	18364						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JN502	1526977				2022-12-25	WOS:A1992JN50200021
J	ING, NH; BEEKMAN, JM; TSAI, SY; TSAI, MJ; OMALLEY, BW				ING, NH; BEEKMAN, JM; TSAI, SY; TSAI, MJ; OMALLEY, BW			MEMBERS OF THE STEROID-HORMONE RECEPTOR SUPERFAMILY INTERACT WITH TFIIB (S300-II)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ESTROGEN-RECEPTOR; RNA POLYMERASE-II; TRANSCRIPTION FACTOR-TFIIB; CELL-FREE TRANSCRIPTION; PREINITIATION COMPLEX; FUNCTIONAL DOMAINS; ACTIVATION DOMAIN; OVALBUMIN GENE; TATA FACTOR; BINDING	The S300-II factor was discovered as an activator of ovalbumin gene transcription with the chicken ovalbumin upstream promoter-transcription factor (COUP-TF, Sagami, I., Tsai, S. Y., Wang, H., Tsai, M.J., and O'Malley, B. W. (1986) Mol. Cell. Biol. 6, 4259-4267). Although S300-II does not bind DNA selectively, it stabilizes the binding of COUP-TF to its ciselement (Tsai, S. Y., Sagami, I., Wang, H., Tsai, M.-J., and O'Malley, B. W. (1987) Cell 50, 701-709). Purified S300-11 is also required for steroid receptor-activated transcription. Cloning and sequencing of S300-II showed that it is the general transcription factor TFIIB. Specific protein-protein interactions between recombinant S300-II/TFIIB and three members of the steroid hormone receptor superfamily, COUP-TF, estrogen receptor, and progesterone receptor, indicate that S300-II/TFIIB is one of the targets of these transactivators. Interestingly, a truncated estrogen receptor construct containing only the N-terminal transcription activation function 1 did not interact with S300-II/TFIIB in our assay, revealing that individual transcription activation functions of a single steroid hormone receptor may contact different targets. Demonstration of a direct association of S300-II/TFIIB and COUP-TF, independent of additional "adaptor" proteins, suggests that members of the steroid hormone receptor superfamily facilitate the transcription of activated genes at least in part via protein-protein interactions with the general transcription factor TFIIB.	BAYLOR COLL MED,HOUSTON,TX 77030	Baylor College of Medicine			Ing, Nancy/AAC-9927-2020					ALLAN GF, 1991, J BIOL CHEM, V266, P5905; BRADSHAW MS, 1991, J BIOL CHEM, V266, P16684; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; ELLISTON JF, 1992, J BIOL CHEM, V267, P5193; ELLISTON JF, 1990, MOL CELL BIOL, V10, P6607, DOI 10.1128/MCB.10.12.6607; FLANAGAN PM, 1991, NATURE, V350, P436, DOI 10.1038/350436a0; FRANKEL AD, 1991, CELL, V65, P717, DOI 10.1016/0092-8674(91)90378-C; GREEN S, 1986, NATURE, V320, P134, DOI 10.1038/320134a0; GREENBLATT J, 1991, CELL, V66, P1067, DOI 10.1016/0092-8674(91)90027-V; HA I, 1991, NATURE, V352, P689, DOI 10.1038/352689a0; HOFFMANN A, 1990, NATURE, V346, P387, DOI 10.1038/346387a0; HORIKOSHI M, 1988, CELL, V54, P665, DOI 10.1016/S0092-8674(88)80011-4; HORIKOSHI M, 1988, CELL, V54, P1033, DOI 10.1016/0092-8674(88)90118-3; HORIKOSHI N, 1991, P NATL ACAD SCI USA, V88, P5124, DOI 10.1073/pnas.88.12.5124; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; KLEINHITPASS L, 1990, CELL, V60, P247, DOI 10.1016/0092-8674(90)90740-6; KUMAR V, 1987, CELL, V51, P941, DOI 10.1016/0092-8674(87)90581-2; LEE WS, 1991, CELL, V67, P365, DOI 10.1016/0092-8674(91)90188-5; LEWIN B, 1990, CELL, V61, P1161, DOI 10.1016/0092-8674(90)90675-5; LICHTSTEINER S, 1989, CELL, V57, P1179, DOI 10.1016/0092-8674(89)90055-X; LIEBERMAN PM, 1991, GENE DEV, V5, P2441, DOI 10.1101/gad.5.12b.2441; LIN YS, 1991, CELL, V64, P971, DOI 10.1016/0092-8674(91)90321-O; LIN YS, 1991, NATURE, V353, P569, DOI 10.1038/353569a0; MALIK S, 1991, P NATL ACAD SCI USA, V88, P9553, DOI 10.1073/pnas.88.21.9553; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MIYAJIMA N, 1988, NUCLEIC ACIDS RES, V16, P11057, DOI 10.1093/nar/16.23.11057; NORMAN C, 1988, CELL, V55, P989, DOI 10.1016/0092-8674(88)90244-9; PASTORCIC M, 1986, MOL CELL BIOL, V6, P2784, DOI 10.1128/MCB.6.8.2784; PETERSON MG, 1990, SCIENCE, V248, P1625, DOI 10.1126/science.2363050; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; SAGAMI I, 1986, MOL CELL BIOL, V6, P4259, DOI 10.1128/MCB.6.12.4259; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; SHEMSHEDINI L, 1992, J BIOL CHEM, V267, P1834; STRINGER KF, 1990, NATURE, V345, P783, DOI 10.1038/345783a0; TANESE N, 1991, GENE DEV, V5, P2212, DOI 10.1101/gad.5.12a.2212; TASSET D, 1990, CELL, V62, P1177, DOI 10.1016/0092-8674(90)90394-T; TORA L, 1989, CELL, V59, P477, DOI 10.1016/0092-8674(89)90031-7; TSAI SY, 1990, J BIOL CHEM, V265, P17055; TSAI SY, 1987, CELL, V50, P701, DOI 10.1016/0092-8674(87)90328-X; TSAI SY, 1988, CELL, V55, P361, DOI 10.1016/0092-8674(88)90059-1; Wang Lee-Ho, 1991, Gene Expression, V1, P207; WEBSTER NJG, 1988, CELL, V54, P199, DOI 10.1016/0092-8674(88)90552-1; WHITE JH, 1991, P NATL ACAD SCI USA, V88, P7674, DOI 10.1073/pnas.88.17.7674; ZAWEL L, 1992, IN PRESS PROG NUCLEI	44	328	333	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1992	267	25					17617	17623						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JM223	1517211				2022-12-25	WOS:A1992JM22300024
J	KELLER, HJ; ROMANIUK, PJ; GOTTESFELD, JM				KELLER, HJ; ROMANIUK, PJ; GOTTESFELD, JM			INTERACTION OF XENOPUS TFIIIC WITH THE TFIIIA.5-S RNA GENE-COMPLEX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR-IIIA; INTERNAL CONTROL REGION; 5S RNA; POLYMERASE-III; FUNCTIONAL DOMAINS; BINDING DOMAINS; STABLE COMPLEX; DNA-BINDING; FACTOR-TAU; PROMOTER	The general transcription factor TFIIIC is necessary for transcription initiation by RNA polymerase III. TFIIIC binds predominantly to the B-Block promoter element, which is present in tRNA genes, several viral RNA genes and repetitive DNA elements, and to the TFIIIA.DNA complex on 5 S RNA genes. Here we report a characterization of Xenopus laevis TFIIIC and its interaction with the TFIIIA.5 S RNA gene complex. A polypeptide with apparent molecular mass of 85 kDa was specifically cross-linked to a B-Block oligonucleotide by UV light. This polypeptide was present in the partially purified TFIIIC fraction and in a complex with a B-Block double-stranded oligonucleotide isolated by nondenaturing gel electrophoresis. TFIIIC.TFIIIA.DNA gel mobility shift complexes were obtained using B-Block DNA affinity-purified TFIIIC and buffer conditions employing low Mg2+ (1 mM) and high dithiothreitol (7 mm) concentrations. Three TFIIIC.TFIIIA.5 S RNA gene complexes were observed by gel mobility shift analysis. One of these complexes was resistant to dissociation by the addition of competing DNA, but the formation of all three complexes was prevented by the inclusion of excess specific competitor DNA in the initial binding reactions. The apparent affinity of TFIIIC for the TFIIIA-5 S DNA complex was 5-fold higher for the somatic-type 5 S RNA gene than for the oocyte-type 5 S RNA gene. Mutations near the 5' boundary of the TFIIIA binding site alter the DNase I footprint of the TFIIIA.DNA complex and reduce the affinity of TFIIIA-mutant 5 S gene complexes for TFIIIC. Differences in TFIIIC affinity for the two classes of 5 S RNA genes may play a role in the developmental regulation of these gene families.	MED BIOL INST,DIV DEV BIOL,11077 N TORREY PINES RD,LA JOLLA,CA 92037; UNIV VICTORIA,DEPT BIOCHEM & MICROBIOL,VICTORIA V8W 2Y2,BC,CANADA	University of Victoria				Romaniuk, Paul/0000-0002-5931-8879; Gottesfeld, Joel/0000-0002-4643-5777	NIGMS NIH HHS [GM-26453] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026453] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARTHOLOMEW B, 1990, EMBO J, V9, P2197, DOI 10.1002/j.1460-2075.1990.tb07389.x; BIEKER JJ, 1985, CELL, V40, P119, DOI 10.1016/0092-8674(85)90315-0; BLANCO J, 1989, GENE DEV, V3, P1602, DOI 10.1101/gad.3.10.1602; BOGENHAGEN DF, 1981, CELL, V24, P261, DOI 10.1016/0092-8674(81)90522-5; BRAUN BR, 1989, P NATL ACAD SCI USA, V86, P2530, DOI 10.1073/pnas.86.8.2530; CAREY MF, 1986, J BIOL CHEM, V261, P4309; CARRARA G, 1981, CELL, V27, P371, DOI 10.1016/0092-8674(81)90420-7; COHEN I, 1991, NUCLEIC ACIDS RES, V19, P4753, DOI 10.1093/nar/19.17.4753; CROMLISH JA, 1989, J BIOL CHEM, V264, P18100; ENGELKE DR, 1980, CELL, V19, P717, DOI 10.1016/S0092-8674(80)80048-1; ENGELKE DR, 1990, NUCLEIC ACIDS RES, V18, P6031, DOI 10.1093/nar/18.20.6031; GABRIELSEN OS, 1989, J BIOL CHEM, V264, P7505; GEUDUSCHEK EP, 1988, ANN REV BIOCH, V57, P873; GINSBERG AM, 1984, CELL, V39, P479, DOI 10.1016/0092-8674(84)90455-0; GLIKIN GC, 1984, CELL, V37, P33, DOI 10.1016/0092-8674(84)90298-8; HANAS JS, 1984, NUCLEIC ACIDS RES, V12, P2745, DOI 10.1093/nar/12.6.2745; HAYES J, 1989, J BIOL CHEM, V264, P6009; JOHNSON JD, 1984, MOL GEN GENET, V197, P55, DOI 10.1007/BF00327922; KASSAVETIS GA, 1990, CELL, V60, P235, DOI 10.1016/0092-8674(90)90739-2; KELLER HJ, 1990, MOL CELL BIOL, V10, P5166, DOI 10.1128/MCB.10.10.5166; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASSAR AB, 1983, SCIENCE, V222, P740, DOI 10.1126/science.6356356; LIAO XB, 1992, J MOL BIOL, V223, P857, DOI 10.1016/0022-2836(92)90248-I; MCCONKEY GA, 1987, GENE DEV, V2, P205; MILLER J, 1985, EMBO J, V4, P1609, DOI 10.1002/j.1460-2075.1985.tb03825.x; MILLSTEIN L, 1987, J BIOL CHEM, V262, P17100; MURPHY S, 1989, TRENDS GENET, V5, P122, DOI 10.1016/0168-9525(89)90043-7; PALMER JM, 1990, TRENDS BIOCHEM SCI, V15, P300, DOI 10.1016/0968-0004(90)90018-7; PARSONS MC, 1990, J BIOL CHEM, V265, P5095; PECK LJ, 1987, MOL CELL BIOL, V7, P3503, DOI 10.1128/MCB.7.10.3503; PELHAM HRB, 1980, P NATL ACAD SCI-BIOL, V77, P4170, DOI 10.1073/pnas.77.7.4170; PIELER T, 1985, EMBO J, V4, P3751, DOI 10.1002/j.1460-2075.1985.tb04144.x; PIELER T, 1987, CELL, V48, P91, DOI 10.1016/0092-8674(87)90359-X; REYNOLDS WF, 1985, P NATL ACAD SCI USA, V82, P4018, DOI 10.1073/pnas.82.12.4018; ROMANIUK PJ, 1990, J BIOL CHEM, V265, P17593; RUET A, 1984, EMBO J, V3, P343, DOI 10.1002/j.1460-2075.1984.tb01809.x; SAKONJU S, 1982, CELL, V31, P395, DOI 10.1016/0092-8674(82)90133-7; SCHNEIDER HR, 1990, NUCLEIC ACIDS RES, V18, P4743, DOI 10.1093/nar/18.16.4743; SCHNEIDER HR, 1989, NUCLEIC ACIDS RES, V17, P5003, DOI 10.1093/nar/17.13.5003; SCHULTZ P, 1989, EMBO J, V8, P3815, DOI 10.1002/j.1460-2075.1989.tb08559.x; SETZER DR, 1985, J BIOL CHEM, V260, P2483; VRANA KE, 1988, MOL CELL BIOL, V8, P1684, DOI 10.1128/MCB.8.4.1684; WILSON ET, 1985, J MOL BIOL, V183, P153, DOI 10.1016/0022-2836(85)90209-8; WOLFFE AP, 1990, J BIOL CHEM, V265, P4592; WOLFFE AP, 1986, CELL, V47, P217, DOI 10.1016/0092-8674(86)90444-7; WOLFFE AP, 1988, SCIENCE, V241, P1626, DOI 10.1126/science.3420414; WOLFFE AP, 1988, EMBO J, V7, P1071, DOI 10.1002/j.1460-2075.1988.tb02915.x; XING YY, 1989, MOL CELL BIOL, V9, P499, DOI 10.1128/MCB.9.2.499; YOSHINAGA SK, 1987, P NATL ACAD SCI USA, V84, P3585, DOI 10.1073/pnas.84.11.3585; YOSHINAGA SK, 1989, J BIOL CHEM, V264, P10726; YOU QM, 1991, BIOCHEMISTRY-US, V30, P2495, DOI 10.1021/bi00223a028	51	24	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1992	267	25					18190	18198						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JM223	1517247				2022-12-25	WOS:A1992JM22300108
J	SANDSTROM, J; CARLSSON, L; MARKLUND, SL; EDLUND, T				SANDSTROM, J; CARLSSON, L; MARKLUND, SL; EDLUND, T			THE HEPARIN-BINDING DOMAIN OF EXTRACELLULAR SUPEROXIDE DISMUTASE-C AND FORMATION OF VARIANTS WITH REDUCED HEPARIN AFFINITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN CELL-LINES; CARBOXYPEPTIDASE-H; EXPRESSION; PLASMA; ISOENZYMES; SEQUENCE; TISSUES; SYSTEM; DNA	A fundamental property of the secretory tetrameric extracellular superoxide dismutase (EC-SOD) is its affinity for heparin and analogues, in vivo, mediating attachment to heparan sulfate proteoglycans located on cell surfaces and in the connective tissue matrix. EC-SOD is in vivo heterogeneous with regard to heparin affinity and can be divided into subclasses; A which lacks heparin affinity, B with intermediate affinity, and C with strong heparin affinity. The EC-SOD C subunits contain 222 amino acids and among the last 20 carboxyl-terminal amino acids, 10 are positively charged and six of these are located in a cluster in positions 210-215. To analyze if this local accumulation of basic amino acids is responsible for heparin binding we produced three series of recombinant EC-SOD (rEC-SOD) variants, six containing amino acid exchanges in the carboxyl-terminal end, four with truncations, and two with both truncations and substitutions. Exchange of positively or negatively charged amino acids on the carboxyl-terminal side of the cluster results in only minor modifications in heparin affinity, whereas substitution of three of the amino acids in the cluster abrogates the heparin binding. Insertions of stop codons at different positions resulted in either C or A but not B class EC-SOD. In an attempt to produce EC-SODs with intermediate heparin affinities, plasmids defining C and A class EC-SOD were cotransfected into Chinese hamster ovary cells. In addition to the parental A and C class EC-SOD forms, two variants with intermediate heparin affinities were formed. Coincubation of EC-SOD C and A resulted in the appearance of one heterotetramer with intermediate affinity for heparin. We conclude that the cluster of six basic amino acids forms the essential part of the heparin-binding domain and that the composition of the four subunits in the EC-SOD tetramer determines the affinity for heparin. This domain is different from heparin-binding domains of other proteins, and its localization allows the distribution of EC-SOD in vivo to be regulated by proteolytic processing.	UMEA UNIV HOSP, DEPT CLIN CHEM, S-90185 UMEA, SWEDEN	Umea University	SANDSTROM, J (corresponding author), UMEA UNIV, DEPT BIOCHEM, S-90185 UMEA, SWEDEN.							ADACHI T, 1989, J BIOL CHEM, V264, P8537; CARDIN AD, 1989, ARTERIOSCLEROSIS, V9, P21, DOI 10.1161/01.ATV.9.1.21; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRIMWOOD BG, 1989, J BIOL CHEM, V264, P15662; HARR R, 1986, NUCLEIC ACIDS RES, V14, P273, DOI 10.1093/nar/14.1.273; HJALMARSSON K, 1987, P NATL ACAD SCI USA, V84, P6340, DOI 10.1073/pnas.84.18.6340; KARLSSON K, 1988, BIOCHEM J, V255, P223; KARLSSON K, 1988, BIOCHEM J, V256, P29, DOI 10.1042/bj2560029; KARLSSON K, 1987, BIOCHEM J, V242, P55, DOI 10.1042/bj2420055; KARLSSON K, 1988, J CLIN INVEST, V82, P762, DOI 10.1172/JCI113676; KARLSSON K, 1989, LAB INVEST, V60, P659; LEVIN Y, 1982, P NATL ACAD SCI-BIOL, V79, P4618, DOI 10.1073/pnas.79.15.4618; MARKLUND S, 1976, J BIOL CHEM, V251, P7504; MARKLUND SL, 1982, P NATL ACAD SCI-BIOL, V79, P7634, DOI 10.1073/pnas.79.24.7634; MARKLUND SL, 1990, BIOCHEM J, V266, P213, DOI 10.1042/bj2660213; MARKLUND SL, 1984, BIOCHEM J, V222, P649, DOI 10.1042/bj2220649; MARKLUND SL, 1984, J CLIN INVEST, V74, P1398, DOI 10.1172/JCI111550; MARKLUND SL, 1984, BIOCHEM J, V220, P269, DOI 10.1042/bj2200269; MARKLUND SL, 1982, CLIN CHIM ACTA, V126, P41, DOI 10.1016/0009-8981(82)90360-6; MARKLUND SL, 1986, ANN RHEUM DIS, V45, P847, DOI 10.1136/ard.45.10.847; MARKLUND SL, 1985, CRC HDB METHODS OXYG, P249; MARKLUND SL, 1984, OXIDATIVE DAMAGE REL, P411; NAKAMAYE KL, 1986, NUCLEIC ACIDS RES, V14, P9679, DOI 10.1093/nar/14.24.9679; SUBRAMANI S, 1981, MOL CELL BIOL, V1, P854, DOI 10.1128/MCB.1.9.854; TAN FL, 1989, J BIOL CHEM, V264, P13165; TIBELL L, 1987, P NATL ACAD SCI USA, V84, P6634, DOI 10.1073/pnas.84.19.6634; URLAUB G, 1980, P NATL ACAD SCI-BIOL, V77, P4216, DOI 10.1073/pnas.77.7.4216	27	158	167	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 5	1992	267	25					18205	18209						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JM223	1517248				2022-12-25	WOS:A1992JM22300110
J	REDDY, MVR; DESAI, M; JEYAPAUL, J; PRASAD, DDK; SESHAMMA, T; PALMERI, D; KHAN, SA				REDDY, MVR; DESAI, M; JEYAPAUL, J; PRASAD, DDK; SESHAMMA, T; PALMERI, D; KHAN, SA			FUNCTIONAL-ANALYSIS OF THE N-TERMINAL DOMAIN OF TAT PROTEIN OF THE HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1	ONCOGENE			English	Article							ACTIVATION-RESPONSIVE REGION; RNA-BINDING PROTEIN; CELL-FREE SYSTEM; HIV-1 TAT; TRANS-ACTIVATION; MUTATIONAL ANALYSIS; TRANSCRIPTIONAL ACTIVATION; GENE-EXPRESSION; NUCLEAR-PROTEIN; BASIC DOMAIN	The Tat protein of human immunodeficiency virus type 1 (HIV-1) is a potent trans-activator of the viral long terminal repeat (LTR). The N-terminal region of Tat is rich in proline and acidic residues analogous to the activation domains of other transcription factors such as GAL4 and CTF/NF-1. Several basic residues are also present in this region. To investigate the role of these structural features in the Tat-mediated trans-activation, we have chemically synthesized and evaluated Tat analogs with alanine or glutamine replacing one or more of these amino acid residues. Our data show that substitution of Glu-2, His-13, or all the proline in the Pro-Xaa3-Pro triad drastically reduced activity. In contrast, changes at Arg-7, Lys-12 and any one proline residue in the triad moderately reduced, and substitution of Lys-19 showed tittle effect on, activity. These results show that the native structure of the N-terminal 19 amino acid sequence is essential for Tat function. and that the overall topology of this domain and not the acidic residues alone appears necessary for trans-activation.	WISTAR INST,3601 SPRUCE ST,PHILADELPHIA,PA 19104	The Wistar Institute					NIAID NIH HHS [AI27422, AI25380] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI027422, P01AI025380] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BARANY G, 1980, PEPTIDES ANAL SYNTHE, V2, P1; BERKHOUT B, 1990, CELL, V62, P757, DOI 10.1016/0092-8674(90)90120-4; BERKHOUT B, 1989, J VIROL, V63, P5501, DOI 10.1128/JVI.63.12.5501-5504.1989; BRADDOCK M, 1989, CELL, V58, P269, DOI 10.1016/0092-8674(89)90841-6; BRAKE DA, 1990, J VIROL, V64, P962, DOI 10.1128/JVI.64.2.962-965.1990; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P222, DOI 10.1021/bi00699a002; CULLEN BR, 1991, FASEB J, V5, P2361, DOI 10.1096/fasebj.5.10.1712325; CULLEN BR, 1990, CELL, V63, P655, DOI 10.1016/0092-8674(90)90129-3; DINGWALL C, 1989, P NATL ACAD SCI USA, V86, P6925, DOI 10.1073/pnas.86.18.6925; FENG S, 1988, NATURE, V334, P165, DOI 10.1038/334165a0; FRANKEL AD, 1988, SCIENCE, V240, P70, DOI 10.1126/science.2832944; FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2; FRANKEL AD, 1989, P NATL ACAD SCI USA, V86, P7397, DOI 10.1073/pnas.86.19.7397; GARCIA JA, 1989, EMBO J, V8, P765, DOI 10.1002/j.1460-2075.1989.tb03437.x; GARCIA JA, 1988, EMBO J, V7, P3143, DOI 10.1002/j.1460-2075.1988.tb03181.x; GATIGNOL A, 1991, SCIENCE, V251, P1597, DOI 10.1126/science.2011739; GATIGNOL A, 1989, P NATL ACAD SCI USA, V86, P7828, DOI 10.1073/pnas.86.20.7828; GAYNOR R, 1989, P NATL ACAD SCI USA, V86, P4858, DOI 10.1073/pnas.86.13.4858; GREEN M, 1988, CELL, V55, P1179, DOI 10.1016/0092-8674(88)90262-0; HAUBER J, 1988, J VIROL, V62, P673, DOI 10.1128/JVI.62.3.673-679.1988; HAUBER J, 1989, J VIROL, V63, P1181, DOI 10.1128/JVI.63.3.1181-1187.1989; HOPE IA, 1988, NATURE, V333, P635, DOI 10.1038/333635a0; JEYAPAUL J, 1990, P NATL ACAD SCI USA, V87, P7030, DOI 10.1073/pnas.87.18.7030; JEYAPAUL J, 1991, ONCOGENE, V6, P1507; KAO SY, 1987, NATURE, V330, P489, DOI 10.1038/330489a0; KUPPUSWAMY M, 1989, NUCLEIC ACIDS RES, V17, P3551, DOI 10.1093/nar/17.9.3551; LASPIA MF, 1989, CELL, V59, P283, DOI 10.1016/0092-8674(89)90290-0; LATCHMAN DS, 1990, BIOCHEM J, V270, P281, DOI 10.1042/bj2700281; LORET EP, 1991, BIOCHEMISTRY-US, V30, P6013, DOI 10.1021/bi00238a027; MARCINIAK RA, 1990, P NATL ACAD SCI USA, V87, P3624, DOI 10.1073/pnas.87.9.3624; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; MEYERS G, 1989, HUMAN RETROVIRUS AID, P11; OKAMOTO T, 1986, CELL, V47, P29, DOI 10.1016/0092-8674(86)90363-6; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; RAPPAPORT J, 1989, New Biologist, V1, P101; RICE AP, 1990, J VIROL, V64, P1864, DOI 10.1128/JVI.64.4.1864-1868.1990; RICE AP, 1990, J VIROL, V64, P6018, DOI 10.1128/JVI.64.12.6018-6026.1990; ROBSON B, 1986, INTRO PROTEIN PROTEI; ROSEN CA, 1985, CELL, V41, P813, DOI 10.1016/S0092-8674(85)80062-3; ROY S, 1990, GENE DEV, V4, P1365, DOI 10.1101/gad.4.8.1365; RUBEN S, 1989, J VIROL, V63, P1; SELBY MJ, 1990, CELL, V62, P769, DOI 10.1016/0092-8674(90)90121-T; SUBRAMANIAN T, 1991, EMBO J, V10, P2311, DOI 10.1002/j.1460-2075.1991.tb07768.x; TILEY LS, 1990, VIROLOGY, V178, P560, DOI 10.1016/0042-6822(90)90354-T; TRIEZENBERG SJ, 1988, GENE DEV, V2, P718, DOI 10.1101/gad.2.6.718; VARMUS H, 1988, GENE DEV, V2, P1055, DOI 10.1101/gad.2.9.1055	46	12	12	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1992	7	9					1743	1748						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JJ376	1501886				2022-12-25	WOS:A1992JJ37600010
J	KAYSER, H; ZEITLER, R; KANNICHT, C; GRUNOW, D; NUCK, R; REUTTER, W				KAYSER, H; ZEITLER, R; KANNICHT, C; GRUNOW, D; NUCK, R; REUTTER, W			BIOSYNTHESIS OF A NONPHYSIOLOGICAL SIALIC-ACID IN DIFFERENT RAT ORGANS, USING N-PROPANOYL-D-HEXOSAMINES AS PRECURSORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OLIGOSACCHARIDE CHAINS; ACETYLNEURAMINIC ACID; INHIBITION; PROTEIN	In this study it could be shown that in rat the normally occurring N-acetyl neuraminic acid can be modified in its N-acyl moiety by in vivo administration of the chemically synthesized N-propanoyl precursors, N-propanoyl-D-glucosamine or N-propanoyl-D-mannosamine. It could be shown that each of these nonphysiological amino sugar analogues was incorporated into both membrane and serum glycoproteins. After treatment of rats with radiolabeled N-[acyl-1-C-14]D-mannosamine, radioactivity could be removed from serum glycoprotein fractions by incubation with neuraminidase from Clostridium perfringens or from Arthrobacter ureafaciens. Mild acid hydrolysis removed 98% of the radioactivity after in vivo labeling with N-[acetyl-1-C-14]D-mannosamine and 86% after labeling with N-[propanoyl-1-C-14]D-Mannosamine. Chromatographic analysis yielded two compounds, i.e. N-acetyl neuraminic acid and N-propanoyl neuraminic acid, the latter being identified by gas liquid chromatography/mass spectrometry studies. Measurement of protein-bound radioactivity in different rat organs revealed a different organotropy of the natural and the nonphysiological neuraminic acid precursor. Of the glucosamine derivatives, N-acetyl-D-glucosamine showed the higher rate of uptake and incorporation in most organs (except in the submandibulary gland), and especially in kidney cortex and Morris hepatoma 7777. Natural and the unphysiological mannosamine derivatives were incorporated at similar rates, except in liver, where N-acetyl-D-mannosamine was taken up and metabolized more effectively. This finding indicates that it is possible to modify the acyl group of N-acetyl neuraminic acid in vivo by the introduction of an N-propanoyl group and possibly other homologous N-acyl groups. This procedure may provide a tool for a further characterization of the biological function of sialic acids.	FREE UNIV BERLIN,INST MOLEK BIOL & BIOCHEM,ARNIMALLEE 22,W-1000 BERLIN 33,GERMANY	Free University of Berlin								BAUER CH, 1974, BIOCHEM J, V142, P221, DOI 10.1042/bj1420221; ELBEIN AD, 1987, ANNU REV BIOCHEM, V56, P497, DOI 10.1146/annurev.biochem.56.1.497; GROSS HJ, 1988, EUR J BIOCHEM, V177, P583, DOI 10.1111/j.1432-1033.1988.tb14410.x; GRUNHOLZ HJ, 1981, CARBOHYD RES, V96, P259, DOI 10.1016/S0008-6215(00)81876-5; HARMS E, 1973, EUR J BIOCHEM, V32, P254, DOI 10.1111/j.1432-1033.1973.tb02605.x; Jeanloz R.W., 1976, BIOLOGICAL ROLES SIA, P201, DOI [10.1007/978-1-4684-2226-9_7, DOI 10.1007/978-1-4684-2226-9_7]; KAMERLING JP, 1982, CELL BIOL MONOGR, V10, P95; KAYSER H, 1992, FEBS LETT, V301, P137, DOI 10.1016/0014-5793(92)81233-C; LEWIN LM, 1966, ANAL BIOCHEM, V16, P29, DOI 10.1016/0003-2697(66)90077-7; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MANS RJ, 1960, BIOCHEM BIOPH RES CO, V3, P540, DOI 10.1016/0006-291X(60)90171-6; MANZI AE, 1990, ANAL BIOCHEM, V188, P20, DOI 10.1016/0003-2697(90)90523-C; MEINDL P, 1966, MONATSH CHEM VERW TL, V97, P1628, DOI 10.1007/BF00901442; REUTER G, 1986, ANAL BIOCHEM, V157, P39, DOI 10.1016/0003-2697(86)90193-4; SCHAUER R, 1987, METHOD ENZYMOL, V138, P149; SHETLAR MR, 1964, BIOCHIM BIOPHYS ACTA, V83, P93, DOI 10.1016/0926-6526(64)90055-2; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SVENNERHOLM E, 1958, NATURE, V181, P1154, DOI 10.1038/1811154a0; SWEELEY CC, 1963, J AM CHEM SOC, V85, P2497, DOI 10.1021/ja00899a032; VARKI A, 1984, ANAL BIOCHEM, V137, P236, DOI 10.1016/0003-2697(84)90377-4; WEIS W, 1988, NATURE, V333, P426, DOI 10.1038/333426a0; ZEITLER R, 1992, EUR J BIOCHEM, V204, P1165, DOI 10.1111/j.1432-1033.1992.tb16743.x	22	245	267	0	36	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1992	267	24					16934	16938						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JL053	1512235				2022-12-25	WOS:A1992JL05300034
J	YANG, R; KENEALY, WR				YANG, R; KENEALY, WR			EFFECTS OF AMINO-TERMINAL EXTENSIONS AND SPECIFIC MUTATIONS ON THE ACTIVITY OF RESTRICTOCIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-SARCIN; EUKARYOTIC RIBOSOMES; TOXIN RESTRICTOCIN; PROTEIN; SEQUENCE; CLEAVAGE; ACID; MITOGILLIN; EXPRESSION; YEAST	The cytotoxic activities of restrictocin with amino-terminal extensions and specific mutations were investigated using in vivo and in vitro systems. Genes were constructed from the cDNA clone of restrictocin which encode: the native form of restrictocin (including the leader sequence); Met-prorestrictocin, in which a codon for methionine was placed before a putative pro region; Met-mature restrictocin, with a methionine codon prior to the mature form of restrictocin; and three mutated forms of Met-mature restrictocin, E95G, E115G/H136L, and H136L. These constructions were placed under the control of the GAL1 promoter and were transformed into Saccharomyces cerevisiae. Transformants were killed, and a new RNA band formed when any of these genes except those containing the H136L mutation were expressed. Restrictocin protein was detected by immunoblot only in cells expressing the native form of restrictocin and the forms containing the H136L mutation. Native restrictocin, Met-prorestrictocin, and Met-mature restrictocin mRNA were translated in an in vitro system resulting in proteins of the expected molecular weight and inactivation of the translation system. Restrictocin was not inactivated by the presence of the leader sequence and the putative prosequence. Amino acid His136 is putatively in the active site of restrictocin by analogy to ribonuclease U2 and the elimination of toxic effects in the S. cerevisiae expression and in vitro translation systems.	UNIV WISCONSIN, COLL AGR & LIFE SCI, DEPT BIOCHEM, 420 HENRY MALL, MADISON, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison								AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; BARNES G, 1985, P NATL ACAD SCI USA, V82, P1354, DOI 10.1073/pnas.82.5.1354; BECKER DM, 1991, METHOD ENZYMOL, V194, P182; BRANDSHORST TT, 1992, J GEN MICROBIOL, V138, P1429, DOI 10.1099/00221287-138-7-1429; CONDE FP, 1978, FEMS MICROBIOL LETT, V4, P349, DOI 10.1111/j.1574-6968.1978.tb02896.x; DELPOZO AM, 1988, BIOCHIM BIOPHYS ACTA, V953, P280, DOI 10.1016/0167-4838(88)90036-2; ENDO Y, 1982, J BIOL CHEM, V257, P9054; FANDO JL, 1985, EUR J BIOCHEM, V149, P29, DOI 10.1111/j.1432-1033.1985.tb08888.x; HEINEMANN U, 1982, NATURE, V299, P27, DOI 10.1038/299027a0; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; Innis MA, 1990, PCR PROTOCOLS GUIDE, P3; JAKES KS, 1974, P NATL ACAD SCI USA, V71, P3380, DOI 10.1073/pnas.71.9.3380; LAMY B, 1991, NUCLEIC ACIDS RES, V19, P1001, DOI 10.1093/nar/19.5.1001; LOPEZOTIN C, 1984, EUR J BIOCHEM, V143, P621, DOI 10.1111/j.1432-1033.1984.tb08415.x; MILLER SP, 1988, FEBS LETT, V229, P388, DOI 10.1016/0014-5793(88)81162-1; Olson B.H., 1963, Restkictocin, Patent No. [US3104208 (A), 3104208]; OLSON BH, 1965, APPL MICROBIOL, V13, P322, DOI 10.1128/AEM.13.3.322-326.1965; SATO S, 1975, BIOCHEM J, V145, P353, DOI 10.1042/bj1450353; SCHINDLER DG, 1977, NUCLEIC ACIDS RES, V4, P1097, DOI 10.1093/nar/4.4.1097; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; WOOL IG, 1984, TRENDS BIOCHEM SCI, V9, P14, DOI 10.1016/0968-0004(84)90040-9; YANG R, 1992, J GEN MICROBIOL, V138, P1421, DOI 10.1099/00221287-138-7-1421	22	32	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	1992	267	24					16801	16805						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JL053	1512222				2022-12-25	WOS:A1992JL05300013
J	BZDEGA, T; KOSKKOSICKA, D				BZDEGA, T; KOSKKOSICKA, D			REGULATION OF THE ERYTHROCYTE CA2+-ATPASE BY MUTANT CALMODULINS WITH GLU-]ALA SUBSTITUTIONS IN THE CA2+-BINDING DOMAINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-SPECIFIC MUTAGENESIS; LIGHT CHAIN KINASE; CENTRAL HELIX; TARGET ENZYMES; ACTIVATION; CA-2+-ATPASE; CALCIUM; OLIGOMERIZATION; BINDING; FLUORESCENCE	We have used four mutant calmodulins to study the regulation of human erythrocyte Ca2+-ATPase by the calmodulin-dependent pathway; the conserved Glu at position 12 in each of the four Ca2+-binding domains of calmodulin (Glu31, Glu67, Glu104, or Glu140) was replaced by Ala. At pCa 7, where unmodified calmodulin maximally activates the erythrocyte Ca2-ATPase, all four mutants stimulated Ca2+-ATPase activity to the same maximal velocity. However, the concentrations of mutant calmodulins required for half-maximal activation (K(CaM)) were significantly higher than that for unmodified calmodulin and were strongly dependent on the domain in which the mutated Glu was located; substitution in either the first or second Ca2+-binding domain had little effect (2-3-fold increase in K(CaM)), whereas substitution in either the third or fourth domain resulted in a dramatic, 25-71-fold increase in K(CaM). The same order of sensitivity was observed when the Ca2+ dependence of enzyme activation was measured at a constant 100 nM concentration of mutant calmodulin. These data point to dramatic differences in the functional significance of the replacement of the Glu at position 12 in each of the four Ca2+-binding domains for activation of the Ca2+-ATPase. The 2 Glu residues located in the carboxyl-terminal half of calmodulin (particularly Glu140) are crucial for activation of the Ca2+-ATPase at physiologically significant Ca2+ concentrations.	UNIV MARYLAND,SCH MED,DEPT BIOL CHEM,BALTIMORE,MD 21201	University System of Maryland; University of Maryland Baltimore					NIGMS NIH HHS [GM 37143] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037143] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOGUTA G, 1988, BIOPHYS CHEM, V31, P133, DOI 10.1016/0301-4622(88)80017-6; COX JA, 1982, P NATL ACAD SCI-BIOL, V79, P4265, DOI 10.1073/pnas.79.14.4265; CRAIG TA, 1987, J BIOL CHEM, V262, P3278; GUERINI D, 1984, J BIOL CHEM, V259, P5172; HAIECH J, 1991, J BIOL CHEM, V266, P3427; HAIECH J, 1990, ADV EXP MED BIOL, V269, P43; HURWITZ MY, 1988, FEBS LETT, V238, P82, DOI 10.1016/0014-5793(88)80230-8; JAMES PH, 1989, BIOCHEMISTRY-US, V28, P4253, DOI 10.1021/bi00436a020; KLEE CB, 1988, CALMODULIN, P123; KOSKKOSICKA D, 1990, ADV EXP MED BIOL, V269, P169; KOSKKOSICKA D, 1991, BIOCHEMISTRY-US, V30, P65, DOI 10.1021/bi00215a010; KOSKKOSICKA D, 1988, J BIOL CHEM, V263, P18184; KOSKKOSICKA D, 1989, J BIOL CHEM, V264, P19495; KOSKKOSICKA D, 1990, BIOCHEMISTRY-US, V29, P3772, DOI 10.1021/bi00467a025; KOSKKOSICKA D, 1990, BIOCHEMISTRY-US, V29, P1875, DOI 10.1021/bi00459a030; KOSKKOSICKA D, 1990, J CELL BIOCH SE, V14, P18; KOSKKOSICKA D, 1991, J BIOPHYS, V59, pA514; KOSKOSICKA D, 1986, J BIOL CHEM, V261, P3333; KREBS J, 1990, ADV EXP MED BIOL, V269, P163; MARSHAK DR, 1984, BIOCHEMISTRY-US, V23, P2891, DOI 10.1021/bi00308a007; MISSIAEN L, 1989, J BIOCHEM-TOKYO, V263, P361; PERSECHINI A, 1989, J BIOL CHEM, V264, P8052; PERSECHINI A, 1988, J BIOL CHEM, V263, P12175; PUTKEY JA, 1988, J BIOL CHEM, V263, P11242; PUTKEY JA, 1986, J BIOL CHEM, V261, P9896; ROBERTS DM, 1985, BIOCHEMISTRY-US, V24, P5090, DOI 10.1021/bi00340a020; ROBERTS DM, 1984, PLANT PHYSIOL, V75, P796, DOI 10.1104/pp.75.3.796; SCHATZMANN HJ, 1982, MEMBRANE TRANSPORT C, P41; STRYNADKA NCJ, 1989, ANNU REV BIOCHEM, V58, P951, DOI 10.1146/annurev.bi.58.070189.004511; SZYJA W, 1986, CELL CALCIUM, V7, P73, DOI 10.1016/0143-4160(86)90010-2; VANBERKUM MFA, 1990, J BIOL CHEM, V265, P3750; WANG KKW, 1989, J MEMBRANE BIOL, V112, P233, DOI 10.1007/BF01870954; WEBER PC, 1989, PROTEINS, V6, P70, DOI 10.1002/prot.340060107	33	16	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1992	267	7					4394	4397						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HF642	1531652				2022-12-25	WOS:A1992HF64200023
J	BEIMLING, P; MOELLING, K				BEIMLING, P; MOELLING, K			DIRECT INTERACTION OF CREB PROTEIN WITH 21 BP TAX-RESPONSE ELEMENTS OF HTLV-I LTR	ONCOGENE			English	Note							T-CELL LEUKEMIA; VIRUS TYPE-I; LONG TERMINAL REPEAT; TRANS-ACTIVATOR PROTEIN; DNA-BINDING PROTEINS; NUCLEAR FACTOR CREB; GENE-EXPRESSION; CYCLIC-AMP; TRANSCRIPTIONAL ACTIVATION; KINASE-A	The three 21-bp repeats (Tax-responsive elements) of the long terminal repeat (LTR) of the human T-cell leukemia virus (HTLV-I) mediates the response of the Tax protein. Ail three Tax-responsive elements (TREs) contain a TGACG motif, reminiscent of the CREB/ATF-binding site TGACGTCA. DNA-affinity chromatography with the 5'-TRE resulted in a previous study in proteins of about 32, 36 to 42, 50 and 110 kDa. Here we demonstrate that the 42 kDa protein is the cAMP-response element-binding (CREB) protein. This is shown by phosphorylation of the proteins eluted from the DNA-affinity column with protein kinase A (PKA) in vitro and subsequent indirect immunoprecipitation with a CREB-specific antiserum raised against an internal CREB-specific peptide. This method allows detection of phosphorylated proteins by autoradiography with high sensitivity and is superior to metabolic labeling. One of the phosphorylated proteins co-migrates with immuno-affinity-purified CREB protein-also phosphorylated in vitro-and competes with the peptide antigen, which proves the specificity of the reaction. The purified CREB protein leads to specific DNA-protein complexes in DNA mobility-shift analyses with all three TREs. Comparison of these TRE-CREB complexes with those formed by nuclear extracts from the HTLV-I-transformed T-cell line C81-66-45 indicates that additional cellular factors contribute to the complexes, especially to the middle TRE. This is also shown by using CREB-depleted instead of complete nuclear extracts for DNA mobility-shift assays. Antibodies against CREB but not Tax affect the mobility of the DNA-protein complex.	MAX PLANCK INST MOLEC GENET,SCHUSTER ABT,IHNESTR 73,W-1000 BERLIN 33,GERMANY	Max Planck Society								ALTMAN R, 1988, J VIROL, V62, P1339, DOI 10.1128/JVI.62.4.1339-1346.1988; BEIMLING P, 1990, ONCOGENE, V5, P361; BEIMLING P, 1989, ONCOGENE, V4, P511; BOHNLEIN E, 1988, CELL, V53, P827, DOI 10.1016/0092-8674(88)90099-2; BOHNLEIN E, 1989, J VIROL, V63, P1578; BOSSELUT R, 1990, EMBO J, V9, P3137, DOI 10.1002/j.1460-2075.1990.tb07511.x; BRADY J, 1987, J VIROL, V61, P2175, DOI 10.1128/JVI.61.7.2175-2181.1987; CHEN ISY, 1985, SCIENCE, V229, P54, DOI 10.1126/science.2990037; CROSS SL, 1987, CELL, V49, P47, DOI 10.1016/0092-8674(87)90754-9; FELBER BK, 1985, SCIENCE, V229, P675, DOI 10.1126/science.2992082; FUJII M, 1988, P NATL ACAD SCI USA, V85, P8526, DOI 10.1073/pnas.85.22.8526; FUJISAWA J, 1989, J VIROL, V63, P3234, DOI 10.1128/JVI.63.8.3234-3239.1989; FUJISAWA J, 1985, P NATL ACAD SCI USA, V82, P2277, DOI 10.1073/pnas.82.8.2277; FUJISAWA J, 1986, EMBO J, V5, P713, DOI 10.1002/j.1460-2075.1986.tb04272.x; GIAM CZ, 1989, J BIOL CHEM, V264, P15236; GONZALEZ GA, 1989, NATURE, V337, P749, DOI 10.1038/337749a0; HAI T, 1988, GENE DEV, V2, P1216, DOI 10.1101/gad.2.10.1216; HINRICHS SH, 1987, SCIENCE, V237, P1340, DOI 10.1126/science.2888191; HOYOS B, 1989, SCIENCE, V244, P457, DOI 10.1126/science.2497518; INOUE J, 1986, EMBO J, V5, P2883, DOI 10.1002/j.1460-2075.1986.tb04583.x; JEANG KT, 1988, J VIROL, V62, P4499, DOI 10.1128/JVI.62.12.4499-4509.1988; JEANG KT, 1990, SCIENCE, V247, P1082, DOI 10.1126/science.2309119; KADISON P, 1990, J VIROL, V64, P2141, DOI 10.1128/JVI.64.5.2141-2148.1990; LUSCHER B, 1990, NATURE, V344, P517, DOI 10.1038/344517a0; MARRIOTT SJ, 1989, MOL CELL BIOL, V9, P4152, DOI 10.1128/MCB.9.10.4152; MARRIOTT SJ, 1990, MOL CELL BIOL, V10, P4192, DOI 10.1128/MCB.10.8.4192; MARUYAMA M, 1987, CELL, V48, P343, DOI 10.1016/0092-8674(87)90437-5; MONTAGNE J, 1990, EMBO J, V9, P957, DOI 10.1002/j.1460-2075.1990.tb08194.x; MONTMINY MR, 1987, NATURE, V328, P175, DOI 10.1038/328175a0; NYBORG JK, 1990, J BIOL CHEM, V265, P8230; NYBORG JK, 1988, P NATL ACAD SCI USA, V85, P1457, DOI 10.1073/pnas.85.5.1457; PASKALIS H, 1986, P NATL ACAD SCI USA, V83, P6558, DOI 10.1073/pnas.83.17.6558; POIESZ BJ, 1981, NATURE, V294, P268, DOI 10.1038/294268a0; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; POTEAT HT, 1989, J VIROL, V63, P1604, DOI 10.1128/JVI.63.4.1604-1611.1989; POTEAT HT, 1990, J VIROL, V64, P1264, DOI 10.1128/JVI.64.3.1264-1270.1990; ROSEN CA, 1987, P NATL ACAD SCI USA, V84, P4919, DOI 10.1073/pnas.84.14.4919; SALAHUDDIN SZ, 1983, VIROLOGY, V129, P51, DOI 10.1016/0042-6822(83)90395-1; SHIMOTOHNO K, 1986, P NATL ACAD SCI USA, V83, P8112, DOI 10.1073/pnas.83.21.8112; SIEKEVITZ M, 1987, SCIENCE, V238, P1575, DOI 10.1126/science.2825351; SIEKEVITZ M, 1987, P NATL ACAD SCI USA, V84, P5389, DOI 10.1073/pnas.84.15.5389; SMITH MR, 1990, GENE DEV, V4, P1875, DOI 10.1101/gad.4.11.1875; SODROSKI JG, 1984, SCIENCE, V225, P381, DOI 10.1126/science.6330891; TAN TH, 1989, MOL CELL BIOL, V9, P1733, DOI 10.1128/MCB.9.4.1733; TAN TH, 1989, J VIROL, V63, P3761, DOI 10.1128/JVI.63.9.3761-3768.1989; WANO Y, 1988, P NATL ACAD SCI USA, V85, P9733, DOI 10.1073/pnas.85.24.9733; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; YAMAMOTO KK, 1988, NATURE, V334, P494, DOI 10.1038/334494a0; YOSHIDA M, 1982, P NATL ACAD SCI-BIOL, V79, P2031, DOI 10.1073/pnas.79.6.2031; YOSHIMURA T, 1990, EMBO J, V9, P2537, DOI 10.1002/j.1460-2075.1990.tb07434.x	50	67	69	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1992	7	2					257	262						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HG982	1532242				2022-12-25	WOS:A1992HG98200008
J	CLAYTON, LK; DIENER, AC; LERNER, A; TSE, AGD; KOYASU, S; REINHERZ, EL				CLAYTON, LK; DIENER, AC; LERNER, A; TSE, AGD; KOYASU, S; REINHERZ, EL			DIFFERENTIAL REGULATION OF T-CELL RECEPTOR PROCESSING AND SURFACE EXPRESSION AFFECTED BY CD3-THETA, AN ALTERNATIVELY SPLICED PRODUCT OF THE CD3-ZETA/ETA GENE LOCUS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DISULFIDE-LINKED DIMERS; ZETA-CHAIN GENE; ANTIGEN RECEPTOR; MOLECULAR-CLONING; CD3-EPSILON SUBUNITS; GAMMA SUBUNIT; LYMPHOCYTES-T; FC-RECEPTORS; CD3 COMPLEX; ETA-CHAIN	The T-cell receptor (TCR) is a multisubunit complex consisting of the clonotypic Tialpha and beta (or Tigamma and delta) subunits and the invariant CD3gamma, CD3delta, CD3epsilon, CD3zeta, and CD3eta subunits. Herein, we describe an additional product from the CD3zeta/eta gene locus which we have termed CD3theta. The cDNA derives from the first seven exons common to CD3zeta and CD3eta, 94 base pairs (bp) of the CD3eta-specific exon 9 and an additional exon 10 encoding the carboxyl-terminal 15 amino acids and the 3'-untranslated region. The expression of CD3theta is equivalent to that of CD3eta in tissue distribution and level of expression as judged by RNase protection analysis. Despite the identity of the amino-terminal 121 amino acids of CD3zeta, CD3eta, and CD3theta and an additional 31 amino acids shared between CD3eta and CD3theta, transfection of CD3theta into the CD3zeta-eta- T-cell hybridoma, MA5.8, failed to restore detectable surface TCR expression in contrast to transfection with CD3zeta or CD3eta. Analysis of the CD3theta protein in transfectants indicated that CD3theta is associated with the TCR intracellularly. However, unlike with CD3zeta Tialpha-beta chains remain endoglycosidase H sensitive, suggesting a role for the unique COOH-terminal segment of CD3theta in mediating TCR retention and/or degradation in a pre-Golgi compartment.	HARVARD UNIV, SCH MED, IMMUNOBIOL LAB, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT MED, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT PATHOL, BOSTON, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	CLAYTON, LK (corresponding author), HARVARD UNIV, SCH MED, DANA FARBER CANC INST, IMMUNOBIOL LAB, 44 BINNEY ST, BOSTON, MA 02115 USA.		Koyasu, Shigeo/J-5583-2015	Koyasu, Shigeo/0000-0001-9585-3038	NIAID NIH HHS [AI31269, AI19807] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI019807, R37AI019807, R01AI031269, R56AI019807] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BANIYASH M, 1989, J BIOL CHEM, V264, P13252; BANIYASH M, 1988, J BIOL CHEM, V263, P9874; BAUER A, 1991, P NATL ACAD SCI USA, V88, P3842, DOI 10.1073/pnas.88.9.3842; BLUMBERG RS, 1990, P NATL ACAD SCI USA, V87, P7220, DOI 10.1073/pnas.87.18.7220; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; BRENNER MB, 1988, ADV IMMUNOL, V43, P133; CLAYTON LK, 1990, J EXP MED, V172, P1243, DOI 10.1084/jem.172.4.1243; CLAYTON LK, 1991, P NATL ACAD SCI USA, V88, P5202, DOI 10.1073/pnas.88.12.5202; CLEVERS H, 1988, ANNU REV IMMUNOL, V6, P629, DOI 10.1146/annurev.iy.06.040188.003213; DAVIS MM, 1988, NATURE, V334, P395, DOI 10.1038/334395a0; DELAHERA A, 1991, J EXP MED, V173, P7, DOI 10.1084/jem.173.1.7; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FRANK SJ, 1990, SCIENCE, V249, P174, DOI 10.1126/science.2371564; FRIDMAN WH, 1992, IMMUNOL REV, V125, P49, DOI 10.1111/j.1600-065X.1992.tb00625.x; HIGGS DR, 1983, NATURE, V306, P398, DOI 10.1038/306398a0; IRVING BA, 1991, CELL, V64, P891, DOI 10.1016/0092-8674(91)90314-O; JENSEN JP, 1992, J IMMUNOL, V148, P2563; JIN YJ, 1990, J BIOL CHEM, V265, P15850; JIN YJ, 1990, P NATL ACAD SCI USA, V87, P3319, DOI 10.1073/pnas.87.9.3319; KAPPES DJ, 1991, P NATL ACAD SCI USA, V88, P10169; KLAUSNER RD, 1990, ANNU REV CELL BIOL, V6, P403, DOI 10.1146/annurev.cb.06.110190.002155; KONING F, 1990, EUR J IMMUNOL, V20, P299, DOI 10.1002/eji.1830200211; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KOYASU S, 1992, J EXP MED, V175, P203, DOI 10.1084/jem.175.1.203; KUSTER H, 1990, J BIOL CHEM, V265, P6448; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEO O, 1987, P NATL ACAD SCI USA, V84, P1374, DOI 10.1073/pnas.84.5.1374; LERNER A, 1992, EUR J IMMUNOL, V22, P2135, DOI 10.1002/eji.1830220826; LETOURNEUR F, 1992, SCIENCE, V255, P79, DOI 10.1126/science.1532456; LETOURNEUR F, 1991, P NATL ACAD SCI USA, V88, P8905, DOI 10.1073/pnas.88.20.8905; Maniatis T., 1982, MOL CLONING; MANOLIOS N, 1991, EMBO J, V10, P1643, DOI 10.1002/j.1460-2075.1991.tb07687.x; Marrack P, 1986, Adv Immunol, V38, P1, DOI 10.1016/S0065-2776(08)60005-X; MEUER SC, 1984, ANNU REV IMMUNOL, V2, P23, DOI 10.1146/annurev.immunol.2.1.23; MINAMI Y, 1987, P NATL ACAD SCI USA, V84, P2688, DOI 10.1073/pnas.84.9.2688; MOINGEON P, 1990, EUR J IMMUNOL, V20, P1741, DOI 10.1002/eji.1830200818; OHASHI PS, 1985, NATURE, V316, P606, DOI 10.1038/316606a0; OHNO H, 1990, INT IMMUNOL, V2, P1117, DOI 10.1093/intimm/2.11.1117; ORLOFF DG, 1990, NATURE, V347, P189, DOI 10.1038/347189a0; PEZZELLA F, 1990, AM J PATHOL, V137, P225; RACKWITZ HR, 1984, GENE, V30, P195, DOI 10.1016/0378-1119(84)90120-3; RAULET DH, 1989, ANNU REV IMMUNOL, V7, P175, DOI 10.1146/annurev.iy.07.040189.001135; RAVETCH JV, 1991, ANNU REV IMMUNOL, V9, P457, DOI 10.1146/annurev.iy.09.040191.002325; RODEWALD HR, 1991, J BIOL CHEM, V266, P15974; ROMEO C, 1992, CELL, V68, P889, DOI 10.1016/0092-8674(92)90032-8; ROMEO C, 1991, CELL, V64, P1037, DOI 10.1016/0092-8674(91)90327-U; SAMELSON LE, 1983, P NATL ACAD SCI-BIOL, V80, P6972, DOI 10.1073/pnas.80.22.6972; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SUSSMAN JJ, 1988, CELL, V52, P85, DOI 10.1016/0092-8674(88)90533-8; TARENTINO AL, 1974, J BIOL CHEM, V249, P811; VIVIER E, 1991, J IMMUNOL, V147, P4263; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WEISSMAN AM, 1988, SCIENCE, V239, P1018, DOI 10.1126/science.3278377; WEISSMAN AM, 1988, P NATL ACAD SCI USA, V85, P9709, DOI 10.1073/pnas.85.24.9709; WEISSMAN AM, 1989, EMBO J, V8, P3651, DOI 10.1002/j.1460-2075.1989.tb08539.x	55	19	19	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 25	1992	267	36					26023	26030						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KD073	1464613				2022-12-25	WOS:A1992KD07300066
J	VOGEL, SS; CHERNOMORDIK, LV; ZIMMERBERG, J				VOGEL, SS; CHERNOMORDIK, LV; ZIMMERBERG, J			CALCIUM-TRIGGERED FUSION OF EXOCYTOTIC GRANULES REQUIRES PROTEINS IN ONLY ONE MEMBRANE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							SEA-URCHIN EGGS; PH-DEPENDENT FUSION; PLASMA-MEMBRANE; INFLUENZA-VIRUS; RECONSTITUTION; MECHANISMS; LIPOSOMES; RELEASE; CELL	We studied calcium-triggered fusion of sea urchin egg secretory granules to test whether membrane bound fusion proteins are required in both fusing membranes. Using both light scattering assays and video microscopy, we found that native granules fused to granules that had been inactivated with either trypsin or N-ethylmaleimide. Granules also fused with liposomes prepared from lipids extracted from egg cortices and with liposomes made from synthetic phospholipids and cholesterol. Granule-liposome fusion required no cytoplasmic proteins and was inhibited by N-ethylmaleimide. Thus, membrane fusion of exocytotic granules can be promoted by proteins residing on only one of the two membranes.			VOGEL, SS (corresponding author), NICHHD, THEORET & PHYS BIOL LAB, BLDG 10, RM 6C-101, BETHESDA, MD 20892 USA.		Vogel, Steven/A-3585-2012	Vogel, Steven/0000-0002-3005-2667				ALMERS W, 1990, NEURON, V4, P813, DOI 10.1016/0896-6273(90)90134-2; BIRMAN S, 1990, FEBS LETT, V261, P303, DOI 10.1016/0014-5793(90)80577-6; BLOBEL CP, 1992, NATURE, V356, P248, DOI 10.1038/356248a0; BRECKENRIDGE LJ, 1987, P NATL ACAD SCI USA, V84, P1945, DOI 10.1073/pnas.84.7.1945; CRABB JH, 1985, J CELL BIOL, V101, P2263, DOI 10.1083/jcb.101.6.2263; CREUTZ CE, 1981, J CELL BIOL, V91, P247, DOI 10.1083/jcb.91.1.247; DELCOUR AH, 1989, BIOPHYS J, V56, P631, DOI 10.1016/S0006-3495(89)82710-9; Duzgunes N, 1985, Subcell Biochem, V11, P195; GILLOT I, 1991, DEV BIOL, V146, P396, DOI 10.1016/0012-1606(91)90241-T; GOLLINS SW, 1986, J GEN VIROL, V67, P157, DOI 10.1099/0022-1317-67-1-157; HAGGERTY JG, 1983, J BIOL CHEM, V258, P1819; HIGGINS JA, 1987, BIOL MEMBRANES PRACT, P103; HOEKSTRA D, 1989, BIOSCIENCE REP, V9, P273, DOI 10.1007/BF01114682; JACKSON RC, 1985, J CELL BIOL, V101, P6, DOI 10.1083/jcb.101.1.6; KINSEY WH, 1980, J CELL BIOL, V87, P248, DOI 10.1083/jcb.87.1.248; MAEDA T, 1981, P NATL ACAD SCI-BIOL, V78, P4133, DOI 10.1073/pnas.78.7.4133; NOVICK SL, 1988, P NATL ACAD SCI USA, V85, P7433, DOI 10.1073/pnas.85.20.7433; PAPAHADJOPOULOS D, 1990, J BIOENERG BIOMEMBR, V22, P157, DOI 10.1007/BF00762944; ROTHMAN JE, 1992, NATURE, V355, P409, DOI 10.1038/355409a0; THOMAS L, 1988, SCIENCE, V242, P1050, DOI 10.1126/science.2461586; VOGEL SS, 1992, P NATL ACAD SCI USA, V89, P4749, DOI 10.1073/pnas.89.10.4749; VOGEL SS, 1991, ANN NY ACAD SCI, V635, P35, DOI 10.1111/j.1749-6632.1991.tb36479.x; WHALLEY T, 1988, BIOSCIENCE REP, V8, P335, DOI 10.1007/BF01115224; WHITAKER MJ, 1983, PROC R SOC SER B-BIO, V218, P397, DOI 10.1098/rspb.1983.0047; WHITE J, 1983, Q REV BIOPHYS, V16, P151, DOI 10.1017/S0033583500005072; WHITE J, 1980, P NATL ACAD SCI-BIOL, V77, P3273, DOI 10.1073/pnas.77.6.3273; WHITE J, 1982, EMBO J, V1, P217, DOI 10.1002/j.1460-2075.1982.tb01150.x; ZAKS WJ, 1988, MOL MECHANISMS MEMBR, P325; ZIMMERBERG J, 1991, ANN NY ACAD SCI, V635, P307, DOI 10.1111/j.1749-6632.1991.tb36501.x; ZIMMERBERG J, 1988, MOL MECHANISMS MEMBR, P181	30	51	51	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 25	1992	267	36					25640	25643						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KD073	1464584				2022-12-25	WOS:A1992KD07300006
J	WEST, M; MIKOVITS, J; PRINCLER, G; LIU, YL; RUSCETTI, FW; KUNG, HF; RAZIUDDIN				WEST, M; MIKOVITS, J; PRINCLER, G; LIU, YL; RUSCETTI, FW; KUNG, HF; RAZIUDDIN			CHARACTERIZATION AND PURIFICATION OF A NOVEL TRANSCRIPTIONAL REPRESSOR FROM HELA-CELL NUCLEAR EXTRACTS RECOGNIZING THE NEGATIVE REGULATORY ELEMENT REGION OF HUMAN IMMUNODEFICIENCY VIRUS-1 LONG TERMINAL REPEAT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING PROTEIN; RNA POLYMERASE-II; HTLV-III; GENE-EXPRESSION; TRANS-ACTIVATOR; PROMOTER-REGION; REPLICATION; SEQUENCES; ANTIGENS; COMPLEX	Cellular transcription factors play critical roles in regulating human immunodeficiency virus (HIV) gene transcription, although the precise mechanism(s) defining their roles are not well established. Primarily it has been suggested that sequence-specific interaction of trans-activating proteins with cis-acting DNA elements plays a crucial role in regulating the target genes. The negative regulatory element (NRE) of HIV-1 long terminal repeat (LTR) is one such defined region that has been reported to down-regulate LTR-directed HIV gene expression. Information regarding the role of this region in the regulation of HIV expression is lacking. Here we describe an attempt to further characterize the role of NRE cis-elements and define any sequence-specific interaction with cellular factors. Using gel mobility shift DNA-binding and Southwestern blot assays, we have mapped a distinct region of NRE (-290 to -260, a 30-base pair (bp) domain of NRE-A) sequences of HIV-1 LTR, which recognizes a specific DNA-binding protein from HeLa cell nuclear extracts. This factor is a 38-kDa polypeptide which can be affinity-purified to near homogeneity by this 30-bp specific oligonucleotide in affinity chromatography. The cellular factor from HeLa cell nuclear extract exhibits specific interaction only with the 30-bp NRE-A domain of HIV-1 LTR and acts as a strong transcriptional repressor/inhibitor molecule in the DNA-protein gel binding, as well as in in vitro transcriptional studies with the nuclear extracts from cells with productive HIV-1 infection. To our knowledge, this is the first report of a factor recognizing a distinct segment within NRE that has been shown to exert an inhibitory effect on transcriptionally active DNA-protein "pre-initiation" complex formation, suggesting a possible role in HIV-1 gene regulation.	NCI,DIV CANC TREATMENT,BIOL RESPONSE MODIFIERS PROGRAM,BIOCHEM PHYSIOL LABS,FREDERICK,MD 21702; NCI,DIV CANC TREATMENT,BIOL RESPONSE MODIFIERS PROGRAM,MOLEC IMMUNOREGULAT LABS,FREDERICK,MD 21702; FREDERICK CANC RES & DEV CTR,PROGRAM RESOURCES INC DYNCORP,BIOL CARCINOGENESIS & DEV PROGRAM,FREDERICK,MD 21702	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick					OFFICE OF THE DIRECTOR, NCI [N01CO074102, N01CO074101] Funding Source: NIH RePORTER; NCI NIH HHS [N01-CO-74101, N01-CO-74102] Funding Source: Medline	OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CALVERT I, 1991, GENE, V101, P171, DOI 10.1016/0378-1119(91)90408-4; CLOUSE KA, 1989, J IMMUNOL, V142, P431; CULLEN BR, 1986, CELL, V46, P973, DOI 10.1016/0092-8674(86)90696-3; FEINBERG MB, 1986, CELL, V46, P807, DOI 10.1016/0092-8674(86)90062-0; FOLKS T, 1986, SCIENCE, V231, P600, DOI 10.1126/science.3003906; FRANZA BR, 1988, SCIENCE, V239, P1150, DOI 10.1126/science.2964084; GARCIA JA, 1987, EMBO J, V6, P3761, DOI 10.1002/j.1460-2075.1987.tb02711.x; ISHII S, 1987, P NATL ACAD SCI USA, V84, P4374, DOI 10.1073/pnas.84.13.4374; JONES K A, 1989, New Biologist, V1, P127; JONES KA, 1987, CELL, V48, P79, DOI 10.1016/0092-8674(87)90358-8; JONES KA, 1986, SCIENCE, V232, P755, DOI 10.1126/science.3008338; KADONAGA JT, 1986, P NATL ACAD SCI USA, V83, P5889, DOI 10.1073/pnas.83.16.5889; KAUFMAN JD, 1987, MOL CELL BIOL, V7, P3759, DOI 10.1128/MCB.7.10.3759; LENARDO M, 1987, SCIENCE, V236, P1573, DOI 10.1126/science.3109035; MANIATIS T, 1987, SCIENCE, V236, P1237, DOI 10.1126/science.3296191; MIKOVITS JA, 1990, J EXP MED, V171, P1705, DOI 10.1084/jem.171.5.1705; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; OKAMOTO T, 1986, CELL, V47, P29, DOI 10.1016/0092-8674(86)90363-6; PARKER CS, 1984, CELL, V36, P357, DOI 10.1016/0092-8674(84)90229-0; PEDERSEN C, 1987, BRIT MED J, V295, P567, DOI 10.1136/bmj.295.6598.567; RAZIUDDIN MJA, 1991, P NATL ACAD SCI USA, V88, P9426; ROSEN CA, 1988, P NATL ACAD SCI USA, V85, P2071, DOI 10.1073/pnas.85.7.2071; ROSEN CA, 1985, CELL, V41, P813, DOI 10.1016/S0092-8674(85)80062-3; ROSENFELD PJ, 1986, J BIOL CHEM, V261, P1398; SIEKEVITZ M, 1987, SCIENCE, V238, P1575, DOI 10.1126/science.2825351; TONGSTARKSEN SE, 1987, P NATL ACAD SCI USA, V84, P6845, DOI 10.1073/pnas.84.19.6845; VERMA R, 1992, J BIOL CHEM, V267, P1648; WEIL PA, 1979, CELL, V18, P469; WRIGHT CM, 1986, SCIENCE, V234, P988, DOI 10.1126/science.3490693; YAMAMOTO KR, 1985, ANNU REV GENET, V19, P209, DOI 10.1146/annurev.genet.19.1.209	30	16	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1992	267	35					24948	24952						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KB603	1459999				2022-12-25	WOS:A1992KB60300009
J	GODEAU, F; LUESCHER, IF; OJCIUS, DM; SAUCIER, C; MOTTEZ, E; CABANIE, L; KOURILSKY, P				GODEAU, F; LUESCHER, IF; OJCIUS, DM; SAUCIER, C; MOTTEZ, E; CABANIE, L; KOURILSKY, P			PURIFICATION AND LIGAND-BINDING OF A SOLUBLE CLASS-I MAJOR HISTOCOMPATIBILITY COMPLEX MOLECULE CONSISTING OF THE 1ST 3 DOMAINS OF H-2KD FUSED TO BETA-2-MICROGLOBULIN EXPRESSED IN THE BACULOVIRUS-INSECT CELL SYSTEM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TOXIC LYMPHOCYTES-T; HIGH-LEVEL EXPRESSION; B ANTIGENS INVIVO; IMMUNOGENIC PEPTIDES; RAPID TRANSFER; FOREIGN GENES; HEAVY-CHAINS; HLA-A; MHC; PROTEINS	A recombinant baculovirus encoding a single-chain murine major histocompatibility complex class I molecule in which the first three domains of H-2K(d) are fused to beta2-microglobulin (beta2-m) via a 15-amino acid linker has been isolated and used to infect lepidopteran cells. A soluble, 391-amino acid single-chain H-2K(d) (SC-K(d)) molecule of 48 kDa was synthesized and glycosylated in insect cells and could be purified in the absence of detergents by affinity chromatography using the anti-H-2K(d) monoclonal antibody SF1.1.1.1. We tested the ability of SC-K(d) to bind antigenic peptides using a direct binding assay based on photo-affinity labeling. The photoreactive derivative was prepared from the H-2K(d)-restricted Plasmodium berghei circumsporozoite protein (P.b. CS) peptide 253-260 (YIPSAEKI), a probe that we had previously shown to be unable to bind to the H-2K(d) heavy chain in infected cells in the absence of co-expressed beta2-microglobulin. SC-K(d) expressed in insect cells did not require additional mouse beta2-m to bind the photoprobe, indicating that the covalently attached beta2-m could substitute for the free molecule. Similarly, binding of the P.b. CS photoaffinity probe to the purified SC-K(d) molecule was unaffected by the addition of exogenous beta2-m. This is in contrast to H-2K(d)Q10, a soluble H-2K(d) molecule in which beta2-m is noncovalently bound to the soluble heavy chain, whose ability to bind the photoaffinity probe is greatly enhanced in the presence of an excess of exogenous beta2-m. The binding of the probe to SC-K(d) was allele-specific, since labeling was selectively inhibited only by antigenic peptides known to be presented by the H-2K(d) molecule.	INST PASTEUR,UNITE TECHNOL CELLULAIRE,F-75724 PARIS 15,FRANCE; LUDWIG INST CANC RES,CH-1066 EPALINGES,SWITZERLAND	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Ludwig Institute for Cancer Research	GODEAU, F (corresponding author), INSERM,U277,UNITE BIOL MOLEC GENE,28 RUE DU DOCTEUR ROUX,F-75005 PARIS,FRANCE.							BJORKMAN PJ, 1987, NATURE, V329, P506, DOI 10.1038/329506a0; BJORKMAN PJ, 1987, NATURE, V329, P512, DOI 10.1038/329512a0; BLAKE MS, 1984, ANAL BIOCHEM, V136, P175, DOI 10.1016/0003-2697(84)90320-8; BOUILLOT M, 1989, NATURE, V339, P473, DOI 10.1038/339473a0; CERUNDOLO V, 1990, NATURE, V345, P449, DOI 10.1038/345449a0; CHEN BP, 1990, J EXP MED, V172, P931, DOI 10.1084/jem.172.3.931; CHU G, 1987, NUCLEIC ACIDS RES, V15, P1311, DOI 10.1093/nar/15.3.1311; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; DARGEMONT C, 1989, SCIENCE, V246, P803, DOI 10.1126/science.2683083; DEGRAFF BA, 1974, J AM CHEM SOC, V96, P7491, DOI 10.1021/ja00831a017; DOBBERSTEIN B, 1979, CELL, V17, P759, DOI 10.1016/0092-8674(79)90316-7; DOVER WJ, 1988, NUCLEIC ACIDS RES, V16, P6127; ELLIOTT T, 1991, NATURE, V351, P402, DOI 10.1038/351402a0; EY PL, 1978, IMMUNOCHEMISTRY, V15, P429, DOI 10.1016/0161-5890(78)90070-6; FALK K, 1991, NATURE, V351, P290, DOI 10.1038/351290a0; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FRELINGER JA, 1990, J EXP MED, V172, P827, DOI 10.1084/jem.172.3.827; GODEAU F, 1991, RES IMMUNOL, V142, P409, DOI 10.1016/0923-2494(91)90039-L; GODEAU JF, 1992, INT IMMUNOL, V4, P265; GODEAU JF, 1990, TRANSFERT EXPRESSION, P33; HARLOW E, 1988, ANTIBODIES LABORATOR; HUSTON JS, 1988, P NATL ACAD SCI USA, V85, P5879, DOI 10.1073/pnas.85.16.5879; JARDETZKY TS, 1991, NATURE, V353, P326, DOI 10.1038/353326a0; KAST WM, 1989, CELL, V59, P603, DOI 10.1016/0092-8674(89)90006-8; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KRANGEL MS, 1979, CELL, V18, P979, DOI 10.1016/0092-8674(79)90210-1; KVIST S, 1990, NATURE, V348, P446, DOI 10.1038/348446a0; KYHSEANDERSEN J, 1984, J BIOCHEM BIOPH METH, V10, P203, DOI 10.1016/0165-022X(84)90040-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUCKOW VA, 1989, VIROLOGY, V170, P31, DOI 10.1016/0042-6822(89)90348-6; LUESCHER IF, 1987, ELECTROPHORESIS, V8, P508, DOI 10.1002/elps.1150081103; LUESCHER IF, 1991, NATURE, V351, P72, DOI 10.1038/351072a0; LUESCHER IF, 1992, J IMMUNOL, V148, P1003; LURQUIN C, 1989, CELL, V58, P293, DOI 10.1016/0092-8674(89)90844-1; MAEDA S, 1989, ANNU REV ENTOMOL, V34, P351, DOI 10.1146/annurev.en.34.010189.002031; MARGULIES DH, 1986, P NATL ACAD SCI USA, V83, P5252, DOI 10.1073/pnas.83.14.5252; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MATSUURA Y, 1987, J GEN VIROL, V68, P1233, DOI 10.1099/0022-1317-68-5-1233; Merrifield RB, 1976, SCIENCE, V232, P341, DOI DOI 10.1126/SCIENCE.3961484; MILLER LK, 1988, ANNU REV MICROBIOL, V42, P177, DOI 10.1146/annurev.micro.42.1.177; MOTTEZ E, 1991, EUR J IMMUNOL, V21, P467, DOI 10.1002/eji.1830210232; NATORI T, 1976, J IMMUNOGENET, V3, P123; NOVOTNY J, 1991, P NATL ACAD SCI USA, V88, P8646, DOI 10.1073/pnas.88.19.8646; NUTCHERN JG, 1989, NATURE, V339, P223; OWEN MJ, 1980, J BIOL CHEM, V255, P9678; OZATO K, 1980, J IMMUNOL, V125, P2473; REED KC, 1985, NUCLEIC ACIDS RES, V13, P7207, DOI 10.1093/nar/13.20.7207; ROCK KL, 1991, CELL, V65, P611, DOI 10.1016/0092-8674(91)90093-E; ROCK KL, 1991, P NATL ACAD SCI USA, V88, P301, DOI 10.1073/pnas.88.1.301; ROMERO P, 1991, J EXP MED, V174, P603, DOI 10.1084/jem.174.3.603; ROMERO P, 1989, NATURE, V341, P323, DOI 10.1038/341323a0; ROTHBARD JB, 1991, ANNU REV IMMUNOL, V9, P527, DOI 10.1146/annurev.iy.09.040191.002523; Sambrook J, 1989, MOL CLONING LABORATO; SAPER MA, 1991, J MOL BIOL, V219, P277, DOI 10.1016/0022-2836(91)90567-P; SCHNECK J, 1989, CELL, V56, P47, DOI 10.1016/0092-8674(89)90982-3; SCHNEIDER C, 1982, J BIOL CHEM, V257, P766; SEGE K, 1981, BIOCHEMISTRY-US, V20, P4523, DOI 10.1021/bi00519a003; SIBILLE C, 1990, J EXP MED, V172, P35, DOI 10.1084/jem.172.1.35; SILVER ML, 1991, NATURE, V350, P619, DOI 10.1038/350619a0; STERN LJ, 1992, CELL, V68, P465, DOI 10.1016/0092-8674(92)90184-E; TOWNSEND A, 1990, CELL, V62, P285, DOI 10.1016/0092-8674(90)90366-M; TOWNSEND A, 1989, NATURE, V340, P443, DOI 10.1038/340443a0; TOWNSEND A, 1989, ANNU REV IMMUNOL, V7, P601, DOI 10.1146/annurev.iy.07.040189.003125; TOWNSEND ARM, 1986, CELL, V44, P959, DOI 10.1016/0092-8674(86)90019-X; YEWDELL JW, 1989, SCIENCE, V244, P1072, DOI 10.1126/science.2471266	65	35	43	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1992	267	34					24223	24229						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KA263	1447172				2022-12-25	WOS:A1992KA26300015
J	COURTOIS, SJ; LAFONTAINE, DA; ROUSSEAU, GG				COURTOIS, SJ; LAFONTAINE, DA; ROUSSEAU, GG			CHARACTERIZATION OF AN ALTERNATIVE PROMOTER IN THE HUMAN GROWTH-HORMONE GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAJOR LATE PROMOTER; TRANSCRIPTION FACTOR BINDS; DNA-BINDING; STIMULATE TRANSCRIPTION; REGULATORY ELEMENTS; RIBONUCLEIC-ACID; UPSTREAM ELEMENT; MESSENGER-RNAS; CYCLIC-AMP; FACTOR-I	Transcription of the human growth hormone (hGH) gene depends on cis-acting elements contained within 300 base pairs of its 5'-flanking sequence. An earlier in vitro study of the transcriptional activity of this 5'-flanking region suggested that transcription can start upstream from position +1. We have investigated this phenomenon by cell-free transcription and transient transfection of chimeric constructs in cultured pituitary cells and in HeLa cells and by analysis of RNA from human pituitary glands and HeLa cells. Transcription initiation sites were identified at positions -54 and -197 by cell-free transcription assays and by RNase mapping of human pituitary RNA. In transfection assays, the hGH gene 5'-flanking sequence upstream from position -197 displayed transcriptional activity, which critically depended on the upstream stimulatory factor-binding site located between positions -253 and -266. Transcripts initiated upstream from position +1 were detected in human pituitary RNA by polymerase chain reaction amplification and Northern blotting. These transcripts were longer than the mRNA encoding hGH. They might control initiation at position +1 or code for a novel peptide.	CATHOLIC UNIV LOUVAIN,SCH MED,ICP,HORMONE & METAB RES UNIT,BOX 7529,75 AVE HIPPOCRATE,B-1200 BRUSSELS,BELGIUM; INT INST CELLULAR & MOLEC PATHOL,B-1200 BRUSSELS,BELGIUM	Universite Catholique Louvain; Universite Libre de Bruxelles; Vrije Universiteit Brussel								BARRERASALDANA HA, 1983, J BIOL CHEM, V258, P3787; BARRON EA, 1989, MOL CELL BIOL, V9, P817, DOI 10.1128/MCB.9.2.817; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BODNER M, 1987, CELL, V50, P267, DOI 10.1016/0092-8674(87)90222-4; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; BUCHER P, 1986, NUCLEIC ACIDS RES, V14, P10009, DOI 10.1093/nar/14.24.10009; CARLSON M, 1982, CELL, V28, P145, DOI 10.1016/0092-8674(82)90384-1; CARTHEW RW, 1985, CELL, V43, P439, DOI 10.1016/0092-8674(85)90174-6; CARTHEW RW, 1987, GENE DEV, V1, P973, DOI 10.1101/gad.1.9.973; CHELLY J, 1989, P NATL ACAD SCI USA, V86, P2617, DOI 10.1073/pnas.86.8.2617; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHODOSH LA, 1987, SCIENCE, V238, P684, DOI 10.1126/science.3672119; COOKE NE, 1981, J BIOL CHEM, V256, P4007; COURTOIS SJ, 1990, NUCLEIC ACIDS RES, V18, P57, DOI 10.1093/nar/18.1.57; FITZPATRICK SL, 1990, MOL ENDOCRINOL, V4, P1815, DOI 10.1210/mend-4-12-1815; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HALAZONETIS TD, 1991, P NATL ACAD SCI USA, V88, P6162, DOI 10.1073/pnas.88.14.6162; HOWLEY PM, 1983, METHOD ENZYMOL, V101, P387; ISAACS RE, 1987, MOL ENDOCRINOL, V1, P569, DOI 10.1210/mend-1-8-569; JACQUEMIN P, 1990, ARCH INT PHYSL BIOCH, V98, pB77; KOZAK M, 1991, J BIOL CHEM, V266, P19867; Lafontaine D A, 1987, Horm Metab Res Suppl, V17, P5; LANDIS CA, 1989, NATURE, V340, P692, DOI 10.1038/340692a0; LEMAIGRE FP, 1990, MOL CELL BIOL, V10, P1811, DOI 10.1128/MCB.10.4.1811; LEMAIGRE FP, 1991, MOL CELL BIOL, V11, P1099, DOI 10.1128/MCB.11.2.1099; LEMAIGRE FP, 1989, EUR J BIOCHEM, V181, P555, DOI 10.1111/j.1432-1033.1989.tb14760.x; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MACGREGOR GR, 1987, SOMAT CELL MOLEC GEN, V13, P253, DOI 10.1007/BF01535207; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MILLER WL, 1983, ENDOCR REV, V4, P97, DOI 10.1210/edrv-4-2-97; MIYAMOTO NG, 1985, EMBO J, V4, P3563, DOI 10.1002/j.1460-2075.1985.tb04118.x; NATORI S, 1988, J CLIN ENDOCR METAB, V66, P430, DOI 10.1210/jcem-66-2-430; NELSON C, 1988, SCIENCE, V239, P1400, DOI 10.1126/science.2831625; NEWMAN CB, 1987, P NATL ACAD SCI USA, V84, P8110, DOI 10.1073/pnas.84.22.8110; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; PASLEAU F, 1985, GENE, V38, P227, DOI 10.1016/0378-1119(85)90221-5; PERITZ LN, 1988, J BIOL CHEM, V263, P5005; PRENDERGAST GC, 1991, SCIENCE, V251, P186, DOI 10.1126/science.1987636; PROUDFOOT NJ, 1986, NATURE, V322, P562, DOI 10.1038/322562a0; QUINN PG, 1988, MOL CELL BIOL, V8, P3467, DOI 10.1128/MCB.8.8.3467; ROESLER WJ, 1988, J BIOL CHEM, V263, P9063; Sambrook J, 1989, MOL CLONING LABORATO; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; SCHAPIRO LH, 1991, J BIOL CHEM, V266, P11999; SCHIBLER U, 1987, ANNU REV GENET, V21, P237, DOI 10.1146/annurev.ge.21.120187.001321; SCOTTO KW, 1989, GENE DEV, V3, P651, DOI 10.1101/gad.3.5.651; SEEBURG PH, 1982, DNA-J MOLEC CELL BIO, V1, P239, DOI 10.1089/dna.1.1982.1.239; SEIDAH NG, 1983, ARCH BIOCHEM BIOPHYS, V225, P525, DOI 10.1016/0003-9861(83)90063-2; SELBY MJ, 1984, J BIOL CHEM, V259, P3131; SELVANAYAGAM CS, 1984, J BIOL CHEM, V259, P4642; SMITH KP, 1991, BIOCHEM BIOPH RES CO, V177, P790, DOI 10.1016/0006-291X(91)91858-A; TANSEY WP, 1991, J BIOL CHEM, V266, P9805; VOSS JW, 1991, J BIOL CHEM, V266, P12832; YAMASHITA S, 1986, J CLIN ENDOCR METAB, V63, P730, DOI 10.1210/jcem-63-3-730	55	19	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1992	267	27					19736	19743						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JP593	1527095				2022-12-25	WOS:A1992JP59300107
J	GUO, NH; KRUTZSCH, HC; NEGRE, E; ZABRENETZKY, VS; ROBERTS, DD				GUO, NH; KRUTZSCH, HC; NEGRE, E; ZABRENETZKY, VS; ROBERTS, DD			HEPARIN-BINDING PEPTIDES FROM THE TYPE-I REPEATS OF THROMBOSPONDIN - STRUCTURAL REQUIREMENTS FOR HEPARIN BINDING AND PROMOTION OF MELANOMA CELL-ADHESION AND CHEMOTAXIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLATELET THROMBOSPONDIN; SULFATED GLYCOLIPIDS; ENDOTHELIAL-CELLS; GLYCOSAMINOGLYCAN SYNTHESIS; ALTERED METABOLISM; DIFFERENT PROTEINS; NEURITE OUTGROWTH; LIGAND-BINDING; RECEPTOR; ATTACHMENT	Synthetic peptides derived from the type I repeats of human platelet thrombospondin containing a consensus sequence Trp-Ser-Xaa-Trp bind to heparin, promote cell adhesion, and inhibit heparin-dependent interactions of melanoma cells with extracellular matrix components (Guo, N. H., Krutzsch, H. C., Negre, E., Vogel, T., Blake, D. A., and Roberts, D. D. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 3040-3044). In the present study, we further examined the structural requirements for activity of these peptides. The minimal active sequence for heparin or sulfatide binding based on inhibition studies is Trp-Ser-Pro-Trp, although an octapeptide is required for optimal activity. The 2 Trp residues and the Ser residue are essential. Peptides with more than 2 residues between the Trp residues are inactive. The Pro residue is essential for activity of the pentapeptide Trp-Ser-Pro-Trp-Ser, but some larger peptides with substitutions for the Pro residue are active. For direct high affinity binding to heparin, both the consensus sequence and a flanking sequence of basic amino acids are essential. Peptides containing the consensus sequence promote cell adhesion and act cooperatively with the adjacent basic amino acid sequence to promote cell spreading. Chemical modification of the Trp residues in the peptides with amino-terminal basic amino acids abolished both cell adhesion and heparin-binding. Peptides containing the consensus sequence and basic amino acids are chemotactic for A2058 human melanoma cells. The functional importance of this novel heparin and sulfatide-binding motif is suggested by its conservation in other members of the thrombospondin gene family, complement components, and in many members of the cytokine receptor and transforming growth factor beta superfamilies.	NCI, PATHOL LAB, BLDG 10, ROOM 2A33, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Roberts, David D./A-9699-2008	Roberts, David D./0000-0002-2481-2981				ASCH AS, 1992, BIOCHEM BIOPH RES CO, V182, P1208, DOI 10.1016/0006-291X(92)91860-S; ASCH AS, 1987, J CLIN INVEST, V79, P1054, DOI 10.1172/JCI112918; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BLACKBURN MN, 1980, J BIOL CHEM, V255, P824; BORNSTEIN P, 1991, J BIOL CHEM, V266, P12821; BURKE C, 1991, J BIOL CHEM, V266, P19407; CARDIN AD, 1989, ARTERIOSCLEROSIS, V9, P21, DOI 10.1161/01.ATV.9.1.21; DARDIK R, 1987, EUR J BIOCHEM, V168, P347, DOI 10.1111/j.1432-1033.1987.tb13426.x; DAVIS S, 1991, SCIENCE, V253, P59, DOI 10.1126/science.1648265; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; DIXIT VM, 1984, J BIOL CHEM, V259, P100; Frazier WA, 1991, CURR OPIN CELL BIOL, V3, P792, DOI 10.1016/0955-0674(91)90052-Z; FUNAHASHI M, 1982, ANAL BIOCHEM, V126, P414, DOI 10.1016/0003-2697(82)90537-1; GRAF J, 1987, CELL, V48, P989, DOI 10.1016/0092-8674(87)90707-0; GUO NH, 1992, P NATL ACAD SCI USA, V89, P3040, DOI 10.1073/pnas.89.7.3040; HAEFLIGER JA, 1989, J BIOL CHEM, V264, P18041; JACKSON RL, 1991, PHYSIOL REV, V71, P481, DOI 10.1152/physrev.1991.71.2.481; KLAR A, 1992, CELL, V69, P95, DOI 10.1016/0092-8674(92)90121-R; LAHAV J, 1988, EXP CELL RES, V177, P199, DOI 10.1016/0014-4827(88)90037-7; LAWLER J, 1986, J CELL BIOL, V103, P1635, DOI 10.1083/jcb.103.5.1635; MAJACK RA, 1986, P NATL ACAD SCI USA, V83, P9050, DOI 10.1073/pnas.83.23.9050; MCKEOWNLONGO PJ, 1984, J CELL BIOL, V98, P22, DOI 10.1083/jcb.98.1.22; MIYAZAKI T, 1991, EMBO J, V10, P3191, DOI 10.1002/j.1460-2075.1991.tb04881.x; MOSHER DF, 1990, ANNU REV MED, V41, P85; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; MURPHYULLRICH JE, 1989, J CELL BIOL, V109, P1309, DOI 10.1083/jcb.109.3.1309; MURPHYULLRICH JE, 1988, J BIOL CHEM, V263, P6400; MURPHYULLRICH JE, 1987, J CELL BIOL, V105, P1603, DOI 10.1083/jcb.105.4.1603; NEUGEBAUER KM, 1991, NEURON, V6, P345, DOI 10.1016/0896-6273(91)90244-T; OHLSON S, 1988, ANAL BIOCHEM, V169, P204, DOI 10.1016/0003-2697(88)90275-8; PRATER CA, 1991, J CELL BIOL, V112, P1031, DOI 10.1083/jcb.112.5.1031; RICH KA, 1990, SCIENCE, V249, P1574, DOI 10.1126/science.2120774; ROBERTS DD, 1988, CANCER RES, V48, P6785; ROBERTS DD, 1985, J BIOL CHEM, V260, P9405; ROBERTS DD, 1987, J CELL BIOL, V104, P131, DOI 10.1083/jcb.104.1.131; ROBERTS DD, 1985, NATURE, V318, P64, DOI 10.1038/318064a0; SENIOR RM, 1984, J CELL BIOL, V99, P870, DOI 10.1083/jcb.99.3.870; STRACKE ML, 1992, J BIOL CHEM, V267, P2524; SUN XJ, 1989, J BIOL CHEM, V264, P11288; TARABOLETTI G, 1987, J CELL BIOL, V105, P2409, DOI 10.1083/jcb.105.5.2409; TARABOLETTI G, 1990, J CELL BIOL, V111, P765, DOI 10.1083/jcb.111.2.765; TASHIRO K, 1989, J BIOL CHEM, V264, P16174; TODARO GJ, 1980, P NATL ACAD SCI-BIOL, V77, P5258, DOI 10.1073/pnas.77.9.5258; TUSZYNSKI GP, 1991, J CLIN INVEST, V87, P1387, DOI 10.1172/JCI115144; WHARTON KA, 1991, P NATL ACAD SCI USA, V88, P9214, DOI 10.1073/pnas.88.20.9214; WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241; YOSHIMURA A, 1992, J BIOL CHEM, V267, P11619; ZABRENETZKY VS, 1990, CANCER RES, V50, P5937	48	112	118	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 25	1992	267	27					19349	19355						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JP593	1527055				2022-12-25	WOS:A1992JP59300051
J	SARRIA, AJ; PANINI, SR; EVANS, RM				SARRIA, AJ; PANINI, SR; EVANS, RM			A FUNCTIONAL-ROLE FOR VIMENTIN INTERMEDIATE FILAMENTS IN THE METABOLISM OF LIPOPROTEIN-DERIVED CHOLESTEROL IN HUMAN SW-13 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY LIPOPROTEIN; NIEMANN-PICK DISEASE; TRANSGENIC MICE; INTRACELLULAR-TRANSPORT; LIQUID-CHROMATOGRAPHY; CULTURED FIBROBLASTS; PLASMA-MEMBRANE; C FIBROBLASTS; EXPRESSION; PROTEINS	Numerous studies have indicated that cytoplasmic intermediate filaments (cIFs) can associate with cellular lipids. To determine if these interactions might have functional consequences, we have studied the lipid metabolism of human SW-13 adrenal tumor cell lines that either contain vimentin-type cIFs (vim+) or lack any detectable cIF network (vim-). Although there were no significant differences in phospholipid or glyceride synthesis, vim- cell lines had elevated levels of cholesterol synthesis and decreased cholesterol esterification, compared with vim+ cells. These differences in cholesterol synthesis and esterification were found to be due to an impaired ability of vim- cells to utilize low density lipoprotein (LDL)-derived cholesterol, although receptor-mediated endocytosis of LDL and the capacity of these cells to esterify endogenously produced cholesterol were not affected. Expression of a mouse vimentin cDNA in stably transfected cell lines, derived from vim- cells, restored the capacity of these cells to utilize LDL cholesterol. The uptake and metabolism of [H-3]cholesterol linoleate-loaded LDL showed that the impaired ability of vim- cells to esterify LDL cholesterol was not associated with an accumulation of cellular free cholesterol but rather an increase in the appearance of [H-3]cholesterol in the culture medium. These studies indicate that in SW-13 cells, the intracellular movement of LDL-derived cholesterol from the lysosome to the site of esterification is a vimentin-dependent process.	UNIV COLORADO,HLTH SCI CTR,DEPT PATHOL,B-216,4200 E 9TH AVE,DENVER,CO 80262; ELEANOR ROOSEVELT INST,DENVER,CO 80206	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver					NIGMS NIH HHS [GM-42770] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042770] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALMAHBOBI G, 1990, J CELL SCI, V97, P679; ALMAHBOBI G, 1992, J CELL SCI, V101, P383; AMANUMA K, 1986, VIRCHOWS ARCH A, V410, P231; ASCH HL, 1990, BIOCHIM BIOPHYS ACTA, V1034, P303, DOI 10.1016/0304-4165(90)90056-3; BARIBAULT H, 1991, J CELL BIOL, V115, P1675, DOI 10.1083/jcb.115.6.1675; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BRASAEMLE DL, 1990, J LIPID RES, V31, P103; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; BROWN MS, 1975, J BIOL CHEM, V250, P4025; CADIGAN KM, 1990, J CELL BIOL, V110, P295, DOI 10.1083/jcb.110.2.295; CAPETANAKI Y, 1989, J CELL BIOL, V109, P1653, DOI 10.1083/jcb.109.4.1653; CARLSON SE, 1977, CLIN CHIM ACTA, V79, P575, DOI 10.1016/0009-8981(77)90178-4; COULOMBE PA, 1991, J CELL BIOL, V115, P1661, DOI 10.1083/jcb.115.6.1661; DAHL NK, 1992, J BIOL CHEM, V267, P4889; DELLAGI K, 1983, EMBO J, V2, P1509, DOI 10.1002/j.1460-2075.1983.tb01615.x; DUNIA I, 1990, EUR J CELL BIOL, V53, P59; EVANS RM, 1984, J BIOL CHEM, V259, P5372; FAUST JR, 1977, J BIOL CHEM, V252, P4861; FRANKE WW, 1987, CELL, V49, P131, DOI 10.1016/0092-8674(87)90763-X; GILLARD BK, 1992, CELL MOTIL CYTOSKEL, V21, P255, DOI 10.1002/cm.970210402; GILLARD BK, 1991, EXP CELL RES, V192, P433, DOI 10.1016/0014-4827(91)90062-Y; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; HALL PF, 1984, INT REV CYTOL, V86, P53, DOI 10.1016/S0074-7696(08)60177-1; JACKSON BW, 1980, DIFFERENTIATION, V17, P161, DOI 10.1111/j.1432-0436.1980.tb01093.x; JOHNSON WJ, 1990, J BIOL CHEM, V265, P5546; KEMLER R, 1981, J EMBRYOL EXP MORPH, V64, P45; KLYMKOWSKY MW, 1989, CELL MOTIL CYTOSKEL, V14, P309, DOI 10.1002/cm.970140302; Kowal J, 1970, Recent Prog Horm Res, V26, P623; KRUTH HS, 1986, J BIOL CHEM, V261, P6769; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEIBOVITZ A, 1973, JNCI-J NATL CANCER I, V51, P691; LISCUM L, 1989, J CELL BIOL, V108, P1625, DOI 10.1083/jcb.108.5.1625; LISCUM L, 1987, J BIOL CHEM, V262, P17002; LISCUM L, 1990, BIOCHIM BIOPHYS ACTA, V1045, P40, DOI 10.1016/0005-2760(90)90201-8; LUCKENBILL LM, 1966, J CELL BIOL, V31, P195; MARKL J, 1991, J CELL SCI, V98, P261; MCGOOKEY DJ, 1983, J CELL BIOL, V97, P1156, DOI 10.1083/jcb.97.4.1156; MONTEIRO MJ, 1990, J CELL BIOL, V111, P1543, DOI 10.1083/jcb.111.4.1543; NOVIKOFF AB, 1980, J CELL BIOL, V87, P180, DOI 10.1083/jcb.87.1.180; OHARE MJ, 1976, J CHROMATOGR, V125, P357, DOI 10.1016/S0021-9673(00)93831-7; PAULIN D, 1980, EXP CELL RES, V130, P297, DOI 10.1016/0014-4827(80)90006-3; PENTCHEV PG, 1985, P NATL ACAD SCI USA, V82, P8247, DOI 10.1073/pnas.82.23.8247; PENTCHEV PG, 1986, J BIOL CHEM, V261, P6775; REINHART MP, 1990, EXPERIENTIA, V46, P599, DOI 10.1007/BF01939699; ROFF CF, 1992, AM J MED GENET, V42, P593, DOI 10.1002/ajmg.1320420433; SARRIA AJ, 1990, J CELL BIOL, V111, P553, DOI 10.1083/jcb.111.2.553; SARRIA AJ, 1989, RBC-CELL BIOL REV, V22, P1; SCHULTHEISS T, 1991, J CELL BIOL, V114, P953, DOI 10.1083/jcb.114.5.953; SKALLI O, 1991, CELL MOTIL CYTOSKEL, V19, P67, DOI 10.1002/cm.970190202; SOKOL J, 1988, J BIOL CHEM, V263, P3411; STEINERT PM, 1985, CELL, V42, P411, DOI 10.1016/0092-8674(85)90098-4; TRAUB P, 1987, EUR J CELL BIOL, V43, P55; TRAUB P, 1985, FEBS LETT, V193, P217, DOI 10.1016/0014-5793(85)80155-1; TREVOR K T, 1990, New Biologist, V2, P1004; TROY CM, 1992, J CELL BIOL, V117, P1085, DOI 10.1083/jcb.117.5.1085; VASSAR R, 1991, CELL, V64, P365, DOI 10.1016/0092-8674(91)90645-F; VERCAEMST R, 1989, J CHROMATOGR-BIOMED, V494, P43, DOI 10.1016/S0378-4347(00)82655-9; VOELKER DR, 1990, J BIOL CHEM, V265, P14340; WEINSTEIN DE, 1991, J CELL BIOL, V112, P1205, DOI 10.1083/jcb.112.6.1205; WOOD EM, 1967, ANAT REC, V157, P437, DOI 10.1002/ar.1091570304; XU XX, 1991, J BIOL CHEM, V266, P17040	61	98	103	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1992	267	27					19455	19463						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JP593	1527066				2022-12-25	WOS:A1992JP59300067
J	BOUHOURS, D; HANSSON, GC; ANGSTROM, J; JOVALL, PA; BOUHOURS, JF				BOUHOURS, D; HANSSON, GC; ANGSTROM, J; JOVALL, PA; BOUHOURS, JF			2 NOVEL DECAGLYCOSYLCERAMIDES WITH A BLOOD GROUP-A-ACTIVE TETRASACCHARIDE REPEAT IN THE EPITHELIAL-CELLS OF THE SMALL-INTESTINE OF INBRED RATS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-LINKED OLIGOSACCHARIDES; MASS-SPECTROMETRY; CARBOHYDRATE CHAINS; ANIMAL GLYCOPROTEIN; CHEMICAL BASIS; MOUSE KIDNEY; GLYCOSPHINGOLIPIDS; GLYCOLIPIDS; XYLOSE; GANGLIOSIDES	A novel type of blood group A-active glycosphingolipid was isolated from the epithelial cells of the small intestine of one strain of inbred rats. Electron-impact mass spectrometry of the permethylated and LiAlH4-reduced glycolipid indicated that it is a decaglycosyl-ceramide with a branched oligosaccharide chain. Methylation analysis, gas chromatography-mass spectroscopy of the partially methylated alditol acetates, sequential degradation by exoglycosidases and characterization of the reaction products by TLC immunostaining with appropriate anti-A and anti-H antibodies, and H-1 NMR spectrometry resulted in the characterization of a decaglycosylceramide with two variants in a 7/3 ratio. It was termed AA-10. [GRAPHICS] The major variant has only type 1 chains, whereas the minor one has type 2 chain in the C6-linked branch. This is a novel type of glycolipid with a blood group A-active tetrasaccharide repeat. Genetic analysis demonstrated that AA-10 is inherited as an autosomal dominant trait.	INSERM, U76, 6 RUE ALEXANDRE CABANEL, F-75739 PARIS 15, FRANCE; GOTHENBURG UNIV, DEPT MED BIOCHEM, S-40033 GOTHENBURG, SWEDEN	Institut National de la Sante et de la Recherche Medicale (Inserm); University of Gothenburg			Hansson, Gunnar C./AAF-7324-2019; Hansson, Gunnar C/A-1236-2009	Hansson, Gunnar C./0000-0002-1900-1869; Hansson, Gunnar C/0000-0002-1900-1869				ARAKI S, 1987, J BIOL CHEM, V262, P14141; ASPINALL GO, 1983, CAN J CHEM, V61, P1864, DOI 10.1139/v83-319; BOUHOURS D, 1990, ARCH BIOCHEM BIOPHYS, V282, P141, DOI 10.1016/0003-9861(90)90097-I; BOUHOURS D, 1988, J BIOL CHEM, V263, P15540; BOUHOURS D, 1987, GLYCOCONJUGATE J, V4, P59, DOI 10.1007/BF01048445; BOUHOURS D, 1991, J BIOL CHEM, V266, P18613; BREIMER ME, 1982, J BIOL CHEM, V257, P906; BREIMER ME, 1980, FEBS LETT, V114, P51, DOI 10.1016/0014-5793(80)80859-3; BREIMER ME, 1981, FEBS LETT, V124, P299, DOI 10.1016/0014-5793(81)80160-3; BREIMER ME, 1979, BIOMED MASS SPECTROM, V6, P231, DOI 10.1002/bms.1200060603; BREIMER ME, 1982, J BIOL CHEM, V257, P60; CIUCANU I, 1984, CARBOHYD RES, V131, P209, DOI 10.1016/0008-6215(84)85242-8; CLAUSEN H, 1985, P NATL ACAD SCI USA, V82, P1199, DOI 10.1073/pnas.82.4.1199; CLAUSEN H, 1986, BIOCHEMISTRY-US, V25, P7075, DOI 10.1021/bi00370a048; DANDREA G, 1988, GLYCOCONJUGATE J, V5, P151, DOI 10.1007/BF01061204; Festing MFW, 1979, LABORATORY RAT, V1, P55; FOLCH J, 1957, J BIOL CHEM, V226, P497; FUKUDA MN, 1982, J BIOL CHEM, V257, P446; HAKOMORI S, 1976, GLYCOLIPID METHODOLO, P13; HANSSON GC, 1983, J BIOL CHEM, V258, P9612; HANSSON GC, 1985, J IMMUNOL METHODS, V83, P37, DOI 10.1016/0022-1759(85)90055-9; KARLSSON KA, 1979, J BIOL CHEM, V254, P9311; KARLSSON KA, 1974, BIOCHEMISTRY-US, V13, P3643, DOI 10.1021/bi00715a003; Lindberg B, 1972, METHODS ENZYMOL, V28, P178; MAGNANI JL, 1980, ANAL BIOCHEM, V109, P399, DOI 10.1016/0003-2697(80)90667-3; ORIOL R, 1986, VOX SANG, V51, P161, DOI 10.1111/j.1423-0410.1986.tb01946.x; PILLER F, 1984, J BIOL CHEM, V259, P3385; SAITO T, 1971, J LIPID RES, V12, P257; SCHACHTER H, 1989, METHOD ENZYMOL, V179, P351; SEKINE M, 1990, J BIOCHEM-TOKYO, V108, P103, DOI 10.1093/oxfordjournals.jbchem.a123147; SEKINE M, 1987, J BIOCHEM-TOKYO, V101, P553, DOI 10.1093/jb/101.3.553; SMITH EL, 1975, BIOCHEMISTRY-US, V14, P2120, DOI 10.1021/bi00681a012; STELLNER K, 1973, ARCH BIOCHEM BIOPHYS, V155, P464, DOI 10.1016/0003-9861(73)90138-0; TAKAHASHI N, 1986, BIOCHEMISTRY-US, V25, P388, DOI 10.1021/bi00350a018; TANIGUCHI N, 1989, METHOD ENZYMOL, V179, P397; UENO K, 1978, J LIPID RES, V19, P863; VANKUIK JA, 1985, J BIOL CHEM, V260, P3984; VANKUIK JA, 1987, EUR J BIOCHEM, V169, P399; Watkins W M, 1980, Adv Hum Genet, V10, P1; WEISER MM, 1973, J BIOL CHEM, V248, P2536; 1977, LIPIDS, V12, P455	41	11	11	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	1992	267	26					18533	18540						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JN502	1526990				2022-12-25	WOS:A1992JN50200047
J	QUINLAN, JJ; NICKELS, JT; WU, WI; LIN, YP; BROACH, JR; CARMAN, GM				QUINLAN, JJ; NICKELS, JT; WU, WI; LIN, YP; BROACH, JR; CARMAN, GM			THE 45-KDA AND 104-KDA FORMS OF PHOSPHATIDATE PHOSPHATASE FROM SACCHAROMYCES-CEREVISIAE ARE REGULATED DIFFERENTIALLY BY PHOSPHORYLATION VIA CAMP-DEPENDENT PROTEIN-KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLSERINE SYNTHASE; ADENYLATE-CYCLASE; PHOSPHOLIPID BIOSYNTHESIS; COORDINATE REGULATION; PHOSPHATIDYLCHOLINE SYNTHESIS; CDP-DIACYLGLYCEROL; ESCHERICHIA-COLI; RAT-LIVER; YEAST; INOSITOL	Evidence is presented that demonstrated that the 45- and 104-kDa forms of phosphatidate phosphatase from Saccharomyces cerevisiae (Morlock, K. R., McLaughlin, J. J., Lin, Y.-P., and Carman, G. M. (1991) J. Biol. Chem. 266, 3586-3593) were regulated differentially by phosphorylation. Purified 45-kDa phosphatidate phosphatase was phosphorylated by cAMP-dependent protein kinase whereas purified 104-kDa phosphatidate phosphatase was not phosphorylated. cAMP-dependent protein kinase catalyzed the phosphorylation of pure 45-kDa phosphatidate phosphatase at a serine residue which resulted in a stimulation (2.4-fold) of phosphatidate phosphatase activity. Alkaline phosphatase catalyzed the dephosphorylation of pure 45-kDa phosphatidate phosphatase which resulted in an inhibition (1.3-fold) of phosphatidate phosphatase activity. Results of studies using mutants (bcy1 and cyr1) defective in cAMP-dependent protein kinase activity corroborated the results of the phosphorylation studies using pure preparations of phosphatidate phosphatase. The 45-kDa phosphatidate phosphatase phosphorylated in vitro and in vivo had phosphopeptides in common. The activation of the GAL1O-RAS2val19 allele in mutant cells resulted in an increase in the synthesis of diacylglycerols and triacylglycerols. These results were consistent with the phosphorylation and activation of 45-kDa phosphatidate phosphatase by cAMP-dependent protein kinase in vivo.	RUTGERS STATE UNIV, COOK COLL, NEW JERSEY AGR EXPT STN, DEPT FOOD SCI, NEW BRUNSWICK, NJ 08903 USA; PRINCETON UNIV, DEPT MOLEC BIOL, PRINCETON, NJ 08544 USA	Rutgers State University New Brunswick; Princeton University				Broach, James/0000-0003-1197-0312	NCI NIH HHS [CA-41086] Funding Source: Medline; NIGMS NIH HHS [GM-28140] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA041086] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028140] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAELEE MS, 1984, J BIOL CHEM, V259, P857; BAILIS AM, 1987, MOL CELL BIOL, V7, P167, DOI 10.1128/MCB.7.1.167; BERGLUND L, 1982, BIOCHEM BIOPH RES CO, V105, P288, DOI 10.1016/S0006-291X(82)80043-0; BERNARD DW, 1991, J BIOL CHEM, V266, P710; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRINDLEY DN, 1984, PROG LIPID RES, V23, P115, DOI 10.1016/0163-7827(84)90001-8; Broach J R, 1990, Adv Cancer Res, V54, P79, DOI 10.1016/S0065-230X(08)60809-X; CARMAN GM, 1989, ANNU REV BIOCHEM, V58, P635, DOI 10.1146/annurev.biochem.58.1.635; CARSON MA, 1984, J BIOL CHEM, V259, P6267; CARSON MA, 1982, J BIOL CHEM, V257, P8115; CASCALES C, 1984, BIOCHEM J, V219, P911, DOI 10.1042/bj2190911; CASCALES C, 1988, BIOCHIM BIOPHYS ACTA, V963, P384, DOI 10.1016/0005-2760(88)90305-0; CHENG HC, 1986, J BIOL CHEM, V261, P989; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; CULBERTSON MR, 1975, GENETICS, V80, P23; Dennis EA, 1983, ENZYMES, P307; EXTON JH, 1990, J BIOL CHEM, V265, P1; FEDORCHAIKEN M, 1990, CELL, V61, P329, DOI 10.1016/0092-8674(90)90813-T; GREENBERG ML, 1983, J BACTERIOL, V153, P791, DOI 10.1128/JB.153.2.791-799.1983; HENRY SA, 1977, J BACTERIOL, V130, P472, DOI 10.1128/JB.130.1.472-484.1977; HOMANN MJ, 1985, J BACTERIOL, V163, P1265, DOI 10.1128/JB.163.3.1265-1266.1985; HOSAKA K, 1984, BIOCHIM BIOPHYS ACTA, V796, P110; JAMIL H, 1992, J BIOL CHEM, V267, P1752; JOHNSON KE, 1987, J BIOL CHEM, V262, P8636; KATES M, 1955, CAN J BIOCHEM PHYS, V33, P575, DOI 10.1139/y55-072; Kates M., 1986, TECHNIQUES LIPIDOLOG, P186; KAWAMOTO S, 1987, J BIOL CHEM, V262, P7282; Kennedy E. P., 1986, LIPIDS MEMBRANES PRE, P171; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; KHOO JC, 1981, J BIOL CHEM, V256, P2659; KINNEY AJ, 1988, P NATL ACAD SCI USA, V85, P7962, DOI 10.1073/pnas.85.21.7962; KINNEY AJ, 1990, J BACTERIOL, V172, P1133, DOI 10.1128/jb.172.2.1133-1136.1990; KLIG LS, 1985, J BACTERIOL, V162, P1135, DOI 10.1128/JB.162.3.1135-1141.1985; KLIG LS, 1988, J BACTERIOL, V170, P1878, DOI 10.1128/jb.170.4.1878-1886.1988; KREBS EG, 1979, ANNU REV BIOCHEM, V48, P923, DOI 10.1146/annurev.bi.48.070179.004423; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMPING E, 1991, J BACTERIOL, V173, P6432, DOI 10.1128/jb.173.20.6432-6437.1991; LIN YP, 1989, J BIOL CHEM, V264, P8641; LIN YP, 1990, J BIOL CHEM, V265, P166; MARTINEZ MJ, 1990, BIOCHIM BIOPHYS ACTA, V1047, P90, DOI 10.1016/0005-2760(90)90265-Y; MATSUMOTO K, 1982, P NATL ACAD SCI-BIOL, V79, P2355, DOI 10.1073/pnas.79.7.2355; MATSUMOTO K, 1983, CELL, V32, P417, DOI 10.1016/0092-8674(83)90461-0; MATSUMOTO K, 1983, EXP CELL RES, V146, P151, DOI 10.1016/0014-4827(83)90333-6; MIYAKAWA T, 1989, J BACTERIOL, V171, P1417, DOI 10.1128/jb.171.3.1417-1422.1989; MORLOCK KR, 1991, J BIOL CHEM, V266, P3586; MORLOCK KR, 1988, J BACTERIOL, V170, P3561, DOI 10.1128/jb.170.8.3561-3566.1988; OGITA K, 1990, P NATL ACAD SCI USA, V87, P5011, DOI 10.1073/pnas.87.13.5011; OTAKA E, 1986, J BACTERIOL, V167, P713, DOI 10.1128/jb.167.2.713-715.1986; POOLE MA, 1986, J BACTERIOL, V168, P668, DOI 10.1128/jb.168.2.668-672.1986; ROACH PJ, 1991, J BIOL CHEM, V266, P14139; SANGHERA JS, 1989, J BIOL CHEM, V264, P1215; STEINER S, 1972, J BACTERIOL, V109, P81, DOI 10.1128/JB.109.1.81-88.1972; TAYLOR FR, 1979, BIOCHIM BIOPHYS ACTA, V575, P204, DOI 10.1016/0005-2760(79)90022-5; TODA T, 1987, CELL, V50, P277, DOI 10.1016/0092-8674(87)90223-6; TODA T, 1985, CELL, V40, P27, DOI 10.1016/0092-8674(85)90305-8; WAECHTER CJ, 1973, ARCH BIOCHEM BIOPHYS, V158, P401, DOI 10.1016/0003-9861(73)90637-1; WAECHTER CJ, 1971, J BACTERIOL, V105, P837, DOI 10.1128/JB.105.3.837-843.1971; WALSH JP, 1986, J BIOL CHEM, V261, P6239; WANG PC, 1992, MOL BIOL CELL, V3, P275, DOI 10.1091/mbc.3.3.275; WARNER JR, 1991, METHOD ENZYMOL, V194, P423; WATKINS JD, 1992, ARCH BIOCHEM BIOPHYS, V292, P360, DOI 10.1016/0003-9861(92)90003-F; YAMASHITA S, 1980, EUR J BIOCHEM, V104, P611, DOI 10.1111/j.1432-1033.1980.tb04465.x; YAMASHITA S, 1982, EUR J BIOCHEM, V128, P589	63	28	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 5	1992	267	25					18013	18020						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JM223	1517235				2022-12-25	WOS:A1992JM22300082
J	ABO, A; BOYHAN, A; WEST, I; THRASHER, AJ; SEGAL, AW				ABO, A; BOYHAN, A; WEST, I; THRASHER, AJ; SEGAL, AW			RECONSTITUTION OF NEUTROPHIL NADPH OXIDASE ACTIVITY IN THE CELL-FREE SYSTEM BY 4 COMPONENTS - P67-PHOX, P47-PHOX, P21RAC1, AND CYTOCHROME-B-245	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							CHRONIC GRANULOMATOUS-DISEASE; DEPENDENT SUPEROXIDE PRODUCTION; RESPIRATORY BURST OXIDASE; SODIUM DODECYL-SULFATE; STIMULATED NEUTROPHILS; CYTOSOLIC COMPONENT; PHAGOCYTIC-CELLS; ACTIVATION; PROTEIN; PURIFICATION	Activation of the NADPH oxidase of phagocytes in the cell-free system requires the association of several cytosolic components with membrane-bound cytochrome b. In this study we were able to fully reconstitute NADPH oxidase activity in the cell-free system with three recombinant proteins: p67-phox, p47-phox, p21rac1, and pure cytochrome b-245. Activity was dependent upon the concentration of the proteins, with maximal activity observed with roughly equimolar ratios of the cytochrome b and p67-phox (133 and 163 mol/s/mol, respectively) and concentrations of the other two proteins approximately 1 order of magnitude greater. No activity was observed in the absence of any one of these components. In addition, activation was dependent upon p21rac1 being preloaded with GTP, the cytochrome b being reconstituted with lipid, and the presence of FAD during activation. Half-maximal activity was observed at a concentration of NADPH of approximately 50-mu-M. These findings confirm our recent description of the membrane-bound cytochrome b as a FAD-containing flavocytochrome b containing the NADPH binding site, and implicate the three cytosolic proteins in its activation.			ABO, A (corresponding author), UNIV LONDON UNIV COLL,RAYNE INST,DEPT MED,UNIV ST,LONDON WC1E 6JJ,ENGLAND.			Segal, Anthony/0000-0001-7602-9043	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ABO A, 1991, J BIOL CHEM, V266, P23577; ABO A, 1991, NATURE, V353, P668, DOI 10.1038/353668a0; BABIOR BM, 1988, J BIOL CHEM, V263, P1713; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROMBERG Y, 1984, CELL IMMUNOL, V88, P213, DOI 10.1016/0008-8749(84)90066-2; BROMBERG Y, 1985, J BIOL CHEM, V260, P3539; CASIMIR CM, 1991, P NATL ACAD SCI USA, V88, P2753, DOI 10.1073/pnas.88.7.2753; CHARLES J, 1980, ANAL BIOCHEM, V104, P10; CURNUTTE JT, 1985, J CLIN INVEST, V75, P1740, DOI 10.1172/JCI111885; KNAUS UG, 1991, SCIENCE, V254, P1512, DOI 10.1126/science.1660188; KNOLLER S, 1991, J BIOL CHEM, V266, P2795; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LETO TL, 1990, SCIENCE, V248, P727, DOI 10.1126/science.1692159; LETO TL, 1991, J BIOL CHEM, V266, P19812; LOMAX KJ, 1989, SCIENCE, V245, P409, DOI 10.1126/science.2547247; LOMAX KJ, 1989, SCIENCE, V246, P987, DOI 10.1126/science.2587992; MCPHAIL LC, 1985, J CLIN INVEST, V75, P1735, DOI 10.1172/JCI111884; MOREL F, 1991, EUR J BIOCHEM, V201, P523, DOI 10.1111/j.1432-1033.1991.tb16312.x; NUNOI H, 1988, SCIENCE, V242, P1298, DOI 10.1126/science.2848319; QUINN MT, 1989, NATURE, V342, P198, DOI 10.1038/342198a0; SEGAL AW, 1987, NATURE, V326, P88, DOI 10.1038/326088a0; SEGAL AW, 1985, NATURE, V316, P547, DOI 10.1038/316547a0; SEGAL AW, 1992, BIOCHEM J, V284, P781, DOI 10.1042/bj2840781; SEGAL AW, 1980, FEBS LETT, V110, P111, DOI 10.1016/0014-5793(80)80035-4; SEGAL AW, 1978, NATURE, V276, P515, DOI 10.1038/276515a0; SEGAL AW, 1989, J CLIN INVEST, V83, P1785, DOI 10.1172/JCI114083; SHPUNGIN S, 1989, J BIOL CHEM, V264, P9195; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SMITH RM, 1991, BLOOD, V77, P673; TAMURA M, 1992, J BIOL CHEM, V267, P7529; TEAHAN CG, 1990, BIOCHEM J, V267, P485, DOI 10.1042/bj2670485; VOLPP BD, 1989, P NATL ACAD SCI USA, V86, P7195, DOI 10.1073/pnas.86.18.7195; VOLPP BD, 1988, SCIENCE, V242, P1295, DOI 10.1126/science.2848318	33	265	267	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1992	267	24					16767	16770						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JL053	1512217				2022-12-25	WOS:A1992JL05300006
J	LOWE, ME				LOWE, ME			THE CATALYTIC SITE RESIDUES AND INTERFACIAL BINDING OF HUMAN PANCREATIC LIPASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITROPHENYL PHOSPHATE; DIRECTED MUTAGENESIS; CHOLESTEROL ESTERASE; HEPATIC LIPASE; SERINE; HYDROLYSIS; COLIPASE; PROTEINS; ENZYME; TRIAD	In this study, the essential serine residue and 2 other amino acids in human pancreatic triglyceride lipase (triacylglycerol acylhydrolase, EC 3.1.1.3) were tested for their contribution to the enzyme's catalytic site or interfacial binding site. By site-specific mutagenesis of the cDNA for human pancreatic lipase, amino acid substitutions were made at Ser153, His264, and Asp177. The mutant cDNAs were expressed in transfected COS-1 cells. Both the medium and the cells were examined for the presence of pancreatic lipase by Western blot analysis. The activity of the expressed proteins against triolein and the interfacial binding was measured. Proteins with mutations in Ser153 were secreted by the cells and bound to interfaces but had no detectable activity. Changing His264 to a leucine or Asp177 to an asparagine also produced inactive lipase. Substituting glutamic acid for Asp177 produced an active protein. These results demonstrate that Ser153 is involved in the catalytic site of pancreatic lipase and is not crucial for interfacial binding. Moreover, the essential roles of His264 and Asp177 in catalysis were demonstrated. A Ser-His-Asp catalytic triad similar to that present in serine proteases is present in human pancreatic lipase.			LOWE, ME (corresponding author), WASHINGTON UNIV, SCH MED, DEPT PEDIAT, BOX 8116, ST LOUIS, MO 63101 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK042120] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK42120-02] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BELFRAGE P, 1969, J LIPID RES, V10, P341; BENZONANA G, 1965, BIOCHIM BIOPHYS ACTA, V105, P121, DOI 10.1016/S0926-6593(65)80181-3; BLOW D, 1990, NATURE, V343, P694, DOI 10.1038/343694a0; BORGSTROM B, 1975, J LIPID RES, V16, P411; BORGSTROM B, 1984, LIPASES, P152; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRADY L, 1990, NATURE, V343, P767, DOI 10.1038/343767a0; BRENNER S, 1988, NATURE, V334, P528, DOI 10.1038/334528a0; BROCKMAN HL, 1973, J BIOL CHEM, V248, P4965; BRZOZOWSKI AM, 1991, NATURE, V351, P491, DOI 10.1038/351491a0; CARTER P, 1988, NATURE, V332, P564, DOI 10.1038/332564a0; CHAPUS C, 1976, BIOCHEMISTRY-US, V15, P4988, DOI 10.1021/bi00668a007; CULLEN BR, 1984, NATURE, V307, P241, DOI 10.1038/307241a0; DATTA S, 1988, J BIOL CHEM, V263, P1107; DAVIS RC, 1990, J BIOL CHEM, V265, P6291; DECARO JD, 1989, BIOCHIMIE, V71, P1211, DOI 10.1016/0300-9084(89)90026-6; DECARO JD, 1986, EUR J BIOCHEM, V158, P601; DIPERSIO LP, 1990, J BIOL CHEM, V265, P16801; GARNER CW, 1980, J BIOL CHEM, V255, P5064; GASKIN KJ, 1982, J CLIN INVEST, V69, P427, DOI 10.1172/JCI110466; GUIDONI A, 1981, BIOCHIM BIOPHYS ACTA, V660, P148, DOI 10.1016/0005-2744(81)90120-0; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAIRON D, 1978, BIOCHEMISTRY-US, V17, P205, DOI 10.1021/bi00595a001; LOWE ME, 1989, J BIOL CHEM, V264, P20042; LOWE ME, 1990, CANCER RES, V50, P3956; MICKEL FS, 1989, J BIOL CHEM, V264, P12895; MOREAU H, 1991, BIOCHEMISTRY-US, V30, P1037, DOI 10.1021/bi00218a022; NEGRE A, 1984, BIOCHIM BIOPHYS ACTA, V794, P89, DOI 10.1016/0005-2760(84)90301-1; RILEY DJS, 1990, BIOCHEMISTRY-US, V29, P3848, DOI 10.1021/bi00468a007; Sambrook J, 1989, MOL CLONING LABORATO; SCHRAG JD, 1991, NATURE, V351, P761, DOI 10.1038/351761a0; WINKLER FK, 1990, NATURE, V343, P771, DOI 10.1038/343771a0	34	86	86	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	1992	267	24					17069	17073						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JL053	1512245				2022-12-25	WOS:A1992JL05300053
J	NOVAK, JM; STEIN, MP; LITTLE, SF; LEPPLA, SH; FRIEDLANDER, AM				NOVAK, JM; STEIN, MP; LITTLE, SF; LEPPLA, SH; FRIEDLANDER, AM			FUNCTIONAL-CHARACTERIZATION OF PROTEASE-TREATED BACILLUS-ANTHRACIS PROTECTIVE ANTIGEN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PSEUDOMONAS EXOTOXIN; ADENYLATE-CYCLASE; DIPHTHERIA-TOXIN; LETHAL TOXIN; EUKARYOTIC CELLS; RECEPTOR-BINDING; LOW PH; ENTRY; PURIFICATION; ENDOCYTOSIS	Characterization of the functional domains of Bacillus anthracis protective antigen (PA, 83-kDa), the common cellular binding molecule for both anthrax edema toxin and anthrax lethal toxin, is important for understanding the mechanism of entry and action of the anthrax toxins. In this study, we generated both biologically active (facilitates killing of J774A.1 cells in combination with lethal factor, LF) and inactive preparations of PA by protease treatment. Limited proteolytic digestion of PA in vitro with trypsin generated a 20-kDa fragment and a biologically active 63-kDa fragment. In contrast, limited digestion of PA with chymotrypsin yielded a preparation containing 37- and 47-kDa fragments defective for biological activity. Treatment with both chymotrypsin and trypsin generated three major fragments, 20, "17," and 47 kDa as determined by sodium dodecyl sulfate-polyacrylamide gel electrophoresis. This PA preparation was also biologically inactive. To investigate the nature of the defect resulting from chymotrypsin treatment, we assayed PA preparations for the ability to bind to the cellular receptor and to bind and internalize I-125-LF. All radiolabeled PA preparations bound with specificity to J774A.1 cells and exhibited affinities similar to native 83-kDa PA. Once bound to the cell surface receptor, both trypsin-treated PA and chymotrypsin/trypsin-treated PA specifically bound I-125-LF with high affinity. Finally, these PA preparations delivered I-125-LF to a Pronase-resistant cellular compartment in a time- and temperature-dependent fashion. Thus, the biological defect exhibited by chymotrypsin-treated PA is not at the level of cell binding or internalization but at a step later, such as toxin routing or processing by J774A.1 cells. These protease-treated preparations of PA should prove useful in both elucidating the intracellular processing of anthrax lethal toxin and determining the structure-function relationship of PA and LF.	NIDR, MICROBIAL ECOL LAB, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	NOVAK, JM (corresponding author), USA, MED RES INST INFECT DIS, DIV BACTERIOL, FT DETRICK, FREDERICK, MD 21702 USA.							ALLURED VS, 1985, J BIOL CHEM, V260, P5012; BEALL FA, 1962, J BACTERIOL, V83, P1274, DOI 10.1128/JB.83.6.1274-1280.1962; BHATNAGAR R, 1989, INFECT IMMUN, V57, P2107, DOI 10.1128/IAI.57.7.2107-2114.1989; BLAUSTEIN RO, 1989, P NATL ACAD SCI USA, V86, P2209, DOI 10.1073/pnas.86.7.2209; BOURDENET S, 1990, EUR J BIOCHEM, V192, P379, DOI 10.1111/j.1432-1033.1990.tb19238.x; ESCUYER V, 1991, INFECT IMMUN, V59, P3381, DOI 10.1128/IAI.59.10.3381-3386.1991; EZZELL JW, 1984, INFECT IMMUN, V45, P761, DOI 10.1128/IAI.45.3.761-767.1984; FRIEDLANDER AM, 1986, J BIOL CHEM, V261, P7123; FRIEDLANDER AM, 1990, TRAFFICKING BACTERIA, P121; GORDON VM, 1988, INFECT IMMUN, V56, P1066, DOI 10.1128/IAI.56.5.1066-1069.1988; IACONOCONNORS LC, 1990, INFECT IMMUN, V58, P366, DOI 10.1128/IAI.58.2.366-372.1990; IDZIOREK T, 1990, INFECT IMMUN, V58, P1415, DOI 10.1128/IAI.58.5.1415-1420.1990; JIANG JX, 1990, J BIOL CHEM, V265, P8636; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Leppla S.H., 1991, SOURCEBOOK BACTERIAL, P277; LEPPLA SH, 1988, METHOD ENZYMOL, V165, P103; LEPPLA SH, 1991, METHOD ENZYMOL, V195, P153; LEPPLA SH, 1984, ADV CYCLIC NUCL PROT, V17, P189; LEPPLA SH, 1982, P NATL ACAD SCI-BIOL, V79, P3162, DOI 10.1073/pnas.79.10.3162; LEPPLA SH, 1985, MICROBIOLOGY 1985, P63; Leppla SH, 1988, BACTERIAL PROTEIN TO, P111; LITTLE SF, 1988, INFECT IMMUN, V56, P1807, DOI 10.1128/IAI.56.7.1807-1813.1988; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MOSKAUG JO, 1987, J BIOL CHEM, V262, P10339; OBRIEN AD, 1987, MICROBIOL REV, V51, P206, DOI 10.1128/MMBR.51.2.206-220.1987; OGATA M, 1990, J BIOL CHEM, V265, P20678; OLSNES S, 1988, TRENDS BIOCHEM SCI, V13, P348, DOI 10.1016/0968-0004(88)90105-3; ROLF JM, 1990, J BIOL CHEM, V265, P7331; SAELINGER CB, 1990, TRAFFICKING BACTERIA, P1; SANDVIG K, 1987, J CELL BIOL, V105, P679, DOI 10.1083/jcb.105.2.679; SANDVIG K, 1988, BACTERIAL PROTEIN TO, P135; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SINGH Y, 1989, J BIOL CHEM, V264, P11099; SINGH Y, 1991, J BIOL CHEM, V266, P15493; SINGH Y, 1989, J BIOL CHEM, V264, P19103; STANLEY JL, 1961, J GEN MICROBIOL, V26, P49, DOI 10.1099/00221287-26-1-49; VODKIN MH, 1983, CELL, V34, P693, DOI 10.1016/0092-8674(83)90402-6; WELKOS SL, 1988, GENE, V69, P287, DOI 10.1016/0378-1119(88)90439-8; [No title captured]	40	57	80	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	1992	267	24					17186	17193						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JL053	1512256				2022-12-25	WOS:A1992JL05300071
J	DEVARAJAN, P; JOHNSTON, JJ; GINSBERG, SS; VANWART, HE; BERLINER, N				DEVARAJAN, P; JOHNSTON, JJ; GINSBERG, SS; VANWART, HE; BERLINER, N			STRUCTURE AND EXPRESSION OF NEUTROPHIL GELATINASE CDNA - IDENTITY WITH TYPE-IV COLLAGENASE FROM HT1080 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE FAMILY; STROMELYSIN; METALLOPROTEINASES; BIOSYNTHESIS; FIBROBLASTS; MACROPHAGES; METASTASIS; HOMOLOGY; SECRETE; PROTEIN	Neutrophils synthesize and store intracellularly a 92-kDa type IV collagenase (gelatinase), the primary structure of which is unknown. We designed a primer based on the highly conserved cysteine-switch region of metalloproteinases and employed the polymerase chain reaction to generate a probe of the human neutrophil gelatinase (HNG) gene. This probe was used to clone the cDNA encoding HNG by screening a chronic granulocytic leukemia cDNA library. In vitro translation of the cDNA-derived HNG mRNA yielded a major product of 78 kDa and smaller autolytically activated or degraded products, all of which were recognized by anti-HNG antibody. The HNG cDNA sequence is nearly identical to that encoding a 92-kDa gelatinase secreted by HT1080 cells. In addition, primer extension and S1 analysis reveal that the above two gelatinase transcripts have similar initiation sites. The HNG cDNA hybridized to a 2.8-kilobase mRNA from chronic granulocytic leukemia cells. HNG mRNA expression was absent from uninduced HL60 cells and from HL60 cells induced to granulocytic maturation with Me2SO. However, unlike other neutrophil secondary granule genes, HNG mRNA was detected in HL60 cells induced to monocytic maturation with 12-O-tetradecanoylphorbol 13-acetate. This suggests that the HNG gene may be subject to differential control pathways in two related but distinct hematopoietic lineages.	YALE UNIV,HEMATOL SECT,WWW 423,333 CEDAR ST,NEW HAVEN,CT 06510; SYNTEX RES,INST CANC & DEV BIOL,PALO ALTO,CA 94303	Yale University; Syntex Corporation					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042347] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM027939] Funding Source: NIH RePORTER; NICHD NIH HHS [HD-22297] Funding Source: Medline; NIDDK NIH HHS [DK-42347] Funding Source: Medline; NIGMS NIH HHS [GM-27939] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77; CHIN JR, 1985, J BIOL CHEM, V260, P2367; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COLLIER IE, 1988, J BIOL CHEM, V263, P6579; COLLINS SJ, 1977, NATURE, V270, P347, DOI 10.1038/270347a0; DEVARAJAN P, 1991, BLOOD, V77, P2731; FIBACH E, 1982, LEUKEMIA RES, V6, P781, DOI 10.1016/0145-2126(82)90060-1; GOLDBERG GI, 1986, J BIOL CHEM, V261, P6600; HASTY KA, 1990, J BIOL CHEM, V265, P11421; HIBBS MS, 1985, J BIOL CHEM, V260, P2493; HUHTALA P, 1991, J BIOL CHEM, V266, P16485; Innis MA, 1990, PCR PROTOCOLS GUIDE, P3; JOHNSTON J, 1992, GENOMICS, V12, P459, DOI 10.1016/0888-7543(92)90435-U; JOHNSTON J, 1989, J BIOL CHEM, V264, P15754; JOHNSTON J, 1992, IN PRESS BLOOD; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; MAXAM AM, 1977, P NATL ACAD SCI USA, V74, P560, DOI 10.1073/pnas.74.2.560; MULLER D, 1988, BIOCHEM J, V253, P187, DOI 10.1042/bj2530187; MURPHY G, 1989, J CELL SCI, V92, P487; RADO TA, 1987, BLOOD, V70, P989; RADO TA, 1984, BLOOD, V64, P1103; SAUS J, 1988, J BIOL CHEM, V263, P6742; STETLERSTEVENSON WG, 1990, CANCER METAST REV, V9, P289, DOI 10.1007/BF00049520; VANWART HE, 1990, P NATL ACAD SCI USA, V87, P5578, DOI 10.1073/pnas.87.14.5578; VANWART HE, 1990, BIOL RESPONSE MODIFI, P23; WELGUS HG, 1990, J CLIN INVEST, V86, P1496, DOI 10.1172/JCI114867; WELGUS HG, 1983, J BIOL CHEM, V258, P4162; WHITHAM SE, 1986, BIOCHEM J, V240, P913, DOI 10.1042/bj2400913; WILHELM SM, 1987, P NATL ACAD SCI USA, V84, P6725, DOI 10.1073/pnas.84.19.6725; WILHELM SM, 1989, J BIOL CHEM, V264, P17213; [No title captured]	31	69	73	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1992	267	35					25228	25232						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KB603	1460022				2022-12-25	WOS:A1992KB60300049
J	OGATA, M; FRYLING, CM; PASTAN, I; FITZGERALD, DJ				OGATA, M; FRYLING, CM; PASTAN, I; FITZGERALD, DJ			CELL-MEDIATED CLEAVAGE OF PSEUDOMONAS EXOTOXIN BETWEEN ARG(279) AND GLY(280) GENERATES THE ENZYMATICALLY ACTIVE FRAGMENT WHICH TRANSLOCATES TO THE CYTOSOL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIPHTHERIA-TOXIN; ESCHERICHIA-COLI; CHIMERIC TOXINS; AERUGINOSA; SEQUENCE; EXPRESSION; DELETION; GENE; SITE	Pseudomonas exotoxin (PE) is a three-domain toxin which is cleaved by a cellular protease within cells and then reduced to generate two prominent fragments (Ogata, M., Chaudhary, V. K., Pastan, I., and Fitz-Gerald, D. J. (1990) J. Biol. Chem. 265, 20678-20685). The N-terminal fragment is 28 kDa in size and contains the binding domain. The 37-kDa C-terminal fragment, which translocates to the cytosol, contains the translocation domain and the ADP-ribosylation domain. Cleavage followed by reduction is essential for toxicity since mutant forms of the toxin that cannot be cleaved by cells are nontoxic. Previous results with these mutants suggested that cleavage occurred in an arginine-rich (arginine residues are at positions 274, 276, and 279) disulfide loop near the beginning of the translocation domain, but the exact site of cleavage was not determined. Since very few molecules of the 37-kDa fragment are generated within cells it was not possible to determine the site of cleavage by performing a conventional N-terminal sequence analysis of the 37-kDa fragment. Two experimental approaches were used to overcome this limitation. First, existing amino acids near the cleavage sites were replaced with methionine residues; this was followed by the addition of [S-35]methionine-labeled versions of these toxins to cells. The pattern of radioactive toxin fragments recovered from the cells indicated that the toxin was cleaved either just before or just after Arg279. Second, [H-3]leucine-labeled toxin was produced and added to the cells. Sequential Edman degradations were performed on the small amount of radioactive 37-kDa fragment that could be recovered from toxin-treated cells. A peak of radioactivity in the fifth fraction indicated that leucine was the 5th amino acid on the C-terminal side of the cleavage site. This result confirmed that cleavage was between Arg279 and Gly280.	NCI,MOLEC BIOL LAB,9000 ROCKVILLE PIKE,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			pastan, ira/P-9319-2019	pastan, ira/0000-0002-9223-0270	NATIONAL CANCER INSTITUTE [P30CA012197] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR004869] Funding Source: NIH RePORTER; NCI NIH HHS [CA-12197] Funding Source: Medline; NCRR NIH HHS [RR-04869] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ALLURED VS, 1986, P NATL ACAD SCI USA, V83, P1320, DOI 10.1073/pnas.83.5.1320; CHAUDHARY VK, 1990, P NATL ACAD SCI USA, V87, P308, DOI 10.1073/pnas.87.1.308; COLLIER RJ, 1971, J BIOL CHEM, V246, P1496; DELANGE RJ, 1976, P NATL ACAD SCI USA, V73, P69, DOI 10.1073/pnas.73.1.69; FITZGERALD D, 1980, CELL, V21, P867, DOI 10.1016/0092-8674(80)90450-X; GRAY GL, 1984, P NATL ACAD SCI-BIOL, V81, P2645, DOI 10.1073/pnas.81.9.2645; HARLEY SM, 1985, PLANT SCI, V41, P111, DOI 10.1016/0168-9452(85)90111-6; HWANG J, 1987, CELL, V48, P129, DOI 10.1016/0092-8674(87)90363-1; IGLEWSKI BH, 1975, P NATL ACAD SCI USA, V72, P2284, DOI 10.1073/pnas.72.6.2284; JINNO Y, 1989, J BIOL CHEM, V264, P15953; KOUNNAS MZ, 1992, J BIOL CHEM, V267, P12420; LUKAC M, 1988, INFECT IMMUN, V56, P3095, DOI 10.1128/IAI.56.12.3095-3098.1988; MONTFORT W, 1987, J BIOL CHEM, V262, P5398; MORRIS RE, 1985, SURV SYN PATHOL RES, V4, P34; MOSKAUG JO, 1989, J BIOL CHEM, V264, P15709; NEVILLE DM, 1986, ANNU REV BIOCHEM, V55, P195, DOI 10.1146/annurev.biochem.55.1.195; OGATA M, 1990, J BIOL CHEM, V265, P20678; Olsnes S, 1991, Semin Cell Biol, V2, P7; PAPPENHEIMER AM, 1977, ANNU REV BIOCHEM, V46, P69, DOI 10.1146/annurev.bi.46.070177.000441; PASTAN I, 1989, J BIOL CHEM, V264, P15157; SEETHARAM S, 1991, J BIOL CHEM, V266, P17376; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; THEUER CP, 1992, J BIOL CHEM, V267, P16872; THOMPSON MR, 1991, J BIOL CHEM, V266, P2390; WICK MJ, 1990, ANNU REV MICROBIOL, V44, P335, DOI 10.1146/annurev.mi.44.100190.002003; WILLIAMS DP, 1990, J BIOL CHEM, V265, P20673	26	152	161	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1992	267	35					25396	25401						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KB603	1460035				2022-12-25	WOS:A1992KB60300074
J	PRONGAY, AJ; WILLIAMS, CH				PRONGAY, AJ; WILLIAMS, CH			OXIDATION-REDUCTION PROPERTIES OF ESCHERICHIA-COLI THIOREDOXIN REDUCTASE ALTERED AT EACH ACTIVE-SITE CYSTEINE RESIDUE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MECHANISMS; SULFUR; FLAVIN	Thioredoxin is a small oxidation-reduction (redox) mediator protein. Its reduction by NADPH is catalyzed by the flavoenzyme thioredoxin reductase. Site-directed mutagenesis has provided forms of the reductase in which Cys135 and Cys138 have each been changed to a serine residue (Prongay, A. J., Engelke, D. R., and Williams, C. H., Jr. (1989) J. Biol. Chem. 264, 2656-2664). Cys135 and Cys138 form the redox-active disulfide in the oxidized enzyme. The redox properties of the two altered forms of Escherichia coli thioredoxin reductase have been determined from pH 6.0 to 9.0. Photoreduction of TRR(Ser135,Cys138) produces the blue, neutral semiquinone species, which disproportionates (K(f) = 0.73) to an apparent maximum of 29% of the total enzyme as the semiquinone. In contrast, the semiquinone formed on TRR(Cys135,Ser138) during a photoreductive titration does not disproportionate and 70% of the enzyme is stabilized as the semiquinione. Reductive titrations have demonstrated that 1 mol of sodium dithionite (2 electrons)/mol of FAD is required to fully reduce TRR(Ser135,Cys138) whereas 2 mol of dithionite/mol of FAD are required to fully reduce TRR(Cys135,Ser138). The oxidation-reduction midpoint potentials for the 1-electron and 2-electron reductions of TRR(Ser135,Cys138) have been determined by NADH/NAD+ titrations in the presence of a mediator, benzyl viologen. The midpoint potential for the 2-electron reduction of TRR(Ser135,Cys138) is -280 mV, at pH 7.0 and 20-degrees-C. Thus, the redox potential is similar to that of the FAD/FADH2 couple in the dithiol form of wild type enzyme, -270 mV (corrected to 20-degrees-C) (O'Donnell, M. E., and Williams, C. H., Jr. (1983) J. Biol. Chem. 258,13795-13805). The DELTAE(m)/DELTApH is -57.1 mV, which corresponds to a proton stoichiometry of 2 H+/2 e-. A maximum of 19% of the enzyme forms a stable semiquinone species during the titration, and the potentials for the oxidized enzyme/semiquinone couple, E2, and the semiquinone/reduced enzyme couple, E1, are -306 and -256 mV, respectively, at pH 7.0 and 20-degrees-C. These studies provide evidence that the residue at position 138 exerts a greater effect on the FAD than does the residue at position 135.	VET AFFAIRS MED CTR, MED RES SERV 151, 2215 FULLER RD, ANN ARBOR, MI 48105 USA; UNIV MICHIGAN, DEPT BIOL CHEM, ANN ARBOR, MI 48105 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Michigan System; University of Michigan					NIGMS NIH HHS [GM21444] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Capozzi G., 1974, CHEM THIOL GROUP 2; CLARK WM, 1960, OXIDATION REDUCTION, P186; Crampton MR., 1974, CHEM THIOL GROUP, P379; HOLMGREN A, 1985, ANNU REV BIOCHEM, V54, P237, DOI 10.1146/annurev.bi.54.070185.001321; KICE JL, 1980, ADV PHYS ORG CHEM, V17, P65; KURIYAN J, 1991, NATURE, V352, P172, DOI 10.1038/352172a0; MASSEY V, 1978, BIOCHEMISTRY-US, V17, P9, DOI 10.1021/bi00594a002; MASSEY V, 1977, J BIOL CHEM, V252, P5612; MASSEY V, 1978, BIOCHEMISTRY-US, V17, P1, DOI 10.1021/bi00594a001; MOORE EC, 1964, J BIOL CHEM, V239, P3453; ODONNELL ME, 1983, J BIOL CHEM, V258, P3795; POOLE LB, 1989, J BIOL CHEM, V264, P12330; PRONGAY AJ, 1989, J BIOL CHEM, V264, P2656; PRONGAY AJ, 1990, J BIOL CHEM, V265, P18968; SCHIERBEEK AJ, 1989, J MOL BIOL, V206, P365, DOI 10.1016/0022-2836(89)90486-5; SCHULZ GE, 1978, NATURE, V273, P120, DOI 10.1038/273120a0; SMITH WW, 1977, J MOL BIOL, V117, P195, DOI 10.1016/0022-2836(77)90031-6; SNYDER JP, 1977, J AM CHEM SOC, V99, P2931, DOI 10.1021/ja00451a014; THELANDER L, 1968, EUR J BIOCHEM, V4, P407, DOI 10.1111/j.1432-1033.1968.tb00227.x; WILLIAMS CH, 1979, METHOD ENZYMOL, V62, P183; ZANETTI G, 1968, J BIOL CHEM, V243, P4013; ZANETTI G, 1967, J BIOL CHEM, V242, P5232	22	20	20	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	1992	267	35					25181	25188						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KB603	1460018				2022-12-25	WOS:A1992KB60300042
J	BORHANI, DW; HARTER, TM; PETRASH, JM				BORHANI, DW; HARTER, TM; PETRASH, JM			THE CRYSTAL-STRUCTURE OF THE ALDOSE REDUCTASE.NADPH BINARY COMPLEX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRELIMINARY CRYSTALLOGRAPHIC ANALYSIS; PARA-HYDROXYBENZOATE HYDROXYLASE; DIABETIC COMPLICATIONS; DIHYDROFOLATE-REDUCTASE; GLUTATHIONE-REDUCTASE; DINUCLEOTIDE BINDING; ESCHERICHIA-COLI; HUMAN-TISSUES; CRYSTALLIZATION; ALDEHYDE	Aldose reductase is an NADPH-dependent oxidoreductase that catalyzes the reduction of a broad range of aldehydes, including glucose. Since aldose reductase has been strongly implicated in the development of the chronic complications of diabetes mellitus, much effort has been devoted to understanding the structure and mechanism of this enzyme, and many aldose reductase inhibitors have been developed as potential drugs for the treatment of these complications. We describe here the 2.75 angstrom crystal structure of recombinant human aldose reductase (Cys-298 to Ser mutant) complexed with NADPH. This mutant displays unusual kinetic behavior characterized by high K(m)/high V(max) substrate kinetics and reduced sensitivity to certain aldose reductase inhibitors. The crystal structure revealed that the enzyme is a beta/alpha-barrel with the coenzyme-binding domain located at the carboxyl-terminal end of the parallel strands of the barrel. The enzyme undergoes a large conformational change upon binding NADPH which involves the reorientation of loop 7 to a position which appears to lock the coenzyme into place. NADPH is bound to aldose reductase in an unusual manner, more similar to FAD- rather than NAD(P)-dependent oxidoreductases. No disulfide bridges were observed in the crystal structure.	WASHINGTON UNIV,SCH MED,DEPT OPHTHALMOL & VISUAL SCI,660 S EUCLID AVE,CAMPUS BOX 8096,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT GENET,ST LOUIS,MO 63110; BIOCRYST PHARMACEUT INC,BIRMINGHAM,AL 35244	Washington University (WUSTL); Washington University (WUSTL)				Borhani, David/0000-0002-8486-8792; Harter, Theresa/0000-0002-7039-2236	NATIONAL EYE INSTITUTE [R23EY005856, R01EY005856, R55EY005856] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P60DK020579] Funding Source: NIH RePORTER; NEI NIH HHS [EY05856] Funding Source: Medline; NIDDK NIH HHS [P60 DK20579] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADAMS JA, 1991, BIOCHEMISTRY-US, V30, P11046, DOI 10.1021/bi00110a006; ALBER T, 1981, PHILOS T ROY SOC B, V293, P159, DOI 10.1098/rstb.1981.0069; ANDERSSON I, 1989, NATURE, V337, P229, DOI 10.1038/337229a0; BOULTON AJM, 1990, DIABETOLOGIA, V33, P431, DOI 10.1007/BF00404095; BYSTROFF C, 1990, BIOCHEMISTRY-US, V29, P3263, DOI 10.1021/bi00465a018; Crowther R. A., 1972, MOL REPLACEMENT METH, P173; DAS B, 1985, DIABETES, V34, P1145, DOI 10.2337/diabetes.34.11.1145; DELCORSO A, 1990, ARCH BIOCHEM BIOPHYS, V283, P512, DOI 10.1016/0003-9861(90)90675-O; EKLUND H, 1984, BIOCHEMISTRY-US, V23, P5982, DOI 10.1021/bi00320a014; ELKABBANI O, 1991, J MOL BIOL, V218, P695, DOI 10.1016/0022-2836(91)90257-7; FELDMAN HB, 1977, BIOCHIM BIOPHYS ACTA, V480, P14, DOI 10.1016/0005-2744(77)90316-3; FITA I, 1985, P NATL ACAD SCI USA, V82, P1604, DOI 10.1073/pnas.82.6.1604; FLYNN TG, 1982, BIOCHEM PHARMACOL, V31, P2705, DOI 10.1016/0006-2952(82)90123-X; FLYNN TG, 1975, J BIOL CHEM, V250, P2933; GONZALEZ AM, 1986, DIABETES, V35, P1200, DOI 10.2337/diabetes.35.11.1200; GREENE D, 1988, METABOLISM, V37, P25, DOI 10.1016/0026-0495(88)90184-9; GRIMSHAW CE, 1990, BIOCHEMISTRY-US, V29, P9947, DOI 10.1021/bi00494a027; GRIMSHAW CE, 1989, BIOCHEMISTRY-US, V28, P5343, DOI 10.1021/bi00439a006; HAYMAN S, 1965, J BIOL CHEM, V240, P877; HOWARD AJ, 1987, J APPL CRYSTALLOGR, V20, P383, DOI 10.1107/S0021889887086436; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; KADOR PF, 1988, MED RES REV, V8, P325, DOI 10.1002/med.2610080302; KARPLUS PA, 1987, J MOL BIOL, V195, P701, DOI 10.1016/0022-2836(87)90191-4; KINOSHITA JH, 1988, DIABETES METAB REV, V4, P323, DOI 10.1002/dmr.5610040403; KUBISESKI TJ, 1992, J BIOL CHEM, V267, P6510; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P376; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINDQVIST Y, 1985, P NATL ACAD SCI USA, V82, P6855, DOI 10.1073/pnas.82.20.6855; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; MCPHERSON A, 1990, EUR J BIOCHEM, V189, P1, DOI 10.1111/j.1432-1033.1990.tb15454.x; PETRASH JM, 1992, J BIOL CHEM, V267, P24833; Ramachandran G N, 1968, Adv Protein Chem, V23, P283, DOI 10.1016/S0065-3233(08)60402-7; RONDEAU JM, 1987, J MOL BIOL, V195, P945, DOI 10.1016/0022-2836(87)90498-0; RONDEAU JM, 1992, NATURE, V355, P469, DOI 10.1038/355469a0; RONDEAU JM, 1992, J MOL BIOL, V355, P469; Rossman M.G., 1975, ENZYMES, V11, P61, DOI 10.1016/S1874-6047(08)60210-3; ROSSMANN MG, 1990, ACTA CRYSTALLOGR A, V46, P73, DOI 10.1107/S0108767389009815; SCHIERING N, 1991, NATURE, V352, P168, DOI 10.1038/352168a0; SCHREUDER HA, 1988, J MOL BIOL, V199, P637, DOI 10.1016/0022-2836(88)90307-5; SKARZYNSKI T, 1987, J MOL BIOL, V193, P171, DOI 10.1016/0022-2836(87)90635-8; SPIELBERG SP, 1991, ANN INTERN MED, V114, P720, DOI 10.7326/0003-4819-114-9-720; SRIVASTAVA SK, 1982, CURR EYE RES, V2, P407, DOI 10.3109/02713688209000786; STURA EA, 1983, J MOL BIOL, V170, P529, DOI 10.1016/S0022-2836(83)80160-0; SUSSMAN JL, 1977, ACTA CRYSTALLOGR A, V33, P800, DOI 10.1107/S0567739477001958; TILTON RG, 1992, KIDNEY INT, V41, P778, DOI 10.1038/ki.1992.121; TILTON RG, 1989, DIABETES, V38, P1258, DOI 10.2337/diabetes.38.10.1258; TUCKLE IJ, 1985, MOL REPLACEMENT, P22; VANDERJAGT DL, 1990, J BIOL CHEM, V265, P20982; WEBB LE, 1973, BIOCHEMISTRY-US, V12, P5101, DOI 10.1021/bi00749a013; WIERENGA RK, 1985, BIOCHEMISTRY-US, V24, P1346, DOI 10.1021/bi00327a012; WIERENGA RK, 1983, J MOL BIOL, V167, P725, DOI 10.1016/S0022-2836(83)80106-5; WILMANNS M, 1991, BIOCHEMISTRY-US, V30, P9161, DOI 10.1021/bi00102a006; WILSON DK, 1992, SCIENCE, V257, P81, DOI 10.1126/science.1621098; ZENON GJ, 1990, CLIN PHARMACY, V9, P446; 1979, CCP4 DAR LAB SERC UK; 1990, ARCH OPHTHALMOL-CHIC, V108, P1234	56	113	115	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1992	267	34					24841	24847						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KA263	1447221				2022-12-25	WOS:A1992KA26300102
J	GAIDO, KW; MANESS, SC; LEONARD, LS; GREENLEE, WF				GAIDO, KW; MANESS, SC; LEONARD, LS; GREENLEE, WF			2,3,7,8-TETRACHLORODIBENZO-PARA-DIOXIN-DEPENDENT REGULATION OF TRANSFORMING GROWTH FACTORS-ALPHA AND FACTOR-BETA(2) EXPRESSION IN A HUMAN KERATINOCYTE CELL-LINE INVOLVES BOTH TRANSCRIPTIONAL AND POSTTRANSCRIPTIONAL CONTROL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER RIBONUCLEIC-ACID; FACTOR-BETA; EPITHELIAL-CELLS; TERMINAL DIFFERENTIATION; TGF-BETA; DIOXIN; CLONING; RNA; INDUCTION; TCDD	2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD), a potent modulator of epithelial cell growth and differentiation, has been shown to induce transforming growth factor (TGF)-alpha in cultures of human keratinocytes and in the human keratinocyte cell line, SCC-12F. In this report, we investigated the mechanisms by which TCDD alters TGF-alpha expression. In addition, we studied the actions of TCDD on TGF-beta1 and TGF-beta2 expression. Treatment of SCC-12F cells with TCDD resulted in an increase in TGF-alpha and a reduction in TGF-beta2 mRNA levels while mRNA levels for TGF-beta1 were unchanged. Changes in TGF-alpha and TGF-beta2 expression were maximal by 24 h. No change in the rate of transcription of TGF-alpha was detected following treatment with TCDD as determined by nuclear run-off analysis. TCDD treatment resulted in a stabilization of TGF-alpha mRNA as judged by an approximately 2-fold higher level of TGF-alpha mRNA in treated versus control cells in the presence of actinomycin D. In contrast to TGF-alpha, the rate of transcription of TGF-beta2 was significantly reduced following TCDD treatment. These findings demonstrate that the induction of TGF-alpha expression in SCC-12F cells by TCDD occurs post-transcriptionally, primarily by mRNA stabilization, while TGF-beta2 expression is reduced due to a decrease in the rate of TGF-beta2 gene transcription.			GAIDO, KW (corresponding author), CHEM IND INST TOXICOL, POB 12137, RES TRIANGLE PK, NC 27709 USA.							BARNARD JA, 1990, BIOCHIM BIOPHYS ACTA, V1032, P79, DOI 10.1016/0304-419X(90)90013-Q; BARRANDON Y, 1987, CELL, V50, P1131, DOI 10.1016/0092-8674(87)90179-6; BASCOM CC, 1989, MOL CELL BIOL, V9, P5508, DOI 10.1128/MCB.9.12.5508; CHOI EJ, 1991, J BIOL CHEM, V266, P9591; DERYNCK R, 1988, EMBO J, V7, P3737, DOI 10.1002/j.1460-2075.1988.tb03257.x; DERYNCK R, 1990, MOL REPROD DEV, V27, P3, DOI 10.1002/mrd.1080270104; DERYNCK R, 1985, NATURE, V316, P701, DOI 10.1038/316701a0; DUGAICZYK A, 1983, BIOCHEMISTRY-US, V22, P1605, DOI 10.1021/bi00276a013; ECKERT RL, 1986, CELL, V46, P583, DOI 10.1016/0092-8674(86)90884-6; GLICK AB, 1989, CELL REGUL, V1, P87, DOI 10.1091/mbc.1.1.87; GLICK AB, 1990, MOL ENDOCRINOL, V4, P46, DOI 10.1210/mend-4-1-46; GOUSTIN AS, 1986, CANCER RES, V46, P1015; GREENLEE WF, 1990, PROG CLIN BIOL RES, V331, P177; GREENLEE WF, 1987, REV BIOCHEM TOXICOL, V8, P1; HEBERT CD, 1990, CARCINOGENESIS, V11, P1335, DOI 10.1093/carcin/11.8.1335; HUDSON LG, 1983, BIOCHEM BIOPH RES CO, V115, P611, DOI 10.1016/S0006-291X(83)80188-0; ISRAEL DI, 1984, J BIOL CHEM, V259, P5400; JAKOWLEW SB, 1988, MOL ENDOCRINOL, V2, P747, DOI 10.1210/mend-2-8-747; JONES PBC, 1985, SCIENCE, V227, P1499, DOI 10.1126/science.3856321; KNUTSON JC, 1982, CELL, V30, P225, DOI 10.1016/0092-8674(82)90028-9; MADISEN L, 1988, DNA-J MOLEC CELL BIO, V7, P1, DOI 10.1089/dna.1988.7.1; MASSAGUE J, 1990, J BIOL CHEM, V265, P21393; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MILSTONE LM, 1984, J INVEST DERMATOL, V82, P532, DOI 10.1111/1523-1747.ep12261149; NEVINS JR, 1987, METHOD ENZYMOL, V152, P234; OHTA M, 1987, NATURE, V329, P539, DOI 10.1038/329539a0; OSBORNE R, 1985, TOXICOL APPL PHARM, V77, P434, DOI 10.1016/0041-008X(85)90183-8; PAEK I, 1987, MOL CELL BIOL, V7, P1496, DOI 10.1128/MCB.7.4.1496; PARTRIDGE M, 1989, BRIT J CANCER, V60, P542, DOI 10.1038/bjc.1989.310; PASCO DS, 1988, J BIOL CHEM, V263, P8671; PELTZ S W, 1991, Critical Reviews in Eukaryotic Gene Expression, V1, P99; POLAND A, 1982, ANNU REV PHARMACOL, V22, P517, DOI 10.1146/annurev.pa.22.040182.002505; QUATTROCHI LC, 1985, DNA-J MOLEC CELL BIO, V4, P395, DOI 10.1089/dna.1985.4.395; RHEINWALD JG, 1983, HUMAN CARCINOGENESIS, P85; RICE RH, 1984, CARCINOGENESIS, V5, P367, DOI 10.1093/carcin/5.3.367; RICE RH, 1989, ENVIRON HEALTH PERSP, V80, P239, DOI 10.2307/3430749; ROSA F, 1988, SCIENCE, V239, P783, DOI 10.1126/science.3422517; ROSA F, 1992, J BIOL CHEM, V267, P8050; SPORN MB, 1990, CELL REGUL, V1, P875, DOI 10.1091/mbc.1.12.875; STAIANOCOICO L, 1990, EXP CELL RES, V191, P286, DOI 10.1016/0014-4827(90)90016-4; SUSKIND RR, 1985, SCAND J WORK ENV HEA, V11, P165, DOI 10.5271/sjweh.2240; SUTTER TR, 1991, SCIENCE, V254, P415, DOI 10.1126/science.1925598; TODARO GJ, 1980, P NATL ACAD SCI-BIOL, V77, P5258, DOI 10.1073/pnas.77.9.5258; WHITLOCK JP, 1990, ANNU REV PHARMACOL, V30, P251; WHITLOCK JP, 1988, GENE SIGNAL TRANSDUC, P207; WILLEY JC, 1984, CARCINOGENESIS, V5, P209, DOI 10.1093/carcin/5.2.209	46	136	139	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 5	1992	267	34					24591	24595						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KA263	1447203				2022-12-25	WOS:A1992KA26300067
J	RETZINGER, GS; CHANDLER, LJ; COOK, BC				RETZINGER, GS; CHANDLER, LJ; COOK, BC			COMPLEXATION WITH HEPARIN PREVENTS ADHESION BETWEEN FIBRIN-COATED SURFACES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TERNARY COMPLEX; HUMAN-PLASMA; THROMBIN; PROTEINS; BINDING; GLYCOSAMINOGLYCANS; ANTITHROMBIN; INTERFACE; POLYMER; MONOMER	Heparin, in Langmuirian fashion, binds stoichiometrically with high affinity, K(d) is similar to 100 nM, to both fibrinogen and fibrin adsorbed as monomolecular films to lecithin-coated, microscopic, polystyrene-divinylbenzene beads. Complex formation inhibits aggregation of fibrin-coated beads, and it also results in dissociation of preformed aggregates of fibrin-coated beads. These phenomena are not caused by desorption of fibrin(ogen), indirect inhibition of thrombin activity, or mere electrostatic repulsion of charged particles. Instead, these data are consistent with the proposal that the complexed heparin interferes directly with dimer formation between fibrin molecules adsorbed to colliding beads. We describe these phenomena and their application to the development of sensitive analytical methods for quantitating heparin. Based on these observations, we also propose a role for endogenous heparin in the physiologic regulation of fibrin-mediated adhesion of surfaces.			RETZINGER, GS (corresponding author), MED COLL WISCONSIN, DEPT PATHOL, MILWAUKEE, WI 53226 USA.							AZAROVA LA, 1991, GEMATOL TRANSFUZIOL, V36, P23; BABA M, 1988, P NATL ACAD SCI USA, V85, P6132, DOI 10.1073/pnas.85.16.6132; BAGNALL RD, 1978, J BIOMED MATER RES, V12, P203, DOI 10.1002/jbm.820120206; Baier R E, 1969, J Biomed Mater Res, V3, P191, DOI 10.1002/jbm.820030115; Barrowcliffe T. W., 1989, HEPARIN CHEM BIOL PR, P393; BENGTSSONOLIVECRONA G, 1985, BIOCHEM J, V226, P409, DOI 10.1042/bj2260409; BLOMBACK B, 1966, BIOCHIM BIOPHYS ACTA, V115, P371, DOI 10.1016/0304-4165(66)90437-5; BRAY B, 1989, BIOCHEM J, V262, P225, DOI 10.1042/bj2620225; CHANDY T, 1985, J COLLOID INTERF SCI, V108, P104, DOI 10.1016/0021-9797(85)90240-1; COLVIN RB, 1975, J EXP MED, V142, P1377, DOI 10.1084/jem.142.6.1377; COOK BC, 1992, J COLLOID INTERF SCI, V153, P1, DOI 10.1016/0021-9797(92)90292-T; COPLEY AL, 1983, ANN NY ACAD SCI, V416, P377, DOI 10.1111/j.1749-6632.1983.tb35200.x; DAMUS PS, 1973, NATURE, V246, P355, DOI 10.1038/246355a0; EDELMAN ER, 1990, P NATL ACAD SCI USA, V87, P3773, DOI 10.1073/pnas.87.10.3773; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; HEMKER HC, 1989, ANN NY ACAD SCI, V556, P146; HOGG PJ, 1990, J BIOL CHEM, V265, P248; HOGG PJ, 1989, P NATL ACAD SCI USA, V86, P3619, DOI 10.1073/pnas.86.10.3619; HOGG PJ, 1990, J BIOL CHEM, V265, P241; HORNE MK, 1988, BLOOD, V71, P273; JACOBSSON K-G, 1979, Thrombosis and Haemostasis, V42, P84; KEFALIDES NA, 1987, HEMOSTASIS THROMBOSI, P798; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lindahl, 1989, HEPARIN CHEM BIOL PR, P51; LINDON JN, 1986, BLOOD, V68, P355; MAAT B, 1981, J CANCER RES CLIN, V101, P275, DOI 10.1007/BF00410113; MATTOCK P, 1971, NATURE-NEW BIOL, V233, P277, DOI 10.1038/newbio233277a0; MIHALYI E, 1968, BIOCHEMISTRY-US, V7, P208, DOI 10.1021/bi00841a026; Nader H. B., 1989, HEPARIN CHEM BIOL PR, P81; RETZINGER GS, 1991, ANAL BIOCHEM, V195, P18, DOI 10.1016/0003-2697(91)90288-5; RETZINGER GS, 1990, ANAL BIOCHEM, V186, P169, DOI 10.1016/0003-2697(90)90592-W; RETZINGER GS, 1985, ANAL BIOCHEM, V150, P131, DOI 10.1016/0003-2697(85)90451-8; RETZINGER GS, 1981, J BIOL CHEM, V256, P8208; ROSENBERG RD, 1987, HEMOSTASIS THROMBOSI, P1373; SEAMAN GVH, 1986, AM CLIN PROD REV, V5, P25; SNOW AD, 1987, BIOMED BIOCHIM ACTA, V46, P537; STAPRANS I, 1985, J CLIN INVEST, V76, P1984, DOI 10.1172/JCI112198; THUNBERG L, 1980, THROMB HAEMOSTASIS, V44, P125; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRIANTAPHYLLOPO.DC, 1964, NATURE, V204, P1096, DOI 10.1038/2041096b0; WOLFENSTEINTODEL C, 1980, P NATL ACAD SCI-BIOL, V77, P5069, DOI 10.1073/pnas.77.9.5069; YAMAOKA K, 1981, J PHARMACOBIO-DYNAM, V4, P879, DOI 10.1248/bpb1978.4.879; ZUCKER MB, 1977, FED PROC, V36, P47	44	14	16	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 5	1992	267	34					24356	24362						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KA263	1447186				2022-12-25	WOS:A1992KA26300035
J	FISCH, P; BOEHM, T; LAVENIR, I; LARSON, T; ARNO, J; FORSTER, A; RABBITTS, TH				FISCH, P; BOEHM, T; LAVENIR, I; LARSON, T; ARNO, J; FORSTER, A; RABBITTS, TH			T-CELL ACUTE LYMPHOBLASTIC LYMPHOMA INDUCED IN TRANSGENIC MICE BY THE RBTN1 AND RBTN2 LIM-DOMAIN GENES	ONCOGENE			English	Article							TISSUE-SPECIFIC EXPRESSION; DNA-BINDING MOTIF; HUMAN CD2 GENE; C-MYC GENE; CHROMOSOMAL TRANSLOCATION; MESSENGER-RNAS; CHAIN GENE; LEUKEMIA; PROTEIN; ONCOGENE	Two members of the RBTN gene family, RBTN1/Ttg-1 and RBTN2/Ttg-2, were found by their association with T-cell tumour-specific chromosomal translocations and are thought to be involved in the aetiology of such T-cell tumours. Here a transgenic mouse model is described in which T-cell tumours are induced by the presence of RBTN1 and RBTN2 transgenes that direct expression in thymus-derived cells. The latency period for lymphoid tumour appearance is variable, and tumours occur in a small proportion of transgenic animals that develop T-cell acute lymphoblastic malignancies. No significant increase in the rate of tumour development was observed in RBTN1 transgenic mice infected with Moloney murine leukaemia virus, nor did tumours arise in mice bearing a construct in which RBTN1 was expressed from the insulin transcriptional promoter. These data, which provide formal proof of the oncogenic activity of these genes, suggest that aberrant expression of transcription factor genes, such as RBTN1 and RBTN2, functions in tumour aetiology by disturbing some aspect of T-cell differentiation.	MRC, MOLEC BIOL LAB, HILLS RD, CAMBRIDGE CB2 2QH, ENGLAND; ADDENBROOKES HOSP, DEPT HISTOPATHOL, CAMBRIDGE CB2 2QQ, ENGLAND	MRC Laboratory Molecular Biology; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge			Rabbitts, Terence/D-6262-2016	Rabbitts, Terence/0000-0002-4982-2609				ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; ADAMS JM, 1991, SCIENCE, V254, P1161, DOI 10.1126/science.1957168; ALLEN ND, 1988, NATURE, V333, P852, DOI 10.1038/333852a0; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BEGLEY CG, 1989, P NATL ACAD SCI USA, V86, P10128, DOI 10.1073/pnas.86.24.10128; BERNARD O, 1990, GENE CHROMOSOME CANC, V1, P194, DOI 10.1002/gcc.2870010303; BLUESTONE JA, 1987, NATURE, V326, P82, DOI 10.1038/326082a0; BOEHM T, 1990, EMBO J, V9, P857, DOI 10.1002/j.1460-2075.1990.tb08183.x; BOEHM T, 1990, ONCOGENE, V5, P1103; BOEHM T, 1988, EMBO J, V7, P385, DOI 10.1002/j.1460-2075.1988.tb02825.x; BOEHM T, 1991, ONCOGENE, V6, P695; BOEHM T, 1988, EMBO J, V7, P2011, DOI 10.1002/j.1460-2075.1988.tb03040.x; BOEHM T, 1991, P NATL ACAD SCI USA, V88, P4367, DOI 10.1073/pnas.88.10.4367; BRUGGEMANN M, 1991, EUR J IMMUNOL, V21, P1323, DOI 10.1002/eji.1830210535; CATHALA G, 1983, DNA-J MOLEC CELL BIO, V2, P329, DOI 10.1089/dna.1983.2.329; CHEN Q, 1990, EMBO J, V9, P415, DOI 10.1002/j.1460-2075.1990.tb08126.x; CLEARY ML, 1991, CELL, V66, P619, DOI 10.1016/0092-8674(91)90105-8; DUBE ID, 1991, BLOOD, V78, P2996; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FORONI L, 1992, J MOL BIOL, V226, P747, DOI 10.1016/0022-2836(92)90630-3; FREYD G, 1990, NATURE, V344, P876, DOI 10.1038/344876a0; GREENBERG JM, 1990, NATURE, V344, P158, DOI 10.1038/344158a0; HANAHAN D, 1985, NATURE, V315, P115, DOI 10.1038/315115a0; HARRIS AW, 1988, J EXP MED, V167, P353, DOI 10.1084/jem.167.2.353; HATANO M, 1991, SCIENCE, V253, P79, DOI 10.1126/science.1676542; HAUPT Y, 1991, CELL, V65, P753, DOI 10.1016/0092-8674(91)90383-A; HEIM S, 1991, REC ADV PATH, V3, P37; KARLSSON O, 1990, NATURE, V344, P879, DOI 10.1038/344879a0; KENNEDY MA, 1991, P NATL ACAD SCI USA, V88, P8900, DOI 10.1073/pnas.88.20.8900; KRIMPENFORT P, 1988, EMBO J, V7, P745, DOI 10.1002/j.1460-2075.1988.tb02871.x; LAKE RA, 1990, EMBO J, V9, P3129, DOI 10.1002/j.1460-2075.1990.tb07510.x; LANG G, 1988, EMBO J, V7, P1675, DOI 10.1002/j.1460-2075.1988.tb02995.x; LEDER A, 1986, CELL, V45, P485, DOI 10.1016/0092-8674(86)90280-1; LU M, 1991, EMBO J, V10, P2905, DOI 10.1002/j.1460-2075.1991.tb07840.x; MALISSEN M, 1984, CELL, V37, P1101, DOI 10.1016/0092-8674(84)90444-6; MCGUIRE EA, 1992, MOL CELL BIOL, V12, P4186, DOI 10.1128/MCB.12.9.4186; MCGUIRE EA, 1991, BLOOD, V77, P599; MCGUIRE EA, 1989, MOL CELL BIOL, V9, P2124, DOI 10.1128/MCB.9.5.2124; MELLENTIN JD, 1989, CELL, V58, P77, DOI 10.1016/0092-8674(89)90404-2; RABBITTS TH, 1985, EMBO J, V4, P2217, DOI 10.1002/j.1460-2075.1985.tb03917.x; RABBITTS TH, 1983, NATURE, V306, P760, DOI 10.1038/306760a0; RABBITTS TH, 1991, ADV IMMUNOL, V50, P119; RABBITTS TH, 1991, CELL, V67, P641, DOI 10.1016/0092-8674(91)90057-6; ROYERPOKORA B, 1991, ONCOGENE, V6, P1887; SANCHEZGARCIA I, 1991, ONCOGENE, V6, P577; THICK J, 1992, IN PRESS GENES CHROM, V5; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; VANLOHUIZEN M, 1989, CELL, V56, P673, DOI 10.1016/0092-8674(89)90589-8; VANLOHUIZEN M, 1991, CELL, V65, P737, DOI 10.1016/0092-8674(91)90382-9; WAY JC, 1988, CELL, V54, P5, DOI 10.1016/0092-8674(88)90174-2; XIA Y, 1991, P NATL ACAD SCI USA, V88, P11416, DOI 10.1073/pnas.88.24.11416	51	113	118	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	1992	7	12					2389	2397						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KA856	1461647				2022-12-25	WOS:A1992KA85600003
J	LAU, KS; HERRING, WJ; CHUANG, JL; MCKEAN, M; DANNER, DJ; COX, RP; CHUANG, DT				LAU, KS; HERRING, WJ; CHUANG, JL; MCKEAN, M; DANNER, DJ; COX, RP; CHUANG, DT			STRUCTURE OF THE GENE ENCODING DIHYDROLIPOYL TRANSACYLASE-(E2) COMPONENT OF HUMAN BRANCHED-CHAIN ALPHA-KETO ACID DEHYDROGENASE COMPLEX AND CHARACTERIZATION OF AN E2 PSEUDOGENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYRUP-URINE-DISEASE; BOVINE LIVER; ESCHERICHIA-COLI; NUCLEOTIDE-SEQUENCE; SUBUNIT STRUCTURE; LIPOYL-BEARING; MESSENGER-RNA; FAR-UPSTREAM; 3T3-L1 CELLS; CORE DOMAIN	We have determined the structural organization of the dihydrolipoyl transacylase (E2) gene of the human branched chain alpha-keto acid dehydrogenase complex. The single copy E2 gene spans approximately 68 kilobases of genomic DNA. The complete coding region consisting of the 5'- and 3'-untranslated regions, the mitochondrial targeting sequence (61 amino acids), and the mature E2 sequence (421 amino acids) are encoded by 11 exons ranging from 62 to 2239 base pairs. All the donor and acceptor splice sites conform to the gt-ag rule. Sequence analysis of the promoter-regulatory region showed the presence of a "CAAT box"-like sequence 537 bases upstream of the transcription initiation site. The "TATA box"-like sequence is absent. Also located in this region are sequences resembling glucocorticoid-responsive and cAMP-responsive elements, fat-specific elements, and Sp1- and AP-2-binding sites. Several sets of direct and inverted repeats are also present. Promoter assays using human hepatoma cells (Hep-G2) and Swiss mouse preadipocytes (3T3-L1) showed that a 4.1-kilobase PstI fragment upstream of the transcription start site confers high expression of the luciferase reporter gene. Moreover, an intronless E2 pseudogene was isolated. It corresponds to the complete mitochondrial presequence and the lipoyl-bearing domain that are encoded by exons I through IV of the functional E2 gene. However, the E2 pseudogene contains multiple base changes, deletions, and insertions, and is flanked by short direct repeats. The data indicate that the E2 pseudogene is a retroposon.	UNIV TEXAS,SW MED CTR,DEPT BIOCHEM,5323 HARRY HINES BLVD,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT INTERNAL MED,DALLAS,TX 75235; EMORY UNIV,SCH MED,DEPT PEDIAT,DIV MED GENET,ATLANTA,GA 30322	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Emory University					NIDDK NIH HHS [DK-26758, DK-37373] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037373, R01DK026758] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BATES DL, 1977, NATURE, V268, P313, DOI 10.1038/268313a0; BROWN RM, 1990, SOMAT CELL MOLEC GEN, V16, P487, DOI 10.1007/BF01233198; CATE RL, 1980, J BIOL CHEM, V255, P7556; CHUANG DT, 1983, BIOCHEM J, V214, P177, DOI 10.1042/bj2140177; CHUANG DT, 1984, J BIOL CHEM, V259, P9277; CHUANG DT, 1985, J BIOL CHEM, V260, P3779; COLLINS JH, 1977, P NATL ACAD SCI USA, V74, P4223, DOI 10.1073/pnas.74.10.4223; DAMUNI Z, 1984, P NATL ACAD SCI-BIOL, V81, P4335, DOI 10.1073/pnas.81.14.4335; DANNER DJ, 1989, J BIOL CHEM, V264, P7742; Danner DJ, 1989, METABOLIC BASIS INHE, P671; DAVIS LG, 1986, BASIC METHODS MOL BI, P185; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DISTEL RJ, 1987, CELL, V49, P835, DOI 10.1016/0092-8674(87)90621-0; FATANIA HR, 1983, FEBS LETT, V158, P234, DOI 10.1016/0014-5793(83)80585-7; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FISHER CW, 1991, BIOCHEM BIOPH RES CO, V174, P804, DOI 10.1016/0006-291X(91)91489-Y; FRERMAN FE, 1983, J BIOL CHEM, V258, P7087; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8993; GRIFFIN TA, 1988, J BIOL CHEM, V263, P14008; HEFFELFINGER SC, 1983, BIOCHEMISTRY-US, V22, P5519, DOI 10.1021/bi00293a011; HERRING WJ, 1991, AM J HUM GENET, V48, P342; HERRING WJ, 1992, BIOCHIM BIOPHYS ACTA, V1138, P236, DOI 10.1016/0925-4439(92)90043-M; HU CWC, 1986, J BIOL CHEM, V261, P343; HU CWC, 1988, J BIOL CHEM, V263, P9007; HUMMEL KB, 1988, J BIOL CHEM, V263, P6165; HUNT CR, 1986, P NATL ACAD SCI USA, V83, P3786, DOI 10.1073/pnas.83.11.3786; JANTZEN HM, 1987, CELL, V49, P29, DOI 10.1016/0092-8674(87)90752-5; KADONAGA JT, 1986, TRENDS BIOCHEM SCI, V11, P20, DOI 10.1016/0968-0004(86)90226-4; KIMURA M, 1983, EVOLUTION GENES PROT, P797; KOZAK M, 1987, J MOL BIOL, V196, P947, DOI 10.1016/0022-2836(87)90418-9; LAU KS, 1991, FEBS LETT, V279, P229, DOI 10.1016/0014-5793(91)80155-V; LAU KS, 1988, BIOCHEMISTRY-US, V27, P1972, DOI 10.1021/bi00406a025; LAU KS, 1982, FEBS LETT, V144, P57, DOI 10.1016/0014-5793(82)80568-1; MITCHELL PJ, 1987, CELL, V50, P847, DOI 10.1016/0092-8674(87)90512-5; MITSUBUCHI H, 1991, J BIOL CHEM, V266, P14686; MITSUBUCHI H, 1991, J CLIN INVEST, V87, P1207, DOI 10.1172/JCI115120; NOBUKUNI Y, 1989, BIOCHEM BIOPH RES CO, V161, P1035, DOI 10.1016/0006-291X(89)91347-8; PAXTON R, 1982, J BIOL CHEM, V257, P4433; PETIT FH, 1978, P NATL ACAD SCI USA, V75, P4881; REED LJ, 1980, ENZYME REGULATION ME, P47; ROESLER WJ, 1988, J BIOL CHEM, V263, P9063; ROGERS JH, 1985, INT REV CYTOL, V93, P187, DOI 10.1016/S0074-7696(08)61375-3; ROSENTHAL N, 1987, METHOD ENZYMOL, V152, P704; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; THEISEN M, 1986, EMBO J, V5, P719, DOI 10.1002/j.1460-2075.1986.tb04273.x; WYMAN AR, 1985, P NATL ACAD SCI USA, V82, P2880, DOI 10.1073/pnas.82.9.2880; ZNEIMER SM, 1991, GENOMICS, V10, P740, DOI 10.1016/0888-7543(91)90458-Q	48	25	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1992	267	33					24090	24096						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JZ239	1429740				2022-12-25	WOS:A1992JZ23900099
J	RAO, VN; REDDY, ESP				RAO, VN; REDDY, ESP			ELK-1 DOMAINS RESPONSIBLE FOR AUTONOMOUS DNA-BINDING, SRE-SRF INTERACTION AND NEGATIVE REGULATION OF DNA-BINDING	ONCOGENE			English	Article							PUTATIVE ONCOGENE SPI-1; MURINE LEUKEMIA-VIRUS; LONG TERMINAL REPEAT; ETS PROTO-ONCOGENE; C-ETS; V-ETS; TRANSCRIPTIONAL ACTIVATION; C-ETS-1 PROTOONCOGENE; GENE; SEQUENCE	The ets oncogene superfamily consists of a family of sequence-specific DNA-binding transcriptional activator proteins. We have previously identified, cloned and characterized one of the divergent ets-related members elk-1 and shown that it codes for a sequence-specific DNA-binding transcriptional activator. We have also shown that elk-1 forms SRF (Serum Response Factor) dependent ternary complex with SRE (Serum Response Element), similar to p62TCF. In this report, we have mapped the DNA-binding domain of the elk-1 protein (EDB, elk-1 DNA Binding domain) to the 76 amino acid ets homology region. We have also mapped the SRF interaction domain of the elk-1 protein (ESI, elk-1 SRF Interaction domain) to the carboxy-terminal region of the EDB domain. Ternary complex formation by elk-1 requires both EDB and ESI domains of the elk-1 protein. Our results also show that the EDB domain of the elk-1 protein (residues1-89) binds SRE autonomously, unlike full-length elk-1 protein, suggesting the presence of a potential Negative Regulatory DNA binding domain (NRD) which prevents the binding of elk-1 protein to SRE. Interaction of SRF with the ESI domain allows the elk-1 protein to bind to SRE. Thus elk-1 belongs to a class of transcriptional factors that are involved in gene regulation not only by autonomous DNA binding but also by indirect DNA binding through recruitment by cellular factors.			RAO, VN (corresponding author), JEFFERSON CANC INST,BLUMLE LIFE SCI BLDG,233 S 10TH ST,PHILADELPHIA,PA 19107, USA.							ANTON IA, 1988, NATURE, V336, P719, DOI 10.1038/336719a0; BENDAVID Y, 1991, GENE DEV, V5, P908, DOI 10.1101/gad.5.6.908; BENDAVID Y, 1990, P NATL ACAD SCI USA, V87, P1332, DOI 10.1073/pnas.87.4.1332; BEUG H, 1984, CELL, V39, P579, DOI 10.1016/0092-8674(84)90465-3; BOSSELUT R, 1990, EMBO J, V9, P3137, DOI 10.1002/j.1460-2075.1990.tb07511.x; BOULUKOS KE, 1989, MOL CELL BIOL, V9, P5718, DOI 10.1128/MCB.9.12.5718; BOULUKOS KE, 1988, EMBO J, V7, P697, DOI 10.1002/j.1460-2075.1988.tb02865.x; BURTIS KC, 1990, CELL, V61, P85, DOI 10.1016/0092-8674(90)90217-3; CHEN JH, 1988, ONCOGENE RES, V2, P371; CLARK SP, 1983, P NATL ACAD SCI-BIOL, V80, P5037, DOI 10.1073/pnas.80.16.5037; COQUILLAND M, 1988, ONCOGENE RES, V2, P335; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; DIAZ MO, 1986, SCIENCE, V231, P265, DOI 10.1126/science.3455787; DUDEK H, 1992, P NATL ACAD SCI USA, V89, P1291, DOI 10.1073/pnas.89.4.1291; FUJIWARA S, 1988, ONCOGENE, V2, P99; FUJIWARA S, 1988, MOL CELL BIOL, V8, P4700, DOI 10.1128/MCB.8.11.4700; GOEBL MG, 1990, CELL, V61, P1165, DOI 10.1016/0092-8674(90)90676-6; GOLAY J, 1988, CELL, V55, P1147, DOI 10.1016/0092-8674(88)90259-0; GUNTHER CV, 1990, GENE DEV, V4, P667, DOI 10.1101/gad.4.4.667; HIPSKIND RA, 1991, NATURE, V354, P531, DOI 10.1038/354531a0; HO IC, 1990, SCIENCE, V250, P814, DOI 10.1126/science.2237431; HOLLAND CA, 1987, P NATL ACAD SCI USA, V84, P8662, DOI 10.1073/pnas.84.23.8662; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; LAMARCO K, 1991, SCIENCE, V253, P789, DOI 10.1126/science.1876836; LEPRINCE D, 1983, NATURE, V306, P395, DOI 10.1038/306395a0; LEPRINCE D, 1988, J VIROL, V62, P3233, DOI 10.1128/JVI.62.9.3233-3241.1988; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; MOREAUGACHELIN F, 1989, ONCOGENE, V4, P1449; MOSCOVICI MG, 1983, VIROLOGY, V129, P65, DOI 10.1016/0042-6822(83)90396-3; NUNN MF, 1983, NATURE, V306, P391, DOI 10.1038/306391a0; NUNN MF, 1989, J VIROL, V63, P398, DOI 10.1128/JVI.63.1.398-402.1989; POGNONEC P, 1989, ONCOGENE, V4, P691; RADKE K, 1982, CELL, V31, P643, DOI 10.1016/0092-8674(82)90320-8; RAO VN, 1992, ONCOGENE, V7, P65; RAO VN, 1987, SCIENCE, V237, P635, DOI 10.1126/science.3299708; RAO VN, 1988, ONCOGENE, V3, P497; RAO VN, 1989, SCIENCE, V244, P66, DOI 10.1126/science.2539641; REDDY ESP, 1988, ONCOGENE RES, V3, P239; REDDY ESP, 1987, P NATL ACAD SCI USA, V84, P6131, DOI 10.1073/pnas.84.17.6131; REDDY ESP, 1991, ONCOGENE, V6, P2285; REDDY ESP, 1992, GUIDE BOOK ONCOGENES; REDDY ESP, 1990, CANCER RES, V50, P5013; SAIKUMAR P, 1990, P NATL ACAD SCI USA, V87, P8452, DOI 10.1073/pnas.87.21.8452; SETH A, 1989, P NATL ACAD SCI USA, V86, P7833, DOI 10.1073/pnas.86.20.7833; SETH A, 1990, ONCOGENE, V5, P1761; SHAW PE, 1989, CELL, V56, P563, DOI 10.1016/0092-8674(89)90579-5; THOMPSON CB, 1992, MOL CELL BIOL, V12, P1043, DOI 10.1128/MCB.12.3.1043; TREISMAN R, 1986, CELL, V46, P567, DOI 10.1016/0092-8674(86)90882-2; TREISMAN R, 1990, CANCER BIOL, V1, P47; URNESS LD, 1990, CELL, V63, P47, DOI 10.1016/0092-8674(90)90287-O; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WATSON DK, 1988, P NATL ACAD SCI USA, V85, P7862, DOI 10.1073/pnas.85.21.7862; XIN JH, 1992, GENE DEV, V6, P481, DOI 10.1101/gad.6.3.481	53	40	40	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1992	7	11					2335	2340						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JW665	1437156				2022-12-25	WOS:A1992JW66500028
J	BURNS, K; HELGASON, CD; BLEACKLEY, RC; MICHALAK, M				BURNS, K; HELGASON, CD; BLEACKLEY, RC; MICHALAK, M			CALRETICULIN IN LYMPHOCYTES-T - IDENTIFICATION OF CALRETICULIN IN LYMPHOCYTES-T AND DEMONSTRATION THAT ACTIVATION OF T-CELLS CORRELATES WITH INCREASED LEVELS OF CALRETICULIN MESSENGER-RNA AND PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							CALCIUM-BINDING PROTEIN; MUSCLE SARCOPLASMIC-RETICULUM; GLUCOSE-REGULATED PROTEINS; ENDOPLASMIC-RETICULUM; BIOCHEMICAL-CHARACTERIZATION; DISULFIDE ISOMERASE; MOLECULAR-CLONING; EXPRESSION; AFFINITY; CA-2+	Ca2+ is an essential second messenger for T cell activation, but the exact mechanisms of its action are poorly understood. The cytosolic Ca2+ concentration is significantly increased upon the stimulation of T cells with either mitogen, cross-linking antibodies, or their cognate ligands. In this study, expression of calreticulin, a major Ca2+-binding (storage), KDEL protein of the endoplasmic reticulum was examined in resting and concanavalin A (ConA)-stimulated mouse and human T-lymphocytes. Both resting, mouse and human lymphocytes contain very low levels of calreticulin mRNA and protein. Mouse splenocytes stimulated with ConA exhibited an induction in calreticulin mRNA which peaked by Day 4. A 5-fold increase in the immunoreactive calreticulin protein band was also observed, in the cells during this period of stimulation. Similarly when human lymphocytes were cultured with ConA a significant increase in the levels of the calreticulin mRNA and protein was observed. The peak of calreticulin mRNA was observed at Day 1 rather than Day 4 as seen for the mouse. These results clearly demonstrate the presence of calreticulin, a Ca2+-binding protein originally characterized in muscle tissue, in activated T-lymphocytes. Furthermore, we show that expression of calreticulin correlates with T-lymphocyte activation. Our, results suggest that calreticulin may be involved in the signaling pathway for the induction of Ca2+-dependent processes and may represent one regulatory mechanism operating in activation of T-lymphocytes.	UNIV ALBERTA,DEPT BIOCHEM,EDMONTON T6G 2S2,ALBERTA,CANADA	University of Alberta	BURNS, K (corresponding author), UNIV ALBERTA,CARDIOVASC DIS RES GRP,EDMONTON T6G 2S2,ALBERTA,CANADA.							AHERN T, 1975, EXP CELL RES, V92, P513, DOI 10.1016/0014-4827(75)90410-3; ASHMAN RF, 1984, FUNDAMENTAL IMMUNOLO, P267; AZRBER S, 1992, J CELL BIOL, V116, P113; BAKSH S, 1991, J BIOL CHEM, V266, P21458; BERRIDGE MJ, 1990, J BIOL CHEM, V265, P9585; CARAFOLI E, 1987, ANNU REV BIOCHEM, V56, P395, DOI 10.1146/annurev.biochem.56.1.395; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CLEMENTI E, 1992, J BIOL CHEM, V267, P2164; COOPER HL, 1981, J BIOL CHEM, V256, P7461; DEMAUREX N, 1992, J BIOL CHEM, V267, P2318; DORNER AJ, 1990, J BIOL CHEM, V265, P22029; DUDOV KP, 1984, CELL, V37, P457, DOI 10.1016/0092-8674(84)90376-3; FLIEGEL L, 1989, J BIOL CHEM, V264, P21522; FRIEDMAN J, 1991, CELL, V66, P799, DOI 10.1016/0092-8674(91)90123-G; GARDNER P, 1989, CELL, V59, P15, DOI 10.1016/0092-8674(89)90865-9; GELFAND EW, 1984, J CELL PHYSIOL, V121, P533, DOI 10.1002/jcp.1041210312; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; HAAS IG, 1983, NATURE, V306, P387, DOI 10.1038/306387a0; HESKETH TR, 1983, J BIOL CHEM, V258, P4876; KOZUTSUMI Y, 1988, NATURE, V332, P462, DOI 10.1038/332462a0; KRAUSE KH, 1990, BIOCHEM J, V270, P545, DOI 10.1042/bj2700545; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEDERMAN HM, 1984, P NATL ACAD SCI-BIOL, V81, P6827, DOI 10.1073/pnas.81.21.6827; LEE AS, 1984, J BIOL CHEM, V259, P4616; LENNY N, 1991, J BIOL CHEM, V266, P520; LEWIS MJ, 1985, J BIOL CHEM, V260, P3050; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; MASON MJ, 1991, J BIOL CHEM, V266, P10872; MAZZARELLA RA, 1990, J BIOL CHEM, V265, P1094; MAZZARELLA RA, 1987, J BIOL CHEM, V262, P8875; MCCAULIFFE DP, 1990, J CLIN INVEST, V85, P1379, DOI 10.1172/JCI114582; MICHALAK M, 1991, EXP CELL RES, V179, P91; MILNER RE, 1991, J BIOL CHEM, V266, P7155; MUNRO S, 1986, CELL, V46, P291, DOI 10.1016/0092-8674(86)90746-4; OPAS M, 1991, J CELL PHYSIOL, V149, P160, DOI 10.1002/jcp.1041490120; OSTWALD TJ, 1974, J BIOL CHEM, V249, P974; PELHAM HRB, 1989, ANNU REV CELL BIOL, V5, P1, DOI 10.1146/annurev.cb.05.110189.000245; PUTNEY JW, 1990, CELL CALCIUM, V11, P611, DOI 10.1016/0143-4160(90)90016-N; TAYLOR MV, 1984, NATURE, V312, P462, DOI 10.1038/312462a0; TIEMEIER DC, 1977, GENE, V2, P173, DOI 10.1016/0378-1119(77)90016-6; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TSIEN RY, 1982, NATURE, V295, P68, DOI 10.1038/295068a0; WELCH WJ, 1983, J BIOL CHEM, V258, P7102	43	45	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1992	267	27					19039	19042						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JP593	1527030				2022-12-25	WOS:A1992JP59300005
J	JOYAL, JL; APRILLE, JR				JOYAL, JL; APRILLE, JR			THE ATP-MG/PI CARRIER OF RAT-LIVER MITOCHONDRIA CATALYZES A DIVALENT ELECTRONEUTRAL EXCHANGE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE POOL SIZE; ADENINE-NUCLEOTIDES; PHOSPHATE TRANSPORT; MECHANISM; HEPATOCYTES; KINETICS; EFFLUX	Net transport of ATP-Mg or ADP in exchange for phosphate in isolated rat liver mitochondria has been shown to be an electroneutral process mediated by the ATP-Mg/P(i) carrier. We compared the steady state distribution ratios of phosphate, ATP-Mg, and ADP at a pH of 7.4 to determine whether the divalent or monovalent form of these anions is the transported substrate. The log of the divalent ATP-Mg distribution ratio (in/out) approached the log of the divalent phosphate distribution ratio (approximately 0.85), which was approximately twice the value of the DELTApH (approximately 0.40) across the inner mitochondrial membrane. This steady state relationship held under several different conditions, e.g. when the medium ATP concentration was varied or if the Phosphate gradient was modified by partial uncoupling with the proton ionophore, carbonyl cyanide p-trifluoromethoxyphenylhydrazone. Unidirectional ADP efflux in exchange for external ADP or ATP-Mg was stimulated by an increase in matrix H+. The log of the trivalent ADP distribution ratio (approximately 1.20) approached 3 times the value of DELTApH. All these data are consistent with the model of an electroneutral exchange of divalent phosphate (HPO42-) for divalent ATP-Mg (ATP-Mg2-) or for divalent protonated ADP (HADP2-). We conclude that this transport mechanism accounts for the adenine nucleotide concentration gradient that normally exists between the matrix and external medium.	TUFTS UNIV, DEPT BIOL, MITOCHONDRIAL PHYSIOL UNIT, MEDFORD, MA 02155 USA	Tufts University					NICHD NIH HHS [HD16936] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD016936] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		APRILLE JR, 1990, REPROD BIOL, P101; APRILLE JR, 1982, BIOCHEM BIOPH RES CO, V108, P834, DOI 10.1016/0006-291X(82)90905-6; APRILLE JR, 1981, ARCH BIOCHEM BIOPHYS, V212, P689, DOI 10.1016/0003-9861(81)90413-6; APRILLE JR, 1988, FASEB J, V2, P2547, DOI 10.1096/fasebj.2.10.3290024; APRILLE JR, 1988, INTEGRATION MITOCHON, P393; AUSTIN J, 1983, ARCH BIOCHEM BIOPHYS, V222, P321, DOI 10.1016/0003-9861(83)90529-5; AUSTIN J, 1984, J BIOL CHEM, V259, P154; AW TY, 1987, AM J PHYSIOL, V252, pC356, DOI 10.1152/ajpcell.1987.252.4.C356; AW TY, 1985, AM J PHYSIOL, V249, pC385, DOI 10.1152/ajpcell.1985.249.5.C385; BAGINSKI ES, 1967, CLIN CHIM ACTA, V15, P155, DOI 10.1016/0009-8981(67)90340-3; BARBOUR RL, 1981, J BIOL CHEM, V256, P1940; Bartfai T, 1979, Adv Cyclic Nucleotide Res, V10, P219; COTY WA, 1974, J BIOL CHEM, V249, P2593; DUYCKAERTS C, 1980, EUR J BIOCHEM, V106, P1; GEHNRICH SC, 1988, COMP BIOCHEM PHYS B, V91, P11, DOI 10.1016/0305-0491(88)90107-1; GIRARD J, 1982, BIOCH DEV FETUS NEON, P517; GREENBAUM NL, 1985, J BIOL CHEM, V260, P873; HAYNES RC, 1986, J BIOL CHEM, V261, P6121; HOEK JB, 1971, BIOCHIM BIOPHYS ACTA, V226, P297, DOI 10.1016/0005-2728(71)90096-X; Jaworek D, 1974, METHODS ENZYMATIC AN, P2127, DOI 10.1016/B978-0-12-091304-6.50066-5; KLINGENBERG M, 1977, EUR J BIOCHEM, V73, P125, DOI 10.1111/j.1432-1033.1977.tb11298.x; LAMPRECHT W, 1974, METHOD ENZYMAT AN, V4, P2101; LANOUE KF, 1979, ANNU REV BIOCHEM, V48, P871, DOI 10.1146/annurev.bi.48.070179.004255; LANOUE KF, 1984, BIOENERGETICS, P221; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MEYER AJ, 1969, BIOCHIM BIOPHYS ACTA, V189, P136, DOI 10.1016/0005-2728(69)90236-9; NAKAZAWA T, 1977, J BIOCHEM-TOKYO, V82, P1575, DOI 10.1093/oxfordjournals.jbchem.a131852; NOSEK MT, 1990, J BIOL CHEM, V265, P8444; NOSEK MT, 1992, ARCH BIOCHEM BIOPHYS, V296, P691, DOI 10.1016/0003-9861(92)90628-A; PALMIERI F, 1971, EUR J BIOCHEM, V22, P66, DOI 10.1111/j.1432-1033.1971.tb01515.x; PAPA S, 1971, EUR J BIOCHEM, V22, P134, DOI 10.1111/j.1432-1033.1971.tb01524.x; ROTTENBERG H, 1990, FEBS LETT, V274, P65, DOI 10.1016/0014-5793(90)81330-Q; STRZELECKI T, 1984, J BIOL CHEM, V259, P4122; SUTTON R, 1978, DIFFERENTIATION, V12, P15; WATANABE F, 1983, J BIOCHEM-TOKYO, V94, P493, DOI 10.1093/oxfordjournals.jbchem.a134380; [No title captured]	36	40	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1992	267	27					19198	19203						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JP593	1527042				2022-12-25	WOS:A1992JP59300031
J	KIM, IY; VERES, Z; STADTMAN, TC				KIM, IY; VERES, Z; STADTMAN, TC			ESCHERICHIA-COLI MUTANT SELD ENZYMES - THE CYSTEINE-17 RESIDUE IS ESSENTIAL FOR SELENOPHOSPHATE FORMATION FROM ATP AND SELENIDE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIOPHAGE-T7 RNA-POLYMERASE; SELENOCYSTEINE SYNTHASE; GENES; NUCLEOSIDE; EXPRESSION; SEQUENCE; CHAIN	Synthesis of a labile selenium donor compound, selenophosphate, from selenide and ATP by the Escherichia coli SELD enzyme was reported previously from this laboratory. From the gene sequence, SELD is a 37-kDa protein that contains 7 cysteine residues, 2 of which are located at positions 17 and 19 in the sequence -Gly-Ala-Cys-Gly-Cys-Lys-Ile-(Leinfelder, W., Forchhammer, K., Veprek, B., Zehelein, E., and Bock, A. (1990) Proc. Natl. Acad. Sci. U. S. A. 73, 543-547). Inactivation of the enzyme by alkylation with iodoacetamide indicated that at least 1 cysteine residue in the protein is essential for enzyme activity. To test the possibility that the Cys17 and/or Cys19 residue might be essential, these were changed to serine residues by site-specific mutagenesis. The biological activities of the wild type and mutant proteins were studied using E. coli MB08 (selD-) transformed with plasmids containing the selD genes. The plasmid containing the Cys17-mutated gene failed to complement MB08, whereas the Cys19-mutated gene was indistinguishable from wild type. The mutant proteins, like the wild type enzyme, bound to an ATP-agarose matrix, showing that their affinities for ATP were unimpaired. Selenide-dependent formation of AMP from ATP was abolished by mutation of Cys17, but the Cys19 mutation had no effect on the ability of the enzyme to catalyze the reaction. These results indicate that Cys17 has an essential role in the catalytic process that leads to the formation of selenophosphate from ATP and selenide.	NHLBI, BIOCHEM LAB, BLDG 3, RM 108, 9000 ROCKVILLE PIKE, BETHESDA, MD 20892 USA; HUNGARIAN ACAD SCI, CENT RES INST CHEM, H-1525 BUDAPEST, HUNGARY	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Hungarian Academy of Sciences; Hungarian Research Centre for Natural Sciences								BAGNARA AS, 1972, ANAL BIOCHEM, V45, P24, DOI 10.1016/0003-2697(72)90004-8; Bock A, 1988, Biofactors, V1, P245; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; CAVALLINI D, 1966, NATURE, V212, P294, DOI 10.1038/212294a0; ELLMAN GL, 1958, ARCH BIOCHEM BIOPHYS, V74, P443, DOI 10.1016/0003-9861(58)90014-6; FORCHHAMMER K, 1991, J BIOL CHEM, V266, P6318; FORCHHAMMER K, 1991, J BIOL CHEM, V266, P6324; GARFIN DE, 1990, METHOD ENZYMOL, V182, P425; HADDOCK BA, 1982, BIOCHEM SOC T, V10, P478, DOI 10.1042/bst0100478; LEINFELDER W, 1988, J BACTERIOL, V170, P540, DOI 10.1128/jb.170.2.540-546.1988; LEINFELDER W, 1990, P NATL ACAD SCI USA, V87, P543, DOI 10.1073/pnas.87.2.543; LIU F, 1992, J BIOL CHEM, V267, P2388; Maniatis T, 1989, MOL CLONING; PECK HD, 1957, J BACTERIOL, V73, P706, DOI 10.1128/JB.73.6.706-721.1957; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; SEEFELDT LC, 1992, J BIOL CHEM, V267, P6680; STADTMAN T C, 1989, Biofactors, V2, P35; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; VERES Z, 1992, P NATL ACAD SCI USA, V89, P2975, DOI 10.1073/pnas.89.7.2975; WITTWER AJ, 1986, ARCH BIOCHEM BIOPHYS, V248, P540, DOI 10.1016/0003-9861(86)90507-2; WITTWER AJ, 1984, BIOCHEMISTRY-US, V23, P4650, DOI 10.1021/bi00315a021	23	53	55	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 25	1992	267	27					19650	19654						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JP593	1527085				2022-12-25	WOS:A1992JP59300094
J	CHONN, A; SEMPLE, SC; CULLIS, PR				CHONN, A; SEMPLE, SC; CULLIS, PR			ASSOCIATION OF BLOOD PROTEINS WITH LARGE UNILAMELLAR LIPOSOMES INVIVO - RELATION TO CIRCULATION LIFETIMES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COATED LIPOSOMES; PLASMA-PROTEINS; CHOLESTEROL; CLEARANCE; LIVER; SIZE; ADSORPTION; STABILITY; INVITRO; CHARGE	The proteins associated with liposomes in the circulation of mice were analyzed in order to determine whether bound proteins significantly influence the fate of liposomes in vivo. Liposomes were administered intravenously via the dorsal tail vein of CD1 mice and were isolated from blood after 2 min in the absence of coagulation inhibitors using a rapid "spin column" procedure. Various negatively charged liposomes exhibiting markedly different clearance properties were studied; notably, these included liposomes containing 10 mol % ganglioside G(M1) which has been previously shown to effectively limit liposomal uptake by the fixed macrophages of the reticuloendothelial system. The protein binding ability (P(B); g of protein/mol of lipid) of the liposomes was quantitated and related to the Circulation half-life (tau-1/2) of the liposomes. Liposomes having similar membrane surface charge imparted by different anionic phospholipids were found to exhibit markedly different protein binding potentials. Furthermore, P(B) values determined from the in vivo experiments were found to be inversely related to circulation half-lives. P(B) values in excess of 50 g of protein/mol of lipid were observed for rapidly cleared liposomes such as those containing cardiolipin or phosphatidic acid (tau-1/2 < 2 min). P(B) values for ganglioside G(M1)-containing liposomes (tau-1/2 > 2 h) were significantly less (PB < 15 g of total protein/mol of total lipid). P(B) values were also determined for liposomes recovered from in vitro incubations with isolated human serum; relative P(B) values obtained from these in vitro experiments were in agreement with relative P(B) values measured from in vivo experiments. P(B) values, therefore, could be a useful parameter for predicting the clearance behavior of liposomes in the circulation. Liposomes exhibiting increased P(B) values in vivo were shown by immunoblot analysis to bind more immune opsonins, leading to a higher probability of phagocytic uptake. Finally, based on results obtained using the in vitro system, it is suggested that the mechanism by which ganglioside G(M1) prolongs the murine circulation half-life of liposomes is by reducing the total amount of blood protein bound to the liposomes in a relatively nonspecific manner.			CHONN, A (corresponding author), UNIV BRITISH COLUMBIA, FAC MED, DEPT BIOCHEM, 2146 HLTH SCI MALL, VANCOUVER V6T 1Z3, BC, CANADA.							ABRA RM, 1981, BIOCHIM BIOPHYS ACTA, V666, P493, DOI 10.1016/0005-2760(81)90311-8; ALLEN TM, 1987, FEBS LETT, V223, P42, DOI 10.1016/0014-5793(87)80506-9; ALVING CR, 1984, BIOCHEM SOC T, V12, P342, DOI 10.1042/bst0120342; ANDRADE JD, 1987, ANN NY ACAD SCI, V516, P158, DOI 10.1111/j.1749-6632.1987.tb33038.x; BLACK CDV, 1976, BIOCHEM SOC T, V4, P253; BLUME G, 1990, BIOCHIM BIOPHYS ACTA, V1029, P91, DOI 10.1016/0005-2736(90)90440-Y; BONTE F, 1986, CHEM PHYS LIPIDS, V40, P359, DOI 10.1016/0009-3084(86)90079-4; CHONN A, 1991, BIOCHIM BIOPHYS ACTA, V1070, P215, DOI 10.1016/0005-2736(91)90167-7; CHONN A, 1991, J IMMUNOL, V146, P4234; DERKSEN JTP, 1987, BIOCHIM BIOPHYS ACTA, V931, P33, DOI 10.1016/0167-4889(87)90047-4; Fiske CH, 1925, J BIOL CHEM, V66, P375; GABIZON A, 1988, P NATL ACAD SCI USA, V85, P6949, DOI 10.1073/pnas.85.18.6949; GREEN SR, 1989, J LIPID RES, V30, P1405; GREGORIADIS G, 1980, FEBS LETT, V119, P43, DOI 10.1016/0014-5793(80)80994-X; Gregoriadis G., 1988, LIPOSOMES DRUG CARRI, P3; Halperin G, 1986, Methods Enzymol, V129, P816; HOPE MJ, 1985, BIOCHIM BIOPHYS ACTA, V812, P55, DOI 10.1016/0005-2736(85)90521-8; HORBETT TA, 1987, PROTEINS INTERFACES, P1; JULIANO RL, 1975, BIOCHEM BIOPH RES CO, V63, P651, DOI 10.1016/S0006-291X(75)80433-5; JULIANO RL, 1980, LIPOSOMES IMMUNOBIOL, P49; KESSLER RJ, 1986, ANAL BIOCHEM, V159, P138, DOI 10.1016/0003-2697(86)90318-0; KIRBY C, 1980, BIOCHEM J, V186, P591, DOI 10.1042/bj1860591; KLIBANOV AL, 1990, FEBS LETT, V268, P235, DOI 10.1016/0014-5793(90)81016-H; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; PAPAHADJOPOULOS D, 1987, ANN NY ACAD SCI, V507, P64, DOI 10.1111/j.1749-6632.1987.tb45792.x; PATEL HM, 1983, BIOCHIM BIOPHYS ACTA, V761, P142, DOI 10.1016/0304-4165(83)90223-4; RABILLOUD T, 1988, ELECTROPHORESIS, V9, P288, DOI 10.1002/elps.1150090608; ROERDINK FH, 1989, BIOCHIM BIOPHYS ACTA, V980, P234, DOI 10.1016/0005-2736(89)90404-5; SENIOR J, 1986, FEBS LETT, V196, P54, DOI 10.1016/0014-5793(86)80213-7; SENIOR JH, 1987, CRC CR REV THER DRUG, V3, P123; SOMMERMAN EF, 1966, THESIS U BRIT COLUMB; STEIN Y, 1980, FEBS LETT, V111, P104, DOI 10.1016/0014-5793(80)80771-X; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6	33	391	402	0	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	1992	267	26					18759	18765						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JN502	1527006				2022-12-25	WOS:A1992JN50200078
J	KURZCHALIA, TV; GORVEL, JP; DUPREE, P; PARTON, R; KELLNER, R; HOUTHAEVE, T; GRUENBERG, J; SIMONS, K				KURZCHALIA, TV; GORVEL, JP; DUPREE, P; PARTON, R; KELLNER, R; HOUTHAEVE, T; GRUENBERG, J; SIMONS, K			INTERACTIONS OF RAB5 WITH CYTOSOLIC PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING-PROTEIN; SIGNAL RECOGNITION PARTICLE; MOLECULAR-CLONING; SACCHAROMYCES-CEREVISIAE; ENDOPLASMIC-RETICULUM; NASCENT PREPROLACTIN; VESICULAR TRANSPORT; MUTATIONAL ANALYSIS; SYNAPTIC VESICLES; SEQUENCE-ANALYSIS	Rab proteins, one of the subfamilies of ras-like small GTP-binding proteins, are attached to cellular compartments or transport vesicles and may determine the specificity of fusion between these compartments and vesicles. It has been proposed that they alternate between a membrane-bound and a cytosolic state during their functional cycle. We have used a photo-cross-linking approach to identify their cytosolic interaction partners. In vitro synthesized rab5 was cross-linked in the presence of ATP mainly to three cytosolic proteins of 52, 65, and 85 kDa. Sucrose density gradient centrifugation of the cross-linked products suggested that they were part of a 10-14 S complex. Furthermore, rab5 was cross-linked to these and additional cytosolic proteins of 42, 48, and 160 kDa in the absence of ATP. Unexpectedly, upon ATP depletion of the cytosol cross-linked and noncross-linked rab5 was found in a sedimentable high molecular weight structure. Other members of the rab subfamily, but not N-ras, also sedimented under these conditions. Electrophoretic and electron microscopic analysis of the pelleted material revealed that it contained actin filament bundles and intermediate filaments. Our data suggest that cytosolic rab proteins interact with several proteins in a 10-14 S complex, and that the rab proteins may interact directly or indirectly via this complex with the cytoskeleton.	EUROPEAN MOLEC BIOL LAB,POSTFACH 102209,W-6900 HEIDELBERG,GERMANY	European Molecular Biology Laboratory (EMBL)			Gorvel, Jean-Pierre/O-1332-2018; Dupree, Paul/T-2568-2018; Parton, Robert G/C-5673-2009	Gorvel, Jean-Pierre/0000-0002-2829-9804; Dupree, Paul/0000-0001-9270-6286; Parton, Robert G/0000-0002-7494-5248; Simons, Kai/0000-0002-9231-9996				BAKER D, 1988, CELL, V54, P335, DOI 10.1016/0092-8674(88)90196-1; BECKER J, 1991, EMBO J, V10, P785, DOI 10.1002/j.1460-2075.1991.tb08010.x; BOURNE HR, 1988, CELL, V53, P669, DOI 10.1016/0092-8674(88)90081-5; BOWSER R, 1991, J CELL BIOL, V112, P1117, DOI 10.1083/jcb.112.6.1117; CHAVRIER P, 1990, CELL, V62, P317, DOI 10.1016/0092-8674(90)90369-P; CHAVRIER P, 1990, MOL CELL BIOL, V10, P6578, DOI 10.1128/MCB.10.12.6578; CHAVRIER P, 1991, NATURE, V353, P769, DOI 10.1038/353769a0; ECKERSKORN C, 1989, CHROMATOGRAPHIA, V28, P92, DOI 10.1007/BF02290390; FUKUMOTO Y, 1990, ONCOGENE, V5, P1321; GLOMSET JA, 1990, TRENDS BIOCHEM SCI, V15, P139, DOI 10.1016/0968-0004(90)90213-U; GODA Y, 1988, CELL, V55, P309, DOI 10.1016/0092-8674(88)90054-2; GORVEL JP, 1991, CELL, V64, P915, DOI 10.1016/0092-8674(91)90316-Q; GOUD B, 1990, NATURE, V345, P553, DOI 10.1038/345553a0; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HAUBRUCK H, 1987, EMBO J, V6, P4049, DOI 10.1002/j.1460-2075.1987.tb02750.x; HEUKESHOVEN J, 1988, ELECTROPHORESIS, V9, P28, DOI 10.1002/elps.1150090106; JOHNSTON GC, 1991, J CELL BIOL, V113, P539, DOI 10.1083/jcb.113.3.539; KAWATA M, 1990, P NATL ACAD SCI USA, V87, P8960, DOI 10.1073/pnas.87.22.8960; KURZCHALIA TV, 1986, NATURE, V320, P634, DOI 10.1038/320634a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAPETINA EG, 1987, P NATL ACAD SCI USA, V84, P2261, DOI 10.1073/pnas.84.8.2261; MATSUI Y, 1990, MOL CELL BIOL, V10, P4116, DOI 10.1128/MCB.10.8.4116; MELANCON P, 1987, CELL, V51, P1053, DOI 10.1016/0092-8674(87)90591-5; MOLITORIS BA, 1991, J CLIN INVEST, V88, P462, DOI 10.1172/JCI115326; MORII N, 1991, J BIOL CHEM, V266, P7646; NAIR J, 1990, J CELL BIOL, V110, P1897, DOI 10.1083/jcb.110.6.1897; NAKAJIMA H, 1991, J CELL BIOL, V113, P245, DOI 10.1083/jcb.113.2.245; PFEFFER SR, 1987, ANNU REV BIOCHEM, V56, P829, DOI 10.1146/annurev.biochem.56.1.829; PLUTNER H, 1991, J CELL BIOL, V115, P31, DOI 10.1083/jcb.115.1.31; SALMINEN A, 1987, CELL, V49, P527, DOI 10.1016/0092-8674(87)90455-7; SALMINEN A, 1989, J CELL BIOL, V109, P1023, DOI 10.1083/jcb.109.3.1023; SEABRA MC, 1991, CELL, V65, P429, DOI 10.1016/0092-8674(91)90460-G; SEWELL JL, 1988, P NATL ACAD SCI USA, V85, P4620, DOI 10.1073/pnas.85.13.4620; TOUCHOT N, 1987, P NATL ACAD SCI USA, V84, P8210, DOI 10.1073/pnas.84.23.8210; UETSUKI T, 1989, J BIOL CHEM, V264, P5791; VANDERSLUIJS P, 1991, P NATL ACAD SCI USA, V88, P6313, DOI 10.1073/pnas.88.14.6313; VONMOLLARD GF, 1990, P NATL ACAD SCI USA, V87, P1988, DOI 10.1073/pnas.87.5.1988; VONMOLLARD GF, 1991, NATURE, V349, P79, DOI 10.1038/349079a0; WALWORTH NC, 1989, EMBO J, V8, P1685, DOI 10.1002/j.1460-2075.1989.tb03560.x; WANDINGERNESS A, 1990, J CELL BIOL, V111, P987, DOI 10.1083/jcb.111.3.987; WIEDMANN M, 1987, J CELL BIOL, V104, P201, DOI 10.1083/jcb.104.2.201; WOLFMAN A, 1990, SCIENCE, V248, P67, DOI 10.1126/science.2181667; YAMAMOTO T, 1990, J BIOL CHEM, V265, P16626; ZAHRAOUI A, 1989, J BIOL CHEM, V264, P12394	44	24	24	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1992	267	26					18419	18423						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JN502	1526983				2022-12-25	WOS:A1992JN50200031
J	JHUN, BH; RAMPAL, AL; LIU, HZ; LACHAAL, M; JUNG, CY				JHUN, BH; RAMPAL, AL; LIU, HZ; LACHAAL, M; JUNG, CY			EFFECTS OF INSULIN ON STEADY-STATE KINETICS OF GLUT4 SUBCELLULAR-DISTRIBUTION IN RAT ADIPOCYTES - EVIDENCE OF CONSTITUTIVE GLUT4 RECYCLING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REGULATABLE GLUCOSE TRANSPORTER; FACTOR-II RECEPTORS; PLASMA-MEMBRANE; STIMULATED TRANSLOCATION; ADIPOSE CELL; TRANSFERRIN RECEPTORS; POTENTIAL MECHANISM; REDISTRIBUTION; SURFACE; 3-O-METHYLGLUCOSE	We labeled rat adipocyte cell surface glucose transporters with an impermeable, photoreactive glucose analogue, 1,3-bis-(3-deoxy-D-glucopyranose-3-yloxy)-2-propyl 4-benzoylbenzoate (B3GL) and its radioactive tracer [H-3]B3GL. The labeling did not affect glucose transporter subcellular distribution in basal and insulin-stimulated adipocytes. When basal or insulin-stimulated adipocytes were labeled with [H-3]B3GL and incubated at 37-degrees-C in steady state, labeled GLUT4 was rapidly reduced at the cell surface and stoichiometrically recovered in microsomes without any change in GLUT4 protein levels in either pool. The labeled GLUT4 equilibrium exchange was found to be a simple first order process describable by two first order rate constants, one for internalization (k(in)) and the other for externalization (k(ex)). Insulin affected both rate constants, reducing k(in) by 2.8-fold and increasing k(ex) by 3.3-fold. It is concluded that GLUT4 constantly and rapidly recycles in adipocytes between the cell surface and its storage pool, and insulin increases the cell surface GLUT4 level in rat adipocytes by modulating both the internalization and the externalization steps of constitutively recycling GLUT4.	VET ADM MED CTR, BIOPHYS LAB, 3495 BAILEY AVE, BUFFALO, NY 14215 USA; SUNY BUFFALO, DEPT BIOPHYS SCI, BUFFALO, NY 14215 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); State University of New York (SUNY) System; State University of New York (SUNY) Buffalo					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK013376] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK13376] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BELL GI, 1990, DIABETES CARE, V13, P198, DOI 10.2337/diacare.13.3.198; CHEN WS, 1989, CELL, V59, P33, DOI 10.1016/0092-8674(89)90867-2; CORVERA S, 1985, P NATL ACAD SCI USA, V82, P7314, DOI 10.1073/pnas.82.21.7314; CORVERA S, 1988, P NATL ACAD SCI USA, V85, P7567, DOI 10.1073/pnas.85.20.7567; CUSHMAN SW, 1980, J BIOL CHEM, V255, P4758; DAVIS RJ, 1986, J BIOL CHEM, V261, P8708; EZAKI O, 1982, J BIOL CHEM, V257, P4306; HOLMAN GD, 1990, J BIOL CHEM, V265, P18172; JAMES DE, 1989, P NATL ACAD SCI USA, V86, P8368, DOI 10.1073/pnas.86.21.8368; JAMES DE, 1989, NATURE, V338, P83, DOI 10.1038/338083a0; JHUN BH, 1991, J BIOL CHEM, V266, P22260; JHUN BH, 1991, BIOCHIM BIOPHYS ACTA, V1061, P149, DOI 10.1016/0005-2736(91)90279-H; JUNG CY, 1971, BIOCHIM BIOPHYS ACTA, V241, P613, DOI 10.1016/0005-2736(71)90059-9; KARNIELI E, 1981, J BIOL CHEM, V256, P4772; KOTYK A, 1970, CELL MEMBRANE TRANSP, P151; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIENHARD GE, 1989, INT CONGR SER, V866, P313; MAEGAWA H, 1988, J BIOL CHEM, V263, P8912; MARTZ A, 1986, J BIOL CHEM, V261, P3606; OKA Y, 1984, P NATL ACAD SCI-BIOL, V81, P4028, DOI 10.1073/pnas.81.13.4028; OKA Y, 1985, J BIOL CHEM, V260, P9435; SIMPSON IA, 1983, BIOCHIM BIOPHYS ACTA, V763, P393, DOI 10.1016/0167-4889(83)90101-5; SIMPSON IA, 1986, ANNU REV BIOCHEM, V55, P1095; SLOT JW, 1991, J CELL BIOL, V113, P123, DOI 10.1083/jcb.113.1.123; SMITH RM, 1991, P NATL ACAD SCI USA, V88, P6893, DOI 10.1073/pnas.88.15.6893; SUZUKI K, 1980, P NATL ACAD SCI-BIOL, V77, P2542, DOI 10.1073/pnas.77.5.2542; TANNER LI, 1987, J BIOL CHEM, V262, P8975; WARDZALA LJ, 1984, J BIOL CHEM, V259, P8378; WHITESELL RR, 1979, J BIOL CHEM, V254, P5276; ZORZANO A, 1989, J BIOL CHEM, V264, P12358	30	220	224	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1992	267	25					17710	17715						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JM223	1517217				2022-12-25	WOS:A1992JM22300037
J	HOLBROOK, PG; PANNELL, LK; MURATA, Y; DALY, JW				HOLBROOK, PG; PANNELL, LK; MURATA, Y; DALY, JW			MOLECULAR-SPECIES ANALYSIS OF A PRODUCT OF PHOSPHOLIPASE-D ACTIVATION - PHOSPHATIDYLETHANOL IS FORMED FROM PHOSPHATIDYLCHOLINE IN PHORBOL ESTER-STIMULATED AND BRADYKININ-STIMULATED PC12-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; TANDEM MASS-SPECTROMETRY; FATTY-ACID COMPOSITION; FAST ATOM BOMBARDMENT; GLIOMA HYBRID-CELLS; PHOSPHATIDIC-ACID; DIACYLGLYCEROL FORMATION; P2-PURINERGIC AGONISTS; SIGNAL TRANSDUCTION; HL-60 GRANULOCYTES	Tumor-promoting phorbol esters or calcium-mobilizing receptor ligands stimulate phosphatidylcholine breakdown and in many cells this is accompanied by phospholipase D (PLD) activation. We tested whether or not a direct relationship exists between these two phenomena. Pheochromocytoma (PC12) cells were stimulated with the phorbol ester 12-O-tetradecanoylphorbol-13-acetate or with the calcium-mobilizing receptor ligand bradykinin in media containing 1% ethanol. The fatty acid composition of the molecular species of phosphatidylethanol (PEt), a product of PLD activation, formed in stimulated cells was compared with the molecular species of endogenous phospholipids isolated from unstimulated PC12 cells. PEt was isolated and analyzed by fast atom bombardment-mass spectrometry (FAB-MS) in the negative ion mode. Fatty acid composition and headgroup structure of the major PEt molecular ions were confirmed by linked scan analysis. Phosphatidylcholine, phosphatidylethanolamine, phosphatidylserine, and phosphatidylinositol were isolated from unstimulated cells and converted into phosphatidic acids using PLD. Mass spectra of the respective phosphatidic acids were obtained by fast atom bombardment-mass spectrometry as described above. The molecular species of PEt formed in 12-O-tetradecanoylphorbol-13-acetate- and bradykinin-stimulated PC12 cell were identical to those of phosphatidylcholine isolated from untreated cells.			HOLBROOK, PG (corresponding author), NIDDKD,BIOORGAN CHEM LAB,BLDG 10,RM 5N307,BETHESDA,MD 20814, USA.							AGWU DE, 1989, J BIOL CHEM, V264, P1405; AUGERT G, 1989, J BIOL CHEM, V264, P21689; BANSCHBACH MW, 1981, BIOCHIM BIOPHYS ACTA, V663, P34, DOI 10.1016/0005-2760(81)90192-2; BERRIDGE MJ, 1984, NATURE, V312, P315, DOI 10.1038/312315a0; BILLAH MM, 1989, J BIOL CHEM, V264, P9069; BILLAH MM, 1990, BIOCHEM J, V269, P281, DOI 10.1042/bj2690281; BJERVE KS, 1984, BIOCHEM J, V219, P781, DOI 10.1042/bj2190781; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOCCKINO SB, 1985, J BIOL CHEM, V260, P4201; BOCCKINO SB, 1987, FEBS LETT, V225, P201, DOI 10.1016/0014-5793(87)81157-2; BOCCKINO SB, 1987, J BIOL CHEM, V262, P15309; CABOT MC, 1988, BIOCHIM BIOPHYS ACTA, V959, P46, DOI 10.1016/0005-2760(88)90148-8; COCKCROFT S, 1984, BIOCHEM J, V222, P557, DOI 10.1042/bj2220557; COCKCROFT S, 1984, BIOCHIM BIOPHYS ACTA, V795, P37, DOI 10.1016/0005-2760(84)90102-4; CORRADETTI R, 1983, J PHARMACOL EXP THER, V226, P826; DANIEL LW, 1986, J BIOL CHEM, V261, P9128; DAWSON RMC, 1967, BIOCHEM J, V102, P205, DOI 10.1042/bj1020205; EXTON JH, 1990, J BIOL CHEM, V265, P1; GUSTAVSSON L, 1989, ATLA-ALTERN LAB ANIM, V16, P257; GUY GR, 1982, CANCER RES, V42, P1980; HOLBROOK PG, 1990, BIOCHIM BIOPHYS ACTA, V1046, P185, DOI 10.1016/0005-2760(90)90187-3; HOLBROOK PG, 1991, BIOCHIM BIOPHYS ACTA, V1084, P155, DOI 10.1016/0005-2760(91)90214-3; HOLBROOK PG, 1992, BIOCHIM BIOPHYS ACTA, V1125, P330, DOI 10.1016/0005-2760(92)90063-2; Holub B J, 1978, Adv Lipid Res, V16, P1; HUANG CF, 1990, J BIOL CHEM, V265, P14858; IRVING HR, 1987, J BIOL CHEM, V262, P3440; JENSEN NJ, 1986, LIPIDS, V21, P580, DOI 10.1007/BF02534056; KAYGANICH K, 1991, J AM SOC MASS SPECTR, V2, P45, DOI 10.1016/1044-0305(91)80060-K; KENNERLY DA, 1987, J BIOL CHEM, V262, P16305; LEACH KL, 1991, J BIOL CHEM, V266, P3215; LISCOVITCH M, 1987, J BIOL CHEM, V262, P17487; LISCOVITCH M, 1989, J BIOL CHEM, V264, P1450; LUTHRA MG, 1976, J NEUROCHEM, V27, P1503, DOI 10.1111/j.1471-4159.1976.tb02636.x; MARTIN TW, 1989, J BIOL CHEM, V264, P8847; MICHELL RH, 1975, BIOCHIM BIOPHYS ACTA, V415, P81, DOI 10.1016/0304-4157(75)90017-9; MUFSON RA, 1981, CARCINOGENESIS, V2, P1095; MUNSTER H, 1988, BIOL CHEM H-S, V369, P303, DOI 10.1515/bchm3.1988.369.1.303; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; PAI JK, 1988, J BIOL CHEM, V263, P12472; PAI JK, 1987, CARCINOGENESIS, V8, P173, DOI 10.1093/carcin/8.1.173; PAPPU AS, 1983, NEUROCHEM RES, V8, P1565, DOI 10.1007/BF00964158; PESSIN MS, 1991, CELL REGUL, V2, P383, DOI 10.1091/mbc.2.5.383; PESSIN MS, 1989, J BIOL CHEM, V264, P8729; PREISS J, 1986, J BIOL CHEM, V261, P8597; PUTNEY JW, 1980, NATURE, V284, P345, DOI 10.1038/284345a0; RINK TJ, 1988, NATURE, V334, P649, DOI 10.1038/334649a0; ROTHMAN JE, 1977, SCIENCE, V195, P743, DOI 10.1126/science.402030; RUBIN R, 1988, BIOCHEM BIOPH RES CO, V156, P1090, DOI 10.1016/S0006-291X(88)80744-7; SALMON DM, 1980, NATURE, V284, P344, DOI 10.1038/284344a0; SHUKLA SD, 1991, LIFE SCI, V48, P851, DOI 10.1016/0024-3205(91)90031-6; SVANBORG A, 1961, ACTA MED SCAND, V169, P43; TETTENBORN CS, 1988, BIOCHEM BIOPH RES CO, V155, P249, DOI 10.1016/S0006-291X(88)81076-3; TSIEN RW, 1990, ANNU REV CELL BIOL, V6, P715, DOI 10.1146/annurev.cb.06.110190.003435; WRIGHT TM, 1988, J BIOL CHEM, V263, P9374; YANG SF, 1967, J BIOL CHEM, V242, P477	55	48	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1992	267	24					16834	16840						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JL053	1512226				2022-12-25	WOS:A1992JL05300019
J	MUTUCUMARANA, VP; DUFFY, EJ; LOLLAR, P; JOHNSON, AE				MUTUCUMARANA, VP; DUFFY, EJ; LOLLAR, P; JOHNSON, AE			THE ACTIVE-SITE OF FACTOR-IXA IS LOCATED FAR ABOVE THE MEMBRANE-SURFACE AND ITS CONFORMATION IS ALTERED UPON ASSOCIATION WITH FACTOR-VIIIA - A FLUORESCENCE STUDY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELONGATION-FACTOR-TU; PORCINE FACTOR-VIII; ENERGY-TRANSFER MEASUREMENT; COAGULATION FACTOR-VA; E-RECEPTOR COMPLEX; CLOTTING FACTOR-X; PHOSPHOLIPID SURFACE; GUANOSINE 5'-TRIPHOSPHATE; PROTHROMBINASE COMPLEX; SUBUNIT STRUCTURE	The topography of membrane-bound blood coagulation factor IXa (fIXa) and the nature of its interaction with its cofactor, factor VIIIa (fVIIIa), were examined using fluorescent derivatives of fIXa. A fluorescein dye was covalently attached to the active-site histidine of fIXa via a D-Phe-Pro-Arg tripeptide tether to form Fl-A-FPR-fIXa; similarly, a 5-dimethylaminonaphthalene-1-sulfonyl (dansyl) dye was covalently attached via Glu-Gly-Arg to form DEGR-fIXa. When either Fl-A-FPR-fIXa or DEGR-fIXa was titrated with phosphatidylcholine-phosphatidylserine vesicles containing octadecylrhodamine in the presence of Ca2+, fluorescence energy transfer was observed. Assuming a random orientation of dyes, the distance of closest approach between the donor dyes in the active sites of the membrane-bound enzymes and the acceptor dyes at the membrane surface was found to be 89 +/- 3 angstrom for Fl-A-FPR-fIXa and 73 +/- 4 angstrom for DEGR-fIXa. Although the exact distance remains uncertain, it is clear that the active site of fIXa is positioned more than 70 angstrom above the surface, and hence that the elongated fIXa molecule projects approximately perpendicularly from the surface when bound to the membrane. The binding of fVIIIa to membrane-bound Fl-A-FPR-fIXa or DEGR-fIXa did not alter the location of the active site relative to the membrane surface, but did alter both the emission intensity and anisotropy of the fluorescein and dansyl probes and hence their environments. Cofactor stimulation of fIXa activity therefore appears to be mediated, at least in part, by a conformational change in the active site that occurs when fVIIIa binds to the enzyme on the phospholipid surface.	UNIV OKLAHOMA, DEPT CHEM & BIOCHEM, NORMAN, OK 73019 USA; EMORY UNIV, DEPT MED, DIV HEMATOL ONCOL, ATLANTA, GA 30322 USA	University of Oklahoma System; University of Oklahoma - Norman; Emory University			Johnson, Arthur E/G-3457-2012		NHLBI NIH HHS [HL 32934, HL 40921] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL040921, R01HL032934] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADKINS HJ, 1983, BIOCHEMISTRY-US, V22, P1208, DOI 10.1021/bi00274a034; ALCALA JR, 1987, BIOPHYS J, V51, P587, DOI 10.1016/S0006-3495(87)83383-0; ARMSTRONG SA, 1990, J BIOL CHEM, V265, P6210; BEALS JM, 1986, BIOCHEM J, V236, P861, DOI 10.1042/bj2360861; BOCK PE, 1988, BIOCHEMISTRY-US, V27, P6633, DOI 10.1021/bi00417a063; BODE W, 1989, EMBO J, V8, P3467, DOI 10.1002/j.1460-2075.1989.tb08511.x; CERIONE RA, 1983, BIOCHEMISTRY-US, V22, P769, DOI 10.1021/bi00273a010; DALE RE, 1979, BIOPHYS J, V26, P161, DOI 10.1016/S0006-3495(79)85243-1; DELL VA, 1990, BIOCHEMISTRY-US, V29, P1757, DOI 10.1021/bi00459a014; DEWEY TG, 1980, BIOPHYS J, V32, P1023, DOI 10.1016/S0006-3495(80)85033-8; DUFFY EJ, 1992, J BIOL CHEM, V267, P7821; DUFFY EJ, 1992, J BIOL CHEM, V267, P17006; EHRLICH HJ, 1990, EMBO J, V9, P2367, DOI 10.1002/j.1460-2075.1990.tb07411.x; ESMON CT, 1979, J BIOL CHEM, V254, P964; Fujikawa K, 1976, Methods Enzymol, V45, P89; FUNG BKK, 1978, BIOCHEMISTRY-US, V17, P5241, DOI 10.1021/bi00617a025; FURIE B, 1988, CELL, V53, P505, DOI 10.1016/0092-8674(88)90567-3; GREEN GDJ, 1979, ANAL BIOCHEM, V93, P223, DOI 10.1016/S0003-2697(79)80070-6; GUINTO ER, 1982, J BIOL CHEM, V257, P38; HAPAK RC, 1992, FASEB J, V6, pA330; HAZLETT TL, 1989, BIOCHEMISTRY-US, V28, P4109, DOI 10.1021/bi00435a073; HILLEUBANKS DC, 1990, J BIOL CHEM, V265, P17854; HOLOWKA D, 1983, BIOCHEMISTRY-US, V22, P3475, DOI 10.1021/bi00283a026; HOLOWKA D, 1983, BIOCHEMISTRY-US, V22, P3466, DOI 10.1021/bi00283a025; HUANG C, 1978, P NATL ACAD SCI USA, V75, P308, DOI 10.1073/pnas.75.1.308; HUSTEN EJ, 1987, J BIOL CHEM, V262, P12953; ISAACS BS, 1986, BIOCHEMISTRY-US, V25, P4958, DOI 10.1021/bi00365a036; JANIAK F, 1990, BIOCHEMISTRY-US, V29, P4268, DOI 10.1021/bi00470a002; LAMY F, 1953, J BIOL CHEM, V203, P489; LAUE TM, 1984, BIOCHEMISTRY-US, V23, P1339, DOI 10.1021/bi00302a001; LEBONNIEC BF, 1991, P NATL ACAD SCI USA, V88, P7371, DOI 10.1073/pnas.88.16.7371; LIM TK, 1977, BIOCHEMISTRY-US, V16, P4177, DOI 10.1021/bi00638a007; LOLLAR P, 1990, J BIOL CHEM, V265, P1688; LOLLAR P, 1984, ARCH BIOCHEM BIOPHYS, V233, P438, DOI 10.1016/0003-9861(84)90465-X; LOLLAR P, 1984, BLOOD, V63, P1303; LOLLAR P, 1989, BIOCHEMISTRY-US, V28, P666, DOI 10.1021/bi00428a038; LU RL, 1989, J BIOL CHEM, V264, P12956; MANN KG, 1988, ANNU REV BIOCHEM, V57, P915, DOI 10.1146/annurev.bi.57.070188.004411; MERCOLA DA, 1972, BIOCHEMISTRY-US, V11, P3860, DOI 10.1021/bi00771a005; NELSESTUEN GL, 1978, BIOCHEMISTRY-US, V17, P2134, DOI 10.1021/bi00604a017; NELSESTUEN GL, 1977, BIOCHEMISTRY-US, V16, P4172, DOI 10.1021/bi00638a006; PARKER CA, 1960, ANALYST, V85, P587, DOI 10.1039/an9608500587; ROSING J, 1980, J BIOL CHEM, V255, P274; SCOTT TG, 1970, J AM CHEM SOC, V92, P687, DOI 10.1021/ja00706a043; VANDIEIJEN G, 1981, J BIOL CHEM, V256, P3433; YE J, 1991, J BIOL CHEM, V266, P23016	46	97	99	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	1992	267	24					17012	17021						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JL053	1512240				2022-12-25	WOS:A1992JL05300046
J	WANG, ZY; LIN, XH; QIU, QQ; DEUEL, TF				WANG, ZY; LIN, XH; QIU, QQ; DEUEL, TF			MODULATION OF TRANSCRIPTION OF THE PLATELET-DERIVED GROWTH-FACTOR A-CHAIN GENE BY A PROMOTER REGION SENSITIVE TO S1 NUCLEASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIMIAN SARCOMA-VIRUS; ALTERED DNA CONFORMATION; BETA-GLOBIN GENE; NF-KAPPA-B; S1-HYPERSENSITIVE SITES; C-FOS; SEQUENCES; BINDING; ENHANCERS; ENCODES	Homodimers of the platelet-derived growth factor (PDGF) A-chain are strong mitogens for cells of mesenchymal origin. Differences in the levels of expression of the PDGF A-chain gene have been reported in both normal and transformed cell lines, suggesting that transcription of the PDGF A-chain gene is highly regulated. We have now identified two S1-hypersensitive sites which flank a 13-base pair oligo(dG).oligo(dC) sequence located 70-82 base pairs upstream of the transcription initiation site. Three lines of evidence suggest that these S1-sensitive sites contribute to optimum promoter activity. Nuclear protein(s) binding to these sites were detected in gel mobility shift assays. Deletion of the S1-sensitive sites results in a 2-3-fold decrease in the transcriptional activity and eliminated sensitivity to S1 nuclease. Deletions in the oligo(dG).oligo(dC) motif also eliminated sensitivity to Sl and resulted in a 2.5-fold decrease of the promoter activity in the stable transfection assays. The results suggest that the highly G+C-rich region in the PDGF A-chain gene promoter locally induces the formation of non-B-form DNA under torsional stress which appears to be important in the transcriptional regulation of the PDGF A-chain gene in vivo.	WASHINGTON UNIV,JEWISH HOSP ST LOUIS,MED CTR,DEPT MED,ST LOUIS,MO 63110; WASHINGTON UNIV,JEWISH HOSP ST LOUIS,MED CTR,DEPT BIOCHEM & MOLEC BIOPHYS,ST LOUIS,MO 63110	Barnes-Jewish Hospital; Washington University (WUSTL); Barnes-Jewish Hospital; Washington University (WUSTL)					NCI NIH HHS [CA49712] Funding Source: Medline; NHLBI NIH HHS [HL14147, HL31102] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA049712] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL014147, R01HL031102, R37HL031102] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARNOTT S, 1974, J MOL BIOL, V88, P551, DOI 10.1016/0022-2836(74)90502-6; BALDWIN AS, 1988, P NATL ACAD SCI USA, V85, P723, DOI 10.1073/pnas.85.3.723; BETSHOLTZ C, 1986, NATURE, V320, P695, DOI 10.1038/320695a0; CHRISTY BA, 1988, P NATL ACAD SCI USA, V85, P7857, DOI 10.1073/pnas.85.21.7857; CLARK L, 1988, GENE DEV, V2, P991, DOI 10.1101/gad.2.8.991; CRICK F, 1971, NATURE, V234, P25, DOI 10.1038/234025a0; DEUEL TF, 1987, NEW ENGL J MED, V317, P236, DOI 10.1056/NEJM198707233170409; DEUEL TF, 1987, ANNU REV CELL BIOL, V3, P443, DOI 10.1146/annurev.cb.03.110187.002303; DOOLITTLE RF, 1983, SCIENCE, V221, P275, DOI 10.1126/science.6304883; DYAN WS, 1985, NATURE, V316, P774; EMERSON BM, 1985, CELL, V41, P21, DOI 10.1016/0092-8674(85)90057-1; EVANS T, 1984, NUCLEIC ACIDS RES, V12, P8043, DOI 10.1093/nar/12.21.8043; GAILLARD C, 1990, J MOL BIOL, V215, P245, DOI 10.1016/S0022-2836(05)80343-2; GALLIOT B, 1989, DEVELOPMENT, V107, P343; GODING CR, 1983, NUCLEIC ACIDS RES, V11, P21, DOI 10.1093/nar/11.1.21; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HAMMACHER A, 1988, J BIOL CHEM, V263, P16493; HEBERLEIN U, 1985, NATURE, V317, P179; HERBOMEL P, 1984, CELL, V39, P653, DOI 10.1016/0092-8674(84)90472-0; JOHNSSON A, 1984, EMBO J, V3, P921, DOI 10.1002/j.1460-2075.1984.tb01908.x; JOSEPHS SF, 1984, SCIENCE, V223, P487, DOI 10.1126/science.6318322; KOHWI Y, 1988, P NATL ACAD SCI USA, V85, P3781, DOI 10.1073/pnas.85.11.3781; KOHWISHIGEMATSU T, 1985, CELL, V43, P199, DOI 10.1016/0092-8674(85)90024-8; LARSEN A, 1982, CELL, V29, P609, DOI 10.1016/0092-8674(82)90177-5; LEMAIRE P, 1988, P NATL ACAD SCI USA, V85, P4691, DOI 10.1073/pnas.85.13.4691; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; Maniatis T., 1982, MOL CLONING; MARE HAF, 1983, NATURE, V304, P555; MCCALL M, 1985, J MOL BIOL, V183, P385, DOI 10.1016/0022-2836(85)90009-9; MCKEON C, 1984, J BIOL CHEM, V259, P6636; MERCOLA M, 1988, DEVELOPMENT, V102, P451; MILBRANDT J, 1987, SCIENCE, V238, P797, DOI 10.1126/science.3672127; MULLER HP, 1990, TRENDS GENET, V6, P300, DOI 10.1016/0168-9525(90)90236-Y; NICKOL JM, 1983, CELL, V35, P467, DOI 10.1016/0092-8674(83)90180-0; OSHIMA RG, 1990, GENE DEV, V4, P835, DOI 10.1101/gad.4.5.835; ROSS R, 1986, CELL, V46, P155, DOI 10.1016/0092-8674(86)90733-6; SCHON E, 1983, CELL, V35, P837, DOI 10.1016/0092-8674(83)90116-2; STROOBANT P, 1984, EMBO J, V3, P2963, DOI 10.1002/j.1460-2075.1984.tb02241.x; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; TAKIMOTO Y, 1991, P NATL ACAD SCI USA, V88, P1686, DOI 10.1073/pnas.88.5.1686; WATERFIELD MD, 1983, NATURE, V304, P35, DOI 10.1038/304035a0; WEINTRAUB H, 1983, CELL, V29, P609; WELLS RD, 1988, FASEB J, V2, P2934; YANO O, 1987, EMBO J, V6, P3317, DOI 10.1002/j.1460-2075.1987.tb02652.x	45	33	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1992	267	24					17022	17031						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JL053	1512241				2022-12-25	WOS:A1992JL05300047
J	WATANABE, Y; USUDA, N; TSUGANE, S; KOBAYASHI, R; HIDAKA, H				WATANABE, Y; USUDA, N; TSUGANE, S; KOBAYASHI, R; HIDAKA, H			CALVASCULIN, AN ENCODED PROTEIN FROM MESSENGER-RNA TERMED PEL-98, 18A2, 42A, OR P9KA, IS SECRETED BY SMOOTH-MUSCLE CELLS IN CULTURE AND EXHIBITS CA2+-DEPENDENT BINDING TO 36-KDA MICROFIBRIL-ASSOCIATED GLYCOPROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTROPHORETIC TRANSFER; POLYACRYLAMIDE GELS; NITROCELLULOSE; POLYPEPTIDES; CALMODULIN; QUANTITIES; S-100; VIRUS	Calvasculin, an EF-hand protein with a molecular mass of 11 kDa on sodium dodecyl sulfate-polyacrylamide gel electrophoresis, is present abundantly in bovine aorta (Watanabe, Y., Kobayashi, R., Ishikawa, T., and Hidaka, H. (1992) Arch. Biochem. Biophys. 292, 563-569). This protein is synthesized constitutively by bovine aortic smooth muscle (BASM) cells and rat embryo fibroblast 3Y1 cells in culture. We discovered that calvasculin was secreted by BASM cells and 3Y1 cells. Immunofluorescence staining of BASM cells showed a granular distribution for calvasculin that was typical of a secreted protein. This protein bound with an extracellular matrix protein, 36-kDa microfibril-associated glycoprotein (36-kDa MAP), in a Ca2+-dependent manner in vitro. A stoichiometry analysis showed that the 36-kDa MAP bound 2.2 calvasculin eq/mol of protein. Solid-phase binding assays indicated a preferential affinity of native calvasculin for 36-kDa MAP among the extracellular matrices in a Ca2+-dependent manner. These results suggest that calvasculin, intracellular Ca2+-binding protein, is released to the extracellular space and binds with 36-kDa MAP.	NAGOYA UNIV,SCH MED,DEPT PHARMACOL,SHOWA KU,NAGOYA,AICHI 466,JAPAN; SHINSHU UNIV,SCH MED,DEPT ANAT & CELL BIOL,MATSUMOTO,NAGANO 390,JAPAN	Nagoya University; Shinshu University			Tsugane, Shoichiro/A-2424-2015	Tsugane, Shoichiro/0000-0003-4105-2774; Watanabe, Yasuo/0000-0003-2232-0091				BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; ENDO T, 1981, J BIOL CHEM, V256, P2485; FAIRBANKS G, 1971, BIOCHEMISTRY-US, V10, P2606, DOI 10.1021/bi00789a030; GLENNEY JR, 1980, J BIOL CHEM, V255, P551; HEIZMANN CW, 1991, TRENDS BIOCHEM SCI, V16, P98, DOI 10.1016/0968-0004(91)90041-S; HIDAKA H, 1983, J BIOL CHEM, V258, P2705; KOBAYASHI R, 1989, J BIOL CHEM, V264, P17437; LAMB RA, 1976, VIROLOGY, V74, P504, DOI 10.1016/0042-6822(76)90356-1; MARTIN RG, 1961, J BIOL CHEM, V236, P1372; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; ROSE JK, 1982, CELL, V30, P753, DOI 10.1016/0092-8674(82)90280-X; SAGE H, 1989, J CELL BIOL, V109, P341, DOI 10.1083/jcb.109.1.341; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; SUZUKI F, 1987, J NEUROCHEM, V49, P1557, DOI 10.1111/j.1471-4159.1987.tb01027.x; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WATANABE Y, 1992, ARCH BIOCHEM BIOPHYS, V292, P563, DOI 10.1016/0003-9861(92)90031-Q	18	50	50	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1992	267	24					17136	17140						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JL053	1512251				2022-12-25	WOS:A1992JL05300064
J	ROTHSTEIN, DM; SAITO, H; STREULI, M; SCHLOSSMAN, SF; MORIMOTO, C				ROTHSTEIN, DM; SAITO, H; STREULI, M; SCHLOSSMAN, SF; MORIMOTO, C			THE ALTERNATIVE SPLICING OF THE CD45 TYROSINE PHOSPHATASE IS CONTROLLED BY NEGATIVE REGULATORY TRANS-ACTING SPLICING FACTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKOCYTE-COMMON ANTIGEN; PRE-MESSENGER-RNA; BRANCH POINT LOCATION; T-CELLS; SITE SELECTION; MONOCLONAL-ANTIBODY; GENE-EXPRESSION; HELPER-INDUCER; 2H4 MOLECULE; DIFFERENTIATION	CD45, a receptor-type protein tyrosine phosphatase involved in lymphocyte activation, consists of five isoforms generated by alternative mRNA splicing. The pattern of CD45 splicing depends upon cell type, state of activation, and thymic development. We previously showed that mouse B and thymocyte cell lines transfected with a human CD45 minigene construct appropriately splice the alternative exons, demonstrating the presence of trans-acting tissue-specific splicing factors. To study the regulation of CD45 alternative splicing, cells having different splicing patterns were transiently fused, and mRNA was analyzed using reverse transcription-polymerase chain reaction. Human B cells, normally producing only the largest CD45 mRNAs, could splice out the alternative exons after fusion with mouse thymocytes. In contrast, the splicing pattern of human T cell lines (smaller CD45 isoforms) was unaltered by fusion with mouse B cells. This suggests that cells expressing the smallest CD45 isoform contain negatively acting trans-factor(s) that allow the alternative exons to be skipped, and that the full length isoform containing all three alternative exons is the default pattern of splicing. In agreement, incubation of thymocytes or T cell subsets with cycloheximide increased mRNA corresponding to the larger isoforms. CD45 isoform expression can now be interpreted in terms of the presence or absence of negative regulatory trans-acting splicing factors.	BRIGHAM & WOMENS HOSP, DIV NEPHROL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT MED, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT BIOL CHEM & MOLEC PHARMACOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT PATHOL, BOSTON, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	ROTHSTEIN, DM (corresponding author), HARVARD UNIV, SCH MED, DANA FARBER CANC INST, DIV TUMOR IMMUNOL, BOSTON, MA 02115 USA.		Saito, Haruo/AAF-6113-2019	Saito, Haruo/0000-0001-7891-1689	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI026598] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR033713] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K08DK002011] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-26598] Funding Source: Medline; NIAMS NIH HHS [AR33713] Funding Source: Medline; NIDDK NIH HHS [1KO8DK02011-01A1] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AKBAR AN, 1988, J IMMUNOL, V140, P2171; ALT FW, 1980, CELL, V20, P293, DOI 10.1016/0092-8674(80)90615-7; AMREIN H, 1988, CELL, V55, P1025, DOI 10.1016/0092-8674(88)90247-4; BARCLAY AN, 1987, EMBO J, V6, P1259, DOI 10.1002/j.1460-2075.1987.tb02362.x; BARON MH, 1986, CELL, V46, P591, DOI 10.1016/0092-8674(86)90885-8; BELL EB, 1990, NATURE, V348, P163, DOI 10.1038/348163a0; BELL LR, 1988, CELL, V55, P1037, DOI 10.1016/0092-8674(88)90248-6; BERGER AE, 1981, HUM IMMUNOL, V3, P231, DOI 10.1016/0198-8859(81)90020-3; BOGGS RT, 1987, CELL, V50, P739, DOI 10.1016/0092-8674(87)90332-1; BREITBART RE, 1987, CELL, V49, P793, DOI 10.1016/0092-8674(87)90617-9; BROD SA, 1989, J EXP MED, V170, P2147, DOI 10.1084/jem.170.6.2147; CHANG HL, 1991, J IMMUNOL, V147, P1687; CHANG HL, 1989, J IMMUNOL, V143, P315; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLEMENT LT, 1988, J IMMUNOL, V141, P1464; CYBULSKY MI, 1991, P NATL ACAD SCI USA, V88, P7859, DOI 10.1073/pnas.88.17.7859; DEANS JP, 1989, J IMMUNOL, V143, P1233; ENOCH T, 1986, MOL CELL BIOL, V6, P801, DOI 10.1128/MCB.6.3.801; EPERON LP, 1986, NATURE, V324, P280, DOI 10.1038/324280a0; FU XY, 1988, EMBO J, V7, P809, DOI 10.1002/j.1460-2075.1988.tb02879.x; GE H, 1990, CELL, V62, P25, DOI 10.1016/0092-8674(90)90236-8; GOUXPELLETAN M, 1990, EMBO J, V9, P241, DOI 10.1002/j.1460-2075.1990.tb08101.x; HALL LR, 1988, J IMMUNOL, V141, P2781; HELFMAN DM, 1988, GENE DEV, V2, P1627, DOI 10.1101/gad.2.12a.1627; HERSHBERGER RP, 1990, MOL CELL BIOL, V10, P662, DOI 10.1128/MCB.10.2.662; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.biochem.54.1.897; KEDES DH, 1987, P NATL ACAD SCI USA, V84, P7928, DOI 10.1073/pnas.84.22.7928; KORETZKY GA, 1990, NATURE, V346, P66, DOI 10.1038/346066a0; KORNBLIHTT AR, 1984, NUCLEIC ACIDS RES, V12, P5853, DOI 10.1093/nar/12.14.5853; KRAINER AR, 1990, CELL, V62, P35, DOI 10.1016/0092-8674(90)90237-9; LEDBETTER JA, 1985, J IMMUNOL, V135, P1819; LEDBETTER JA, 1988, P NATL ACAD SCI USA, V85, P8628, DOI 10.1073/pnas.85.22.8628; LEFRANCOIS L, 1985, J IMMUNOL, V135, P374; LOWERY DE, 1988, MOL CELL BIOL, V8, P2610, DOI 10.1128/MCB.8.6.2610; Maniatis T., 1982, MOL CLONING; McKeown M, 1990, Genet Eng (N Y), V12, P139; MILLER SC, 1988, GENE DEV, V2, P330, DOI 10.1101/gad.2.3.330; MORIMOTO C, 1985, J IMMUNOL, V134, P1508; MORIMOTO C, 1986, J IMMUNOL, V137, P3247; MULLEN MP, 1991, GENE DEV, V5, P642, DOI 10.1101/gad.5.4.642; NEWMAN W, 1982, P NATL ACAD SCI-BIOL, V79, P3858, DOI 10.1073/pnas.79.12.3858; PINGEL JT, 1989, CELL, V58, P1055, DOI 10.1016/0092-8674(89)90504-7; RALPH SJ, 1987, EMBO J, V6, P1251, DOI 10.1002/j.1460-2075.1987.tb02361.x; REED R, 1988, GENE DEV, V2, P1268, DOI 10.1101/gad.2.10.1268; ROTHSTEIN DM, 1990, CELL IMMUNOL, V129, P449, DOI 10.1016/0008-8749(90)90220-L; ROTHSTEIN DM, 1991, J IMMUNOL, V146, P1175; SAGA Y, 1987, P NATL ACAD SCI USA, V84, P5364, DOI 10.1073/pnas.84.15.5364; SAGA Y, 1988, MOL CELL BIOL, V8, P4889, DOI 10.1128/MCB.8.11.4889; SAGA Y, 1990, P NATL ACAD SCI USA, V87, P3728, DOI 10.1073/pnas.87.10.3728; SAGAY, 1991, IMMUNOGENETICS, V31, P296; SANDERS ME, 1988, IMMUNOL TODAY, V9, P195, DOI 10.1016/0167-5699(88)91212-1; SANDERS ME, 1988, J IMMUNOL, V140, P1401; SANTONI MJ, 1989, EMBO J, V8, P385, DOI 10.1002/j.1460-2075.1989.tb03389.x; SERRA HM, 1988, J IMMUNOL, V140, P1435; SMITH CWJ, 1989, CELL, V56, P749, DOI 10.1016/0092-8674(89)90678-8; SMITH CWJ, 1989, ANNU REV GENET, V23, P527, DOI 10.1146/annurev.genet.23.1.527; SMITH SH, 1986, IMMUNOLOGY, V58, P63; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STAMENKOVIC I, 1991, CELL, V66, P1133, DOI 10.1016/0092-8674(91)90036-X; STREULI M, 1987, J EXP MED, V166, P1548, DOI 10.1084/jem.166.5.1548; STREULI M, 1988, J IMMUNOL, V141, P3910; STREULI M, 1989, EMBO J, V8, P787, DOI 10.1002/j.1460-2075.1989.tb03439.x; TAKEUCHI T, 1989, EUR J IMMUNOL, V19, P747, DOI 10.1002/eji.1830190427; TEDDER TF, 1985, J IMMUNOL, V134, P2983; TEDDER TF, 1985, J IMMUNOL, V134, P2989; THOMAS ML, 1989, ANNU REV IMMUNOL, V7, P339, DOI 10.1146/annurev.immunol.7.1.339; TONKS N K, 1988, Biochemistry, V27, P8695, DOI 10.1021/bi00424a001; TSAI AYM, 1989, MOL CELL BIOL, V9, P4550, DOI 10.1128/MCB.9.10.4550; [No title captured]	69	52	53	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 5	1992	267	10					7139	7147						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HM053	1532394				2022-12-25	WOS:A1992HM05300105
J	DATTA, B; WEINER, AM				DATTA, B; WEINER, AM			CROSS-LINKING OF U1 SNRNA USING NITROGEN-MUSTARD - EVIDENCE FOR HIGHER-ORDER STRUCTURE .2.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMALL NUCLEAR-RNA; RIBONUCLEOPROTEIN PARTICLE; LOOP-I; 3-DIMENSIONAL MODEL; GENETIC-ANALYSIS; STEM-LOOP; PROTEIN; U2; BINDING; INVITRO	Secondary structures for all five spliceosomal small nuclear (sn) RNAs (U1, U2, U4, U5, and U6 snRNAs) have been derived from phylogenetic, biochemical, and genetic data, but tertiary structure information has been more difficult to obtain. Here we have used the general cross-linking reagent nitrogen mustard (bis-(2-chloroethyl)methylamine) to explore the tertiary conformation of naked U1 snRNA. We detected two intramolecularly cross-linked U1 species (X-U1#1 and X-U1#2) after cross-linking of deproteinized HeLa nuclear extract. We determined the cross-linked sites and found that X-U1#1 is cross-linked between the C82-A85 and U129, while X-U1#2 is cross-linked between U105-G108 and A118. We then tested the ability of these two cross-linked species to bind small nuclear ribonucleoprotein (snRNP) proteins in vitro (in HeLa nuclear extract or S100) and in vivo (in Xenopus oocytes). Both X-U1#1 and X-U1#2 were found to reconstitute efficiently in vitro and in vivo, as judged by immunoprecipitation with antibodies specific for Sm and U1-specific proteins. Our data suggest that (i) the Sm-binding site lies on the surface of the native U1 snRNP, since the cross-link in X-U1#1 involves the Sm-binding site but does not block snRNP assembly, and (ii) U1 snRNA may adopt the correct tertiary conformation even in the absence of U1 snRNP proteins.			DATTA, B (corresponding author), YALE UNIV, SCH MED, DEPT MOLEC BIOPHYS & BIOCHEM, NEW HAVEN, CT 06510 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031073] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM31073] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARES M, 1990, GENE DEV, V4, P2132, DOI 10.1101/gad.4.12a.2132; BARABINO SML, 1989, EMBO J, V8, P4171, DOI 10.1002/j.1460-2075.1989.tb08602.x; BLACK DL, 1985, CELL, V42, P737, DOI 10.1016/0092-8674(85)90270-3; BRIMACOMBE R, 1988, METHOD ENZYMOL, V164, P287; BRUZIK JP, 1990, CELL, V62, P889, DOI 10.1016/0092-8674(90)90264-F; CALVET JP, 1987, J MOL BIOL, V197, P543, DOI 10.1016/0022-2836(87)90563-8; DATTA B, 1992, J BIOL CHEM, V267, P4497; DATTA B, 1991, NATURE, V352, P821, DOI 10.1038/352821a0; DONISKELLER H, 1977, NUCLEIC ACIDS RES, V4, P2527, DOI 10.1093/nar/4.8.2527; GUTHRIE C, 1988, ANNU REV GENET, V22, P387, DOI 10.1146/annurev.ge.22.120188.002131; HAMM J, 1987, EMBO J, V6, P3479, DOI 10.1002/j.1460-2075.1987.tb02672.x; HAMM J, 1988, MOL CELL BIOL, V8, P4787, DOI 10.1128/MCB.8.11.4787; HAUSNER TP, 1990, GENE DEV, V4, P2146, DOI 10.1101/gad.4.12a.2146; JONES MH, 1990, EMBO J, V9, P2555, DOI 10.1002/j.1460-2075.1990.tb07436.x; KELLER EB, 1985, NUCLEIC ACIDS RES, V13, P4971, DOI 10.1093/nar/13.13.4971; KIM SH, 1987, P NATL ACAD SCI USA, V84, P8788, DOI 10.1073/pnas.84.24.8788; KROL A, 1990, NUCLEIC ACIDS RES, V18, P3803, DOI 10.1093/nar/18.13.3803; LUHRMANN R, 1988, STRUCTURE FUNCTION M, P71; MANGIN M, 1985, SCIENCE, V229, P272, DOI 10.1126/science.2409601; MOUNT SM, 1983, CELL, V33, P509, DOI 10.1016/0092-8674(83)90432-4; NAGAI K, 1990, NATURE, V348, P515, DOI 10.1038/348515a0; PATTON JR, 1987, MOL CELL BIOL, V7, P4030, DOI 10.1128/MCB.7.11.4030; PATTON JR, 1988, P NATL ACAD SCI USA, V85, P747, DOI 10.1073/pnas.85.3.747; QUERY CC, 1989, MOL CELL BIOL, V9, P4872, DOI 10.1128/MCB.9.11.4872; Reddy R., 1988, STRUCTURE FUNCTION M, P1, DOI 10.1007/978-3-642-73020-7_1; Steitz J. A., 1988, STRUCTURE FUNCTION M, P115; SUROWY CS, 1989, MOL CELL BIOL, V9, P4179, DOI 10.1128/MCB.9.10.4179; TSCHUDI C, 1990, CELL, V61, P459, DOI 10.1016/0092-8674(90)90527-L; WEIBEN ED, 1983, P NATL ACAD SCI USA, V80, P1217; WU J, 1991, NATURE, V352, P818, DOI 10.1038/352818a0; YUO CY, 1989, GENE DEV, V3, P697, DOI 10.1101/gad.3.5.697	31	4	4	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	1992	267	7					4503	4507						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HF642	1531654				2022-12-25	WOS:A1992HF64200036
J	FREEZE, HH; HINDSGAUL, O; ICHIKAWA, M				FREEZE, HH; HINDSGAUL, O; ICHIKAWA, M			A NOVEL PATHWAY FOR PHOSPHORYLATED OLIGOSACCHARIDE BIOSYNTHESIS - IDENTIFICATION OF AN OLIGOSACCHARIDE-SPECIFIC PHOSPHATE METHYLTRANSFERASE IN DICTYOSTELIUM DISCOIDEUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASPARAGINE-LINKED OLIGOSACCHARIDES; MANNOSE 6-PHOSPHATE RECEPTORS; LYSOSOMAL-ENZYMES; METHYLPHOSPHOMANNOSYL RESIDUES; CARBOHYDRATE CHAINS; PRESPORE VACUOLES; HUMAN-FIBROBLASTS; RAT-LIVER; CELLS; GLYCOPROTEINS	The N-linked oligosaccharides on three lysosomal enzymes in Dictyostelium discoideum were found to contain mannose 6-phosphomethyl residues. We have identified and partially characterized a novel S-adenosylmethionine-dependent methyltransferase that is probably responsible for the synthesis of this unusual diester from Man-6-P. The enzyme selectively methylates the phosphate group of Man-6-P (K(m) 4.3 mM). Glucose-6-P and fructose-1-P are relatively poor acceptors; however, the enzyme is inactive against a broad array of other phosphorylated compounds. Using model di-, tri-, and pentasaccharide acceptors that include portions of the three different branches of high mannose-type oligosaccharides, we found that the enzyme prefers terminal alpha-1 --> 2-linked Man-6-P residues (K(m) 0.15-1.25 mM) found on the known phosphorylated branches. The enzyme is membrane bound, has a neutral pH optimum and cofractionates on sucrose gradients with GlcNAc-1-P transferase, which resembles its mammalian counterpart, and is, presumably, the first enzyme in the phosphorylation pathway. Based on the substrate specificity and colocalization with GlcNAc-1-P transferase, the phosphate methyltransferase is likely to be responsible for the generation of mannose-6-phosphomethyldiester on Dictyostelium oligosaccharides.	UNIV ALBERTA,DEPT CHEM,EDMONTON T6G 2G2,ALBERTA,CANADA	University of Alberta	FREEZE, HH (corresponding author), LA JOLLA CANC RES FDN,10901 N TORREY PINES RD,LA JOLLA,CA 92037, USA.			Freeze, Hudson/0000-0001-6316-0501	PHS HHS [32485] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BARANSKI TJ, 1990, CELL, V63, P281, DOI 10.1016/0092-8674(90)90161-7; BUSH JM, 1989, J BIOL CHEM, V264, P7630; Cardelli J.A., 1988, P363; COUSO R, 1987, J BIOL CHEM, V262, P4521; COUSO R, 1986, J BIOL CHEM, V261, P6326; DAHMS NM, 1989, J BIOL CHEM, V264, P12115; EBERT DL, 1989, ARCH BIOCHEM BIOPHYS, V273, P479, DOI 10.1016/0003-9861(89)90507-9; FREEZE HH, 1989, J BIOL CHEM, V264, P19278; FREEZE HH, 1983, J BIOL CHEM, V258, P8928; FREEZE HH, 1986, J BIOL CHEM, V261, P135; FREEZE HH, 1985, J BIOL CHEM, V260, P8857; FREEZE HH, 1983, J BIOL CHEM, V258, P4874; FREEZE HH, 1986, J BIOL CHEM, V261, P157; GABEL CA, 1984, J BIOL CHEM, V259, P3762; HERZOG V, 1987, EMBO J, V6, P555, DOI 10.1002/j.1460-2075.1987.tb04790.x; HOFLACK B, 1987, J BIOL CHEM, V262, P123; HOFLACK B, 1985, P NATL ACAD SCI USA, V82, P4428, DOI 10.1073/pnas.82.13.4428; HOHMANN HP, 1985, J BIOL CHEM, V260, P3869; JUDELSON HS, 1988, ARCH BIOCHEM BIOPHYS, V267, P151, DOI 10.1016/0003-9861(88)90018-5; KAPLAN A, 1977, P NATL ACAD SCI USA, V74, P2026, DOI 10.1073/pnas.74.5.2026; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; LANG L, 1986, J BIOL CHEM, V261, P6320; LEE SJ, 1988, J BIOL CHEM, V263, P3521; MADIYALAKAN R, 1987, BIOCHEM BIOPH RES CO, V142, P354, DOI 10.1016/0006-291X(87)90281-6; OYAMA M, 1984, PROTOPLASMA, V123, P152, DOI 10.1007/BF01283585; PADH H, 1989, J CELL BIOL, V108, P865, DOI 10.1083/jcb.108.3.865; PURCHIO AF, 1988, J BIOL CHEM, V263, P14211; SHARKEY DJ, 1991, J BIOL CHEM, V266, P18477; SINGH R, 1989, P NATL ACAD SCI USA, V86, P8280, DOI 10.1073/pnas.86.21.8280; SRIVASTAVA OP, 1986, CARBOHYD RES, V155, P57, DOI 10.1016/S0008-6215(00)90133-2; SRIVASTAVA OP, 1987, J ORG CHEM, V52, P2869, DOI 10.1021/jo00389a039; SRIVASTAVA OP, 1987, CARBOHYD RES, V161, P195, DOI 10.1016/S0008-6215(00)90077-6; SRIVASTAVA OP, 1986, CAN J CHEM, V64, P2324, DOI 10.1139/v86-382; TAKEMOTO K, 1985, J CELL SCI, V77, P93; TODDERUD G, 1988, J BIOL CHEM, V263, P17893; TOWNSEND RR, 1988, ANAL BIOCHEM, V174, P459, DOI 10.1016/0003-2697(88)90044-9; USDIN E, 1979, TRANSMETHYLATION, P1; VARKI A, 1981, J BIOL CHEM, V256, P9937; VONFIGURA K, 1986, ANNU REV BIOCHEM, V55, P167, DOI 10.1146/annurev.biochem.55.1.167	40	14	14	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1992	267	7					4431	4439						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HF642	1531653				2022-12-25	WOS:A1992HF64200028
J	OHUCHI, T; KURITA, Y; SASAI, H; MIYOSHI, J; NOMURA, T; TOYOSHIMA, K				OHUCHI, T; KURITA, Y; SASAI, H; MIYOSHI, J; NOMURA, T; TOYOSHIMA, K			ONCOGENIC ACTIVATION OF MURINE MOS PROTEIN-KINASE BY DNA REARRANGEMENT OF ITS N-TERMINAL CODING REGION	ONCOGENE			English	Article							C-MOS; SARCOMA-VIRUS; SEQUENCE; PRODUCT; MATURATION; VECTORS; CLONING; GENOME; GENES; EGGS	An activated c-mos oncogene was detected by DNA transfection assay of hamster SHOK cells with DNAs from X-ray-induced mouse osteosarcoma. It was molecularly cloned by the cosmid rescue method and found to form transformed foci of SHOK cells. Genomic DNA sequencing revealed that in this oncogene the N-terminal coding region of the mouse proto-mos gene was deleted and replaced by a hamster-derived sequence in the primary transformant, suggesting that activation was due to the rearrangement during transfection. The gene product was about 37 kDa and was immunoprecipitated with anti-mos antibody from a lysate of a SHOK cell transfectant. This truncated mos (t-mos) gene transformed SHOK cells more effectively than v-mos. A chimeric gene construct of this hamster-derived upstream sequence and normal mouse c-mos also transformed SHOK cells at a lower level, whereas neither t-mos nor the chimeric c-mos gene transformed NIH3T3 cells appreciably. The high transforming efficiency of t-mos in SHOK cells was due not only to truncation of the coding region but also to its integration under a putative promoter sequence derived from the hamster genome. This is the first report of detection of an activated c-mos gene by DNA transfection assay.	OSAKA UNIV,MICROBIAL DIS RES INST,DEPT ONCOGENE RES,SUITA,OSAKA 565,JAPAN; OSAKA UNIV,DEPT RADIAT BIOL,SUITA,OSAKA 565,JAPAN	Osaka University; Osaka University								BASU M, 1984, NATURE, V311, P477, DOI 10.1038/311477a0; BLAIR DG, 1986, CELL, V46, P785, DOI 10.1016/0092-8674(86)90354-5; BLAIR DG, 1981, SCIENCE, V212, P941, DOI 10.1126/science.7233190; BOLD RJ, 1985, MOL CELL BIOL, V5, P3131, DOI 10.1128/MCB.5.11.3131; BRADY G, 1984, GENE, V27, P223, DOI 10.1016/0378-1119(84)90143-4; CANAANI E, 1983, P NATL ACAD SCI-BIOL, V80, P7118, DOI 10.1073/pnas.80.23.7118; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COHEN JB, 1983, NATURE, V306, P797, DOI 10.1038/306797a0; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; FUJIMOTO S, 1985, P NATL ACAD SCI USA, V82, P2072, DOI 10.1073/pnas.82.7.2072; GERBAUD C, 1981, CURR GENET, V3, P173, DOI 10.1007/BF00429819; HIGASHI T, 1990, P NATL ACAD SCI USA, V87, P2409, DOI 10.1073/pnas.87.7.2409; Maniatis T, 1989, DECONTAMINATION DILU; MAXWELL SA, 1985, VIROLOGY, V143, P321, DOI 10.1016/0042-6822(85)90119-9; MIYOSHI J, 1991, IN PRESS MOL CELL BI; MOLONEY JOHN B., 1966, NAT CANCER INST MONOGR, V22, P139; NAHARRO G, 1983, J VIROL, V47, P611, DOI 10.1128/JVI.47.3.611-619.1983; NOMURA T, 1982, NATURE, V296, P575, DOI 10.1038/296575a0; OKAZAKI K, 1991, JPN J CANCER RES, V82, P250, DOI 10.1111/j.1349-7006.1991.tb01837.x; OSKARSSON M, 1980, SCIENCE, V207, P1222, DOI 10.1126/science.6243788; PAPKOFF J, 1981, CELL, V27, P109, DOI 10.1016/0092-8674(81)90365-2; SAGATA N, 1989, NATURE, V342, P512, DOI 10.1038/342512a0; SAGATA N, 1989, SCIENCE, V245, P643, DOI 10.1126/science.2474853; SAGATA N, 1988, NATURE, V335, P519, DOI 10.1038/335519a0; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; VANBEVEREN C, 1981, CELL, V27, P97, DOI 10.1016/0092-8674(81)90364-0; WATANABE N, 1989, NATURE, V342, P505, DOI 10.1038/342505a0	27	5	5	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1992	7	2					331	338						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HG982	1532243				2022-12-25	WOS:A1992HG98200019
J	PAL, PK; MA, ZP; COLEMAN, PS				PAL, PK; MA, ZP; COLEMAN, PS			THE AMP-BINDING DOMAIN ON ADENYLATE KINASE - EVIDENCE FOR A CONFORMATIONAL CHANGE DURING BINARY-TO-TERNARY COMPLEX-FORMATION VIA PHOTOAFFINITY-LABELING ANALYSES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENOSINE-TRIPHOSPHATE TRANSPHOSPHORYLASES; AMINO-ACID-SEQUENCE; ATP-BINDING; ESCHERICHIA-COLI; BETA-SUBUNIT; X-RAY; SITE; F1-ATPASE; PROTEINS; MUSCLE	The topological location of the nucleotide substrate binding environments on adenylate kinase has been explored with the fluorescent molecule [4-benzoyl]benzoyl-1-amidofluorescein (BzAF) and the nucleotide analog 3'-O-[4-benzoyl]benzoyl-ATP (BzATP), which are site-directed photoaffinity probes that bind covalently at the individual nucleotide sites. The MgBzATP substituted for MgATP as a substrate for this enzyme, whereas BzAF, which is neither a substrate nor a nucleotide, behaved as a competitive inhibitor for each nucleotide site independently. BzAF could be directed specifically to either of the nucleotide sites by near saturation of the second site with its natural nucleotide substrate. Using this second site blocking approach, each nucleotide site, in turn, could be protected competitively from BzAF-induced photoinhibition by the presence of its natural substrate. This strategy showed that under photolysis, the K(d(BzAF)) of 0.1 mM (for the MgATP site) and 0.2 mM (for the AMP site) were nearly identical with the K(m(app)) values determined for MgATP and AMP, respectively. Pseudo first-order photolysis kinetics with [H-3]BzAF revealed covalent binding stoichiometries for full inhibition of 1 mol of probe/mol of enzyme at either site. Thus, we prepared the binary complex {[H-3]BzAF-enzyme} by photo-labeling the MgATP site-blocked enzyme with [H-3]BzAF to 1:1 molar stoichiometry. Tryptic digestion followed by partial sequencing of the [H-3]BzAF-labeled enzyme disclosed that BzAF was bound specifically within the peptide span Gly64 --> Arg77. This amino acid domain therefore probably constitutes the neighborhood identifiable with AMP binding. Furthermore, we also achieved double photocovalent labeling of adenylate kinase with both photoprobes, by first cross-linking with approximately 1 mol of MgBzATP, followed by approximately 0.9 mol of [H-3]BzAF, thus generating a ternary covalent complex. Comparison of the fluorescence of the binary species and the ternary {BzATP-enzyme-[H-3]BzAF} complex revealed altered fluorescence emission profiles, which could indicate that a conformational change occurs during formation of the ternary (or transition state) complex.	BOSTON BIOMED RES INST, DEPT METAB REGULAT, 20 STANIFORD ST, BOSTON, MA 02114 USA	Boston Biomedical Research Institute					NIGMS NIH HHS [GM-36619] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036619] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALOISE P, 1991, J BIOL CHEM, V266, P10368; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHUAN H, 1989, J BIOL CHEM, V264, P7981; COLE DG, 1990, J BIOL CHEM, V265, P22537; CORNISHBOWDEN A, 1979, FUNDAMENTALS ENZYME, P20; DREUSICKE D, 1988, J MOL BIOL, V199, P359, DOI 10.1016/0022-2836(88)90319-1; DUNCAN TM, 1986, FEBS LETT, V208, P1, DOI 10.1016/0014-5793(86)81519-8; EGNER U, 1987, J MOL BIOL, V195, P649, DOI 10.1016/0022-2836(87)90188-4; FRY DC, 1986, P NATL ACAD SCI USA, V83, P907, DOI 10.1073/pnas.83.4.907; FRY DC, 1985, BIOCHEMISTRY-US, V24, P4680, DOI 10.1021/bi00338a030; FRY DC, 1987, BIOCHEMISTRY-US, V26, P1645, DOI 10.1021/bi00380a024; GARBOCZI DN, 1988, BIOCHEMISTRY-US, V27, P553, DOI 10.1021/bi00402a008; HAMADA M, 1978, ARCH BIOCHEM BIOPHYS, V190, P772, DOI 10.1016/0003-9861(78)90338-7; HAMADA M, 1991, STUDY ENZYMES, V2, P403; KIM HJ, 1990, BIOCHEMISTRY-US, V29, P1107, DOI 10.1021/bi00457a002; KUBY SA, 1978, ARCH BIOCHEM BIOPHYS, V187, P34, DOI 10.1016/0003-9861(78)90004-8; KUBY SA, 1984, BIOCHEMISTRY-US, V23, P2393, DOI 10.1021/bi00306a012; Lakowicz J.R., 1983, PRINCIPLES FLUORESCE; MARTIN MM, 1975, J LUMIN, V10, P381, DOI 10.1016/0022-2313(75)90003-4; MILDVAN AS, 1987, ADV ENZYMOL RAMB, V59, P241; MOLLER W, 1985, FEBS LETT, V186, P1, DOI 10.1016/0014-5793(85)81326-0; NODA L, 1975, EUR J BIOCHEM, V51, P229, DOI 10.1111/j.1432-1033.1975.tb03923.x; NODA L, 1957, J BIOL CHEM, V226, P541; OKAJIMA T, 1991, J BIOL CHEM, V266, P11442; PAI EF, 1989, NATURE, V341, P209, DOI 10.1038/341209a0; PAI EF, 1977, J MOL BIOL, V114, P37, DOI 10.1016/0022-2836(77)90281-9; PAL PK, 1990, J BIOL CHEM, V265, P14996; PENEFSKY H, 1991, ADV ENZYMOL REL AREA, V64, P173; PENEFSKY HS, 1977, J BIOL CHEM, V252, P2891; RAO BDN, 1978, J BIOL CHEM, V253, P1149; REINSTEIN J, 1988, BIOCHEMISTRY-US, V27, P4712, DOI 10.1021/bi00413a020; RHOADS DG, 1968, J BIOL CHEM, V243, P3963; ROHATGI KK, 1972, J INDIAN CHEM SOC, V49, P1311; SACHSENHEIMER W, 1977, J MOL BIOL, V114, P23, DOI 10.1016/0022-2836(77)90280-7; SALVUCCI ME, 1992, BIOCHEMISTRY-US, V31, P4479, DOI 10.1021/bi00133a014; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; SCHIRMER I, 1970, FEBS LETT, V10, P333, DOI 10.1016/0014-5793(70)80466-5; SCHULZ GE, 1986, EUR J BIOCHEM, V161, P127, DOI 10.1111/j.1432-1033.1986.tb10132.x; THUMA E, 1972, BIOCHIM BIOPHYS ACTA, V268, P81, DOI 10.1016/0005-2744(72)90200-8; TSAI MD, 1991, BIOCHEMISTRY-US, V30, P6806, DOI 10.1021/bi00242a002; VETTER IR, 1991, BIOCHEMISTRY-US, V30, P4137, DOI 10.1021/bi00231a005; VOGEL PD, 1991, J BIOL CHEM, V266, P6101; VONZABERN I, 1976, EUR J BIOCHEM, V68, P281; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; YAGAMI T, 1988, FEBS LETT, V229, P261, DOI 10.1016/0014-5793(88)81137-2; YAN HG, 1990, BIOCHEMISTRY-US, V29, P6385, DOI 10.1021/bi00479a007	46	14	14	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	1992	267	35					25003	25009						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KB603	1460003				2022-12-25	WOS:A1992KB60300017
J	SUN, S; CHASTEEN, ND				SUN, S; CHASTEEN, ND			FERROXIDASE KINETICS OF HORSE SPLEEN APOFERRITIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-RAY ABSORPTION; IRON DEPOSITION; FERRITIN; MECHANISM; COMPLEX; BINDING; OXIDATION; SPECTROSCOPY; SUPEROXIDE; PROTEIN	Protein ferroxidase site(s), which catalyze the reaction between ferrous ion and dioxygen, have long been thought to play a role in core formation in ferritin; however, the mechanism of the reaction has never been studied in detail. In the present work, the enzymatic activity of ferritin was examined using oximetry, the net Fe2+ oxidation reaction being as follows. Fe2+ + 1/2O2 + 2H2O --> FeOOH(core) + 1/2H2O2 + 2H+ (Reaction 1S) The reaction exhibits saturation kinetics with respect to both Fe2+ and O2 (apparent Michaelis constants: K(m,Fe) = 0.35 +/- 0.01 mM and K(m,O2) = 0.14 +/- 0.03 mM). The enzyme has a turnover number k(cat) = 80 +/- 3 min-1 at 20-degrees-C with maximal activity at pH 7. The kinetics are discussed in terms of two mechanisms, one involving monomeric and the other dimeric iron protein complexes. In both instances Fe(II) oxidation occurs in 1-electron steps. Zinc(II) is a competitive inhibitor of iron(II) oxidation at Zn2+/apoprotein ratios greater-than-or-equal-to 6 (inhibitor constant K(I,Zn) = 0.067 +/- 0.011 mM) but appears to be a noncompetitive inhibitor at lower ratios (less-than-or-equal-to 2), indicating the presence of more than one type of zinc binding site on the protein. At increments of 50 Fe2+/protein or less, all of the iron is oxidized via the protein ferroxidase site(s), independent of the amount of core already present. However, when larger increments are employed, some iron oxidation appears to occur on the surface of the mineral core. The results of these studies emphasize the role of the protein shell in all phases of core growth and confirm the presence of a functionally important catalytic site in ferritin in addition to other binding sites on the protein for iron.	UNIV NEW HAMPSHIRE, DEPT CHEM, PARSONS HALL, DURHAM, NH 03824 USA	University System Of New Hampshire; University of New Hampshire					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM020194, R37GM020194] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM20194] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADELMAN TG, 1975, BIOCHEM BIOPH RES CO, V63, P1056, DOI 10.1016/0006-291X(75)90676-2; AROSIO P, 1978, J BIOL CHEM, V253, P4451; BAKKER GR, 1986, J BIOL CHEM, V261, P3182; BAUMINGER ER, 1991, BIOCHIM BIOPHYS ACTA, V1118, P48, DOI 10.1016/0167-4838(91)90440-B; BAUMINGER ER, 1989, BIOCHEMISTRY-US, V28, P5486, DOI 10.1021/bi00439a025; BI X, 1991, J BIOL CHEM, V266, P19965; BORGGAARD OK, 1972, ACTA CHEM SCAND, V26, P393, DOI 10.3891/acta.chem.scand.26-0393; CHASTEEN ND, 1985, J BIOL CHEM, V260, P2926; CHASTEEN ND, 1982, J BIOL CHEM, V257, P7672; CHENG YG, 1991, BIOCHEMISTRY-US, V30, P2947, DOI 10.1021/bi00225a031; CRICHTON RR, 1978, J MOL CATAL, V4, P75; DESILVA D, 1992, ARCH BIOCHEM BIOPHYS, V293, P409, DOI 10.1016/0003-9861(92)90413-Q; Eigen M., 1965, MECH INORGANIC REACT, P55, DOI [10.1021/ba-1965-0049.ch003, DOI 10.1021/BA-1965-0049.CH003]; FORD GC, 1984, PHILOS T R SOC B, V304, P551, DOI 10.1098/rstb.1984.0046; GRADY JK, 1989, J BIOL CHEM, V264, P20224; GRADY JK, 1991, IRON BIOMINERALS, P315; HANNA PM, 1991, J BIOL CHEM, V266, P886; HARRIS DC, 1973, BIOCHIM BIOPHYS ACTA, V329, P156, DOI 10.1016/0304-4165(73)90019-6; HARRISON PM, 1991, ADV INORG CHEM, V36, P449, DOI 10.1016/S0898-8838(08)60046-X; HARRISON PM, 1986, J INORG BIOCHEM, V27, P287, DOI 10.1016/0162-0134(86)80068-X; HARRISON PM, 1986, FRONTIERS BIOINORGAN, P268; HEUSTERSPREUTE M, 1981, FEBS LETT, V129, P322, DOI 10.1016/0014-5793(81)80193-7; HEWKIN DJ, 1970, COORDIN CHEM REV, V5, P45, DOI 10.1016/S0010-8545(00)80074-0; JACOBS D, 1989, BIOCHEMISTRY-US, V28, P9216, DOI 10.1021/bi00449a038; KURIMURA Y, 1969, B CHEM SOC JPN, V42, P2238, DOI 10.1246/bcsj.42.2238; KURIMURA Y, 1968, B CHEM SOC JPN, V41, P2234, DOI 10.1246/bcsj.41.2234; LAWSON DM, 1989, FEBS LETT, V254, P207, DOI 10.1016/0014-5793(89)81040-3; LAWSON DM, 1991, NATURE, V349, P541, DOI 10.1038/349541a0; LEVI S, 1989, BIOCHEMISTRY-US, V28, P5179, DOI 10.1021/bi00438a040; MACARA IG, 1972, BIOCHEM J, V126, P151, DOI 10.1042/bj1260151; MACARA IG, 1973, BIOCHEM J, V135, P343, DOI 10.1042/bj1350343; MCCLUNE GJ, 1977, J AM CHEM SOC, V99, P5220, DOI 10.1021/ja00457a074; MERRITT MV, 1977, J AM CHEM SOC, V99, P3713, DOI 10.1021/ja00453a033; NG FTT, 1980, CAN J CHEM, V58, P1773, DOI 10.1139/v80-280; ROBERTS DV, 1977, ENZYME KINETICS, P83; ROHRER JS, 1987, J BIOL CHEM, V262, P13385; SADA E, 1987, IND ENG CHEM RES, V26, P1468, DOI 10.1021/ie00067a033; SAWYER DT, 1981, ACCOUNTS CHEM RES, V14, P393, DOI 10.1021/ar00072a005; SEGEL IH, 1975, KINETICS MECHANISMS, P884; THEIL EC, 1990, ADV ENZYMOL RAMB, V63, P421; TREFFRY A, 1984, J INORG BIOCHEM, V21, P9, DOI 10.1016/0162-0134(84)85035-7; TREFFRY A, 1992, FEBS LETT, V302, P108, DOI 10.1016/0014-5793(92)80417-F; Treffry A., 1977, PROTEINS IRON METABO, P3; Walsh C., 1979, ENZYMATIC REACTION M, P33; WARDESKA JG, 1986, J BIOL CHEM, V261, P6677; WILKINS RG, 1991, KINETICS MECH REACTI, P202; YANG CY, 1987, BIOCHEMISTRY-US, V26, P497, DOI 10.1021/bi00376a023; ZERNER B, 1964, J AM CHEM SOC, V86, P3674, DOI 10.1021/ja01072a016; [No title captured]	49	97	97	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	1992	267	35					25160	25166						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KB603	1460015				2022-12-25	WOS:A1992KB60300039
J	DELLIS, S; SCHATZ, T; RUTLIN, K; INMAN, RB; FILUTOWICZ, M				DELLIS, S; SCHATZ, T; RUTLIN, K; INMAN, RB; FILUTOWICZ, M			2 ALTERNATIVE STRUCTURES CAN BE FORMED BY IHF PROTEIN-BINDING TO THE PLASMID-R6K GAMMA-ORIGIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTEGRATION HOST FACTOR; ESCHERICHIA-COLI BINDS; DNA-REPLICATION; TRANSCRIPTIONAL ACTIVATION; BACTERIOPHAGE-LAMBDA; CHROMOSOMAL ORIGIN; INITIATOR PROTEIN; SITES; R6K; TELESTABILITY	Escherichia coli integration host factor (IHF) contributes to the regulation of R6K plasmid copy number by counteracting the inhibitory activity of the plasmid-encoded replication protein pi. Two IHF-binding sites (ihf1 and ihf2) flank seven iterons in the origin which bind pi protein. As previously shown by electron microscopy, IHF can compact a large segment of the R6K gamma origin DNA, encompassing site ihf1, an AT-rich domain containing ihf1, and some of the seven iterons located downstream of ihf1. We termed this phenomenon IHF-mediated DNA folding. This folding requires a high IHF concentration, and the region of the origin (replication enhancer) located to the left of the AT-rich domain. However, site ihf2 is not necessary in forming the folded structure. As reported here, IHF binding to ihf2 can be detected in gel mobility shift assays only if the leftmost enhancer region is absent. Sites ihf1 and ihf2 each contain two consensus IHF sequences. Site-directed mutagenesis was performed to determine which sequences are recognized by IHF protein and which sites are involved in forming the various gamma origin-IHF complexes. Finally, we define the boundaries of protection from DNaseI digestion when IHF is bound to ihf2. We propose a model in which IHF protein bound to ihf1, in the absence of the enhancer region, facilitates IHF binding to ihf2.	UNIV WISCONSIN,DEPT BACTERIOL,MADISON,WI 53706; UNIV WISCONSIN,INST MOLEC VIROL,MADISON,WI 53706; UNIV WISCONSIN,DEPT BIOCHEM,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison					NIGMS NIH HHS [GM 40314, GM 14711] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040314, R01GM014711] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADHYA S, 1990, J BIOL CHEM, V265, P10797; BAKER TA, 1988, CELL, V55, P113, DOI 10.1016/0092-8674(88)90014-1; BIEK DP, 1989, J BACTERIOL, V171, P2056, DOI 10.1128/jb.171.4.2056-2065.1989; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; BRAMHILL D, 1988, CELL, V54, P915, DOI 10.1016/0092-8674(88)90102-X; BRAMHILL D, 1988, CELL, V52, P743, DOI 10.1016/0092-8674(88)90412-6; BURD JF, 1975, J BIOL CHEM, V250, P6002; BURD JF, 1975, J BIOL CHEM, V250, P5109; CRAIG NL, 1984, CELL, V39, P707, DOI 10.1016/0092-8674(84)90478-1; DELLIS S, 1991, J BACTERIOL, V173, P1279, DOI 10.1128/jb.173.3.1279-1286.1991; DIXON NE, 1984, P NATL ACAD SCI-BIOL, V81, P424, DOI 10.1073/pnas.81.2.424; DODSON M, 1986, P NATL ACAD SCI USA, V83, P7638, DOI 10.1073/pnas.83.20.7638; DRLICA K, 1987, MICROBIOL REV, V51, P301, DOI 10.1128/MMBR.51.3.301-319.1987; FILUTOWICZ M, 1991, J BIOL CHEM, V266, P24077; FILUTOWICZ M, 1988, NUCLEIC ACIDS RES, V16, P3829, DOI 10.1093/nar/16.9.3829; FILUTOWICZ M, 1990, New Biologist, V2, P818; FILUTOWICZ M, 1985, J MOL BIOL, V187, P225; FRIEDMAN DI, 1988, CELL, V55, P545, DOI 10.1016/0092-8674(88)90213-9; GAMAS P, 1986, MOL GEN GENET, V204, P85, DOI 10.1007/BF00330192; GARDNER JF, 1986, J MOL BIOL, V191, P181, DOI 10.1016/0022-2836(86)90255-X; GERMINO J, 1983, CELL, V34, P125, DOI 10.1016/0092-8674(83)90142-3; GOODRICH JA, 1990, NUCLEIC ACIDS RES, V18, P4993, DOI 10.1093/nar/18.17.4993; GREENSTEIN D, 1988, P NATL ACAD SCI USA, V85, P6262, DOI 10.1073/pnas.85.17.6262; HOOVER TR, 1990, CELL, V63, P11, DOI 10.1016/0092-8674(90)90284-L; KELLEY WL, 1991, J BIOL CHEM, V266, P15924; KOLTER R, 1979, THESIS U CALIFORNIA; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KUR J, 1989, GENE, V81, P1, DOI 10.1016/0378-1119(89)90331-4; LEONG JM, 1985, J BIOL CHEM, V260, P4468; LILLEY DMJ, 1988, TRENDS GENET, V4, P111, DOI 10.1016/0168-9525(88)90099-6; Maniatis T., 1982, MOL CLONING; MENSAWILMOT K, 1989, EMBO J, V8, P2393, DOI 10.1002/j.1460-2075.1989.tb08369.x; MUKERJI P, 1992, J BACTERIOL, V74, P4777; ROUVIEREYANIV J, 1975, P NATL ACAD SCI USA, V72, P3428, DOI 10.1073/pnas.72.9.3428; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHNOS M, 1988, CELL, V52, P385, DOI 10.1016/S0092-8674(88)80031-X; STALKER DM, 1979, P NATL ACAD SCI USA, V76, P1150, DOI 10.1073/pnas.76.3.1150; STENZEL TT, 1987, CELL, V49, P709, DOI 10.1016/0092-8674(87)90547-2; SULLIVAN KM, 1988, NUCLEIC ACIDS RES, V16, P1079, DOI 10.1093/nar/16.3.1079; SULLIVAN KM, 1986, CELL, V47, P817, DOI 10.1016/0092-8674(86)90524-6; TANAKA I, 1984, NATURE, V310, P376, DOI 10.1038/310376a0; WHITE SW, 1989, PROTEINS, V5, P281, DOI 10.1002/prot.340050405; WOOD WI, 1985, P NATL ACAD SCI USA, V82, P1585, DOI 10.1073/pnas.82.6.1585; WU F, 1992, NUCLEIC ACIDS RES, V20, P811, DOI 10.1093/nar/20.4.811; WU HM, 1984, NATURE, V308, P509, DOI 10.1038/308509a0; YANG CC, 1989, CELL, V57, P869, DOI 10.1016/0092-8674(89)90801-5	46	9	9	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1992	267	34					24426	24432						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KA263	1447190				2022-12-25	WOS:A1992KA26300046
J	JUVONEN, M; PIHLAJANIEMI, T				JUVONEN, M; PIHLAJANIEMI, T			CHARACTERIZATION OF THE SPECTRUM OF ALTERNATIVE SPLICING OF ALPHA-1(XIII) COLLAGEN TRANSCRIPTS IN HT-1080 CELLS AND CALVARIAL TISSUE RESULTED IN IDENTIFICATION OF 2 PREVIOUSLY UNIDENTIFIED ALTERNATIVELY SPLICED SEQUENCES, ONE PREVIOUSLY UNIDENTIFIED EXON, AND 9 NEW MESSENGER-RNA VARIANTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIPLE FORMS; XIII COLLAGEN; 5' END; GENE; CHAIN; ISOFORMS; DOMAINS; PROCOLLAGEN; EXPRESSION; INHIBITORS	Amplification of a COL1-encoding region of alpha1(XIII) collagen transcripts of HT-1080 cell RNA suggested that exon 3 of the alpha1(XIII) collagen gene, which was previously deduced to be of 35 base pairs (bp) may consist of a constitutive 8-bp exon and an alternatively spliced 27-bp exon, termed here exons 3A and 3B, respectively. Furthermore, a previously unidentified alternatively spliced Gly-Xaa-Yaa-encoding exon designated as 4B was found between the sequences encoded by exons 4, redesignated here as 4A and 5. Six of the 16 potential combinations of the four consecutive alternatively spliced exons 3B, 4A, 4B, and 5 were found to exist in mRNAs, and as a result, the length of the COL1 domain may vary between 57 and 104 amino acid residues. Most of the NC2 domain is encoded by the alternatively spliced exons 12 and 13. Where previous analysis of cDNAs indicated that mRNA variants exist that contain either exon 12 or 13 sequences, amplification studies indicated here that there are also variants that lack both exons 12 and 13 but none that contain both exons simultaneously. Thus, the predicted length of this domain is either 12, 31, or 34 residues. Analyses covering both the COL1 and NC2 domains demonstrate that at least 12 mRNA species exist through the alternations of exons 3B-5, 12, and 13.	UNIV OULU, DEPT MED BIOCHEM, KAJAANINTIE 52A, SF-90220 OULU, FINLAND; UNIV OULU, BIOCTR, COLLAGEN RES UNIT, SF-90220 OULU, FINLAND	University of Oulu; University of Oulu				Pihlajaniemi, Taina/0000-0002-1664-9045				BALDWIN AS, 1985, P NATL ACAD SCI USA, V82, P8080, DOI 10.1073/pnas.82.23.8080; BENNETT VD, 1989, J BIOL CHEM, V264, P8402; BENNETT VD, 1990, J BIOL CHEM, V265, P2223; BREITBART RE, 1985, CELL, V41, P67, DOI 10.1016/0092-8674(85)90062-5; BURGESON RE, 1988, ANNU REV CELL BIOL, V4, P551, DOI 10.1146/annurev.cb.04.110188.003003; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHU ML, 1990, EMBO J, V9, P385, DOI 10.1002/j.1460-2075.1990.tb08122.x; COOPER TA, 1985, J BIOL CHEM, V260, P1140; DOLIANA R, 1990, J CELL BIOL, V111, P2197, DOI 10.1083/jcb.111.5.2197; ENGEL J, 1991, ANNU REV BIOPHYS BIO, V20, P137, DOI 10.1146/annurev.biophys.20.1.137; KUIVANIEMI H, 1991, FASEB J, V5, P2052, DOI 10.1096/fasebj.5.7.2010058; LEESMILLER JP, 1990, MOL CELL BIOL, V10, P1729, DOI 10.1128/MCB.10.4.1729; MANIATIS T, 1991, SCIENCE, V251, P33, DOI 10.1126/science.1824726; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; NADALGINARD B, 1991, ADV ENZYME REGUL, V31, P261, DOI 10.1016/0065-2571(91)90017-G; NISHIMURA I, 1989, J BIOL CHEM, V264, P20033; PIHLAJANIEMI T, 1990, J BIOL CHEM, V265, P16922; PIHLAJANIEMI T, 1987, P NATL ACAD SCI USA, V84, P940, DOI 10.1073/pnas.84.4.940; PIHLAJANIEMI T, 1987, METHOD ENZYMOL, V145, P213; REED R, 1988, GENE DEV, V2, P1268, DOI 10.1101/gad.2.10.1268; REYES AA, 1991, MOL CELL BIOL, V11, P1654, DOI 10.1128/MCB.11.3.1654; ROWE DW, 1978, BIOCHEMISTRY-US, V17, P1581, DOI 10.1021/bi00602a001; RUSKIN B, 1984, CELL, V38, P317, DOI 10.1016/0092-8674(84)90553-1; RYAN MC, 1990, J BIOL CHEM, V265, P10334; SAITTA B, 1990, J BIOL CHEM, V265, P6473; SANDBERG M, 1989, J CELL BIOL, V109, P1371, DOI 10.1083/jcb.109.3.1371; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANTONI MJ, 1989, EMBO J, V8, P385, DOI 10.1002/j.1460-2075.1989.tb03389.x; TIKKA L, 1991, J BIOL CHEM, V266, P17713; TIKKA L, 1988, P NATL ACAD SCI USA, V85, P7491, DOI 10.1073/pnas.85.20.7491; VANDERREST M, 1991, FASEB J, V5, P2814, DOI 10.1096/fasebj.5.13.1916105; VUORIO E, 1990, ANNU REV BIOCHEM, V59, P837, DOI 10.1146/annurev.bi.59.070190.004201	32	27	28	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 5	1992	267	34					24693	24699						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KA263	1447209				2022-12-25	WOS:A1992KA26300082
J	VOLLAND, C; GARNIER, C; HAGUENAUERTSAPIS, R				VOLLAND, C; GARNIER, C; HAGUENAUERTSAPIS, R			INVIVO PHOSPHORYLATION OF THE YEAST URACIL PERMEASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; AMINO-ACID PERMEASES; SACCHAROMYCES-CEREVISIAE; PLASMA-MEMBRANE; SECRETORY PATHWAY; GENE; GLUCOSE; TRANSPORT; SEQUENCE; INACTIVATION	The uptake of uracil by the yeast Saccharomyces cerevisiae is mediated by a specific permease encoded by the FUR4 gene. This uracil permease is a multispanning membrane protein that follows the secretory pathway to the plasma membrane. We have used in vivo pulse labeling and immunoprecipitation to show that the uracil permease is phosphorylated. Phosphoamino acid analysis indicates that the phosphorylation occurs on seryl residues. Experiments with temperature sensitive secretory mutants, blocked at successive steps of the secretory pathway, have established that the phosphorylation of the permease takes place at the plasma membrane. Under steady state conditions, Western immunoblotting showed multiple phosphorylated permease species. Their relative abundance appeared susceptible to metabolic conditions. This study is, therefore, a first step toward identifying a molecular mechanism involved in the post-translational control of a yeast transporter.	UNIV PARIS 07, INST J MONOD, TOUR 43, 2 PL JUSSIEU, F-75251 PARIS 05, FRANCE	UDICE-French Research Universities; Universite Paris Cite			Haguenauer-Tsapis, Rosine/C-5446-2012					BEGGS JD, 1981, GENETIC ENG, V2, P175; BEHRENS MM, 1988, BIOCHEM BIOPH RES CO, V151, P561, DOI 10.1016/0006-291X(88)90631-6; CELENZA JL, 1988, P NATL ACAD SCI USA, V85, P2130, DOI 10.1073/pnas.85.7.2130; CHANG A, 1991, J CELL BIOL, V115, P289, DOI 10.1083/jcb.115.2.289; CHEVALLIER MR, 1982, MOL CELL BIOL, V2, P977, DOI 10.1128/MCB.2.8.977; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; EMR SD, 1984, MOL CELL BIOL, V4, P2347, DOI 10.1128/MCB.4.11.2347; FRANZUSOFF A, 1989, EMBO J, V8, P2695, DOI 10.1002/j.1460-2075.1989.tb08410.x; GRENSON M, 1983, EUR J BIOCHEM, V133, P135, DOI 10.1111/j.1432-1033.1983.tb07438.x; HARE JF, 1990, BIOCHIM BIOPHYS ACTA, V1031, P71, DOI 10.1016/0304-4157(90)90003-U; HUNTER T, 1991, METHOD ENZYMOL, V200, P3; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JAUNIAUX JC, 1990, EUR J BIOCHEM, V190, P39, DOI 10.1111/j.1432-1033.1990.tb15542.x; JUND R, 1988, EUR J BIOCHEM, V171, P417, DOI 10.1111/j.1432-1033.1988.tb13806.x; KOLAROV J, 1988, J BIOL CHEM, V263, P10613; KRUCKEBERG AL, 1990, MOL CELL BIOL, V10, P5903, DOI 10.1128/MCB.10.11.5903; LEVIN DE, 1990, CELL, V62, P213, DOI 10.1016/0092-8674(90)90360-Q; NOVICK P, 1981, CELL, V25, P461, DOI 10.1016/0092-8674(81)90064-7; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; RAMOS J, 1989, J BACTERIOL, V171, P3545, DOI 10.1128/jb.171.6.3545-3548.1989; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SILVE S, 1991, MOL CELL BIOL, V11, P1114, DOI 10.1128/MCB.11.2.1114; SILVE S, 1987, MOL CELL BIOL, V7, P3306, DOI 10.1128/MCB.7.9.3306; SMITH DE, 1984, J CELL BIOL, V99, P20, DOI 10.1083/jcb.99.1.20; THEVELEIN JM, 1987, J GEN MICROBIOL, V133, P2197; TSCHOPP JF, 1986, J BACTERIOL, V166, P313, DOI 10.1128/jb.166.1.313-318.1986; VANDENBOL M, 1990, MOL GEN GENET, V222, P393, DOI 10.1007/BF00633845; WEBER E, 1990, MOL MICROBIOL, V4, P585, DOI 10.1111/j.1365-2958.1990.tb00627.x; WEGENER AD, 1984, J BIOL CHEM, V259, P1834	29	60	60	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	1992	267	33					23767	23771						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JZ239	1429716				2022-12-25	WOS:A1992JZ23900053
J	AUWERX, J; SASSONECORSI, P				AUWERX, J; SASSONECORSI, P			AP-1 (FOS-JUN) REGULATION BY IP-1 - EFFECT OF SIGNAL TRANSDUCTION PATHWAYS AND CELL-GROWTH	ONCOGENE			English	Article							NF-KAPPA-B; DNA-BINDING PROTEINS; TRANSCRIPTION FACTOR AP-1; C-JUN; PROTO-ONCOGENE; GENE-EXPRESSION; KINASE-C; V-JUN; RAPIDLY DISSOCIATE; LEUCINE ZIPPERS	Transcription factor AP-1 is constituted by the various products of the fos and jun proto-oncogene family members, which associate as dimers to bind with variable efficiency to 12-O-tetradecanoyl phorbol 13-acetate (TPA)-responsive promoter elements (TREs). We have recently shown that DNA binding of AP-1 is regulated by an inhibitory protein, IP-1, whose activity is modulated by phosphorylation. Here it is shown that although AP-1 has a very high affinity for its recognition sequence, its binding to the TRE can be quickly inhibited by the addition of IP-1. IP-1 is more active on AP-1 complexes formed during a shorter period of time. IP-1 activity is blocked by stimulation of the protein kinase C (PKC) signal transducation pathway, achieved by treating HeLa cells with phorbol esters or with a diacylglycerol analog. We observed an increase in AP-1-DNA, binding after treatment of the cells with either the calcium ionophore A-23187 or dibutyryl cAMP; this could be ascribed to inhibition of IP-1 activity. A decreased IP-1 activity also correlates with the increase in AP-1-DNA binding after stimulating cells with serum. This suggests that IP-1 is an important target of the various signal transduction pathways. No effect on AP-1 and IP-1 was detected in cells transformed by Ki-ras or v-raf; nor could an effect of inhibition of protein synthesis be observed. We also analysed IP-1 regulation upon differentiation of P19 embryonal carcinoma cells by retinoic acid. We conclude that IP-1 regulation has a pivotal role in the final modulation of Fos-Jun by signal transduction pathways.	CATHOLIC UNIV LEUVEN,DEPT DEV BIOL,EXPTL MED & ENDOCRINOL LAB,B-3000 LOUVAIN,BELGIUM; CNRS,UMR 134,CTR BIOCHEM,F-06108 NICE,FRANCE; FAC MED STRASBOURG,GENET MOLEC EUCARYOTES LAB,CNRS,U184,INSERM,F-67085 STRASBOURG,FRANCE	KU Leuven; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg				Auwerx, Johan/0000-0002-5065-5393				ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; AUWERX J, 1990, NUCLEIC ACIDS RES, V18, P221, DOI 10.1093/nar/18.2.221; AUWERX J, 1991, CELL, V64, P983, DOI 10.1016/0092-8674(91)90322-P; AUWERX JH, 1989, P NATL ACAD SCI USA, V86, P1133, DOI 10.1073/pnas.86.4.1133; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BAICHWAL VR, 1991, NATURE, V352, P165, DOI 10.1038/352165a0; BAICHWAL VR, 1990, CELL, V63, P815, DOI 10.1016/0092-8674(90)90147-7; BARBER JR, 1987, MOL CELL BIOL, V7, P2201, DOI 10.1128/MCB.7.6.2201; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BOHMANN D, 1989, CELL, V59, P709, DOI 10.1016/0092-8674(89)90017-2; BOS TJ, 1990, GENE DEV, V4, P1677, DOI 10.1101/gad.4.10.1677; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; BUSCH SJ, 1990, TRENDS GENET, V6, P36, DOI 10.1016/0168-9525(90)90071-D; CAMBIER JC, 1987, NATURE, V327, P619; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; DEGROOT RP, 1990, EMBO J, V9, P1831, DOI 10.1002/j.1460-2075.1990.tb08308.x; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DISTEL RJ, 1987, CELL, V49, P835, DOI 10.1016/0092-8674(87)90621-0; FOULKES NS, 1991, CELL, V64, P739, DOI 10.1016/0092-8674(91)90503-Q; FRANZA BR, 1988, SCIENCE, V239, P1150, DOI 10.1126/science.2964084; FRIED MG, 1983, NUCLEIC ACIDS RES, V11, P141, DOI 10.1093/nar/11.1.141; GAUTHIERROUVIERE C, 1990, EMBO J, V9, P171, DOI 10.1002/j.1460-2075.1990.tb08093.x; GENTZ R, 1989, SCIENCE, V243, P1695, DOI 10.1126/science.2494702; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HALAZONETIS TD, 1988, CELL, V55, P917, DOI 10.1016/0092-8674(88)90147-X; HIRAI SI, 1989, EMBO J, V8, P1433, DOI 10.1002/j.1460-2075.1989.tb03525.x; HIRAI SI, 1990, ONCOGENE, V5, P39; JACKSON SP, 1988, CELL, V55, P125, DOI 10.1016/0092-8674(88)90015-3; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; KOUZARIDES T, 1988, NATURE, V336, P646, DOI 10.1038/336646a0; KRUIJER W, 1984, NATURE, V312, P711, DOI 10.1038/312711a0; LAMPH WW, 1988, NATURE, V334, P629, DOI 10.1038/334629a0; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MITCHELL RL, 1985, CELL, V40, P209, DOI 10.1016/0092-8674(85)90324-1; MULLER R, 1984, NATURE, V312, P716, DOI 10.1038/312716a0; MURAKAMI Y, 1990, ONCOGENE, V5, P5; NAKABEPPU Y, 1988, CELL, V55, P907, DOI 10.1016/0092-8674(88)90146-8; NARANJO JR, 1991, NEURON, V6, P307; NEUBERG M, 1989, NATURE, V338, P589, DOI 10.1038/338589a0; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; PICARD D, 1988, CELL, V54, P1073, DOI 10.1016/0092-8674(88)90122-5; QUANTIN B, 1988, NATURE, V334, P538, DOI 10.1038/334538a0; RAUSCHER FJ, 1988, CELL, V52, P471, DOI 10.1016/S0092-8674(88)80039-4; RAUSCHER FJ, 1988, SCIENCE, V240, P1010, DOI 10.1126/science.3130660; RISSE G, 1989, EMBO J, V8, P3825, DOI 10.1002/j.1460-2075.1989.tb08560.x; ROESLER WJ, 1988, J BIOL CHEM, V263, P9063; ROUX P, 1990, CELL, V63, P341, DOI 10.1016/0092-8674(90)90167-D; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; RYSECK RP, 1988, NATURE, V334, P535, DOI 10.1038/334535a0; SASSONECORSI P, 1989, MOL CELL BIOL, V9, P3174, DOI 10.1128/MCB.9.8.3174; SASSONECORSI P, 1986, TRENDS GENET, V2, P215, DOI 10.1016/0168-9525(86)90233-7; SASSONECORSI P, 1988, NATURE, V336, P692, DOI 10.1038/336692a0; SASSONECORSI P, 1988, CELL, V54, P553, DOI 10.1016/0092-8674(88)90077-3; SCHONTHAL A, 1988, CELL, V54, P325, DOI 10.1016/0092-8674(88)90195-X; SCHUERMANN M, 1989, CELL, V56, P507, DOI 10.1016/0092-8674(89)90253-5; SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X; SHENG M, 1988, MOL CELL BIOL, V8, P2787, DOI 10.1128/MCB.8.7.2787; SISTONEN L, 1989, EMBO J, V8, P815, DOI 10.1002/j.1460-2075.1989.tb03442.x; TREACY MN, 1991, NATURE, V350, P577, DOI 10.1038/350577a0; TURNER R, 1989, SCIENCE, V243, P1689, DOI 10.1126/science.2494701; VERMA IM, 1987, CELL, V51, P513, DOI 10.1016/0092-8674(87)90115-2; VOGT PK, 1989, TRENDS BIOCHEM SCI, V14, P172, DOI 10.1016/0968-0004(89)90268-5; YAMAMOTO KK, 1988, NATURE, V334, P494, DOI 10.1038/334494a0; YANG-YEN H-F, 1990, New Biologist, V2, P351; YOSHIMASA T, 1987, NATURE, V327, P67, DOI 10.1038/327067a0; ZABEL U, 1990, CELL, V61, P255, DOI 10.1016/0092-8674(90)90806-P; ZERIAL M, 1989, EMBO J, V8, P805, DOI 10.1002/j.1460-2075.1989.tb03441.x	74	45	45	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1992	7	11					2271	2280						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JW665	1437149				2022-12-25	WOS:A1992JW66500020
J	NETO, JBC; GENTIL, A; CABRAL, REC; SARASIN, A				NETO, JBC; GENTIL, A; CABRAL, REC; SARASIN, A			MUTATION SPECTRUM OF HEAT-INDUCED ABASIC SITES ON A SINGLE-STRANDED SHUTTLE VECTOR REPLICATED IN MAMMALIAN-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APURINIC APYRIMIDINIC SITES; DEOXYRIBONUCLEIC-ACID; XERODERMA PIGMENTOSUM; SIMIAN VIRUS-40; POINT MUTATIONS; PLASMID DNA; MUTAGENESIS; INVITRO; DEPURINATION; SPECIFICITY	The mutational potency of apurinic/apyrimidinic (AP) sites induced by heat-treatment under acidic conditions has been studied in mammalian cells. Abasic sites were induced on a single-stranded DNA shuttle vector carrying the supF tRNA gene, eliminating, therefore, any ambiguity concerning the damaged strand. This vector was able to replicate both in mammalian cells and in bacteria where the mutations induced in animal cells on the supF tRNA gene were screened by the white/blue beta-galactosidase assay in the presence of isopropyl-1-thio-beta-D-galactopyranoside and 5-bromo-4-chloro-3-indoyl-beta-D-galactoside. All white colonies contained plasmid with a mutation on the target gene which was directly sequenced. Our results show that one AP site was induced/22 min of heating as measured by sensitivity of DNA to alkali denaturation or treatment with the AP-endonuclease activity of the FPG protein (Fapy-DNA glycosylase). Putative AP sites decrease survival of the plasmid with a lethal hit of one AP site/single-stranded molecule. Mutation frequency was increased by a factor of approximately six after 2 h at 70-degrees-C. Most of the induced mutations were point mutations not distributed at random and clustered in the gene region which will give rise to the mature tRNA. Mutations were abolished by treatments that eliminated AP sites such as alkali treatment or incubation with the Fapy-DNA glycosylase protein. Under our experimental conditions, when only single mutations were taken into account, the order of base insertion opposite AP sites was G > A > T > C.	INST RECH SCI CANC,MOLEC GENET LAB,UPR 42,BP8,F-94801 VILLEJUIF,FRANCE									BOITEUX S, 1982, BIOCHEMISTRY-US, V21, P6746, DOI 10.1021/bi00269a020; BOITEUX S, 1990, J BIOL CHEM, V265, P3916; BOURRE F, 1989, MUTAT RES, V220, P107, DOI 10.1016/0165-1110(89)90016-X; BREDBERG A, 1986, P NATL ACAD SCI USA, V83, P8273, DOI 10.1073/pnas.83.21.8273; DRAKE JW, 1976, ANNU REV BIOCHEM, V45, P11, DOI 10.1146/annurev.bi.45.070176.000303; DUBRIDGE RB, 1988, MUTAGENESIS, V3, P1, DOI 10.1093/mutage/3.1.1; GENTIL A, 1984, MUTAT RES, V129, P141, DOI 10.1016/0027-5107(84)90146-5; GENTIL A, 1990, BIOCHEM BIOPH RES CO, V173, P704, DOI 10.1016/S0006-291X(05)80092-0; GENTIL A, 1992, IN PRESS J MOL BIOL; GORDON AJE, 1990, MUTAT RES, V223, P95; HAUSER J, 1986, MOL CELL BIOL, V6, P277, DOI 10.1128/MCB.6.1.277; KEYSE SM, 1988, MOL CELL BIOL, V8, P5425, DOI 10.1128/MCB.8.12.5425; KRAEMER KH, 1989, MUTAT RES, V220, P61, DOI 10.1016/0165-1110(89)90011-0; KUNKEL TA, 1984, P NATL ACAD SCI-BIOL, V81, P1494, DOI 10.1073/pnas.81.5.1494; KUNKEL TA, 1983, BIOCHEMISTRY-US, V22, P2378, DOI 10.1021/bi00279a012; LINDAHL T, 1974, BIOCHEMISTRY-US, V13, P3405, DOI 10.1021/bi00713a035; LINDAHL T, 1972, BIOCHEMISTRY-US, V11, P3610, DOI 10.1021/bi00769a018; LINDAHL T, 1972, BIOCHEMISTRY-US, V11, P3618, DOI 10.1021/bi00769a019; LOEB LA, 1986, ANNU REV GENET, V20, P201, DOI 10.1146/annurev.ge.20.120186.001221; LOEB LA, 1985, CELL, V40, P483, DOI 10.1016/0092-8674(85)90191-6; MACCUTCHAM JH, 1968, J NATL CANCER I, V41, P351; MADZAK C, 1989, J MOL BIOL, V205, P501, DOI 10.1016/0022-2836(89)90221-0; MADZAK C, 1992, MUTAT RES, V274, P135, DOI 10.1016/0921-8777(92)90060-G; MARGISON GP, 1973, BIOCHIM BIOPHYS ACTA, V331, P349, DOI 10.1016/0005-2787(73)90021-X; MILLER JF, 1988, P NATL ACAD SCI USA, V85, P856, DOI 10.1073/pnas.85.3.856; MOORE P, 1979, NATURE, V278, P664, DOI 10.1038/278664a0; MORAES EC, 1990, CARCINOGENESIS, V11, P283, DOI 10.1093/carcin/11.2.283; MURIEL WJ, 1991, MUTAT RES, V254, P119, DOI 10.1016/0921-8777(91)90002-7; RANDALL SK, 1987, J BIOL CHEM, V262, P6864; SAGHER D, 1983, BIOCHEMISTRY-US, V22, P4518, DOI 10.1021/bi00288a026; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARASIN A, 1989, J PHOTOCH PHOTOBIO B, V3, P143, DOI 10.1016/1011-1344(89)80057-0; SEETHARAM S, 1987, J CLIN INVEST, V80, P1613, DOI 10.1172/JCI113248; SEIDMAN MM, 1987, P NATL ACAD SCI USA, V84, P4944, DOI 10.1073/pnas.84.14.4944; SHAAPER RM, 1983, P NATL ACAD SCI USA, V80, P487; SHAAPER RM, 1981, P NATL ACAD SCI USA, V78, P1773; SHAAPER RM, 1982, CANCER RES, V42, P3480; SHAAPER RM, 1982, MUTAT RES, V106, P1; Shaper N L, 1980, Methods Enzymol, V65, P216; SHAPIRO R, 1966, BIOCHEMISTRY-US, V5, P2358, DOI 10.1021/bi00871a026; SOCKETT H, 1991, MOL GEN GENET, V227, P252, DOI 10.1007/BF00259678; STARY A, 1992, IN PRESS J GEN VIROL, V73; STARY A, 1992, IN PRESS MUTAT RES; Strauss B, 1975, MOL MECHANISMS REPAI, P13; YAGI T, 1992, MUTAT RES, V273, P213, DOI 10.1016/0921-8777(92)90082-E	45	67	67	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1992	267	27					19718	19723						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JP593	1527092				2022-12-25	WOS:A1992JP59300104
J	CAPLAN, AJ; TSAI, J; CASEY, PJ; DOUGLAS, MG				CAPLAN, AJ; TSAI, J; CASEY, PJ; DOUGLAS, MG			FARNESYLATION OF YDJ1P IS REQUIRED FOR FUNCTION AT ELEVATED GROWTH TEMPERATURES IN SACCHAROMYCES-CEREVISIAE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LAMBDA-DNA-REPLICATION; HEAT-SHOCK PROTEIN; RAS PROTEINS; POSTTRANSLATIONAL MODIFICATION; CAAX MOTIF; NUCLEOPROTEIN STRUCTURES; ENDOPLASMIC-RETICULUM; CARBOXYL-METHYLATION; CYSTEINE RESIDUE; A-FACTOR	The Saccharomyces cerevisiae YDJ1 protein (YDJ1p) contains a C-terminal "CaaX box" motif common to proteins that are modified by prenylation. In the present study we show that YDJ1p is a specific substrate for both yeast and mammalian protein farnesyltransferase enzymes in vitro. A mutant form of YDJ1p, in which the conserved cysteine of the CaaX box is mutated to a serine (ydj1-S406p), cannot be farnesylated in vitro. After expression in S. cerevisiae, ydj1-S406p displays a reduced electrophoretic mobility and an increased cytosolic localization in subcellular fractionation experiments when compared to wild type YDJ1p. Expression of ydj1-S406 in cells lacking YDJ1 results in a temperature-sensitive growth phenotype in S. cerevisiae. These data indicate that farnesylation of YDJ1p is required for its function at elevated temperatures.	UNIV N CAROLINA,DEPT BIOCHEM & BIOPHYS,CHAPEL HILL,NC 27599; DUKE UNIV,CELL GROWTH & ONCOGENESIS SECT,DURHAM,NC 27710; DUKE UNIV,DEPT BIOCHEM,DURHAM,NC 27710	University of North Carolina; University of North Carolina Chapel Hill; Duke University; Duke University			Caplan, Avrom/GPT-0824-2022	Casey, Patrick/0000-0002-7366-9309	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036536, R01GM041758] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 36536, GM 41758] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALFANO C, 1989, J BIOL CHEM, V264, P10709; ALFANO C, 1989, J BIOL CHEM, V264, P10699; ANG D, 1991, J BIOL CHEM, V266, P24233; ATENCIO DP, 1992, MOL CELL BIOL, V12, P283, DOI 10.1128/MCB.12.1.283; BLUMBERG H, 1991, NATURE, V349, P327; BOEKE JD, 1984, MOL GEN GENET, V197, P345, DOI 10.1007/BF00330984; CAPLAN AJ, 1991, J CELL BIOL, V114, P609, DOI 10.1083/jcb.114.4.609; CASEY PJ, 1989, P NATL ACAD SCI USA, V86, P8323, DOI 10.1073/pnas.86.21.8323; CASEY PJ, 1991, P NATL ACAD SCI USA, V88, P8631, DOI 10.1073/pnas.88.19.8631; CHABERLAIN JP, 1981, ANAL BIOCHEM, V98, P132; CHEN WJ, 1991, CELL, V66, P327, DOI 10.1016/0092-8674(91)90622-6; DESHAIES RJ, 1991, NATURE, V349, P806, DOI 10.1038/349806a0; FARNSWORTH CC, 1989, J BIOL CHEM, V264, P20422; FINEGOLD AA, 1991, P NATL ACAD SCI USA, V88, P4448, DOI 10.1073/pnas.88.10.4448; GEORGOPOULOS C, 1990, STRESS PROTEINS BIOL, P191; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GLOMSET JA, 1990, TRENDS BIOCHEM SCI, V15, P139, DOI 10.1016/0968-0004(90)90213-U; GOODMAN LE, 1990, P NATL ACAD SCI USA, V87, P9665, DOI 10.1073/pnas.87.24.9665; GUTIERREZ L, 1989, EMBO J, V8, P1093, DOI 10.1002/j.1460-2075.1989.tb03478.x; HANCOCK JF, 1990, CELL, V63, P133, DOI 10.1016/0092-8674(90)90294-O; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HE B, 1991, P NATL ACAD SCI USA, V88, P11373, DOI 10.1073/pnas.88.24.11373; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; HOLTZ D, 1989, CELL, V59, P969, DOI 10.1016/0092-8674(89)90753-8; HRYCYNA CA, 1991, EMBO J, V10, P1699, DOI 10.1002/j.1460-2075.1991.tb07694.x; KINSELLA BT, 1991, P NATL ACAD SCI USA, V88, P8934, DOI 10.1073/pnas.88.20.8934; KITTEN GT, 1991, J CELL BIOL, V113, P13, DOI 10.1083/jcb.113.1.13; KOHL NE, 1991, J BIOL CHEM, V266, P18884; LIBEREK K, 1991, P NATL ACAD SCI USA, V88, P2874, DOI 10.1073/pnas.88.7.2874; LIBEREK K, 1990, J BIOL CHEM, V265, P3022; LUKE MM, 1991, J CELL BIOL, V114, P623, DOI 10.1083/jcb.114.4.623; MALTESE WA, 1990, FASEB J, V4, P3319, DOI 10.1096/fasebj.4.15.2123808; POLLARD KM, 1990, MOL CELL BIOL, V10, P2164, DOI 10.1128/MCB.10.5.2164; SADLER I, 1989, J CELL BIOL, V109, P2665, DOI 10.1083/jcb.109.6.2665; SAMBROOK J, 1990, MOL CLONING LABORATO; SCHAFER WR, 1990, SCIENCE, V249, P1133, DOI 10.1126/science.2204115; Sherman F., 1986, METHODS YEAST GENETI; SIKORSKI RS, 1989, GENETICS, V122, P19; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; VORBURGER K, 1989, EMBO J, V8, P4007, DOI 10.1002/j.1460-2075.1989.tb08583.x; WICKNER S, 1991, P NATL ACAD SCI USA, V88, P7903, DOI 10.1073/pnas.88.18.7903	41	158	161	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1992	267	26					18890	18895						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JN502	1527016				2022-12-25	WOS:A1992JN50200096
J	CHEN, ZX; POTEMPA, J; POLANOWSKI, A; WIKSTROM, M; TRAVIS, J				CHEN, ZX; POTEMPA, J; POLANOWSKI, A; WIKSTROM, M; TRAVIS, J			PURIFICATION AND CHARACTERIZATION OF A 50-KDA CYSTEINE PROTEINASE (GINGIPAIN) FROM PORPHYROMONAS-GINGIVALIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLACK-PIGMENTED BACTEROIDES; TRYPSIN-LIKE; ACTINOBACILLUS-ACTINOMYCETEMCOMITANS; COLLAGENOLYTIC ACTIVITY; PROTEASE; DEGRADATION; IMMUNOGLOBULIN; INACTIVATION; INHIBITORS; VIRULENT	Porphyromonas gingivalis, a Gram-negative anaerobic rod, has been closely associated with the initiation and progression of periodontal disease. This organism has been shown to produce a large number of proteolytic enzymes which can degrade a variety of tissue proteins, and these are considered to be major virulence factors. One of the proteinases produced by this organism, referred to as gingipain-1, has been purified to homogeneity from P. gingivalis culture medium by a combination of gel filtration and ion-exchange chromatography. The enzyme was found to have a molecular mass near 50 kDa by sodium dodecyl sulfate-polyacrylamide gel electrophoresis, a pH optimum in the neutral to alkaline range, and a requirement for cysteine for activation and Ca2+ for stabilization. Amino-terminal sequence analysis indicated that gingipain belongs to a new, so far unknown, subfamily of cysteine proteinases. Three unusual features of this proteinase are: (a) the stimulation of amidolytic activity by glycine-containing dipeptides; (b) a narrow specificity which is limited to peptide bonds containing arginine residues; and (c) resistance to inhibition by proteinase inhibitors in human plasma.	UNIV GEORGIA, DEPT BIOCHEM, ATHENS, GA 30602 USA; JAGIELLONIAN UNIV, INST MOLEC BIOL, PL-31120 KRAKOW, POLAND; UNIV WROCLAW, DEPT BIOCHEM, PL-50137 WROCLAW, POLAND; GOTHENBURG UNIV, DEPT ORAL MICROBIOL, S-41346 GOTHENBURG, SWEDEN	University System of Georgia; University of Georgia; Jagiellonian University; University of Wroclaw; University of Gothenburg					NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE009761] Funding Source: NIH RePORTER; NIDCR NIH HHS [DE 09761] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		BIRKEDALHANSEN H, 1988, J PERIODONTAL RES, V23, P258, DOI 10.1111/j.1600-0765.1988.tb01369.x; CARLSSON J, 1984, INFECT IMMUN, V43, P644, DOI 10.1128/IAI.43.2.644-648.1984; CARLSSON J, 1984, J MED MICROBIOL, V18, P39, DOI 10.1099/00222615-18-1-39; CHEN ZX, 1991, INFECT IMMUN, V59, P2846, DOI 10.1128/IAI.59.8.2846-2850.1991; FUJIMURA S, 1987, INFECT IMMUN, V55, P716, DOI 10.1128/IAI.55.3.716-720.1987; GRENIER D, 1987, J CLIN MICROBIOL, V25, P738, DOI 10.1128/JCM.25.4.738-740.1987; GRENIER D, 1987, INFECT IMMUN, V55, P3131, DOI 10.1128/IAI.55.12.3131-3136.1987; GRENIER D, 1989, INFECT IMMUN, V57, P95, DOI 10.1128/IAI.57.1.95-99.1989; HERRMANN BF, 1985, SCAND J DENT RES, V93, P153; KILIAN M, 1981, INFECT IMMUN, V34, P757, DOI 10.1128/IAI.34.3.757-765.1981; LANTZ MS, 1986, INFECT IMMUN, V54, P654, DOI 10.1128/IAI.54.3.654-658.1986; MARSH PD, 1989, FEMS MICROBIOL LETT, V59, P181; MOORE WEC, 1982, INFECT IMMUN, V38, P1137, DOI 10.1128/IAI.38.3.1137-1148.1982; NILSSON T, 1985, INFECT IMMUN, V50, P467, DOI 10.1128/IAI.50.2.467-471.1985; Ono M, 1987, Oral Microbiol Immunol, V2, P77, DOI 10.1111/j.1399-302X.1987.tb00294.x; OTSUKA M, 1987, J PERIODONTAL RES, V22, P491, DOI 10.1111/j.1600-0765.1987.tb02060.x; SAGLIE FR, 1988, J PERIODONTOL, V59, P259, DOI 10.1902/jop.1988.59.4.259; SATO M, 1987, ARCH ORAL BIOL, V32, P235, DOI 10.1016/0003-9969(87)90016-1; SCHENKEIN HA, 1988, J PERIODONTAL RES, V23, P187, DOI 10.1111/j.1600-0765.1988.tb01356.x; SCHENKEIN HA, 1988, J PERIODONTAL RES, V23, P308, DOI 10.1111/j.1600-0765.1988.tb01422.x; SLOTS J, 1986, J CLIN PERIODONTOL, V13, P570, DOI 10.1111/j.1600-051X.1986.tb00849.x; SMALLEY JW, 1989, ORAL MICROBIOL IMMUN, V4, P178, DOI 10.1111/j.1399-302X.1989.tb00249.x; SORSA T, 1987, J PERIODONTAL RES, V22, P375, DOI 10.1111/j.1600-0765.1987.tb01602.x; SUIDO H, 1987, J PERIODONTAL RES, V22, P412, DOI 10.1111/j.1600-0765.1987.tb01608.x; SUNDQVIST G, 1985, J MED MICROBIOL, V19, P85, DOI 10.1099/00222615-19-1-85; SUNDQVIST G, 1987, J PERIODONTAL RES, V22, P300, DOI 10.1111/j.1600-0765.1987.tb01589.x; SUNDQVIST G, 1988, ORAL MICROBIOL IMMUN, V87, P111; TSUTSUI H, 1987, INFECT IMMUN, V55, P420, DOI 10.1128/IAI.55.2.420-427.1987; UITTO VJ, 1989, INFECT IMMUN, V57, P213, DOI 10.1128/IAI.57.1.213-218.1989; UITTO VJ, 1987, J PERIODONTAL RES, V22, P58, DOI 10.1111/j.1600-0765.1987.tb01540.x; WHITE D, 1981, J PERIODONTAL RES, V16, P259, DOI 10.1111/j.1600-0765.1981.tb00974.x; WIKSTROM M, 1986, INFECT IMMUN, V51, P707; WIKSTROM MB, 1983, J CLIN MICROBIOL, V17, P759; WINGROVE JA, 1992, J BIOL CHEM, V267, P18902; YONEDA M, 1990, INFECT IMMUN, V58, P406, DOI 10.1128/IAI.58.2.406-411.1990; ZAMBON JJ, 1981, INFECT IMMUN, V32, P198, DOI 10.1128/IAI.32.1.198-203.1981	36	193	203	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	1992	267	26					18896	18901						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JN502	1527017				2022-12-25	WOS:A1992JN50200097
J	DETRICH, HW; FITZGERALD, TJ; DINSMORE, JH; MARCHESERAGONA, SP				DETRICH, HW; FITZGERALD, TJ; DINSMORE, JH; MARCHESERAGONA, SP			BRAIN AND EGG TUBULINS FROM ANTARCTIC FISHES ARE FUNCTIONALLY AND STRUCTURALLY DISTINCT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICROTUBULE ASSEMBLY INVITRO; DIVERGENT BETA-TUBULIN; ALPHA-TUBULIN; CHICKEN ERYTHROCYTES; BOVINE BRAIN; ISOTYPES; POLYMERIZATION; HETEROGENEITY; EXPRESSION; SEQUENCE	The multitubulin hypothesis proposes that chemically distinct tubulins may possess different polymerization properties or may form functionally different microtubules. To test this hypothesis, we have examined the functional properties and the structures of singlet-specific nonneural and neural tubulins from Antarctic fishes. Tubulins were purified from eggs of Notothenia coriiceps neglecta, and from brain tissues of N. coriiceps neglecta or N. gibberifrons, by DEAE ion-exchange chromatography and cycles of microtubule assembly/disassembly. At temperatures between 0 and 20-degrees-C, each of these tubulins polymerized efficiently in vitro to yield microtubules of normal morphology. Critical concentrations for polymerization of egg tubulin ranged from 0.057 mg/ml at 3-degrees-C to 0.002 mg/ml at 18-degrees-C, whereas those for brain tubulin at like temperatures were 4-10-fold larger. Polymerization of both tubulins was entropically driven, but the apparent standard enthalpy and entropy changes for microtubule elongation by egg tubulin (DELTA-H(app)o = +33.9 kcal/mol, DELTA-S(app)o = +151 entropy units) were significantly greater than values observed for brain tubulin (DELTA-H(app)o = +26.5 kcal/mol, DELTA-S(app)o = +121 entropy units). Egg tubulin was composed of approximately six alpha and two beta-chains and lacked the beta(III) isotype, whereas brain tubulin was more complex (greater-than-or-equal-to of each chain type). Furthermore, egg a tubulins were more basic, and their carboxyl termini more resistant to cleavage by subtilisin, than were the a chains of brain. We conclude that brain and egg tubulins from the Antarctic fishes are functionally distinct in vitro, due either to qualitative or quantitative differences in isotypic composition, to differential posttranslational modification of shared isotypes, or to both.	ST JUDE CHILDRENS RES HOSP, DEPT VIROL & MOLEC BIOL, MEMPHIS, TN 38101 USA; MIT, DEPT BIOL, CAMBRIDGE, MA 02139 USA; PENN STATE UNIV, DEPT MOLEC & CELL BIOL, University Pk, PA 16802 USA	St Jude Children's Research Hospital; Massachusetts Institute of Technology (MIT); Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	DETRICH, HW (corresponding author), NORTHEASTERN UNIV, DEPT BIOL, 414 MUGAR HALL, 360 HUNTINGTON AVE, BOSTON, MA 02115 USA.							ALEXANDER JE, 1991, P NATL ACAD SCI USA, V88, P4685, DOI 10.1073/pnas.88.11.4685; BANERJEE A, 1990, J BIOL CHEM, V265, P1794; BHATTACHARYYA B, 1985, J BIOL CHEM, V260, P208; BIBRING T, 1977, DEV BIOL, V55, P191, DOI 10.1016/0012-1606(77)90330-X; BORISY GG, 1975, ANN NY ACAD SCI, V253, P107, DOI 10.1111/j.1749-6632.1975.tb19196.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CRESTFIELD AM, 1963, J BIOL CHEM, V238, P622; DETRICH HW, 1986, J BIOL CHEM, V261, P922; DETRICH HW, 1987, J BIOL CHEM, V262, P8360; DETRICH HW, 1985, J BIOL CHEM, V260, P9479; DETRICH HW, 1988, COMP BIOCHEM PHYS B, V90, P593, DOI 10.1016/0305-0491(88)90300-8; DETRICH HW, 1983, BIOCHEMISTRY-US, V22, P2453, DOI 10.1021/bi00279a023; DETRICH HW, 1990, CELL MOTIL CYTOSKEL, V17, P174, DOI 10.1002/cm.970170305; DETRICH HW, 1978, BIOCHEMISTRY-US, V17, P3900, DOI 10.1021/bi00612a002; DETRICH HW, 1989, BIOCHEMISTRY-US, V28, P10085, DOI 10.1021/bi00452a031; DETRICH HW, 1987, J CELL BIOL, V105, pA278; DETRICH HW, 1990, J CELL BIOL, V111, pA412; EDDE B, 1990, SCIENCE, V247, P83, DOI 10.1126/science.1967194; FARRELL KW, 1984, BIOCHEMISTRY-US, V23, P3741, DOI 10.1021/bi00311a027; FIELD DJ, 1984, P NATL ACAD SCI-BIOL, V81, P4041, DOI 10.1073/pnas.81.13.4041; FIELD DJ, 1985, ANAL BIOCHEM, V144, P584, DOI 10.1016/0003-2697(85)90157-5; Fulton C., 1976, CELL MOTILITY, P987; Gros E., 1967, METHOD ENZYMOL, V11, P238; HIGGINS RC, 1979, ANAL BIOCHEM, V93, P257, DOI 10.1016/S0003-2697(79)80077-9; HITT AL, 1990, J BIOL CHEM, V265, P1639; HOYLE HD, 1990, J CELL BIOL, V111, P1009, DOI 10.1083/jcb.111.3.1009; JOHNSON KA, 1975, MOL CELL MOVEMENT, P119; JOSHI HC, 1990, CELL MOTIL CYTOSKEL, V16, P159, DOI 10.1002/cm.970160302; JOSHI HC, 1987, J CELL BIOL, V105, P2179, DOI 10.1083/jcb.105.5.2179; LEE DSC, 1984, J IMMUNOL METHODS, V74, P181, DOI 10.1016/0022-1759(84)90379-X; LEE MK, 1990, P NATL ACAD SCI USA, V87, P7195, DOI 10.1073/pnas.87.18.7195; LEWIS SA, 1987, CELL, V49, P539, DOI 10.1016/0092-8674(87)90456-9; LEWIS SA, 1988, J CELL BIOL, V106, P2023, DOI 10.1083/jcb.106.6.2023; LOPATA MA, 1987, J CELL BIOL, V105, P1707, DOI 10.1083/jcb.105.4.1707; MONTEIRO MJ, 1988, J MOL BIOL, V199, P439, DOI 10.1016/0022-2836(88)90616-X; MURPHY DB, 1987, J BIOL CHEM, V262, P14305; MURPHY DB, 1983, J BIOL CHEM, V258, P8357; MURPHY DB, 1983, J BIOL CHEM, V258, P7870; MURPHY DB, 1985, J BIOL CHEM, V260, P2293; Murphy DB, 1991, CURR OPIN CELL BIOL, V3, P43, DOI 10.1016/0955-0674(91)90164-T; PIERSON GB, 1978, J CELL BIOL, V76, P223, DOI 10.1083/jcb.76.1.223; PRATT LF, 1988, EMBO J, V7, P931, DOI 10.1002/j.1460-2075.1988.tb02898.x; RAFF EC, 1984, J CELL BIOL, V99, P1, DOI 10.1083/jcb.99.1.1; ROTHWELL SW, 1986, ANN NY ACAD SCI, V466, P103, DOI 10.1111/j.1749-6632.1986.tb38387.x; SACKETT DL, 1985, J BIOL CHEM, V260, P43; SCHROER TA, 1991, ANNU REV PHYSIOL, V53, P629, DOI 10.1146/annurev.ph.53.030191.003213; SERRANO L, 1984, P NATL ACAD SCI-BIOL, V81, P5989, DOI 10.1073/pnas.81.19.5989; SKOUFIAS DA, 1992, CELL MOTIL CYTOSKEL, V21, P272, DOI 10.1002/cm.970210403; STEPHENS RE, 1975, MOL CELL MOVEMENT, P181; SULLIVAN KF, 1988, ANNU REV CELL BIOL, V4, P687, DOI 10.1146/annurev.cb.04.110188.003351; VALLEE RB, 1991, ANNU REV NEUROSCI, V14, P59, DOI 10.1146/annurev.ne.14.030191.000423; VALLEE RB, 1990, ANNU REV BIOCHEM, V59, P909, DOI 10.1146/annurev.biochem.59.1.909; VILLASANTE A, 1986, MOL CELL BIOL, V6, P2409, DOI 10.1128/MCB.6.7.2409; WANG D, 1986, J CELL BIOL, V103, P1903, DOI 10.1083/jcb.103.5.1903; WEI G, 1988, J CELL BIOL, V106, P2011, DOI 10.1083/jcb.106.6.2011; WILLIAMS RC, 1985, BIOCHEMISTRY-US, V24, P2790, DOI 10.1021/bi00332a029; WILLIAMS RC, 1982, METHOD ENZYMOL, V85, P376	57	28	28	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	1992	267	26					18766	18775						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JN502	1527007				2022-12-25	WOS:A1992JN50200079
J	CURMI, PMG; CASCIO, D; SWEET, RM; EISENBERG, D; SCHREUDER, H				CURMI, PMG; CASCIO, D; SWEET, RM; EISENBERG, D; SCHREUDER, H			CRYSTAL-STRUCTURE OF THE UNACTIVATED FORM OF RIBULOSE-1,5-BISPHOSPHATE CARBOXYLASE OXYGENASE FROM TOBACCO REFINED AT 2.0-A-CIRCLE RESOLUTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBULOSE-BISPHOSPHATE CARBOXYLASE; SITE-DIRECTED MUTAGENESIS; RUBRUM RIBULOSEBISPHOSPHATE CARBOXYLASE; AMINO-ACID-SEQUENCE; RHODOSPIRILLUM-RUBRUM; SMALL SUBUNIT; ACTIVE-SITE; NICOTIANA-TABACUM; 3-DIMENSIONAL STRUCTURE; PROTEINS	The structure of the unactivated form of ribulose-1,5-bisphosphate carboxylase/oxygenase was refined at a resolution of 2.0 angstrom to an R-factor of 17.1%. The previous model (Chapman et al., 1988) was extensively rebuilt, and the small subunit was retraced. The refined model consists of residues 22-63 and 69-467 of the large subunit and the complete small subunit. A striking feature of the model is that several loops have very high B-factors, probably representing mobile regions of the molecule. An examination of the intersubunit contacts shows that the L8S8 hexadecamer is composed of four L2 dimers. The dominant contacts between these L2 dimers are formed by the small subunits. This suggests that the small subunits may be essential for maintaining the integrity of the L8S8 structure. The active site shows differences between the unactivated form and the quaternary complex. In particular, Lys334 has moved out of the active site by about 10 angstrom. This residue lies on loop 6 of the alpha-beta-barrel, which is a particularly mobile loop. The site of ribulose-1,5-bisphosphate carboxylase/oxygenase activation is well ordered in the absence of the carbamylation of Lys201 and Mg2+ binding. The residues are held poised by a network of hydrogen bonds. In the unactivated state, the active site is accessible to substrate binding.	UNIV CALIF LOS ANGELES,DEPT CHEM & BIOCHEM,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,INST MOLEC BIOL,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles			Curmi, Paul/G-7185-2011	Curmi, Paul/0000-0001-5762-7638; Schreuder, Herman/0000-0003-2249-2782	NIGMS NIH HHS [GM31299] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM031299] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMIRI I, 1984, BIOCHIM BIOPHYS ACTA, V784, P116, DOI 10.1016/0167-4838(84)90117-1; ANDERSSON I, 1989, NATURE, V337, P229, DOI 10.1038/337229a0; Andrews T.J., 1987, BIOCH PLANTS, P131, DOI 10.1016/B978-0-12-675410-0.50009-9; BADGER MR, 1976, ARCH BIOCHEM BIOPHYS, V15, P723; BAKER TS, 1975, J MOL BIOL, V91, P391, DOI 10.1016/0022-2836(75)90267-3; BAKER TS, 1907, P NATL ACAD SCI US A, V74, P1037; BRANDEN CI, 1990, NATURE, V343, P687, DOI 10.1038/343687a0; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CHAN PH, 1972, SCIENCE, V176, P1145, DOI 10.1126/science.176.4039.1145; CHAPMAN MS, 1986, PHILOS T ROY SOC B, V313, P367, DOI 10.1098/rstb.1986.0044; CHAPMAN MS, 1988, SCIENCE, V241, P71, DOI 10.1126/science.3133767; CHAPMAN MS, 1987, NATURE, V329, P354, DOI 10.1038/329354a0; CHOU PY, 1977, J MOL BIOL, V115, P135, DOI 10.1016/0022-2836(77)90094-8; ELLIS RJ, 1979, TRENDS BIOCHEM SCI, V4, P241, DOI 10.1016/0968-0004(79)90212-3; ESTELLE M, 1985, J BIOL CHEM, V260, P9523; FINZEL BC, 1987, J APPL CRYSTALLOGR, V20, P53, DOI 10.1107/S0021889887087144; FOX GC, 1966, ACTA CRYSTALLOGR, V20, P886, DOI 10.1107/S0365110X66002007; FRENCH S, 1978, ACTA CRYSTALLOGR A, V34, P517, DOI 10.1107/S0567739478001114; HAINING RL, 1990, J BIOL CHEM, V265, P5434; HARTMAN FC, 1987, BIOCHEM BIOPH RES CO, V145, P1158, DOI 10.1016/0006-291X(87)91558-0; HARTMAN FC, 1987, J BIOL CHEM, V262, P3496; HENDRICKSON WA, 1985, METHOD ENZYMOL, V115, P252; HUDSON GS, 1990, J BIOL CHEM, V265, P808; IGARASHI Y, 1985, BIOCHEMISTRY-US, V24, P3957, DOI 10.1021/bi00336a024; JONES TA, 1985, METHOD ENZYMOL, V115, P157; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P67, DOI 10.1107/S0021889887009737; KNIGHT S, 1989, SCIENCE, V244, P702, DOI 10.1126/science.244.4905.702; KNIGHT S, 1990, J MOL BIOL, V215, P113, DOI 10.1016/S0022-2836(05)80100-7; LEE EH, 1986, P NATL ACAD SCI USA, V83, P9383, DOI 10.1073/pnas.83.24.9383; LESLIE AGW, 1987, COMPUTATIONAL ASPECT, P39; LORIMER GH, 1976, BIOCHEMISTRY-US, V15, P529, DOI 10.1021/bi00648a012; LORIMER GH, 1988, J BIOL CHEM, V263, P6468; LORIMER GH, 1981, BIOCHEMISTRY-US, V20, P136; LORIMER GH, 1987, PLANT MOL BIOL, P21; LUNDQVIST T, 1991, BIOCHEMISTRY-US, V30, P904, DOI 10.1021/bi00218a004; LUZZATI V, 1952, ACTA CRYSTALLOGR, V5, P802, DOI 10.1107/S0365110X52002161; MAZUR BJ, 1985, NUCLEIC ACIDS RES, V13, P2373, DOI 10.1093/nar/13.7.2373; MULLER KD, 1983, BIOCHIM BIOPHYS ACTA, V742, P78, DOI 10.1016/0167-4838(83)90361-8; NYBORG J, 1977, ROTATION METHOD CRYS; ONEAL JK, 1987, NUCLEIC ACIDS RES, V615, P8661; PAI EF, 1989, NATURE, V341, P209, DOI 10.1038/341209a0; PINCK M, 1984, BIOCHIMIE, V66, P539, DOI 10.1016/0300-9084(84)90148-2; PON NG, 1963, BIOCHEM Z, V338, P7; PORTIS AR, 1990, CURRENT RES PHOTOSYN, V44, P119; QUIOCHO FA, 1987, NATURE, V329, P561, DOI 10.1038/329561a0; Ramachandran G, 1968, ADV PROTEIN CHEM, V23, P325; RICHARDSON J, 1981, ADV PROTEIN CHEM, V34, P204; RICHMOND TJ, 1984, J MOL BIOL, V178, P63, DOI 10.1016/0022-2836(84)90231-6; SCHNEIDER G, 1990, EMBO J, V9, P2045, DOI 10.1002/j.1460-2075.1990.tb07371.x; SCHNEIDER G, 1986, EMBO J, V5, P3409, DOI 10.1002/j.1460-2075.1986.tb04662.x; SCHNEIDER G, 1990, J MOL BIOL, V211, P989, DOI 10.1016/0022-2836(90)90088-4; SCHREUDER HA, 1990, 1990 P CCP4 STUD WEE, P73; SHERIFF S, 1987, J APPL CRYSTALLOGR, V20, P55, DOI 10.1107/S0021889887087132; SOPER TS, 1988, PROTEIN ENG, V2, P39, DOI 10.1093/protein/2.1.39; STROBAEK S, 1976, CARLSBERG RES COMMUN, V41, P335, DOI 10.1007/BF02906141; VOORINTHOLT R, 1989, J MOL GRAPHICS, V7, P243, DOI 10.1016/0263-7855(89)80010-4; WIERENGA RK, 1985, BIOCHEMISTRY-US, V24, P1346, DOI 10.1021/bi00327a012; WINKLER FK, 1979, ACTA CRYSTALLOGR A, V35, P901, DOI 10.1107/S0567739479002035	58	86	95	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1992	267	24					16980	16989						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JL053	1512238				2022-12-25	WOS:A1992JL05300041
J	FURUKAWA, Y; UENOYAMA, S; OHTA, M; TSUNODA, A; GRIFFIN, JD; SAITO, M				FURUKAWA, Y; UENOYAMA, S; OHTA, M; TSUNODA, A; GRIFFIN, JD; SAITO, M			TRANSFORMING GROWTH-FACTOR-BETA INHIBITS PHOSPHORYLATION OF THE RETINOBLASTOMA SUSCEPTIBILITY GENE-PRODUCT IN HUMAN MONOCYTIC LEUKEMIA-CELL LINE JOSK-I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SV40 LARGE-T; FISSION YEAST; HISTONE-H1 KINASE; CONSTITUTIVE PRODUCTION; PROTEIN-KINASE; OSTEO-SARCOMA; S-TRANSITION; CDC2 PROTEIN; CYCLE; EXPRESSION	Proliferation of the human monocytic leukemia cell line JOSK-I is inhibited by transforming growth factor-beta (TGF-beta). Growth inhibition by TGF-beta was not due to either a toxic effect or to induction of differentiation. TGF-beta induced a cell cycle arrest at late G1 phase and was not found to be inhibitory to JOSK-I cells in S phase or G2/M. This G1 cell cycle arrest was associated with an accumulation of the unphosphorylated form of the retinoblastoma susceptibility gene product (Rb) in good correlation with inhibition of DNA synthesis. In contrast to the effects of TGF-beta, two other agents which induced a G1 arrest of JOSK-I cells had a different effect on Rb. Aphidicolin blocked cells at G1/S but could not reduce Rb phosphorylation as great as that seen with TGF-beta. 12-O-Tetradecanoylphorbol-13-acetate, an inducer of differentiation, did reduce Rb phosphorylation, but not until 72 h, when differentiation had already occurred. The identities of the Rb kinases are unknown, but recent evidence suggests that the cdc2 gene product could participate in Rb phosphorylation. Although cdc2 mRNA and total protein levels were not affected, TGF-beta inhibited the rate of translation and kinase activity of cdc2 in JOSK-I cells. These results suggest that growth inhibition of hematopoietic cells by TGF-beta is linked to suppression of Rb phosphorylation to retain Rb in an unphosphorylated, growth-inhibitory state. The suppression of Rb phosphorylation is suggested to be mediated through inhibition of cdc2 kinase activity by TGF-beta.	JICHI MED SCH,INST HEMATOL,DIV HEMOPOIESIS,MINAMI KAWACHI,TOCHIGI 32904,JAPAN; HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV TUMOR IMMUNOL,BOSTON,MA 02115	Jichi Medical University; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School			Furukawa, Yusuke/Y-1342-2018	Furukawa, Yusuke/0000-0002-7249-6418				ARION D, 1988, CELL, V55, P371, DOI 10.1016/0092-8674(88)90060-8; AYUSAWA D, 1983, J BIOL CHEM, V258, P2448; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CANCE WG, 1990, NEW ENGL J MED, V323, P1457, DOI 10.1056/NEJM199011223232105; CAVENEE WK, 1983, NATURE, V305, P779, DOI 10.1038/305779a0; CHAMBARD JC, 1988, J CELL PHYSIOL, V135, P101, DOI 10.1002/jcp.1041350114; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; COFFEY RJ, 1988, MOL CELL BIOL, V8, P3088, DOI 10.1128/MCB.8.8.3088; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DRAETTA G, 1988, CELL, V54, P17, DOI 10.1016/0092-8674(88)90175-4; DUBOIS CM, 1990, J EXP MED, V172, P737, DOI 10.1084/jem.172.3.737; DUNPHY WG, 1988, CELL, V54, P423, DOI 10.1016/0092-8674(88)90205-X; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; FURUKAWA Y, 1987, CANCER RES, V47, P2589; FURUKAWA Y, 1990, P NATL ACAD SCI USA, V87, P2770, DOI 10.1073/pnas.87.7.2770; FURUKAWA Y, 1990, SCIENCE, V250, P805, DOI 10.1126/science.2237430; FURUKAWA Y, 1991, ONCOGENE, V6, P1343; GAUTIER J, 1988, CELL, V54, P433, DOI 10.1016/0092-8674(88)90206-1; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; HOROWITZ JM, 1989, SCIENCE, V243, P937, DOI 10.1126/science.2521957; HOWE PH, 1991, MOL CELL BIOL, V11, P1185, DOI 10.1128/MCB.11.3.1185; ISHIDA Y, 1992, J CELL PHYSIOL, V150, P484, DOI 10.1002/jcp.1041500308; JOHNSON LF, 1982, EXP CELL RES, V138, P79, DOI 10.1016/0014-4827(82)90093-3; KUME TU, 1988, J MOL BIOL, V202, P779, DOI 10.1016/0022-2836(88)90558-X; LACHMAN HM, 1984, NATURE, V310, P592, DOI 10.1038/310592a0; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; LEE MG, 1987, NATURE, V327, P31, DOI 10.1038/327031a0; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; LIN BTY, 1991, EMBO J, V10, P857, DOI 10.1002/j.1460-2075.1991.tb08018.x; LUDLOW JW, 1989, CELL, V56, P57, DOI 10.1016/0092-8674(89)90983-5; LUDLOW JW, 1990, CELL, V60, P387, DOI 10.1016/0092-8674(90)90590-B; LUND LR, 1991, EMBO J, V10, P3399, DOI 10.1002/j.1460-2075.1991.tb04904.x; MASSAGUE J, 1987, CELL, V49, P437, DOI 10.1016/0092-8674(87)90443-0; MCGOWAN CH, 1990, MOL CELL BIOL, V10, P3847, DOI 10.1128/MCB.10.7.3847; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; MORENO S, 1990, CELL, V61, P549, DOI 10.1016/0092-8674(90)90463-O; MOSES HL, 1990, CELL, V63, P245, DOI 10.1016/0092-8674(90)90155-8; NURSE P, 1981, NATURE, V292, P558, DOI 10.1038/292558a0; OHTA M, 1986, CANCER RES, V46, P3067; OHTA M, 1987, NATURE, V329, P539, DOI 10.1038/329539a0; PIETENPOL JA, 1990, CELL, V61, P777, DOI 10.1016/0092-8674(90)90188-K; PIETENPOL JA, 1990, P NATL ACAD SCI USA, V87, P3758, DOI 10.1073/pnas.87.10.3758; SIMANIS V, 1986, CELL, V45, P261, DOI 10.1016/0092-8674(86)90390-9; SING GK, 1988, BLOOD, V72, P1504; SMELAND EB, 1987, EXP CELL RES, V171, P213, DOI 10.1016/0014-4827(87)90264-3; SORRENTINO V, 1989, ONCOGENE, V4, P569; TAKEHARA K, 1987, CELL, V49, P415, DOI 10.1016/0092-8674(87)90294-7; TANG A, 1988, SCIENCE, V242, P263, DOI 10.1126/science.3175651; TAYA Y, 1989, BIOCHEM BIOPH RES CO, V164, P580, DOI 10.1016/0006-291X(89)91759-2; TOGUCHIDA J, 1989, NATURE, V338, P156, DOI 10.1038/338156a0; TROWBRIDGE IS, 1981, P NATL ACAD SCI-BIOL, V78, P3039, DOI 10.1073/pnas.78.5.3039; WELCH PJ, 1992, P NATL ACAD SCI USA, V89, P3093, DOI 10.1073/pnas.89.7.3093; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0	54	64	64	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1992	267	24					17121	17127						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JL053	1512249				2022-12-25	WOS:A1992JL05300062
J	HYLEMON, PB; GURLEY, EC; STRAVITZ, RT; LITZ, JS; PANDAK, WM; CHIANG, JYL; VLAHCEVIC, ZR				HYLEMON, PB; GURLEY, EC; STRAVITZ, RT; LITZ, JS; PANDAK, WM; CHIANG, JYL; VLAHCEVIC, ZR			HORMONAL-REGULATION OF CHOLESTEROL-7-ALPHA-HYDROXYLASE MESSENGER-RNA LEVELS AND TRANSCRIPTIONAL ACTIVITY IN PRIMARY RAT HEPATOCYTE CULTURES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BILE-ACID SYNTHESIS; CHOLESTEROL 7-ALPHA-HYDROXYLASE ACTIVITY; CHICK-EMBRYO HEPATOCYTES; CIRCADIAN-RHYTHM; MONOLAYER-CULTURES; MALIC ENZYME; CYCLIC-AMP; LIVER; METABOLISM; GENE	In primary cultures of adult rat hepatocytes the level of cholesterol 7-alpha-hydroxylase steady-state mRNA markedly decreased by 72 h. However, the addition of L-thyroxine (T4) and dexamethasone synergistically returned cholesterol 7-alpha-hydroxylase steady-state mRNA levels near to that of cholestyramine-fed animals. The maximal responses to T4 and dexamethasone in serum-free medium were at 1.0 and 0.1-mu-M, respectively. The addition of T4 in combination with dexamethasone resulted in an 11-fold increase in transcriptional activity of the cholesterol 7-alpha-hydroxylase gene as compared to no addition controls. The specific activities of cholesterol 7-alpha-hydroxylase in microsomes prepared from cultures treated with dexamethasone and T4 were 1.56 +/- 1.17 nmol/h/mg protein which is similar to that of intact liver (1.70 +/- 0.062 nmol/h/mg protein), but lower than cholestyramine-fed animals. Cholesterol 7-alpha-hydroxylase activity was not detectable (<0.020 nmol/h/mg protein) at 72 h in cultures without the addition of both dexamethasone and T4. In the presence of optimal concentrations of dexamethasone and T4, glucagon (0.2-mu-M), or dibutyryl cAMP (50-mu-M) decreased (90%) cholesterol 7-alpha-hydroxylase mRNA within 6 h. Transcriptional activity decreased (62%) in 6 h following the addition of glucagon (0.2-mu-M) to the culture medium. The results reported in this paper suggest an important role for multiple hormones in the regulation of cholesterol 7-alpha-hydroxylase in the liver.	NE OHIO UNIV,COLL MED,DEPT BIOCHEM & MOLEC PATHOL,ROOTSTOWN,OH 44272; VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT MED,RICHMOND,VA 23298	Northeast Ohio Medical University (NEOMED); Virginia Commonwealth University	HYLEMON, PB (corresponding author), VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT MICROBIOL,RICHMOND,VA 23298, USA.			Chiang, John/0000-0001-9360-7650	NIDDK NIH HHS [R01 DK044442, 2P01DK38030] Funding Source: Medline; NIGMS NIH HHS [GM-31584] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK038030, R01DK044442] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031584] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BALASUBRAMANIAM S, 1972, BILE ACIDS HUMAN DIS, P97; BERGSTROM S, 1958, ACTA PHYSIOL SCAND, V43, P1, DOI 10.1111/j.1748-1716.1958.tb01572.x; Bissell D M, 1980, Ann N Y Acad Sci, V349, P85, DOI 10.1111/j.1749-6632.1980.tb29518.x; BJORKHEM I, 1991, BIOCHIM BIOPHYS ACTA, V1085, P329, DOI 10.1016/0005-2760(91)90137-7; BJORKHEM I, 1985, STEROLS BILE ACIDS, P231; BOSTROM H, 1982, J BIOL CHEM, V257, P1755; CHIANG JYL, 1990, J BIOL CHEM, V265, P3889; CHIANG JYL, 1990, J BIOL CHEM, V265, P7646; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COHEN P, 1991, BIOCHIM BIOPHYS ACTA, V1094, P292, DOI 10.1016/0167-4889(91)90089-G; CRITCHLOW V, 1963, AM J PHYSIOL, V205, P807, DOI 10.1152/ajplegacy.1963.205.5.807; DANIELSON PE, 1988, DNA-J MOLEC CELL BIO, V7, P261, DOI 10.1089/dna.1988.7.261; DANIELSSON H, 1975, ANNU REV BIOCHEM, V44, P233, DOI 10.1146/annurev.bi.44.070175.001313; DAVIS RA, 1983, J BIOL CHEM, V258, P3661; FOLCH J, 1957, J BIOL CHEM, V226, P497; GOODRIDGE AG, 1987, ANNU REV NUTR, V7, P157, DOI 10.1146/annurev.nu.07.070187.001105; GOODRIDGE AG, 1976, J BIOL CHEM, V251, P3027; GOODRIDGE AG, 1968, BIOCHEM J, V108, P667, DOI 10.1042/bj1080667; HENRY JB, 1991, CLIN DIAGNOSIS MANAG, P1367; HEUMAN DM, 1989, J LIPID RES, V30, P1161; HYLEMON PB, 1989, ANAL BIOCHEM, V182, P212, DOI 10.1016/0003-2697(89)90581-2; HYLEMON PB, 1985, J BIOL CHEM, V260, P1015; JELINEK DF, 1990, BIOCHEMISTRY-US, V29, P7781, DOI 10.1021/bi00486a001; JELINEK DF, 1990, J BIOL CHEM, V265, P8190; KUBASKA WM, 1985, J BIOL CHEM, V260, P3459; LARUSSO NF, 1977, GASTROENTEROLOGY, V72, P132; LEIGHTON JK, 1991, MOL CELL BIOL, V11, P2049, DOI 10.1128/MCB.11.4.2049; LI YC, 1990, J BIOL CHEM, V265, P12012; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MYANT NB, 1977, J LIPID RES, V18, P133; NESS GC, 1990, BIOCHEM BIOPH RES CO, V172, P1150, DOI 10.1016/0006-291X(90)91568-D; NOSHIRO M, 1989, FEBS LETT, V257, P97, DOI 10.1016/0014-5793(89)81795-8; NOSHIRO M, 1990, J BIOL CHEM, V265, P10036; PANDAK WM, 1991, J BIOL CHEM, V266, P3416; POOLER PA, 1988, HEPATOLOGY, V8, P1140, DOI 10.1002/hep.1840080530; PRINCEN HMG, 1990, BIOCHEM J, V272, P273, DOI 10.1042/bj2720273; PRINCEN HMG, 1989, BIOCHEM J, V262, P341, DOI 10.1042/bj2620341; SALATI LM, 1991, J BIOL CHEM, V266, P4010; SHEFER S, 1969, J LIPID RES, V10, P646; SHEFFER S, 1970, J LIPID RES, V11, P404; STAPLETON SR, 1990, J BIOL CHEM, V265, P18442; STORY JA, 1974, BIOCHEM MED METAB B, V10, P214, DOI 10.1016/0006-2944(74)90024-6; TAKEUCHI N, 1974, ATHEROSCLEROSIS, V20, P481, DOI 10.1016/0021-9150(74)90029-X; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; TINT GS, 1986, GASTROENTEROLOGY, V91, P1007, DOI 10.1016/0016-5085(86)90708-0; VLAHCEVIC ZR, 1991, HEPATOLOGY, V13, P590, DOI 10.1002/hep.1840130331; WADA F, 1969, J BIOCHEM-TOKYO, V66, P699	47	132	135	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1992	267	24					16866	16871						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JL053	1512229				2022-12-25	WOS:A1992JL05300024
J	PARK, JW; MA, MC; RUEDI, JM; SMITH, RM; BABIOR, BM				PARK, JW; MA, MC; RUEDI, JM; SMITH, RM; BABIOR, BM			THE CYTOSOLIC COMPONENTS OF THE RESPIRATORY BURST OXIDASE EXIST AS A MR-SIMILAR-TO-240,000 COMPLEX THAT ACQUIRES A MEMBRANE-BINDING SITE DURING ACTIVATION OF THE OXIDASE IN A CELL-FREE SYSTEM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEUTROPHIL NADPH OXIDASE; G-PROTEIN; IDENTIFICATION; NUCLEOTIDE	Sodium dodecyl sulfate (SDS) treatment of a mixture of cytosol and plasma membranes from resting neutrophils resulted in the activation of the respiratory burst oxidase, a complicated enzyme that catalyzes the production of O2- from NADPH and oxygen. Activation was accompanied by translocation to the plasma membranes of the oxidase components p47phox and p67phox, which in resting cytosol were found in a M(r) approximately 240,000 complex. This translocation, which appeared to take place without a major change in the size of the cytosolic complex, did not occur if the membranes lacked cytochrome b558, and was inhibited by the peptide PRGVHFIFNK, a sequence found near the carboxyl terminus of cytochrome b558 that was known from earlier work to inhibit O2- production by the cell-free system (Rotrosen, D., Kleinberg, M. E., Nunoi, H., Leto, T., Gallin, J. I., and Malech, H. L. (1990) J. Biol. Chem. 265, 8745-8750). Cytosols pretreated with the cross-linking agents 3,3'-dithiobis(sulfosuccinimidyl) propionate (DTSSP) (cleavable by 2-mercaptoethanol) and bis(sulfosuccinimidyl) suberate (not cleavable by 2-mercaptoethanol) lost most of their ability to support O2- production in the cell-free system, and oxidase components from DTSSP-treated cytosol failed to translocate to the plasma membrane. When DTSSP-treated cytosols were incubated with 2-mercaptoethanol, however, both O2- production and translocation were partly restored, indicating that the functional impairment in DTSSP-treated cytosols was probably due at least in part to a restriction in the conformational mobility of the cross-linked peptide chains in the approximately 240,000 complex. These findings provide further support for the idea that the cytosolic components of the respiratory burst oxidase exist in the form of a approximately 240,000 complex, and suggest that the exposure of this complex to SDS induces a structural change that may or may not be associated with the loss of an inhibitory subunit too small to cause a detectable change in the size of the complex. This SDS-induced change allows translocation to take place by creating a membrane-binding site on the surface of the complex.	UNIV CALIF SAN DIEGO, SCH MED, DEPT MED, LA JOLLA, CA 92093 USA	University of California System; University of California San Diego	PARK, JW (corresponding author), SCRIPPS RES INST, DEPT MOLEC & EXPTL MED, LA JOLLA, CA 92037 USA.				NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000833] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI024227, R01AI028479, R01AI024227] Funding Source: NIH RePORTER; NCRR NIH HHS [RR-00833] Funding Source: Medline; NIAID NIH HHS [AI-24227, AI-28479] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABO A, 1991, NATURE, V353, P668, DOI 10.1038/353668a0; BABIOR BM, 1988, J BIOL CHEM, V263, P1713; BABIOR BM, 1978, NEW ENGL J MED, V298, P659, DOI 10.1056/NEJM197803232981205; BABIOR BM, 1992, ADV ENZYMOL, V65, P49; BROMBERG Y, 1984, CELL IMMUNOL, V88, P213, DOI 10.1016/0008-8749(84)90066-2; CLARK RA, 1987, J BIOL CHEM, V262, P4065; CLARK RA, 1990, J CLIN INVEST, V85, P714, DOI 10.1172/JCI114496; CURNUTTE JT, 1987, J BIOL CHEM, V262, P5563; CURNUTTE JT, 1985, J CLIN INVEST, V75, P1740, DOI 10.1172/JCI111885; EKLUND EA, 1991, J BIOL CHEM, V266, P13964; FUJIMOTO S, 1989, J BIOL CHEM, V264, P21629; GABIG TG, 1987, J BIOL CHEM, V262, P1685; HEYNEMAN RA, 1984, J LEUKOCYTE BIOL, V36, P751, DOI 10.1002/jlb.36.6.751; HEYWORTH PG, 1990, BLOOD, V76, pA183; KNAUS UG, 1991, SCIENCE, V254, P1512, DOI 10.1126/science.1660188; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MALECH HL, 1987, NEW ENGL J MED, V317, P687, DOI 10.1056/NEJM198709103171107; MARKERT M, 1984, METHOD ENZYMOL, V105, P358; MCPHAIL LC, 1985, J CLIN INVEST, V75, P1735, DOI 10.1172/JCI111884; OKAMURA N, 1990, J CLIN INVEST, V85, P1583, DOI 10.1172/JCI114608; PICK E, 1987, J BIOL CHEM, V262, P16476; ROTROSEN D, 1990, J BIOL CHEM, V265, P8745; SCHWARZ HP, 1985, BLOOD, V66, P1452; SMITH RM, 1989, J BIOL CHEM, V264, P12243; SMITH RM, 1989, J BIOL CHEM, V264, P1958; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; UMEI T, 1991, J BIOL CHEM, V266, P6019; VOLPP BD, 1988, SCIENCE, V242, P1295, DOI 10.1126/science.2848318; WOODMAN RC, 1991, J CLIN INVEST, V87, P1345, DOI 10.1172/JCI115138	29	153	153	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	1992	267	24					17327	17332						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JL053	1512268				2022-12-25	WOS:A1992JL05300089
J	PARK, S; LIU, XQ; PAWSON, T; JOVE, R				PARK, S; LIU, XQ; PAWSON, T; JOVE, R			ACTIVATED SRC TYROSINE KINASE PHOSPHORYLATES TYR-457 OF BOVINE GTPASE-ACTIVATING PROTEIN (GAP) INVITRO AND THE CORRESPONDING RESIDUE OF RAT GAP INVIVO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; P21 GTPASE; TRANSFORMATION; ONCOGENE; CELLS; REQUIREMENT; SUPPRESSION; STIMULATION; CLONING; DOMAINS	GTPase-activating protein (GAP) is a key regulator of the cellular Ras protein, which is implicated in oncogenic signal transduction pathways downstream of the viral Src (v-Src) kinase. Previous studies demonstrated that v-Src induces tyrosine phosphorylation of GAP, suggesting that GAP may provide a biochemical link between v-Src and Ras signaling pathways. To determine the precise residues in GAP phosphorylated by Src kinases, we used a baculovirus/insect cell expression system for investigating in vitro phosphorylation of GAP. Phosphopeptide mapping analysis revealed that v-Src and normal cellular Src (c-Src) phosphorylate tyrosine residues in bovine GAP at one major site and one minor site in vitro. Significantly, the major site of GAP phosphorylation in vitro is also the major site of in vivo tyrosine phosphorylation of GAP in rat fibroblasts transformed by v-Src. Analyses of GAP deletion mutants and TrpE-GAP fusion proteins established that Tyr-457 of bovine GAP (and the corresponding residue of rat and human GAP) is the major site of tyrosine phosphorylation. Our results demonstrate that the v-Src kinase induces phosphorylation of the same tyrosine residue of GAP in vitro and in vivo, suggesting that GAP is a direct substrate of activated Src kinases in vivo. Because epidermal growth factor receptor phosphorylates the equivalent tyrosine residue in human GAP (Tyr-460), these findings are consistent with the hypothesis that specific phosphorylation of GAP at this site may have a physiologically important role in regulating mitogenic Ras signaling pathways.	UNIV MICHIGAN, SCH MED, DEPT MICROBIOL & IMMUNOL, 6606 MED SCI II, ANN ARBOR, MI 48109 USA; MT SINAI HOSP, SAMUEL LUNENFELD RES INST, TORONTO M5G 1X5, ONTARIO, CANADA	University of Michigan System; University of Michigan; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute			Pawson, Tony J/E-4578-2013	Park, Soochul/0000-0002-7029-3414; Liu, X. Johne/0000-0003-3381-5030	NATIONAL CANCER INSTITUTE [R29CA047809] Funding Source: NIH RePORTER; NCI NIH HHS [CA47809] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BISHOP JM, 1984, RNA TUMOR VIRUSES, P999; BOUTON AH, 1991, MOL CELL BIOL, V11, P945, DOI 10.1128/MCB.11.2.945; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BROTT BK, 1991, MOL CELL BIOL, V11, P5059, DOI 10.1128/MCB.11.10.5059; BROTT BK, 1991, P NATL ACAD SCI USA, V88, P755, DOI 10.1073/pnas.88.3.755; COOPER JA, 1983, CURR TOP MICROBIOL, V107, P125; DECLUE JE, 1991, MOL CELL BIOL, V11, P2819, DOI 10.1128/MCB.11.5.2819; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; GIBBS JB, 1990, J BIOL CHEM, V265, P20437; GIBBS JB, 1990, ADP RIBOSYLATING TOX, P381; GOLDEN A, 1988, ONCOGENE HDB, P149; HALL A, 1990, CELL, V61, P921, DOI 10.1016/0092-8674(90)90054-I; Hanafusa H., 1986, ONCOGENES GROWTH CON, P100; HSIEH CL, 1989, SOMAT CELL MOLEC GEN, V15, P579, DOI 10.1007/BF01534919; JOVE R, 1987, ANNU REV CELL BIOL, V3, P31, DOI 10.1146/annurev.cellbio.3.1.31; KAWAI S, 1980, J VIROL, V34, P772, DOI 10.1128/JVI.34.3.772-776.1980; KOERNER TJ, 1991, METHOD ENZYMOL, V194, P477; LIU XQ, 1991, MOL CELL BIOL, V11, P2511, DOI 10.1128/MCB.11.5.2511; LUO K, 1990, ONCOGENE, V5, P921; MARSHALL MS, 1989, EMBO J, V8, P1105, DOI 10.1002/j.1460-2075.1989.tb03480.x; MCCORMICK F, 1989, CELL, V56, P5, DOI 10.1016/0092-8674(89)90976-8; MORAN MF, 1991, MOL CELL BIOL, V11, P1804, DOI 10.1128/MCB.11.4.1804; MORAN MF, 1990, P NATL ACAD SCI USA, V87, P8622, DOI 10.1073/pnas.87.21.8622; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; NORI M, 1991, MOL CELL BIOL, V11, P2812, DOI 10.1128/MCB.11.5.2812; PARK S, 1992, J BIOL CHEM, V267, P11612; PARSONS JT, 1989, CURR TOP MICROBIOL, V147, P79; PIWNICAWORMS H, 1990, J VIROL, V64, P61, DOI 10.1128/JVI.64.1.61-68.1990; PIWNICAWORMS H, 1988, CURRENT PROTOCOLS MO; SATOH T, 1990, P NATL ACAD SCI USA, V87, P7926, DOI 10.1073/pnas.87.20.7926; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; SUMMERS MD, 1988, MANUAL METHODS BACUL; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0	35	28	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	1992	267	24					17194	17200						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JL053	1512257				2022-12-25	WOS:A1992JL05300072
J	MURPHY, AJ; COLL, RJ				MURPHY, AJ; COLL, RJ			FLUORIDE IS A SLOW, TIGHT-BINDING INHIBITOR OF THE CALCIUM ATPASE OF SARCOPLASMIC-RETICULUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENOSINE-TRIPHOSPHATASE; ACTIVE-SITE; FLUORESCEIN ISOTHIOCYANATE; DIHYDROFOLATE-REDUCTASE; DIVALENT-CATIONS; GAMMA-PHOSPHATE; HIGH-AFFINITY; VANADATE; CA-2+-ATPASE; ALUMINUM	Addition of sodium fluoride in the millimolar concentration range to a solution containing the sarcoplasmic reticulum CaATPase undergoing turnover in its vesicular or nonionic detergent-solubilized forms produced a slow (time range of minutes) complete loss of enzymatic activity. In the presence of magnesium and the absence of calcium, similar results were obtained under nonturnover conditions. Time courses were adequately fit by a function corresponding to a monophasic transformation with a pseudo first order rate constant k(obs). In the absence of Mg2+ (EDTA present) no inhibition developed; k(obs) depended hyperbolically on the Mg2+ concentration with the half maximal effect occurring near 4 mM. The fluoride concentration dependence of k(obs) showed no evidence of approaching saturation (highest [F-] used was 40 mM) and corresponded to a rate law which was approximately second-order with respect to fluoride. A number of ligands known to bind to the CaATPase were found to decrease k(obs). Calcium prevented onset of fluoride inhibition with a midpoint in the micromolar range, implying an effect due to binding at the high affinity transport sites. ATP also protected with a midpoint in the micromolar range, consistent with an effect caused by active site binding of the nucleotide; protection was only partial, suggesting the ATPase can bind fluoride and ATP simultaneously. Prevention of fluoride inhibition by P(i) occurred with a [Pi]1/2 of 12 mM at pH 6.5, a concentration similar to that which produces active site phosphorylation. Finally, protection by orthovanadate was found to be competitive and have a midpoint of 5-mu-M. These results point to an effect exerted at or near the phosphorylation site. The value of k(obs) increased from essentially zero above pH 8 to a plateau below pH 6; the transition had a midpoint near pH 7.2. Inhibition persisted after removal (with EGTA present) of unbound fluoride by dialysis. Reversal of fluoride inhibition was very slow, with a t1/2 of 16 h at 37-degrees-C. These results suggest that fluoride behaves like a slow, tight-binding inhibitor of the ATPase and that the resulting complex is a stable transition (or intermediate) state analog. Plausible molecular bases for our results are that fluoride acts at the phosphorylation site as an analog of P(i) or of hydroxide, which may be considered a substrate in the normal hydrolysis of the phosphorylated enzyme. A role for aluminum was ruled out after finding that the addition of EGTA to 10 mM or aluminum sulfate to 0.2 mM or deferoxamine to 0.5 mM produced no significant change in k(obs).			MURPHY, AJ (corresponding author), UNIV PACIFIC,SCH DENT,DEPT BIOCHEM,SAN FRANCISCO,CA 94115, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031083] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM31083] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSEN JP, 1985, BIOCHIM BIOPHYS ACTA, V815, P9, DOI 10.1016/0005-2736(85)90467-5; ANDERSON KW, 1983, J BIOL CHEM, V258, P4276; Bevington PR, 1969, DATA REDUCTION ERROR; BIGAY J, 1985, FEBS LETT, V191, P181, DOI 10.1016/0014-5793(85)80004-1; BLACKMORE PF, 1985, J BIOL CHEM, V260, P4477; BLAKLEY RL, 1985, BIOCHEMISTRY-US, V24, P4772, DOI 10.1021/bi00339a010; CHABRE M, 1990, TRENDS BIOCHEM SCI, V15, P6, DOI 10.1016/0968-0004(90)90117-T; CHIESI M, 1980, BIOCHEMISTRY-US, V19, P2912, DOI 10.1021/bi00554a015; COLL RJ, 1987, BIOCHIM BIOPHYS ACTA, V904, P227, DOI 10.1016/0005-2736(87)90372-5; COLL RJ, 1984, J BIOL CHEM, V259, P4249; COLL RJ, 1985, FEBS LETT, V187, P131, DOI 10.1016/0014-5793(85)81228-X; COLL RJ, 1986, BIOCHEM BIOPH RES CO, V138, P652, DOI 10.1016/S0006-291X(86)80546-0; COLL RJ, 1991, BIOCHEMISTRY-US, V30, P1456, DOI 10.1021/bi00220a002; COMBEAU C, 1989, J BIOL CHEM, V264, P19017; CRANS DC, 1990, BIOCHEMISTRY-US, V29, P6698, DOI 10.1021/bi00480a020; DEGANI C, 1973, J BIOL CHEM, V248, P8222; DUPONT Y, 1980, EUR J BIOCHEM, V109, P231, DOI 10.1111/j.1432-1033.1980.tb04788.x; DUPONT Y, 1982, ANN NY ACAD SCI, V402, P569, DOI 10.1111/j.1749-6632.1982.tb25779.x; DUPUIS A, 1989, FEBS LETT, V255, P47, DOI 10.1016/0014-5793(89)81058-0; ELETR S, 1972, BIOCHIM BIOPHYS ACTA, V282, P174, DOI 10.1016/0005-2736(72)90321-5; FRIEDEN C, 1980, BIOCHEMISTRY-US, V19, P5303, DOI 10.1021/bi00564a024; GARDNER GL, 1976, J DENT RES, V55, P343; HIGHSMITH S, 1985, BIOCHIM BIOPHYS ACTA, V817, P123, DOI 10.1016/0005-2736(85)90074-4; INESI G, 1990, PHYSIOL REV, V70, P749, DOI 10.1152/physrev.1990.70.3.749; INESI G, 1984, J BIOL CHEM, V259, P996; JENCKS WP, 1989, J BIOL CHEM, V264, P18855; KANAZAWA T, 1975, J BIOL CHEM, V250, P113; LEVY D, 1990, J BIOL CHEM, V265, P19524; MACLENNAN DH, 1990, BIOPHYS J, V58, P1355, DOI 10.1016/S0006-3495(90)82482-6; MARKUS S, 1986, BIOCHIM BIOPHYS ACTA, V874, P128, DOI 10.1016/0167-4838(86)90109-3; MARKUS S, 1989, BIOCHEMISTRY-US, V28, P793, DOI 10.1021/bi00428a057; MARQUARDT DW, 1963, J SOC IND APPL MATH, V11, P431, DOI 10.1137/0111030; MARTELL AE, 1974, CRITICAL STABILITY C, V1, P269; MCINTOSH DB, 1983, BIOCHEMISTRY-US, V22, P2867, DOI 10.1021/bi00281a015; MORRISON JF, 1988, ADV ENZYMOL RAMB, V61, P201; MORRISON JF, 1983, BIOCHEMISTRY-US, V22, P5507, DOI 10.1021/bi00293a009; MUPRHY AJ, 1990, BIOCHEMISTRY-US, V29, P11236; MURPHY AJ, 1988, BIOCHIM BIOPHYS ACTA, V946, P57, DOI 10.1016/0005-2736(88)90457-9; MURPHY AJ, 1978, J BIOL CHEM, V253, P385; NAKAMOTO RK, 1984, J BIOL CHEM, V259, P2961; ONEAL SG, 1979, BIOCHEM BIOPH RES CO, V89, P845, DOI 10.1016/0006-291X(79)91855-2; ORTIZ A, 1984, BIOCHEM J, V221, P213, DOI 10.1042/bj2210213; PICK U, 1982, J BIOL CHEM, V257, P6111; PICKART CM, 1984, J BIOL CHEM, V259, P1629; ROBINSON JD, 1986, J BIOENERG BIOMEMBR, V18, P521, DOI 10.1007/BF00743148; SIMONS TJB, 1979, NATURE, V281, P337, DOI 10.1038/281337a0; SMITH EW, 1989, PHARMACEUT RES, V6, P431, DOI 10.1023/A:1015995818613; Smith R. M., 1976, CRITICAL STABILITY C, V4, P96; STERNWEIS PC, 1982, P NATL ACAD SCI-BIOL, V79, P4888, DOI 10.1073/pnas.79.16.4888; STURR MG, 1990, ARCH MICROBIOL, V155, P22, DOI 10.1007/BF00291269; TAKAKUWA Y, 1979, BIOCHEM BIOPH RES CO, V88, P1209, DOI 10.1016/0006-291X(79)91108-2; TAYLOR JS, 1979, J BIOL CHEM, V254, P4402; WATANABE T, 1981, BIOCHEMISTRY-US, V20, P6617, DOI 10.1021/bi00526a015; WILLIAMS JW, 1979, BIOCHEMISTRY-US, V18, P2567, DOI 10.1021/bi00579a021; YAMAMOTO H, 1989, J BIOCHEM-TOKYO, V106, P1121, DOI 10.1093/oxfordjournals.jbchem.a122976	55	57	58	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1992	267	8					5229	5235						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HH747	1531981				2022-12-25	WOS:A1992HH74700038
J	PAIVA, WD; GROSSMAN, T; SILVERMAN, PM				PAIVA, WD; GROSSMAN, T; SILVERMAN, PM			CHARACTERIZATION OF F-PILIN AS AN INNER MEMBRANE COMPONENT OF ESCHERICHIA-COLI K12	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOCLONAL-ANTIBODIES; CONJUGATIVE PILI; PROTEIN; PHYSIOLOGY; SEQUENCE; REGION; OUTER; K-12; GENE; POOL	Antipeptide antibodies were used to detect, purify, and characterize nonfilament F-pilin in the cell envelope of an F'tra+ strain of Escherichia coli. Affinity-purified goat antibodies raised against a peptide corresponding to the amino-terminal 14 amino acids of F-pilin detected F-pilin in immuno-overlay ("Western") blots of electrophoretically separated inner and outer membrane proteins. As expected, the molecule was absent from inner membrane preparations of F- or F'traA[Am] strains. Immunoreactive material was purified from inner membrane fractions and shown to be F-pilin by amino acid analysis. The anti-peptide antibodies also detected membrane forms of F-pilin produced by cells containing plasmid pTG801 (Grossman, T. & Silverman, P. (1989) J. Bacteriol. 171, 650-656). Most cell envelope pilin was in the inner membrane fraction, but a significant quantity fractionated with the outer membrane as well. The hydropathy profile of F-pilin suggested that the molecule is an integral membrane protein with two membrane-spanning domains. In confirmation, F-pilin and pTG8O1 pilins in inner membrane preparations were solubilized by a single extraction with the nonionic detergents Nonidet P-40 (2%) or Triton X- 100 (2%), but not by 2 M KCl or 0.1 M NaOH. Moreover, analysis of traA'-'phoA constructs indicated that both the amino and carboxyl termini of F-pilin face the periplasm. The periplasmic location of the amino terminus was confirmed by immunoelectron microscopy of spheroplasts from F' and pTG801 strains, using a monoclonal antibody that recognizes an amino-terminal epitope. These data suggest a specific structure for membrane F-pilin. We discuss that structure in relation to the probable structure of filament F-pilin.	OKLAHOMA MED RES FDN,PROGRAM MOLEC & CELL BIOL,825 NE 13TH ST,OKLAHOMA CITY,OK 73104; UNIV OKLAHOMA,DEPT BOT & MICROBIOL,NORMAN,OK 73019; YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT MOLEC GENET,BRONX,NY 10461	Oklahoma Medical Research Foundation; University of Oklahoma System; University of Oklahoma - Norman; Yeshiva University; Albert Einstein College of Medicine	SILVERMAN, PM (corresponding author), OKLAHOMA MED RES FDN,PROGRAM MOLEC & CELL BIOL,825 NE 13TH ST,OKLAHOMA CITY,OK 73104, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038657] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM38657] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ACHTMAN M, 1971, J BACTERIOL, V106, P529, DOI 10.1128/JB.106.2.529-538.1971; ACHTMAN M, 1978, J BACTERIOL, V135, P1053, DOI 10.1128/JB.135.3.1053-1061.1978; BAUER KA, 1984, J CLIN INVEST, V74, P2033, DOI 10.1172/JCI111626; BEARD JP, 1975, J BACTERIOL, V122, P59, DOI 10.1128/JB.122.1.59-65.1975; BIEBRICHER CK, 1984, J GEN MICROBIOL, V130, P951; Brinton C C Jr, 1971, CRC Crit Rev Microbiol, V1, P105, DOI 10.3109/10408417109104479; CUOZZO M, 1986, J BIOL CHEM, V261, P5175; DATE T, 1977, BIOCHEMISTRY-US, V16, P5579, DOI 10.1021/bi00644a030; DEPAMPHI.ML, 1971, J BACTERIOL, V105, P396, DOI 10.1128/JB.105.1.396-407.1971; FOLKHARD W, 1979, J MOL BIOL, V130, P145, DOI 10.1016/0022-2836(79)90423-6; FROST LS, 1984, J BACTERIOL, V160, P395, DOI 10.1128/JB.160.1.395-401.1984; FROST LS, 1988, MOL GEN GENET, V213, P134, DOI 10.1007/BF00333409; FROST LS, 1986, J BACTERIOL, V168, P192, DOI 10.1128/jb.168.1.192-198.1986; FROST LS, 1991, J BACTERIOL, V173, P7728, DOI 10.1128/jb.173.23.7728-7731.1991; GROSSMAN TH, 1989, J BACTERIOL, V171, P650, DOI 10.1128/jb.171.2.650-656.1989; GROSSMAN TH, 1990, J BACTERIOL, V172, P1174, DOI 10.1128/jb.172.3.1174-1179.1990; GUTIERREZ C, 1989, NUCLEIC ACIDS RES, V17, P3999, DOI 10.1093/nar/17.10.3999; HELMUTH R, 1978, P NATL ACAD SCI USA, V775, P1237; Hurn B A, 1980, Methods Enzymol, V70, P104; IPPENIHLER K, 1972, J BACTERIOL, V110, P857, DOI 10.1128/JB.110.3.857-863.1972; IPPENIHLER KA, 1986, ANNU REV GENET, V20, P593, DOI 10.1146/annurev.ge.20.120186.003113; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAINE S, 1985, PLASMIDS BACTERIA, P535; LAWN A M, 1970, Journal of Hygiene, V68, P683; MANNING PA, 1979, BACTERIAL OUTER MEMB, P409; MANOIL C, 1986, SCIENCE, V233, P1403, DOI 10.1126/science.3529391; MANOIL C, 1985, P NATL ACAD SCI USA, V82, P8129, DOI 10.1073/pnas.82.23.8129; MARVIN DA, 1986, J MOL BIOL, V191, P299, DOI 10.1016/0022-2836(86)90267-6; MEYNELL E, 1978, PILI, P207; MICHAELIS S, 1983, J BACTERIOL, V154, P366, DOI 10.1128/JB.154.1.366-374.1983; MOORE D, 1981, J BACTERIOL, V146, P251, DOI 10.1128/JB.146.1.251-259.1981; NAMBUDRIPAD R, 1991, SCIENCE, V252, P1305, DOI 10.1126/science.1925543; OSBORN MJ, 1972, J BIOL CHEM, V247, P3962; PANICKER MM, 1985, J BACTERIOL, V162, P584, DOI 10.1128/JB.162.2.584-590.1985; PARANCHYCH W, 1988, ADV MICROB PHYSIOL, V29, P53, DOI 10.1016/S0065-2911(08)60346-X; SILVERMAN PM, 1987, BACTERIAL OUTER MEMB, P277; SMIT J, 1987, J CELL BIOL, V105, P1821, DOI 10.1083/jcb.105.4.1821; SOWA BA, 1983, J BACTERIOL, V153, P962, DOI 10.1128/JB.153.2.962-968.1983; Valentine R. C., 1969, ADV MICROB PHYSIOL, V3, P1, DOI 10.1016/S0065-2911(08)60364-1; VALENTINE RC, 1965, SCIENCE, V148, P511, DOI 10.1126/science.148.3669.511; WILLETTS N, 1987, ESCHERICHIA COLI SAL, P1110	41	20	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1992	267	36					26191	26197						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KD073	1464628				2022-12-25	WOS:A1992KD07300089
J	ZHANG, ZY; CLEMENS, JC; SCHUBERT, HL; STUCKEY, JA; FISCHER, MWF; HUME, DM; SAPER, MA; DIXON, JE				ZHANG, ZY; CLEMENS, JC; SCHUBERT, HL; STUCKEY, JA; FISCHER, MWF; HUME, DM; SAPER, MA; DIXON, JE			EXPRESSION, PURIFICATION, AND PHYSICOCHEMICAL CHARACTERIZATION OF A RECOMBINANT YERSINIA PROTEIN TYROSINE PHOSPHATASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIOPHAGE-T7 RNA-POLYMERASE; VIRULENCE DETERMINANT; HYDROLYSIS; GENES; CATALYSIS; ENZYMES; CLONING; SYSTEM; AXONS	The Yersinia protein tyrosine phosphatase (PTPase) Yop51, a C235R point mutation (Yop51*), and a protein lacking the first 162 amino acids at the NH2 terminus (Yop51*DELTA162) have been overexpressed in Escherichia coli and purified to homogeneity through the use of CM Sephadex C25 cation exchange chromatography followed by Sephadex G-100 gel filtration. Greater than 50 mg of homogeneous Yop51* and Yop51*DELTA162 can be obtained from a single liter of bacterial culture, whereas the same procedure yields only 5 mg of pure Yop51. Large, diffraction-quality crystals have been obtained for Yop51*DELTA162. Size exclusion chromatography, sedimentation equilibrium, and enzyme concentration dependence experiments have established that the Yersinia PTPases exist and function as monomers in solution. Yop51 and Yop51* display identical UV, CD, and fluorescence spectra and have identical kinetic and structural stability properties. These full-length Yersinia PTPases have 31% alpha-helix, an emission maximum of 342 nm, a turn-over number of 1200 s-1 at pH 5.0, 30-degrees-C, and an unfolding DELTAG value of 6 kcal/mol at 25-degrees-C. Yop51*DELTA162 has very similar kinetic and fluorescence characteristics to the full-length molecules, whereas its CD and UV spectra show noticeable differences due to the elimination of 162 NH2-terminal residues. The Yersinia PTPases are by far the most active PTPases known, and their kinetic parameters are extremely sensitive to the ionic strength of reaction medium.	UNIV MICHIGAN,DEPT BIOL CHEM,ANN ARBOR,MI 48109; UNIV MICHIGAN,DIV BIOPHYS RES,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan					PHS HHS [18849] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BLISKA JB, 1991, P NATL ACAD SCI USA, V88, P1187, DOI 10.1073/pnas.88.4.1187; CHERVENKA CH, 1973, MANUAL METHODS ANAL, P55; CHO HJ, 1992, BIOCHEMISTRY-US, V31, P133, DOI 10.1021/bi00116a019; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; Cohn E. J., 1943, PROTEINS AMINO ACIDS, P370; COOL DE, 1990, P NATL ACAD SCI USA, V87, P7280, DOI 10.1073/pnas.87.18.7280; DUMPHY WG, 1991, CELL, V67, P189; FISCHER EH, 1991, SCIENCE, V253, P401, DOI 10.1126/science.1650499; FRANGIONI JV, 1992, CELL, V68, P545, DOI 10.1016/0092-8674(92)90190-N; GOLDSTEIN L, 1972, BIOCHEMISTRY-US, V11, P4072, DOI 10.1021/bi00772a009; GUAN KL, 1990, P NATL ACAD SCI USA, V87, P1501, DOI 10.1073/pnas.87.4.1501; GUAN KL, 1990, SCIENCE, V249, P553, DOI 10.1126/science.2166336; GUAN KL, 1991, J BIOL CHEM, V266, P17026; HARTLEY RW, 1968, BIOCHEMISTRY-US, V7, P2401, DOI 10.1021/bi00846a050; HUNTER T, 1989, CELL, V58, P1013, DOI 10.1016/0092-8674(89)90496-0; HUNTER T, 1986, ENZYMES, V17, P191; JANCARIK J, 1991, J APPL CRYSTALLOGR, V24, P409, DOI 10.1107/S0021889891004430; KESVATERA T, 1990, BIOORG CHEM, V18, P13, DOI 10.1016/0045-2068(90)90011-S; KRUEGER NX, 1990, EMBO J, V9, P3241, DOI 10.1002/j.1460-2075.1990.tb07523.x; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MATTHEW JB, 1982, BIOCHEMISTRY-US, V21, P4989, DOI 10.1021/bi00263a024; MATTHEWS B, 1968, J MOL BIOL, V33, P5036; Pace C N, 1986, Methods Enzymol, V131, P266; POT DA, 1991, J BIOL CHEM, V266, P19688; SANTORO MM, 1992, BIOCHEMISTRY-US, V31, P4901, DOI 10.1021/bi00135a022; SHEN BW, 1975, J AM CHEM SOC, V97, P1205, DOI 10.1021/ja00838a040; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; TIAN SS, 1991, CELL, V67, P675, DOI 10.1016/0092-8674(91)90063-5; TONKS NK, 1988, J BIOL CHEM, V263, P6731; TONKS NK, 1989, TRENDS BIOCHEM SCI, V14, P497, DOI 10.1016/0968-0004(89)90184-9; WOODFORDTHOMAS TA, 1992, J CELL BIOL, V117, P401, DOI 10.1083/jcb.117.2.401; YAMAOKA K, 1981, J PHARMACOBIO-DYNAM, V4, P879, DOI 10.1248/bpb1978.4.879; YANG JT, 1986, METHOD ENZYMOL, V130, P208; YANG XH, 1991, CELL, V67, P661, DOI 10.1016/0092-8674(91)90062-4; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; ZHANG ZY, 1991, J BIOL CHEM, V266, P15591; ZHANG ZY, 1991, J BIOL CHEM, V266, P1516	38	185	190	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1992	267	33					23759	23766						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JZ239	1429715				2022-12-25	WOS:A1992JZ23900052
J	ERICSSON, J; THELIN, A; CHOJNACKI, T; DALLNER, G				ERICSSON, J; THELIN, A; CHOJNACKI, T; DALLNER, G			SUBSTRATE-SPECIFICITY OF CIS-PRENYLTRANSFERASE IN RAT-LIVER MICROSOMES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UNDECAPRENYL PYROPHOSPHATE SYNTHETASE; DOLICHYL PHOSPHATE BIOSYNTHESIS; STEROL SYNTHESIS; PIG-LIVER; DIPHOSPHATE; PATHWAY; IDENTIFICATION; CHOLESTEROL; PROTEINS	Long chain cis-prenyltransferase in rat liver microsomes was studied using various allylic isoprenoid substrates. Microsomes could utilize trans-geranyl pyrophosphate, but not cis-geranyl pyrophosphate for polyprenyl pyrophosphate synthesis. Both trans, trans-farnesyl pyrophosphate and trans,cis-farnesyl pyrophosphate were used as substrates with K(m) values of 24 and 5 muM, respectively. trans,trans,cis-Geranyl-geranyl pyrophosphate could be used as substrate with an apparent K(m) of 36 muM. trans,trans,trans-Geranyl-geranyl pyrophosphate was also utilized as substrate, but with a very low affinity . After pulse labeling for 4 min, using [H-3]isopentenyl pyrophosphate and trans,trans-farnesyl pyrophosphate, the only product formed was trans,trans,cis-geranylgeranyl pyrophosphate, which, upon chasing, yielded polyprenyl pyrophosphate. Independent of the nature of the substrate used, even in the case of polyprenyl 12-pyrophosphate and all-trans-nonaprenyl pyrophosphate, the chain lengths of the products were identical, i.e. polyprenyl pyrophosphates with 15-18 isoprene residues. Microsomes were able to synthesize trans,trans-farnesyl pyrophosphate using trans-geranyl pyrophosphate as substrate. The results indicate that rat liver microsomes contain a farnesyl pyrophosphate synthase activity and that the reaction catalyzed by cis-prenyl-transferase may consist of two individual steps, i.e. synthesis of trans,trans,cis-geranylgeranyl pyrophosphate and elongation of this product to long chain polyprenyl pyrophosphates.	KAROLINSKA INST,HUDDINGE HOSP,CLIN RES CTR,S-14186 HUDDINGE,SWEDEN; POLISH ACAD SCI,DEPT BIOCHEM & BIOPHYS,PL-02532 WARSAW,POLAND	Karolinska Institutet; Polish Academy of Sciences	ERICSSON, J (corresponding author), UNIV STOCKHOLM,DEPT BIOCHEM,S-10691 STOCKHOLM,SWEDEN.		Ericsson, Johan/AAA-6664-2020	Ericsson, Johan/0000-0003-1186-6574				ADAIR WL, 1987, ARCH BIOCHEM BIOPHYS, V259, P589; ADAIR WL, 1984, J BIOL CHEM, V259, P4441; ADAIR WL, 1983, BIOCHIM BIOPHYS ACTA, V208, P532; BABA T, 1980, ARCH BIOCHEM BIOPHYS, V200, P474, DOI 10.1016/0003-9861(80)90379-3; BABA T, 1987, ARCH BIOCHEM BIOPHYS, V252, P440, DOI 10.1016/0003-9861(87)90050-6; BABA T, 1978, BIOCHEMISTRY-US, V17, P5598, DOI 10.1021/bi00619a003; CHEN Z, 1988, ARCH BIOCHEM BIOPHYS, V266, P98, DOI 10.1016/0003-9861(88)90240-8; CHOJNACKI T, 1988, BIOCHEM J, V251, P1; CHOJNACKI T, 1984, ACTA BIOCHIM POL, V31, P115; CHOJNACKI T, 1975, ANAL BIOCHEM, V69, P505; CLARKE CF, 1987, MOL CELL BIOL, V7, P3138, DOI 10.1128/MCB.7.9.3138; COHEN LH, 1986, BIOCHEM BIOPH RES CO, V138, P335, DOI 10.1016/0006-291X(86)90285-8; CRICK DC, 1991, J NEUROCHEM, V57, P1354, DOI 10.1111/j.1471-4159.1991.tb08301.x; DALEO GR, 1977, FEBS LETT, V81, P411, DOI 10.1016/0014-5793(77)80566-8; ERICSSON J, 1991, J BIOL CHEM, V266, P10602; ERICSSON J, 1991, EUR J BIOCHEM, V209, P789; FARNSWORTH CC, 1990, SCIENCE, V247, P320, DOI 10.1126/science.2296721; FAUST JR, 1979, ARCH BIOCHEM BIOPHYS, V192, P86, DOI 10.1016/0003-9861(79)90074-2; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; GORNALL AG, 1949, J BIOL CHEM, V177, P751; HEMMING FW, 1983, BIOSYNTHESIS ISOPREN, V2, P305; ISHII K, 1983, J BIOCHEM-TOKYO, V93, P1635, DOI 10.1093/oxfordjournals.jbchem.a134302; JAMES MJ, 1979, J BIOL CHEM, V254, P8442; JOLY A, 1991, J BIOL CHEM, V266, P13495; KENNAN RW, 1976, BIOCHEMISTRY-US, V15, P1586; POPJAK G, 1962, J BIOL CHEM, V237, P56; POTTER JER, 1981, J BIOL CHEM, V256, P2371; Poulter C. D., 1981, BIOSYNTHESIS ISOPREN, V1, P161; REISS Y, 1992, J BIOL CHEM, V267, P6403; REISS Y, 1991, J BIOL CHEM, V266, P10672; SAGAMI H, 1991, J BIOL CHEM, V266, P3458; SAGAMI H, 1985, METHOD ENZYMOL, V110, P184; SAGAMI H, 1978, BIOCHEM BIOPH RES CO, V85, P572, DOI 10.1016/0006-291X(78)91201-9; SAGAMI H, 1989, BIOCHIM BIOPHYS ACTA, V266, P218; SCHMIDT RA, 1984, J BIOL CHEM, V259, P175; SINENSKY M, 1990, J BIOL CHEM, V265, P19937; TAKAHASHI I, 1982, J BIOCHEM-TOKYO, V92, P1527, DOI 10.1093/oxfordjournals.jbchem.a134077; TOLLBOM O, 1988, J BIOL CHEM, V263, P1347; Van Dessel G, 1990, Subcell Biochem, V16, P227; WONG TK, 1982, J BIOL CHEM, V257, P6619	40	44	44	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1992	267	27					19730	19735						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JP593	1527094				2022-12-25	WOS:A1992JP59300106
J	MAHONEY, CW; SHUMAN, J; MCKNIGHT, SL; CHEN, HC; HUANG, KP				MAHONEY, CW; SHUMAN, J; MCKNIGHT, SL; CHEN, HC; HUANG, KP			PHOSPHORYLATION OF CCAAT-ENHANCER BINDING-PROTEIN BY PROTEIN-KINASE-C ATTENUATES SITE-SELECTIVE DNA-BINDING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR FACTOR CREB; LEUCINE ZIPPER; TRANSCRIPTION FACTOR; NUCLEOTIDE-SEQUENCE; NEUROSPORA-CRASSA; CYCLIC-AMP; 3T3 CELLS; GENE; EXPRESSION; ONCOGENE	Four DNA-recombinant proteins, corresponding to the DNA-binding domain of CCAAT/enhancer binding protein (C/EBP), were phosphorylated in vitro by protein kinase C (PKC). High-performance liquid chromatography-peptide mapping of P-32-labeled C/EBP indicated the presence of three major P-32-labeled peptides: S299 (P)RDK, AKKS277 (P)VDK, and GAAGLP-GPGGS248 (P)LK. Phosphorylation of C/EBP by PKC or M-kinase resulted in an attenuation of binding to a P-32-labeled CCAAT oligodeoxynucleotide. Three other truncated forms of C/EBP, C/EBP87, C/EBP87S-C, and C/EBP60, were studied to define the sites of phosphorylation affecting DNA binding. Phosphorylation of the C/EBP87, containing sites Ser299 and Ser277, and C/EBP60, containing only site Ser299, by PKC also resulted in attenuation of DNA binding. In contrast, phosphorylation of C/EBP87S-C, which retained Ser277 but had a Cys in place of Ser299, had no effect on DNA binding. Ser299 could not be phosphorylated by PKC if the protein is already bound to specific DNA. Phosphorylation of intact C/EBP from liver nuclear extract by PKC or M-kinase occurred at Ser299 and Ser277 and at an additional site, as demonstrated by immunoprecipitation and peptide mapping.	NICHHD,ENDOCRINOL & REPROD RES BRANCH,BLDG 10,RM B1L400,BETHESDA,MD 20892; CARNEGIE INST WASHINGTON,DEPT EMBRYOL,BALTIMORE,MD 21210	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Carnegie Institution for Science				Shuman, Jon/0000-0001-8412-9087				ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; BELL RM, 1991, J BIOL CHEM, V266, P4661; BENMOREPARSONS M, 1989, ARCH BIOCHEM BIOPHYS, V272, P274; BIRKENMEIER EH, 1989, GENE DEV, V3, P1146, DOI 10.1101/gad.3.8.1146; CASTAGNA M, 1982, J BIOL CHEM, V257, P7847; FARAGO A, 1990, FEBS LETT, V268, P350, DOI 10.1016/0014-5793(90)81284-U; FU YH, 1989, MOL CELL BIOL, V9, P1120, DOI 10.1128/MCB.9.3.1120; GONZALEZ GA, 1989, NATURE, V337, P749, DOI 10.1038/337749a0; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HINNEBUSCH AG, 1984, P NATL ACAD SCI-BIOL, V81, P6442, DOI 10.1073/pnas.81.20.6442; HOEFFLER JP, 1988, SCIENCE, V242, P1430, DOI 10.1126/science.2974179; HUANG FL, 1987, J BIOL CHEM, V262, P15714; HUANG K-P, 1990, Biofactors, V2, P171; HUANG KP, 1976, ANAL BIOCHEM, V72, P593, DOI 10.1016/0003-2697(76)90571-6; HUANG KP, 1986, J BIOL CHEM, V261, P4781; JOHNSON PF, 1987, GENE DEV, V1, P133, DOI 10.1101/gad.1.2.133; JOHNSON PF, 1989, ANNU REV BIOCHEM, V58, P799, DOI 10.1146/annurev.biochem.58.1.799; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KATAGIRI F, 1989, NATURE, V340, P727, DOI 10.1038/340727a0; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KITABAYASHI I, 1990, NUCLEIC ACIDS RES, V18, P3400, DOI 10.1093/nar/18.11.3400; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDSCHULZ WH, 1989, SCIENCE, V243, P1681, DOI 10.1126/science.2494700; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LANDSCHULZ WH, 1988, GENE DEV, V2, P786, DOI 10.1101/gad.2.7.786; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; MAHONEY CW, 1988, CELL FUNCTION DISEAS, P115; MAKI Y, 1987, P NATL ACAD SCI USA, V84, P2848, DOI 10.1073/pnas.84.9.2848; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MOHN KL, 1990, J BIOL CHEM, V265, P21914; MOYEROWLEY WS, 1989, GENE DEV, V3, P283, DOI 10.1101/gad.3.3.283; NAKABAYASHI H, 1988, J BIOL CHEM, V263, P298; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; NORMAN C, 1988, CELL, V55, P989, DOI 10.1016/0092-8674(88)90244-9; PALUH JL, 1988, P NATL ACAD SCI USA, V85, P3728, DOI 10.1073/pnas.85.11.3728; PEARSON RB, 1991, EUR J BIOCHEM, V200, P723, DOI 10.1111/j.1432-1033.1991.tb16237.x; ROGUE P, 1990, J BIOL CHEM, V265, P4161; ROSKOSKI R, 1983, METHOD ENZYMOL, V99, P3; SANTORO C, 1988, NATURE, V334, P218, DOI 10.1038/334218a0; SHARKEY NA, 1984, P NATL ACAD SCI-BIOL, V81, P607, DOI 10.1073/pnas.81.2.607; SHUMAN JD, 1990, SCIENCE, V249, P771, DOI 10.1126/science.2202050; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TABATA T, 1989, SCIENCE, V245, P965, DOI 10.1126/science.2772648; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; UMEK RM, 1991, SCIENCE, V251, P288, DOI 10.1126/science.1987644; VANSTRAATEN F, 1983, P NATL ACAD SCI-BIOL, V80, P3183; VINSON CR, 1989, SCIENCE, V246, P911, DOI 10.1126/science.2683088; WHITHAM SE, 1986, BIOCHEM J, V240, P913, DOI 10.1042/bj2400913; WHITING P, 1990, BIOCHEM J, V272, P465, DOI 10.1042/bj2720465; YAMAMOTO KK, 1988, NATURE, V334, P494, DOI 10.1038/334494a0; YOSHIDA Y, 1988, J BIOL CHEM, V263, P9868	52	112	113	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1992	267	27					19396	19403						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JP593	1527059				2022-12-25	WOS:A1992JP59300059
J	GABBARA, S; BHAGWAT, AS				GABBARA, S; BHAGWAT, AS			INTERACTION OF ECORII ENDONUCLEASE WITH DNA SUBSTRATES CONTAINING SINGLE RECOGNITION SITES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESTRICTION ENDONUCLEASE; INVIVO METHYLATION; REFRACTORY DNA; CLEAVAGE	EcoRII is unusual among type II restriction enzymes in that, while it cleaves substrates such as pBR322 and bacteriophage-lambda that contain several recognition sites for the enzyme efficiently, substrates such as the genomes of bacteriophages T3 and T7 which contain a small number of recognition sites are cut poorly by it. Interestingly, pBR322, or a short DNA duplex containing a single site for the enzyme, can activate the enzyme to cleave resistant substrates. We show here that, at low concentrations, activator short duplexes are themselves cleaved poorly by the enzyme. Further, the reaction shows substrate cooperativity, and at high concentrations, the duplexes are both activators and good substrates for the enzyme. This supports the model that the activation of EcoRII involves binding of more than one DNA molecule and provides a simple system to study the mechanism of activation. Using a gel mobility shift assay, we show that the enzyme forms sequence-specific, methylation-sensitive complexes with the duplexes in the absence of activating DNA. Therefore, resistance of the short duplexes to the enzyme at low concentrations cannot be due to an inability of the enzyme to bind the duplexes. Interestingly, these complexes are stable in the presence of Mg2+, the cofactor for the enzyme, and the complexes obtained in the presence of Mg2+ do not contain DNA that is cleaved by the enzyme. The inefficient step in the action of EcoRII on resistant substrates must occur subsequent to initial substrate binding and it is this step that the activating DNA must regulate.	WAYNE STATE UNIV,DEPT CHEM,DETROIT,MI 48202	Wayne State University			Bhagwat, Ashok/ABA-3861-2020; Bhagwat, Ashok/AAU-4186-2021	Bhagwat, Ashok/0000-0003-1188-0579	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040576] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM40576] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AIKEN C, 1988, NUCLEIC ACIDS RES, V16, P7901, DOI 10.1093/nar/16.16.7901; BHAGWAT AS, 1992, METHOD ENZYMOL, V216, P199; BROOKS JE, 1987, METHOD ENZYMOL, V152, P113; BROWN NL, 1977, P NATL ACAD SCI USA, V74, P3213, DOI 10.1073/pnas.74.8.3213; FLIESS A, 1988, NUCLEIC ACIDS RES, V16, P11781, DOI 10.1093/nar/16.24.11781; FORSBLOM S, 1976, NUCLEIC ACIDS RES, V3, P3255, DOI 10.1093/nar/3.12.3255; FUCHS R, 1983, METHOD ENZYMOL, V100, P3; GINGERAS TR, 1983, P NATL ACAD SCI-BIOL, V80, P402, DOI 10.1073/pnas.80.2.402; Hatfull GF, 1988, GENETIC RECOMBINATIO, P357; HATTMAN S, 1979, J VIROL, V32, P845, DOI 10.1128/JVI.32.3.845-851.1979; JACK WE, 1982, P NATL ACAD SCI-BIOL, V79, P4010, DOI 10.1073/pnas.79.13.4010; KRUGER DH, 1988, NUCLEIC ACIDS RES, V16, P3997; KUBAREVA EA, 1991, BIOCHIM BIOPHYS ACTA, V1088, P395, DOI 10.1016/0167-4781(91)90131-5; LANDY A, 1989, ANNU REV BIOCHEM, V58, P913, DOI 10.1146/annurev.biochem.58.1.913; Modrich P., 1982, NUCLEASES, P109; NARDONE G, 1987, RESTRICTION ENDONUCL, P147; NATH K, 1981, GENE AMPLIFICATION A, P113; OLLER AR, 1991, BIOCHEMISTRY-US, V30, P2543, DOI 10.1021/bi00223a035; PEIN CD, 1989, FEBS LETT, V245, P141, DOI 10.1016/0014-5793(89)80208-X; PEIN CD, 1991, NUCLEIC ACIDS RES, V19, P5139, DOI 10.1093/nar/19.19.5139; REUTER M, 1990, GENE, V95, P161, DOI 10.1016/0378-1119(90)90429-U; REVZIN A, 1986, ANAL BIOCHEM, V153, P172, DOI 10.1016/0003-2697(86)90077-1; SCHLAGMAN S, 1976, J BACTERIOL, V126, P990, DOI 10.1128/JB.126.2.990-996.1976; THOMAS M, 1975, J MOL BIOL, V91, P315, DOI 10.1016/0022-2836(75)90383-6; TOPAL MD, 1991, BIOCHEMISTRY-US, V30, P2006, DOI 10.1021/bi00221a038; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; WANG JC, 1985, ANNU REV BIOCHEM, V54, P665, DOI 10.1146/annurev.biochem.54.1.665	27	42	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1992	267	26					18623	18630						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JN502	1526995				2022-12-25	WOS:A1992JN50200058
J	NICHOLSON, DW; ALI, A; KLEMBA, MW; MUNDAY, NA; ZAMBONI, RJ; FORDHUTCHINSON, AW				NICHOLSON, DW; ALI, A; KLEMBA, MW; MUNDAY, NA; ZAMBONI, RJ; FORDHUTCHINSON, AW			HUMAN LEUKOTRIENE-C(4) SYNTHASE EXPRESSION IN DIMETHYL SULFOXIDE-DIFFERENTIATED U937 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUINEA-PIG LUNG; PARTIAL-PURIFICATION; GLUTATHIONE; PROTEIN; BIOSYNTHESIS; EICOSANOIDS; LEUKEMIA; MEMBRANE; RAT; IDENTIFICATION	Leukotriene C4 (LTC4) synthase was highly expressed in the human U937 monoblast leukemia cell line when differentiated into monocyte/macrophage-like cells by growth in the presence of dimethyl sulfoxide. The specific activity of LTC4 synthase in differentiated cells (399.0 +/- 84.1 pmol of LTC4 formed.min-1.mg-1) was markedly higher (10-fold; p < 0.001) than in undifferentiated U937 cells (39.9 +/- 16.7 pmol of LTC4 formed.min-1.mg-1) or freshly isolated blood monocytes (21.5 +/- 4.8 pmol of LTC4 formed.min-1.mg-1). The increase in LTC4 synthase activity following dimethyl sulfoxide-induced differentiation was substantially higher than the increase observed for other proteins involved in leukotriene biosynthesis. LTC4 synthase activity was unaffected in U937 cells differentiated by growth in the presence of phorbol 12-myristate 13-acetate. The HL-60 myeloblast leukemia cell line expressed higher LTC4 synthase levels when differentiated into either neutrophil-like or macrophage-like cells by growth in the presence of dimethyl sulfoxide or phorbol 12-myristate 13-acetate (respectively), but reached a specific activity comparable only to undifferentiated U937 cells. Human LTC4 synthase was found to be a unique membrane-bound enzymatic activity completely distinct from alpha, mu, pi, theta, and microsomal glutathione S-transferases, as determined by differential detergent solubilization, chromatographic separation, substrate specificity, and Western blot analysis. An 18-kDa polypeptide was specifically labeled in membranes from dimethyl sulfoxide-differentiated U937 cells using azido I-125-LTC4, a photoaffinity probe based on the product of the LTC4 synthase-catalyzed reaction. Photolabeling of the 18-kDa polypeptide was specifically competed for by LTC4 (>50% at 0.1-mu-M) but not by 100,000-fold higher concentrations of reduced glutathione (10 mM). Elevation of both the level of the specifically photolabeled 18-kDa polypeptide and of LTC4 synthase specific activity occurred concomitantly with dimethyl sulfoxide differentiation of U937 cells. We conclude that differentiation of U937 cells into monocyte/macrophage-like cells by growth in the presence of dimethyl sulfoxide results in high levels of expression of LTC4 synthase activity. Human LTC4 synthase is a unique enzyme with a high degree of specificity for LTA4 and may therefore be dedicated exclusively to the formation of LTC4 in vivo. An 18-kDa membrane polypeptide, specifically labeled by a photoaffinity derivative of LTC4, is a candidate for being either LTC4 synthase or a subunit thereof.	MERCK FROSST CTR THERAPEUT RES, DEPT MED CHEM, POINTE CLAIRE H9R 4P8, QUEBEC, CANADA; MCGILL UNIV, DEPT PHARMACOL & THERAPEUT, MONTREAL H3G 1Y6, QUEBEC, CANADA	Merck & Company; McGill University	NICHOLSON, DW (corresponding author), MERCK FROSST CTR THERAPEUT RES, DEPT PHARMACOL, POB 1005, POINTE CLAIRE H9R 4P8, QUEBEC, CANADA.							BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CARRIER DJ, 1988, PROSTAG LEUKOTR ESS, V34, P27, DOI 10.1016/0952-3278(88)90021-X; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; COLLINS SJ, 1977, NATURE, V270, P347, DOI 10.1038/270347a0; DIXON RAF, 1990, NATURE, V343, P282, DOI 10.1038/343282a0; FORDHUTCHINSON AW, 1991, TRENDS PHARMACOL SCI, V12, P68, DOI 10.1016/0165-6147(91)90500-R; FORDHUTCHINSON AW, 1990, CRIT REV IMMUNOL, V10, P1; GALLAGHER R, 1979, BLOOD, V54, P713; HABIG WH, 1974, J BIOL CHEM, V249, P7130; HARRIS P, 1985, J LEUKOCYTE BIOL, V37, P407, DOI 10.1002/jlb.37.4.407; ISHIKAWA T, 1990, J BIOL CHEM, V265, P19279; IZUMI T, 1989, ADV PROSTAG THROMB L, V19, P90; IZUMI T, 1988, BIOCHIM BIOPHYS ACTA, V959, P305; JI TH, 1982, ANAL BIOCHEM, V121, P286, DOI 10.1016/0003-2697(82)90481-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAGARDE M, 1989, BIOCHEM J, V257, P313, DOI 10.1042/bj2570313; LAM BK, 1989, J BIOL CHEM, V264, P12885; LEWIS RA, 1990, NEW ENGL J MED, V323, P645; MACLOUF J, 1989, PHARMACOL RES, V21, P1, DOI 10.1016/1043-6618(89)90115-1; MANCINI J, 1991, 11TH P INT WASH SPRI; MARCUS AJ, 1986, PROG HEMOST THROMB, V8, P127; MCLELLAN LI, 1989, BIOCHEM J, V258, P87, DOI 10.1042/bj2580087; MEYER DJ, 1991, BIOCHEM J, V274, P409, DOI 10.1042/bj2740409; MILLER DK, 1990, NATURE, V343, P278, DOI 10.1038/343278a0; MOSIALOU E, 1990, CHEM-BIOL INTERACT, V74, P275, DOI 10.1016/0009-2797(90)90044-N; PIPER PJ, 1984, PHYSIOL REV, V64, P744, DOI 10.1152/physrev.1984.64.2.744; ROUZER CA, 1990, J BIOL CHEM, V265, P1436; Samuelsson B, 1985, Adv Prostaglandin Thromboxane Leukot Res, V15, P1; SAMUELSSON B, 1983, SCIENCE, V220, P568, DOI 10.1126/science.6301011; SARAU HM, 1989, ADV PROSTAG THROMB L, V19, P180; SHARP JD, 1991, J BIOL CHEM, V266, P14850; SHIMIZU T, 1988, INT J BIOCHEM, V20, P661, DOI 10.1016/0020-711X(88)90160-7; SODERSTROM M, 1990, METHOD ENZYMOL, V187, P306; SUNDSTROM C, 1976, INT J CANCER, V17, P565, DOI 10.1002/ijc.2910170504; TATE SS, 1978, P NATL ACAD SCI USA, V75, P4806, DOI 10.1073/pnas.75.10.4806; TAYLOR GW, 1988, PROSTAG LEUKOTR ESS, V34, P51, DOI 10.1016/0952-3278(88)90025-7; WYNALDA MA, 1982, ANAL CHEM, V54, P1079, DOI 10.1021/ac00244a014; YOSHIMOTO T, 1988, J CLIN INVEST, V81, P866, DOI 10.1172/JCI113396; YOSHIMOTO T, 1985, P NATL ACAD SCI USA, V82, P8399, DOI 10.1073/pnas.82.24.8399	40	69	73	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 5	1992	267	25					17849	17857						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JM223	1517222				2022-12-25	WOS:A1992JM22300058
J	HEGNER, M; VONKIECKEBUSCHGUCK, A; FALCHETTO, R; JAMES, P; SEMENZA, G; MANTEI, N				HEGNER, M; VONKIECKEBUSCHGUCK, A; FALCHETTO, R; JAMES, P; SEMENZA, G; MANTEI, N			SINGLE AMINO-ACID SUBSTITUTIONS CAN CONVERT THE UNCLEAVED SIGNAL-ANCHOR OF SUCRASE-ISOMALTASE TO A CLEAVED SIGNAL SEQUENCE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CO-TRANSLATIONAL TRANSLOCATION; SITE-SPECIFIC MUTAGENESIS; DUPLEX DNA APPROACH; CHARGED RESIDUES; PROTEIN TRANSLOCATION; PHENOTYPIC SELECTION; SECRETORY PROTEIN; ESCHERICHIA-COLI; A-II; MEMBRANE	A hydrophobic segment near the amino terminus (positions 12-32) of rabbit sucrase-isomaltase functions both as a membrane anchor and as a signal sequence for translocation into the endoplasmic reticulum. Unlike most signal sequences, that of sucrase-isomaltase is not cleaved by signal peptidase. Using in vitro transcription and translation systems, we have found that substitution of a single proline, at position 28 or 29, converted the signal-anchor to a cleaved signal sequence, with cleavage occurring after alanine 26 and the introduced proline thereby occupying position +2 or +3 relative to the cleavage site. Two deletions that shorten the transmembrane domain by 8 amino acids were also effective, whereas various other changes upstream and downstream of this domain were without effect. We conclude that susceptibility to mammalian signal peptidase is influenced both by the length of the hydrophobic region and by the secondary structure downstream of the cleavage site.	SWISS FED INST TECHNOL,DEPT BIOCHEM,CH-8092 ZURICH,SWITZERLAND	ETH Zurich				Hegner, Martin/0000-0003-1514-3437				ANDREWS DW, 1988, J BIOL CHEM, V263, P15791; BELTZER JP, 1991, J BIOL CHEM, V266, P973; BELTZER JP, 1989, FEBS LETT, V253, P93, DOI 10.1016/0014-5793(89)80937-8; BOS TJ, 1984, P NATL ACAD SCI-BIOL, V81, P2327, DOI 10.1073/pnas.81.8.2327; BRIGGS MS, 1986, ADV PROTEIN CHEM, V38, P109, DOI 10.1016/S0065-3233(08)60527-6; BURGESS TL, 1987, J CELL BIOL, V105, P659, DOI 10.1083/jcb.105.2.659; CIOFFI JA, 1989, J BIOL CHEM, V264, P15052; DUFFAUD G, 1988, J BIOL CHEM, V263, P10224; FOLZ RJ, 1987, J BIOL CHEM, V262, P17221; FOLZ RJ, 1986, J BIOL CHEM, V261, P4752; FOLZ RJ, 1988, J BIOL CHEM, V263, P2070; GHERSA P, 1986, J BIOL CHEM, V261, P7969; HARTMANN E, 1989, P NATL ACAD SCI USA, V86, P5786, DOI 10.1073/pnas.86.15.5786; HONG WJ, 1990, J CELL BIOL, V111, P323, DOI 10.1083/jcb.111.2.323; HONG WJ, 1987, P NATL ACAD SCI USA, V84, P7962, DOI 10.1073/pnas.84.22.7962; HUNZIKER W, 1986, CELL, V46, P227, DOI 10.1016/0092-8674(86)90739-7; INOUYE S, 1986, J BIOL CHEM, V261, P970; JAGUS R, 1987, METHOD ENZYMOL, V152, P267; KRAMER W, 1984, NUCLEIC ACIDS RES, V12, P9441, DOI 10.1093/nar/12.24.9441; KRAMER W, 1988, NUCLEIC ACIDS RES, V16, P7207, DOI 10.1093/nar/16.14.7207; KRAMER W, 1987, METHOD ENZYMOL, V154, P360; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIPP J, 1986, CELL, V46, P1103, DOI 10.1016/0092-8674(86)90710-5; MELTON D, 1987, METHOD ENZYMOL, V4152, P288; MUMFORD RA, 1981, BIOCHEM BIOPH RES CO, V103, P565, DOI 10.1016/0006-291X(81)90489-7; NELSON RM, 1989, ANAL BIOCHEM, V180, P147, DOI 10.1016/0003-2697(89)90103-6; NOTHWEHR SF, 1990, J BIOL CHEM, V265, P21797; NOTHWEHR SF, 1989, J BIOL CHEM, V264, P3979; PARKS GD, 1991, CELL, V64, P777, DOI 10.1016/0092-8674(91)90507-U; PAYVAR F, 1979, J BIOL CHEM, V254, P7636; PERARA E, 1985, J CELL BIOL, V101, P2292, DOI 10.1083/jcb.101.6.2292; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHMID SR, 1988, J BIOL CHEM, V263, P16886; SIEGEL V, 1985, J CELL BIOL, V100, P1913, DOI 10.1083/jcb.100.6.1913; SPRIGGS MK, 1990, J CELL BIOL, V111, P31, DOI 10.1083/jcb.111.1.31; VLASUK GP, 1984, J BIOL CHEM, V259, P6195; VONHEIJNE G, 1984, EMBO J, V3, P2315, DOI 10.1002/j.1460-2075.1984.tb02132.x; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; VONHEIJNE G, 1983, EUR J BIOCHEM, V133, P17; VONHEIJNE G, 1986, J MOL BIOL, V189, P239, DOI 10.1016/0022-2836(86)90394-3; VONHEIJNE G, 1984, J MOL BIOL, V173, P243, DOI 10.1016/0022-2836(84)90192-X; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4; WALTER P, 1983, METHOD ENZYMOL, V96, P84; WALTER P, 1981, J CELL BIOL, V91, P545, DOI 10.1083/jcb.91.2.545; WATERS MG, 1988, J BIOL CHEM, V263, P6209; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; YAMAMOTO Y, 1989, BIOCHEMISTRY-US, V28, P2728, DOI 10.1021/bi00432a054	49	32	34	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1992	267	24					16928	16933						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JL053	1512234				2022-12-25	WOS:A1992JL05300033
J	SILVA, MM; ROGERS, PH; ARNONE, A				SILVA, MM; ROGERS, PH; ARNONE, A			A 3RD QUATERNARY STRUCTURE OF HUMAN HEMOGLOBIN-A AT 1.7-A-ANGSTROM RESOLUTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-MAGNETIC-RESONANCE; X-RAY; DEOXYHEMOGLOBIN; BINDING; COWTOWN; STEREOCHEMISTRY; ADULT	Previous crystallographic studies have shown that human hemoglobin A can adopt two stable quaternary structures, one for deoxyhemoglobin (the T-state) and one for liganded hemoglobin (the R-state). In this paper we report our finding of a second quaternary structure (the R2-state) for liganded hemoglobin A. The magnitudes of the spatial differences between the R- and R2-states are as large as those between the R- and T-states. Of particular interest are the structural changes that occur as a result of R-T and R-R2 transitions at the so-called "switch" region of the critical alpha-1-beta-2 interface. In the R-state, His-97-beta-2 is positioned between Thr-38-alpha-1 and Thr-41-alpha-1, whereas in transition to the T-state His 97-beta-2 must "jump" a turn in the alpha-1 C helix to form nonpolar contacts with Thr-41-alpha-1 and Pro-44-alpha-1. This facet of the R-T transition presents a major steric barrier to the quaternary structure change. In the R2-state, His-97-beta-2 simply rotates away from threonines 38-alpha-1 and 41-alpha-1, breaking contact with these residues and allowing water access to the center of the alpha-1-beta-2 interface. With the switch region in an open position in the R2-state, His-97-beta-2 should be able to move by Thr-41-alpha-1 and make the transition to the T-state with a steric barrier that is less than that for the R-T transition. Thus the R2-state may function as a stable intermediate along a R-R2-T pathway. The T-, R-, and R2-states must coexist in solution. That is, the fact that these states can be crystallized implies that they are all energetically accessible structures. What remains to be determined are the T-to-R, T-to-R2, and R-to-R2 equilibrium constants for hemoglobin under various solution conditions and ligation states. Although this may prove to be difficult, we discuss previously published results which indicate that low concentrations of inorganic anions or low pH may favor the R2-state and at least one alpha-1-beta-2 interface mutation stabilizes a quaternary structure that is very similar to the R2-state.	UNIV IOWA,DEPT BIOCHEM,4-470 BOWEN SCI BLDG,IOWA CITY,IA 52242	University of Iowa					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL040453] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040852] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-40453] Funding Source: Medline; NIGMS NIH HHS [GM-40852] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		[Anonymous], 1968, J CRYST GROWTH, DOI [rg/10.1016/00220248(68)900717, DOI 10.1016/0022-0248(68)90071-7]; BALDWIN J, 1979, J MOL BIOL, V129, P175, DOI 10.1016/0022-2836(79)90277-8; BUSCH MR, 1991, BIOCHEMISTRY-US, V30, P1865, DOI 10.1021/bi00221a020; CAMBILLAU C, 1989, SILICON GRAPHICS GEO, P69; COX JM, 1967, J MOL BIOL, V28, P151, DOI 10.1016/S0022-2836(67)80083-4; DEREWENDA Z, 1990, J MOL BIOL, V211, P515, DOI 10.1016/0022-2836(90)90262-K; FANTL WJ, 1987, J BIOL CHEM, V262, P12700; FERMI G, 1984, J MOL BIOL, V175, P159, DOI 10.1016/0022-2836(84)90472-8; FITZGERALD PMD, 1988, J APPL CRYSTALLOGR, V21, P273, DOI 10.1107/S0021889887012299; GREEN DW, 1954, PROC R SOC LON SER-A, V225, P287, DOI 10.1098/rspa.1954.0203; HENDRICKSON WA, 1985, METHOD ENZYMOL, V115, P252; JONES TA, 1985, METHOD ENZYMOL, V115, P157; KABSCH W, 1976, ACTA CRYSTALLOGR A, V32, P922, DOI 10.1107/S0567739476001873; KAMINAKA S, 1992, J AM CHEM SOC, V114, P3256, DOI 10.1021/ja00035a015; KAVANAUGH JS, 1992, BIOCHEMISTRY-US, V31, P4111, DOI 10.1021/bi00131a030; KILMARTIN JV, 1977, TRENDS BIOCHEM SCI, V2, P247, DOI 10.1016/0968-0004(77)90214-6; KILMARTIN JV, 1973, P NATL ACAD SCI USA, V70, P1246, DOI 10.1073/pnas.70.4.1246; LADNER RC, 1977, J MOL BIOL, V114, P385, DOI 10.1016/0022-2836(77)90256-X; MONOD J, 1965, J MOL BIOL, V12, P88, DOI 10.1016/S0022-2836(65)80285-6; MUIRHEAD H, 1967, J MOL BIOL, V28, P117, DOI 10.1016/S0022-2836(67)80082-2; ODONNELL S, 1979, J BIOL CHEM, V254, P2204; PERUTZ MF, 1970, NATURE, V228, P726, DOI 10.1038/228726a0; PERUTZ MF, 1984, P NATL ACAD SCI-BIOL, V81, P4781, DOI 10.1073/pnas.81.15.4781; PERUTZ MF, 1968, NATURE, V219, P131, DOI 10.1038/219131a0; PERUTZ MF, 1946, T FARADAY SOC      B, V42, P187; PETTIGREW DW, 1982, P NATL ACAD SCI-BIOL, V79, P1849, DOI 10.1073/pnas.79.6.1849; RIGGS AF, 1988, ANNU REV PHYSIOL, V50, P181, DOI 10.1146/annurev.ph.50.030188.001145; ROSSMANN MG, 1990, ACTA CRYSTALLOGR A, V46, P73, DOI 10.1107/S0108767389009815; RUSSU IM, 1989, BIOCHEMISTRY-US, V28, P5298, DOI 10.1021/bi00438a057; SAWICKI CA, 1976, J BIOL CHEM, V251, P1533; SHAANAN B, 1983, J MOL BIOL, V171, P31, DOI 10.1016/S0022-2836(83)80313-1; SHIH DTB, 1987, J MOL BIOL, V195, P419, DOI 10.1016/0022-2836(87)90660-7; SMITH FR, 1991, PROTEINS, V10, P81, DOI 10.1002/prot.340100202; TURNER GJ, 1989, THESIS J HOPKINS U; WARD KB, 1975, J MOL BIOL, V98, P161, DOI 10.1016/S0022-2836(75)80107-0; WLODAWER A, 1975, P NATL ACAD SCI USA, V72, P398, DOI 10.1073/pnas.72.1.398	36	263	266	1	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1992	267	24					17248	17256						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JL053	1512262				2022-12-25	WOS:A1992JL05300079
J	YUSA, K; OHHARA, T; TSUKAHARA, S; TSURUO, T				YUSA, K; OHHARA, T; TSUKAHARA, S; TSURUO, T			HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 INDUCES 1-BETA-D-ARABINOFURANOSYLCYTOSINE RESISTANCE IN HUMAN H9-CELL LINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELLS; PURIFICATION; INFECTION; ASSAY	We have found that chronically HIV-1(IIIB)-infected H9 cells showed 21-fold resistance to 1-beta-D-arabinofuranosylcytosine (ARA-C) compared with uninfected H9 cells. In the infected H9 cells, a 37% increase of dCTP pool and a 34% increase of dATP were observed, and no alteration of dTTP and dGTP was observed, compared with the uninfected H9 cells. A marked decrease of ARA-CTP generation was observed in the infected H9 cells after 3-h incubation with 0.1-10-mu-M ARA-C. The level of deoxycytidine kinase activity with ARA-C as substrate was similar in both the infected and the uninfected cells; however, a 37-fold increase of cytidine deaminase activity was observed in the infected H9 cells. These results indicate that the induction of cytidine deaminase activity by HIV-1(IIIB) infection conferred ARA-C resistance to H9 cells. This conclusion was supported by the observation that a marked reversal of ARA-C resistance in the infected H9 cells occurred after treatment with the inhibitor of cytidine deaminase, 3,4,5,6-tetrahydrouridine. The understanding of these cellular alterations in drug sensitivity may facilitate the development of effective therapeutic strategies against HIV-1-infected cells.	JAPANESE FDN CANC RES, CTR CANC CHEMOTHERAPY, 1-37-1 KAMI IKEBUKURO, TOSHIMA KU, TOKYO 170, JAPAN; UNIV TOKYO, INST APPL MICROBIOL, BUNKYO KU, TOKYO 113, JAPAN	Japanese Foundation for Cancer Research; University of Tokyo								CHABNER BA, 1974, J CLIN INVEST, V53, P922, DOI 10.1172/JCI107633; CHENG YC, 1977, BIOCHIM BIOPHYS ACTA, V481, P481, DOI 10.1016/0005-2744(77)90281-9; GARRETT C, 1979, ANAL BIOCHEM, V99, P268, DOI 10.1016/S0003-2697(79)80005-6; GARTNER S, 1986, SCIENCE, V233, P215, DOI 10.1126/science.3014648; HORI K, 1984, CANCER RES, V44, P172; KOENIG S, 1986, SCIENCE, V233, P1089, DOI 10.1126/science.3016903; LANGHOFF E, 1991, P NATL ACAD SCI USA, V88, P7998, DOI 10.1073/pnas.88.18.7998; LEVY JA, 1985, VIROLOGY, V147, P441, DOI 10.1016/0042-6822(85)90146-1; MACATONIA SE, 1990, IMMUNOLOGY, V71, P38; MANN DL, 1989, AIDS RES HUM RETROV, V5, P253, DOI 10.1089/aid.1989.5.253; MCELRATH MJ, 1989, P NATL ACAD SCI USA, V86, P675, DOI 10.1073/pnas.86.2.675; MITSUYA H, 1990, SCIENCE, V249, P1533, DOI 10.1126/science.1699273; MOMPARLER RL, 1968, J BIOL CHEM, V243, P4298; POPOVIC M, 1984, SCIENCE, V224, P497, DOI 10.1126/science.6200935; ROSENBERG ZF, 1989, ADV IMMUNOL, V47, P377; SCHNITTMAN SM, 1989, SCIENCE, V245, P305, DOI 10.1126/science.2665081; TSURUO T, 1979, CANCER RES, V39, P1063; WEISLOW OS, 1989, JNCI-J NATL CANCER I, V81, P577, DOI 10.1093/jnci/81.8.577; YUSA K, 1989, CANCER RES, V49, P5002	19	19	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	1992	267	24					16848	16850						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JL053	1512227				2022-12-25	WOS:A1992JL05300021
J	FERREIRA, GC; PEDERSEN, PL				FERREIRA, GC; PEDERSEN, PL			OVEREXPRESSION OF HIGHER EUKARYOTIC MEMBRANE-PROTEINS IN BACTERIA - NOVEL INSIGHTS OBTAINED WITH THE LIVER MITOCHONDRIAL PROTON PHOSPHATE SYMPORTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACULOVIRUS EXPRESSION SYSTEM; HEAT-SHOCK RESPONSE; ESCHERICHIA-COLI; AFFECTS PROTEOLYSIS; ATP SYNTHASE; TRANSPORT; GENE; CDNA; PURIFICATION; SEQUENCE	In order to better understand why higher eukaryotic membrane proteins, in contrast to soluble proteins, are not readily expressed in Escherichia coli, the gene encoding the liver mitochondrial phosphate transporter (H+/P(i) symporter) (Ferreira, G. C., Pratt, R. D., and Pedersen, P. L. (1989) J. Biol. Chem. 264, 15628-15633), was subcloned into a plasmid (pFOG402) containing the alkaline phosphatase promoter and leader sequence. Although this system is highly efficient in overexpressing soluble mitochondrial proteins in E. coli, e.g. alpha and beta-subunits of the liver ATP synthase, it fails to express the H+/P(i) transporter. Expression is not obtained by truncation of the transporter gene from either the 3' or 5' end, by fusing the mature transporter gene to genes encoding either the alpha or beta-ATP synthase subunits, or by using different expression plasmids. Significantly, the H+/P(i) transporter is overexpressed in E. coli provided its cDNA is first truncated at the 3' end (carboxyl-terminal end) and fused to a cDNA fragment derived from the ATP synthase alpha-subunit gene. In fact, progressive deletions from the 3' end of the transporter cDNA produce a ladder of increasingly overexpressed fusion proteins which account from the largest to the smallest for approximately 2.5-14% of the total bacterial cell protein. The minimal truncation necessary from the 3' end is 192 base pairs corresponding to 64 COOH-terminal amino acids. This corresponds to 20% of the transporter and involves removal of one of the six predicted membrane-spanning segments. In a variety of additional experiments designed to define the molecular basis for E. coli's inability to express the complete liver H+/P(i) transporter, problems related to cell toxicity and transcription were ruled out. However, in vitro transcription-translation assays revealed that the complete transporter is readily expressed when eukaryotic, but not prokaryotic, ribosomes are present. Significantly, the fused transporter gene (i.e. P(i) transporter cDNA truncated at the 3' end + ATP synthase alpha-subunit cDNA) is expressed when prokaryotic ribosomes are present. These results support the view that the difficulty in expressing higher eukaryotic membrane proteins in bacteria may be related in some cases to a problem at the level of translation.	JOHNS HOPKINS UNIV,SCH MED,DEPT BIOL CHEM,MOLEC & CELLULAR BIOENERGET LAB,BALTIMORE,MD 21205	Johns Hopkins University			Ferreira, Gloria C/A-4709-2012	Ferreira, Gloria C/0000-0001-9279-2217				ARORA KK, 1990, J BIOL CHEM, V265, P6481; BAKER TA, 1984, P NATL ACAD SCI-BIOL, V81, P6779, DOI 10.1073/pnas.81.21.6779; BUCHELER US, 1990, GENE, V96, P271, DOI 10.1016/0378-1119(90)90263-Q; COTY WA, 1974, J BIOL CHEM, V249, P2593; DOMINGO DL, 1988, J BIOL CHEM, V263, P13386; EMR SD, 1981, CELL, V23, P79, DOI 10.1016/0092-8674(81)90272-5; FERREIRA GC, 1989, J BIOL CHEM, V264, P15628; GARBOCZI DN, 1988, J BIOL CHEM, V263, P15694; GUTMAN GA, 1989, P NATL ACAD SCI USA, V86, P3699, DOI 10.1073/pnas.86.10.3699; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HERRERA R, 1988, J BIOL CHEM, V263, P5560; HOHEISEL J, 1986, NUCLEIC ACIDS RES, V14, P3605, DOI 10.1093/nar/14.8.3605; KAPLAN RS, 1986, J BIOL CHEM, V261, P2767; KARNIK SS, 1987, J BIOL CHEM, V262, P9255; KOLBE HVJ, 1984, J BIOL CHEM, V259, P9115; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE JH, 1990, J BIOL CHEM, V265, P4664; Maniatis T., 1982, MOL CLONING; MILTON DL, 1986, J BIOL CHEM, V261, P6604; MOTT JE, 1985, P NATL ACAD SCI USA, V82, P88, DOI 10.1073/pnas.82.1.88; PAGE MJ, 1989, J BIOL CHEM, V264, P19147; PARKER EM, 1991, J BIOL CHEM, V266, P9987; PRATT RD, 1991, J BIOL CHEM, V266, P1276; RUNSWICK MJ, 1990, BIOCHEMISTRY-US, V29, P11033, DOI 10.1021/bi00502a004; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARKAR HK, 1988, P NATL ACAD SCI USA, V85, P5463, DOI 10.1073/pnas.85.15.5463; SHORTLE D, 1986, J CELL BIOCHEM, V30, P281, DOI 10.1002/jcb.240300402; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TAGLICHT D, 1991, J BIOL CHEM, V266, P11289; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VISSAVAJJHALA P, 1990, J BIOL CHEM, V265, P4746; WEHRLE JP, 1989, J MEMBRANE BIOL, V111, P199, DOI 10.1007/BF01871006; ZUBAY G, 1973, ANNU REV GENET, V7, P267, DOI 10.1146/annurev.ge.07.120173.001411	34	22	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1992	267	8					5460	5466						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HH747	1531983				2022-12-25	WOS:A1992HH74700070
J	KLIONSKY, DJ; NELSON, H; NELSON, N				KLIONSKY, DJ; NELSON, H; NELSON, N			COMPARTMENT ACIDIFICATION IS REQUIRED FOR EFFICIENT SORTING OF PROTEINS TO THE VACUOLE IN SACCHAROMYCES-CEREVISIAE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							H+-ATPASE; ADENOSINE-TRIPHOSPHATASE; TRANSLOCATING ATPASE; MOLECULAR-STRUCTURE; YEAST MUTANTS; GENE; SUBUNIT; BIOGENESIS; ACTIVATION; BIOSYNTHESIS	The vacuole of the yeast Saccharomyces cerevisiae contains a proton-translocating ATPase that acidifies the vacuolar lumen and generates a pH gradient across the vacuole membrane. We have investigated the role of compartment acidification of the vacuolar system in the sorting of vacuolar proteins. Strains with chromosomal disruptions of the genes encoding the A, B, or c subunit of the vacuolar ATPase are unable to acidify their vacuoles. These vat mutant strains accumulate and secrete precursor forms of the soluble vacuolar hydrolases carboxypeptidase Y and proteinase A. The kinetics of secretion suggests that missorting occurs in the Golgi complex or in post-Golgi vesicles. The presence of mature forms of the vacuolar proteins within the cell indicates that vat mutations do not cause defects in zymogen processing. Precursor forms of the membrane-associated vacuolar hydrolase alkaline phosphatase are also accumulated in vat mutant cells but to a lesser extent, suggesting that sorting of vacuolar membrane proteins is less sensitive to changes in the lumenal pH. A similar type of missorting defect can be induced in wild-type cells at pH 7.5. These results indicate that acidification of the vacuolar system is important for efficient sorting of proteins to the vacuole.	ROCHE INST MOLEC BIOL,ROCHE RES CTR,NUTLEY,NJ 07110	Roche Holding	KLIONSKY, DJ (corresponding author), UNIV CALIF DAVIS,DEPT MICROBIOL,DAVIS,CA 95616, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043684] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK43684] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BANTA LM, 1990, MOL CELL BIOL, V10, P4638, DOI 10.1128/MCB.10.9.4638; BANTA LM, 1988, J CELL BIOL, V107, P1369, DOI 10.1083/jcb.107.4.1369; BEDWELL DM, 1987, MOL CELL BIOL, V7, P4038, DOI 10.1128/MCB.7.11.4038; BOWMAN EJ, 1988, P NATL ACAD SCI USA, V85, P7972, DOI 10.1073/pnas.85.21.7972; DODYK F, 1964, ARCH BIOCHEM BIOPHYS, V104, P478, DOI 10.1016/0003-9861(64)90492-8; DOUGLAS MG, 1986, MICROBIOL REV, V50, P166, DOI 10.1128/MMBR.50.2.166-178.1986; GRIFFITHS G, 1986, SCIENCE, V234, P438, DOI 10.1126/science.2945253; HASILIK A, 1982, EUR J BIOCHEM, V125, P317, DOI 10.1111/j.1432-1033.1982.tb06685.x; HERMAN PK, 1991, CELL, V64, P425, DOI 10.1016/0092-8674(91)90650-N; HIRATA R, 1990, J BIOL CHEM, V265, P6726; JAMES MNG, 1986, NATURE, V319, P33, DOI 10.1038/319033a0; JOHNSON LM, 1987, CELL, V48, P875, DOI 10.1016/0092-8674(87)90084-5; KANE PM, 1990, SCIENCE, V250, P651, DOI 10.1126/science.2146742; KANE PM, 1989, J BIOL CHEM, V264, P19236; KLIONSKY DJ, 1989, EMBO J, V8, P2241, DOI 10.1002/j.1460-2075.1989.tb08348.x; KLIONSKY DJ, 1990, J BIOL CHEM, V265, P5349; KLIONSKY DJ, 1988, MOL CELL BIOL, V8, P2105, DOI 10.1128/MCB.8.5.2105; KLIONSKY DJ, 1990, MICROBIOL REV, V54, P266, DOI 10.1128/MMBR.54.3.266-292.1990; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; MECHLER B, 1987, EMBO J, V6, P2157, DOI 10.1002/j.1460-2075.1987.tb02483.x; MELLMAN I, 1986, ANNU REV BIOCHEM, V55, P663, DOI 10.1146/annurev.biochem.55.1.663; MORIYAMA Y, 1989, J BIOL CHEM, V264, P18445; MORIYAMA Y, 1989, J BIOL CHEM, V264, P3577; NELSON H, 1989, FEBS LETT, V247, P147, DOI 10.1016/0014-5793(89)81259-1; NELSON H, 1989, J BIOL CHEM, V264, P1775; NELSON H, 1990, P NATL ACAD SCI USA, V87, P3503, DOI 10.1073/pnas.87.9.3503; NOUMI T, 1991, P NATL ACAD SCI USA, V88, P1938, DOI 10.1073/pnas.88.5.1938; PRESTON RA, 1989, P NATL ACAD SCI USA, V86, P7027, DOI 10.1073/pnas.86.18.7027; RAYMOND CK, 1990, J CELL BIOL, V111, P877, DOI 10.1083/jcb.111.3.877; ROBERTS CJ, 1989, J CELL BIOL, V108, P1363, DOI 10.1083/jcb.108.4.1363; ROBINSON JS, 1988, MOL CELL BIOL, V8, P4936, DOI 10.1128/MCB.8.11.4936; ROTHMAN JH, 1989, J CELL BIOL, V109, P93, DOI 10.1083/jcb.109.1.93; SHIH CK, 1988, MOL CELL BIOL, V8, P3094, DOI 10.1128/MCB.8.8.3094; UCHIDA E, 1985, J BIOL CHEM, V260, P1090; WOOLFORD CA, 1986, MOL CELL BIOL, V6, P2500, DOI 10.1128/MCB.6.7.2500; YAMASHIRO CT, 1990, MOL CELL BIOL, V10, P3737, DOI 10.1128/MCB.10.7.3737; YOSHIHISA T, 1990, J BIOL CHEM, V265, P22418	37	71	71	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 15	1992	267	5					3416	3422						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HD154	1531340				2022-12-25	WOS:A1992HD15400092
J	KRAUSE, SM; JACOBUS, WE				KRAUSE, SM; JACOBUS, WE			SPECIFIC ENHANCEMENT OF THE CARDIAC MYOFIBRILLAR ATPASE BY BOUND CREATINE-KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENERGY PHOSPHATE-METABOLISM; RAT-HEART MITOCHONDRIA; M-LINE PROTEIN; SARCOPLASMIC-RETICULUM; SKELETAL-MUSCLE; OXIDATIVE-PHOSPHORYLATION; KINETIC-PROPERTIES; RIGOR TENSION; PHOSPHOCREATINE; PHOSPHOKINASE	The kinetic influence of bound creatine kinase (CK) on the Ca2+-activated myosin ATPase was evaluated. ATPase rates were measured from 0.8-mu-M to 3.2 mM MgATP. Under control conditions, the apparent K(mATP) was 79.9 +/- 13.3-mu-M. In contrast, the addition of 12.2 mm phosphocreatine (PCr) decreased the apparent K(mATP) to a value of 13.6 +/- 1.4-mu-M. To determine if this reduction was merely the result of an ATP maintenance system, ATP was regenerated using either phosphoenolpyruvate and pyruvate kinase (PEP-PK), or PCr and soluble bovine cardiac CK. Data obtained with PEP + PK indicated an apparent K(mATP) of 65.5 +/- 7.3-mu-M. To study the effects of exogenous CK, the endogenous CK was irreversibly inhibited with 1 mM iodoacetamide. The kinetics of the ATPase were then examined by adding soluble CK to the incubation medium. Under these conditions, the K(mATP) was 56.4 +/- 0.86-mu-M. Therefore, these two ATP regeneration systems could not duplicate the effects of endogenous CK. The reduction of the apparent K(mATP) by endogenous CK was not the result of an altered inhibition by MgADP. MgADP inhibition was determined to be noncompetitive, with a K(i) of 5.0 +/- 0.1 mM. These data suggest that the observed kinetic effects reflect the proximity of the enzymes in the myofibrillar bundle, thus emphasizing the importance of bound CK for the localized regeneration of MgATP utilized by the myosin ATPase.	JOHNS HOPKINS UNIV, SCH MED, DEPT MED, PETER BELFER LAB MYOCARDIAL RES, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT BIOL CHEM, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT ANESTHESIOL & CRIT CARE MED, BALTIMORE, MD 21205 USA; THOMAS JEFFERSON UNIV, JEFFERSON MED COLL, DEPT PHYSIOL, PHILADELPHIA, PA 19107 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Jefferson University					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL033592, P50HL017655] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-33592, HL-20658, P50 HL-17655] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		[Anonymous], CELL MUSCLE MOTILITY; BASKIN RJ, 1970, J BIOL CHEM, V245, P1345; BASSON CT, 1985, MOL CELL BIOCHEM, V67, P151, DOI 10.1007/BF02370174; BESSMAN SP, 1980, BIOCHEM BIOPH RES CO, V96, P1414, DOI 10.1016/0006-291X(80)90108-4; BESSMAN SP, 1981, SCIENCE, V211, P448, DOI 10.1126/science.6450446; Eggleton P, 1943, BIOCHEM J, V37, P526, DOI 10.1042/bj0370526; FABIATO A, 1981, J GEN PHYSIOL, V78, P457, DOI 10.1085/jgp.78.5.457; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P457; GUDBJARNASON S, 1970, Journal of Molecular and Cellular Cardiology, V1, P325; HESS ML, 1981, J MOL CELL CARDIOL, V13, P715, DOI 10.1016/0022-2828(81)90254-6; JACOBS H, 1964, BIOCHEM BIOPH RES CO, V16, P516, DOI 10.1016/0006-291X(64)90185-8; JACOBUS WE, 1985, BIOCHEM BIOPH RES CO, V133, P1035, DOI 10.1016/0006-291X(85)91240-9; JACOBUS WE, 1973, J BIOL CHEM, V248, P4803; JACOBUS WE, 1982, ARCH BIOCHEM BIOPHYS, V219, P167, DOI 10.1016/0003-9861(82)90146-1; JACOBUS WE, 1985, ANNU REV PHYSIOL, V47, P707; JACOBUS WE, 1986, J BIOL CHEM, V261, P6579; KRAUSE SM, 1986, BIOPHYS J, V49, pA248; KRAUSE SM, 1986, CIRCULATION, V74, P432; KRAUSE SM, 1985, CIRCULATION, V72, P335; LAMPRECHT W, 1974, METHOD ENZYMAT AN, V4, P2101; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MANI RS, 1980, INT J BIOCHEM, V12, P333, DOI 10.1016/0020-711X(80)90111-1; MANI RS, 1976, BIOCHIM BIOPHYS ACTA, V453, P391, DOI 10.1016/0005-2795(76)90134-3; MCCLELLAN G, 1983, AM J PHYSIOL, V245, pC423, DOI 10.1152/ajpcell.1983.245.5.C423; MEYER RA, 1984, AM J PHYSIOL, V246, pC365, DOI 10.1152/ajpcell.1984.246.5.C365; MOREADITH RW, 1982, J BIOL CHEM, V257, P899; MORIMOTO K, 1972, J BIOL CHEM, V247, P3052; PAGE A, 1987, COMPUT APPL BIOSCI, V3, P49; PENNEY CL, 1976, ANAL BIOCHEM, V75, P201, DOI 10.1016/0003-2697(76)90071-3; ROSSI AM, 1990, J BIOL CHEM, V265, P5258; SAKS VA, 1976, FEBS LETT, V62, P293, DOI 10.1016/0014-5793(76)80078-6; SAKS VA, 1985, J BIOL CHEM, V260, P7757; SAKS VA, 1984, BIOCHIM BIOPHYS ACTA, V803, P254, DOI 10.1016/0167-4889(84)90115-0; SAKS VA, 1978, CAN J PHYSIOL PHARM, V56, P691, DOI 10.1139/y78-113; Segel I.H., 1975, ENZYME KINETICS BEHA, Vsecond, P100; SMITH RM, 1956, J AM CHEM SOC, V78, P2376, DOI 10.1021/ja01592a009; SMITH RM, 1956, J PHYS CHEM-US, V60, P180, DOI 10.1021/j150536a010; SOLARO RJ, 1971, BIOCHIM BIOPHYS ACTA, V245, P259, DOI 10.1016/0005-2728(71)90033-8; TSIEN RY, 1980, BIOCHEMISTRY-US, V19, P2396, DOI 10.1021/bi00552a018; TURNER DC, 1973, P NATL ACAD SCI USA, V70, P702, DOI 10.1073/pnas.70.3.702; VEKSLER VI, 1984, BIOCHIM BIOPHYS ACTA, V803, P265, DOI 10.1016/0167-4889(84)90116-2; VENTURACLAPIER R, 1985, PFLUG ARCH EUR J PHY, V404, P157, DOI 10.1007/BF00585412; WALLIMANN T, 1983, J CELL BIOL, V96, P1772, DOI 10.1083/jcb.96.6.1772; WATTS DC, 1962, BIOCHEM J, V85, P507, DOI 10.1042/bj0850507; ZWEIER JL, 1987, J BIOL CHEM, V262, P8015	45	49	51	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 5	1992	267	4					2480	2486						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HB532	1531142				2022-12-25	WOS:A1992HB53200057
J	SCHUURING, E; VERHOEVEN, E; MOOI, WJ; MICHALIDES, RJAM				SCHUURING, E; VERHOEVEN, E; MOOI, WJ; MICHALIDES, RJAM			IDENTIFICATION AND CLONING OF 2 OVEREXPRESSED GENES, U21B31/PRAD1 AND EMS1, WITHIN THE AMPLIFIED CHROMOSOME 11Q13 REGION IN HUMAN CARCINOMAS	ONCOGENE			English	Article							SQUAMOUS-CELL CARCINOMAS; PROTO-ONCOGENE; BREAST-CANCER; FREQUENT AMPLIFICATION; MOLECULAR-CLONING; ESCHERICHIA-COLI; HUMAN-TUMORS; BCL-1 LOCUS; INT-2 GENE; 5 GENES	Amplification of the chromosome 11q13 region is frequently found in human breast cancer and in squamous cell carcinomas of the head and neck, and has been associated with an unfavourable clinical course of disease. The known oncogenes within the amplified 11q13 region, INT2 and HSTF1, are rarely expressed in these tumours, indicating that another, hitherto unidentified, gene or genes confer(s) the biological (prognostic) significance to the amplification of the 11q13 region. To identify the gene or genes, we have constructed a cDNA library from a cell line with an 11q13 amplification and have performed differential cDNA cloning using [P-32]dCTP-labelled cDNAs from human squamous cell carcinoma cell lines with and without an 11q13 amplification. We isolated two cDNA clones, U21B31 and U21C8, which recognize two genes amplified and overexpressed in cell lines harbouring an 11q13 amplification. In breast carcinomas and in squamous cell carcinomas amplification of both the U21B31 and the U21C8 gene was found in most tumours with an amplification of the 11q13 region, despite the large distance between both genes. Sequence analysis of the U21C8 cDNA clone revealed no homology to known genes; we call this gene EMS1. The U21B31 cDNA clone corresponded to the 3' end of the PRAD1 proto-oncogene, recently cloned from a parathyroid adenoma. Both gene products are of interest as potential markers to identify tumours with an 11q13 amplification.	NETHERLANDS CANC INST, DIV TUMOR BIOL, 1066 CX AMSTERDAM, NETHERLANDS	Netherlands Cancer Institute								ADNANE J, 1989, ONCOGENE, V4, P1389; ARNOLD A, 1989, J CLIN INVEST, V83, P2034, DOI 10.1172/JCI114114; AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; BERENSON JR, 1989, ONCOGENE, V4, P1111; BERENSON JR, 1990, ONCOGENE, V5, P1343; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; BORG A, 1991, BRIT J CANCER, V63, P136, DOI 10.1038/bjc.1991.28; BUSSEMAKERS MJG, 1991, CANCER RES, V51, P606; CASEY G, 1986, MOL CELL BIOL, V6, P502, DOI 10.1128/MCB.6.2.502; DEBRUIJN MHL, 1986, MOL CELL BIOL, V6, P4717, DOI 10.1128/MCB.6.12.4717; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FANTL V, 1990, EUR J CANCER, V26, P423, DOI 10.1016/0277-5379(90)90009-I; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HANAHAN D, 1980, GENE, V10, P63, DOI 10.1016/0378-1119(80)90144-4; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; JIN YH, 1990, GENE CHROMOSOME CANC, V2, P198, DOI 10.1002/gcc.2870020306; KITAGAWA Y, 1991, CANCER RES, V51, P1504; KODURU PRK, 1989, ONCOGENE, V4, P929; LAMMIE GA, 1991, ONCOGENE, V6, P439; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LIDEREAU R, 1988, ONCOGENE RES, V2, P285; LISCIA DS, 1989, ONCOGENE, V4, P1219; LITTLE CD, 1983, NATURE, V306, P194, DOI 10.1038/306194a0; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MEDEIROS LJ, 1990, BLOOD, V76, P2086; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; NAU MM, 1985, NATURE, V318, P69, DOI 10.1038/318069a0; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PROCTOR AJ, 1991, ONCOGENE, V6, P789; RABBITTS PH, 1988, ONCOGENE, V3, P99; ROSENBERG CL, 1991, ONCOGENE, V6, P449; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHWAB M, 1983, NATURE, V305, P245, DOI 10.1038/305245a0; SCHWAB M, 1990, GENE CHROMOSOME CANC, V1, P181, DOI 10.1002/gcc.2870010302; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SOMERS KD, 1990, ONCOGENE, V5, P915; STOW MW, 1991, BIOCHIM BIOPHYS ACTA, V1092, P7, DOI 10.1016/0167-4889(91)90171-S; THEILLET C, 1989, ONCOGENE, V4, P915; TSUDA H, 1989, CANCER RES, V49, P3104; TSUDA T, 1989, CANCER RES, V49, P5505; TSUJIMOTO Y, 1984, SCIENCE, V224, P1403, DOI 10.1126/science.6610211; TSUJIMOTO Y, 1985, NATURE, V315, P340, DOI 10.1038/315340a0; VANDERBLIEK AM, 1986, MOL CELL BIOL, V6, P1671, DOI 10.1128/MCB.6.5.1671; VANDEVIJVER M, 1987, MOL CELL BIOL, V7, P2019, DOI 10.1128/MCB.7.5.2019; VANLOHUIZEN M, 1991, CELL, V65, P737, DOI 10.1016/0092-8674(91)90382-9; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D	49	346	356	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	1992	7	2					355	361						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HG982	1532244				2022-12-25	WOS:A1992HG98200022
J	HOROWITZ, A; TRYBUS, KM				HOROWITZ, A; TRYBUS, KM			INHIBITION OF SMOOTH-MUSCLE MYOSINS ACTIVITY AND ASSEMBLY BY AN ANTIROD MONOCLONAL-ANTIBODY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED ATPASE ACTIVITY; HEAVY-CHAIN PHOSPHORYLATION; DICTYOSTELIUM MYOSIN; REVERSIBLE PHOSPHORYLATION; CONFORMATIONAL STATES; PROTEOLYTIC REMOVAL; SLIDING MOVEMENT; ACTIN FILAMENT; MEROMYOSIN; INVITRO	Monoclonal antibodies specific for the rod region can affect smooth muscle myosin's motor properties. Actin movement by phosphorylated myosin was inhibited by an antibody (LMM.4) which binds to the COOH-terminal end of the coiled-coil rod, a region thought to be involved in filament assembly. The actin-activated ATPase activity of the myosin-antibody LMM.4 complex was also reduced 10-fold at actin concentrations that gave maximal turnover rates with filamentous myosin. Metal-shadowing of the phosphorylated myosin-antibody complex at low ionic strength showed small bundles of parallel extended molecules, instead of filaments. Five other anti-rod antibodies had little or no effect on myosin's ability to act as a motor. This is the first demonstration that a muscle myosin's activity is affected by its state of assembly. A common theme that emerges from the studies on both muscle and non-muscle myosins is that assembly into a filamentous structure stimulates the activity of the individual myosin molecules.			HOROWITZ, A (corresponding author), BRANDEIS UNIV, ROSENSTIEL BASIC MED SCI RES CTR, WALTHAM, MA 02254 USA.		Horowitz, Arie/AAT-9482-2021; Horowitz, Arie/F-4628-2015	Horowitz, Arie/0000-0001-6239-1287	NCRR NIH HHS [S07 RR07044] Funding Source: Medline; NHLBI NIH HHS [HL38113] Funding Source: Medline; NIAMS NIH HHS [AR17350] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [S07RR007044] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL038113, R01HL038113] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR017350, R37AR017350] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ADELSTEIN RS, 1981, J BIOL CHEM, V256, P7501; ATKINSON MAL, 1989, J BIOL CHEM, V264, P4127; ATKINSON MAL, 1987, J BIOL CHEM, V262, P15809; CITI S, 1988, J MUSCLE RES CELL M, V9, P306, DOI 10.1007/BF01773874; CROSS RA, 1986, FEBS LETT, V200, P355, DOI 10.1016/0014-5793(86)81168-1; CROSS RA, 1986, EMBO J, V5, P2637, DOI 10.1002/j.1460-2075.1986.tb04545.x; FUKUI Y, 1990, J CLEL BIOL, V1110, P357; GANGULY C, 1990, J BIOL CHEM, V265, P9993; GRIFFITH LM, 1987, J CELL BIOL, V104, P1309, DOI 10.1083/jcb.104.5.1309; HARRINGTON WF, 1990, P NATL ACAD SCI USA, V87, P7453, DOI 10.1073/pnas.87.19.7453; HOROWITZ A, 1991, Journal of Cell Biology, V115, p184A; KIEHART DP, 1984, NATURE, V308, P864, DOI 10.1038/308864a0; KISHINO A, 1988, NATURE, V334, P74, DOI 10.1038/334074a0; KRON SJ, 1991, METHOD ENZYMOL, V196, P399; KUCZMARSKI ER, 1980, P NATL ACAD SCI-BIOL, V77, P7292, DOI 10.1073/pnas.77.12.7292; KUZNICKI J, 1985, J BIOL CHEM, V260, P1967; LAEMMLI UK, 1970, NATURE, V286, P412; MARGOSSIAN SS, 1991, P NATL ACAD SCI USA, V88, P4941, DOI 10.1073/pnas.88.11.4941; MARGOSSIAN SS, 1982, METHOD ENZYMOL, V85, P55; OHALLORAN TJ, 1990, J CELL BIOL, V110, P63, DOI 10.1083/jcb.110.1.63; PAGH K, 1986, J CELL BIOL, V103, P1527, DOI 10.1083/jcb.103.4.1527; PARDEE JD, 1982, METHOD ENZYMOL, V85, P164; PASTERNAK C, 1989, J CELL BIOL, V109, P203, DOI 10.1083/jcb.109.1.203; PELTZ G, 1981, J CELL BIOL, V89, P104, DOI 10.1083/jcb.89.1.104; PERRIE WT, 1970, BIOCHEM J, V119, P31, DOI 10.1042/bj1190031; ROVNER AS, 1986, AM J PHYSIOL, V250, pC861, DOI 10.1152/ajpcell.1986.250.6.C861; SATHYAMOORTHY V, 1990, BIOCHEMISTRY-US, V29, P3793, DOI 10.1021/bi00467a028; SELLERS JR, 1982, J BIOL CHEM, V257, P3880; SELLERS JR, 1981, J BIOL CHEM, V256, P3137; SMILLIE LB, 1982, METHOD ENZYMOL, V85, P234; TAUSSKY HH, 1953, J BIOL CHEM, V202, P675; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TOYOSHIMA YY, 1987, NATURE, V328, P536, DOI 10.1038/328536a0; TRUONG T, 1992, J BIOL CHEM, V267, P9767; TRYBUS KM, 1989, J CELL BIOL, V109, P2887, DOI 10.1083/jcb.109.6.2887; TRYBUS KM, 1989, J CELL BIOL, V109, P2879, DOI 10.1083/jcb.109.6.2879; TRYBUS KM, 1984, J BIOL CHEM, V259, P8564; UMEMOTO S, 1990, J BIOL CHEM, V265, P14864; UYEDA TQP, 1990, J MOL BIOL, V214, P699, DOI 10.1016/0022-2836(90)90287-V; WARSHAW DM, 1990, J CELL BIOL, V111, P453, DOI 10.1083/jcb.111.2.453; WARSHAW DM, 1991, J BIOL CHEM, V266, P24339; WHITE HD, 1982, METHOD ENZYMOL, V85, P698; WORK SS, 1992, ANAL BIOCHEM, V202, P275, DOI 10.1016/0003-2697(92)90106-H; YANAGISAWA M, 1987, J MOL BIOL, V198, P143, DOI 10.1016/0022-2836(87)90302-0	44	11	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 25	1992	267	36					26091	26096						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KD073	1464620				2022-12-25	WOS:A1992KD07300076
J	SYMINGTON, BE				SYMINGTON, BE			FIBRONECTIN RECEPTOR MODULATES CYCLIN-DEPENDENT KINASE-ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOBLASTOMA GENE-PRODUCT; CELL-CYCLE; TRANSFORMED PHENOTYPE; PROTEIN-KINASE; PHOSPHORYLATION; ACTIVATION; FAMILY; SUPPRESSION; COMPLEX; CANCER	The high affinity fibronectin receptor (FNR) is expressed by hematopoietic cells, fibroblasts, and proliferating epidermal cells. Expression of this integrin is altered by chemical and viral transformation, suggesting that FNR dysfunction may play a role in growth control. This study demonstrates that exposing FA-K562 cells to glycine-arginine-glycine-aspartate-serine (GRGDS), a peptide ligand of the FNR, specifically stimulates p34/cdc2- and cyclin A-associated kinase activities. This occurs within 2 h of peptide addition. The 110-kDa form of the retinoblastoma protein appears within 3 h of GRGDS addition, consistent with activation of a G1/S kinase. DNA staining profiles demonstrate that GRGDS induces cell cycle progression within 24 h. Increased anchorage-independent growth is subsequently observed in GRGDS-treated FA-K562 cells. The control peptide, GRGES, which cannot bind the FNR, has none of these effects. This demonstrates that an extracellular integrin ligand can regulate cell proliferation. Furthermore, these results suggest that integrins link the extracellular environment and intracellular growth regulators.			SYMINGTON, BE (corresponding author), FRED HUTCHINSON CANC RES CTR,DIV BASIC SCI,M477,SEATTLE,WA 98104, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K11HL002216] Funding Source: NIH RePORTER; NHLBI NIH HHS [K11 HL02216] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BANDARA LR, 1991, NATURE, V352, P249, DOI 10.1038/352249a0; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; DRAETTA G, 1988, CELL, V54, P17, DOI 10.1016/0092-8674(88)90175-4; ELLEDGE SJ, 1992, P NATL ACAD SCI USA, V89, P2907, DOI 10.1073/pnas.89.7.2907; FANG F, 1991, CELL, V66, P731, DOI 10.1016/0092-8674(91)90117-H; FAVA RA, 1987, J CELL PHYSIOL, V131, P184, DOI 10.1002/jcp.1041310207; GIANCOTTI FG, 1990, CELL, V60, P849, DOI 10.1016/0092-8674(90)90098-Y; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; HEMLER ME, 1990, ANNU REV IMMUNOL, V8, P365, DOI 10.1146/annurev.iy.08.040190.002053; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; HUNTER T, 1991, CELL, V66, P1071, DOI 10.1016/0092-8674(91)90028-W; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; KOFF A, 1991, CELL, V66, P1217, DOI 10.1016/0092-8674(91)90044-Y; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; LUDLOW JW, 1990, CELL, V60, P387, DOI 10.1016/0092-8674(90)90590-B; MATSUYAMA T, 1989, J EXP MED, V170, P1133, DOI 10.1084/jem.170.4.1133; NASMYTH K, 1991, NEW BIOL, V3, P955; NOJIMA Y, 1990, J EXP MED, V172, P1185, DOI 10.1084/jem.172.4.1185; NORBURY C, 1991, EMBO J, V10, P3321, DOI 10.1002/j.1460-2075.1991.tb04896.x; OLDEN K, 1977, CELL, V11, P957, DOI 10.1016/0092-8674(77)90307-5; PLANTEFABER LC, 1989, CELL, V56, P281, DOI 10.1016/0092-8674(89)90902-1; SYMINGTON BE, 1989, J BIOL CHEM, V264, P13258; SYMINGTON BE, 1990, CELL REGUL, V1, P637, DOI 10.1091/mbc.1.9.637; YIN BTY, 1991, EMBO J, V10, P857	24	64	67	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1992	267	36					25744	25747						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KD073	1464591				2022-12-25	WOS:A1992KD07300026
J	SZEPETOWSKI, P; OLLENDORFF, V; GROSGEORGE, J; COURSEAUX, A; BIRNBAUM, D; THEILLET, C; GAUDRAY, P				SZEPETOWSKI, P; OLLENDORFF, V; GROSGEORGE, J; COURSEAUX, A; BIRNBAUM, D; THEILLET, C; GAUDRAY, P			DNA AMPLIFICATION AT 11Q13.5-Q14 IN HUMAN BREAST-CANCER	ONCOGENE			English	Note							GENE; 11Q13; CELL; TUMORS; CHROMOSOME-11Q13; CARCINOMAS; SEQUENCES; HST	Band q13 of chromosome 11 is frequently amplified in human breast cancers, but the gene(s) responsible for the emergence of this amplicon remain(s) elusive as yet. As a tribute to the complexity of the amplification events involving 11q13 sequences in human breast cancer, we have now studied a more telomeric region at 11q13.5-q14 defined by a new transcription unit, D11S833E. We have observed that amplicons present in cell lines and primary tumors amplified for both BCL1 and D11S833E could be interrupted between these two loci. Such discontinuities were demonstrated by using a probe for the KRN1 gene, which we have localized between the BCL1/FGF4 region and D11S833E. In fact, KRN1 was not present in 4 out of 10 amplicons bearing both BCL1 and D11S833E. Furthermore, we have observed tumors in which D11S833E could be amplified in the absence of amplification of other known markers of 11q13. Therefore, D11S833E defines a new and independent amplification unit in this region.	FAC MED NICE,LGMCH,CNRS,URA 1462,F-06107 NICE,FRANCE; UNIV MONTPELLIER 2,CNRS,URA 1191,F-34095 MONTPELLIER,FRANCE; INSERM,U119,F-13009 MARSEILLE,FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur; Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; Institut National de la Sante et de la Recherche Medicale (Inserm)	GAUDRAY, P (corresponding author), FAC MED NICE,LGMCH,CNRS,URA 1462,F-06107 NICE,FRANCE.		Theillet, Charles/O-7634-2018	Birnbaum, Daniel/0000-0001-7920-9883; Ollendorff, Vincent/0000-0001-9751-2202; Theillet, Charles/0000-0001-5555-2759				ARNOLD A, 1989, J CLIN INVEST, V83, P2034, DOI 10.1172/JCI114114; GAUDRAY P, 1992, MUTAT RES, V276, P317, DOI 10.1016/0165-1110(92)90018-5; HAGEMEIJER A, 1991, GENE CHROMOSOME CANC, V3, P210, DOI 10.1002/gcc.2870030307; LAFAGE M, 1990, GENE CHROMOSOME CANC, V2, P171, DOI 10.1002/gcc.2870020302; LAFAGE M, 1992, IN PRESS GENES CHROM, V4; LAMMIE GA, 1991, CANCER CELL-MON REV, V3, P413; LAMMIE GA, 1991, ONCOGENE, V6, P439; LIDEREAU R, 1988, ONCOGENE RES, V2, P285; MACKINNON PJ, 1991, MAMM GENOME, V1, P53, DOI 10.1007/BF00350846; OLLENDORFF V, 1992, MAMM GENOME, V2, P195, DOI 10.1007/BF00302877; PROCTOR AJ, 1991, ONCOGENE, V6, P789; RICHARD CW, 1991, AM J HUM GENET, V49, P1189; SAITO I, 1989, MOL CELL BIOL, V9, P2445, DOI 10.1128/MCB.9.6.2445; SHILOH Y, 1985, P NATL ACAD SCI USA, V82, P3761, DOI 10.1073/pnas.82.11.3761; STARK GR, 1989, CELL, V57, P901, DOI 10.1016/0092-8674(89)90328-0; SZEPETOWSKI P, 1992, ONCOGENE, V7, P751; SZEPETOWSKI P, 1992, GENOMICS, V122, P738; THEILLET C, 1990, ONCOGENE, V5, P147; THEILLET C, 1989, ONCOGENE, V4, P915; WADA A, 1988, BIOCHEM BIOPH RES CO, V157, P828, DOI 10.1016/S0006-291X(88)80324-3	20	39	40	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1992	7	12					2513	2517						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KA856	1461654				2022-12-25	WOS:A1992KA85600017
J	HUGHES, MJ; JIRICNY, J				HUGHES, MJ; JIRICNY, J			THE PURIFICATION OF A HUMAN MISMATCH-BINDING PROTEIN AND IDENTIFICATION OF ITS ASSOCIATED ATPASE AND HELICASE ACTIVITIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASE-PAIR MISMATCHES; ESCHERICHIA-COLI; HUMAN-CELLS; NUCLEAR EXTRACTS; GENE-PRODUCT; STREPTOCOCCUS-PNEUMONIAE; SALMONELLA-TYPHIMURIUM; EXCISION REPAIR; DNA HELICASE; G.T MISPAIRS	A mismatch-binding protein has been purified an estimated 4500-fold from HeLa nuclear extracts using four different chromatographic steps. Two polypeptides of apparent molecular weight of 160,000 and 100,000 were present in the final affinity-purified fraction as determined by sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Partial proteolytic clipping of the protein-DNA complexes visualized after UV treatment indicated that the 100-kDa polypeptide is most likely a degradation product of the 160-kDa polypeptide. UV cross-linking experiments have shown that both these polypeptides bind specifically to oligonucleotide duplexes containing G/T mismatches. Direct DNA binding studies and band-shift competition assays showed that although the mismatch-binding protein binds with highest affinity to oligonucleotides containing G/T mismatches, it is also capable of binding to oligonucleotides containing other mispairs. The purified protein has an associated Mg2+-dependent ATPase activity, which is markedly enhanced in the presence of single-stranded DNA. A helicase capable of unwinding a 34-mer oligonucleotide, annealed to a complementary sequence in single-stranded M13, also copurified with the mismatch-binding protein. This reaction occurs in an ATP- and magnesium-dependent manner.	IST RIC BIOL MOLEC, VIA PONTINA KM 30600, I-00040 POMEZIA, ITALY									AU KG, 1989, P NATL ACAD SCI USA, V86, P8877, DOI 10.1073/pnas.86.22.8877; BARRAS F, 1989, TRENDS GENET, V5, P139, DOI 10.1016/0168-9525(89)90054-1; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN TC, 1987, CELL, V50, P945, DOI 10.1016/0092-8674(87)90521-6; BROWN TC, 1988, CELL, V54, P705, DOI 10.1016/S0092-8674(88)80015-1; BURK RR, 1983, METHOD ENZYMOL, V91, P246; CLAVERYS JP, 1986, MICROBIOL REV, V50, P133, DOI 10.1128/MMBR.50.2.133-165.1986; DIGNAM JD, 1990, METHOD ENZYMOL, V182, P194; FUJII H, 1989, J BIOL CHEM, V264, P10057; GRILLEY M, 1989, J BIOL CHEM, V264, P1000; HABER LT, 1991, EMBO J, V10, P2707, DOI 10.1002/j.1460-2075.1991.tb07815.x; HENNECKE F, 1991, NATURE, V353, P776, DOI 10.1038/353776a0; HOLMES J, 1990, P NATL ACAD SCI USA, V87, P5837, DOI 10.1073/pnas.87.15.5837; HUGHES MJ, 1991, BIOMETHODS, V5, P221; HUGHES MJ, 1990, NUCLEIC ACIDS RES, V17, P8511; JIRICNY J, 1988, P NATL ACAD SCI USA, V85, P8860, DOI 10.1073/pnas.85.23.8860; JIRICNY J, 1986, NUCLEIC ACIDS RES, V14, P6579, DOI 10.1093/nar/14.16.6579; KADONAGA JT, 1986, P NATL ACAD SCI USA, V83, P5889, DOI 10.1073/pnas.83.16.5889; LACKS SA, 1982, CELL, V31, P327, DOI 10.1016/0092-8674(82)90126-X; LIEB M, 1987, J BACTERIOL, V169, P5241, DOI 10.1128/jb.169.11.5241-5246.1987; LIEB M, 1985, MOL GEN GENET, V199, P465; LIEB M, 1983, MOL GEN GENET, V191, P118, DOI 10.1007/BF00330898; LINTON JP, 1989, MOL CELL BIOL, V9, P3058, DOI 10.1128/MCB.9.7.3058; LU AL, 1983, P NATL ACAD SCI-BIOL, V80, P4639, DOI 10.1073/pnas.80.15.4639; LU AL, 1988, CELL, V54, P805, DOI 10.1016/S0092-8674(88)91109-9; MODRICH P, 1987, ANNU REV BIOCHEM, V56, P435, DOI 10.1146/annurev.biochem.56.1.435; MODRICH P, 1989, J BIOL CHEM, V264, P6597; PRIEBE SD, 1988, J BACTERIOL, V170, P190, DOI 10.1128/jb.170.1.190-196.1988; Sambrook J, 1989, MOL CLONING LABORATO; SCHREIBER E, 1988, EMBO J, V7, P4221, DOI 10.1002/j.1460-2075.1988.tb03319.x; SMITH ML, 1990, MOL CELL BIOL, V10, P6003, DOI 10.1128/MCB.10.11.6003; STEPHENSON C, 1989, J BIOL CHEM, V264, P21177; SU SS, 1986, P NATL ACAD SCI USA, V83, P5057, DOI 10.1073/pnas.83.14.5057; SU SS, 1988, J BIOL CHEM, V263, P6829; THOMAS DC, 1991, J BIOL CHEM, V266, P3744; TUTEJA N, 1990, NUCLEIC ACIDS RES, V18, P6785, DOI 10.1093/nar/18.23.6785; TUTEJA N, 1991, NUCLEIC ACIDS RES, V19, P3613, DOI 10.1093/nar/19.13.3613; WELSH KM, 1987, J BIOL CHEM, V262, P15624; WIEBAUER K, 1990, P NATL ACAD SCI USA, V87, P5842, DOI 10.1073/pnas.87.15.5842; WIEBAUER K, 1989, NATURE, V339, P234, DOI 10.1038/339234a0; WOOD RD, 1991, BIOESSAYS, V13, P447, DOI 10.1002/bies.950130904; WOOD SG, 1986, NUCLEIC ACIDS RES, V14, P6591, DOI 10.1093/nar/14.16.6591; ZELL R, 1987, EMBO J, V6, P1809, DOI 10.1002/j.1460-2075.1987.tb02435.x	43	77	86	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	1992	267	33					23876	23882						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JZ239	1429725				2022-12-25	WOS:A1992JZ23900067
J	PERIDES, G; RAHEMTULLA, F; LANE, WS; ASHER, RA; BIGNAMI, A				PERIDES, G; RAHEMTULLA, F; LANE, WS; ASHER, RA; BIGNAMI, A			ISOLATION OF A LARGE AGGREGATING PROTEOGLYCAN FROM HUMAN BRAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYALURONIC-ACID; POLYACRYLAMIDE GELS; BINDING-PROTEIN; CARTILAGE PROTEOGLYCANS; EXTRACELLULAR-MATRIX; CHROMATOGRAPHY; SEQUENCE; COMPLEX	A large proteoglycan (365 kDa), identified with monoclonal antibodies raised against chondroitin sulfate, was isolated from human brain. The isolation required anion-exchange chromatography followed by gel filtration through a Sephacryl S-500 column. The proteoglycan bound specifically to [H-3]hyaluronate (HA). The binding was not reduced by high salt concentrations (up to 4 M) and was inhibited at low pH (<4.0). The binding was inhibited by the octamer and decamer (but not the hexamer) oligosaccharides of HA. Limited proteolysis of the proteoglycan gave rise to a relatively stable polypeptide (80 kDa). The amino-terminal sequence of the 80-kDa polypeptide was identical to the cDNA-derived amino-terminal sequence of versican, a large human fibroblast proteoglycan. A monoclonal antibody raised against bovine proteoglycans and recognizing the versican core protein reacted by immunoblotting with the proteoglycan isolated from human brain. The antibody was used to localize the proteoglycan in acetone-fixed cryostat sections of bovine spinal cord. The localization of the proteoglycan in the central nervous system was identical to that previously reported for glial hyaluronate-binding protein (GHAP), a 60-kDa glycoprotein of the brain extracellular matrix (ECM). However, a major difference was observed with respect to the sensitivity of the two antigens to hyaluronidase. As previously reported, GHAP was released from the tissue by hyaluronidase digestion, whereas the proteoglycan persisted under these conditions. We conclude that the protein-hyaluronate aggregates in brain ECM contain both GHAP and versican, that GHAP is only retained in the ECM by its interaction with hyaluronate, and that the proteoglycan is anchored in some other manner and probably connects cell surfaces with the ECM since it was not released by hyaluronidase digestion.	DEPT VET AFFAIRS MED CTR, SPINAL CORD INJURY RES LAB, BOSTON, MA 02132 USA; UNIV ALABAMA, SCH MED, DEPT ORAL BIOL, BIRMINGHAM, AL 35294 USA; HARVARD UNIV, BIOL LABS, MICROCHEM FACIL, CAMBRIDGE, MA 02138 USA	University of Alabama System; University of Alabama Birmingham; Harvard University	PERIDES, G (corresponding author), HARVARD UNIV, SCH MED, DEPT PATHOL, BOSTON, MA 02115 USA.				NIDCR NIH HHS [DE 08466] Funding Source: Medline; NINDS NIH HHS [NS 13034] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE008466] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS013034] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ASHER R, 1991, J NEUROSCI RES, V28, P410, DOI 10.1002/jnr.490280314; BIGNAMI A, 1989, BRAIN RES BULL, V22, P67, DOI 10.1016/0361-9230(89)90129-9; BIGNAMI A, 1992, ADV STRUCTURAL BIOL, V1, P1; BRATT P, 1992, IN PRESS INT J BIOCH; COUCHMAN JR, 1984, NATURE, V307, P650, DOI 10.1038/307650a0; DOEGE KJ, 1991, J BIOL CHEM, V266, P894; EBERT RF, 1986, ANAL BIOCHEM, V154, P431, DOI 10.1016/0003-2697(86)90010-2; FALTZ LL, 1979, J BIOL CHEM, V254, P1381; FRYER HJL, 1992, J BIOL CHEM, V267, P9874; HARDINGHAM TE, 1972, BIOCHIM BIOPHYS ACTA, V279, P401, DOI 10.1016/0304-4165(72)90160-2; HASCALL VC, 1974, J BIOL CHEM, V249, P4232; KNUDSEN PJ, 1980, J CHROMATOGR, V187, P373, DOI 10.1016/S0021-9673(00)80469-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARJAVA H, 1992, BIOCHEM J, V284, P267, DOI 10.1042/bj2840267; LEBARON RG, 1992, J BIOL CHEM, V267, P10003; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; NICHOLSON C, 1986, ANN NY ACAD SCI, V481, P55, DOI 10.1111/j.1749-6632.1986.tb27139.x; PERIDES G, 1989, J BIOL CHEM, V264, P5981; PERIDES G, 1991, BIOCHIM BIOPHYS ACTA, V1075, P248, DOI 10.1016/0304-4165(91)90273-J; RAHEMTULLA F, 1988, J DENT RES, V67, pA373; ROUGHLEY PJ, 1985, BIOCHEM J, V231, P129, DOI 10.1042/bj2310129; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; UNDERHILL CB, 1987, CONNECT TISSUE RES, V16, P225, DOI 10.3109/03008208709006978; WALL RS, 1988, ANAL BIOCHEM, V175, P298, DOI 10.1016/0003-2697(88)90392-2; ZIMMERMANN DR, 1989, EMBO J, V8, P2975, DOI 10.1002/j.1460-2075.1989.tb08447.x	26	70	71	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	1992	267	33					23883	23887						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JZ239	1429726				2022-12-25	WOS:A1992JZ23900068
J	CAPON, C; LABOISSE, CL; WIERUSZESKI, JM; MAORET, JJ; AUGERON, C; FOURNET, B				CAPON, C; LABOISSE, CL; WIERUSZESKI, JM; MAORET, JJ; AUGERON, C; FOURNET, B			OLIGOSACCHARIDE STRUCTURES OF MUCINS SECRETED BY THE HUMAN COLONIC-CANCER CELL-LINE CL.16E	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAGNETIC-RESONANCE SPECTROSCOPY; PERFORMANCE LIQUID-CHROMATOGRAPHY; BOMBARDMENT MASS-SPECTROMETRY; MUCUS GLYCOPROTEINS; MALIGNANT TRANSFORMATION; NEUTRAL OLIGOSACCHARIDES; MECONIUM GLYCOPROTEINS; MONOCLONAL-ANTIBODY; CARBOHYDRATE CHAINS; METHYL GLYCOSIDES	Cl.16E, a stably differentiated clonal derivative of the human colonic cancer cell line HT29, was used to investigate the structure of oligosaccharide chains of mucins in colonic cancer. Secretory mucins were purified by equilibrium density gradient centrifugation in CsCl. Oligosaccharide side chains were isolated after beta-elimination. Compositional analysis of oligosaccharide-alditols performed after purification by gel filtration on a Bio-gel P-6 column showed 1) that GalNAc residues were located exclusively at the reducing ends of the chains, and 2) that fucose was absent from the preparation. Oligosaccharide-alditols were separated by high performance liquid chromatography (HPLC) on quaternary amine packings into a minor neutral fraction representing about 6.5% by weight of released oligosaccharides and four acidic fractions. Two acidic fractions, namely FI and FII encompassing mono- and disialylated structures, respectively, and containing 78% of total oligosaccharide alditols, were separated by HPLC. Structural determinations were carried out using methylation analysis, H-1 NMR spectroscopy, and fast atom bombardment-mass spectrometry. Twelve oligosaccharide structures were determined which ranged in size from 3 to 8 residues. These oligosaccharides were based on core types 1, 2, and 4. Elongation of oligosaccharide chains was terminated by addition of sialic acid in alpha2-3 linkage to Galbeta1-3R and to Galbeta1-4R residues. The predominant structure was a hexasaccharide (fraction FII-4). This contrasts with normal colonic mucins whose oligosaccharides were previously found to be based on core 3 structures and carry sialic acids in alpha(2-6) linkage to Galbeta1-3R, to Galbeta1-4R, and to GaINAcalpha-R (Podolsky, D. K. (1985) J. Biol. Chem. 260, 8262-8271; Podolsky, D. K. (1985) J. Biol. Chem. 260, 15510-15515). Collectively our findings suggest that Cl.16E colon cancer cells are able to synthesize mucin oligosaccharides of gastric type whose elongation is truncated by premature sialylation.	FAC XAVIER BICHAT,INSERM,U239,16 RUE HUCHARD,F-75018 PARIS,FRANCE; USTL,CHIM BIOL LAB,CNRS,UMA 111,F-59655 VILLENEUVE DASCQ,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); Universite de Lille - ISITE; Universite de Lille								AMINOFF D, 1980, ANAL BIOCHEM, V101, P44, DOI 10.1016/0003-2697(80)90038-X; AUGERON C, 1984, CANCER RES, V44, P3961; BAENZIGER JU, 1981, ANAL BIOCHEM, V112, P357, DOI 10.1016/0003-2697(81)90305-5; BARA J, 1980, BRIT J CANCER, V41, P209, DOI 10.1038/bjc.1980.32; BOLAND CR, 1990, GASTROENTEROLOGY, V98, P1170, DOI 10.1016/0016-5085(90)90330-4; BOLAND CR, 1982, P NATL ACAD SCI-BIOL, V79, P2051, DOI 10.1073/pnas.79.6.2051; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREG J, 1987, EUR J BIOCHEM, V168, P57, DOI 10.1111/j.1432-1033.1987.tb13387.x; BROCKHAUSEN I, 1983, CAN J BIOCHEM CELL B, V61, P1322, DOI 10.1139/o83-169; BROCKHAUSEN I, 1985, BIOCHEMISTRY-US, V24, P1866, DOI 10.1021/bi00329a010; BROCKHAUSEN I, 1990, BIOCHEMISTRY-US, V29, P10206, DOI 10.1021/bi00496a008; CAPON C, 1988, J CHROMATOGR-BIOMED, V425, P35, DOI 10.1016/0378-4347(88)80004-5; CAPON C, 1989, EUR J BIOCHEM, V182, P139, DOI 10.1111/j.1432-1033.1989.tb14810.x; CARRAWAY KL, 1989, BIOESSAYS, V10, P117, DOI 10.1002/bies.950100406; CHANTRET I, 1987, CANCER RES, V47, P1426; CHEN TR, 1977, EXP CELL RES, V104, P255, DOI 10.1016/0014-4827(77)90089-1; CIUCANU I, 1984, CARBOHYD RES, V131, P209, DOI 10.1016/0008-6215(84)85242-8; COOPER HS, 1978, AM J CLIN PATHOL, V69, P594; CORFIELD AP, 1990, INT J CANCER, V15, P1059; DELL A, 1983, INT J MASS SPECTROM, V46, P415, DOI 10.1016/0020-7381(83)80140-5; EGGE H, 1987, MASS SPECTROM REV, V6, P331, DOI 10.1002/mas.1280060302; FILIPE MI, 1976, MUCUS HLTH DISEASE, P413; Fogh J., 1975, HUMAN TUMOR CELLS IN, VVolume 1, P115, DOI [10.1007/978-1-4757-1647-4_5, DOI 10.1007/978-1-4757-1647-4_5]; FOURNET B, 1981, ANAL BIOCHEM, V116, P489, DOI 10.1016/0003-2697(81)90393-6; HOUNSELL EF, 1989, EUR J BIOCHEM, V186, P597, DOI 10.1111/j.1432-1033.1989.tb15250.x; HUET C, 1987, J CELL BIOL, V105, P345, DOI 10.1083/jcb.105.1.345; KAMERLING JP, 1975, BIOCHEM J, V151, P491, DOI 10.1042/bj1510491; KANANI A, 1990, CANCER RES, V50, P5003; KORREL SAM, 1984, EUR J BIOCHEM, V140, P571, DOI 10.1111/j.1432-1033.1984.tb08140.x; KUROSAKA A, 1988, J BIOL CHEM, V263, P8724; KUROSAKA A, 1987, FEBS LETT, V215, P137, DOI 10.1016/0014-5793(87)80128-X; KUROSAKA A, 1983, J BIOL CHEM, V258, P1594; Laboisse C. L., 1989, CELL MOL BIOL COLON, P27; LABURTHE M, 1989, AM J PHYSIOL, V256, pG443, DOI 10.1152/ajpgi.1989.256.3.G443; LAMBLIN G, 1984, EUR J BIOCHEM, V143, P227, DOI 10.1111/j.1432-1033.1984.tb08363.x; LESUFFLEUR T, 1991, INT J CANCER, V49, P731, DOI 10.1002/ijc.2910490517; LESUFFLEUR T, 1990, CANCER RES, V50, P6334; MAORET JJ, 1989, BIOCHEM J, V258, P793, DOI 10.1042/bj2580793; Montreuil J, 1986, CARBOHYDRATE ANAL PR, P143; PARASKEVA C, 1984, INT J CANCER, V34, P49, DOI 10.1002/ijc.2910340109; PILLER V, 1990, J BIOL CHEM, V265, P9264; PODOLSKY DK, 1985, J BIOL CHEM, V260, P5510; PODOLSKY DK, 1985, J BIOL CHEM, V260, P8262; SAVAGE AV, 1990, EUR J BIOCHEM, V192, P427, DOI 10.1111/j.1432-1033.1990.tb19244.x; SCHACHTER H, 1982, ADV EXP MED BIOL, V144, P3; SCHOENTAG R, 1987, CANCER RES, V47, P1695; SLOMIANY A, 1984, J BIOL CHEM, V259, P4743; SLOMIANY BL, 1984, J BIOL CHEM, V259, P2863; SZULMAN AE, 1960, J EXP MED, V111, P785, DOI 10.1084/jem.111.6.785; VANHALBEEK H, 1981, FEBS LETT, V133, P45, DOI 10.1016/0014-5793(81)80467-X; VANHALBEEK H, 1988, EUR J BIOCHEM, V177, P443; VANHALBEEK H, 1980, BIOCHIM BIOPHYS ACTA, V623, P295, DOI 10.1016/0005-2795(80)90257-3; VLIEGENTHART JFG, 1983, ADV CARBOHYD CHEM BI, V41, P209, DOI 10.1016/S0065-2318(08)60059-1; VLIEGENTHART JFG, 1982, CELL BIOL MONOGR, V10, P127	54	67	68	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1992	267	27					19248	19257						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JP593	1527047				2022-12-25	WOS:A1992JP59300038
J	NAKAI, K; WARD, AM; GANNON, M; RIFKIND, AB				NAKAI, K; WARD, AM; GANNON, M; RIFKIND, AB			BETA-NAPHTHOFLAVONE INDUCTION OF A CYTOCHROME-P-450 ARACHIDONIC-ACID EPOXYGENASE IN CHICK-EMBRYO LIVER DISTINCT FROM THE ARYL-HYDROCARBON HYDROXYLASE AND FROM PHENOBARBITAL-INDUCED ARACHIDONATE EPOXYGENASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER; MICROSOMAL CYTOCHROME-P-450; OXIDATIVE-METABOLISM; PURIFICATION; ISOZYMES; FORMS; SEQUENCE; 2,3,7,8-TETRACHLORODIBENZO-PARA-DIOXIN; IDENTIFICATION; INHIBITION	Cytochrome P-450-mediated arachidonic acid metabolism in chick embryo liver microsomes was increased by both Ah receptor-dependent (2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) and beta-naphthoflavone) and independent (phenobarbital) P-450 inducers. Arachidonic acid epoxides and monohydroxyeicosatetraenoic acids were increased 9-12-fold. Omega-1-OH arachidonic acid was also significantly increased by TCDD and beta-naphthoflavone while omega-OH arachidonic acid, the main metabolite in uninduced livers, was decreased by all three agents. The P-450s catalyzing the enhanced arachidonate metabolism in beta-naphthoflavone- and phenobarbital-treated liver were investigated in reconstituted systems containing wholly or partially purified P-450s. Beta-naphthoflavone induced formation of a 55-kDa P-450 selective for arachidonate metabolism and for epoxygenation in particular. This P-450 was purified (betaNF(AA)). It was found to be distinct from a 54.5-kDa beta-naphthoflavone-induced P-450 catalyzing aryl hydrocarbon hydroxylase and 7-ethoxyresorufin deethylase (designated NF1). Mean turnover numbers for arachidonate epoxygenase, aryl hydrocarbon hydroxylase, and 7-ethoxyresorufin deethylase were 11.2, 0.56, and 0.04, respectively, for reconstituted betaNF(AA) and 0.33, 11.8, and 2.4 for NF1. BetaNF(AA) and NF1 also differed in chromatography elution characteristics and N-terminal amino acid sequences. Both were low spin, with carbon monoxide binding peaks at 448 nm. The phenobarbital-induced arachidonate epoxygenation was catalyzed by P-450 fractions containing the main 48- and 49-kDa phenobarbital-induced P-450s; fractions in which the 49-kDa P-450 predominated were the most active. Turnover numbers for arachidonic acid epoxygenation were not correlated with those for aminopyrine demethylation or 7-ethoxycoumarin deethylation for P-450s from phenobarbital-treated livers or with aryl hydrocarbon hydroxylase, 7-ethoxyresorufin deethylase, or 7-ethoxycoumarin deethylase for P-450s from beta-naphthoflavone-treated livers. Also, different P-450s catalyzed the epoxygenation and the omega-hydroxylation of arachidonic acid in both beta-naphthoflavone- and phenobarbital-treated livers. The findings support a physiologic role for P-450-induced arachidonate metabolism and provide a basis for a possible link between TCDD's induction of P-450 and alterations of cellular homeostasis.	CORNELL UNIV, MED CTR, COLL MED, DEPT PHARMACOL, 1300 YORK AVE, NEW YORK, NY 10021 USA; CORNELL UNIV, MED CTR, COLL MED, DEPT MED, NEW YORK, NY 10021 USA	Cornell University; Cornell University			Gannon, Maureen A/F-9060-2012		NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES003606] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES-03606] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BLACK SD, 1987, ADV ENZYMOL RAMB, V60, P35; CAPDEVILA J, 1985, ARCH BIOCHEM BIOPHYS, V243, P8, DOI 10.1016/0003-9861(85)90768-4; CAPDEVILA J, 1981, P NATL ACAD SCI-BIOL, V78, P5362, DOI 10.1073/pnas.78.9.5362; CAPDEVILA JH, 1990, METHOD ENZYMOL, V187, P385; CAPDEVILA JH, 1990, J BIOL CHEM, V265, P10865; CARROLL MA, 1991, J BIOL CHEM, V266, P12306; DULLEY JR, 1975, ANAL BIOCHEM, V64, P136, DOI 10.1016/0003-2697(75)90415-7; FALCK JR, 1990, J BIOL CHEM, V265, P10244; FAVREAU LV, 1991, J BIOL CHEM, V266, P4556; FITZPATRICK FA, 1988, PHARMACOL REV, V40, P229; FOGH K, 1989, PROSTAGLANDINS, V37, P213, DOI 10.1016/0090-6980(89)90058-0; GUENGERICH FP, 1982, BIOCHEMISTRY-US, V21, P6019, DOI 10.1021/bi00266a045; GUPTA RP, 1990, ARCH BIOCHEM BIOPHYS, V282, P170, DOI 10.1016/0003-9861(90)90101-4; HANSEN AJ, 1989, DNA-J MOLEC CELL BIO, V8, P179, DOI 10.1089/dna.1.1989.8.179; HOKAMA Y, 1988, J BIOCHEM-TOKYO, V104, P355, DOI 10.1093/oxfordjournals.jbchem.a122473; IMAOKA S, 1988, J BIOCHEM-TOKYO, V104, P481, DOI 10.1093/oxfordjournals.jbchem.a122494; KANETOSHI A, 1992, FASEB J, V6, pA1201; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANIADOSCHWARTZMAN M, 1988, J BIOL CHEM, V263, P2536; LENTNEK M, 1991, BIOCHEM BIOPH RES CO, V174, P1267, DOI 10.1016/0006-291X(91)91558-T; LOCK EA, 1989, ANNU REV PHARMACOL, V29, P145; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MCCONKEY DJ, 1988, SCIENCE, V242, P256, DOI 10.1126/science.3262923; MCPHAUL MJ, 1988, J BIOL CHEM, V263, P16358; MORTENSEN PB, 1984, DAN MED BULL, V31, P121; NEBERT DW, 1991, DNA CELL BIOL, V10, P1, DOI 10.1089/dna.1991.10.1; OLIW EH, 1982, J BIOL CHEM, V257, P3771; OMURA T, 1964, J BIOL CHEM, V239, P2370; PARKINSON A, 1983, ARCH BIOCHEM BIOPHYS, V225, P203, DOI 10.1016/0003-9861(83)90024-3; PHILLIPS AH, 1962, J BIOL CHEM, V237, P2652; POLAND A, 1982, ANNU REV PHARMACOL, V22, P517, DOI 10.1146/annurev.pa.22.040182.002505; RIFKIND AB, 1985, TOXICOL APPL PHARM, V78, P268, DOI 10.1016/0041-008X(85)90290-X; RIFKIND AB, 1990, BIOCHEM BIOPH RES CO, V172, P1180, DOI 10.1016/0006-291X(90)91573-B; RIFKIND AB, 1982, J BIOL CHEM, V257, P1717; SINCLAIR JF, 1990, BIOCHEM J, V269, P85, DOI 10.1042/bj2690085; SINCLAIR JF, 1992, IN PRESS HDB EXPT PH; SINCLAIR P, 1989, BIOCHEM J, V258, P237, DOI 10.1042/bj2580237; SPATZ L, 1971, P NATL ACAD SCI USA, V68, P1042, DOI 10.1073/pnas.68.5.1042; WAXMAN DJ, 1982, J BIOL CHEM, V257, P446; WEST SB, 1979, ARCH BIOCHEM BIOPHYS, V193, P42, DOI 10.1016/0003-9861(79)90006-7; WHITLOCK JP, 1990, ANNU REV PHARMACOL, V30, P251; WOLF CR, 1986, BIOCHEM J, V240, P27, DOI 10.1042/bj2400027; YASUKOCHI Y, 1976, J BIOL CHEM, V251, P5337	44	57	60	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 25	1992	267	27					19503	19512						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JP593	1527070				2022-12-25	WOS:A1992JP59300074
J	HU, RJ; WATANABE, M; BENNETT, V				HU, RJ; WATANABE, M; BENNETT, V			CHARACTERIZATION OF HUMAN BRAIN CDNA-ENCODING THE GENERAL ISOFORM OF BETA-SPECTRIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ERYTHROCYTE-MEMBRANE SKELETON; NONERYTHROID ALPHA-SPECTRIN; DROSOPHILA SPECTRIN; COMPLETE SEQUENCE; BINDING-SITES; ACTIN-BINDING; PROTEIN; ANKYRIN; CELLS; CALMODULIN	The complete primary structure of the general form of human beta-spectrin (beta(G)) has been deduced from cDNAs isolated from human brain. Beta(G)-spectrin is encoded by a gene located on human chromosome 2. Beta(G)-spectrin and erythrocyte beta-spectrin (beta(R)) share identical domain organization, with sequence identity of 60% and sequence similarity of 77%. Beta-spectrins have closely related N-terminal domains implicated in binding to actin, and 17 copies of a 106-residue repeat motif with consensus residues that are highly conserved between beta-spectrins as well as alpha-spectrins. C-terminal domains of beta(G) and the 270-kDa beta(R)-spectrins are candidate regions to associate with alpha-spectrin, and exhibit 75% similarity. Beta(G)- and beta(R)-spectrins exhibit different patterns of expression in tissues and follow different developmental programs in those tissues where they are co-expressed. Beta(G)-spectrin is present in all tissues examined except for erythrocytes, while beta(R)-spectrin could be detected only in erythrocytes, brain, and heart. Beta(G)- and beta(R)-spectrins are both expressed in brain, but beta(R) appeared later in post-natal development and was highly enriched in cerebellum in contrast to the broad regional distribution of beta(G)-spectrin. Beta-spectrins are likely to perform related but distinct functions, with beta(G) in a general, constitutive role and beta(R)-spectrin involved in more specialized activities of differentiated cells.	DUKE UNIV,MED CTR,DEPT BIOCHEM,DURHAM,NC 27710	Duke University	HU, RJ (corresponding author), DUKE UNIV,MED CTR,HOWARD HUGHES MED INST,DURHAM,NC 27710, USA.							AUNIS D, 1988, J EXP BIOL, V139, P253; BARON MD, 1987, J BIOL CHEM, V262, P17623; BENNETT V, 1990, PHYSIOL REV, V70, P1029, DOI 10.1152/physrev.1990.70.4.1029; BENNETT V, 1982, NATURE, V299, P126, DOI 10.1038/299126a0; BLOCH RJ, 1989, J CELL BIOL, V108, P481, DOI 10.1083/jcb.108.2.481; BYERS TJ, 1989, J CELL BIOL, V109, P1633, DOI 10.1083/jcb.109.4.1633; BYERS TJ, 1985, P NATL ACAD SCI USA, V82, P6153, DOI 10.1073/pnas.82.18.6153; BYERS TJ, 1987, J CELL BIOL, V105, P2103, DOI 10.1083/jcb.105.5.2103; DAVIS J, 1983, J BIOL CHEM, V258, P7757; DAVIS LH, 1990, J BIOL CHEM, V265, P10589; DAVISON MD, 1988, CELL, V52, P159, DOI 10.1016/0092-8674(88)90503-X; DUBREUIL R, 1987, J CELL BIOL, V105, P2095, DOI 10.1083/jcb.105.5.2095; DUBREUIL RR, 1990, J CELL BIOL, V111, P1849, DOI 10.1083/jcb.111.5.1849; DUBREUIL RR, 1989, J CELL BIOL, V109, P2197, DOI 10.1083/jcb.109.5.2197; GLENNEY JR, 1982, CELL, V28, P843, DOI 10.1016/0092-8674(82)90063-0; GOLDBERG DA, 1980, P NATL ACAD SCI-BIOL, V77, P5794, DOI 10.1073/pnas.77.10.5794; HARRIS AS, 1990, P NATL ACAD SCI USA, V87, P3009, DOI 10.1073/pnas.87.8.3009; HU RJ, 1991, J BIOL CHEM, V266, P18200; KARINCH AM, 1990, J BIOL CHEM, V265, P11833; KENNEDY SP, 1991, J CELL BIOL, V115, P267, DOI 10.1083/jcb.115.1.267; KOENIG M, 1988, CELL, V53, P219, DOI 10.1016/0092-8674(88)90383-2; KOZAK M, 1991, J BIOL CHEM, V266, P19867; LAZARIDES E, 1983, SCIENCE, V220, P1295, DOI 10.1126/science.6190228; LETO TL, 1988, MOL CELL BIOL, V8, P1; LEVINE J, 1981, J CELL BIOL, V90, P631, DOI 10.1083/jcb.90.3.631; LIU SC, 1987, J CELL BIOL, V104, P527, DOI 10.1083/jcb.104.3.527; MARCHESI V. T., 1968, SCIENCE, V159, P203, DOI 10.1126/science.159.3811.203; MICHAUD D, 1991, FEBS LETT, V294, P77, DOI 10.1016/0014-5793(91)81347-B; MOON RT, 1990, J BIOL CHEM, V265, P4427; NELSON WJ, 1987, J CELL BIOL, V104, P1527, DOI 10.1083/jcb.104.6.1527; NELSON WJ, 1989, J CELL BIOL, V108, P893, DOI 10.1083/jcb.108.3.893; OHANIAN V, 1984, BIOCHEMISTRY-US, V23, P4416, DOI 10.1021/bi00314a027; PALEK J, 1990, SEMIN HEMATOL, V27, P290; PRCHAL JT, 1987, P NATL ACAD SCI USA, V84, P7468, DOI 10.1073/pnas.84.21.7468; RIEDERER BM, 1986, J CELL BIOL, V102, P2088, DOI 10.1083/jcb.102.6.2088; RIEDERER BM, 1987, J NEUROSCI, V7, P864; SAHR KE, 1990, J BIOL CHEM, V265, P4434; Sambrook J, 1989, MOL CLONING LABORATO; SHEN BW, 1986, J CELL BIOL, V102, P997, DOI 10.1083/jcb.102.3.997; SHOWS T, 1984, SOMAT CELL MOLEC GEN, V10, P315, DOI 10.1007/BF01535253; STEINER JP, 1988, J BIOL CHEM, V263, P14417; STEINER JP, 1989, J BIOL CHEM, V264, P2783; WASENIUS VM, 1989, J CELL BIOL, V108, P79, DOI 10.1083/jcb.108.1.79; WINKELMANN JC, 1990, J BIOL CHEM, V265, P20449; WINKELMANN JC, 1990, J BIOL CHEM, V265, P11827; WINKELMANN JC, 1988, BLOOD, V72, P328; YU J, 1973, Journal of Supramolecular Structure, V1, P233, DOI 10.1002/jss.400010308	47	92	96	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1992	267	26					18715	18722						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JN502	1527002				2022-12-25	WOS:A1992JN50200072
J	LIN, YZ; FUSEK, M; LIN, XL; HARTSUCK, JA; KEZDY, FJ; TANG, J				LIN, YZ; FUSEK, M; LIN, XL; HARTSUCK, JA; KEZDY, FJ; TANG, J			PH-DEPENDENCE OF KINETIC-PARAMETERS OF PEPSIN, RHIZOPUSPEPSIN, AND THEIR ACTIVE-SITE HYDROGEN-BOND MUTANTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PORCINE PEPSIN; ASPARTIC PROTEINASES; DIRECTED MUTAGENESIS; 1.8-A RESOLUTION; ACID PROTEINASES; PURIFICATION	The pH dependence of the kinetic parameters of pepsin, rhizopuspepsin, and their active-site hydrogen bond mutants has been determined. These data have permitted the calculation of two active-site ionization constants in the free enzymes (pK(e1) and pK(e2)) and in the enzyme-substrate complexes (pK(es1) and pK(es2)). The pk(e1) of rhizopuspepsin (2.8) is near that of a normal carboxyl group and near the pK(e1) of human immunodeficiency virus type 1 (HIV-1) protease (3.32) (Ido, E., Han, H. P., Kezdy, F. J., and Tang, J. (1991) J. Biol. Chem. 266, 24359-24366). The pK(e1) of pepsin (1.57) is thus abnormally low. The pK(e2) of rhizopuspepsin (4.44) is lower than that of pepsin (5.02) and HIV protease (6.80). The binding of substrate to rhizopuspepsin causes the lowering of pK(es1) to 1.8 and the elevating of pK(es2) to above 6. The pK(a) shifts due to substrate binding are much less pronounced in pepsin. Thus, the two enzyme-substrate complexes have similar pK(a) values. For both pepsin and rhizopuspepsin, the removal of hydrogen bonds to the active-site carboxyls by mutagenesis results in negligible changes in the four pK(a) values. The major alteration caused by these mutations is the decrease in k(cat) values, while there is little change in K(m). These observations suggest that these hydrogen bonds to the active-site aspartyls contribute little to the pH-activity relationships of the aspartic proteases. The role of the active-site hydrogen bonds may well be to preserve the conformational rigidity of the catalytic apparatus.	UNIV OKLAHOMA,HLTH SCI CTR,DEPT BIOCHEM & MOLEC BIOL,OKLAHOMA CITY,OK 73104; UPJOHN CO,BIOPOLYMER CHEM UNIT,KALAMAZOO,MI 49001	University of Oklahoma System; University of Oklahoma Health Sciences Center; Pfizer	LIN, YZ (corresponding author), OKLAHOMA MED RES FDN,PROT STUDIES PROGRAM,OKLAHOMA CITY,OK 73104, USA.		Fusek, Martin/AAG-7725-2019		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK001107] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-01107] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABADZAPATERO C, 1990, PROTEINS, V8, P62, DOI 10.1002/prot.340080109; BRYAN P, 1986, P NATL ACAD SCI USA, V83, P3743, DOI 10.1073/pnas.83.11.3743; CHEN Z, 1991, J BIOL CHEM, V266, P11718; COOPER JB, 1990, J MOL BIOL, V214, P199, DOI 10.1016/0022-2836(90)90156-G; DAVIES DR, 1990, ANNU REV BIOPHYS BIO, V19, P189, DOI 10.1146/annurev.bb.19.060190.001201; FRUTON JS, 1976, ADV ENZYMOL RAMB, V44, P1; FUSEK M, 1990, J BIOL CHEM, V265, P1496; GOLDBLUM A, 1990, FEBS LETT, V261, P241, DOI 10.1016/0014-5793(90)80562-W; GOLDBLUM A, 1988, BIOCHEMISTRY-US, V27, P1653, DOI 10.1021/bi00405a040; HARTSUCK JA, 1992, PROTEINS, V13, P1, DOI 10.1002/prot.340130102; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; IDO E, 1991, J BIOL CHEM, V266, P24359; JASKOLSKI M, 1990, BIOCHEMISTRY-US, V29, P5889, DOI 10.1021/bi00477a002; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LIN XL, 1989, J BIOL CHEM, V264, P4482; LIN XL, 1991, ASPARTIC PROTEASES, P1; OKA T, 1974, ARCH BIOCHEM BIOPHYS, V165, P65, DOI 10.1016/0003-9861(74)90142-8; REBHOLZ KL, 1991, BIOCHEM BIOPH RES CO, V176, P65, DOI 10.1016/0006-291X(91)90890-J; SIELECKI AR, 1990, J MOL BIOL, V214, P143, DOI 10.1016/0022-2836(90)90153-D; STUDIER WF, 1990, METHOD ENZYMOL, V185, P60, DOI DOI 10.1016/0076-6879(90)85008-C; SUGUNA K, 1987, J MOL BIOL, V196, P877, DOI 10.1016/0022-2836(87)90411-6; VEERAPANDIAN B, 1992, PROTEIN SCI, V1, P322; WONG JTF, 1975, KINETICS ENZYME MECH, P210; YAMAOKA K, 1981, J PHARMACOBIO-DYNAM, V4, P879, DOI 10.1248/bpb1978.4.879; ZOLLER MJ, 1983, METHOD ENZYMOL, V100, P468	25	51	53	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1992	267	26					18413	18418						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JN502	1526982				2022-12-25	WOS:A1992JN50200030
J	SIRISENA, DM; BROZEK, KA; MACLACHLAN, PR; SANDERSON, KE; RAETZ, CRH				SIRISENA, DM; BROZEK, KA; MACLACHLAN, PR; SANDERSON, KE; RAETZ, CRH			THE RFAC GENE OF SALMONELLA-TYPHIMURIUM - CLONING, SEQUENCING, AND ENZYMATIC FUNCTION IN HEPTOSE TRANSFER TO LIPOPOLYSACCHARIDE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI K-12; CORE BIOSYNTHESIS; DNA RESTRICTION; PLASMID DNA; LIPID-A; MUTANTS; REGION; STRAINS; ROUGH; TRANSFORMATION	We have cloned a gene from a Salmonella typhimurium with the ability to complement the rfaC mutation (heptose-deficient lipopolysaccharide, sensitivity to rough-specific bacteriophages, and susceptibility to hydrophobic antibiotics). A 1018-base pair EcoRV-Tth111I fragment, subcloned into the pBluescriptKS+ vector to yield pKZ103, retains complementing activity. Nucleotide sequencing revealed an open reading frame corresponding to a protein of 317 amino acids (M(r) approximately 35,100). The plasmid pKZ103, which has a properly aligned T7 promoter, can overexpress a protein of M(r) = 31,000 when T7 RNA polymerase is supplied. An in vitro system was established for analysis of heptose addition to the precursor [4'-P-32](KDO)2-IV(A) (Brozek, K. A., Hosaka, K., Robertson, A. D., and Raetz, C. R. H. (1989) J. Biol. Chem. 264, 6956-6966). Soluble fractions from wild-type or heptose-deficient rfa mutants were tested for their ability to convert [4'-P-32](KDO)2-IV(A) to more polar substances. In wild-type extracts, these conversions required addition of ATP or ADP-heptose. In extracts of rfaC-, rfaD-, or rfaE-deficient strains, no polar products were observed with ATP. ADP-heptose restored synthesis in rfaD and rfaE but not rfaC extracts, indicating that rfaD and rfaE are involved in ADP-heptose formation. When the cloned rfaC gene was introduced into an rfaC-deficient mutant, extracts from such cells regained the ability to metabolize [4'-P-32](KDO)2-IV(A), showing that rfaC encodes the enzyme that attaches the proximal heptose to lipopolysaccharide.	UNIV CALGARY,DEPT BIOL SCI,CALGARY T2N 1N4,ALBERTA,CANADA; UNIV WISCONSIN,DEPT BIOCHEM,MADISON,WI 53706	University of Calgary; University of Wisconsin System; University of Wisconsin Madison					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK019551] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-19551] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AUSTIN EA, 1990, J BACTERIOL, V172, P5312, DOI 10.1128/jb.172.9.5312-5325.1990; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; BOMAN HG, 1975, J BACTERIOL, V121, P455, DOI 10.1128/JB.121.2.455-464.1975; BROZEK KA, 1989, J BIOL CHEM, V264, P6956; BROZEK KA, 1990, J BIOL CHEM, V265, P15410; BULLAS LR, 1983, J BACTERIOL, V156, P471, DOI 10.1128/JB.156.1.471-474.1983; COLEMAN WG, 1983, J BIOL CHEM, V258, P1985; Davis R., 1980, ADV BACTERIAL GENETI; DOWER WJ, 1988, NUCLEIC ACIDS RES, V16, P6127, DOI 10.1093/nar/16.13.6127; DROGE W, 1968, EUR J BIOCHEM, V4, P134, DOI 10.1111/j.1432-1033.1968.tb00183.x; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; HAWLEY DK, 1983, NUCLEIC ACIDS RES, V11, P2237, DOI 10.1093/nar/11.8.2237; HELANDER IM, 1989, EUR J BIOCHEM, V185, P541, DOI 10.1111/j.1432-1033.1989.tb15147.x; HITCHCOCK PJ, 1983, J BACTERIOL, V154, P269, DOI 10.1128/JB.154.1.269-277.1983; JOUSIMIES H, 1974, J BACTERIOL, V119, P753, DOI 10.1128/JB.119.3.753-759.1974; KADAM SK, 1985, J BACTERIOL, V161, P277, DOI 10.1128/JB.161.1.277-284.1985; KONTROHR T, 1986, J CHROMATOGR, V354, P417, DOI 10.1016/S0021-9673(01)87042-4; KUO TT, 1972, J BACTERIOL, V112, P48, DOI 10.1128/JB.112.1.48-57.1972; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEHMANN V, 1973, EUR J BIOCHEM, V32, P268, DOI 10.1111/j.1432-1033.1973.tb02607.x; LENNOX ES, 1955, VIROLOGY, V1, P190, DOI 10.1016/0042-6822(55)90016-7; LI SC, 1984, CELL, V38, P851, DOI 10.1016/0092-8674(84)90280-0; MACLACHLAN PR, 1991, J BACTERIOL, V173, P7151, DOI 10.1128/jb.173.22.7151-7163.1991; MACLACHLAN PR, 1985, J BACTERIOL, V161, P442, DOI 10.1128/JB.161.1.442-445.1985; Makela P. H., 1984, HDB ENDOTOXIN, P59; Maniatis T., 1982, MOL CLONING; MAURER R, 1984, GENETICS, V108, P1; MILLERJF, 1972, EXPT MOL GENETICS; MUHLRADT P, 1968, EUR J BIOCHEM, V4, P139, DOI 10.1111/j.1432-1033.1968.tb00184.x; MUHLRADT P, 1969, EUR J BIOCHEM, V11, P241, DOI 10.1111/j.1432-1033.1969.tb00766.x; MURRAY NE, 1977, MOL GEN GENET, V150, P53, DOI 10.1007/BF02425325; NIKAIDO H, 1976, BIOCHIM BIOPHYS ACTA, V433, P118, DOI 10.1016/0005-2736(76)90182-6; NIKAIDO H, 1987, ESCHERICHIA COLI SAL, V1, P7; PARKER CT, 1992, J BACTERIOL, V174, P2525, DOI 10.1128/jb.174.8.2525-2538.1992; PEGUES JC, 1990, J BACTERIOL, V172, P4652, DOI 10.1128/jb.172.8.4652-4660.1990; PORTNOY DA, 1981, INFECT IMMUN, V31, P775, DOI 10.1128/IAI.31.2.775-782.1981; RAETZ CRH, 1990, ANNU REV BIOCHEM, V59, P129, DOI 10.1146/annurev.bi.59.070190.001021; RAETZ CRH, 1987, ESCHERICHIA COLI SAL, V1, P498; REED KC, 1985, NUCLEIC ACIDS RES, V13, P7207, DOI 10.1093/nar/13.20.7207; RICK PD, 1987, ESCHERICHIA COLI SAL, V1, P648; ROANTREE RJ, 1977, J GEN MICROBIOL, V103, P223, DOI 10.1099/00221287-103-2-223; RONCERO C, 1992, J BACTERIOL, V174, P3250, DOI 10.1128/jb.174.10.3250-3260.1992; SANDERSON KE, 1974, CAN J MICROBIOL, V20, P1127, DOI 10.1139/m74-175; SANDERSON KE, 1988, MICROBIOL REV, V52, P485, DOI 10.1128/MMBR.52.4.485-532.1988; SANDERSON KE, 1972, J BACTERIOL, V112, P58, DOI 10.1128/JB.112.1.58-63.1972; SANGER F, 1975, J MOL BIOL, V94, P441, DOI 10.1016/0022-2836(75)90213-2; SCHNAITMAN CA, 1991, J BACTERIOL, V173, P7410, DOI 10.1128/jb.173.23.7410-7411.1991; Silhavy T.J., 1984, EXPT GENE FUSIONS; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; WALENGA RW, 1980, J BIOL CHEM, V255, P4257; WILKINSON RG, 1972, J GEN MICROBIOL, V70, P527, DOI 10.1099/00221287-70-3-527; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	52	64	66	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1992	267	26					18874	18884						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JN502	1527014				2022-12-25	WOS:A1992JN50200094
J	EISENREICH, W; BACHER, A				EISENREICH, W; BACHER, A			BIOSYNTHESIS OF METHANOFURAN IN METHANOBACTERIUM-THERMOAUTOTROPHICUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED ACETIC-ACID; METHANOGENIC BACTERIA; AUTOTROPHIC SYNTHESIS; 2 CO2; FORMYLMETHANOFURAN; ARCHAEBACTERIA; SPECTROSCOPY; SUBUNIT; NMR	The C-13 NMR signals of methanofuran were assigned by two-dimensional H-1 and C-13 NMR experiments. On this basis, the incorporation of C-13-labeled acetate and pyruvate into methanofuran by growing cells of Methanobacterium thermoautotrophicum was analyzed by one- and two-dimensional C-13 NMR experiments. The data were analyzed by a retrobiosynthetic approach based on a comparison of labeling patterns in a variety of metabolites. The data show that the furan ring is formed by condensation of two molecules from the pyruvate/triose pool. The tetracarbocylic acid moiety is assembled from ketoglutarate, two molecules of acetyl CoA, and one molecule of carbon dioxide.			EISENREICH, W (corresponding author), TECH UNIV MUNICH,LEHRSTUHL ORGAN CHEM & BIOCHEM,LICHTENBERGSTR 4,W-8046 GARCHING,GERMANY.		Eisenreich, Wolfgang/A-1258-2013	Eisenreich, Wolfgang/0000-0002-9832-8279				BAX A, 1986, J AM CHEM SOC, V108, P2093, DOI 10.1021/ja00268a061; BAX A, 1986, J MAGN RESON, V67, P565, DOI 10.1016/0022-2364(86)90395-1; BEALE JM, 1986, J AM CHEM SOC, V108, P331, DOI 10.1021/ja00262a043; BORNER G, 1989, FEBS LETT, V244, P21, DOI 10.1016/0014-5793(89)81153-6; BOTHNERBY AA, 1984, J AM CHEM SOC, V106, P811, DOI 10.1021/ja00315a069; BRAUNSCHWEILER L, 1983, J MAGN RESON, V53, P521, DOI 10.1016/0022-2364(83)90226-3; BREITUNG J, 1990, FEBS LETT, V275, P226, DOI 10.1016/0014-5793(90)81477-6; DIMARCO AA, 1990, ANNU REV BIOCHEM, V59, P355, DOI 10.1146/annurev.biochem.59.1.355; EISENREICH W, 1991, J BIOL CHEM, V266, P23840; EISENREICH W, 1991, J BIOL CHEM, V266, P9622; FUCHS G, 1980, ARCH MICROBIOL, V127, P267, DOI 10.1007/BF00427203; FUCHS G, 1978, ARCH MICROBIOL, V118, P121, DOI 10.1007/BF00406084; JONES WJ, 1987, MICROBIOL REV, V51, P135, DOI 10.1128/MMBR.51.1.135-177.1987; KARRASCH M, 1989, FEBS LETT, V253, P226, DOI 10.1016/0014-5793(89)80964-0; LEIGH JA, 1984, J AM CHEM SOC, V106, P3636, DOI 10.1021/ja00324a037; STRAUSS G, 1992, EUR J BIOCHEM, V205, P853, DOI 10.1111/j.1432-1033.1992.tb16850.x; STUPPERICH E, 1984, ARCH MICROBIOL, V139, P14, DOI 10.1007/BF00692705; STUPPERICH E, 1984, ARCH MICROBIOL, V139, P8, DOI 10.1007/BF00692704; THAUER RK, 1990, BIOCHIM BIOPHYS ACTA, V1018, P256, DOI 10.1016/0005-2728(90)90261-2; WHITE RH, 1987, BIOCHEMISTRY-US, V26, P3163, DOI 10.1021/bi00385a033; WHITE RH, 1988, BIOCHEMISTRY-US, V27, P4415, DOI 10.1021/bi00412a031; WHITE RH, 1989, ARCH BIOCHEM BIOPHYS, V270, P691, DOI 10.1016/0003-9861(89)90552-3	22	9	9	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1992	267	25					17574	17580						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JM223	1517208				2022-12-25	WOS:A1992JM22300018
J	PAJARES, MA; DURAN, C; CORRALES, F; PLIEGO, MM; MATO, JM				PAJARES, MA; DURAN, C; CORRALES, F; PLIEGO, MM; MATO, JM			MODULATION OF RAT-LIVER S-ADENOSYLMETHIONINE SYNTHETASE-ACTIVITY BY GLUTATHIONE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THIOL DISULFIDE EXCHANGE; METHIONINE ADENOSYLTRANSFERASE ISOZYMES; SULFHYDRYL-GROUPS; OXIDATION; ENZYME; PHOSPHOFRUCTOKINASE; FRACTIONATION; INACTIVATION; PURIFICATION; MESSENGER	Rat liver S-adenosylmethionine (AdoMet) synthetase appears as high-M(r) (tetramer) and low-M(r) (dimer) forms. Both are inhibited in the presence of GSSG at pH 8. The calculated K(i) values are 2.14 and 4.03 mM for the high- and low-M(r) forms, respectively. No effect on enzyme activity was observed in the presence of GSH, but modulation of inhibition by GSSG can be obtained by addition of GSH. At a total glutathione concentration (GSH + GSSG) of 10 mM, a K(ox) of 1.74 was calculated for the high-M(r) form, whereas this constant was 2.85 for the low-M(r) AdoMet synthetase. No incorporation of [S-35]GSSG was observed in either of the enzyme forms, and inhibition of enzyme activity was correlated with dissociation of both AdoMet synthetases to a monomer. The data obtained in the presence of GSSG seem to suggest that oxidation leads to the formation of an intrasubunit disulfide. The possible regulation of AdoMet synthetase activity by the GSH/GSSG ratio is discussed, as well as its in vivo significance.			PAJARES, MA (corresponding author), CSIC,INST INVEST BIOMED,ARTURO DUPERIER 4,E-28029 MADRID,SPAIN.		MATO, JOSE/A-5187-2011; Pajares, Maria Angeles/I-5952-2012	MATO, JOSE/0000-0003-1264-3153; Corrales, Fernando/0000-0002-0231-5159; Pajares, Maria Angeles/0000-0002-4714-9051				ADIBI SA, 1973, AM J PHYSIOL, V255, P408; AKERBOOM TPM, 1982, J BIOL CHEM, V257, P4248; ALVAREZ L, 1991, FEBS LETT, V290, P142, DOI 10.1016/0014-5793(91)81245-4; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CABRERO C, 1987, EUR J BIOCHEM, V170, P299, DOI 10.1111/j.1432-1033.1987.tb13699.x; CANTONI GL, 1975, ANNU REV BIOCHEM, V44, P435, DOI 10.1146/annurev.bi.44.070175.002251; CAPPEL RE, 1986, J BIOL CHEM, V261, P5378; CAPPEL RE, 1988, J BIOL CHEM, V263, P12204; CORRALES F, 1990, HEPATOLOGY, V11, P216, DOI 10.1002/hep.1840110210; De Rey-Pailhade MJ., 1888, C R HEBD SEANCES ACA, V106, P1683; DOTAN I, 1982, BIOCHIM BIOPHYS ACTA, V713, P427, DOI 10.1016/0005-2760(82)90262-4; ERNEST MJ, 1974, J BIOL CHEM, V249, P5011; GILBERT HF, 1984, METHOD ENZYMOL, V107, P330; GILBERT HF, 1982, J BIOL CHEM, V257, P2086; GRIFFITH OW, 1987, METHOD ENZYMOL, V143, P366; Hillson DA, 1979, BIOCHEM SOC T, V7, P573, DOI 10.1042/bst0070573; HISSIN PJ, 1976, ANAL BIOCHEM, V74, P214, DOI 10.1016/0003-2697(76)90326-2; HOFFMAN JL, 1983, METHOD ENZYMOL, V94, P223; Hopkins FG, 1921, BIOCHEM J, V15, P286, DOI 10.1042/bj0150286; HORIKAWA S, 1989, EUR J BIOCHEM, V184, P497, DOI 10.1111/j.1432-1033.1989.tb15042.x; Kendall EC, 1930, J BIOL CHEM, V88, P409; KUNZ GL, 1980, ARCH BIOCHEM BIOPHYS, V202, P565, DOI 10.1016/0003-9861(80)90463-4; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIAU MC, 1979, CANCER RES, V39, P2113; LOMBARDINI JB, 1973, BIOCHEM J, V135, P43, DOI 10.1042/bj1350043; LOMBARDINI JB, 1970, MOL PHARMACOL, V6, P481; MEISTER A, 1983, ANNU REV BIOCHEM, V52, P711, DOI 10.1146/annurev.bi.52.070183.003431; NAKANISHI Y, 1989, BIOCHIM BIOPHYS ACTA, V996, P209, DOI 10.1016/0167-4838(89)90249-5; OKADA G, 1981, BIOCHEMISTRY-US, V20, P934, DOI 10.1021/bi00507a045; ORRALES F, 1991, HEPATOLOGY BALTIMORE, V14, P528; PAJARES MA, 1991, BIOCHEM J, V274, P225, DOI 10.1042/bj2740225; Pontremoli S, 1970, CURRENT TOPICS CELLU, V2, P173; REED DJ, 1977, BIOCHEM BIOPH RES CO, V77, P1257, DOI 10.1016/S0006-291X(77)80115-0; RUPPERSBERG JP, 1991, NATURE, V352, P711, DOI 10.1038/352711a0; SHIMAZU T, 1978, J BIOL CHEM, V253, P7376; STADTMAN ER, 1966, ADV ENZYMOL RAMB, V28, P41; STOOPS JK, 1982, BIOCHEM BIOPH RES CO, V104, P1018, DOI 10.1016/0006-291X(82)91351-1; STURMAN JA, 1969, BIOCHEM MED METAB B, V3, P244, DOI 10.1016/0006-2944(69)90023-4; SULLIVAN DM, 1983, BIOCHEMISTRY-US, V22, P1636, DOI 10.1021/bi00276a017; SUMA Y, 1983, BIOCHIM BIOPHYS ACTA, V755, P287, DOI 10.1016/0304-4165(83)90216-7; TAEISHI N, 1989, GLUTATHIONE CENTENNI, P57; WALTERS DW, 1986, J BIOL CHEM, V261, P5372; WALTERS DW, 1986, J BIOL CHEM, V261, P3135; ZIEGLER DM, 1985, ANNU REV BIOCHEM, V54, P305, DOI 10.1146/annurev.bi.54.070185.001513	44	131	134	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1992	267	25					17598	17605						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JM223	1517209				2022-12-25	WOS:A1992JM22300021
J	PRICE, SR; WELSH, CF; HAUN, RS; STANLEY, SJ; MOSS, J; VAUGHAN, M				PRICE, SR; WELSH, CF; HAUN, RS; STANLEY, SJ; MOSS, J; VAUGHAN, M			EFFECTS OF PHOSPHOLIPID AND GTP ON RECOMBINANT ADP-RIBOSYLATION FACTORS (ARFS) - MOLECULAR-BASIS FOR DIFFERENCES IN REQUIREMENTS FOR ACTIVITY OF MAMMALIAN ARFS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHOLERA-TOXIN; ADENYLATE-CYCLASE; NUCLEOTIDE-BINDING; BOVINE BRAIN; REGULATORY COMPONENT; PROTEIN ACTIVATOR; GOLGI-COMPLEX; EXPRESSION; GENE; COFACTOR	ADP-ribosylation factors (ARFs) are highly conserved approximately 20-kDa guanine nucleotide-binding proteins that were first identified based on their ability to stimulate the cholera toxin-catalyzed ADP-ribosylation of G(s-alpha) and thus activate adenylyl cyclase. Proteins with ARF activity have been characterized from different mammalian tissues and exhibited different requirements for activity, stability, and phospholipid. Based on molecular cloning and mRNA distribution, at least six mammalian ARFs, which fall into three classes, have been identified. To test whether individual ARFs might have different requirements for optimal activity, as judged by their ability to enhance cholera toxin ADP-ribosyltransferase activity, four ARFs from classes I, II, and III were produced as recombinant proteins in Escherichia coli and characterized. Recombinant bovine ARF 2 (rARF 2) and human ARF 3 (rARF 3) (class I), human ARF 5 (rARF 5, class II), and human ARF 6 (rARF 6, class III) differed in the effects of phospholipid and detergent on their ability to enhance cholera toxin activity; rARFs 2, 3, and 5 required dimyristoylphosphatidylcholine (DMPC) and cholate, whereas rARF 6 did not require phospholipid/detergent for activity. Further characterization of two of the more divergent ARFs (ARFs 2 and 6) showed that both exhibited guanosine 5'-O-(3-thio)triphosphate binding which was enhanced by DMPC/cholate. In the transferase assay, rARF 2 required approximately 4-mu-M GTP for half-maximal stimulation of toxin activity, whereas rARF 6 required 0.05-mu-M GTP. rARF 6 exhibited a delay in activation of toxin not detected with rARF 2 that may be related to a requirement for guanine nucleotide exchange and/or GTP binding. These findings are consistent with the conclusion that the highly conserved members of the ARF family have different requirements for optimal activity.	NHLBI,CELLULAR METAB LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)								ALSIP GR, 1986, NUCLEIC ACIDS RES, V14, P2123, DOI 10.1093/nar/14.5.2123; BALCH WE, 1990, TRENDS BIOCHEM SCI, V15, P473, DOI 10.1016/0968-0004(90)90301-Q; Bernard H U, 1979, Methods Enzymol, V68, P482; BERNARD HU, 1979, GENE, V5, P59, DOI 10.1016/0378-1119(79)90092-1; BOBAK DA, 1989, P NATL ACAD SCI USA, V86, P6101, DOI 10.1073/pnas.86.16.6101; BOBAK DA, 1990, BIOCHEMISTRY-US, V29, P855, DOI 10.1021/bi00456a600; BOBAK DA, 1990, ADP RIBOSYLATING TOX, P439; CROWL R, 1985, GENE, V38, P31, DOI 10.1016/0378-1119(85)90200-8; DRIVAS GT, 1991, BIOCHEM BIOPH RES CO, V176, P1130, DOI 10.1016/0006-291X(91)90402-S; ENOMOTO K, 1979, J SUPRAMOL STR CELL, V10, P51, DOI 10.1002/jss.400100106; HAUN RS, 1992, GENE, V112, P37, DOI 10.1016/0378-1119(92)90300-E; KAHN RA, 1984, J BIOL CHEM, V259, P6228; KAHN RA, 1988, J BIOL CHEM, V263, P8282; KAHN RA, 1991, J BIOL CHEM, V266, P2606; KAHN RA, 1986, J BIOL CHEM, V261, P7906; LEVINE H, 1981, BIOCHIM BIOPHYS ACTA, V672, P248, DOI 10.1016/0304-4165(81)90291-9; MONACO L, 1990, P NATL ACAD SCI USA, V87, P2206, DOI 10.1073/pnas.87.6.2206; MURTAGH JJ, 1991, CLIN RES, V39, pA156; NEWMAN AP, 1990, BIOESSAYS, V12, P485, DOI 10.1002/bies.950121006; NODA M, 1990, BIOCHIM BIOPHYS ACTA, V1034, P195, DOI 10.1016/0304-4165(90)90076-9; PINKETT MO, 1982, BIOCHIM BIOPHYS ACTA, V714, P337, DOI 10.1016/0304-4165(82)90342-7; PRICE SR, 1988, P NATL ACAD SCI USA, V85, P5488, DOI 10.1073/pnas.85.15.5488; PRICE SR, 1990, ADP RIBOSYLATING TOX, P397; SCHLEIFER LS, 1982, J BIOL CHEM, V257, P20; SERAFINI T, 1991, CELL, V67, P239, DOI 10.1016/0092-8674(91)90176-Y; SEWELL JL, 1988, P NATL ACAD SCI USA, V85, P4620, DOI 10.1073/pnas.85.13.4620; STEARNS T, 1990, MOL CELL BIOL, V10, P6690, DOI 10.1128/MCB.10.12.6690; STEARNS T, 1990, P NATL ACAD SCI USA, V87, P1238, DOI 10.1073/pnas.87.3.1238; TSAI SC, 1987, P NATL ACAD SCI USA, V84, P5139, DOI 10.1073/pnas.84.15.5139; TSAI SC, 1988, J BIOL CHEM, V263, P1768; TSAI SC, 1991, J BIOL CHEM, V266, P23053; TSAI SC, 1991, J BIOL CHEM, V266, P8213; TSAI SC, 1991, BIOCHEMISTRY-US, V30, P3697, DOI 10.1021/bi00229a015; TSUCHIYA M, 1991, J BIOL CHEM, V266, P2772; WEISS O, 1989, J BIOL CHEM, V264, P21066	35	40	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1992	267	25					17766	17772						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JM223	1517219				2022-12-25	WOS:A1992JM22300047
J	KOTANI, K; KIKUCHI, A; DOI, K; KISHIDA, S; SAKODA, T; KISHI, K; TAKAI, Y				KOTANI, K; KIKUCHI, A; DOI, K; KISHIDA, S; SAKODA, T; KISHI, K; TAKAI, Y			THE FUNCTIONAL DOMAIN OF THE STIMULATORY GDP GTP EXCHANGE PROTEIN (SMG GDS) WHICH INTERACTS WITH THE C-TERMINAL GERANYLGERANYLATED REGION OF RAP-1/KREV-1/SMG-P21	ONCOGENE			English	Article							BOVINE BRAIN MEMBRANES; BINDING PROTEIN; MOLECULAR-WEIGHT; EFFECTOR DOMAIN; HUMAN-PLATELETS; RAS PROTEINS; ACTIVATING PROTEINS; PLASMA-MEMBRANE; PURIFICATION; P21	rap1/Krev-1/smg p21 (smg p21), a member of the small GTP-binding protein (G protein) superfamily, has a geranylgeranylated cysteine residue and clustered basic amino acids in the C-terminal region. The GDP/GTP exchange reaction of smg p21 is regulated by smg GDS, which is also active on Ki-ras p21 and rho p21. The C-terminal region of smg p21 is essential for its interaction with smg GDS. Moreover, smg p21 is phosphorylated by cyclic AMP- and cyclic GMP-dependent protein kinases at the serine residue between the polybasic region and the prenylated cysteine residue, and this phosphorylation initiates the smg GDS-induced smg p21 activation. Thus, the C-terminal cationic and hydrophobic region is important for the regulation of the smg p21 activity. In the present study, we attempted to determine the functional domain of smg GDS which interacts with the C-terminal region of smg p21 by use of a cross-link method and a site-directed mutagenesis method. The region of smg GDS cross-linked with the C-terminal region of smg p21B was residues 444-492, which is located at the C-terminal fifth of smg GDS. On deletion of these residues, smg GDS became inactive on smg p21B, Ki-ras p21 and rhoA p21. These results indicate that residues 444-492 of smg GDS are at least one of the domains which interact with the C-terminal region of its substrate small G proteins.	KOBE UNIV,SCH MED,DEPT BIOCHEM,KOBE 650,JAPAN	Kobe University				kishida, shosei/0000-0003-0405-851X				BECHTEL PJ, 1977, J BIOL CHEM, V252, P2691; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUSS JE, 1991, MOL CELL BIOL, V11, P1523, DOI 10.1128/MCB.11.3.1523; EATON D, 1986, BIOCHEMISTRY-US, V25, P505, DOI 10.1021/bi00350a035; HANCOCK JF, 1990, CELL, V63, P133, DOI 10.1016/0092-8674(90)90294-O; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HATA Y, 1991, J BIOL CHEM, V266, P6571; HIROYOSHI M, 1991, J BIOL CHEM, V266, P2962; KAIBUCHI K, 1991, MOL CELL BIOL, V11, P2873, DOI 10.1128/MCB.11.5.2873; KAWAMURA S, 1991, BIOCHEM BIOPH RES CO, V174, P1095, DOI 10.1016/0006-291X(91)91533-I; KAWATA M, 1988, J BIOL CHEM, V263, P18965; KAWATA M, 1990, P NATL ACAD SCI USA, V87, P8960, DOI 10.1073/pnas.87.22.8960; KAWATA M, 1989, J BIOL CHEM, V264, P15688; KIKUCHI A, 1989, J BIOL CHEM, V264, P9133; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOMANT AJ, 1976, J MOL BIOL, V104, P243, DOI 10.1016/0022-2836(76)90011-5; MATSUI Y, 1990, BIOCHEM BIOPH RES CO, V166, P1010, DOI 10.1016/0006-291X(90)90911-6; MIURA Y, 1992, FEBS LETT, V297, P171, DOI 10.1016/0014-5793(92)80353-I; MIZUNO T, 1991, P NATL ACAD SCI USA, V88, P6442, DOI 10.1073/pnas.88.15.6442; NICE EC, 1992, J BIOL CHEM, V267, P1546; OHMORI T, 1989, J BIOL CHEM, V264, P1877; PIZON V, 1988, NUCLEIC ACIDS RES, V16, P7719, DOI 10.1093/nar/16.15.7719; PIZON V, 1988, ONCOGENE, V3, P201; POLAKIS PG, 1991, P NATL ACAD SCI USA, V88, P239, DOI 10.1073/pnas.88.1.239; QUILLIAM LA, 1991, J IMMUNOL, V147, P1628; Sambrook J, 1989, MOL CLONING LABORATO; SHIRATAKI H, 1991, J BIOL CHEM, V266, P20672; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TAKAI Y, 1992, INT REV CYTOL, V133, P187, DOI 10.1016/S0074-7696(08)61861-6; UEDA T, 1989, BIOCHEM BIOPH RES CO, V159, P1411, DOI 10.1016/0006-291X(89)92267-5; YAMAMOTO K, 1988, J BIOL CHEM, V263, P9926; YAMAMOTO T, 1990, J BIOL CHEM, V265, P16626	33	10	10	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1992	7	9					1699	1704						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JJ376	1501882				2022-12-25	WOS:A1992JJ37600004
J	LAM, EWF; ROBINSON, C; WATSON, RJ				LAM, EWF; ROBINSON, C; WATSON, RJ			CHARACTERIZATION AND CELL CYCLE-REGULATED EXPRESSION OF MOUSE B-MYB	ONCOGENE			English	Article							DNA-POLYMERASE-ALPHA; MURINE ERYTHROLEUKEMIA-CELLS; HUMAN HEMATOPOIETIC-CELLS; C-MYB; GENE-EXPRESSION; ERYTHROID-DIFFERENTIATION; BINDING ACTIVITY; MESSENGER-RNA; A-MYB; PROLIFERATION	We have isolated a full-length mouse B-myb cDNA clone and used this to examine cell cycle-regulated expression of this gene. Mouse B-Myb was predicted to comprise 704 amino acids and to be 84% homologous with human B-Myb. There were three regions of extensive amino acid homology which may indicate functional domains: the first corresponded to the c-Myb DNA-binding domain, while the second had no counterpart in c-Myb but was instead homologous to a short segment of the related A-myb protein. The third region of homology is partially conserved in both c-Myb and A-Myb and may correspond to the c-Myb negative regulator domain. Stimulation of quiescent 3T3 fibroblasts with serum was found to result in induction of B-myb expression in late G1 and to lead to high levels of gene transcripts that persisted through S phase. Similarly, maximum B-myb mRNA levels were reached in G2/M synchronized cells prior to entry into S phase. These results are consistent with a role in G1/S transition as has been suggested for c-myb.	ST MARYS HOSP,SCH MED,LUDWIG INST CANC RES,NORFOLK PL,LONDON W2 1PG,ENGLAND	Imperial College London; Ludwig Institute for Cancer Research			Lam, Eric W-F/AAW-8566-2020	Lam, Eric W-F/0000-0003-1274-3576				BIEDENKAPP H, 1988, NATURE, V335, P835, DOI 10.1038/335835a0; CLARKE MF, 1988, MOL CELL BIOL, V8, P884, DOI 10.1128/MCB.8.2.884; COLL J, 1983, EXP CELL RES, V149, P151, DOI 10.1016/0014-4827(83)90388-9; DENTE L, 1985, DNA CLONING PRACTICA, V1, P101; GEWIRTZ AM, 1989, SCIENCE, V245, P180, DOI 10.1126/science.2665077; GEWIRTZ AM, 1988, SCIENCE, V242, P1303, DOI 10.1126/science.2461588; GOLAY J, 1991, BLOOD, V77, P149; GONDA TJ, 1982, MOL CELL BIOL, V2, P617, DOI 10.1128/MCB.2.6.617; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HOWE KM, 1991, NUCLEIC ACIDS RES, V19, P3913, DOI 10.1093/nar/19.14.3913; HOWE KM, 1990, EMBO J, V9, P161, DOI 10.1002/j.1460-2075.1990.tb08092.x; KIRSCH IR, 1986, J CELL BIOCHEM, V32, P11, DOI 10.1002/jcb.240320103; MCMAHON J, 1988, ONCOGENE, V3, P717; MIZUGUCHI G, 1990, J BIOL CHEM, V265, P9280; NISHINA Y, 1989, NUCLEIC ACIDS RES, V17, P107, DOI 10.1093/nar/17.1.107; NOMURA N, 1988, NUCLEIC ACIDS RES, V16, P11075, DOI 10.1093/nar/16.23.11075; PROCHOWNIK EV, 1986, NATURE, V322, P848, DOI 10.1038/322848a0; RAMSAY RG, 1986, P NATL ACAD SCI USA, V83, P6849, DOI 10.1073/pnas.83.18.6849; RAMSAY RG, 1991, ONCOGENE, V6, P1875; SAKURA H, 1989, P NATL ACAD SCI USA, V86, P5758, DOI 10.1073/pnas.86.15.5758; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; TERADA M, 1977, P NATL ACAD SCI USA, V74, P248, DOI 10.1073/pnas.74.1.248; TRAVALI S, 1991, MOL CELL BIOL, V11, P731, DOI 10.1128/MCB.11.2.731; VENTURELLI D, 1990, P NATL ACAD SCI USA, V87, P5963, DOI 10.1073/pnas.87.15.5963; WAHL AF, 1988, MOL CELL BIOL, V8, P5016, DOI 10.1128/MCB.8.11.5016; WATSON RJ, 1988, ONCOGENE, V2, P267; WATSON RJ, 1988, MOL CELL BIOL, V8, P3938, DOI 10.1128/MCB.8.9.3938; WESTIN EH, 1982, P NATL ACAD SCI-BIOL, V79, P2194, DOI 10.1073/pnas.79.7.2194; WESTON K, 1989, CELL, V58, P85, DOI 10.1016/0092-8674(89)90405-4; WONG SW, 1988, EMBO J, V7, P37, DOI 10.1002/j.1460-2075.1988.tb02781.x	30	98	100	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1992	7	9					1885	1890						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JJ376	1501895				2022-12-25	WOS:A1992JJ37600027
J	PLET, A; TOURKINE, N; MECHTI, N; JEANTEUR, P; BLANCHARD, JM				PLET, A; TOURKINE, N; MECHTI, N; JEANTEUR, P; BLANCHARD, JM			INVIVO FOOTPRINTS BETWEEN THE MURINE C-MYC P1 AND P2 PROMOTERS	ONCOGENE			English	Article							E2F TRANSCRIPTION FACTOR; TRANS-ACTIVATION; GENE-REGULATION; PROTEIN; ELEMENT; INVITRO; TRANSACTIVATION; INITIATION; EXPRESSION; ACCURATE	Assuming that when transcription starts at the P2 promoter of the c-myc gene sites located immediately upstream from P2 are occupied whereas in the absence of initiation they are not, the polymerase chain reaction (PCR)-based method of Mueller & Wold 1(1989). Science, 246, 780-7861 was used to map in vivo footprints upstream from the P2 promoter in various mouse cell lines. In cultured Friend erythroleukemic cells induced to differentiate with dimethysulfoxide (DMSO), a clear protection corresponding to ME1a2 and E2F sites was observed, consistent with in vitro band-shift and footprint data. However, in cell lines in which the gene was either silent or truncated the footprints were no longer visible. Friend c-myc transcripts decreased to a barely detectable level after 3 h of DMSO treatment. Transcription, as measured by in vitro run-on, was turned off at the level of RNA polymerase elongation rather than initiation [Mechti N., Piechaczyk, M. Blanchard, J.-M., Marty, L., Bonnieu, A., Jeanteur. Ph. & Lebler, B. (1986). Nucleic Acids Res., 24, 9653-96661. The state of occupancy of the sites did not vary from the first hours up to 9 days of DMSO treatment, suggesting that DNA occupancy per se cannot explain premature termination, which rather would involve a more complex phenomenon.			PLET, A (corresponding author), CNRS, URA 1191, 2 PL EUGENE BATAILLON, F-34095 MONTPELLIER 5, FRANCE.							ASSELIN C, 1989, ONCOGENE, V4, P549; BAGCHI S, 1991, CELL, V65, P1063, DOI 10.1016/0092-8674(91)90558-G; BANDARA LR, 1991, NATURE, V351, P494, DOI 10.1038/351494a0; BLANCHARD JM, 1988, BIOCHIMIE, V70, P877, DOI 10.1016/0300-9084(88)90228-3; BRAITHWAITE AW, 1991, NEW BIOL, V3, P18; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHITTENDEN T, 1991, CELL, V65, P1073, DOI 10.1016/0092-8674(91)90559-H; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FAHRLANDER PD, 1985, EMBO J, V4, P3195, DOI 10.1002/j.1460-2075.1985.tb04065.x; FIERING S, 1990, GENE DEV, V4, P1823, DOI 10.1101/gad.4.10.1823; HALL DJ, 1990, ONCOGENE, V5, P47; HERRERA RE, 1989, NATURE, V340, P68, DOI 10.1038/340068a0; HIEBERT SW, 1991, J VIROL, V65, P3547, DOI 10.1128/JVI.65.7.3547-3552.1991; HIEBERT SW, 1989, P NATL ACAD SCI USA, V86, P3594, DOI 10.1073/pnas.86.10.3594; KERPPOLA TK, 1988, MOL CELL BIOL, V8, P4389, DOI 10.1128/MCB.8.10.4389; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; MARCU KB, 1987, BIOESSAYS, V6, P28, DOI 10.1002/bies.950060108; MECHTI N, 1986, NUCLEIC ACIDS RES, V14, P9653, DOI 10.1093/nar/14.24.9653; MILLER H, 1989, MOL CELL BIOL, V9, P5340, DOI 10.1128/MCB.9.12.5340; MOBERG KH, 1991, J CELL PHYSIOL, V148, P75, DOI 10.1002/jcp.1041480110; MUDRYJ M, 1990, EMBO J, V9, P2179, DOI 10.1002/j.1460-2075.1990.tb07387.x; MUELLER PR, 1988, GENE DEV, V2, P412, DOI 10.1101/gad.2.4.412; MUELLER PR, 1989, SCIENCE, V246, P780, DOI 10.1126/science.2814500; NISHIKURA K, 1986, MOL CELL BIOL, V6, P4093, DOI 10.1128/MCB.6.11.4093; PIECHACZYK M, 1987, TRENDS GENET, V3, P47, DOI 10.1016/0168-9525(87)90166-1; SACCA R, 1990, ONCOGENE, V5, P1499; SOBCZAK J, 1989, ONCOGENE, V4, P1503; SPENCER CA, 1990, GENE DEV, V4, P75, DOI 10.1101/gad.4.1.75; SPENCER CA, 1991, ADV CANCER RES, V56, P1; THALMEIER K, 1989, GENE DEV, V3, P527, DOI 10.1101/gad.3.4.527; TOURKINE N, 1989, ONCOGENE, V4, P973; WATSON RJ, 1988, MOL CELL BIOL, V8, P3938, DOI 10.1128/MCB.8.9.3938	32	16	16	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	1992	7	9					1847	1851						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JJ376	1501892				2022-12-25	WOS:A1992JJ37600021
J	DIGIROLAMO, M; DARCANGELO, D; CACCIAMANI, T; GIERSCHIK, P; CORDA, D				DIGIROLAMO, M; DARCANGELO, D; CACCIAMANI, T; GIERSCHIK, P; CORDA, D			K-RAS TRANSFORMATION GREATLY INCREASES THE TOXIN-DEPENDENT ADP-RIBOSYLATION OF GTP BINDING-PROTEINS IN THYROID-CELLS - INVOLVEMENT OF AN INHIBITOR OF THE ADP-RIBOSYLATION REACTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE REGULATORY UNIT; ADENYLATE-CYCLASE ACTIVITY; MURINE SARCOMA-VIRUS; PERTUSSIS TOXIN; ALPHA-SUBUNIT; ENDOGENOUS INHIBITOR; SIGNAL TRANSDUCTION; GUANINE-NUCLEOTIDES; EPITHELIAL-CELLS; PHOSPHOLIPASE-C	The GTP binding (G) proteins of normal (FRTL5) and ras-transformed thyroid cells (KiKi) were characterized by cholera and pertussis toxin-induced ADP-ribosylation and immunoblot analysis. Two pertussis toxin substrates with molecular masses of 40 and 41 kDa were identified in normal cells as the alpha(i2) and alpha(i3) subunits. The molecular masses of the cholera toxin substrates were 42 and 45 kDa. The same cholera and pertussis toxin substrates were present in the K-ras-transformed cell line. However, the toxin-dependent ADP-ribosylation was markedly higher in KiKi than in normal cell membranes (more than 50-fold). The reason for this difference was investigated; it could not be explained by the relative amounts of G proteins in the two cell systems, since the levels of alpha(i2) subunit as measured by quantitative immunoblot in K-ras-transformed cells were only slightly (65%) higher than in normal cells. The difference in ADP-ribosylation was not due to poly-ADP-ribosylation nor to a different degree of subunit dissociation of G proteins in the two cell lines. Rather, the enhanced ADP-ribosylation in K-ras-transformed cells appears to be due to the loss of an inhibitory factor present in the normal cells. Partial characterization indicates that such a factor is a peripheral membrane protein of <25 kDa capable of directly interfering with the ADP-ribosylation reaction.	CONSORZIO MARIO NEGRI SUD,IST RIC FARMACOL MARIO NEGRI,CELLULAR & MOLEC ENDOCRINOL LAB,I-66030 SANTA MARIA IMBAR,ITALY; UNIV HEIDELBERG,DEPT PHARMACOL,W-6900 HEIDELBERG,GERMANY	Consorzio Mario Negri Sud; Istituto di Ricerche Farmacologiche Mario Negri IRCCS; Ruprecht Karls University Heidelberg			Corda, Daniela/K-6385-2016; D'Arcangelo, Daniela/K-6533-2016	Corda, Daniela/0000-0002-3614-751X; D'Arcangelo, Daniela/0000-0002-7862-3289				AMBESIIMPIOMBAT.FS, 1982, COLD SPRING HARBOR C, V9, P483; BAHER W, 1982, J BIOL CHEM, V257, P6452; BIRNBAUMER L, 1990, BIOCHIM BIOPHYS ACTA, V1031, P163, DOI 10.1016/0304-4157(90)90007-Y; BIZZARRI C, 1990, P NATL ACAD SCI USA, V87, P4889, DOI 10.1073/pnas.87.12.4889; BOHM M, 1990, CIRCULATION, V82, P1249, DOI 10.1161/01.CIR.82.4.1249; BURCH RM, 1986, J BIOL CHEM, V261, P1236; CASSEL D, 1978, P NATL ACAD SCI USA, V75, P2669, DOI 10.1073/pnas.75.6.2669; COLLETTA G, 1988, FEBS LETT, V228, P37, DOI 10.1016/0014-5793(88)80579-9; CORDA D, 1987, EUR J BIOCHEM, V166, P475, DOI 10.1111/j.1432-1033.1987.tb13540.x; CORDA D, 1989, ADV EXP MED BIOL, V261, P245; CORDA D, 1986, BIOCHEM BIOPH RES CO, V141, P1000, DOI 10.1016/S0006-291X(86)80143-7; DEERY WJ, 1990, BIOCHEM BIOPH RES CO, V144, P536; DEWOLF MJS, 1985, BIOCHEM J, V226, P415, DOI 10.1042/bj2260415; DIGIROLAMO M, 1991, ACTA ENDOCRINOL-COP, V125, P192, DOI 10.1530/acta.0.1250192; DOMENIGHINI M, 1991, MOL MICROBIOL, V5, P23, DOI 10.1111/j.1365-2958.1991.tb01822.x; FUSCO A, 1981, INT J CANCER, V28, P655, DOI 10.1002/ijc.2910280519; FUSCO A, 1982, CANCER RES, V42, P618; GIERSCHIK P, 1987, FEBS LETT, V224, P219, DOI 10.1016/0014-5793(87)80451-9; GIERSCHIK P, 1989, J BIOL CHEM, V264, P21470; GIERSCHIK P, 1989, EUR J BIOCHEM, V183, P97, DOI 10.1111/j.1432-1033.1989.tb14901.x; GIERSCHIK P, 1985, P NATL ACAD SCI USA, V82, P727, DOI 10.1073/pnas.82.3.727; GILL DM, 1988, BIOCHIM BIOPHYS ACTA, V954, P65, DOI 10.1016/0167-4838(88)90056-8; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GOLDSMITH P, 1988, J BIOL CHEM, V263, P6476; GOLDSMITH P, 1987, J BIOL CHEM, V262, P14683; GRAZIANO MP, 1989, J BIOL CHEM, V264, P409; HARAYOKOYAMA M, 1988, FEBS LETT, V234, P27, DOI 10.1016/0014-5793(88)81295-X; HARAYOKOYAMA M, 1989, BIOCHEM BIOPH RES CO, V160, P67, DOI 10.1016/0006-291X(89)91621-5; HODGES TD, 1989, MOL PHARMACOL, V36, P72; JONES TLZ, 1990, P NATL ACAD SCI USA, V87, P568, DOI 10.1073/pnas.87.2.568; KAHN RA, 1990, G PROTEINS, P201; KAZIRO Y, 1990, G PROTEINS, P63; KOHN LD, 1985, BIOCHEM ACTION HORM, P457; LINDER ME, 1991, J BIOL CHEM, V266, P4654; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; MOSS J, 1985, P NATL ACAD SCI USA, V82, P5603, DOI 10.1073/pnas.82.17.5603; Moss J., 1990, G PROTEINS, P179; MUMBY SM, 1990, P NATL ACAD SCI USA, V87, P728, DOI 10.1073/pnas.87.2.728; NEER EJ, 1987, BIOCHEM J, V241, P325, DOI 10.1042/bj2410325; NEER EJ, 1988, NATURE, V333, P129, DOI 10.1038/333129a0; NEER EJ, 1984, J BIOL CHEM, V259, P4222; NICOSIA A, 1986, P NATL ACAD SCI USA, V83, P4631, DOI 10.1073/pnas.83.13.4631; RIBEIRONETO F, 1987, MOL ENDOCRINOL, V1, P472, DOI 10.1210/mend-1-7-472; SATO K, 1990, ARCH BIOCHEM BIOPHYS, V281, P298, DOI 10.1016/0003-9861(90)90447-7; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SIMONDS WF, 1991, J BIOL CHEM, V266, P5363; SPICHER K, 1991, BIOCHEM BIOPH RES CO, V175, P473, DOI 10.1016/0006-291X(91)91588-4; STERNWEIS PC, 1984, J BIOL CHEM, V259, P3806; STONE PR, 1973, EUR J BIOCHEM, V38, P146, DOI 10.1111/j.1432-1033.1973.tb03044.x; TANUMA S, 1990, FEBS LETT, V261, P381, DOI 10.1016/0014-5793(90)80597-C; TAYLOR SJ, 1990, J BIOL CHEM, V265, P17150; VALENTE WA, 1983, ENDOCRINOLOGY, V112, P71, DOI 10.1210/endo-112-1-71; VALITUTTI S, 1991, CELL SIGNAL, V3, P321, DOI 10.1016/0898-6568(91)90061-X	53	13	13	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1992	267	24					17397	17403						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JL053	1512271				2022-12-25	WOS:A1992JL05300099
J	FENG, Y; FORGAC, M				FENG, Y; FORGAC, M			CYSTEINE 254 OF THE 73-KDA A SUBUNIT IS RESPONSIBLE FOR INHIBITION OF THE COATED VESICLE (H+)-ATPASE UPON MODIFICATION BY SULFHYDRYL-REAGENTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VACUOLAR H+-ATPASE; TRANSLOCATING ADENOSINE-TRIPHOSPHATASE; AMINO-ACID-SEQUENCE; BETA-SUBUNIT; PROTON PUMP; ESCHERICHIA-COLI; ALPHA-SUBUNIT; NEUROSPORA-CRASSA; MEMBRANE ATPASE; F1-ATPASE	The vacuolar class of (H+)-ATPases are highly sensitive to sulfhydryl reagents, such as N-ethylmaleimide. The cysteine residue which is responsible for inhibition of the coated vesicle (H+)-ATPase upon modification by N-ethylmaleimide is located in subunit A and is able to form a disulfide bond with the cysteine moiety of cystine through an exchange reaction. This unique property distinguishes this cysteine residue from the remaining cysteine residues of the (H+)-ATPase. Using this reaction, we selectively labeled the cystine-reactive cysteine residue of subunit A with fluorescein-maleimide. After complete digestion of the labeled subunit A by V8 protease, a single labeled fragment of molecular mass 3.9 kDa was isolated and the amino-terminal sequence was determined. This fragment contains 2 cysteine residues, Cys240 and Cys254 Since Cys254 is conserved among all vacuolar (H+)-ATPases whereas CyS240 is not, it is likely that Cys254 is the residue which is responsible for the sensitivity of the vacuolar (H+)-ATPase to sulfhydryl reagents.	TUFTS UNIV, SCH MED, DEPT CELLULAR & MOLEC PHYSIOL, BOSTON, MA 02111 USA	Tufts University					NIGMS NIH HHS [R01 GM034478, GM-34478] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM034478, R01GM034478] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADACHI I, 1990, J BIOL CHEM, V265, P967; ADACHI I, 1990, J BIOL CHEM, V265, P960; ANDREWS WW, 1984, J BIOL CHEM, V259, P4378; APPS DK, 1989, BIOCHEM J, V263, P81, DOI 10.1042/bj2630081; ARAI H, 1987, BIOCHEMISTRY-US, V26, P6632, DOI 10.1021/bi00395a011; ARAI H, 1988, J BIOL CHEM, V263, P8796; BOWMAN BJ, 1989, J BIOL CHEM, V264, P15606; BOWMAN EJ, 1988, J BIOL CHEM, V263, P13994; BOWMAN EJ, 1986, P NATL ACAD SCI USA, V83, P48, DOI 10.1073/pnas.83.1.48; CHIN DJ, 1984, NATURE, V308, P613, DOI 10.1038/308613a0; DENDA K, 1988, J BIOL CHEM, V263, P6012; Drapeau G R, 1977, Methods Enzymol, V47, P189; EGNER U, 1987, J MOL BIOL, V195, P649, DOI 10.1016/0022-2836(87)90188-4; FLING SP, 1986, ANAL BIOCHEM, V155, P83, DOI 10.1016/0003-2697(86)90228-9; FORGAC M, 1983, P NATL ACAD SCI-BIOL, V80, P1300, DOI 10.1073/pnas.80.5.1300; FORGAC M, 1989, PHYSIOL REV, V69, P765, DOI 10.1152/physrev.1989.69.3.765; GARBOCZI DN, 1988, J BIOL CHEM, V263, P812; GLUCK S, 1987, J BIOL CHEM, V262, P15780; HIRATA R, 1990, J BIOL CHEM, V265, P6726; INATOMI KI, 1989, J BIOL CHEM, V264, P10954; KANE PM, 1989, J BIOL CHEM, V264, P19236; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAI SP, 1988, J BIOL CHEM, V263, P16731; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MANDALA S, 1986, J BIOL CHEM, V261, P2850; MORIYAMA Y, 1989, J BIOL CHEM, V264, P3577; MORIYAMA Y, 1987, J BIOL CHEM, V262, P14723; OAKLEY BR, 1980, ANAL BIOCHEM, V105, P361, DOI 10.1016/0003-2697(80)90470-4; PARRY RV, 1989, J BIOL CHEM, V264, P20025; PARSONAGE D, 1988, J BIOL CHEM, V263, P4740; PARSONAGE D, 1987, J BIOL CHEM, V262, P6301; PUOPOLO K, 1991, J BIOL CHEM, V266, P24564; RUNSWICK MJ, 1983, J BIOL CHEM, V258, P3081; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; TAGAYA M, 1988, FEBS LETT, V233, P347, DOI 10.1016/0014-5793(88)80457-5; WALKER JE, 1985, J MOL BIOL, V184, P677, DOI 10.1016/0022-2836(85)90313-4; ZIMNIAK L, 1988, J BIOL CHEM, V263, P9102; [No title captured]	38	117	118	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	1992	267	9					5817	5822						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HK318	1532573				2022-12-25	WOS:A1992HK31800018
J	INABA, T; YAMADA, N; GOTODA, T; SHIMANO, H; SHIMADA, M; MOMOMURA, K; KADOWAKI, T; MOTOYOSHI, K; TSUKADA, T; MORISAKI, N; SAITO, Y; YOSHIDA, S; TAKAKU, F; YAZAKI, Y				INABA, T; YAMADA, N; GOTODA, T; SHIMANO, H; SHIMADA, M; MOMOMURA, K; KADOWAKI, T; MOTOYOSHI, K; TSUKADA, T; MORISAKI, N; SAITO, Y; YOSHIDA, S; TAKAKU, F; YAZAKI, Y			EXPRESSION OF M-CSF RECEPTOR ENCODED BY C-FMS ON SMOOTH-MUSCLE CELLS DERIVED FROM ARTERIOSCLEROTIC LESION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATING FACTOR PRODUCTION; DENSITY-LIPOPROTEIN RECEPTOR; PERIPHERAL-BLOOD MONOCYTES; GROWTH-FACTOR; ATHEROSCLEROTIC LESIONS; MESSENGER-RNA; FACTOR-I; RABBIT; FIBROBLASTS; PROLIFERATION	Vascular smooth muscle cells in atherosclerotic lesions are phenotypically different from those in the normal arterial wall, and no expression of macrophage colony stimulating factor (M-CSF) receptor encoded by the proto-oncogene c-fms has been demonstrated in normal smooth muscle cells. In the present study, we demonstrated expression of c-fms and high affinity binding of M-CSF in smooth muscle cells isolated from an experimental rabbit model of arteriosclerosis (intimal smooth muscle cells), while no expression of c-fms was shown in medial smooth muscle cells. In the immunocytochemical analysis, both types of smooth muscle cells similarly reacted with an antibody specific to muscle cells (HHF 35) but did not react with an antibody specific to rabbit macrophages (RAM 11). In intimal smooth muscle cells, when cells were incubated with acetylated low density lipoproteins (LDL), the binding of acetylated LDL and foam cell formation were observed. In response to M-CSF, tyrosine-phosphorylation, as analyzed by the detection of anti-phosphotyrosine-reactive proteins, and an increased rate of cell proliferation were observed in intimal smooth muscle cells. These results indicated that intimal smooth muscle cells have the characteristics of monocyte-macrophages such as the expression of c-fms, which may be related to their proliferation and phenotypic conversion into foam cells in atheromatous lesions.	UNIV TOKYO,DEPT INTERNAL MED 3,TOKYO 113,JAPAN; SANRAKU HOSP,TOKYO,JAPAN; CHIBA UNIV,DEPT INTERNAL MED 2,CHIBA,JAPAN	University of Tokyo; Chiba University			Shimano, Hitoshi/V-1761-2019; Shimano, Hitoshi/AAI-5648-2020	Shimano, Hitoshi/0000-0002-5562-5572; 				BEISIEGEL U, 1982, J BIOL CHEM, V257, P3150; CLARK SC, 1987, SCIENCE, V236, P1229, DOI 10.1126/science.3296190; FISHERDZOGA K, 1973, EXP MOL PATHOL, V18, P162, DOI 10.1016/0014-4800(73)90014-2; GILLILAND G, 1990, P NATL ACAD SCI USA, V87, P2725, DOI 10.1073/pnas.87.7.2725; GOTODA T, 1989, BIOCHEM BIOPH RES CO, V164, P1391, DOI 10.1016/0006-291X(89)91824-X; HAMPE A, 1984, P NATL ACAD SCI-BIOL, V81, P85, DOI 10.1073/pnas.81.1.85; HANSSON GK, 1989, ARTERIOSCLEROSIS, V9, P567, DOI 10.1161/01.ATV.9.5.567; ISHIBASHI S, 1990, J BIOL CHEM, V265, P14109; JAAKKOLA O, 1988, ATHEROSCLEROSIS, V69, P257, DOI 10.1016/0021-9150(88)90022-6; KADOWAKI T, 1987, J BIOL CHEM, V262, P7342; KODAMA T, 1990, NATURE, V343, P531, DOI 10.1038/343531a0; MOTOYOSHI K, 1989, EXP HEMATOL, V17, P68; NAVARRO S, 1989, J IMMUNOL, V142, P4339; PITAS RE, 1990, J BIOL CHEM, V265, P12722; PITAS RE, 1981, ARTERIOSCLEROSIS, V1, P177, DOI 10.1161/01.ATV.1.3.177; PITAS RE, 1983, ARTERIOSCLEROSIS, V3, P2, DOI 10.1161/01.ATV.3.1.2; ROBERTS WM, 1988, CELL, V55, P665; ROSS R, 1986, CELL, V46, P155, DOI 10.1016/0092-8674(86)90733-6; SAITO Y, 1988, ATHEROSCLEROSIS, V69, P161; SHERR CJ, 1985, CELL, V41, P665, DOI 10.1016/S0092-8674(85)80047-7; SHIMANO H, 1990, J BIOL CHEM, V265, P12869; STANLEY ER, 1985, METHOD ENZYMOL, V116, P564; THYBERG J, 1990, ARTERIOSCLEROSIS, V10, P966, DOI 10.1161/01.ATV.10.6.966; TSUKADA T, 1986, ARTERIOSCLEROSIS, V6, P601, DOI 10.1161/01.ATV.6.6.601; WARREN MK, 1986, J IMMUNOL, V137, P2281; WILCOX JN, 1988, J CLIN INVEST, V82, P1134, DOI 10.1172/JCI113671; WONG GG, 1987, SCIENCE, V235, P1504, DOI 10.1126/science.3493529; YEUNG YG, 1987, P NATL ACAD SCI USA, V84, P1268, DOI 10.1073/pnas.84.5.1268	28	76	82	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1992	267	8					5693	5699						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HH747	1531986				2022-12-25	WOS:A1992HH74700104
J	HEGUY, A; BALDARI, CT; MACCHIA, G; TELFORD, JL; MELLI, M				HEGUY, A; BALDARI, CT; MACCHIA, G; TELFORD, JL; MELLI, M			AMINO-ACIDS CONSERVED IN INTERLEUKIN-1 RECEPTORS (IL-1RS) AND THE DROSOPHILA TOLL PROTEIN ARE ESSENTIAL FOR IL-1R SIGNAL TRANSDUCTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; DORSAL-VENTRAL POLARITY; TRANSCRIPTION FACTOR; GENE-EXPRESSION; CYCLIC-AMP; KINASE-C; CLONING; EMBRYO; CELLS; ESTABLISHMENT	The cytoplasmic domain of the human T cell-type interleukin-1 receptor (hIL-1R) is not involved in the binding, internalization, or nuclear localization of interleukin-1 (IL-1), but is essential for signal transduction. We have previously localized a 50-amino acid region (residues 477-527) critical for IL-1-mediated activation of the interleukin-2 promoter in T cells. This region displays a striking degree of amino acid conservation in human, murine, and chicken IL-1Rs. Here we report the results of a site-directed mutational analysis of the cytoplasmic domain of the hIL-1R. We have introduced single-amino acid substitutions at positions conserved in all three receptors and at nonconserved positions and identified key amino acids for IL-1R function in signal transduction. Three basic (Arg431, Lys515, and Arg518) and 3 aromatic (Phe513, Trp514, and Tyr519) amino acids that are conserved in human, murine, and chicken IL-1Rs could not be replaced without abolishing IL-1R-mediated signal transduction. A substitution at another conserved position (Pro521) reduces significantly the ability of the IL-1R to transmit the IL-1 signal. Nonconserved residues could be replaced without affecting signal transduction. The cytoplasmic domain of the IL-1R is related to that of the Drosophila Toll protein, with a 26% identity and a 43% similarity in amino acid sequence. The amino acids shown to be essential for IL-1R function are conserved in the Toll protein. Our experimental data indicate that the amino acid sequence similarity between the IL-1R and the Drosophila toll protein reflects a functional homology between the two proteins.	UNIV SIENA, DEPT EVOLUT BIOL, I-53100 SIENNA, ITALY	University of Siena	HEGUY, A (corresponding author), UNIV SIENA, SCLAVO RES CTR, I-53100 SIENNA, ITALY.		Telford, John Laird/ABG-8144-2020	Baldari, Cosima/0000-0002-4414-6744				ANDERSON KV, 1985, CELL, V42, P791, DOI 10.1016/0092-8674(85)90275-2; ANDERSON KV, 1985, CELL, V42, P779, DOI 10.1016/0092-8674(85)90274-0; BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BALDARI CT, 1991, J BIOL CHEM, V266, P19103; BANERJI J, 1983, CELL, V33, P729, DOI 10.1016/0092-8674(83)90015-6; CASAGLI MC, 1989, PREP BIOCHEM, V19, P23, DOI 10.1080/10826068908544894; CURTIS BM, 1989, P NATL ACAD SCI USA, V86, P3045, DOI 10.1073/pnas.86.9.3045; DINARELLO CA, 1989, ADV IMMUNOL, V44, P153, DOI [10.1016/s0065-2776(08)60642-2, 10.1016/S0065-2776(08)60642-2, DOI 10.1016/S0065-2776(08)60642-2]; GALLIS B, 1989, J IMMUNOL, V143, P3235; GAY NJ, 1991, NATURE, V351, P355, DOI 10.1038/351355b0; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; GILLIS S, 1980, J EXP MED, V152, P1709, DOI 10.1084/jem.152.6.1709; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GUIDA S, 1992, IN PRESS GENE; HASHIMOTO C, 1988, CELL, V52, P269, DOI 10.1016/0092-8674(88)90516-8; HEGUY A, 1991, CELL GROWTH DIFFER, V2, P311; HOUSE C, 1987, J BIOL CHEM, V262, P772; HOYOS B, 1989, SCIENCE, V244, P457, DOI 10.1126/science.2497518; JOHNSON D, 1986, CELL, V47, P545, DOI 10.1016/0092-8674(86)90619-7; KEITH FJ, 1990, EMBO J, V9, P4299, DOI 10.1002/j.1460-2075.1990.tb07878.x; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; MACCHIA G, 1990, MOL CELL BIOL, V10, P2731, DOI 10.1128/MCB.10.6.2731; MIZEL SB, 1990, IMMUNOL TODAY, V11, P390, DOI 10.1016/0167-5699(90)90154-2; ONEILL LAJ, 1990, IMMUNOL TODAY, V11, P392, DOI 10.1016/0167-5699(90)90155-3; ROSOFF PM, 1988, CELL, V54, P73, DOI 10.1016/0092-8674(88)90181-X; ROTH S, 1989, CELL, V59, P1189, DOI 10.1016/0092-8674(89)90774-5; RUSHLOW CA, 1989, CELL, V59, P1165, DOI 10.1016/0092-8674(89)90772-1; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; SCHNEIDER DS, 1991, GENE DEV, V5, P797, DOI 10.1101/gad.5.5.797; SHIRAKAWA F, 1989, MOL CELL BIOL, V9, P959, DOI 10.1128/MCB.9.3.959; SIMS JE, 1989, P NATL ACAD SCI USA, V86, P8946, DOI 10.1073/pnas.86.22.8946; STEIN D, 1991, CELL, V65, P725, DOI 10.1016/0092-8674(91)90381-8; STEWARD R, 1989, CELL, V59, P1179, DOI 10.1016/0092-8674(89)90773-3; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K	35	163	171	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 5	1992	267	4					2605	2609						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HB532	1531143				2022-12-25	WOS:A1992HB53200077
J	BISHOPRIC, NH; JAYASENA, V; WEBSTER, KA				BISHOPRIC, NH; JAYASENA, V; WEBSTER, KA			POSITIVE REGULATION OF THE SKELETAL ALPHA-ACTIN GENE BY FOS AND JUN IN CARDIAC MYOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEFT-VENTRICULAR HYPERTROPHY; TRANSCRIPTION FACTOR AP-1; RAT-HEART; ALPHA-1-ADRENERGIC RECEPTOR; C-FOS; PROTOONCOGENE INDUCTION; MUSCLE DIFFERENTIATION; CELL HYPERTROPHY; THYROID-HORMONE; BINDING PROTEIN	Transcription of the skeletal alpha-actin gene is selectively activated in rat myocardiocytes undergoing hypertrophy both in vivo and in vitro. In most of these models, transient expression of certain proto-oncogene transcription factors precedes hypertrophy and sarcomeric gene induction. Using expression vectors encoding Fos and Jun, the main constituents of transcriptional activator protein AP-1, we analyzed the role of these oncoproteins in mediating the transcriptional induction of skeletal alpha-actin by adrenergic stimulation. Both c-fos and c-jun were induced early after beta-adrenergic stimulation, with peak mRNA levels preceding skeletal alpha-actin induction by several hours. A second peak of c-jun mRNA coincided with skeletal alpha-actin induction. Co-transfection assays in cardiac myocytes and P19 teratocarcinoma cells demonstrated that over-expression of c-jun, or c-fos plus c-jun, transactivated the skeletal alpha-actin promoter by about 5-fold. Comparable activation was not seen for alpha-myosin heavy chain or cardiac alpha-actin promoters. Skeletal alpha-actin promoter sequences between -153 and -36 were required for maximal transactivation by c-fos/c-jun, and purified Fos and Jun were bound specifically within this region. A direct physiological role is suggested for the AP-1 transcription factor complex in regulating skeletal alpha-actin gene expression and alpha-actin isoform switching during the onset of signal-mediated cardiac myocyte hypertrophy.	UNIV CALIF SAN FRANCISCO, CARDIOVASC RES INST, DEPT MED, SAN FRANCISCO, CA 94143 USA; VET AFFAIRS MED CTR, SAN FRANCISCO, CA 94121 USA	University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA)	BISHOPRIC, NH (corresponding author), SRI INT, DIV LIFE SCI, M111, 333 RAVENSWOOD AVE, MENLO PK, CA 94025 USA.			Webster, Keith A/0000-0002-6431-3642	NHLBI NIH HHS [HL44578] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL044578, R29HL044578] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABATE C, 1990, P NATL ACAD SCI USA, V87, P1032, DOI 10.1073/pnas.87.3.1032; ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BAICHWAL VR, 1990, CELL, V63, P815, DOI 10.1016/0092-8674(90)90147-7; BISHOPRIC NH, 1987, J CLIN INVEST, V80, P1194, DOI 10.1172/JCI113179; BISHOPRIC NH, 1991, P NATL ACAD SCI USA, V88, P2132, DOI 10.1073/pnas.88.6.2132; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BUCKINGHAM ME, 1985, ESSAYS BIOCHEM, V20, P77; CHIEN KR, 1991, FASEB J, V5, P3037, DOI 10.1096/fasebj.5.15.1835945; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CLAYCOMB WC, 1975, J BIOL CHEM, V250, P3229; COMB M, 1986, NATURE, V323, P353, DOI 10.1038/323353a0; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; EDWARDS MKS, 1983, MOL CELL BIOL, V3, P2280, DOI 10.1128/MCB.3.12.2280; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; Frohlich E D, 1990, Adv Nephrol Necker Hosp, V19, P87; GAUB MP, 1990, CELL, V63, P1267, DOI 10.1016/0092-8674(90)90422-B; GIUS D, 1990, MOL CELL BIOL, V10, P4243, DOI 10.1128/MCB.10.8.4243; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GUSTAFSON TA, 1987, P NATL ACAD SCI USA, V84, P3122, DOI 10.1073/pnas.84.10.3122; HOH E, 1990, CIRCULATION, V82, P351; HU MCT, 1986, MOL CELL BIOL, V6, P15, DOI 10.1128/MCB.6.1.15; IWAKI K, 1990, J BIOL CHEM, V265, P13809; IZUMO S, 1988, P NATL ACAD SCI USA, V85, P339, DOI 10.1073/pnas.85.2.339; KLEIN I, 1986, J CLIN INVEST, V77, P1694, DOI 10.1172/JCI112488; KOMURO I, 1991, J BIOL CHEM, V266, P1265; KORNHAUSER JM, 1992, SCIENCE, V255, P1581, DOI 10.1126/science.1549784; KOVACICMILIVOJEVIC B, 1992, MOL CELL BIOL, V12, P292, DOI 10.1128/MCB.12.1.292; KOVARY K, 1991, MOL CELL BIOL, V11, P2451, DOI 10.1128/MCB.11.5.2451; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LONG CS, 1989, J CLIN INVEST, V83, P1078, DOI 10.1172/JCI113951; MANN DL, 1989, CIRC RES, V64, P1079, DOI 10.1161/01.RES.64.6.1079; MINTY A, 1986, MOL CELL BIOL, V6, P2125, DOI 10.1128/MCB.6.6.2125; MINTY AJ, 1982, CELL, V30, P185, DOI 10.1016/0092-8674(82)90024-1; MIWA T, 1987, MOL CELL BIOL, V7, P2803, DOI 10.1128/MCB.7.8.2803; MIWA T, 1987, P NATL ACAD SCI USA, V84, P6702, DOI 10.1073/pnas.84.19.6702; MORGAN HE, 1991, CIRCULATION, V83, P13, DOI 10.1161/01.CIR.83.1.13; MORKIN E, 1989, UCLA S MOL CELLULAR, V93, P381; MUSCAT GEO, 1987, MOL CELL BIOL, V7, P4089, DOI 10.1128/MCB.7.11.4089; NADALGINARD B, 1989, J CLIN INVEST, V84, P1693, DOI 10.1172/JCI114351; NARANJO JR, 1991, NEURON, V6, P607, DOI 10.1016/0896-6273(91)90063-6; ORDAHL CP, 1986, DEV BIOL, V117, P488, DOI 10.1016/0012-1606(86)90315-5; OWEN TA, 1990, P NATL ACAD SCI USA, V87, P9990, DOI 10.1073/pnas.87.24.9990; PARKER TG, 1990, P NATL ACAD SCI USA, V87, P7066, DOI 10.1073/pnas.87.18.7066; PARKER TG, 1991, ANNU REV PHYSIOL, V53, P179; RANSONE LJ, 1990, ANNU REV CELL BIOL, V6, P539, DOI 10.1146/annurev.cellbio.6.1.539; RAUSCHER FJ, 1988, GENE DEV, V2, P1687, DOI 10.1101/gad.2.12b.1687; RAUSCHER FJ, 1988, SCIENCE, V240, P1010, DOI 10.1126/science.3130660; SARTORELLI V, 1992, P NATL ACAD SCI USA, V89, P4047, DOI 10.1073/pnas.89.9.4047; SCHUNKERT H, 1991, P NATL ACAD SCI USA, V88, P11480, DOI 10.1073/pnas.88.24.11480; SCHWARTZ K, 1981, J MOL CELL CARDIOL, V13, P1071, DOI 10.1016/0022-2828(81)90297-2; SCHWARTZ K, 1986, CIRC RES, V59, P551, DOI 10.1161/01.RES.59.5.551; SIMPSON P, 1982, CIRC RES, V51, P787, DOI 10.1161/01.RES.51.6.787; SIMPSON P, 1985, CIRC RES, V56, P884, DOI 10.1161/01.RES.56.6.884; SONNENBERG JL, 1989, SCIENCE, V246, P1622, DOI 10.1126/science.2512642; STARKSEN NF, 1986, P NATL ACAD SCI USA, V83, P8348, DOI 10.1073/pnas.83.21.8348; TAKAHASHI T, 1992, J CLIN INVEST, V89, P939, DOI 10.1172/JCI115675; TAKIMOTO M, 1989, J BIOL CHEM, V264, P8992; TARAZI RC, 1982, EUR HEART J, V3, P103, DOI 10.1093/eurheartj/3.suppl_A.103; TARAZI RC, 1983, AM J MED, V75, P80, DOI 10.1016/0002-9343(83)90123-7; TAYLOR A, 1988, GENOMICS, V3, P323, DOI 10.1016/0888-7543(88)90123-1; TRIMARCO B, 1989, AM J HYPERTENS, V2, pS278, DOI 10.1093/ajh/2.11.278S; WASPE LE, 1990, J CLIN INVEST, V85, P1206, DOI 10.1172/JCI114554	64	71	73	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	1992	267	35					25535	25540						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KB603	1460048				2022-12-25	WOS:A1992KB60300093
J	MITCHELL, PJ; COOPER, CS				MITCHELL, PJ; COOPER, CS			THE HUMAN TPR GENE ENCODES A PROTEIN OF 2094 AMINO-ACIDS THAT HAS EXTENSIVE COILED-COIL REGIONS AND AN ACIDIC C-TERMINAL DOMAIN	ONCOGENE			English	Note							MET ONCOGENIC REARRANGEMENT; TYROSINE KINASE; ACTIVATION; SEQUENCES; RAF	We recently provided evidence that the human tpr gene encodes a 726 amino acid protein (designated tpr-S) and identified an alternatively spliced transcript that encodes a larger tpr protein with an extended C-terminal domain. In this study, through isolation and sequencing of tpr cDNA clones, we have established that this alternatively spliced transcript encodes a protein of 2094 amino acids (designated tpr-L). The larger tpr protein is predicted to have extensive regions of alpha-helix and several stretches of a heptad repeat that is characteristic of proteins adopting a coiled-coil conformation. Furthermore the carboxy domain of this protein is very rich in acidic residues and exhibits homology (58-80%) to the acidic regions of several nuclear proteins, including the Drosophila engrailed protein, Escherichia coli RNA polymerase sigma subunit and nucleolin. To gain additional insight into the function of tpr we examined the expression of tpr transcripts in tissues from adult rat. The highest levels of tpr transcripts were observed in testis, lung, thymus and spleen.			MITCHELL, PJ (corresponding author), INST CANC RES,MOLEC CARCINOGENESIS SECT,15 COTSWOLD RD,SUTTON SM2 5NG,SURREY,ENGLAND.		Mitchell, Philip J/F-6393-2013					CHAN AML, 1987, ONCOGENE, V1, P229; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GONZATTIHACES M, 1988, P NATL ACAD SCI USA, V85, P21, DOI 10.1073/pnas.85.1.21; GRECO A, 1992, ONCOGENE, V7, P237; ISHIKAWA F, 1987, MOL CELL BIOL, V7, P1226, DOI 10.1128/MCB.7.3.1226; KARPLUS PA, 1985, NATURWISSENSCHAFTEN, V72, P212, DOI 10.1007/BF01195768; KING HWS, 1988, ONCOGENE, V2, P617; KOPCHICK JJ, 1981, ANAL BIOCHEM, V115, P419, DOI 10.1016/0003-2697(81)90027-0; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; MIKI T, 1989, GENE, V83, P137, DOI 10.1016/0378-1119(89)90411-3; MITCHELL PJ, 1992, ONCOGENE, V7, P383; PARK M, 1986, COLD SPRING HARB SYM, V51, P967, DOI 10.1101/SQB.1986.051.01.110; PARK M, 1986, CELL, V45, P895, DOI 10.1016/0092-8674(86)90564-7; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SOMAN NR, 1991, P NATL ACAD SCI USA, V88, P4892, DOI 10.1073/pnas.88.11.4892; SOMAN NR, 1990, P NATL ACAD SCI USA, V87, P738, DOI 10.1073/pnas.87.2.738; TEMPEST PR, 1986, CARCINOGENESIS, V7, P2051, DOI 10.1093/carcin/7.12.2051; TEMPEST PR, 1986, FEBS LETT, V209, P357, DOI 10.1016/0014-5793(86)81142-5	22	40	43	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1992	7	11					2329	2333						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JW665	1437155				2022-12-25	WOS:A1992JW66500027
J	KESSLER, SP; GALLOWAY, DR				KESSLER, SP; GALLOWAY, DR			PSEUDOMONAS-AERUGINOSA EXOTOXIN-A INTERACTION WITH EUKARYOTIC ELONGATION FACTOR-II - ROLE OF THE HIS(426) RESIDUE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-SEQUENCE; ESCHERICHIA-COLI; GENE; EXPRESSION; CLONING	Pseudomonas aeruginosa exotoxin A (ETA) catalyzes the transfer of the ADP-ribose moiety of NAD+ onto eucaryotic elongation factor 2 (EF-2). To study the ETA site of interaction with EF-2, an immobilized EF-2 binding assay was developed. This assay demonstrates that ETA, in the presence of NAD+, binds to immobilized EF-2. Additionally, diphtheria toxin was also found to bind to the immobilized EF-2 in the presence of NAD+. Comparative analysis was performed with a mutated form of ETA (CRM 66) in which a histidine residue at position 426 has been replaced with a tyrosine residue. This immunologically cross-reactive, ADP-ribosyl transferase-deficient toxin does not bind to immobilized EF-2, thus explaining its lack of ADPRT activity. ETA bound to immobilized EF-2 cannot bind the monoclonal antibody TC-1 which specifically recognizes the ETA epitope containing His426. Immunoprecipitation of native ETA by mAb TC-1 is only achieved by incubating ETA in the presence of NAD+. Diethyl pyrocarbonate modification of the His426 residue blocks ETA binding to EF-2 and prevents the binding of the TC-1 antibody. Analogs of NAD+ containing a reduced nicotinamide ring or modified adenine moieties cannot substitute for NAD+ in the immobilized binding assay. Collectively, these data support our proposal that the site of ETA interaction with EF-2 includes His426 and that a molecule of NAD+ is required for stable interaction.	OHIO STATE UNIV,DEPT MICROBIOL,484 W 12TH AVE,COLUMBUS,OH 43210	University System of Ohio; Ohio State University					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K04AI000876] Funding Source: NIH RePORTER; NIAID NIH HHS [AI00876-02, AI12349-04] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALLURED VS, 1986, P NATL ACAD SCI USA, V83, P1320, DOI 10.1073/pnas.83.5.1320; BREITENBERGER CA, 1979, ANAL BIOCHEM, V99, P434, DOI 10.1016/S0003-2697(79)80029-9; DOUGLAS CM, 1987, J BACTERIOL, V169, P4967, DOI 10.1128/jb.169.11.4967-4971.1987; ENGVALL E, 1971, IMMUNOCHEMISTRY, V8, P871, DOI 10.1016/0019-2791(71)90454-X; GALLOWAY DR, 1984, INFECT IMMUN, V44, P262, DOI 10.1128/IAI.44.2.262-267.1984; GALLOWAY DR, 1989, J BIOL CHEM, V264, P14869; GRAY GL, 1984, P NATL ACAD SCI-BIOL, V81, P2645, DOI 10.1073/pnas.81.9.2645; HWANG J, 1987, CELL, V48, P129, DOI 10.1016/0092-8674(87)90363-1; IGLEWSKI BH, 1977, INFECT IMMUN, V15, P138, DOI 10.1128/IAI.15.1.138-144.1977; KANDEL J, 1974, J BIOL CHEM, V249, P2088; LEPPLA SH, 1976, INFECT IMMUN, V14, P1077, DOI 10.1128/IAI.14.4.1077-1086.1976; LIU PV, 1980, J INFECT DIS, V142, P538; MCGOWAN JL, 1990, J BIOL CHEM, V266, P4911; Miles E W, 1977, Methods Enzymol, V47, P431; MOZOLA MA, 1984, J BACTERIOL, V159, P683, DOI 10.1128/JB.159.2.683-687.1984; SPREMULLI LL, 1977, ARCH BIOCHEM BIOPHYS, V178, P565, DOI 10.1016/0003-9861(77)90227-2; WOZNIAK DJ, 1987, NUCLEIC ACIDS RES, V15, P2123, DOI 10.1093/nar/15.5.2123; WOZNIAK DJ, 1988, P NATL ACAD SCI USA, V77, P7199	18	16	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1992	267	27					19107	19111						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JP593	1527035				2022-12-25	WOS:A1992JP59300018
J	MARSZALEK, J; KAGUNI, JM				MARSZALEK, J; KAGUNI, JM			DEFECTIVE REPLICATION ACTIVITY OF A DOMINANT-LETHAL DNAB GENE-PRODUCT FROM ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-STRANDED-DNA; PROTEIN ACTION; ENZYMATIC REPLICATION; BACTERIOPHAGE-LAMBDA; PHYSICAL-PROPERTIES; NUCLEOTIDE-SEQUENCE; CHROMOSOMAL ORIGIN; RNA-POLYMERASE; INITIATION; MECHANISM	dnaB protein of Escherichia coli is an essential replication protein. A missense mutant has been obtained which results in replacement of an arginine residue with cysteine at position 231 of the protein (P. Shrimankar, L. Shortle, and R. Maurer, unpublished data). This mutant displays a dominant-lethal phenotype in strains that are heterodiploid for dnaB. Biochemical analysis of the altered form of dnaB protein revealed that it was inactive in replication in several purified enzyme systems which involve specific and nonspecific primer formation on single-stranded DNAs, and in replication of plasmids containing the E. coli chromosomal origin. Inactivity in replication appeared to be due to its inability to bind to single-stranded DNA. The altered dnaB protein was inhibitory to the activity of wild type dnaB protein in replication by sequestering dnaC protein which is also required for replication. By contrast, it was not inhibitory to dnaB protein in priming of single-stranded DNA by primase in the absence of single-stranded DNA binding protein. Sequestering of dnaC protein into inactive complexes may relate to the dominant-lethal phenotype of this dnaB mutant.	MICHIGAN STATE UNIV,DEPT BIOCHEM,E LANSING,MI 48824	Michigan State University			Marszalek, Jaroslaw/F-5824-2011	Kaguni, Jon/0000-0002-3096-4447; Marszalek, Jaroslaw/0000-0002-6978-1189	NIGMS NIH HHS [R01 GM033992, GM33992] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEN GC, 1991, J BIOL CHEM, V266, P22096; ARAI K, 1981, J BIOL CHEM, V256, P5260; ARAI K, 1981, P NATL ACAD SCI-BIOL, V78, P69, DOI 10.1073/pnas.78.1.69; ARAI K, 1981, J BIOL CHEM, V256, P5247; ARAI K, 1981, J BIOL CHEM, V256, P5267; ARAI K, 1981, J BIOL CHEM, V256, P5273; ARAI K, 1981, J BIOL CHEM, V256, P5253; ARAI KI, 1981, P NATL ACAD SCI-BIOL, V78, P707, DOI 10.1073/pnas.78.2.707; BAKER TA, 1986, CELL, V45, P53, DOI 10.1016/0092-8674(86)90537-4; BAKER TA, 1987, J BIOL CHEM, V262, P6877; BRAMHILL D, 1988, CELL, V54, P915, DOI 10.1016/0092-8674(88)90102-X; BRAMHILL D, 1988, CELL, V52, P743, DOI 10.1016/0092-8674(88)90412-6; FINCH PW, 1984, NUCLEIC ACIDS RES, V12, P5789, DOI 10.1093/nar/12.14.5789; FULLER RS, 1981, P NATL ACAD SCI-BIOL, V78, P7370, DOI 10.1073/pnas.78.12.7370; HWANG DS, 1988, J BIOL CHEM, V263, P10633; KAGUNI JM, 1984, CELL, V38, P183, DOI 10.1016/0092-8674(84)90539-7; KOBORI JA, 1982, J BIOL CHEM, V257, P13763; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANKA E, 1983, NUCLEIC ACIDS RES, V11, P987, DOI 10.1093/nar/11.4.987; LEBOWITZ JH, 1985, P NATL ACAD SCI USA, V82, P3988, DOI 10.1073/pnas.82.12.3988; LEBOWITZ JH, 1984, NUCLEIC ACIDS RES, V12, P3069, DOI 10.1093/nar/12.7.3069; LEBOWITZ JH, 1986, J BIOL CHEM, V261, P4738; MASAI H, 1990, J BIOL CHEM, V265, P15134; MCMACKEN R, 1977, P NATL ACAD SCI USA, V74, P4190, DOI 10.1073/pnas.74.10.4190; MINDEN JS, 1985, J BIOL CHEM, V260, P9316; MOK M, 1987, J BIOL CHEM, V262, P16644; NAKAYAMA N, 1984, J BIOL CHEM, V259, P97; OGAWA T, 1985, P NATL ACAD SCI USA, V82, P3562, DOI 10.1073/pnas.82.11.3562; REHAKRANTZ LJ, 1978, J BIOL CHEM, V253, P4051; REHAKRANTZ LJ, 1978, J BIOL CHEM, V253, P4043; SCHEKMAN R, 1975, J BIOL CHEM, V250, P5859; SCLAFANI RA, 1981, J BACTERIOL, V146, P418, DOI 10.1128/JB.146.1.418-421.1981; SEKIMIZU K, 1987, CELL, V50, P259, DOI 10.1016/0092-8674(87)90221-2; SPICER EK, 1984, J BIOL CHEM, V259, P5425; STAUDENBAUER WL, 1979, MOL GEN GENET, V177, P113, DOI 10.1007/BF00267260; STAUDENBAUER WL, 1978, MOL GEN GENET, V162, P243, DOI 10.1007/BF00268849; VANDERENDE A, 1985, P NATL ACAD SCI USA, V82, P3954; WAHLE E, 1989, J BIOL CHEM, V264, P2469; WAHLE E, 1989, J BIOL CHEM, V264, P2463; WECHSLER JA, 1971, MOL GEN GENET, V113, P273, DOI 10.1007/BF00339547; WICKNER S, 1974, P NATL ACAD SCI USA, V71, P4120, DOI 10.1073/pnas.71.10.4120; WOLD MS, 1982, P NATL ACAD SCI-BIOL, V79, P6176, DOI 10.1073/pnas.79.20.6176	42	21	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1992	267	27					19334	19340						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JP593	1527054				2022-12-25	WOS:A1992JP59300049
J	BRADFUTE, DL; SILVA, CJ; SIMONI, RD				BRADFUTE, DL; SILVA, CJ; SIMONI, RD			SQUALENE SYNTHASE-DEFICIENT MUTANT OF CHINESE-HAMSTER OVARY CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COENZYME-A REDUCTASE; HMG COA REDUCTASE; 3-HYDROXY-3-METHYLGLUTARYL-COA REDUCTASE; ENDOPLASMIC-RETICULUM; REGULATED DEGRADATION; SYNTHETASE-ACTIVITY; HUMAN-FIBROBLASTS; PATHWAY; GALACTOSIDASE; PURIFICATION	Squalene synthase (farnesyldiphosphate:farnesyldiphosphate farnesyl transferase, EC 2.5.1.21) converts farnesyl pyrophosphate to squalene, the first metabolic step committed solely to the biosynthesis of sterols. Using a fluorescence-activated cell sorting technique designed to screen for cells defective in the regulated degradation of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, we isolated a squalene synthase-deficient mutant of Chinese hamster ovary cells. The mutant cell line, designated SSD, exhibits less than 7% of the squalene synthase activity of the parental cell line, CHO-HMGal. Both the SSD and the parental cells stably express HMGal, a model protein for studying the regulated degradation of HMG-COA reductase, which consists of the membrane domain of HMG-COA reductase fused to bacterial beta-galactosidase (Skalnik, D. G., Narita, H., Kent, C., and Simoni, R. D. (1988) J. Biol. Chem. 263, 6836-6841). In this study, the regulatory effects of mevalonate and compactin on the activity levels of HMGal are substantially reduced in SSD cells as compared to the parental cell line. In lipid-poor medium, SSD cell growth is arrested. The rate of [H-3]acetate incorporation into cholesterol for the mutant SSD cells is less than 2% of the rate for the parental cells. However, the incorporation of [H-3] squalene into sterols is essentially wild type for SSD cells. When the mutant SSD cells are fed [H-3]acetate, radioactivity accumulates in farnesol, much of which is secreted into the medium. By growing SSD cells in lipid-poor medium, a revertant cell type, designated SSR, was isolated. In every assay performed the revertant SSR cells exhibited a phenotype that was essentially wild type, demonstrating that the SSD mutant phenotype was the result of a single mutation.	STANFORD UNIV,DEPT BIOL SCI,STANFORD,CA 94305	Stanford University			Silva, Christopher/T-9568-2019; Silva, Christopher/AAC-6593-2019	Silva, Christopher/0000-0003-4521-6377; 	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL026502] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL26502] Funding Source: Medline; NIGMS NIH HHS [GM07276] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGNEW WS, 1985, METHOD ENZYMOL, V110, P359; BARTIZAL KF, 1991, Patent No. 5026554; BILLER SA, 1988, J MED CHEM, V31, P1869, DOI 10.1021/jm00118a001; BROWN MS, 1980, J LIPID RES, V21, P505; CHEN HW, 1988, J BIOL CHEM, V263, P1248; CHIN DJ, 1985, MOL CELL BIOL, V5, P634, DOI 10.1128/MCB.5.4.634; CHUN KT, 1990, J BIOL CHEM, V265, P22004; CHUN KT, 1992, J BIOL CHEM, V267, P4236; COHEN LH, 1989, BIOCHIM BIOPHYS ACTA, V1002, P69, DOI 10.1016/0005-2760(89)90065-9; COHEN LH, 1986, BIOCHEM BIOPH RES CO, V138, P335, DOI 10.1016/0006-291X(86)90285-8; FAUST JR, 1979, P NATL ACAD SCI USA, V76, P5018, DOI 10.1073/pnas.76.10.5018; FAUST JR, 1979, ARCH BIOCHEM BIOPHYS, V192, P86, DOI 10.1016/0003-9861(79)90074-2; GIBBONS GF, 1982, BIOCH CHOLESTEROL, P172; GIL G, 1985, CELL, V41, P249, DOI 10.1016/0092-8674(85)90078-9; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; INOUE S, 1991, J BIOL CHEM, V266, P13311; JENNINGS SM, 1991, P NATL ACAD SCI USA, V88, P6038, DOI 10.1073/pnas.88.14.6038; KARST F, 1977, MOL GEN GENET, V154, P269, DOI 10.1007/BF00571282; KUSWIKRABIEGA G, 1987, J BIOL CHEM, V262, P1505; LOWRY OH, 1951, J BIOL CHEM, V193, P265; NAKANISHI M, 1988, J BIOL CHEM, V263, P8929; NOLAN GP, 1988, P NATL ACAD SCI USA, V85, P2603, DOI 10.1073/pnas.85.8.2603; OLENDER EH, 1992, J BIOL CHEM, V267, P4223; POPJAK G, 1969, J BIOL CHEM, V244, P1897; RILLING HC, 1966, J BIOL CHEM, V241, P3233; ROITELMAN J, 1991, J BIOL CHEM, V266, P16085; ROTHBLAT GH, 1976, IN VITRO CELL DEV B, V12, P554; SASIAK K, 1988, ARCH BIOCHEM BIOPHYS, V260, P622, DOI 10.1016/0003-9861(88)90490-0; SHECHTER I, 1992, J BIOL CHEM, V267, P8628; SILVA CJ, 1991, COMP BIOCHEM PHYS B, V99, P763, DOI 10.1016/0305-0491(91)90140-9; SKALNIK DG, 1988, J BIOL CHEM, V263, P6836	31	25	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1992	267	26					18308	18314						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JN502	1526971				2022-12-25	WOS:A1992JN50200013
J	WITKOWSKI, A; NAGGERT, J; WITKOWSKA, HE; RANDHAWA, ZI; SMITH, S				WITKOWSKI, A; NAGGERT, J; WITKOWSKA, HE; RANDHAWA, ZI; SMITH, S			UTILIZATION OF AN ACTIVE SERINE 101 -] CYSTEINE MUTANT TO DEMONSTRATE THE PROXIMITY OF THE CATALYTIC SERINE 101 AND HISTIDINE 237 RESIDUES IN THIOESTERASE-II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACID SYNTHETASE; RAT MAMMARY-GLAND; MODIFIES PRODUCT SPECIFICITY; THIO ESTER HYDROLASE; MOLECULAR-CLONING; SEQUENCE-ANALYSIS; ESCHERICHIA-COLI; UROPYGIAL GLAND; PURIFICATION; SYNTHASE	Thioesterase II is a 29-kDa monomer which, in certain specialized tissues, acts as a chain terminator in fatty acid synthesis by hydrolyzing medium-chain fatty acids from the fatty acid synthase. As with serine proteases, hydrolysis appears to involve acylation of the active site serine residue (Ser-101) assisted by a histidine, tentatively identified as His-237. To determine whether in the folded protein His-237 is close enough to accept a proton from the Ser-101 hydroxyl, we have made use of a Ser101Cys mutant which retains up to 90% of catalytic activity. Unlike the wild-type enzyme, the S101C thioesterase is inhibited with stoichiometric amounts of the bifunctional alkylating reagent 1,3-dibromopropanone. To facilitate identification of the alkylated residue(s), the keto group introduced into the dibromopropanone-modified S101C mutant was radiolabeled by reduction with sodium [H-3] borohydride. The protein was then digested and the radiolabeled peptides analyzed by amino acid sequencing and mass spectrometry. The experimental data unambiguously showed that dibromopropanone cross-linked the active site Cys-101 with His-237, demonstrating that these residues are positioned within 5 angstrom of each other. These data strongly support the hypothesis that in the wild-type thioesterase His-237 accepts a proton from Ser-101, thus increasing its nucleophilic character and improving the catalytic efficiency of the enzyme. The possibility that exchange of cysteine and serine active site residues has occurred in the evolution of thioesterases is discussed.	CHILDRENS HOSP,OAKLAND RES INST,747 52ND ST,OAKLAND,CA 94609; OTSUKA AMER PHARMACEUT INC,ROCKVILLE,MD 20850	Children's Hospital Los Angeles; Children's Hospital Oakland Research Institute				Witkowski, Andrzej/0000-0002-0442-4586	NIDDK NIH HHS [DK16073] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK016073] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BEVITT DJ, 1992, EUR J BIOCHEM, V204, P39, DOI 10.1111/j.1432-1033.1992.tb16603.x; BRENNER S, 1988, NATURE, V334, P528, DOI 10.1038/334528a0; DERENOBALES M, 1980, ARCH BIOCHEM BIOPHYS, V205, P464, DOI 10.1016/0003-9861(80)90129-0; DONADIO S, 1991, SCIENCE, V252, P675, DOI 10.1126/science.2024119; DRENTH J, 1968, NATURE, V218, P929, DOI 10.1038/218929a0; GIBNEY G, 1990, P NATL ACAD SCI USA, V87, P7546, DOI 10.1073/pnas.87.19.7546; HARDIE DG, 1985, BIOCHIM BIOPHYS ACTA, V828, P380, DOI 10.1016/0167-4838(85)90320-6; HIGAKI JN, 1989, BIOCHEMISTRY-US, V28, P9256, DOI 10.1021/bi00450a004; HUSAIN SS, 1968, BIOCHEM J, V108, P855, DOI 10.1042/bj1080855; HUSAIN SS, 1968, BIOCHEM J, V108, P861, DOI 10.1042/bj1080861; IRWIN DM, 1988, NATURE, V336, P429, DOI 10.1038/336429b0; KNUDSEN J, 1976, BIOCHEM J, V160, P683, DOI 10.1042/bj1600683; KRATZSCHMAR J, 1989, J BACTERIOL, V171, P5422; LIBERTINI L, 1976, FED PROC, V35, P1069; LIBERTINI LJ, 1978, J BIOL CHEM, V253, P1393; LIN CY, 1978, J BIOL CHEM, V253, P1954; LINN TC, 1981, ARCH BIOCHEM BIOPHYS, V209, P613, DOI 10.1016/0003-9861(81)90320-9; MCGRATH ME, 1989, BIOCHEMISTRY-US, V28, P9264, DOI 10.1021/bi00450a005; NAGGERT J, 1991, BIOCHEM J, V273, P787, DOI 10.1042/bj2730787; NAGGERT J, 1988, J BIOL CHEM, V263, P1146; NEET KE, 1966, P NATL ACAD SCI USA, V56, P1606, DOI 10.1073/pnas.56.5.1606; PAZIRANDEH M, 1991, J BIOL CHEM, V266, P20946; POLGAR L, 1966, J AM CHEM SOC, V88, P153; POULOSE AJ, 1985, J BIOL CHEM, V260, P5953; RAIBAUD A, 1991, J BACTERIOL, V173, P4454, DOI 10.1128/JB.173.14.4454-4463.1991; RANDHAWA ZI, 1987, BIOCHEMISTRY-US, V26, P1365, DOI 10.1021/bi00379a024; RANDHAWA ZI, 1987, EUR J BIOCHEM, V162, P577, DOI 10.1111/j.1432-1033.1987.tb10678.x; ROGERS L, 1982, J BIOL CHEM, V257, P880; SAFFORD R, 1987, BIOCHEMISTRY-US, V26, P1358, DOI 10.1021/bi00379a023; Smith S, 1981, Methods Enzymol, V71 Pt C, P188, DOI 10.1016/0076-6879(81)71027-9; WITKOWSKA HE, 1990, J BIOL CHEM, V265, P5662; WITKOWSKI A, 1991, J BIOL CHEM, V266, P18514; YANG CY, 1988, BIOCHEMISTRY-US, V27, P7773, DOI 10.1021/bi00420a028; YOKOSAWA H, 1977, J BIOCHEM-TOKYO, V82, P869, DOI 10.1093/oxfordjournals.jbchem.a131763	35	38	39	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1992	267	26					18488	18492						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JN502	1526985				2022-12-25	WOS:A1992JN50200040
J	ZANOTTI, G; SCAPIN, G; SPADON, P; VEERKAMP, JH; SACCHETTINI, JC				ZANOTTI, G; SCAPIN, G; SPADON, P; VEERKAMP, JH; SACCHETTINI, JC			3-DIMENSIONAL STRUCTURE OF RECOMBINANT HUMAN MUSCLE FATTY ACID-BINDING PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-RAY DATA; HUMAN SKELETAL-MUSCLE; ESCHERICHIA-COLI; CRYSTAL-STRUCTURE; CRYSTALLIZATION; CRYSTALLOGRAPHY; PURIFICATION; EXPRESSION; RESOLUTION	The three-dimensional structure of recombinant human muscle fatty acid-binding protein with a bound fatty acid has been solved and refined with x-ray diffraction data to 2.1 angstrom resolution. The refined model has a crystallographic R factor of 19.5% for data between 9.0 and 2.1 angstrom (7243 unique reflections) and root-mean-square deviations in bond length and bond angle of 0.013 angstrom and 2.7-degrees. The protein contains 10 antiparallel beta-strands and two short alpha-helices which are arranged into two approximately orthogonal beta-sheets. Difference electron density maps and a multiple isomorphous derivative electron density map showed the presence of a single bound molecule of a long chain fatty acid within the interior core of the protein. The hydrocarbon tail of the fatty acid was found to be in a "U-shaped" conformation. Seven ordered water molecules were also identified within the interior of the protein in a pocket on the pseudo-si face of the fatty acid's bent hydrocarbon tail. The methylene tail of the fatty acid forms van der Waals interactions with atoms from 13 residues and three ordered waters. The carboxylate of the fatty acid is located in the interior of the protein where it forms hydrogen bonds with the side chains of Tyr128 and Arg126 and two ordered water molecules. A comparison of the three-dimensional structure of human muscle fatty acid-binding protein and rat intestinal fatty acid-binding protein shows strong similarity. Both proteins bind a single fatty acid within their interior cores, but the bound fatty acids are very different in their conformations and interactions. These findings suggest that the intestinal and muscle fatty acid-binding proteins have evolved distinct binding sites in order to satisfy different requirements within the tissues where they are expressed.	YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT BIOCHEM,BRONX,NY 10461; CATHOLIC UNIV NIJMEGEN,DEPT BIOCHEM,6500 HB NIJMEGEN,NETHERLANDS	Yeshiva University; Albert Einstein College of Medicine; Radboud University Nijmegen	ZANOTTI, G (corresponding author), UNIV PADUA,BIOPOLYMER RES CTR,DEPT ORGAN CHEM,I-35126 PADUA,ITALY.			Zanotti, Giuseppe/0000-0002-0945-6501	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045859] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM45859] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERGFORS T, 1987, J MOL BIOL, V198, P357, DOI 10.1016/0022-2836(87)90319-6; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; BRUNGER AT, 1990, XPLOR VERSION 2 1 MA; BUELT MK, 1991, J BIOL CHEM, V266, P12266; CROWTHER RA, 1972, MOL REPLACEMENT METH; FITZGERALD PMD, 1988, J APPL CRYSTALLOGR, V21, P273, DOI 10.1107/S0021889887012299; JONES TA, 1988, EMBO J, V7, P1597, DOI 10.1002/j.1460-2075.1988.tb02985.x; JONES TA, 1985, METHOD ENZYMOL, V115, P157; LUZZATI V, 1952, ACTA CRYSTALLOGR, V5, P802, DOI 10.1107/S0365110X52002161; MCPHERSON A, 1982, PREPARATION ANAL PRO, P96; MULLERFAHRNOW A, 1991, EUR J BIOCHEM, V199, P271, DOI 10.1111/j.1432-1033.1991.tb16120.x; NEWCOMER ME, 1981, J BIOL CHEM, V256, P8162; PAEHLER A, 1985, FEBS LETT, V184, P185; PEETERS RA, 1989, ARCH BIOCHEM BIOPHYS, V274, P556, DOI 10.1016/0003-9861(89)90470-0; PEETERS RA, 1991, BIOCHEM J, V276, P203, DOI 10.1042/bj2760203; PEETERS RA, 1991, BIOCHEM J, V278, P361, DOI 10.1042/bj2780361; Richardson J S, 1981, Adv Protein Chem, V34, P167, DOI 10.1016/S0065-3233(08)60520-3; SACCHETTINI JC, 1987, J BIOL CHEM, V262, P15756; SACCHETTINI JC, 1989, J MOL BIOL, V208, P327, DOI 10.1016/0022-2836(89)90392-6; SACCHETTINI JC, 1989, P NATL ACAD SCI USA, V86, P7736, DOI 10.1073/pnas.86.20.7736; SACCHETTINI JC, 1987, J BIOL CHEM, V262, P5428; SACCHETTINI JC, 1990, J BIOL CHEM, V265, P19199; SCAPIN G, 1992, J BIOL CHEM, V267, P4253; SCAPIN G, 1990, MOL CELL BIOCHEM, V98, P95; SCAPIN G, 1988, FEBS LETT, V240, P196, DOI 10.1016/0014-5793(88)80367-3; SRIMANI BN, 1990, CIRC RES, V66, P1535, DOI 10.1161/01.RES.66.6.1535; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489, DOI 10.1107/S0108767387099124; VEERKAMP JH, 1991, BIOCHIM BIOPHYS ACTA, V1081, P1, DOI 10.1016/0005-2760(91)90244-C; WANG BC, 1985, METHOD ENZYMOL, V115, P90; WINTER NS, 1990, J BIOL CHEM, V265, P10955; XU ZH, 1992, BIOCHEMISTRY-US, V31, P3484, DOI 10.1021/bi00128a024; XU ZH, 1991, J BIOL CHEM, V266, P14367; XUONG NH, 1985, J APPL CRYSTALLOGR, V18, P342, DOI 10.1107/S0021889885010433	33	172	176	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1992	267	26					18541	18550						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JN502	1526991				2022-12-25	WOS:A1992JN50200048
J	RANDALL, TD; BREWER, JW; CORLEY, RB				RANDALL, TD; BREWER, JW; CORLEY, RB			DIRECT EVIDENCE THAT J-CHAIN REGULATES THE POLYMERIC STRUCTURE OF IGM IN ANTIBODY-SECRETING B-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNOGLOBULIN-J-CHAIN; A IGA; MOUSE; DIFFERENTIATION; BIOSYNTHESIS; EXPRESSION; IDENTIFICATION; TRANSCRIPTS; ENZYME	IgM is secreted in two functional polymeric forms. Secreted IgM was originally thought to be exclusively a pentameric molecule containing J (joining) chain, but many B cells also secrete hexameric IgM lacking J chain. Hexameric IgM may play an important role in the immune system, since it is up to 20 times more active than pentameric IgM in initiating the complement cascade. The predominant polymeric form of IgM secreted by B cell lines, either pentameric or hexameric, correlates with the concentration of J chain present during polymerization, and cells that express high levels of J chain secrete mostly IgM pentamers. The B cell lymphoma WEHI-231 does not express J chain, and the majority of its secreted IgM is polymerized as hexamers. When a J chain-encoding cDNA was expressed in these cells, the secreted IgM was found to be almost exclusively pentameric. However, although the expression of J chain dramatically altered the phenotype of the IgM secreted by these cells, it had little effect on their secretory rate. We conclude that J chain regulates the structure and function of the IgM polymers secreted by B cells, but it is not necessary for either IgM polymerization or secretion.	DUKE UNIV,MED CTR,DEPT IMMUNOL,BOX 3010,DURHAM,NC 27710	Duke University				Corley, Ronald/0000-0002-7498-0545	NIAID NIH HHS [AI31209] Funding Source: Medline; NIGMS NIH HHS [GM07184, GM07754] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI031209] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007754, T32GM007184] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ausubel FM, 1989, CURRENT PROTOCOLS MO, V1-3; BORSOS T, 1965, SCIENCE, V150, P505, DOI 10.1126/science.150.3695.505; CATTANEO A, 1987, EMBO J, V6, P2753, DOI 10.1002/j.1460-2075.1987.tb02569.x; CONGER JD, 1989, J IMMUNOL, V143, P4044; DAVIS AC, 1988, EUR J IMMUNOL, V18, P1001, DOI 10.1002/eji.1830180705; DAVIS AC, 1989, EMBO J, V8, P2519, DOI 10.1002/j.1460-2075.1989.tb08389.x; DELLACOR.E, 1973, BIOCHEM J, V136, P597; FEINBERG AP, 1983, ANAL BIOCHEM, V32, P6; GUNNING P, 1987, P NATL ACAD SCI USA, V84, P4831, DOI 10.1073/pnas.84.14.4831; HALPERN MS, 1970, NATURE, V228, P1276, DOI 10.1038/2281276a0; KAJI H, 1974, NATURE, V249, P45, DOI 10.1038/249045a0; KING LB, 1989, P NATL ACAD SCI USA, V86, P2814, DOI 10.1073/pnas.86.8.2814; KOSHLAND ME, 1985, ANNU REV IMMUNOL, V3, P425; KOWNATZKI E, 1973, IMMUNOL COMMUN, V2, P105, DOI 10.3109/08820137309022886; LOCASCIO NJ, 1984, J MOL CELL IMMUNOL, V1, P177; LUND FE, 1991, J EXP MED, V174, P1439, DOI 10.1084/jem.174.6.1439; MATSUUCHI L, 1986, P NATL ACAD SCI USA, V83, P456, DOI 10.1073/pnas.83.2.456; MENG YG, 1988, J IMMUNOL, V141, P2684; MILSTEIN CP, 1975, BIOCHEM J, V151, P615, DOI 10.1042/bj1510615; MOSTOV KE, 1983, METHOD ENZYMOL, V98, P458; PARKHOUSE RM, 1970, IMMUNOLOGY, V18, P575; PARKHOUSE RM, 1973, BIOCHEM J, V136, P607, DOI 10.1042/bj1360607; RANDALL TD, 1990, EUR J IMMUNOL, V20, P1971, DOI 10.1002/eji.1830200915; RANDALL TD, 1992, P NATL ACAD SCI USA, V89, P962, DOI 10.1073/pnas.89.3.962; ROTH RA, 1981, J BIOL CHEM, V256, P4633; RSCHKE WC, 1979, P NATL ACAD SCI USA, V76, P3469; SHARMA S, 1988, J IMMUNOL, V141, P2510; WOODLAND DL, 1991, J EXP MED, V174, P1255, DOI 10.1084/jem.174.5.1255	28	80	86	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1992	267	25					18002	18007						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JM223	1517233				2022-12-25	WOS:A1992JM22300080
J	REYLAND, ME; PRACK, MM; WILLIAMS, DL				REYLAND, ME; PRACK, MM; WILLIAMS, DL			ELEVATED LEVELS OF PROTEIN-KINASE-C IN Y1-CELLS WHICH EXPRESS APOLIPOPROTEIN-E DECREASE BASAL STEROIDOGENESIS BY INHIBITING EXPRESSION OF P450-CHOLESTEROL SIDE-CHAIN CLEAVAGE MESSENGER-RNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHORBOL ESTER; ADRENOCORTICAL-CELLS; ADRENAL-CELLS; HUMAN-FETAL; ACTIVATORS; BINDING; KIDNEY; GLAND; ACTH; ACID	We have previously reported that steroidogenesis is dramatically reduced in mouse Y1 adrenocortical cells which express the human apolipoprotein E gene (Y1-E cells). This suppression results in part from inhibition of cAMP-mediated events. In this report we have examined the expression of protein kinase C (PKC) in the Y1-E cell lines. Total cellular PKC activity in vitro is increased 3-5-fold in the Y1-E cell lines. PKC activity in the particulate and cytosolic fractions is increased to the same relative extent. Increased PKC activity reflects increased levels of PKC mRNA, as determined by Northern blot analysis, and PKC protein, as determined by immunoblot analysis. Increased expression of PKC in the Y1-E cell lines is accompanied by a 23-fold increase in diacylglycerol, an in vivo activator of PKC. To determine the contribution of elevated PKC expression to the Y1-E cell phenotype, we utilized the PKC inhibitors, staurosporine and calphostin C. Upon treatment with staurosporine or calphostin C, expression of P450-cholesterol side chain cleavage mRNA is increased severalfold to a level equal to, or greater than, basal expression in the Y1-neo control cell line. Treatment with calphostin C also results in recovery of steroidogenesis in the Y1-E cells to a level comparable to the basal level observed in the Y1-neo control cell line. These results indicate that increased expression of PKC in the Y1-E cell lines decreases basal steroidogenesis by suppressing P450-cholesterol side chain cleavage mRNA expression. Inhibition of PKC, however, does not reverse the block in cAMP-stimulated steroidogenesis in Y1-E cells, suggesting that the pleiotropic effects of apoE expression are not mediated entirely through altered PKC expression.			REYLAND, ME (corresponding author), SUNY STONY BROOK,DEPT PHARMACOL SCI,STONY BROOK,NY 11794, USA.				NHLBI NIH HHS [HL32868] Funding Source: Medline; NIDDK NIH HHS [1T32DK07521] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL032868] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007521] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BELL RM, 1986, CELL, V45, P631, DOI 10.1016/0092-8674(86)90774-9; BELL RM, 1986, METHOD ENZYMOL, V141, P399; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BLUE ML, 1983, P NATL ACAD SCI-BIOL, V80, P283, DOI 10.1073/pnas.80.1.283; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CULTY M, 1984, BIOCHEM BIOPH RES CO, V121, P499, DOI 10.1016/0006-291X(84)90210-9; DYER CA, 1988, J BIOL CHEM, V263, P10965; GROSS JL, 1990, BIOCHEM PHARMACOL, V40, P343, DOI 10.1016/0006-2952(90)90697-J; GWYNNE JT, 1980, J BIOL CHEM, V255, P875; ILVESMAKI V, 1991, ENDOCRINOLOGY, V128, P1450, DOI 10.1210/endo-128-3-1450; KIMURA E, 1990, J BIOL CHEM, V265, P3518; KOBAYASHI E, 1989, BIOCHEM BIOPH RES CO, V159, P548, DOI 10.1016/0006-291X(89)90028-4; KOWAL J, 1968, ARCH BIOCHEM BIOPHYS, V128, P406, DOI 10.1016/0003-9861(68)90047-7; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MASON JI, 1986, ENDOCR RES, V12, P447, DOI 10.3109/07435808609035450; MCALLISTER JM, 1988, ENDOCRINOLOGY, V122, P2012, DOI 10.1210/endo-122-5-2012; MOORE CCD, 1990, MOL CELL BIOL, V10, P6013, DOI 10.1128/MCB.10.11.6013; NASEERUDDIN SA, 1990, ENDOCRINOLOGY, V127, P1673, DOI 10.1210/endo-127-4-1673; NICOSIA M, 1992, MOL ENDOCRINOL, V6, P288, DOI 10.1210/me.6.2.288; ORMEJOHNSON NR, 1990, BIOCHIM BIOPHYS ACTA, V1020, P213, DOI 10.1016/0005-2728(90)90151-S; PELOSIN JM, 1991, MOL CELL ENDOCRINOL, V75, P149, DOI 10.1016/0303-7207(91)90229-L; PEPE MG, 1986, J IMMUNOL, V136, P3716; PRACK MM, 1991, J LIPID RES, V32, P1611; PRACK MM, 1991, CIRCULATION, V84, P2259; PREISS J, 1986, J BIOL CHEM, V261, P8597; PRICE BD, 1989, J BIOL CHEM, V264, P16638; REYLAND ME, 1991, J BIOL CHEM, V266, P21099; REYLAND ME, 1991, P NATL ACAD SCI USA, V88, P2375, DOI 10.1073/pnas.88.6.2375; SIMPSON ER, 1988, ANNU REV PHYSIOL, V50, P427, DOI 10.1146/annurev.ph.50.030188.002235; WIDMAIER EP, 1985, MOL CELL ENDOCRINOL, V43, P181, DOI 10.1016/0303-7207(85)90082-6; WILLIAMS DL, 1985, J BIOL CHEM, V260, P2444; WONG M, 1989, J BIOL CHEM, V264, P9016; YASUDA I, 1990, BIOCHEM BIOPH RES CO, V166, P1220, DOI 10.1016/0006-291X(90)90996-Z	34	12	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1992	267	25					17933	17938						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JM223	1517229				2022-12-25	WOS:A1992JM22300069
J	FANTOZZI, DA; TAYLOR, SS; HOWARD, PW; MAURER, RA; FERAMISCO, JR; MEINKOTH, JL				FANTOZZI, DA; TAYLOR, SS; HOWARD, PW; MAURER, RA; FERAMISCO, JR; MEINKOTH, JL			EFFECT OF THE THERMOSTABLE PROTEIN-KINASE INHIBITOR ON INTRACELLULAR-LOCALIZATION OF THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN-KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMP RESPONSE ELEMENT; NUCLEAR FACTOR CREB; CYCLIC-AMP; GENE-TRANSCRIPTION; SEQUENCE REQUIREMENTS; ESCHERICHIA-COLI; PROLACTIN GENE; HEPATOMA-CELLS; LIVING CELLS; LARGE-T	cAMP-dependent protein kinase mediates a variety of cellular responses in most eukaryotic cells. Many of these responses are cytoplasmic, whereas others appear to require nuclear localization of the catalytic subunit. In order to understand further the molecular basis for subcellular localization of the catalytic subunit, the effect of the heat stable protein kinase inhibitor (PKI) was investigated. The subcellular localization of the catalytic (C) subunit was determined both in the presence and absence of PKI, by microinjecting fluorescently labeled C subunit into single living cells. When injected alone, a significant fraction of the dissociated C subunit localized to the nucleus. When coinjected with an excess of PKI, little of the C subunit localized to the nucleus, suggesting that accumulation of catalytic subunit in the nucleus requires either enzymatic activity or a nuclear localization signal. Inactivation of the catalytic subunit in vitro by treatment with N-ethylmaleimide did not prevent localization in the nucleus, indicating that enzymatic activity was not a prerequisite for nuclear localization. In an effort to search for a specific signal that might mediate nuclear localization, a complex of the catalytic subunit with a 20-residue inhibitory peptide derived from PKI (PKI(5-24)) was microinjected. In contrast to intact PKI, the peptide was not sufficient to block nuclear accumulation. In the presence of PKI(5-24), the C subunit localized to the nucleus in a fashion analogous to that of dissociated, active C subunit despite evidence of no catalytic activity in situ. Thus, nuclear localization of the C subunit appears to be independent of enzymatic activity but most likely dependent upon a signal. The signal is apparently masked by both the regulatory subunit and PKI but not by the inhibitory peptide.	UNIV CALIF SAN DIEGO,DEPT MED,9500 GILMAN DR,SAN DIEGO,CA 92103; UNIV CALIF SAN DIEGO,DEPT CHEM,SAN DIEGO,CA 92103; UNIV CALIF SAN DIEGO,DEPT PHARMACOL,SAN DIEGO,CA 92103; UNIV CALIF SAN DIEGO,CTR CANC,SAN DIEGO,CA 92103; UNIV IOWA HOSP & CLIN,DEPT PHYSIOL,IOWA CITY,IA 52242; UNIV IOWA HOSP & CLIN,DEPT BIOPHYS,IOWA CITY,IA 52242	University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; University of Iowa; University of Iowa			Meinkoth, Judy L/G-2900-2010		NATIONAL CANCER INSTITUTE [R01CA039811] Funding Source: NIH RePORTER; NCI NIH HHS [CA39811] Funding Source: Medline; NHLBI NIH HHS [HL14388] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADAMS SR, 1991, NATURE, V349, P694, DOI 10.1038/349694a0; BEAVO JA, 1974, P NATL ACAD SCI USA, V71, P3580, DOI 10.1073/pnas.71.9.3580; BECHTEL PJ, 1977, J BIOL CHEM, V252, P2691; BOSHART M, 1991, CELL, V66, P849, DOI 10.1016/0092-8674(91)90432-X; BYUS CV, 1982, J CELL BIOL, V93, P727, DOI 10.1083/jcb.93.3.727; CHELSKY D, 1989, MOL CELL BIOL, V9, P2487, DOI 10.1128/MCB.9.6.2487; COOK PF, 1982, BIOCHEMISTRY-US, V21, P5794, DOI 10.1021/bi00266a011; DANG CV, 1988, MOL CELL BIOL, V8, P4048, DOI 10.1128/MCB.8.10.4048; DAY RN, 1989, J BIOL CHEM, V264, P431; GARCIABUSTOS J, 1991, BIOCHIM BIOPHYS ACTA, V1071, P83, DOI 10.1016/0304-4157(91)90013-M; GIBBS CS, 1992, J BIOL CHEM, V267, P4806; GONZALEZ GA, 1989, NATURE, V337, P749, DOI 10.1038/337749a0; GROVE JR, 1987, SCIENCE, V238, P530; HABENER JF, 1990, MOL ENDOCRINOL, V4, P1087, DOI 10.1210/mend-4-8-1087; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; HOEFFLER JP, 1988, SCIENCE, V242, P1430, DOI 10.1126/science.2974179; KALDERON D, 1984, NATURE, V311, P33, DOI 10.1038/311033a0; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; Krebs EG, 1986, ENZYMES, V17, P3, DOI 10.1016/S1874-6047(08)60426-6; LANG I, 1986, J CELL BIOL, V102, P1183, DOI 10.1083/jcb.102.4.1183; MAEKAWA T, 1989, EMBO J, V8, P2023, DOI 10.1002/j.1460-2075.1989.tb03610.x; MAURER RA, 1989, J BIOL CHEM, V264, P6870; MEINKOTH JL, 1990, P NATL ACAD SCI USA, V87, P9595, DOI 10.1073/pnas.87.24.9595; MEINKOTH JL, 1991, MOL CELL BIOL, V11, P1759, DOI 10.1128/MCB.11.3.1759; MELLON PL, 1989, P NATL ACAD SCI USA, V86, P4887, DOI 10.1073/pnas.86.13.4887; MONTMINY MR, 1987, NATURE, V328, P175, DOI 10.1038/328175a0; Nigg E A, 1990, Adv Cancer Res, V55, P271, DOI 10.1016/S0065-230X(08)60471-6; NIGG EA, 1985, EMBO J, V4, P2801, DOI 10.1002/j.1460-2075.1985.tb04006.x; PAINE PL, 1975, NATURE, V254, P109, DOI 10.1038/254109a0; RICHARDSON WD, 1986, CELL, V44, P77, DOI 10.1016/0092-8674(86)90486-1; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; ROESLER WJ, 1988, J BIOL CHEM, V263, P9063; SLICE LW, 1989, J BIOL CHEM, V264, P20940; TAYLOR SS, 1990, ANNU REV BIOCHEM, V59, P971, DOI 10.1146/annurev.bi.59.070190.004543; THOMAS J, 1991, J BIOL CHEM, V266, P10906; UENO K, 1988, MOL CELL BIOL, V8, P4529, DOI 10.1128/MCB.8.10.4529; Walsh D.A., 2018, PEPT PROT PHOSPH, P43; WHITEHOUSE S, 1983, J BIOL CHEM, V258, P3682; Zetterqvist O.Z., 1990, PEPTIDES PROTEIN PHO, P171; ZHAO LJ, 1988, CELL, V55, P1005, DOI 10.1016/0092-8674(88)90245-0	41	54	56	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1992	267	24					16824	16828						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JL053	1512225				2022-12-25	WOS:A1992JL05300017
J	HUANG, CF; WYKLE, RL; DANIEL, LW; CABOT, MC				HUANG, CF; WYKLE, RL; DANIEL, LW; CABOT, MC			IDENTIFICATION OF PHOSPHATIDYLCHOLINE-SELECTIVE AND PHOSPHATIDYLINOSITOL-SELECTIVE PHOSPHOLIPASES-D IN MADIN-DARBY CANINE KIDNEY-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; BRADYKININ-INDUCED CHANGES; PHOSPHATIDIC-ACID; ENDOTHELIAL-CELLS; HUMAN-PLATELETS; PHORBOL ESTERS; INOSITOL TRISPHOSPHATE; SIGNAL TRANSDUCTION; HUMAN-NEUTROPHILS; ARACHIDONIC-ACID	Intact cells and cell-free systems were employed to characterize phospholipase D (PLD) activity in Madin-Darby canine kidney (MDCK) cells. In cells prelabeled with [H-3]glycerol, 12-O-tetradecanoylphorbol-13-acetate (TPA) elicited phosphatidylcholine (PC) hydrolysis by PLD, as shown by the prolonged formation of [H-3]phosphatidylethanol (PEt) and an accompanying decrease in [H-3]PC. In contrast, bradykinin elicited rapid formation of [H-3]PEt (approximately 1 min) accompanied by a decrease in [H-3]phosphatidylinositol (PI). When the agonists were administered simultaneously, [H-3]PEt formation was biphasic. In cells prelabeled with [H-3]choline, at times <1 min, bradykinin failed to induce significant change in [H-3]choline release. Bradykinin-induced formation of [H-3]PEt in the [H-3]glycerol-labeled cells was strictly dependent on extracellular Ca2+, whereas TPA-induced formation of [H-3]PEt did not require extracellular Ca2+. Cell-free assays for PLD were used to assess the enzyme location, substrate specificity, and cofactor requirements. The PC-PLD activity (PEt formation) against [H-3]stearoyl-PI was primarily localized in the 440 x g pellet (membrane- and nuclear-associated), preferred PC as a substrate, required detergent, and was not influenced by Ca2+ at low concentrations but was inhibited by Ca2+ in excess of 0.5 mM. The PI-PLD activity against [H-3]stearoyl-PI was found largely in the 100,000 x g supernatant (cytosol), was strictly Ca2+-dependent, and did not require detergent. From these data, we conclude that MDCK cells contain two PLD subtypes: 1) a membrane-associated, PC-selective enzyme that responds to TPA resulting in prolonged hydrolysis of PC (the PC-PLD is Ca2+-independent, but requires detergent); 2) a cytosolic, PI-selective enzyme that responds rapidly but transiently to bradykinin (the PI-PLD requires Ca2+ but not detergent).			HUANG, CF (corresponding author), WAKE FOREST UNIV,BOWMAN GRAY SCH MED,DEPT BIOCHEM,MED CTR BLVD,WINSTON SALEM,NC 27157, USA.				NCI NIH HHS [CA46530, CA 48995] Funding Source: Medline; NIAID NIH HHS [AI 17287] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA046530, R01CA048995] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI017287] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABDELLATIF AA, 1986, PHARMACOL REV, V38, P227; AGWU DE, 1989, J BIOL CHEM, V264, P1405; BALSINDE J, 1988, BIOCHEM BIOPH RES CO, V154, P502, DOI 10.1016/0006-291X(88)90168-4; BALSINDE J, 1989, EUR J BIOCHEM, V186, P717, DOI 10.1111/j.1432-1033.1989.tb15265.x; BELL RM, 1991, J BIOL CHEM, V266, P4661; BERRIDGE MJ, 1984, NATURE, V312, P315, DOI 10.1038/312315a0; BILLAH MM, 1989, J BIOL CHEM, V264, P9069; BILLAH MM, 1990, BIOCHEM J, V269, P281, DOI 10.1042/bj2690281; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOCCKINO SB, 1987, J BIOL CHEM, V262, P15309; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CABOT MC, 1988, BIOCHIM BIOPHYS ACTA, V959, P46, DOI 10.1016/0005-2760(88)90148-8; CHATTOPADHYAY J, 1991, J NEUROCHEM, V57, P1429, DOI 10.1111/j.1471-4159.1991.tb08310.x; COCKCROFT S, 1984, BIOCHIM BIOPHYS ACTA, V795, P37, DOI 10.1016/0005-2760(84)90102-4; DANIEL LW, 1986, J BIOL CHEM, V261, P9128; DAVITZ MA, 1987, SCIENCE, V238, P81, DOI 10.1126/science.2443973; EXTON JH, 1990, J BIOL CHEM, V265, P1; FU T, 1988, BIOCHEM BIOPH RES CO, V157, P1429; GAMMON CM, 1989, J NEUROCHEM, V53, P95, DOI 10.1111/j.1471-4159.1989.tb07299.x; GILES KW, 1965, NATURE, V206, P93, DOI 10.1038/206093a0; GUSTAVSSON L, 1990, J NEUROCHEM, V54, P737, DOI 10.1111/j.1471-4159.1990.tb02313.x; HII CST, 1989, FEBS LETT, V257, P35, DOI 10.1016/0014-5793(89)81779-X; HOKIN LE, 1985, ANNU REV BIOCHEM, V54, P205, DOI 10.1146/annurev.biochem.54.1.205; HOKINNEAVERSON M, 1975, BIOCHEM BIOPH RES CO, V67, P1537, DOI 10.1016/0006-291X(75)90201-6; HORWITZ J, 1991, J NEUROCHEM, V56, P509, DOI 10.1111/j.1471-4159.1991.tb08179.x; HUANG CF, 1990, J BIOL CHEM, V265, P17468; HUANG CF, 1990, J BIOL CHEM, V265, P14858; KANOH H, 1991, LIPIDS, V26, P426, DOI 10.1007/BF02536068; KNAUSS TC, 1990, J BIOL CHEM, V265, P14457; LISCOVITCH M, 1989, J BIOL CHEM, V264, P1450; LOFFELHOLZ K, 1989, BIOCHEM PHARMACOL, V38, P1543, DOI 10.1016/0006-2952(89)90299-2; LOW MG, 1988, P NATL ACAD SCI USA, V85, P980, DOI 10.1073/pnas.85.4.980; MARTIN TW, 1988, BIOCHEM BIOPH RES CO, V157, P1271, DOI 10.1016/S0006-291X(88)81012-X; MARTIN TW, 1988, BIOCHIM BIOPHYS ACTA, V962, P282, DOI 10.1016/0005-2760(88)90258-5; MOOLENAAR WH, 1986, NATURE, V323, P171, DOI 10.1038/323171a0; MORRISON WR, 1964, J LIPID RES, V5, P600; MUELLER GC, 1988, P NATL ACAD SCI USA, V85, P9778, DOI 10.1073/pnas.85.24.9778; MURAYAMA T, 1987, J BIOL CHEM, V262, P5522; MYERS DE, 1989, CELL SIGNAL, V1, P335, DOI 10.1016/0898-6568(89)90052-1; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; OLSON SC, 1991, J BIOL CHEM, V266, P17236; PAI JK, 1987, CARCINOGENESIS, V8, P173, DOI 10.1093/carcin/8.1.173; PANAGIA V, 1991, BIOCHIM BIOPHYS ACTA, V1064, P242, DOI 10.1016/0005-2736(91)90308-U; PORTILLA D, 1986, BIOCHEM BIOPH RES CO, V140, P644, DOI 10.1016/0006-291X(86)90780-1; QIAN Z, 1990, J NEUROCHEM, V54, P1632, DOI 10.1111/j.1471-4159.1990.tb01215.x; RUBIN R, 1988, BIOCHEM BIOPH RES CO, V156, P1090, DOI 10.1016/S0006-291X(88)80744-7; SKIPSKI VP, 1964, BIOCHEM J, V90, P374, DOI 10.1042/bj0900374; SLIVKA SR, 1988, J BIOL CHEM, V263, P14640; SOTTOCASA GL, 1967, J CELL BIOL, V32, P415, DOI 10.1083/jcb.32.2.415; TAKI T, 1979, J BIOL CHEM, V254, P9761; VANVELDHOVEN PP, 1991, J BIOL CHEM, V266, P12502; WANG P, 1991, J BIOL CHEM, V266, P14877; WATSON SP, 1985, P NATL ACAD SCI USA, V82, P2623, DOI 10.1073/pnas.82.9.2623; ZAVOICO GB, 1985, P NATL ACAD SCI USA, V82, P3859, DOI 10.1073/pnas.82.11.3859	54	103	103	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1992	267	24					16859	16865						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JL053	1512228				2022-12-25	WOS:A1992JL05300023
J	JOHNSTONE, SA; HUBAISHY, I; WAISMAN, DM				JOHNSTONE, SA; HUBAISHY, I; WAISMAN, DM			PHOSPHORYLATION OF ANNEXIN-II TETRAMER BY PROTEIN-KINASE-C INHIBITS AGGREGATION OF LIPID VESICLES BY THE PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA-2+-DEPENDENT PHOSPHOLIPID-BINDING; DEPENDENT 35-KILODALTON SUBSTRATE; AFFINITY COLUMN CHROMATOGRAPHY; FACTOR RECEPTOR KINASE; AMINO-ACID-SEQUENCE; LIPOCORTIN-I; CHROMAFFIN CELLS; TYROSINE KINASE; CALPACTIN-I; DOMAIN-STRUCTURE	Annexin II tetramer (A-IIt) is a member of the annexin family of Ca2+ and phospholipid-binding proteins. The ability of this protein to aggregate both phospholipid vesicles and chromaffin granules has suggested a role for the protein in membrane trafficking events such as exocytosis. A-IIt is also a major intracellular substrate of both pp60src and protein kinase C; however, the effect of phosphorylation on the activity of this protein is unknown. In the current report we have examined the effect of phosphorylation on the lipid vesicle aggregation activity of the protein,Protein kinase C catalyzed the incorporation of 2.1 +/- 0.8 mol of phosphate/mol of A-IIt. Phosphorylation of A-IIt caused a dramatic decrease in the rate and extent of lipid vesicle aggregation without significantly effecting Ca2+-dependent lipid binding by the phosphorylated protein. Phosphorylation of A-IIt increased the A50%(Ca2+) of lipid vesicle aggregation from 0.18 muM to 0.65 mM. Activation of A-IIt phosphorylation, concomitant with activation of lipid vesicle aggregation, inhibited both the rate and extent of lipid vesicle aggregation but did not cause disassembly of the aggregated lipid vesicles. These results suggest that protein kinase C-dependent phosphorylation of A-IIt blocks the ability of the protein to aggregate phospholipid vesicles without affecting the lipid vesicle binding properties of the protein.	UNIV CALGARY, DEPT MED BIOCHEM, MRC, SIGNAL TRANSDUCT GRP, CALGARY T2N 4N1, ALBERTA, CANADA	University of Calgary	WAISMAN, DM (corresponding author), UNIV CALGARY, DEPT MED BIOCHEM, MRC, SIGNAL TRANSDUCT GRP, CALGARY T2N 4N1, ALBERTA, CANADA.			Waisman, David/0000-0002-5097-9662				ALI SM, 1989, NATURE, V340, P313, DOI 10.1038/340313a0; ALI SM, 1990, CELL SIGNAL, V2, P265, DOI 10.1016/0898-6568(90)90054-E; ANDO Y, 1989, J BIOL CHEM, V264, P6948; BLACKWOOD RA, 1990, BIOCHEM J, V266, P195, DOI 10.1042/bj2660195; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURGOYNE RD, 1989, CELL CALCIUM, V10, P1, DOI 10.1016/0143-4160(89)90038-9; BURGOYNE RD, 1990, ANNU REV PHYSIOL, V52, P647; DE BK, 1986, J BIOL CHEM, V261, P3784; DEDMAN JR, 1986, CELL CALCIUM, V7, P297, DOI 10.1016/0143-4160(86)90034-5; DRUST DS, 1988, NATURE, V331, P88, DOI 10.1038/331088a0; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; FAVA RA, 1984, J BIOL CHEM, V259, P2636; GEISOW MJ, 1990, PROG CLIN BIOL RES, V349, P111; GEISOW MJ, 1986, NATURE, V320, P636, DOI 10.1038/320636a0; GEISOW MJ, 1986, FEBS LETT, V203, P99, DOI 10.1016/0014-5793(86)81445-4; GERKE V, 1984, EMBO J, V3, P227, DOI 10.1002/j.1460-2075.1984.tb01789.x; GERKE V, 1985, J BIOL CHEM, V260, P1688; GLENNEY J, 1986, J BIOL CHEM, V261, P7247; GLENNEY JR, 1985, P NATL ACAD SCI USA, V82, P7884, DOI 10.1073/pnas.82.23.7884; GLENNEY JR, 1985, FEBS LETT, V192, P79, DOI 10.1016/0014-5793(85)80047-8; GLENNEY JR, 1987, BIOESSAYS, V7, P173, DOI 10.1002/bies.950070408; GOULD KL, 1986, MOL CELL BIOL, V6, P2738, DOI 10.1128/MCB.6.7.2738; HANNUN YA, 1986, J BIOL CHEM, V261, P7184; IKEBUCHI NW, 1990, J BIOL CHEM, V265, P3392; JOHNSSON N, 1990, PROG CLIN BIOL RES, V349, P123; JOHNSSON N, 1986, FEBS LETT, V198, P361, DOI 10.1016/0014-5793(86)80437-9; KHANNA N, 1987, BIOCHEM BIOPH RES CO, V137, P397; KHANNA NC, 1986, BIOCHEM BIOPH RES CO, V141, P547, DOI 10.1016/S0006-291X(86)80208-X; KHANNA NC, 1990, BIOCHEMISTRY-US, V29, P4852, DOI 10.1021/bi00472a015; KHANNA NC, 1987, CELL CALCIUM, V8, P217, DOI 10.1016/0143-4160(87)90020-0; Kitano T, 1986, Methods Enzymol, V124, P349; KLEE CB, 1988, BIOCHEMISTRY-US, V27, P6645, DOI 10.1021/bi00418a001; KRETSINGER RH, 1986, NATURE, V320, P573, DOI 10.1038/320573a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MICHENER ML, 1986, J BIOL CHEM, V261, P6548; MOSS SE, 1990, TRENDS BIOCHEM SCI, V15, P11, DOI 10.1016/0968-0004(90)90118-U; PEPINSKY RB, 1988, J BIOL CHEM, V263, P10799; PIGAULT C, 1990, BIOCHIM BIOPHYS ACTA, V1037, P106, DOI 10.1016/0167-4838(90)90108-R; POWELL MA, 1987, BIOCHEM J, V247, P321, DOI 10.1042/bj2470321; REEVES JP, 1969, J CELL PHYSIOL, V73, P49, DOI 10.1002/jcp.1040730108; RUSSOMARIE F, 1986, PATHOL BIOL, V34, P227; SARAFIAN T, 1991, J CELL BIOL, V114, P1135, DOI 10.1083/jcb.114.6.1135; SARIS CJM, 1986, CELL, V46, P210; SCHLAEPFER DD, 1988, BIOCHEMISTRY-US, V27, P4253, DOI 10.1021/bi00412a008; SCHLAEPFER DD, 1987, J BIOL CHEM, V262, P6931; SHARMA RK, 1986, J BIOL CHEM, V261, P1322; SUDHOF TC, 1988, P NATL ACAD SCI USA, V85, P664, DOI 10.1073/pnas.85.3.664; VARTICOVSKI L, 1988, BIOCHEMISTRY-US, V27, P3682, DOI 10.1021/bi00410a024; WEBER K, 1986, FEBS LETT, V203, P95, DOI 10.1016/0014-5793(86)81444-2; WEBER K, 1987, EMBO J, V6, P1599, DOI 10.1002/j.1460-2075.1987.tb02406.x; WOOTEN MW, 1987, EUR J BIOCHEM, V164, P461, DOI 10.1111/j.1432-1033.1987.tb11079.x; WU YN, 1991, FEBS LETT, V282, P197, DOI 10.1016/0014-5793(91)80476-J; ZAKS WJ, 1991, BIOCHEMISTRY-US, V30, P9607, DOI 10.1021/bi00104a007	53	89	90	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 25	1992	267	36					25976	25981						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KD073	1464610				2022-12-25	WOS:A1992KD07300059
J	LANGEN, R; JENSEN, GM; JACOB, U; STEPHENS, PJ; WARSHEL, A				LANGEN, R; JENSEN, GM; JACOB, U; STEPHENS, PJ; WARSHEL, A			PROTEIN CONTROL OF IRON-SULFUR CLUSTER REDOX POTENTIALS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							AZOTOBACTER-VINELANDII FERREDOXIN; PEPTOCOCCUS-AEROGENES FERREDOXIN; SITE-DIRECTED MUTAGENESIS; BACTERIAL FERREDOXINS; 4FE-4S FERREDOXIN; FE4S4 CLUSTERS; REDUCTION; RESOLUTION; REFINEMENT; REACTIVITY	The relationship between the three-dimensional structures of iron-sulfur proteins and the redox potentials of their iron-sulfur clusters is of fundamental importance. We report calculations of the redox potentials of the [Fe4S4(S-CYS)4]-2/-3 couple in four crystallographically characterized proteins: Azotobacter vinelandii ferredoxin I, Peptococcus aerogenes ferredoxin, Bacillus thermoproteolyticus ferredoxin, and Chromatium vinosum high potential iron protein (HiPIP). Our calculations use the "protein dipoles Langevin dipoles" microscopic electrostatic model, which includes both protein and solvent water. The variations in calculated redox potentials are in excellent agreement with experimental data. In particular, our results confirm the important role of amide groups close to the cluster in separating the potential of C. vinosum HiPIP from those of the other three proteins. However, the potentials of these latter exhibit a substantial range despite extremely similar amide group environments of their clusters. Our results show that the potentials in these proteins are tuned in part by varying the access of solvent water to the neighborhood of the cluster. Our calculations provide the first successful quantitative modeling of the protein control of iron-sulfur cluster redox potentials.	UNIV SO CALIF,DEPT CHEM,LOS ANGELES,CA 90089	University of Southern California	STEPHENS, PJ (corresponding author), UNIV SO CALIF,DEPT CHEM,LOS ANGELES,CA 90089, USA.				NIGMS NIH HHS [GM-28386, R01-GM-45209, GM-40283] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040283, R01GM028386, R01GM045209] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADMAN E, 1975, P NATL ACAD SCI USA, V72, P4854, DOI 10.1073/pnas.72.12.4854; ADMAN ET, 1976, J BIOL CHEM, V251, P3801; BACIOU L, 1991, BIOCHEMISTRY-US, V30, P9111; BACKES G, 1991, J AM CHEM SOC, V113, P2055, DOI 10.1021/ja00006a027; BEINERT H, 1990, FASEB J, V4, P2483, DOI 10.1096/fasebj.4.8.2185975; CAMMACK R, 1973, BIOCHEM BIOPH RES CO, V54, P548, DOI 10.1016/0006-291X(73)91457-5; CARTER CW, 1974, J BIOL CHEM, V249, P4212; CARTER CW, 1972, P NATL ACAD SCI USA, V69, P3526, DOI 10.1073/pnas.69.12.3526; Carter Jr C. W., 1977, IRON SULFUR PROTEINS, V3, P157; CHURG AK, 1986, BIOCHEMISTRY-US, V25, P1675, DOI 10.1021/bi00355a035; FREER ST, 1975, J BIOL CHEM, V250, P46; FUKUYAMA K, 1989, J MOL BIOL, V210, P383, DOI 10.1016/0022-2836(89)90338-0; FUKUYAMA K, 1988, J MOL BIOL, V199, P183, DOI 10.1016/0022-2836(88)90388-9; FUNK WD, 1990, BIOCHEMISTRY-US, V29, P5500, DOI 10.1021/bi00475a013; IISMAA SE, 1991, J BIOL CHEM, V266, P21563; LAMM G, 1990, P NATL ACAD SCI USA, V87, P9033, DOI 10.1073/pnas.87.22.9033; LANGEN R, 1992, J MOL BIOL, V224, P589, DOI 10.1016/0022-2836(92)90546-V; MARTIN AE, 1990, P NATL ACAD SCI USA, V87, P598, DOI 10.1073/pnas.87.2.598; MULLINGER RN, 1975, BIOCHEM J, V151, P75, DOI 10.1042/bj1510075; NAVARRO JA, 1989, BIOCHEMISTRY-US, V28, P6057, DOI 10.1021/bi00440a050; NOODLEMAN L, 1985, J AM CHEM SOC, V107, P3418, DOI 10.1021/ja00298a004; REES DC, 1980, J MOL BIOL, V141, P323, DOI 10.1016/0022-2836(80)90184-9; REID LS, 1984, J AM CHEM SOC, V106, P2182, DOI 10.1021/ja00319a045; SOMAN J, 1991, J BIOL CHEM, V266, P21558; STOMBAUGH NA, 1976, BIOCHEMISTRY-US, V15, P2633, DOI 10.1021/bi00657a024; STOUT CD, 1989, J MOL BIOL, V205, P545, DOI 10.1016/0022-2836(89)90225-8; WARSHEL A, 1984, Q REV BIOPHYS, V17, P283, DOI 10.1017/S0033583500005333; WARSHEL A, 1991, ANNU REV BIOPHYS BIO, V20, P267, DOI 10.1146/annurev.biophys.20.1.267; Warshel A, 1989, COMPUTER SIMULATIONS, P120	29	157	157	0	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1992	267	36					25625	25627						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KD073	1464583				2022-12-25	WOS:A1992KD07300002
J	LI, YS; HOFFMAN, RM; LEBEAU, MM; ESPINOSA, R; JENKINS, NA; GILBERT, DJ; COPELAND, NG; DEUEL, TF				LI, YS; HOFFMAN, RM; LEBEAU, MM; ESPINOSA, R; JENKINS, NA; GILBERT, DJ; COPELAND, NG; DEUEL, TF			CHARACTERIZATION OF THE HUMAN PLEIOTROPHIN GENE - PROMOTER REGION AND CHROMOSOMAL LOCALIZATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EMBRYONAL CARCINOMA-CELLS; FIBROBLAST GROWTH-FACTORS; HEPARIN-BINDING-PROTEIN; RETINOIC ACID; MOUSE EMBRYOGENESIS; IDENTIFICATION; DISTINCT; DIFFERENTIATION; PURIFICATION; ORGANIZATION	The protein (PTN) encoded by the pleiotrophin (PTN) gene belongs to a recently described family of heparin-binding cytokines whose expression is temporally and spatially regulated during development. We have now isolated genomic clones of the human PTN gene, characterized its promoter region, determined its transcription initiation site(s), and established functional activity of the PTN promoter. A fragment -550/+191 that contains a CAAT box, no apparent TATA box, and four consensus sites for the binding of MyoD is sufficient to provide optimal promoter activity. A serum response element is found at -559 to -568. We also have identified the human PTN gene on chromosome 7, band q33 and the mouse Ptn gene on chromosome 6, respectively. The data thus identify and characterize the 5' end of the PTN gene and its promoter region, suggest potential regions that may contribute to the regulation of its transcriptional activity, and localize the PTN gene in human and mouse chromosomes.	WASHINGTON UNIV,JEWISH HOSP ST LOUIS,SCH MED,DEPT BIOCHEM & MOLEC BIOPHYS,ST LOUIS,MO 63110; UNIV CHICAGO,DEPT MED,HEMATOL ONCOL SECT,CHICAGO,IL 60637; NCI,FREDERICK CANC RES & DEV CTR,ABL BASIC RES PROGRAM,MAMMALIAN GENET LAB,FREDERICK,MD 21702	Barnes-Jewish Hospital; Washington University (WUSTL); University of Chicago; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	LI, YS (corresponding author), WASHINGTON UNIV,JEWISH HOSP ST LOUIS,SCH MED,DEPT MED,ST LOUIS,MO 63110, USA.				NCI NIH HHS [CA49712] Funding Source: Medline; NHLBI NIH HHS [HL14147, HL31102] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA049712] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL031102, R37HL031102, P50HL014147] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COPELAND NG, 1991, TRENDS GENET, V7, P113, DOI 10.1016/0168-9525(91)90455-Y; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; Favaloro J, 1980, Methods Enzymol, V65, P718; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM F, 1973, VIROLOGY, V52, P452; Green EL, 1981, GENETICS PROBABILITY, P77; GREEN MC, 1989, GENETIC VARIANTS STR, P164; HERBOMEL P, 1984, CELL, V39, P653, DOI 10.1016/0092-8674(84)90472-0; HOHN PA, 1989, J BIOL CHEM, V264, P13412; JENKINS NA, 1982, J VIROL, V43, P26, DOI 10.1128/JVI.43.1.26-36.1982; JONES KA, 1985, CELL, V42, P559, DOI 10.1016/0092-8674(85)90113-8; KADOMATSU K, 1988, BIOCHEM BIOPH RES CO, V151, P1312, DOI 10.1016/S0006-291X(88)80505-9; LASSAR AB, 1989, CELL, V58, P823, DOI 10.1016/0092-8674(89)90935-5; LEE F, 1984, NUCLEIC ACIDS RES, V12, P4191, DOI 10.1093/nar/12.10.4191; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LI YS, 1990, SCIENCE, V250, P1690, DOI 10.1126/science.2270483; LI YS, 1992, BIOCHEM BIOPH RES CO, V184, P427, DOI 10.1016/0006-291X(92)91211-8; LUO XN, 1991, J BIOL CHEM, V266, P21004; MATSUBARA S, 1990, J BIOL CHEM, V265, P9441; MILNER PG, 1989, BIOCHEM BIOPH RES CO, V165, P1096, DOI 10.1016/0006-291X(89)92715-0; MURAMATSU H, 1991, BIOCHEM BIOPH RES CO, V177, P652, DOI 10.1016/0006-291X(91)91838-4; NG SY, 1985, MOL CELL BIOL, V5, P2720, DOI 10.1128/MCB.5.10.2720; RAULAIS D, 1991, BIOCHEM BIOPH RES CO, V174, P708, DOI 10.1016/0006-291X(91)91475-R; RAUVALA H, 1989, EMBO J, V8, P2933, DOI 10.1002/j.1460-2075.1989.tb08443.x; REGNIER DC, 1989, J VIROL, V63, P3678, DOI 10.1128/JVI.63.9.3678-3682.1989; ROWLEY JD, 1990, P NATL ACAD SCI USA, V87, P9358, DOI 10.1073/pnas.87.23.9358; ROY AL, 1991, NATURE, V354, P245, DOI 10.1038/354245a0; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SIRACUSA LD, 1991, GENETICS, V127, P169; SMITH R, 1988, EMBO J, V7, P1013, DOI 10.1002/j.1460-2075.1988.tb02908.x; TEZUKA K, 1990, BIOCHEM BIOPH RES CO, V173, P246, DOI 10.1016/S0006-291X(05)81048-4; TREISMAN R, 1986, CELL, V46, P567, DOI 10.1016/0092-8674(86)90882-2	34	64	68	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1992	267	36					26011	26016						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KD073	1464612				2022-12-25	WOS:A1992KD07300064
J	YOSHIMOTO, T; ARAKAWA, T; HADA, T; YAMAMOTO, S; TAKAHASHI, E				YOSHIMOTO, T; ARAKAWA, T; HADA, T; YAMAMOTO, S; TAKAHASHI, E			STRUCTURE AND CHROMOSOMAL LOCALIZATION OF HUMAN ARACHIDONATE 12-LIPOXYGENASE GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-SPECIFIC 15-LIPOXYGENASE; INSITU HYBRIDIZATION; PORCINE LEUKOCYTES; MOLECULAR-CLONING; COMPLETE SEQUENCE; MESSENGER-RNA; EXPRESSION; PROMOTER; CDNA; LIPOXYGENASES	Arachidonate 12-lipoxygenase introduces a molecular oxygen into the C-12 position of arachidonic acid to produce 12(S)-hydroperoxy-5,8,10,14-eicosatetraenoic acid. With the aid of cDNA probes for the enzyme, we isolated overlapping lambda clones encompassing the human 12-lipoxygenase gene and flanking regions from a human genomic library. The gene consists of 14 exons with 13 introns and spans approximately 15 kilobases of DNA. All the exon-intron junctions conform to the GT/AG rule. Neither a typical TATA box nor a CAAT box was found in approximately 1-kb sequence of 5'-upstream region of the translation initiation site. However, this region contains several regulatory elements including four GC boxes, two CACCC boxes, three AP-2 binding sequences, and a glucocorticoid-responsive element. The major transcription initiation site was determined by primer-extension analysis as an adenosine residue at 306 bases upstream from the translation initiation codon. The chromosomal localization of the human 12-lipoxygenase gene was examined by fluorescence in situ hybridization, and the gene was assigned to the sub-band p13.1 of chromosome 17.	UNIV TOKUSHIMA,SCH MED,DEPT BIOCHEM,KURAMOTO CHO,TOKUSHIMA 770,JAPAN; NATL INST RADIOL SCI,DIV GENET,CHIBA 260,JAPAN	Tokushima University; National Institutes for Quantum Science & Technology								ARAKAWA T, 1992, J BIOL CHEM, V267, P12188; FLEMING J, 1989, GENE, V79, P181, DOI 10.1016/0378-1119(89)90103-0; FUNK CD, 1992, P NATL ACAD SCI USA, V89, P3962, DOI 10.1073/pnas.89.9.3962; FUNK CD, 1989, P NATL ACAD SCI USA, V86, P2587, DOI 10.1073/pnas.86.8.2587; FUNK CD, 1991, FASEB J, V5, P2304, DOI 10.1096/fasebj.5.9.1907252; FUNK CD, 1990, P NATL ACAD SCI USA, V87, P5638, DOI 10.1073/pnas.87.15.5638; HADA T, 1991, BIOCHIM BIOPHYS ACTA, V1083, P89, DOI 10.1016/0005-2760(91)90128-5; HANSBROUGH JR, 1990, J BIOL CHEM, V265, P1771; IZUMI T, 1990, P NATL ACAD SCI USA, V87, P7477, DOI 10.1073/pnas.87.19.7477; JANTZEN HM, 1987, CELL, V49, P29, DOI 10.1016/0092-8674(87)90752-5; KADONAGA JT, 1986, TRENDS BIOCHEM SCI, V11, P20, DOI 10.1016/0968-0004(86)90226-4; MITCHELL PJ, 1987, CELL, V50, P847, DOI 10.1016/0092-8674(87)90512-5; MYERS RM, 1986, SCIENCE, V232, P613, DOI 10.1126/science.3457470; NICOLETTA DM, 1992, AM J PHYSIOL, V262, pL198; NISHIYAMA M, 1992, J NEUROCHEM, V58, P1395, DOI 10.1111/j.1471-4159.1992.tb11355.x; OPREY J, 1989, GENE, V84, P493, DOI 10.1016/0378-1119(89)90526-X; RUSKIN B, 1985, NATURE, V317, P732, DOI 10.1038/317732a0; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHINJO F, 1986, J BIOL CHEM, V261, P3377; TAKAHASHI E, 1990, HUM GENET, V86, P14; TAKAHASHI E, 1991, HUM GENET, V88, P119, DOI 10.1007/BF00204942; TAKAHASHI Y, 1988, ARCH BIOCHEM BIOPHYS, V266, P613, DOI 10.1016/0003-9861(88)90294-9; UEDA N, 1990, J BIOL CHEM, V265, P2311; YAMAMOTO S, 1991, FREE RADICAL BIO MED, V10, P149, DOI 10.1016/0891-5849(91)90008-Q; YOKOYAMA C, 1986, J BIOL CHEM, V261, P6714; YOSHIMOTO T, 1990, P NATL ACAD SCI USA, V87, P2142, DOI 10.1073/pnas.87.6.2142; YOSHIMOTO T, 1982, BIOCHIM BIOPHYS ACTA, V713, P638; YOSHIMOTO T, 1990, BIOCHEM BIOPH RES CO, V172, P1230, DOI 10.1016/0006-291X(90)91580-L	29	40	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1992	267	34					24805	24809						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KA263	1447217				2022-12-25	WOS:A1992KA26300097
J	WILLADSEN, KA; BUTTERS, CA; HILL, LE; TOBACMAN, LS				WILLADSEN, KA; BUTTERS, CA; HILL, LE; TOBACMAN, LS			EFFECTS OF THE AMINO-TERMINAL REGIONS OF TROPOMYOSIN AND TROPONIN-T ON THIN FILAMENT ASSEMBLY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCLE ALPHA-TROPOMYOSIN; RABBIT SKELETAL-MUSCLE; COOPERATIVE EQUILIBRIUM BINDING; MYOSIN SUBFRAGMENT-1; LABELED TROPOMYOSIN; ACTIN; COMPLEX; FLUORESCENCE; FRAGMENTS; MODEL	Bacterially expressed a-tropomyosin lacks the amino-terminal acetylation present in muscle tropomyosin and binds poorly to actin (Hitchcock-DeGregori, S. E., and Heald, R. W. (1987) J. Biol. Chem. 262, 9730-9735). Using a linear lattice model, we determined the affinity (K(o)) of unacetylated tropomyosin or troponin-unacetylated tropomyosin for an isolated site on the actin filament and the fold increase in affinity (y) when binding is to an adjacent site. The absence of tropomyosin acetylation decreased K(o) 2 orders of magnitude in the absence of troponin. Tropomyosin acetylation also enhanced troponin-tropomyosin binding to actin, not by increasing cooperativity (y), but rather by increasing K(o). These results suggest that the amino-terminal region of tropomyosin is a crucial actin binding site. Troponin promoted unacetylated tropomyosin binding to actin, increasing K(o) more than 1,000-fold. Troponin70-259, which lacks the troponin T peptide (1-69) spanning the overlap between adjacent tropomyosins, behaved similarly to intact troponin. Cooperative interactions between adjacent troponin-tropomyosin complexes remained strong despite the use of a non-polymerizable tropomyosin and a troponin unable to bridge neighboring tropomyosins physically. The K(o) for troponin70-259-unacetylated tropomyosin was 500-fold greater than for troponin159-259-unacetylated tropomyosin, indicating that troponin T residues 70-158 are critical for anchoring troponin-tropomyosin to F-actin. The mechanism of cooperative thin filament assembly is discussed.	UNIV IOWA,COLL MED,DEPT INTERNAL MED,IOWA CITY,IA 52242; UNIV IOWA,COLL MED,DEPT BIOCHEM,IOWA CITY,IA 52242	University of Iowa; University of Iowa					NHLBI NIH HHS [HL38834] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038834, R29HL038834] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BREMEL RD, 1972, NATURE-NEW BIOL, V238, P97, DOI 10.1038/newbio238097a0; BULLARD B, 1988, J MOL BIOL, V204, P621, DOI 10.1016/0022-2836(88)90360-9; CHO YJ, 1990, J BIOL CHEM, V265, P538; FLICKER PF, 1982, J MOL BIOL, V162, P495, DOI 10.1016/0022-2836(82)90540-X; FYRBERG E, 1990, J MOL BIOL, V216, P657, DOI 10.1016/0022-2836(90)90390-8; GREENE L, 1982, J BIOL CHEM, V257, P3993; GREENE LE, 1980, P NATL ACAD SCI-BIOL, V77, P2616, DOI 10.1073/pnas.77.5.2616; HEALD RW, 1988, J BIOL CHEM, V263, P5254; HELFMAN DM, 1984, J BIOL CHEM, V259, P4136; HILL LE, 1992, J BIOL CHEM, V267, P16106; HILL TL, 1980, P NATL ACAD SCI-BIOL, V77, P3186, DOI 10.1073/pnas.77.6.3186; HILL TL, 1983, P NATL ACAD SCI-BIOL, V80, P60, DOI 10.1073/pnas.80.1.60; HILL TL, 1985, COOPERATIVITY THEORY, P344; HITCHCOCKDEGREGORI SE, 1990, J MOL BIOL, V214, P885, DOI 10.1016/0022-2836(90)90343-K; HITCHCOCKDEGREGORI SE, 1987, J BIOL CHEM, V262, P9730; ISHII Y, 1987, BIOCHEMISTRY-US, V26, P4922, DOI 10.1021/bi00390a005; LEHRER SS, 1988, BIOCHEMISTRY-US, V27, P5899, DOI 10.1021/bi00416a012; MAK AS, 1980, J BIOL CHEM, V255, P3647; MARGOSSIAN SS, 1982, METHOD ENZYMOL, V85, P55; MCGHEE JD, 1974, J MOL BIOL, V86, P469, DOI 10.1016/0022-2836(74)90031-X; MORRIS EP, 1984, BIOCHEMISTRY-US, V23, P2214, DOI 10.1021/bi00305a018; OHTSUKI I, 1974, J BIOCHEM-TOKYO, V75, P753, DOI 10.1093/oxfordjournals.jbchem.a130448; PEARLSTONE JR, 1983, J BIOL CHEM, V258, P2534; POTTER JD, 1982, METHOD ENZYMOL, V85, P241; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TOBACMAN LS, 1987, BIOCHEMISTRY-US, V26, P492, DOI 10.1021/bi00376a022; TOBACMAN LS, 1990, J BIOL CHEM, V265, P931; WHITE SP, 1987, NATURE, V325, P826, DOI 10.1038/325826a0; WILLIAMS DL, 1988, BIOCHEMISTRY-US, V27, P6987, DOI 10.1021/bi00418a048; ZASEDATELEV A S, 1971, Molekulyarnaya Biologiya (Moscow), V5, P245	32	49	49	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1992	267	33					23746	23752						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JZ239	1429713				2022-12-25	WOS:A1992JZ23900050
J	GIBSON, AW; YE, R; JOHNSTON, RN; BROWDER, LW				GIBSON, AW; YE, R; JOHNSTON, RN; BROWDER, LW			A POSSIBLE ROLE FOR C-MYC ONCOPROTEINS IN POSTTRANSCRIPTIONAL REGULATION OF RIBOSOMAL-RNA	ONCOGENE			English	Note							MESSENGER-RNA; XENOPUS-LAEVIS; PROTO-ONCOGENE; DNA-SYNTHESIS; 2-NITRO-5-THIOCYANOBENZOIC ACID; CELL-DIVISION; GROWTH-FACTOR; EXPRESSION; BINDING; GENE	Overexpression of members of the myc family of oncogenes contributes to the development of many vertebrate malignancies. Although several functions for myc gene products have been proposed, the targets for Myc activity during oncogenesis or normal development remain to be identified. Oocytes of Xenopus laevis, which are non-dividing cells that accumulate abundant c-Myc protein, provide an unusual opportunity to examine c-Myc function. We have investigated whether the accumulation of massive amounts of ribosomal RNA (rRNA) by Xenopus laevis oocytes may be related to their elevated expression of myc proto-oncogenes. Our data show that anti-Myc antibodies and some (but not all) c-Myc peptides from conserved regions of the c-Myc protein enhance the turnover of rRNA synthesized in homogenates of oocyte nuclei. These results suggest that one or more members of the Myc protein family may be involved in post-transcriptional regulation of rRNA metabolism. The regulation by c-Myc of rRNA could account, in part, for the generalized stimulation of cells during tumorigenesis.	UNIV CALGARY,DEPT BIOL SCI,CALGARY T2N 1N4,ALBERTA,CANADA	University of Calgary	GIBSON, AW (corresponding author), UNIV CALGARY,SO ALBERTA CANC RES CTR,DEPT MED BIOCHEM,CALGARY T2N 4N1,ALBERTA,CANADA.		Johnston, Randal/B-9247-2009					ABELSON HT, 1979, BIOCHIM BIOPHYS ACTA, V561, P269, DOI 10.1016/0005-2787(79)90136-9; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; Cole MD, 1990, CURR OPIN CELL BIOL, V2, P502, DOI 10.1016/0955-0674(90)90134-Z; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; COOPER HL, 1970, NATURE, V227, P1105, DOI 10.1038/2271105a0; COOPER HL, 1971, J BIOL CHEM, V246, P5059; COWLEY BD, 1987, P NATL ACAD SCI USA, V84, P8394, DOI 10.1073/pnas.84.23.8394; DEGANI Y, 1974, BIOCHEMISTRY-US, V13, P1, DOI 10.1021/bi00698a001; DUMONT JN, 1972, J MORPHOL, V136, P153, DOI 10.1002/jmor.1051360203; ENDO T, 1986, MOL CELL BIOL, V6, P1412, DOI 10.1128/MCB.6.5.1412; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; GIBSON AW, 1992, IN PRESS BIOCH CELL; GODEAU F, 1986, EMBO J, V5, P3571, DOI 10.1002/j.1460-2075.1986.tb04684.x; GRAMMAGE MD, 1991, CLIN SCI, V80, P405; GUTIERREZ C, 1987, MOL CELL BIOL, V7, P4594, DOI 10.1128/MCB.7.12.4594; HANN SR, 1988, CELL, V52, P15; HILL JM, 1975, J CELL BIOL, V64, P260, DOI 10.1083/jcb.64.1.260; HIPSKIND RA, 1980, J BIOL CHEM, V255, P7896; INGHIRAMI G, 1990, SCIENCE, V250, P682, DOI 10.1126/science.2237417; JOHNSON LF, 1976, J CELL BIOL, V71, P933, DOI 10.1083/jcb.71.3.933; KACZMAREK L, 1985, SCIENCE, V228, P1313, DOI 10.1126/science.4001943; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KERKHOFF E, 1991, ONCOGENE, V6, P93; KING MW, 1986, MOL CELL BIOL, V6, P4499, DOI 10.1128/MCB.6.12.4499; LIAO TH, 1979, J BIOL CHEM, V254, P9602; LUSCHER B, 1989, EMBO J, V8, P111; NATH P, 1987, EXP CELL RES, V169, P215, DOI 10.1016/0014-4827(87)90239-4; PLEDGER WJ, 1977, P NATL ACAD SCI USA, V74, P4481, DOI 10.1073/pnas.74.10.4481; PRENDERGAST GC, 1990, MOL CELL BIOL, V10, P1265, DOI 10.1128/MCB.10.3.1265; PRENDERGAST GC, 1989, MOL CELL BIOL, V9, P124, DOI 10.1128/MCB.9.1.124; RUSTGI AK, 1991, NATURE, V352, P541, DOI 10.1038/352541a0; SCHER CD, 1979, BIOCHIM BIOPHYS ACTA, V560, P217, DOI 10.1016/0304-419X(79)90020-9; SPECTOR DL, 1987, ONCOGENE, V1, P5; STECK TL, 1976, BIOCHEMISTRY-US, V15, P1154, DOI 10.1021/bi00650a030; TAYLOR MV, 1986, EMBO J, V5, P3563, DOI 10.1002/j.1460-2075.1986.tb04683.x; VIZE PD, 1990, DEVELOPMENT, V110, P885; VRIZ S, 1989, EMBO J, V8, P4091, DOI 10.1002/j.1460-2075.1989.tb08593.x; WENZEL A, 1991, EMBO J, V10, P3703, DOI 10.1002/j.1460-2075.1991.tb04938.x	38	7	7	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1992	7	11					2363	2367						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JW665	1437160				2022-12-25	WOS:A1992JW66500033
J	NAKAZAWA, H; AGUELON, AM; YAMASAKI, H				NAKAZAWA, H; AGUELON, AM; YAMASAKI, H			IDENTIFICATION AND QUANTIFICATION OF A CARCINOGEN-INDUCED MOLECULAR INITIATION EVENT IN CELL-TRANSFORMATION	ONCOGENE			English	Article							BALB/C 3T3 CELLS; JUNCTIONAL INTERCELLULAR COMMUNICATION; HARVEY-RAS ONCOGENE; HA-RAS; MOUSE SKIN; CHEMICAL CARCINOGENESIS; TUMOR PROMOTERS; P53 GENE; ACTIVATION; MUTATION	All transformed foci of Balb/c 3T3 clone A31-1-1 cells induced by 7,12-dimethylbenz[a]anthracene (DMBA) (42 out of 42 examined) contained an A to T transversion at codon 61 (A182 to T) of the Ki-ras gene. The transformants induced by other carcinogens tested did not contain such a mutation, except one out of nine 12-O-tetradecanoyl phorbol 13-acetate (TPA)-induced transformed foci. Thus, we hypothesized that this mutation is a specific DMBA-induced initiating event in Balb/c 3T3 cell transformation and we have measured its frequency of induction before transformation occurs, employing our recently developed method. Such mutations can be detected in the cell population as early as 3 days after exposure to DMBA. The same mutation was also detected in the Ha-ras gene. No detectable level (<10(-6)) of these mutations was induced by other carcinogens tested. The mutation frequency of the Ha-ras gene reached a plateau after 1 week's exposure, but that of the Ki-ras gene continued to increase. These results suggest that the A182 to T mutation of the Ki-ras gene, but not that of the Ha-ras gene, contributes to morphological transformation of Balb/c 3T3 cells. We have demonstrated that the level of expression of ras genes determines the rate of recruitment of cells into transformation. Quantitative analysis of the frequencies of ras gene mutations (initiation) and of transformation suggests that about 25% of those cells with the Ki-ras mutation were recruited into the full transformation process and that, in the presence of the tumor promoter TPA, about 56% of them completed morphological cell transformation.			NAKAZAWA, H (corresponding author), INT AGCY RES CANC,MULTISTAGE CARCINOGENESIS UNIT,150 COURS ALBERT THOMAS,F-69372 LYON,FRANCE.				NCI NIH HHS [R01 CA40534] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA040534] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBERTINI RJ, 1991, IN PRESS ANN REV GEN; BALMAIN A, 1988, ADV CANCER RES, V51, P147, DOI 10.1016/S0065-230X(08)60222-5; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BARBU V, 1989, NUCLEIC ACIDS RES, V17, P7115, DOI 10.1093/nar/17.17.7115; Barrett J.C., 1985, MECHANISMS TOXICITY, P171; BIGNAMI M, 1988, MOL CARCINOGEN, V1, P67, DOI 10.1002/mc.2940010113; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; BIZUB D, 1986, P NATL ACAD SCI USA, V83, P604; BORRELLO MG, 1987, CANCER RES, V47, P75; BRASH DE, 1991, P NATL ACAD SCI US, V88; BRESSAC B, 1991, NATURE, V350, P429, DOI 10.1038/350429a0; CHAKRABORTY AK, 1991, P NATL ACAD SCI USA, V88, P2217, DOI 10.1073/pnas.88.6.2217; CHANDLER LA, 1987, CELL, V50, P711, DOI 10.1016/0092-8674(87)90329-1; DANDEKAR S, 1986, MOL CELL BIOL, V6, P4104, DOI 10.1128/MCB.6.11.4104; ENOMOTO T, 1985, CANCER RES, V45, P2681; ENOMOTO T, 1984, CANCER RES, V44, P5200; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FEINBERG AP, 1983, BIOCHEM BIOPH RES CO, V111, P47, DOI 10.1016/S0006-291X(83)80115-6; FITZGERALD DJ, 1989, MUTAGENESIS, V4, P286, DOI 10.1093/mutage/4.4.286; FUJIKI H, 1989, MOL CARCINOGEN, V2, P184, DOI 10.1002/mc.2940020403; GREENHALGH DA, 1989, MOL CARCINOGEN, V2, P199, DOI 10.1002/mc.2940020406; HARRIS CC, 1991, CANCER RES, V51, pS5023; Hayashi K, 1991, PCR Methods Appl, V1, P34; HILLOVA J, 1986, J NATL CANCER I, V77, P721, DOI 10.1093/jnci/77.3.721; HSU IC, 1991, NATURE, V350, P427, DOI 10.1038/350427a0; KAKUNAGA T, 1973, INT J CANCER, V12, P463, DOI 10.1002/ijc.2910120217; KAKUNAGA T, 1980, SCIENCE, V209, P505, DOI 10.1126/science.7394516; KATOH F, 1991, CARCINOGENESIS, V12, P1923, DOI 10.1093/carcin/12.10.1923; KAWASAKI E, 1989, AMPLIFICATIONS PERKI, V4, P5; KOVARY K, 1989, ONCOGENE RES, V4, P55; KUMAR R, 1990, ONCOGENE, V5, P1271; KUROKI T, 1985, TRANSFORMATION ASSAY, P93; LEON J, 1987, MOL CELL BIOL, V7, P1535, DOI 10.1128/MCB.7.4.1535; LERMAN LS, 1987, METHOD ENZYMOL, V155, P482; LERMAN LS, 1984, ANNU REV BIOPHYS BIO, V13, P339; LOKTIONOV A, 1990, MOL CARCINOGEN, V3, P134, DOI 10.1002/mc.2940030306; METTER J, 1989, NUCLEIC ACIDS RES, V17, P7089, DOI 10.1093/nar/17.17.7089; MURRAY AW, 1979, BIOCHEM BIOPH RES CO, V91, P395, DOI 10.1016/0006-291X(79)91535-3; NAKAZAWA H, 1990, MOL CARCINOGEN, V3, P202, DOI 10.1002/mc.2940030407; OHNO S, 1986, Cancer Reviews, V2, P65; PIERCEALL WE, 1991, ONCOGENE, V6, P2085; PUISSANT C, 1990, BIOTECHNIQUES, V8, P148; QUINTANILLA M, 1986, NATURE, V322, P78, DOI 10.1038/322078a0; REDMOND SMS, 1988, ONCOGENE, V2, P259; REYNOLDS VL, 1987, ONCOGENE, V1, P323; ROOP DR, 1986, NATURE, V323, P822, DOI 10.1038/323822a0; ROSL F, 1988, EMBO J, V7, P1321, DOI 10.1002/j.1460-2075.1988.tb02947.x; Sambrook J., 1989, MOL CLONING; SUGIMURA T, 1986, SCIENCE, V233, P312, DOI 10.1126/science.3088728; THILLY WG, 1985, METHODS DETECTING DN, P511; TOFTGARD R, 1985, CARCINOGENESIS, V6, P655, DOI 10.1093/carcin/6.4.655; TOMATIS L, 1989, JPN J CANCER RES, V80, P795, DOI 10.1111/j.1349-7006.1989.tb01717.x; TOPAL MD, 1988, CARCINOGENESIS, V9, P691, DOI 10.1093/carcin/9.5.691; Trosko J E, 1982, Carcinog Compr Surv, V7, P565; VANDERLUBBE JLM, 1988, ONCOGENE RES, V3, P9; WEINSTEIN IB, 1991, SCIENCE, V251, P387, DOI 10.1126/science.1989073; YAMASAKI H, 1987, CANCER RES, V47, P5658; YAMASAKI H, 1988, CANCER RES, V48, P3490; YOTTI LP, 1979, SCIENCE, P2681; YUSPA SH, 1985, ROLE CHEM RAD ETIOLO, P201; ZARBL H, 1985, NATURE, V315, P382, DOI 10.1038/315382a0; ZHANG R, 1991, CELL GROWTH DIFFER, V2, P1; 1985, CANCER RES, V45, P2395	63	26	26	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1992	7	11					2295	2301						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JW665	1437151				2022-12-25	WOS:A1992JW66500023
J	CONBOY, JG; COX, TC; BOTTOMLEY, SS; BAWDEN, MJ; MAY, BK				CONBOY, JG; COX, TC; BOTTOMLEY, SS; BAWDEN, MJ; MAY, BK			HUMAN ERYTHROID 5-AMINOLEVULINATE SYNTHASE - GENE STRUCTURE AND SPECIES-SPECIFIC DIFFERENCES IN ALTERNATIVE RNA SPLICING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DELTA-AMINOLEVULINATE SYNTHASE; MAMMALIAN-CELLS; MESSENGER-RNA; X-CHROMOSOME; PROTEIN 4.1; EXPRESSION; DIFFERENTIATION; ANKYRIN; CDNA; ISOFORMS	Erythroid 5-aminolevulinate synthase (ALAS) is expressed exclusively in differentiating erythroid cells as the principal isoform of the enzyme to catalyze the first step of the heme biosynthetic pathway. The human gene encoding this isozyme was isolated from a cosmid library, and its structure was characterized with restriction mapping followed by sequencing of fragments. The gene is 22 kilobases long and has 11 exons. Exon 2 encodes the N-terminal signal sequence required for mitochondrial import, exons 3 and 4 encode a variable portion of the N-terminal end, and exons 5-11 the highly conserved C-terminal portion of the mature protein, respectively. Enzymatic amplification of human reticulocyte RNA using PCR techniques revealed two erythroid ALAS mRNA transcripts predicted to encode both the prototypical 64-kDa isoform as well as a novel smaller isoform with a deletion of 37 amino acids near the N terminus. The two mRNA isoforms are generated by alternative splicing of exon 4 and are expressed in fetal erythroid cells as well as at all stages of erythroid development tested, so that there is no evidence of differentiation-specific regulation of exon 4 splicing. However, striking species-specific differences were observed in that alternative splicing of exon 4 was found in man but not dog or mouse; also, the previously described alternative splicing within exon 3 in mouse was not observed in man. This transcript heterogeneity suggests the existence of erythroid ALAS protein isoforms with potentially distinct functional or regulatory roles. The occurrence of species-specific splicing in the least conserved region of the enzyme may reflect another mechanism of gene evolution in eukaryotes.	LAWRENCE BERKELEY LAB,DIV CELL & MOLEC BIOL,BERKELEY,CA 94720; UNIV OKLAHOMA,COLL MED,DEPT MED,OKLAHOMA CITY,OK 73104; VET AFFAIRS MED CTR,OKLAHOMA CITY,OK 73104	United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center; US Department of Veterans Affairs; Veterans Health Administration (VHA)	CONBOY, JG (corresponding author), UNIV ADELAIDE,DEPT BIOCHEM,ADELAIDE,SA 5001,AUSTRALIA.				NHLBI NIH HHS [HL 45182] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045182] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BISHOP DF, 1990, GENOMICS, V7, P207, DOI 10.1016/0888-7543(90)90542-3; BOTTOMLEY SS, 1988, SEMIN HEMATOL, V25, P282; BOTTOMLEY SS, 1992, WINTROBES CLIN HEMAT; CHOO KH, 1986, GENE, V46, P277, DOI 10.1016/0378-1119(86)90412-9; CONBOY JG, 1991, J BIOL CHEM, V266, P8273; CONBOY JG, 1988, P NATL ACAD SCI USA, V85, P9062, DOI 10.1073/pnas.85.23.9062; CONBOY JG, 1991, BLOOD, V78, P2438, DOI 10.1182/blood.V78.9.2438.bloodjournal7892438; COX TC, 1991, EMBO J, V10, P1891, DOI 10.1002/j.1460-2075.1991.tb07715.x; COX TC, 1990, AM J HUM GENET, V46, P107; DANDEKAR T, 1991, EMBO J, V10, P19036; DEEN DF, 1986, CANCER RES, V46, P1599; Dierks P, 1990, BIOSYNTHESIS HEME CH, P201; ELFERINK CJ, 1988, J BIOL CHEM, V263, P13012; ELLIOTT WH, 1989, BIOCHEM SOC SYMP, V55, P13; FUJITA H, 1991, J BIOL CHEM, V266, P17494; Goossens M, 1981, Methods Enzymol, V76, P805; HALL TG, 1987, J BIOL CHEM, V262, P10537; HENDRIKS W, 1990, BIOCHIM BIOPHYS ACTA, V1037, P58, DOI 10.1016/0167-4838(90)90101-K; JOHNSON D, 1989, MOL CELL BIOL, V9, P2220, DOI 10.1128/MCB.9.5.2220; KUHN LC, 1991, BRIT J HAEMATOL, V79, P1, DOI 10.1111/j.1365-2141.1991.tb07998.x; LAMBERT S, 1990, P NATL ACAD SCI USA, V87, P1730, DOI 10.1073/pnas.87.5.1730; LASKI FA, 1982, NUCLEIC ACIDS RES, V10, P4609, DOI 10.1093/nar/10.15.4609; LUX SE, 1990, NATURE, V344, P36, DOI 10.1038/344036a0; MAGUIRE DJ, 1986, NUCLEIC ACIDS RES, V4, P1379; MAY BK, 1990, MOL BIOL MED, V7, P405; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; RIDDLE RD, 1989, P NATL ACAD SCI USA, V86, P792, DOI 10.1073/pnas.86.3.792; SAMBROOK J, 1990, MOL CLONING LABORATO; SCHOENHAUT DS, 1989, NUCLEIC ACIDS RES, V17, P7013, DOI 10.1093/nar/17.17.7013; SUTHERLAND GR, 1988, AM J HUM GENET, V43, P331; TANG TK, 1988, P NATL ACAD SCI USA, V85, P3713, DOI 10.1073/pnas.85.11.3713; THEIL EC, 1990, J BIOL CHEM, V265, P4771; TSAI SF, 1989, NATURE, V339, P446, DOI 10.1038/339446a0; VUILLETGAUGLER MH, 1990, BLOOD, V75, P865	34	58	59	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1992	267	26					18753	18758						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JN502	1527005				2022-12-25	WOS:A1992JN50200077
J	JANKOWSKI, JA; SCHROEDER, TJ; HOLZ, RW; WIGHTMAN, RM				JANKOWSKI, JA; SCHROEDER, TJ; HOLZ, RW; WIGHTMAN, RM			QUANTAL SECRETION OF CATECHOLAMINES MEASURED FROM INDIVIDUAL BOVINE ADRENAL-MEDULLARY CELLS PERMEABILIZED WITH DIGITONIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHROMAFFIN CELLS; DEPENDENT EXOCYTOSIS; PLASMA-MEMBRANES; CALCIUM	Secretion of catecholamines from individual bovine adrenal medullary cells grown in primary culture has been investigated with a carbon-fiber microelectrode placed adjacent to the cells. Oxidation of catecholamines at the electrode surface results in changes in current, which give a real-time measure of catecholamine secretion. Chemical agents are introduced to the individual cells by pressure ejection from micropipettes. When incubated in Ca2+-containing buffers, secretion is not observed. However, permeabilization of the cell by exposure to 20-mu-M digitonin for approximately 15 s results in a Ca2+-dependent secretion, and the contents of individual vesicles are detected in the form of sharp spikes. The rate at which spikes occur is a function of the Ca2+ concentration in the external media and reaches a maximum at 19-mu-M Ca2+. The area of the spikes range from 0.1 to >10 picocoulombs, but the majority are less than 2 picocoulombs, corresponding to less than 6 x 10(6) molecules detected per spike. Histograms of the spike areas are essentially independent of the Ca2+ concentration, indicating that the population of vesicles which undergo exocytosis is the same for all concentrations. Exocytotic secretion can be distinguished from nonexocytotic release by analysis of the shape of the spikes.	UNIV N CAROLINA, DEPT CHEM, CHAPEL HILL, NC 27599 USA; UNIV MICHIGAN, DEPT PHARMACOL, ANN ARBOR, MI 48109 USA	University of North Carolina; University of North Carolina Chapel Hill; University of Michigan System; University of Michigan					PHS HHS [R01-27959] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BAKER PF, 1978, NATURE, V276, P620, DOI 10.1038/276620a0; BURGOYNE RD, 1984, BIOCHIM BIOPHYS ACTA, V779, P201, DOI 10.1016/0304-4157(84)90009-1; BURGOYNE RD, 1991, BIOCHIM BIOPHYS ACTA, V1071, P174, DOI 10.1016/0304-4157(91)90024-Q; CHANG D, 1988, COMPUT BIOL MED, V18, P351, DOI 10.1016/0010-4825(88)90022-4; CHOW RH, 1992, NATURE, V356, P60, DOI 10.1038/356060a0; CIOLKOWSKI EL, 1992, J AM CHEM SOC, V114, P2815, DOI 10.1021/ja00034a009; COUPLAND RE, 1968, NATURE, V217, P384, DOI 10.1038/217384a0; DUNN LA, 1983, J BIOL CHEM, V258, P4989; FISKUM G, 1985, CELL CALCIUM, V6, P25, DOI 10.1016/0143-4160(85)90032-6; HAMPTON RY, 1983, J CELL BIOL, V96, P1082, DOI 10.1083/jcb.96.4.1082; HOLZ RW, 1985, J NEUROCHEM, V45, P1548, DOI 10.1111/j.1471-4159.1985.tb07226.x; HOLZ RW, 1989, J BIOL CHEM, V264, P5412; KAWAGOE KT, 1991, ANAL CHEM, V63, P1589, DOI 10.1021/ac00015a017; KELNER KL, 1986, P NATL ACAD SCI USA, V83, P2998, DOI 10.1073/pnas.83.9.2998; LESZCZYSZYN DJ, 1991, J NEUROCHEM, V56, P1855, DOI 10.1111/j.1471-4159.1991.tb03441.x; MORO MA, 1990, ANAL BIOCHEM, V185, P243, DOI 10.1016/0003-2697(90)90287-J; PERLMAN RL, 1976, BIOCHEM PHARMACOL, V25, P1035, DOI 10.1016/0006-2952(76)90492-5; SCHAFER T, 1987, J NEUROCHEM, V49, P1697, DOI 10.1111/j.1471-4159.1987.tb02427.x; Smith RM, 1974, CRITICAL STABILITY C, V1-6; SUDHOF TC, 1982, BIOCHIM BIOPHYS ACTA, V74, P70; WIGHTMAN RM, 1991, P NATL ACAD SCI USA, V88, P10754, DOI 10.1073/pnas.88.23.10754; WILSON SP, 1983, J BIOL CHEM, V258, P4994; WILSON SP, 1976, J NEUROCHEM, V27, P1289, DOI 10.1111/j.1471-4159.1976.tb02606.x; [No title captured]	24	56	57	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	1992	267	26					18329	18335						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JN502	1526972				2022-12-25	WOS:A1992JN50200016
J	MURRAY, V; MOTYKA, H; ENGLAND, PR; WICKHAM, G; LEE, HH; DENNY, WA; MCFADYEN, WD				MURRAY, V; MOTYKA, H; ENGLAND, PR; WICKHAM, G; LEE, HH; DENNY, WA; MCFADYEN, WD			THE USE OF TAQ DNA-POLYMERASE TO DETERMINE THE SEQUENCE SPECIFICITY OF DNA DAMAGE CAUSED BY CIS-DIAMMINEDICHLOROPLATINUM(II), ACRIDINE-TETHERED PLATINUM(II) DIAMMINE COMPLEXES OR 2 ANALOGS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTITUMOR DRUG CIS-DIAMMINEDICHLOROPLATINUM(II); ADDUCTS; TRANS-DIAMMINEDICHLOROPLATINUM(II); LESIONS; INVITRO; SITE	cis-Diamminedichloroplatinum(II) (cisplatin) forms adducts with DNA. The sequence specificity of formation of cisplatin adducts with plasmid DNA was investigated using Taq DNA polymerase. This procedure involved the extension of an oligonucleotide primer by Taq DNA polymerase up to the cisplatin adduct. Using thermal cycling, this process is repeated many times in order to amplify the signal. The products of this linear amplification can then be examined on DNA sequencing gels, and the sequence specificity of cisplatin adduct formation can be determined to the exact base pair. In the pUC8 plasmid, the sequences that produced the most intense damage sites (as determined by densitometry) were runs of two or more Gs. Adducts could also be detected at GA, AG, and GC dinucleotides. Four other cisplatin analogues were also tested in the system. Two of these analogues contained an attached intercalating chromophore, and the strong damage with these compounds was similar to that found for cisplatin, but the medium and weak damage tended to be different. Weak damage was also detected with trans-diamminedichloroplatinum(II). With this compound, a large number of the damage sites were at the CG dinucleotide. This technique represents a simple, accurate, and quick method for determining the sequence specificity of damage for a cisplatin analogue in any DNA sequence.	VICTORIAN COLL PHARM,PARKVILLE,VIC 3052,AUSTRALIA; UNIV AUCKLAND,SCH MED,CANC RES LAB,AUCKLAND,NEW ZEALAND; UNIV MELBOURNE,SCH SCI & MATH EDUC,INST EDUC,PARKVILLE,VIC 3052,AUSTRALIA	University of Auckland; University of Melbourne	MURRAY, V (corresponding author), UNIV NEW S WALES,SCH BIOCHEM,POB 1,KENSINGTON,NSW 2033,AUSTRALIA.							BERNGES F, 1991, NUCLEIC ACIDS RES, V19, P1483, DOI 10.1093/nar/19.7.1483; BUTOUR JL, 1986, BIOCHEMISTRY-US, V25, P4534, DOI 10.1021/bi00364a012; EASTMAN A, 1983, BIOCHEMISTRY-US, V22, P3927, DOI 10.1021/bi00285a031; FICHTINGERSCHEPMAN AMJ, 1985, BIOCHEMISTRY-US, V24, P707, DOI 10.1021/bi00324a025; GRALLA JD, 1987, CANCER RES, V47, P5092; HANSSON J, 1989, NUCLEIC ACIDS RES, V17, P8073, DOI 10.1093/nar/17.20.8073; JOHNSON GL, 1966, INORG SYNTH, V8, P242; KAUFFMAN GB, 1963, INORG SYN, V7, P239, DOI 10.1002/9780470132388.ch63; LEE HH, 1991, IN PRESS J MED CHEM; LOEHRER PJ, 1984, ANN INTERN MED, V100, P704, DOI 10.7326/0003-4819-100-5-704; MURRAY V, 1989, NUCLEIC ACIDS RES, V17, P8889, DOI 10.1093/nar/17.21.8889; PINTO AL, 1985, P NATL ACAD SCI USA, V82, P4616, DOI 10.1073/pnas.82.14.4616; PONTI M, 1991, NUCLEIC ACIDS RES, V19, P2929, DOI 10.1093/nar/19.11.2929; ROYERPOKORA B, 1981, NUCLEIC ACIDS RES, V9, P4595, DOI 10.1093/nar/9.18.4595; SALUZ H, 1989, P NATL ACAD SCI USA, V86, P2602, DOI 10.1073/pnas.86.8.2602; SCHWARTZ A, 1989, BIOCHEMISTRY-US, V28, P7975, DOI 10.1021/bi00446a001; VIEIRA J, 1982, GENE, V19, P259, DOI 10.1016/0378-1119(82)90015-4	17	91	91	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1992	267	26					18805	18809						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JN502	1527009				2022-12-25	WOS:A1992JN50200084
J	YU, Y; RADISKY, E; LEIBOLD, EA				YU, Y; RADISKY, E; LEIBOLD, EA			THE IRON-RESPONSIVE ELEMENT BINDING-PROTEIN - PURIFICATION, CLONING, AND REGULATION IN RAT-LIVER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FERRITIN MESSENGER-RNA; 3' UNTRANSLATED REGION; SODIUM DODECYL-SULFATE; TRANSFERRIN RECEPTOR; K562 CELLS; TRANSLATIONAL REPRESSION; AFFINITY PURIFICATION; CYTOSOLIC PROTEIN; HEAVY-SUBUNIT; RABBIT LIVER	The iron-responsive element binding protein (IRE-BP) is a cytosolic protein that binds a highly conserved sequence in the untranslated regions of mRNAs involved in iron metabolism including ferritin, transferrin receptor, and erythroid 5-aminolevulinate acid synthase. This conserved sequence is termed the iron-responsive element and is necessary for the post-transcriptional regulation of these mRNAs by iron. The rat liver IRE-BP was purified to homogeneity by chromatographic methods and partial amino acid sequence was obtained. A cDNA was isolated from a rat liver cDNA library and sequenced. The amino acid sequence deduced from the cDNA sequence corresponds to a protein of 889 amino acids with a predicted molecular weight of 97,946. The NH2-terminal sequence obtained by Edman degradation matched the deduced amino acid sequence obtained from the cDNA, confirming the translational start site. Rat liver IRE-BP shares 95% identity with human IRE-BP and 98% identity with mouse IRE-BP indicating that the IRE-BPs have remained highly conserved during evolution. The 5'-untranslated region is at least 236 nucleotides and contains interesting structural features including two direct repeats, an inverted repeat, and three small open reading frames. The rat IRE-BP mRNA is approximately 3600 nucleotides and is expressed in a variety of rat tissues including liver, spleen, and gut. Over the course of 16 h following an intraperitoneal injection of iron in rats, IRE-BP RNA binding activity decreases to 50% of control levels. The decrease in IRE-BP RNA binding activity in extracts from iron-treated rats is reversible by pretreatment of the extracts with reducing agents. The steady-state levels of IRE-BP mRNA remain constant during iron treatment. These data suggest that the decrease in IRE-BP RNA binding activity by iron in rat liver is due to post-translational changes in the RNA binding affinity of the IRE-BP and not due a decrease in the transcription of the IRE-BP gene or to the destabilization of the IRE-BP mRNA.	UNIV UTAH, PROGRAM HUMAN MOLEC BIOL & GENET, BLDG 533, RM 4220, SALT LAKE CITY, UT 84112 USA; UNIV UTAH, DEPT MED, SALT LAKE CITY, UT 84112 USA	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah			Radisky, Evette S/C-8526-2012	Radisky, Evette S/0000-0003-3121-109X	NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES [R01AM020630] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045201] Funding Source: NIH RePORTER; NCI NIH HHS [CA420114-06] Funding Source: Medline; NIADDK NIH HHS [R01AM20630] Funding Source: Medline; NIGMS NIH HHS [R01GM45201] Funding Source: Medline	NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIADDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; AZIZ N, 1986, NUCLEIC ACIDS RES, V14, P915, DOI 10.1093/nar/14.2.915; AZIZ N, 1987, P NATL ACAD SCI USA, V89, P915; BANDZIULIS RJ, 1989, GENE DEV, V3, P431, DOI 10.1101/gad.3.4.431; BEINERT H, 1989, EUR J BIOCHEM, V186, P5, DOI 10.1111/j.1432-1033.1989.tb15170.x; BRIDGES KR, 1984, J BIOL CHEM, V259, P2970; BROWN PH, 1989, J BIOL CHEM, V264, P13383; CALNAN BJ, 1991, GENE DEV, V5, P201, DOI 10.1101/gad.5.2.201; CASEY JL, 1989, EMBO J, V8, P3693, DOI 10.1002/j.1460-2075.1989.tb08544.x; CASEY JL, 1988, SCIENCE, V240, P924, DOI 10.1126/science.2452485; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; COX TC, 1991, EMBO J, V10, P1891, DOI 10.1002/j.1460-2075.1991.tb07715.x; DANDEKAR T, 1991, EMBO J, V10, P1903, DOI 10.1002/j.1460-2075.1991.tb07716.x; DAUTRYVARSAT A, 1983, P NATL ACAD SCI-BIOL, V80, P2258, DOI 10.1073/pnas.80.8.2258; DEVER TE, 1992, CELL, V68, P585, DOI 10.1016/0092-8674(92)90193-G; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Eisenstein R S, 1990, Adv Inorg Biochem, V8, P91; EMPTAGE MH, 1991, METAL CLUSTERS PROTE, P343; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; GANGLOFF SP, 1990, MOL CELL BIOL, V10, P3551, DOI 10.1128/MCB.10.7.3551; HAGER DA, 1980, ANAL BIOCHEM, V109, P76, DOI 10.1016/0003-2697(80)90013-5; HAILE DJ, 1989, MOL CELL BIOL, V9, P5055, DOI 10.1128/MCB.9.11.5055; HARRELL CM, 1991, P NATL ACAD SCI USA, V88, P4166, DOI 10.1073/pnas.88.10.4166; HENTZE MW, 1989, SCIENCE, V244, P357, DOI 10.1126/science.2711187; HENTZE MW, 1987, SCIENCE, V238, P1570, DOI 10.1126/science.3685996; KAPTAIN S, 1991, P NATL ACAD SCI USA, V88, P10109, DOI 10.1073/pnas.88.22.10109; KENAN DJ, 1991, TRENDS BIOCHEM SCI, V16, P214, DOI 10.1016/0968-0004(91)90088-D; KLAUSNER RD, 1989, SCIENCE, V246, P870, DOI 10.1126/science.2683086; KLAUSNER RD, 1983, P NATL ACAD SCI-BIOL, V80, P2263, DOI 10.1073/pnas.80.8.2263; KOELLER DM, 1989, P NATL ACAD SCI USA, V86, P3574, DOI 10.1073/pnas.86.10.3574; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KOZAK M, 1987, MOL CELL BIOL, V7, P3438, DOI 10.1128/MCB.7.10.3438; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LAZINSKI D, 1989, CELL, V59, P207, DOI 10.1016/0092-8674(89)90882-9; LEIBOLD EA, 1988, P NATL ACAD SCI USA, V85, P2171, DOI 10.1073/pnas.85.7.2171; LEIBOLD EA, 1992, ANNU REV NUTR, V12, P345, DOI 10.1146/annurev.nu.12.070192.002021; LEIBOLD EA, 1990, NUCLEIC ACIDS RES, V18, P1819, DOI 10.1093/nar/18.7.1819; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MATTIA E, 1984, J BIOL CHEM, V259, P2689; MULLNER EW, 1989, CELL, V58, P373, DOI 10.1016/0092-8674(89)90851-9; MULLNER EW, 1988, CELL, V53, P815, DOI 10.1016/0092-8674(88)90098-0; NEUPERT B, 1990, NUCLEIC ACIDS RES, V18, P51, DOI 10.1093/nar/18.1.51; OWEN D, 1987, EMBO J, V6, P1287, DOI 10.1002/j.1460-2075.1987.tb02366.x; PATINO MM, 1992, J BIOL CHEM, V267, P19011; PELICCI PG, 1982, FEBS LETT, V145, P350, DOI 10.1016/0014-5793(82)80198-1; PRIGODICH RV, 1986, BIOCHEMISTRY-US, V25, P3666, DOI 10.1021/bi00360a029; PROUDFOOT NJ, 1976, NATURE, V263, P211, DOI 10.1038/263211a0; QUERY CC, 1989, CELL, V57, P89, DOI 10.1016/0092-8674(89)90175-X; ROBBINS AH, 1989, P NATL ACAD SCI USA, V86, P3639, DOI 10.1073/pnas.86.10.3639; ROGERS J, 1987, P NATL ACAD SCI USA, V84, P2277, DOI 10.1073/pnas.84.8.2277; ROTHENBERGER S, 1990, NUCLEIC ACIDS RES, V18, P1175, DOI 10.1093/nar/18.5.1175; ROUAULT TA, 1988, SCIENCE, V241, P1207, DOI 10.1126/science.3413484; ROUAULT TA, 1989, P NATL ACAD SCI USA, V86, P5768, DOI 10.1073/pnas.86.15.5768; ROUAULT TA, 1991, CELL, V64, P881, DOI 10.1016/0092-8674(91)90312-M; ROUAULT TA, 1990, P NATL ACAD SCI USA, V87, P7958, DOI 10.1073/pnas.87.20.7958; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; THEIL EC, 1990, J BIOL CHEM, V265, P4771; THEIL EC, 1990, ADV ENZYMOL RAMB, V63, P421; WALDEN WE, 1988, P NATL ACAD SCI USA, V85, P9503, DOI 10.1073/pnas.85.24.9503; WALDEN WE, 1989, J BIOL CHEM, V264, P13765; WARD JH, 1982, J BIOL CHEM, V257, P317; WHITE K, 1988, J BIOL CHEM, V263, P8938; ZAHRINGER J, 1976, P NATL ACAD SCI USA, V73, P857, DOI 10.1073/pnas.73.3.857; ZHENG LM, 1990, J BIOL CHEM, V265, P2814	66	79	80	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	1992	267	26					19005	19010						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JN502	1527027				2022-12-25	WOS:A1992JN50200112
J	LI, WH; SHARIATMADAR, Z; POWERS, M; SUN, XC; LANE, RD; GARLID, KD				LI, WH; SHARIATMADAR, Z; POWERS, M; SUN, XC; LANE, RD; GARLID, KD			RECONSTITUTION, IDENTIFICATION, PURIFICATION, AND IMMUNOLOGICAL CHARACTERIZATION OF THE 110-KDA NA+/CA2+ ANTIPORTER FROM BEEF-HEART MITOCHONDRIA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER MITOCHONDRIA; CALCIUM-TRANSPORT; EXTRAMITOCHONDRIAL CA-2+; NA+/H+ ANTIPORTER; K+-TRANSPORT; SODIUM; MECHANISM; PROTEINS; RELEASE; EFFLUX	The mitochondrial Na+/Ca2+ antiporter plays a key role in the physiological regulation of intramitochondrial Ca2+, which in turn attunes mitochondrial enzymes to the changing demands of the cell for ATP. We have now purified the Na+/Ca2+ antiporter from beef heart mitochondria by assaying detergent-solubilized chromatography fractions for reconstitutive activity. Na+ and Ca2+ transport were assayed using the fluorescent probes, sodium-binding benzofuran isophthalate and Fura-2, respectively. This approach enabled us to identify Na+/Ca2+ exchange activity with a 110-kDa inner membrane protein that catalyzed Na+-dependent Ca2+ transport and Ca2+-dependent Na+ transport. A new finding was that the Na/Ca2+ antiporter also catalyzed Na+/Li+ exchange in the absence of Ca2+. All modes of transport were electroneutral and were inhibited by diltiazem and tetraphenylphosphonium cation. Monospecific polyclonal antibodies to the 110-kDa protein inhibited Na+/Ca2+ and Na+/Li+ exchange in the reconstituted system and recognized 110-kDa proteins in mitochondrial membranes isolated from rat heart, liver, and kidney.	MED COLL OHIO, DEPT PHARMACOL, TOLEDO, OH 43699 USA; MED COLL OHIO, DEPT ANAT, TOLEDO, OH 43699 USA					Garlid, Keith/0000-0002-6777-1235	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL036573, R01HL043814] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 43814, HL 36573] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAYSAL K, 1991, ARCH BIOCHEM BIOPHYS, V291, P383, DOI 10.1016/0003-9861(91)90150-H; BEAVIS AD, 1985, J BIOL CHEM, V260, P3424; BLAKE MS, 1984, ANAL BIOCHEM, V136, P175, DOI 10.1016/0003-2697(84)90320-8; BLINKS JR, 1982, PROG BIOPHYS MOL BIO, V40, P1, DOI 10.1016/0079-6107(82)90011-6; BRAND MD, 1985, BIOCHEM J, V229, P161, DOI 10.1042/bj2290161; CARAFOLI E, 1974, J MOL CELL CARDIOL, V6, P361, DOI 10.1016/0022-2828(74)90077-7; CARONI P, 1978, FEBS LETT, V96, P339, DOI 10.1016/0014-5793(78)80431-1; CROMPTON M, 1977, EUR J BIOCHEM, V79, P549, DOI 10.1111/j.1432-1033.1977.tb11839.x; CROMPTON M, 1976, EUR J BIOCHEM, V69, P453, DOI 10.1111/j.1432-1033.1976.tb10930.x; CROMPTON M, 1978, EUR J BIOCHEM, V82, P25, DOI 10.1111/j.1432-1033.1978.tb11993.x; DAUM G, 1982, J BIOL CHEM, V257, P3028; DENTON RM, 1985, AM J PHYSIOL, V249, pE543, DOI 10.1152/ajpendo.1985.249.6.E543; FISKUM G, 1979, J BIOL CHEM, V254, P6236; GARLID KD, 1991, J BIOL CHEM, V266, P6518; GARLID KD, 1986, J BIOL CHEM, V261, P1529; GARLID KD, 1988, INTEGRATION MITOCHON, P257; GOLDSTONE TP, 1982, BIOCHEM J, V204, P369, DOI 10.1042/bj2040369; GOOD NE, 1966, BIOCHEMISTRY-US, V5, P467, DOI 10.1021/bi00866a011; GUNTER TE, 1990, AM J PHYSIOL, V258, pC755, DOI 10.1152/ajpcell.1990.258.5.C755; HANSFORD RG, 1985, REV PHYSIOL BIOCH P, V102, P1, DOI 10.1007/BFb0034084; HAYAT LH, 1987, BIOCHEM J, V244, P533, DOI 10.1042/bj2440533; JEZEK P, 1990, J BIOL CHEM, V265, P10522; KAKAR SS, 1987, J BIOL CHEM, V262, P42; KAPLAN RS, 1985, ANAL BIOCHEM, V150, P97, DOI 10.1016/0003-2697(85)90445-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lai J C, 1979, Methods Enzymol, V55, P51; LANE RD, 1989, HYBRIDOMA, V8, P661, DOI 10.1089/hyb.1989.8.661; LAYNE E, 1957, METHOD ENZYMOL, V3, P447, DOI 10.1016/S0076-6879(57)03413-8; LI W, 1990, BIPHY J, V59, pA333; LI W, 1990, J MOL CELL CARDIOL, V23, pS78; LI XQ, 1990, J BIOL CHEM, V265, P15316; MARTIN WH, 1986, J BIOL CHEM, V261, P2300; MCCORMACK JG, 1990, PHYSIOL REV, V70, P391, DOI 10.1152/physrev.1990.70.2.391; MITCHELL P, 1969, EUR J BIOCHEM, V9, P149, DOI 10.1111/j.1432-1033.1969.tb00588.x; MIYATA H, 1991, AM J PHYSIOL, V261, pH1123, DOI 10.1152/ajpheart.1991.261.4.H1123; NEDERGAARD J, 1984, EUR J BIOCHEM, V144, P159, DOI 10.1111/j.1432-1033.1984.tb08444.x; NICHOLLS D, 1982, BIOCHIM BIOPHYS ACTA, V683, P57, DOI 10.1016/0304-4173(82)90013-1; NICHOLLS DG, 1980, FEBS LETT, V111, P261, DOI 10.1016/0014-5793(80)80806-4; NICOLL DA, 1990, SCIENCE, V250, P562, DOI 10.1126/science.1700476; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; PUSKIN JS, 1976, BIOCHEMISTRY-US, V15, P3834, DOI 10.1021/bi00662a029; SAMMONS DW, 1981, ELECTROPHORESIS, V2, P135, DOI 10.1002/elps.1150020303; SCARPA A, 1973, J GEN PHYSIOL, V62, P756, DOI 10.1085/jgp.62.6.756; VAGHY PL, 1982, J BIOL CHEM, V257, P6000; WINGROVE DE, 1986, J BIOL CHEM, V261, P5166; ZWIERS H, 1985, J NEUROCHEM, V44, P1083, DOI 10.1111/j.1471-4159.1985.tb08728.x	46	64	66	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 5	1992	267	25					17983	17989						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JM223	1517231				2022-12-25	WOS:A1992JM22300077
J	TING, SM; BOGNER, P; DIGNAM, JD				TING, SM; BOGNER, P; DIGNAM, JD			ISOLATION OF PROLYL-TRANSFER RNA-SYNTHETASE AS A FREE FORM AND AS A FORM ASSOCIATED WITH GLUTAMYL-TRANSFER RNA-SYNTHETASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALANYL-TRANSFER RNA; BOMBYX-MORI; CHLOROPHYLL BIOSYNTHESIS; MACROMOLECULAR COMPLEXES; MULTIENZYME COMPLEX; ELONGATION-FACTOR; SENSITIVE METHOD; GLYCYL-TRANSFER; RABBIT LIVER; SHEEP LIVER	Rat liver prolyl-tRNA synthetase was purified as a dimer of M(r) 60,000 subunits not associated with other aminoacyl-tRNA synthetases and as a form associated with glutamyl-tRNA synthetase. Proteolysis of the dimeric enzyme generated a less active form with M(r) 52,000 subunits and an inactive form with M(r) 40,000 subunits. A second species was isolated with polypeptides of M(r) 60,000 and 150,000. This form dissociated during gel filtration chromatography being partially resolved into the M(r) 150,000 and 60,000 components; glutamyl-tRNA synthetase was associated with the larger polypeptide and prolyl-tRNA synthetase with the smaller component. Antibodies against the M(r) 60,000 polypeptide reacted with the M(r) 60,000 and 150,000 polypeptides. Gel filtration of extracts revealed multiple forms of prolyl- and glutamyl-tRNA synthetase. Antibody against the M(r) 60,000 component detected the M(r) 60,000 and 150,000 polypeptides throughout the chromatogram; these forms could be partially separated by polyethylene glycol fractionation. The M(r) 150,000 and 60,000 polypeptides were detected by Western blot analysis of crude extracts prepared under several conditions. Antibody to prolyl-tRNA synthetase reacted with a M(r) 150,000 polypeptide of the aminoacyl-tRNA synthetase core complex identified previously as glutamyl-tRNA synthetase.	MED COLL OHIO, DEPT BIOCHEM & MOLEC BIOL, POB 10008, TOLEDO, OH 43699 USA						NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE009669] Funding Source: NIH RePORTER; NIDCR NIH HHS [DE09669] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		BEC G, 1989, J BIOL CHEM, V264, P21131; BEC G, 1989, J BIOL CHEM, V264, P21138; BEELEY JG, 1968, BIOCHEMISTRY-US, V7, P1239, DOI 10.1021/bi00843a047; BLAKE MS, 1984, ANAL BIOCHEM, V136, P175, DOI 10.1016/0003-2697(84)90320-8; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CERINI C, 1991, EMBO J, V10, P4267, DOI 10.1002/j.1460-2075.1991.tb05005.x; CHERNIACK AD, 1990, CELL, V62, P745, DOI 10.1016/0092-8674(90)90119-Y; DANG CV, 1986, BIOCHEM J, V239, P249, DOI 10.1042/bj2390249; DANG CV, 1982, BIOCHEMISTRY-US, V21, P1959; DEUTSCHER MP, 1967, J BIOL CHEM, V242, P1123; DIGNAM JD, 1991, EUR J BIOCHEM, V198, P201, DOI 10.1111/j.1432-1033.1991.tb16002.x; DIGNAM SS, 1984, J BIOL CHEM, V259, P4043; FETT R, 1991, J BIOL CHEM, V266, P1448; GILLAM IC, 1981, SELECTED METHODS ENZ, P43; GODAR DE, 1988, BIOCHEMISTRY-US, V27, P6921, DOI 10.1021/bi00418a038; Hirs CHW, 1967, METHOD ENZYMOL, P59, DOI [10.1016/S0076-6879(67)11008-2, DOI 10.1016/S0076-6879(67)11008-2]; HUANG DD, 1986, J BIOL CHEM, V261, P3451; HUNKAPILLAR MW, 1983, METHOD ENZYMOL, V91, P60; KELLERMANN O, 1978, EUR J BIOCHEM, V88, P205, DOI 10.1111/j.1432-1033.1978.tb12439.x; KELLERMANN O, 1982, J BIOL CHEM, V257, P1041; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAZARD M, 1985, BIOCHEMISTRY-US, V24, P5099, DOI 10.1021/bi00340a021; MIRANDE M, 1985, EUR J BIOCHEM, V147, P281, DOI 10.1111/j.1432-1033.1985.tb08748.x; MIRANDE M, 1991, PROG NUCLEIC ACID RE, V40, P95; MIRANDE M, 1982, J BIOL CHEM, V257, P1056; MIRANDE M, 1982, J BIOL CHEM, V257, P1049; MISETA A, 1991, J BIOL CHEM, V266, P19158; MOTORIN YA, 1988, FEBS LETT, V238, P262, DOI 10.1016/0014-5793(88)80492-7; NORCUM MT, 1989, J BIOL CHEM, V264, P15043; SCHIMMEL P, 1987, ANNU REV BIOCHEM, V56, P125, DOI 10.1146/annurev.bi.56.070187.001013; SCHON A, 1986, NATURE, V322, P281, DOI 10.1038/322281a0; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; SMITH DE, 1984, J CELL BIOL, V99, P20, DOI 10.1083/jcb.99.1.20; TANFORD C, 1974, BIOCHEMISTRY-US, V13, P2369, DOI 10.1021/bi00708a021; VISWANATHAN S, 1988, DEV BIOL, V129, P350, DOI 10.1016/0012-1606(88)90382-X; VISWANATHAN S, 1988, J BIOL CHEM, V263, P535; WEBER K, 1969, J BIOL CHEM, V244, P4406; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2; YANG DCH, 1985, CURR TOP CELL REGUL, V26, P325	39	25	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 5	1992	267	25					17701	17709						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JM223	1517216				2022-12-25	WOS:A1992JM22300036
J	REILLY, CF; HUTZELMANN, JE				REILLY, CF; HUTZELMANN, JE			PLASMINOGEN-ACTIVATOR INHIBITOR-1 BINDS TO FIBRIN AND INHIBITS TISSUE-TYPE PLASMINOGEN ACTIVATOR-MEDIATED FIBRIN DISSOLUTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; ENDOTHELIAL-CELLS; EXTRACELLULAR-MATRIX; KINETIC-ANALYSIS; CANINE MODEL; HUMAN-PLASMA; ONE-CHAIN; PURIFICATION; VITRONECTIN; PAI-1	Plasminogen activator inhibitor-1 (PAI-1) accumulates within thrombi and forming whole blood clots. To explore this phenomenon at the molecular level, PAI-1 binding to fibrin was examined. The experiments were performed by adding I-125-PAI-1, which retains its complete tissue-type plasminogen (t-PA) inhibitory activity, to fibrin matrices formed in 2-cm2 tissue culture wells. Guanidine HCl-activated PAI-1 binding was reversible and was inhibited in the presence of excess, unlabeled PAI-1. Activated I-125-PAI-1 recognized 2 sites on fibrin: a very small number of high affinity sites (K(d) < 1 nM) and principally a large number of low affinity sites with an approximate K(d) of 3.8-mu-M. Latent PAI-1 bound to fibrin at a site indistinguishable from the lower affinity site recognized by activated PAI-1. Fibrin, pretreated with activated PAI-1, was protected from t-PA-mediated plasmin degradation in a PAI-1 dose-responsive manner (IC50 = 12.3 nM). Clot protection correlated with partial occupancy of the low affinity PAI-1 binding site on fibrin and was due to the formation of sodium dodecyl sulfate-stable, PAI-1.t-PA complexes. Latent PAI-1 (27 nM) did not protect the fibrin from dissolution. The localization of PAI-1 to a thrombus by virtue of its fibrin binding potential could result in significant protection of the thrombus from the degradative effects of the fibrinolytic system.			REILLY, CF (corresponding author), MERCK SHARP & DOHME LTD, DEPT PHARMACOL, W42-300, West Point, PA 19486 USA.							ALESSI MC, 1988, EUR J BIOCHEM, V175, P531, DOI 10.1111/j.1432-1033.1988.tb14225.x; ALMER LO, 1987, THROMB RES, V47, P335, DOI 10.1016/0049-3848(87)90147-2; BOOTH NA, 1987, EUR J BIOCHEM, V165, P595, DOI 10.1111/j.1432-1033.1987.tb11481.x; CHMIELEWSKA J, 1987, Fibrinolysis, V1, P67, DOI 10.1016/0268-9499(87)90012-9; DECLERCK PJ, 1988, BLOOD, V71, P220; DECLERCK PJ, 1988, J BIOL CHEM, V263, P15454; DEUTSCH DG, 1970, SCIENCE, V170, P1095, DOI 10.1126/science.170.3962.1095; FAY WP, 1990, ARTERIOSCLEROSIS, V10, pA910; FELDMAN HA, 1983, J BIOL CHEM, V258, P2865; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; FUJII S, 1990, CIRCULATION, V82, P1485, DOI 10.1161/01.CIR.82.4.1485; HAMSTEN A, 1987, LANCET, V2, P3; HAYMAN EG, 1983, P NATL ACAD SCI-BIOL, V80, P4003, DOI 10.1073/pnas.80.13.4003; HEKMAN CM, 1985, J BIOL CHEM, V260, P11581; HUSAIN SS, 1989, BLOOD, V74, P999; Jackson C., 1989, J APPL POLYM SCI APP, V43, P99; KNUDSEN BS, 1987, J CLIN INVEST, V80, P1082, DOI 10.1172/JCI113164; KRUITHOF EKO, 1987, BLOOD, V70, P1645; LAMBERS JWJ, 1987, J BIOL CHEM, V262, P17492; LAWRENCE DA, 1986, BIOCHEMISTRY-US, V25, P6351, DOI 10.1021/bi00369a001; LEVI M, 1992, CIRCULATION, V85, P305, DOI 10.1161/01.CIR.85.1.305; LINDAHL TL, 1990, BIOCHEM J, V265, P109, DOI 10.1042/bj2650109; LINDAHL TL, 1989, THROMB HAEMOSTASIS, V62, P748; LUCAS MA, 1983, J BIOL CHEM, V258, P4249; MASSON C, 1988, BIOCHEM J, V256, P237, DOI 10.1042/bj2560237; MAYER EJ, 1990, BLOOD, V76, P1514; MIMURO J, 1989, J BIOL CHEM, V264, P936; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; PARAMO JA, 1985, BRIT MED J, V291, P573, DOI 10.1136/bmj.291.6495.573; QUAX PHA, 1990, J BIOL CHEM, V265, P15560; REILLY CF, 1991, J BIOL CHEM, V266, P9419; REILLY CF, 1991, ARTERIOSCLER THROMB, V11, P1276, DOI 10.1161/01.ATV.11.5.1276; REILLY CF, 1991, CIRCULATION, V84, P287, DOI 10.1161/01.CIR.84.1.287; REILLY CF, 1991, FIBRINOLYSIS, V5, P99, DOI 10.1016/0268-9499(91)90050-E; RIJKEN DC, 1982, J BIOL CHEM, V257, P2920; SAKATA Y, 1980, J CLIN INVEST, V65, P290, DOI 10.1172/JCI109671; SALONEN EM, 1989, J BIOL CHEM, V264, P6339; SCHLEEF RR, 1988, HAEMOSTASIS, V18, P328; SEIFFERT D, 1991, BIOCHIM BIOPHYS ACTA, V1078, P23, DOI 10.1016/0167-4838(91)90087-G; SPRENGERS ED, 1987, BLOOD, V69, P381; SUFFREDINI AF, 1989, NEW ENGL J MED, V320, P1165, DOI 10.1056/NEJM198905043201802; URANO T, 1988, BIOCHEM BIOPH RES CO, V150, P45, DOI 10.1016/0006-291X(88)90484-6; VANLOON P, 1990, FIBRINOLYSIS, V4, pA7; WAGNER OF, 1989, J CLIN INVEST, V84, P647, DOI 10.1172/JCI114211	44	55	58	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	1992	267	24					17128	17135						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JL053	1512250				2022-12-25	WOS:A1992JL05300063
J	WAKAMATSU, N; KOBAYASHI, H; MIYATAKE, T; TSUJI, S				WAKAMATSU, N; KOBAYASHI, H; MIYATAKE, T; TSUJI, S			A NOVEL EXON MUTATION IN THE HUMAN BETA-HEXOSAMINIDASE BETA SUBUNIT GENE AFFECTS 3' SPLICE SITE SELECTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-MESSENGER RNA; SMALL NUCLEAR RIBONUCLEOPROTEIN; SINGLE NUCLEOTIDE SUBSTITUTION; SECONDARY STRUCTURE; SANDHOFF DISEASE; GLOBIN GENE; INTERVENING SEQUENCE; EXTENSIVE HOMOLOGY; GM2 GANGLIOSIDOSIS; DOWNSTREAM EXON	The molecular basis of a dramatically decreased steady state level of beta-hexosaminidase beta-subunit mRNA in a patient with juvenile Sandhoff disease was investigated. Nucleotide sequence analysis of the HEXB gene coding for the beta-subunit revealed two single base substitutions, one in exon 2 (A to G, a known polymorphism) and the other in exon 11 (C to T). Analysis of the beta-subunit mRNA species demonstrated activation of a cryptic splice site in exon 11 as well as skipping of the exon. A transfection assay using a chimeric gene containing intron 10 flanked by cDNA sequences carrying the mutation confirmed that the single base substitution located at position 8 of exon 11 inhibits the selection of the normal 3' splice site. The results demonstrate a new type of exon mutation affecting 3' splice site selection.	NIIGATA UNIV, BRAIN RES INST, DEPT NEUROL, 1 ASAHIMACHI, NIIGATA 951, JAPAN	Niigata University				Wakamatsu, Nobuaki/0000-0001-5693-2227; Nobuaki, Wakamatsu/0000-0003-1956-8977				ANTONARAKIS SE, 1984, P NATL ACAD SCI-BIOL, V81, P1154, DOI 10.1073/pnas.81.4.1154; ATWEH GF, 1985, NUCLEIC ACIDS RES, V13, P777, DOI 10.1093/nar/13.3.777; BIKKER H, 1989, HUM GENET, V81, P287, DOI 10.1007/BF00279006; BINDEREIF A, 1987, EMBO J, V6, P2415, DOI 10.1002/j.1460-2075.1987.tb02520.x; BLACK DL, 1985, CELL, V42, P737, DOI 10.1016/0092-8674(85)90270-3; CARSTENS RP, 1991, AM J HUM GENET, V48, P1105; CHABOT B, 1985, SCIENCE, V230, P1344, DOI 10.1126/science.2933810; CHEBLI K, 1989, MOL CELL BIOL, V9, P4852, DOI 10.1128/MCB.9.11.4852; CHEN EY, 1985, DNA-J MOLEC CELL BIO, V4, P165, DOI 10.1089/dna.1985.4.165; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOI YD, 1986, SCIENCE, V231, P1534, DOI 10.1126/science.3952495; CLADARAS C, 1987, J BIOL CHEM, V262, P2310; CONZELMANN E, 1979, H-S Z PHYSIOL CHEM, V360, P1837, DOI 10.1515/bchm2.1979.360.2.1837; DLOTT B, 1990, J BIOL CHEM, V265, P17921; EPERON LP, 1988, CELL, V54, P393, DOI 10.1016/0092-8674(88)90202-4; EPERON LP, 1986, NATURE, V324, P280, DOI 10.1038/324280a0; FU XD, 1991, GENE DEV, V5, P211, DOI 10.1101/gad.5.2.211; FURDON PJ, 1988, MOL CELL BIOL, V8, P860, DOI 10.1128/MCB.8.2.860; GARCIABLANCO MA, 1989, GENE DEV, V3, P1874, DOI 10.1101/gad.3.12a.1874; GERKE V, 1986, CELL, V47, P973, DOI 10.1016/0092-8674(86)90812-3; GILBERT F, 1975, P NATL ACAD SCI USA, V72, P263, DOI 10.1073/pnas.72.1.263; GREEN MR, 1986, ANNU REV GENET, V20, P671, DOI 10.1146/annurev.ge.20.120186.003323; HALFTER H, 1988, NUCLEIC ACIDS RES, V16, P10413, DOI 10.1093/nar/16.22.10413; HAMPSON RK, 1989, MOL CELL BIOL, V9, P1604, DOI 10.1128/MCB.9.4.1604; HEDLEY ML, 1989, J IMMUNOL, V143, P1018; HUBBES M, 1989, FEBS LETT, V249, P316, DOI 10.1016/0014-5793(89)80649-0; KAZAZIAN HH, 1988, BLOOD, V72, P1107; KORNELUK RG, 1986, J BIOL CHEM, V261, P8407; KUIVANIEMI H, 1988, J BIOL CHEM, V263, P11407; KYTZIA HJ, 1984, HUM GENET, V67, P414, DOI 10.1007/BF00291402; LALLEY PA, 1974, P NATL ACAD SCI USA, V71, P1569, DOI 10.1073/pnas.71.4.1569; LIGTENBERG MJL, 1991, NUCLEIC ACIDS RES, V19, P297, DOI 10.1093/nar/19.2.297; MAHURAN DJ, 1988, J BIOL CHEM, V263, P4612; MAHURAN DJ, 1982, P NATL ACAD SCI-BIOL, V79, P1602, DOI 10.1073/pnas.79.5.1602; MANIATIS T, 1987, NATURE, V325, P673, DOI 10.1038/325673a0; MARDON HJ, 1987, NUCLEIC ACIDS RES, V15, P7725, DOI 10.1093/nar/15.19.7725; MITCHELL PJ, 1986, MOL CELL BIOL, V6, P1926, DOI 10.1128/MCB.6.6.1926; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; MULES EH, 1991, AM J HUM GENET, V48, P1181; MYEROWITZ R, 1985, P NATL ACAD SCI USA, V82, P7830, DOI 10.1073/pnas.82.23.7830; NAKANO T, 1989, J BIOL CHEM, V264, P5155; NEOTE K, 1988, GENOMICS, V3, P279, DOI 10.1016/0888-7543(88)90116-4; NEOTE K, 1990, J CLIN INVEST, V86, P1524, DOI 10.1172/JCI114871; ODOWD BF, 1985, P NATL ACAD SCI USA, V82, P1184, DOI 10.1073/pnas.82.4.1184; ODOWD BF, 1986, J BIOL CHEM, V261, P2680; OKAYAMA H, 1983, MOL CELL BIOL, V3, P280, DOI 10.1128/MCB.3.2.280; ORKIN SH, 1984, ANNU REV GENET, V18, P131; ORKIN SH, 1983, J BIOL CHEM, V258, P7249; PADANILAM BJ, 1986, AM J HEMATOL, V22, P259, DOI 10.1002/ajh.2830220306; PADGETT RA, 1986, ANNU REV BIOCHEM, V55, P1119, DOI 10.1146/annurev.bi.55.070186.005351; PROIA RL, 1988, P NATL ACAD SCI USA, V85, P1883, DOI 10.1073/pnas.85.6.1883; QUON DVK, 1989, J BIOL CHEM, V264, P3380; RAPPOLEE DA, 1988, SCIENCE, V241, P708, DOI 10.1126/science.3041594; REED R, 1986, CELL, V46, P681, DOI 10.1016/0092-8674(86)90343-0; RUSKIN B, 1988, CELL, V52, P207, DOI 10.1016/0092-8674(88)90509-0; RUSKIN B, 1985, NATURE, V317, P732, DOI 10.1038/317732a0; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sandhoff KCE, 1989, METABOLIC BASIS INHE, V2, P1807; SATOKATA I, 1990, P NATL ACAD SCI USA, V87, P9908, DOI 10.1073/pnas.87.24.9908; SHAPIRO MB, 1987, NUCLEIC ACIDS RES, V15, P7155, DOI 10.1093/nar/15.17.7155; SHARP PA, 1987, SCIENCE, V235, P766, DOI 10.1126/science.3544217; SHARP PA, 1987, HARVEY LECT, V81, P1; SOLNICK D, 1985, CELL, V43, P667, DOI 10.1016/0092-8674(85)90239-9; SOLNICK D, 1987, MOL CELL BIOL, V7, P3194, DOI 10.1128/MCB.7.9.3194; SOMASEKHAR MB, 1985, NUCLEIC ACIDS RES, V13, P5591, DOI 10.1093/nar/13.15.5591; SPRITZ RA, 1981, P NATL ACAD SCI-BIOL, V78, P2455, DOI 10.1073/pnas.78.4.2455; SWANSON MS, 1988, EMBO J, V7, P3519, DOI 10.1002/j.1460-2075.1988.tb03228.x; TAZI J, 1986, CELL, V47, P755, DOI 10.1016/0092-8674(86)90518-0; TROMP G, 1988, P NATL ACAD SCI USA, V85, P5254, DOI 10.1073/pnas.85.14.5254; WAHL GM, 1979, P NATL ACAD SCI USA, V76, P3683, DOI 10.1073/pnas.76.8.3683; WAKAMATSU N, 1988, American Journal of Human Genetics, V43, pA74; WAKAMATSU N, 1990, AM J HUM GENET, V47, pA169; WATAKABE A, 1989, NUCLEIC ACIDS RES, V17, P8159, DOI 10.1093/nar/17.20.8159; WESTAWAY D, 1981, NUCLEIC ACIDS RES, V9, P1777, DOI 10.1093/nar/9.8.1777; WIGLER M, 1978, CELL, V14, P725, DOI 10.1016/0092-8674(78)90254-4; WONG C, 1989, BLOOD, V73, P914	76	92	96	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 5	1992	267	4					2406	2413						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HB532	1531140				2022-12-25	WOS:A1992HB53200047
J	ANGELASTRO, JM; PURICH, DL				ANGELASTRO, JM; PURICH, DL			2'-DEOXY-GTP IN THE MICROTUBULE CYTOSKELETON OF NEURONAL CELLS CULTURED WITH NERVE GROWTH-FACTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROMOTED NEURITE OUTGROWTH; PC12 CELLS; GUANOSINE TRIPHOSPHATE; COORDINATE INDUCTION; GTP HYDROLYSIS; TUBULIN; NUCLEOTIDES; SEPARATION; SYSTEM	Tubulin, widely recognized as a GTP/GDP-binding protein, has been isolated in its polymerized state from rat PC12 cells and embryonic chick dorsal root ganglion neurons by Triton X-100 detergent extraction of the cytoskeletal fraction. Perchloric acid extraction and deproteinization of this fraction permitted subsequent analysis of nucleotide identity and content by high performance liquid chromatography. PC12 cells grown in the absence of nerve growth factor (NGF) contained ADP, ATP, GDP, and GTP at levels consistent with the actin and tubulin content of the cytoskeletal fraction. Microtubules from PC12 cells cultured in the presence of NGF contain an additional nucleotide that we have identified as dGTP. Analysis of whole cell nucleotide extracts from PC12 cells grown in the absence or presence of NGF revealed no evidence for the presence of dGTP at 4 and 14 days, respectively. We have determined that embryonic chick dorsal root ganglion neurons also contain this deoxyribonucleotide, and we found virtually no ADP or ATP in the extracted dorsal root ganglion cytoskeletal fraction. On the basis of metabolic labeling studies with [C-14] guanine, we have inferred that the presence of dGTP in NGF-treated PC 12 cells probably arises either from binding to the nonexchangeable nucleotide site of tubulin undergoing dynamic assembly/disassembly or from binding to the exchangeable site of tubulin subsequently incorporated into highly stabilized microtubules.	UNIV FLORIDA, COLL MED, HLTH SCI CTR, DEPT BIOCHEM & MOLEC BIOL, GAINESVILLE, FL 32610 USA	State University System of Florida; University of Florida	PURICH, DL (corresponding author), UNIV FLORIDA, COLL MED, HLTH SCI CTR, DEPT BIOCHEM & MOLEC BIOL, GAINESVILLE, FL 32610 USA.							ANGELASTRO JM, 1990, EUR J BIOCHEM, V191, P507, DOI 10.1111/j.1432-1033.1990.tb19150.x; BENNETT GS, 1991, J NEUROCHEM, V57, P120, DOI 10.1111/j.1471-4159.1991.tb02106.x; BERRY RW, 1972, J MOL BIOL, V71, P71, DOI 10.1016/0022-2836(72)90401-9; BLACK MM, 1986, J CELL BIOL, V103, P545, DOI 10.1083/jcb.103.2.545; BRYLAWSKI BP, 1983, J BIOL CHEM, V258, P760; DRUBIN DG, 1985, J CELL BIOL, V101, P1799, DOI 10.1083/jcb.101.5.1799; GEAHLEN RL, 1979, J BIOL CHEM, V254, P1982; GREENE LA, 1982, DEV BIOL, V91, P305, DOI 10.1016/0012-1606(82)90037-9; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; GREENHUT J, 1985, J CHROMATOGR, V319, P461, DOI 10.1016/S0021-9673(01)90591-6; HAMEL E, 1984, BIOCHEMISTRY-US, V23, P5314, DOI 10.1021/bi00317a033; IGNATIUS MJ, 1985, J NEUROSCI, V5, P343; KHYM JX, 1975, CLIN CHEM, V21, P1245; KOBAYASHI T, 1975, J BIOCHEM-TOKYO, V77, P1193; LEVIMONTALCINI R, 1968, PHYSIOL REV, V48, P534, DOI 10.1152/physrev.1968.48.3.534; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MACCIONI RB, 1978, ARCH BIOCHEM BIOPHYS, V185, P262, DOI 10.1016/0003-9861(78)90166-2; MACNEAL RK, 1978, J BIOL CHEM, V253, P4683; MCILWAIN H, 1972, BIOCH CENTRAL NERVOU, P46; OKABE S, 1988, J CELL BIOL, V107, P651, DOI 10.1083/jcb.107.2.651; PENNINGROTH SM, 1978, BIOCHEMISTRY-US, V17, P734, DOI 10.1021/bi00597a028; SOLOMON F, 1986, METHOD ENZYMOL, V134, P139; SPIEGELMAN BM, 1977, CELL, V12, P587, DOI 10.1016/0092-8674(77)90259-8; TERRY BJ, 1982, ADV ENZYMOL RAMB, V53, P113	24	7	7	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 25	1992	267	36					25685	25689						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KD073	1464585				2022-12-25	WOS:A1992KD07300016
J	MULLIGAN, GJ; GUO, W; WORMSLEY, S; HELFMAN, DM				MULLIGAN, GJ; GUO, W; WORMSLEY, S; HELFMAN, DM			POLYPYRIMIDINE TRACT BINDING-PROTEIN INTERACTS WITH SEQUENCES INVOLVED IN ALTERNATIVE SPLICING OF BETA-TROPOMYOSIN PREMESSENGER RNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMALL NUCLEAR RIBONUCLEOPROTEIN; BIOCHEMICAL-CHARACTERIZATION; AUXILIARY FACTOR; HELA-CELLS; INVITRO; IDENTIFICATION; PARTICLES; PURIFICATION; SELECTION; GENE	Previous studies of alternative splicing of the rat beta-tropomyosin gene have shown that nonmuscle cells contain factors that block the use of the skeletal muscle exon 7 (Guo, W., Mulligan, G. J., Wormsley, S., and Helfman, D. M. (1991) Genes & Dev. 5, 2095-2106). Using an RNA mobility-shift assay we have identified factors in HeLa cell nuclear extracts that specifically interact with sequences responsible for exon blockage. Here we present the purification to apparent homogeneity of a protein that exhibits these sequence specific RNA binding properties. This protein is identical to the polypyrimidine tract binding protein (PTB) which other studies have suggested is involved in the recognition and efficient use of 3'-splice sites. PTB binds to two distinct functional elements within intron 6 of the beta-tropomyosin pre-mRNA: 1) the polypyrimidine tract sequences required for the use of branch points associated with the splicing of exon 7, and 2) the intron regulatory element that is involved in the repression of exon 7. Our results demonstrate that the sequence requirements for PTB binding are different than previously reported and shows that PTB binding cannot be predicted solely on the basis of pyrimidine content. In addition, PTB fails to bind stably to sequences within intron 5 and intron 7 of beta-TM pre-mRNA, yet forms a stable complex with sequences in intron 6, which is not normally spliced in HeLa cells in vitro and in vivo. The nature of the interactions of PTB within this regulated intron reveals several new details about the binding specificity of PTB and suggests that PTB does not function exclusively in a positive manner in the recognition and use of 3'-splice sites.	COLD SPRING HARBOR LAB, POB 100, COLD SPRING HARBOR, NY 11724 USA; SUNY STONY BROOK, GRAD PROGRAM CELLULAR & DEV BIOL, STONY BROOK, NY 11790 USA; COLD SPRING HARBOR LAB, DEPT BIOCHEM & CELL BIOL, COLD SPRING HARBOR, NY 11724 USA	Cold Spring Harbor Laboratory; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Cold Spring Harbor Laboratory			Helfman, David M./C-2058-2011		NCI NIH HHS [CA46370] Funding Source: Medline; NIGMS NIH HHS [GM43049] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA046370] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043049] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AST G, 1991, EMBO J, V10, P425, DOI 10.1002/j.1460-2075.1991.tb07964.x; BANDZIULIS RJ, 1989, GENE DEV, V3, P431, DOI 10.1101/gad.3.4.431; BINGHAM PM, 1988, TRENDS GENET, V4, P134, DOI 10.1016/0168-9525(88)90136-9; BOTHWELL ALM, 1991, J BIOL CHEM, V266, P24657; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUNEL F, 1991, NUCLEIC ACIDS RES, V19, P5237, DOI 10.1093/nar/19.19.5237; CHOI YD, 1986, SCIENCE, V231, P1534, DOI 10.1126/science.3952495; CHUNG S Y, 1986, Proteins Structure Function and Genetics, V1, P195, DOI 10.1002/prot.340010302; DREYFUSS G, 1986, ANNU REV CELL BIOL, V2, P459, DOI 10.1146/annurev.cellbio.2.1.459; FU XD, 1990, NATURE, V343, P437, DOI 10.1038/343437a0; GARCIABLANCO MA, 1989, GENE DEV, V3, P1874, DOI 10.1101/gad.3.12a.1874; GE H, 1990, CELL, V62, P25, DOI 10.1016/0092-8674(90)90236-8; GERKE V, 1986, CELL, V47, P973, DOI 10.1016/0092-8674(86)90812-3; GHETTI A, 1992, NUCLEIC ACIDS RES, V20, P3671, DOI 10.1093/nar/20.14.3671; GIL A, 1991, GENE DEV, V5, P1224, DOI 10.1101/gad.5.7.1224; GREEN MR, 1991, ANNU REV CELL BIOL, V7, P559, DOI 10.1146/annurev.cellbio.7.1.559; GUO W, 1991, GENE DEV, V5, P2096, DOI 10.1101/gad.5.11.2096; GUTHRIE C, 1991, SCIENCE, V253, P157, DOI 10.1126/science.1853200; HARLOW E, 1989, ANTIBODIES LABORATOR; HEDLEY ML, 1991, CELL, V65, P579, DOI 10.1016/0092-8674(91)90090-L; HELFMAN DM, 1990, GENE DEV, V4, P98, DOI 10.1101/gad.4.1.98; HELFMAN DM, 1988, GENE DEV, V2, P1627, DOI 10.1101/gad.2.12a.1627; HELFMAN DM, 1989, NUCLEIC ACIDS RES, V17, P5633, DOI 10.1093/nar/17.14.5633; HELFMAN DM, 1986, MOL CELL BIOL, V6, P3582, DOI 10.1128/MCB.6.11.3582; JIN W, 1990, NUCLEIC ACIDS RES, V18, P5995, DOI 10.1093/nar/18.20.5995; KONARSKA MM, 1986, CELL, V46, P845, DOI 10.1016/0092-8674(86)90066-8; KONARSKA MM, 1984, CELL, V38, P731, DOI 10.1016/0092-8674(84)90268-X; KRAINER AR, 1990, GENE DEV, V4, P1158, DOI 10.1101/gad.4.7.1158; KRAINER AR, 1985, CELL, V42, P725, DOI 10.1016/0092-8674(85)90269-7; KRAINER AR, 1990, CELL, V62, P35, DOI 10.1016/0092-8674(90)90237-9; KRAMER A, 1991, EMBO J, V10, P1503, DOI 10.1002/j.1460-2075.1991.tb07670.x; KRANIER AR, 1988, TRANSCRIPTION SPLICI, P131; MANIATIS T, 1991, SCIENCE, V251, P33, DOI 10.1126/science.1824726; MAYEDA A, 1992, CELL, V68, P365, DOI 10.1016/0092-8674(92)90477-T; McKeown M, 1990, Genet Eng (N Y), V12, P139; MULLEN MP, 1991, GENE DEV, V5, P642, DOI 10.1101/gad.5.4.642; NAGAI K, 1990, NATURE, V348, P515, DOI 10.1038/348515a0; PATTON JG, 1991, GENE DEV, V5, P1237, DOI 10.1101/gad.5.7.1237; PERKINS KK, 1986, P NATL ACAD SCI USA, V83, P887, DOI 10.1073/pnas.83.4.887; PINOLROMA S, 1989, J CELL BIOL, V109, P2575, DOI 10.1083/jcb.109.6.2575; PINOLROMA S, 1988, GENE DEV, V2, P215, DOI 10.1101/gad.2.2.215; QUERY CC, 1989, CELL, V57, P89, DOI 10.1016/0092-8674(89)90175-X; ROBINOW S, 1988, SCIENCE, V242, P1570, DOI 10.1126/science.3144044; RUBY SW, 1991, TRENDS GENET, V7, P79; SIERAKOWSKA H, 1986, NUCLEIC ACIDS RES, V14, P5241, DOI 10.1093/nar/14.13.5241; STOLOW DT, 1991, P NATL ACAD SCI USA, V88, P320, DOI 10.1073/pnas.88.2.320; TAZI J, 1986, CELL, V47, P755, DOI 10.1016/0092-8674(86)90518-0; ZAMORE PD, 1991, EMBO J, V10, P207, DOI 10.1002/j.1460-2075.1991.tb07937.x; ZAMORE PD, 1989, P NATL ACAD SCI USA, V86, P9243, DOI 10.1073/pnas.86.23.9243	49	135	135	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	1992	267	35					25480	25487						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KB603	1460042				2022-12-25	WOS:A1992KB60300086
J	GABRIEL, DA; MUGA, K; BOOTHROYD, EM				GABRIEL, DA; MUGA, K; BOOTHROYD, EM			THE EFFECT OF FIBRIN STRUCTURE ON FIBRINOLYSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMINOGEN-ACTIVATOR; POLYACRYLAMIDE GELS; POLYMERIZATION; PLATELET	Fibrin structure contributes to the regulation of the fibrinolytic rate. As the fibrin fiber size is decreased, the fibrinolytic rate also decreases. Fibrin structure was altered by either changing the ratio of thrombin to fibrinogen, i.e. altering the assembly rate or by adding a fibrin assembly inhibitor, iopamidol. Changes in the fibrinolytic rate were followed by measuring the time dependence of the decrease in the fiber mass/length ratio during fibrinolysis. A measure of the overall fibrinolytic rate was determined from the decrease in the mass/length ratio versus time. An 8-fold reduction in the fibrinolytic rate was seen on decreasing the mass/length ratio from 2.7 x 10(12) daltons/cm to 0.5 x 10(12) daltons/cm. It is shown that thin fibrin fibers have a decreased rate of conversion of plasminogen to plasmin by tissue plasminogen activator and that thin fibrin fibers are lysed more slowly than thick fibrin fibers.			GABRIEL, DA (corresponding author), UNIV N CAROLINA,CTR THROMBOSIS & HEMOSTASIS,DEPT MED,DIV HEMATOL,CB 7035,CHAPEL HILL,NC 27599, USA.							ALLEN RA, 1981, THROMB HAEMOSTASIS, V45, P43; BALE MD, 1986, J BIOL CHEM, V261, P862; BLOMBACK B, 1978, NATURE, V275, P501, DOI 10.1038/275501a0; CARR ME, 1980, MACROMOLECULES, V13, P1473, DOI 10.1021/ma60078a022; CARR ME, 1989, BIOCHEMISTRY-US, V28, P1384, DOI 10.1021/bi00429a066; CARR ME, 1987, THROMB RES, V45, P539, DOI 10.1016/0049-3848(87)90316-1; CARR ME, 1980, J LAB CLIN MED, V96, P985; CARRELL N, 1983, BLOOD, V62, P439; CHIBBER BAK, 1990, INT J PEPT PROT RES, V35, P73; COLLEN D, 1980, THROMB HAEMOSTASIS, V43, P77; GABRIEL DA, 1983, J LAB CLIN MED, V101, P545; GABRIEL DA, 1991, CIRC RES, V68, P881, DOI 10.1161/01.RES.68.3.881; GABRIEL DA, 1991, THROMB HAEMOSTASIS, V65, pA737; GALANAKIS DK, 1987, BIOCHEMISTRY-US, V26, P2389, DOI 10.1021/bi00382a046; GIBBS SJ, 1991, MACROMOLECULES, V24, P6110, DOI 10.1021/ma00023a010; HOLVOET P, 1985, J BIOL CHEM, V260, P2106; JANMEY PA, 1985, BIOCHIM BIOPHYS ACTA, V841, P151, DOI 10.1016/0304-4165(85)90016-9; NIEUWENHUIZEN W, 1983, BIOCHIM BIOPHYS ACTA, V755, P531, DOI 10.1016/0304-4165(83)90261-1; PARK IH, 1990, MACROMOLECULES, V23, P1548, DOI 10.1021/ma00207a052; PING JB, 1991, THROMB HAEMOSTASIS, V65, pA735; RAKOCZI I, 1978, BIOCHIM BIOPHYS ACTA, V540, P295, DOI 10.1016/0304-4165(78)90142-3; RIJKEN DC, 1982, J BIOL CHEM, V257, P2920; ROBBINS KC, 1967, J BIOL CHEM, V242, P2333; SHEN LL, 1977, J BIOL CHEM, V252, P6184; SHEN LL, 1975, THROMB RES, V6, P255, DOI 10.1016/0049-3848(75)90073-0; SOTTRUPJENSEN L, 1978, ATLAS PROTEIN SEQ S3, V5, P73; STEWART UA, 1985, BIOPOLYMERS, V27, P173; VOSKUILEN M, 1987, J BIOL CHEM, V262, P5944; WALLEN P, 1972, BIOCHIM BIOPHYS ACTA, V257, P122, DOI 10.1016/0005-2795(72)90261-9; WALLEN P, 1977, THROMBOSIS UROKINASE, V9, P91; YONEKAWA O, 1992, BIOCHEM J, V283, P187, DOI 10.1042/bj2830187	31	235	247	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1992	267	34					24259	24263						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KA263	1447176				2022-12-25	WOS:A1992KA26300021
J	MAKRIDES, SC; SCESNEY, SM; FORD, PJ; EVANS, KS; CARSON, GR; MARSH, HC				MAKRIDES, SC; SCESNEY, SM; FORD, PJ; EVANS, KS; CARSON, GR; MARSH, HC			CELL-SURFACE EXPRESSION OF THE C3B/C4B RECEPTOR (CR-1) PROTECTS CHINESE-HAMSTER OVARY CELLS FROM LYSIS BY HUMAN-COMPLEMENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DECAY-ACCELERATING FACTOR; C5 CONVERTASE; C3B RECEPTOR; C3B-BINDING SITE; CR-1; BINDING; TYPE-1; MEMBRANE; PATHWAY; C4B	The C3b/C4b receptor, also known as complement receptor type 1 (CR1, CD35), is a single chain glycoprotein consisting of 30 repeating homologous protein domains known as short consensus repeats (SCR) followed by transmembrane and cytoplasmic domains. A series of recombinant proteins derived from CRI has been prepared and assessed for the capacity to inhibit complement lysis of the host Chinese hamster ovary (CHO) cells. The full-length recombinant CR1 inhibited human complement-mediated CHO cell lysis, and the efficiency of inhibition was directly proportional to the number of receptors/cell. The SCR 15-18 of CR1, but not SCR 15-16, inhibited complement lysis of the host CHO cell, bound monomeric C3b (K(d,app) = 6.5 x 10(-7) M), and dimeric C3b (K(d) = 1.8 x 10(-8) M), and served as a cofactor in the proteolysis of C3b by factor I, confirming and extending the observations of Fearon and colleagues (Kalli, K. R., Hsu, P., Bartow, T. J., Ahearn, J. M., Matsumoto, A. K., Klickstein, L. B., and Fearon, D. T. (1991) J. Exp. Med. 174, 1451-1460). The SCR 1-4 of CR1, but not SCR 1-2, also inhibited complement lysis of the host CHO cell, indicating that more than two SCR are necessary and that four SCR are sufficient for optimal C4b binding to CR1. Thus, the structural requirements for C4b binding are analogous to those for C3b binding, namely, four SCR of CR1 form the binding sites for each of these proteins. CR1 has long been recognized to regulate extrinsic complement activation, that is, to bind to and promote the degradation of fluid phase C3b and of C3b attached to immune complex. These results demonstrate that CR1 is also an intrinsic regulator of complement activation in that, under appropriate conditions, CRI inhibits complement-mediated lysis of the cell on which it is expressed.	T CELL SCI INC,38 SIDNEY ST,CAMBRIDGE,MA 02139					Marsh, Henry/0000-0001-5637-6013				ARNAOUT MA, 1981, J IMMUNOL, V127, P1348; ARNAOUT MA, 1983, IMMUNOLOGY, V48, P229; BARLOW PN, 1992, BIOCHEMISTRY-US, V31, P3626, DOI 10.1021/bi00129a011; BARLOW PN, 1991, BIOCHEMISTRY-US, V30, P997, DOI 10.1021/bi00218a016; BOKISCH VA, 1969, J EXP MED, V129, P1109, DOI 10.1084/jem.129.5.1109; CARSON GR, 1991, J BIOL CHEM, V266, P7883; FEARON DT, 1975, J EXP MED, V142, P856, DOI 10.1084/jem.142.4.856; FEARON DT, 1979, P NATL ACAD SCI USA, V76, P5867, DOI 10.1073/pnas.76.11.5867; FEARON DT, 1983, J IMMUNOL, V130, P370; GIGLI I, 1981, FED PROC, V40, P1172; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HAMMER CH, 1981, J BIOL CHEM, V256, P3995; HAMMER CH, 1988, COMPLEMENT SYSTEM, P17; HOURCADE D, 1988, J EXP MED, V168, P1255, DOI 10.1084/jem.168.4.1255; IIDA K, 1981, J EXP MED, V153, P1138, DOI 10.1084/jem.153.5.1138; KALLI KR, 1991, J EXP MED, V174, P1451, DOI 10.1084/jem.174.6.1451; KINOSHITA T, 1988, J IMMUNOL, V141, P3895; KLICKSTEIN LB, 1988, J EXP MED, V168, P1699, DOI 10.1084/jem.168.5.1699; KLICKSTEIN LB, 1987, J EXP MED, V165, P1095, DOI 10.1084/jem.165.4.1095; KOZONO H, 1990, J BIOL CHEM, V265, P14444; KRYCH M, 1991, P NATL ACAD SCI USA, V88, P4353, DOI 10.1073/pnas.88.10.4353; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUBLIN DM, 1991, J EXP MED, V174, P35, DOI 10.1084/jem.174.1.35; LUBLIN DM, 1988, J EXP MED, V168, P181, DOI 10.1084/jem.168.1.181; MARDINEY MR, 1968, AM J PATHOL, V53, P253; MEDOF ME, 1984, J EXP MED, V160, P1558, DOI 10.1084/jem.160.5.1558; MEDOF ME, 1982, J EXP MED, V156, P1739, DOI 10.1084/jem.156.6.1739; MEDOF ME, 1987, P NATL ACAD SCI USA, V84, P2007, DOI 10.1073/pnas.84.7.2007; MEDVED LV, 1989, BIOCHEMISTRY-US, V28, P5408, DOI 10.1021/bi00439a014; Morrison D A, 1979, Methods Enzymol, V68, P326; NORMAN DG, 1991, J MOL BIOL, V219, P717, DOI 10.1016/0022-2836(91)90666-T; OGLESBY TJ, 1992, J EXP MED, V175, P1547, DOI 10.1084/jem.175.6.1547; PRUITT SK, 1991, J SURG RES, V50, P350, DOI 10.1016/0022-4804(91)90202-W; PRUITT SK, 1991, TRANSPLANTATION, V52, P868, DOI 10.1097/00007890-199111000-00022; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; TACK BF, 1981, METHOD ENZYMOL, V80, P64; TACK BF, 1976, BIOCHEMISTRY-US, V15, P4512; TAKATA Y, 1987, J EXP MED, V165, P1494, DOI 10.1084/jem.165.6.1494; URLAUB G, 1980, P NATL ACAD SCI-BIOL, V77, P4216, DOI 10.1073/pnas.77.7.4216; WALSH LA, 1991, EUR J IMMUNOL, V21, P847, DOI 10.1002/eji.1830210349; WEISMAN HF, 1990, SCIENCE, V249, P146, DOI 10.1126/science.2371562; WONG WW, 1991, J IMMUNOL, V146, P656; WONG WW, 1985, J IMMUNOL METHODS, V82, P303, DOI 10.1016/0022-1759(85)90362-X; YEH CG, 1991, J IMMUNOL, V146, P250; ZHAO J, 1991, J BIOL CHEM, V266, P13418	47	52	59	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1992	267	34					24754	24761						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KA263	1447213				2022-12-25	WOS:A1992KA26300090
J	SCHNITZER, JE; SUNG, A; HORVAT, R; BRAVO, J				SCHNITZER, JE; SUNG, A; HORVAT, R; BRAVO, J			PREFERENTIAL INTERACTION OF ALBUMIN-BINDING PROTEINS, GP30 AND GP18, WITH CONFORMATIONALLY MODIFIED ALBUMINS - PRESENCE IN MANY CELLS AND TISSUES WITH A POSSIBLE ROLE IN CATABOLISM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICROVASCULAR ENDOTHELIUM; SERUM-ALBUMIN; CAPILLARY ENDOTHELIUM; SCAVENGER RECEPTOR; BONE-MARROW; RAT; TRANSCYTOSIS; SURFACE; PERMEABILITY; ENDOCYTOSIS	Albumin binding to the endothelial surface apparently initiates its transcytosis via plasmalemmal vesicles and also increases capillary permselectivity. Several albumin-binding proteins, which we call gp60, gp30, and gp18, have been identified; however, their functional relationship to each other is unclear. In this study, we show that gp30 and gp18 are both variably expressed by cultured rat fibroblasts, smooth muscle cells, and endothelial cells and are present in all tissues examined (heart, lung, skeletal muscle, diaphragm, duodenum, kidney, fat, brain, adrenal, pancreas, and liver). The binding of albumin-gold complexes (A-Au) to gp30 and gp18 was compared with that of native and modified albumins. Monomeric native bovine serum albumin (BSA) interacted much less avidly than A-Au and BSA that was chemically modified by formaldehyde (Fm-BSA) or maleic anhydride (Mal-BSA). Mal-BSA and A-Au have similar affinity constants for gp30 and gp18 (K(D) approximately 3-7 mug/ml (50-100 nM)), which is 1000-fold greater than BSA. These interactions were Ca2+-independent but sensitive to pH (<6.0) and high salt concentrations (greater-than-or-equal-to 1.0 M). Comparative biochemical characterization provided evidence of conformational changes for Mal-BSA, Fm-BSA, and A-Au. Anti-native BSA serum recognizes BSA much more avidly than modified BSA. Mal-BSA, Fm-BSA, and A-Au are much more sensitive to trypsin digestion than BSA. Cellular processing was also examined. A-Au and Mal-BSA bound at the endothelial cell surface were degraded, whereas BSA was not. Our results indicate that: (i) gp30 and gp18, unlike gp60, are expressed in all tissues tested regardless of the type of endothelia lining the microvasculature and the local mechanism of transendothelial albumin transport; (ii) BSA conformationally modified by either surface adsorption or chemical means not only interacts more avidly with gp30 and gp18 than native albumin but also is preferentially degraded by the cells; (iii) A-Au and native albumin are not equivalent probes for detecting albumin interaction sites; and (iv) gp30 and gp18 exhibit binding behavior resembling scavenger receptors. The possible roles of gp30 and gp18 in albumin binding, transcytosis, endocytosis, and even protein catabolism are discussed.	UNIV CALIF SAN DIEGO,SCH MED,DEPT PATHOL,DIV CELLULAR & MOLEC MED,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,SCH MED,INST BIOMED ENGN,LA JOLLA,CA 92093	University of California System; University of California San Diego; University of California System; University of California San Diego	SCHNITZER, JE (corresponding author), UNIV CALIF SAN DIEGO,SCH MED,DEPT MED,9500 GILMAN DR,LA JOLLA,CA 92093, USA.		Bravo, Jose/F-8861-2015	Bravo, Jose/0000-0001-5752-2406	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL043278] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL43278] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Andrade J.D., 1985, SURFACE CHEM PHYS, V1; BOEYNAEMS JM, 1980, OUTLINES RECEPTOR TH, P1; BRAVO J, 1992, FASEB J, V6, pA1322; BUMBASIREVIC V, 1990, J SUBMICR CYTOL PATH, V22, P135; BUTLER PJG, 1969, BIOCHEM J, V112, P679, DOI 10.1042/bj1120679; CURRY FE, 1987, J PHYSIOL-LONDON, V387, P69, DOI 10.1113/jphysiol.1987.sp016563; CURRY FRE, 1985, FED PROC, V44, P2610; DEBRUYN PPH, 1985, CELL TISSUE RES, V240, P1; GALIS Z, 1988, EUR J CELL BIOL, V47, P358; GAMBLE J, 1983, J PHYSIOL-LONDON, V339, P505, DOI 10.1113/jphysiol.1983.sp014730; GEOFFROY JS, 1984, J ULTRA MOL STRUCT R, V89, P223, DOI 10.1016/S0022-5320(84)80039-8; GHINEA N, 1989, J BIOL CHEM, V264, P4755; GHINEA N, 1988, J CELL BIOL, V107, P231, DOI 10.1083/jcb.107.1.231; GHITESCU L, 1986, J CELL BIOL, V102, P1304, DOI 10.1083/jcb.102.4.1304; HABEEB AFS, 1966, ANAL BIOCHEM, V14, P328, DOI 10.1016/0003-2697(66)90275-2; HABERLAND ME, 1985, P NATL ACAD SCI USA, V82, P2693, DOI 10.1073/pnas.82.9.2693; HORIUCHI S, 1985, J BIOL CHEM, V260, P475; HORIUCHI S, 1986, J BIOL CHEM, V261, P4962; HUXLEY VH, 1985, AM J PHYSIOL, V248, pH264, DOI 10.1152/ajpheart.1985.248.2.H264; LEVICK JR, 1973, Q J EXP PHYSIOL CMS, V58, P87, DOI 10.1113/expphysiol.1973.sp002194; MANN GE, 1981, J PHYSIOL-LONDON, V319, P311, DOI 10.1113/jphysiol.1981.sp013910; MANS GE, 1971, CHEM MODIFICATION PR, P125; MICHEL CC, 1980, J PHYSIOL-LONDON, V309, P341, DOI 10.1113/jphysiol.1980.sp013512; MILICI AJ, 1987, J CELL BIOL, V105, P2603, DOI 10.1083/jcb.105.6.2603; PARDRIDGE WM, 1985, AM J PHYSIOL, V249, pE264, DOI 10.1152/ajpendo.1985.249.3.E264; PETERS T, 1985, ADV PROTEIN CHEM, V37, P161, DOI 10.1016/S0065-3233(08)60065-0; PREDESCU D, 1988, J CELL BIOL, V107, P1729, DOI 10.1083/jcb.107.5.1729; REED RG, 1989, J BIOL CHEM, V264, P9867; SCHNEEBERGER EE, 1984, AM J PHYSIOL, V247, pH206, DOI 10.1152/ajpheart.1984.247.2.H206; SCHNEEBERGER EE, 1990, AM J PHYSIOL, V258, pL89, DOI 10.1152/ajplung.1990.258.2.L89; SCHNITZER JE, 1990, EUR J CELL BIOL, V52, P241; SCHNITZER JE, 1988, P NATL ACAD SCI USA, V85, P6773, DOI 10.1073/pnas.85.18.6773; SCHNITZER JE, 1990, P NATL ACAD SCI USA, V87, P6843, DOI 10.1073/pnas.87.17.6843; SCHNITZER JE, 1988, AM J PHYSIOL, V254, pH425, DOI 10.1152/ajpheart.1988.254.3.H425; SCHNITZER JE, 1992, AM J PHYSIOL, V262, pH246, DOI 10.1152/ajpheart.1992.262.1.H246; SCHNITZER JE, 1991, FASEB J, V5, pA529; SIFLINGERBIRNBOIM A, 1991, J CELL PHYSIOL, V149, P575, DOI 10.1002/jcp.1041490329; SIMIONESCU M, 1988, J SUBMICR CYTOL PATH, V20, P243; SIMIONESCU M, 1984, HDB PHYSL, P41; SPARROW CP, 1989, J BIOL CHEM, V264, P2599; Taylor AE, 1984, HDB PHYSL 2, V4, P467; VILLASCHI S, 1986, MICROVASC RES, V32, P190, DOI 10.1016/0026-2862(86)90053-1; Waldmann T. A., 1977, ALBUMIN STRUCTURE FU, P255; YEDGAR S, 1983, AM J PHYSIOL, V244, pE101, DOI 10.1152/ajpendo.1983.244.1.E101; YOKOTA S, 1983, BIOMED RES-TOKYO, V4, P577, DOI 10.2220/biomedres.4.577	45	130	131	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1992	267	34					24544	24553						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KA263	1447200				2022-12-25	WOS:A1992KA26300061
J	TANG, CK; CHIN, J; HARFORD, JB; KLAUSNER, RD; ROUAULT, TA				TANG, CK; CHIN, J; HARFORD, JB; KLAUSNER, RD; ROUAULT, TA			IRON REGULATES THE ACTIVITY OF THE IRON-RESPONSIVE ELEMENT BINDING-PROTEIN WITHOUT CHANGING ITS RATE OF SYNTHESIS OR DEGRADATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FERRITIN MESSENGER-RNA; AFFINITY PURIFICATION; UNTRANSLATED REGION; IRE-BP; ACONITASE; TRANSLATION; EXPRESSION; REPRESSOR; MECHANISM; SEQUENCE	The iron-responsive element binding protein (IRE-BP) interacts with specific sequence/structure motifs (iron-responsive elements) within the mRNAs encoding ferritin and the transferrin receptor and thereby post-transcriptionally regulates the expression of these two proteins involved in cellular iron homeostasis. The activity of the IRE-BP is itself regulated by iron such that when cells are treated with an iron source, the RNA binding activity is decreased. The expression of recombinant human IRE-BP in murine cells has been examined as have the expressions of the endogenous IRE-BP of both human and rabbit cells. In all cases, iron down-modulated the RNA binding activity of the IRE-BP, but in no instance was this decrease in activity accompanied by a decrease in the level of the protein as judged by quantitative Western blots. Moreover, the rate of synthesis of the IRE-BP and its rate of degradation have been found to be unaltered by iron manipulation of cells in culture. Consistent with IRE-BP regulation occurring post-translationally, the iron regulation of its activity was found to be unaffected by cycloheximide. These data are discussed in terms of a model of IRE-BP regulation involving the modification of the protein's iron-sulfur center.			TANG, CK (corresponding author), NICHHD,CELL BIOL & METAB BRANCH,BETHESDA,MD 20892, USA.							BEINERT H, 1989, EUR J BIOCHEM, V186, P5, DOI 10.1111/j.1432-1033.1989.tb15170.x; CASEY JL, 1989, EMBO J, V8, P3693, DOI 10.1002/j.1460-2075.1989.tb08544.x; EISENSTEIN RS, 1991, P NATL ACAD SCI USA, V88, P688, DOI 10.1073/pnas.88.3.688; EISENSTEIN RS, 1990, ENZYME, V44, P42, DOI 10.1159/000468746; GOESSLING LS, 1992, SCIENCE, V256, P670, DOI 10.1126/science.1316633; HAILE DJ, 1989, MOL CELL BIOL, V9, P5055, DOI 10.1128/MCB.9.11.5055; HAILE DJ, 1992, P NATL ACAD SCI USA, V89, P7536, DOI 10.1073/pnas.89.16.7536; HARFORD JB, 1990, ENZYME, V44, P28, DOI 10.1159/000468745; Harlow E, 1988, ANTIBODIES LAB MANUA, P139; HENTZE MW, 1989, SCIENCE, V244, P357, DOI 10.1126/science.2711187; HENTZE MW, 1991, NUCLEIC ACIDS RES, V19, P1739, DOI 10.1093/nar/19.8.1739; HIRLING H, 1992, NUCLEIC ACIDS RES, V20, P33, DOI 10.1093/nar/20.1.33; KAPTAIN S, 1991, P NATL ACAD SCI USA, V88, P10109, DOI 10.1073/pnas.88.22.10109; KLAUSNER RD, 1989, SCIENCE, V246, P870, DOI 10.1126/science.2683086; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAUBLE H, 1992, BIOCHEMISTRY-US, V31, P2735, DOI 10.1021/bi00125a014; LEIBOLD EA, 1988, P NATL ACAD SCI USA, V85, P2171, DOI 10.1073/pnas.85.7.2171; LIN JJ, 1990, BIOCHIM BIOPHYS ACTA, V1050, P146, DOI 10.1016/0167-4781(90)90156-V; NEUPERT B, 1990, NUCLEIC ACIDS RES, V18, P51, DOI 10.1093/nar/18.1.51; PHILPOTT CC, 1991, NUCLEIC ACIDS RES, V19, P6333, DOI 10.1093/nar/19.22.6333; ROTHENBERGER S, 1990, NUCLEIC ACIDS RES, V18, P1175, DOI 10.1093/nar/18.5.1175; ROUAULT TA, 1988, SCIENCE, V241, P1207, DOI 10.1126/science.3413484; ROUAULT TA, 1989, P NATL ACAD SCI USA, V86, P5768, DOI 10.1073/pnas.86.15.5768; ROUAULT TA, 1991, CELL, V64, P881, DOI 10.1016/0092-8674(91)90312-M; ROUAULT TA, 1990, P NATL ACAD SCI USA, V87, P7958, DOI 10.1073/pnas.87.20.7958; SHOWS TB, 1977, CYTOGENET CELL GENET, V19, P26, DOI 10.1159/000130791; WALDEN WE, 1988, P NATL ACAD SCI USA, V85, P9503, DOI 10.1073/pnas.85.24.9503; WALDEN WE, 1989, J BIOL CHEM, V264, P13765; YU Y, 1992, J BIOL CHEM, V267, P19005	29	63	63	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1992	267	34					24466	24470						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KA263	1447194				2022-12-25	WOS:A1992KA26300051
J	ROUER, E; BENAROUS, R				ROUER, E; BENAROUS, R			ALTERNATIVE SPLICING IN THE HUMAN LCK GENE LEADS TO THE DELETION OF EXON-1' AND RESULTS IN A NEW TYPE-II LCK TRANSCRIPT	ONCOGENE			English	Note							TYROSINE-PROTEIN-KINASE; MESSENGER-RNAS; CELL-LINES; EXPRESSION; P56LCK; ACID; CD4	In this study we describe a new lck mRNA transcribed from the type II promoter, resulting from alternative splicing, in the deletion of exon 1' which comprises the AUG initiation codon. In this type IIB lck transcript, as a consequence of exon 1' deletion, a new AUG codon in exon 1, located 35 nt upstream from the regular initiation codon in exon 1', and normally out of frame, is now in frame with exon 2 and the following lck coding sequence. In this type IIB lck transcript, 10 residues encoded by exon 1 from the new AUG codon replace the first 35 residues encoded by exon 1'. Strikingly, in this new N-terminal amino acid sequence, a glycine residue, needed for myristylation and anchorage in the plasma membrane, is present at position 2. This alternative splicing has been observed in T-cell lines, normal mature T cells and in peripheral blood lymphocytes from different leukemic patients. Different ratios of regular type IIA lck mRNA (with exon 1') to spliced type IIB lck mRNA (without exon 1') have been observed depending on the patient.			ROUER, E (corresponding author), ICGM,INSERM,U332,22 RUE MECHAIN,F-75014 PARIS,FRANCE.							CHEUNG RK, 1991, J BIOL CHEM, V266, P8667; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Cooper J.A, 1990, PEPT PROT PHOSPH, P85; DANIELIAN S, 1989, EUR J IMMUNOL, V19, P2183, DOI 10.1002/eji.1830191202; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; LOCK P, 1991, MOL CELL BIOL, V11, P4363, DOI 10.1128/MCB.11.9.4363; MARCHILDON GA, 1984, P NATL ACAD SCI-BIOL, V81, P7679, DOI 10.1073/pnas.81.24.7679; PERLMUTTER RM, 1988, J CELL BIOCHEM, V38, P117, DOI 10.1002/jcb.240380206; RENSHAW MW, 1988, MOL CELL BIOL, V8, P4547, DOI 10.1128/MCB.8.10.4547; ROUER E, 1989, GENE, V84, P105, DOI 10.1016/0378-1119(89)90144-3; SARTOR O, 1989, MOL CELL BIOL, V9, P2983, DOI 10.1128/MCB.9.7.2983; STEFANOVA I, 1991, SCIENCE, V254, P1016, DOI 10.1126/science.1719635; TAKADERA T, 1989, MOL CELL BIOL, V9, P2173, DOI 10.1128/MCB.9.5.2173; TURNER JM, 1990, CELL, V60, P755, DOI 10.1016/0092-8674(90)90090-2; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; VEILLETTE A, 1987, ONCOGENE RES, V1, P357	17	9	9	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1992	7	12					2535	2538						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KA856	1461657				2022-12-25	WOS:A1992KA85600021
J	BAUNOCH, DA; XU, M; TEWARI, A; CHRISTMAN, JK; LANE, MA				BAUNOCH, DA; XU, M; TEWARI, A; CHRISTMAN, JK; LANE, MA			INSITU DEPHOSPHORYLATION OF P53 PROTEIN BY CALF INTESTINAL ALKALINE-PHOSPHATASE TREATMENT	ONCOGENE			English	Note							BREAST	The monoclonal antibody (mAb) 1801 has been reported to identify an N-terminal determinant within the tumor-suppressor protein p53 located between amino acids 32 and 79. This region contains two potential sites for serine phosphorylation at amino acids 33 and 46. Using a novel technique which dephosphorylates proteins in situ in fixed permeabilized cells, we have unmasked determinants in p53 recognized by mAb 1801, allowing additional sites of p53 protein to be detected in immunohistochemically reacted cells. This result indicates that phosphorylation at one or both sites within the determinant recognized by mAb 1801 previously blocked antibody-ligand interaction. It further suggests that in situ dephosphorylation may be of more general use in identifying antibodies which can only bind to epitopes in a particular phosphorylation state.	MICHIGAN CANC FDN,MOLEC GENET LAB,110 E WARREN AVE,DETROIT,MI 48201; WAYNE STATE UNIV,SCH MED,DEPT MOLEC BIOL & GENET,DETROIT,MI 48201; MICHIGAN CANC FDN,MOLEC BIOL PROGRAM,DETROIT,MI 48201	Wayne State University					NCI NIH HHS [P30 CA-22453, T32 CA09531] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA022453, T32CA009531] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARTEK J, 1991, ONCOGENE, V6, P1699; BUCHKOVICH K, 1989, CELL, V58, P1079; CATTORETTI G, 1988, INT J CANCER, V41, P178, DOI 10.1002/ijc.2910410204; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; TAIT L, 1990, CANCER RES, V50, P6087	6	9	9	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1992	7	11					2351	2353						3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JW665	1437159				2022-12-25	WOS:A1992JW66500031
J	HEVEZI, P; ALIN, K; REESJONES, R; GOFF, SP				HEVEZI, P; ALIN, K; REESJONES, R; GOFF, SP			BONE MARROW-TRANSFORMING ACTIVITY OF LINKER INSERTION MUTANTS OF ABELSON MURINE LEUKEMIA-VIRUS	ONCOGENE			English	Note							SRC HOMOLOGY REGION-2; PROTEIN-TYROSINE KINASE; LYMPHOID-CELLS; SIGNAL TRANSDUCTION; CHAIN GENES; C-SRC; V-ABL; SEQUENCES; DOMAINS; SEGMENT	Two sets of mutants of the Abelson murine leukemia virus, generated by linker insertion mutagenesis of a cloned proviral DNA, were tested for their ability to transform bone marrow cultures in vitro. All the viruses retained an intact tyrosine kinase domain and were competent for transformation of NIH3T3 fibroblasts in culture. One series contained 12-bp linker insertions in the regions flanking the kinase domain, and the other contained frameshift mutations that truncated the gene product downstream of the kinase domain. The majority of the 12-bp insertion mutants retained full bone marrow-transforming activity; only one insertion in the SH2 domain showed reduced activity. This mutant suggests that some aspect of the SH2 domain may be more important in transformation of lymphocytes than fibroblasts. In contrast to the first set of mutants, the bone marrow-transforming activity of the majority of the truncation mutants was significantly reduced or completely lost. We conclude that there is a broad requirement for an intact C-terminal domain of the v-abl protein for the transformation of pre-B cells, but that no single part of this domain is critical.	COLUMBIA UNIV, DEPT MICROBIOL, NEW YORK, NY 10032 USA; COLUMBIA UNIV, DEPT MED, NEW YORK, NY 10032 USA	Columbia University; Columbia University								ABELSON HT, 1970, CANCER RES, V30, P2208; ABELSON HT, 1970, CANCER RES, V30, P2213; ALT F, 1981, CELL, V27, P381, DOI 10.1016/0092-8674(81)90421-9; BALTIMORE D, 1979, IMMUNOL REV, V48, P3, DOI 10.1111/j.1600-065X.1979.tb00296.x; COLICELLI J, 1988, J MOL BIOL, V199, P47, DOI 10.1016/0022-2836(88)90378-6; COOK WD, 1982, P NATL ACAD SCI-BIOL, V79, P2917, DOI 10.1073/pnas.79.9.2917; ENGELMAN A, 1990, J VIROL, V64, P4242, DOI 10.1128/JVI.64.9.4242-4251.1990; GOFF SP, 1982, J VIROL, V41, P271, DOI 10.1128/JVI.41.1.271-285.1982; GOFF SP, 1980, CELL, V22, P777, DOI 10.1016/0092-8674(80)90554-1; GOFF SP, 1982, ADV VIRAL ONCOL, P127; HIRAI H, 1990, P NATL ACAD SCI USA, V87, P8592, DOI 10.1073/pnas.87.21.8592; HIRAI H, 1990, GENE DEV, V4, P2342, DOI 10.1101/gad.4.12b.2342; KIPREOS ET, 1992, SCIENCE, V256, P382, DOI 10.1126/science.256.5055.382; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; MATHEYPREVOT B, 1988, MOL CELL BIOL, V8, P234, DOI 10.1128/MCB.8.1.234; MAYER BJ, 1991, P NATL ACAD SCI USA, V88, P627, DOI 10.1073/pnas.88.2.627; MCCUTCHAN JH, 1968, JNCI-J NATL CANCER I, V41, P351; MORAN MF, 1990, P NATL ACAD SCI USA, V87, P8622, DOI 10.1073/pnas.87.21.8622; MURTAGH K, 1986, J VIROL, V60, P599, DOI 10.1128/JVI.60.2.599-606.1986; PARMAR K, 1991, IN PRESS J VIROL, V65; PAWSON T, 1988, ONCOGENE, V3, P491; PENDERGAST AM, 1991, CELL, V66, P161, DOI 10.1016/0092-8674(91)90148-R; PERRY RP, 1980, P NATL ACAD SCI-BIOL, V77, P1937, DOI 10.1073/pnas.77.4.1937; PRATT DM, 1977, CELL, V12, P683, DOI 10.1016/0092-8674(77)90268-9; PRYWES R, 1985, J VIROL, V54, P123, DOI 10.1128/JVI.54.1.123-132.1985; PRYWES R, 1983, CELL, V34, P569, DOI 10.1016/0092-8674(83)90389-6; PRYWES R, 1985, J VIROL, V54, P114, DOI 10.1128/JVI.54.1.114-122.1985; RASCHKE WC, 1978, CELL, V15, P261, DOI 10.1016/0092-8674(78)90101-0; REESJONES RW, 1989, MOL CELL BIOL, V9, P278, DOI 10.1128/MCB.9.1.278; REESJONES RW, 1988, J VIROL, V62, P978, DOI 10.1128/JVI.62.3.978-986.1988; REYNOLDS FH, 1980, J VIROL, V36, P374, DOI 10.1128/JVI.36.2.374-386.1980; RISSER R, 1989, CURR TOP MICROBIOL, V147, P129; ROSENBERG N, 1976, J EXP MED, V143, P1453, DOI 10.1084/jem.143.6.1453; ROSENBERG N, 1975, P NATL ACAD SCI USA, V72, P1932, DOI 10.1073/pnas.72.5.1932; ROSENBERG N, 1988, ADV VIRUS RES, V35, P39; ROSENBERG N, 1980, VIRAL ONCOLOGY, P187; ROSENBERG NE, 1980, J VIROL, V36, P766, DOI 10.1128/JVI.36.3.766-774.1980; SADOWSKI I, 1986, MOL CELL BIOL, V6, P4396, DOI 10.1128/MCB.6.12.4396; SCHER CD, 1975, NATURE, V253, P729, DOI 10.1038/253729a0; SEFTON BM, 1981, P NATL ACAD SCI-BIOL, V78, P1552, DOI 10.1073/pnas.78.3.1552; SIDEN E, 1981, P NATL ACAD SCI-BIOL, V78, P1823, DOI 10.1073/pnas.78.3.1823; SIDEN EJ, 1979, CELL, V16, P389, DOI 10.1016/0092-8674(79)90014-X; SRINIVASAN A, 1982, P NATL ACAD SCI-BIOL, V79, P5508, DOI 10.1073/pnas.79.18.5508; WATANABE SM, 1983, J VIROL, V45, P1028, DOI 10.1128/JVI.45.3.1028-1036.1983; WITTE ON, 1980, P NATL ACAD SCI-BIOL, V77, P4993, DOI 10.1073/pnas.77.8.4993; WITTE ON, 1980, NATURE, V283, P826, DOI 10.1038/283826a0; WITTE ON, 1983, CURR TOP MICROBIOL, V103, P127; ZIEGLER SF, 1981, CELL, V27, P477, DOI 10.1016/0092-8674(81)90389-5	48	7	7	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	1992	7	11					2323	2328						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JW665	1437154				2022-12-25	WOS:A1992JW66500026
J	NEUMANN, M; TSAPOS, K; SCHEPPLER, JA; ROSS, J; FRANZA, BR				NEUMANN, M; TSAPOS, K; SCHEPPLER, JA; ROSS, J; FRANZA, BR			IDENTIFICATION OF COMPLEX-FORMATION BETWEEN 2 INTRACELLULAR TYROSINE KINASE SUBSTRATES - HUMAN C-REL AND THE P105 PRECURSOR OF P50 NF-KAPPA-B	ONCOGENE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; ENHANCER-BINDING-PROTEIN; LONG TERMINAL REPEAT; DNA-BINDING; V-REL; TRANSCRIPTION FACTORS; CELLULAR PROTEINS; STRAIN-T; ACTIVATION; CELLS	Immune complexes of the product of the c-rel protooncogene and of p105, the p50 NF-kappaB precursor, isolated from human T-lymphoblastoid cell lines are comprised of multiple proteins. Only p105 and human c-Rel (hc-Rel) are common to complexes precipitated with antiserum directed against either p105 or hc-Rel. Both proteins are inducible by phytohemagglutinin (PHA) and phorbol 12-myristate 13-acetate (PMA) and their subcellular distribution is affected by this induction. We demonstrate that the Rel immune complex contains a protein with a molecular weight in the 40 kDa range (p40) which apparently is exclusively cytoplasmic. We were not able to detect p40 in the p105 immune complex, though hc-Rel is present. This indicates that hc-Rel exists in different multi-protein complexes and fits a model of functional regulation mediated by differential protein-protein interaction. We also demonstrate considerable isoform diversity of both hc-Rel and p105. We show that this heterogeneity is, in part, the result of phosphorylation. Furthermore, we demonstrate that p105 and hc-Rel are tyrosine kinase substrates. This finding indicates a role for both proteins in intracellular signal transduction pathways which are modulated by modification of their phosphorylation status.	COLD SPRING HARBOR LAB, FREEMAN LAB CANC CELL BIOL, COLD SPRING HARBOR, NY 11724 USA	Cold Spring Harbor Laboratory					NIAID NIH HHS [NIAID 32028] Funding Source: Medline; NCPDCID CDC HHS [NCI 40512] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI032028] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCPDCID CDC HHS; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BALLARD DW, 1990, CELL, V63, P803, DOI 10.1016/0092-8674(90)90146-6; BLANK V, 1991, EMBO J, V10, P4159, DOI 10.1002/j.1460-2075.1991.tb04994.x; BOHNLEIN E, 1988, CELL, V53, P827, DOI 10.1016/0092-8674(88)90099-2; BOURS V, 1992, MOL CELL BIOL, V12, P685, DOI 10.1128/MCB.12.2.685; BULL P, 1990, MOL CELL BIOL, V10, P5473, DOI 10.1128/MCB.10.10.5473; CAPOBIANCO AJ, 1990, ONCOGENE, V5, P257; CROSS SL, 1989, SCIENCE, V244, P466, DOI 10.1126/science.2497520; DALEY GQ, 1991, ADV CANCER RES, V57, P151; DAVIS JN, 1990, ONCOGENE, V5, P1109; DAVIS N, 1991, SCIENCE, V253, P1268, DOI 10.1126/science.1891714; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DINTER H, 1987, EMBO J, V6, P4067, DOI 10.1002/j.1460-2075.1987.tb02752.x; FAN CM, 1991, NATURE, V354, P395, DOI 10.1038/354395a0; FISCHER EH, 1991, SCIENCE, V253, P401, DOI 10.1126/science.1650499; FRANZA BR, 1990, UCLA SYM BI, V119, P181; FRANZA BR, 1987, NATURE, V330, P391, DOI 10.1038/330391a0; GARRELS JI, 1989, J BIOL CHEM, V264, P5283; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; GILMORE TD, 1990, CELL, V62, P841, DOI 10.1016/0092-8674(90)90257-F; GILMORE TD, 1988, J VIROL, V62, P703, DOI 10.1128/JVI.62.3.703-714.1988; GILMORE TD, 1991, TRENDS GENET, V7, P318, DOI 10.1016/0168-9525(91)90200-A; HENKEL T, 1992, CELL, V68, P1121, DOI 10.1016/0092-8674(92)90083-O; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.biochem.54.1.897; INOUE J, 1992, CELL, V68, P1109, DOI 10.1016/0092-8674(92)90082-N; IP YT, 1991, CELL, V64, P439; KABRUN N, 1991, P NATL ACAD SCI USA, V88, P1783, DOI 10.1073/pnas.88.5.1783; KAMENS J, 1990, MOL CELL BIOL, V10, P2840, DOI 10.1128/MCB.10.6.2840; KAUFMAN JD, 1987, MOL CELL BIOL, V7, P3759, DOI 10.1128/MCB.7.10.3759; KERR LD, 1991, GENE DEV, V5, P1464, DOI 10.1101/gad.5.8.1464; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; KOCHEL T, 1991, ONCOGENE, V6, P615; KOCHEL T, 1992, ONCOGENE, V7, P567; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE JH, 1991, ONCOGENE, V6, P665; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; LEWIN B, 1991, CELL, V64, P303, DOI 10.1016/0092-8674(91)90640-K; LI YC, 1991, MOL CELL BIOL, V11, P1883, DOI 10.1128/MCB.11.4.1883; LUX SE, 1990, NATURE, V344, P36, DOI 10.1038/344036a0; MORRISON LE, 1989, ONCOGENE, V4, P677; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; NAKAYAMA K, 1992, MOL CELL BIOL, V12, P1736, DOI 10.1128/MCB.12.4.1736; NERI A, 1991, CELL, V67, P1075, DOI 10.1016/0092-8674(91)90285-7; NOLAN GP, 1991, CELL, V64, P961, DOI 10.1016/0092-8674(91)90320-X; NSRURTLR PS, 1988, DVIRNVR, V242, P540; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; RICE NR, 1988, ONCOGENE HDB, P495; RICHARDSON PM, 1991, J VIROL, V65, P3122, DOI 10.1128/JVI.65.6.3122-3130.1991; RIVIERE Y, 1991, NATURE, V350, P625, DOI 10.1038/350625a0; ROBINSON FR, 1974, AVIAN DIS, V18, P278, DOI 10.2307/1589142; ROTH S, 1989, CELL, V59, P1189, DOI 10.1016/0092-8674(89)90774-5; RYSECK RP, 1992, MOL CELL BIOL, V12, P674, DOI 10.1128/MCB.12.2.674; SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; SIEKEVITZ M, 1987, SCIENCE, V238, P1575, DOI 10.1126/science.2825351; SIMEK S, 1988, J VIROL, V62, P4730, DOI 10.1128/JVI.62.12.4730-4736.1988; STEWARD R, 1987, SCIENCE, V238, P692, DOI 10.1126/science.3118464; STOVER DR, 1991, P NATL ACAD SCI USA, V88, P7704, DOI 10.1073/pnas.88.17.7704; TONGSTARKSEN SE, 1987, P NATL ACAD SCI USA, V84, P6845, DOI 10.1073/pnas.84.19.6845; URBAN MB, 1990, GENE DEV, V4, P1975, DOI 10.1101/gad.4.11.1975; WILHELMSEN KC, 1984, J VIROL, V52, P172, DOI 10.1128/JVI.52.1.172-182.1984	61	45	45	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	1992	7	11					2095	2104						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JW665	1437141				2022-12-25	WOS:A1992JW66500001
J	ACHARYA, JK; RAO, NA				ACHARYA, JK; RAO, NA			A NOVEL INTERMEDIATE IN THE INTERACTION OF THIOSEMICARBAZIDE WITH SHEEP LIVER SERINE HYDROXYMETHYLTRANSFERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PYRIDOXAL 5'-PHOSPHATE; SLOW-BINDING; AMINOTRANSFERASE; INHIBITION; METABOLISM; MECHANISM	An unusual intermediate bound to the enzyme was detected in the interaction of thiosemicarbazide with sheep liver serine hydroxymethyltransferase. This intermediate had absorbance maxima at 464 and 440 nm. Such spectra are characteristic of resonance stabilized intermediates detected in the interaction of substrates and quasisubstrates with pyridoxal phosphate enzymes. An intermediate of this kind has not been detected in the interaction of thiosemicarbazide with other pyridoxal phosphate enzymes. This intermediate was generated slowly (t1/2 = 4 min) following the addition of thiosemicarbazide (200 muM) to sheep liver serine hydroxymethyltransferase (5 muM). It was bound to the enzyme as evidenced by circular dichroic bands at 464 and 440 nm and the inability to be removed upon Centricon filtration. The kinetics of interaction revealed that thiosemicarbazide was a slow binding reversible inhibitor in this phase with a k(on) of 11 M-1 s-1 and a k(off) of 5 x 10(-4) s-1. The intermediate was converted very slowly (k = 4 x 10(-5) s-1) to the final products, namely the apoenzyme and the thiosemicarbazone of pyridoxal phosphate. A minimal kinetic mechanism involving the initial conversion to the intermediate absorbing at longer wavelengths and the conversion of this intermediate to the final product, as well as, the formation of pyridoxal phosphate-thiosemicarbazone directly by an alternate pathway is proposed.	INDIAN INST SCI,DEPT BIOCHEM,BANGALORE 560012,KARNATAKA,INDIA	Indian Institute of Science (IISC) - Bangalore				Acharya, Jairaj/0000-0001-7366-4228				ACHARYA JK, 1991, INDIAN J BIOCHEM BIO, V28, P381; BADET B, 1986, BIOCHEMISTRY-US, V25, P3275, DOI 10.1021/bi00359a029; BASKARAN N, 1989, BIOCHEMISTRY-US, V28, P9613, DOI 10.1021/bi00451a010; BASKARAN N, 1989, BIOCHEMISTRY-US, V28, P9607, DOI 10.1021/bi00451a009; BAYLEY PM, 1975, EUR J BIOCHEM, V56, P455, DOI 10.1111/j.1432-1033.1975.tb02252.x; DAVIES LP, 1974, J NEUROCHEM, V22, P107, DOI 10.1111/j.1471-4159.1974.tb12185.x; FISHER SK, 1974, J NEUROCHEM, V23, P427, DOI 10.1111/j.1471-4159.1974.tb04375.x; FURST A, 1967, P SOC EXP BIOL MED, V124, P172; GREENFIE.N, 1969, BIOCHEMISTRY-US, V8, P4108, DOI 10.1021/bi00838a031; HATEFI Y, 1960, BIOCHEM PREP, V7, P89; JENKINS WT, 1966, BIOCHEMISTRY-US, V5, P2900, DOI 10.1021/bi00873a018; JENKINS WT, 1961, J BIOL CHEM, V236, P1121; KLOSTERMAN HJ, 1986, VITAMIN B6 PYRIDOXAL, P391; MANOHAR R, 1982, J BIOSCIENCES, V4, P31, DOI 10.1007/BF02702579; MANOHAR R, 1984, BIOCHEMISTRY-US, V23, P4116, DOI 10.1021/bi00313a016; MARTINEZCARRION M, 1970, BIOCHEMISTRY-US, V9, P2574, DOI 10.1021/bi00815a004; MATHEW RG, 1990, CHEM REV, V90, P1275, DOI DOI 10.1021/CR00105A010; MILES EW, 1977, J BIOL CHEM, V252, P6594; MILES EW, 1980, BIOCH MED ASPECTS TR, P137; MORRISON JF, 1988, ADV ENZYMOL RAMB, V61, P201; MORRISON JF, 1982, TRENDS BIOCHEM SCI, V7, P102, DOI 10.1016/0968-0004(82)90157-8; PALEKAR AG, 1973, J BIOL CHEM, V248, P1158; QUASHNOCK JM, 1983, J BIOL CHEM, V258, P503; RAO NA, 1991, NEW TRENDS BIOL CHEM, P333; RAUNIO RP, 1984, ARCH BIOCHEM BIOPHYS, V233, P43, DOI 10.1016/0003-9861(84)90599-X; SCHIRCH L, 1964, J BIOL CHEM, V239, P3801; SCHIRCH L, 1964, J BIOL CHEM, V239, P3797; Schirch L. V., 1984, FOLATES PTERINS CHEM, V1, P399; SIZER IW, 1962, METHOD ENZYMOL, V5, P677, DOI 10.1016/S0076-6879(62)05295-7; SIZER IW, 1963, P S CHEM BIOL ASPECT, P123; SLOW YL, 1990, ANN NY ACAD SCI, V585, P173; SNELL K, 1984, ADV ENZYME REGUL, V22, P325, DOI 10.1016/0065-2571(84)90021-9; TAYLOR RT, 1965, ANAL BIOCHEM, V13, P80, DOI 10.1016/0003-2697(65)90120-X; TENDLER SJB, 1989, J CHEM SOC PERK T 2, P431, DOI 10.1039/p29890000431; TORCHINSKY YM, 1964, BIOCHIM BIOPHYS ACTA, V79, P426; ULEVITCH RJ, 1977, BIOCHEMISTRY-US, V16, P5355, DOI 10.1021/bi00643a029; WENTWORTH DF, 1974, BIOCHEMISTRY-US, V13, P4715, DOI 10.1021/bi00720a006; Williams J W, 1979, Methods Enzymol, V63, P437; WILSON EM, 1966, BIOCHEMISTRY-US, V5, P1166, DOI 10.1021/bi00868a008; WOOD JD, 1971, J NEUROCHEM, V18, P1017, DOI 10.1111/j.1471-4159.1971.tb12031.x; WOOD JD, 1974, J NEUROCHEM, V23, P703, DOI 10.1111/j.1471-4159.1974.tb04394.x	41	15	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1992	267	27					19066	19071						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JP593	1527031				2022-12-25	WOS:A1992JP59300011
J	ADACHI, Y; KITAHARAOZAWA, A; SUGAMURA, K; LEE, WJ; YODOI, J; MAKI, M; MURACHI, T; HATANAKA, M				ADACHI, Y; KITAHARAOZAWA, A; SUGAMURA, K; LEE, WJ; YODOI, J; MAKI, M; MURACHI, T; HATANAKA, M			EXPRESSION OF CALPAIN-II GENE IN HUMAN HEMATOPOIETIC SYSTEM CELLS INFECTED WITH HUMAN T-CELL LEUKEMIA-VIRUS TYPE-I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA-2+-ACTIVATED NEUTRAL PROTEASE; HUMAN INTERLEUKIN-2 RECEPTOR; CALCIUM-DEPENDENT PROTEASE; LONG TERMINAL REPEAT; MOLECULAR-CLONING; MESSENGER-RNA; LARGE SUBUNIT; MONOCLONAL-ANTIBODY; KINASE-C; HTLV-I	We examined the distribution of calpains I and II in human hematopoietic system cell lines by Western and Northern blot analyses and enzyme activity assay. Expression of calpain I, a low Ca2+-requiring cysteine protease, was observed in all human T-cell lines tested. By contrast, expression of calpain II, a high Ca2+-requiring form, in human T-cells was closely correlated with human T-cell leukemia virus type I (HTLV-I) infection, which is known to result in the expression of adult T-cell leukemia-associated antigens, interleukin-2 (IL-2) receptor alpha, and Ca2+-dependent cell proliferation. Specific expression of calpain II in HTLV-I-infected cells occurred at the mRNA level. Furthermore, expression of calpain II in human natural killer-like cells was augmented by HTLV-I pX gene transfection. In HTLV-I-infected cells, the trans-acting transcriptional activation of the long terminal repeat and control elements for the IL-2 receptor alpha, c-fos, and granulocyte-macrophage colony-stimulating factor genes by the Tax from the pX gene is already known. Our results suggest that the similar trans-activation occurs to the calpain II gene in HTLV-I-infected hematopoietic system cells.	KYOTO UNIV,INST VIRUS RES,KYOTO 606,JAPAN; KYOTO UNIV,FAC MED,DEPT CLIN SCI,KYOTO 606,JAPAN; KYOTO UNIV,FAC MED,MED LAB,KYOTO 606,JAPAN; TOHOKU UNIV,FAC MED,DEPT MICROBACTERIOL,SENDAI,MIYAGI 980,JAPAN	Kyoto University; Kyoto University; Kyoto University; Tohoku University			Maki, Masatoshi/AAM-6839-2021	Maki, Masatoshi/0000-0001-9144-5491				ADACHI Y, 1988, BIOL CHEM H-S, V369, P223; ADACHI Y, 1990, BIOMED RES-TOKYO, V11, P313, DOI 10.2220/biomedres.11.313; ADACHI Y, 1986, BIOCHEM BIOPH RES CO, V136, P1090, DOI 10.1016/0006-291X(86)90445-6; AOKI K, 1986, FEBS LETT, V205, P313, DOI 10.1016/0014-5793(86)80919-X; FELBER BK, 1985, SCIENCE, V229, P675, DOI 10.1126/science.2992082; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; FUJII M, 1988, P NATL ACAD SCI USA, V85, P6526; FUJISAWA J, 1985, P NATL ACAD SCI USA, V82, P2277, DOI 10.1073/pnas.82.8.2277; GOLL DE, 1990, INTRACELLULAR CALCIU, P4; HATA A, 1989, J BIOL CHEM, V264, P6404; HATANAKA M, 1983, BIOMED RES-TOKYO, V4, P381; HATTORI S, 1983, JPN J CANCER RES, V74, P790; HATTORI T, 1981, BLOOD, V58, P645; HAWKES R, 1982, ANAL BIOCHEM, V119, P142, DOI 10.1016/0003-2697(82)90677-7; HINUMA Y, 1981, P NATL ACAD SCI-BIOL, V78, P6476, DOI 10.1073/pnas.78.10.6476; IMAJOH S, 1988, BIOCHEMISTRY-US, V27, P8122, DOI 10.1021/bi00421a022; INOUE J, 1986, EMBO J, V5, P2883, DOI 10.1002/j.1460-2075.1986.tb04583.x; INOUE M, 1977, J BIOL CHEM, V252, P7610; KAGEYAMA R, 1989, CELL, V59, P815, DOI 10.1016/0092-8674(89)90605-3; KALYANARAMAN VS, 1982, P NATL ACAD SCI-BIOL, V79, P1653, DOI 10.1073/pnas.79.5.1653; KALYANARAMAN VS, 1981, J VIROL, V38, P906, DOI 10.1128/JVI.38.3.906-915.1981; KANAMORI H, 1990, EMBO J, V9, P4161, DOI 10.1002/j.1460-2075.1990.tb07639.x; KISHIMOTO A, 1983, J BIOL CHEM, V258, P1156; KITAHARA A, 1984, J BIOCHEM-TOKYO, V95, P1759; KUBONISHI I, 1983, International Journal of Cell Cloning, V1, P105; MANZARI V, 1983, P NATL ACAD SCI-BIOL, V80, P1574, DOI 10.1073/pnas.80.6.1574; MELLONI E, 1985, P NATL ACAD SCI USA, V82, P6435, DOI 10.1073/pnas.82.19.6435; MIYATAKE S, 1988, MOL CELL BIOL, V8, P5581, DOI 10.1128/MCB.8.12.5581; MIYOSHI I, 1977, NATURE, V267, P843, DOI 10.1038/267843a0; MURACHI T, 1983, TRENDS BIOCHEM SCI, V8, P167, DOI 10.1016/0968-0004(83)90165-2; MURACHI T, 1990, INTRACELLULAR CALCIU, P158; NIKAIDO T, 1984, NATURE, V311, P631, DOI 10.1038/311631a0; ROBERTGUROFF M, 1981, J EXP MED, V154, P1957, DOI 10.1084/jem.154.6.1957; SABE H, 1988, INT J CANCER, V41, P880, DOI 10.1002/ijc.2910410619; SCHOLLMEYER JE, 1988, SCIENCE, V240, P911, DOI 10.1126/science.2834825; SHIRAKAWA F, 1986, CANCER RES, V46, P658; SODROSKI JG, 1984, SCIENCE, V225, P381, DOI 10.1126/science.6330891; SRIVASTAVA BIS, 1975, J NATL CANCER I, V55, P11, DOI 10.1093/jnci/55.1.11; SUGAMURA K, 1984, INT J CANCER, V34, P221, DOI 10.1002/ijc.2910340213; SUGAMURA K, 1980, J IMMUNOL, V124, P1045; TAKANO E, 1988, BIOCHEM INT, V16, P391; Takatsuki K., 1977, TOPICS HEMATOLOGY, P73; TANAKA A, 1990, P NATL ACAD SCI USA, V87, P1071, DOI 10.1073/pnas.87.3.1071; TOKUNAGA K, 1986, NUCLEIC ACIDS RES, V14, P2829; TSUDO M, 1983, BLOOD, V61, P1014; UCHIYAMA T, 1977, BLOOD, V50, P481, DOI 10.1182/blood.V50.3.481.481; WONGSTAAL F, 1983, NATURE, V302, P626, DOI 10.1038/302626a0; YAMAMOTO N, 1982, SCIENCE, V217, P737, DOI 10.1126/science.6980467; YAMAMOTO N, 1982, INT J CANCER, V30, P289, DOI 10.1002/ijc.2910300306; YOSHIDA M, 1982, P NATL ACAD SCI-BIOL, V79, P2031, DOI 10.1073/pnas.79.6.2031; YOSHIMURA N, 1984, J BIOL CHEM, V259, P9847	51	25	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1992	267	27					19373	19378						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JP593	1527057				2022-12-25	WOS:A1992JP59300055
J	ALESHIN, A; GOLUBEV, A; FIRSOV, LM; HONZATKO, RB				ALESHIN, A; GOLUBEV, A; FIRSOV, LM; HONZATKO, RB			CRYSTAL-STRUCTURE OF GLUCOAMYLASE FROM ASPERGILLUS-AWAMORI VAR X100 TO 2.2-ANGSTROM RESOLUTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST SACCHAROMYCOPSIS-FIBULIGERA; STARCH-AFFINITY SITE; CYCLODEXTRIN GLYCOSYLTRANSFERASE; TRYPTOPHANYL RESIDUES; MOLECULAR-CLONING; VAR KAWACHI; 2 FORMS; NIGER; GENE; GLYCOPROTEIN	The crystal structure of a catalytically active fragment of glucoamylase-I from Aspergillus awamori var. X100 has been determined to a resolution of 2.2 angstrom. Twelve of its 13 alpha-helices are arranged into an "alpha/alpha-barrel." An inner core of six mutually parallel alpha-helices are connected to each other through a peripheral set of six alpha-helices. The peripheral helices are parallel to each other, but approximately antiparallel to the inner core of alpha-helices. The putative active site lies in the packing void of the inner set of helices. The last 30 residues of the enzyme comprise a separate domain containing 10 sites of O-glycosylation. Each instance of O-glycosylation involves a serine or threonine side chain linked to the alpha-anomer of a single mannosyl residue. The O-glycosylated domain is in an extended conformation, wrapping around the "waist" of the alpha/alpha-barrel. Two additional sites of N-glycosylation contribute well ordered glycosyl chains that lie in proximity to the belt of O-glycosylation. The model developed for glucoamylase is a rare and valuable structural example of a glycoprotein and an exo-acting amylolytic enzyme.	IOWA STATE UNIV SCI & TECHNOL,DEPT BIOCHEM & BIOPHYS,1210 MOLEC BIOL BLDG,AMES,IA 50011; LENINGRAD NUCL PHYS INST,DEPT MOLEC BIOL,ST PETERSBURG 188350,USSR	Iowa State University					NCRR NIH HHS [2-S07-RR07034-24] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [S07RR007034] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		BARLOW DJ, 1988, J MOL BIOL, V201, P601, DOI 10.1016/0022-2836(88)90641-9; BLOW DM, 1959, ACTA CRYSTALLOGR, V14, P1195; BOEL E, 1990, BIOCHEMISTRY-US, V29, P6244, DOI 10.1021/bi00478a019; BOEL E, 1984, EMBO J, V3, P1097, DOI 10.1002/j.1460-2075.1984.tb01935.x; BUISSON G, 1987, EMBO J, V6, P3909, DOI 10.1002/j.1460-2075.1987.tb02731.x; CAMBILLAU C, 1987, J MOL GRAPHICS, V5, P174, DOI 10.1016/0263-7855(87)80024-3; CHU SSC, 1968, ACTA CRYSTALL B-STRU, VB 24, P830, DOI 10.1107/S0567740868003250; CLARKE AJ, 1984, CARLSBERG RES COMMUN, V49, P559, DOI 10.1007/BF02908684; CLARKE AJ, 1984, CARLSBERG RES COMMUN, V49, P111, DOI 10.1007/BF02913970; EINSPHAR HM, 1989, T AM CRYSTALLOGR ASS, V25, P1; GUNNARSSON A, 1984, EUR J BIOCHEM, V145, P463, DOI 10.1111/j.1432-1033.1984.tb08578.x; HAYASHIDA S, 1976, AGR BIOL CHEM TOKYO, V40, P141, DOI 10.1080/00021369.1976.10862015; HAYASHIDA S, 1989, AGR BIOL CHEM TOKYO, V53, P135, DOI 10.1080/00021369.1989.10869272; HAYASHIDA S, 1989, AGR BIOL CHEM TOKYO, V53, P923, DOI 10.1080/00021369.1989.10869434; HENDRICKSON WA, 1980, COMPUTING CRYSTALLOG; HOFMANN BE, 1989, J MOL BIOL, V209, P793, DOI 10.1016/0022-2836(89)90607-4; ITOH T, 1989, AGR BIOL CHEM TOKYO, V53, P3159, DOI 10.1080/00021369.1989.10869825; ITOH T, 1987, J BACTERIOL, V169, P4171, DOI 10.1128/jb.169.9.4171-4176.1987; KLEIN C, 1991, J MOL BIOL, V217, P737, DOI 10.1016/0022-2836(91)90530-J; LINEBACK DR, 1972, CEREAL CHEM, V49, P283; LONGCHAMBON PF, 1976, ACTA CRYSTALLOGR B, V32, P1822; MATSUURA Y, 1984, J BIOCHEM-TOKYO, V95, P697, DOI 10.1093/oxfordjournals.jbchem.a134659; MATTHEWS BW, 1975, ACTA CRYSTALLOGR A, V31, P480, DOI 10.1107/S0567739475001040; NEUSTROEV K N, 1990, Biokhimiya, V55, P776; NUNBERG JH, 1984, MOL CELL BIOL, V4, P2306, DOI 10.1128/MCB.4.11.2306; PAZUR JH, 1980, CARBOHYD RES, V84, P103, DOI 10.1016/S0008-6215(00)85434-8; PAZUR JH, 1960, J BIOL CHEM, V235, P297; PAZUR JH, 1962, J BIOL CHEM, V237, P1002; RAMACHANDRAN GN, 1963, J MOL BIOL, V7, P95, DOI 10.1016/S0022-2836(63)80023-6; Richardson J S, 1981, Adv Protein Chem, V34, P167, DOI 10.1016/S0065-3233(08)60520-3; Robyt J.F., 1984, STARCH CHEM TECHNOLO, P87; SAHA BC, 1989, STARCH-STARKE, V41, P57, DOI 10.1002/star.19890410206; SIERKS MR, 1990, PROTEIN ENG, V3, P193, DOI 10.1093/protein/3.3.193; SIERKS MR, 1989, PROTEIN ENG, V2, P621, DOI 10.1093/protein/2.8.621; SVENSSON B, 1982, CARLSBERG RES COMMUN, V47, P55, DOI 10.1007/BF02907797; SVENSSON B, 1983, CARLSBERG RES COMMUN, V48, P529, DOI 10.1007/BF02907555; SVENSSON B, 1986, CARLSBERG RES COMMUN, V51, P61, DOI 10.1007/BF02907996; SVENSSON B, 1991, DENPUN KAGAKU, V38, P125; WEILL CE, 1954, CEREAL CHEM, V31, P150; Wilson AJC, 1942, NATURE, V150, P151, DOI 10.1038/150152a0; YAMASHITA I, 1989, AGR BIOL CHEM TOKYO, V53, P483, DOI 10.1080/00021369.1989.10869305	41	229	236	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1992	267	27					19291	19298						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JP593	1527049				2022-12-25	WOS:A1992JP59300043
J	BLASCO, MA; LAZARO, JM; BERNAD, A; BLANCO, L; SALAS, M				BLASCO, MA; LAZARO, JM; BERNAD, A; BLANCO, L; SALAS, M			PHI-29 DNA-POLYMERASE ACTIVE-SITE - MUTANTS IN CONSERVED RESIDUES TYR(254) AND TYR(390) ARE AFFECTED IN DNTP BINDING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; BACTERIOPHAGE-T7 RNA-POLYMERASE; ESCHERICHIA-COLI; TERMINAL PROTEIN; KLENOW FRAGMENT; APHIDICOLIN RESISTANCE; DIRECTED MUTAGENESIS; PHENOTYPIC SELECTION; SECONDARY-STRUCTURE; REPLICATION	Phi29 DNA polymerase shares with other alpha-like DNA polymerases several regions of amino acid similarity. Among them, the two conserved regions characterized by the amino acid motifs "D-NSLYP" and "K-NS(L/V)YG," regions 1 and 2a, respectively, according to Blanco et al. (Blanco, L., Bernad, A., Blasco, M. A. and Salas, M. (1991) Gene (Amst.) 100, 27-38) have been proposed to be part of the polymerization active site of alpha-like DNA polymerases. One phi29 DNA polymerase mutant in residue Tyr254, located in conserved region 1, and two mutants in residue Tyr390, located in conserved region 2a, have been characterized. The three phi29 DNA polymerase mutant proteins were affected in polymerization when Mg2+-dNTPs were used as substrate. However, when the substrate was Mn2+-dNTP, mutants behaved as the wild-type phi29 DNA polymerase. Mutant Tyr254 to Phe (Y254F) was strongly affected in the protein-primed initiation step of phi29 DNA replication showing a decreased affinity for Me2+dATP, the initiating nucleotide. Furthermore, the analysis of the template-independent deoxynucleotidylation of the TP by Y254F mutant polymerase is consistent with a change in the relative affinity for dNTPs. On the other hand, mutants Y390F and Y390S were found to be hypersensitive to the dNTP analogs 2-(p-n-butylanilino)dATP and N2-(p-n-butylphenyl) dGTP. The results obtained indicate that residues Tyr254 and Tyr390 are involved, directly or indirectly, in Me2+-dNTP binding.	UNIV AUTONOMA MADRID,CTR BIOL MOLEC,CANTO BLANCO,E-28049 MADRID,SPAIN	Autonomous University of Madrid			Bernad, Antonio/P-8573-2017; Blanco, Luis/I-1848-2015; Blasco, Maria A./M-1694-2014; Salas, Margarita/J-9873-2014	Blasco, Maria A./0000-0002-4211-233X; Salas, Margarita/0000-0001-5939-3441; Bernad, Antonio/0000-0003-0620-9668	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM027242] Funding Source: NIH RePORTER; NIGMS NIH HHS [5R01 GM27242-12] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARGOS P, 1987, J MOL BIOL, V197, P331, DOI 10.1016/0022-2836(87)90127-6; BASU A, 1987, BIOCHEMISTRY-US, V26, P1704, DOI 10.1021/bi00380a032; BASU S, 1988, BIOCHEMISTRY-US, V27, P6710, DOI 10.1021/bi00418a011; BERNAD A, 1990, GENE, V94, P45, DOI 10.1016/0378-1119(90)90466-5; BERNAD A, 1987, EMBO J, V6, P4219, DOI 10.1002/j.1460-2075.1987.tb02770.x; BERNAD A, 1989, CELL, V59, P219, DOI 10.1016/0092-8674(89)90883-0; BERNAD A, 1990, P NATL ACAD SCI USA, V87, P4610, DOI 10.1073/pnas.87.12.4610; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; BLANCO L, 1985, NUCLEIC ACIDS RES, V13, P1239, DOI 10.1093/nar/13.4.1239; BLANCO L, 1985, P NATL ACAD SCI USA, V82, P6404, DOI 10.1073/pnas.82.19.6404; BLANCO L, 1989, J BIOL CHEM, V264, P8935; BLANCO L, 1991, GENE, V100, P27, DOI 10.1016/0378-1119(91)90346-D; BLANCO L, 1986, VIROLOGY, V153, P179, DOI 10.1016/0042-6822(86)90021-8; BLANCO L, 1984, P NATL ACAD SCI-BIOL, V81, P5325, DOI 10.1073/pnas.81.17.5325; BLANCO L, 1992, J BIOL CHEM, V267, P1225; BLASCO MA, 1991, J BIOL CHEM, V266, P7904; BUTLER MM, 1990, NUCLEIC ACIDS RES, V18, P7381, DOI 10.1093/nar/18.24.7381; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; DEFILIPPES FM, 1989, J VIROL, V63, P4060, DOI 10.1128/JVI.63.9.4060-4063.1989; DELARUE M, 1990, PROTEIN ENG, V3, P461, DOI 10.1093/protein/3.6.461; EGER BT, 1991, BIOCHEMISTRY-US, V30, P1441, DOI 10.1021/bi00219a039; ESTEBAN JA, 1992, BIOCHEMISTRY-US, V31, P350, DOI 10.1021/bi00117a006; GARMENDIA C, 1992, J BIOL CHEM, V267, P2594; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GIBBS JS, 1988, P NATL ACAD SCI USA, V85, P6672, DOI 10.1073/pnas.85.18.6672; HALL JD, 1989, NUCLEIC ACIDS RES, V17, P9231, DOI 10.1093/nar/17.22.9231; INCIARTE MR, 1976, VIROLOGY, V74, P314, DOI 10.1016/0042-6822(76)90338-X; ITO J, 1991, NUCLEIC ACIDS RES, V19, P4045, DOI 10.1093/nar/19.15.4045; JOYCE CM, 1987, TRENDS BIOCHEM SCI, V12, P288, DOI 10.1016/0968-0004(87)90143-5; KHAN NN, 1991, NUCLEIC ACIDS RES, V19, P1627, DOI 10.1093/nar/19.7.1627; KHAN NN, 1984, NUCLEIC ACIDS RES, V12, P3695, DOI 10.1093/nar/12.8.3695; KUNKEL TA, 1985, J BIOL CHEM, V260, P5787; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LARDER BA, 1987, EMBO J, V6, P169, DOI 10.1002/j.1460-2075.1987.tb04735.x; MATSUMOTO K, 1989, GENE, V84, P247; MATTHEWS JT, 1989, J VIROL, V63, P4913, DOI 10.1128/JVI.63.11.4913-4918.1989; OLLIS DL, 1985, NATURE, V313, P762, DOI 10.1038/313762a0; PENALVA MA, 1982, P NATL ACAD SCI-BIOL, V79, P5522, DOI 10.1073/pnas.79.18.5522; POLESKY AH, 1990, J BIOL CHEM, V265, P14579; RUSH J, 1990, J BIOL CHEM, V265, P4821; SALAS M, 1991, ANNU REV BIOCHEM, V60, P39, DOI 10.1146/annurev.bi.60.070191.000351; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; STRAUSS EC, 1986, ANAL BIOCHEM, V154, P353, DOI 10.1016/0003-2697(86)90536-1; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; WATABE K, 1984, P NATL ACAD SCI-BIOL, V81, P5374, DOI 10.1073/pnas.81.17.5374; WONG SW, 1988, EMBO J, V7, P37, DOI 10.1002/j.1460-2075.1988.tb02781.x; ZABALLOS A, 1989, GENE, V83, P187, DOI 10.1016/0378-1119(89)90104-2	49	59	65	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1992	267	27					19427	19434						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JP593	1527062				2022-12-25	WOS:A1992JP59300063
J	KANG, D; OKUBO, K; HAMASAKI, N; KURODA, N; SHIRAKI, H				KANG, D; OKUBO, K; HAMASAKI, N; KURODA, N; SHIRAKI, H			A STRUCTURAL STUDY OF THE MEMBRANE DOMAIN OF BAND-3 BY TRYPTIC DIGESTION - CONFORMATIONAL CHANGE OF BAND-3 INSITU INDUCED BY ALKALI TREATMENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-ERYTHROCYTE MEMBRANES; ANION-TRANSPORT PROTEIN; RED BLOOD-CELL; PHOSPHATE BINDING-SITE; PHOSPHOENOLPYRUVATE TRANSPORT; CHEMICAL MODIFICATION; PEPTIDE; SYSTEM; PERMEABILITY; LOCALIZATION	Nine peptides derived from the transmembrane domain of band 3 were purified and sequenced. All of the sequences agreed completely with deduced sequences from cDNA of human erythroid band 3. Five peptides, KS-1 to KS-5, were released from the band 3 molecule when alkali-stripped membranes were digested with trypsin, while four other peptides, KM-6 to KM-9, were obtained following subsequent urea treatment. This indicates that at least 13 new in situ cleavage sites were demonstrable by these procedures, that the released peptides are parts of hydrophilic connector loops, and that the other peptide portions constitute membrane-spanning helices. The topological designations are consistent with the hydropathy prediction of murine band 3 according to Passow ((1986) Rev. Physiol. Biochem. Pharmacol. 103, 61-203). One mol of histidine residue was found/mole of KS-1, KS-2, KS-4, and KM-6. The conformation of band 3 in situ was apparently changed by alkali treatment of erythrocyte membranes, i.e. the amount of KS-1, KS-2, and KS-4 peptides released by trypsin treatment increased as NaOH concentration was raised from 10 to 100 mM. Similarly, [H-3]dihydro-4,4'-diisothiocyanostilbene-2,2'-disulfonic acid was found to bind to band 3 in membranes treated with 10 mM NaOH as well as to band 3 in white ghosts, but not to membranes treated with 100 mM NaOH. In addition, alkali treatment of membranes tended to increase the amount of band 3 cross-linked by 4,4'-diisothiocyanostilbene-2,2'-disulfonic acid (DIDS). The conformational change in band 3 by alkali treatment was also supported by the interaction of antibodies against peptides released by trypsin. The release of KS-1, KS-2, and KS-4 from the membrane was strongly inhibited by pretreating the erythrocyte membrane with DIDS, suggesting that the DIDS-band 3 complex which is in the outward facing form, is more compact and becomes resistant to trypsin compared to band 3 without DIDS.	FUKUOKA UNIV,SCH MED,DEPT CLIN CHEM & LAB MED,FUKUOKA 81401,JAPAN; NAGASAKI UNIV,FAC PHARMACEUT SCI,DEPT ANALYT CHEM,NAGASAKI 852,JAPAN; FUKUOKA RED CROSS BLOOD CTR,FUKUOKA 818,JAPAN	Fukuoka University; Nagasaki University								APPELL KC, 1982, BIOCHEMISTRY-US, V21, P2151, DOI 10.1021/bi00538a026; CABANTCHIK ZI, 1974, J MEMBRANE BIOL, V15, P207, DOI 10.1007/BF01870088; HAMASAKI N, 1987, TRENDS BIOCHEM SCI, V12, P183, DOI 10.1016/0968-0004(87)90089-2; HAMASAKI N, 1983, EUR J BIOCHEM, V132, P531, DOI 10.1111/j.1432-1033.1983.tb07394.x; HAMASAKI N, 1989, ANION TRANSPORT RED, P47; IZUHARA K, 1989, BIOCHEMISTRY-US, V28, P4725, DOI 10.1021/bi00437a032; JENNINGS ML, 1982, J BIOL CHEM, V257, P7554; JENNINGS ML, 1984, J BIOL CHEM, V259, P4652; JENNINGS ML, 1987, J BIOL CHEM, V262, P1691; JENNINGS ML, 1979, BIOCHIM BIOPHYS ACTA, V554, P498, DOI 10.1016/0005-2736(79)90387-0; KAWANO Y, 1986, J BIOCHEM-TOKYO, V100, P191, DOI 10.1093/oxfordjournals.jbchem.a121692; KAWANO Y, 1988, J BIOL CHEM, V263, P8232; KNAUF PA, 1971, J GEN PHYSIOL, V58, P190, DOI 10.1085/jgp.58.2.190; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIEBERMAN DM, 1987, BIOCHIM BIOPHYS ACTA, V903, P37, DOI 10.1016/0005-2736(87)90153-2; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUX SE, 1989, P NATL ACAD SCI USA, V86, P9089, DOI 10.1073/pnas.86.23.9089; MATSUYAMA H, 1986, J BIOCHEM-TOKYO, V99, P495, DOI 10.1093/oxfordjournals.jbchem.a135504; OKUBO K, 1991, J BIOL CHEM, V266, P16420; PASSOW H, 1986, REV PHYSIOL BIOCH P, V103, P61; TAM JP, 1989, P NATL ACAD SCI USA, V86, P9084, DOI 10.1073/pnas.86.23.9084; TAM JP, 1988, P NATL ACAD SCI USA, V85, P5409, DOI 10.1073/pnas.85.15.5409; TANNER MJA, 1988, BIOCHEM J, V256, P703, DOI 10.1042/bj2560703; WIETH JO, 1982, J GEN PHYSIOL, V79, P283, DOI 10.1085/jgp.79.2.283; ZAKI L, 1981, BIOCHEM BIOPH RES CO, V99, P243, DOI 10.1016/0006-291X(81)91738-1; ZAKI L, 1975, J CELL PHYSIOL, V86, P471, DOI 10.1002/jcp.1040860305	26	51	55	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1992	267	27					19211	19217						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JP593	1527044				2022-12-25	WOS:A1992JP59300033
J	KOUNS, WC; HADVARY, P; HAERING, P; STEINER, B				KOUNS, WC; HADVARY, P; HAERING, P; STEINER, B			CONFORMATIONAL MODULATION OF PURIFIED GLYCOPROTEIN (GP)-IIB-IIIA ALLOWS PROTEOLYTIC GENERATION OF ACTIVE FRAGMENTS FROM EITHER ACTIVE OR INACTIVE GPIIB-IIIA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBOXY-TERMINAL SEGMENT; IIB-IIIA; FIBRINOGEN-BINDING; PLATELET-AGGREGATION; SYNTHETIC PEPTIDES; RECOGNITION SITE; MONOCLONAL-ANTIBODIES; ADHESION RECEPTOR; DEPENDENT EPITOPE; DISULFIDE BONDS	This study characterized conformational states of platelet glycoprotein IIb-IIIa (GPIIb-IIIa) and regions of the molecule required for fibrinogen binding. Platelet lysates were passed sequentially over concanavalin A and aminoethylglycine (Aeg)RGDS affinity columns. Approximately 10% of the total GPIIb-IIIa bound to the Aeg-RGDS column. The non-binding GPIIb-IIIa was further purified by S300 gel filtration. Only GPIIb-IIIa which recognized immobilized RGDS bound fibrinogen. The functional difference between the Aeg-RGDS binding GPIIb-IIIa (active) and the S300-purified complex (inactive) suggested that the two populations existed in different conformations. This was confirmed immunochemically and in an assay utilizing endoproteinase Arg-C. Active GPIIb-IIIa was heavily degraded by Arg-C, whereas inactive GPIIb-IIIa was highly resistant to degradation. Receptor occupancy by RGDV or peptidomimetic inhibitors prevented degradation of regions of the active complex and stimulated hydrolysis of the inactive receptor such that the two populations yielded fragments of identical electrophoretic mobility. Induction of hydrolysis of inactive GPIIb-IIIa required 15-fold higher concentrations of RGDV than protection of the active complex. Upon removal of inhibitor, fragments generated from either active or inactive GPIIb-IIIa bound fibrinogen. The ability of carboxypeptidase Y to digest inhibitor-protected GPIIb-IIIa was also examined. GPIIb was cleaved to a 58-kDa NH2-terminal fragment, whereas GPIIIa remained essentially intact. The complexed fragments bound fibrinogen with similar affinity as intact GPIIb-IIIa. This binding was inhibited by both RGDV and HHLGGAKQAGDV peptides. These data suggest that: 1) purified active and inactive GPIIb-IIIa exist in different conformations and have different affinities for RGDV; 2) certain peptidomimetic inhibitors (Ro 42-1499 and Ro 43-5054) alter the conformation of inactive GPIIb-IIIa; 3) GPIIIa and a 58-kDa NH2-terminal fragment of GPIIb, form a high affinity fibrinogen binding complex.			KOUNS, WC (corresponding author), F HOFFMANN LA ROCHE & CO LTD,DIV PHARMA,GRENZACHERSTR 124,CH-4002 BASEL,SWITZERLAND.							BENNETT JS, 1979, J CLIN INVEST, V64, P1393, DOI 10.1172/JCI109597; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CALVETE JJ, 1991, BIOCHEM J, V274, P63, DOI 10.1042/bj2740063; CALVETE JJ, 1989, BIOCHEM J, V261, P551, DOI 10.1042/bj2610551; CALVETE JJ, 1991, BIOCHEM J, V273, P767, DOI 10.1042/bj2730767; COLLER BS, 1985, J CLIN INVEST, V76, P101, DOI 10.1172/JCI111931; DEMARCO L, 1986, J CLIN INVEST, V77, P1272, DOI 10.1172/JCI112430; DSOUZA SE, 1988, J BIOL CHEM, V263, P3943; DSOUZA SE, 1991, NATURE, V350, P66, DOI 10.1038/350066a0; DSOUZA SE, 1988, SCIENCE, V242, P91, DOI 10.1126/science.3262922; DU XP, 1991, CELL, V65, P409, DOI 10.1016/0092-8674(91)90458-B; FITZGERALD LA, 1985, ANAL BIOCHEM, V151, P169, DOI 10.1016/0003-2697(85)90067-3; FRELINGER AL, 1988, J BIOL CHEM, V263, P12397; FRELINGER AL, 1990, J BIOL CHEM, V265, P6346; GARTNER TK, 1985, J BIOL CHEM, V260, P1891; GEORGE JN, 1984, NEW ENGL J MED, V311, P1084, DOI 10.1056/NEJM198410253111705; GINSBERG M, 1985, J BIOL CHEM, V260, P3931; GINSBERG MH, 1986, J CLIN INVEST, V78, P1103, DOI 10.1172/JCI112667; GINSBERG MH, 1990, BLOOD, V76, P2017; HAERING P, 1985, P NATL ACAD SCI USA, V82, P4837; HEATH TL, 1991, BLOOD, V78, pA138; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; KLOCZEWIAK M, 1982, BIOCHEM BIOPH RES CO, V107, P181, DOI 10.1016/0006-291X(82)91686-2; KLOCZEWIAK M, 1984, BIOCHEMISTRY-US, V23, P1767, DOI 10.1021/bi00303a028; KOUNS WC, 1990, J BIOL CHEM, V265, P20594; KOUNS WC, 1991, THROMB RES, V63, P343, DOI 10.1016/0049-3848(91)90137-L; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAM SCT, 1989, BLOOD, V73, P1513; LAM SCT, 1987, J BIOL CHEM, V262, P947; LAM SCT, 1992, J BIOL CHEM, V267, P5649; LOFTUS JC, 1990, SCIENCE, V249, P915, DOI 10.1126/science.2392682; MARGUERIE GA, 1980, J BIOL CHEM, V255, P154; NURDEN AT, 1975, NATURE, V255, P720, DOI 10.1038/255720a0; OTOOLE TE, 1990, CELL REGUL, V1, P883, DOI 10.1091/mbc.1.12.883; PARISE LV, 1987, J BIOL CHEM, V262, P12597; PHILLIPS DR, 1988, BLOOD, V71, P841; PIERSCHBACHER MD, 1984, P NATL ACAD SCI-BIOL, V81, P5985, DOI 10.1073/pnas.81.19.5985; PLOW EF, 1985, P NATL ACAD SCI USA, V82, P8057, DOI 10.1073/pnas.82.23.8057; PYTELA R, 1986, SCIENCE, V231, P1559, DOI 10.1126/science.2420006; RUGGERI ZM, 1986, P NATL ACAD SCI USA, V83, P5708, DOI 10.1073/pnas.83.15.5708; SANTORO SA, 1987, CELL, V48, P867, DOI 10.1016/0092-8674(87)90083-3; SAVAGE B, 1990, J BIOL CHEM, V265, P11766; SHATTIL SJ, 1985, J BIOL CHEM, V260, P1107; SIMS PJ, 1991, J BIOL CHEM, V266, P7345; STEINER B, 1989, J BIOL CHEM, V264, P13102; STEINER B, 1991, J BIOL CHEM, V256, P14986; STEINER B, 1991, BLOOD, V78, pA393; TURITTO VT, 1984, J CLIN INVEST, V74, P1730, DOI 10.1172/JCI111591	49	67	67	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1992	267	26					18844	18851						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JN502	1527012				2022-12-25	WOS:A1992JN50200090
J	OKAMURAIKEDA, K; FUJIWARA, K; MOTOKAWA, Y				OKAMURAIKEDA, K; FUJIWARA, K; MOTOKAWA, Y			MOLECULAR-CLONING OF A CDNA-ENCODING CHICKEN T-PROTEIN OF THE GLYCINE CLEAVAGE SYSTEM AND EXPRESSION OF THE FUNCTIONAL PROTEIN IN ESCHERICHIA-COLI - EFFECT OF MESSENGER-RNA SECONDARY STRUCTURE IN THE TRANSLATIONAL INITIATION REGION ON EXPRESSION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID SEQUENCE; H-PROTEIN; P-PROTEIN; PURIFICATION; MECHANISM; LIVER; COMPONENT	DNA clones encoding chicken T-protein of the glycine cleavage system were isolated from chicken liver lambda-gt10 cDNA libraries. Three overlapping clones provided an open reading frame of 1176 nucleotides that predicts a polypeptide of 392 amino acids (M(r) 42,056) comprised of a 16-residue mitochondrial targeting sequence and a 376-residue mature protein (M(r) 40,292). The amino acid sequence predicted for the mature protein showed 67% identity with that of bovine T-protein. A cDNA encoding mature T-protein was constructed, and the nucleotide sequence just downstream of the initiation codon was modified without amino acid substitution to reduce the free energy of formation for the folded mRNA. Expression plasmids containing these cDNA variants produced large amounts of T-protein in Escherichia coli, while very low expression was observed with a plasmid containing wild type cDNA. Enzymatically active T-protein was obtained when the expression was conducted at 30-degrees-C with 25 mu-M isopropyl-1-thio-beta-D-galactopyranoside. Under the full inducing condition (at 37-degrees-C and 1 mM inducer), the expressed T-protein was recovered as insoluble and inactive protein. The recombinant T-protein was purified to near homogeneity with a yield of about 30%. Apparent molecular weight on sodium dodecyl sulfate-polyacrylamide gel electrophoresis is approximately 40,000, similar to the size of T-protein purified from chicken liver. NH2-terminal amino acid sequence analysis (9 residues) revealed 100% identity with chicken T-protein determined chemically. The kinetic properties of the recombinant T-protein resembled those of the native chicken T-protein.	UNIV TOKUSHIMA,INST ENZYME RES,KURAMOTOCHO 3 CHOME,TOKUSHIMA 770,JAPAN	Tokushima University								BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWNER MF, 1991, PROTEIN ENG, V4, P351, DOI 10.1093/protein/4.3.351; FUJIWARA K, 1979, ARCH BIOCHEM BIOPHYS, V197, P454, DOI 10.1016/0003-9861(79)90267-4; FUJIWARA K, 1987, BIOCHEM BIOPH RES CO, V149, P621, DOI 10.1016/0006-291X(87)90413-X; FUJIWARA K, 1983, J BIOL CHEM, V258, P8156; FUJIWARA K, 1986, J BIOL CHEM, V261, P8836; FUJIWARA K, 1990, J BIOL CHEM, V265, P17463; FUJIWARA K, 1984, J BIOL CHEM, V259, P664; GROSS G, 1990, J BIOL CHEM, V265, P17627; HIREL PH, 1989, P NATL ACAD SCI USA, V86, P8247, DOI 10.1073/pnas.86.21.8247; JATON JC, 1979, IMMUNOLOGICAL METHOD, P43; KINGSTON RE, 1987, CURRENT PROTOCOLS MO; KOCHI H, 1974, J BIOCHEM, V75, P1113, DOI 10.1093/oxfordjournals.jbchem.a130483; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KUME A, 1991, J BIOL CHEM, V266, P3323; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARSTON FAO, 1986, BIOCHEM J, V240, P1, DOI 10.1042/bj2400001; MENDOZA JA, 1991, J BIOL CHEM, V266, P13044; OKAMURAIKEDA K, 1987, J BIOL CHEM, V262, P6746; OKAMURAIKEDA K, 1982, J BIOL CHEM, V257, P135; OKAMURAIKEDA K, 1991, J BIOL CHEM, V266, P4917; OSTERMANN J, 1989, NATURE, V341, P125, DOI 10.1038/341125a0; OTULAKOWSKI G, 1987, J BIOL CHEM, V262, P17313; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SELDEN RF, 1987, CURRENT PROTOCOLS MO; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; ZUKER M, 1981, NUCLEIC ACIDS RES, V9, P133, DOI 10.1093/nar/9.1.133	28	21	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1992	267	26					18284	18290						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JN502	1526969				2022-12-25	WOS:A1992JN50200009
J	WADA, Y; OHSUMI, Y; ANRAKU, Y				WADA, Y; OHSUMI, Y; ANRAKU, Y			GENES FOR DIRECTING VACUOLAR MORPHOGENESIS IN SACCHAROMYCES-CEREVISIAE .1. ISOLATION AND CHARACTERIZATION OF 2 CLASSES OF VAM MUTANTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTON MOTIVE FORCE; MEMBRANE-VESICLES; ALPHA-MANNOSIDASE; SECRETORY PATHWAY; ACTIVE-TRANSPORT; YEAST VACUOLE; AMINO-ACIDS; PEP4 GENE; BIOGENESIS; TRIPHOSPHATASE	We identified nine VAM genes (for vacuolar morphology) by genetic analyses on mutants with defective vacuolar morphologies and assembly in the yeast Saccharomyces cerevisiae. The nine VAM genes were classified into two classes according to the mutant phenotypes. The class I vam mutants (vam1, vam5, vam8, and vam9) show a few small vesicles that are stained with histochemical markers for the vacuolar compartment. They also have defects in the maturation of vacuolar marker proteins, and their growth is hypersensitive to high concentrations of CaCl2 or a temperature of 37-degrees-C. There are apparent genetic overlaps among the class I vam mutations and other mutations including cls, end, pep, and vps, which have been shown to be involved in the expression of the vacuolar functions. The class II vam mutants (vam2, vam3, vam4, vam6, and vam7) contain numerous small vesicles stained with the vacuolar histochemical markers and mature forms of the vacuolar proteins and do not show any apparent growth defects in the presence of CaCl2 or at 37-degrees-C.	UNIV TOKYO,FAC SCI,DEPT BIOL,BUNKYO KU,TOKYO 113,JAPAN	University of Tokyo			Ohsumi, Yoshinori/C-6449-2009	Ohsumi, Yoshinori/0000-0003-2384-2166				AMMERER G, 1986, MOL CELL BIOL, V6, P2490, DOI 10.1128/MCB.6.7.2490; ANRAKU Y, 1989, J BIOENERG BIOMEMBR, V21, P589, DOI 10.1007/BF00808115; ANRAKU Y, 1987, BIOENERGETICS STRUCT, P249; ANRAKU Y, 1991, NEW ERA BIOENERGETIC, P133; BANKAITIS VA, 1986, P NATL ACAD SCI USA, V83, P9075, DOI 10.1073/pnas.83.23.9075; BANTA LM, 1988, J CELL BIOL, V107, P1369, DOI 10.1083/jcb.107.4.1369; CURRIER HB, 1956, PROTOPLASMA, V45, P552, DOI 10.1007/BF01252676; KAKINUMA Y, 1981, J BIOL CHEM, V256, P859; KITAMOTO K, 1988, J BACTERIOL, V170, P2683, DOI 10.1128/jb.170.6.2683-2686.1988; KITAMOTO K, 1988, J BACTERIOL, V170, P2687, DOI 10.1128/jb.170.6.2687-2691.1988; KLIONSKY DJ, 1990, MICROBIOL REV, V54, P266, DOI 10.1128/MMBR.54.3.266-292.1990; LENZ AG, 1984, ARCH MICROBIOL, V137, P104, DOI 10.1007/BF00414448; MATILE P, 1978, ANNU REV PLANT PHYS, V29, P193, DOI 10.1146/annurev.pp.29.060178.001205; MOEHLE CM, 1989, J CELL BIOL, V108, P309, DOI 10.1083/jcb.108.2.309; NISHIKAWA S, 1990, J BIOL CHEM, V265, P7440; OHSUMI Y, 1981, J BIOL CHEM, V256, P2079; OHSUMI Y, 1983, J BIOL CHEM, V258, P5614; OHYA Y, 1986, J GEN MICROBIOL, V132, P979; PRESTON RA, 1989, P NATL ACAD SCI USA, V86, P7027, DOI 10.1073/pnas.86.18.7027; PRINGLE JR, 1989, METHOD CELL BIOL, V31, P358; RAYMOND CK, 1992, IN PRESS INT REV CEL; RIEZMAN H, 1985, CELL, V40, P1001, DOI 10.1016/0092-8674(85)90360-5; ROBERTS CJ, 1989, J CELL BIOL, V108, P1363, DOI 10.1083/jcb.108.4.1363; ROBINSON JS, 1988, MOL CELL BIOL, V8, P4936, DOI 10.1128/MCB.8.11.4936; ROMAN H, 1956, COLD SPRING HARB SYM, V21, P175, DOI 10.1101/SQB.1956.021.01.015; ROTHMAN JH, 1986, P NATL ACAD SCI USA, V83, P3248, DOI 10.1073/pnas.83.10.3248; ROTHMAN JH, 1989, EMBO J, V8, P2057, DOI 10.1002/j.1460-2075.1989.tb03614.x; ROTHMAN JH, 1986, CELL, V47, P1041, DOI 10.1016/0092-8674(86)90819-6; SATO T, 1984, J BIOL CHEM, V259, P1505; Sherman F, 1979, METHODS YEAST GENETI; STEVENS T, 1982, CELL, V30, P439, DOI 10.1016/0092-8674(82)90241-0; UCHIDA E, 1985, J BIOL CHEM, V260, P1090; WADA Y, 1987, J BIOL CHEM, V262, P17260; WADA Y, 1990, MOL CELL BIOL, V10, P2214, DOI 10.1128/MCB.10.5.2214; WADA Y, 1992, J BIOL CHEM, V267, P18671; WADA Y, 1992, IN PRESS BIOCH BIOPH; WEISMAN LS, 1988, SCIENCE, V241, P589, DOI 10.1126/science.3041591; WEISMAN LS, 1987, J CELL BIOL, V105, P1539, DOI 10.1083/jcb.105.4.1539; WOOLFORD CA, 1986, MOL CELL BIOL, V6, P2500, DOI 10.1128/MCB.6.7.2500; YOSHIHISA T, 1989, BIOCHEM BIOPH RES CO, V163, P908, DOI 10.1016/0006-291X(89)92308-5; YOSHIHISA T, 1990, J BIOL CHEM, V265, P22418	41	159	161	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1992	267	26					18665	18670						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JN502	1526998				2022-12-25	WOS:A1992JN50200064
J	SUZU, S; OHTSUKI, T; MAKISHIMA, M; YANAI, N; KAWASHIMA, T; NAGATA, N; MOTOYOSHI, K				SUZU, S; OHTSUKI, T; MAKISHIMA, M; YANAI, N; KAWASHIMA, T; NAGATA, N; MOTOYOSHI, K			BIOLOGICAL-ACTIVITY OF A PROTEOGLYCAN FORM OF MACROPHAGE COLONY-STIMULATING FACTOR AND ITS BINDING TO TYPE-V COLLAGEN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST GROWTH-FACTOR; PLASMINOGEN-ACTIVATOR PRODUCTION; HEPARAN-SULFATE; CELL-SURFACE; FACTOR-BETA; RECEPTOR; LIPOPROTEINS; DEGRADATION; EXPRESSION; MECHANISM	Two different types of macrophage colony-stimulating factors (M-CSF) were found, one with an apparent molecular mass of 85 kDa and the other greater than 200 kDa. The high molecular mass M-CSF was identified as a proteoglycan carrying chondroitin sulfate glycosaminoglycan and was designated as the proteoglycan form of M-CSF (PG-M-CSF). In this study, we compared the biological activity of the 85-kDa M-CSF and PG-M-CSF and examined the binding properties of these two M-CSF to certain extracellular matrix proteins, i.e. types I-V collagen and fibronectin, using a modified enzyme-linked immunosorbent assay. PG-M-CSF was capable of supporting the formation of murine macrophage colonies, and pretreatment of PG-M-CSF with chondroitinase AC, which degrades chondroitin sulfate, did not alter its colony-stimulating activity. The specific activity of PG-M-CSF was similar to that of the 85-kDa M-CSF. The 85-kDa M-CSF had no apparent affinity for the extracellular matrix proteins examined, whereas PG-M-CSF had an appreciable binding capacity to type V collagen, but did not bind to types I, II, III, and IV collagen or to fibronectin. Pretreatment of PG-M-CSF with chondroitinase AC completely abolished the binding of the species to type V collagen. Addition of exogeneous chondroitin sulfate inhibited the binding of PG-M-CSF to type V collagen in a dose-dependent manner. These data indicated that the interaction between PG-M-CSF and type V collagen was mediated by the chondroitin sulfate chain of PG-M-CSF. PG-M-CSF bound to type V collagen could stimulate the proliferation of bone marrow macrophages, indicating that the matrix protein-bound PG-M-CSF retained its biological activity. This interaction between PG-M-CSF and type V collagen implies that the role of PG-M-CSF may be distinct from that of 85-kDa M-CSF.	NATL DEF MED COLL,DEPT INTERNAL MED,3-2 NAMIKI,TOKOROZAWA,SAITAMA 359,JAPAN; MORINAGA MILK IND CO LTD,BIOCHEM RES LAB,ZAMA,KANAGAWA 228,JAPAN	National Defense Medical College - Japan; Morinaga Milk Industry Company, Ltd			Ohtsuki, Tomoaki/D-7179-2014; Suzu, Shinya/F-5786-2013	Suzu, Shinya/0000-0003-2531-4770				ANDRES JL, 1989, J CELL BIOL, V109, P3137, DOI 10.1083/jcb.109.6.3137; BASKIN P, 1989, BIOCHEMISTRY-US, V28, P1737; BENTLEY SA, 1990, J CELL PHYSIOL, V145, P53, DOI 10.1002/jcp.1041450109; CLARK SC, 1987, SCIENCE, V236, P1229, DOI 10.1126/science.3296190; CLINTON SK, 1992, AM J PATHOL, V140, P301; FLAUMENHAFT R, 1989, J CELL PHYSIOL, V140, P75, DOI 10.1002/jcp.1041400110; GORDON MY, 1987, NATURE, V326, P403, DOI 10.1038/326403a0; GOSPODAROWICZ D, 1986, J CELL PHYSIOL, V128, P475, DOI 10.1002/jcp.1041280317; HANAMURA T, 1988, BLOOD, V72, P886; ISHIBASHI S, 1990, J BIOL CHEM, V265, P14109; KODA JE, 1985, J BIOL CHEM, V260, P8157; LEBARON RG, 1989, J BIOL CHEM, V264, P7950; MANOS MM, 1988, MOL CELL BIOL, V8, P5035, DOI 10.1128/MCB.8.11.5035; MAYNE R, 1986, ARTERIOSCLEROSIS, V6, P585, DOI 10.1161/01.ATV.6.6.585; MORTON LF, 1982, ATHEROSCLEROSIS, V42, P41, DOI 10.1016/0021-9150(82)90124-1; MOSCATELLI D, 1987, J CELL PHYSIOL, V131, P123, DOI 10.1002/jcp.1041310118; MOTOYOSHI K, 1989, LANCET, V2, P326; OIKE Y, 1980, BIOCHEM J, V191, P193, DOI 10.1042/bj1910193; OOSHIMA A, 1981, SCIENCE, V213, P666, DOI 10.1126/science.7256267; OZAWA K, 1982, EXP HEMATOL, V10, P145; POLLARD JW, 1987, NATURE, V330, P484, DOI 10.1038/330484a0; RETTENMIER CW, 1988, MOL CELL BIOL, V8, P5026, DOI 10.1128/MCB.8.11.5026; ROBERTS R, 1988, NATURE, V332, P376, DOI 10.1038/332376a0; ROSENFELD ME, 1992, AM J PATHOL, V140, P291; RUOSLAHTI E, 1991, CELL, V64, P867, DOI 10.1016/0092-8674(91)90308-L; RUOSLAHTI E, 1989, J BIOL CHEM, V264, P13369; SHIMANO H, 1990, J BIOL CHEM, V265, P12869; SUZU S, 1991, BLOOD, V77, P2160; SUZU S, 1992, J BIOL CHEM, V267, P4345; TUSHINSKI RJ, 1982, CELL, V28, P71, DOI 10.1016/0092-8674(82)90376-2; WONG GG, 1987, SCIENCE, V235, P1504, DOI 10.1126/science.3493529; YAMAGUCHI Y, 1990, NATURE, V346, P281, DOI 10.1038/346281a0; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W	34	51	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1992	267	24					16812	16815						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JL053	1512223				2022-12-25	WOS:A1992JL05300015
J	BRANDT, P; NEVE, RL; KAMMESHEIDT, A; RHOADS, RE; VANAMAN, TC				BRANDT, P; NEVE, RL; KAMMESHEIDT, A; RHOADS, RE; VANAMAN, TC			ANALYSIS OF THE TISSUE-SPECIFIC DISTRIBUTION OF MESSENGER-RNAS ENCODING THE PLASMA-MEMBRANE CALCIUM-PUMPING ATPASES AND CHARACTERIZATION OF AN ALTERNATELY SPLICED FORM OF PMCA4 AT THE CDNA AND GENOMIC LEVELS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA-2+-PUMPING ATPASE; MOLECULAR-CLONING; CA-2+ PUMP; CA-2+-TRANSPORTING ATPASE; ERYTHROCYTE-MEMBRANE; REGULATORY DOMAIN; PROTEIN-KINASE; DNA; PROTEOLYSIS; CALMODULIN	The plasma membrane Ca2+-pumping ATPase (Ca2+-ATPase) mRNAs are encoded on four different genes designated PMCA1-PMCA4. The primary transcripts from some of these genes are known to be alternately spliced in the region encoding the regulatory domains of the enzymes. The known alternately spliced forms of these Ca2+-ATPase mRNAs and a new spliced variant of PMCA4 (PMCA4b), presented here, represent at least nine different mRNAs encoding the Ca2+-ATPases. In this report, the examination of the tissue-specific distribution of these alternately spliced mRNAs using polymerase chain reaction amplification of cDNA coupled with Southern blotting revealed that each spliced variant had a unique tissue distribution. PMCA1b and PMCA4a were present in all tissues examined. PMCA1a, PMCA1b, and PMCA4b were expressed in excitable tissues, whereas PMCA1d was expressed only in muscle tissues. PMCA2 was found in liver, adrenal gland, spinal cord, and brain. PMCA3a was present in spinal cord, and PMCA3b in thymus, adrenal gland, spinal cord, and brain. The mRNA for a new spliced variant of PMCA4 (PMCA4b) was detected in this study. Complementary DNAs for this isoform were isolated and characterized from human and bovine brain. This alternately spliced form of the PMCA4 mRNA contained an exon inserted at the splice junction immediately following the sequence encoding the calmodulin-binding domain. As has also been shown for PMCA1a, this insertion produced a shift in the reading frame at the 3'-end of the PMCA4 mRNA that yielded a sequence encoding a Ca2+-ATPase lacking a large portion of the C-terminal regulatory domain. When the human PMCA4 gene spanning this region of variable exon splicing was sequenced, it confirmed the intron-exon boundaries where alternate splicing occurs to produce PMCA4a and PMCA4b.	UNIV CALIF IRVINE,DEPT PSYCHOBIOL,IRVINE,CA 92717; UNIV KENTUCKY,MED CTR,DEPT BIOCHEM,LEXINGTON,KY 40536	University of California System; University of California Irvine; University of Kentucky					NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS028406, R01NS021868] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM20818] Funding Source: Medline; NINDS NIH HHS [NS21868, NS28406] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BENAIM G, 1984, J BIOL CHEM, V259, P8471; BIGGIN MD, 1983, P NATL ACAD SCI-BIOL, V80, P3963, DOI 10.1073/pnas.80.13.3963; BOND GH, 1973, BIOCHIM BIOPHYS ACTA, V323, P592, DOI 10.1016/0005-2736(73)90167-3; BRANDT P, 1988, P NATL ACAD SCI USA, V85, P2914, DOI 10.1073/pnas.85.9.2914; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; CARAFOLI E, 1982, BIOCHIM BIOPHYS ACTA, V683, P278; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GALO MG, 1981, J BIOL CHEM, V256, P7113; GREEB J, 1989, J BIOL CHEM, V264, P18569; GREENE JM, 1987, CURRENT PROTOCOLS MO; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; JAMES P, 1991, FEBS LETT, V278, P155, DOI 10.1016/0014-5793(91)80106-D; JAMES PH, 1989, BIOCHEMISTRY-US, V28, P4253, DOI 10.1021/bi00436a020; KELLER EB, 1984, P NATL ACAD SCI-BIOL, V81, P7417, DOI 10.1073/pnas.81.23.7417; KESSLER F, 1990, J BIOL CHEM, V265, P16012; KINGSTON RE, 1987, CURRENT PROTOCOLS MO; KOSKKOSICKA D, 1988, J BIOL CHEM, V263, P18184; KUO TH, 1991, J BIOL CHEM, V266, P2520; LAWN RM, 1978, CELL, V15, P1157, DOI 10.1016/0092-8674(78)90043-0; LIN SH, 1982, ENDOCRINOLOGY, V113, P2268; LOTERSZTAJN S, 1985, BIOCHIMIE, V67, P1169, DOI 10.1016/S0300-9084(85)80116-4; MANIATIS T, 1982, MOL CLONING LABORATO, P318; NEVE RL, 1983, GENE, V23, P355, DOI 10.1016/0378-1119(83)90024-0; NEVE RL, 1986, MOL BRAIN RES, V1, P193, DOI 10.1016/0169-328X(86)90011-2; NEVE RL, 1988, NEURON, V1, P669, DOI 10.1016/0896-6273(88)90166-3; NEYSES L, 1985, J BIOL CHEM, V260, P283; PRPIC V, 1984, J BIOL CHEM, V259, P1382; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARKADI B, 1986, J BIOL CHEM, V261, P9552; SEED B, 1983, NUCLEIC ACIDS RES, V11, P2427, DOI 10.1093/nar/11.8.2427; SHULL GE, 1988, J BIOL CHEM, V263, P8646; SMALLWOOD JI, 1988, J BIOL CHEM, V263, P2195; SOLOFF MS, 1982, J BIOL CHEM, V257, P687; STREHLER EE, 1990, J BIOL CHEM, V265, P2835; STREHLER EE, 1989, P NATL ACAD SCI USA, V86, P6908, DOI 10.1073/pnas.86.18.6908; TABOR S, 1987, CURRENT PROTOCOLS MO; VERMA AK, 1988, J BIOL CHEM, V263, P14152; WALTER JRF, 1989, AM J PHYSIOL, V256, P9124; WANG KKW, 1991, J BIOL CHEM, V266, P9078; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; ZURINI M, 1984, J BIOL CHEM, V259, P618	42	111	112	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1992	267	7					4376	4385						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HF642	1531651				2022-12-25	WOS:A1992HF64200021
J	BAI, W; SINGH, B; YANG, Y; RAMAGLI, LS; NASH, M; HERZOG, NK; ARLINGHAUS, RB				BAI, W; SINGH, B; YANG, Y; RAMAGLI, LS; NASH, M; HERZOG, NK; ARLINGHAUS, RB			THE PHYSICAL INTERACTIONS BETWEEN P37ENV-MOS AND TUBULIN STRUCTURES	ONCOGENE			English	Article							PROTEIN-KINASE ACTIVITY; MURINE SARCOMA-VIRUS; V-MOS; SACCHAROMYCES-CEREVISIAE; PROTOONCOGENE PRODUCT; MEIOTIC MATURATION; ONCOGENE PRODUCT; XENOPUS OOCYTES; BETA-TUBULIN; P85GAG-MOS	The c-mos protein has been reported to be complexed with tubulin and to co-localize with microtubules in unfertilized Xenopus eggs as well as in NIH3T3 cells transformed by the Xenopus c-mos gene. We performed experiments to determine whether the viral mos protein, p37v-mos, also associates with tubulin. Both mouse c-mos and v-mos proteins synthesized in vitro co-polymerized with tubulin. Upon incubation at 37-degrees-C, essentially all of the mos protein (both viral and cellular) co-polymerized with tubulin, while more than 50% of the tubulin remained in the depolymerized state. The mos-tubulin interaction was specific, as indicated by the insolubility of the v-mos protein following a second cycle of temperature-dependent depolymerization/polymerization. Beta-tubulin was shown to co-precipitate with p37v-mos and to be phosphorylated by the mos kinase in vitro. Although both v-mos and c-mos proteins co-polymerize with tubulin, p37v-mos behaved differently from p39c-mos on gel filtration columns under conditions that favor disassembly of microtubules. Like Xenopus c-mos, the bulk of the mouse c-mos protein synthesized in vitro appeared in structures that fractionate at about 500 kDa. In contrast to c-mos, the majority of the v-mos protein, either isolated from stably transformed NIH3T3 cells or synthesized in vitro, eluted in the 100 kDa fraction, cofractionating with tubulin dimers. Therefore, the v-mos protein appears to have a higher affinity for unpolymerized tubulin than c-mos, under conditions that favor disassembly of microtubules.	UNIV TEXAS, MD ANDERSON CANCER CTR,DEPT MOLEC PATHOL,BOX 89, 1515 HOLCOMBE BLVD, HOUSTON, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center			Bai, Wenlong/A-8977-2013	Bai, Wenlong/0000-0002-9536-0556	NATIONAL CANCER INSTITUTE [R01CA045125, P30CA016672] Funding Source: NIH RePORTER; NCI NIH HHS [CA45125, CA16672] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAI WL, 1991, ONCOGENE, V6, P1715; BALL JK, 1973, VIROLOGY, V56, P268, DOI 10.1016/0042-6822(73)90305-X; BLAIR DG, 1981, SCIENCE, V212, P941, DOI 10.1126/science.7233190; BURKE D, 1989, MOL CELL BIOL, V9, P1049, DOI 10.1128/MCB.9.3.1049; FREEMAN RS, 1990, J CELL BIOL, V111, P533, DOI 10.1083/jcb.111.2.533; FREEMAN RS, 1989, P NATL ACAD SCI USA, V86, P5805, DOI 10.1073/pnas.86.15.5805; FREEMAN RS, 1991, MOL CELL BIOL, V11, P1713, DOI 10.1128/MCB.11.3.1713; FRIEL J, 1987, J VIROL, V61, P889, DOI 10.1128/JVI.61.3.889-897.1987; GALLICK GE, 1985, J GEN VIROL, V66, P945, DOI 10.1099/0022-1317-66-5-945; HERZOG NK, 1988, ONCOGENE, V3, P225; HERZOG NK, 1990, J VIROL, V64, P3093, DOI 10.1128/JVI.64.6.3093-3096.1990; IZUMI T, 1991, MOL CELL BIOL, V11, P3860, DOI 10.1128/MCB.11.8.3860; KATZ W, 1990, MOL CELL BIOL, V10, P5286, DOI 10.1128/MCB.10.10.5286; KLOETZER WS, 1983, P NATL ACAD SCI-BIOL, V80, P412, DOI 10.1073/pnas.80.2.412; KROHNE G, 1982, J CELL BIOL, V94, P749, DOI 10.1083/jcb.94.3.749; LIU JX, 1990, ONCOGENE, V5, P171; MAXWELL SA, 1985, J GEN VIROL, V66, P2135, DOI 10.1099/0022-1317-66-10-2135; MAXWELL SA, 1991, CELL GROWTH DIFFER, V2, P115; MUTTER GL, 1987, P NATL ACAD SCI USA, V84, P5301, DOI 10.1073/pnas.84.15.5301; OKEEFE SJ, 1989, P NATL ACAD SCI USA, V86, P7038, DOI 10.1073/pnas.86.18.7038; OSKARSSON M, 1980, SCIENCE, V207, P1222, DOI 10.1126/science.6243788; PAULES RS, 1989, P NATL ACAD SCI USA, V86, P5395, DOI 10.1073/pnas.86.14.5395; PROPST F, 1987, MOL CELL BIOL, V7, P1629, DOI 10.1128/MCB.7.5.1629; ROY LM, 1990, CELL, V61, P825, DOI 10.1016/0092-8674(90)90192-H; SAGATA N, 1989, NATURE, V342, P512, DOI 10.1038/342512a0; SAGATA N, 1989, SCIENCE, V245, P643, DOI 10.1126/science.2474853; SAGATA N, 1988, NATURE, V335, P519, DOI 10.1038/335519a0; SINGH B, 1988, ONCOGENE, V3, P79; SINGH B, 1987, J VIROL, V61, P3625, DOI 10.1128/JVI.61.11.3625-3629.1987; SINGH B, 1986, J VIROL, V60, P1148, DOI 10.1128/JVI.60.3.1148-1152.1986; SINGH B, 1988, VIROLOGY, V164, P114, DOI 10.1016/0042-6822(88)90626-5; SOLOMON F, 1986, METHOD ENZYMOL, V134, P139; VALE RD, 1991, CELL, V64, P827, DOI 10.1016/0092-8674(91)90511-V; WEINSTEIN B, 1990, MOL CELL BIOL, V10, P5295, DOI 10.1128/MCB.10.10.5295; WESTENDORF JM, 1989, J CELL BIOL, V108, P1431, DOI 10.1083/jcb.108.4.1431; WONG PKY, 1978, J VIROL, V25, P187, DOI 10.1128/JVI.25.1.187-192.1978; YEN TJ, 1988, NATURE, V334, P580, DOI 10.1038/334580a0; YEW N, 1991, MOL CELL BIOL, V11, P604, DOI 10.1128/MCB.11.2.604; ZHAO X, 1990, ONCOGENE, V5, P1727; ZHOU R, 1991, CELL GROWTH DIFFER, V2, P257; ZHOU RP, 1991, SCIENCE, V251, P671, DOI 10.1126/science.1825142	41	19	19	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	1992	7	3					493	500						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HK005	1532247				2022-12-25	WOS:A1992HK00500014
J	HABERLAND, ME; FLESS, GM; SCANU, AM; FOGELMAN, AM				HABERLAND, ME; FLESS, GM; SCANU, AM; FOGELMAN, AM			MALONDIALDEHYDE MODIFICATION OF LIPOPROTEIN(A) PRODUCES AVID UPTAKE BY HUMAN MONOCYTE-MACROPHAGES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; MOUSE PERITONEAL-MACROPHAGES; HUMAN-PLASMA LIPOPROTEIN; APOLIPOPROTEIN-B; SCAVENGER RECEPTOR; LP(A) LIPOPROTEIN; HUMAN-FIBROBLASTS; BINDING-SITE; PLASMINOGEN; APOPROTEINS	Increased plasma levels of the apoB-100-containing lipoprotein(a) (Lp(a)) are associated with an increased risk for atherosclerosis and myocardial infarction, but the mechanisms by which lipoprotein(a) may accelerate these processes remain obscure. In this study we have investigated the impact of the association of apoprotein(a) with the low density lipoprotein (LDL)-like Lp(a) particle upon specificity of receptor recognition after lipoprotein modification by malondialdehyde or transition metal-induced oxidation. We have determined that radioiodination labels both apoprotein components of Lp(a), that malondialdehyde modification produces an anionic lipoprotein comparable to native Lp(a) in Stokes' radius, and that N,N'-disubstituted 1-amino-3-iminopropene derivatives preferentially cross-link apoprotein(a) to apoB-100 protein. Like LDL, native Lp(a) is recognized in human monocyte-macrophages by the LDL receptor. Like LDL, progressive modification of Lp(a) by malondialdehyde abolishes lipoprotein recognition by the LDL receptor and produces uptake and hydrolysis by the scavenger receptor of human monocyte-macrophages. We propose that intimal retention of Lp(a) by extracellular components of the atherosclerotic reaction places the lipoprotein in a microenvironment favoring subsequent peroxidative modification. The chronic production of lipid peroxide-modified Lp(a) together with unmitigated cellular clearance by scavenger receptors may contribute to the accumulation of lipoprotein-derived lipid in macrophage-derived foam cells of the atherosclerotic reaction.	UNIV CHICAGO, PRITZKER SCH MED, DEPT MED, CHICAGO, IL 60637 USA; UNIV CHICAGO, PRITZKER SCH MED, DEPT BIOCHEM & MOLEC BIOL, CHICAGO, IL 60637 USA	University of Chicago; University of Chicago	HABERLAND, ME (corresponding author), UNIV CALIF LOS ANGELES, SCH MED, DEPT MED, DIV CARDIOL, CHS 47-123, LOS ANGELES, CA 90024 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL018577, P01HL030568] Funding Source: NIH RePORTER; NCRR NIH HHS [RR865] Funding Source: Medline; NHLBI NIH HHS [HL 30568, HL-18577] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARAI H, 1989, BIOCHEM BIOPH RES CO, V159, P1375, DOI 10.1016/0006-291X(89)92262-6; ARMSTRONG VW, 1985, J LIPID RES, V26, P1314; BIHARIVARGA M, 1988, ARTERIOSCLEROSIS, V8, P851, DOI 10.1161/01.ATV.8.6.851; BILHEIMER DW, 1972, BIOCHIM BIOPHYS ACTA, V260, P212, DOI 10.1016/0005-2760(72)90034-3; CAMPOS E, 1986, ARCH BIOCHEM BIOPHYS, V249, P455, DOI 10.1016/0003-9861(86)90022-6; COLEMAN RD, 1990, BIOCHIM BIOPHYS ACTA, V1037, P129, DOI 10.1016/0167-4838(90)90111-R; CUSHING GL, 1989, ARTERIOSCLEROSIS, V9, P593, DOI 10.1161/01.ATV.9.5.593; DAHLEN G, 1978, CLIN GENET, V14, P115; EATON DL, 1987, P NATL ACAD SCI USA, V84, P3224, DOI 10.1073/pnas.84.10.3224; ESTERBAUER H, 1989, FREE RADICAL RES COM, V6, P67, DOI 10.3109/10715768909073429; FLESS GM, 1989, J LIPID RES, V30, P651; FLESS GM, 1984, J BIOL CHEM, V259, P1470; FLESS GM, 1986, J BIOL CHEM, V261, P8712; FLOREN CH, 1981, BIOCHEM BIOPH RES CO, V102, P636, DOI 10.1016/S0006-291X(81)80179-9; FOGELMAN AM, 1988, J LIPID RES, V29, P1243; FOGELMAN AM, 1981, J LIPID RES, V22, P1131; FOGELMAN AM, 1980, P NATL ACAD SCI-BIOL, V77, P2214, DOI 10.1073/pnas.77.4.2214; GAUBATZ JW, 1987, J LIPID RES, V28, P69; GAUBATZ JW, 1983, J BIOL CHEM, V258, P4582; Girotti A W, 1985, J Free Radic Biol Med, V1, P87; GOLDSTEIN JL, 1974, J BIOL CHEM, V249, P5153; GOLDSTEIN JL, 1979, P NATL ACAD SCI USA, V76, P333, DOI 10.1073/pnas.76.1.333; GONZALEZGRONOW M, 1989, BIOCHEMISTRY-US, V28, P2374, DOI 10.1021/bi00432a005; HABERLAND ME, 1984, J BIOL CHEM, V259, P1305; HABERLAND ME, 1988, SCIENCE, V241, P215, DOI 10.1126/science.2455346; HABERLAND ME, 1982, P NATL ACAD SCI USA, V79, P922; HAJJAR KA, 1989, NATURE, V339, P303, DOI 10.1038/339303a0; HARPEL PC, 1989, P NATL ACAD SCI USA, V86, P3847, DOI 10.1073/pnas.86.10.3847; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; HOCHSCHWENDER SM, 1983, ARCH BIOCHEM BIOPHYS, V223, P58, DOI 10.1016/0003-9861(83)90571-4; HOFMANN SL, 1990, J CLIN INVEST, V85, P1542, DOI 10.1172/JCI114602; KNOTT TJ, 1986, NATURE, V323, P734, DOI 10.1038/323734a0; KODAMA T, 1990, NATURE, V343, P531, DOI 10.1038/343531a0; KREMPLER F, 1984, J LIPID RES, V25, P283; LACKNER C, 1991, J CLIN INVEST, V87, P2153, DOI 10.1172/JCI115248; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOSCALZO J, 1990, ARTERIOSCLEROSIS, V10, P240, DOI 10.1161/01.ATV.10.2.240; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAHLEY RW, 1979, J CLIN INVEST, V64, P743, DOI 10.1172/JCI109518; MCFARLANE AS, 1958, NATURE, V182, P53, DOI 10.1038/182053a0; MCLEAN JW, 1987, NATURE, V330, P132, DOI 10.1038/330132a0; MILES LA, 1989, NATURE, V339, P301, DOI 10.1038/339301a0; NARUSZEWICZ M, 1990, ARTERIOSCLEROSIS, V10, pA808; NOBLE RP, 1968, J LIPID RES, V9, P693; PARTHASARATHY S, 1985, P NATL ACAD SCI USA, V82, P3000, DOI 10.1073/pnas.82.9.3000; PEPIN JM, 1991, J LIPID RES, V32, P317; RATH M, 1989, ARTERIOSCLEROSIS, V9, P579, DOI 10.1161/01.ATV.9.5.579; SALONEN EM, 1989, EMBO J, V8, P4035, DOI 10.1002/j.1460-2075.1989.tb08586.x; SATTLER W, 1991, BIOCHIM BIOPHYS ACTA, V1081, P65, DOI 10.1016/0005-2760(91)90251-C; SCANU AM, 1990, J CLIN INVEST, V85, P1709, DOI 10.1172/JCI114625; SEVANIAN A, 1985, ANNU REV NUTR, V5, P365, DOI 10.1146/annurev.nu.05.070185.002053; SHECHTER I, 1981, J LIPID RES, V22, P63; SNYDER ML, 1992, J BIOL CHEM, V267, P339; SPARROW CP, 1989, J BIOL CHEM, V264, P2599; STEINBRECHER UP, 1987, ARTERIOSCLEROSIS, V7, P135, DOI 10.1161/01.ATV.7.2.135; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRIEU VN, 1990, BIOCHEMISTRY-US, V29, P5919, DOI 10.1021/bi00477a006; TRIEU VN, 1991, J BIOL CHEM, V266, P5480; UTERMANN G, 1989, SCIENCE, V246, P904, DOI 10.1126/science.2530631; YANG CY, 1990, P NATL ACAD SCI USA, V87, P5523, DOI 10.1073/pnas.87.14.5523; YE SQ, 1988, J BIOL CHEM, V263, P6337; ZIONCHECK TF, 1991, J CLIN INVEST, V87, P767, DOI 10.1172/JCI115079	62	137	139	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	1992	267	6					4143	4151						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HE607	1531481				2022-12-25	WOS:A1992HE60700085
J	NEGELE, JC; DOTSON, DG; LIU, W; SWEENEY, HL; PUTKEY, JA				NEGELE, JC; DOTSON, DG; LIU, W; SWEENEY, HL; PUTKEY, JA			MUTATION OF THE HIGH-AFFINITY CALCIUM-BINDING SITES IN CARDIAC TROPONIN-C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; RABBIT SKELETAL-MUSCLE; 2 MAJOR ISOFORMS; CONFORMATIONAL-CHANGES; ATPASE ACTIVITY; CALMODULIN; MYOFIBRILS; CONTRACTION; RESOLUTION; SUBSTITUTION	Fast skeletal and cardiac troponin C (TnC) contain two high affinity Ca2+/Mg2+ binding sites within the C-terminal domain that are thought to be important for association of TnC with the troponin complex of the thin filament. To test directly the function of these high affinity sites in cardiac TnC they were systematically altered by mutagenesis to generate proteins with a single inactive site III or IV (CBM-III and CBM-IV, respectively), or with both sites III and IV inactive (CBM-III-IV). Equilibrium dialysis indicated that the mutated sites did not bind Ca2+ at pCa 4. Both CBM-III and CBM-IV were similar to the wild type protein in their ability to regulate Ca2+-dependent contraction in slow skeletal muscle fibers, and Ca2+-dependent ATPase activity in fast skeletal and cardiac muscle myofibrils. The mutant CBM-III-IV is capable of regulating contraction in permeabilized slow muscle fibers but only if the fibers are maintained in a contraction solution containing a high concentration of the mutant protein. CBM-III-IV also regulates myofibril ATPase activity in fast skeletal and cardiac myofibrils but only at concentrations 10-100-fold greater than the normal protein. The pCa50 and Hill coefficient values for Ca2+-dependent activation of fast skeletal muscle myofibril ATPase activity by the normal protein and all three mutants are essentially the same. Competition between active and inactive forms of cardiac and slow TnC in a functional assay demonstrates that mutation of both sites III and IV greatly reduces the affinity of cardiac and slow TnC for its functionally relevant binding site in the myofibrils. The data indicate that although neither high affinity site is absolutely essential for regulation of muscle contraction in vitro, at least one active C-terminal site is required for tight association of cardiac troponin C with myofibrils. This requirement can be satisfied by either site III or IV.	UNIV TEXAS,HLTH SCI CTR,SCH MED,DEPT BIOCHEM & MOLEC BIOL,POB 20708,6431 FANNIN ST,HOUSTON,TX 77225; UNIV PENN,SCH MED,DEPT PHYSIOL,PHILADELPHIA,PA 19104	Baylor College of Medicine; University of Texas System; University of Texas Health Science Center Houston; University of Pennsylvania			Sweeney, H Lee/F-1862-2010		NIAMS NIH HHS [AR-39210] Funding Source: Medline	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BABU A, 1987, J BIOL CHEM, V262, P5815; BABU YS, 1985, NATURE, V315, P37, DOI 10.1038/315037a0; BRANDT PW, 1984, J MOL BIOL, V180, P379, DOI 10.1016/S0022-2836(84)80010-8; BRITO RMM, 1991, BIOCHEMISTRY-US, V30, P10236, DOI 10.1021/bi00106a023; COLLINS JH, 1991, J MUSCLE RES CELL M, V12, P3, DOI 10.1007/BF01781170; COLLINS JH, 1991, BIOCHEMISTRY-US, V30, P702, DOI 10.1021/bi00217a017; COLLINS JH, 1977, J BIOL CHEM, V252, P6356; COX JA, 1981, BIOCHEM J, V195, P205, DOI 10.1042/bj1950205; EASTWOOD AB, 1979, TISSUE CELL, V11, P553, DOI 10.1016/0040-8166(79)90062-4; Fiske CH, 1925, J BIOL CHEM, V66, P375; FUJISAWA T, 1989, J BIOCHEM-TOKYO, V105, P377, DOI 10.1093/oxfordjournals.jbchem.a122672; HERZBERG O, 1985, NATURE, V313, P653, DOI 10.1038/313653a0; HINCKE MT, 1978, CAN J BIOCHEM CELL B, V56, P384, DOI 10.1139/o78-061; JOHNSON JD, 1979, J BIOL CHEM, V254, P3497; KERRICK WGL, 1980, PFLUG ARCH EUR J PHY, V386, P207, DOI 10.1007/BF00587470; KOBAYASHI T, 1989, J BIOL CHEM, V264, P18247; KRETSINGER RH, 1973, J BIOL CHEM, V248, P3313; KRUDY GA, 1992, IN PRESS BIOCHEMISTR; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LEAVIS PC, 1978, ARCH BIOCHEM BIOPHYS, V186, P411, DOI 10.1016/0003-9861(78)90453-8; MORIMOTO S, 1988, J BIOCHEM-TOKYO, V104, P149, DOI 10.1093/oxfordjournals.jbchem.a122412; MORIMOTO S, 1987, J BIOCHEM-TOKYO, V101, P291, DOI 10.1093/oxfordjournals.jbchem.a121913; MOSS RL, 1985, J GEN PHYSIOL, V86, P585, DOI 10.1085/jgp.86.4.585; NAGY B, 1979, J BIOL CHEM, V254, P2732; POTTER JD, 1982, METHOD ENZYMOL, V85, P241; POTTER JD, 1975, J BIOL CHEM, V250, P4628; PUTKEY JA, 1989, J BIOL CHEM, V264, P12370; PUTKEY JA, 1991, J BIOL CHEM, V266, P14881; ROBERTSON SP, 1981, BIOPHYS J, V34, P559, DOI 10.1016/S0006-3495(81)84868-0; SHENG ZL, 1990, J BIOL CHEM, V265, P21554; SOLARO RJ, 1971, BIOCHIM BIOPHYS ACTA, V245, P259, DOI 10.1016/0005-2728(71)90033-8; STRYNADKA NCJ, 1989, ANNU REV BIOCHEM, V58, P951, DOI 10.1146/annurev.bi.58.070189.004511; SUNDARALINGAM M, 1985, SCIENCE, V227, P945, DOI 10.1126/science.3969570; SUTOH K, 1980, BIOCHEMISTRY-US, V19, P1977, DOI 10.1021/bi00550a038; SWEENEY HL, 1990, P NATL ACAD SCI USA, V87, P9538, DOI 10.1073/pnas.87.24.9538; TAKAGI T, 1983, J BIOCHEM-TOKYO, V94, P1753, DOI 10.1093/oxfordjournals.jbchem.a134526; TSUDA S, 1990, BIOCHEMISTRY-US, V29, P4951, DOI 10.1021/bi00472a027; VANEERD JP, 1972, BIOCHEM BIOPH RES CO, V47, P859, DOI 10.1016/0006-291X(72)90572-4; VANEERD JP, 1976, BIOCHEMISTRY-US, V15, P1171, DOI 10.1021/bi00650a033; VANEERD JP, 1975, BIOCHEM BIOPH RES CO, V64, P122, DOI 10.1016/0006-291X(75)90227-2; VANEYK JE, 1988, J BIOL CHEM, V263, P1726; WNUK W, 1989, J BIOL CHEM, V264, P18240; ZOT HG, 1982, J BIOL CHEM, V257, P7678	43	51	51	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 15	1992	267	2					825	831						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY960	1530938				2022-12-25	WOS:A1992GY96000025
J	QIN, W; SMITH, JB; SMITH, DL				QIN, W; SMITH, JB; SMITH, DL			RATES OF CARBAMYLATION OF SPECIFIC LYSYL RESIDUES IN BOVINE ALPHA-CRYSTALLINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							QUATERNARY STRUCTURE; MASS-SPECTROMETRY; TERMINAL REGION; LENS PROTEINS; CYANATE; CATARACT; PHOSPHORYLATION; PEPTIDES; INVITRO; MODEL	Previous investigations indicate that some forms of cataract may be due to the reactions of isocyanate with lens proteins. The present investigation was directed toward identifying the products of these reactions and determining rate constants for their formation. Bovine alpha-crystallins were incubated with isocyanate and separated into alphaA- and alphaB-crystallins by reversed-phase HPLC (high-performance liquid chromatography). Products of the reaction of isocyanate with alpha-crystallins were analyzed by mass spectrometry and isoelectric focusing. Proteolytic digests of carbamylated alphaA were analyzed by HPLC and fast atom bombardment mass spectrometry to determine the extent of reaction of each of the 7 lysyl residues present in alphaA. These results demonstrate that incubation of alpha-crystallins in 0.1 M KNCO leads to partial carbamylation of all 7 lysines of alphaA-crystallin. The extent of modification after 24 h of incubation varied from 7% at Lys 88 to 61% at Lys 11. Rate constants for the reaction of specific lysyl residues with isocyanate ranged from 5 to 54 x 10(-2) m-1 h-1. The distribution of reaction products, as determined by isoelectric focusing, indicates that the physiologically relevant initial stages of carbamylation of the 7 lysyl residues of alphaA proceed in a noncooperative manner.	PURDUE UNIV, DEPT MED CHEM & PHARMACOGNOSY, W LAFAYETTE, IN 47907 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus	SMITH, JB (corresponding author), PURDUE UNIV, DEPT MED CHEM & PHARMACOGNOSY, W LAFAYETTE, IN 47907 USA.				NATIONAL EYE INSTITUTE [R01EY007609] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI027713] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040384] Funding Source: NIH RePORTER; NEI NIH HHS [EY RO1 07609] Funding Source: Medline; NIAID NIH HHS [AI P30 27713] Funding Source: Medline; NIGMS NIH HHS [GM RO1 40384] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BESWICK HT, 1984, BIOCHEM J, V223, P221, DOI 10.1042/bj2230221; CAPRIOLI RM, 1986, ANAL BIOCHEM, V154, P596, DOI 10.1016/0003-2697(86)90035-7; CERAMI A, 1972, NEW ENGL J MED, V287, P807, DOI 10.1056/NEJM197210192871606; CROMPTON M, 1985, EXP EYE RES, V40, P297, DOI 10.1016/0014-4835(85)90014-4; DIRNHUBER P, 1948, BIOCHEM J, V42, P628, DOI 10.1042/bj0420628; GARCIACASTINEIRAS S, 1983, INVEST OPHTH VIS SCI, V24, P1181; HABEEB AFS, 1966, ANAL BIOCHEM, V14, P328, DOI 10.1016/0003-2697(66)90275-2; HARDING JJ, 1980, EXP EYE RES, V31, P567, DOI 10.1016/S0014-4835(80)80015-7; IFEANYI F, 1991, EXP EYE RES, V53, P305, DOI 10.1016/0014-4835(91)90234-6; KEMP JA, 1956, J CHEM SOC, V191, P900; MAITI M, 1988, FEBS LETT, V236, P109, DOI 10.1016/0014-5793(88)80295-3; NICHOLSON DH, 1976, ARCH OPHTHALMOL-CHIC, V94, P927; NIGEN AM, 1976, J BIOL CHEM, V251, P7638; SCHURTENBERGER P, 1991, BIOPOLYMERS, V31, P1229, DOI 10.1002/bip.360311011; SIEZEN RJ, 1979, EUR J BIOCHEM, V96, P431, DOI 10.1111/j.1432-1033.1979.tb13055.x; SLEBE JC, 1976, J BIOL CHEM, V251, P5663; SMITH JB, 1991, ANAL BIOCHEM, V193, P118, DOI 10.1016/0003-2697(91)90050-4; SMITH JB, 1992, PROTEIN SCI, V1, P601, DOI 10.1002/pro.5560010506; SPECTOR A, 1985, P NATL ACAD SCI USA, V82, P4712, DOI 10.1073/pnas.82.14.4712; STARK GR, 1960, J BIOL CHEM, V235, P3177; STARK GR, 1965, BIOCHEMISTRY-US, V4, P1030, DOI 10.1021/bi00882a008; TAKEMOTO L, 1989, BIOCHIM BIOPHYS ACTA, V995, P259, DOI 10.1016/0167-4838(89)90044-7; TAKEMOTO LJ, 1990, EXP EYE RES, V50, P695, DOI 10.1016/0014-4835(90)90116-C; TARDIEU A, 1986, J MOL BIOL, V192, P711, DOI 10.1016/0022-2836(86)90023-9; VANDENOETELAAR PJM, 1990, BIOCHEMISTRY-US, V29, P3488, DOI 10.1021/bi00466a010; VANDENOETELAAR PJM, 1985, J BIOL CHEM, V260, P4030; VANHEYNINGEN R, 1986, LANCET, V1, P1111; VOORTER CEM, 1986, EUR J BIOCHEM, V160, P203; WALSH MT, 1991, J BIOL CHEM, V266, P20079; WEN Q, 1992, EXP EYE RES, V54, P23, DOI 10.1016/0014-4835(92)90065-Z; YANG CC, 1981, TOXICON, V19, P783, DOI 10.1016/0041-0101(81)90075-1	31	28	30	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 25	1992	267	36					26128	26133						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KD073	1464624				2022-12-25	WOS:A1992KD07300081
J	SPARKS, DL; LUNDKATZ, S; PHILLIPS, MC				SPARKS, DL; LUNDKATZ, S; PHILLIPS, MC			THE CHARGE AND STRUCTURAL STABILITY OF APOLIPOPROTEIN-A-I IN DISCOIDAL AND SPHERICAL RECOMBINANT HIGH-DENSITY-LIPOPROTEIN PARTICLES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUANIDINE-HYDROCHLORIDE DENATURATION; CELL-DERIVED CHOLESTEROL; THERMODYNAMIC PROPERTIES; CIRCULAR-DICHROISM; PLASMA-LIPOPROTEINS; SECONDARY STRUCTURE; PROTEIN; COMPLEXES; METABOLISM; LECITHIN	The details of how high density lipoprotein (HDL) microstructure affects the conformation and net charge of apolipoprotein (apo) A-I in various classes of HDL particles have been investigated in homogeneous recombinant HDL (rHDL) particles containing apoA-I, palmitoyl-oleoyl phosphatidylcholine (POPC) and cholesteryl oleate. Isothermal denaturation with guanidine HCl was used to monitor alpha-helix structural stability, whereas electrokinetic analyses and circular dichroism were used to determine particle charge and apoA-1 secondary structure, respectively. Electrokinetic analyses show that at pH 8.6 apoA-I has a net negative charge on discoidal (POPC . apoA-I) particles (-5.2 electronic units/mol of apoA-I) which is significantly greater than that of apoA-I either free in solution or on spherical (POPC . cholesteryl oleate . apoA-I) rHDL (almost-equal-to -3.5 electronic units). Raising the POPC content (32-128 mol/mol of apoA-I) of discoidal particles 1) increases the particle major diameter from 9.3 to 12.1 nm, 2) increases the alpha-helix content from 62 to 77%, and 3) stabilizes the helical segments by increasing the free energy of unfolding (DELTAG(D)-degrees) from 1.4 to 3.0 kcal/mol of apoA-I. Raising the POPC conTent (28-58 mol/mol of apoA-I) of spherical particles I) increases the particle diameter from 7.4 to 12.6 nm, 2) increases the percent alpha-helix from 62 to 69%, and 3) has no significant effect on DELTAG(D)-degrees (2.2 kcal/mol of apoA-I). This study shows that different HDL subspecies maintain particular apoA-I conformations that confer unique charge and structural characteristics on the particles. It is likely that the charge and conformation of apoA-I are critical molecular properties that modulate the metabolism of HDL particles and influence their role in cholesterol transport.			SPARKS, DL (corresponding author), MED COLL PENN,DEPT BIOCHEM,PHILADELPHIA,PA 19129, USA.			Phillips, Michael/0000-0002-7147-8007	NHLBI NIH HHS [HL22633] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL022633] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABRAMSON HA, 1942, ELECTROPHORESIS PROT, P105; ANDREWS AL, 1976, EUR J BIOCHEM, V64, P549, DOI 10.1111/j.1432-1033.1976.tb10335.x; ASSMANN G, 1974, P NATL ACAD SCI USA, V71, P989, DOI 10.1073/pnas.71.3.989; AUNE KC, 1969, BIOCHEMISTRY-US, V8, P4586, DOI 10.1021/bi00839a053; BAUMSTARK M, 1983, BIOCHIM BIOPHYS ACTA, V751, P108, DOI 10.1016/0005-2760(83)90262-X; BONOMO EA, 1988, J LIPID RES, V29, P380; BRASSEUR R, 1990, BIOCHIM BIOPHYS ACTA, V1043, P245, DOI 10.1016/0005-2760(90)90023-Q; BRINTON EA, 1991, J CLIN INVEST, V87, P536, DOI 10.1172/JCI115028; CASTRO GR, 1988, BIOCHEMISTRY-US, V27, P25, DOI 10.1021/bi00401a005; CHEN GC, 1986, METHOD ENZYMOL, V128, P519; COMPTON LA, 1986, ANAL BIOCHEM, V155, P155, DOI 10.1016/0003-2697(86)90241-1; EDELSTEIN C, 1980, J BIOL CHEM, V255, P5747; EISENBERG S, 1984, J LIPID RES, V25, P1017; FRANCONE OL, 1989, J BIOL CHEM, V264, P7066; GOLDBERG IJ, 1990, J CLIN INVEST, V86, P463, DOI 10.1172/JCI114732; GWYNNE J, 1974, J BIOL CHEM, V250, P2269; Henry DC, 1931, P R SOC LOND A-CONTA, V133, P106, DOI 10.1098/rspa.1931.0133; JOHNSON WC, 1990, PROTEINS, V7, P205, DOI 10.1002/prot.340070302; JONAS A, 1990, J BIOL CHEM, V265, P22123; JONAS A, 1989, J BIOL CHEM, V264, P4818; JONAS A, 1985, BIOCHEMISTRY-US, V24, P3508, DOI 10.1021/bi00335a018; KIELLEY WW, 1960, BIOCHIM BIOPHYS ACTA, V41, P401; LE NA, 1988, METABOLISM, V37, P614, DOI 10.1016/0026-0495(88)90077-7; LUX SE, 1972, J BIOL CHEM, V247, P2598; MARCEL YL, 1991, J BIOL CHEM, V266, P3644; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; MILLER GJ, 1975, LANCET, V1, P16; PACE CN, 1979, BIOCHEMISTRY-US, V18, P288, DOI 10.1021/bi00569a008; PACE CN, 1986, METHOD ENZYMOL, V131, P267; Pace CN, 1989, PROTEIN STRUCTURE PR, P311; PATTNAIK NM, 1979, J BIOL CHEM, V254, P2782; PITTMAN RC, 1987, J BIOL CHEM, V262, P2435; Prevelige P., 1989, PREDICTION PROTEIN S, P391; PRIVALOV PL, 1974, J MOL BIOL, V86, P665, DOI 10.1016/0022-2836(74)90188-0; REIJNGOUD DJ, 1982, BIOCHEMISTRY-US, V21, P2969, DOI 10.1021/bi00541a026; REIJNGOUD DJ, 1984, BIOCHEMISTRY-US, V23, P726, DOI 10.1021/bi00299a022; REYNOLDS JA, 1976, J BIOL CHEM, V251, P6013; SAKU K, 1985, METABOLISM, V34, P754, DOI 10.1016/0026-0495(85)90027-7; SEGREST JP, 1992, J LIPID RES, V33, P141; SOKOLOFF L, 1974, P SOC EXP BIOL MED, V146, P1166; SPARKS DL, 1992, J LIPID RES, V33, P123; SPARKS DL, 1992, J BIOL CHEM, V267, P25830; SWANEY JB, 1986, METHOD ENZYMOL, V128, P613; TALL AR, 1976, J BIOL CHEM, V251, P3749; TALL AR, 1977, J BIOL CHEM, V252, P4701; TANFORD C, 1969, ADV PROTEIN CHEM, V7, P69; WALD JH, 1990, J BIOL CHEM, V265, P20037; WALD JH, 1990, J BIOL CHEM, V265, P20044; WETTERAU JR, 1983, J BIOL CHEM, V258, P2637	49	164	170	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1992	267	36					25839	25847						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KD073	1464598				2022-12-25	WOS:A1992KD07300041
J	LUND, E; BREUER, O; BJORKHEM, I				LUND, E; BREUER, O; BJORKHEM, I			EVIDENCE THAT 24-HYDROXYLATION AND 27-HYDROXYLATION ARE NOT INVOLVED IN THE CHOLESTEROL-INDUCED DOWN-REGULATION OF HYDROXYMETHYLGLUTARYL-COA REDUCTASE IN MOUSE-LIVER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXYSTEROL-BINDING-PROTEIN; RAT-LIVER; EXPRESSION; ENZYME; SERUM; ACID; 26-HYDROXYCHOLESTEROL; 7-ALPHA-HYDROXYLASE; 26-HYDROXYLATION; CLONING	Several authors have suggested that 27-hydroxycholesterol may be an important physiological regulator of cholesterol homeostasis. In the present study we investigated the possibility that 24- or 27-hydroxylation of cholesterol is of importance for the down-regulation of hydroxymethylglutaryl (HMG)-CoA reductase in mouse liver induced by dietary cholesterol. Using an accurate method based on isotope dilution-mass spectrometry with deuterated internal standards, we were able to detect significant levels of both 24- and 27-hydroxycholesterol in liver homogenates from normal mice. Feeding cholesterol, 2% for 4 days, increased the levels by 80 and 30%, respectively. No significant hepatic levels of 25-hydroxycholesterol could be demonstrated in untreated mice, and the level of this steroid in cholesterol-treated mice was just above the detection limit. Mouse liver mitochondria were able to catalyze 24- as well as 27-hydroxylation, but not 25-hydroxylation of cholesterol. There was no such conversion in liver microsomes. When using 24-H-2(2)- or 23,23,24,24,25-H-2(5)-labeled cholesterol as substrate a kinetic isotope effect of about 4.5 was observed for the mitochondrial 24-hydroxylation. When using 26,26,26,27,27,27-H-2(6)-labeled cholesterol as substrate a kinetic isotope effect of about 2.5 was observed for the 27-hydroxylation. Use of those deuterium-labeled cholesterol species thus allowed a specific suppression of the rate of 24- and 27-hydroxylation. Feeding mice with 0.05% unlabeled pure cholesterol in the diet for 24 h inhibited the hepatic HMG-CoA reductase activity by about 50%. The same degree of suppression was obtained after feeding with 23,23,24,24,25-H-2(5)- and 26,26,26,27,27,27-H-2(6)-labeled cholesterol. Were mitochondrial 24- and 27-hydroxylation of importance, one would expect reduced suppression of HMG-CoA reductase when feeding deuterated cholesterol, due to the isotope effects. As this was not the case, it is concluded that neither 24-hydroxylation nor 27-hydroxylation are critical for the cholesterol-induced down-regulation of HMG-CoA reductase in mouse liver.	KAROLINSKA INST,HUDDINGE HOSP,DEPT CLIN CHEM,S-14186 HUDDINGE,SWEDEN	Karolinska Institutet				Bjorkhem, Ingemar/0000-0002-0575-9425; Bjorkhem, Ingemar/0000-0001-6087-9190				ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; ANGELIN B, 1984, J LIPID RES, V25, P1159; BIEMANN K, 1986, MASS SPECTROMETRY AN; BJORKHEM I, 1992, J LIPID RES, V33, P455; BJORKHEM I, 1988, J LIPID RES, V29, P136; BJORKHEM I, 1977, PHARMACOL THER PT A, V1, P327, DOI 10.1016/0362-5478(77)90021-3; BJORKHEM I, 1978, J BIOL CHEM, V253, P842; BJORKHEM I, 1974, CLIN CHIM ACTA, V54, P185, DOI 10.1016/0009-8981(74)90236-8; BJORKHEM I, 1974, J BIOL CHEM, V249, P2528; BREUER O, 1990, STEROIDS, V55, P185, DOI 10.1016/0039-128X(90)90109-O; BUCHER NLR, 1959, J BIOL CHEM, V234, P262; COREY EJ, 1972, J AM CHEM SOC, V94, P6190, DOI 10.1021/ja00772a043; DAHLBACK H, 1989, LIVER MITOCHONDRIAL; DAWSON PA, 1989, J BIOL CHEM, V264, P16798; ESTERMAN AL, 1983, J LIPID RES, V24, P1304; GUPTA A, 1986, J BIOL CHEM, V261, P8348; JAVITT NB, 1981, J BIOL CHEM, V256, P2644; KALUZNY MA, 1985, J LIPID RES, V26, P135; KANDUTSCH AA, 1978, SCIENCE, V201, P498, DOI 10.1126/science.663671; LUND E, 1992, J BIOL CHEM, V267, P12462; MAKITA A, 1973, ANAL BIOCHEM, V5, P523; Melander L.C.S., 1960, ISOTOPE EFFECTS REAC; NORTHROP DB, 1981, ANNU REV BIOCHEM, V50, P103, DOI 10.1146/annurev.bi.50.070181.000535; OFTEBRO H, 1980, J CLIN INVEST, V65, P1418, DOI 10.1172/JCI109806; REIHNER E, 1989, GASTROENTEROLOGY, V97, P1498, DOI 10.1016/0016-5085(89)90395-8; RENNERT H, 1990, ENDOCRINOLOGY, V127, P738, DOI 10.1210/endo-127-2-738; SAUCIER SE, 1989, J BIOL CHEM, V264, P6863; SMITH LL, 1989, FREE RADICAL BIO MED, V7, P285, DOI 10.1016/0891-5849(89)90136-6; SPENCER TA, 1985, J BIOL CHEM, V260, P3391; TAKAGI K, 1989, J BIOL CHEM, V264, P12352; TANABE M, 1969, LIFE SCI PT 1 PHYSI, V8, P1123, DOI 10.1016/0024-3205(69)90166-0; TAYLOR FR, 1985, CHEM PHYS LIPIDS, V38, P187, DOI 10.1016/0009-3084(85)90066-0	32	44	44	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1992	267	35					25092	25097						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KB603	1460011				2022-12-25	WOS:A1992KB60300030
J	HILBUSH, BS; LEVINE, JM				HILBUSH, BS; LEVINE, JM			MODULATION OF A CA2+ SIGNALING PATHWAY BY G(M1) GANGLIOSIDE IN PC12 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; TYROSINE-HYDROXYLASE; GM1 GANGLIOSIDE; PROTEIN-KINASE; PHEOCHROMOCYTOMA CELLS; NEURITE OUTGROWTH; NEURONAL DIFFERENTIATION; NEUROTRANSMITTER RELEASE; MEDIATED MODULATION; CYTOSOLIC CALCIUM	The effects of exogenous G(M1) ganglioside on depolarization and ligand-induced Ca2+ signaling were investigated in PC12 cells. Cellular responses to K+ depolarization and bradykinin application in control and G(M1)-treated cells were examined with respect to: 1) changes in the intracellular Ca2+ concentration ([Ca2+]i) measured using fura-2 fluorescence in single cells, and 2) changes in Ca2+-dependent protein kinase activity as assayed by two-dimensional phosphopeptide analysis of the site-specific phosphorylation of tyrosine hydroxylase. Pretreatment of cells with G(M1) (10 or 100 muM) enhanced K+ depolarization-stimulated increases in [Ca2+]i and in (PO4)-P-32 incorporation into tyrosine hydroxylase phosphopeptide T2, a Ca2+/calmodulin-dependent protein kinase II substrate. In contrast, G(M1) treatment had no effect on the transient increases in [Ca2+]i evoked by bradykinin or on bradykinin-induced increases in the site-specific phosphorylation of tyrosine hydroxylase. The depolarization-induced and G(M1)-enhanced increases in [Ca2+]i and T2 phosphorylation were prevented by removal of external Ca2+ or pretreatment with 1 muM nitrendipine, suggesting that these increases result from Ca2+ entry through dihydropyridine-sensitive Ca2+ Channels. The ability of exogenous gangliosides to potentiate increases in [Ca2+]i may underlie their diverse neuritogenic and neurotrophic actions in the nervous system.	SUNY STONY BROOK,DEPT NEUROBIOL & BEHAV,STONY BROOK,NY 11794	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook								APPELL KC, 1989, BIOCHEM J, V263, P11, DOI 10.1042/bj2630011; BREMER EG, 1984, J BIOL CHEM, V259, P6818; BREMER EG, 1986, J BIOL CHEM, V261, P2434; BUSH AB, 1991, J NEUROCHEM, V57, P562, DOI 10.1111/j.1471-4159.1991.tb03787.x; CAHILL AL, 1989, NEUROSCIENCE, V30, P811, DOI 10.1016/0306-4522(89)90172-3; CALLIES R, 1977, EUR J BIOCHEM, V80, P425, DOI 10.1111/j.1432-1033.1977.tb11897.x; CAMPBELL DG, 1986, J BIOL CHEM, V261, P489; CHAN KFJ, 1987, J BIOL CHEM, V262, P5248; CIMINO M, 1987, ACTA PHYSIOL SCAND, V130, P317, DOI 10.1111/j.1748-1716.1987.tb08143.x; CONTRERAS ML, 1987, J NEUROCHEM, V48, P1466, DOI 10.1111/j.1471-4159.1987.tb05687.x; FASOLATO C, 1988, J BIOL CHEM, V263, P17350; FERRARI G, 1983, DEV BRAIN RES, V8, P215, DOI 10.1016/0165-3806(83)90006-8; GOLDENRING JR, 1985, J NEUROCHEM, V44, P1229, DOI 10.1111/j.1471-4159.1985.tb08748.x; GORIO A, 1980, BRAIN RES, V197, P236, DOI 10.1016/0006-8993(80)90451-5; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HASHIMOTO S, 1986, J NEUROCHEM, V46, P1599, DOI 10.1111/j.1471-4159.1986.tb01782.x; HAYCOCK JW, 1990, J BIOL CHEM, V265, P11682; HEIDELBERGER R, 1991, P NATL ACAD SCI USA, V88, P7135, DOI 10.1073/pnas.88.16.7135; HILBUSH BS, 1991, P NATL ACAD SCI USA, V88, P5616, DOI 10.1073/pnas.88.13.5616; HILLE B, 1975, PHILOS T R SOC B, V270, P301, DOI 10.1098/rstb.1975.0011; HILLE B, 1984, IONIC CHANNELS EXCIT, P316; KATER SB, 1991, J NEUROSCI, V11, P891; KATOHSEMBA R, 1984, J NEUROSCI RES, V12, P299, DOI 10.1002/jnr.490120217; KIM JYH, 1986, J NEUROSCI RES, V15, P159, DOI 10.1002/jnr.490150205; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANKFORD KL, 1989, J CELL BIOL, V109, P1229, DOI 10.1083/jcb.109.3.1229; LAZAROVICI P, 1989, J NEUROSCI RES, V23, P1, DOI 10.1002/jnr.490230102; LEDEEN RW, 1978, J SUPRAMOL STR CELL, V8, P1, DOI 10.1002/jss.400080102; LEDEEN RW, 1984, J NEUROSCI RES, V12, P147, DOI 10.1002/jnr.490120204; LEON A, 1984, J NEUROSCI RES, V12, P277, DOI 10.1002/jnr.490120215; LEVINE JM, 1984, J NEUROSCI, V4, P820; MACNICOL M, 1990, J BIOL CHEM, V265, P18055; MCDANIEL RV, 1984, BIOCHEMISTRY-US, V23, P4618, DOI 10.1021/bi00315a016; MCLAUGHLIN S, 1989, ANNU REV BIOPHYS BIO, V18, P113, DOI 10.1146/annurev.biophys.18.1.113; MCTIGUE M, 1985, J BIOL CHEM, V260, P9047; MELDOLESI J, 1984, P NATL ACAD SCI-BIOL, V81, P620, DOI 10.1073/pnas.81.2.620; NEHER E, 1989, NEUROMUSCULAR JUNCTI, P65; ODERFELDNOWAK B, 1984, J NEUROSCI RES, V12, P409, DOI 10.1002/jnr.490120225; PANDIELLAALONSO A, 1986, FEBS LETT, V208, P48, DOI 10.1016/0014-5793(86)81529-0; PLUMMER MR, 1989, NEURON, V2, P1453, DOI 10.1016/0896-6273(89)90191-8; REBER BFX, 1991, J PHYSIOL-LONDON, V435, P145, DOI 10.1113/jphysiol.1991.sp018502; SKAPER SD, 1985, DEV BRAIN RES, V23, P19, DOI 10.1016/0165-3806(85)90003-3; SPOERRI PE, 1990, DEV BRAIN RES, V56, P177, DOI 10.1016/0165-3806(90)90080-I; STALLCUP WB, 1979, J PHYSIOL-LONDON, V286, P525, DOI 10.1113/jphysiol.1979.sp012635; SUZUKI K, 1965, J NEUROCHEM, V17, P209; SVENNERHOLM L, 1963, J NEUROCHEM, V10, P613, DOI 10.1111/j.1471-4159.1963.tb08933.x; TOLL L, 1982, J BIOL CHEM, V257, P13189; WILLINGER M, 1980, DEV BIOL, V74, P101, DOI 10.1016/0012-1606(80)90055-X; WU GS, 1990, J NEUROCHEM, V55, P484, DOI 10.1111/j.1471-4159.1990.tb04161.x	50	37	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1992	267	34					24789	24795						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KA263	1447216				2022-12-25	WOS:A1992KA26300095
J	FITZSIMONS, DP; HERRING, BP; STULL, JT; GALLAGHER, PJ				FITZSIMONS, DP; HERRING, BP; STULL, JT; GALLAGHER, PJ			IDENTIFICATION OF BASIC RESIDUES INVOLVED IN ACTIVATION AND CALMODULIN BINDING OF RABBIT SMOOTH-MUSCLE MYOSIN LIGHT CHAIN KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASES; PHOSPHORYLATION; DOMAIN; SITE; AUTOINHIBITION; CALCINEURIN; LOCATION; SEQUENCE	It is postulated that basic residues in the regulatory region of myosin light chain kinase are important for conferring autoinhibition by binding to the catalytic core. To investigate this proposal, 10 basic amino acids within the regulatory region of rabbit smooth muscle myosin light chain kinase (Lys961-Lys979) were replaced either singularly or in combination with acidic or nonpolar residues by site-directed mutagenesis. All active mutant kinases were dependent on Ca2+/calmodulin for catalytic activity. None of the mutants was active in the absence of Ca2+/calmodulin, suggesting that the autoinhibitory region has not been defined completely. Charge reversal mutants at Arg974, Arg975, and Lys976 resulted in loss of high affinity binding of calmodulin and increased the concentration of calmodulin required for half-maximal activation (K(CaM)). The charge reversal mutant at Lys979 also increased K(CaM) but to a lesser extent. Charge reversal mutants at Lys965 and Arg967 resulted in an inactive myosin light chain kinase that could not be proteolytically activated. When these residues were mutated to Ala, the expressed kinase was dependent upon Ca2+/calmodulin for activity and exhibited a decrease in K(CaM). Charge reversal mutants in Lys961 and Lys962 also had decreased K(CaM) values. These basic residues amino-terminal of the calmodulin binding domain may play an important role in the activation of the kinase.	UNIV TEXAS, SW MED CTR, DEPT PHYSIOL, 5323 HARRY HINES BLVD, DALLAS, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL026043, R01HL026043] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL026043, R01 HL026043-20, R37 HL026043, HL26043] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; BAGCHI IC, 1992, J BIOL CHEM, V267, P3024; BAGCHI IC, 1992, MOL ENDOCRINOL, V6, P621, DOI 10.1210/me.6.4.621; BILLINGSLEY ML, 1985, P NATL ACAD SCI USA, V82, P7585, DOI 10.1073/pnas.82.22.7585; BLUMENTHAL DK, 1985, P NATL ACAD SCI USA, V82, P3187, DOI 10.1073/pnas.82.10.3187; BLUMENTHAL DK, 1980, BIOCHEMISTRY-US, V19, P5608, DOI 10.1021/bi00565a023; BLUMENTHAL DK, 1982, BIOCHEMISTRY-US, V21, P2386, DOI 10.1021/bi00539a017; BOWMAN BF, 1992, J BIOL CHEM, V267, P5346; FOSTER C, 1986, ARCH BIOCHEM BIOPHYS, V251, P616, DOI 10.1016/0003-9861(86)90371-1; GALLAGHER P, 1988, J CELL BIOL, V107, P2059, DOI 10.1083/jcb.107.6.2059; GALLAGHER PJ, 1991, J BIOL CHEM, V266, P23936; HATHAWAY DR, 1983, ANAL BIOCHEM, V135, P37, DOI 10.1016/0003-2697(83)90726-1; HERRING BP, 1991, J BIOL CHEM, V266, P11838; HERRING BP, 1990, J BIOL CHEM, V265, P16588; HUBBARD MJ, 1987, J BIOL CHEM, V262, P15062; IKEBE M, 1989, J BIOL CHEM, V264, P6967; IKEBE M, 1987, J BIOL CHEM, V262, P13828; IKURA M, 1992, SCIENCE, V256, P632, DOI 10.1126/science.1585175; ITO M, 1991, BIOCHEMISTRY-US, V30, P3498, DOI 10.1021/bi00228a021; Kamm K E, 1987, Prog Clin Biol Res, V245, P183; KAMM KE, 1985, ANNU REV PHARMACOL, V25, P593, DOI 10.1146/annurev.pharmtox.25.1.593; KEMP BE, 1983, P NATL ACAD SCI-BIOL, V80, P7471, DOI 10.1073/pnas.80.24.7471; KEMP BE, 1985, J BIOL CHEM, V260, P3355; KEMP BE, 1991, BIOCHIM BIOPHYS ACTA, V1094, P67, DOI 10.1016/0167-4889(91)90027-U; KEMP BE, 1987, J BIOL CHEM, V262, P2542; LUKAS TJ, 1986, BIOCHEMISTRY-US, V25, P1458, DOI 10.1021/bi00354a041; MILLER JR, 1983, MOL PHARMACOL, V24, P235; OLSON NJ, 1990, P NATL ACAD SCI USA, V87, P2284, DOI 10.1073/pnas.87.6.2284; PEARSON RB, 1988, SCIENCE, V241, P970, DOI 10.1126/science.3406746; POTTER JD, 1975, J BIOL CHEM, V250, P4628; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHOEMAKER MO, 1990, J CELL BIOL, V111, P1107, DOI 10.1083/jcb.111.3.1107; SODERLING TR, 1990, J BIOL CHEM, V265, P1823; STULL JT, 1990, PROG CLIN BIOL RES, V327, P107; STULL JT, 1990, J BIOL CHEM, V265, P16683; STULL JT, 1984, ADV ENZYME REGUL, V23, P123, DOI 10.1016/0065-2571(85)90043-3; VANBERKUM MFA, 1991, J BIOL CHEM, V266, P21488	38	44	46	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	1992	267	33					23903	23909						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JZ239	1429728				2022-12-25	WOS:A1992JZ23900071
J	BONHAM, L; MACKENZIE, K; WOOD, S; ROWE, PB; SYMONDS, G				BONHAM, L; MACKENZIE, K; WOOD, S; ROWE, PB; SYMONDS, G			BOTH MYELOPROLIFERATIVE DISEASE AND LEUKEMIA ARE INDUCED BY TRANSPLANTATION OF BONE-MARROW CELLS EXPRESSING V-MYC	ONCOGENE			English	Article							HEMATOPOIETIC STEM-CELLS; RECOMBINANT MURINE RETROVIRUS; CHRONIC MYELOGENOUS LEUKEMIA; C-MYC; TRANSGENIC MICE; ADENOSINE-DEAMINASE; MEDIATED TRANSFER; GENE-TRANSFER; VIRUS; TRANSFORMATION	An in vivo system has been established to investigate v-myc-induced hematopoietic neoplasia in mice. A Moloney murine leukemia virus (Mo-MLV)-derived recombinant retrovirus containing v-myc was used to infect immature bone marrow cells, and these celts were then transplanted into lethally irradiated recipients. All provirus-positive reconstituted mice were found to develop hematopoietic proliferative disorders and, in certain cases, overt leukemia-myeloblastic, myelomonocytic and T lymphocytic. In all cases expression of v-myc was high and the disease type did not correlate with the level of expression. We have isolated immortalized monocytes, myeloid progenitors and T lymphocytes from several of these mice and shown tumorigenicity in secondary syngeneic recipients. This system provides a model for investigating the progression from a pre-leukemic disease to malignancy. In addition, we describe a recombinant v-myc-containing retrovirus that directs high-level v-myc expression from the Mo-MLV promoter in all the hematopoietic cell types examined.	CHILDRENS MED RES FDN, 214 HAWKESBURY RD, SYDNEY, NSW 2145, AUSTRALIA	Children's Medical Research Institute - Australia			Wood, Stephen A/E-8357-2011; Mackenzie, Karen/F-1310-2011; MacKenzie, Karen/N-5849-2019	Wood, Stephen A/0000-0002-2576-7457; MacKenzie, Karen/0000-0003-2996-1617				ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; ALITALO K, 1983, NATURE, V306, P274, DOI 10.1038/306274a0; BAUMBACH WR, 1986, J VIROL, V59, P276, DOI 10.1128/JVI.59.2.276-283.1986; BECKENGESER G, 1991, HUM GENE THER, V2, P61, DOI 10.1089/hum.1991.2.1-61; BENDER MA, 1987, J VIROL, V61, P1639, DOI 10.1128/JVI.61.5.1639-1646.1987; BENNETT JM, 1976, BRIT J HAEMATOL, V33, P451, DOI 10.1111/j.1365-2141.1976.tb03563.x; BIRCHENALLROBERTS MC, 1989, ONCOGENE, V4, P731; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; BISHOP JM, 1985, MOL BIOL TUMOR VIRUS, P249; BOWTELL DDL, 1988, J VIROL, V62, P2464, DOI 10.1128/JVI.62.7.2464-2473.1988; BOWTELL DDL, 1987, MOL BIOL MED, V4, P229; BRIGHTMAN BK, 1988, J IMMUNOL, V141, P2844; BRIGHTMAN BK, 1986, J VIROL, V60, P68, DOI 10.1128/JVI.60.1.68-81.1986; BURGESS A, 1983, GROWTH FACTORS STEM, P68; CHANG JM, 1989, BLOOD, V73, P1487; CHATIS PA, 1983, P NATL ACAD SCI-BIOL, V80, P4408, DOI 10.1073/pnas.80.14.4408; CHISHOLM O, 1992, IN PRESS ONCOGENE; CHUNG SW, 1991, P NATL ACAD SCI USA, V88, P1585, DOI 10.1073/pnas.88.4.1585; COFFMAN RL, 1983, IMMUNOL REV, V69, P5, DOI 10.1111/j.1600-065X.1983.tb00446.x; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; CROSS M, 1991, CELL, V64, P271, DOI 10.1016/0092-8674(91)90638-F; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; DARLIX JL, 1986, J MOL BIOL, V189, P421, DOI 10.1016/0022-2836(86)90314-1; DUNBAR CE, 1991, ONCOGENE RES, V6, P39; ELEFANTY AG, 1990, EMBO J, V9, P1069, DOI 10.1002/j.1460-2075.1990.tb08212.x; EMERMAN M, 1984, J VIROL, V50, P42, DOI 10.1128/JVI.50.1.42-49.1984; EMERMAN M, 1986, MOL CELL BIOL, V6, P792, DOI 10.1128/MCB.6.3.792; ERBA HP, 1988, MOL CELL BIOL, V8, P1775, DOI 10.1128/MCB.8.4.1775; GAUSTCH JW, 1976, VIROLOGY, V72, P509; GONDA TJ, 1989, EMBO J, V8, P1767, DOI 10.1002/j.1460-2075.1989.tb03570.x; GRAF T, 1978, BIOCHIM BIOPHYS ACTA, V516, P269, DOI 10.1016/0304-419X(78)90011-2; GREEN SM, 1989, ONCOGENE, V4, P737; GREENBERG PL, 1983, BLOOD, V61, P1035; GREZ M, 1990, P NATL ACAD SCI USA, V87, P9202, DOI 10.1073/pnas.87.23.9202; GREZ M, 1991, J VIROL, V65, P4691, DOI 10.1128/JVI.65.9.4691-4698.1991; GRIESSER H, 1989, BLOOD, V73, P1402; HAYFLICK J, 1985, P NATL ACAD SCI USA, V82, P2718, DOI 10.1073/pnas.82.9.2718; HEARD JM, 1987, CELL, V51, P663, DOI 10.1016/0092-8674(87)90135-8; HIDDEMANN W, 1984, CYTOMETRY, V5, P445, DOI 10.1002/cyto.990050502; HU WS, 1990, SCIENCE, V250, P1227, DOI 10.1126/science.1700865; JOHNSON GR, 1989, EMBO J, V8, P441, DOI 10.1002/j.1460-2075.1989.tb03396.x; KELLER G, 1985, NATURE, V318, P149, DOI 10.1038/318149a0; KELLER G, 1989, GENE DEV, V3, P827, DOI 10.1101/gad.3.6.827; KELLIHER MA, 1990, P NATL ACAD SCI USA, V87, P6649, DOI 10.1073/pnas.87.17.6649; LEDER A, 1986, CELL, V45, P485, DOI 10.1016/0092-8674(86)90280-1; Maniatis T, 1989, MOL CLONING; MANN R, 1983, CELL, V33, P153, DOI 10.1016/0092-8674(83)90344-6; MCIVOR RS, 1990, VIROLOGY, V176, P652, DOI 10.1016/0042-6822(90)90039-T; MCIVOR RS, 1987, MOL CELL BIOL, V7, P838, DOI 10.1128/MCB.7.2.838; MORELLO D, 1989, ONCOGENE RES, V4, P111; PULSINELLI GA, 1991, J VIROL, V65, P4786, DOI 10.1128/JVI.65.9.4786-4797.1991; RALPH P, 1975, J IMMUNOL, V114, P898; SACHS L, 1987, SCIENCE, V238, P1374, DOI 10.1126/science.3317831; SAWYERS CL, 1991, CELL, V64, P337, DOI 10.1016/0092-8674(91)90643-D; SCHMIDT EV, 1988, P NATL ACAD SCI USA, V85, P6047, DOI 10.1073/pnas.85.16.6047; SCOTT ML, 1991, P NATL ACAD SCI USA, V88, P6506, DOI 10.1073/pnas.88.15.6506; STAPLETON P, 1991, ONCOGENE, V6, P807; SYMONDS G, 1982, EMBO J, V1, P1343, DOI 10.1002/j.1460-2075.1982.tb01320.x; SYMONDS G, 1989, ONCOGENE, V4, P285; THIESEN HJ, 1988, J VIROL, V62, P614, DOI 10.1128/JVI.62.2.614-618.1988; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; VENNSTROM B, 1984, EMBO J, V3, P3223, DOI 10.1002/j.1460-2075.1984.tb02282.x; WAGNER EF, 1990, EMBO J, V9, P3025, DOI 10.1002/j.1460-2075.1990.tb07498.x; WEINBERG RA, 1989, CANCER RES, V49, P3713; WILLIAMS DA, 1986, P NATL ACAD SCI USA, V83, P2566, DOI 10.1073/pnas.83.8.2566; WILLIAMS WJ, 1983, HEMATOLOGY; WOLFF L, 1990, J VIROL, V64, P155, DOI 10.1128/JVI.64.1.155-160.1990; WONG PMC, 1989, MOL CELL BIOL, V9, P798, DOI 10.1128/MCB.9.2.798; XU L, 1989, VIROLOGY, V171, P331, DOI 10.1016/0042-6822(89)90600-4	69	15	15	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	1992	7	11					2219	2229						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JW665	1437146				2022-12-25	WOS:A1992JW66500014
J	NAKAFUKU, M; SATOH, T; KAZIRO, Y				NAKAFUKU, M; SATOH, T; KAZIRO, Y			DIFFERENTIATION FACTORS, INCLUDING NERVE GROWTH-FACTOR, FIBROBLAST GROWTH-FACTOR, AND INTERLEUKIN-6, INDUCE AN ACCUMULATION OF AN ACTIVE RAS.GTP COMPLEX IN RAT PHEOCHROMOCYTOMA PC12 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; STIMULATES TYROSINE PHOSPHORYLATION; GTPASE ACTIVATING PROTEIN; TRK PROTOONCOGENE PRODUCT; NEURONAL DIFFERENTIATION; PHOSPHOLIPASE C-GAMMA-1; SIGNAL-TRANSDUCTION; P21RAS ACTIVATION; RECEPTOR; ONCOGENES	Ras has been thought to be involved in neuronal differentiation of rat pheochromocytoma PC12 cells. PC 12 cells are immature adrenal chromaffin-like cells which undergo differentiation to sympathetic neuron-like cells in response to nerve growth factor (NGF). Fibroblast growth factor (FGF) and interleukin (IL)-6 can also induce differentiation of PC12 cells. In this paper, we report that NGF, FGF, and IL-6 induce an accumulation of an active Ras.GTP complex. In the serum-starved culture of PC12 cells, 6% of the Ras protein was complexed with GTP. Upon stimulation with NGF, the percentage of Ras.GTP increased to 24% after 2 min, and the high level of Ras.GTP was maintained for at least 16 h. On the other hand, the activation of Ras by FGF and IL-6 showed distinct kinetics; about 3-fold increase of Ras-GTP was detected at 10 min, and afterward, the level returned to the basal level within 60 min. These observations provide direct evidence that activation of Ras is involved in signal transduction from these differentiation factors. In addition, it was found that growth factors, including epidermal growth factor, insulin, and insulin-like growth factor-1, and a tumor promoter, 12-O-tetradecanoylphorbol-13-acetate (TPA), can also activate Ras under the same conditions. A tyrosine kinase-specific inhibitor, genistein, inhibited the increase of Ras.GTP induced by NGF and other factors. On the other hand, down-regulation of protein kinase C (PKC) by prolonged treatment with TPA, which sufficiently blocked TPA-induced Ras activation, did not abolish the formation of Ras.GTP by NGF. These results suggest that tyrosine kinases rather than PKC play a major role in the NGF-induced activation of Ras in PC12 cells.	DNAX RES INST MOLEC & CELLULAR BIOL INC,901 CALIF AVE,PALO ALTO,CA 94304	Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.			Satoh, Takaya/K-2628-2014; Nakafuku, Masato/J-3068-2013	Nakafuku, Masato/0000-0001-7783-9005				AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BARSAGI D, 1985, CELL, V42, P841, DOI 10.1016/0092-8674(85)90280-6; BENITO M, 1991, SCIENCE, V253, P565, DOI 10.1126/science.1857988; BURGERING BMT, 1991, EMBO J, V10, P1103, DOI 10.1002/j.1460-2075.1991.tb08050.x; CHAN BL, 1989, P NATL ACAD SCI USA, V86, P1756, DOI 10.1073/pnas.86.6.1756; DAHMER MK, 1988, ENDOCRINOLOGY, V122, P2109, DOI 10.1210/endo-122-5-2109; DARMER MK, 1989, J NEUROCHEM, V53, P1036; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; DURONIO V, 1992, P NATL ACAD SCI USA, V89, P1587, DOI 10.1073/pnas.89.5.1587; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; FORCE T, 1991, J BIOL CHEM, V266, P6650; GIBBS JB, 1990, J BIOL CHEM, V265, P20437; GOLDEN A, 1989, P NATL ACAD SCI USA, V86, P901, DOI 10.1073/pnas.86.3.901; GRAVES JD, 1991, J IMMUNOL, V146, P3709; Greene LA., 1982, ADV CELL NEUROBIOL, V3, P373, DOI [10.1016/B978-0-12-008303-9.50016-5, DOI 10.1016/B978-0-12-008303-9.50016-5]; HAGAG N, 1986, NATURE, V319, P680, DOI 10.1038/319680a0; HAGIWARA M, 1990, CANCER RES, V50, P5515; HAMA T, 1986, P NATL ACAD SCI USA, V83, P2353, DOI 10.1073/pnas.83.8.2353; HUFF K, 1981, J CELL BIOL, V88, P189, DOI 10.1083/jcb.88.1.189; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; KAPLAN DR, 1991, SCIENCE, V252, P554, DOI 10.1126/science.1850549; KAZIRO Y, 1991, ANNU REV BIOCHEM, V60, P349, DOI 10.1146/annurev.bi.60.070191.002025; KIM UH, 1991, J BIOL CHEM, V266, P1359; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; LORD KA, 1991, MOL CELL BIOL, V11, P4371, DOI 10.1128/MCB.11.9.4371; MEDEMA RH, 1991, J BIOL CHEM, V266, P21186; MOLLOY CJ, 1989, NATURE, V342, P711, DOI 10.1038/342711a0; MORGAN JI, 1991, ANNU REV NEUROSCI, V14, P421, DOI 10.1146/annurev.ne.14.030191.002225; MUROYA K, 1992, ONCOGENE, V7, P277; NAKAJIMA K, 1991, MOL CELL BIOL, V11, P1409, DOI 10.1128/MCB.11.3.1409; NEBREDA AR, 1991, SCIENCE, V252, P558, DOI 10.1126/science.1850550; NISHIBE S, 1990, SCIENCE, V250, P1253, DOI 10.1126/science.1700866; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; NODA M, 1985, NATURE, V318, P73, DOI 10.1038/318073a0; Qui MS, 1991, NEURON, V7, P937, DOI [DOI 10.1016/0896-6273(91)90339-2, 10.1016/0896-6273(91)90339-2]; RYDEL RE, 1987, J NEUROSCI, V7, P3639; SATOH T, 1992, J BIOL CHEM, V267, P2537; SATOH T, 1990, P NATL ACAD SCI USA, V87, P5993, DOI 10.1073/pnas.87.15.5993; SATOH T, 1988, MOL CELL BIOL, V8, P3546, DOI 10.1128/MCB.8.8.3546; SATOH T, 1988, FEBS LETT, V236, P185, DOI 10.1016/0014-5793(88)80311-9; SATOH T, 1991, P NATL ACAD SCI USA, V88, P3314, DOI 10.1073/pnas.88.8.3314; SATOH T, 1990, P NATL ACAD SCI USA, V87, P7926, DOI 10.1073/pnas.87.20.7926; SCHECHTER AL, 1981, CELL, V24, P867, DOI 10.1016/0092-8674(81)90112-4; SZEBERENYI J, 1990, MOL CELL BIOL, V10, P5324, DOI 10.1128/MCB.10.10.5324; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; TOGARI A, 1985, J NEUROSCI, V5, P307; TORTI M, 1992, J BIOL CHEM, V267, P8293; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VETTER ML, 1991, P NATL ACAD SCI USA, V88, P5650, DOI 10.1073/pnas.88.13.5650; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O	51	183	184	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1992	267	27					19448	19454						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JP593	1527065				2022-12-25	WOS:A1992JP59300066
J	TAI, PKK; LIAO, JF; HOSSLER, PA; CASTOR, CW; CARTERSU, C				TAI, PKK; LIAO, JF; HOSSLER, PA; CASTOR, CW; CARTERSU, C			REGULATION OF GLUCOSE TRANSPORTERS BY CONNECTIVE-TISSUE ACTIVATING PEPTIDE-III ISOFORMS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN INTERLEUKIN-8 RECEPTOR; GROWTH-STIMULATORY ACTIVITY; INSULIN-RESPONSIVE TISSUES; PLATELET FACTOR 4; CTAP-III; HUMAN-NEUTROPHILS; MESSENGER-RNA; FIBROBLAST PROLIFERATION; DIFFERENTIAL REGULATION; MOLECULAR-CLONING	Connective tissue activating peptide-III (CTAP-III) is a component of platelet alpha-granules which elicits a series of responses in connective tissue cells referred to as activation, including increased glucose consumption and mitogenesis and increased secretion of hyaluronic acid and glycosaminoglycans. As anticipated by a requirement for glucose or glucose precursors in the activation process, an early event following CTAP-III activation of connective tissue cells is an increase in glucose transport. The present study investigates the molecular basis for this increase in glucose transport. Murine 3T3-F442A fibroblasts were found to respond to CTAP-III in a manner similar to human connective tissue cells (synovial cells, chondrocytes, skin fibroblasts). CTAP-III increases the rate of glucose transport to similar extents at 4 and 24 h, and at physiologic (micrograms/ml) concentrations of CTAP-III. A proteolytic cleavage product of recombinant CTAP-III (rCTAP-III-Leu-21 (des-1-15)), also known as neutrophil-activating peptide-2 (NAP-2), was found to be equally effective as CTAP-III, whereas NAP-1/interleukin-8, another member of the CTAP-III superfamily, was ineffective in stimulating glucose transport. This contrasts with neutrophil chemotaxis, in which CTAP-III (des-1-15)/NAP-2 acts similarly to NAP-1/interleukin 8 while CTAP-III is ineffective. CTAP-III appears to elicit a different type of glucose transport response than many other growth factors in that its response is sustained (greater-than-or-equal-to 24 h) rather than transient (peak approximately 4 h) in confluent as well as in subconfluent cells. Western blot analysis using antibodies to the GLUT-1 glucose transporter revealed an increased level of GLUT-1 protein in response to CTAP-III isoforms that corresponded in magnitude (on a percentage basis) to the increased level of glucose transport. The increased levels of GLUT-1 protein in response to CTAP-III and rCTAP-III-Leu-21 (des-1-15)/NAP-2 were accompanied by an increase in levels of GLUT-1 mRNA of a magnitude sufficient to account for observed increased levels of GLUT-1. These results are consistent with CTAP-III isoforms stimulating glucose transport in connective tissue cells by increasing levels of GLUT-1 mRNA and is one of the few known instances in which increases in levels of GLUT-1 mRNA and protein are sufficient to account for observed increases in glucose transport. They also provide further evidence that CTAP-III (des-1-15)/NAP-2 binds to more than one type of receptor and that CTAP-III acts in a manner different than other well characterized growth factors (e.g. platelet-derived growth factor, transforming growth factor-beta) in that it causes a sustained (greater-than-or-equal-to 24 h) elevation in glucose transport in confluent as well as subconfluent cells.	UNIV MICHIGAN, SCH MED, DEPT PHYSIOL, ANN ARBOR, MI 48109 USA; UNIV MICHIGAN, SCH MED, DEPT INTERNAL MED, ANN ARBOR, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan					NIAMS NIH HHS [AR-10728, AR-40740] Funding Source: Medline; NIDDK NIH HHS [DK-30516, P60 DK020572] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR040740, R01AR010728] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK030516] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANISOWICZ A, 1987, P NATL ACAD SCI USA, V84, P7188, DOI 10.1073/pnas.84.20.7188; BEDARD PA, 1987, P NATL ACAD SCI USA, V84, P6715, DOI 10.1073/pnas.84.19.6715; BIBER JW, 1986, J BIOL CHEM, V261, P6180; BIRD TA, 1990, J BIOL CHEM, V265, P13578; BIRNBAUM MJ, 1986, P NATL ACAD SCI USA, V83, P5784, DOI 10.1073/pnas.83.16.5784; CAR BD, 1991, BIOCHEM J, V275, P581, DOI 10.1042/bj2750581; CARTERSU C, 1987, AM J PHYSIOL, V252, pE441, DOI 10.1152/ajpendo.1987.252.4.E441; CASTOR C W, 1986, Arthritis and Rheumatism, V29, pS43; CASTOR CW, 1983, P NATL ACAD SCI-BIOL, V80, P765, DOI 10.1073/pnas.80.3.765; CASTOR CW, 1981, ARTHRITIS RHEUM, V24, P504; CASTOR CW, 1990, J LAB CLIN MED, V116, P516; CASTOR CW, 1989, BIOCHEM BIOPH RES CO, V163, P1071, DOI 10.1016/0006-291X(89)92330-9; CASTOR CW, 1991, METHOD ENZYMOL, V198, P405; CASTOR CW, 1988, METHOD ENZYMOL, V163, P731; CASTOR CW, 1979, ARTHRITIS RHEUM-US, V22, P260, DOI 10.1002/art.1780220308; CASTOR CW, 1985, BIOCHEMISTRY-US, V24, P1762, DOI 10.1021/bi00328a029; CASTOR CW, 1992, ARTHRITIS RHEUM-US, V35, P783, DOI 10.1002/art.1780350712; CASTOR CW, 1983, ARTHRITIS RHEUM, V26, P522, DOI 10.1002/art.1780260411; CASTOR CW, 1981, IN VITRO CELL DEV B, V17, P777; CASTOR CW, 1977, ARTHRITIS RHEUM-US, V20, P859, DOI 10.1002/art.1780200316; CHARRON MJ, 1989, P NATL ACAD SCI USA, V86, P2535, DOI 10.1073/pnas.86.8.2535; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAYER JM, 1979, J CLIN INVEST, V64, P1386, DOI 10.1172/JCI109596; DEUEL TF, 1977, P NATL ACAD SCI USA, V74, P2256, DOI 10.1073/pnas.74.6.2256; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FUKUMOTO H, 1989, J BIOL CHEM, V264, P7776; GROB PM, 1990, J BIOL CHEM, V265, P8311; HAN ZC, 1990, INT J CELL CLONING, V8, P253, DOI 10.1002/stem.5530080409; HASPEL HC, 1988, J BIOL CHEM, V263, P398; HASPEL HC, 1985, J BIOL CHEM, V260, P7219; HIRAKI Y, 1988, J BIOL CHEM, V263, P13655; HOLMES WE, 1991, SCIENCE, V253, P1278, DOI 10.1126/science.1840701; JAMES DE, 1988, NATURE, V333, P183, DOI 10.1038/333183a0; JAMES DE, 1989, NATURE, V338, P83, DOI 10.1038/338083a0; JOHNSON PH, 1986, FASEB J, V45, P1790; KITAGAWA T, 1989, BIOCHIM BIOPHYS ACTA, V980, P100, DOI 10.1016/0005-2736(89)90205-8; KITAGAWA T, 1991, J BIOL CHEM, V266, P18066; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEONARD EJ, 1991, J LEUKOCYTE BIOL, V49, P258, DOI 10.1002/jlb.49.3.258; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUSTER AD, 1985, NATURE, V315, P672, DOI 10.1038/315672a0; MATSUSHIMA K, 1988, J EXP MED, V167, P1883, DOI 10.1084/jem.167.6.1883; MOSER B, 1991, J BIOL CHEM, V266, P10666; MURPHY PM, 1991, SCIENCE, V253, P1280, DOI 10.1126/science.1891716; POSTLETHWAITE AE, 1984, ARTHRITIS RHEUM, V27, P995, DOI 10.1002/art.1780270905; RAGSDALE CG, 1984, ARTHRITIS RHEUM, V27, P663, DOI 10.1002/art.1780270609; RICHMOND A, 1988, EMBO J, V7, P2025, DOI 10.1002/j.1460-2075.1988.tb03042.x; ROLLINS BJ, 1988, J BIOL CHEM, V263, P16523; SCHMIDT JA, 1982, J IMMUNOL, V128, P2177; SISSON JC, 1980, J LAB CLIN MED, V96, P189; SMITH WC, 1989, MOL ENDOCRINOL, V3, P984, DOI 10.1210/mend-3-6-984; STECK TL, 1974, J CELL BIOL, V62, P1, DOI 10.1083/jcb.62.1.1; SUGANO S, 1987, CELL, V49, P321, DOI 10.1016/0092-8674(87)90284-4; TAI PKK, 1988, BIOCHEMISTRY-US, V27, P6062, DOI 10.1021/bi00416a035; TAI PKK, 1990, J BIOL CHEM, V265, P21828; THOMAS KM, 1991, J BIOL CHEM, V266, P14839; TORDJMAN KM, 1989, P NATL ACAD SCI USA, V86, P7761, DOI 10.1073/pnas.86.20.7761; WALZ A, 1989, J EXP MED, V170, P1745, DOI 10.1084/jem.170.5.1745; WALZ A, 1991, J LEUKOCYTE BIOL, V50, P279, DOI 10.1002/jlb.50.3.279; ZORZANO A, 1989, J BIOL CHEM, V264, P12358	60	17	17	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 25	1992	267	27					19579	19586						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JP593	1527075				2022-12-25	WOS:A1992JP59300084
J	UCHIUMI, T; KOMINAMI, R				UCHIUMI, T; KOMINAMI, R			DIRECT EVIDENCE FOR INTERACTION OF THE CONSERVED GTPASE DOMAIN WITHIN 28-S RNA WITH MAMMALIAN RIBOSOMAL ACIDIC PHOSPHOPROTEINS AND L12	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYSTEMIC LUPUS-ERYTHEMATOSUS; RAT-LIVER RIBOSOMES; ESCHERICHIA-COLI; BINDING-SITE; SACCHAROMYCES-CEREVISIAE; CROSS-LINKING; INVITRO SYNTHESIS; ARTEMIA-SALINA; FACTOR-II; 23S RNA	A complex consisting of the acidic phosphoproteins P0, P1, and P2 (P proteins), L12, and RNA fragments was isolated from rat liver ribosomes after treatment with RNase T1 in the presence of EDTA. The complex was reactive with the anti-28 S RNA antibody specific for the highly conserved "GTPase domain' within 28 S rRNA. This suggests an association of these proteins with the RNA domain. To characterize this complex, the P proteins and L12 were isolated and tested for their binding specificity to the RNA by RNase T1 protection and gel retardation assays. Protein L12 and the P protein complex (P complex) both bound to rat 28 S rRNA and protected sequences comprising residues 1859-1921 and 1838-1936, respectively. The sequences overlap each other and lie in the GTPase domain. An in vitro transcript covering residues 1841-1936 of the 28 S rRNA as well as the protected RNA fragments also showed an ability to bind to the P complex and L12, and the binding was cooperative. RNA sequence elements within residues 1841-1936 required for protein binding were defined using site-directed mutagenesis. A unique internal loop including residues 1858 and 1859 and a distinct subregion comprising residues 1867-1914 in this domain were necessary for the binding of the P complex and L12, respectively. These results indicate that P proteins and L12 bind to restricted sites in the GTPase domain and that the complex constitutes the GTPase-related functional site in mammalian ribosomes.			UCHIUMI, T (corresponding author), NIIGATA UNIV,SCH MED,DEPT BIOCHEM,757 ASAHIMACHI DORI 1,NIIGATA 951,JAPAN.							BEAUCLERK AAD, 1984, J BIOL CHEM, V259, P6559; CASIANO C, 1991, J BIOL CHEM, V266, P21578; CHAN YL, 1983, NUCLEIC ACIDS RES, V11, P7819, DOI 10.1093/nar/11.22.7819; CHU JL, 1991, J EXP MED, V174, P507, DOI 10.1084/jem.174.3.507; Cundliffe E., 1980, RIBOSOMES STRUCTURE, P555; DAHLBERG AE, 1989, CELL, V57, P525, DOI 10.1016/0092-8674(89)90122-0; DONISKELLER H, 1980, NUCLEIC ACIDS RES, V8, P3133, DOI 10.1093/nar/8.14.3133; DRAPER DE, 1989, TRENDS BIOCHEM SCI, V14, P335, DOI 10.1016/0968-0004(89)90167-9; EGEBJERG J, 1989, EMBO J, V8, P607, DOI 10.1002/j.1460-2075.1989.tb03415.x; EGEBJERG J, 1990, J MOL BIOL, V213, P275, DOI 10.1016/S0022-2836(05)80190-1; ELBARADI TTAL, 1987, J MOL BIOL, V195, P909, DOI 10.1016/0022-2836(87)90494-3; ELKON K, 1986, P NATL ACAD SCI USA, V83, P7419, DOI 10.1073/pnas.83.19.7419; ELKON KB, 1985, J EXP MED, V162, P459, DOI 10.1084/jem.162.2.459; GORSKI JL, 1987, J MOL EVOL, V24, P236, DOI 10.1007/BF02111237; GUTELL RR, 1988, NUCLEIC ACIDS RES, V16, pR175, DOI 10.1093/nar/16.suppl.r175; GUTELL RR, 1985, PROG NUCLEIC ACID RE, V32, P155, DOI 10.1016/S0079-6603(08)60348-7; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LILLEHAUG JR, 1975, BIOCHEMISTRY-US, V14, P1225, DOI 10.1021/bi00677a021; MACCONNELL WP, 1982, J BIOL CHEM, V257, P5359; MATHESON AT, 1980, RIBOSOMES STRUCTURE, P297; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MIZUSHIMA S, 1970, NATURE, V226, P1214, DOI 10.1038/2261214a0; MOAZED D, 1988, NATURE, V334, P362, DOI 10.1038/334362a0; MOLLER W, 1975, P NATL ACAD SCI USA, V72, P4744, DOI 10.1073/pnas.72.12.4744; MOUGEL M, 1987, J MOL BIOL, V198, P91, DOI 10.1016/0022-2836(87)90460-8; MUSTERS W, 1991, P NATL ACAD SCI USA, V88, P1469, DOI 10.1073/pnas.88.4.1469; NOLLER HF, 1984, ANNU REV BIOCHEM, V53, P119, DOI 10.1146/annurev.bi.53.070184.001003; NOLLER HF, 1991, ANNU REV BIOCHEM, V60, P191, DOI 10.1146/annurev.biochem.60.1.191; PETTERSSON I, 1979, NUCLEIC ACIDS RES, V6, P2637, DOI 10.1093/nar/6.7.2637; PETTERSSON I, 1979, FEBS LETT, V98, P139, DOI 10.1016/0014-5793(79)80170-2; PORTER RR, 1959, BIOCHEM J, V73, P119, DOI 10.1042/bj0730119; PUCCIARELLI MG, 1990, NUCLEIC ACIDS RES, V18, P4409, DOI 10.1093/nar/18.15.4409; RAMIREZ C, 1989, CAN J MICROBIOL, V35, P234, DOI 10.1139/m89-036; RICH BE, 1987, MOL CELL BIOL, V7, P4065, DOI 10.1128/MCB.7.11.4065; RYAN PC, 1991, P NATL ACAD SCI USA, V88, P6308, DOI 10.1073/pnas.88.14.6308; RYAN PC, 1991, J MOL BIOL, V221, P1257, DOI 10.1016/0022-2836(91)80125-E; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SATO T, 1990, BIOCHEM BIOPH RES CO, V172, P496, DOI 10.1016/0006-291X(90)90700-W; SATO T, 1991, J RHEUMATOL, V18, P1681; SCHMIDT FJ, 1981, J BIOL CHEM, V256, P2301; SHIMMIN LC, 1989, J MOL EVOL, V29, P448, DOI 10.1007/BF02602915; SKOLD SE, 1983, NUCLEIC ACIDS RES, V11, P4923, DOI 10.1093/nar/11.14.4923; STERN S, 1989, SCIENCE, V244, P783, DOI 10.1126/science.2658053; SUZUKI K, 1990, BIOCHEM BIOPH RES CO, V172, P35, DOI 10.1016/S0006-291X(05)80169-X; THOMPSON J, 1979, EUR J BIOCHEM, V98, P261, DOI 10.1111/j.1432-1033.1979.tb13184.x; THOMPSON J, 1982, J BIOL CHEM, V257, P7915; UCHIUMI T, 1986, J BIOL CHEM, V261, P9668; UCHIUMI T, 1990, J BIOL CHEM, V265, P89; UCHIUMI T, 1986, EUR J BIOCHEM, V156, P37, DOI 10.1111/j.1432-1033.1986.tb09545.x; UCHIUMI T, 1987, P NATL ACAD SCI USA, V84, P5580, DOI 10.1073/pnas.84.16.5580; UCHIUMI T, 1983, EUR J BIOCHEM, V132, P495, DOI 10.1111/j.1432-1033.1983.tb07388.x; UCHIUMI T, 1991, J BIOL CHEM, V266, P2054; WITTMANNLIEBOLD B, 1990, RIBOSOME, P598; WOOL IG, 1990, RIBOSOME, P203; Zimmermann R. A., 1980, RIBOSOMES STRUCTURE, P135	56	60	60	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1992	267	27					19179	19185						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JP593	1527039				2022-12-25	WOS:A1992JP59300028
J	HOVIUS, R; FABER, B; BRIGOT, B; NICOLAY, K; DEKRUIJFF, B				HOVIUS, R; FABER, B; BRIGOT, B; NICOLAY, K; DEKRUIJFF, B			ON THE MECHANISM OF THE MITOCHONDRIAL DECARBOXYLATION OF PHOSPHATIDYLSERINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER MITOCHONDRIA; CONTACT SITES; SACCHAROMYCES-CEREVISIAE; INNER MEMBRANE; YEAST; PHOSPHOLIPIDS; TRANSLOCATION; BIOSYNTHESIS; PHOSPHATIDYLETHANOLAMINE; PROTEIN	To study intramitochondrial phospholipid flow, radiolabeled phosphatidylserine was introduced into isolated rat liver mitochondria from donor vesicles through the action of a nonspecific lipid transfer protein. Imported phosphatidylserine was rapidly decarboxylated to phosphatidylethanolamine. Both the imported phosphatidylserine and the formed phosphatidylethanolamine were confined to the outer membrane. The enzyme phosphatidylserine decarboxylase was shown to be located exclusively in the inner membrane. It was not enriched in isolated contact site fractions. 1,4-Dinitrophenol caused an inhibition of the decarboxylation of phosphatidylserine. This inhibition was not due to the uncoupling of the oxidative phosphorylation itself, but possibly due to a decrease in the number of contact sites. This suggests that phosphatidylserine flows from the outer membrane to the inner membrane through contact sites between inner and outer membrane to become decarboxylated and that the formed phosphatidylethanolamine flows directly back to the outer membrane, without mixing with inner membrane phosphatidylethanolamine.	UNIV UTRECHT,CTR BIOMEMBRANES & LIPID ENZYMOL,DEPT MEMBRANE BIOCHEM,3584 CH UTRECHT,NETHERLANDS; UNIV UTRECHT,INST MOLEC BIOL & MED BIOTECHNOL,3584 CH UTRECHT,NETHERLANDS; UNIV UTRECHT,BIJVOET CTR BIOMOLEC RES,3584 CH UTRECHT,NETHERLANDS	Utrecht University; Utrecht University; Utrecht University			Nicolay, Klaas/F-4192-2010	Nicolay, Klaas/0000-0002-4179-616X; Faber, Bart/0000-0001-6808-1204				ARDAIL D, 1991, J BIOL CHEM, V266, P7978; BIERMANS W, 1990, BIOCHIM BIOPHYS ACTA, V1018, P225, DOI 10.1016/0005-2728(90)90254-2; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BLOK MC, 1971, BIOCHIM BIOPHYS ACTA, V233, P61, DOI 10.1016/0005-2736(71)90358-0; BORKENHAGEN L, 1961, J BIOL CHEM, V236, pPC28; BRDICZKA D, 1986, MYOCARDIAL SKELETAL, P55; BUCHELER K, 1991, BIOCHIM BIOPHYS ACTA, V1056, P233, DOI 10.1016/S0005-2728(05)80054-4; BUTLER M, 1983, J NEUROCHEM, V41, P1445, DOI 10.1111/j.1471-4159.1983.tb00844.x; CARMAN GM, 1989, ANNU REV BIOCHEM, V58, P635, DOI 10.1146/annurev.biochem.58.1.635; CHANCE B, 1955, J BIOL CHEM, V217, P409; COMFURIUS P, 1977, BIOCHIM BIOPHYS ACTA, V488, P36, DOI 10.1016/0005-2760(77)90120-5; DAUM G, 1985, BIOCHIM BIOPHYS ACTA, V822, P1, DOI 10.1016/0304-4157(85)90002-4; DAUM G, 1986, BIOCHIM BIOPHYS ACTA, V878, P93, DOI 10.1016/0005-2760(86)90347-4; DENNIS EA, 1972, J LIPID RES, V13, P263; Fiske CH, 1925, J BIOL CHEM, V66, P375; HARTL FU, 1990, SCIENCE, V247, P930, DOI 10.1126/science.2406905; HOSTETLER KY, 1971, BIOCHIM BIOPHYS ACTA, V239, P113, DOI 10.1016/0005-2760(71)90201-3; HOVIUS R, 1990, BIOCHIM BIOPHYS ACTA, V1021, P217, DOI 10.1016/0005-2736(90)90036-N; KNOLL G, 1983, BIOCHIM BIOPHYS ACTA, V733, P102, DOI 10.1016/0005-2736(83)90095-0; LEVRAT C, 1989, BIOCHEM INT, V18, P813; MCMURRAY WC, 1969, BIOCHEM J, V112, P91, DOI 10.1042/bj1120091; PERCY AK, 1983, ARCH BIOCHEM BIOPHYS, V223, P484, DOI 10.1016/0003-9861(83)90613-6; POORTHUIS BJHM, 1983, METHOD ENZYMOL, V98, P592; SAUNER MT, 1971, J LIPID RES, V12, P71; SCHWAIGER M, 1987, J CELL BIOL, V105, P235, DOI 10.1083/jcb.105.1.235; SIMBENI R, 1991, J BIOL CHEM, V266, P10047; SIMBENI R, 1990, J BIOL CHEM, V265, P281; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SPERKAGOTTLIEB CDM, 1988, BIOCHIM BIOPHYS ACTA, V946, P227, DOI 10.1016/0005-2736(88)90397-5; SUDA T, 1974, BIOCHIM BIOPHYS ACTA, V369, P331, DOI 10.1016/0005-2760(74)90147-7; TAKI T, 1973, JPN J EXP MED, V43, P219; VANCE JE, 1988, BIOCHIM BIOPHYS ACTA, V963, P10, DOI 10.1016/0005-2760(88)90332-3; VANCE JE, 1991, J BIOL CHEM, V266, P89; VANDEENEN LLM, 1964, ADV LIPID RES, V2, P167; VANGOLDE LM, 1974, BIOCHIM BIOPHYS ACTA, V360, P179, DOI 10.1016/0005-2760(74)90168-4; Voelker D R, 1988, Prog Clin Biol Res, V282, P153; VOELKER DR, 1984, P NATL ACAD SCI-BIOL, V81, P2669, DOI 10.1073/pnas.81.9.2669; VOELKER DR, 1985, J BIOL CHEM, V260, P4671; VOELKER DR, 1989, J BIOL CHEM, V264, P8019; VOELKER DR, 1989, P NATL ACAD SCI USA, V86, P9921, DOI 10.1073/pnas.86.24.9921; WEISSBACH H, 1960, J BIOL CHEM, V235, P1160; WOJTCZAK L, 1971, BIOCHIM BIOPHYS ACTA, V249, P41, DOI 10.1016/0005-2736(71)90081-2; ZBOROWSKI J, 1983, FEBS LETT, V157, P179, DOI 10.1016/0014-5793(83)81141-7; ZELINSKI TA, 1982, CAN J BIOCHEM CELL B, V60, P817, DOI 10.1139/o82-102	44	38	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1992	267	24					16790	16795						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JL053	1512221				2022-12-25	WOS:A1992JL05300011
J	PHILLIPS, WJ; CERIONE, RA				PHILLIPS, WJ; CERIONE, RA			RHODOPSIN TRANSDUCIN INTERACTIONS .1. CHARACTERIZATION OF THE BINDING OF THE TRANSDUCIN-BETA-GAMMA SUBUNIT COMPLEX TO RHODOPSIN USING FLUORESCENCE SPECTROSCOPY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ROD OUTER SEGMENTS; GUANINE-NUCLEOTIDE EXCHANGE; CGMP PHOSPHODIESTERASE; ALPHA-SUBUNIT; INTRINSIC FLUORESCENCE; PROTEIN; ANTIBODIES; RECEPTOR; PHOTOTRANSDUCTION; BEHAVIOR	In this work we have used fluorescence spectroscopic approaches to examine the binding of the beta-gamma(T) subunit complex of transducin to the photoreceptor, rhodopsin. To do this, we have covalently labeled the beta-gamma(T) subunit complex with the environmentally sensitive fluorescent cysteine reagent 2-(4'-maleimidylanilino)naphthalene-6-sulfonic acid (MIANS). By using the MIANS moiety as a fluorescent reporter group, we were able to monitor directly the binding of the MIANS-beta-gamma(T) complex to light-activated rhodopsin, which was reconstituted into phosphatidylcholine vesicles, through an enhancement (30-50%) in the MIANS fluorescence. Phosphatidylcholine vesicles, alone, elicited only minor changes in the MIANS-beta-gamma(T) fluorescence (i.e. < 10% enhancement), whereas the addition of rhodopsin in the absence of lipid vesicles and in minimal detergent fully mimicked the effects of reconstituted rhodopsin and caused a significant enhancement of the MIANS fluorescence. The interactions between the MIANS-beta-gamma(T) complex and rhodopsin also resulted in a quenching of the rhodopsin tryptophan fluorescence (approximately 30%), which most likely reflected resonance energy transfer between the tryptophan residues and the MIANS moieties. The binding of the MIANS-beta-gamma(T) species to the alpha(T) subunit was accompanied by an enhancement of the MIANS fluorescence (30-50%) and a slight blue shift of the emission maximum, as described previously (Phillips, W. J., and Cerione, R. A. (1991) J. Biol. Chem. 266, 11017-11024). However, the alpha(T)-induced enhancement of the MIANS-beta-gamma(T) fluorescence was not additive with the enhancement elicited by rhodopsin. Conditions which resulted in the activation of the alpha(T) subunit reversed the alpha(T)-induced enhancement of the MIANS emission, whereas the rhodopsin-induced enhancement persisted, thereby suggesting that the rhodopsin-beta-gamma(T) complex can remain intact throughout the G protein activation event. Studies with synthetic peptides representing different regions of the cytoplasmic domain of rhodopsin demonstrated that a portion of the putative carboxyl-terminal tail (amino acid residues 310-324) was capable of eliciting changes in the MIANS-beta-gamma(T) fluorescence as well as inhibiting the MIANS-beta-gamma(T)-induced quenching of the rhodopsin tryptophan fluorescence. These results suggest that this region of the rhodopsin molecule may constitute a portion of the binding domain for the beta-gamma(T) complex.	CORNELL UNIV, COLL VET MED, DEPT PHARMACOL, SCHURMAN HALL, ITHACA, NY 14853 USA	Cornell University					NATIONAL EYE INSTITUTE [R01EY006429] Funding Source: NIH RePORTER; NEI NIH HHS [EY06429] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		BAEHR W, 1979, J BIOL CHEM, V254, P1669; BENNETT N, 1985, J BIOL CHEM, V260, P4156; CERIONE RA, 1991, BIOCHIM BIOPHYS ACTA, V1071, P473, DOI 10.1016/0304-4157(91)90007-J; CHABRE M, 1985, ANNU REV BIOPHYS BIO, V14, P331, DOI 10.1146/annurev.biophys.14.1.331; ERICKSON JW, 1991, BIOCHEMISTRY-US, V30, P7112, DOI 10.1021/bi00243a011; FLORIO VA, 1985, J BIOL CHEM, V260, P3477; FUNG BKK, 1983, J BIOL CHEM, V258, P495; GIERSCHIK P, 1984, FEBS LETT, V172, P321, DOI 10.1016/0014-5793(84)81149-7; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GUY PM, 1990, BIOCHEMISTRY-US, V29, P6954, DOI 10.1021/bi00482a003; HALPERN JL, 1987, BIOCHEMISTRY-US, V26, P1655, DOI 10.1021/bi00380a025; HINGORANI VN, 1988, J BIOL CHEM, V263, P6916; HO YK, 1984, J BIOL CHEM, V259, P6694; KELLEHER DJ, 1988, MOL PHARMACOL, V34, P452; KHORANA HG, 1992, J BIOL CHEM, V267, P1; LEFKOWITZ RJ, 1988, J BIOL CHEM, V263, P4993; LITMAN BJ, 1982, METHOD ENZYMOL, V81, P150; OVCHINNIKOV YA, 1988, FEBS LETT, V230, P1, DOI 10.1016/0014-5793(88)80628-8; PHILLIPS WJ, 1988, J BIOL CHEM, V263, P15498; PHILLIPS WJ, 1989, J BIOL CHEM, V264, P16679; PHILLIPS WJ, 1992, J BIOL CHEM, V267, P17040; PHILLIPS WJ, 1991, J BIOL CHEM, V266, P11017; PINES M, 1985, P NATL ACAD SCI USA, V82, P4095, DOI 10.1073/pnas.82.12.4095; STRYER L, 1991, J BIOL CHEM, V266, P10711; WESSLINGRESNICK M, 1987, J BIOL CHEM, V262, P12444; WESSLINGRESNICK M, 1987, J BIOL CHEM, V262, P3697	26	96	96	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	1992	267	24					17032	17039						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JL053	1512242				2022-12-25	WOS:A1992JL05300048
J	MUKHOPADHYAY, A; ZHOU, XQ; UH, M; MUELLER, DM				MUKHOPADHYAY, A; ZHOU, XQ; UH, M; MUELLER, DM			HETEROLOGOUS EXPRESSION, PURIFICATION, AND BIOCHEMISTRY OF THE OLIGOMYCIN SENSITIVITY CONFERRING PROTEIN (OSCP) FROM YEAST	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL ADENOSINE-TRIPHOSPHATASE; HEART SUBMITOCHONDRIAL PARTICLES; SUBUNIT STOICHIOMETRY; COUPLING FACTOR; BINDING-SITES; DELTA-SUBUNIT; ATP-SYNTHASE; BETA-SUBUNIT; RECONSTITUTION; F1-ATPASE	Yeast Saccharomyces cerevisiae oligomycin sensitivity conferring proteins (OSCP) have been expressed in Escherichia coli. Heterologous expression results in production of a protein that is identical to yeast mature OSCP, including the absence of the initiating methionine residue. Yeast OSCP expressed in E. coli has been purified to homogeneity and it is able to reconstitute oligomycin-sensitive ATPase using purified F1-and F1/OSCP-depleted membranes (electron transport particles (ETP)). Binding of F1 to ETP is dependent on the addition of OSCP. Binding studies using S-35-OSCP indicate that OSCP binds to ETP with a K(d) of 200 nM and a capacity of 420 pmol/mg particle protein, whereas OSCP does not interact with F1 in the absence of ETP. These data indicate that yeast OSCP must first form a specific complex with F0, which then binds F1 forming the functional complex. To identify functional domains in yeast OSCP, two deletion mutants have been made. Antibodies directed to these deletion products do not inhibit OSCP-dependent binding of F1 to ETP. However, antibodies directed against the last one-third of OSCP greatly reduce the oligomycin sensitivity of the reconstituted ATPase. These data suggest that OSCP is involved in a functional role in energy transduction or proton translocation and serves a structural role in the yeast mitochondrial ATP synthase.	UNIV HLTH SCI CHICAGO MED SCH, DEPT BIOL CHEM, N CHICAGO, IL 60064 USA	Chicago Medical School	MUELLER, DM (corresponding author), UNIV HLTH SCI CHICAGO MED SCH, DEPT BIOL CHEM, N CHICAGO, IL 60064 USA.				NIGMS NIH HHS [1RO1GM44412] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044412] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOULAY F, 1985, BIOCHEMISTRY-US, V24, P7372, DOI 10.1021/bi00346a052; CROSS RL, 1982, J BIOL CHEM, V257, P2874; DAUM G, 1982, J BIOL CHEM, V257, P3028; DUNN SD, 1980, J BIOL CHEM, V255, P113; DUPUIS A, 1983, BIOCHEMISTRY-US, V22, P5951, DOI 10.1021/bi00294a039; DUPUIS A, 1987, BIOCHEMISTRY-US, V26, P410, DOI 10.1021/bi00376a011; DUPUIS A, 1983, FEBS LETT, V156, P99, DOI 10.1016/0014-5793(83)80256-7; DUSZYNSKI J, 1988, BIOCHEMISTRY-US, V27, P6288, DOI 10.1021/bi00417a014; ENGELBRECHT S, 1990, EUR J BIOCHEM, V189, P193, DOI 10.1111/j.1432-1033.1990.tb15476.x; ENGELBRECHT S, 1986, EUR J BIOCHEM, V160, P635, DOI 10.1111/j.1432-1033.1986.tb10085.x; ERNSTER L, 1986, METHOD ENZYMOL, V126, P428; ESCH FS, 1979, J BIOL CHEM, V254, P740; FESSENDENRADEN JM, 1972, J BIOL CHEM, V247, P2351; JOUNOUCHI M, 1992, ARCH BIOCHEM BIOPHYS, V292, P376, DOI 10.1016/0003-9861(92)90005-H; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEATHERBARROW RG, 1990, GRAFIT VERSION 2 0; Maniatis T., 1982, MOL CLONING; MUELLER DM, 1988, J BIOL CHEM, V263, P5634; NOUMI T, 1984, J BIOL CHEM, V259, P76; NOUMI T, 1984, J BIOL CHEM, V259, P71; Penefsky H S, 1979, Methods Enzymol, V56, P527; PENIN F, 1986, BIOCHIM BIOPHYS ACTA, V852, P55, DOI 10.1016/0005-2728(86)90056-3; PENIN F, 1985, BIOCHIM BIOPHYS ACTA, V810, P346, DOI 10.1016/0005-2728(85)90220-8; PRINGLE MJ, 1990, J BIOL CHEM, V265, P7632; SANDRI G, 1985, ARCH BIOCHEM BIOPHYS, V239, P597; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SENIOR AE, 1983, J MEMBRANE BIOL, V73, P105, DOI 10.1007/BF01870434; STOSCHECK CM, 1990, METHOD ENZYMOL, V182, P50; STUDIER FW, 1990, METHOD ENZYMOL, V185, P61; TAKESHIGE K, 1976, H-S Z PHYSIOL CHEM, V357, P1605, DOI 10.1515/bchm2.1976.357.2.1605; TODD RD, 1980, J BIOL CHEM, V255, P5461; TODD RD, 1981, J BIOL CHEM, V256, P6984; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TZAGOLOFF A, 1970, J BIOL CHEM, V245, P1545; Tzagoloff A, 1979, Methods Enzymol, V55, P351; UH M, 1990, J BIOL CHEM, V265, P19047; VIGNAIS PV, 1984, MOL CELL BIOCHEM, V60, P33; WALKER JE, 1984, BIOCHIM BIOPHYS ACTA, V768, P164, DOI 10.1016/0304-4173(84)90003-X; WALKER JE, 1985, J MOL BIOL, V184, P677, DOI 10.1016/0022-2836(85)90313-4	40	16	16	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 25	1992	267	36					25690	25696						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KD073	1464586				2022-12-25	WOS:A1992KD07300017
J	SOZERI, O; VOLLMER, K; LIYANAGE, M; FRITH, D; KOUR, G; MARK, GE; STABEL, S				SOZERI, O; VOLLMER, K; LIYANAGE, M; FRITH, D; KOUR, G; MARK, GE; STABEL, S			ACTIVATION OF THE C-RAF PROTEIN-KINASE BY PROTEIN-KINASE-C PHOSPHORYLATION	ONCOGENE			English	Note							TYROSINE PHOSPHORYLATION; GROWTH; CELLS; EXPRESSION; INSULIN; C-RAF-1; SERINE; RECEPTOR; PROTOONCOGENE; DEFINITION	The product of the c-raf-1 proto-oncogene is a cytoplasmic serine/threonine protein kinase that appears to be activated in signal transduction from a variety of cell-surface receptors. The mechanism of c-Raf activation upon stimulation of cell-surface receptors is not clear, but there seem to exist multiple pathways of activation which involve tyrosine and/or serine phosphorylation of the c-Raf protein in vivo. The activated state of Raf is reflected in an increased apparent molecular weight of the Raf protein in sodium dodecyl sulfate-polyacrylamide gels owing to hyperphosphorylation. The tumor promoter 12-O-tetradecanoyl phorbol 13-acetate (TPA) is one of the agents able to induce this hyperphosphorylation of Raf in vivo, suggesting that protein kinase C (PKC) may be involved in the activation of c-Raf in particular situations. Using recombinant baculoviruses expressing PKC and Raf polypeptides, we show here that conventional PKC types (alpha, beta, gamma) but not novel types (delta, zeta, eta) or the unrelated Mos kinase are able to activate c-Raf in a TPA-dependent manner upon coexpression in insect cells. Direct phosphorylation of the Raf protein with PKC in vitro also enhanced the kinase activity of c-Raf, suggesting that c-Raf acts immediately down-stream of PKC in a protein kinase cascade which is triggered by TPA and may lead to transcriptional activation of TPA-inducible genes and tumor promotion.	MAX PLANCK GESELL, MAX DELBRUCK LAB, CARL VON LINNE WEG 10, W-5000 COLOGNE 30, GERMANY; MERCK SHARP & DOHME LTD, RAHWAY, NJ 07065 USA; IMPERIAL CANC RES FUND, LINCOLNS INN FIELDS, LONDON WC2A 3PX, ENGLAND	Max Planck Society; Merck & Company; Cancer Research UK								ANDERSON NG, 1991, BIOCHEM J, V277, P573, DOI 10.1042/bj2770573; APP H, 1991, MOL CELL BIOL, V11, P913, DOI 10.1128/MCB.11.2.913; BACCARINI M, 1991, J BIOL CHEM, V266, P10941; BACCARINI M, 1990, EMBO J, V9, P3649, DOI 10.1002/j.1460-2075.1990.tb07576.x; BLACKSHEAR PJ, 1990, J BIOL CHEM, V265, P12131; BONNER TI, 1986, NUCLEIC ACIDS RES, V14, P1009, DOI 10.1093/nar/14.2.1009; CARROLL MP, 1990, J BIOL CHEM, V265, P19812; FREISEWINKEL I, 1991, FEBS LETT, V280, P262, DOI 10.1016/0014-5793(91)80307-O; HEIDECKER G, 1992, ADV CANCER RES, V58, P53, DOI 10.1016/S0065-230X(08)60290-0; HEIDECKER G, 1990, MOL CELL BIOL, V10, P2503, DOI 10.1128/MCB.10.6.2503; IZUMI T, 1991, J BIOL CHEM, V266, P7933; JAMAL S, 1990, ANTURE, V344, P43; KAIBUCHI K, 1989, J BIOL CHEM, V264, P20855; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; KOVACINA KS, 1990, J BIOL CHEM, V265, P12115; LEE RM, 1991, J BIOL CHEM, V266, P10351; LI P, 1991, CELL, V64, P479, DOI 10.1016/0092-8674(91)90228-Q; LIYANAGE M, 1992, BIOCHEM J, V283, P781, DOI 10.1042/bj2830781; MOLDERS H, 1985, EMBO J, V4, P693, DOI 10.1002/j.1460-2075.1985.tb03685.x; MORRISON DK, 1989, CELL, V58, P649, DOI 10.1016/0092-8674(89)90100-1; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; ONO Y, 1989, P NATL ACAD SCI USA, V86, P3099, DOI 10.1073/pnas.86.9.3099; PATEL G, 1989, CELL SIGNAL, V1, P227, DOI 10.1016/0898-6568(89)90040-5; PFEIFER AMA, 1989, P NATL ACAD SCI USA, V86, P10075, DOI 10.1073/pnas.86.24.10075; RAPP UR, 1991, ONCOGENE, V6, P495; RAPP UR, 1983, P NATL ACAD SCI-BIOL, V80, P4218, DOI 10.1073/pnas.80.14.4218; SIEGFRIED Z, 1990, MOL CELL BIOL, V10, P6073, DOI 10.1128/MCB.10.11.6073; STABEL S, 1991, PHARMACOL THERAPEUT, V51, P71, DOI 10.1016/0163-7258(91)90042-K; STABEL S, 1991, METHOD ENZYMOL, V200, P670; STANTON VP, 1989, MOL CELL BIOL, V9, P639, DOI 10.1128/MCB.9.2.639; SUMMERS MD, 1987, TEXAS AGR EXPT STATI, V1555, P1; TURNER B, 1991, P NATL ACAD SCI USA, V88, P1227, DOI 10.1073/pnas.88.4.1227; WASYLYK C, 1989, MOL CELL BIOL, V9, P247; WAYS DK, 1992, J BIOL CHEM, V267, P4799; WSIEGEL JN, 1990, J BIOL CHEM, V265, P18472; ZMUIDZINAS A, 1991, MOL CELL BIOL, V11, P2794, DOI 10.1128/MCB.11.5.2794	36	304	305	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	1992	7	11					2259	2262						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JW665	1437148				2022-12-25	WOS:A1992JW66500018
J	MCCLURE, DB; WALLS, JD; GRINNELL, BW				MCCLURE, DB; WALLS, JD; GRINNELL, BW			POSTTRANSLATIONAL PROCESSING EVENTS IN THE SECRETION PATHWAY OF HUMAN PROTEIN-C, A COMPLEX VITAMIN-K-DEPENDENT ANTITHROMBOTIC FACTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-CARBOXYGLUTAMIC ACID; HUMAN FACTOR-IX; RECOGNITION SITE; MAMMALIAN-CELLS; CA-2+ BINDING; FACTOR-X; EXPRESSION; ACTIVATION; PROPEPTIDE; CARBOXYLASE	Human protein C (HPC) undergoes several post-translational modifications, including gamma-carboxylation, N-linked glycosylation, and internal proteolytic processing. We have utilized a recombinant human kidney cell line (293) secreting correctly modified HPC (rHPC) to study the processing reactions for the modification of this complex protein. Gamma-carboxylation was shown to proceed via a vitamin K-dependent pathway and was required for both efficient secretion and anticoagulant activity. rHPC was rapidly secreted following the addition of vitamin K to depleted cells, and secretion was not inhibited by cyclohexamide indicating that non gamma-carboxylated rHPC accumulates as an intracellular releasable pool. However, in cells grown in the presence of vitamin K, the majority of intracellular rHPC was gamma-carboxylated, suggesting that this post-translational modification is not rate limiting for secretion under conditions optimal for vitamin K-dependent carboxylation. Nonglycosylated rHPC was found to be secreted inefficiently, and processing of the N-linked core in the endoplasmic reticulum, but not in the Golgi, was required for secretion. Further, the intracellular rHPC present in vitamin K-supplemented cells was core glycosylated, but not processed past the high mannose step. Gamma-carboxylation occurred after core glycosylation, indicating that this modification is not cotranslational. Further, glycosylation and gamma-carboxylation were not coupled and did not need to proceed sequentially. Proteolytic processing of the internal KR dipeptide was found to occur late in the secretion pathway, and the cleavage was calcium-dependent. The secretion rate of rHPC was also calcium-dependent but was independent of the calcium effect on internal KR dipeptide removal, indicating that cleavage is not required for efficient secretion. Our results define the sequence of processing events, the subcellular localization of the processing reactions, and the rate-limiting steps in the secretion pathway for this complex protein.	ELI LILLY & CO, LILLY RES LAB, LILLY CORP CTR, DEPT CARDIOVASC RES, INDIANAPOLIS, IN 46285 USA; ELI LILLY & CO, LILLY RES LAB, LILLY CORP CTR, DEPT BIOTECHNOL, INDIANAPOLIS, IN 46285 USA	Eli Lilly; Eli Lilly								ANSON DS, 1985, NATURE, V315, P683, DOI 10.1038/315683a0; BAJAJ SP, 1981, J BIOL CHEM, V256, P253; BRESNAHAN PA, 1990, J CELL BIOL, V111, P2851, DOI 10.1083/jcb.111.6.2851; BUSBY S, 1985, NATURE, V316, P271, DOI 10.1038/316271a0; CARLISLE TL, 1980, BIOCHEMISTRY-US, V19, P1161, DOI 10.1021/bi00547a019; CHEUNG AY, 1988, CURRENT ADV VITAMIN, P3; DANGELO SV, 1986, J CLIN INVEST, V77, P416, DOI 10.1172/JCI112319; DELASALLE H, 1985, NATURE, V316, P268, DOI 10.1038/316268a0; ESMON CT, 1987, SCIENCE, V235, P1348, DOI 10.1126/science.3029867; ESMON CT, 1989, J BIOL CHEM, V264, P4743; ESMON NL, 1989, PROG HEMOST THROMB, V9, P29; ESMON NL, 1982, J BIOL CHEM, V257, P859; ESMON NL, 1983, J BIOL CHEM, V258, P5548; FAIR DS, 1984, BLOOD, V64, P194; FOSTER DC, 1987, BIOCHEMISTRY-US, V26, P7003, DOI 10.1021/bi00396a022; GARDNER JE, 1983, PROGR HEMATOLOGY, P265; GRINNELL BW, 1991, J BIOL CHEM, V266, P9778; GRINNELL BW, 1987, BIO-TECHNOL, V5, P1189, DOI 10.1038/nbt1187-1189; GRINNELL BW, 1990, PROTEIN C RELATED AN, P13; JOHNSON AE, 1983, J BIOL CHEM, V258, P5554; JORGENSEN MJ, 1987, CELL, V48, P185, DOI 10.1016/0092-8674(87)90422-3; KAUFMAN RJ, 1986, J BIOL CHEM, V261, P9622; KISIEL W, 1981, METHOD ENZYMOL, V80, P320; KISIEL W, 1979, J CLIN INVEST, V64, P761, DOI 10.1172/JCI109521; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARLAR RA, 1982, BLOOD, V59, P1067; MILETICH JP, 1990, J BIOL CHEM, V265, P11397; OHLIN AK, 1988, J BIOL CHEM, V263, P7411; OHLIN AK, 1988, J BIOL CHEM, V263, P19240; OLSON RE, 1983, POSTTRANSLATIONAL CO, P295; OPPENHEIMER C, 1988, CURRENT ADV VITAMIN, P165; PAN LC, 1985, P NATL ACAD SCI USA, V82, P6109, DOI 10.1073/pnas.82.18.6109; STEARNS DJ, 1988, J BIOL CHEM, V263, P826; SUTTIE JW, 1987, P NATL ACAD SCI USA, V84, P634, DOI 10.1073/pnas.84.3.634; SUTTIE JW, 1986, THROMB RES, V44, P129, DOI 10.1016/0049-3848(86)90189-1; WU SM, 1991, SCIENCE, V254, P1634, DOI 10.1126/science.1749935; YAN SCB, 1990, BIO-TECHNOL, V8, P655, DOI 10.1038/nbt0790-655; YAN SCB, 1989, TRENDS BIOCHEM SCI, V14, P264, DOI 10.1016/0968-0004(89)90060-1	38	51	55	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 25	1992	267	27					19710	19717						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JP593	1527091				2022-12-25	WOS:A1992JP59300103
J	OLOFSSON, A; MIYAZONO, K; KANZAKI, T; COLOSETTI, P; ENGSTROM, U; HELDIN, CH				OLOFSSON, A; MIYAZONO, K; KANZAKI, T; COLOSETTI, P; ENGSTROM, U; HELDIN, CH			TRANSFORMING GROWTH FACTOR-BETA-1, FACTOR-BETA-2, AND FACTOR-BETA-3 SECRETED BY A HUMAN GLIOBLASTOMA CELL-LINE - IDENTIFICATION OF SMALL AND DIFFERENT FORMS OF LARGE LATENT COMPLEXES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-WEIGHT COMPLEX; BETA-GENE FAMILY; TGF-BETA; HUMAN-PLATELETS; MARFAN-SYNDROME; STRUCTURAL CHARACTERIZATION; MESSENGER-RNA; KIDNEY-CELLS; PROTEIN; EXPRESSION	Transforming growth factor-beta1 (TGF-beta1) has been found to occur as latent high molecular weight complexes, with or without an associated component denoted latent TGF-beta1-binding protein (LTBP). We show here that a human glioblastoma cell line (U-1240 MG) secretes all isoforms of TGF-betas found in mammalian cells (TGF-beta1, -beta2, and -beta3). Approximately 26% of the secreted TGF-beta is in an active form. Latent TGF-betas were partially purified from medium conditioned by the U-1240 MG cell line using anion exchange chromatography. Analysis of the different fractions by immunoblotting using antisera against precursor parts of the different TGF-beta isoforms, and against LTBP, revealed that not only TGF-beta1 but also other isoforms of TGF-beta may occur in high molecular weight forms containing LTBP. In addition, each one of the TGF-beta isoforms occurred in smaller forms not containing LTBP. Interestingly, each of the TGF-beta isoforms was also seen in complexes of about 210 kDa containing associated component(s) distinct from LTBP. These results indicate that each of the different isoforms of TGF-beta is synthesized and secreted by this glioblastoma cell line in several different high molecular weight latent forms; the biological importance of the various latent TGF-beta complexes is discussed.	BIOMED CTR, LUDWIG INST CANC RES, BOX 595, S-75124 UPPSALA, SWEDEN	Ludwig Institute for Cancer Research			Colosetti, Pascal/ABH-4585-2020					ALTMAN DJ, 1990, J EXP MED, V172, P1391, DOI 10.1084/jem.172.5.1391; ANDRES JL, 1989, J CELL BIOL, V109, P3137, DOI 10.1083/jcb.109.6.3137; BLOBEL G, 1975, J CELL BIOL, V67, P835, DOI 10.1083/jcb.67.3.835; BODMER S, 1990, BIOCHEM BIOPH RES CO, V171, P890, DOI 10.1016/0006-291X(90)91229-L; BODMER S, 1989, J IMMUNOL, V143, P3222; BONEWALD LF, 1991, MOL ENDOCRINOL, V5, P741, DOI 10.1210/mend-5-6-741; Brownh PD, 1990, GROWTH FACTORS, V3, DOI 10.3109/08977199009037500; CHEIFETZ S, 1990, J BIOL CHEM, V265, P20533; DAVIS C G, 1990, New Biologist, V2, P410; DEMARTIN R, 1987, EMBO J, V6, P3673, DOI 10.1002/j.1460-2075.1987.tb02700.x; DERYNCK R, 1987, NUCLEIC ACIDS RES, V15, P3188, DOI 10.1093/nar/15.7.3188; DIETZ HC, 1991, NATURE, V352, P337, DOI 10.1038/352337a0; FAVA RA, 1987, J CELL PHYSIOL, V131, P184, DOI 10.1002/jcp.1041310207; FEHON RG, 1990, CELL, V61, P523, DOI 10.1016/0092-8674(90)90534-L; GENTRY LE, 1987, MOL CELL BIOL, V7, P3418, DOI 10.1128/MCB.7.10.3418; GENTRY LE, 1988, MOL CELL BIOL, V8, P4162, DOI 10.1128/MCB.8.10.4162; GRAYCAR JL, 1989, MOL ENDOCRINOL, V3, P1977, DOI 10.1210/mend-3-12-1977; HAMMACHER A, 1988, J BIOL CHEM, V263, P16493; HUANG SS, 1988, J BIOL CHEM, V263, P1535; KANZAKI T, 1990, CELL, V61, P1051, DOI 10.1016/0092-8674(90)90069-Q; KELLEY MR, 1987, CELL, V51, P539, DOI 10.1016/0092-8674(87)90123-1; LEE B, 1991, NATURE, V352, P330, DOI 10.1038/352330a0; LIOUBIN MN, 1991, ENDOCRINOLOGY, V128, P2291, DOI 10.1210/endo-128-5-2291; LYONS RM, 1988, J CELL BIOL, V106, P1659, DOI 10.1083/jcb.106.5.1659; LYONS RM, 1990, EUR J BIOCHEM, V187, P467, DOI 10.1111/j.1432-1033.1990.tb15327.x; Madisen L, 1990, GROWTH FACTORS, V3, P129, DOI 10.3109/08977199009108275; MASLEN CL, 1991, NATURE, V352, P334, DOI 10.1038/352334a0; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MIYAZONO K, 1991, CIBA F SYMP, V157, P81; MIYAZONO K, 1989, NATURE, V338, P158, DOI 10.1038/338158a0; MIYAZONO K, 1989, BIOCHEMISTRY-US, V28, P1704, DOI 10.1021/bi00430a042; MIYAZONO K, 1992, J BIOL CHEM, V267, P5668; MIYAZONO K, 1991, EMBO J, V10, P1091, DOI 10.1002/j.1460-2075.1991.tb08049.x; MIYAZONO K, 1988, J BIOL CHEM, V263, P6407; MOORADIAN DL, 1989, J CELL BIOCHEM, V41, P189, DOI 10.1002/jcb.240410404; MURPHYULLRICH JE, 1992, MOL BIOL CELL, V3, P181, DOI 10.1091/mbc.3.2.181; NISTER M, 1988, CANCER RES, V48, P3910; OCONNORMCCOURT MD, 1987, J BIOL CHEM, V262, P14090; OKADA F, 1989, J BIOCHEM-TOKYO, V106, P304, DOI 10.1093/oxfordjournals.jbchem.a122849; PARALKAR VM, 1991, DEV BIOL, V143, P303, DOI 10.1016/0012-1606(91)90081-D; PIRCHER R, 1984, CANCER RES, V44, P5538; READ SM, 1981, ANAL BIOCHEM, V116, P53, DOI 10.1016/0003-2697(81)90321-3; ROBERTS AB, 1991, CIBA F SYMP, V157, P7; ROBERTS AB, 1990, PEPTIDE GROWTH FACTO, P419; SATO Y, 1989, J CELL BIOL, V109, P309, DOI 10.1083/jcb.109.1.309; TENDIJKE P, 1988, P NATL ACAD SCI USA, V85, P4715; TSUJI T, 1990, P NATL ACAD SCI USA, V87, P8835, DOI 10.1073/pnas.87.22.8835; Wakefield LM, 1989, GROWTH FACTORS, V1, P203, DOI 10.3109/08977198908997997; WAKEFIELD LM, 1988, J BIOL CHEM, V263, P7646; WAKEFIELD LM, 1987, J CELL BIOL, V105, P965, DOI 10.1083/jcb.105.2.965; WESTERMARK B, 1973, ACTA PATH MICRO IM A, VA 81, P791; YAMAGUCHI Y, 1990, NATURE, V346, P281, DOI 10.1038/346281a0	52	178	180	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 25	1992	267	27					19482	19488						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JP593	1527069				2022-12-25	WOS:A1992JP59300071
J	BIDWAI, AP; HANNA, DE; GLOVER, CVC				BIDWAI, AP; HANNA, DE; GLOVER, CVC			PURIFICATION AND CHARACTERIZATION OF CASEIN KINASE-II (CKII) FROM DELTA-CKA1 DELTA-CKA2 SACCHAROMYCES-CEREVISIAE RESCUED BY DROSOPHILA CKII SUBUNITS - THE FREE CATALYTIC SUBUNIT OF CASEIN KINASE-II IS NOT TOXIC INVIVO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; ALPHA-SUBUNIT; BETA-SUBUNIT; CAENORHABDITIS-ELEGANS; ESCHERICHIA-COLI; FISSION YEAST; PHOSPHORYLATION; GENE; POLYPEPTIDES; SPECIFICITY	Casein kinase II (CKII) is composed of a catalytic (alpha) and a regulatory (beta) subunit which unite to form an alpha-2-beta-2 holoenzyme. Saccharomyces cerevisiae CKII consists of two distinct catalytic (Sc-alpha and Sc-alpha') and regulatory (Sc-beta and Sc-beta') subunits. Simultaneous disruption of the CKA1 and CKA2 genes (encoding the alpha and alpha' subunits, respectively) is lethal. Such double disruptions can be rescued by GAL1, 10-induced expression of the Drosophila a and beta-subunits (Dm-alpha+beta) together or by GAL10-induced expression of the Drosophila alpha-subunit (Dm-alpha) alone (Padmanabha, R., Chen-Wu, J. L.-P., Hanna, D. E., and Glover, C. V. C. (1990) Mol. Cell. Biol. 10, 4089-4099). Here we report quantitation, purification, and characterization of casein kinase II activity from such rescued strains. Casein kinase II activity from a strain rescued by Dm-alpha alone purifies as a free, catalytically active alpha-subunit monomer, whereas that from a strain rescued by Dm-alpha+beta purifies as a mixture of tetrameric holoenzyme and monomeric alpha-subunit. Interestingly, neither Sc-beta nor Sc-beta' is present at detectable levels in the enzyme obtained from either strain, raising the possibility that rescue by Dm-alpha alone may be mediated via the free, monomeric catalytic subunit. Overexpression of total casein kinase II activity from 6- to 18-fold is not toxic and indeed has no overt phenotypic consequences. Production of large amounts of free catalytic subunit also appears to be without effect, even though free catalytic subunit is normally undetectable in S. cerevisiae.			BIDWAI, AP (corresponding author), UNIV GEORGIA,DEPT BIOCHEM,ATHENS,GA 30602, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033237] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM33237] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BENSADOUN A, 1976, ANAL BIOCHEM, V70, P241, DOI 10.1016/S0003-2697(76)80064-4; BIRNBAUM MJ, 1992, PROTEIN EXPRES PURIF, V3, P142, DOI 10.1016/S1046-5928(05)80098-1; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHENWU JLP, 1988, MOL CELL BIOL, V8, P4981, DOI 10.1128/MCB.8.11.4981; COCHET C, 1983, J BIOL CHEM, V258, P1403; DAHMUS GK, 1984, J BIOL CHEM, V259, P9001; GLOVER CVC, 1986, J BIOL CHEM, V261, P14349; GLOVER CVC, 1983, J BIOL CHEM, V258, P3258; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; GRANKOWSKI N, 1991, EUR J BIOCHEM, V198, P25, DOI 10.1111/j.1432-1033.1991.tb15982.x; HATHAWAY GM, 1980, J BIOL CHEM, V255, P8038; HELLERHARRISON RA, 1991, J BIOL CHEM, V266, P14435; HU E, 1990, J BIOL CHEM, V265, P20609; HU ED, 1990, J BIOL CHEM, V265, P5072; KUENZEL EA, 1985, P NATL ACAD SCI USA, V82, P737, DOI 10.1073/pnas.82.3.737; KUENZEL EA, 1987, J BIOL CHEM, V262, P9136; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIN WJ, 1991, J BIOL CHEM, V266, P5664; LITCHFIELD DW, 1990, J BIOL CHEM, V265, P7638; Maller JL, 1991, CURR OPIN CELL BIOL, V3, P269; MARCHIORI F, 1988, BIOCHIM BIOPHYS ACTA, V971, P332; MARIDOR G, 1991, J BIOL CHEM, V266, P2362; MARIN O, 1986, EUR J BIOCHEM, V160, P239, DOI 10.1111/j.1432-1033.1986.tb09962.x; MEGGIO F, 1983, FEBS LETT, V162, P235, DOI 10.1016/0014-5793(83)80762-5; MEGGIO F, 1987, FEBS LETT, V215, P241, DOI 10.1016/0014-5793(87)80154-0; MEISNER H, 1989, BIOCHEMISTRY-US, V28, P4072, DOI 10.1021/bi00435a066; MENDENHALL MD, 1988, P NATL ACAD SCI USA, V85, P4426, DOI 10.1073/pnas.85.12.4426; MULNERLORILLON O, 1990, EUR J BIOCHEM, V193, P529, DOI 10.1111/j.1432-1033.1990.tb19368.x; PADMANABHA R, 1987, J BIOL CHEM, V262, P1829; PADMANABHA R, 1990, MOL CELL BIOL, V10, P4089, DOI 10.1128/MCB.10.8.4089; PINES J, 1990, New Biologist, V2, P389; PINNA LA, 1990, BIOCHIM BIOPHYS ACTA, V1054, P267, DOI 10.1016/0167-4889(90)90098-X; RUSSELL P, 1986, CELL, V45, P145, DOI 10.1016/0092-8674(86)90546-5; Sherman F., 1986, METHODS YEAST GENETI, P163; SIKORSKI RS, 1989, GENETICS, V122, P19; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TUAZON PT, 1990, ADV 2ND MESSENGER PH, P123	37	48	49	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1992	267	26					18790	18796						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JN502	1527008				2022-12-25	WOS:A1992JN50200082
J	CALLE, R; GANESAN, S; SMALLWOOD, JI; RASMUSSEN, H				CALLE, R; GANESAN, S; SMALLWOOD, JI; RASMUSSEN, H			GLUCOSE-INDUCED PHOSPHORYLATION OF MYRISTOYLATED ALANINE-RICH C-KINASE SUBSTRATE (MARCKS) IN ISOLATED RAT PANCREATIC-ISLETS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAJOR SPECIFIC SUBSTRATE; PROTEIN-KINASE; INSULIN-SECRETION; PHORBOL ESTERS; RELEASE; CELLS; STAUROSPORINE; CALMODULIN; LANGERHANS; ACTIVATION	In order to further evaluate the role of protein kinase C activation in glucose-induced insulin secretion, the extent of phosphorylation of the myristoylated alanine-rich C kinase substrate (MARCKS) was examined in freshly isolated rat pancreatic islets prelabeled with [P-32]orthophosphate. The islets were incubated with either 2.75 mM glucose alone, 2.75 mM glucose + 1-mu-M phorbol myristate acetate, 20 mM glucose, or 20 mM glucose + 50 nM staurosporine. After stimulation, the homogenized islets were processed by immunoprecipitation with a specific polyclonal anti-MARCKS antibody, followed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Densitometric analysis of autoradiograms revealed that phorbol myristate acetate caused a 3.78 +/- 0.97-fold increase in MARCKS phosphorylation over control. In the islets exposed to 20 mM glucose, an increase of 3.43 +/- 0.46-fold over control was observed. In islets exposed to G20 + 50 nM staurosporine, MARCKS phosphorylation was inhibited by 90 +/- 4% compared with control islets exposed to 20 mM glucose alone. Islets similarly treated (but incubated without P-32) were examined by immunocytochemistry using an alpha-PKC-specific monoclonal antibody and visualized by confocal immunofluorescence microscopy. The alpha-PKC redistributed from the cytosol to the plasma membrane in the beta-cells of islets exposed to 20 mM glucose. In separate experiments, unlabeled but similarly treated islets were shown to respond with a 5-7-fold increase in insulin secretion in static incubation. Thus, when freshly isolated rat pancreatic islets are exposed to stimulatory glucose concentrations, they exhibit both a translocation of alpha-PKC and a significant increase in the extent of phosphorylation of MARCKS protein. These data suggest that alpha-PKC is activated during glucose-induced insulin secretion.			CALLE, R (corresponding author), YALE UNIV,SCH MED,DEPT INTERNAL MED,NEW HAVEN,CT 06510, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041230, R37DK019813, R01DK019813, K08DK002054] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-19813, NIDDK-41230, DK-02054] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALBANO JDM, 1972, ACTA ENDOCRINOL-COP, V70, P487, DOI 10.1530/acta.0.0700487; ALBERT KA, 1986, P NATL ACAD SCI USA, V83, P2822, DOI 10.1073/pnas.83.9.2822; BLACKSHEAR PJ, 1986, J BIOL CHEM, V261, P1459; BLACKSHEAR PJ, 1985, J BIOL CHEM, V260, P3304; BRATTSAND G, 1989, SCAND J IMMUNOL, V30, P233, DOI 10.1111/j.1365-3083.1989.tb01206.x; DRAZNIN B, 1986, ENDOCRINOLOGY, V118, P1054, DOI 10.1210/endo-118-3-1054; DRAZNIN B, 1988, AM J MED, V85, P44, DOI 10.1016/0002-9343(88)90397-X; DUNLOP ME, 1986, ARCH BIOCHEM BIOPHYS, V248, P562, DOI 10.1016/0003-9861(86)90509-6; EASOM RA, 1989, BIOCHEM J, V264, P27, DOI 10.1042/bj2640027; EASOM RA, 1990, J BIOL CHEM, V265, P14938; GANESAN S, 1990, P NATL ACAD SCI USA, V87, P9893, DOI 10.1073/pnas.87.24.9893; GRAFF JM, 1991, J BIOL CHEM, V266, P14390; GRAFF JM, 1989, J BIOL CHEM, V264, P21818; GRILL V, 1974, J BIOL CHEM, V249, P4196; GYLFE E, 1988, J BIOL CHEM, V263, P13750; JAMES G, 1989, J BIOL CHEM, V264, P20928; KAISER N, 1991, ENDOCRINOLOGY, V129, P2067, DOI 10.1210/endo-129-4-2067; LACY PE, 1967, DIABETES, V16, P35, DOI 10.2337/diab.16.1.35; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIANG Y, 1990, J BIOL CHEM, V265, P16863; MCILROY BK, 1991, J BIOL CHEM, V266, P4959; METZ SA, 1988, DIABETES, V37, P3, DOI 10.2337/diabetes.37.1.3; NIEDEL J E, 1986, P47; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; OHTA M, 1990, J BIOL CHEM, V265, P17525; OUIMET CC, 1990, J NEUROSCI, V10, P1683; PERSAUD SJ, 1989, FEBS LETT, V245, P80, DOI 10.1016/0014-5793(89)80196-6; ROSEN A, 1990, J EXP MED, V172, P1211, DOI 10.1084/jem.172.4.1211; RUEGG UT, 1989, TRENDS PHARMACOL SCI, V10, P218, DOI 10.1016/0165-6147(89)90263-0; SALARI H, 1990, BIOCHEM J, V267, P689, DOI 10.1042/bj2670689; SHARP GWG, 1980, DIABETES, V29, P74, DOI 10.2337/diabetes.29.1.74; SVENSSON C, 1991, DIABETES, V40, P771, DOI 10.2337/diabetes.40.6.771; TAMAOKI T, 1986, BIOCHEM BIOPH RES CO, V135, P397, DOI 10.1016/0006-291X(86)90008-2; TRILIVAS I, 1989, J BIOL CHEM, V264, P3102; WOLLHEIM CB, 1990, FEBS LETT, V268, P376, DOI 10.1016/0014-5793(90)81289-Z; ZAWALICH W, 1984, CELL CALCIUM, V5, P551, DOI 10.1016/0143-4160(84)90031-9; ZAWALICH W, 1983, BIOCHEM BIOPH RES CO, V117, P448, DOI 10.1016/0006-291X(83)91221-4; ZAWALICH WS, 1991, BIOCHEM J, V279, P807, DOI 10.1042/bj2790807; ZAWALICH WS, 1988, DIABETES, V37, P1294, DOI 10.2337/diabetes.37.9.1294	39	66	71	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1992	267	26					18723	18727						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JN502	1527003				2022-12-25	WOS:A1992JN50200073
J	TAKAGAKI, K; NAKAMURA, T; TAKEDA, Y; DAIDOUJI, K; ENDO, M				TAKAGAKI, K; NAKAMURA, T; TAKEDA, Y; DAIDOUJI, K; ENDO, M			A NEW ENDO-BETA-GALACTOSIDASE ACTING ON THE GAL-BETA-1-3GAL LINKAGE OF THE PROTEOGLYCAN LINKAGE REGION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SWARM RAT CHONDROSARCOMA; CHONDROITIN SULFATE; KERATAN SULFATE; OLIGOSACCHARIDES; GLYCOPROTEINS; XYLOSIDASE; DEPOLYMERIZATION; GLUCURONIDASE; PURIFICATION; HEPARANASE	A new type of endo-beta-galactosidase acting on the linkage region of peptidochondroitin sulfate was isolated from the mid-gut gland of the mollusk Patinopecten. The purification procedure included ammonium sulfate precipitation, Sephacryl S-200HR gel filtration, DEAE-Sephacel chromatography, and TSKgel Phenyl-5PW RP high performance liquid chromatography. The purified enzyme was free from exoglycosidases, sulfatases, and phosphatases. The specificity of the enzyme was as follows. 1) It acted on the internal galactoside linkage of sugar chains; 2) it specifically hydrolyzed the galactosylgalactose (Gal-beta-1-3Gal) linkage, but not the galactosylxylose (Gal-beta-1-4Xyl) linkage in the linkage region of peptidoglycans; 3) the enzyme activity was unaffected by the type of glycosaminoglycan, chondroitin sulfate, dermatan sulfate or heparan sulfate used as a substrate; 4) keratan sulfate and some oligosaccharides from glycolipid were not degraded by the enzyme. These properties of the endo-beta-galactosidase characterize it as a new endo-beta-galactosidase with unique specificity.	HIROSAKI UNIV,SCH MED,DEPT BIOCHEM,5 ZAIFU CHO,HIROSAKI,AOMORI 036,JAPAN	Hirosaki University								ARONSON NN, 1967, J BIOL CHEM, V242, P437; BARRETT AJ, 1972, LYSOSOMES LABORATORY, P110; COWMAN MK, 1981, BIOCHEMISTRY-US, V20, P1379, DOI 10.1021/bi00508a053; DEGASPERI R, 1986, J BIOL CHEM, V261, P5696; DELUCA S, 1980, J BIOL CHEM, V255, P6077; FRANSSON LA, 1985, J BIOL CHEM, V260, P4722; FUKUDA MN, 1985, BIOCHEMISTRY-US, V24, P2154, DOI 10.1021/bi00330a008; FUKUDA MN, 1976, J BIOL CHEM, V251, P6218; FUSHUKU N, 1987, J BIOL CHEM, V262, P10086; Hascall V. C., 1981, BIOL CARBOHYDRATES, V1, P1; HASE S, 1984, J BIOCHEM-TOKYO, V95, P197, DOI 10.1093/oxfordjournals.jbchem.a134585; HEINEGARD D, 1974, J BIOL CHEM, V249, P4250; IRIMURA T, 1986, BIOCHEMISTRY-US, V25, P5322, DOI 10.1021/bi00366a050; KITAMIKADO M, 1981, J BIOL CHEM, V256, P3906; KON A, 1991, J BIOCHEM-TOKYO, V110, P132, DOI 10.1093/oxfordjournals.jbchem.a123531; LEVVY GA, 1952, BIOCHEM J, V52, P464, DOI 10.1042/bj0520464; LINDAHL U, 1966, J BIOL CHEM, V241, P2113; Lindahl U., 1972, GLYCOPROTEINS THEIR, P491; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MALEY F, 1989, ANAL BIOCHEM, V180, P195, DOI 10.1016/0003-2697(89)90115-2; MATSUE H, 1987, BIOCHIM BIOPHYS ACTA, V923, P470, DOI 10.1016/0304-4165(87)90056-0; NAKAJIMA M, 1984, J BIOL CHEM, V259, P2283; NAKAMURA T, 1990, BIOCHEM BIOPH RES CO, V172, P70, DOI 10.1016/S0006-291X(05)80174-3; NORDEN AGW, 1974, J BIOL CHEM, V249, P7969; OEGEMA TR, 1984, J BIOL CHEM, V259, P1720; RAPPORT MM, 1951, J AM CHEM SOC, V73, P2416, DOI 10.1021/ja01150a003; Roden L., 1980, BIOCH GLYCOPROTEINS, P267; SAITO H, 1968, J BIOL CHEM, V243, P1536; SCUDDER P, 1983, BIOCHEM J, V213, P485, DOI 10.1042/bj2130485; SUGAHARA K, 1988, J BIOL CHEM, V263, P10168; TAKAGAKI K, 1990, BIOCHEM BIOPH RES CO, V169, P15, DOI 10.1016/0006-291X(90)91426-S; TAKAGAKI K, 1990, J BIOL CHEM, V265, P854; TAKAGAKI K, 1988, J BIOL CHEM, V263, P7000; TAKAGAKI K, 1988, BIOCHIM BIOPHYS ACTA, V966, P94, DOI 10.1016/0304-4165(88)90132-8; TAKAGAKI K, 1989, J BIOCHEM BIOPH METH, V19, P207, DOI 10.1016/0165-022X(89)90027-4; THUNBERG L, 1982, J BIOL CHEM, V257, P278; VARADI DP, 1967, BIOCHIM BIOPHYS ACTA, V141, P103, DOI 10.1016/0304-4165(67)90249-8; WASTESON A, 1971, BIOCHIM BIOPHYS ACTA, V252, P13, DOI 10.1016/0304-4165(71)90087-0	38	13	14	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1992	267	26					18558	18563						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JN502	1526992				2022-12-25	WOS:A1992JN50200050
J	HSUANYU, YC; DUNFORD, HB				HSUANYU, YC; DUNFORD, HB			PROSTAGLANDIN-H SYNTHASE KINETICS - THE EFFECT OF SUBSTITUTED PHENOLS ON CYCLOOXYGENASE ACTIVITY AND THE SUBSTITUENT EFFECT ON PHENOLIC PEROXIDATIC ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGHER OXIDATION-STATES; VESICULAR GLAND MICROSOMES; ELECTRON-PARAMAGNETIC-RES; HORSERADISH-PEROXIDASE; ENDOPEROXIDE SYNTHETASE; COMPOUND-II; LIPID PEROXIDES; BIOSYNTHESIS; HYDROPEROXIDE; PURIFICATION	A series of p- and m-substituted phenols were examined for their effect on the cyclooxygenase activity of prostaglandin H synthase in 0.1 M phosphate buffer at pH 8.0 and 25.0 +/- 0.1-degrees-C. A biphasic response was observed. At low concentrations phenols stimulate, but at higher concentrations inhibit, cyclooxygenase activity. Both enhancement and inhibition are increased by phenolic substituents which are electron-donating, quantified by Hammett sigma-constants, and hydrophobic, quantified by Hantsch pi-constants. The same series of substituted phenols was also reacted with compound II of prostaglandin H synthase at 4.0 +/- 0.5-degrees-C. The compound II data fit the Hammett rho-sigma-equation; no hydrophobicity factors are required. Phenols inhibit cyclooxygenase activity by interfering with the binding of arachidonic acid to compound I and by competing directly with arachidonic acid as reducing substrates for compound I. Phenols stimulate cyclooxygenase activity by acting as reducing substrates for compound II, thereby accelerating the peroxidatic cycle. Phenols also protect the enzyme from self-catalyzed inactivation, most likely by removing the free radical of prostaglandin G2 by reducing it to prostaglandin G2. Kinetic parameters K(m) and k(cat) for cyclooxygenase activity were determined in the presence of phenols. Identical values of K(m) (15.3 +/- 0.5 mM) and k(cat) (89 +/- 2 s-1) were obtained regardless of which phenol was employed. Therefore these represent the true K(m) and k(cat) values for cyclooxygenase activity.	UNIV ALBERTA,DEPT CHEM,EDMONTON T6G 2G2,ALBERTA,CANADA	University of Alberta								ATKINS WM, 1988, BIOCHEMISTRY-US, V27, P1610, DOI 10.1021/bi00405a033; BOHNE C, 1987, J BIOL CHEM, V262, P3572; DEWHIRST FE, 1980, PROSTAGLANDINS, V20, P209, DOI 10.1016/S0090-6980(80)80040-2; DIETZ R, 1988, EUR J BIOCHEM, V171, P321, DOI 10.1111/j.1432-1033.1988.tb13793.x; DUNFORD HB, 1986, ARCH BIOCHEM BIOPHYS, V251, P536, DOI 10.1016/0003-9861(86)90361-9; EASTMOND DA, 1987, TOXICOL APPL PHARM, V91, P85, DOI 10.1016/0041-008X(87)90196-7; Egan R W, 1980, Adv Prostaglandin Thromboxane Res, V6, P153; EGAN RW, 1976, J BIOL CHEM, V251, P7329; ELING TE, 1990, ANN REV PHARM TOXICO, V30, P10; GUENGERICH FP, 1991, J BIOL CHEM, V266, P10019; HAMBERG M, 1974, P NATL ACAD SCI USA, V71, P345, DOI 10.1073/pnas.71.2.345; Hansch C., 1979, SUBSTITUENT CONSTANT, P49; HANSCH C, 1975, ADV PHARMACOL CHEMOT, V13, P45; HARVISON PJ, 1988, CHEM-BIOL INTERACT, V64, P251, DOI 10.1016/0009-2797(88)90101-9; HEMLER M, 1976, J BIOL CHEM, V251, P5575; HEMLER ME, 1980, ARCH BIOCHEM BIOPHYS, V201, P586, DOI 10.1016/0003-9861(80)90548-2; HEMLER ME, 1979, ARCH BIOCHEM BIOPHYS, V193, P340, DOI 10.1016/0003-9861(79)90038-9; HEMLER ME, 1980, J BIOL CHEM, V255, P6253; HEMLER ME, 1978, BIOCHEM BIOPH RES CO, V85, P1325, DOI 10.1016/0006-291X(78)91148-8; HEWSON WD, 1976, J BIOL CHEM, V251, P6043; HEWSON WD, 1976, J BIOL CHEM, V251, P6036; HSUANYU Y, 1990, ARCH BIOCHEM BIOPHYS, V281, P282, DOI 10.1016/0003-9861(90)90445-5; HSUANYU Y, 1991, ANAL BIOCHEM, V198, P174, DOI 10.1016/0003-2697(91)90524-W; HSUANYU YC, 1990, BIOCHEM CELL BIOL, V68, P965, DOI 10.1139/o90-142; HSUANYU YC, 1992, ARCH BIOCHEM BIOPHYS, V292, P213, DOI 10.1016/0003-9861(92)90070-D; JOB D, 1976, EUR J BIOCHEM, V66, P607, DOI 10.1111/j.1432-1033.1976.tb10588.x; KARTHEIN R, 1988, EUR J BIOCHEM, V171, P313, DOI 10.1111/j.1432-1033.1988.tb13792.x; KULMACZ RJ, 1985, BIOCHEM BIOPH RES CO, V130, P918, DOI 10.1016/0006-291X(85)90504-2; KULMACZ RJ, 1983, PROSTAGLANDINS, V25, P531, DOI 10.1016/0090-6980(83)90025-4; KULMACZ RJ, 1986, ARCH BIOCHEM BIOPHYS, V249, P273, DOI 10.1016/0003-9861(86)90003-2; KULMACZ RJ, 1984, J BIOL CHEM, V259, P6358; KULMACZ RJ, 1985, J BIOL CHEM, V260, P2572; LAMBEIR AM, 1985, J BIOL CHEM, V260, P4894; LASSMANN G, 1991, J BIOL CHEM, V266, P20045; MACDONALD ID, 1989, BIOCHEM CELL BIOL, V67, P301; MARKEY CM, 1987, J BIOL CHEM, V262, P6266; MARNETT LJ, 1984, MOL PHARMACOL, V26, P328; MARNETT LJ, 1977, BIOCHIM BIOPHYS ACTA, V487, P222, DOI 10.1016/0005-2760(77)90058-3; MARSHALL PJ, 1987, J BIOL CHEM, V262, P3510; MIYAMOTO T, 1976, J BIOL CHEM, V251, P2629; NUGTEREN DH, 1973, BIOCHIM BIOPHYS ACTA, V326, P448, DOI 10.1016/0005-2760(73)90145-8; ODENWALLER R, 1990, ADV PROSTAGLANDIN TH, V21, P81; OHKI S, 1979, J BIOL CHEM, V254, P829; PAGELS WR, 1983, J BIOL CHEM, V258, P6517; PANGANAMALA RV, 1979, PROSTAGLANDINS, V17, P155, DOI 10.1016/0090-6980(79)90035-2; PLE P, 1989, J BIOL CHEM, V264, P13983; PORTER TD, 1991, J BIOL CHEM, V266, P13469; RAAG R, 1991, BIOCHEMISTRY-US, V30, P2674, DOI 10.1021/bi00224a016; ROBAK J, 1978, BIOCHEM PHARMACOL, V27, P393, DOI 10.1016/0006-2952(78)90367-2; ROTH GJ, 1980, J BIOL CHEM, V255, P1301; RUF HH, 1984, FEBS LETT, V165, P293, DOI 10.1016/0014-5793(84)80189-1; SCHLOSSER MJ, 1989, ENVIRON HEALTH PERSP, V82, P229, DOI 10.2307/3430780; SHIMOKAWA T, 1991, J BIOL CHEM, V266, P6168; SMITH WL, 1972, BIOCHEMISTRY-US, V11, P3276, DOI 10.1021/bi00767a024; SMITH WL, 1991, BIOCHIM BIOPHYS ACTA, V1083, P1, DOI 10.1016/0005-2760(91)90119-3; VANDEROUDERAA FJ, 1979, BIOCHIM BIOPHYS ACTA, V572, P29, DOI 10.1016/0005-2760(79)90197-8	56	65	66	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1992	267	25					17649	17657						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JM223	1517213				2022-12-25	WOS:A1992JM22300029
J	KELLY, KO; DEUTSCHER, MP				KELLY, KO; DEUTSCHER, MP			CHARACTERIZATION OF ESCHERICHIA-COLI RNASE PH	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRECURSORS	We have previously shown that the orfE gene of Escherichia coli encodes RNase PH. Here we show that the OrfE protein (purified as described in the accompanying paper) (Jensen, K. F., Andersen, J. T., and Poulsen, P. (1992) J. BioL Chem. 267, 17147-17152) has both the degradative and synthetic activities of RNase PH. This highly purified protein was used to characterize the enzymatic and structural properties of RNase PH. The enzyme requires a divalent cation and phosphate for activity, the latter property indicating that RNase PH is exclusively a phosphorolytic enzyme. Among tRNA-type substrates, the enzyme is most active against synthetic tRNA precursors containing extra residues following the -CCA sequence, and it can act on these molecules to generate mature tRNA with amino acid acceptor activity; 3'-phosphoryl-terminated molecules are not active as substrates. The equilibrium constant for RNase PH is near unity, suggesting that at the phosphate concentration present in vivo, the enzyme would participate in RNA degradation. The synthetic reaction of RNase PH displays a nonlinear response to increasing enzyme concentrations, and this may be due to self-aggregation of the protein. Higher order multimers of RNase PH could be detected by gel filtration at higher protein concentrations and by protein cross-linking. The possible role of RNase PH in tRNA processing is discussed.	UNIV CONNECTICUT,CTR HLTH,DEPT BIOCHEM,FARMINGTON,CT 06030	University of Connecticut					NIGMS NIH HHS [GM16137] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CUDNY H, 1988, J BIOL CHEM, V263, P1518; CUDNY H, 1980, P NATL ACAD SCI-BIOL, V77, P837, DOI 10.1073/pnas.77.2.837; DEUTSCHER MP, 1978, NUCLEIC ACIDS RES, V5, P3821, DOI 10.1093/nar/5.10.3821; DEUTSCHER MP, 1988, P NATL ACAD SCI USA, V85, P4710, DOI 10.1073/pnas.85.13.4710; DIGNAM JD, 1980, BIOCHEMISTRY-US, V19, P4978, DOI 10.1021/bi00563a007; EVANS JA, 1976, J BIOL CHEM, V251, P6646; GRUNBERGMANAGO M, 1955, J AM CHEM SOC, V77, P3165, DOI 10.1021/ja01616a093; JENSEN KF, 1992, J BIOL CHEM, V267, P17147; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; OST KA, 1991, J BACTERIOL, V173, P5589, DOI 10.1128/jb.173.17.5589-5591.1991; OST KA, 1990, BIOCHIMIE, V72, P813, DOI 10.1016/0300-9084(90)90190-R; POULSEN P, 1984, EMBO J, V3, P1783, DOI 10.1002/j.1460-2075.1984.tb02046.x	13	42	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1992	267	24					17153	17158						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JL053	1512253				2022-12-25	WOS:A1992JL05300067
J	PUOPOLO, K; SCZEKAN, M; MAGNER, R; FORGAC, M				PUOPOLO, K; SCZEKAN, M; MAGNER, R; FORGAC, M			THE 40-KDA SUBUNIT ENHANCES BUT IS NOT REQUIRED FOR ACTIVITY OF THE COATED VESICLE PROTON PUMP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VACUOLAR H+-ATPASE; CHROMAFFIN GRANULES; NEUROSPORA-CRASSA; MEMBRANE ATPASE; CDNA SEQUENCE; TRANSLOCATING ATPASE; TONOPLAST ATPASE; BOVINE KIDNEY; OAT ROOTS; POLYPEPTIDE	We have previously demonstrated reassembly of a functional vacuolar (H+)-ATPase from clathrin-coated vesicles using the dissociated peripheral domain (V1) and the membrane-bound integral domain (V0) (Puopolo, K., and Forgac, M. (1990) J. Biol. Chem. 265, 14836-14841). We have used this reassembly procedure to test the function of the 40-kDa subunit of the coated vesicle (H+)-ATPase. In the absence of V0, a fraction of the peripheral subunits reassemble into a V1 subcomplex which contains the 73-kDa A subunit, the 58-kDa B subunit, and the 34- and 33-kDa subunits but lacks the 40-kDa subunit. This subcomplex, which sediments with a mass of approximately 500 kDa, can be separated from the remaining monomeric subunits (and the 40-kDa subunit) by density gradient sedimentation. When dissociated with 0.36 M KI, 2.5 mM ATP, and 2.5 mM MgSO4, and added to membranes from which V1 has been dissociated, this V1(-40 kDa) subcomplex is able to reassemble with V0 to give a (H+)-ATPase with a proton pumping activity approximately half that obtained in the presence of the 40-kDa subunit. The undissociated subcomplex is not competent for assembly of a functional (H+)-ATPase. Interestingly, the monomeric fraction obtained from density gradient sedimentation contains the 40-kDa subunit but lacks the 34-kDa subunit. This monomeric fraction is nevertheless also able to assemble with V0 to give a functional proton pump. The V1V0 complexes assembled in the absence of either the 40- or 34-kDa subunits, while active, are not stable to detergent solubilization and immunoprecipitation, suggesting that both of these subunits play a role in stabilization of the (H+)-ATPase complex. Evidence for interaction between the 40- and 33-kDa subunits is also presented.	TUFTS UNIV, SCH MED, DEPT PHYSIOL, BOSTON, MA 02111 USA	Tufts University			Puopolo, Karen/AAY-7748-2021		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK034928] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034478, R37GM034478] Funding Source: NIH RePORTER; NIDDK NIH HHS [P30 DK 34928] Funding Source: Medline; NIGMS NIH HHS [R01 GM034478, GM 34478] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADACHI I, 1990, J BIOL CHEM, V265, P967; ADACHI I, 1990, J BIOL CHEM, V265, P960; APPS DK, 1989, BIOCHEM J, V263, P81, DOI 10.1042/bj2630081; ARAI H, 1987, J BIOL CHEM, V262, P11006; ARAI H, 1987, BIOCHEMISTRY-US, V26, P6632, DOI 10.1021/bi00395a011; ARAI H, 1989, BIOCHEMISTRY-US, V28, P3075, DOI 10.1021/bi00433a051; ARAI H, 1988, J BIOL CHEM, V263, P8796; BOWMAN BJ, 1988, J BIOL CHEM, V263, P14002; BOWMAN BJ, 1989, J BIOL CHEM, V264, P15606; BOWMAN EJ, 1983, J BIOL CHEM, V258, P5238; BOWMAN EJ, 1988, J BIOL CHEM, V263, P13994; BOWMAN EJ, 1986, P NATL ACAD SCI USA, V83, P48, DOI 10.1073/pnas.83.1.48; FORGAC M, 1984, J BIOL CHEM, V259, P8101; FORGAC M, 1989, PHYSIOL REV, V69, P765, DOI 10.1152/physrev.1989.69.3.765; FUTAI M, 1989, ANNU REV BIOCHEM, V58, P111; GLUCK S, 1987, J BIOL CHEM, V262, P15780; HIRSCH S, 1988, P NATL ACAD SCI USA, V85, P3004, DOI 10.1073/pnas.85.9.3004; KAESTNER KH, 1988, J BIOL CHEM, V263, P1282; KANE PM, 1989, J BIOL CHEM, V264, P19236; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAI SP, 1988, J BIOL CHEM, V263, P16731; MANDALA S, 1986, J BIOL CHEM, V261, P2850; MANDEL M, 1988, P NATL ACAD SCI USA, V85, P5521, DOI 10.1073/pnas.85.15.5521; MANOLSON MF, 1985, J BIOL CHEM, V260, P2273; MANOLSON MF, 1988, J BIOL CHEM, V263, P17987; MORIYAMA Y, 1989, J BIOL CHEM, V264, P3577; NELSON H, 1989, J BIOL CHEM, V264, P1775; NELSON H, 1990, J BIOL CHEM, V265, P20390; NELSON N, 1989, TRENDS BIOCHEM SCI, V14, P113, DOI 10.1016/0968-0004(89)90134-5; OAKLEY BR, 1980, ANAL BIOCHEM, V105, P361, DOI 10.1016/0003-2697(80)90470-4; PARRY RV, 1989, J BIOL CHEM, V264, P20025; PEDERSEN PL, 1987, TRENDS BIOCHEM SCI, V12, P146, DOI 10.1016/0968-0004(87)90071-5; PERIN MS, 1991, J BIOL CHEM, V266, P3877; PUOPOLO K, 1990, J BIOL CHEM, V265, P14836; PUOPOLO K, 1991, J BIOL CHEM, V266, P24564; RANDALL SK, 1987, J BIOL CHEM, V262, P7135; SENIOR AE, 1988, PHYSIOL REV, V68, P177, DOI 10.1152/physrev.1988.68.1.177; SUN SZ, 1987, J BIOL CHEM, V262, P14790; UCHIDA E, 1988, J BIOL CHEM, V263, P45; UCHIDA E, 1985, J BIOL CHEM, V260, P1090; WANG SY, 1988, J BIOL CHEM, V263, P17638; YOUNG GPH, 1988, P NATL ACAD SCI USA, V85, P9590, DOI 10.1073/pnas.85.24.9590; YSERN X, 1988, J BIOENERG BIOMEMBR, V20, P423, DOI 10.1007/BF00762202; ZIMNIAK L, 1988, J BIOL CHEM, V263, P9102; [No title captured]	45	68	69	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 15	1992	267	8					5171	5176						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HH747	1531980				2022-12-25	WOS:A1992HH74700028
J	BRUNDAGE, L; FIMMEL, CJ; MIZUSHIMA, S; WICKNER, W				BRUNDAGE, L; FIMMEL, CJ; MIZUSHIMA, S; WICKNER, W			SECY, SECE, AND BAND-1 FORM THE MEMBRANE-EMBEDDED DOMAIN OF ESCHERICHIA-COLI PREPROTEIN TRANSLOCASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TRANSLOCATION; PRECURSOR PROTEINS; PLASMA-MEMBRANE; TRIGGER FACTOR; PRLA SECY; EXPORT; BINDING; COMPONENT; PROOMPA; GENE	The preprotein translocase of Escherichia coli is a multisubunit enzyme with two domains, the peripheral membrane protein SecA and the membrane-embedded SecY/E protein. SecY/E has been isolated as a complex of three polypeptides, SecY, SecE, and band 1. We now present four lines of evidence that the active species of SecY/E is composed of a tightly associated complex of these three subunits: 1) antibodies to SecY efficiently precipitate SecY/E activity as well as all three polypeptides; 2) the proportions of SecY, SecE, and band 1 in the immunoprecipitates are the same as in the starting fraction; 3) the immunoprecipitable complex is not disrupted by treatment with either high salt or urea but is disrupted by brief incubation at 20-degrees-C, and the kinetics of dissociation of both band 1 and SecE from SecY at 20-degrees-C parallel the loss of translocation ATPase activity; 4) upon immunoprecipitation of similar units of activity of translocase from detergent solutions from either wild-type membranes or a SecY and SecE overproducer strain, the SecE and band 1 subunits are recovered in the same proportions. These data establish that the subunits of SecY/E are firmly associated and that it is the associated complex which is active for translocation.	UNIV CALIF LOS ANGELES, INST MOLEC BIOL, LOS ANGELES, CA 90024 USA; UNIV CALIF LOS ANGELES, DEPT BIOL CHEM, LOS ANGELES, CA 90024 USA; UNIV TOKYO, INST APPL MICROBIOL, BUNKYO KU, TOKYO 113, JAPAN	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of Tokyo					NCI NIH HHS [CA09056] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKIMARU J, 1991, P NATL ACAD SCI USA, V88, P6545, DOI 10.1073/pnas.88.15.6545; AKITA M, 1990, J BIOL CHEM, V265, P8164; AKIYAMA Y, 1990, BIOCHEM BIOPH RES CO, V167, P711, DOI 10.1016/0006-291X(90)92083-C; BIEKER KL, 1990, J BIOENERG BIOMEMBR, V22, P291, DOI 10.1007/BF00763169; BIEKER KL, 1990, CELL, V61, P833, DOI 10.1016/0092-8674(90)90193-I; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUNDAGE L, 1990, CELL, V62, P649, DOI 10.1016/0092-8674(90)90111-Q; CERRETTI DP, 1983, NUCLEIC ACIDS RES, V11, P2599, DOI 10.1093/nar/11.9.2599; CHANG CN, 1979, P NATL ACAD SCI USA, V76, P1251, DOI 10.1073/pnas.76.3.1251; CROOKE E, 1988, CELL, V54, P1003, DOI 10.1016/0092-8674(88)90115-8; CUNNINGHAM K, 1989, EMBO J, V8, P955, DOI 10.1002/j.1460-2075.1989.tb03457.x; DESHAIES RJ, 1991, NATURE, V349, P806, DOI 10.1038/349806a0; DRIESSEN AJM, 1990, P NATL ACAD SCI USA, V87, P3107, DOI 10.1073/pnas.87.8.3107; GARDEL C, 1990, EMBO J, V9, P3209, DOI 10.1002/j.1460-2075.1990.tb07519.x; HARLOW E, 1988, ANTIBODIES LABORATOR, P109; HARTL FU, 1990, CELL, V63, P269, DOI 10.1016/0092-8674(90)90160-G; HENDRICK JP, 1991, J BIOL CHEM, V266, P24596; ITO K, 1984, MOL GEN GENET, V197, P204, DOI 10.1007/BF00330964; KIEBLER M, 1990, NATURE, V348, P610, DOI 10.1038/348610a0; KUMAMOTO CA, 1989, P NATL ACAD SCI USA, V86, P5320, DOI 10.1073/pnas.86.14.5320; LECKER S, 1989, EMBO J, V8, P2703, DOI 10.1002/j.1460-2075.1989.tb08411.x; LECKER SH, 1990, EMBO J, V9, P2309, DOI 10.1002/j.1460-2075.1990.tb07402.x; LILL R, 1990, CELL, V60, P271, DOI 10.1016/0092-8674(90)90742-W; LILL R, 1989, EMBO J, V8, P961, DOI 10.1002/j.1460-2075.1989.tb03458.x; MATSUYAMA S, 1990, FEBS LETT, V269, P96, DOI 10.1016/0014-5793(90)81128-B; OLIVER DB, 1982, CELL, V30, P311, DOI 10.1016/0092-8674(82)90037-X; SCHATZ PJ, 1990, ANNU REV GENET, V24, P215, DOI 10.1146/annurev.ge.24.120190.001243; SCHATZ PJ, 1989, GENE DEV, V3, P1035, DOI 10.1101/gad.3.7.1035; SCHIEBEL E, 1991, CELL, V64, P927, DOI 10.1016/0092-8674(91)90317-R; SUGIMURA K, 1988, J BACTERIOL, V170, P3650, DOI 10.1128/jb.170.8.3650-3654.1988; TOKUDA H, 1991, FEBS LETT, V279, P233, DOI 10.1016/0014-5793(91)80156-W; TRAVERS AA, 1969, NATURE, V222, P537, DOI 10.1038/222537a0; VERNER K, 1988, SCIENCE, V241, P1307, DOI 10.1126/science.2842866; VESTWEBER D, 1989, NATURE, V341, P205, DOI 10.1038/341205a0; WATANABE M, 1989, P NATL ACAD SCI USA, V86, P1895, DOI 10.1073/pnas.86.6.1895; WICKNER W, 1972, P NATL ACAD SCI USA, V69, P965, DOI 10.1073/pnas.69.4.965; WICKNER W, 1991, ANNU REV BIOCHEM, V60, P101, DOI 10.1146/annurev.bi.60.070191.000533	37	106	106	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	1992	267	6					4166	4170						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HE607	1531482				2022-12-25	WOS:A1992HE60700088
J	KOYASU, S; MCCONKEY, DJ; CLAYTON, LK; ABRAHAM, S; YANDAVA, B; KATAGIRI, T; MOINGEON, P; YAMAMOTO, T; REINHERZ, EL				KOYASU, S; MCCONKEY, DJ; CLAYTON, LK; ABRAHAM, S; YANDAVA, B; KATAGIRI, T; MOINGEON, P; YAMAMOTO, T; REINHERZ, EL			PHOSPHORYLATION OF MULTIPLE CD3-ZETA TYROSINE RESIDUES LEADS TO FORMATION OF PP21 INVITRO AND INVIVO - STRUCTURAL-CHANGES UPON T-CELL RECEPTOR STIMULATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTIGEN RECEPTOR; ZETA-CHAIN; MOLECULAR-CLONING; ETA-CHAIN; POSSIBLE IDENTIFICATION; SIGNAL TRANSDUCTION; DISULFIDE LINKAGE; KINASE P56LCK; COMPLEX; GENE	T lymphocyte activation resulting from antigen recognition involves a protein tyrosine kinase pathway which triggers phosphorylation of several cellular substrates including the CD3-zeta subunit of the T cell receptor (TCR) to form pp21. The homologous TCR-associated protein, CD3-eta, is an alternatively spliced product of the same gene locus as CD3-zeta. CD3-eta lacks one of six cytoplasmic tyrosine residues (Tyr-132) found in CD3-zeta and is itself not phosphorylated. Site-directed mutagenesis in conjunction with in vitro and in vivo phosphorylation studies herein demonstrates that Tyr-132 is required for the formation of pp21. Moreover, the differential phosphorylation of CD3-zeta versus CD3-eta is not due to a selective association of the known TCR-associated protein tyrosine kinase, p59fyn; p59fyn but not p56lck or p62yes is associated with each of the three TCR isoforms containing CD3-zeta-2, CD3-eta-2, or CD3-zeta-eta. This association occurs through components of the TCR complex distinct from CD3-zeta or CD3-eta. In addition we show that pp21 formation is not only dependent on Tyr-132 but results from concomitant phosphorylation of other CD3-zeta residues including Tyr-121. Mutation of Tyr-90, -121, or -132 does not alter primary signal transduction as shown by the ability of individual CD3-zeta Tyr --> Phe mutants to produce interleukin-2 upon TCR stimulation. Thus, the substantial structural changes in CD3-zeta upon TCR stimulation as reflected by alteration in its mobility in sodium dodecyl sulfate-polyacrylamide gel electrophoresis may affect subsequent events such as receptor desensitization, receptor movement, and/or protein associations.	HARVARD UNIV, SCH MED, DEPT PATHOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT MED, BOSTON, MA 02115 USA; UNIV TOKYO, INST MED SCI, MINATO KU, TOKYO 108, JAPAN	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; University of Tokyo	KOYASU, S (corresponding author), HARVARD UNIV, SCH MED, DANA FARBER CANC INST, IMMUNOBIOL LAB, BOSTON, MA 02115 USA.		Koyasu, Shigeo/J-5583-2015	Koyasu, Shigeo/0000-0001-9585-3038; Moingeon, Philippe/0000-0002-2380-9983	NIAID NIH HHS [AI19807, AI21226, AI31269] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R56AI019807, R01AI019807, R37AI019807, R01AI021226, R01AI031269] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ASHWELL JD, 1990, ANNU REV IMMUNOL, V8, P139, DOI 10.1146/annurev.immunol.8.1.139; BANIYASH M, 1988, J BIOL CHEM, V263, P18225; BANIYASH M, 1988, J BIOL CHEM, V263, P9874; BAUER A, 1991, P NATL ACAD SCI USA, V88, P3842, DOI 10.1073/pnas.88.9.3842; BLANK U, 1989, NATURE, V337, P187, DOI 10.1038/337187a0; BRENNER MB, 1988, ADV IMMUNOL, V43, P133; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CLAYTON LK, 1990, J EXP MED, V172, P1243, DOI 10.1084/jem.172.4.1243; CLAYTON LK, 1991, P NATL ACAD SCI USA, V88, P5202, DOI 10.1073/pnas.88.12.5202; CLEVERS H, 1988, ANNU REV IMMUNOL, V6, P629, DOI 10.1146/annurev.iy.06.040188.003213; COOPER JA, 1984, J BIOL CHEM, V259, P7835; DAVIS MM, 1988, NATURE, V334, P395, DOI 10.1038/334395a0; FLIER JS, 1989, NEW ENGL J MED, V321, P1383, DOI 10.1056/NEJM198911163212007; FRANK SJ, 1990, SCIENCE, V249, P174, DOI 10.1126/science.2371564; GOLD DP, 1987, P NATL ACAD SCI USA, V84, P1664, DOI 10.1073/pnas.84.6.1664; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.biochem.54.1.897; IRVING BA, 1991, CELL, V64, P891, DOI 10.1016/0092-8674(91)90314-O; JIN YJ, 1990, P NATL ACAD SCI USA, V87, P3319, DOI 10.1073/pnas.87.9.3319; JUNE CH, 1990, J IMMUNOL, V144, P1591; JUNE CH, 1990, P NATL ACAD SCI USA, V87, P7722, DOI 10.1073/pnas.87.19.7722; KATAGIRI T, 1989, P NATL ACAD SCI USA, V86, P10064, DOI 10.1073/pnas.86.24.10064; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KOYASU S, 1991, CURR OPIN IMMUNOL, V3, P32, DOI 10.1016/0952-7915(91)90073-A; KRISSANSEN GW, 1986, EMBO J, V5, P1799, DOI 10.1002/j.1460-2075.1986.tb04429.x; KUSTER H, 1990, J BIOL CHEM, V265, P6448; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEO O, 1987, P NATL ACAD SCI USA, V84, P1374, DOI 10.1073/pnas.84.5.1374; MARRACK P, 1987, SCIENCE, V238, P1073, DOI 10.1126/science.3317824; MEUER SC, 1984, ANNU REV IMMUNOL, V2, P23, DOI 10.1146/annurev.immunol.2.1.23; MUSTELIN T, 1990, SCIENCE, V247, P1584, DOI 10.1126/science.2138816; NAKAYAMA T, 1989, NATURE, V341, P651, DOI 10.1038/341651a0; OHASHI PS, 1985, NATURE, V316, P606, DOI 10.1038/316606a0; OHNO H, 1990, INT IMMUNOL, V2, P1117, DOI 10.1093/intimm/2.11.1117; ORLOFF DG, 1990, NATURE, V347, P189, DOI 10.1038/347189a0; PARK DJ, 1991, P NATL ACAD SCI USA, V88, P5453, DOI 10.1073/pnas.88.12.5453; RAMARLI D, 1987, P NATL ACAD SCI USA, V84, P8598, DOI 10.1073/pnas.84.23.8598; RAULET DH, 1989, ANNU REV IMMUNOL, V7, P175, DOI 10.1146/annurev.iy.07.040189.001135; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; RODEWALD HR, 1991, J BIOL CHEM, V266, P15974; ROMEO C, 1991, CELL, V64, P1037, DOI 10.1016/0092-8674(91)90327-U; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; SAMELSON LE, 1983, P NATL ACAD SCI-BIOL, V80, P6972, DOI 10.1073/pnas.80.22.6972; SECRIST JP, 1991, J BIOL CHEM, V266, P12135; SIBLEY DR, 1987, CELL, V48, P913, DOI 10.1016/0092-8674(87)90700-8; STANLEY JB, 1990, J IMMUNOL, V145, P2189; SUKEGAWA J, 1990, ONCOGENE, V5, P611; SUSSMAN JJ, 1988, CELL, V52, P85, DOI 10.1016/0092-8674(88)90533-8; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VANDENELSEN P, 1985, P NATL ACAD SCI USA, V82, P2920, DOI 10.1073/pnas.82.9.2920; VEILLETTE A, 1988, MOL CELL BIOL, V8, P4353, DOI 10.1128/MCB.8.10.4353; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; WEISS A, 1991, P NATL ACAD SCI USA, V88, P5484, DOI 10.1073/pnas.88.13.5484; WEISSMAN AM, 1988, SCIENCE, V239, P1018, DOI 10.1126/science.3278377; WEISSMAN AM, 1988, P NATL ACAD SCI USA, V85, P9709, DOI 10.1073/pnas.85.24.9709; WEISSMAN AM, 1989, EMBO J, V8, P3651, DOI 10.1002/j.1460-2075.1989.tb08539.x	56	61	61	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 15	1992	267	5					3375	3381						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HD154	1531339				2022-12-25	WOS:A1992HD15400086
J	DEMAUREX, N; LEW, DP; KRAUSE, KH				DEMAUREX, N; LEW, DP; KRAUSE, KH			CYCLOPIAZONIC ACID DEPLETES INTRACELLULAR CA2+ STORES AND ACTIVATES AN INFLUX PATHWAY FOR DIVALENT-CATIONS IN HL-60 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOSOLIC FREE CALCIUM; INOSITOL 1,4,5-TRISPHOSPHATE; HUMAN-NEUTROPHILS; PLASMA-MEMBRANE; HUMAN-LEUKOCYTES; CA-2+ INFLUX; INHIBITOR; CHANNELS; ENTRY; CA-2+-ATPASE	The filling state of intracellular Ca2+ stores has been proposed to regulate Ca2+ influx across the plasma membrane in a variety of tissues. To test this hypothesis, we have used three structurally unrelated inhibitors of the Ca2+-ATPase of intracellular Ca2+ stores and investigated their effect on Ca" homeostasis in HL-60 cells. Without increasing cellular inositol (1,4,5)trisphosphate levels, all three inhibitors (cyclopiazonic acid, thapsigargin, and 2, 5-Di-tert-butylhydroquinone) released Ca2+ from intracellular stores, resulting in total depletion of agonist-sensitive Ca2+ stores. The Ca2+ release was relatively slow with a lag time of 5 s and a time to peak of 60 s. After a lag time of approximately 15 s, all three Ca2+-ATPase inhibitors activated a pathway for divalent cation influx across the plasma membrane. At a given concentration of an inhibitor, the plasma membrane permeability for divalent cations closely correlated with the extent of depletion of Ca2+ stores. The influx pathway activated by Ca2+-ATPase inhibitors conducted Ca2+, Mn2+, Co2+, Zn2+, and Ba2+ and was blocked, at similar concentrations, by La3+, Ni2+, Cd2+, as well as by the imidazole derivate SK&F 96365. The divalent cation influx in response to the chemotactic peptide fMLP had the same characteristics, suggesting a common pathway for Ca2+ entry. Our results support the idea that the filling state of intracellular Ca2+ stores regulates Ca2+ influx in HL-60 cells.			DEMAUREX, N (corresponding author), UNIV GENEVA,HOP CANTONAL,DIV INFECT DIS,CH-1211 GENEVA 4,SWITZERLAND.		Krause, Karl-Heinz/E-8030-2011	Krause, Karl-Heinz/0000-0002-9033-6768; Demaurex, Nicolas/0000-0002-9933-6772				ANDERSSON T, 1986, MOL PHARMACOL, V30, P437; BRUNE B, 1991, FEBS LETT, V284, P1, DOI 10.1016/0014-5793(91)80747-Q; BURGESS GM, 1984, FEBS LETT, V176, P193, DOI 10.1016/0014-5793(84)80939-4; CROFTS JN, 1990, BIOCHEM J, V269, P579, DOI 10.1042/bj2690579; DOUGHERTY RW, 1984, BIOCHEM J, V222, P307, DOI 10.1042/bj2220307; FOX AP, 1987, J PHYSIOL-LONDON, V394, P149, DOI 10.1113/jphysiol.1987.sp016864; HASSELBACH W, 1978, BIOCHIM BIOPHYS ACTA, V515, P23, DOI 10.1016/0304-4157(78)90007-2; HIDE M, 1991, J BIOL CHEM, V266, P15221; KASS GEN, 1990, J BIOL CHEM, V265, P17486; KASS GEN, 1989, J BIOL CHEM, V264, P15192; KRAUSE KH, 1985, J CLIN INVEST, V76, P1348, DOI 10.1172/JCI112109; LEW PD, 1986, J BIOL CHEM, V261, P3121; LLOPIS J, 1991, BIOCHEM J, V277, P553, DOI 10.1042/bj2770553; MERRITT JE, 1990, BIOCHEM J, V271, P515, DOI 10.1042/bj2710515; MONTERO M, 1990, BIOCHEM J, V271, P535, DOI 10.1042/bj2710535; MOORE GA, 1987, FEBS LETT, V224, P331, DOI 10.1016/0014-5793(87)80479-9; NACHSHEN DA, 1984, J GEN PHYSIOL, V83, P941, DOI 10.1085/jgp.83.6.941; NASMITH PE, 1987, FEBS LETT, V221, P95, DOI 10.1016/0014-5793(87)80359-9; NILIUS B, 1985, NATURE, V316, P443, DOI 10.1038/316443a0; PITTET D, 1989, J BIOL CHEM, V264, P18489; PITTET D, 1989, J BIOL CHEM, V264, P7251; POZZAN T, 1983, SCIENCE, V221, P1413, DOI 10.1126/science.6310757; PRENTKI M, 1984, J BIOL CHEM, V259, P3777; PUTNEY JW, 1986, CELL CALCIUM, V7, P1, DOI 10.1016/0143-4160(86)90026-6; PUTNEY JW, 1990, CELL CALCIUM, V11, P611, DOI 10.1016/0143-4160(90)90016-N; SEIDLER NW, 1989, J BIOL CHEM, V264, P17816; TAKEMURA H, 1989, BIOCHEM J, V258, P409, DOI 10.1042/bj2580409; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; TSIEN RW, 1987, ANNU REV BIOPHYS BIO, V16, P265; VONTSCHARNER V, 1986, NATURE, V324, P339	30	284	286	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1992	267	4					2318	2324						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HB532	1531138				2022-12-25	WOS:A1992HB53200033
J	LI, Z; CASTELLINO, FJ				LI, Z; CASTELLINO, FJ			INFLUENCE OF SPECIFIC GAMMA-CARBOXYGLUTAMIC ACID RESIDUES ON THE INTEGRITY OF THE CALCIUM-DEPENDENT CONFORMATION OF HUMAN PROTEIN-C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLOOD CLOT LYSIS; STRUCTURAL REQUIREMENTS; CA2+ BINDING; FACTOR-IX; ACTIVATION; PLASMA; ANTICOAGULANT; PROTHROMBIN; THROMBIN; COFACTOR	The concentration of Ca2+ that produced 50% of the saturable intrinsic fluorescence change (C50) of wild-type (wt) recombinant (r) human protein C (PC) was 0.40 mM. The C50 for Ca2+ increased <2.5-fold for the following r-PC variants (Gla is gamma-carboxyglutamic acid): [Gla6 --> Asp]r-PC, [Gla7 --> Asp]r-PC, [Gla14 --> Asp]r-PC, [Gla19 --> Asp]r-PC, or [Gla25 --> Asp]r-PC, and approximately 4-6-fold for [Gla20 --> Asp]r-PC and [Gla29 --> Asp]r-PC. Much more dramatic increases in the C50 for Ca2+ were observed for [Gla16 --> Asp]r-PC (>75-fold) and [Gla26 --> Asp]r-PC (ca. 30-fold). A substantially larger maximum fluorescence change (>3-fold) as compared to that for wtr-PC, was also found in the case of the Ca2+/[Gla16 --> Asp]r-PC complex, suggesting that the final Ca2+-induced conformation for this variant is dissimilar to that for wtr-PC and the above mutants. When a mutation was constructed at Arg15 ([Arg15 --> Leu]r-PC), a residue conserved in all Gla-containing coagulation proteins, no fluorescence alteration occurred upon addition of Ca2+. The C50 for Ca2+ for promotion of the binding of the Ca2+-dependent, Gla-domain-directed, conformational monoclonal antibodies, JTC-1 and JTC-3, to wtr-PC was 3.0 and 4.0 mM, respectively. A similar C50 value was found for [Gla6 --> Asp]r-PC. In the case of each antibody, approximately 4-6-fold higher C50 values for Ca2+ were found for the mutants; [Gla14 --> Asp]r-PC, [Gla19 --> Asp]r-PC, and [Gla29 --> Asp]r-PC. Ca2+ did not promote binding of either of these antibodies to the following variants; [Gla6 --> Asp]r-PC, [Gla7 --> Asp] r-PC, [Arg15 --> Leu]r-PC, [Gla16 --> Asp]r-PC, [Gla20 --> Asp]r-PC, and [Gla26 --> Asp]r-PC. The results of this study suggest that adoption of the Ca2+-dependent conformation of PC is greatly dependent upon the presence of specific essential Gla residues, particularly those, namely Gla16 and Gla26, shown in the crystal structure of the prothrombin Gla domain/Ca2+ complex to be involved with coordination of Ca2+ ions not exposed to the surface. Of similar importance is Arg15. On the other hand, Gla residues at positions 14 and 19 are much less important in directing this same conformation. This finding is readily reconciled with the above crystal structure, which shows that these latter 2 residues are mainly responsible for coordination of a surface-exposed Ca2+ that is present at the end of the Ca2+-ion channel.	UNIV NOTRE DAME,DEPT CHEM & BIOCHEM,NOTRE DAME,IN 46556	University of Notre Dame	CASTELLINO, FJ (corresponding author), UNIV NOTRE DAME,DEPT CHEM & BIOCHEM,NOTRE DAME,IN 46556, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL019982] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-19982] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AMPHLETT GW, 1981, BIOCHEMISTRY-US, V20, P2156, DOI 10.1021/bi00511a013; ASTERMARK J, 1991, J BIOL CHEM, V266, P2430; BAJZAR L, 1991, THROMB HAEMOSTASIS, V65, P1199; BAJZAR L, 1990, J BIOL CHEM, V265, P16948; BECKMANN RJ, 1985, NUCLEIC ACIDS RES, V13, P5233, DOI 10.1093/nar/13.14.5233; COMP PC, 1981, J CLIN INVEST, V68, P1221, DOI 10.1172/JCI110368; DEFOUW NJ, 1986, BLOOD, V67, P1189; DEGEN SJF, 1983, BIOCHEMISTRY-US, V22, P2087, DOI 10.1021/bi00278a008; DRAKENBERG T, 1983, P NATL ACAD SCI-BIOL, V80, P1802, DOI 10.1073/pnas.80.7.1802; ESMON NL, 1982, J BIOL CHEM, V257, P859; ESMON NL, 1983, J BIOL CHEM, V258, P5548; FOSTER D, 1985, P NATL ACAD SCI USA, V81, P4766; FOSTER DC, 1985, P NATL ACAD SCI USA, V82, P4673, DOI 10.1073/pnas.82.14.4673; HAGEN FS, 1986, P NATL ACAD SCI USA, V83, P2412, DOI 10.1073/pnas.83.8.2412; HEEB MJ, 1988, THROMB RES, V52, P33, DOI 10.1016/0049-3848(88)90038-2; HILL KAW, 1987, ARCH BIOCHEM BIOPHYS, V254, P196, DOI 10.1016/0003-9861(87)90095-6; JOHNSON AE, 1983, J BIOL CHEM, V258, P5554; KISIEL W, 1979, J CLIN INVEST, V64, P761, DOI 10.1172/JCI109521; KISIEL W, 1977, BIOCHEMISTRY-US, V16, P5824, DOI 10.1021/bi00645a029; KURACHI K, 1982, P NATL ACAD SCI-BIOL, V79, P6461, DOI 10.1073/pnas.79.21.6461; MANN KG, 1988, ANNU REV BIOCHEM, V57, P915, DOI 10.1146/annurev.bi.57.070188.004411; NELSESTUEN GL, 1976, J BIOL CHEM, V251, P5648; OHLIN AK, 1988, J BIOL CHEM, V263, P7411; PERSSON E, 1991, J BIOL CHEM, V266, P2444; REZAIE AR, 1992, J BIOL CHEM, V267, P11701; SAKATA Y, 1986, BLOOD, V68, P1218; SORIANOGARCIA M, 1992, BIOCHEMISTRY-US, V31, P2554, DOI 10.1021/bi00124a016; TAYLOR FB, 1985, THROMB RES, V37, P639, DOI 10.1016/0049-3848(85)90193-8; VEHAR GA, 1980, BIOCHEMISTRY-US, V19, P401, DOI 10.1021/bi00544a001; WAKABAYASHI K, 1986, J BIOL CHEM, V261, P1097; WALKER FJ, 1981, J BIOL CHEM, V256, P1128; WALKER FJ, 1980, J BIOL CHEM, V255, P5521; WEINSTEIN RE, 1991, THROMB RES, V63, P123, DOI 10.1016/0049-3848(91)90275-2; YAN SCB, 1990, BIO-TECHNOL, V8, P655, DOI 10.1038/nbt0790-655; ZHANG L, 1990, BIOCHEMISTRY-US, V29, P10828, DOI 10.1021/bi00500a016; ZHANG L, 1992, BLOOD, V80, P942; ZHANG L, 1991, BIOCHEMISTRY-US, V30, P6696, DOI 10.1021/bi00241a009	37	0	0	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1992	267	36					26078	26084						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KD073	1464619				2022-12-25	WOS:A1992KD07300074
J	GULATI, J; BABU, A; SU, H				GULATI, J; BABU, A; SU, H			FUNCTIONAL DELINEATION OF THE CA2+-DEFICIENT EF-HAND IN CARDIAC-MUSCLE, WITH GENETICALLY ENGINEERED CARDIAC-SKELETAL CHIMERIC TROPONIN-C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; AMINO-ACID SEQUENCE; CONTRACTION; CALMODULIN; SUBSTITUTION; ACTIVATION; DEPENDENCE; RESOLUTION; PROTEINS; BINDING	Cardiac and fast skeletal isoforms of TnC each comprise four putative EF-hand (helix-loop-helix) motifs as potential Ca2+-binding sites (sites 1-4), except that site 1 in cardiac TnC is deficient in Ca2+ coordination. In skeletal TnC, the N-terminal sites 1 and 2 are both essential for the trigger mechanism of the contraction switch. However, the mechanism in cardiac muscle is unsettled; it is obscure whether the cardiac site 1 is functionally inert due to calcium deficiency and consequently site 2 is the lone trigger site, or whether sites 1 and 2 perform interactively despite the impairment. These possibilities were addressed by mutagenizing site 1 in skeletal TnC to mimic the cardiac response. In one mutant (STnC-1), two selected Ca2+-ligands were abolished. In another (C1/S chimera), 41 N-terminal residues from cardiac TnC were spliced to STnC. The Ca2+-binding capacities as well as skinned fiber responses were measured. The STnC-1 derivative failed to switch on contraction. In contrast, the chimeric construct expressed close to full contractile potential in myocardium (74 +/- 3% P0; P0 = maximal tension) and also the manifest cardiac phenotype. By devising supplemental chimeric constructs, cardiac-type N-terminal overhang together with cardiac-type EF-hand for site 1 both were found essential for the phenotype. We conclude that cardiac TnC site 1 is actively engaged in the trigger mechanism and in fact dominates the phenotype despite the inability to chelate Ca2+. The N-terminal overhang also participates in this mechanism, which is a novel finding. The conclusion that a non-chelating site functions interactively with a proximal site in cardiac TnC may have wider significance, inasmuch as similar pairings of disparate EF-hands are of common occurrence.	YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT BIOPHYS,BRONX,NY 10461	Yeshiva University; Albert Einstein College of Medicine	GULATI, J (corresponding author), YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT MED & PHYSIOL,DIV CARDIOL,MOLEC PHYSIOL LAB,BRONX,NY 10461, USA.			Akella, Aravind/0000-0002-3396-7598	NHLBI NIH HHS [HL37412] Funding Source: Medline; NIAMS NIH HHS [AR33736] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL037412] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR033736] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AMPHLETT GW, 1976, FEBS LETT, V72, P193; BABU A, 1989, J PHYSIOL-LONDON, V417, pP58; BABU A, 1988, J BIOL CHEM, V263, P15485; BABU A, 1988, SCIENCE, V240, P74, DOI 10.1126/science.3353709; BABU A, 1989, FEBS LETT, V251, P177, DOI 10.1016/0014-5793(89)81450-4; BABU A, 1987, J BIOL CHEM, V262, P5815; BABU A, 1992, J BIOL CHEM, V267, P15469; CHANTLER PD, 1980, J MOL BIOL, V138, P473, DOI 10.1016/S0022-2836(80)80013-1; FERRETTI L, 1986, P NATL ACAD SCI USA, V83, P599, DOI 10.1073/pnas.83.3.599; GEORGE SE, 1990, J BIOL CHEM, V265, P9228; GERDAY C, 1988, CALCIUM CALCIUM BIND, P23; GRABAREK Z, 1986, J BIOL CHEM, V261, P608; GULATI J, 1989, FEBS LETT, V248, P5, DOI 10.1016/0014-5793(89)80420-X; GULATI J, 1988, FEBS LETT, V236, P441, DOI 10.1016/0014-5793(88)80073-5; GULATI J, 1991, J PHYSIOL-LONDON, V441, P305, DOI 10.1113/jphysiol.1991.sp018753; GULATI J, 1992, MECHANISMS MYOFILAME; HERZBERG O, 1988, J MOL BIOL, V203, P761, DOI 10.1016/0022-2836(88)90208-2; KOBAYASHI T, 1989, J BIOCHEM-TOKYO, V105, P823, DOI 10.1093/oxfordjournals.jbchem.a122752; KRETSINGER RH, 1992, CELL CALCIUM, V13, P363, DOI 10.1016/0143-4160(92)90050-3; LEACHMAN SA, 1992, J BIOL CHEM, V267, P4930; MORIMOTO S, 1987, J BIOCHEM-TOKYO, V101, P291, DOI 10.1093/oxfordjournals.jbchem.a121913; MOSS RL, 1986, J BIOL CHEM, V261, P6096; PUTKEY JA, 1989, J BIOL CHEM, V264, P12370; REINACH FC, 1986, NATURE, V322, P80, DOI 10.1038/322080a0; SATYSHUR KA, 1988, J BIOL CHEM, V263, P1628; SHENG ZL, 1990, J BIOL CHEM, V265, P21554; TANABE T, 1990, NATURE, V346, P567, DOI 10.1038/346567a0; VANEERD JP, 1975, BIOCHEM BIOPH RES CO, V64, P122, DOI 10.1016/0006-291X(75)90227-2; XU GQ, 1988, J BIOL CHEM, V263, P13962	29	33	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1992	267	35					25073	25077						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KB603	1460008				2022-12-25	WOS:A1992KB60300027
J	HARDER, J; ELIASSON, R; PONTIS, E; BALLINGER, MD; REICHARD, P				HARDER, J; ELIASSON, R; PONTIS, E; BALLINGER, MD; REICHARD, P			ACTIVATION OF THE ANAEROBIC RIBONUCLEOTIDE REDUCTASE FROM ESCHERICHIA-COLI BY S-ADENOSYLMETHIONINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PYRUVATE FORMATE-LYASE; LYSINE 2,3-AMINOMUTASE; TRIPHOSPHATE REDUCTASE; ENZYME	The anaerobic ribonucleoside triphosphate reductase from Escherichia coli reduces CTP to dCTP in the presence of a second protein, named dA1, and a Chelex-treated boiled extract of the bacteria, named RT. The reaction requires S-adenosylmethionine, NADPH, dithiothreitol, ATP, and Mg2+ and K+ ions. It occurs only under anaerobic conditions. We now show that the overall reaction occurs in two steps. The first is an activation of the reductase by dA1 and RT and requires S-adenosylmethionine, NADPH, dithiothreitol, and possibly K+ ions. In the second step, the activated reductase reduces CTP to dCTP with ATP acting as an allosteric effector. During activation, S-adenosylmethionine is cleaved reductively to methionine + 5'-deoxyadenosine. This step is inhibited strongly by S-adenosylhomocysteine and various chelators. The activation of the anaerobic reductase shows a considerable similarity to that of pyruvate formate-lyase (Knappe, J., Neugebauer, F. A., Blaschkowski, H. P., and Ganzler, M. (1984) Proc. Natl. Acad. Sci. U. S. A. 81, 1332-1335).	KAROLINSKA INST, MED NOBEL INST, DEPT BIOCHEM, S-10401 STOCKHOLM 60, SWEDEN; UNIV WISCONSIN, GRAD SCH, INST ENZYME RES, MADISON, WI 53705 USA; UNIV WISCONSIN, COLL AGR & LIFE SCI, DEPT BIOCHEM, MADISON, WI 53705 USA	Karolinska Institutet; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK028607, R37DK028607] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK28607] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABELES RH, 1967, J BIOL CHEM, V242, P3589; Abeles RH., 1971, ENZYMES, V5, P481; BALLINGER MD, 1992, BIOCHEMISTRY-US, V31, P949, DOI 10.1021/bi00119a001; BARANIAK J, 1989, J BIOL CHEM, V264, P1357; CHIRPICH TP, 1970, J BIOL CHEM, V245, P1778; CONRADT H, 1984, ARCH BIOCHEM BIOPHYS, V228, P133, DOI 10.1016/0003-9861(84)90054-7; ELIASSON R, 1990, P NATL ACAD SCI USA, V87, P3314, DOI 10.1073/pnas.87.9.3314; ELIASSON R, 1992, J BIOL CHEM, V267, P25541; FONTECAVE M, 1989, J BIOL CHEM, V264, P9164; FONTECAVE M, 1992, ADV ENZYMOL RAMB, V65, P147; FONTECAVE M, 1989, P NATL ACAD SCI USA, V86, P2147, DOI 10.1073/pnas.86.7.2147; HOFFMAN JL, 1986, BIOCHEMISTRY-US, V25, P4444, DOI 10.1021/bi00363a041; HOGENKAMP HP, 1968, J BIOL CHEM, V243, P799; KNAPPE J, 1984, P NATL ACAD SCI-BIOL, V81, P1332, DOI 10.1073/pnas.81.5.1332; MOSS ML, 1990, J BIOL CHEM, V265, P18112; PETROVICH RM, 1991, J BIOL CHEM, V266, P7656; REICHARD P, 1988, ANNU REV BIOCHEM, V57, P349, DOI 10.1146/annurev.bi.57.070188.002025; STADTMAN TC, 1973, ADV ENZYMOL RAMB, V38, P413; STUBBE J, 1990, ADV ENZYMOL RAMB, V63, P349; UNKRIG V, 1989, EUR J BIOCHEM, V184, P723, DOI 10.1111/j.1432-1033.1989.tb15072.x; WAGNER AFV, 1992, P NATL ACAD SCI USA, V89, P996, DOI 10.1073/pnas.89.3.996	21	66	66	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	1992	267	35					25548	25552						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KB603	1460050				2022-12-25	WOS:A1992KB60300095
J	OLIVER, KG; BULLER, RML; HUGHES, PJ; PUTNEY, JW; PALUMBO, GJ				OLIVER, KG; BULLER, RML; HUGHES, PJ; PUTNEY, JW; PALUMBO, GJ			INHIBITION OF AGONIST-INDUCED ACTIVATION OF PHOSPHOLIPASE-C FOLLOWING POXVIRUS INFECTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; ACTIN-BINDING PROTEIN; RAT PAROTID-GLAND; VACCINIA VIRUS; REGULATORY PROTEIN; INOSITOL 1,4,5-TRISPHOSPHATE; PHOSPHOINOSITIDE METABOLISM; PANCREATOMA CELLS; FACTOR RECEPTOR; HYDROLYSIS	Recent studies indicate that viruses may influence polyphosphoinositide levels. This study has examined the effects of vaccinia virus infection on phospholipase C activity. Infection of BS-C-1 cells, an African Green Monkey kidney cell line, or A431 cells, a human carcinoma cell line, with vaccinia virus inhibits receptor-mediated phospholipase C activation. As a consequence, agonist-mediated Ca2+ mobilization in BS-C-1 cells also was inhibited by vaccinia virus infection. Alleviation of the inhibition of phospholipase C activation was observed in vaccinia virus-infected cells treated with cycloheximide without influencing uninfected cells. Treatment of infected cells with alpha-amanitin, an inhibitor of host mRNA synthesis but not virus mRNA synthesis, failed to alleviate the inhibition of phospholipase C activation. Together these results suggest that a virus-encoded gene product mediates the inhibition of phospholipase C activation without the need of a virus-induced host factor. Analysis of the processes involved in the formation of inositol (1,4,5)-trisphosphate and mobilization of intracellular Ca2+ indicate that the vaccinia virus gene product exerts its inhibitory effects at the level of phospholipase C activity. This may occur by either directly reducing the amount of phospholipase C, reducing the specific activity of phospholipase C, or by inhibiting the association of phospholipase C with its substrate, phosphatidylinositol 4,5-bisphosphate.	NIAID,VIRAL DIS LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	OLIVER, KG (corresponding author), NIEHS,NATL TOXICOL PROGRAM,CELLULAR & MOLEC PHARMACOL,CALCIUM REGULAT SECT,MAIL DROP 7-10,RES TRIANGLE PK,NC 27709, USA.		Putney, James W/F-7247-2019	Putney, James W/0000-0002-3379-4789				AGRANOFF BW, 1985, INOSITOL PHOSPHOINOS, pR21; ALBRECHT T, 1990, INTERVIROLOGY, V31, P68, DOI 10.1159/000150140; BECKER Y, 1964, P NATL ACAD SCI USA, V54, P577; BENTON HP, 1989, BIOCHEM J, V258, P861, DOI 10.1042/bj2580861; BIRD GSJ, 1991, BIOCHEM J, V273, P541, DOI 10.1042/bj2730541; BLACKMORE PF, 1985, J BIOL CHEM, V260, P4477; BLASCO R, 1991, J VIROL, V65, P4598, DOI 10.1128/JVI.65.9.4598-4608.1991; BLOMQUIST MC, 1984, P NATL ACAD SCI-BIOL, V81, P7363, DOI 10.1073/pnas.81.23.7363; BOYER JL, 1989, TRENDS PHARMACOL SCI, V10, P360, DOI 10.1016/0165-6147(89)90008-4; BROWN JP, 1985, NATURE, V313, P491, DOI 10.1038/313491a0; BULLER RML, 1988, J VIROL, V62, P866, DOI 10.1128/JVI.62.3.866-874.1988; BULLER RML, 1991, MICROBIOL REV, V55, P80, DOI 10.1128/MMBR.55.1.80-122.1991; CARPENTER CL, 1990, BIOCHEMISTRY-US, V29, P11147, DOI 10.1021/bi00503a001; CLARKE NG, 1981, BIOCHEM J, V195, P301, DOI 10.1042/bj1950301; DOWNES CP, 1983, BIOCHEM J, V216, P633, DOI 10.1042/bj2160633; DOWNES CP, 1986, BIOCHEM J, V238, P501, DOI 10.1042/bj2380501; Downie AW, 1939, J PATHOL BACTERIOL, V48, P361, DOI 10.1002/path.1700480212; GOEBEL SJ, 1990, VIROLOGY, V179, P247, DOI 10.1016/0042-6822(90)90294-2; GOLDSCHMIDTCLERMONT PJ, 1990, SCIENCE, V247, P1575, DOI 10.1126/science.2157283; GOLDSCHMIDTCLERMONT PJ, 1991, SCIENCE, V251, P1231, DOI 10.1126/science.1848725; GUINEA R, 1989, J BIOL CHEM, V264, P21923; HANAFUSA T, 1960, BIKEN J, V3, P313; HORSTMAN DA, 1988, J BIOL CHEM, V263, P15297; HRUBY DE, 1979, P NATL ACAD SCI USA, V76, P1887, DOI 10.1073/pnas.76.4.1887; HUGHES AR, 1991, MOL PHARMACOL, V40, P254; JUNGWIRT.C, 1968, J VIROL, V2, P401, DOI 10.1128/JVI.2.5.401-408.1968; KIM HK, 1991, CELL, V65, P435, DOI 10.1016/0092-8674(91)90461-7; KING CS, 1986, MOL CELL BIOL, V6, P332, DOI 10.1128/MCB.6.1.332; KIT S, 1962, VIROLOGY, V18, P274, DOI 10.1016/0042-6822(62)90014-4; LIANG M, 1991, J BIOL CHEM, V266, P13342; MENNITI FS, 1990, J BIOL CHEM, V265, P11167; MORGAN RO, 1987, J BIOL CHEM, V262, P1166; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; MOSS B, 1968, J VIROL, V2, P1028, DOI 10.1128/JVI.2.10.1028-1037.1968; MOSS B, 1990, ANNU REV BIOCHEM, V59, P661, DOI 10.1146/annurev.biochem.59.1.661; PALUMBO GJ, 1989, VIROLOGY, V172, P262, DOI 10.1016/0042-6822(89)90128-1; PERKUS ME, 1991, VIROLOGY, V180, P406, DOI 10.1016/0042-6822(91)90047-F; PERNEY TM, 1989, J BIOL CHEM, V264, P7317; POGGIOLI J, 1983, MOL PHARMACOL, V23, P71; PUTNEY JW, 1990, CELL CALCIUM, V11, P611, DOI 10.1016/0143-4160(90)90016-N; REISNER AH, 1985, NATURE, V313, P801, DOI 10.1038/313801a0; RHEE SG, 1991, TRENDS BIOCHEM SCI, V16, P297, DOI 10.1016/0968-0004(91)90122-C; Schacht J, 1981, Methods Enzymol, V72, P626; SHEARS SB, 1987, BIOCHEM J, V242, P393, DOI 10.1042/bj2420393; SHEARS SB, 1991, PHARMACOL THERAPEUT, V49, P79, DOI 10.1016/0163-7258(91)90023-F; STROOBANT P, 1985, CELL, V42, P383, DOI 10.1016/S0092-8674(85)80133-1; TAYLOR CW, 1986, BIOCHEM BIOPH RES CO, V136, P362, DOI 10.1016/0006-291X(86)90919-8; TAYLOR SJ, 1991, NATURE, V350, P516, DOI 10.1038/350516a0; THOMAS KL, 1989, NEUROPEPTIDES, V13, P191, DOI 10.1016/0143-4179(89)90091-7; TWARDZIK DR, 1985, P NATL ACAD SCI USA, V82, P5300, DOI 10.1073/pnas.82.16.5300; VALYINAGY T, 1988, ARCH VIROL, V101, P199, DOI 10.1007/BF01311001; WAHL MI, 1987, BIOCHEM BIOPH RES CO, V142, P688, DOI 10.1016/0006-291X(87)91469-0; WHITMAN M, 1988, Biochimica et Biophysica Acta, V948, P327	53	2	2	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1992	267	35					25098	25103						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KB603	1460012				2022-12-25	WOS:A1992KB60300031
J	MCGEE, MP; LI, LC; XIONG, H				MCGEE, MP; LI, LC; XIONG, H			DIFFUSION CONTROL IN BLOOD-COAGULATION - ACTIVATION OF FACTOR-X BY FACTOR-IXA FACTOR-VIIIA ASSEMBLED ON HUMAN MONOCYTE MEMBRANES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTHROMBINASE COMPLEX; FACTOR-VA; HUMAN LEUKOCYTES; PROTEIN; ASSOCIATION; KINETICS; BINDING; ENZYMES; PHOSPHOLIPIDS; PHAGOCYTOSIS	This study examines mechanisms that regulate the activation of blood coagulation proteases on intact cell membranes. The activation of factor X by factors IXa and VIIIa assembled on viable monocytes is presented as a biologically relevant model for membrane-dependent proteolysis of coagulation zymogens. The hypothesis that this reaction is limited by diffusion was tested by comparing predicted with observed concentration dependence, temperature dependence, and effective rate coefficient. Rates of factor X catalysis were measured using a chromogenic substrate specific for the product, factor Xa. The value of K(R) and of K1/2, i.e. concentrations giving half-maximal rates in reciprocal functional titrations with substrate and enzyme, respectively, were directly correlated with the concentration of the titrated component. Arrhenius plots constructed over temperatures encompassing 10-35-degrees-C were biphasic with downward concavity. Apparent activation energies were 6.01 +/- 0.93 and 35.84 +/- 8.9 kcal/mol for the interval above and below the inflection point, respectively. The effective rate coefficient calculated from apparent kinetic parameters was 3.58 +/- 0.1 x 10(12) M-1 s-1. This rate is similar to the maximal rate of collision between factor X molecules and the monocyte, i.e. 2.9 x 10(12) M-1 s-1 estimated from the steady-state von Smoluchowski equation for uniformly reacting spherical particles. The observed agreement between predicted and experimental results indicates that under biologically relevant conditions, the rate of factor X activation by the intrinsic protease is controlled by diffusion of factor X toward the catalytic site.			MCGEE, MP (corresponding author), BOWMAN GRAY SCH MED,DEPT MED,RHEUMATOL SECT,MED CTR BLVD,WINSTON SALEM,NC 27157, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL042812] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-42812] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABBOTT AJ, 1987, BIOCHEMISTRY-US, V26, P7994, DOI 10.1021/bi00398a067; AHMAD SS, 1989, J BIOL CHEM, V264, P20012; BARTON PG, 1969, BIOCHIM BIOPHYS ACTA, V187, P319, DOI 10.1016/0005-2760(69)90005-8; BERG HC, 1977, BIOPHYS J, V20, P193, DOI 10.1016/S0006-3495(77)85544-6; BERG OG, 1985, ANNU REV BIOPHYS BIO, V14, P131, DOI 10.1146/annurev.biophys.14.1.131; BLOOM JW, 1979, BIOCHEMISTRY-US, V18, P4419, DOI 10.1021/bi00587a023; CALEF F, 1983, ANNU REV PHYS CHEM, V34, P126; Chandrasekhar S, 1943, REV MOD PHYS, V15, P0001, DOI 10.1103/RevModPhys.15.1; COHN ZA, 1982, CIBA F SYMP, V92, P15; DAEMEN FJM, 1965, THROMB DIATH HAEMOST, V13, P194; DELISI C, 1981, P NATL ACAD SCI-BIOL, V78, P5569, DOI 10.1073/pnas.78.9.5569; DOUGLAS KT, 1984, CHEM ENZYME ACTION, P114; Einstein A, 1926, INVESTIGATIONS THEOR, DOI DOI 10.2307/2298685; FELDERHOF BU, 1976, J CHEM PHYS, V64, P4551, DOI 10.1063/1.432087; GAVISH B, 1979, BIOCHEMISTRY-US, V18, P1269, DOI 10.1021/bi00574a023; GIESEN PLA, 1991, J BIOL CHEM, V266, P1379; GLASSTONE S, 1963, ELEMENTS PHYSICAL CH; HIGGINS DL, 1985, J BIOL CHEM, V260, P3604; ILLSLEY NP, 1987, BIOCHEMISTRY-US, V26, P446, DOI 10.1021/bi00376a016; JAHNIG F, 1982, BIOCHIM BIOPHYS ACTA, V690, P310, DOI 10.1016/0005-2736(82)90337-6; JORGENSEN PL, 1982, ANN NY ACAD SCI, V402, P2207; Laidler K J, 1980, Methods Enzymol, V64, P227; LEE AG, 1988, LIPID DOMAINS RELATI, P135; LI CY, 1973, J HISTOCHEM CYTOCHEM, V21, P1; MAHONEY EM, 1977, P NATL ACAD SCI USA, V74, P4895, DOI 10.1073/pnas.74.11.4895; MANN KG, 1990, BLOOD, V76, P1; MARQUARDT DW, 1963, J SOC IND APPL MATH, V11, P431, DOI 10.1137/0111030; MAYER LD, 1983, BIOCHIM BIOPHYS ACTA, V734, P48, DOI 10.1016/0005-2736(83)90073-1; MCGEE MP, 1991, J BIOL CHEM, V266, P8079; MCGEE MP, 1992, J EXP MED, V176, P27, DOI 10.1084/jem.176.1.27; NAWROTH PP, 1986, P NATL ACAD SCI USA, V83, P3460, DOI 10.1073/pnas.83.10.3460; NELSESTUEN GL, 1981, BIOCHEMISTRY-US, V20, P351, DOI 10.1021/bi00505a019; NEMERSON Y, 1988, BLOOD, V71, P1; NESHEIM ME, 1984, J BIOL CHEM, V259, P1447; NESHEIM ME, 1981, J BIOL CHEM, V256, P9874; NOYES RM, 1961, PROG REACT KINET MEC, V1, P129; OFLAHERTY JT, 1978, AM J PATHOL, V90, P537; PISZKIEWICZ D, 1977, KINETICS CHEM ENZYME, P27; PUSEY ML, 1983, BIOCHEM BIOPH RES CO, V114, P526, DOI 10.1016/0006-291X(83)90812-4; RAWALASHEIKH R, 1990, BIOCHEMISTRY-US, V29, P2606, DOI 10.1021/bi00462a025; RICHTER PH, 1974, BIOPHYS CHEM, V2, P255, DOI 10.1016/0301-4622(74)80050-5; ROSING J, 1985, BLOOD, V65, P319; SCHURR JM, 1970, BIOPHYS J, V10, P717, DOI 10.1016/S0006-3495(70)86331-7; SEGEL IH, 1975, ENZYME KINETICS, P72; SHINITZKY M, 1976, BIOCHIM BIOPHYS ACTA, V433, P133, DOI 10.1016/0005-2736(76)90183-8; Shinitzky M, 1979, Int Rev Cytol, V60, P121, DOI 10.1016/S0074-7696(08)61261-9; SHINITZKY M, 1978, BIOCHIM BIOPHYS ACTA, V515, P367, DOI 10.1016/0304-4157(78)90010-2; SHOUP D, 1982, BIOPHYS J, V40, P33, DOI 10.1016/S0006-3495(82)84455-X; SMITH RL, 1973, J BIOL CHEM, V248, P2418; STOSSEL TP, 1974, NEW ENGL J MED, V290, P774, DOI 10.1056/NEJM197404042901405; SUNDARAM PV, 1970, CAN J CHEMISTRY, V48, P1498, DOI 10.1139/v70-245; SWEET WD, 1986, BIOCHEM J, V239, P301, DOI 10.1042/bj2390301; SWEET WD, 1988, LIPID DOMAINS RELATI, P17; THOMAS D, 1972, BIOCHIMIE, V54, P229, DOI 10.1016/S0300-9084(72)80108-1; TRACY PB, 1985, J BIOL CHEM, V260, P2119; TREVAN MD, 1980, IMMOBILIZED ENZYMES, P37; VANRIJN JLML, 1984, BIOCHEMISTRY-US, V23, P4557, DOI 10.1021/bi00315a008; WALLWORK SC, 1960, PHYSICAL CHEM, P145; WIEGEL FW, 1983, PHYS REP, V95, P289; ZIMMERMAN TS, 1988, SEMIN HEMATOL, V25, P25; ZWANZIG R, 1990, P NATL ACAD SCI USA, V87, P5856, DOI 10.1073/pnas.87.15.5856	61	22	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1992	267	34					24333	24339						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KA263	1447184				2022-12-25	WOS:A1992KA26300032
J	DELAFAILLE, MAC; WIRTH, DF				DELAFAILLE, MAC; WIRTH, DF			CREATION OF NULL/+ MUTANTS OF THE ALPHA-TUBULIN GENE IN LEISHMANIA-ENRIETTII BY GENE-CLUSTER DELETION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEOMYCIN PHOSPHOTRANSFERASE GENE; BETA-TUBULIN; TRYPANOSOMA-BRUCEI; MESSENGER-RNAS; SACCHAROMYCES-CEREVISIAE; PARASITIC PROTOZOAN; AUTOREGULATED INSTABILITY; SCHIZOSACCHAROMYCES-POMBE; PELLICULAR MICROTUBULES; EXPRESSION	Tubulins are abundant structural proteins in the Leishmania parasite, and tubulin genes are examples of highly expressed genes, which are present in multiple copies arranged in tandem repeats. Functional analysis of such multicopy genes using genetic manipulation has not yet been possible. Here we describe a method for creating deletions of alpha-tubulin gene clusters by targeted gene replacement and report the isolation of null/+ mutants deleted for either of the two allelic tubulin clusters. We also report null/null mutants in which both clusters have been deleted from their chromosomal loci and in which alpha-tubulin genes are present as episomal elements. Characterization of tubulin mRNA expression in these mutants indicated a post-transcriptional up-regulation of alpha-tubulin mRNA stability in null/+ mutants which contained only one-third the normal number of alpha-tubulin genes. A parallel increase in beta-tubulin mRNA levels indicated coordinate regulation of tubulin mRNA in Leishmania.	HARVARD UNIV,SCH PUBL HLTH,DEPT TROP PUBL HLTH,665 HUNTINGTON AVE,BOSTON,MA 02115	Harvard University; Harvard T.H. Chan School of Public Health					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI021365] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 21365] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADACHI Y, 1986, MOL CELL BIOL, V6, P2168, DOI 10.1128/MCB.6.6.2168; AGABIAN N, 1990, CELL, V61, P1157, DOI 10.1016/0092-8674(90)90674-4; ANDERSON WA, 1965, J PROTOZOOL, V12, P483, DOI 10.1111/j.1550-7408.1965.tb03247.x; ANGELOPOULOS E, 1970, J PROTOZOOL, V17, P39, DOI 10.1111/j.1550-7408.1970.tb05157.x; BECK E, 1982, GENE, V19, P327, DOI 10.1016/0378-1119(82)90023-3; BENZEEV A, 1979, CELL, V17, P319, DOI 10.1016/0092-8674(79)90157-0; BEVERLEY SM, 1988, NUCLEIC ACIDS RES, V16, P925, DOI 10.1093/nar/16.3.925; BEVERLEY SM, 1991, ANNU REV MICROBIOL, V45, P417, DOI 10.1146/annurev.mi.45.100191.002221; BORST P, 1986, ANNU REV BIOCHEM, V55, P701, DOI 10.1146/annurev.bi.55.070186.003413; BURKE D, 1989, MOL CELL BIOL, V9, P1049, DOI 10.1128/MCB.9.3.1049; CAIRNS BR, 1989, P NATL ACAD SCI USA, V86, P7682, DOI 10.1073/pnas.86.20.7682; CARON JM, 1985, NATURE, V317, P648, DOI 10.1038/317648a0; CHANG KP, 1985, LEISHMANIASIS, V1, P1; CLEVELAND DW, 1983, J CELL BIOL, V97, P919, DOI 10.1083/jcb.97.3.919; CLEVELAND DW, 1988, TRENDS BIOCHEM SCI, V13, P339, DOI 10.1016/0968-0004(88)90103-X; COMEAU AM, 1986, MOL BIOCHEM PARASIT, V21, P161, DOI 10.1016/0166-6851(86)90019-8; CRUZ A, 1991, P NATL ACAD SCI USA, V88, P7170, DOI 10.1073/pnas.88.16.7170; CRUZ A, 1990, NATURE, V348, P171, DOI 10.1038/348171a0; DELAFAILLE MAC, 1992, P NATL ACAD SCI USA, V89, P2703, DOI 10.1073/pnas.89.7.2703; EIDS JE, 1991, GENE DEV, V5, P2024; EIDS JE, 1991, P NATL ACAD SCI USA, V88, P2118; FONG D, 1981, P NATL ACAD SCI-BIOL, V78, P7624, DOI 10.1073/pnas.78.12.7624; GARDENER PJ, 1974, ANN TROP MED PARASIT, V68, P167, DOI 10.1080/00034983.1974.11686935; GARVEY EP, 1986, SCIENCE, V233, P535, DOI 10.1126/science.3726545; GRITZ L, 1983, GENE, V25, P179, DOI 10.1016/0378-1119(83)90223-8; HIRAOKA Y, 1984, CELL, V39, P349, DOI 10.1016/0092-8674(84)90013-8; HUANG PL, 1984, MOL CELL BIOL, V4, P1372, DOI 10.1128/MCB.4.7.1372; LABAN A, 1989, P NATL ACAD SCI USA, V86, P9119, DOI 10.1073/pnas.86.23.9119; LABAN A, 1990, NATURE, V343, P572, DOI 10.1038/343572a0; LANDFEAR SM, 1986, MOL BIOCHEM PARASIT, V21, P235, DOI 10.1016/0166-6851(86)90129-5; LANDFEAR SM, 1983, MOL CELL BIOL, V3, P1070, DOI 10.1128/MCB.3.6.1070; LEE MGS, 1990, SCIENCE, V250, P1583, DOI 10.1126/science.2177225; LENAR DF, 1981, MOL BIOCHEM PARASIT, V3, P377; LEON W, 1978, NUCLEIC ACIDS RES, V5, P491, DOI 10.1093/nar/5.2.491; MACRAE TH, 1989, BIOCHEM CELL BIOL, V67, P770, DOI 10.1139/o89-116; MESSIER PE, 1971, J PROTOZOOL, V18, P223, DOI 10.1111/j.1550-7408.1971.tb03312.x; MEYER H, 1976, J PROTOZOOL, V23, P385, DOI 10.1111/j.1550-7408.1976.tb03792.x; NEFF NF, 1983, CELL, V33, P211, DOI 10.1016/0092-8674(83)90350-1; ORRWEAVER TL, 1981, P NATL ACAD SCI-BIOL, V78, P6354, DOI 10.1073/pnas.78.10.6354; PITTENGER MF, 1985, J CELL BIOL, V101, P1941, DOI 10.1083/jcb.101.5.1941; SAIKI RK, 1986, NATURE, V324, P163, DOI 10.1038/324163a0; Sambrook J, 1989, MOL CLONING LABORATO; SCHATZ PJ, 1986, MOL CELL BIOL, V6, P3722, DOI 10.1128/MCB.6.11.3722; SEEBECK T, 1983, P NATL ACAD SCI-BIOL, V80, P4634, DOI 10.1073/pnas.80.15.4634; SISODIA S S, 1990, New Biologist, V2, P66; STARK GR, 1984, ANNU REV BIOCHEM, V53, P447, DOI 10.1146/annurev.bi.53.070184.002311; TENASBROEK ALMA, 1990, NATURE, V348, P174, DOI 10.1038/348174a0; THOMASHOW LS, 1983, CELL, V32, P35, DOI 10.1016/0092-8674(83)90494-4; TOBIN JF, 1992, J BIOL CHEM, V267, P4752; TODA T, 1984, CELL, V37, P233, DOI 10.1016/0092-8674(84)90319-2; VICKERMAN K, 1970, J CELL SCI, V6, P365; WEINSTEIN B, 1990, MOL CELL BIOL, V10, P5295, DOI 10.1128/MCB.10.10.5295; YEN TJ, 1988, NATURE, V334, P580, DOI 10.1038/334580a0	53	36	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1992	267	33					23839	23846						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JZ239	1429722				2022-12-25	WOS:A1992JZ23900062
J	YAMAMOTO, M; NAKAGAKI, T; KISIEL, W				YAMAMOTO, M; NAKAGAKI, T; KISIEL, W			TISSUE FACTOR-DEPENDENT AUTOACTIVATION OF HUMAN BLOOD-COAGULATION FACTOR-VII	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTRINSIC PATHWAY INHIBITOR; BOVINE FACTOR-VII; FACTOR-X; PHOSPHOLIPID-VESICLES; HAGEMAN-FACTOR; ACTIVATION; PURIFICATION; BINDING; PLASMA; ASSOCIATION	We recently showed that single-chain zymogen factor VII is converted to two-chain factor VIIa in an autocatalytic manner following complex formation with either cell-surface or solution-phase relipidated tissue factor apoprotein (Nakagaki, T., Foster, D. C., Berkner, K. L., and Kisiel, W. (1991) Biochemistry 30, 10819-10824). We have now performed a detailed kinetic analysis of the autoactivation of human plasma factor VII in the presence of relipidated recombinant tissue factor apoprotein and calcium. Incubation of factor VII with equimolar amounts of relipidated tissue factor apoprotein resulted in the formation of factor VIIa amidolytic activity coincident with the conversion of factor VII to factor VIIa. The time course for the generation of factor VIIa amidolytic activity in this system was sigmoidal, characterized by an initial lag phase followed by a rapid linear phase until activation was complete. The duration of the lag phase was decreased by the addition of exogenous recombinant factor VIIa. Relipidated tissue factor apoprotein was essential for factor VII autoactivation. No factor VII activation was observed following complex formation between factor VII and a recombinant soluble tissue factor apoprotein construct consisting of the amino-terminal extracellular domain in the presence or absence of phospholipids. Kinetic analyses revealed that factor VII activation in the presence of relipidated tissue factor apoprotein can be defined by a second-order reaction mechanism in which factor VII is activated by factor VIIa with an apparent second-order rate constant of 7.2 x 10(3) M-1 s-1. Benzamidine inhibited factor VII autoactivation with an apparent K(i) of 1.8 mM, which is identical to the apparent K(i) for the inhibition of factor VIIa amidolytic activity by this active site competitive inhibitor. Our data are consistent with a factor VII autoactivation mechanism in which trace amounts of factor VIIa rapidly activate tissue factor-bound factor VII by limited proteolysis.	UNIV NEW MEXICO,SCH MED,DEPT PATHOL,BLOOD SYST RES FDN LAB,ALBUQUERQUE,NM 87131	University of New Mexico					NHLBI NIH HHS [HL 35246] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL035246] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BACH R, 1986, BIOCHEMISTRY-US, V25, P4007, DOI 10.1021/bi00362a005; BAJAJ SP, 1981, J BIOL CHEM, V256, P253; BARENHOLZ Y, 1977, BIOCHEMISTRY-US, V16, P2806, DOI 10.1021/bi00631a035; BOM VJJ, 1990, BIOCHEM J, V265, P327, DOI 10.1042/bj2650327; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROZE GJ, 1981, METHOD ENZYMOL, V80, P228; BROZE GJ, 1980, J BIOL CHEM, V255, P1242; BROZE GJ, 1985, J BIOL CHEM, V260, P917; FRACKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849; KISIEL W, 1977, BIOCHEMISTRY-US, V16, P4189, DOI 10.1021/bi00638a009; KONDO S, 1987, BLOOD, V70, P1947; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAWSON JH, 1992, J BIOL CHEM, V267, P4834; MACIK BG, 1991, BLOOD S, V78, pA61; MASYS DR, 1982, BLOOD, V60, P1143; MORRISSEY JH, 1991, ARTERIOSCLER THROMB, V11, pA1544; NAKAGAKI T, 1991, BIOCHEMISTRY-US, V30, P10819, DOI 10.1021/bi00109a001; NELSESTUEN GL, 1978, BIOCHEMISTRY-US, V17, P2134, DOI 10.1021/bi00604a017; NEMERSON Y, 1985, THROMB RES, V40, P351, DOI 10.1016/0049-3848(85)90270-1; PABORSKY LR, 1989, BIOCHEMISTRY-US, V28, P8072, DOI 10.1021/bi00446a016; PABORSKY LR, 1991, J BIOL CHEM, V266, P21911; PEDERSEN AH, 1990, J BIOL CHEM, V265, P16786; PEDERSEN AH, 1989, BIOCHEMISTRY-US, V28, P9331, DOI 10.1021/bi00450a013; PEDERSEN AH, 1991, THROMB HAEMOSTASIS, V65, P528; RADCLIFFE R, 1976, J BIOL CHEM, V251, P4797; RAO LVM, 1988, P NATL ACAD SCI USA, V85, P6687, DOI 10.1073/pnas.85.18.6687; RAO VM, 1990, CIRCULATION, V82, P132; RUF W, 1991, J BIOL CHEM, V266, P2158; RUF W, 1991, J BIOL CHEM, V266, P15719; SAKAI T, 1989, J BIOL CHEM, V264, P9980; TANS G, 1987, J BIOL CHEM, V262, P11308; TANS G, 1983, J BIOL CHEM, V258, P8215; THIM L, 1988, BIOCHEMISTRY-US, V27, P7785, DOI 10.1021/bi00420a030; WILDGOOSE P, 1990, BIOCHEMISTRY-US, V29, P3413, DOI 10.1021/bi00465a039; WILDGOOSE P, 1989, BLOOD, V73, P1888; WILDGOOSE P, 1992, THROMB HAEMOSTASIS, V67, P679; WILLIAMS EB, 1989, J BIOL CHEM, V264, P7536	37	58	58	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1992	267	27					19089	19094						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JP593	1527033				2022-12-25	WOS:A1992JP59300015
J	PAESEN, GC; SCHWARTZ, MB; PEFEROEN, M; WEYDA, F; HAPP, GM				PAESEN, GC; SCHWARTZ, MB; PEFEROEN, M; WEYDA, F; HAPP, GM			AMINO-ACID-SEQUENCE OF SP23, A STRUCTURAL PROTEIN OF THE SPERMATOPHORE OF THE MEALWORM BEETLE, TENEBRIO-MOLITOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACCESSORY-GLANDS; SECONDARY-STRUCTURE; MONOCLONAL-ANTIBODY; GLOBULAR PROTEINS; PLASMID DNA; CYTODIFFERENTIATION; BACTERIOPHAGE; LIBRARIES; PATTERNS; EXTENSIN	In this paper we present the amino acid sequence of Sp23, a structural protein of the spermatophore of the mealworm beetle (Tenebrio molitor). This is the first report of the primary structure of a spermatophorin. The protein is rich in proline (24%), relatively rich in tyrosine (9%) and glutamine (10%), and does not contain sulfur-containing amino acids. In the carboxyl-terminal half of the protein a peptide motif is repeated which is similar to a repetitive motif in a group of dipteran chorion proteins.	UNIV VERMONT,DEPT ZOOL,BURLINGTON,VT 05405	University of Vermont					NIAID NIH HHS [AI-15662] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI015662] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AGGELI A, 1991, INT J BIOL MACROMOL, V13, P307, DOI 10.1016/0141-8130(91)90032-P; BLACK PN, 1982, DEV BIOL, V94, P106, DOI 10.1016/0012-1606(82)90073-2; CHEESEMAN MT, 1990, J EXP ZOOL, V255, P193, DOI 10.1002/jez.1402550208; CHEN J, 1985, EMBO J, V4, P2145, DOI 10.1002/j.1460-2075.1985.tb03908.x; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; COX DL, 1987, INSECT BIOCHEM, V17, P457, DOI 10.1016/0020-1790(87)90006-0; DAILEY PJ, 1983, J MORPHOL, V178, P139, DOI 10.1002/jmor.1051780206; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; GADZAMA NM, 1974, TISSUE CELL, V6, P95, DOI 10.1016/0040-8166(74)90025-1; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GATEHOUSE LN, 1990, PLANT SCI, V71, P223, DOI 10.1016/0168-9452(90)90012-D; GILHAM PT, 1964, J AM CHEM SOC, V86, P4982, DOI 10.1021/ja01076a049; GRIMNES KA, 1986, INSECT BIOCHEM, V16, P635, DOI 10.1016/0020-1790(86)90006-5; GRIMNES KA, 1986, J EXP ZOOL, V240, P275, DOI 10.1002/jez.1402400214; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HAPP GM, 1977, J EXP ZOOL, V200, P223, DOI 10.1002/jez.1402000204; KANN ML, 1989, HISTOCHEMISTRY, V91, P221, DOI 10.1007/BF00490136; KAWASAKI H, 1975, INSECT BIOCHEM, V5, P25, DOI 10.1016/0020-1790(75)90004-9; KONSOLAKI M, 1989, NUCLEIC ACIDS RES, V18, P731; LEMOINE A, 1986, INSECT BIOCHEM, V16, P483, DOI 10.1016/0020-1790(86)90025-9; LEVITT M, 1978, BIOCHEMISTRY-US, V17, P4277, DOI 10.1021/bi00613a026; Maniatis T., 1982, MOL CLONING; MIERENDORF RC, 1987, METHOD ENZYMOL, V152, P458; MIERENDORF RC, 1987, METHOD ENZYMOL, V152, P556; MILLER H, 1987, METHOD ENZYMOL, V152, P145; PAESEN GC, 1992, INSECT BIOCHEM MOLEC, V22, P387, DOI 10.1016/0965-1748(92)90077-R; PAU RN, 1986, ARCH INSECT BIOCH PH, V3, P59; PINNA LA, 1990, BIOCHIM BIOPHYS ACTA, V1054, P267, DOI 10.1016/0167-4889(90)90098-X; Prevelige P., 1989, PREDICTION PROTEIN S, P391; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1975, J MOL BIOL, V94, P441, DOI 10.1016/0022-2836(75)90213-2; SHINBO H, 1987, J BIOL CHEM, V262, P4794; SHORT JM, 1988, NUCLEIC ACIDS RES, V16, P7583, DOI 10.1093/nar/16.15.7583; SMITH S. G., 1960, CAN J GENET CYTOL, V2, P66; Sugumaran M., 1988, Advances in Insect Physiology, V21, P179, DOI 10.1016/S0065-2806(08)60124-1; TALBO G, 1991, EUR J BIOCHEM, V195, P495, DOI 10.1111/j.1432-1033.1991.tb15730.x; TUNG JS, 1972, ANAL BIOCHEM, V48, P153, DOI 10.1016/0003-2697(72)90179-0; VONHEIJNE G, 1983, EUR J BIOCHEM, V133, P17; WILLIS JH, 1987, ARCH INSECT BIOCH PH, V6, P204; WOODGETT JR, 1986, EUR J BIOCHEM, V161, P177, DOI 10.1111/j.1432-1033.1986.tb10139.x	41	12	14	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1992	267	26					18852	18857						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JN502	1527013				2022-12-25	WOS:A1992JN50200091
J	KOMABA, A; LI, QQ; HARA, H; YOKOYAMA, S				KOMABA, A; LI, QQ; HARA, H; YOKOYAMA, S			RESISTANCE OF SMOOTH-MUSCLE CELLS TO ASSEMBLY OF HIGH-DENSITY-LIPOPROTEINS WITH EXTRACELLULAR FREE APOLIPOPROTEINS AND TO REDUCTION OF INTRACELLULARLY ACCUMULATED CHOLESTEROL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-SKIN FIBROBLASTS; FOAM CELLS; ENDOTHELIAL-CELLS; RECEPTOR; EFFLUX; ASSOCIATION; MECHANISM; PLASMA; ATHEROGENESIS; SUBFRACTIONS	Removal of intracellularly accumulated cholesterol by lipid-free human apolipoproteins (apo) A-I and A-II was studied for aortic smooth muscle cells (SMC) of rat, monkey and rabbit, human skin fibroblasts (FB), and mouse peritoneal macrophages (MP). The reaction generated high density lipoprotein (HDL)-like lipoproteins as did those and other helical apolipoproteins with MP, causing efflux of cellular cholesterol. From FB and MP, the maximum efflux rates with apoA-I and A-II per 24 h were as much as 30% of the apparent maximum efflux rate of prelabeled cellular cholesterol to human HDL. From rat SMC these rates were 7.2 and 6.8%, respectively, being independent of cellular cholesterol content. Those from monkey and rabbit SMC were also very low. When standardized for the initial cellular unesterified cholesterol pool size, the maximum efflux rates/24 h were 5.4 and 5.0% for apoA-I and A-II from rat SMC and even less from monkey and rabbit SMC in contrast to 42.4 and 39.7% from FB, and 53.0 and 45.5% from MP, respectively. The standardized apparent maximum efflux to HDL was 76% from rat SMC, 45 and 31% from monkey and rabbit SMC, 139% from FB and 166% from MP. Accordingly, the reaction with free apolipoproteins caused significant net reduction of cellular cholesterol, predominantly in cholesteryl ester, in FB and MP, but not in SMC. While the efflux K(m) with apoA-I and A-II were 7.5 and 4.5-mu-g/ml for MP, those for SMC and FB were both 1-mu-g/ml or lower, as low as 1/1500 and 1/500 of their plasma concentrations, respectively. The apparent efflux K(m) for HDL were, on the other hand, all in the range of 36 to 65-mu-g of protein/ml for SMC, FB, and MP, showing that the mode of cholesterol exchange of these cells with lipoprotein surface is not significantly different from each other. Thus, peripheral cells such as FB may provide a significant source of HDL by interacting with extracellular free apolipoproteins in interstitial fluid, reducing intracellularly accumulated cholesterol. However, SMC seem very resistant to this interaction, suggesting that atheromatous lesions predominantly consisting of SMC are resistant to regression.	UNIV ALBERTA,DEPT MED,LIPID & LIPOPROT RES GRP,EDMONTON T6G 2S2,ALBERTA,CANADA	University of Alberta								BASU SK, 1976, P NATL ACAD SCI USA, V73, P3178, DOI 10.1073/pnas.73.9.3178; BONOMO EA, 1990, BIOCHEMISTRY-US, V29, P5094, DOI 10.1021/bi00473a014; BROWN MS, 1980, J BIOL CHEM, V255, P9344; BURNS CH, 1969, BIOCHIM BIOPHYS ACTA, V176, P616, DOI 10.1016/0005-2760(69)90228-8; CASTRO GR, 1988, BIOCHEMISTRY-US, V27, P25, DOI 10.1021/bi00401a005; DANIELS RJ, 1981, J BIOL CHEM, V256, P4978; DEKROON AIPM, 1991, BIOCHEMISTRY-US, V30, P1155, DOI 10.1021/bi00218a038; FIELDING C J, 1981, Proceedings of the National Academy of Sciences of the United States of America, V78, P3911, DOI 10.1073/pnas.78.6.3911; FRANCIS GA, 1991, BIOCHIM BIOPHYS ACTA, V1084, P159, DOI 10.1016/0005-2760(91)90215-4; FUNAHASHI T, 1989, J BIOCHEM-TOKYO, V105, P582, DOI 10.1093/oxfordjournals.jbchem.a122708; GEER JC, 1965, LAB INVEST, V14, P1764; GERRITY RG, 1981, AM J PATHOL, V103, P191; GERRITY RG, 1981, AM J PATHOL, V103, P181; GLOMSET JA, 1968, J LIPID RES, V9, P155; GUNTHER S, 1980, CIRC RES, V47, P278, DOI 10.1161/01.RES.47.2.278; GUO LSS, 1982, J LIPID RES, V23, P543; HAMILTON RL, 1976, J CLIN INVEST, V58, P667, DOI 10.1172/JCI108513; HAMILTON RL, 1991, J LIPID RES, V32, P560; HARA H, 1992, LIPIDS, V27, P302, DOI 10.1007/BF02536480; HARA H, 1992, BIOCHEMISTRY-US, V31, P2040, DOI 10.1021/bi00122a021; HARA H, 1991, J BIOL CHEM, V266, P3080; HO YK, 1980, J LIPID RES, V21, P391; JOHNSON WJ, 1986, J BIOL CHEM, V261, P5766; JOHNSON WJ, 1988, J BIOL CHEM, V263, P14099; JOHNSON WJ, 1991, BIOCHIM BIOPHYS ACTA, V1085, P273, DOI 10.1016/0005-2760(91)90132-2; LANGE Y, 1985, J BIOL CHEM, V260, P5592; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MIIDA T, 1990, BIOCHEMISTRY-US, V29, P10469, DOI 10.1021/bi00498a007; OKABE H, 1988, J BIOCHEM, V104, P141, DOI 10.1093/oxfordjournals.jbchem.a122411; ORAM JF, 1981, J BIOL CHEM, V256, P8348; ROSS R, 1986, NEW ENGL J MED, V314, P488, DOI 10.1056/NEJM198602203140806; ROTHBLAT GH, 1982, J BIOL CHEM, V257, P4775; SAVION N, 1989, EUR J BIOCHEM, V183, P363, DOI 10.1111/j.1432-1033.1989.tb14937.x; SHEN BW, 1977, P NATL ACAD SCI USA, V74, P837, DOI 10.1073/pnas.74.3.837; STEIN O, 1976, BIOCHIM BIOPHYS ACTA, V431, P347, DOI 10.1016/0005-2760(76)90155-7; TABAS I, 1984, J BIOL CHEM, V259, P3897; TAJIMA S, 1983, J BIOL CHEM, V258, P73; TAKANASHI Y, 1992, NEUROSURGERY, V30, P346, DOI 10.1227/00006123-199203000-00006; VANCE JE, 1991, J LIPID RES, V32, P1971; VANCE JE, 1990, EXPERIENTIA, V46, P560, DOI 10.1007/BF01939694; VOELKER DR, 1991, BIOCH LIPIDS LIPOPRO, P489; WERB Z, 1971, J EXP MED, V134, P1545, DOI 10.1084/jem.134.6.1545; YAMAMOTO A, 1989, ARTERIOSCLEROSIS S, V9, P66; YAO ZM, 1988, J BIOL CHEM, V263, P2998; YOKOYAMA S, 1985, J BIOL CHEM, V260, P6375	45	41	42	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1992	267	25					17560	17566						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JM223	1517206				2022-12-25	WOS:A1992JM22300016
J	VITALI, J; MARTIN, PD; MALKOWSKI, MG; ROBERTSON, WD; LAZAR, JB; WINANT, RC; JOHNSON, PH; EDWARDS, BFP				VITALI, J; MARTIN, PD; MALKOWSKI, MG; ROBERTSON, WD; LAZAR, JB; WINANT, RC; JOHNSON, PH; EDWARDS, BFP			THE STRUCTURE OF A COMPLEX OF BOVINE ALPHA-THROMBIN AND RECOMBINANT HIRUDIN AT 2.8-A-ANGSTROM RESOLUTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR MAGNETIC-RESONANCE; LEAST-SQUARES REFINEMENT; NATURAL ANTICOAGULANT; DISTANCE GEOMETRY; CRYSTAL-STRUCTURE; BINDING; SITE; PROTHROMBIN; INHIBITION; RESIDUES	Crystals of the complex of bovine alpha-thrombin with recombinant hirudin variant 1 have space group C222(1) with cell constants a = 59.11, b = 102.62, and c = 143.26 angstrom. The orientation and position of the thrombin component was determined by molecular replacement and the hirudin molecule was fit in 2\F(o)\ - \F(c)\ electron density maps. The structure was refined by restrained least.squares and simulated annealing to R = 0.161 at 2.8-angstrom resolution. The binding of hirudin to thrombin is generally similar to that observed in the crystals of human thrombin-hirudin. Several differences in the interactions of the COOH-terminal polypeptide of hirudin, specifically of residues Asp-55h, Phe-56h, Glu-57h, and Glu-58h, and a few differences in the interactions of the hirudin core, specifically of residues Asp-5h, Ser-19h, and Asn-20h, with thrombin from human thrombin-hirudin suggest that there is some flexibility in the binding of these 2 molecules. Most of the residues in the 9 subsites that bind fibrinopeptide A7-16 to thrombin also interact with the NH2-terminal domain of hirudin. The S1 subsite is a notable exception in that only 1 of its 6 residues, namely Ser-214, interacts with hirudin. The only difference between human and bovine thrombins that appears to influence the binding of hirudin is the replacement of Lys-149E by an acidic glutamate in the bovine enzyme.	WAYNE STATE UNIV, DEPT BIOCHEM, DETROIT, MI 48201 USA; SRI INT, DEPT MOLEC BIOL, MENLO PK, CA 94025 USA	Wayne State University; SRI International			Malkowski, Michael G/G-4939-2011	Malkowski, Michael G/0000-0003-1025-0014; Malkowski, Michael/0000-0002-1203-7463	NIGMS NIH HHS [GM 33192] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033192] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGARWAL RC, 1978, ACTA CRYSTALLOGR A, V34, P791, DOI 10.1107/S0567739478001618; BERLINER LJ, 1977, BIOCHEMISTRY-US, V16, P4622, DOI 10.1021/bi00640a015; BETZ A, 1991, BIOCHEMISTRY-US, V30, P9848, DOI 10.1021/bi00105a006; Bing D H, 1981, Ann N Y Acad Sci, V370, P496, DOI 10.1111/j.1749-6632.1981.tb29758.x; BODE W, 1989, EMBO J, V8, P3467, DOI 10.1002/j.1460-2075.1989.tb08511.x; BRUNGER AT, 1988, J MOL BIOL, V203, P803, DOI 10.1016/0022-2836(88)90211-2; BURLEY SK, 1985, SCIENCE, V229, P23, DOI 10.1126/science.3892686; BUTKOWSKI RJ, 1977, J BIOL CHEM, V252, P4942; CHOU PY, 1977, J MOL BIOL, V115, P135, DOI 10.1016/0022-2836(77)90094-8; CLORE GM, 1987, EMBO J, V6, P529, DOI 10.1002/j.1460-2075.1987.tb04785.x; Crowther R. A., 1972, MOL REPLACEMENT METH, P173; CROWTHER RA, 1967, ACTA CRYSTALLOGR, V23, P544, DOI 10.1107/S0365110X67003172; DAVIE EW, 1991, BIOCHEMISTRY-US, V30, P10363, DOI 10.1021/bi00107a001; DEGEN SJF, 1983, BIOCHEMISTRY-US, V22, P2087, DOI 10.1021/bi00278a008; DIMAIO J, 1990, J BIOL CHEM, V265, P21698; DITTMAN WA, 1990, BLOOD, V75, P329; DODT J, 1988, FEBS LETT, V229, P87, DOI 10.1016/0014-5793(88)80803-2; DODT J, 1990, J BIOL CHEM, V265, P713; ESMON CT, 1987, SCIENCE, V235, P1348, DOI 10.1126/science.3029867; FENTON JW, 1986, ANN NY ACAD SCI, V485, P5, DOI 10.1111/j.1749-6632.1986.tb34563.x; FINZEL BC, 1987, J APPL CRYSTALLOGR, V20, P53, DOI 10.1107/S0021889887087144; FITZGERALD PMD, 1988, J APPL CRYSTALLOGR, V23, P544; FOLKERS PJM, 1989, BIOCHEMISTRY-US, V28, P2601, DOI 10.1021/bi00432a038; GRUTTER MG, 1990, EMBO J, V9, P2361, DOI 10.1002/j.1460-2075.1990.tb07410.x; HARUYAMA H, 1989, BIOCHEMISTRY-US, V28, P4301, DOI 10.1021/bi00436a027; Hendrickson W. A., 1981, BIOMOLECULAR STRUCTU, V1, P43; HOWARD AJ, 1987, J APPL CRYSTALLOGR, V20, P383, DOI 10.1107/S0021889887086436; HUBER R, 1978, ACCOUNTS CHEM RES, V11, P114, DOI 10.1021/ar50123a006; JANIN J, 1976, J MOL BIOL, V100, P197, DOI 10.1016/S0022-2836(76)80148-9; JOHNSON PH, 1991, HAEMOSTASIS, V21, P41; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAZAR JB, 1991, J BIOL CHEM, V266, P685; MACGILLIVRAY RTA, 1984, BIOCHEMISTRY-US, V23, P1626, DOI 10.1021/bi00303a007; MAGNUSSON S, 1975, PROTEASES BIOL CONTR, P123; MANN KG, 1987, TRENDS BIOCHEM SCI, V12, P229, DOI 10.1016/0968-0004(87)90115-0; MARAGANORE JM, 1989, J BIOL CHEM, V264, P8692; MARKWARDT F, 1991, SEMIN THROMB HEMOST, V17, P79, DOI 10.1055/s-2007-1002592; Markwardt F., 1970, METHOD ENZYMOL, V19, P924, DOI [10.1016/0076-6879(70)19082-3, DOI 10.1016/0076-6879(70)19082-3]; MARTIN PD, 1983, FED PROC, V42, P1861; READ RJ, 1986, PROTEINASE INHIBITOR, P301; RUHLMANN A, 1973, J MOL BIOL, V77, P417, DOI 10.1016/0022-2836(73)90448-8; RYDEL TJ, 1990, SCIENCE, V249, P277, DOI 10.1126/science.2374926; RYDEL TJ, 1991, J MOL BIOL, V221, P583, DOI 10.1016/0022-2836(91)80074-5; SATOW Y, 1986, J MOL BIOL, V190, P593, DOI 10.1016/0022-2836(86)90245-7; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; SKRZYPCZAKJANKUN E, 1991, J MOL BIOL, V221, P1379; SONDER SA, 1984, BIOCHEMISTRY-US, V23, P1818, DOI 10.1021/bi00303a037; STONE SR, 1986, BIOCHEMISTRY-US, V25, P4622, DOI 10.1021/bi00364a025; WALEH NS, 1992, GENE, V117, P7, DOI 10.1016/0378-1119(92)90483-6; WALZ DA, 1986, PROTHROMBIN OTHER VI, V1, P125; WARD KB, 1975, J MOL BIOL, V98, P161, DOI 10.1016/S0022-2836(75)80107-0; WINANT RC, 1991, BIOCHEMISTRY-US, V30, P1271, DOI 10.1021/bi00219a016	52	49	52	0	2	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 5	1992	267	25					17670	17678						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JM223	1517214				2022-12-25	WOS:A1992JM22300032
J	HASEGAWA, M; MORISHIMAKAWASHIMA, M; TAKIO, K; SUZUKI, M; TITANI, K; IHARA, Y				HASEGAWA, M; MORISHIMAKAWASHIMA, M; TAKIO, K; SUZUKI, M; TITANI, K; IHARA, Y			PROTEIN-SEQUENCE AND MASS-SPECTROMETRIC ANALYSES OF TAU IN THE ALZHEIMERS-DISEASE BRAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PAIRED HELICAL FILAMENTS; ABNORMAL PHOSPHORYLATION; NEUROFIBRILLARY TANGLES; ISOFORMS; EPITOPE; EXPRESSION; PATHOLOGY; KINASE; IDENTIFICATION; LOCALIZATION	Tau with unusually slow mobilities in sodium dodecyl sulfate-polyacrylamide gel electrophoresis was purified from the Sarkosyl-insoluble pellet of Alzheimer's disease brain homogenates. Such species of tau (PHF-tau) are considered to construct the framework of the sodium dodecyl sulfate-soluble form of paired helical filaments (PHF). Detailed comparison of peptide maps of PHF-tau and normal tau before and after dephosphorylation pointed to three anomalously eluted peaks which contained abnormally phosphorylated peptides, residues 191-225, 226-240, 260-267, and 386-438, according to the numbering of the longest tau isoform (Goedert, M., Spillantini, M. G., Jakes, R., Rutherford, D., and Crowther, R. A. (1989) Neuron 3, 519-526). Protein sequence and mass spectrometric analyses localized Thr-231 and Ser-235 as the abnormal phosphorylation sites and further indicated that each tau 1 site (residues 191-225) and the most carboxyl-terminal portion of the protein (residues 386-438) carries more than two abnormal phosphates. Ser-262 was also phosphorylated in a fraction of PHF-tau. Modifications other than phosphorylation, removal of the initiator methionine, and N(alpha)-acetylation at the amino terminus and deamidation at 2 asparaginyl residues were found in PHF-tau, but these modifications were also present in normal tau.	UNIV TOKYO, FAC MED,INST BRAIN RES,DEPT NEUROPATHOL, 7-3-1 HONGO,BUNKYO KU, TOKYO 113, JAPAN; RIKEN, CTR BIOMOLEC CHARACTERIZAT, WAKO, SAITAMA 35101, JAPAN; FUJITA HLTH UNIV, SCH MED, INST COMPREHENS MED SCI, DIV BIOMED POLYMER SCI, TOYOAKE, AICHI 47011, JAPAN	University of Tokyo; RIKEN; Fujita Health University								BANCHER C, 1991, BRAIN RES, V539, P11, DOI 10.1016/0006-8993(91)90681-K; BRION JP, 1991, BIOCHEM J, V279, P831, DOI 10.1042/bj2790831; BRUINS AP, 1987, ANAL CHEM, V59, P2642, DOI 10.1021/ac00149a003; DEGARCINI EM, 1986, BIOCHEM BIOPH RES CO, V141, P790, DOI 10.1016/S0006-291X(86)80242-X; FLAMENT S, 1989, J NEUROL SCI, V92, P133, DOI 10.1016/0022-510X(89)90131-7; GOEDERT M, 1991, NEUROSCI LETT, V126, P149, DOI 10.1016/0304-3940(91)90541-Z; GOEDERT M, 1989, EMBO J, V8, P393, DOI 10.1002/j.1460-2075.1989.tb03390.x; GOEDERT M, 1992, NEURON, V8, P159, DOI 10.1016/0896-6273(92)90117-V; GOEDERT M, 1989, NEURON, V3, P519, DOI 10.1016/0896-6273(89)90210-9; GREENBERG SG, 1990, P NATL ACAD SCI USA, V87, P5827, DOI 10.1073/pnas.87.15.5827; GRUNDKEIQBAL I, 1986, P NATL ACAD SCI USA, V83, P4913, DOI 10.1073/pnas.83.13.4913; HASEGAWA M, 1990, NEURON, V4, P909, DOI 10.1016/0896-6273(90)90144-5; IHARA Y, 1983, NATURE, V304, P727, DOI 10.1038/304727a0; IHARA Y, 1990, GERONTOLOGY, V36, P15; IHARA Y, 1986, J BIOCHEM-TOKYO, V99, P1807, DOI 10.1093/oxfordjournals.jbchem.a135662; IHARA Y, 1988, BRAIN RES, V459, P138, DOI 10.1016/0006-8993(88)90293-4; ISHIGURO K, 1991, NEUROSCI LETT, V128, P195, DOI 10.1016/0304-3940(91)90259-V; ISHIGURO K, 1988, J BIOCHEM-TOKYO, V104, P319, DOI 10.1093/oxfordjournals.jbchem.a122465; ISHIGURO K, 1991, J BIOCHEM-TOKYO, V128, P195; JAKES R, 1991, EMBO J, V10, P2725, DOI 10.1002/j.1460-2075.1991.tb07820.x; KANAI Y, 1989, J CELL BIOL, V109, P1173, DOI 10.1083/jcb.109.3.1173; KANEMARU K, 1992, J NEUROCHEM, V58, P1667, DOI 10.1111/j.1471-4159.1992.tb10039.x; KONDO J, 1988, NEURON, V1, P827, DOI 10.1016/0896-6273(88)90130-4; KOSIK KS, 1989, NEURON, V2, P1389, DOI 10.1016/0896-6273(89)90077-9; KOSIK KS, 1988, NEURON, V1, P817, DOI 10.1016/0896-6273(88)90129-8; KSIEZAKREDING H, 1990, J NEUROSCI RES, V25, P420, DOI 10.1002/jnr.490250320; KSIEZAKREDING H, 1991, NEURON, V6, P717, DOI 10.1016/0896-6273(91)90169-Z; KUZUHARA S, 1991, INT CONGR SER, V946, P87; LEE VMY, 1988, P NATL ACAD SCI USA, V85, P7384, DOI 10.1073/pnas.85.19.7384; LEE VMY, 1991, SCIENCE, V251, P675, DOI 10.1126/science.1899488; MASAKI T, 1981, BIOCHIM BIOPHYS ACTA, V660, P51, DOI 10.1016/0005-2744(81)90107-8; MCKEE AC, 1991, ANN NEUROL, V30, P156, DOI 10.1002/ana.410300206; MORENO S, 1990, CELL, V61, P549, DOI 10.1016/0092-8674(90)90463-O; MORI H, 1987, SCIENCE, V235, P1641, DOI 10.1126/science.3029875; MORI H, 1989, BIOCHEM BIOPH RES CO, V159, P1221, DOI 10.1016/0006-291X(89)92240-7; MORI H, 1989, ENCY NEUROSCIENCE S, V1, P165; NOVAK M, 1991, P NATL ACAD SCI USA, V88, P5837, DOI 10.1073/pnas.88.13.5837; NUKINA N, 1985, J BIOCHEM-TOKYO, V98, P1715, DOI 10.1093/oxfordjournals.jbchem.a135443; Robinson A B, 1974, Curr Top Cell Regul, V8, P247; SELKOE DJ, 1982, SCIENCE, V215, P1243, DOI 10.1126/science.6120571; UCHIDA Y, 1991, NEURON, V7, P337, DOI 10.1016/0896-6273(91)90272-2; VULLIET PR, 1989, J BIOL CHEM, V264, P16292; WEINGARTEN MD, 1975, P NATL ACAD SCI USA, V72, P1858, DOI 10.1073/pnas.72.5.1858; WISCHIK CM, 1988, P NATL ACAD SCI USA, V85, P4506, DOI 10.1073/pnas.85.12.4506; WOLOZIN BL, 1986, SCIENCE, V232, P648, DOI 10.1126/science.3083509	45	370	400	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1992	267	24					17047	17054						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JL053	1512244				2022-12-25	WOS:A1992JL05300050
J	PAPAC, DI; THORNBURG, KR; BULLESBACH, EE; CROUCH, RK; KNAPP, DR				PAPAC, DI; THORNBURG, KR; BULLESBACH, EE; CROUCH, RK; KNAPP, DR			PALMITYLATION OF A G-PROTEIN COUPLED RECEPTOR - DIRECT ANALYSIS BY TANDEM MASS-SPECTROMETRY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYELIN PROTEOLIPID PROTEIN; BOVINE RHODOPSIN; PALMITIC ACID; ACYLATION; CYSTEINE; PEPTIDES; ORIENTATION; FRAGMENTS; DIGESTS; PHASE	Bovine rhodopsin has been reported to be S-palmitylated at cysteines 322 and 323 (Ovchinnikov, Y. A., Abdulaev, N. G., and Bogachuk, A. S. (1988) FEBS Lett. 230, 1-5). Using a combination of enzymatic and chemical cleavage techniques in conjunction with tandem mass spectrometry, the sites of incorporation of the palmityl groups are shown. Bovine rhodopsin in disc membranes was digested with thermolysin to generate the C-terminal fragment (241-327), which was subsequently cleaved with cyanogen bromide to generate the peptide Val-Thr-Thr-Leu-Cys-Cys-Gly-Lys-Asn-Pro (318-327). A bis-S-palmitylated synthetic standard had the same retention time by reversed-phase high performance liquid chromatography as the isolated peptide and the same molecular weight (MH+ 1511.7) by liquid secondary ion mass spectrometry. Dithiothreitol reduction of both the isolated and the synthetic peptide cleaved the two thioester-linked palmityl groups to produce reduction products of the same appropriately decreased molecular weight (MH+ 1035.5). Tandem mass spectrometry of the isolated and the synthetic peptide identified the sites of attachment of the palmityl groups on cysteines 322 and 323. These results prove the modification of cysteines 322 and 323 with palmitic acid in bovine rhodopsin, and illustrate the utility of mass spectrometry to characterize the post-translational modifications in G-protein coupled receptors.	MED UNIV S CAROLINA, DEPT CELL & MOLEC PHARMACOL, CHARLESTON, SC 29425 USA; MED UNIV S CAROLINA, DEPT EXPTL THERAPEUT, CHARLESTON, SC 29425 USA; MED UNIV S CAROLINA, DEPT BIOCHEM & MOLEC BIOL, CHARLESTON, SC 29425 USA; MED UNIV S CAROLINA, DEPT OPHTHALMOL, CHARLESTON, SC 29425 USA	Medical University of South Carolina; Medical University of South Carolina; Medical University of South Carolina; Medical University of South Carolina					NEI NIH HHS [EY08239, EY04939] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY008239, R01EY004939] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ALSALEH S, 1987, BIOCHEM J, V246, P131, DOI 10.1042/bj2460131; BAYRAMASHVILI DI, 1984, EUR J BIOCHEM, V142, P583, DOI 10.1111/j.1432-1033.1984.tb08326.x; BIEMANN K, 1990, METHOD ENZYMOL, V193, P455, DOI 10.1016/0076-6879(90)93433-L; BIEMANN K, 1990, METHOD ENZYMOL, V193, P886, DOI 10.1016/0076-6879(90)93460-3; BIZZOZERO OA, 1986, J NEUROCHEM, V47, P772; BIZZOZERO OA, 1987, J BIOL CHEM, V262, P13550; BIZZOZERO OA, 1990, BIOCHEM BIOPH RES CO, V170, P375, DOI 10.1016/0006-291X(90)91284-Y; BRUENNER BA, 1991, 39TH P ASMS C MASS S, P1445; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; GERBER GE, 1979, P NATL ACAD SCI USA, V76, P227, DOI 10.1073/pnas.76.1.227; GOODLETT DR, 1990, ANAL BIOCHEM, V186, P116, DOI 10.1016/0003-2697(90)90583-U; HARGRAVE P A, 1980, Neurochemistry International, V1, P231, DOI 10.1016/0197-0186(80)90063-7; HARGRAVE PA, 1977, J SUPRAMOL STR CELL, V6, P559, DOI 10.1002/jss.400060409; HARGRAVE PA, 1982, VISION RES, V22, P1429, DOI 10.1016/0042-6989(82)90205-X; JAMES G, 1990, BIOCHEMISTRY-US, V29, P2623, DOI 10.1021/bi00463a001; KARNIK SS, 1988, P NATL ACAD SCI USA, V85, P8459, DOI 10.1073/pnas.85.22.8459; KNAPP DR, 1990, METHOD ENZYMOL, V193, P314, DOI 10.1016/0076-6879(90)93423-I; MERGLER M, 1988, TETRAHEDRON LETT, V29, P4005, DOI 10.1016/S0040-4039(00)80405-0; MOLENAAR CMT, 1988, EMBO J, V7, P971, DOI 10.1002/j.1460-2075.1988.tb02903.x; MORODER L, 1989, BIOL CHEM H-S, V370, P365, DOI 10.1515/bchm3.1989.370.1.365; MORRISON DF, 1991, J BIOL CHEM, V266, P20118; NAKAYAMA TA, 1990, J BIOL CHEM, V265, P15762; NAYLOR S, 1986, J AM CHEM SOC, V108, P6359, DOI 10.1021/ja00280a037; OBRIEN PJ, 1984, J BIOL CHEM, V259, P5054; OBRIEN PJ, 1987, J BIOL CHEM, V262, P5210; ODOWD BF, 1989, J BIOL CHEM, V264, P7564; OVCHINNIKOV YA, 1988, FEBS LETT, V230, P1, DOI 10.1016/0014-5793(88)80628-8; PAPERMASTER DS, 1974, BIOCHEMISTRY-US, V13, P2438, DOI 10.1021/bi00708a031; PUCCI P, 1992, BIOL MASS SPECTROM, V21, P22, DOI 10.1002/bms.1200210106; ROSE JK, 1984, P NATL ACAD SCI-BIOL, V81, P2050, DOI 10.1073/pnas.81.7.2050; SCHMIDT MFG, 1989, BIOCHIM BIOPHYS ACTA, V988, P411, DOI 10.1016/0304-4157(89)90013-0; STONE WL, 1979, EXP EYE RES, V28, P387, DOI 10.1016/0014-4835(79)90114-3; TARR GE, 1983, ANAL BIOCHEM, V131, P99, DOI 10.1016/0003-2697(83)90140-9; VATH JE, 1990, INT J MASS SPECTROM, V100, P287, DOI 10.1016/0168-1176(90)85079-H	34	90	93	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	1992	267	24					16889	16894						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JL053	1512231				2022-12-25	WOS:A1992JL05300028
J	GUTHER, MLS; DEALMEIDA, MLC; YOSHIDA, N; FERGUSON, MAJ				GUTHER, MLS; DEALMEIDA, MLC; YOSHIDA, N; FERGUSON, MAJ			STRUCTURAL STUDIES ON THE GLYCOSYLPHOSPHATIDYLINOSITOL MEMBRANE ANCHOR OF TRYPANOSOMA-CRUZI 1G7-ANTIGEN - THE STRUCTURE OF THE GLYCAN CORE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VARIANT SURFACE GLYCOPROTEIN; HUMAN-ERYTHROCYTE ACETYLCHOLINESTERASE; GLYCOSYL-PHOSPHATIDYLINOSITOL ANCHOR; METACYCLIC TRYPOMASTIGOTES; LEISHMANIA-MAJOR; MASS-SPECTROMETRY; PROTEINS; LIPOPHOSPHOGLYCAN; BIOSYNTHESIS; INOSITOL	The 1G7-antigen is expressed by the infective metacyclic trypomastigote stage of the protozoan parasite Trypanosoma cruzi. The 1G7-antigen is a 90-kDa glycoprotein, present at about 40,000 copies/cell, which is anchored in the plasma membrane via a glycosylphosphatidylinositol (GPI) membrane anchor. The glycan of the GPI anchor has been isolated from immunopurified 1G7-antigen and its structure determined using a combination of methylation linkage analysis and exoglycosidase sequencing. The structure of the glycan is Man-alpha-1-2Man-alpha-1-2Man-alpha-1-6Man-alpha-1-4GlcNH2. The glucosamine residue is in glycosidic linkage to a phosphatidylinositol moiety. The penultimate nonreducing alpha-Man residue is substituted with phosphate, which is most likely part of an ethanolamine phosphate bridge linking the GPI anchor to the 1G7-antigen polypeptide. The glycan sequence was obtained from 1.1 nmol of glycoprotein isolated from a detergent lysate of whole cells. The procedures reported here represent a high sensitivity protocol for determining GPI glycan structures from small quantities of biological material. The structure of the 1G7-antigen GPI anchor is consistent with the conserved core structure of all GPI anchors analyzed to date and is similar to that of the T. cruzi lipopeptidophosphoglycan. The biosynthesis of GPI anchors and lipopeptidophosphoglycan in T. cruzi is discussed in the light of this structural homology.	UNIV DUNDEE, DEPT BIOCHEM, DUNDEE DD1 4HN, SCOTLAND; ESCOLA PAULISTA MED SCH, DEPT MICROBIOL IMMUNOL & PARASITOL, BR-04023 SAO PAULO, BRAZIL	University of Dundee; Universidade Federal de Sao Paulo (UNIFESP)			Ferguson, Michael A. J./F-7829-2010	Ferguson, Michael A. J./0000-0003-1321-8714	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ADROHER FJ, 1988, CELL DIFFER DEV, V22, P165, DOI 10.1016/0045-6039(88)90029-2; ARAGUTH MF, 1988, PARASITE IMMUNOL, V10, P707, DOI 10.1111/j.1365-3024.1988.tb00256.x; BALDWIN MA, 1990, ANAL BIOCHEM, V191, P174, DOI 10.1016/0003-2697(90)90405-X; BONALDO MC, 1988, J CELL BIOL, V106, P1349, DOI 10.1083/jcb.106.4.1349; CamargO E. P., 1964, Revista do Instituto de Medicina Tropical de Sao Paulo, V6, P93; CIUCANU I, 1984, CARBOHYD RES, V131, P209, DOI 10.1016/0008-6215(84)85242-8; CROSS GAM, 1984, J CELL BIOCHEM, V24, P79, DOI 10.1002/jcb.240240107; CROSS GAM, 1990, ANNU REV CELL BIOL, V6, P1, DOI 10.1146/annurev.cb.06.110190.000245; Ferguson M.A.J., 1989, P121; FERGUSON MAJ, 1988, PARASITE IMMUNOL, V10, P465, DOI 10.1111/j.1365-3024.1988.tb00236.x; FERGUSON MAJ, 1988, SCIENCE, V239, P753, DOI 10.1126/science.3340856; FERGUSON MAJ, 1988, ANNU REV BIOCHEM, V57, P285; Ferguson MAJ, 1991, CURR OPIN STRUC BIOL, V1, P522, DOI 10.1016/S0959-440X(05)80072-7; GONZALEZ J, 1991, INFECT IMMUN, V59, P863; GRACE TDC, 1962, NATURE, V195, P788, DOI 10.1038/195788a0; HITCHCOCK PJ, 1983, EUR J BIOCHEM, V133, P685, DOI 10.1111/j.1432-1033.1983.tb07517.x; HOMANS SW, 1988, NATURE, V333, P269, DOI 10.1038/333269a0; KOBATA A, 1987, METHOD ENZYMOL, V138, P779; Kobata A., 1984, BIOL CARBOHYDRATES, V2, P87; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEDERKREMER RM, 1990, EUR J BIOCHEM, V192, P337; LEDERKREMER RM, 1985, EUR J BIOCHEM, V151, P539; LEDERKREMER RM, 1991, J BIOL CHEM, V266, P23670; LOW MG, 1989, BIOCHIM BIOPHYS ACTA, V988, P427, DOI 10.1016/0304-4157(89)90014-2; MASTERSON WJ, 1989, CELL, V56, P793, DOI 10.1016/0092-8674(89)90684-3; MASTERSON WJ, 1990, CELL, V62, P73, DOI 10.1016/0092-8674(90)90241-6; MCCONVILLE MJ, 1990, J BIOL CHEM, V265, P7385; MCCONVILLE MJ, 1991, J BIOL CHEM, V266, P15170; MCCONVILLE MJ, 1990, J BIOL CHEM, V265, P19611; MCCONVILLE MJ, 1991, BIOCH PROTOZOOLOGY B, V6, P504; MORTARA RA, 1988, PARASITE IMMUNOL, V10, P369, DOI 10.1111/j.1365-3024.1988.tb00227.x; NATSUKA S, 1987, ANAL BIOCHEM, V167, P154, DOI 10.1016/0003-2697(87)90146-1; PREVIATO JO, 1990, J BIOL CHEM, V265, P2518; ROBERTS WL, 1988, J BIOL CHEM, V263, P18766; ROBERTS WL, 1988, J BIOL CHEM, V263, P18776; SCHENKMAN S, 1988, MOL BIOCHEM PARASIT, V29, P141, DOI 10.1016/0166-6851(88)90069-2; SCHNEIDER P, 1990, J BIOL CHEM, V265, P16955; SMITH R, 1987, BIOCHEM J, V248, P285, DOI 10.1042/bj2480285; TEIXEIRA MMG, 1986, MOL BIOCHEM PARASIT, V18, P271, DOI 10.1016/0166-6851(86)90085-X; THOMAS JR, 1990, BIOCHEMISTRY-US, V29, P5413, DOI 10.1021/bi00475a001; TSAI CM, 1982, ANAL BIOCHEM, V119, P115, DOI 10.1016/0003-2697(82)90673-X; TURCO SJ, 1990, EXP PARASITOL, V70, P241, DOI 10.1016/0014-4894(90)90105-L; TURCO SJ, 1989, J BIOL CHEM, V264, P6711; YOSHIDA N, 1990, MOL BIOCHEM PARASIT, V39, P39, DOI 10.1016/0166-6851(90)90006-8; ZAMZE SE, 1988, EUR J BIOCHEM, V176, P527, DOI 10.1111/j.1432-1033.1988.tb14310.x	45	74	74	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 5	1992	267	10					6820	6828						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HM053	1532392				2022-12-25	WOS:A1992HM05300056
J	MARTINEZSERRANO, A; BLANCO, P; SATRUSTEGUI, J				MARTINEZSERRANO, A; BLANCO, P; SATRUSTEGUI, J			CALCIUM-BINDING TO THE CYTOSOL AND CALCIUM EXTRUSION MECHANISMS IN INTACT SYNAPTOSOMES AND THEIR ALTERATIONS WITH AGING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-BRAIN SYNAPTOSOMES; PRESYNAPTIC NERVE-TERMINALS; INTRACELLULAR CALCIUM; PLASMA-MEMBRANE; CA-2+ TRANSPORT; EXCHANGE; AGE; EFFLUX; VESICLES; PROTEIN	A simple method to measure cytosolic calcium binding in intact presynaptic nerve terminals (synaptosomes) from rat brain, which is based on the simultaneous determination of [Ca2+]i and total [Ca-45(2+)] in quin2-loaded synaptosomes undergoing a switch from high- to low-calcium containing medium, is presented. Binding to the cytosolic compartment alone was obtained following depletion of calcium storing organelles in the presence of carbonyl cyanide p-trifluoromethoxyphenylhydrazone/oligomycin plus caffeine. Synaptosomes, as compared to various cells types, have a high calcium binding capacity to the cytosolic compartment; maximum binding, Ca.B(max), was 4.76 mM and calculated s0.5, was 218 nM. Calcium binding to the cytosolic compartment as a function of aging was also determined; Ca.B(max) was reduced to 1.84 mM and s0.5 increased to 492 nM in 30-month-old rats, indicating that the buffering of high calcium loads is impaired in old animals. The results obtained for binding of calcium to mitochondria and caffeine-sensitive calcium stores are consistent with an age-dependent reduction in calcium bound to mitochondria, whereas caffeine-sensitive calcium stores were unaffected. Finally, we have estimated the net rates of calcium extrusion in intact synaptosomes, and found that calcium efflux through the Na/Ca exchanger and Ca2+-ATPase was markedly reduced in old rats.	UNIV AUTONOMA MADRID, CTR BIOL MOLEC, DEPT BIOL MOLEC, CONSEJO SUPER INVEST CIENT, E-28049 MADRID, SPAIN	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC)			Satrustegui, Jorgina/R-6732-2019; Martínez-Serrano, Alberto/J-8146-2014	Satrustegui Gil Delgado, Jorgina/0000-0003-3377-2667; Blanco Morales, Pablo/0000-0003-1933-6818; Martinez Serrano, Alberto/0000-0003-3927-6699				BAIMBRIDGE KG, 1982, BRAIN RES, V245, P223, DOI 10.1016/0006-8993(82)90804-6; BLANCO P, 1990, CELL CALCIUM, V11, P25, DOI 10.1016/0143-4160(90)90046-W; BLAUSTEIN MP, 1988, TRENDS NEUROSCI, V11, P438, DOI 10.1016/0166-2236(88)90195-6; BOOTH RFG, 1978, BIOCHEM J, V176, P365, DOI 10.1042/bj1760365; CARAFOLI E, 1987, ANNU REV BIOCHEM, V56, P395, DOI 10.1146/annurev.biochem.56.1.395; CARONI P, 1980, P NATL ACAD SCI-BIOL, V77, P6354, DOI 10.1073/pnas.77.11.6354; COUTINHO OP, 1984, BRAIN RES, V290, P261, DOI 10.1016/0006-8993(84)90943-0; GANDHI CR, 1987, NEUROCHEM RES, V12, P67, DOI 10.1007/BF00971366; GARCIASEGURA LM, 1984, BRAIN RES, V296, P75, DOI 10.1016/0006-8993(84)90512-2; GILL DL, 1981, J BIOL CHEM, V256, P184; GILL DL, 1984, J BIOL CHEM, V259, P807; IACOPINO AM, 1990, P NATL ACAD SCI USA, V87, P4078, DOI 10.1073/pnas.87.11.4078; JOHANSSON JS, 1988, J MEMBRANE BIOL, V104, P147, DOI 10.1007/BF01870927; KACZOROWSKI GJ, 1984, J BIOL CHEM, V259, P9395; MARTINEZ A, 1987, BRAIN RES, V435, P249, DOI 10.1016/0006-8993(87)91608-8; MARTINEZ A, 1988, NEUROSCI LETT, V88, P336, DOI 10.1016/0304-3940(88)90234-0; MARTINEZSERRANO A, 1989, BIOCHEM BIOPH RES CO, V161, P965, DOI 10.1016/0006-291X(89)91337-5; MCBURNEY RN, 1987, TRENDS NEUROSCI, V10, P164, DOI 10.1016/0166-2236(87)90042-7; MELDOLESI J, 1990, BIOCHIM BIOPHYS ACTA, V1055, P130, DOI 10.1016/0167-4889(90)90113-R; MELDOLESI J, 1987, IN VITRO METHODS STU, P289; MELZER W, 1986, J PHYSIOL-LONDON, V372, P261, DOI 10.1113/jphysiol.1986.sp016008; MICHAELIS EK, 1983, J BIOL CHEM, V258, P6101; MICHAELIS M L, 1987, Society for Neuroscience Abstracts, V13, P720; MICHAELIS ML, 1984, MECH AGEING DEV, V25, P215, DOI 10.1016/0047-6374(84)90142-8; MICHAELIS ML, 1987, J BIOL CHEM, V262, P4182; NACHSHEN DA, 1988, J GEN PHYSIOL, V91, P289, DOI 10.1085/jgp.91.2.289; NACHSHEN DA, 1986, J PHYSIOL-LONDON, V381, P17, DOI 10.1113/jphysiol.1986.sp016309; NUNEZ AM, 1982, J NEUROCHEM, V38, P1342, DOI 10.1111/j.1471-4159.1982.tb07911.x; PARADISO AM, 1984, P NATL ACAD SCI-BIOL, V81, P7436, DOI 10.1073/pnas.81.23.7436; PETERSON C, 1985, NEUROBIOL AGING, V6, P297, DOI 10.1016/0197-4580(85)90007-7; RASGADOFLORES H, 1987, AM J PHYSIOL, V252, pC588, DOI 10.1152/ajpcell.1987.252.6.C588; RINK TJ, 1982, J CELL BIOL, V95, P189, DOI 10.1083/jcb.95.1.189; SANCHEZARMASS S, 1987, AM J PHYSIOL, V252, pC595, DOI 10.1152/ajpcell.1987.252.6.C595; SATRUSTEGUI J, 1990, THEORETICAL BASIS AG, P265; SCHARFMAN HE, 1989, SCIENCE, V246, P257, DOI 10.1126/science.2508225; SCHWEITZER ES, 1980, BIOCHIM BIOPHYS ACTA, V600, P912, DOI 10.1016/0005-2736(80)90493-9; SNELLING R, 1985, BIOCHEM J, V226, P225, DOI 10.1042/bj2260225; TSIEN R, 1989, METHOD ENZYMOL, V172, P230; VITORICA J, 1986, BRAIN RES, V378, P36, DOI 10.1016/0006-8993(86)90284-2; VITORICA J, 1986, BIOCHIM BIOPHYS ACTA, V851, P209, DOI 10.1016/0005-2728(86)90127-1; VONTSCHARNER V, 1986, J BIOL CHEM, V261, P163	41	94	96	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	1992	267	7					4672	4679						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HF642	1531657				2022-12-25	WOS:A1992HF64200061
J	COLLINS, RN; WARREN, G				COLLINS, RN; WARREN, G			SPHINGOLIPID TRANSPORT IN MITOTIC HELA-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REQUIRING PYRIDINE-NUCLEOTIDE; VESICULAR STOMATITIS-VIRUS; SYNTHESIZED G-PROTEIN; GOLGI-APPARATUS; BREFELDIN-A; RAT-LIVER; GANGLIOSIDE BIOSYNTHESIS; MEIOTIC MATURATION; CERAMIDE SYNTHESIS; SURFACE FUNCTIONS	Mitotic and interphase HeLa cells were labeled with [H-3]serine. Ceramide and its derivatives, lactosylceramide and sphingomyelin, were biosynthetically labeled under both conditions. Only in the absence of nocodazole, as the cells entered telophase, was an additional glycosphingolipid synthesized which was identified as G(A2) (GalNAc(beta1,4)Gal(beta1,4)Glc(beta1,1)Cer). Ceramide, the basic sphingolipid precursor, is synthesized in the endoplasmic reticulum, whereas its immediate derivatives are synthesized in early Golgi compartments. Transport of newly synthesized proteins from the endoplasmic reticulum to the Golgi is inhibited in mitotic cells while ceramide acquires early Golgi modifications under the same conditions, suggesting that ceramide can be delivered to the Golgi by a different route. Since G(A2) is synthesized in late Golgi, its absence in mitotic cells strongly argues for an in vivo inhibition of intra-Golgi transport, an observation with important implications for the mechanism of Golgi division.			COLLINS, RN (corresponding author), IMPERIAL CANC RES FUND,CELL BIOL LAB,44 LINCOLNS INN FIELDS,LONDON WC2A 3PX,ENGLAND.							ANSELL GB, 1982, NEW COMPREHENSIVE BI, V4, P1; BASU M, 1987, METHOD ENZYMOL, V138, P575; BERLIN RD, 1980, J CELL BIOL, V85, P660, DOI 10.1083/jcb.85.3.660; BERLIN RD, 1978, CELL, V15, P327, DOI 10.1016/0092-8674(78)90002-8; CHEGE NW, 1990, J CELL BIOL, V111, P893, DOI 10.1083/jcb.111.3.893; CLARK RW, 1986, J CELL BIOL, V103, pA305; Cleves A, 1991, Trends Cell Biol, V1, P30, DOI 10.1016/0962-8924(91)90067-J; COLMAN A, 1985, J CELL BIOL, V101, P313, DOI 10.1083/jcb.101.1.313; COSTE H, 1985, BIOCHIM BIOPHYS ACTA, V814, P1, DOI 10.1016/0005-2736(85)90412-2; DEUTSCHER SL, 1986, J BIOL CHEM, V261, P96; FAWCETT DW, 1965, J HISTOCHEM CYTOCHEM, V13, P75, DOI 10.1177/13.2.75; FEATHERSTONE C, 1985, J CELL BIOL, V101, P2036, DOI 10.1083/jcb.101.6.2036; FOLCH J, 1957, J BIOL CHEM, V226, P497; GERACE L, 1988, ANNU REV CELL BIOL, V4, P335, DOI 10.1146/annurev.cb.04.110188.002003; GRAY GM, 1967, BIOCHIM BIOPHYS ACTA, V144, P511, DOI 10.1016/0005-2760(67)90039-2; HESKETH TR, 1984, J CELL BIOL, V98, P2250, DOI 10.1083/jcb.98.6.2250; JECKEL D, 1990, FEBS LETT, V261, P155, DOI 10.1016/0014-5793(90)80659-7; KEENAN TW, 1974, J BIOL CHEM, V249, P310; KOBAYASHI T, 1989, J BIOL CHEM, V264, P5966; KREINER T, 1990, CELL REGUL, V1, P415, DOI 10.1091/mbc.1.5.415; LASKEY RA, 1975, EUR J BIOCHEM, V56, P335, DOI 10.1111/j.1432-1033.1975.tb02238.x; LEAF DS, 1990, DEV BIOL, V141, P1, DOI 10.1016/0012-1606(90)90097-3; LI SC, 1970, J BIOL CHEM, V245, P5153; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; LIPSKY NG, 1985, SCIENCE, V228, P745, DOI 10.1126/science.2581316; LIPSKY NG, 1985, J CELL BIOL, V100, P27, DOI 10.1083/jcb.100.1.27; LUCOCQ JM, 1989, J CELL BIOL, V109, P463, DOI 10.1083/jcb.109.2.463; LUCOCQ JM, 1987, J CELL BIOL, V104, P865, DOI 10.1083/jcb.104.4.865; MORELL P, 1969, BIOCHEMISTRY-US, V8, P506, DOI 10.1021/bi00830a008; MORENO S, 1990, CELL, V61, P549, DOI 10.1016/0092-8674(90)90463-O; PAGANO RE, 1985, SCIENCE, V229, P1051, DOI 10.1126/science.4035344; PAGANO RE, 1989, J CELL BIOL, V109, P2067, DOI 10.1083/jcb.109.5.2067; PAGANO RE, 1988, TRENDS BIOCHEM SCI, V13, P202, DOI 10.1016/0968-0004(88)90082-5; PINES J, 1990, New Biologist, V2, P389; POHLENTZ G, 1988, P NATL ACAD SCI USA, V85, P7044, DOI 10.1073/pnas.85.19.7044; PYPAERT M, 1987, EUR J CELL BIOL, V45, P23; PYPAERT M, 1991, J CELL BIOL, V114, P1159, DOI 10.1083/jcb.114.6.1159; SAGER PR, 1984, CELL, V39, P275, DOI 10.1016/0092-8674(84)90005-9; SAITO M, 1984, BIOCHEMISTRY-US, V23, P1043, DOI 10.1021/bi00301a001; SCHACHTER H, 1980, BIOCH GLYCOPROTEINS, P85; SINGH I, 1980, ARCH BIOCHEM BIOPHYS, V202, P93, DOI 10.1016/0003-9861(80)90409-9; SRIBNEY M, 1966, BIOCHIM BIOPHYS ACTA, V125, P542, DOI 10.1016/0005-2760(66)90042-7; STANLEY P, 1980, ACS SYM SER, V128, P213; STEIN J, 1982, TECH LIPID MEMBR BIO, V404, P1; TRINCHERA M, 1989, J BIOL CHEM, V264, P15766; TUOMIKOSKI T, 1989, NATURE, V342, P942, DOI 10.1038/342942a0; ULMER JB, 1989, P NATL ACAD SCI USA, V86, P6992, DOI 10.1073/pnas.86.18.6992; VAN MEER G, 1987, J CELL BIOL, V105, P1623, DOI 10.1083/jcb.105.4.1623; VAN MEER G, 1989, ANNU REV CELL BIOL, V5, P247, DOI 10.1146/annurev.cellbio.5.1.247; VANECHTEN G, 1990, EUR J CELL BIOL, V51, P135; WARREN G, 1989, NATURE, V342, P857, DOI 10.1038/342857a0; WARREN G, 1984, EMBO J, V3, P2217, DOI 10.1002/j.1460-2075.1984.tb02119.x; WARREN G, 1983, J CELL BIOL, V97, P1623, DOI 10.1083/jcb.97.5.1623; WARREN G, 1985, TRENDS BIOCHEM SCI, V10, P439, DOI 10.1016/0968-0004(85)90027-1; WATTENBERG BW, 1990, J CELL BIOL, V111, P421, DOI 10.1083/jcb.111.2.421; WOODMAN PG, 1992, J CELL BIOL, V116, P331, DOI 10.1083/jcb.116.2.331; YOUNG WW, 1990, P NATL ACAD SCI USA, V87, P6838, DOI 10.1073/pnas.87.17.6838; YUSUF HKM, 1983, P NATL ACAD SCI-BIOL, V80, P7075, DOI 10.1073/pnas.80.23.7075; ZIEVE GW, 1980, EXP CELL RES, V126, P397, DOI 10.1016/0014-4827(80)90279-7	59	49	50	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1992	267	34					24906	24911						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KA263	1447226				2022-12-25	WOS:A1992KA26300111
J	LI, LM; LAGARIAS, JC				LI, LM; LAGARIAS, JC			PHYTOCHROME ASSEMBLY - DEFINING CHROMOPHORE STRUCTURAL REQUIREMENTS FOR COVALENT ATTACHMENT AND PHOTOREVERSIBILITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INVITRO ATTACHMENT; POLYACRYLAMIDE GELS; PHYCOCYANOBILIN; BIOSYNTHESIS; ADDUCT; APOPHYCOCYANIN; PROTEINS; BILINS; HOLOPHYTOCHROME; APOPHYTOCHROME	Assembly of holophytochrome in the plant cell requires covalent attachment of the linear tetrapyrrole chromophore precursor, phytochromobilin, to a unique cysteine in the nascent apoprotein. In this investigation we compare chromophore analogs with the natural chromophore precursor for their ability to attach covalently to recombinant oat apophytochrome and to form photoactive holoproteins. Ethylidene-containing analogs readily form covalent adducts with apophytochrome, whereas chromophores lacking this double bond are poor substrates for attachment. Kinetic measurements establish that although the chromophore binding site on apophytochrome is best tailored to phytochromobilin, apophytochrome will accommodate the two analogs with modified D-rings, phycocyanobilin and phycoerythrobilin. The phycocyanobilin-apophytochrome adduct is photoactive and undergoes a light-induced protein conformational change similar to the native holoprotein. By contrast, the phycoerythrobilin adduct is locked into a photochemically inactive protein conformation that is similar to the red light-absorbing P(r) form of phytochrome. These results support the hypothesis that the photoconversion from P(r) to P(fr), the far red light- absorbing form of phytochrome, involves the photoisomerization of the C15 double bond. Knowledge gained from these studies provides impetus for rational design of chromophore analogs whose insertion into apophytochrome should elicit profound changes in light-mediated plant growth and development.	UNIV CALIF DAVIS, DEPT BIOCHEM & BIOPHYS, DAVIS, CA 95616 USA	University of California System; University of California Davis			Lagarias, John Clark/L-3139-2013	Lagarias, John Clark/0000-0002-2093-0403				ARCIERO DM, 1988, J BIOL CHEM, V263, P18343; ARCIERO DM, 1988, J BIOL CHEM, V263, P18358; ARCIERO DM, 1988, J BIOL CHEM, V263, P18350; BEALE SI, 1991, J BIOL CHEM, V266, P22328; BERKELMAN TR, 1986, ANAL BIOCHEM, V156, P194, DOI 10.1016/0003-2697(86)90173-9; CHAPMAN DJ, 1967, J AM CHEM SOC, V89, P5976, DOI 10.1021/ja00999a058; COLE WJ, 1967, J AM CHEM SOC, V89, P3643, DOI 10.1021/ja00990a055; CORNEJO J, 1992, J BIOL CHEM, V267, P14790; DEFORCE L, 1991, P NATL ACAD SCI USA, V88, P10392, DOI 10.1073/pnas.88.23.10392; DUMONT ME, 1987, EMBO J, V6, P235, DOI 10.1002/j.1460-2075.1987.tb04744.x; ELICH TD, 1989, J BIOL CHEM, V264, P12902; ELICH TD, 1989, J BIOL CHEM, V264, P183; ELICH TD, 1987, PLANT PHYSIOL, V84, P304, DOI 10.1104/pp.84.2.304; FODOR SPA, 1990, BIOCHEMISTRY-US, V29, P11141, DOI 10.1021/bi00502a018; JONES AM, 1986, PLANT PHYSIOL, V81, P1014, DOI 10.1104/pp.81.4.1014; KONOMI K, 1986, PLANT CELL PHYSIOL, V27, P1507; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAGARIAS JC, 1985, J BIOL CHEM, V260, P2415; LAGARIAS JC, 1980, J AM CHEM SOC, V102, P4821, DOI 10.1021/ja00534a042; LAGARIAS JC, 1989, P NATL ACAD SCI USA, V86, P5778, DOI 10.1073/pnas.86.15.5778; LAGARIAS JC, 1987, PHOTOCHEM PHOTOBIOL, V46, P5, DOI 10.1111/j.1751-1097.1987.tb04729.x; LITTS JC, 1983, J BIOL CHEM, V258, P1025; McDonagh A. F., 1979, PORPHYRINS, VVI; PARKS BM, 1991, PLANT CELL, V3, P1177, DOI 10.1105/tpc.3.11.1177; Pratt L. H., 1986, Photomorphogenesis in plants, P61; QUAIL PH, 1991, ANNU REV GENET, V25, P389, DOI 10.1146/annurev.ge.25.120191.002133; QUAIL PH, 1973, PLANT PHYSIOL, V52, P128, DOI 10.1104/pp.52.2.128; RUDIGER W, 1983, P NATL ACAD SCI-BIOL, V80, P6244, DOI 10.1073/pnas.80.20.6244; SMITH H, 1990, PLANT CELL ENVIRON, V13, P695, DOI 10.1111/j.1365-3040.1990.tb01084.x; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; TERRY MJ, 1991, J BIOL CHEM, V266, P22215; THUMMLER F, 1983, TETRAHEDRON, V39, P1943, DOI 10.1016/S0040-4020(01)88709-3; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Vierstra R. D., 1986, Photomorphogenesis in plants, P35; VIERSTRA RD, 1984, PLANTA, V160, P521, DOI 10.1007/BF00411140; WAHLEITHNER JA, 1991, P NATL ACAD SCI USA, V88, P10387, DOI 10.1073/pnas.88.23.10387; WELLER JP, 1980, CHEM BER-RECL, V113, P1603, DOI 10.1002/cber.19801130439	37	94	97	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1992	267	27					19204	19210						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JP593	1527043				2022-12-25	WOS:A1992JP59300032
J	MAY, LT; VIGUET, H; KENNEY, JS; IDA, N; ALLISON, AC; SEHGAL, PB				MAY, LT; VIGUET, H; KENNEY, JS; IDA, N; ALLISON, AC; SEHGAL, PB			HIGH-LEVELS OF COMPLEXED INTERLEUKIN-6 IN HUMAN BLOOD	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATOCYTE-STIMULATING FACTOR; AMNIOTIC-FLUID INTERLEUKIN-6; FACTOR-II; HUMAN-FIBROBLASTS; MULTIPLE FORMS; GROWTH-FACTOR; INFECTION; SERUM; IL-6; CYTOKINES	The biochemical nature of endogenous interleukin-6 (IL-6) as it exists in human serum or plasma was investigated. Serum from a patient following bone marrow (BM) transplantation and fresh plasma samples from patients with epidermolysis bullosa or psoriasis, as well as from normal volunteers, were fractionated through G-200 columns and each of the eluted fractions assayed for IL (interleukin)-6 content using enzyme-linked immunosorbent assays (ELISAs) based on the monoclonal antibody (mAb) pairs IG61/5IL6 or 4IL6/5IL6 and in the B9 hybridoma growth factor bioassay. The IG61/5IL6 ELISA and the B9 assay detected IL-6 in BM serum almost exclusively of molecular mass approximately 20 kDa. In contrast, the 4IL6/5IL6 ELISA detected strong IL-6 immunoreactivity in complexes of size 100-150 and 400-500 kDa. IL-6 present in the 100-150- and 400-500-kDa complexes was purified by immunoaffinity chromatography through a 5IL6 mAb column. The 5IL6 mAb immunoaffinity column eluate of the respective pools from BM serum contained IL-6 at concentrations approaching 1 mug/ml as characterized by Western blotting. Sufficient IL-6 and associated proteins were purified by 5IL6 mAb immunoaffinity column chromatography of the 100-150-kDa complex from 0.8 ml of BM serum to allow (i) verification of three of the polypeptides as IL-6 by amino-terminal sequencing (estimate of IL-6 in original serum sample: 5-10 mug/ml), (ii) identification by amino acid sequencing of the "associated" proteins as complement factor C3b (carboxyl-terminal of the alpha-chain), complement factor C4b (gamma-chain), C-reactive protein, and albumin, and (iii) detection of an "associated" polypeptide consistent with the soluble IL-6 receptor. Taken together, these data establish that IL-6 is present at unexpectedly high concentrations in human blood in novel biochemical complexes that include other plasma proteins, which in turn, can camouffage IL-6 immunoreactivity and bioactivity as measured in conventional assays.	NEW YORK MED COLL, DEPT MICROBIOL & IMMUNOL, BASIC SCI BLDG, VALHALLA, NY 10595 USA; NEW YORK MED COLL, DEPT MED, VALHALLA, NY 10595 USA; ROCKEFELLER UNIV, CELL PHYSIOL & VIROL LAB, NEW YORK, NY 10021 USA; SYNTEX INC, DEPT INFLAMMAT BIOL & IMMUNOL, PALO ALTO, CA 94304 USA; TORAY INDUSTRIES LTD, BASIC RES LABS, KAMAKURA 248, JAPAN	New York Medical College; New York Medical College; Rockefeller University; Syntex Corporation; Toray Industries, Inc.					NIAID NIH HHS [AI-16262] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI016262] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Aarden L, 1985, LYMPHOKINES, V10, P175; DEBRUIJN MHL, 1985, P NATL ACAD SCI USA, V82, P708; FONG YM, 1989, J IMMUNOL, V142, P2321; FREI K, 1988, J EXP MED, V168, P449, DOI 10.1084/jem.168.1.449; GARMAN RD, 1987, P NATL ACAD SCI USA, V84, P7629, DOI 10.1073/pnas.84.21.7629; GAULDIE J, 1987, P NATL ACAD SCI USA, V84, P7251, DOI 10.1073/pnas.84.20.7251; GROSSMAN RM, 1989, P NATL ACAD SCI USA, V86, P6367, DOI 10.1073/pnas.86.16.6367; GUISEZ Y, 1991, EUR J BIOCHEM, V198, P217, DOI 10.1111/j.1432-1033.1991.tb16004.x; HEINRICH PC, 1990, BIOCHEM J, V265, P621, DOI 10.1042/bj2650621; HELFGOTT DC, 1989, J IMMUNOL, V142, P948; HIRANO T, 1986, NATURE, V324, P73, DOI 10.1038/324073a0; HIRANO T, 1985, P NATL ACAD SCI USA, V82, P5490, DOI 10.1073/pnas.82.16.5490; HIRANO T, 1992, CLIN IMMUNOL IMMUNOP, V62, pS60, DOI 10.1016/0090-1229(92)90042-M; HONDA M, 1990, J IMMUNOL, V145, P4059; HONDA M, 1992, J IMMUNOL, V148, P2175; IDA N, 1990, J IMMUNOL METHODS, V133, P279, DOI 10.1016/0022-1759(90)90369-7; JABLONS DM, 1989, J IMMUNOL, V142, P1542; KENNEY JS, 1987, J IMMUNOL, V138, P4236; KIRNBAUER R, 1991, J INVEST DERMATOL, V96, P484, DOI 10.1111/1523-1747.ep12470181; KISHIMOTO T, 1989, BLOOD, V74, P1, DOI 10.1182/blood.V74.1.1.1; KOHASE M, 1987, MOL CELL BIOL, V7, P273, DOI 10.1128/MCB.7.1.273; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIBERMANN TA, 1990, MOL CELL BIOL, V10, P2327, DOI 10.1128/MCB.10.5.2327; MATSUDA T, 1989, J IMMUNOL, V142, P148; MAY LT, 1988, J BIOL CHEM, V263, P7760; MAY LT, 1991, J BIOL CHEM, V266, P9950; MAY LT, 1991, CYTOKINE, V3, P204, DOI 10.1016/1043-4666(91)90018-9; MAY LT, 1988, BIOCHEM BIOPH RES CO, V152, P1144, DOI 10.1016/S0006-291X(88)80404-2; MOOS M, 1988, J BIOL CHEM, V263, P6005; NIJSTEN MWN, 1987, LANCET, V2, P921; RAY A, 1988, P NATL ACAD SCI USA, V85, P6701, DOI 10.1073/pnas.85.18.6701; RAY A, 1989, MOL CELL BIOL, V9, P5537, DOI 10.1128/MCB.9.12.5537; ROMERO R, 1990, J CLIN INVEST, V85, P1392, DOI 10.1172/JCI114583; SANTHANAM U, 1991, CYTOKINE, V3, P155, DOI 10.1016/1043-4666(91)90037-E; SANTHANAM U, 1989, ARCH BIOCHEM BIOPHYS, V274, P161, DOI 10.1016/0003-9861(89)90427-X; SATOH T, 1988, MOL CELL BIOL, V8, P3546, DOI 10.1128/MCB.8.8.3546; SEHGAL PB, 1990, P SOC EXP BIOL MED, V195, P183; SHIMIZU H, 1990, MOL CELL BIOL, V10, P561, DOI 10.1128/MCB.10.2.561; SYMINGTON FW, 1992, IN PRESS TRANSPLANTA; TAMM I, 1989, J EXP MED, V170, P1649, DOI 10.1084/jem.170.5.1649; TOSATO G, 1988, SCIENCE, V239, P502, DOI 10.1126/science.2829354; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; URBANSKI A, 1990, J INVEST DERMATOL, V94, P808, DOI 10.1111/1523-1747.ep12874666; VANOERS MHJ, 1988, CLIN EXP IMMUNOL, V71, P314; VANSNICK J, 1990, ANNU REV IMMUNOL, V8, P253, DOI 10.1146/annurev.immunol.8.1.253; WALTHER Z, 1988, J IMMUNOL, V140, P974; WIETZERBIN J, 1989, ANN NY ACAD SCI, V557, P162	47	128	129	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 25	1992	267	27					19698	19704						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JP593	1527089				2022-12-25	WOS:A1992JP59300101
J	LANDGRAF, BE; GOLDSTEIN, B; WILLIAMS, DP; MURPHY, JR; SANA, TR; SMITH, KA; CIARDELLI, TL				LANDGRAF, BE; GOLDSTEIN, B; WILLIAMS, DP; MURPHY, JR; SANA, TR; SMITH, KA; CIARDELLI, TL			RECOMBINANT INTERLEUKIN-2 ANALOGS - DYNAMIC PROBES FOR RECEPTOR STRUCTURE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTORS; BETA-CHAIN; MOLECULAR-CLONING; ALPHA-CHAIN; BINDS INTERLEUKIN-2; GM-CSF; EXPRESSION; IL-2; IDENTIFICATION; SUBUNIT	Interleukin-2 (IL-2) and its receptor complex have become one of the most studied members of a growing family of protein hormones characterized by structural similarities in both ligands and their receptors. Structure-function studies of IL-2 have been complicated by the multimeric nature of its receptor. Two receptor subunits (55- and 75-kDa type I cell surface proteins) can participate to form the high affinity binding site. Although the IL-2 is apparently unique in some respects, similar subunit cooperativity has now been shown to be a common feature for other members of this receptor family. The availability of cell lines expressing the individual IL-2 receptor subunits has allowed detailed analysis of subunit binding characteristics. Results regarding the relationship of molecular recognition at each subunit to the mechanism of ligand binding at the high affinity site, however, have led to different interpretations. In this study we have employed previously prepared C-terminal IL-2 mutant proteins to examine receptor binding at all three classes using a variety of equilibrium and kinetic techniques. These results indicate that the high affinity IL-2 receptor complex includes the p55/p75 heterodimer prior to IL-2 binding and that both receptor subunits participate simultaneously in ligand capture.	DARTMOUTH COLL,HITCHCOCK MED CTR,DARTMOUTH MED SCH,DEPT PHARMACOL & TOXICOL,HANOVER,NH 03756; DARTMOUTH COLL,HITCHCOCK MED CTR,DARTMOUTH MED SCH,DEPT MED,HANOVER,NH 03756; CYTOMED INC,CAMBRIDGE,MA 02139; LOS ALAMOS NATL LAB,DIV THEORET,THEORET BIOL & BIOPHYS GRP,LOS ALAMOS,NM 87545; SERAGEN INC,HOPKINTON,MA 01748; BOSTON UNIV HOSP,MED CTR,DEPT BIOMOLEC MED,BOSTON,MA 02218; VET ADM MED CTR,WHITE RIVER JCT,VT 05001	Dartmouth College; Dartmouth College; United States Department of Energy (DOE); Los Alamos National Laboratory; Boston University; US Department of Veterans Affairs; Veterans Health Administration (VHA)					NCI NIH HHS [CA17643, CA4176] Funding Source: Medline; NIAID NIH HHS [AI23398] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA017643] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI023398] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARIMA N, 1991, J IMMUNOL, V147, P3396; BAZAN JF, 1989, BIOCHEM BIOPH RES CO, V164, P788, DOI 10.1016/0006-291X(89)91528-3; BERNDT WG, 1992, INTERLEUKIN 2; BRANDHUBER BJ, 1987, SCIENCE, V238, P1707, DOI 10.1126/science.3500515; BREMS DN, 1991, J BIOL CHEM, V266, P1611; CALIGIURI MA, 1990, J EXP MED, V171, P1509, DOI 10.1084/jem.171.5.1509; CANTRELL DA, 1984, SCIENCE, V224, P1312, DOI 10.1126/science.6427923; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; CIARDELLI T, 1989, TRENDS PHARMACOL SCI, V10, P239, DOI 10.1016/0165-6147(89)90269-1; COLLINS L, 1988, P NATL ACAD SCI USA, V85, P7709, DOI 10.1073/pnas.85.20.7709; CUNNINGHAM BC, 1991, SCIENCE, V254, P826; DANDREA A, 1989, CELL, V58, P1023, DOI 10.1016/0092-8674(89)90499-6; DUKOVICH M, 1987, NATURE, V327, P518, DOI 10.1038/327518a0; DURUM SK, 1991, IMMUNOL TODAY, V12, P54, DOI 10.1016/0167-5699(91)90157-O; Efron B, 1986, STAT SCI, V1, P54, DOI DOI 10.1214/SS/1177013815; FUNG MR, 1988, J EXP MED, V168, P1923, DOI 10.1084/jem.168.5.1923; GILLIS S, 1978, J IMMUNOL, V120, P2027; GOLDSTEIN B, 1992, INT IMMUNOL, V4, P23, DOI 10.1093/intimm/4.1.23; HATAKEYAMA M, 1989, SCIENCE, V244, P551, DOI 10.1126/science.2785715; HAYASHIDA K, 1990, P NATL ACAD SCI USA, V87, P9655, DOI 10.1073/pnas.87.24.9655; HEMPSTEAD BL, 1991, NATURE, V350, P678, DOI 10.1038/350678a0; JOHNSON WC, 1990, PROTEINS, V7, P205, DOI 10.1002/prot.340070302; KITAMURA T, 1991, CELL, V66, P1165, DOI 10.1016/0092-8674(91)90039-2; LANDGRAF B, 1989, J BIOL CHEM, V264, P816; LANDGRAF BE, 1991, PROTEINS, V9, P207, DOI 10.1002/prot.340090306; LEONARD WJ, 1984, NATURE, V311, P626, DOI 10.1038/311626a0; MIYOSHI I, 1980, GANN, V71, P155; MOTULSKY HJ, 1984, MOL PHARMACOL, V25, P1; MUNCK A, 1976, RECEPTORS MECHANIS 1, P1; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NICOLA NA, 1991, CELL, V67, P1, DOI 10.1016/0092-8674(91)90564-F; NIKAIDO T, 1984, NATURE, V311, P631, DOI 10.1038/311631a0; OKAMOTO Y, 1990, P NATL ACAD SCI USA, V87, P6584, DOI 10.1073/pnas.87.17.6584; PARRY DAD, 1988, J MOL RECOGNIT, V1, P1107; PIELA L, 1987, BIOPOLYMERS, V26, P1589; ROBB RJ, 1981, J EXP MED, V154, P1455, DOI 10.1084/jem.154.5.1455; Sabe H, 1984, Mol Biol Med, V2, P379; SAITO Y, 1988, J EXP MED, V168, P1563, DOI 10.1084/jem.168.5.1563; SARAGOVI H, 1988, J IMMUNOL, V141, P476; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SHARON M, 1986, SCIENCE, V234, P859, DOI 10.1126/science.3095922; SMITH KA, 1989, ANNU REV CELL BIOL, V5, P397; SMITH KA, 1988, SCIENCE, V240, P1169, DOI 10.1126/science.3131876; SMITH KA, 1990, REGULATORY CYTOKINES, P9; STEINMAN RM, 1974, J CELL BIOL, V63, P949, DOI 10.1083/jcb.63.3.949; STERNBERG MJE, 1990, PROTEIN ENG, V3, P245, DOI 10.1093/protein/3.4.245; TAGA T, 1989, CELL, V58, P573, DOI 10.1016/0092-8674(89)90438-8; TAKESHITA T, 1992, J IMMUNOL, V148, P2154; TAVERNIER J, 1991, CELL, V66, P1175, DOI 10.1016/0092-8674(91)90040-6; TAYLOR JW, 1987, METHOD ENZYMOL, V154, P473; TESHIGAWARA K, 1987, J EXP MED, V165, P223, DOI 10.1084/jem.165.1.223; TSUDO M, 1986, P NATL ACAD SCI USA, V83, P9694, DOI 10.1073/pnas.83.24.9694; TSUDO M, 1990, J IMMUNOL, V145, P599; WANG HM, 1987, J EXP MED, V166, P1055, DOI 10.1084/jem.166.4.1055; WATOWICH SS, 1992, P NATL ACAD SCI USA, V89, P2140, DOI 10.1073/pnas.89.6.2140; WILLIAMS DP, 1988, NUCLEIC ACIDS RES, V16, P10453, DOI 10.1093/nar/16.22.10453	56	36	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1992	267	26					18511	18519						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JN502	1526987				2022-12-25	WOS:A1992JN50200044
J	MEHTA, PP; BUSSIERE, DE; HOFFMAN, DW; BASTIA, D; WHITE, SW				MEHTA, PP; BUSSIERE, DE; HOFFMAN, DW; BASTIA, D; WHITE, SW			CRYSTALLIZATION AND PRELIMINARY STRUCTURAL-ANALYSIS OF THE REPLICATION TERMINATOR PROTEIN OF BACILLUS-SUBTILIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI CHROMOSOME; DNA-REPLICATION; PLASMID REPLICATION; BINDING DOMAIN; SEQUENCE; REPRESSOR; OPERATOR; REGION; R6K; SITES	The replication terminator protein (RTP) is a dimeric molecule that binds specific sequences within the replication terminus of the Bacillus subtilis chromosome and prevents the passage of replication forks. The gene for RTP has been expressed in Escherichia coli, and the protein has been purified in amounts sufficient for structural studies by nuclear magnetic resonance (NMR) and x-ray crystallography. One-dimensional NMR experiments show that the protein has a well-folded compact tertiary structure, as well as a high alpha-helical content. Circular dichroism (CD) studies confirm this finding and show that approximately 32% of the protein is a-helical. The terminator protein has been crystallized as monoclinic plates that diffract to better than 2.5 angstrom and are suitable for high resolution structural analysis. Precession photographs show the space group to be C2 with unit cell dimensions a = 77 angstrom, b = 53 angstrom, c = 70 angstrom, and beta = 90-degrees, and two molecules occupy the asymmetric unit. With a view to producing crystals of an RTP.DNA complex, gel-shift assays were performed to establish the shortest sequence of DNA that is required for tight binding to RTP. These clearly show that two turns of DNA are required, centered on an 8-base pair consensus sequence, to elicit relatively stable binding.	DUKE UNIV, MED CTR, DEPT MICROBIOL, DURHAM, NC 27710 USA; DUKE UNIV, MED CTR, PROGRAM CELL & MOLEC BIOL, DURHAM, NC 27710 USA	Duke University; Duke University			White, Stephen W/N-8164-2018					ANDERSON J, 1984, P NATL ACAD SCI-BIOL, V81, P1307, DOI 10.1073/pnas.81.5.1307; BASTIA D, 1981, P NATL ACAD SCI-BIOL, V78, P2095, DOI 10.1073/pnas.78.4.2095; CHEN YH, 1971, BIOCHEM BIOPH RES CO, V44, P1285, DOI 10.1016/S0006-291X(71)80225-5; CROSA JH, 1978, J MOL BIOL, V124, P443, DOI 10.1016/0022-2836(78)90181-X; DEMASSY B, 1987, P NATL ACAD SCI USA, V84, P1759; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; GAHN TA, 1989, CELL, V58, P527, DOI 10.1016/0092-8674(89)90433-9; GERMINO J, 1981, CELL, V23, P681, DOI 10.1016/0092-8674(81)90431-1; HANDELI S, 1989, CELL, V57, P909, DOI 10.1016/0092-8674(89)90329-2; HIDAKA M, 1988, CELL, V55, P467, DOI 10.1016/0092-8674(88)90033-5; HILL TM, 1987, P NATL ACAD SCI USA, V84, P1754, DOI 10.1073/pnas.84.7.1754; HILL TM, 1988, CELL, V55, P459, DOI 10.1016/0092-8674(88)90032-3; JORDAN SR, 1985, SCIENCE, V230, P1383; KHATRI GS, 1989, CELL, V59, P667, DOI 10.1016/0092-8674(89)90012-3; KOLTER R, 1978, J MOL BIOL, V124, P425, DOI 10.1016/0022-2836(78)90180-8; LAI CJ, 1975, J MOL BIOL, V97, P113, DOI 10.1016/S0022-2836(75)80026-X; LEWIS PJ, 1989, J BACTERIOL, V171, P3564, DOI 10.1128/jb.171.6.3564-3567.1989; LEWIS PJ, 1990, J MOL BIOL, V214, P73, DOI 10.1016/0022-2836(90)90147-E; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; OLLIS D, 1990, METHOD ENZYMOL, V182, P646; OLLIS DL, 1987, CHEM REV, V87, P981, DOI 10.1021/cr00081a006; OTWINOWSKI Z, 1988, NATURE, V335, P321, DOI 10.1038/335321a0; PABO CO, 1982, NATURE, V298, P443, DOI 10.1038/298443a0; SISTA PR, 1989, P NATL ACAD SCI USA, V86, P3026, DOI 10.1073/pnas.86.9.3026; TANAKA I, 1984, NATURE, V310, P376, DOI 10.1038/310376a0; VALENZUELA MS, 1976, J MOL BIOL, V102, P569, DOI 10.1016/0022-2836(76)90335-1; WEISS AS, 1984, CELL, V39, P683, DOI 10.1016/0092-8674(84)90475-6; WISHART DS, 1992, BIOCHEMISTRY-US, V31, P1647, DOI 10.1021/bi00121a010	28	11	11	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	1992	267	26					18885	18889						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JN502	1527015				2022-12-25	WOS:A1992JN50200095
J	WADA, Y; ANRAKU, Y				WADA, Y; ANRAKU, Y			GENES FOR DIRECTING VACUOLAR MORPHOGENESIS IN SACCHAROMYCES-CEREVISIAE .2. VAM7, A GENE FOR REGULATING MORPHOGENIC ASSEMBLY OF THE VACUOLES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; PROTON MOTIVE FORCE; MEMBRANE-VESICLES; NUCLEOTIDE-SEQUENCE; DNA-SEQUENCE; YEAST; TRANSPORT; SYSTEM; PROTEIN; DRIVEN	VAM7 gene function has shown to be required for proper morphogenesis of the vacuole in yeast. The DNA fragments that complemented the defective vacuolar morphology of the vam7-1 mutation were isolated from a yeast genomic library. An overlapping 2.5-kilobase BglII-HindIII region was found to be sufficient for complementation of the vam7-1 phenotype. This fragment was integrated at the chromosomal VAM7 locus, indicating that it contained an authentic VAM7 gene. On nucleotide sequencing of the VAM7 gene, an open reading frame of 948 base pairs, coding for a hydrophilic polypeptide of 316 amino acid residues, was identified. The deduced amino acid sequence of the carboxyl-terminal region of the VAM7 gene product has heptad repeats and shows potential ability to form a coiled-coil structure. Disruption of VAM7 was not lethal; cells with a disrupted VAM7 gene did not, however, have a prominent large vacuoles but rather numerous small compartments that accumulated the histochemical marker molecule of the vacuolar compartment. They contained mature forms of the vacuolar marker proteins carboxypeptidase Y and vacuolar glycoprotein vgp72. A mutant with both vam7 and vam5 null mutations was constructed and shown to have neither vacuolar structures stained with ade-related fluorochrome nor mature forms of vacuolar marker proteins. These findings suggested that the VAM7 gene product functions in the process of morphogenic assembly of the vacuolar compartment but is not involved in the protein sorting and delivery to the vacuole.	UNIV TOKYO,FAC SCI,DEPT BIOL,BUNKYO KU,TOKYO 113,JAPAN	University of Tokyo								ANRAKU Y, 1989, J BIOENERG BIOMEMBR, V21, P589, DOI 10.1007/BF00808115; BADER BL, 1986, EMBO J, V5, P1865, DOI 10.1002/j.1460-2075.1986.tb04438.x; BASI GS, 1986, J BIOL CHEM, V261, P817; BOTSTEIN D, 1979, GENE, V8, P17, DOI 10.1016/0378-1119(79)90004-0; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; GALLWITZ D, 1982, P NATL ACAD SCI-BIOL, V79, P3493, DOI 10.1073/pnas.79.11.3493; GRUENBAUM Y, 1988, J CELL BIOL, V106, P585, DOI 10.1083/jcb.106.3.585; HENIKOFF S, 1987, METHOD ENZYMOL, V155, P156; KARN J, 1983, P NATL ACAD SCI-BIOL, V80, P4253, DOI 10.1073/pnas.80.14.4253; KITAMOTO K, 1988, J BACTERIOL, V170, P2683, DOI 10.1128/jb.170.6.2683-2686.1988; KITAMOTO K, 1988, J BACTERIOL, V170, P2687, DOI 10.1128/jb.170.6.2687-2691.1988; Maniatis T., 1982, MOL CLONING; MCLACHLAN AD, 1982, NATURE, V299, P226, DOI 10.1038/299226a0; MIYAMOTO S, 1987, GENE, V54, P125, DOI 10.1016/0378-1119(87)90354-4; NISHIKAWA S, 1990, J BIOL CHEM, V265, P7440; OHSUMI Y, 1988, J BACTERIOL, V170, P2676, DOI 10.1128/jb.170.6.2676-2682.1988; OHSUMI Y, 1981, J BIOL CHEM, V256, P2079; OHSUMI Y, 1983, J BIOL CHEM, V258, P5614; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SATO T, 1984, J BIOL CHEM, V259, P1509; SIKORSKI RS, 1989, GENETICS, V122, P19; WADA Y, 1987, J BIOL CHEM, V262, P17260; WADA Y, 1990, MOL CELL BIOL, V10, P2214, DOI 10.1128/MCB.10.5.2214; WADA Y, 1992, J BIOL CHEM, V267, P18665; WADA Y, 1992, IN PRESS BIOCH BIOPH; YOSHIHISA T, 1989, BIOCHEM BIOPH RES CO, V163, P908, DOI 10.1016/0006-291X(89)92308-5	26	49	50	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1992	267	26					18671	18675						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JN502	1526999				2022-12-25	WOS:A1992JN50200065
J	RENNELL, D; POTEETE, AR; BEAULIEU, M; KUO, DZ; LEW, RA; HUMPHREYS, RE				RENNELL, D; POTEETE, AR; BEAULIEU, M; KUO, DZ; LEW, RA; HUMPHREYS, RE			CRITICAL FUNCTIONAL-ROLE OF THE COOH-TERMINAL ENDS OF LONGITUDINAL HYDROPHOBIC STRIPS IN ALPHA-HELICES OF T4-LYSOZYME	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNTHETIC NONSENSE SUPPRESSORS; BACTERIOPHAGE-T4 LYSOZYME; TRANSFER-RNA; LAC REPRESSOR; AMINO-ACIDS; PROTEIN; MOLECULES; BINDING; AMBER; CONSTRUCTION	The sensitivity of bacteriophage T4 lysozyme function to amino acid substitutions at defined positions in and around the longitudinal, hydrophobic strips of 9 alpha-helices was assessed after systematic replacement of each residue in the protein with a series of 13 amino acids. The hydrophobic strips were defined by identifying the longitudinal sectors in the helices with the highest mean residue hydrophobicities. Sensitivity to mutation (the percentage of replacements leading to loss of function) was calculated for each residue in the following positions: whole protein, helices, hydrophobic strips, other positions within the helices, and various positions within the hydrophobic strips as well as their extensions beyond the helices. Substitutions at positions in the hydrophobic strips led more frequently to loss of function than substitutions in the protein as a whole. One subset, the COOH-terminal hydrophobic strip residues, is apparently critical; substitutions of these residues (but not of their NH2-terminal counterparts) led at least as frequently to loss of function as substitutions of solvent-inaccessible residues, and nearly as frequently as substitutions of the most highly conserved residues.	UNIV MASSACHUSETTS,SCH MED,DEPT PHARMACOL,55 LAKE AVE N,WORCESTER,MA 01655; UNIV MASSACHUSETTS,SCH MED,DEPT MOLEC GENET & MICROBIOL,WORCESTER,MA 01605; UNIV MASSACHUSETTS,SCH MED,DEPT MED,WORCESTER,MA 01605; UNIV MASSACHUSETTS,SCH MED,PROGRAM MOLEC MED,WORCESTER,MA 01605	University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester					NIAID NIH HHS [AI-24083] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI024083] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BOWIE JU, 1989, P NATL ACAD SCI USA, V86, P2152, DOI 10.1073/pnas.86.7.2152; BRANDEN C, 1991, INTRO PROTEIN STRUCT, P20; FALK K, 1991, NATURE, V351, P290, DOI 10.1038/351290a0; HARDY LW, 1991, BIOCHEMISTRY-US, V30, P9457, DOI 10.1021/bi00103a010; HILL CM, 1991, J IMMUNOL, V147, P189; KLEINA LG, 1990, J MOL BIOL, V212, P295, DOI 10.1016/0022-2836(90)90126-7; LEIGHTON J, 1991, J IMMUNOL, V147, P198; LIM WA, 1989, NATURE, V339, P31, DOI 10.1038/339031a0; LOEB DD, 1989, NATURE, V340, P397, DOI 10.1038/340397a0; LU S, 1992, VACCINE, V10, P3, DOI 10.1016/0264-410X(92)90410-L; LU S, 1991, TRENDS BIOTECHNOL, V9, P238, DOI 10.1016/0167-7799(91)90077-U; MATSUMURA M, 1988, NATURE, V334, P406, DOI 10.1038/334406a0; MATTHEWS BW, 1987, BIOCHEMISTRY-US, V26, P6885, DOI 10.1021/bi00396a001; MCCLAIN WH, 1988, SCIENCE, V241, P1804, DOI 10.1126/science.2459773; NORMANLY J, 1990, J MOL BIOL, V213, P719, DOI 10.1016/S0022-2836(05)80258-X; NORMANLY J, 1986, P NATL ACAD SCI USA, V83, P6548, DOI 10.1073/pnas.83.17.6548; OSULLIVAN D, 1991, J IMMUNOL, V146, P1240; PERUTZ MF, 1965, J MOL BIOL, V13, P669, DOI 10.1016/S0022-2836(65)80134-6; POTEETE AR, 1992, PROTEINS, V13, P38, DOI 10.1002/prot.340130104; REIDHAAROLSON JF, 1988, SCIENCE, V241, P53, DOI 10.1126/science.3388019; REMINGTON SJ, 1978, J MOL BIOL, V118, P81, DOI 10.1016/0022-2836(78)90245-0; RENNELL D, 1991, J MOL BIOL, V222, P67, DOI 10.1016/0022-2836(91)90738-R; REYES VE, 1990, MOL IMMUNOL, V27, P1021, DOI 10.1016/0161-5890(90)90125-J; ROMERO P, 1991, J EXP MED, V174, P603, DOI 10.1084/jem.174.3.603; ROSE GD, 1985, SCIENCE, V229, P834, DOI 10.1126/science.4023714; SHORTLE D, 1990, BIOCHEMISTRY-US, V29, P8033, DOI 10.1021/bi00487a007; TORGERSON RR, 1991, J BIOL CHEM, V266, P5521; VAZQUEZ SR, 1992, J BIOL CHEM, V267, P7406; WEAVER LH, 1987, J MOL BIOL, V193, P189, DOI 10.1016/0022-2836(87)90636-X; WINSTON F, 1979, J BACTERIOL, V137, P433, DOI 10.1128/JB.137.1.433-439.1979	30	6	7	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1992	267	25					17748	17752						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JM223	1517218				2022-12-25	WOS:A1992JM22300044
J	MERCOLA, D; CARPENTER, PM; GROVERBARDWICK, A; MERCOLA, M				MERCOLA, D; CARPENTER, PM; GROVERBARDWICK, A; MERCOLA, M			RAPID, COMPLETE AND REVERSIBLE TRANSFORMATION BY V-SIS PRECEDES IRREVERSIBLE TRANSFORMATION	ONCOGENE			English	Article							SIMIAN SARCOMA-VIRUS; HUMAN-TUMOR CELLS; FACTOR A-CHAIN; GROWTH-FACTOR; HUMAN-FIBROBLASTS; B-CHAIN; C-FOS; AUTOCRINE STIMULATION; PDGF RECEPTORS; ANTISENSE RNA	v-sis is the oncogene of simian sarcoma virus, but whether tumor growth is maintained by v-sis expression alone or requires additional changes is unknown. To distinguish these possibilities we studied a model of reversible transformation including tumorigenicity using NIH3T3 cells bearing a metallothionein promoter-v-sis construction. Cells subcultured from 10 out of 18 tumors from athymic mice, all < 0.1 g and less-than-or-equal-to 21 days in age, reverted to a normal phenotype but exhibited transformation upon addition of zinc as judged by morphology, growth rate, saturation density and anchorage independence of growth. Thus, activation of v-sis alone is sufficient for initiation and early autocrine-based growth of tumors. However, the cells from the remaining and predominantly larger, 0.5 +/- 0.7 g, tumors did not revert and exhibited zinc-independent transformation as judged by the same criteria. Southern analysis and examination of the regulation of v-sis product expression in cells derived from these tumors showed no change in zinc-dependent and reversible regulation of v-sis sequences. These results suggest that subsequent tumor growth strongly favors acquisition of additional irreversible change(s) in the tumor cell genome at high frequency (44%). Thus an earl event of a multistep process stimulated by v-sis-dependent transformation best accounts for the sum of results.	UNIV CALIF SAN DIEGO, CTR MOLEC GENET, LA JOLLA, CA 92093 USA; DEPT VET AFFAIRS MED CTR, SAN DIEGO, CA 92161 USA; HARVARD UNIV, DEPT PHYSIOL, BOSTON, MA 02115 USA	University of California System; University of California San Diego; Harvard University	MERCOLA, D (corresponding author), UNIV CALIF SAN DIEGO, DEPT PATHOL, LA JOLLA, CA 92093 USA.		mercola, dan/L-4182-2013	mercola, dan/0000-0002-0281-9840	NCI NIH HHS [CA 49963] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA049963] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BECKMANN MP, 1988, SCIENCE, V241, P1346, DOI 10.1126/science.2842868; BETSHOLTZ C, 1984, CELL, V39, P447, DOI 10.1016/0092-8674(84)90452-5; BISHOP JM, 1982, MOL BIOL TUMOR VIR 3; BRONZERT DA, 1987, P NATL ACAD SCI USA, V84, P5763, DOI 10.1073/pnas.84.16.5763; BYWATER M, 1988, MOL CELL BIOL, V8, P2753, DOI 10.1128/MCB.8.7.2753; CAVENEE W, 1988, RECESSIVE ONCOGENES; COLLINS T, 1987, NATURE, V328, P621, DOI 10.1038/328621a0; CROSS M, 1991, CELL, V64, P271, DOI 10.1016/0092-8674(91)90638-F; DER CJ, 1988, ONCOGENE, V3, P105; DEVARE SG, 1983, P NATL ACAD SCI-BIOL, V80, P731, DOI 10.1073/pnas.80.3.731; DREWS RE, 1992, MOL CELL BIOL, V12, P198, DOI 10.1128/MCB.12.1.198; DURNAM DM, 1981, J BIOL CHEM, V256, P5712; EVA A, 1982, NATURE, V295, P116, DOI 10.1038/295116a0; FAVERA RD, 1981, NATURE, V292, P31; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FRY DG, 1988, MUTAT RES, V199, P341, DOI 10.1016/0027-5107(88)90213-8; GIESE NA, 1987, SCIENCE, V236, P1315, DOI 10.1126/science.3035718; GLANVILLE N, 1981, NATURE, V292, P267, DOI 10.1038/292267a0; GRAVES D, 1984, P NATL ACAD SCI USA, V83, P4636; GROVER A, 1985, J BIOL CHEM, V260, P2252; GROVERBARDWICK A, 1991, BIOTECHNOLOGY CELL R, V4, P227; HAMMER RE, 1984, NATURE, V311, P65, DOI 10.1038/311065a0; HANNINK M, 1988, J CELL BIOL, V107, P287, DOI 10.1083/jcb.107.1.287; HELDIN CH, 1989, EUR J BIOCHEM, V184, P487, DOI 10.1111/j.1432-1033.1989.tb15041.x; HELDIN CH, 1986, NATURE, V319, P511, DOI 10.1038/319511a0; HUANG SS, 1988, J BIOL CHEM, V263, P12608; IGARASHI H, 1987, ONCOGENE, V1, P79; JOHNSSON A, 1985, NATURE, V317, P438, DOI 10.1038/317438a0; KEATING MT, 1988, SCIENCE, V239, P914, DOI 10.1126/science.2829358; KELLY JD, 1985, EMBO J, V4, P3399, DOI 10.1002/j.1460-2075.1985.tb04096.x; KHOKHA R, 1989, SCIENCE, V243, P947, DOI 10.1126/science.2465572; KOVARY K, 1991, MOL CELL BIOL, V11, P4466, DOI 10.1128/MCB.11.9.4466; LEAL F, 1985, SCIENCE, V230, P327, DOI 10.1126/science.2996133; MATSUI T, 1989, SCIENCE, V243, P800, DOI 10.1126/science.2536956; MEKUTH M, 1990, BIOCHIM BIOPHYS ACTA, V103, P1; MERCOLA D, 1988, GENE, V72, P253, DOI 10.1016/0378-1119(88)90151-5; MERCOLA D, 1989, BIOCHEM BIOPH RES CO, V147, P854; MERCOLA D, 1991, GENE REGULATION ANTI, P329; MERCOLA D, 1991, PROSPECTS APPLICATIO, P83; MERCOLA D, 1992, 1991 OST RES C; NISHIKURA K, 1987, MOL CELL BIOL, V7, P639, DOI 10.1128/MCB.7.2.639; NISTER M, 1988, CANCER RES, V48, P3910; NISTER M, 1984, P NATL ACAD SCI-BIOL, V81, P926, DOI 10.1073/pnas.81.3.926; NOWELL PC, 1986, CANCER RES, V46, P2203; OSNOBE MH, 1991, ONCOGENE, V6, P1531; PAULSSON Y, 1987, NATURE, V328, P715, DOI 10.1038/328715a0; PECH M, 1989, P NATL ACAD SCI USA, V86, P2693, DOI 10.1073/pnas.86.8.2693; RAUSCHER FJ, 1988, GENE DEV, V2, P1687, DOI 10.1101/gad.2.12b.1687; RIABOWOL KT, 1988, MOL CELL BIOL, V8, P1670, DOI 10.1128/MCB.8.4.1670; ROBBINS K, 1988, SCIENCE, V241, P1346; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; STEVENS CW, 1988, MOL CELL BIOL, V8, P2089, DOI 10.1128/MCB.8.5.2089; SUKUMAR S, 1989, CURR TOP MICROBIOL, V148, P93; VANDENBERG S, 1991, MOL CARCINOGEN, V4, P460, DOI 10.1002/mc.2940040609; VERSNEL MA, 1988, ONCOGENE, V2, P601; WESTERMARK B, 1986, P NATL ACAD SCI USA, V83, P7197, DOI 10.1073/pnas.83.19.7197; WU JX, 1990, ONCOGENE, V5, P989; [No title captured]	59	13	14	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	1992	7	9					1793	1803						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JJ376	1501889				2022-12-25	WOS:A1992JJ37600016
J	MANGROO, D; GERBER, GE				MANGROO, D; GERBER, GE			PHOTOAFFINITY-LABELING OF FATTY ACID-BINDING PROTEINS INVOLVED IN LONG-CHAIN FATTY-ACID TRANSPORT IN ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FADL GENE; OUTER-MEMBRANE; POLYACRYLAMIDE GELS; PLASMA-MEMBRANES; RECEPTOR PROTEIN; RAT-LIVER; VESICLES; ELECTROPHORESIS; IDENTIFICATION; MECHANISM	The photoreactive fatty acid 11-m-diazirinophenoxy-[11-H-3]undecanoate was shown to be taken up specifically by the fatty acid transport system expressed in Escherichia coli grown on oleate. This photoreactive fatty acid analogue was therefore used to identify proteins involved in fatty acid uptake in E. coli. The fadL protein was labeled by the probe, confirmed to be exclusively in the outer membrane and to exhibit the heat modifiable behavior typical of outer membrane proteins. The apparent pI of the incompletely denatured form of the protein having the mobility of a 33-kDa protein was 4.6 while that of the fully denatured form was consistent with the calculated value of 5.2. The denaturation was reversible depending upon the protein to detergent ratios. The photoreactive fatty acid partitions into the outer membrane, resulting in extensive photolabeling of the lipid; a high affinity fatty acid-binding site is not apparent in total membranes labeled using free fatty acids due to this large binding capacity of the outer membrane. However, when the free fatty acid concentration was controlled by supplying it as a bovine serum albumin complex, the fadL protein exhibited saturable high affinity fatty acid binding, having an apparent K(d) for the probe of 63 nM. The methods described very readily identify fatty acid-binding proteins: the fact that even when the sensitivity was increased 500-fold, no evidence was found for the presence of a fatty acid-binding protein in the inner membrane is consistent with the proposal that fatty acid permeation across the plasma membrane is not protein mediated but occurs by a simple diffusive mechanism.	MCMASTER UNIV, DEPT BIOCHEM, HAMILTON L8N 3Z5, ONTARIO, CANADA	McMaster University								AMES GFL, 1976, BIOCHEMISTRY-US, V15, P616, DOI 10.1021/bi00648a026; BAILEY H, 1983, PHOTOGENERATED REAGE, P1; BERK PD, 1990, P NATL ACAD SCI USA, V87, P3484, DOI 10.1073/pnas.87.9.3484; BLACK PN, 1987, J BIOL CHEM, V262, P1412; BLACK PN, 1990, BIOCHIM BIOPHYS ACTA, V1046, P97, DOI 10.1016/0005-2760(90)90099-J; BLACK PN, 1991, J BACTERIOL, V173, P435, DOI 10.1128/jb.173.2.435-442.1991; BONNER WM, 1974, EUR J BIOCHEM, V46, P83, DOI 10.1111/j.1432-1033.1974.tb03599.x; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CAPONE J, 1983, J BIOL CHEM, V258, P1395; COOPER RB, 1989, J LIPID RES, V30, P1719; EISELE JL, 1990, J BIOL CHEM, V265, P10217; FRERMAN FE, 1973, ARCH BIOCHEM BIOPHYS, V159, P434, DOI 10.1016/0003-9861(73)90471-2; GINSBURGH CL, 1984, J BIOL CHEM, V259, P8437; GREENBERG GR, 1976, P NATL ACAD SCI USA, V73, P86, DOI 10.1073/pnas.73.1.86; Kaback H. R., 1971, METHOD ENZYMOL, V22, P99, DOI DOI 10.1016/0076-6879(71)22015-2; KAMEDA K, 1985, BIOCH INT, V14, P227; KLEIN K, 1971, EUR J BIOCHEM, V19, P442, DOI 10.1111/j.1432-1033.1971.tb01334.x; KUMAR GB, 1991, J BIOL CHEM, V266, P1348; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEBLANC P, 1984, CAN J BIOCHEM CELL B, V62, P375, DOI 10.1139/o84-052; LEBLANC P, 1984, CAN J CHEM, V62, P1767, DOI 10.1139/v84-302; LEBLANC P, 1982, J BIOL CHEM, V257, P4586; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUCKEY M, 1980, BIOCHEM BIOPH RES CO, V93, P166, DOI 10.1016/S0006-291X(80)80261-0; LUCKEY M, 1980, P NATL ACAD SCI-BIOL, V77, P167, DOI 10.1073/pnas.77.1.167; MAIER C, 1988, J BIOL CHEM, V263, P2493; MALOY SR, 1981, J BIOL CHEM, V256, P3735; MANGROO D, 1991, FASEB J, V5, pA1509; NOY N, 1985, BIOCHEMISTRY-US, V24, P3521, DOI 10.1021/bi00335a020; NUNN WD, 1986, MICROBIOL REV, V50, P179, DOI 10.1128/MMBR.50.2.179-192.1986; NUNN WD, 1978, P NATL ACAD SCI USA, V75, P3377, DOI 10.1073/pnas.75.7.3377; NUNN WD, 1979, J BIOL CHEM, V254, P9130; NUNN WD, 1986, J BIOL CHEM, V261, P167; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; OLSEN WL, 1979, J BACTERIOL, V137, P1443, DOI 10.1128/JB.137.3.1443-1446.1979; OSBORN MJ, 1972, J BIOL CHEM, V247, P3962; OVERATH P, 1969, EUR J BIOCHEM, V7, P559; OVERATH P, 1967, BIOCHEM BIOPH RES CO, V29, P28, DOI 10.1016/0006-291X(67)90535-9; RAMOS S, 1977, BIOCHEMISTRY-US, V16, P854, DOI 10.1021/bi00624a007; Sambrook J, 1989, MOL CLONING LABORATO; SPECTOR AA, 1969, J LIPID RES, V10, P56; STORCH J, 1986, BIOCHEMISTRY-US, V25, P1717, DOI 10.1021/bi00355a041; STREMMEL W, 1985, P NATL ACAD SCI USA, V82, P4, DOI 10.1073/pnas.82.1.4; STREMMEL W, 1986, P NATL ACAD SCI USA, V83, P3584, DOI 10.1073/pnas.83.11.3584; WITHOLT B, 1976, ANAL BIOCHEM, V74, P160, DOI 10.1016/0003-2697(76)90320-1	45	19	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	1992	267	24					17095	17101						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JL053	1512247				2022-12-25	WOS:A1992JL05300058
J	MOOMAW, JF; CASEY, PJ				MOOMAW, JF; CASEY, PJ			MAMMALIAN PROTEIN GERANYLGERANYLTRANSFERASE - SUBUNIT COMPOSITION AND METAL REQUIREMENTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEIN; SACCHAROMYCES-CEREVISIAE; RAS PROTEINS; FARNESYLTRANSFERASE; P21RAS; CELLS; YEAST; GENE; SPECIFICITY; FARNESYL	An enzyme capable of specifically modifying, with a geranylgeranyl isoprenoid, candidate proteins containing a consensus prenylation sequence ending in leucine has been purified from bovine brain. This protein geranylgeranyltransferase (PGGT), isolated using affinity chromatography on an immobilized peptide column, contains two subunits with molecular masses of 48 and 43 kDa, designated alpha and beta, respectively. An antiserum raised to the alpha-subunit of the related enzyme, protein farnesyltransferase (PFT), also recognizes this chromatographically identical alpha-subunit of the PGGT by immunoblot analysis. The PGGT and PFT enzymes from bovine brain are shown to be dependent on both Mg2+ and Zn2+ for optimal activity. Demonstration of the Zn2+ dependence of the enzymes requires prolonged incubation or purification in the presence of a chelating agent; we therefore propose that these enzymes be placed into the category of metalloenzymes. Under optimal assay conditions, these enzymes show high specificity toward their prenyl diphosphate substrates, with only a weak competition observed with farnesyl diphosphate in the PGGT reaction or geranylgeranyl diphosphate in the PFT reaction. The two enzymes are differentially sensitive to several detergents tested to determine suitable ones for product stabilization in the reactions. These results confirm previous predictions on the subunit structure of the PGGT and provide an avenue to initiating a molecular analysis of the geranylgeranyl modification of many mammalian proteins.	DUKE UNIV,MED CTR,CELL GROWTH REGULAT & ONCOGENESIS SECT,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT BIOCHEM,DURHAM,NC 27710	Duke University; Duke University				Casey, Patrick/0000-0002-7366-9309				CASEY PJ, 1989, P NATL ACAD SCI USA, V86, P8323, DOI 10.1073/pnas.86.21.8323; CASEY PJ, 1991, P NATL ACAD SCI USA, V88, P8631, DOI 10.1073/pnas.88.19.8631; CHEN WJ, 1991, CELL, V66, P327, DOI 10.1016/0092-8674(91)90622-6; FARNSWORTH CC, 1991, P NATL ACAD SCI USA, V88, P6196, DOI 10.1073/pnas.88.14.6196; FARNSWORTH CC, 1990, SCIENCE, V247, P320, DOI 10.1126/science.2296721; FEIG LA, 1986, P NATL ACAD SCI USA, V83, P4607, DOI 10.1073/pnas.83.13.4607; FINEGOLD AA, 1991, P NATL ACAD SCI USA, V88, P4448, DOI 10.1073/pnas.88.10.4448; GLOMSET JA, 1990, TRENDS BIOCHEM SCI, V15, P139, DOI 10.1016/0968-0004(90)90213-U; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HE B, 1991, P NATL ACAD SCI USA, V88, P11373, DOI 10.1073/pnas.88.24.11373; HIGGINS J, 1992, FASEB J, V6, pA97; HORIUCHI H, 1991, J BIOL CHEM, V266, P16981; KINSELLA BT, 1991, J BIOL CHEM, V266, P8540; KOHL NE, 1991, J BIOL CHEM, V266, P18884; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MALTESE WA, 1990, FASEB J, V4, P3319, DOI 10.1096/fasebj.4.15.2123808; MOORES SL, 1991, J BIOL CHEM, V266, P14603; MUMBY SM, 1986, P NATL ACAD SCI USA, V83, P265, DOI 10.1073/pnas.83.2.265; OHYA Y, 1991, J BIOL CHEM, V266, P12356; REISS Y, 1991, P NATL ACAD SCI USA, V88, P732, DOI 10.1073/pnas.88.3.732; REISS Y, 1990, CELL, V62, P81, DOI 10.1016/0092-8674(90)90242-7; SCHAFER WR, 1990, SCIENCE, V249, P1133, DOI 10.1126/science.2204115; SEABRA MC, 1991, CELL, V65, P429, DOI 10.1016/0092-8674(91)90460-G; Spiro T.G., 1983, ZINC ENZYMES; STERNWEIS PC, 1981, J BIOL CHEM, V256, P1517; VALLEE BL, 1983, ZINC ENZYMES, P25; YOKOYAMA K, 1991, P NATL ACAD SCI USA, V88, P5302, DOI 10.1073/pnas.88.12.5302	27	162	173	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1992	267	24					17438	17443						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JL053	1512274				2022-12-25	WOS:A1992JL05300105
J	LINDGREN, PE; SPEZIEALE, P; MCGAVIN, M; MONSTEIN, HJ; HOOK, M; VISAI, L; KOSTIAINEN, T; BOZZINI, S; LINDBERG, M				LINDGREN, PE; SPEZIEALE, P; MCGAVIN, M; MONSTEIN, HJ; HOOK, M; VISAI, L; KOSTIAINEN, T; BOZZINI, S; LINDBERG, M			CLONING AND EXPRESSION OF 2 DIFFERENT GENES FROM STREPTOCOCCUS-DYSGALACTIAE ENCODING FIBRONECTIN RECEPTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-PLASMA FIBRONECTIN; STAPHYLOCOCCUS-AUREUS; BINDING PROTEIN; ESCHERICHIA-COLI; GROUP-A	Binding of bacteria to fibronectin has been implicated as a mechanism of bacterial adhesion to the host tissue. In this report we have analyzed the binding of a strain of Streptococcus dysgalactiae to fibronectin. The cells bind to a site in the NH2-terminal domain of the protein via trypsin-sensitive cell surface components. Furthermore, a lysate prepared by sonication of streptococcal cells contained fibronectin-binding proteins that inhibit the binding of the ligand to intact bacteria. When the proteins were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis, blotted to an Immobilon-P filter, and probed with I-125-labeled fibronectin, a 140-kDa fibronectin-binding protein was identified along with a number of smaller binding proteins. A genomic DNA library was constructed and screened for the expression of fibronectin-binding proteins. Two clones were isolated and shown to contain unrelated inserts by restriction mapping and cross-hybridization experiments. The two encoded proteins were also immunologically distinct although both bound to the same region of the fibronectin molecule, and both effectively inhibited the binding of I-125-fibronectin to bacterial cells. Immunological analyses showed that only one of the two proteins tentatively identified as fibronectin receptors was expressed in detectable quantities in the Streptococcus dysgalactiae strain under the culture conditions employed.	UNIV PAVIA, DEPT BIOCHEM, I-27100 PAVIA, ITALY; UNIV ALABAMA, DEPT BIOCHEM, BIRMINGHAM, AL 35294 USA	University of Pavia; University of Alabama System; University of Alabama Birmingham	LINDGREN, PE (corresponding author), SWEDISH UNIV AGR SCI, DEPT MICROBIOL, BOX 7025, S-75007 UPPSALA, SWEDEN.		Visai, Livia/R-7397-2017	Visai, Livia/0000-0003-1181-3632; McGavin, Martin/0000-0001-5955-0689	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020624] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 20624] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BEACHEY EH, 1982, INFECTION, V10, P107, DOI 10.1007/BF01816738; CARTER P, 1985, NUCLEIC ACIDS RES, V13, P4431, DOI 10.1093/nar/13.12.4431; CHHATWAL GS, 1987, COMP IMMUNOL MICROB, V10, P99, DOI 10.1016/0147-9571(87)90003-8; ESPERSEN F, 1982, INFECT IMMUN, V37, P526, DOI 10.1128/IAI.37.2.526-531.1982; FLOCK JI, 1987, EMBO J, V6, P2351, DOI 10.1002/j.1460-2075.1987.tb02511.x; FROMAN G, 1987, J BIOL CHEM, V262, P6564; GARCIAPARDO A, 1983, J BIOL CHEM, V258, P2670; Hook M, 1989, FIBRONECTIN, P295; HUNTER WM, 1978, HDB EXPT IMMUNOLOGY, P141; HYNES R, 1985, ANNU REV CELL BIOL, V1, P67, DOI 10.1146/annurev.cb.01.110185.000435; KUUSELA P, 1984, INFECT IMMUN, V45, P433, DOI 10.1128/IAI.45.2.433-436.1984; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAMO W, 1987, MICROB PATHOGENESIS, V2, P417, DOI 10.1016/0882-4010(87)90048-9; Maniatis T., 1982, MOL CLONING; MARMUR J, 1961, J MOL BIOL, V3, P208, DOI 10.1016/S0022-2836(61)80047-8; MIEKKA SI, 1982, THROMB RES, V27, P1, DOI 10.1016/0049-3848(82)90272-9; MONSTEIN HJ, 1986, BIOCHEM INT, V12, P889; MOSHER DF, 1980, SCIENCE, V209, P927, DOI 10.1126/science.7403857; MYHRE EB, 1983, INFECT IMMUN, V40, P29, DOI 10.1128/IAI.40.1.29-34.1983; NORRANDER J, 1983, GENE, V26, P101, DOI 10.1016/0378-1119(83)90040-9; OLSEN A, 1989, NATURE, V338, P652, DOI 10.1038/338652a0; PRAUSER H, 1965, Z ALLG MIKROBIOL, V5, P308, DOI 10.1002/jobm.3630050406; RUOSLAHTI E, 1988, ANNU REV BIOCHEM, V57, P375, DOI 10.1146/annurev.bi.57.070188.002111; SIGNAS C, 1989, P NATL ACAD SCI USA, V86, P699, DOI 10.1073/pnas.86.2.699; Switalski L M, 1982, Eur J Clin Microbiol, V1, P381, DOI 10.1007/BF02019939; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VALENTINWEIGAND P, 1988, AM J VET RES, V49, P1485; VUENTO M, 1979, BIOCHEM J, V183, P331, DOI 10.1042/bj1830331; YAMADA KM, 1983, ANNU REV BIOCHEM, V52, P761, DOI 10.1146/annurev.bi.52.070183.003553	29	39	40	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 25	1992	267	3					1924	1931						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HA485	1530943				2022-12-25	WOS:A1992HA48500081
J	LIGHTFOOT, SJ; HOLMES, DF; BRASS, A; GRANT, ME; BYERS, PH; KADLER, KE				LIGHTFOOT, SJ; HOLMES, DF; BRASS, A; GRANT, ME; BYERS, PH; KADLER, KE			TYPE-I PROCOLLAGENS CONTAINING SUBSTITUTIONS OF ASPARTATE, ARGININE, AND CYSTEINE FOR GLYCINE IN THE PRO-ALPHA-1(I) CHAIN ARE CLEAVED SLOWLY BY N-PROTEINASE, BUT ONLY THE CYSTEINE SUBSTITUTION INTRODUCES A KINK IN THE MOLECULE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LETHAL OSTEOGENESIS IMPERFECTA; TRIPLE-HELICAL CONFORMATION; POINT MUTATION; ALPHA-1 CHAIN; GENE COLIAI; COLLAGEN; PHENOTYPE; MOSAICISM; INVITRO; VARIANT	Type I procollagen was purified from the medium of dermal fibroblasts cultured from four individuals with osteogenesis imperfecta (OI) type II who had mutations in the COL1A1 gene of type I procollagen. The procollagens were mixtures of normal molecules and molecules that contained substitutions of aspartate for glycine 97, arginine for glycine 550, cysteine for glycine 718, and aspartate for glycine 883 in one or both of the alpha1(I) chains of the molecule. The procollagens were cleaved more slowly than control type I procollagen by procollagen N-proteinase. Double-reciprocal plots of initial relative velocities and initial substrate concentrations indicated that the OI procollagens were all cleaved slowly by N-proteinase because of decreased V(max), rather than increased K(m). This suggested that slow cleavage of the OI procollagens by N-proteinase was the result of slow conversion of the N-proteinase-procollagen complex. Further experiments showed that the vertebrate collagenase A fragment of the aspartate for glycine alpha1(I) 883 OI procollagen that contained the N-proteinase cleavage site but not the site of the substitution was also cleaved more slowly by N-proteinase than the normal vertebrate collagenase A fragments in the samples. These data show, for the first time, that an altered triple-helical structure is propagated from the site of a substitution of a bulky residue for glycine to the amino-terminal end of the procollagen molecule and disrupts the conformation of the N-proteinase cleavage site. Rotary shadowing electron microscopy of molecules in the preparation of cysteine for glycine alpha1(I)-718 showed the presence of a kink in approximately 5% of a population of molecules in which 60% were abnormal and 20% contained a disulfide bond. In contrast, procollagens containing aspartate and arginine for glycine were indistinguishable by rotary shadowing electron microscopy from those in control samples. The results here confirm previous suggestions that substitution of cysteine for glycine in the alpha1(I) chain of type I collagen can introduce a kink near the site of the substitution. However, the presence of a kink is not a prerequisite for delayed cleavage of abnormal procollagens by N-proteinase.	UNIV MANCHESTER,DEPT BIOCHEM & MOLEC BIOL,OXFORD RD,MANCHESTER M13 9PT,LANCS,ENGLAND; UNIV WASHINGTON,DEPT PATHOL,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT MED,SEATTLE,WA 98195	University of Manchester; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle			KADLER, KARL/ABI-2403-2020	KADLER, KARL/0000-0003-4977-4683; Brass, Andrew/0000-0002-0389-7058; Byers, Peter H./0000-0001-7786-7030	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR021557, R01AR041223] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR21557, AR41223] Funding Source: Medline; Wellcome Trust Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); Wellcome Trust(Wellcome TrustEuropean Commission)		BERGER J, 1985, BIOCHEMISTRY-US, V25, P600; BRUCKNER P, 1981, ANAL BIOCHEM, V110, P360, DOI 10.1016/0003-2697(81)90204-9; BYERS PH, 1991, J MED GENET, V28, P433, DOI 10.1136/jmg.28.7.433; BYERS PH, 1989, METABOLIC BASIS INHE, P2805; COHN DH, 1990, AM J HUM GENET, V46, P591; Dixon M, 1964, ENZYMES, P54; DOMBROWSKI KE, 1988, J BIOL CHEM, V263, P16545; ENGEL J, 1987, METHOD ENZYMOL, V145, P3; FIEDLERNAGY C, 1981, ARCH BIOCHEM BIOPHYS, V212, P668, DOI 10.1016/0003-9861(81)90411-2; HAWKINS JR, 1991, J BIOL CHEM, V266, P22370; HELSETH DL, 1981, J BIOL CHEM, V256, P7118; HOFMANN H, 1984, J MOL BIOL, V172, P325, DOI 10.1016/S0022-2836(84)80029-7; HOJIMA Y, 1989, J BIOL CHEM, V264, P11336; KADLER KE, 1987, J BIOL CHEM, V262, P15696; KADLER KE, 1991, BIOCHEMISTRY-US, V30, P5081, DOI 10.1021/bi00234a035; KUIVANIEMI H, 1991, FASEB J, V5, P2052, DOI 10.1096/fasebj.5.7.2010058; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MOULD AP, 1985, J ULTRA MOL STRUCT R, V91, P66, DOI 10.1016/0889-1605(85)90077-1; NA G, 1989, BIOCHEMISTRY-US, V28, P153; PELTONEN L, 1980, P NATL ACAD SCI USA, V71, P6179; STARMAN BJ, 1989, J CLIN INVEST, V84, P1206, DOI 10.1172/JCI114286; TANZAWA K, 1985, J BIOL CHEM, V260, P1120; TORREBLANCO A, 1992, J BIOL CHEM, V267, P2650; VOGEL BE, 1987, J BIOL CHEM, V262, P14737; VOGEL BE, 1988, J BIOL CHEM, V263, P19249; WALLIS GA, 1990, J BIOL CHEM, V265, P18628; WALLIS GA, 1990, AM J HUM GENET, V46, P1034; WALLIS GA, 1992, J BIOL CHEM, V267, P25529; WOESSNER JF, 1961, ARCH BIOCHEM BIOPHYS, V93, P440, DOI 10.1016/0003-9861(61)90291-0	29	45	45	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1992	267	35					25521	25528						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KB603	1460046				2022-12-25	WOS:A1992KB60300091
J	STADDON, JM; BOUZYK, MM; ROZENGURT, E				STADDON, JM; BOUZYK, MM; ROZENGURT, E			INTERCONVERSION OF GRP78/BIP - A NOVEL EVENT IN THE ACTION OF PASTEURELLA-MULTOCIDA TOXIN, BOMBESIN, AND PLATELET-DERIVED GROWTH-FACTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; SWISS 3T3 CELLS; GLUCOSE-REGULATED PROTEIN; CHAIN-BINDING-PROTEIN; ADP-RIBOSYLATION; ENDOPLASMIC-RETICULUM; POTENT MITOGEN; BIOCHEMICAL-CHARACTERIZATION; HAMSTER FIBROBLASTS; RESPONSIVE GENES	Incubation of Swiss 3T3 cells with [2-H-3]adenine,as in other cell types, reveals the ADP-ribosylation of GRP78 (the 78-kDa glucose-regulated protein, also known as BiP, the immunoglobulin heavy chain-binding protein), a resident endoplasmic reticulum Protein that assists in the processing of proteins destined for secretion or cell surface expression. Here we show that Pasteurella multocida toxin, a potent growth factor for cultured fibroblasts, decreased the ADP-ribosylation of GRP78/BiP to 16 +/- 6% of the control value (n = 23). The action of the toxin occurred after a lag period, was blocked by lysosomotrophic agents, and potentiated by increased incubation time (ED50 4 ng/ml and 1 ng/ml in 4 and 8 h, respectively), thus indicating that the toxin enters the cells to act. Bombesin and platelet-derived growth factor (PDGF) similarly decreased the ADP-ribosylation of GRP78/BiP (ED50 0.5 nM and 2.5 ng/ml, respectively) but acted more rapidly than the toxin. Signaling pathways activated by the toxin, bombesin, and PDGF had effects on the ADP-ribosylation of GRP78/BiP. Thus, activation of protein kinase C alone by phorbol 12,13-dibutyrate was partially effective, and down-regulation of protein kinase C attenuated but did not block the action of the toxin, bombesin, and PDGF. Agents that mobilize Ca2+ from the endoplasmic reticulum (A23187, ionomycin, and thapsigargin) caused a decrease in the ADP-ribosylation of GRP78/BiP that was similar in magnitude to that achieved by the toxin, bombesin, and PDGF, implicating a role for inositol 1,4,5-trisphosphate-mediated Ca2+ mobilization in the action of the mitogenic agents. The growth factor-induced decrease in the ADP-ribosylation of GRP78/BiP may represent its conversion from an inactive to an active state.	IMPERIAL CANC RES FUND, POB 123, 44 LINCOLNS INN FIELDS, LONDON WC2A 3PX, ENGLAND	Cancer Research UK								BATTEY JF, 1991, P NATL ACAD SCI USA, V88, P395, DOI 10.1073/pnas.88.2.395; BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.bi.56.070187.001111; BOLE DG, 1986, J CELL BIOL, V102, P1558, DOI 10.1083/jcb.102.5.1558; BRAVO R, 1990, CELL GROWTH DIFFER, V1, P305; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARLSSON L, 1983, P NATL ACAD SCI-BIOL, V80, P4664, DOI 10.1073/pnas.80.15.4664; CHANTER N, 1986, J GEN MICROBIOL, V132, P1089; CLAIRMONT CA, 1992, J BIOL CHEM, V267, P3983; COFFER A, 1990, FEBS LETT, V263, P80, DOI 10.1016/0014-5793(90)80710-Z; DICKER P, 1980, NATURE, V287, P607, DOI 10.1038/287607a0; DRUMMOND IAS, 1987, J BIOL CHEM, V262, P12801; ERUSALIMSKY JD, 1988, J BIOL CHEM, V263, P19188; FLYNN GC, 1989, SCIENCE, V245, P385, DOI 10.1126/science.2756425; FLYNN GC, 1991, NATURE, V353, P726, DOI 10.1038/353726a0; FREIDEN PJ, 1992, EMBO J, V11, P63, DOI 10.1002/j.1460-2075.1992.tb05028.x; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; HAAS IG, 1988, P NATL ACAD SCI USA, V85, P2250, DOI 10.1073/pnas.85.7.2250; HENDERSHOT LM, 1988, MOL CELL BIOL, V8, P4250, DOI 10.1128/MCB.8.10.4250; HIGGINS TE, 1992, P NATL ACAD SCI USA, V89, P4240, DOI 10.1073/pnas.89.10.4240; ISSANDOU M, 1990, J BIOL CHEM, V265, P11890; KIM HK, 1991, CELL, V65, P435, DOI 10.1016/0092-8674(91)90461-7; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAX AJ, 1990, J GEN MICROBIOL, V136, P81, DOI 10.1099/00221287-136-1-81; LEDFORD BE, 1986, EUR J BIOCHEM, V161, P661, DOI 10.1111/j.1432-1033.1986.tb10491.x; LEE AS, 1984, J BIOL CHEM, V259, P4616; LENO GH, 1989, EUR J BIOCHEM, V186, P205, DOI 10.1111/j.1432-1033.1989.tb15196.x; LENO GH, 1990, FEBS LETT, V276, P29, DOI 10.1016/0014-5793(90)80499-9; LOPEZRIVAS A, 1984, AM J PHYSIOL, V247, pC156, DOI 10.1152/ajpcell.1984.247.3.C156; MACER DRJ, 1988, J CELL SCI, V91, P61; Mehmet H, 1990, GROWTH FACTORS, V3, P83, DOI 10.3109/08977199009108271; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; MENDOZA SA, 1986, J CELL BIOL, V102, P2223, DOI 10.1083/jcb.102.6.2223; MILLAR JBA, 1990, J BIOL CHEM, V265, P12052; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; MUNRO S, 1986, CELL, V46, P291, DOI 10.1016/0092-8674(86)90746-4; NANBERG E, 1988, EMBO J, V7, P2741, DOI 10.1002/j.1460-2075.1988.tb03128.x; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; PELHAM HRB, 1989, ANNU REV CELL BIOL, V5, P1, DOI 10.1146/annurev.cb.05.110189.000245; RODRIGUEZPENA A, 1984, BIOCHEM BIOPH RES CO, V120, P1053, DOI 10.1016/S0006-291X(84)80213-2; ROSS R, 1986, CELL, V46, P155, DOI 10.1016/0092-8674(86)90733-6; ROZENGURT E, 1990, P NATL ACAD SCI USA, V87, P123, DOI 10.1073/pnas.87.1.123; ROZENGURT E, 1988, PROG NUCLEIC ACID RE, V35, P261, DOI 10.1016/S0079-6603(08)60616-9; ROZENGURT E, 1983, P NATL ACAD SCI-BIOL, V80, P2936, DOI 10.1073/pnas.80.10.2936; ROZENGURT E, 1986, SCIENCE, V234, P161, DOI 10.1126/science.3018928; ROZENGURT E, 1990, J CELL SCI, P43; STADDON JM, 1991, J CELL BIOL, V115, P949, DOI 10.1083/jcb.115.4.949; STADDON JM, 1991, J BIOL CHEM, V266, P4840; STADDON JM, 1990, J BIOL CHEM, V265, P11841; SUZUKI CK, 1991, J CELL BIOL, V114, P189, DOI 10.1083/jcb.114.2.189; TAKEMURA H, 1989, J BIOL CHEM, V264, P12266; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; TODARO GJ, 1963, J CELL BIOL, V17, P299, DOI 10.1083/jcb.17.2.299; TSIEN RW, 1990, ANNU REV CELL BIOL, V6, P715, DOI 10.1146/annurev.cb.06.110190.003435; VOGEL JP, 1990, J CELL BIOL, V110, P1885, DOI 10.1083/jcb.110.6.1885; WATOWICH SS, 1988, MOL CELL BIOL, V8, P393, DOI 10.1128/MCB.8.1.393; WELCH WJ, 1983, J BIOL CHEM, V258, P7102; WELCH WJ, 1991, CURR TOP MICROBIOL, V167, P31; ZACHARY I, 1986, J CELL BIOL, V102, P2211, DOI 10.1083/jcb.102.6.2211; ZACHARY I, 1987, J BIOL CHEM, V262, P3947	60	22	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	1992	267	35					25239	25245						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KB603	1460024				2022-12-25	WOS:A1992KB60300051
J	UNNI, E; MEISTRICH, ML				UNNI, E; MEISTRICH, ML			PURIFICATION AND CHARACTERIZATION OF THE RAT SPERMATID BASIC NUCLEAR PROTEIN-TP4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAJOR CHROMOSOMAL PROTEIN; TRANSITION PROTEIN-2; MAMMALIAN SPERMATIDS; MOUSE SPERMATIDS; TESTIS; SPERMATOGENESIS; CDNA; BOAR; BULL; TP2	Following elongation of spermatids in mammals, the histones are replaced by a set of basic nuclear transition proteins; in the rat there are four, named TP1-TP4. Of these, TP1 and TP2 are well characterized. Here we report the purification to homogeneity of TP4 from rat spermatids. It is a low molecular mass (about 13-20 kDa) basic protein with arginine and lysine constituting 24 mol % and histidine 2.2 mol %. Its 25 N-terminal amino acids were sequenced, and no sequence homologies with any known protein were found. Polyclonal antibodies raised against it in rabbit did not cross-react with other transition proteins, protamines, or histones. The presence of TP4 during sperm development was monitored by cell separation studies. No TP4 was detected in round spermatids, and along with TP1 and TP2, it is present in step 13-15 spermatids and its amount decreased in steps 16-19. Trace amounts of TP4 were also detected in epididymal sperm. A possible role for TP4 in spermatid and sperm chromatin structure is discussed.			UNNI, E (corresponding author), UNIV TEXAS,MD ANDERSON CANC CTR,DEPT EXPTL RADIOTHERAPY,HOUSTON,TX 77030, USA.				NCI NIH HHS [CA-16672] Funding Source: Medline; NICHD NIH HHS [HD-16843] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD016843] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKAMA K, 1990, BIOCHIM BIOPHYS ACTA, V1041, P264, DOI 10.1016/0167-4838(90)90282-K; BALHORN R, 1984, EXP CELL RES, V150, P298, DOI 10.1016/0014-4827(84)90572-X; Balhorn R., 1989, P366; BASKARAN R, 1990, J BIOL CHEM, V265, P21039; BASKARAN R, 1991, BIOCHEM BIOPH RES CO, V179, P1491, DOI 10.1016/0006-291X(91)91741-T; BUNICK D, 1990, EXP CELL RES, V188, P147, DOI 10.1016/0014-4827(90)90290-Q; COURTENS JL, 1981, J ULTRA MOL STRUCT R, V74, P327, DOI 10.1016/S0022-5320(81)80124-4; DUPRESSOIR T, 1985, EXP CELL RES, V161, P63, DOI 10.1016/0014-4827(85)90490-2; GRIMES SR, 1977, EXP CELL RES, V110, P31, DOI 10.1016/0014-4827(77)90266-X; GRIMES SR, 1986, COMP BIOCHEM PHYS B, V83, P495, DOI 10.1016/0305-0491(86)90285-3; Hecht N.B., 1989, P396; HECHT NB, 1990, J REPROD FERTIL, V88, P679, DOI 10.1530/jrf.0.0880679; Hecht NB, 1989, HISTONES OTHER BASIC, P347; HEIDARAN MA, 1988, J CELL BIOL, V106, P1427, DOI 10.1083/jcb.106.5.1427; HEIDARAN MA, 1987, J BIOL CHEM, V262, P13309; KISTLER WS, 1989, HISTONES OTHER BASIC, P331; KLEENE KC, 1987, J BIOL CHEM, V262, P17272; KREMLING H, 1989, DIFFERENTIATION, V40, P184, DOI 10.1111/j.1432-0436.1989.tb00597.x; LANNEAU M, 1982, J REPROD FERTIL, V65, P163, DOI 10.1530/jrf.0.0650163; LOIR M, 1978, BIOCHEM BIOPH RES CO, V80, P975, DOI 10.1016/0006-291X(78)91341-4; LUERSSEN H, 1989, NUCLEIC ACIDS RES, V17, P3585, DOI 10.1093/nar/17.9.3585; MARUSHIGE K, 1971, J BIOL CHEM, V246, P5799; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MATTICE WL, 1976, BIOCHEMISTRY-US, V15, P4264, DOI 10.1021/bi00664a020; MAYER JF, 1981, BIOL REPROD, V25, P1041, DOI 10.1095/biolreprod25.5.1041; Meistrich M., 1989, HISTONES OTHER BASIC, P165; Meistrich M L, 1977, Methods Cell Biol, V15, P15, DOI 10.1016/S0091-679X(08)60207-1; MEISTRICH ML, 1980, FED PROC, V39, P1884; MEISTRICH ML, 1992, MOL REPROD DEV, V31, P170, DOI 10.1002/mrd.1080310303; MEISTRICH ML, 1978, FED PROC, V37, P2522; MEISTRICH ML, 1981, BIOREGULATORS REPROD, P151; Platz R D, 1977, Methods Cell Biol, V16, P297; REINHART N, 1991, BIOL CHEM H-S, V372, P431, DOI 10.1515/bchm3.1991.372.1.431; RISLEY MS, 1990, CHROMOSOMES EUKARYOT, V2, P61; SEYEDIN SM, 1980, J BIOL CHEM, V255, P5949; SINGH J, 1987, INDIAN J BIOCHEM BIO, V24, P181; SINGH J, 1987, J BIOL CHEM, V262, P734; SINGH J, 1988, BIOCHEM INT, V17, P701; TROSTLEWEIGE PK, 1982, J BIOL CHEM, V257, P5560; WHITE FH, 1967, METHOD ENZYMOL, V11, P481	40	39	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1992	267	35					25359	25363						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KB603	1460032				2022-12-25	WOS:A1992KB60300068
J	JACQUET, E; VANONI, M; FERRARI, C; ALBERGHINA, L; MARTEGANI, E; PARMEGGIANI, A				JACQUET, E; VANONI, M; FERRARI, C; ALBERGHINA, L; MARTEGANI, E; PARMEGGIANI, A			A MOUSE CDC25-LIKE PRODUCT ENHANCES THE FORMATION OF THE ACTIVE GTP COMPLEX OF HUMAN RAS-P21 AND SACCHAROMYCES-CEREVISIAE RAS2 PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							GUANINE-NUCLEOTIDE EXCHANGE; ADENYLATE-CYCLASE PATHWAY; MOLECULAR-CLONING; GENE; GDP; P21RAS; SITE	GDP-dissociation stimulators (GDSs) are the key element for the regeneration of the active state of ras proteins, but despite intensive investigations, little is so far known about their functional and structural properties, particularly in mammals. A growing number of genes from various organisms have been postulated to encode GDSs on the basis of sequence similarity with the Saccharomyces cerevisiae CDC25 gene, whose product acts as a GDS of RAS proteins. However, except for CDC25 and the related SDC25 C-domain, no biochemical evidence of ras GDS activity for these CDC25-like proteins has yet been available. We show that the product of a recently isolated mouse CDC25-like gene (CDC25Mm) can strongly enhance (more than 1000 times) the GDP release from both human c-Ha-ras p21 and yeast RAS2 in vitro. As a consequence, the CDC25Mm induces a rapid formation of the biologically active Ras.GTP complex. This GDS is much more active on the GDP than on the GTP complex and has a narrow substrate specificity, since it was found to be inactive on several ras-like proteins. The mouse GDS can efficiently substitute for yeast CDC25 in an in vitro adenylylcyclase assay on RAS2 cdc25 yeast membranes. Our results show that a cloned GDP to GTP exchange factor of mammalian ras belongs to the novel family of CDC25-like proteins.	ECOLE POLYTECH,BIOCHIM,CNRS,STRUCT DIVERSE INTERVENT 61840,F-91128 PALAISEAU,FRANCE; UNIV MILAN,DIPARTIMENTO FISIOL & BIOCHIM GEN,SEZ BIOCHIM COMPARATA,I-20133 MILAN,ITALY	Centre National de la Recherche Scientifique (CNRS); Institut Polytechnique de Paris; University of Milan				JACQUET, Eric/0000-0001-6366-8436; Alberghina, Lilia/0000-0003-1694-931X; VANONI, MARCO ERCOLE/0000-0002-8690-2587; Martegani, Enzo/0000-0001-9196-4224				BONFINI L, 1992, SCIENCE, V255, P603, DOI 10.1126/science.1736363; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BROEK D, 1987, CELL, V48, P789, DOI 10.1016/0092-8674(87)90076-6; CAMONIS JH, 1986, EMBO J, V5, P375, DOI 10.1002/j.1460-2075.1986.tb04222.x; CASPERSON GF, 1983, J BIOL CHEM, V258, P7911; CHANT J, 1991, CELL, V65, P1213, DOI 10.1016/0092-8674(91)90016-R; CRECHET JB, 1990, J BIOL CHEM, V265, P1563; CRECHET JB, 1990, SCIENCE, V248, P866, DOI 10.1126/science.2188363; DOWNWARD J, 1990, P NATL ACAD SCI USA, V87, P5998, DOI 10.1073/pnas.87.15.5998; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; HART MJ, 1991, NATURE, V354, P311, DOI 10.1038/354311a0; HIRAOKA K, 1992, BIOCHEM BIOPH RES CO, V182, P921, DOI 10.1016/0006-291X(92)91820-G; HUGHES DA, 1990, NATURE, V344, P357; JONES S, 1991, MOL CELL BIOL, V11, P2641, DOI 10.1128/MCB.11.5.2641; MARTEGANI E, 1986, EMBO J, V5, P2363, DOI 10.1002/j.1460-2075.1986.tb04505.x; MARTEGANI E, 1992, EMBO J, V11, P2151, DOI 10.1002/j.1460-2075.1992.tb05274.x; MISTOU MY, 1992, EMBO J, V11, P2391, DOI 10.1002/j.1460-2075.1992.tb05303.x; ROBINSON LC, 1987, SCIENCE, V235, P1218, DOI 10.1126/science.3547648; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; TUCKER J, 1986, EMBO J, V5, P1351, DOI 10.1002/j.1460-2075.1986.tb04366.x; WEST M, 1990, FEBS LETT, V259, P245, DOI 10.1016/0014-5793(90)80019-F; WICKNER RB, 1987, YEAST, V3, P51, DOI 10.1002/yea.320030108; WOLFMAN A, 1990, SCIENCE, V248, P67, DOI 10.1126/science.2181667	24	39	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1992	267	34					24181	24183						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KA263	1447167				2022-12-25	WOS:A1992KA26300009
J	ONNO, M; NAKAMURA, T; HILLOVA, J; HILL, M				ONNO, M; NAKAMURA, T; HILLOVA, J; HILL, M			REARRANGEMENT OF THE HUMAN TRE ONCOGENE BY HOMOLOGOUS RECOMBINATION BETWEEN ALU REPEATS OF NUCLEOTIDE-SEQUENCES FROM 2 DIFFERENT CHROMOSOMES	ONCOGENE			English	Note							B-CELL NEOPLASMS; BCR GENE; FAMILIAL HYPERCHOLESTEROLEMIA; STRUCTURAL ALTERATIONS; RECIPROCAL PARTNERS; MOLECULAR-CLONING; TRANSFORMING GENE; ACUTE LEUKEMIAS; DNA FRAGMENTS; C-MYC	The rearranged region of the tre oncogene originating from chromosomes 5q23q31 and 18q12 was cloned from tumor genomic DNA, sequenced and aligned with wild-type sequences cloned from a normal human genomic library. In the breakpoint region each wild-type sequence contained two Alu repeats. The recombination occurred between the 3'-most Alu from chromosome 5 and the 5'-most Alu from chromosome 18 and, consequently, resulted in a hybrid Alu flanked with one Alu on either side. The recombinant joint was located to a 20-bp homology region in left arms of the Alu repeats involved in recombination. The same homology region was identified in the hybrid Alu of the rearranged tre. At its 5' extremity the homology region overlaps the B box of Alu-borne RNA polymerase III promoter. The 100% identity score in the region of homology suggests that the recombination process was conservative and not error prone.	INST CANC & IMMUNOGENET, CELLULAR & MOLEC BIOL LAB, 14 AVE PAUL VAILLANT COUTURIER, F-94804 VILLEJUIF, FRANCE; INST CANC & IMMUNOGENET, CNRS, UNITE SDI 6204, F-94804 VILLEJUIF, FRANCE	Centre National de la Recherche Scientifique (CNRS)								ANACHKOVA B, 1985, BIOCHEM BIOPH RES CO, V128, P101, DOI 10.1016/0006-291X(85)91650-X; ANDERSON RA, 1986, MOL CELL BIOL, V6, P3246, DOI 10.1128/MCB.6.9.3246; AVIDI L, 1980, HUMAN GENET, V55, P281; BAKHSHI A, 1987, P NATL ACAD SCI USA, V84, P2396, DOI 10.1073/pnas.84.8.2396; BEEN MD, 1984, NUCLEIC ACIDS RES, V12, P3097, DOI 10.1093/nar/12.7.3097; BENTON WD, 1977, SCIENCE, V196, P180, DOI 10.1126/science.322279; BIRCHMEIER C, 1986, MOL CELL BIOL, V6, P3109, DOI 10.1128/MCB.6.9.3109; BOVI PD, 1987, P NATL ACAD SCI USA, V84, P5660, DOI 10.1073/pnas.84.16.5660; BROWN L, 1990, EMBO J, V9, P3343, DOI 10.1002/j.1460-2075.1990.tb07535.x; BULLOCK P, 1985, SCIENCE, V230, P954, DOI 10.1126/science.2997924; CANNING S, 1989, P NATL ACAD SCI USA, V86, P5044, DOI 10.1073/pnas.86.13.5044; CHEN SJ, 1989, NUCLEIC ACIDS RES, V17, P7631, DOI 10.1093/nar/17.19.7631; CHEN SJ, 1989, ONCOGENE, V4, P195; DEAN M, 1987, MOL CELL BIOL, V7, P921, DOI 10.1128/MCB.7.2.921; DEKLEIN A, 1986, NUCLEIC ACIDS RES, V14, P7071, DOI 10.1093/nar/14.17.7071; DEPAMPHILIS ML, 1988, CELL, V52, P635, DOI 10.1016/0092-8674(88)90398-4; EVA A, 1987, ONCOGENE, V1, P355; HALVERSON D, 1990, ONCOGENE, V5, P1085; HEISTERKAMP N, 1985, NATURE, V315, P758, DOI 10.1038/315758a0; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HIRST MC, 1991, ONCOGENE, V6, P153; HUEBNER K, 1988, ONCOGENE, V3, P449; HYRIEN O, 1987, EMBO J, V6, P2401, DOI 10.1002/j.1460-2075.1987.tb02518.x; IHLE JN, 1989, J VIROL, V63, P2959, DOI 10.1128/JVI.63.7.2959-2966.1989; JURKA J, 1988, P NATL ACAD SCI USA, V85, P4775, DOI 10.1073/pnas.85.13.4775; KORNREICH R, 1990, J BIOL CHEM, V265, P9319; LANGLOIS S, 1988, AM J HUM GENET, V43, P60; LAZO PA, 1988, J VIROL, V62, P788, DOI 10.1128/JVI.62.3.788-794.1988; LEBEAU MM, 1986, BLOOD, V67, P849; LEHRMAN MA, 1987, CELL, V48, P827, DOI 10.1016/0092-8674(87)90079-1; MARKERT ML, 1988, J CLIN INVEST, V81, P1323, DOI 10.1172/JCI113458; MATERA AG, 1990, MOL CELL BIOL, V10, P5424, DOI 10.1128/MCB.10.10.5424; MONTIEL JF, 1984, NUCLEIC ACIDS RES, V12, P1049, DOI 10.1093/nar/12.2.1049; NAKAMURA T, 1992, ONCOGENE, V7, P733; NAKAMURA T, 1988, ONCOGENE RES, V2, P357; NALBANTOGLU J, 1988, J MOL BIOL, V200, P449, DOI 10.1016/0022-2836(88)90535-9; NICHOLLS RD, 1987, CELL, V49, P369, DOI 10.1016/0092-8674(87)90289-3; NOTTENBURG C, 1987, J VIROL, V61, P1828, DOI 10.1128/JVI.61.6.1828-1833.1987; PAOLELLA G, 1983, EMBO J, V2, P691, DOI 10.1002/j.1460-2075.1983.tb01486.x; PICCOLI SP, 1984, NATURE, V310, P327, DOI 10.1038/310327a0; ROUYER F, 1987, CELL, V51, P417, DOI 10.1016/0092-8674(87)90637-4; SILVER J, 1989, J VIROL, V63, P1924, DOI 10.1128/JVI.63.5.1924-1928.1989; STANTON VP, 1987, MOL CELL BIOL, V7, P1171, DOI 10.1128/MCB.7.3.1171; STOPPALYONNET D, 1990, P NATL ACAD SCI USA, V87, P1551, DOI 10.1073/pnas.87.4.1551; TAKAHASHI M, 1985, CELL, V42, P581, DOI 10.1016/0092-8674(85)90115-1; TSUJIMOTO Y, 1988, ONCOGENE, V2, P347; TSUJIMOTO Y, 1985, SCIENCE, V229, P1390, DOI 10.1126/science.3929382; TURCCAREL C, 1984, CANCER GENET CYTOGEN, V12, P1, DOI 10.1016/0165-4608(84)90002-5; YOUNG D, 1986, CELL, V45, P711, DOI 10.1016/0092-8674(86)90785-3	49	37	40	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	1992	7	12					2519	2523						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KA856	1461655				2022-12-25	WOS:A1992KA85600018
J	BLASQUEZ, VC; HALE, MA; TREVORROW, KW; GARRARD, WT				BLASQUEZ, VC; HALE, MA; TREVORROW, KW; GARRARD, WT			IMMUNOGLOBULIN-KAPPA GENE ENHANCERS SYNERGISTICALLY ACTIVATE GENE-EXPRESSION BUT INDEPENDENTLY DETERMINE CHROMATIN STRUCTURE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-TYPE SPECIFICITY; SEQUENCE ELEMENTS; HYPERSENSITIVE SITES; CONSERVED SEQUENCE; STABLE INTEGRATION; INTRONIC MAR; DNA-SEQUENCE; 5' ENDS; TRANSCRIPTION; BINDING	Previous studies have located transcriptional enhancer elements within both the intron and 3'-region of the mouse kappa immunoglobulin gene. Here we address the role of these two enhancers in specifying gene activity and specific chromatin structures. MOPC41 kappa gene constructs, either intact or containing deletions of one or both enhancers, were introduced into S194 mouse plasmacytoma cells for transient and stable expression studies. Transient expression assays revealed that the basal level expression exhibited by enhancerless constructs was activated 100-200-fold by the two enhancers together in a synergistic fashion. A similar trend was observed when both enhancers were present in stably integrated constructs, although the synergy was less pronounced. Analysis of DNase I hypersensitive sites in the chromatin revealed that stably integrated constructs established hypersensitive sites about the enhancer sequences. These sites demonstrated the same nuclease susceptibility as those associated with the endogenous gene(s), and their establishment was independent of the presence of the other enhancer. Thus, although both enhancers are required for maximal gene expression, the elements act independently in determining specific chromatin structures.	UNIV NOTRE DAME,DEPT CHEM & BIOCHEM,NOTRE DAME,IN 46556	University of Notre Dame	GARRARD, WT (corresponding author), UNIV TEXAS,SW MED CTR,DEPT BIOCHEM,DALLAS,TX 75235, USA.				NIGMS NIH HHS [GM29935, GM22201, GM31689] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029935, P01GM031689, R01GM022201] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERGMAN Y, 1984, P NATL ACAD SCI-BIOL, V81, P7041, DOI 10.1073/pnas.81.22.7041; BLASQUEZ VC, 1989, J BIOL CHEM, V264, P21183; CHUNG SY, 1983, P NATL ACAD SCI-BIOL, V80, P2427, DOI 10.1073/pnas.80.9.2427; CURRIE RA, 1989, MOL CELL BIOL, V9, P4239, DOI 10.1128/MCB.9.10.4239; FALKNER FG, 1984, NATURE, V310, P71, DOI 10.1038/310071a0; FOSTER J, 1985, NATURE, V315, P423, DOI 10.1038/315423a0; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GOSSLER A, 1989, SCIENCE, V244, P463, DOI 10.1126/science.2497519; GROSS DS, 1988, ANNU REV BIOCHEM, V57, P159, DOI 10.1146/annurev.bi.57.070188.001111; GROSSCHEDL R, 1985, CELL, V41, P885, DOI 10.1016/S0092-8674(85)80069-6; GUNNING P, 1983, MOL CELL BIOL, V3, P787, DOI 10.1128/MCB.3.5.787; LENARDO M, 1987, SCIENCE, V236, P1573, DOI 10.1126/science.3109035; MEYER KB, 1990, NUCLEIC ACIDS RES, V18, P5609, DOI 10.1093/nar/18.19.5609; MEYER KB, 1989, EMBO J, V8, P1959, DOI 10.1002/j.1460-2075.1989.tb03601.x; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; PARSLOW TG, 1983, NUCLEIC ACIDS RES, V11, P4775, DOI 10.1093/nar/11.14.4775; PARSLOW TG, 1982, NATURE, V299, P449, DOI 10.1038/299449a0; PARSLOW TG, 1984, P NATL ACAD SCI-BIOL, V81, P2650, DOI 10.1073/pnas.81.9.2650; PICARD D, 1984, NATURE, V307, P80, DOI 10.1038/307080a0; PONGUBALA JMR, 1991, MOL CELL BIOL, V11, P1040, DOI 10.1128/MCB.11.2.1040; PONGUBALA JMR, 1992, MOL CELL BIOL, V12, P368, DOI 10.1128/MCB.12.1.368; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; QUEEN C, 1984, MOL CELL BIOL, V4, P1042, DOI 10.1128/MCB.4.6.1042; QUEEN C, 1983, CELL, V33, P741, DOI 10.1016/0092-8674(83)90016-8; REUDELHUBER TL, 1982, NUCLEIC ACIDS RES, V10, P1311, DOI 10.1093/nar/10.4.1311; SEIDMAN JG, 1978, NATURE, V276, P790, DOI 10.1038/276790a0; SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; WU C, 1980, NATURE, V286, P854, DOI 10.1038/286854a0; XU M, 1986, J BIOL CHEM, V261, P3838; XU M, 1989, J BIOL CHEM, V264, P21190; XU M, 1989, THESIS U TEXAS SW ME	33	29	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1992	267	33					23888	23893						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JZ239	1429727				2022-12-25	WOS:A1992JZ23900069
J	WU, WS; LIN, JK; WU, FYH				WU, WS; LIN, JK; WU, FYH			DIFFERENTIAL INDUCTION OF C-FOS AND C-JUN PROTOONCOGENES AND AP-1 ACTIVITY BY TUMOR PROMOTER 12-O-TETRADECANOYL PHORBOL 13-ACETATE IN CELLS AT DIFFERENT STAGES OF TUMOR PROMOTION INVITRO	ONCOGENE			English	Article							TRANSCRIPTION FACTOR AP-1; INDUCIBLE ENHANCER ELEMENTS; IMMEDIATE EARLY GENES; EPIDERMAL JB6 CELLS; KINASE-C; CHEMICAL CARCINOGENESIS; 67-BASE-PAIR SEQUENCE; COORDINATE REGULATION; TRANSFORMING GENE; NONCODING REGION	A two-stage (initiation and promotion) model of chemical transformation of mouse embryonic fibroblasts was used to elucidate the molecular mechanisms of tumor promotion in vitro. C3H10T1/2 cells which had been initiated with a subcarcinogenic dose (0.5 mug ml-1) of benzo[a]pyrene (B[a]P) were isolated after 12-O-tetradecanoyl phorbol 13-acetate (TPA) treatment lasting 12, 24 or 36 days. These series of partially promoted cells were designated T-12, T-24 and T-36 cells. T-12 and T-24 cells exhibited higher anchorage-independent growth on soft agar in the presence of TPA than did the initiated or T-36 cells. Cytosolic protein kinase C (PKC) in the resting state was slightly depleted in T-24 and T-36 cells. Proteolytic down-regulation of membrane-bound PKC was enhanced in T-12 cells compared with the initiated cells after 3h of TPA treatment. Induction of c-fos and c-jun proto-oncogene expression increased two- to threefold in T-12 cells. Moreover, the basal level of c-fos mRNA progressively increased in T-12, T-24 and T-36 cells. As compared with other cell types, T-12 cells had the highest AP-1 DNA-binding activity at both the basal level and at 30 min after TPA treatment. These results indicate that deregulation of the TPA-induced cellular responses occurs in the cells at various stages of tumor promotion, and might be associated with transforming processes.	ACAD SINICA,INST BIOMED SCI,TAIPEI 11529,TAIWAN	Academia Sinica - Taiwan								ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BALLESTER R, 1985, J BIOL CHEM, V260, P5194; BARBER JR, 1987, MOL CELL BIOL, V7, P2201, DOI 10.1128/MCB.7.6.2201; BERNSTEIN LR, 1989, SCIENCE, V244, P566, DOI 10.1126/science.2541502; BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.bi.56.070187.001111; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; CARTER TH, 1987, MECH ENV CARCINOGENE, P47; CASTAGNA M, 1982, J BIOL CHEM, V257, P7847; CHIDA K, 1986, CANCER RES, V46, P1055; CHIDA K, 1986, J BIOL CHEM, V261, P3013; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; CURRAN T, 1982, J VIROL, V44, P674, DOI 10.1128/JVI.44.2.674-682.1982; FOURNIER A, 1987, NATURE, V330, P767, DOI 10.1038/330767a0; GREENBERG ME, 1985, CANCER CELL, V3, P307; HANSEN LA, 1990, CANCER RES, V50, P5740; ITO M, 1988, BIOCHEM BIOPH RES CO, V153, P648, DOI 10.1016/S0006-291X(88)81144-6; KIKKAWA U, 1983, J BIOL CHEM, V258, P1442; KISCHEL T, 1989, BIOCHEM BIOPH RES CO, V165, P981, DOI 10.1016/0006-291X(89)92699-5; LAMPH WW, 1988, NATURE, V334, P629, DOI 10.1038/334629a0; LAU LF, 1987, P NATL ACAD SCI USA, V84, P1182, DOI 10.1073/pnas.84.5.1182; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LERMAN MI, 1988, TUMOR PROMOTION BIOL, P357; Maniatis T., 1982, MOL CLONING; MANIATIS T, 1982, MOL CLONING, V2; MARC C, 1990, ONCOGENE, V5, P1541; MEIJLINK F, 1985, P NATL ACAD SCI USA, V82, P4987, DOI 10.1073/pnas.82.15.4987; MILLER EC, 1978, CANCER RES, V38, P1479; MONDAL S, 1976, CANCER RES, V36, P2254; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; PIETTE J, 1988, P NATL ACAD SCI USA, V85, P3401, DOI 10.1073/pnas.85.10.3401; RODRIGUEZPENA A, 1984, BIOCHEM BIOPH RES CO, V120, P1053, DOI 10.1016/S0006-291X(84)80213-2; RYDER K, 1988, P NATL ACAD SCI USA, V85, P8464, DOI 10.1073/pnas.85.22.8464; RYSECK RP, 1988, NATURE, V334, P535, DOI 10.1038/334535a0; Sambrook J, 1989, MOL CLONING LABORATO; TSO JY, 1985, NUCLEIC ACIDS RES, V13, P2485, DOI 10.1093/nar/13.7.2485; VERMA IM, 1987, CELL, V51, P513, DOI 10.1016/0092-8674(87)90115-2; WEINSTEIN IB, 1981, J SUPRAMOL STR CELL, V17, P99, DOI 10.1002/jsscb.380170202; WEINSTEIN IB, 1988, CANCER RES, V48, P4135; WEINSTEIN IB, 1987, J CELL BIOCHEM, V33, P213, DOI 10.1002/jcb.240330308; WEINSTEIN IB, 1984, CANCER CELL, V1, P229; WEYMAN CM, 1988, CANCER RES, V48, P5740	43	29	30	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1992	7	11					2287	2294						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JW665	1437150				2022-12-25	WOS:A1992JW66500022
J	FRANCO, P; MASTRONICOLA, MR; DECESARE, D; NOLLI, ML; WUN, TC; VERDE, P; BLASI, F; STOPPELLI, MP				FRANCO, P; MASTRONICOLA, MR; DECESARE, D; NOLLI, ML; WUN, TC; VERDE, P; BLASI, F; STOPPELLI, MP			SEPARATION AND CHARACTERIZATION OF NONPHOSPHORYLATED AND SERINE-PHOSPHORYLATED UROKINASE - CATALYTIC PROPERTIES AND SENSITIVITY TO PLASMINOGEN-ACTIVATOR INHIBITOR TYPE-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-BOUND UROKINASE; PRO-UROKINASE; AFFINITY-CHROMATOGRAPHY; SARCOMA-CELLS; DEGRADATION; PURIFICATION; PROENZYME; MONOCYTES; BINDING; PAI-1	Urokinase synthesized by human A431 epidermoid carcinoma cells is phosphorylated on serine (Mastronicola, M. R., Stoppelli, M. P., Migliaccio, A., Auricchio, F., and Blasi, F. (1990) FEBS Lett. 266, 109-114). To test the possibility that phosphorylation may have specific effects on urokinase function, the phosphorylated and nonphosphorylated forms of urokinase were separated by Fe3+-Sepharose chromatography. Both forms exhibit indistinguishable K(m) and k(cat) for plasminogen activation. On the other hand, their sensitivity toward the specific plasminogen activator inhibitor type 1 is different as assessed by measuring both the stability of the covalent complex and the residual enzymatic activity. Phosphorylated urokinase was 50% inhibited at a concentration of plasminogen activator inhibitor type 1 4-fold higher than nonphosphorylated urokinase (0.7 versus 0.15 nM). Furthermore about 10% of phosphorylated urokinase was resistant to plasminogen activator inhibitor type 1 at a concentration as high as 20 nM. Thus, phosphorylation affects urokinase sensitivity to plasminogen activator inhibitor type 1, therefore resulting in a net, although indirect, increase of urokinase activity. These results suggest the existence of a novel cellular regulatory mechanism of extracellular proteolysis.	UNIV COPENHAGEN,INST MICROBIOL,OSTER FARIMAGSGADE 2A,DK-1353 COPENHAGEN,DENMARK; CNR,INT INST GENET & BIOPHYS,NAPLES,ITALY	University of Copenhagen; Consiglio Nazionale delle Ricerche (CNR); Istituto di Genetica e Biofisica "Adriano Buzzati-Traverso" (IGB-CNR)			Franco, Paola/O-5897-2015	Franco, Paola/0000-0002-3289-7284; Blasi, Francesco/0000-0001-9406-1784				ANDERSSON L, 1986, ANAL BIOCHEM, V154, P250, DOI 10.1016/0003-2697(86)90523-3; ANDREASEN PA, 1986, J BIOL CHEM, V261, P7644; BLASI F, 1988, Fibrinolysis, V2, P73, DOI 10.1016/0268-9499(88)90370-0; BLASI F, 1987, J CELL BIOL, V104, P801, DOI 10.1083/jcb.104.4.801; BLASI F, 1991, CELL DIFF DEV, V32, P247; CUBELLIS MV, 1990, EMBO J, V9, P1079, DOI 10.1002/j.1460-2075.1990.tb08213.x; CUBELLIS MV, 1989, P NATL ACAD SCI USA, V86, P4828, DOI 10.1073/pnas.86.13.4828; DANO K, 1985, ADV CANCER RES, V44, P139, DOI 10.1016/S0065-230X(08)60028-7; DEUTSCH DG, 1970, SCIENCE, V170, P1095, DOI 10.1126/science.170.3962.1095; ELLIS V, 1989, J BIOL CHEM, V264, P2185; ESTREICHER A, 1990, J CELL BIOL, V111, P783, DOI 10.1083/jcb.111.2.783; FABRICANT RN, 1977, P NATL ACAD SCI USA, V74, P565, DOI 10.1073/pnas.74.2.565; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; JENSEN PH, 1990, CELL REGUL, V1, P1043, DOI 10.1091/mbc.1.13.1043; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MASTRONICOLA MR, 1990, FEBS LETT, V266, P109, DOI 10.1016/0014-5793(90)81519-T; MICHEL HP, 1987, FEBS LETT, V212, P103, DOI 10.1016/0014-5793(87)81565-X; NOLLI ML, 1986, THROMB HAEMOSTASIS, V56, P214; NOLLI ML, 1989, FIBRINOLYSIS, V3, P101, DOI 10.1016/0268-9499(89)90038-6; REICH E, 1978, MOL BASIS BIOL DEGRA, P155; STEPHENS RW, 1989, J CELL BIOL, V108, P1987, DOI 10.1083/jcb.108.5.1987; STOPPELLI MP, 1986, CELL, V45, P675, DOI 10.1016/0092-8674(86)90782-8; WUN TC, 1989, J BIOL CHEM, V264, P7862	23	15	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1992	267	27					19369	19372						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JP593	1527056				2022-12-25	WOS:A1992JP59300054
J	COLOTTA, F; POLENTARUTTI, N; SIRONI, M; MANTOVANI, A				COLOTTA, F; POLENTARUTTI, N; SIRONI, M; MANTOVANI, A			EXPRESSION AND INVOLVEMENT OF C-FOS AND C-JUN PROTOONCOGENES IN PROGRAMMED CELL-DEATH INDUCED BY GROWTH-FACTOR DEPRIVATION IN LYMPHOID-CELL LINES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYELOID-LEUKEMIA CELLS; GENE-EXPRESSION; ANTISENSE OLIGOMER; T-CELLS; APOPTOSIS; INDUCTION; SURVIVAL; ACTIVATION; BCL-2; TRANSGLUTAMINASE	Cell death induced by growth factor withdrawal is a programed event in which gene transcription and translation are required. Thus, it is likely that genes encoding for transcriptional factors can play an important role in this process. We have tested this hypothesis by analyzing c-fos and c-jun protooncogene expression and involvement in lymphoid cells deprived of growth factors. Interleukin (IL)-6- and IL-2-dependent mouse cell lines undergo programed cell death after growth factor deprivation. Northern blot analysis shows that c-fos and c-jun protooncogenes are rapidly induced (within 60 min) after growth factor deprivation in IL-6- and IL-2-dependent mouse cells. Induction is transient, being undetectable at 120 min after deprivation. Induction of these protooncogenes is at the transcriptional level, as demonstrated by actinomycin D and nuclear run-off experiments. Antisense oligonucleotides directed against c-fos and c-jun mRNAs consistently reduced the expression of these genes in treated cells. This reduction was associated with increased survival of growth factor-deprived lymphoid cells, thus suggesting that the expression of c-fos and c-jun protooncogenes may represent an important early event in the activation of the genetic program of cell death.			COLOTTA, F (corresponding author), MARIO NEGRI INST PHARMACOL RES,VIA ERITREA 62,I-20157 MILAN,ITALY.		Mantovani, Alberto/HCI-7449-2022; Sironi, Marina/AAB-5757-2020	Mantovani, Alberto/0000-0001-5578-236X; Colotta, Francesco/0000-0001-8601-2309; Sironi, Marina/0000-0002-3342-1149				ANDREWS GK, 1987, MOL CELL BIOL, V7, P3452, DOI 10.1128/MCB.7.10.3452; BURTON K, 1956, BIOCHEM J, V62, P315, DOI 10.1042/bj0620315; BUTTYAN R, 1988, MOL ENDOCRINOL, V2, P650, DOI 10.1210/mend-2-7-650; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COLOTTA F, 1990, BIOCHEM BIOPH RES CO, V168, P1013, DOI 10.1016/0006-291X(90)91130-K; COLOTTA F, 1987, J EXP MED, V165, P1224, DOI 10.1084/jem.165.4.1224; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; DATTA R, 1990, BLOOD, V76, P298; DUKE RC, 1986, LYMPHOKINE RES, V5, P289; ELLIS HM, 1986, CELL, V44, P817, DOI 10.1016/0092-8674(86)90004-8; FAGARASAN MO, 1990, P NATL ACAD SCI USA, V87, P7871, DOI 10.1073/pnas.87.20.7871; FESUS L, 1989, FEBS LETT, V245, P150, DOI 10.1016/0014-5793(89)80210-8; FESUS L, 1987, FEBS LETT, V224, P104, DOI 10.1016/0014-5793(87)80430-1; Golay J, 1991, PCR Methods Appl, V1, P144; HARRIGAN MT, 1989, MOL CELL BIOL, V9, P3438, DOI 10.1128/MCB.9.8.3438; HENDERSON S, 1991, CELL, V65, P1107, DOI 10.1016/0092-8674(91)90007-L; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; HOLLANDER MC, 1989, CANCER RES, V49, P1687; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; KHARBANDA SM, 1990, J CLIN INVEST, V86, P1517, DOI 10.1172/JCI114870; KOURY MJ, 1990, SCIENCE, V248, P378, DOI 10.1126/science.2326648; LOPEZ AF, 1986, J CLIN INVEST, V78, P1220, DOI 10.1172/JCI112705; MAIER JAM, 1990, SCIENCE, V249, P1570, DOI 10.1126/science.2218499; NUNEZ G, 1990, J IMMUNOL, V144, P3602; OWENS GP, 1991, MOL CELL BIOL, V11, P4177, DOI 10.1128/MCB.11.8.4177; PIERCE GB, 1989, P NATL ACAD SCI USA, V86, P3654, DOI 10.1073/pnas.86.10.3654; REED JC, 1990, CANCER RES, V50, P6565; SELLINS KS, 1987, J IMMUNOL, V139, P3199; SMITH CA, 1989, NATURE, V337, P181, DOI 10.1038/337181a0; VENTURELLI D, 1990, P NATL ACAD SCI USA, V87, P5963, DOI 10.1073/pnas.87.15.5963; WADEWITZ AG, 1988, FEBS LETT, V241, P19, DOI 10.1016/0014-5793(88)81022-6; WILLIAMS GT, 1990, NATURE, V343, P76, DOI 10.1038/343076a0; WYLLIE AH, 1984, J PATHOL, V142, P67, DOI 10.1002/path.1711420112; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; YAMAGUCHI Y, 1991, BLOOD, V10, P2542; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0	36	400	405	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1992	267	26					18278	18283						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JN502	1526968				2022-12-25	WOS:A1992JN50200008
J	LI, HM; SULLIVAN, TD; KEEGSTRA, K				LI, HM; SULLIVAN, TD; KEEGSTRA, K			INFORMATION FOR TARGETING TO THE CHLOROPLASTIC INNER ENVELOPE MEMBRANE IS CONTAINED IN THE MATURE REGION OF THE MAIZE BT1-ENCODED PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSIT PEPTIDE; PEA-CHLOROPLASTS; PHOSPHATE TRANSLOCATOR; SPINACH-CHLOROPLASTS; IMPORT RECEPTOR; THYLAKOID LUMEN; OUTER-MEMBRANE; TRANSPORT; SEQUENCE; INVITRO	Based on the protein sequence deduced from a cDNA clone, it has been proposed that the maize bt1 locus encodes an amyloplast membrane metabolite translocator protein (Sullivan, T. D., Strelow, L. I., Illingworth, C. A., Phillips, R. L., and Nelson, 0. E., Jr. (1991) Plant Cell 3, 1337-1348). The present work provides further evidence for this hypothesis by showing that the gene product of Bt1 could be imported into chloroplasts in vitro and processed to lower molecular weight mature proteins. More importantly, the imported mature proteins were localized to the inner envelope membrane, where metabolite translocators are located in plastids. In addition, the location of information for targeting to the inner membrane was investigated by constructing and analyzing the import of chimeric precursor proteins. A chimeric protein with the transit peptide of the precursor to the small subunit of ribulose-1,5-bisphosphate carboxylase fused to the mature region of the Bt1-encoded protein was targeted to the inner envelope membrane of chloroplasts. Moreover, a chimeric protein with the transit peptide of the Bt1-encoded protein fused to the mature protein of the light-harvesting chlorophyll a/b binding protein was targeted to the thylakoid. These results indicate that the transit peptide of the Bt1-encoded protein functions primarily as a stromal targeting sequence. The information for targeting to the chloroplastic inner envelope membrane is contained in the mature region of the protein.	UNIV WISCONSIN, DEPT BOT, MADISON, WI 53706 USA; UNIV WISCONSIN, DEPT GENET, MADISON, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison			Li, Hsou-min/AAZ-8011-2021	Li, Hsou-min/0000-0002-0211-7339				ANDREWS J, 1983, PLANT PHYSIOL, V72, P735, DOI 10.1104/pp.72.3.735; BAUERLE C, 1991, J BIOL CHEM, V266, P5884; CLINE K, 1981, P NATL ACAD SCI-BIOL, V78, P3595, DOI 10.1073/pnas.78.6.3595; CLINE K, 1983, PLANT PHYSIOL, V71, P366, DOI 10.1104/pp.71.2.366; CLINE K, 1985, J BIOL CHEM, V260, P3691; DEBOER D, 1988, EMBO J, V7, P2631, DOI 10.1002/j.1460-2075.1988.tb03115.x; DRESESWERRINGLOER U, 1991, EUR J BIOCHEM, V195, P361, DOI 10.1111/j.1432-1033.1991.tb15714.x; FLUGGE UI, 1989, EMBO J, V8, P39, DOI 10.1002/j.1460-2075.1989.tb03346.x; FLUGGE UI, 1991, NATURE, V353, P364, DOI 10.1038/353364a0; GAVEL Y, 1990, FEBS LETT, V261, P455, DOI 10.1016/0014-5793(90)80614-O; GLASER SM, 1988, J CELL BIOCHEM, V36, P275, DOI 10.1002/jcb.240360308; HAGEMAN J, 1990, PLANT CELL, V2, P479, DOI 10.1105/tpc.2.5.479; HAND JM, 1989, EMBO J, V8, P3195, DOI 10.1002/j.1460-2075.1989.tb08478.x; HARTL FU, 1989, BIOCHIM BIOPHYS ACTA, V988, P1, DOI 10.1016/0304-4157(89)90002-6; KLOSGEN RB, 1991, MOL GEN GENET, V225, P297, DOI 10.1007/BF00269862; KLOSGEN RB, 1989, MOL GEN GENET, V217, P155, DOI 10.1007/BF00330955; KO K, 1989, EMBO J, V8, P3187, DOI 10.1002/j.1460-2075.1989.tb08477.x; LAMPPA GK, 1988, J BIOL CHEM, V263, P14996; LI HM, 1991, PLANT CELL, V3, P709, DOI 10.1105/tpc.3.7.709; LUBBEN TH, 1988, PHOTOSYNTH RES, V17, P173, DOI 10.1007/BF00047688; LUBBEN TH, 1986, P NATL ACAD SCI USA, V83, P5502, DOI 10.1073/pnas.83.15.5502; MAHLKE K, 1990, EUR J BIOCHEM, V192, P551, DOI 10.1111/j.1432-1033.1990.tb19260.x; Mangelsdorf P.C., 1926, CONN AGR EXP STN B, V279, P509; MEADOWS JW, 1989, FEBS LETT, V253, P244, DOI 10.1016/0014-5793(89)80968-8; PERRY SE, 1991, METHOD CELL BIOL, V34, P327; REED JE, 1990, EUR J BIOCHEM, V194, P33, DOI 10.1111/j.1432-1033.1990.tb19423.x; SALOMON M, 1990, P NATL ACAD SCI USA, V87, P5778, DOI 10.1073/pnas.87.15.5778; SANGER F, 1980, J MOL BIOL, V143, P161, DOI 10.1016/0022-2836(80)90196-5; SCHNELL DJ, 1990, J CELL BIOL, V111, P1825, DOI 10.1083/jcb.111.5.1825; SHACKLETON JB, 1991, J BIOL CHEM, V266, P12152; SULLIVAN TD, 1991, PLANT CELL, V3, P1337, DOI 10.1105/tpc.3.12.1337; VANHEIJNE G, 1989, EUR J BIOCHEM, V180, P535; VANLOON APGM, 1987, EMBO J, V6, P2441, DOI 10.1002/j.1460-2075.1987.tb02523.x; WILLEY DL, 1991, PLANTA, V183, P451, DOI 10.1007/BF00197745	34	61	66	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	1992	267	26					18999	19004						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JN502	1527026				2022-12-25	WOS:A1992JN50200111
J	VANHOEK, AN; VERKMAN, AS				VANHOEK, AN; VERKMAN, AS			FUNCTIONAL RECONSTITUTION OF THE ISOLATED ERYTHROCYTE WATER CHANNEL CHIP28	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							MEMBRANE; PROTEINS; PERMEABILITY; KIDNEY; EXPRESSION; TRANSPORT; EPITHELIA; BAND-3; FAMILY; CELLS	Measurements of water permeability indicate the existence of a facilitated water transporting pathway in erythrocytes, kidney tubules and amphibian urinary bladder. Two lines of evidence suggest that one type of water channel is an approximately 30-kDa protein: the approximately 30-kDa target size determined by radiation inactivation (van Hoek, A. N., Hom, M. L., Luthjens, L. H., de Jong, M. D., Dempster, J. A., and van Os, C. H. (1991) J. Biol. Chem. 266, 16633-16635) and the increased water permeability in oocytes that express mRNA encoding a 28-kDa erythrocyte protein (CHIP28, Preston, B. M., Carroll, T. P., Guggino, W. B., and Agre, P. (1992) Science 256, 385-387). We report direct evidence that CHIP28 is the erythrocyte water channel. Osmotic water permeability (P(f)) remained high (0.029 cm/s, 37-degrees-C) when erythrocyte membranes were stripped of nearly all proteins except for CHIP28. N-terminal sequence analysis confirmed that the 28-kDa protein was CHIP28. P(f) in proteoliposomes reconstituted with solubilized CHIP28 was high (P(f) = 0.03 cm/s, 37-degrees-C), the activation energy was low (2.2 kcal/mol), and P(f) was decreased by >50-fold by mercurial sulfhydryl reagents and Me2SO. The single-channel water permeability was approximately 10(-13) cm3/s, slightly higher than that of the gramicidin A channel. The water channel excluded the small solute urea. These data establish a procedure to reconstitute functional water channels into liposomes and demonstrate that CHIP28 is the erythrocyte water channel.	UNIV CALIF SAN FRANCISCO,CARDIOVASC RES INST,DEPT PHYSIOL,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco	VANHOEK, AN (corresponding author), UNIV CALIF SAN FRANCISCO,CARDIOVASC RES INST,DEPT MED,1065 HLTH SCI E TOWER,SAN FRANCISCO,CA 94143, USA.			Van Hoek, Alfred/0000-0003-2724-6855	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK035124, R01DK035124] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK35124] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BENNETT V, 1983, METHOD ENZYMOL, V96, P313; DEMPSTER JA, 1991, PFLUG ARCH EUR J PHY, V419, P249, DOI 10.1007/BF00371103; ECHEVARRIA M, 1992, J GEN PHYSIOL, V99, P573, DOI 10.1085/jgp.99.4.573; FINKELSTEIN A, 1987, WATER MOVEMENT LIPID, P66; FISCHBARG J, 1990, P NATL ACAD SCI USA, V87, P3244, DOI 10.1073/pnas.87.8.3244; GALLUCCI E, 1971, ARCH INT PHYS BIOCH, V79, P881, DOI 10.3109/13813457109104847; GORIN MB, 1984, CELL, V39, P49, DOI 10.1016/0092-8674(84)90190-9; HARRIS HW, 1991, J CLIN INVEST, V91, P1; HASEGAWA H, 1992, IN PRESS PED PULMON; KLAUSNER RD, 1984, METHOD ENZYMOL, V104, P340; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVY D, 1990, BIOCHIM BIOPHYS ACTA, V1025, P179, DOI 10.1016/0005-2736(90)90096-7; MACEY RI, 1984, AM J PHYSIOL, V246, pC195, DOI 10.1152/ajpcell.1984.246.3.C195; PAO GM, 1991, MOL MICROBIOL, V5, P33, DOI 10.1111/j.1365-2958.1991.tb01823.x; PRESTON BM, 1992, SCIENCE, V256, P385; PRESTON GM, 1991, P NATL ACAD SCI USA, V88, P11110, DOI 10.1073/pnas.88.24.11110; ROSENBERG PA, 1978, J GEN PHYSIOL, V72, P341, DOI 10.1085/jgp.72.3.341; SMITH BL, 1991, J BIOL CHEM, V266, P6407; VANHOEK AN, 1990, BIOCHIM BIOPHYS ACTA, V1030, P203, DOI 10.1016/0005-2736(90)90296-Z; VANHOEK AN, 1991, J BIOL CHEM, V266, P16633; VANHOEK AN, 1992, BIOCHEM BIOPH RES CO, V184, P1331, DOI 10.1016/S0006-291X(05)80028-2; VERKMAN AS, 1989, AM J PHYSIOL, V257, pC837, DOI 10.1152/ajpcell.1989.257.5.C837; VERKMAN AS, 1992, ANNU REV PHYSIOL, V54, P97, DOI 10.1146/annurev.physiol.54.1.97; VERKMAN AS, 1988, NATURE, V333, P268, DOI 10.1038/333268a0; VERKMAN AS, 1989, J BIOL CHEM, V264, P20608; ZEIDEL ML, 1992, BIOCHEMISTRY-US, V31, P589, DOI 10.1021/bi00117a041; ZHANG R, 1990, J BIOL CHEM, V265, P15375; ZHANG R, 1991, J CLIN INVEST, V88, P1553, DOI 10.1172/JCI115466	28	194	196	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1992	267	26					18267	18269						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JN502	1526967				2022-12-25	WOS:A1992JN50200005
J	CENTRA, M; RATYCH, RE; CAO, GL; LI, J; WILLIAMS, E; TAYLOR, RM; ROSEN, GM				CENTRA, M; RATYCH, RE; CAO, GL; LI, J; WILLIAMS, E; TAYLOR, RM; ROSEN, GM			CULTURE OF BOVINE PULMONARY-ARTERY ENDOTHELIAL-CELLS ON GELFOAM BLOCKS	FASEB JOURNAL			English	Article						ENDOTHELIAL CELLS; GELFOAM	DIFFERENTIATION	Conventional methods of endothelial cell culture on monolayers and beads require enzymatic digestion, traumatic scraping, or centrifugation to transfer cells to other experimental systems. Gelfoam, a porous gelatin block, not only supports the growth of bovine pulmonary artery endothelial cells but also allows the rapid transfer of cell-laden blocks from one experimental system to another with minimal intervention. This property has been shown to be especially useful for the rapid fixation of endothelial cells for microscopy using standard histologic methods. Histology confirmed that the trabecular nature of the substrate allows endothelial cells to line the interstices of the sponge matrix and grow in a configuration that simulates the appearance of the endothelium in small vessels and capillaries. The inoculation of 1 x 10(5) endothelial cells on 7.5 mg Gelfoam (24 x 8 x 2 mm blocks) was enhanced by fibroblast growth factor and resulted in cell attachment by day 2 with a cell doubling time of 1.7 days. In addition, endothelial cells completely infiltrated 1, 5 and 7.5 mg Gelfoam blocks, as verified by histology. Assays to quantify cell number and protein were easily performed. To facilitate cell counting, the Gelfoam matrix was rapidly removed by the addition of 0.05 mg/ml collagenase, a concentration that interfered minimally with the assay for cellular protein concentration. The data demonstrate that Gelfoam is a suitable support growth matrix for the in vitro culture of bovine pulmonary artery endothelial cells.	UNIV MARYLAND, SCH PHARM, DEPT PHARMACOL & TOXICOL, BALTIMORE, MD 21201 USA; JOHNS HOPKINS MED INST, DEPT SURG, BALTIMORE, MD 21205 USA; JOHNS HOPKINS MED INST, DEPT PATHOL & DERMATOL, BALTIMORE, MD 21205 USA	University System of Maryland; University of Maryland Baltimore; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine					NHLBI NIH HHS [HL-33550] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL033550] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARNOLD JR, 1986, J ULTRA MOL STRUCT R, V94, P30, DOI 10.1016/0889-1605(86)90049-2; BOOYSE FM, 1975, THROMB DIATH HAEMOST, V34, P825, DOI 10.1055/s-0038-1654001; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; FOLKMAN J, 1979, P NATL ACAD SCI USA, V76, P5217, DOI 10.1073/pnas.76.10.5217; GRANT DS, 1989, CELL, V58, P933, DOI 10.1016/0092-8674(89)90945-8; HOGAN ME, 1989, AM J ANAT, V185, P296, DOI 10.1002/aja.1001850222; INGBER DE, 1989, CELL, V58, P803, DOI 10.1016/0092-8674(89)90928-8; JAFFE EA, 1973, J CLIN INVEST, V52, P2757, DOI 10.1172/JCI107471; KLEINSOYER C, 1989, BIOMATERIALS, V10, P85, DOI 10.1016/0142-9612(89)90036-7; LAWLEY TJ, 1989, J INVEST DERMATOL, V93, pS59, DOI 10.1111/1523-1747.ep12581070; LUNA LG, 1968, MANUAL HISTOLOGIC ST, P00012; MADRI JA, 1983, J CELL BIOL, V97, P153, DOI 10.1083/jcb.97.1.153; RADOMSKI JS, 1987, J SURG RES, V42, P133, DOI 10.1016/0022-4804(87)90110-7; RYAN US, 1980, TISSUE CELL, V12, P619, DOI 10.1016/0040-8166(80)90017-8; RYAN US, 1978, TISSUE CELL, V10, P535, DOI 10.1016/S0040-8166(16)30347-0; SCHOR SL, 1979, J CELL SCI, V38, P267; SOROUR O, 1975, J NEUROSURG, V43, P742, DOI 10.3171/jns.1975.43.6.0742; THOMPSON JA, 1988, SCIENCE, V241, P1349, DOI 10.1126/science.2457952	18	35	40	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	1992	6	12					3117	3121		10.1096/fasebj.6.12.1521742	http://dx.doi.org/10.1096/fasebj.6.12.1521742			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	JN505	1521742				2022-12-25	WOS:A1992JN50500014
J	FEINSTEIN, E; GALE, RP; REED, J; CANAANI, E				FEINSTEIN, E; GALE, RP; REED, J; CANAANI, E			EXPRESSION OF THE NORMAL P53 GENE INDUCES DIFFERENTIATION OF K562 CELLS	ONCOGENE			English	Article							CHRONIC MYELOGENOUS LEUKEMIA; WILD-TYPE P53; CYCLE CONTROL; LINE; GROWTH; SUPPRESSION; MECHANISMS; PROTEIN	The multistep nature of human cancers is well illustrated by chronic myelogenous leukemia (CML), a clonal hematologic malignancy with two distinct phases: chronic and acute. Transition between these phases is characterized by unregulated growth and loss of differentiation of myeloid cells and their progenitors. We recently reported that loss of normal p53 expression correlates with transition from the chronic to acute phase in at least 25% of cases of CML. However, the precise relationship between this loss and biologic features of acute-phase CMI, is uncertain. To study this question, we artificially expressed normal p53 in K562, an erythroid acute-phase CML cell line lacking normal p53 expression. Biological effects were assessed by determining several growth parameters and by measuring synthesis of hemoglobin, a feature of mature erythroid cells. K562 cells expressing normal p53 had an increased proportion of cells in G1 versus S + G2, a longer doubling time and a lower growth saturation density than control K562 cells or K562 cells with antisense p53. Cells with normal p53 also expressed up to 50-fold more hemoglobin than controls. These data are consistent with the notion that loss of p53 expression may be responsible for many of the features of acute-phase CML cells. The data also demonstrate direct involvement of p53 in differentiation processes.	WEIZMANN INST SCI,DEPT CHEM IMMUNOL,IL-76100 REHOVOT,ISRAEL; UNIV CALIF LOS ANGELES,CTR HLTH SCI,DEPT MED,LOS ANGELES,CA 90024; UNIV PENN,DEPT PATHOL,PHILADELPHIA,PA 19103; THOMAS JEFFERSON UNIV,JEFFERSON CANC INST,DEPT MICROBIOL,PHILADELPHIA,PA 19107	Weizmann Institute of Science; University of California System; University of California Los Angeles; University of Pennsylvania; Jefferson University								ARLINGHAUS RB, 1991, MOL APPROACHES STUDY; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766; CHAMPLIN RE, 1985, BLOOD, V65, P1039; CHEN PL, 1990, SCIENCE, V250, P1576, DOI 10.1126/science.2274789; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; EISBRUCH A, 1988, CANCER-AM CANCER SOC, V62, P1171, DOI 10.1002/1097-0142(19880915)62:6<1171::AID-CNCR2820620621>3.0.CO;2-8; FEINSTEIN E, 1991, P NATL ACAD SCI USA, V88, P6293, DOI 10.1073/pnas.88.14.6293; FEINSTEIN E, 1987, NATURE, V330, P386; GREAVES DR, 1989, CELL, V56, P979, DOI 10.1016/0092-8674(89)90631-4; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LOZZIO CB, 1975, BLOOD, V45, P321, DOI 10.1182/blood.V45.3.321.321; LUBBERT M, 1988, J EXP MED, V167, P873, DOI 10.1084/jem.167.3.873; LUFTIG RB, 1977, J VIROL, V23, P799, DOI 10.1128/JVI.23.3.799-810.1977; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; Milner J, 1991, CURR OPIN CELL BIOL, V3, P282, DOI 10.1016/0955-0674(91)90153-P; NOWELL PC, 1960, JNCI-J NATL CANCER I, V25, P85; REED JC, 1989, ONCOGENE, V4, P1123; RICHARDSON JM, 1987, CANCER RES, V47, P4066; ROWLEY JD, 1973, NATURE, V243, P290, DOI 10.1038/243290a0; SHAULSKY G, 1991, P NATL ACAD SCI USA, V88, P8982, DOI 10.1073/pnas.88.20.8982; STURZBECHER HW, 1990, ONCOGENE, V5, P795; SUGDEN B, 1985, MOL CELL BIOL, V5, P410, DOI 10.1128/MCB.5.2.410	24	118	123	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1992	7	9					1853	1857						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JJ376	1501893				2022-12-25	WOS:A1992JJ37600022
J	BOYER, SK; SHOTWELL, MA; LARKINS, BA				BOYER, SK; SHOTWELL, MA; LARKINS, BA			EVIDENCE FOR THE TRANSLATIONAL CONTROL OF STORAGE PROTEIN GENE-EXPRESSION IN OAT SEEDS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER-RNA; ESCHERICHIA-COLI; MESSENGER-RNAS; EUKARYOTIC RIBOSOMES; HEMOGLOBIN-SYNTHESIS; CODON USAGE; SEQUENCE; GLOBULIN; AVENIN; LOCALIZATION	We employed a rapid fractionation method coupled with a sensitive enzyme-linked immunosorbent assay to quantify the globulins and avenins in developing and mature oat seeds. On a molar basis, there is approximately 10-11 times as much globulin as avenin. Pulse labeling of endosperm proteins indicated that the rate of globulin synthesis is approximately nine times that of avenin. In addition, neither protein class showed any signs of degradation during this experiment. Analysis of the storage protein mRNAs indicates that both globulin and avenin transcripts are associated with membrane-bound polysomes and are found in similar concentrations within the membrane-bound polysome fraction. We found that avenin and globulin mRNAs are fully loaded with ribosomes, suggesting that initiation is not rate-limiting for translation of either protein. Rates of globulin and avenin synthesis were similar when synthetic storage protein mRNAs were translated in vitro. Translation of equimolar amounts of globulin and avenin mRNAs in the same reaction showed equivalent amounts of protein synthesized when compared with globulin and avenin mRNAs translated in separate reaction mixes. We propose that translation elongation or termination reactions are likely regulatory steps for controlling storage protein synthesis in oat endosperm.	UNIV ARIZONA,DEPT PLANT SCI,TUCSON,AZ 85721	University of Arizona								ANGENON G, 1990, FEBS LETT, V271, P144, DOI 10.1016/0014-5793(90)80392-V; AOTA S, 1986, NUCLEIC ACIDS RES, V14, P6345, DOI 10.1093/nar/14.16.6345; BARKER SJ, 1988, P NATL ACAD SCI USA, V85, P458, DOI 10.1073/pnas.85.2.458; BENICOURT C, 1976, J VIROL, V20, P196, DOI 10.1128/JVI.20.1.196-202.1976; BENNETZEN JL, 1982, J BIOL CHEM, V257, P3026; BERGMANN JE, 1979, J BIOL CHEM, V254, P1927; BONEKAMP F, 1989, J BACTERIOL, V171, P5812, DOI 10.1128/jb.171.11.5812-5816.1989; BRINEGAR AC, 1982, ARCH BIOCHEM BIOPHYS, V219, P71, DOI 10.1016/0003-9861(82)90135-7; CASKEY CT, 1980, TRENDS BIOCHEM SCI, V5, P234, DOI 10.1016/S0968-0004(80)80809-7; CHAVANCY G, 1981, BIOCHIMIE, V63, P187, DOI 10.1016/S0300-9084(81)80192-7; CHESNUT RS, 1989, PLANT CELL, V1, P913, DOI 10.1105/tpc.1.9.913; COLYER TE, 1984, PLANT PHYSIOL, V74, P455, DOI 10.1104/pp.74.2.455; de Boer HA., 1986, MAXIMIZING GENE EXPR, P225; GALILI G, 1988, J BIOL CHEM, V263, P5764; GROSJEAN H, 1982, GENE, V18, P199, DOI 10.1016/0378-1119(82)90157-3; IKEMURA T, 1981, J MOL BIOL, V146, P1, DOI 10.1016/0022-2836(81)90363-6; KIM SI, 1978, BIOCHIM BIOPHYS ACTA, V537, P22, DOI 10.1016/0005-2795(78)90599-8; KNECHT DA, 1984, ANAL BIOCHEM, V136, P180, DOI 10.1016/0003-2697(84)90321-X; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; KOZAK M, 1990, P NATL ACAD SCI USA, V87, P8301, DOI 10.1073/pnas.87.21.8301; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; LABUDA D, 1984, J MOL BIOL, V174, P587, DOI 10.1016/0022-2836(84)90085-8; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARKINS BA, 1978, PLANT PHYSIOL, V62, P256, DOI 10.1104/pp.62.2.256; LARKINS BA, 1985, MOD METHOD PLANT, V1, P331; LAZ T, 1987, TRANSLATIONAL REGULA, P413; LENDING CR, 1989, PLANTA, V178, P315, DOI 10.1007/BF00391859; LUTCKE HA, 1987, EMBO J, V6, P43, DOI 10.1002/j.1460-2075.1987.tb04716.x; LUTHE DS, 1983, PLANT PHYSIOL, V84, P337; PETERSON DM, 1976, CROP SCI, V16, P67, DOI 10.2135/cropsci1976.0011183X001600010017x; PETERSON DM, 1976, CROP SCI, V16, P663, DOI 10.2135/cropsci1976.0011183X001600050016x; POST LE, 1979, P NATL ACAD SCI USA, V76, P1697, DOI 10.1073/pnas.76.4.1697; SHARP PM, 1989, NUCLEIC ACIDS RES, V17, P5029, DOI 10.1093/nar/17.13.5029; SHOTWELL MA, 1990, J BIOL CHEM, V265, P9652; SMITH DWE, 1975, SCIENCE, V190, P529, DOI 10.1126/science.1103288; THOMAS LK, 1988, P NATL ACAD SCI USA, V85, P4242, DOI 10.1073/pnas.85.12.4242; VERMA DPS, 1976, P NATL ACAD SCI USA, V73, P3843, DOI 10.1073/pnas.73.11.3843; WALLACE JC, 1990, PLANT PHYSIOL, V265, P9652; WALLBURG G, 1983, PLANT PHYSIOL, V72, P161; ZHAO WM, 1983, FEBS LETT, V162, P96, DOI 10.1016/0014-5793(83)81056-4	40	13	13	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1992	267	24					17449	17457						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JL053	1512276				2022-12-25	WOS:A1992JL05300107
J	WEBER, DJ; BERKOWITZ, P; PANEK, MG; HUH, NW; PEDERSEN, LG; HISKEY, RG				WEBER, DJ; BERKOWITZ, P; PANEK, MG; HUH, NW; PEDERSEN, LG; HISKEY, RG			MODIFICATIONS OF BOVINE PROTHROMBIN FRAGMENT-1 IN THE PRESENCE AND ABSENCE OF CA(II) IONS - LOSS OF POSITIVE COOPERATIVITY IN CA(II) ION BINDING FOR THE MODIFIED PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-CARBOXYGLUTAMIC ACID; K-DEPENDENT PROTEINS; VITAMIN-K; MEMBRANE-BINDING; PHOSPHOLIPID-VESICLES; FUNCTIONAL-PROPERTIES; BLOOD-COAGULATION; CALCIUM-BINDING; RESIDUES 1-45; METAL-IONS	Chemical modification of bovine prothrombin fragment 1 according to the procedure of D. J. Welsch and G. L. Nelsestuen (1988) [Biochemistry 27, 4946-4952 and earlier papers] provided a series of fragment 1 derivatives in which various nitrogen-containing side chains were N-acetylated and/or N-2,4,6-trinitrophenylated. In addition the des-[Ala-1,Asn-2]- and des-[Ala-1,Asn-2,Lys-3]-fragment 1 derivatives were prepared by limited enzymatic hydrolysis of fragment 1 using cathepsin C and plasmin, respectively. Quantitative studies on the Ca(II) binding of these proteins have been accomplished using Ca-45(II) equilibrium dialysis. Binding of these fragment 1 derivatives to phosphatidylserine/phosphatidylcholine (PS/PC) vesicles (25:75) in the presence of Ca(II) ions has been studied using the light-scattering technique. Acylation of the 5 lysine residues of fragment 1 by the action of acetic anhydride (500-fold molar excess) in the presence of 75 mM Ca(II), pH 8.0, results in loss of positive cooperativity in Ca(II) binding (Scatchard plot) and an increase in the number of Ca(II) ions bound. The Ca(II)-dependent PS/PC binding of the acylated protein is reduced. Removal of 2 and 3 residues from the amino terminus likewise leads to loss of positive cooperativity in Ca(II) binding and reduced binding affinity to PS/PC vesicles. The important role of the amino-terminal 1-10 sequence is discussed. We conclude that positive cooperativity in Ca(II) binding is not a prerequisite for the Ca(II)-dependent binding of bovine prothrombin fragment 1 to PS/PC vesicles.			WEBER, DJ (corresponding author), UNIV N CAROLINA, DEPT CHEM, CHAPEL HILL, NC 27599 USA.		Pedersen, Lee G/E-3405-2013; Weber, David J/B-5349-2011	Pedersen, Lee G/0000-0003-1262-9861; Weber, David J/0000-0002-8824-1110	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL020161, R01HL020161, R01HL027995] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-27995, HL-06350, HL-20161] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BARENHOLZ Y, 1977, BIOCHEMISTRY-US, V16, P2806, DOI 10.1021/bi00631a035; BERKOWITZ P, 1992, J BIOL CHEM, V267, P4570; CHURCH WR, 1988, J BIOL CHEM, V263, P6259; CHURCH WR, 1989, J BIOL CHEM, V264, P17882; DEERFIELD DW, 1986, J BIOL CHEM, V261, P4833; DEERFIELD DW, 1987, J BIOL CHEM, V262, P4017; ESMON CT, 1987, SCIENCE, V235, P1348, DOI 10.1126/science.3029867; Fields R, 1972, Methods Enzymol, V25, P464, DOI 10.1016/S0076-6879(72)25042-X; FURIE BC, 1984, CALCIUM CELL FUNCTIO, V2; GRANT RB, 1959, J BIOL CHEM, V234, P466; HODGSON DJ, 1990, INORG CHEM, V29, P3612, DOI 10.1021/ic00343a059; HUANG CH, 1969, BIOCHEMISTRY-US, V8, P344, DOI 10.1021/bi00829a048; Mann K G, 1976, Methods Enzymol, V45, P123; MYCEK MK, 1970, METHOD ENZYMOL, V28, P285; NELSESTUEN GL, 1977, BIOCHEMISTRY-US, V16, P4164, DOI 10.1021/bi00638a005; NELSESTUEN GL, 1984, MET IONS BIOL SYST, V17, P353; NESHEIM ME, 1984, J BIOL CHEM, V259, P1447; PAPAHADJOPOULOS D, 1964, BIOCHIM BIOPHYS ACTA, V90, P436, DOI 10.1016/0304-4165(64)90220-X; POLLOCK JS, 1988, J BIOL CHEM, V263, P14216; POLLOCK JS, 1988, CURRENT ADV VITAMIN, P325; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCHWALBE RA, 1989, J BIOL CHEM, V264, P20288; STAROS JV, 1982, BIOCHEMISTRY-US, V21, P3950, DOI 10.1021/bi00260a008; SUTTIE JW, 1980, FED PROC, V39, P2730; SUTTIE JW, 1977, PHYSIOL REV, V57, P1, DOI 10.1152/physrev.1977.57.1.1; SUTTIE JW, 1980, CRC CR REV BIOCH MOL, V8, P191, DOI 10.3109/10409238009105469; WALKER FJ, 1986, BIOCHEMISTRY-US, V25, P6305, DOI 10.1021/bi00368a071; WALKER FJ, 1981, J BIOL CHEM, V256, P1128; WEBER DJ, 1988, BIOCHEM BIOPH RES CO, V155, P230, DOI 10.1016/S0006-291X(88)81073-8; WELSCH DJ, 1988, BIOCHEMISTRY-US, V27, P4946, DOI 10.1021/bi00413a053; WELSCH DJ, 1988, BIOCHEMISTRY-US, V27, P4939, DOI 10.1021/bi00413a052; WELSCH DJ, 1988, BIOCHEMISTRY-US, V27, P4933, DOI 10.1021/bi00413a051; WELSCH DJ, 1988, BIOCHEMISTRY-US, V27, P7513, DOI 10.1021/bi00419a050; WELSCH DJ, 1988, CURRENT ADV VITAMIN, P371; YOKOMORI Y, 1988, INORG CHEM, V27, P2300, DOI 10.1021/ic00286a017; ZAPATA GA, 1988, J BIOL CHEM, V263, P8150; ZELL A, 1985, BIOCHEMISTRY-US, V24, P533, DOI 10.1021/bi00323a043	37	14	27	0	2	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	1992	267	7					4564	4569						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HF642	1531656				2022-12-25	WOS:A1992HF64200045
J	ANDERSEN, JP; VILSEN, B; MACLENNAN, DH				ANDERSEN, JP; VILSEN, B; MACLENNAN, DH			FUNCTIONAL CONSEQUENCES OF ALTERATIONS TO GLY310, GLY770, AND GLY801 LOCATED IN THE TRANSMEMBRANE DOMAIN OF THE CA2+-ATPASE OF SARCOPLASMIC-RETICULUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; ADENOSINE-TRIPHOSPHATASE; CONFORMATIONAL CHANGE; INORGANIC-PHOSPHATE; NUCLEOTIDE-BINDING; CALCIUM-TRANSPORT; COMPLEMENTARY-DNA; MOLECULAR-CLONING; CA-2+-ATPASE; ATPASE	Site-specific mutagenesis was used to replace Gly310, Gly770, and Gly801, located in the transmembrane domain of the sarcoplasmic reticulum Ca2+-ATPase, with either alanine or valine. In addition, Gly310 was substituted with proline. In the Gly310 --> Ala mutant, the V(max) for Ca2+ transport and ATPase activity was reduced to about 40% of the wild type activity, but the apparent Ca2+ affinity was close to normal. The Gly310 --> Val and Gly310 --> Pro mutants were devoid of Ca2+ transport or ATPase activity and displayed more than a 20-fold reduction in the apparent Ca2+ affinities measured in the phosphorylation assays with either ATP or P(i). In these mutants, the rate of phosphoenzyme hydrolysis was reduced, and the ADP-insensitive phosphoenzyme intermediate accumulated. The apparent affinity for P(i) was increased in the absence, but not in the presence, of dimethyl sulfoxide. The properties of this new class of Ca2+-ATPase mutants ("E2/E2P" type) are consistent with a conformational state in which the protein-phosphate interaction is stabilized and the Ca2+-protein interaction is destabilized. The Gly770 --> Ala mutant transported Ca2+ with a V(max) close to that of the wild type, but displayed more than a 20-fold reduction of apparent Ca2+ affinity. The Gly770 --> Val mutant was not phosphorylated from either ATP or P(i). The Gly801 --> Ala mutant transported Ca2+ with a V(max) of 126% that of the wild type, hydrolyzed ATP at the same V(max) as the wild type in the presence of calcium ionophore, and displayed a 3-fold reduction in apparent Ca2+ affinity. The Gly801 --> Val mutant was unable to transport Ca2+ and to be phosphorylated from ATP, even at a Ca2+ concentration of 1 mM, but Ca2+ in the micromolar range inhibited phosphorylation from P(i). The ability to bind ATP with normal affinity was retained. The properties of this mutant are consistent with a disruption of one of the two Ca2+ binding sites required for phosphorylation with ATP.	UNIV TORONTO,CHARLES H BEST INST,BANTING & BEST DEPT MED RES,TORONTO M5G 1L6,ONTARIO,CANADA	University of Toronto	ANDERSEN, JP (corresponding author), AARHUS UNIV,INST FRAUENKLIN,DANISH BIOMEMBRANE RES CTR,DK-8000 AARHUS,DENMARK.			Vilsen, Bente/0000-0002-4727-9382; Andersen, Jens Peter/0000-0003-0654-4300				ANDERSEN JP, 1989, J BIOL CHEM, V264, P21018; ANDERSEN JP, 1989, BIOCH BIOPHYS ACTA; ANDERSEN JP, P NATL ACAD SCI USA, V82, P4573; BRANDL CJ, 1986, CELL, V44, P597, DOI 10.1016/0092-8674(86)90269-2; CHAMPEIL P, 1985, BIOCHEMISTRY-US, V24, P69, DOI 10.1021/bi00322a012; CLARKE DM, 1990, J BIOL CHEM, V265, P6262; CLARKE DM, 1989, J BIOL CHEM, V264, P11246; CLARKE DM, 1989, NATURE, V339, P476, DOI 10.1038/339476a0; CLARKE DM, 1990, J BIOL CHEM, V265, P22223; CLARKE DM, 1990, J BIOL CHEM, V265, P14088; DEMEIS L, 1985, BIOCHEMISTRY-US, V24, P922, DOI 10.1021/bi00325a017; DEMEIS L, 1991, J BIOL CHEM, V266, P5736; DEMEIS L, 1981, SARCOPLASMIC RETICUL, V2; DUPONT Y, 1980, EUR J BIOCHEM, V109, P231, DOI 10.1111/j.1432-1033.1980.tb04788.x; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; HASSELBACH W, 1983, Z NATURFORSCH C, V38, P1015; INESI G, 1985, ANNU REV PHYSIOL, V47, P573, DOI 10.1146/annurev.ph.47.030185.003041; KAUFMAN RJ, 1989, MOL CELL BIOL, V9, P946, DOI 10.1128/MCB.9.3.946; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MACLENNAN DH, 1990, BIOPHYS J, V58, P1355, DOI 10.1016/S0006-3495(90)82482-6; MACLENNAN DH, 1985, NATURE, V316, P696, DOI 10.1038/316696a0; MARUYAMA K, 1988, P NATL ACAD SCI USA, V85, P3314, DOI 10.1073/pnas.85.10.3314; MARUYAMA K, 1989, J BIOL CHEM, V264, P13038; MOLLER JV, 1980, J BIOL CHEM, V255, P1912; PETITHORY JR, 1986, BIOCHEMISTRY-US, V25, P4493, DOI 10.1021/bi00364a006; PETITHORY JR, 1988, BIOCHEMISTRY-US, V27, P5553, DOI 10.1021/bi00415a025; ROSS DC, 1987, J BIOL CHEM, V262, P12977; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SERRANO R, 1986, NATURE, V319, P689, DOI 10.1038/319689a0; SHULL GE, 1988, J BIOL CHEM, V263, P8646; SHULL GE, 1986, J BIOL CHEM, V261, P6788; SHULL GE, 1985, NATURE, V316, P691, DOI 10.1038/316691a0; SUZUKI H, 1987, J BIOL CHEM, V262, P15448; VILSEN B, 1991, J BIOL CHEM, V266, P16157; VILSEN B, 1991, J BIOL CHEM, V266, P18839; VILSEN B, 1989, J BIOL CHEM, V264, P21024; ZUBRZYCKAGAARN E, 1984, J BIOENERG BIOMEMBR, V16, P441, DOI 10.1007/BF00743238	38	55	55	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1992	267	4					2767	2774						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HB532	1531144				2022-12-25	WOS:A1992HB53200098
J	HAMILTON, DS; CREIGHTON, DJ				HAMILTON, DS; CREIGHTON, DJ			INHIBITION OF GLYOXALASE I BY THE ENEDIOL MIMIC S-(N-HYDROXY-N-METHYLCARBAMOYL)GLUTATHIONE - THE POSSIBLE BASIS OF A TUMOR-SELECTIVE ANTICANCER STRATEGY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							TRIOSEPHOSPHATE ISOMERASE; GLUTATHIONE DERIVATIVES; PATHWAY; PROBE	In principle, competitive inhibitors of glyoxalase I that also serve as substrates for the thioester hydrolase glyoxalase II might function as tumor-selective anti-cancer agents, given the role of these enzymes in removing cytotoxic methylglyoxal from cells and the observation that glyoxalase II activity is abnormally low in some types of cancer cells. In support of the feasibility of this anticancer strategy, an inhibitor of this type has been synthesized by a thioester-interchange reaction between glutathione and N-hydroxy-N-methylcarbamate 4-chlorophenyl ester to give S-(N-hydroxy-N-methylcarbamoyl) glutathione (1). This compound was designed to be a tight-binding inhibitor of glyoxalase I, on the basis of its stereoelectronic similarity to the enediol(ate) intermediate that forms along the reaction pathway of this enzyme. Indeed, 1 is a competitive inhibitor of yeast glyoxalase I, with an inhibition constant (K(i) = 68 muM) that is approximately 30-fold lower than that reported for S-D-lactoylglutathione and approximately 7-fold lower than the K(m) for glutathione-methylglyoxal thiohemiacetal. In addition, 1 is a substrate for bovine liver glyoxalase II, with a K(m) (0.48 mm) approximately equal to that of the normal substrate S-D-lactoylglutathione and a k(cat) approximately 2 x 10(-5)-fold that of the normal substrate. Membrane transport studies show that 1 can be delivered into human erythrocytes (used here as a model cell) either by direct diffusion of 1 across the cell membrane or by more rapid diffusion of the glycylethyl ester of 1 across the cell membrane, followed by the catalyzed hydrolysis of the ester to give 1.	UNIV MARYLAND,DEPT CHEM & BIOCHEM,CHEM DYNAM LAB,CATONSVILLE,MD 21228									ALTIMARI A, 1986, BIOCHIM BIOPHYS ACTA, V870, P160, DOI 10.1016/0167-4838(86)90020-8; ALTIMARI A, 1986, BIOCHIM BIOPHYS ACTA, V870, P219, DOI 10.1016/0167-4838(86)90225-6; ANDERSON ME, 1989, ANAL BIOCHEM, V183, P16, DOI 10.1016/0003-2697(89)90164-4; ANDERSON ME, 1985, ARCH BIOCHEM BIOPHYS, V239, P538, DOI 10.1016/0003-9861(85)90723-4; ANDERSON ME, 1985, METHOD ENZYMOL, V113, P548; CREIGHTON DJ, 1988, BIOCHEMISTRY-US, V27, P7376, DOI 10.1021/bi00419a031; CREIGHTON DJ, 1988, MOL STRUCTURE ENERGE, V9, P353; GROBNER P, 1974, EUR J MED CHEM, V9, P341; HAMILTON DS, 1992, BIOCHIM BIOPHYS ACTA, V1159, P203, DOI 10.1016/0167-4838(92)90026-A; JERZYKOWSKI T, 1978, INT J BIOCHEM, V9, P853, DOI 10.1016/0020-711X(78)90036-8; JERZYKOWSKI T, 1975, EXPERIENTIA, V31, P32, DOI 10.1007/BF01924663; KELLUM MW, 1978, ANAL BIOCHEM, V85, P586, DOI 10.1016/0003-2697(78)90258-0; MURPHY CM, 1991, 39TH P ASMS C MASS S, P1681; PENNINCKX MJ, 1983, J BIOL CHEM, V258, P6030; POMPLIANO DL, 1990, BIOCHEMISTRY-US, V29, P3186, DOI 10.1021/bi00465a005; Rabenstein D.L., 1989, COENZYMES COFACTORS, V3, P67; RICHARD JP, 1991, BIOCHEMISTRY-US, V30, P4581, DOI 10.1021/bi00232a031; THORNALLEY PJ, 1990, BIOCHEM J, V269, P1; VINCE R, 1969, BIOCHEM BIOPH RES CO, V35, P593, DOI 10.1016/0006-291X(69)90445-8; VINCE R, 1971, J MED CHEM, V14, P35, DOI 10.1021/jm00283a009; WOLFENDEN R, 1972, ACCOUNTS CHEM RES, V5, P10, DOI 10.1021/ar50049a002	21	58	60	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1992	267	35					24933	24936						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KB603	1459997				2022-12-25	WOS:A1992KB60300006
J	ROTHMAN, BS; DEKRUYFF, S; TALEBIAN, M; MENON, JG; SQUIRE, CR; YEH, CH; LEE, TD				ROTHMAN, BS; DEKRUYFF, S; TALEBIAN, M; MENON, JG; SQUIRE, CR; YEH, CH; LEE, TD			APLYSIA PEPTIDE NEUROTRANSMITTERS BETA-BAG CELL PEPTIDE, PHE-MET-ARG-PHE-AMIDE, AND SMALL CARDIOEXCITATORY PEPTIDE-B ARE RAPIDLY DEGRADED BY A LEUCINE AMINOPEPTIDASE-LIKE ACTIVITY IN HEMOLYMPH	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNOCYTOLOGICAL LOCALIZATION; CARDIOACTIVE PEPTIDE; SINGLE GENE; NEUROPEPTIDES; NEURONS; INHIBITOR; FMRFAMIDE; SCPA; CALIFORNICA; SYSTEM	We have been investigating the role of proteolytic enzymes in the inactivation of peptide neurotransmitters in the marine snail Aplysia. Previous studies (Squire, C. R., Talebian, M., Menon, J. G., Dekruyff, S. D., Lee, T. D., Shively, J. E., and Rothman, B. S. (1991) J. Biol. Chem. 266, 22355-22363) showed that neuroactive fragments of the neurotransmitter alpha-bag cell peptide (alpha-BCP) were rapidly degraded (t1/2 = 0.5-2.7 min) in plasma, hemolymph that had been cleared by centrifugation. Degradation was caused by one or more enzymes resembling mammalian leucine aminopeptidase (LAP, EC 3.4.11.1). In this report we show that three other Aplysia peptide neurotransmitters, beta-BCP(1-5) (Arg-Leu-Arg-Phe-His), FMRFa (Phe-Met-Arg-Phe-amide), and SCP(B)(1-9) (Met-Asn-Tyr-Leu-Ala-Phe-Pro-Arg-Met-amide) are rapidly degraded (t1/2 = 0.3-2.4 min) in plasma by apparently the same LAP-like enzyme(s). Our findings strongly suggest that the LAP-like enzyme(s), by means of its broad substrate specificity and access to the extracellular spaces of the nervous system in vivo, plays a significant role in the inactivation of many Aplysia peptide neurotransmitters, and they raise the possibility that proteolytic enzymes in the extracellular fluid contribute significantly to the inactivation of peptide neurotransmitters in other animal species.	CITY HOPE NATL MED CTR, BECKMAN RES INT, DUARTE, CA 91010 USA	City of Hope; Beckman Research Institute of City of Hope	ROTHMAN, BS (corresponding author), SAN FRANCISCO STATE UNIV, DEPT BIOL, SAN FRANCISCO, CA 94132 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK033155] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS024046, K04NS001177] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-33155] Funding Source: Medline; NINDS NIH HHS [NS-01177, NS-24046] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AOYAGI T, 1978, J ANTIBIOT, V31, P636, DOI 10.7164/antibiotics.31.636; BROWN R O, 1984, Society for Neuroscience Abstracts, V10, P691; BROWN RO, 1989, J NEUROSCI, V9, P1443; COGGESHALL RE, 1967, J NEUROPHYSIOL, V30, P1263, DOI 10.1152/jn.1967.30.6.1263; ELLIS S, 1964, BIOCHEM BIOPH RES CO, V16, P502; GREENBERG MJ, 1983, FED PROC, V42, P82; LLOYD PE, 1985, J NEUROSCI, V5, P1851; LLOYD PE, 1987, J NEUROSCI, V7, P1123; LLOYD PE, 1988, J NEUROPHYSIOL, V59, P1613, DOI 10.1152/jn.1988.59.5.1613; LLOYD PE, 1985, J COMP PHYSIOL A, V156, P659, DOI 10.1007/BF00619115; MAHON AC, 1985, P NATL ACAD SCI USA, V82, P3925, DOI 10.1073/pnas.82.11.3925; MCDONALD JK, 1986, MAMMALIAN PROTEASES, V2; MENTLEIN R, 1988, FEBS LETT, V234, P251, DOI 10.1016/0014-5793(88)80092-9; MORRIS HR, 1982, NATURE, V300, P643, DOI 10.1038/300643a0; NEWCOMB R, 1988, J BIOL CHEM, V263, P12514; NEWCOMB R, 1987, J NEUROSCI, V7, P854; OWENS DF, 1992, J NEUROBIOL, V23, P656, DOI 10.1002/neu.480230605; PHARES G A, 1989, Society for Neuroscience Abstracts, V15, P665; PRICE DA, 1977, SCIENCE, V197, P670, DOI 10.1126/science.877582; REED W, 1988, J COMP NEUROL, V272, P358, DOI 10.1002/cne.902720306; ROEPSTORFF P, 1984, BIOMED MASS SPECTROM, V11, P601, DOI 10.1002/bms.1200111109; ROTHMAN B S, 1987, Society for Neuroscience Abstracts, V13, P39; ROTHMAN BS, 1983, P NATL ACAD SCI-BIOL, V80, P5753, DOI 10.1073/pnas.80.18.5753; ROTHMAN BS, 1985, GENE EXPRESSION BRAI, P235; ROTHMAN BS, 1992, T AM SOC NEUROCHEM, V23, P231; SCHAEFER M, 1985, CELL, V41, P457, DOI 10.1016/S0092-8674(85)80019-2; SCHELLER RH, 1983, CELL, V32, P7, DOI 10.1016/0092-8674(83)90492-0; SIGVARDT KA, 1986, J NEUROSCI, V6, P803; SQUIRE CR, 1991, J BIOL CHEM, V266, P22355; SQUIRE CR, 1990, THESIS SAN FRANCISCO; TERENIUS L, 1988, INT REV NEUROBIOL, V30, P101; UMEZAWA H, 1983, J ANTIBIOT, V36, P1572, DOI 10.7164/antibiotics.36.1572; UMEZAWA H, 1985, J ANTIBIOT, V38, P1629, DOI 10.7164/antibiotics.38.1629; UMEZAWA H, 1976, J ANTIBIOT, V29, P97, DOI 10.7164/antibiotics.29.97; UMEZAWA H, 1983, PROTEINASE INHIBITOR, P3	35	11	11	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	1992	267	35					25135	25140						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KB603	1460014				2022-12-25	WOS:A1992KB60300036
J	CHEN, Q; YU, K; STEVENS, JL				CHEN, Q; YU, K; STEVENS, JL			REGULATION OF THE CELLULAR STRESS RESPONSE BY REACTIVE ELECTROPHILES - THE ROLE OF COVALENT BINDING AND CELLULAR THIOLS IN TRANSCRIPTIONAL ACTIVATION OF THE 70-KILODALTON HEAT-SHOCK PROTEIN GENE BY NEPHROTOXIC CYSTEINE CONJUGATES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING; BETA-LYASE; OXIDATIVE STRESS; ADDUCT FORMATION; LLC-PK1 CELLS; INVITRO; HSP70; METABOLISM; TOXICITY; CALCIUM	The cytotoxicity of nephrotoxic cysteine conjugates (NCC) in the renal epithelial cell line, LLC-PK1, is due to the covalent binding of a reactive electrophilic metabolite produced from NCC metabolism by cysteine conjugate beta-lyase. Covalent binding of NCC-derived reactive metabolites leads to a cascade of events including depletion of cellular non-protein sulfhydryls, increased cytosolic free calcium, and lipid peroxidation, which is ultimately responsible for cell death. We have used this model to investigate the signalling mechanism(s) through which reactive electrophiles increase synthesis of the 70-kD heat shock protein (HSP70). NCC treatment resulted in increased HSP70 synthesis as well as time- and dose-dependent increases in hsp70 mRNA in LLC-PK1 cells. The induction of hsp70 mRNA was blocked by actinomycin D, and nuclear run-on experiments showed that the hsp70 gene was transcriptionally activated. Inhibition of protein synthesis did not block the increase in hsp70 mRNA or transcriptional activation of the hsp70 gene suggesting that induction occurs due to activation of existing transcription factors. Inhibiting the covalent binding with a beta-lyase inhibitor, aminooxyacetic acid, blocked the increase in hsp70 mRNA. Agents which do not alter binding but do prevent toxicity by blocking the rise in cytosolic free calcium and lipid peroxidation were not effective inhibitors of hsp70 mRNA accumulation. However, the thiol reducing agent, dithiothreitol, inhibited induction of hsp70 mRNA by NCC. The data suggest that covalent binding and alterations in cellular non-protein thiols serve as signals for activation of pre-existing transcription factors which increase hsp70 gene expression. It is proposed that reactive electrophiles may have a primary effect on protein conformation resulting in activation of the hsp70 gene.	W ALTON JONES CELL SCI CTR,LAKE PLACID,NY 12946						NATIONAL CANCER INSTITUTE [P01CA037589] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038925] Funding Source: NIH RePORTER; NCI NIH HHS [CA37589] Funding Source: Medline; NIDDK NIH HHS [DK38925] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; ABRAVAYA K, 1992, GENE DEV, V6, P1153, DOI 10.1101/gad.6.7.1153; AMIN J, 1988, MOL CELL BIOL, V8, P3761, DOI 10.1128/MCB.8.9.3761; ANANTHAN J, 1986, SCIENCE, V232, P522, DOI 10.1126/science.3083508; ANG D, 1991, J BIOL CHEM, V266, P24233; ANSUBEL FM, 1991, CURRENT PROTOCOLS MO; BANNISTER AJ, 1991, ONCOGENE, V6, P1243; CHEN Q, 1992, J BIOL CHEM, V267, P8207; CHEN Q, 1990, J BIOL CHEM, V265, P21603; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHRISTMAN MF, 1985, CELL, V41, P753, DOI 10.1016/S0092-8674(85)80056-8; CLOS J, 1990, CELL, V63, P1085, DOI 10.1016/0092-8674(90)90511-C; CRAIG EA, 1991, TRENDS BIOCHEM SCI, V16, P135, DOI 10.1016/0968-0004(91)90055-Z; DEKANT W, 1989, DRUG METAB REV, V20, P43, DOI 10.3109/03602538908994144; DIDOMENICO BJ, 1982, CELL, V31, P593, DOI 10.1016/0092-8674(82)90315-4; DRUMMOND IAS, 1986, MOL CELL BIOL, V6, P1767, DOI 10.1128/MCB.6.5.1767; ELLIS JR, 1991, ANNU REV BIOCHEM, V60, P321; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; HARRISON GS, 1987, SOMAT CELL MOLEC GEN, V13, P119, DOI 10.1007/BF01534692; HAYDEN P, 1987, METHOD ENZYMOL, V143, P228; HAYDEN PJ, 1992, CHEM RES TOXICOL, V5, P231, DOI 10.1021/tx00026a013; HAYDEN PJ, 1990, MOL PHARMACOL, V37, P468; HAYDEN PJ, 1991, J BIOL CHEM, V266, P18415; HAYDEN PJ, 1991, BIOCHEMISTRY-US, V30, P5935, DOI 10.1021/bi00238a018; HIGHTOWER LE, 1991, CELL, V66, P191, DOI 10.1016/0092-8674(91)90611-2; HUNT CR, 1985, P NATL ACAD SCI USA, V78, P3775; KINGSTON RE, 1987, MOL CELL BIOL, V7, P1530, DOI 10.1128/MCB.7.4.1530; LARSON JS, 1988, NATURE, V336, P184, DOI 10.1038/336184a0; LARSON JS, 1988, NATURE, V335, P372, DOI 10.1038/335372a0; Lever JE., 1985, TISSUE CULTURE EPITH, P3; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; LINDQUIST S, 1986, ANNU REV BIOCHEM, V55, P1151, DOI 10.1146/annurev.bi.55.070186.005443; Lis J.T., 1990, STRESS PROTEINS BIOL, P411; MORIMOTO R I, 1990, P1; MORIMOTO RI, 1991, CANCER CELL-MON REV, V3, P295; MOSSER DD, 1990, P NATL ACAD SCI USA, V87, P3748, DOI 10.1073/pnas.87.10.3748; PELHAM HRB, 1982, CELL, V30, P517, DOI 10.1016/0092-8674(82)90249-5; PELHAM HRB, 1986, CELL, V46, P959, DOI 10.1016/0092-8674(86)90693-8; PERDEW GH, 1991, J BIOL CHEM, V266, P6708; PERISIC O, 1989, CELL, V59, P797, DOI 10.1016/0092-8674(89)90603-X; SAMBROOK J, 1987, MOL CLONING LABORATO; SANCHEZ ER, 1990, J BIOL CHEM, V265, P22067; SCHAEFFER VH, 1987, MOL PHARMACOL, V31, P506; SHRECK R, 1991, EMBO J, V10, P2247; SHUEY DJ, 1986, J BIOL CHEM, V261, P7934; SMITH DF, 1990, J BIOL CHEM, V265, P3996; SORGER PK, 1991, CELL, V65, P363, DOI 10.1016/0092-8674(91)90452-5; SORGER PK, 1987, NATURE, V329, P81, DOI 10.1038/329081a0; SORGER PK, 1989, CELL, V59, P807, DOI 10.1016/0092-8674(89)90604-1; SORGER PK, 1988, CELL, V54, P855, DOI 10.1016/S0092-8674(88)91219-6; STEVENS J, 1986, J BIOL CHEM, V261, P3325; STEVENS JL, 1986, J BIOL CHEM, V261, P5529; STORZ G, 1990, SCIENCE, V248, P189, DOI 10.1126/science.2183352; VAMVAKAS S, 1990, MOL PHARMACOL, V38, P455; Welch WJ, 1990, STRESS PROTEINS BIOL, P223; WESTWOOD JT, 1991, NATURE, V353, P822, DOI 10.1038/353822a0; WU B, 1985, MOL CELL BIOL, V5, P330, DOI 10.1128/MCB.5.2.330; WU C, 1984, NATURE, V311, P81, DOI 10.1038/311081a0; WU C, 1990, STRESS PROTEINS BIOL, P429; YOST HJ, 1990, TRENDS GENET, V6, P223, DOI 10.1016/0168-9525(90)90183-7; Yost HJ, 1990, STRESS PROTEINS BIOL, P379; YU K, 1991, TOXICOLOGIST, V11, P250; ZIMARINO V, 1990, SCIENCE, V249, P546, DOI 10.1126/science.2200124	64	53	53	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1992	267	34					24322	24327						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KA263	1447182				2022-12-25	WOS:A1992KA26300030
J	COOK, JC; CHOCK, PB				COOK, JC; CHOCK, PB			ISOFORMS OF MAMMALIAN UBIQUITIN-ACTIVATING ENZYME	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE Y-CHROMOSOME; L-CELL DEFECT; ELECTROPHORETIC TRANSFER; DEPENDENT PROTEOLYSIS; GEL-ELECTROPHORESIS; POLYACRYLAMIDE GELS; CONJUGATING ENZYME; MOLECULAR-CLONING; DNA-REPLICATION; GENE	Ubiquitin-activating enzyme,"E1," is the first enzyme in the pathway leading to formation of ubiquitin-protein conjugates and represents a potential target for regulation in the metabolic control of the conjugation reaction. Antiserum raised against human E1 recognizes two immunoreactive proteins in extracts from several human cell lines and animal tissues. We have characterized these two immunoreactive proteins in HeLa cells and present evidence that they are isoforms of E1. We have designated these isoforms as "E1(110 kDa)" and "E1(117 kDa)" to reflect their apparent molecular masses determined from SDS-polyacrylamide gel electrophoresis. These two immunoreactive proteins are immunologically similar, have nearly identical peptide maps, and comigrate with enzymatic activity characteristic of E1 in native polyacrylamide gel electrophoretic separations. Pulse-labeling experiments reveal that both isoforms are long-lived in vivo with degradation rates which are inconsistent with a proenzyme/enzyme model. Furthermore, their rates of degradation, which vary depending on the cell line studied, are kinetically distinguishable in contact-inhibited human lung fibroblasts. This work represents the first demonstration of E1 isoforms in a non-plant species and carries important implications for studies of the regulatory mechanisms controlling ubiquitin conjugation.	NHLBI,BIOCHEM LAB,METAB REGULAT,BLDG 3,RM 202,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)								AEBERSOLD RH, 1987, P NATL ACAD SCI USA, V84, P6970, DOI 10.1073/pnas.84.20.6970; BARTEL B, 1990, EMBO J, V9, P3179, DOI 10.1002/j.1460-2075.1990.tb07516.x; BOND U, 1985, MOL CELL BIOL, V5, P949, DOI 10.1128/MCB.5.5.949; BOND U, 1986, MOL CELL BIOL, V6, P4602, DOI 10.1128/MCB.6.12.4602; BROWN CJ, 1989, SOMAT CELL MOLEC GEN, V15, P93, DOI 10.1007/BF01534674; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CIECHANOVER A, 1982, J BIOL CHEM, V257, P2537; CIECHANOVER A, 1978, BIOCHEM BIOPH RES CO, V81, P1100, DOI 10.1016/0006-291X(78)91249-4; CIECHANOYER A, 1980, J BIOL CHEM, V255, P7525; COOK J, 1988, Biofactors, V1, P133; COOK JC, 1991, P NATL ACAD SCI USA, V88, P11388, DOI 10.1073/pnas.88.24.11388; COOK JC, 1991, BIOCHEM BIOPH RES CO, V174, P564, DOI 10.1016/0006-291X(91)91454-K; FINLEY D, 1987, CELL, V48, P1035, DOI 10.1016/0092-8674(87)90711-2; FINLEY D, 1991, ANNU REV CELL BIOL, V7, P25, DOI 10.1146/annurev.cb.07.110191.000325; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; GOEBL MG, 1988, SCIENCE, V241, P1331, DOI 10.1126/science.2842867; GOLDSTEIN G, 1975, P NATL ACAD SCI USA, V72, P11, DOI 10.1073/pnas.72.1.11; HAAS AL, 1985, J BIOL CHEM, V260, P4694; HAAS AL, 1982, J BIOL CHEM, V257, P2543; HAAS AL, 1982, J BIOL CHEM, V257, P329; HAMMARBACK JA, 1990, J BIOL CHEM, V265, P12763; HANDLEY PM, 1991, P NATL ACAD SCI USA, V88, P258, DOI 10.1073/pnas.88.1.258; HARLOW E, 1988, ANTIBODIES LABORATOR; HATFIELD PM, 1990, J BIOL CHEM, V265, P15813; HATFIELD PM, 1989, BIOCHEMISTRY-US, V28, P735, DOI 10.1021/bi00428a048; HERSHKO A, 1980, P NATL ACAD SCI-BIOL, V77, P1783, DOI 10.1073/pnas.77.4.1783; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; Hurn B A, 1980, Methods Enzymol, V70, P104; JABBEN M, 1989, J BIOL CHEM, V264, P4998; JENTSCH S, 1987, NATURE, V329, P131, DOI 10.1038/329131a0; JENTSCH S, 1990, TRENDS BIOCHEM SCI, V15, P195, DOI 10.1016/0968-0004(90)90161-4; KAY GF, 1991, NATURE, V354, P486, DOI 10.1038/354486a0; KUDO M, 1991, EXP CELL RES, V192, P110, DOI 10.1016/0014-4827(91)90164-P; KULKA RG, 1988, J BIOL CHEM, V263, P15726; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEUNG DW, 1987, NATURE, V330, P537, DOI 10.1038/330537a0; MCGRATH JP, 1991, EMBO J, V10, P227, DOI 10.1002/j.1460-2075.1991.tb07940.x; MINAMIDE LS, 1990, ANAL BIOCHEM, V190, P66, DOI 10.1016/0003-2697(90)90134-U; MITCHELL MJ, 1991, NATURE, V354, P483, DOI 10.1038/354483a0; PICKART CM, 1985, J BIOL CHEM, V260, P1573; RECHLIN M, 1980, METHOD ENZYMOL, V70, P159; RECHSTEINER M, 1987, ANNU REV CELL BIOL, V3, P1, DOI 10.1146/annurev.cb.03.110187.000245; REISS Y, 1988, J BIOL CHEM, V263, P2693; ROSE IA, 1987, P NATL ACAD SCI USA, V84, P1477, DOI 10.1073/pnas.84.6.1477; SALINOVICH O, 1986, ANAL BIOCHEM, V156, P341, DOI 10.1016/0003-2697(86)90263-0; SIEGELMAN M, 1986, SCIENCE, V231, P823, DOI 10.1126/science.3003913; TAKAHASHI E, 1992, CYTOGENET CELL GENET, V59, P268, DOI 10.1159/000133266; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WU RS, 1981, J BIOL CHEM, V256, P5916; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0; ZACKSENHAUS E, 1990, CYTOGENET CELL GENET, V53, P20, DOI 10.1159/000132887; ZACKSENHAUS E, 1990, EMBO J, V9, P2923, DOI 10.1002/j.1460-2075.1990.tb07483.x; ZOLA H, 1987, MONOCLONAL ANTIBODIE, P166	53	27	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1992	267	34					24315	24321						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KA263	1447181				2022-12-25	WOS:A1992KA26300029
J	LEE, RH; LIEBERMAN, BS; YAMANE, HK; BOK, D; FUNG, BKK				LEE, RH; LIEBERMAN, BS; YAMANE, HK; BOK, D; FUNG, BKK			A 3RD FORM OF THE G-PROTEIN BETA-SUBUNIT .1. IMMUNOCHEMICAL IDENTIFICATION AND LOCALIZATION TO CONE PHOTORECEPTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING REGULATORY PROTEINS; ROD OUTER SEGMENTS; HUMAN PLACENTAL MEMBRANES; AMINO-ACID SEQUENCE; GAMMA-SUBUNITS; RETINAL ROD; CYCLIC-GMP; ADENYLATE-CYCLASE; MOLECULAR-CLONING; ALPHA-SUBUNIT	Vertebrate retinal cones play a major role in both photopic vision and color perception. Although the molecular mechanism of visual excitation in the cone is not as well understood as in the rod, it is generally thought to involve a cone-specific G protein (cone transducin) that couples the cone visual pigment to a cGMP phosphodiesterase. Like all other G proteins, cone transducin is most likely a heterotrimer consisting of Galpha, Gbeta, and Ggamma subunits. A Galpha subunit of cone transducin has been localized to the outer segment of bovine cones, but its associated Gbeta and Ggamma subunits are unknown. To identify the Gbeta subunit involved in the phototransduction process of cones, we have developed a panel of antipeptide antisera against the most diverse region of the amino acid sequences encoded by Gbeta1, Gbeta2, and Gbeta3 cDNAs and used them to determine the distribution of the Gbeta isoforms in different retinal preparations. We found that the Gbeta3 subunit is present in bovine retinal transducin and phosducin-Tbetagamma complex preparations which were previously thought to contain only Gbeta1. Analysis of its subcellular distribution indicated that Gbeta3 is predominantly cytoplasmic. Immunocytochemical staining of bovine retinal sections with the anti-Gbeta3 antiserum further revealed a specific localization of Gbeta3 in cones but not in rods. In contrast, anti-Gbeta1 antiserum stained only the rods. These results suggest that Gbeta3 is the Gbeta subunit of cone transducin and confirms the proposition that rods and cones utilize distinct signaling proteins for phototransduction.	UNIV CALIF LOS ANGELES, SCH MED, JULES STEIN EYE INST, LOS ANGELES, CA 90024 USA; UNIV CALIF LOS ANGELES, SCH MED, DEPT ANAT & CELL BIOL, LOS ANGELES, CA 90024 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	LEE, RH (corresponding author), VET ADM MED CTR, MOLEC NEUROBIOL LAB 151B9, SEPULVEDA, CA 91343 USA.				NEI NIH HHS [EY05895, EY00395, EY 00444] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY000444, R37EY000444, R01EY005895] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		AMATRUDA TT, 1988, J BIOL CHEM, V263, P5008; ATTWELL D, 1985, NATURE, V317, P14, DOI 10.1038/317014a0; BIRNBAUMER L, 1990, ANNU REV PHARMACOL, V30, P675; CERIONE RA, 1986, J BIOL CHEM, V261, P9514; CODINA J, 1986, FEBS LETT, V207, P187, DOI 10.1016/0014-5793(86)81486-7; EVANS T, 1986, J BIOL CHEM, V261, P7052; EVANS T, 1987, J BIOL CHEM, V262, P176; FEDERMAN AD, 1992, NATURE, V356, P159, DOI 10.1038/356159a0; FLORIO VA, 1985, J BIOL CHEM, V260, P3477; FONG HKW, 1987, P NATL ACAD SCI USA, V84, P3792, DOI 10.1073/pnas.84.11.3792; FONG HKW, 1986, P NATL ACAD SCI USA, V83, P2126; FUNG BKK, 1992, J BIOL CHEM, V267, P24782; FUNG BKK, 1990, BIOCHEMISTRY-US, V29, P2657, DOI 10.1021/bi00463a006; FUNG BKK, 1990, FEBS LETT, V260, P313, DOI 10.1016/0014-5793(90)80132-3; FUNG BKK, 1983, J BIOL CHEM, V258, P495; FUNG BKK, 1986, PROG RETIN RES, V6, P151; GAO B, 1987, P NATL ACAD SCI USA, V84, P6122, DOI 10.1073/pnas.84.17.6122; GAUTAM N, 1990, P NATL ACAD SCI USA, V87, P7973, DOI 10.1073/pnas.87.20.7973; GAUTAM N, 1989, SCIENCE, V244, P971, DOI 10.1126/science.2499046; GILLESPIE PG, 1988, J BIOL CHEM, V263, P8133; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; HO Y-K, 1990, Investigative Ophthalmology and Visual Science, V31, P215; HURLEY JB, 1984, P NATL ACAD SCI-BIOL, V81, P6948, DOI 10.1073/pnas.81.22.6948; JELSEMA CL, 1987, P NATL ACAD SCI USA, V84, P3623, DOI 10.1073/pnas.84.11.3623; KATADA T, 1984, J BIOL CHEM, V259, P3586; KIM D, 1989, NATURE, V337, P557, DOI 10.1038/337557a0; KUHN H, 1980, NATURE, V283, P587, DOI 10.1038/283587a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE RH, 1990, J BIOL CHEM, V265, P15867; LEE RH, 1987, BIOCHEMISTRY-US, V26, P3983, DOI 10.1021/bi00387a036; LEE RH, 1988, EXP EYE RES, V46, P829, DOI 10.1016/S0014-4835(88)80035-6; LEREA CL, 1986, SCIENCE, V234, P77, DOI 10.1126/science.3529395; LEVINE MA, 1990, P NATL ACAD SCI USA, V87, P2329, DOI 10.1073/pnas.87.6.2329; LOLLEY RN, 1990, FASEB J, V4, P3001, DOI 10.1096/fasebj.4.12.1697545; MUMBY SM, 1986, P NATL ACAD SCI USA, V83, P265, DOI 10.1073/pnas.83.2.265; NAVON SE, 1988, J BIOL CHEM, V263, P489; NAVON SE, 1987, EXP EYE RES, V44, P115, DOI 10.1016/S0014-4835(87)80030-1; NEER EJ, 1988, NATURE, V333, P129, DOI 10.1038/333129a0; OVCHINNIKOV YA, 1985, FEBS LETT, V179, P107, DOI 10.1016/0014-5793(85)80201-5; PUGH EN, 1986, VISION RES, V26, P1613, DOI 10.1016/0042-6989(86)90051-9; ROBISHAW JD, 1989, J BIOL CHEM, V264, P15758; ROOF DJ, 1985, J BIOL CHEM, V260, P6242; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; STERNWEIS PC, 1984, J BIOL CHEM, V259, P3806; STRYER L, 1986, ANNU REV CELL BIOL, V2, P391, DOI 10.1146/annurev.cb.02.110186.002135; STRYER L, 1991, J BIOL CHEM, V266, P10711; SUGIMOTO K, 1985, FEBS LETT, V191, P235, DOI 10.1016/0014-5793(85)80015-6; TAMIR H, 1991, BIOCHEMISTRY-US, V30, P3929, DOI 10.1021/bi00230a018; TANG WJ, 1991, SCIENCE, V254, P1500, DOI 10.1126/science.1962211; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Weizsacker E. V., 1992, BIOCHEM BIOPH RES CO, V183, P350; WHITEWAY M, 1989, CELL, V56, P467, DOI 10.1016/0092-8674(89)90249-3; WOOLKALIS MJ, 1987, MOL PHARMACOL, V32, P1; YATSUNAMI K, 1985, P NATL ACAD SCI USA, V82, P1936, DOI 10.1073/pnas.82.7.1936; YAU KW, 1992, INVEST OPHTH VIS SCI, V33, P1004	55	69	70	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1992	267	34					24776	24781						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KA263	1447215				2022-12-25	WOS:A1992KA26300093
J	KESSLER, DJ; SPICER, DB; LAROSA, FA; SONENSHEIN, GE				KESSLER, DJ; SPICER, DB; LAROSA, FA; SONENSHEIN, GE			A NOVEL NF-KB ELEMENT WITHIN EXON-1 OF THE MURINE C-MYC GENE	ONCOGENE			English	Article							TUMOR NECROSIS FACTOR; DNA-BINDING SUBUNIT; EXPRESS CHLORAMPHENICOL ACETYLTRANSFERASE; CELLS INDUCES TRANSCRIPTION; FOS PROTO-ONCOGENE; I-KAPPA-B; MAMMALIAN-CELLS; RECOMBINANT GENOMES; NEGATIVE REGULATOR; FACTOR-ALPHA	We have mapped a site within exon 1 of the murine c-myc gene that forms a variety of complexes with nuclear proteins derived from the murine WEHI 231 B-lymphoma cell line in exponential growth that are altered following treatment with phorbol ester, when transcription of this gene is reduced [Levine, R.A., McCormack, J.E., Buckler, A.J. & Sonenshein, G.E. (1986). Mol. Cell Biol., 6, 4112-4116]. This site, located at +440 to +459 bp relative to the Pl promoter, contains an NK-kappaB-like binding element. The sequence of this element, AGGGAATTTTT, is unusual in that the stretch of pyrimidines is entirely T residues. Binding of NF-kappaB protein was demonstrated by oligonucleotide competition, induction of binding upon 70Z/3 pre-B- to B-cell differentiation, response to GTP in the binding reaction, reduction of binding upon addition of IkappaB protein and uv cross-linking analysis. Functional activity of this internal regulatory element (IRE) was demonstrated in transfection assays using chloramphenicol acetyl transferase (CAT) reporter constructs containing multimerized copies of the IRE driving a heterologous promoter. Mutation of the IRE within the context of the c-myc promoter prevented NF-kappaB-mediated induction of transcription of this oncogene. Thus additional NF-kappaB elements may be defined by this new sequence.	BOSTON UNIV,SCH MED,DEPT BIOCHEM,80 E CONCORD ST,BOSTON,MA 02118	Boston University					NATIONAL CANCER INSTITUTE [R01CA036355] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI023454] Funding Source: NIH RePORTER; NCI NIH HHS [CA 36355] Funding Source: Medline; NIAID NIH HHS [AI 23454, AI 07309] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BATTEY J, 1983, CELL, V34, P779, DOI 10.1016/0092-8674(83)90534-2; Bencini DA, 1984, BIOTECHNIQUES, V2, P4; BENTLEY DL, 1988, CELL, V53, P245, DOI 10.1016/0092-8674(88)90386-8; BLANK V, 1992, TRENDS BIOCHEM SCI, V17, P135, DOI 10.1016/0968-0004(92)90321-Y; BOHNLEIN E, 1988, CELL, V53, P827, DOI 10.1016/0092-8674(88)90099-2; BOYD AW, 1981, J IMMUNOL, V126, P2466; BUCKLER AJ, 1990, J IMMUNOL, V145, P732; CHANG J, 1991, ONCOGENE, V6, P1979; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; DONOGHUE M, 1988, GENE DEV, V2, P1779, DOI 10.1101/gad.2.12b.1779; DUYAO MP, 1990, P NATL ACAD SCI USA, V87, P4727, DOI 10.1073/pnas.87.12.4727; DUYAO MP, 1992, IN PRESS J BIOL CHEM; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HAY N, 1989, GENE DEV, V3, P293, DOI 10.1101/gad.3.3.293; HOYOS B, 1989, SCIENCE, V244, P457, DOI 10.1126/science.2497518; KAKKIS E, 1989, NATURE, V339, P718, DOI 10.1038/339718a0; KESSLER DJ, 1992, IN PRESS J EXP MED; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; KUWABARA MD, 1987, BIOCHEMISTRY-US, V26, P7234, DOI 10.1021/bi00397a006; LENARDO MJ, 1988, P NATL ACAD SCI USA, V85, P8825, DOI 10.1073/pnas.85.23.8825; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; LEVINE RA, 1986, MOL CELL BIOL, V6, P4112, DOI 10.1128/MCB.6.11.4112; LIEBER MR, 1987, GENE DEV, V1, P751, DOI 10.1101/gad.1.8.751; LIN JX, 1987, J BIOL CHEM, V262, P11908; LINDSTEN T, 1988, EMBO J, V7, P2787, DOI 10.1002/j.1460-2075.1988.tb03133.x; LOWENTHAL JW, 1989, P NATL ACAD SCI USA, V86, P2331, DOI 10.1073/pnas.86.7.2331; MECHTI N, 1986, NUCLEIC ACIDS RES, V14, P9653, DOI 10.1093/nar/14.24.9653; MIKSICEK R, 1986, CELL, V46, P283, DOI 10.1016/0092-8674(86)90745-2; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; NOLAN GP, 1991, CELL, V64, P961, DOI 10.1016/0092-8674(91)90320-X; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; PRENDERGAST GC, 1989, NATURE, V341, P392, DOI 10.1038/341392a0; SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; SIEKEVITZ M, 1987, SCIENCE, V238, P1575, DOI 10.1126/science.2825351; STRAUSS F, 1984, CELL, V37, P889, DOI 10.1016/0092-8674(84)90424-0; TAKIMOTO M, 1989, J BIOL CHEM, V264, P8992; THALMEIER K, 1989, GENE DEV, V3, P527, DOI 10.1101/gad.3.4.527; ZABEL U, 1991, J BIOL CHEM, V266, P252	42	35	35	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1992	7	12					2447	2453						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KA856	1461649				2022-12-25	WOS:A1992KA85600009
J	TING, AT; SCHOON, RA; ABRAHAM, RT; LEIBSON, PJ				TING, AT; SCHOON, RA; ABRAHAM, RT; LEIBSON, PJ			INTERACTION BETWEEN PROTEIN KINASE-C-DEPENDENT AND G-PROTEIN-DEPENDENT PATHWAYS IN THE REGULATION OF NATURAL-KILLER-CELL GRANULE EXOCYTOSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYMPHOCYTE-T ACTIVATION; SIGNAL TRANSDUCTION; ANTIGEN RECEPTOR; PHOSPHOLIPASE-C; CYTO-TOXICITY; SECRETION; CYTOTOXICITY; GENERATION; MECHANISMS	The binding of natural killer (NK) cells to either susceptible tumor cells or antibody-coated targets results in rapid activation of phospholipase C (PLC) in NK cells. PLC activation generates inositol-1,4,5-trisphosphate and sn-1,2-diacylglycerol as second messengers, which, in turn, increase intracellular free calcium concentrations ([Ca2+]i) and protein kinase C (PKC) activity, respectively. These proximal signals initiate a cascade of as yet undefined biochemical events, leading eventually to the exocytosis of preformed cytotoxic granules. To investigate the signal transduction pathways involved in granule exocytosis, we utilized streptolysin-O-permeabilized human NK cells as our experimental model. Our initial studies indicated that the separate activation of either PKC (using the phorbol ester, PMA) or G protein-dependent pathways (using guanosine-5'-O-(3-thiotriphosphate) (GTPgammaS)) stimulated granule exocytosis in a time-, concentration-, and Ca2+-dependent manner. PMA-stimulated exocytosis was inhibited by staurosporine or a PKC pseudosubstrate antagonist peptide, but was not affected by GDP. In contrast, GTPgammaS-stimulated exocytosis was effectively inhibited by GDP, but not by staurosporine or the PKC pseudosubstrate antagonist. These observations suggest that NK cell exocytosis can be stimulated by at least two separate pathways; one involving PKC and the other involving a G protein. However, co-stimulation with PMA and GTPgammaS synergistically enhanced exocytosis, suggesting that even though the two exocytotic pathways were biochemically distinct, cross-talk between the two pathways may potently influence the exocytotic process. These results define a regulatory role for PKC- and G protein-dependent pathways during granule exocytosis from NK cells.	MAYO CLIN & MAYO FDN, DEPT IMMUNOL, ROCHESTER, MN 55905 USA; MAYO CLIN & MAYO FDN, DEPT PHARMACOL, ROCHESTER, MN 55905 USA	Mayo Clinic; Mayo Clinic					NCI NIH HHS [CA47752] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA047752] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALEXANDER DR, 1989, BIOCHEM J, V260, P893, DOI 10.1042/bj2600893; ATKINSON EA, 1990, J LEUKOCYTE BIOL, V47, P39, DOI 10.1002/jlb.47.1.39; AUGUSTINE JA, 1991, J IMMUNOL, V146, P2889; BALCH WE, 1989, J BIOL CHEM, V264, P16965; BARROWMAN MM, 1986, NATURE, V319, P504, DOI 10.1038/319504a0; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BRAHMI Z, 1992, NK CELL MEDIATED CYT, P117; BURGOYNE RD, 1990, ANNU REV PHYSIOL, V52, P647; BURKHARDT JK, 1989, P NATL ACAD SCI USA, V86, P7128, DOI 10.1073/pnas.86.18.7128; COCKCROFT S, 1987, J CELL BIOL, V105, P2745, DOI 10.1083/jcb.105.6.2745; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; FERGUSON WS, 1988, J EXP MED, V167, P528, DOI 10.1084/jem.167.2.528; FISHMAN PH, 1990, ADP RIBOSYLATING TOX, P127; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GOLDFARB RH, 1986, HUM PATHOL, V17, P138, DOI 10.1016/S0046-8177(86)80286-6; GOMPERTS BD, 1990, ANNU REV PHYSIOL, V52, P591; GRAVES SS, 1986, J IMMUNOL, V137, P1977; HENKART P, 1988, PROG ALLERGY, V40, P82; HOLMSEN H, 1989, METHOD ENZYMOL, V169, P336; HOUSE C, 1987, SCIENCE, V238, P1726, DOI 10.1126/science.3686012; KOREN HS, 1987, IMMUNOL TODAY, V8, P69, DOI 10.1016/0167-5699(87)90844-9; LARUSSO NF, 1979, J CLIN INVEST, V64, P948, DOI 10.1172/JCI109561; LEIBSON PJ, 1990, J IMMUNOL, V145, P1498; LEIBSON PJ, 1992, NK CELL MEDIATED CYT, P129; NOVICK P, 1980, CELL, V21, P205, DOI 10.1016/0092-8674(80)90128-2; NUSSE O, 1990, J EXP MED, V171, P775, DOI 10.1084/jem.171.3.775; OWENS JR, 1985, J BIOL CHEM, V260, P5946; PAYA CV, 1990, J IMMUNOL, V144, P4370; PETERS PJ, 1991, J EXP MED, V173, P1099, DOI 10.1084/jem.173.5.1099; PODACK ER, 1991, ANNU REV CELL BIOL, V7, P479, DOI 10.1146/annurev.cellbio.7.1.479; SCHREZENMEIER H, 1988, J IMMUNOL, V141, P3785; SEGEV N, 1988, CELL, V52, P915, DOI 10.1016/0092-8674(88)90433-3; SITKOVSKY MV, 1988, IMMUNOL REV, V103, P127, DOI 10.1111/j.1600-065X.1988.tb00754.x; TAKAYAMA H, 1987, J IMMUNOL METHODS, V104, P183, DOI 10.1016/0022-1759(87)90502-3; TAMAOKI T, 1986, BIOCHEM BIOPH RES CO, V135, P397, DOI 10.1016/0006-291X(86)90008-2; TING AT, 1991, J IMMUNOL, V147, P3122; TRINCHIERI G, 1989, ADV IMMUNOL, V47, P187, DOI 10.1016/S0065-2776(08)60664-1; WINDEBANK KP, 1988, J IMMUNOL, V141, P3951; YOUNG JDE, 1986, J CELL BIOCHEM, V32, P151, DOI 10.1002/jcb.240320207; ZANOVELLO P, 1989, J EXP MED, V170, P665, DOI 10.1084/jem.170.3.665	40	39	39	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	1992	267	33					23957	23962						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JZ239	1429733				2022-12-25	WOS:A1992JZ23900079
J	NEWTON, DL; ILERCIL, O; LASKE, DW; OLDFIELD, E; RYBAK, SM; YOULE, RJ				NEWTON, DL; ILERCIL, O; LASKE, DW; OLDFIELD, E; RYBAK, SM; YOULE, RJ			CYTOTOXIC RIBONUCLEASE CHIMERAS - TARGETED TUMORICIDAL ACTIVITY INVITRO AND INVIVO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EOSINOPHIL CATIONIC PROTEIN; AMINO-ACID-SEQUENCE; MONOCLONAL-ANTIBODIES; SEMINAL RIBONUCLEASE; SCHISTOSOMA-MANSONI; IMMUNOTOXINS; NEUROTOXIN; TOXINS; TUMOR; INHIBITION	Monoclonal antibodies to the transferrin receptor or to the T cell antigen, CD5, were chemically linked to mammalian RNase A and found to specifically inhibit protein synthesis in antigen-positive cells. Antibody-mediated specificity of these cytotoxic ribonuclease chimeras (CRCs) was demonstrated in three ways. 1) Toxicity was due to the chemical linkage of RNase to antibody, as the individual components added separately or in combination did not inhibit protein synthesis; 2) the anti-transferrin receptor CRCs inhibited protein synthesis in those cells expressing the human transferrin receptor (K562, U251, Jurkat cells) but had no detectable toxicity to cells lacking the human transferrin receptor (Vero or NIH 3T3 cells); 3) free antibody to either the human transferrin receptor (454A12 or 5E-9) or to the T cell antigen, CD5 (T101), blocked the cytotoxicity of the respective CRC. Two CRC species, designated P1 and P2, that differed in size and stoichiometry of RNase A to antibody, were purified by size-exclusion high performance liquid chromatography. The higher molecular weight P1 conjugate had an IC50 of 20-30 nm, whereas the P2 conjugate had a higher IC50 of 300-500 nM. Bioactivity could be reversibly increased more than 10-fold by freezing. The cytotoxicity of the CRCs was examined in vivo in a solid tumor animal model. Intratumoral injections of an anti-transferrin receptor CRC into established U251 human glioblastoma tumors grown in the flanks of nude mice prevented tumor growth, whereas RNase A mixed with antibody was ineffective. CRCs, therefore, express cytotoxicity in vitro and in vivo. Mammalian nucleases coupled to antibodies may be utilized as cell type-selective cytotoxins and have potential as pharmacologic reagents. The systemic toxicity and immunogenicity observed with mammalian derived cytotoxins may be significantly less than that of the currently employed plant- and bacterial-derived immunotoxins.			NEWTON, DL (corresponding author), NINCDS, BIOCHEM SECT, SURG NEUROL BRANCH, BETHESDA, MD 20892 USA.							ACKERMAN SJ, 1985, AM J TROP MED HYG, V34, P735, DOI 10.4269/ajtmh.1985.34.735; AKAGI K, 1978, CANCER RES, V38, P2163; ARDELT W, 1991, J BIOL CHEM, V266, P245; BEINTEMA JJ, 1988, PROG BIOPHYS MOL BIO, V51, P165, DOI 10.1016/0079-6107(88)90001-6; CARLSSON J, 1978, BIOCHEM J, V173, P723, DOI 10.1042/bj1730723; CONDE FP, 1989, EUR J BIOCHEM, V178, P795, DOI 10.1111/j.1432-1033.1989.tb14511.x; DEMAIN AL, 1967, CAN J MICROBIOL, V13, P1109, DOI 10.1139/m67-148; Farkas GL, 1982, ENCY PLANT PHYSL B, V14B, P224; FREDENS K, 1982, J ALLERGY CLIN IMMUN, V70, P361, DOI 10.1016/0091-6749(82)90025-2; FRIGAS E, 1991, EUR RESPIR J, V4, pS123; GLEICH GJ, 1986, ADV IMMUNOL, V39, P177; GLEICH GJ, 1986, P NATL ACAD SCI USA, V83, P3146, DOI 10.1073/pnas.83.10.3146; GLUKHOV BN, 1976, ARCH NEUROL-CHICAGO, V33, P598, DOI 10.1001/archneur.1976.00500090004002; GREY HM, 1965, J EXP MED, V122, P619, DOI 10.1084/jem.122.3.619; GULLBERG U, 1986, BIOCHEM BIOPH RES CO, V139, P1239, DOI 10.1016/S0006-291X(86)80310-2; HAYNES BF, 1981, J IMMUNOL, V127, P347; HERRIOTT RM, 1961, NATURE, V189, P817, DOI 10.1038/189817a0; HERTLER AA, 1988, IMMUNOTOXINS, P475; JIN FS, 1991, J IMMUNOL, V146, P1806; JOHNSON VG, 1988, J BIOL CHEM, V263, P1295; KLAUSNER RD, 1983, J BIOL CHEM, V258, P4715; KLEE WA, 1967, BIOCHEMISTRY-US, V6, P3736, DOI 10.1021/bi00864a016; LEONE E, 1973, J REPROD FERTIL, V34, P197; MATOUSEK J, 1973, EXPERIENTIA, V29, P858, DOI 10.1007/BF01946329; MCCLURE BA, 1990, NATURE, V347, P757, DOI 10.1038/347757a0; MCCORMICK JJ, 1974, NATURE, V251, P737, DOI 10.1038/251737a0; MCLAREN DJ, 1984, PARASITOLOGY, V88, P491, DOI 10.1017/S0031182000054755; MIKULSKI SM, 1990, J NATL CANCER I, V82, P151, DOI 10.1093/jnci/82.2.151-a; MOLINA HA, 1988, AM J TROP MED HYG, V38, P327, DOI 10.4269/ajtmh.1988.38.327; MOLINA HA, 1988, IMMUNOLOGY, V64, P725; PASTAN I, 1991, SCIENCE, V254, P1173, DOI 10.1126/science.1683495; PRIOR TI, 1991, CELL, V64, P1017, DOI 10.1016/0092-8674(91)90325-S; REDDI KK, 1975, BIOCHEM BIOPH RES CO, V67, P110, DOI 10.1016/0006-291X(75)90290-9; RICHARDS FM, 1971, ENZYMES, V4, P647; ROTH JS, 1963, CANCER RES, V23, P657; RYBAK SM, 1992, P NATL ACAD SCI USA, V89, P3165, DOI 10.1073/pnas.89.8.3165; RYBAK SM, 1991, J BIOL CHEM, V266, P21202; RYBAK SM, 1991, IMMUNOL ALLERGY CLIN, V11, P359; SAXENA SK, 1991, J BIOL CHEM, V266, P21208; SLIFMAN NR, 1986, J IMMUNOL, V137, P2913; STCLAIR DK, 1988, BIOCHEMISTRY-US, V27, P7263, DOI 10.1021/bi00419a013; STRYDOM DJ, 1985, BIOCHEMISTRY-US, V24, P5486, DOI 10.1021/bi00341a031; SUNG C, 1991, J BIOL CHEM, V266, P14159; THOMPSON TL, 1966, J BACTERIOL, V91, P673, DOI 10.1128/JB.91.2.673-676.1966; VESCIA S, 1980, CANCER RES, V40, P3740	45	64	77	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 25	1992	267	27					19572	19578						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JP593	1527074				2022-12-25	WOS:A1992JP59300083
J	ANDREWS, RK; FOX, JEB				ANDREWS, RK; FOX, JEB			IDENTIFICATION OF A REGION IN THE CYTOPLASMIC DOMAIN OF THE PLATELET MEMBRANE GLYCOPROTEIN-IB-IX COMPLEX THAT BINDS TO PURIFIED ACTIN-BINDING PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOGENOUS CA-2+-DEPENDENT PROTEASE; VEIN ENDOTHELIAL-CELLS; PLASMA-MEMBRANE; FIBRONECTIN RECEPTOR; PURIFICATION; AGGREGATION; SKELETON; ALPHA; EXPRESSION; SUBUNIT	The platelet membrane glycoprotein (GP) Ib-IX complex is a major site of attachment of the platelet membrane skeleton to the plasma membrane. This association is mediated by the interaction of actin-binding protein with the GP Ib-IX complex. The aim of the present work was to identify domains on the GP Ib-IX complex that interact with actin-binding protein. Synthetic peptides corresponding to sequences of the GP Ib alpha-chain and beta-chain cytoplasmic domains were analyzed for their ability to bind to purified actin-binding protein. Two overlapping peptides encompassing a sequence (Thr-536-Phe-568) from the central region of the cytoplasmic domain of GP Ib(alpha) were the most effective in binding I-125-actin-binding protein, as assessed by a microtiter well approach and peptide affinity chromatography. One of the active peptides (Thr-536-Leu-554) was chosen to evaluate the likelihood that the central region of the cytoplasmic domain of GP Ib(alpha) is involved in binding of the intact complex to actin-binding protein. This peptide could be specifically cross-linked to purified actin-binding protein in solution. Rabbit polyclonal antibody against this peptide inhibited the binding of purified actin-binding protein to the purified GP Ib-IX complex. Finally, as in intact platelets, the calpain-induced hydrolytic fragments of purified actin-binding protein (M(r) = 200,000 and M(r) = 91,000) showed little binding to the GP Ib(alpha) peptide. Taken together, these results provided evidence that a region between Thr-536 and Phe-568 of the cytoplasmic domain of GP Ib(alpha) participates in the interaction of the GP Ib-IX complex with actin-binding protein.	UNIV CALIF SAN FRANCISCO,CARDIOVASC RES INST,GLADSTONE INST CARDIOVASC DIS,SAN FRANCISCO,CA 94141	University of California System; University of California San Francisco; The J David Gladstone Institutes					NHLBI NIH HHS [HL30657] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL030657, R23HL030657, R01HL030657] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AAKHUS AM, 1989, ELECTROPHORESIS, V10, P758, DOI 10.1002/elps.1150101105; Andrews RK, 1990, CURR OPIN CELL BIOL, V2, P894, DOI 10.1016/0955-0674(90)90089-W; ANDREWS RK, 1991, J BIOL CHEM, V266, P7144; ARGRAVES WS, 1989, CELL, V58, P623, DOI 10.1016/0092-8674(89)90097-4; ASCH AS, 1988, J CLIN INVEST, V81, P1600, DOI 10.1172/JCI113494; BENNETT V, 1985, ANNU REV BIOCHEM, V54, P273, DOI 10.1146/annurev.biochem.54.1.273; BERNDT MC, 1985, EUR J BIOCHEM, V151, P637, DOI 10.1111/j.1432-1033.1985.tb09152.x; BURRIDGE K, 1988, ANNU REV CELL BIOL, V4, P487, DOI 10.1146/annurev.cb.04.110188.002415; DU XP, 1987, BLOOD, V69, P1524; EDELMAN GM, 1976, SCIENCE, V192, P218, DOI 10.1126/science.769162; EZZELL RM, 1988, J BIOL CHEM, V263, P13303; FOX JEB, 1985, J BIOL CHEM, V260, P1060; FOX JEB, 1985, J CLIN INVEST, V76, P1673, DOI 10.1172/JCI112153; FOX JEB, 1985, J BIOL CHEM, V260, P1970; FOX JEB, 1990, J CELL BIOL, V111, P483, DOI 10.1083/jcb.111.2.483; FOX JEB, 1987, THROMB DIATH HAEMO, P175; GORLIN JB, 1990, J CELL BIOL, V111, P1089, DOI 10.1083/jcb.111.3.1089; HAYASHI Y, 1990, J CELL BIOL, V110, P175, DOI 10.1083/jcb.110.1.175; HICKEY MJ, 1989, P NATL ACAD SCI USA, V86, P6773, DOI 10.1073/pnas.86.17.6773; HOCK RS, 1990, BIOCHEMISTRY-US, V29, P9441, DOI 10.1021/bi00492a019; HORWITZ A, 1986, NATURE, V320, P531, DOI 10.1038/320531a0; IKEDA Y, 1991, J CLIN INVEST, V87, P1234, DOI 10.1172/JCI115124; JAFFE SH, 1990, P NATL ACAD SCI USA, V87, P3589, DOI 10.1073/pnas.87.9.3589; Kemler R, 1989, CURR OPIN CELL BIOL, V1, P892, DOI 10.1016/0955-0674(89)90055-0; KONKLE BA, 1990, J BIOL CHEM, V265, P19833; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LERNER RA, 1981, P NATL ACAD SCI-BIOL, V78, P3403, DOI 10.1073/pnas.78.6.3403; LOPEZ JA, 1987, P NATL ACAD SCI USA, V84, P5615, DOI 10.1073/pnas.84.16.5615; LOPEZ JA, 1988, P NATL ACAD SCI USA, V85, P2135, DOI 10.1073/pnas.85.7.2135; LOPEZ JA, 1992, J BIOL CHEM, V267, P12851; OKITA JR, 1985, J CELL BIOL, V100, P317, DOI 10.1083/jcb.100.1.317; OTEY CA, 1990, J CELL BIOL, V111, P721, DOI 10.1083/jcb.111.2.721; OZAWA M, 1989, EMBO J, V8, P1711, DOI 10.1002/j.1460-2075.1989.tb03563.x; ROSENFELD GC, 1985, J CELL BIOL, V100, P669, DOI 10.1083/jcb.100.3.669; SOLOWSKA J, 1989, J CELL BIOL, V109, P853, DOI 10.1083/jcb.109.2.853; SPRANDIO JD, 1988, BLOOD, V71, P234; STENDAHL OI, 1980, J CELL BIOL, V84, P215, DOI 10.1083/jcb.84.2.215; WALLACH D, 1978, J BIOL CHEM, V253, P3328; WEIHING RR, 1983, BIOCHEMISTRY-US, V22, P1839, DOI 10.1021/bi00277a015; WICKI AN, 1987, EUR J BIOCHEM, V163, P43, DOI 10.1111/j.1432-1033.1987.tb10734.x	40	104	107	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1992	267	26					18605	18611						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JN502	1526994				2022-12-25	WOS:A1992JN50200056
J	BALLA, G; JACOB, HS; BALLA, J; ROSENBERG, M; NATH, K; APPLE, F; EATON, JW; VERCELLOTTI, GM				BALLA, G; JACOB, HS; BALLA, J; ROSENBERG, M; NATH, K; APPLE, F; EATON, JW; VERCELLOTTI, GM			FERRITIN - A CYTOPROTECTIVE ANTIOXIDANT STRATEGEM OF ENDOTHELIUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PYRIDOXAL ISONICOTINOYL HYDRAZONE; HEME OXYGENASE GENE; TRANSCRIPTIONAL ACTIVATION; LIPID-PEROXIDATION; CHAIN FERRITINS; HEPATOMA-CELLS; H-CHAIN; IRON; DAMAGE; IDENTIFICATION	Phagocyte-mediated oxidant damage to vascular endothelium is likely involved in various vasculopathies including atherosclerosis and pulmonary leak syndromes such as adult respiratory distress syndrome. We have shown that heme, a hydrophobic iron chelate, is rapidly incorporated into endothelial cells where, after as little as 1 h, it markedly aggravates cytotoxicity engendered by polymorphonuclear leukocyte oxidants or hydrogen peroxide (H2O2). In contrast, however, if cultured endothelial cells are briefly pulsed with heme and then allowed to incubate for a prolonged period (16 h), the cells become highly resistant to oxidant-mediated injury and to the accumulation of endothelial lipid peroxidation products. This protection is associated with the induction within 4 h of mRNAs for both heme oxygenase and ferritin. After 16 h heme oxygenase and ferritin have increased approximately 50-fold and 10-fold, respectively. Differential induction of these proteins determined that ferritin is probably the ultimate cytoprotectant. Ferritin inhibits oxidant-mediated cytolysis in direct relation to its intracellular concentration. Apoferritin, when added to cultured endothelial cells, is taken up in a dose-responsive manner and appears as cytoplasmic granules by immunofluorescence; in a similar dose-responsive manner, added apoferritin protects endothelial cells from oxidant-mediated cytolysis. Conversely, a site-directed mutant of ferritin (heavy chain Glu62 --> Lys; His65 --> Gly) which lacks ferroxidase activity and is deficient in iron sequestering capacity, is completely ineffectual as a cytoprotectant. We conclude that endothelium and perhaps other cell types may be protected from oxidant damage through the iron sequestrant, ferritin.	UNIV MINNESOTA, DEPT MED, MINNEAPOLIS, MN 55455 USA; UNION UNIV, DEPT PATHOL & LAB MED, ALBANY, NY 12208 USA; UNIV MINNESOTA, DEPT LAB MED, MINNEAPOLIS, MN 55455 USA; UNIV MINNESOTA, DEPT PATHOL, MINNEAPOLIS, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities; Union College; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities				Balla, Jozsef/0000-0001-7923-2645	NHLBI NIH HHS [R01 HL33793, HL28935] Funding Source: Medline; PHS HHS [R32] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL033793, R37HL028935, R01HL028935] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABRAHAM NG, 1988, INT J BIOCHEM, V20, P543, DOI 10.1016/0020-711X(88)90093-6; ALAM J, 1989, J BIOL CHEM, V264, P6371; ANTONOV AS, 1986, ATHEROSCLEROSIS, V59, P1, DOI 10.1016/0021-9150(86)90027-4; BAKKER GR, 1986, J BIOL CHEM, V261, P3182; BALLA G, 1991, LAB INVEST, V64, P648; BALLA G, 1991, CLIN RES, V39, pA724; BOLANN BJ, 1990, EUR J BIOCHEM, V193, P899, DOI 10.1111/j.1432-1033.1990.tb19415.x; BROWN A, 1987, BLOOD CELLS, V13, P123; BROXMEYER HE, 1991, P NATL ACAD SCI USA, V88, P770, DOI 10.1073/pnas.88.3.770; EISENSTEIN RS, 1991, P NATL ACAD SCI USA, V88, P688, DOI 10.1073/pnas.88.3.688; GALBRAITH RA, 1985, J BIOL CHEM, V260, P2198; GANNON DE, 1987, LAB INVEST, V57, P37; GIEGEL JL, 1982, CLIN CHEM, V28, P1894; GUTTERIDGE JMC, 1988, BIOCHEM J, V256, P861, DOI 10.1042/bj2560861; HUNTER GC, 1991, P SOC EXP BIOL MED, V196, P273; IBRAHIM NG, 1982, BRIT J HAEMATOL, V50, P17, DOI 10.1111/j.1365-2141.1982.tb01886.x; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; KEYSE SM, 1990, MOL CELL BIOL, V10, P4967, DOI 10.1128/MCB.10.9.4967; LEONARD TB, 1986, BIOCHEM PHARMACOL, V35, P3057, DOI 10.1016/0006-2952(86)90386-2; LEVI S, 1988, J BIOL CHEM, V263, P18086; LEVI S, 1989, BIOCHEM J, V264, P381, DOI 10.1042/bj2640381; LIN JJ, 1991, P NATL ACAD SCI USA, V88, P6068, DOI 10.1073/pnas.88.14.6068; LIN JJ, 1990, SCIENCE, V247, P74, DOI 10.1126/science.2294594; MAINES MD, 1974, P NATL ACAD SCI USA, V71, P4293, DOI 10.1073/pnas.71.11.4293; Maniatis T., 1982, MOL CLONING; MARIASH CN, 1982, ANAL BIOCHEM, V121, P388, DOI 10.1016/0003-2697(82)90498-5; NATH KA, 1992, IN PRESS J CLIN INVE; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; PONKA P, 1982, BIOCHIM BIOPHYS ACTA, V718, P151, DOI 10.1016/0304-4165(82)90213-6; PONKA P, 1979, FEBS LETT, V97, P317, DOI 10.1016/0014-5793(79)80111-8; REPINE JE, 1981, J BIOL CHEM, V256, P7094; ROGERS J, 1987, P NATL ACAD SCI USA, V84, P2277, DOI 10.1073/pnas.84.8.2277; SADRZADEH SMH, 1988, J CLIN INVEST, V82, P1510, DOI 10.1172/JCI113759; SCHRAUFSTATTER I, 1988, J CLIN INVEST, V82, P1040, DOI 10.1172/JCI113660; SIMIONESCU M, 1991, CELL BIOL REV, V25, P5; TENHUNEN R, 1970, J LAB CLIN MED, V75, P410; THEIL EC, 1990, ADV ENZYMOL RAMB, V63, P421; THOMAS CE, 1985, J BIOL CHEM, V260, P3275; THOMAS CE, 1986, J BIOL CHEM, V261, P3064; VARANI J, 1985, LAB INVEST, V53, P656; VENNERSTROM JL, 1988, J MED CHEM, V31, P1269, DOI 10.1021/jm00402a001; VERCELLOTTI GM, 1988, BLOOD, V71, P1100; VINCENT SH, 1988, ARCH BIOCHEM BIOPHYS, V265, P539, DOI 10.1016/0003-9861(88)90159-2; WHITE K, 1988, J BIOL CHEM, V263, P8938	44	968	1003	1	23	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 5	1992	267	25					18148	18153						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JM223	1517245				2022-12-25	WOS:A1992JM22300102
J	GABRIELLI, BG; LEE, MS; WALKER, DH; PIWNICAWORMS, H; MALLER, JL				GABRIELLI, BG; LEE, MS; WALKER, DH; PIWNICAWORMS, H; MALLER, JL			CDC25 REGULATES THE PHOSPHORYLATION AND ACTIVITY OF THE XENOPUS CDK2 PROTEIN-KINASE COMPLEX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MATURATION-PROMOTING FACTOR; CELL-CYCLE; TYROSINE PHOSPHORYLATION; FISSION YEAST; DNA-REPLICATION; P34CDC2 KINASE; MITOTIC EVENTS; MITOSIS; ACTIVATION; GENE	The Xenopus cdk2 gene encodes a 32-kDa protein kinase with sequence similarity to the 34-kDa product of the cdc2 gene. Previous studies have shown that the kinase activity of the protein product of the cdk2 gene oscillates in the Xenopus embryonic cell cycle with a high in M-phase and a low in interphase. In the present study cdk2 was found not to be associated with any newly synthesized proteins during the cell cycle, but the enzyme did undergo periodic changes in phosphorylation. Upon exit from metaphase, cdk2 became increasingly phosphorylated on both tyrosine and serine residues, and labeling on these residues increased progressively until entry into mitosis, when tyrosine residues were markedly dephosphorylated. Phosphopeptide mapping of cdk2 demonstrated the major sites of phosphorylation were in a phosphopeptide with a pI of 3.7 that contained both phosphoserine and phosphotyrosine. This phosphopeptide accumulated in egg extracts blocked in S-phase with aphidicolin and was not evident in cdc2 immunoprecipitated under the same conditions. Under the same conditions cdc2 was phosphorylated primarily on a phosphopeptide containing both phosphothreonine and phosphotyrosine residues, most likely threonine 14 and tyrosine 15. Affinity-purified human GST-cdc25 was able to dephosphorylate and activate cdk2 isolated from interphase cells. Phosphopeptide mapping demonstrated that the phosphate was specifically removed from the same phosphopeptide identified as the major in vivo site of phosphorylation. These results demonstrate that cdk2 is regulated in the cell cycle by phosphorylation and dephosphorylation on both serine and tyrosine residues. Moreover, the increased phosphorylation of cdk2 in aphidicolin-blocked extracts and the ability of cdc25 to mediate cdk2 dephosphorylation in vitro suggest the possibility that cdk2 is part of the mechanism ensuring mitosis is not initiated until completion of DNA replication. It also implies cdc25 may have other functions in addition to the regulation of cdc2 kinase activity.	UNIV COLORADO, SCH MED,HOWARD HUGHES MED INST,BOX C-236, 4200 E 9TH AVE, DENVER, CO 80262 USA; UNIV COLORADO, SCH MED, DEPT PHARMACOL, DENVER, CO 80262 USA; TUFTS UNIV, DEPT PHYSIOL, BOSTON, MA 02111 USA	Howard Hughes Medical Institute; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Tufts University			Gabrielli, Brian G/B-3655-2011; Piwnica-Worms, Helen/C-5214-2012	Gabrielli, Brian G/0000-0003-3933-1651; 	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047017, R01GM026743] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL07053] Funding Source: Medline; NIGMS NIH HHS [GM47017, GM26743] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		DASSO M, 1990, CELL, V61, P811, DOI 10.1016/0092-8674(90)90191-G; DRAETTA G, 1989, CELL, V56, P829, DOI 10.1016/0092-8674(89)90687-9; DUNPHY WG, 1991, CELL, V67, P189, DOI 10.1016/0092-8674(91)90582-J; DUNPHY WG, 1988, CELL, V54, P423, DOI 10.1016/0092-8674(88)90205-X; ELLEDGE SJ, 1992, P NATL ACAD SCI USA, V89, P2907, DOI 10.1073/pnas.89.7.2907; GABRIELLI BG, 1992, J BIOL CHEM, V267, P1969; GAUTIER J, 1989, NATURE, V339, P626, DOI 10.1038/339626a0; GAUTIER J, 1990, CELL, V60, P487, DOI 10.1016/0092-8674(90)90599-A; GAUTIER J, 1991, CELL, V67, P197, DOI 10.1016/0092-8674(91)90583-K; GAUTIER J, 1988, CELL, V54, P433, DOI 10.1016/0092-8674(88)90206-1; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; HUNTER T, 1991, CELL, V66, P1071, DOI 10.1016/0092-8674(91)90028-W; IZUMI T, 1991, MOL CELL BIOL, V11, P3860, DOI 10.1128/MCB.11.8.3860; KAMPS MP, 1989, ANAL BIOCHEM, V176, P22, DOI 10.1016/0003-2697(89)90266-2; KISHIMOTO T, 1982, EXP CELL RES, V137, P121, DOI 10.1016/0014-4827(82)90014-3; KOFF A, 1991, CELL, V66, P1217, DOI 10.1016/0092-8674(91)90044-Y; KREK W, 1991, EMBO J, V10, P3331, DOI 10.1002/j.1460-2075.1991.tb04897.x; KREK W, 1991, EMBO J, V10, P305, DOI 10.1002/j.1460-2075.1991.tb07951.x; KUMAGAI A, 1991, CELL, V64, P903, DOI 10.1016/0092-8674(91)90315-P; LABBE JC, 1989, EMBO J, V8, P3053, DOI 10.1002/j.1460-2075.1989.tb08456.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGAN TA, 1989, MOL CELL BIOL, V9, P3860, DOI 10.1128/MCB.9.9.3860; LEE MS, 1992, MOL BIOL CELL, V3, P73, DOI 10.1091/mbc.3.1.73; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; LOHKA MJ, 1985, J CELL BIOL, V101, P518, DOI 10.1083/jcb.101.2.518; LOHKA MJ, 1988, P NATL ACAD SCI USA, V85, P3009, DOI 10.1073/pnas.85.9.3009; LUNDGREN K, 1991, CELL, V64, P1111, DOI 10.1016/0092-8674(91)90266-2; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MEIJER L, 1989, EMBO J, V8, P2275, DOI 10.1002/j.1460-2075.1989.tb08353.x; MEIJER L, 1991, EMBO J, V10, P1545, DOI 10.1002/j.1460-2075.1991.tb07674.x; MINSHULL J, 1989, J CELL SCI, P77; MINSHULL J, 1990, EMBO J, V9, P2865, DOI 10.1002/j.1460-2075.1990.tb07476.x; MURRAY AW, 1989, NATURE, V339, P280, DOI 10.1038/339280a0; MURRAY AW, 1989, NATURE, V339, P275, DOI 10.1038/339275a0; NORBURY C, 1991, EMBO J, V10, P3321, DOI 10.1002/j.1460-2075.1991.tb04896.x; PARIS J, 1991, P NATL ACAD SCI USA, V88, P1039, DOI 10.1073/pnas.88.3.1039; PARKER LL, 1991, EMBO J, V10, P1255, DOI 10.1002/j.1460-2075.1991.tb08067.x; PARKER LL, 1992, P NATL ACAD SCI USA, V89, P2917, DOI 10.1073/pnas.89.7.2917; Pines J, 1991, Trends Cell Biol, V1, P117, DOI 10.1016/0962-8924(91)90116-Q; PINES J, 1991, J CELL BIOL, V115, P1, DOI 10.1083/jcb.115.1.1; PIWNICAWORMS H, 1990, CURRENT PROTOCOLS MO, V2; ROSENBLATT J, 1992, P NATL ACAD SCI USA, V89, P2824, DOI 10.1073/pnas.89.7.2824; RUSSELL P, 1986, CELL, V45, P145, DOI 10.1016/0092-8674(86)90546-5; RUSSELL P, 1987, CELL, V49, P559, DOI 10.1016/0092-8674(87)90458-2; SOLOMON MJ, 1990, CELL, V63, P1013, DOI 10.1016/0092-8674(90)90504-8; STRAUSFELD U, 1991, NATURE, V351, P242, DOI 10.1038/351242a0; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; WALKER DH, 1991, NATURE, V354, P314, DOI 10.1038/354314a0	48	58	58	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 5	1992	267	25					18040	18046						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JM223	1517236				2022-12-25	WOS:A1992JM22300086
J	JEANG, KT; BERKHOUT, B				JEANG, KT; BERKHOUT, B			KINETICS OF HIV-1 LONG TERMINAL REPEAT TRANSACTIVATION - USE OF INTRAGENIC RIBOZYME TO ASSESS RATE-LIMITING STEPS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; RNA POLYMERASE-II; TRANSCRIPTION FACTOR ATF; TAT GENE-PRODUCT; TRANSLATIONAL REGULATION; PREINITIATION COMPLEX; PROMOTER INTERACTIONS; INITIATION-COMPLEXES; RESPONSIVE REGION; BINDING PROTEIN	We have examined, using self-cleaving ribozymes, the intracellular trans-activation kinetics of the human immunodeficiency virus type 1 (HIV-1) long terminal repeat (LTR) by viral protein Tat. Experiments were designed to effect a competition (during RNA chain elongation) between cleavage of a nascent RNA containing the Tat-responsive target sequence (TAR) and Tat interaction with the same TAR in the-process of LTR-trans-activation. We found that fast self-cleavage of nascent TAR-containing RNA abolished Tat trans-activation. Slowing the cleavage reaction kinetically rescued trans-activation. Based on our results, we conclude that the rate-limiting step in HIV-1 LTR trans-activation is the initial contact made between Tat/TAR/LTR rather than the promoter proximal pausing of RNA polymerases that are tethered to functional TAR.			JEANG, KT (corresponding author), NIAID,MOLEC MICROBIOL LAB,BETHESDA,MD 20892, USA.		Jeang, Kuan-Teh/A-2424-2008					ABMAYR SM, 1988, GENE DEV, V2, P542, DOI 10.1101/gad.2.5.542; BERKHOUT B, 1989, CELL, V59, P273, DOI 10.1016/0092-8674(89)90289-4; BERKHOUT B, 1990, NUCLEIC ACIDS RES, V18, P1839, DOI 10.1093/nar/18.7.1839; BERKHOUT B, 1990, CELL, V62, P7257; BRADDOCK M, 1989, CELL, V58, P269, DOI 10.1016/0092-8674(89)90841-6; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; CALNAN BJ, 1991, GENE DEV, V5, P201, DOI 10.1101/gad.5.2.201; CORDINGLEY MG, 1990, P NATL ACAD SCI USA, V87, P8985, DOI 10.1073/pnas.87.22.8985; CULLEN BR, 1990, CELL, V63, P655, DOI 10.1016/0092-8674(90)90129-3; CULLEN BR, 1986, CELL, V46, P973, DOI 10.1016/0092-8674(86)90696-3; DAVISON BL, 1983, NATURE, V301, P680, DOI 10.1038/301680a0; DINGWALL C, 1989, P NATL ACAD SCI USA, V86, P6925, DOI 10.1073/pnas.86.18.6925; DINGWALL C, 1990, EMBO J, V9, P4145, DOI 10.1002/j.1460-2075.1990.tb07637.x; DRYSDALE CM, 1991, J VIROL, V65, P3044, DOI 10.1128/JVI.65.6.3044-3051.1991; FALKNER FG, 1988, VIROLOGY, V164, P450, DOI 10.1016/0042-6822(88)90559-4; FEINBERG MB, 1991, P NATL ACAD SCI USA, V88, P4045, DOI 10.1073/pnas.88.9.4045; FIRE A, 1984, J BIOL CHEM, V259, P2509; FORSTER AC, 1987, CELL, V49, P211, DOI 10.1016/0092-8674(87)90562-9; GARCIA JA, 1989, EMBO J, V8, P765, DOI 10.1002/j.1460-2075.1989.tb03437.x; GATIGNOL A, 1991, SCIENCE, V251, P1597, DOI 10.1126/science.2011739; GATIGNOL A, 1989, P NATL ACAD SCI USA, V86, P7828, DOI 10.1073/pnas.86.20.7828; GAYNOR R, 1989, P NATL ACAD SCI USA, V86, P4858, DOI 10.1073/pnas.86.13.4858; GENDELMAN HE, 1986, P NATL ACAD SCI USA, V83, P9759, DOI 10.1073/pnas.83.24.9759; GHAZAL P, 1991, J VIROL, V65, P2299, DOI 10.1128/JVI.65.5.2299-2307.1991; GILL SC, 1990, BIOPHYS CHEM, V37, P239; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HAI T, 1988, CELL, V54, P1043, DOI 10.1016/0092-8674(88)90119-5; HANLY SM, 1989, GENE DEV, V3, P1534, DOI 10.1101/gad.3.10.1534; HARRICH D, 1990, EMBO J, V9, P4417, DOI 10.1002/j.1460-2075.1990.tb07892.x; HASELOFF J, 1989, GENE, V82, P43, DOI 10.1016/0378-1119(89)90028-0; HAUBER J, 1988, J VIROL, V62, P673, DOI 10.1128/JVI.62.3.673-679.1988; HAWLEY DK, 1985, J BIOL CHEM, V260, P8163; HORIKOSHI M, 1988, CELL, V54, P665, DOI 10.1016/S0092-8674(88)80011-4; HORIKOSHI M, 1988, CELL, V54, P1033, DOI 10.1016/0092-8674(88)90118-3; JAKOBOVITS A, 1988, MOL CELL BIOL, V8, P2555, DOI 10.1128/MCB.8.6.2555; JEANG KT, 1988, P NATL ACAD SCI USA, V85, P8291, DOI 10.1073/pnas.85.21.8291; JEANG KT, 1987, J VIROL, V61, P2175; JEYAPAUL J, 1990, P NATL ACAD SCI USA, V87, P7030, DOI 10.1073/pnas.87.18.7030; KAO SY, 1987, NATURE, V330, P489, DOI 10.1038/330489a0; KASHANCHI F, 1989, P NATL ACAD SCI USA, V83, P2850; LASPIA MF, 1990, GENE DEV, V4, P2397, DOI 10.1101/gad.4.12b.2397; LASPIA MF, 1989, CELL, V59, P283, DOI 10.1016/0092-8674(89)90290-0; LEWIN B, 1990, CELL, V61, P1161, DOI 10.1016/0092-8674(90)90675-5; LIN YS, 1991, CELL, V64, P971, DOI 10.1016/0092-8674(91)90321-O; LUSE DS, 1987, J BIOL CHEM, V262, P14990; MARCINIAK RA, 1990, CELL, V63, P791, DOI 10.1016/0092-8674(90)90145-5; MARCINIAK RA, 1990, P NATL ACAD SCI USA, V87, P3642; MCCLURE WR, 1985, ANNU REV BIOCHEM, V54, P171, DOI 10.1146/annurev.bi.54.070185.001131; PAVLAKIS GN, 1990, NEW BIOL, V2; PTASHNE M, 1990, NATURE, V346, P329, DOI 10.1038/346329a0; PUGH BF, 1992, J BIOL CHEM, V267, P679; REINBERG D, 1987, J BIOL CHEM, V262, P3310; RICE AP, 1988, NATURE, V332, P551, DOI 10.1038/332551a0; ROSEN CA, 1986, NATURE, V319, P555, DOI 10.1038/319555a0; ROY S, 1990, GENE DEV, V4, P1365, DOI 10.1101/gad.4.8.1365; RUFFNER DE, 1990, BIOCHEMISTRY-US, V29, P10695, DOI 10.1021/bi00499a018; RUFFNER DE, 1989, GENE, V82, P31, DOI 10.1016/0378-1119(89)90027-9; SELBY MJ, 1990, CELL, V62, P769, DOI 10.1016/0092-8674(90)90121-T; SELBY MJ, 1989, GENE DEV, V3, P547, DOI 10.1101/gad.3.4.547; SENGUPTA DN, 1990, P NATL ACAD SCI USA, V87, P7492, DOI 10.1073/pnas.87.19.7492; SHARP PA, 1991, NATURE, V351, P16, DOI 10.1038/351016d0; SHARP PA, 1989, CELL, V59, P229, DOI 10.1016/0092-8674(89)90279-1; SHATKIN AJ, 1985, CELL, V40, P223, DOI 10.1016/0092-8674(85)90132-1; SHATKIN AJ, 1976, CELL, V9, P645, DOI 10.1016/0092-8674(76)90128-8; SODROSKI J, 1985, SCIENCE, V229, P74, DOI 10.1126/science.2990041; SOUTHGATE C, 1990, NATURE, V345, P640, DOI 10.1038/345640a0; WEEKS KM, 1990, SCIENCE, V249, P1281, DOI 10.1126/science.2205002	67	41	43	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1992	267	25					17891	17899						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JM223	1517225				2022-12-25	WOS:A1992JM22300063
J	TZIANABOS, AO; PANTOSTI, A; BAUMANN, H; BRISSON, JR; JENNINGS, HJ; KASPER, DL				TZIANABOS, AO; PANTOSTI, A; BAUMANN, H; BRISSON, JR; JENNINGS, HJ; KASPER, DL			THE CAPSULAR POLYSACCHARIDE OF BACTEROIDES-FRAGILIS COMPRISES 2 IONICALLY LINKED POLYSACCHARIDES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROUP-B STREPTOCOCCUS; IMMUNOCHEMICAL CHARACTERIZATION; VIRULENCE; RHIZOBIUM; BINDING; EXOPOLYSACCHARIDE; IMMUNITY; STRAINS; MODEL	Recently, we have shown that the capsular polysaccharide of Bacteroides fragilis NCTC 9343 is composed of an aggregate of two discrete large molecular weight polysaccharides (designated polysaccharides A and B). Following disaggregation of this capsular complex by very mild acid treatment, high resolution NMR spectroscopy demonstrated that polysaccharides A and B consist of highly charged repeating unit structures with unusual substituent groups (Baumann, H., Tzianabos, A. O., Brisson, J.-R., Kasper, D. L., and Jennings, H. J. (1992) Biochemistry 31, 4081-4089). Presently, we report that the capsular polysaccharide of B. fragilis represents a complex structure that is formed as a result of ionic interactions between polysaccharides A and B. Electron microscopy of immunogold-labeled organisms (with monoclonal antibodies specific for polysaccharides A and B) demonstrated that the two polysaccharides are co-expressed on the cell surface of B. fragilis. We have shown that the purified capsule complex is made up exclusively of polysaccharide A and polysaccharide B (no other macromolecular structure was detected) in a 1:3.3 ratio and that disaggregation of this complex into the native forms of the constituent polysaccharides could be accomplished by preparative isoelectric focusing. Structural analyses of the native polysaccharides A and B showed that they possessed the same repeating unit structures as the respective acid-derived polysaccharides. The ionic nature of the linkage between polysaccharides A and B was demonstrated by reassociation of the native polysaccharides to form an aggregated polymer comparable to the original complex. The distinctive composition of this macromolecule may provide a rationale for the unusual biologic properties associated with the B. fragilis capsular polysaccharide.	NATL RES COUNCIL CANADA,INST BIOL SCI,OTTAWA K1A 0R6,ONTARIO,CANADA; HARVARD UNIV,BETH ISRAEL HOSP,SCH MED,DIV INFECT DIS,BOSTON,MA 02215	National Research Council Canada; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	TZIANABOS, AO (corresponding author), HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,CHANNING LAB,180 LONGWOOD AVE,BOSTON,MA 02115, USA.		Pantosti, Annalisa/A-7291-2013	Pantosti, Annalisa/0000-0002-8409-4731	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI022807, T32AI007061] Funding Source: NIH RePORTER; NIAID NIH HHS [2T32AI07061-11A1, 1R01 AI 22807] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABE M, 1984, J BACTERIOL, V160, P517, DOI 10.1128/JB.160.2.517-520.1984; BAIUMANN H, 1992, BIOCHEMISTRY-US, V31, P4081; GLAZEBROOK J, 1989, CELL, V56, P661, DOI 10.1016/0092-8674(89)90588-6; GRAY JX, 1990, MOL MICROBIOL, V4, P1425, DOI 10.1111/j.1365-2958.1990.tb02052.x; JENNINGS HJ, 1985, J IMMUNOL, V134, P2651; JENNINGS HJ, 1981, BIOCHEMISTRY-US, V20, P4511, DOI 10.1021/bi00519a001; KASPER DL, 1983, J BACTERIOL, V153, P991, DOI 10.1128/JB.153.2.991-997.1983; MOORE WEC, 1977, P INT METR C, P106; OMAR AS, 1983, ARCH MICROBIOL, V136, P291, DOI 10.1007/BF00425219; ONDERDONK AB, 1982, J CLIN INVEST, V69, P9, DOI 10.1172/JCI110445; ONDERDONK AB, 1977, J INFECT DIS, V136, P82, DOI 10.1093/infdis/136.1.82; OUCHTERLONY O, 1958, PROG ALLERGY, V5, P1, DOI 10.1159/000273347; PANTOSTI A, 1991, INFECT IMMUN, V59, P2075, DOI 10.1128/IAI.59.6.2075-2082.1991; PAOLETTI LC, 1990, J BIOL CHEM, V265, P18278; POLK BF, 1977, ANN INTERN MED, V86, P569, DOI 10.7326/0003-4819-86-5-569; RUBENS CE, 1987, P NATL ACAD SCI USA, V84, P7208, DOI 10.1073/pnas.84.20.7208; SHAPIRO ME, 1982, J EXP MED, V155, P1188, DOI 10.1084/jem.155.4.1188; WESSELS MR, 1987, P NATL ACAD SCI USA, V84, P9170, DOI 10.1073/pnas.84.24.9170; WESSELS MR, 1989, J EXP MED, V169, P2121, DOI 10.1084/jem.169.6.2121; ZALEZNIK DF, 1986, J INFECT DIS, V154, P40, DOI 10.1093/infdis/154.1.40	20	87	97	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1992	267	25					18230	18235						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JM223	1517250				2022-12-25	WOS:A1992JM22300114
J	ULVSBACK, M; LAZURE, C; LILJA, H; SPURR, NK; RAO, VVNG; LOFFLER, C; HANSMANN, I; LUNDWALL, A				ULVSBACK, M; LAZURE, C; LILJA, H; SPURR, NK; RAO, VVNG; LOFFLER, C; HANSMANN, I; LUNDWALL, A			GENE STRUCTURE OF SEMENOGELIN-I AND SEMENOGELIN-II - THE PREDOMINANT PROTEINS IN HUMAN SEMEN ARE ENCODED BY 2 HOMOLOGOUS GENES ON CHROMOSOME-20	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYBRIDIZATION; LOCALIZATION; ANTIGEN; METAPHASE; REGION	The genes for semenogelin I and II, the major protein constituents of the human seminal fluid, have been characterized by three overlapping clones in bacteriophage-lambda, encompassing 31.5 kilobases (kb) of genomic DNA. The two genes are located 11.5 kb apart in the region q12-q13.1 on chromosome 20. Both genes are relatively compact, spanning only 2.7 and 3.1 kb, respectively. The transcription units are composed of three exons, of which the first encodes the signal peptide, the second encodes the secreted protein, while the third solely contains 3'-noncoding nucleotides. The nucleotide sequences exhibit a similarity of close to 90% in the exons and exceeding 80% in the introns and flanking nucleotides.	IMPERIAL CANC RES FUND,POTTERS BAR EN6 3LD,HERTS,ENGLAND; UNIV GOTTINGEN,INST HUMAN GENET,W-3400 GOTTINGEN,GERMANY	University of Gottingen	ULVSBACK, M (corresponding author), UNIV LUND,MALMO GEN HOSP,DEPT CLIN CHEM,S-21401 MALMO,SWEDEN.		Lilja, Hans/S-9703-2019	Lilja, Hans/0000-0001-5871-7846; Lundwall, Ake/0000-0001-9199-9160				BANKIER AT, 1983, TECHNIQUES NUCLEIC A, V85, P1; BEERMANN F, 1988, CYTOGENET CELL GENET, V49, P311, DOI 10.1159/000132685; CHANDLER ME, 1978, CYTOGENET CELL GENET, V22, P352, DOI 10.1159/000130970; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DOLITTLE DP, 1990, MOUSE GENOME, V87, P14; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; JHANWAR SC, 1987, CYTOGENET CELL GENET, V46, P634; KUNZE N, 1989, HUM GENET, V84, P6, DOI 10.1007/BF00210661; LICHTER P, 1988, HUM GENET, V80, P224, DOI 10.1007/BF01790090; LILJA H, 1985, SCAND J CLIN LAB INV, V45, P635, DOI 10.3109/00365518509155271; LILJA H, 1992, IN PRESS P NATL ACAD, V89; LOFFLER C, 1991, HUM GENET, V87, P221, DOI 10.1007/BF00204188; LOFFLER C, 1992, CYTOGENET CELL GENET, V59, P20, DOI 10.1159/000133190; LUNDWALL A, 1989, BIOCHEM BIOPH RES CO, V161, P1151, DOI 10.1016/0006-291X(89)91362-4; LYON MF, 1990, MOUSE GENOME, V87, P28; MCGEE RS, 1987, BIOL REPROD, V37, P431, DOI 10.1095/biolreprod37.2.431; MOHANDAS T, 1984, CYTOGENET CELL GENET, V37, P542; MOLGAARD HV, 1989, LEUKEMIA, V3, P773; OSTROWSKI MC, 1979, J BIOL CHEM, V254, P383; PETERSEN MB, 1987, J MED GENET, V24, P93, DOI 10.1136/jmg.24.2.93; RAO VVNG, 1991, GENOMICS, V10, P257; RYBAK J, 1982, HUM GENET, V60, P328, DOI 10.1007/BF00569213; Sambrook J, 1989, MOL CLONING LABORATO; STADEN R, 1982, NUCLEIC ACIDS RES, V10, P2951, DOI 10.1093/nar/10.9.2951; WIEGANT J, 1991, GENOMICS, V10, P345, DOI 10.1016/0888-7543(91)90318-9	26	57	60	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1992	267	25					18080	18084						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JM223	1517240				2022-12-25	WOS:A1992JM22300092
J	VIJAYALAKSHMI, D; DAGNINO, L; BELT, JA; GATI, WP; CASS, CE; PATERSON, ARP				VIJAYALAKSHMI, D; DAGNINO, L; BELT, JA; GATI, WP; CASS, CE; PATERSON, ARP			L1210/B23.1 CELLS EXPRESS EQUILIBRATIVE, INHIBITOR-SENSITIVE NUCLEOSIDE TRANSPORT ACTIVITY AND LACK 2 PARENTAL NUCLEOSIDE TRANSPORT ACTIVITIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTESTINAL EPITHELIAL-CELLS; MURINE LEUKEMIA-CELLS; HUMAN-ERYTHROCYTES; ANIMAL-CELLS; SUBSTRATE-SPECIFICITY; ADENOSINE TRANSPORT; URIDINE TRANSPORT; MEMBRANE-VESICLES; CULTURED-CELLS; BRUSH-BORDER	Cultured mouse leukemia L1210 cells express the nucleoside-specific membrane transport processes designated es, ei, and cif. The es and ei processes are equilibrative, but may be distinguished by the high sensitivity of the former to 6-[(4-nitrobenzyl)thio]-9-beta-D-ribofuranosylpurine (NBMPR); the cif process is mediated by a Na+/nucleoside cotransporter of low sensitivity to NBMPR. Cells of an ei-deficient clonal line, L1210/MC5-1, were mutagenized, and clones were selected in soft agar medium that contained (i) NBMPR (an inhibitor of es processes), (ii) erythro-9-(2-hydroxy-3-nonyl)adenine (an inhibitor of adenosine deaminase), and (iii) arabinofuranosyladenine (a cytotoxic substrate for the three nucleoside transporters). The selection medium did not allow es activity and selected against cells that expressed the Na+-linked cif process. Cells of the L1210/B23.1 clonal isolate were deficient in cif transport activity, and inward fluxes of formycin B, a poorly metabolized analog of inosine, were virtually abolished by NBMPR in these cells. In the mutant cells, nonisotopic formycin B behaved as a countertransport substrate during influx of [H-3]formycin B, and inward fluxes of the latter were competitively inhibited by purine and pyrimidine nucleosides. The transport behavior of L1210/B23.1 cells indicates that (i) the mutation/selection procedure impaired or deleted the Na+-linked cif process and (ii) es nucleoside transport activity is expressed in the mutant cells.	UNIV ALBERTA, DEPT PHARMACOL, EDMONTON T6G 2H7, ALBERTA, CANADA; UNIV ALBERTA, DEPT BIOCHEM, EDMONTON T6G 2H7, ALBERTA, CANADA; ST JUDE CHILDRENS RES HOSP, DEPT BIOCHEM & CLIN PHARMACOL, MEMPHIS, TN 38101 USA	University of Alberta; University of Alberta; St Jude Children's Research Hospital				Dagnino, Lina/0000-0003-1483-5159				AGBANYO FR, 1988, MOL PHARMACOL, V33, P332; BAER HP, 1990, BIOCHIM BIOPHYS ACTA, V1026, P241, DOI 10.1016/0005-2736(90)90070-5; BELT JA, 1983, MOL PHARMACOL, V24, P479; BELT JA, 1988, J BIOL CHEM, V263, P13819; BELT JA, 1983, BIOCHEM BIOPH RES CO, V110, P417, DOI 10.1016/0006-291X(83)91165-8; BENNETT LL, 1982, P AM ASSOC CANC RES, V23, P6; BLOCH A, 1967, BIOCHIM BIOPHYS ACTA, V138, P10, DOI 10.1016/0005-2787(67)90581-3; CASS CE, 1974, BIOCHIM BIOPHYS ACTA, V345, P1, DOI 10.1016/0005-2736(74)90239-9; CASS CE, 1981, BIOCHIM BIOPHYS ACTA, V649, P769, DOI 10.1016/0005-2736(81)90182-6; CASS CE, 1976, CANCER RES, V36, P1486; CRAWFORD CR, 1990, J BIOL CHEM, V265, P9732; CRAWFORD CR, 1990, J BIOL CHEM, V265, P13730; DAGNINO L, 1987, P AM ASSOC CANC RES, V28, P15; DAGNINO L, 1991, J BIOL CHEM, V266, P6312; DAGNINO L, 1991, J BIOL CHEM, V266, P6308; DAGNINO L, 1988, THESIS U ALBERTA; DAGNINO L, 1990, CANCER RES, V50, P6544; DARNOWSKI JW, 1987, CANCER RES, V47, P2614; DULBECCO R, 1954, J EXP MED, V99, P167, DOI 10.1084/jem.99.2.167; GATI WP, 1989, BIOCHEM J, V263, P957, DOI 10.1042/bj2630957; GTI WP, 1989, RED BLOOD CELL MEMBR, P635; HARLEY ER, 1982, CANCER RES, V42, P1289; JAKOBS ES, 1986, BIOCHEM BIOPH RES CO, V140, P1028, DOI 10.1016/0006-291X(86)90738-2; JAKOBS ES, 1990, J BIOL CHEM, V265, P22210; JARVIS SM, 1981, BIOCHEM J, V194, P331, DOI 10.1042/bj1940331; JARVIS SM, 1987, TOPICS PERSPECTIVES, P102; MOMPARLER RL, 1968, J BIOL CHEM, V243, P4298; OLIVER JM, 1971, CAN J BIOCHEM CELL B, V49, P262, DOI 10.1139/o71-038; PANDE SV, 1976, ANAL BIOCHEM, V74, P25, DOI 10.1016/0003-2697(76)90306-7; PATERSON ARP, 1981, PHARMACOL THERAPEUT, V12, P515, DOI 10.1016/0163-7258(81)90096-6; PATERSON ARP, 1984, BIOCHEM J, V224, P1001, DOI 10.1042/bj2241001; PATERSON ARP, 1987, TOPICS PERSPECTIVES, P89; PATERSON ARP, 1991, ROLE ADENOSINE ADENI, P133; PAUL B, 1975, J MED CHEM, V18, P968, DOI 10.1021/jm00244a003; Plagemann P.G.W., 1980, CURR TOP MEMBR TRANS, P225; PLAGEMANN PGW, 1990, BIOCHIM BIOPHYS ACTA, V1028, P289, DOI 10.1016/0005-2736(90)90178-Q; PLAGEMANN PGW, 1990, BIOCHIM BIOPHYS ACTA, V1025, P32, DOI 10.1016/0005-2736(90)90187-S; PLAGEMANN PGW, 1988, BIOCHIM BIOPHYS ACTA, V947, P405, DOI 10.1016/0304-4157(88)90002-0; PLAGEMANN PGW, 1985, J CELL PHYSIOL, V125, P330, DOI 10.1002/jcp.1041250223; SPECTOR R, 1984, J NEUROCHEM, V42, P1048, DOI 10.1111/j.1471-4159.1984.tb12709.x; VIJAYALAKSHMI D, 1988, J BIOL CHEM, V263, P19419; WILLIAMS TC, 1991, BIOCHEM J, V274, P27, DOI 10.1042/bj2740027; WILLIAMS TC, 1989, BIOCHEM J, V264, P223, DOI 10.1042/bj2640223	43	21	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1992	267	24					16951	16956						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JL053	1512237				2022-12-25	WOS:A1992JL05300037
J	BIGELOW, DJ; SQUIER, TC; INESI, G				BIGELOW, DJ; SQUIER, TC; INESI, G			PHOSPHORYLATION-DEPENDENT CHANGES IN THE SPATIAL RELATIONSHIP BETWEEN CA-ATPASE POLYPEPTIDE-CHAINS IN SARCOPLASMIC-RETICULUM MEMBRANES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA-2+-DEPENDENT CONFORMATIONAL CHANGE; REACTIVE SULFHYDRYL-GROUPS; RESONANCE ENERGY-TRANSFER; CALCIUM-PUMP PROTEIN; X-RAY-DIFFRACTION; ADENOSINE-TRIPHOSPHATASE; ROTATIONAL-DYNAMICS; FLUORESCEIN ISOTHIOCYANATE; VANADATE INHIBITION; STRUCTURAL-CHANGES	In order to investigate possible structural changes associated with the coupling mechanism of the Ca-ATPase in sarcoplasmic reticulum membranes, we have utilized fluorescence resonance energy transfer between spectroscopic probes covalently bound to different domains of the ATPase. Using time-correlated single photon counting, we have directly measured the energy transfer efficiency between 5-{2-[(iodoacetyl)amino]ethyl}aminonaphthalene-1-sulfonic acid (IAEDANS), that is specifically bound to the B tryptic fragment at cysteines 670 and 674 and acceptors covalently bound either near the nucleotide binding site, i.e. fluorescein 5-isothiocyanate at lysine 515, also on the B fragment, or maleimide-directed probes specifically located on the A1 tryptic fragment, i.e. 4-dimethylaminoazobenzene-4'-maleimide (DABmal) or fluorescein-5-maleimide (Fmal), probably at cysteines 344 and 364. All of these donor-acceptor pairs exhibit energy transfer both within and between Ca-ATPase molecules allowing us to investigate spatial relationships between the A1 and B domains and between different ATPase polypeptide chains. Differentiation between the intra- and intermolecular components of energy transfer was accomplished in two ways: 1) by comparing the transfer efficiencies in native membranes before and after detergent solubilization and 2) by reconstituting ATPase chains that have already been labeled with either the donor or acceptor chromophores. Using this approach, we find no significant change in the intramolecular transfer efficiency between any of these donor-acceptor pairs either upon binding of calcium to the high affinity sites or upon stabilization of the phosphoenzyme intermediate, indicating that there are no large structural changes within the B tryptic fragment or, alternatively, between the A1 and B fragments. With respect to intermolecular energy transfer, we observe no effect of calcium binding on the unliganded enzyme with either donor-acceptor pair. However, formation of the phosphoenzyme intermediate results in a measurable increase in the transfer efficiency between IAEDANS and DABmal (or Fmal); this increase is reversible upon phosphoenzyme destabilization by subsequent addition of calcium. There is no corresponding change in the intermolecular component of fluorescence resonance energy transfer between IAEDANS and fluorescein 5-isothiocyanate, indicating that the change in fluorescence resonance energy transfer probably occurs as a result of reorientation of associated ATPase polypeptide chains with respect to one another.	UNIV MARYLAND, SCH MED, DEPT BIOL CHEM, BALTIMORE, MD 21201 USA	University System of Maryland; University of Maryland Baltimore					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL027867] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-27867] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALLEN G, 1980, BIOCHEM J, V187, P591, DOI 10.1042/bj1870591; BALDWIN J, 1979, J MOL BIOL, V129, P175, DOI 10.1016/0022-2836(79)90277-8; BARRABIN H, 1984, BIOCHEMISTRY-US, V23, P1542, DOI 10.1021/bi00302a031; BELDA FF, 1986, BIOCHIM BIOPHYS ACTA, V854, P257, DOI 10.1016/0005-2736(86)90118-5; BENNETT WS, 1984, CRC CR REV BIOCH MOL, V15, P291, DOI 10.3109/10409238409117796; BIGELOW DJ, 1991, BIOCHEMISTRY-US, V30, P2113, DOI 10.1021/bi00222a016; BIGELOW DJ, 1991, BIOPHYS J, V59; BIRCH DJS, 1981, REV SCI INSTRUM, V52, P1206, DOI 10.1063/1.1136742; BIRMACHU W, 1990, BIOCHEMISTRY-US, V29, P3904, DOI 10.1021/bi00468a017; BIRMACHU W, 1989, BIOCHEMISTRY-US, V28, P3940, DOI 10.1021/bi00435a047; BISHOP JE, 1987, J BIOL CHEM, V262, P4658; BISHOP JE, 1988, BIOCHEMISTRY-US, V27, P5233, DOI 10.1021/bi00414a043; BLASIE JK, 1985, BIOPHYS J, V48, P9, DOI 10.1016/S0006-3495(85)83756-5; BLASIE JK, 1990, BIOPHYS J, V58, P687, DOI 10.1016/S0006-3495(90)82411-5; BRANDL CJ, 1986, CELL, V44, P597, DOI 10.1016/0092-8674(86)90269-2; CASTELLANI L, 1985, J MOL BIOL, V185, P579, DOI 10.1016/0022-2836(85)90073-7; CHEN RF, 1974, ANAL BIOCHEM, V57, P593, DOI 10.1016/0003-2697(74)90115-8; DALE RE, 1979, BIOPHYS J, V26, P161, DOI 10.1016/S0006-3495(79)85243-1; DALE RE, 1975, BIOCH FLUORESCENCE C, V1, P115; DEMEIS L, 1980, BIOCHEMISTRY-US, V19, P4252, DOI 10.1021/bi00559a017; DUPONT Y, 1982, FEBS LETT, V139, P237, DOI 10.1016/0014-5793(82)80860-0; ELETR S, 1972, BIOCHIM BIOPHYS ACTA, V282, P174, DOI 10.1016/0005-2736(72)90321-5; HAAS E, 1978, BIOCHEMISTRY-US, V17, P5064, DOI 10.1021/bi00616a032; HIGHSMITH S, 1984, J BIOL CHEM, V259, P4651; HIGHSMITH S, 1987, BIOCHEMISTRY-US, V26, P154, DOI 10.1021/bi00375a022; HIGHSMITH S, 1986, BIOCHEMISTRY-US, V25, P1049, DOI 10.1021/bi00353a015; HUANG WH, 1985, J BIOL CHEM, V260, P7356; HUDSON EN, 1973, BIOCHEMISTRY-US, V12, P4154, DOI 10.1021/bi00745a019; HYMEL L, 1984, J BIOL CHEM, V259, P4890; IKEMOTO N, 1982, ANNU REV PHYSIOL, V44, P297, DOI 10.1146/annurev.ph.44.030182.001501; INESI G, 1990, PHYSIOL REV, V70, P749, DOI 10.1152/physrev.1990.70.3.749; INESI G, 1983, BIOPHYS J, V44, P271, DOI 10.1016/S0006-3495(83)84299-4; INESI G, 1984, J BIOL CHEM, V259, P996; INESI G, 1985, ANNU REV PHYSIOL, V47, P573, DOI 10.1146/annurev.ph.47.030185.003041; Inesi G, 1978, Ann N Y Acad Sci, V307, P224, DOI 10.1111/j.1749-6632.1978.tb41947.x; JENCKS WP, 1989, J BIOL CHEM, V264, P18855; Karplus M, 1986, Methods Enzymol, V131, P283; KNOWLES AF, 1975, J BIOL CHEM, V250, P1949; KRAUSE KL, 1985, P NATL ACAD SCI USA, V82, P1643, DOI 10.1073/pnas.82.6.1643; KUBO K, 1990, BIOCHIM BIOPHYS ACTA, V1040, P251, DOI 10.1016/0167-4838(90)90084-S; Lakowicz J.R., 2010, PRINCIPLE FLUORESCEN, DOI 10.1007/978-0-387-46312-4/COVER; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; LUDI H, 1985, BIOCHIM BIOPHYS ACTA, V821, P137, DOI 10.1016/0005-2736(85)90164-6; LUEDTKE R, 1981, BIOCHEMISTRY-US, V20, P2927, DOI 10.1021/bi00513a033; MACLENNAN DH, 1985, NATURE, V316, P696, DOI 10.1038/316696a0; MASUDA H, 1973, BIOCHEMISTRY-US, V12, P4581, DOI 10.1021/bi00747a006; MITCHINSON C, 1982, FEBS LETT, V146, P87, DOI 10.1016/0014-5793(82)80710-2; ONEAL SG, 1979, BIOCHEM BIOPH RES CO, V89, P845, DOI 10.1016/0006-291X(79)91855-2; PASCOLINI D, 1988, BIOPHYS J, V54, P679, DOI 10.1016/S0006-3495(88)83003-0; PICK U, 1981, FEBS LETT, V123, P127, DOI 10.1016/0014-5793(81)80035-X; SAITONAKATSUKA K, 1987, J BIOCHEM-TOKYO, V101, P365, DOI 10.1093/oxfordjournals.jbchem.a121921; SCOTT TL, 1985, J BIOL CHEM, V260, P4421; SILVIUS Jr, 1984, BIOCHEMISTRY-US, V23, P538, DOI 10.1021/bi00298a022; SQUIER TC, 1990, J BIOL CHEM, V265, P13713; SQUIER TC, 1988, J BIOL CHEM, V263, P9171; SQUIER TC, 1987, J BIOL CHEM, V262, P4748; SQUIER TC, 1988, J BIOL CHEM, V263, P9162; STOKES DL, 1990, BIOPHYS J, V57, P1, DOI 10.1016/S0006-3495(90)82501-7; TAYLOR KA, 1986, J MOL BIOL, V187, P417, DOI 10.1016/0022-2836(86)90442-0; WATANABE T, 1982, BIOCHEMISTRY-US, V21, P3254, DOI 10.1021/bi00257a001; WEBER K, 1969, J BIOL CHEM, V244, P4406; YAMAMOTO T, 1984, J BIOCHEM, V95, P1783, DOI 10.1093/oxfordjournals.jbchem.a134791; YAMASHITA T, 1987, J BIOCHEM, V101, P377, DOI 10.1093/oxfordjournals.jbchem.a121922; YANTORNO RE, 1983, J BIOCHEM-TOKYO, V94, P1137, DOI 10.1093/oxfordjournals.jbchem.a134458; YASUOKAYABE K, 1983, J BIOCHEM-TOKYO, V94, P665, DOI 10.1093/oxfordjournals.jbchem.a134406; [No title captured]	66	33	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 5	1992	267	10					6952	6962						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HM053	1532393				2022-12-25	WOS:A1992HM05300077
J	LEWIS, MJ; SIMONI, RD				LEWIS, MJ; SIMONI, RD			DELETIONS IN HYDROPHILIC DOMAINS OF SUBUNIT-A FROM THE ESCHERICHIA-COLI F1F0-ATP SYNTHASE INTERFERE WITH MEMBRANE INSERTION OR F0 ASSEMBLY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTON-TRANSLOCATING ATPASE; H+-ATPASE; ALPHA-SUBUNIT; UNC OPERON; F0F1-ATPASE; MUTATIONS; PORE; RECONSTITUTION; MUTAGENESIS; FUSIONS	The alpha-subunit is a membrane component of the F1F0-ATP synthase from Escherichia coli. Regions of alpha which appear important for membrane insertion or F0 assembly have been identified by analysis of both deletion mutants and fusion proteins which link the mutant alpha-subunits to alkaline phosphatase. This analysis suggests the hydrophilic, amino-terminal domain of alpha is required for proper membrane targeting and/or insertion of the nascent polypeptide. In addition, the subcellular fractionation of four different alpha-subunit-beta-galactosidase fusion proteins suggests this domain is localized to the periplasm, in agreement with a proposed topological model of the protein (Lewis, M. J., Chang, J. A., and Simoni, R. D. (1990) J. Biol. Chem. 265, 10541-10550). Deletions within the next three putative loops of alpha appear to have no significant effect on membrane targeting or insertion. Rather, they seem to interfere with the subsequent assembly of a functional enzyme.	STANFORD UNIV,DEPT BIOL SCI,STANFORD,CA 94305	Stanford University					NIGMS NIH HHS [GM 18539] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM018539, R37GM018539] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARIS JP, 1985, J BIOL CHEM, V260, P1207; Ausubel FM, 1987, CURRENT PROTOCOLS MO, V1-5; CAIN BD, 1988, J BIOL CHEM, V263, P6606; CAIN BD, 1986, J BIOL CHEM, V261, P43; CAIN BD, 1989, J BIOL CHEM, V264, P3292; CASADABAN MJ, 1980, J MOL BIOL, V138, P179, DOI 10.1016/0022-2836(80)90283-1; DECKER KP, 1982, J BACTERIOL, V152, P815; DECKERSHEBESTREIT G, 1986, EUR J BIOCHEM, V161, P225, DOI 10.1111/j.1432-1033.1986.tb10146.x; DUNN SD, 1981, ARCH BIOCHEM BIOPHYS, V210, P421, DOI 10.1016/0003-9861(81)90206-X; EYA S, 1988, J BIOL CHEM, V263, P10056; EYA S, 1991, ARCH BIOCHEM BIOPHYS, V284, P71, DOI 10.1016/0003-9861(91)90265-K; FERGUSON SJ, 1985, BIOCHIM BIOPHYS ACTA, V811, P47, DOI 10.1016/0304-4173(85)90005-9; FILLINGAME RH, 1975, J BACTERIOL, V124, P870, DOI 10.1128/JB.124.2.870-883.1975; FOSTER DL, 1982, J BIOL CHEM, V257, P2009; FRIEDL P, 1983, EMBO J, V2, P99, DOI 10.1002/j.1460-2075.1983.tb01388.x; FUTAI M, 1989, ANNU REV BIOCHEM, V58, P111; GIBSON TJ, 1984, THESIS CAMBRIDGE; GUNSALUS RP, 1982, P NATL ACAD SCI-BIOL, V79, P320, DOI 10.1073/pnas.79.2.320; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; HERMOLIN J, 1983, J BIOL CHEM, V258, P4550; HOFFMAN CS, 1985, P NATL ACAD SCI USA, V82, P5107, DOI 10.1073/pnas.82.15.5107; HOWITT SM, 1988, BIOCHIM BIOPHYS ACTA, V936, P74, DOI 10.1016/0005-2728(88)90253-8; HOWITT SM, 1990, BIOCHIM BIOPHYS ACTA, V1015, P264, DOI 10.1016/0005-2728(90)90030-8; HSU DKW, 1990, THESIS U MARYLAND BA; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; KANAZAWA H, 1982, ANN NY ACAD SCI, V402, P45, DOI 10.1111/j.1749-6632.1982.tb25731.x; KLAUSNER R D, 1989, New Biologist, V1, P3; KLIONSKY DJ, 1983, J BIOL CHEM, V258, P136; KLIONSKY DJ, 1985, J BIOL CHEM, V260, P1200; KUMAMOTO CA, 1986, J BIOL CHEM, V261, P37; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; LEWIS MJ, 1990, J BIOL CHEM, V265, P10541; LIGHTOWLERS RN, 1988, BIOCHIM BIOPHYS ACTA, V933, P241, DOI 10.1016/0005-2728(88)90031-X; LIGHTOWLERS RN, 1987, BIOCHIM BIOPHYS ACTA, V894, P399, DOI 10.1016/0005-2728(87)90118-6; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Maniatis T., 1982, MOL CLONING; MANOIL C, 1985, P NATL ACAD SCI USA, V82, P8129, DOI 10.1073/pnas.82.23.8129; MANOIL C, 1990, J BACTERIOL, V172, P1035, DOI 10.1128/jb.172.2.1035-1042.1990; Miller J. H., 1972, EXPT MOL GENETICS, P431; NEGRIN RS, 1980, J BIOL CHEM, V255, P5643; PAULE CR, 1989, ARCH BIOCHEM BIOPHYS, V274, P270, DOI 10.1016/0003-9861(89)90439-6; SCHNEIDER E, 1982, EUR J BIOCHEM, V126, P149, DOI 10.1111/j.1432-1033.1982.tb06759.x; SCHNEIDER E, 1985, EMBO J, V4, P515, DOI 10.1002/j.1460-2075.1985.tb03658.x; SCHNEIDER E, 1987, MICROBIOL REV, V51, P477, DOI 10.1128/MMBR.51.4.477-497.1987; SEBALD W, 1980, P NATL ACAD SCI-BIOL, V77, P785, DOI 10.1073/pnas.77.2.785; SENIOR AE, 1988, PHYSIOL REV, V68, P177, DOI 10.1152/physrev.1988.68.1.177; SOLOMON KA, 1989, J BACTERIOL, V171, P3039, DOI 10.1128/jb.171.6.3039-3045.1989; VIK SB, 1988, J BIOL CHEM, V263, P6599; VIK SB, 1990, ARCH BIOCHEM BIOPHYS, V282, P125, DOI 10.1016/0003-9861(90)90095-G; VIK SB, 1987, J BIOL CHEM, V262, P8340; WALKER JE, 1984, BIOCHIM BIOPHYS ACTA, V768, P164, DOI 10.1016/0304-4173(84)90003-X; ZOLLER MJ, 1983, METHOD ENZYMOL, V100, P468	53	17	18	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 15	1992	267	5					3482	3489						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HD154	1531341				2022-12-25	WOS:A1992HD15400101
J	PELISSIER, PP; CAMOUGRAND, NM; MANON, ST; VELOURS, GM; GUERIN, MG				PELISSIER, PP; CAMOUGRAND, NM; MANON, ST; VELOURS, GM; GUERIN, MG			REGULATION BY NUCLEAR GENES OF THE MITOCHONDRIAL SYNTHESIS OF SUBUNIT-6 AND SUBUNIT-8 OF THE ATP SYNTHASE OF SACCHAROMYCES-CEREVISIAE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE; TRANSCRIPTION FACTOR; TRANSLATION SYSTEM; YEAST MITOCHONDRIA; OLI2 REGION; BIOGENESIS; MUTANT; GENOME; DNA; IDENTIFICATION	The nuclear mutant AB1-4A/8/100, a respiratory-competent strain altered in the regulation of ATP synthesis, has been shown to be modified in the relative stoichiometry of the mtDNA-encoded proteolipids of the F0 sector of ATP synthase: the ratios mutant/wild type of the proteolipids were equal to 0.4/0.7/1 for Su8/Su6/Su9, respectively. This defect results from the simultaneous presence of two nuclear genes which promote a cryosensitive phenotype on a nonfermentable carbon source. Measurements of mitochondrial protein synthesis carried out "in vivo" and "in organello" evidenced a specific defect in the synthesis of subunits 6 and 8. Measurements of the steady state levels of mitochondrial mRNA showed that the defect in subunits 6 and 8 was correlated with a modification of the expression of cotranscript ATP8-ATP6. This cotranscript is matured at a unique site to give two cotranscripts of 4600 and 5200 bases in length. In mutant mitochondria, the ratio between both cotranscripts, 5200/4600, was lowered. In parallel, expression of the whole mitochondrial transcription unit supporting the genes COXI, ATP8, ATP6, and RF3 was enhanced. However, despite this over expression, the amount of the long cotranscript ATP8-ATP6 remained lower than in wild type mitochondria.	UNIV BORDEAUX 2,CNRS,INST BIOCHIM CELLULAIRE & NEUROCHIM,1 RUE CAMILLE ST SAENS,F-33077 BORDEAUX,FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite de Bordeaux			Manon, Stéphen/C-7088-2017	Manon, Stephen/0000-0002-5792-1084				ACKERMAN SH, 1990, P NATL ACAD SCI USA, V87, P4986, DOI 10.1073/pnas.87.13.4986; ACKERMAN SH, 1991, FEBS LETT, V278, P234, DOI 10.1016/0014-5793(91)80124-L; ACKERMAN SH, 1990, J BIOL CHEM, V265, P9952; CHRISTIANSON T, 1983, J BIOL CHEM, V258, P4025; COBON GS, 1982, CURR GENET, V5, P97, DOI 10.1007/BF00365700; DEZAMAROCZY M, 1986, GENE, V47, P155, DOI 10.1016/0378-1119(86)90060-0; DIECKMANN CL, 1985, J BIOL CHEM, V260, P1513; DOUGLAS MG, 1976, P NATL ACAD SCI USA, V73, P1083, DOI 10.1073/pnas.73.4.1083; FOX TD, 1988, PHILOS T ROY SOC B, V319, P97, DOI 10.1098/rstb.1988.0034; GILBERT JM, 1970, J BIOL CHEM, V245, P2342; GRIVELL LA, 1989, EUR J BIOCHEM, V182, P477, DOI 10.1111/j.1432-1033.1989.tb14854.x; Guerin B, 1979, Methods Enzymol, V55, P149; GUERIN M, 1992, IN PRESS NUCLEIC ACI; HADIKUSUMO RG, 1988, BIOCHIM BIOPHYS ACTA, V933, P212, DOI 10.1016/0005-2728(88)90072-2; HAFFTER P, 1990, GENETICS, V125, P495; KELLY JL, 1986, J BIOL CHEM, V261, P340; KELLY JL, 1986, J BIOL CHEM, V261, P348; KROCZEK RA, 1990, ANAL BIOCHEM, V184, P90, DOI 10.1016/0003-2697(90)90017-4; KUZELA S, 1988, BIOCHIM BIOPHYS ACTA, V936, P372, DOI 10.1016/0005-2728(88)90013-8; LISOWSKY T, 1989, MOL GEN GENET, V219, P125, DOI 10.1007/BF00261167; MACKEE EE, 1984, J BIOL CHEM, V259, P9320; MANON S, 1988, EUR J BIOCHEM, V174, P399, DOI 10.1111/j.1432-1033.1988.tb14111.x; MANON S, 1989, BIOCHIM BIOPHYS ACTA, V985, P127, DOI 10.1016/0005-2736(89)90356-8; MANON S, 1988, EUR J BIOCHEM, V172, P205, DOI 10.1111/j.1432-1033.1988.tb13874.x; MANON S, 1992, IN PRESS EUR J BIOCH; MUELLER DM, 1986, J BIOL CHEM, V261, P1756; NAKAGAWA K, 1991, J BIOL CHEM, V266, P1977; NOVITSKI CE, 1984, CURR GENET, V8, P135, DOI 10.1007/BF00420226; PAYNE MJ, 1991, CURR GENET, V19, P343, DOI 10.1007/BF00309594; PFISTERER J, 1981, P NATL ACAD SCI-BIOL, V78, P4917, DOI 10.1073/pnas.78.8.4917; RODEL G, 1986, CURR GENET, V11, P41, DOI 10.1007/BF00389424; SCHINKEL AH, 1986, EMBO J, V5, P1041, DOI 10.1002/j.1460-2075.1986.tb04320.x; SENIOR AE, 1988, PHYSIOL REV, V68, P177, DOI 10.1152/physrev.1988.68.1.177; TICHO BS, 1988, J BIOL CHEM, V263, P10096; TZAGOLOFF A, 1986, ANNU REV BIOCHEM, V55, P249, DOI 10.1146/annurev.bi.55.070186.001341; WHITFIELD CD, 1990, J BIOL CHEM, V265, P18852; WINKLEY CS, 1985, J BIOL CHEM, V260, P4214	37	17	18	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1992	267	4					2467	2473						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HB532	1531141				2022-12-25	WOS:A1992HB53200055
J	SASAKI, T; INUI, M; KIMURA, Y; KUZUYA, T; TADA, M				SASAKI, T; INUI, M; KIMURA, Y; KUZUYA, T; TADA, M			MOLECULAR MECHANISM OF REGULATION OF CA2+ PUMP ATPASE BY PHOSPHOLAMBAN IN CARDIAC SARCOPLASMIC-RETICULUM - EFFECTS OF SYNTHETIC PHOSPHOLAMBAN PEPTIDES ON CA2+ PUMP ATPASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3'-5'-MONOPHOSPHATE-DEPENDENT PROTEIN-KINASE; CALCIUM-TRANSPORT; CA-2+ PUMP; MONOCLONAL-ANTIBODY; RAPID PURIFICATION; PHOSPHORYLATION; STIMULATION; RECONSTITUTION; MUSCLE; CA-2+-ATPASE	The molecular mechanism of the regulation of Ca2+ pump ATPase by phospholamban in cardiac sarcoplasmic reticulum was examined using synthetic peptides of phospholamban and purified Ca2+ pump ATPase from cardiac sarcoplasmic reticulum. The phospholamban monomer of 52 amino acid residues contains two distinct domains, the cytoplasmic (amino acids 1-30) and the transmembrane (amino acids 31-52) domains. The peptide corresponding to the amino acids 1-31 of phospholamban (PLN 1-31) decreased the V(max) of the Ca2+-dependent ATPase activity in dose-dependent manner, while it had no effect on the affinity of the ATPase for Ca2+ (K(Ca)). On the other hand, the peptide corresponding to the amino acids 28-47 of phospholamban (PLN 28-47) increased the K(Ca) from 0.52 to 1.33-mu-M without significant change in the V(max) value when reconstituted into vesicles with the ATPase. Essentially the same results as PLN 28-47 were obtained with the peptide corresponding to the amino acids 8-47 of phospholamban (PLN 8-47). The inhibitory effects of PLN 1-31 and PLN 8-47 on the ATPase were reversed by cAMP-dependent phosphorylation of the peptides (Ser16). These results indicate that phospholamban suppresses Ca2+ pump ATPase at two different sites, the cytoplasmic domain for V(max) and the transmembrane domain for K(Ca), and that cAMP-dependent phosphorylation de-suppresses these inhibitory effects on the ATPase.	OSAKA UNIV, SCH MED,DEPT MED 1,1-1-50 FUKUSHIMA,FUKUSHIMA KU, OSAKA 553, JAPAN; OSAKA UNIV, SCH MED, DEPT PATHOPHYSIOL, FUKUSHIMA KU, OSAKA 553, JAPAN; OSAKA UNIV, SCH MED, DEPT NEUROCHEM & NEUROPHARMACOL, OSAKA 553, JAPAN	Osaka University; Osaka University; Osaka University								BARTLETT GR, 1959, J BIOL CHEM, V234, P466; BOYOT P, 1989, ARCH BIOCHEM BIOPHYS, V269, P639, DOI 10.1016/0003-9861(89)90149-5; CHAMBERLAIN BK, 1983, J BIOL CHEM, V258, P6602; CHIESI M, 1989, FEBS LETT, V244, P241, DOI 10.1016/0014-5793(89)81201-3; CLARKE DM, 1990, J BIOL CHEM, V265, P6262; Erickson B. W., 1976, PROTEINS, VII, P255; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; FUJII J, 1989, J BIOL CHEM, V264, P12950; FUJII J, 1987, J CLIN INVEST, V79, P301, DOI 10.1172/JCI112799; FUJII J, 1986, BIOCHEM BIOPH RES CO, V138, P1044, DOI 10.1016/S0006-291X(86)80387-4; FUJII J, 1990, FEBS LETT, V273, P232, DOI 10.1016/0014-5793(90)81092-3; HICKS MJ, 1979, CIRC RES, V44, P384, DOI 10.1161/01.RES.44.3.384; INUI M, 1985, J BIOL CHEM, V260, P3708; INUI M, 1986, J BIOL CHEM, V261, P1794; JAMES P, 1989, NATURE, V342, P90, DOI 10.1038/342090a0; JONES LR, 1985, J BIOL CHEM, V260, P7721; KASAHARA M, 1977, J BIOL CHEM, V252, P7384; KIM HW, 1990, J BIOL CHEM, V265, P1702; KIMURA Y, 1991, IN PRESS J MOL CELL; KIRCHBERGER MA, 1974, J BIOL CHEM, V249, P6616; KIRCHBERGER MA, 1986, BIOCHEMISTRY-US, V24, P5484; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEPEUCH CJ, 1979, BIOCHEMISTRY-US, V18, P5150, DOI 10.1021/bi00590a019; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MALLER JL, 1978, P NATL ACAD SCI USA, V75, P248, DOI 10.1073/pnas.75.1.248; REYNARD AM, 1961, J BIOL CHEM, V236, P2277; SAKAKIBARA S, 1967, B CHEM SOC JPN, V40, P2164, DOI 10.1246/bcsj.40.2164; SHAMOO AE, 1985, CURR TOP MEMBR TRANS, V25, P131; SIMMERMAN HKB, 1986, J BIOL CHEM, V261, P3333; SUZUKI T, 1987, BIOCHEM CELL BIOL, V65, P302, DOI 10.1139/o87-039; SUZUKI T, 1986, J BIOL CHEM, V261, P7018; TADA M, 1975, J BIOL CHEM, V250, P2640; TADA M, 1979, J BIOL CHEM, V254, P319; TADA M, 1983, J MOL CELL CARDIOL, V15, P335, DOI 10.1016/0022-2828(83)91345-7; TADA M, 1989, BIOESSAYS, V10, P157, DOI 10.1002/bies.950100505; TADA M, 1974, J BIOL CHEM, V249, P6174; TADA M, 1982, ANNU REV PHYSIOL, V44, P401, DOI 10.1146/annurev.ph.44.030182.002153; TADA M, 1988, METHOD ENZYMOL, V157, P107; VANWINKLE WB, 1978, J BIOL CHEM, V253, P8671; WEGENER AD, 1984, J BIOL CHEM, V259, P1834; XU ZC, 1989, J BIOL CHEM, V264, P16644; YAMAMOTO Y, 1990, BIOCHEMISTRY-US, V29, P8998, DOI 10.1021/bi00490a017	42	178	180	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 25	1992	267	3					1674	1679						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HA485	1530941				2022-12-25	WOS:A1992HA48500044
J	ORREN, DK; SELBY, CP; HEARST, JE; SANCAR, A				ORREN, DK; SELBY, CP; HEARST, JE; SANCAR, A			POST-INCISION STEPS OF NUCLEOTIDE EXCISION REPAIR IN ESCHERICHIA-COLI - DISASSEMBLY OF THE UVRBC-DNA COMPLEX BY HELICASE-II AND DNA-POLYMERASE-I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							(A)BC EXCINUCLEASE; GENE-PRODUCT; PROTEIN; NUCLEASE; ENZYME	UvrA, UvrB, and UvrC initiate nucleotide excision repair by incising a damaged DNA strand on each side of the damaged nucleotide. This incision reaction is substoichiometric with regard to UvrB and UvrC, suggesting that both proteins remain bound following incision and do not "turn over." The addition of only helicase II to such reaction mixtures turns over UvrC; UvrB turnover requires the addition of helicase II, DNA polymerase I, and deoxynucleoside triphosphates. Column chromatography and psoralen photocross-linking experiments show that following incision, the damaged oligomer remains associated with the undamaged strand, UvrB, and UvrC in a post-incision complex. Helicase II releases the damaged oligomer and UvrC from this complex, making repair synthesis possible; DNase I footprinting experiments show that UvrB remains bound to the resulting gapped DNA until displaced by DNA polymerase I. The specific binding of UvrB to a psoralen adduct in DNA inhibits psoralen-mediated DNA-DNA cross-linking, yet promotes the formation of UrvB-psoralen-DNA cross-links. The discovery of psoralen-UvrB photocross-linking offers the potential of active-site labeling.	UNIV CALIF BERKELEY, LAWRENCE BERKELEY LAB, DEPT CHEM, BERKELEY, CA 94720 USA; UNIV CALIF BERKELEY, LAWRENCE BERKELEY LAB, DIV CHEM BIODYNAM, BERKELEY, CA 94720 USA	United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley	ORREN, DK (corresponding author), UNIV N CAROLINA, SCH MED, DEPT BIOCHEM & BIOPHYS, CHAPEL HILL, NC 27599 USA.				NIGMS NIH HHS [GM32833] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032833] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERTRANDBURGGRAF E, 1991, J MOL BIOL, V219, P27, DOI 10.1016/0022-2836(91)90854-Y; CARON PR, 1985, P NATL ACAD SCI USA, V82, P4925, DOI 10.1073/pnas.82.15.4925; CIMINO GD, 1985, ANNU REV BIOCHEM, V54, P1151, DOI 10.1146/annurev.bi.54.070185.005443; ELLIS RJ, 1989, TRENDS BIOCHEM SCI, V14, P339, DOI 10.1016/0968-0004(89)90168-0; GAMPER H, 1984, PHOTOCHEM PHOTOBIOL, V40, P29, DOI 10.1111/j.1751-1097.1984.tb04549.x; HUSAIN I, 1985, P NATL ACAD SCI USA, V82, P6774, DOI 10.1073/pnas.82.20.6774; KASSAVETIS GA, 1990, CELL, V60, P235, DOI 10.1016/0092-8674(90)90739-2; KUEMMERLE NB, 1980, J BACTERIOL, V142, P535, DOI 10.1128/JB.142.2.535-546.1980; KUMURA K, 1985, NUCLEIC ACIDS RES, V13, P1483, DOI 10.1093/nar/13.5.1483; LIN JJ, 1991, P NATL ACAD SCI USA, V88, P6824, DOI 10.1073/pnas.88.15.6824; MATSON SW, 1986, J BIOL CHEM, V261, P169; OH EY, 1986, NUCLEIC ACIDS RES, V14, P8557, DOI 10.1093/nar/14.21.8557; ORREN DK, 1989, P NATL ACAD SCI USA, V86, P5237, DOI 10.1073/pnas.86.14.5237; ORREN DK, 1990, J BIOL CHEM, V265, P15796; RUNYON GT, 1989, J BIOL CHEM, V264, P17502; RUNYON GT, 1990, P NATL ACAD SCI USA, V87, P6383, DOI 10.1073/pnas.87.16.6383; SANCAR A, 1984, P NATL ACAD SCI-BIOL, V81, P7397, DOI 10.1073/pnas.81.23.7397; SANCAR A, 1983, CELL, V33, P249, DOI 10.1016/0092-8674(83)90354-9; SANCAR A, 1988, ANNU REV BIOCHEM, V57, P29, DOI 10.1146/annurev.bi.57.070188.000333; SEELEY TW, 1990, J BIOL CHEM, V265, P7158; SELBY CP, 1990, MUTAT RES, V236, P203, DOI 10.1016/0921-8777(90)90005-P; SIBGHATULLAH, 1990, NUCLEIC ACIDS RES, V18, P5051, DOI 10.1093/nar/18.17.5051; TANG MS, 1981, MUTAT RES, V80, P15, DOI 10.1016/0027-5107(81)90174-3; THOMAS DC, 1985, J BIOL CHEM, V260, P9875; VANHOUTEN B, 1987, J BIOL CHEM, V262, P13180; VANHOUTEN B, 1988, J BIOL CHEM, V263, P16553; VANHOUTEN B, 1990, MICROBIOL REV, V54, P18, DOI 10.1128/MMBR.54.1.18-51.1990; VANSLUIS CA, 1974, MUTAT RES, V25, P273, DOI 10.1016/0165-1218(74)90004-4; WICKNER S, 1991, NATURE, V350, P165, DOI 10.1038/350165a0; YEUNG AT, 1986, NUCLEIC ACIDS RES, V14, P4539; YOUNGS DA, 1973, J BACTERIOL, V116, P175, DOI 10.1128/JB.116.1.175-182.1973	31	131	131	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 15	1992	267	2					780	788						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY960	1530937				2022-12-25	WOS:A1992GY96000019
J	KRISHNASWAMY, S; FIELD, KA; EDGINGTON, TS; MORRISSEY, JH; MANN, KG				KRISHNASWAMY, S; FIELD, KA; EDGINGTON, TS; MORRISSEY, JH; MANN, KG			ROLE OF THE MEMBRANE-SURFACE IN THE ACTIVATION OF HUMAN COAGULATION FACTOR-X	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE FACTOR PATHWAY; K-DEPENDENT PROTEINS; BOVINE FACTOR-V; FACTOR-VII; PHOSPHOLIPID-VESICLES; BLOOD-COAGULATION; HUMAN-PROTHROMBIN; PROCOAGULANT ACTIVITY; PARA-AMINOBENZAMIDINE; EXTRINSIC PATHWAY	Coagulation factor X is activated by the extrinsic Xase complex composed of factor VIIa associated with the integral membrane protein tissue factor. The kinetics of human factor X activation was studied following reconstitution of this reaction system using purified human proteins and synthetic phospholipid vesicles composed of phosphatidylcholine and phosphatidylserine (PCPS) or phosphatidylcholine alone (PC). Factor X activation was evaluated by discontinuous measurements of the amidolytic activity of the product, factor Xa, or continuously monitored using the fluorescent serine protease inhibitor 4-aminobenzamidine. The results of both techniques were verified by direct physical measurements of zymogen activation using SDS-polyacrylamide gel electrophoresis. The rate of factor X activation with PC vesicles was less than 5% of that observed with PCPS vesicles. Since factor X does not bind to vesicles containing only PC, these data suggested an important role for the substrate-membrane interaction in the catalytic cycle. The importance of the substrate-membrane interaction in the activation process was investigated by using membrane-binding proteins to compete with the substrate for combining sites on PCPS vesicles. Prothrombin fragment 1 was an inhibitor of factor X activation. The dependence of inhibition by fragment 1 on PCPS and factor X was consistent with a significant reduction in initial velocity due to the displacement of factor X from the membrane surface. The inhibition data also suggested that the membrane-bound pool of factor X was the preferred substrate for the human extrinsic Xase complex. The influence of PCPS concentrations on the rate of factor X activation was systematically investigated. Increasing concentrations of PCPS resulted in a modest change in the K(m,app) and a dramatic change in the V(max,app) for the reaction. The initial velocity data could be globally analyzed according to the preferential utilization of membrane-bound factor X with the intrinsic kinetic constants: K(m) congruent-to 1 muM and k(cat) = 37 s-1 at saturating PCPS. In addition, the equilibrium parameters for the factor X-membrane interaction inferred from these studies were in excellent agreement with the directly determined values. Collectively, the data suggest that the substrate-membrane interaction must precede catalysis for the efficient activation of human factor X by the extrinsic Xase complex.	UNIV VERMONT, DEPT BIOCHEM, BURLINGTON, VT 05405 USA; SCRIPPS CLIN & RES FDN, DEPT IMMUNOL, VASC BIOL GRP, LA JOLLA, CA 92037 USA	University of Vermont; Scripps Research Institute	KRISHNASWAMY, S (corresponding author), EMORY UNIV, SCH MED, DEPT MED, DIV HAEMATOL, DRAWER AR, ATLANTA, GA 30322 USA.		Morrissey, James H./GLR-5645-2022; Morrissey, James H/H-4933-2011	Morrissey, James H/0000-0002-1570-1569; Field, Kenneth/0000-0001-7417-4386	NHLBI NIH HHS [HL-34575, HL-35058, HL-38337] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL035058, R37HL034575, R29HL038337, R01HL034575] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BACH R, 1986, BIOCHEMISTRY-US, V25, P4007, DOI 10.1021/bi00362a005; BACH R, 1988, BIOCHEMISTRY-US, V27, P4227, DOI 10.1021/bi00412a004; BACH R, 1990, P NATL ACAD SCI USA, V87, P6995, DOI 10.1073/pnas.87.18.6995; BAJAJ SP, 1981, J BIOL CHEM, V256, P253; BAJAJ SP, 1981, PREP BIOCHEM, V11, P397, DOI 10.1080/00327488108065531; BERG OG, 1985, BIOPHYS J, V47, P1, DOI 10.1016/S0006-3495(85)83870-4; BERG OG, 1985, ANNU REV BIOPHYS BIO, V14, P131, DOI 10.1146/annurev.biophys.14.1.131; BEVILACQUA MP, 1984, J EXP MED, V160, P618, DOI 10.1084/jem.160.2.618; Bevington PR, 1969, DATA REDUCTION ERROR; BLOOM JW, 1979, BIOCHEMISTRY-US, V18, P4419, DOI 10.1021/bi00587a023; BOM VJJ, 1990, BIOCHEM J, V265, P327, DOI 10.1042/bj2650327; CARSON SD, 1980, SCIENCE, V208, P307, DOI 10.1126/science.7367861; CRAIG PA, 1989, J BIOL CHEM, V264, P5452; DISCIPIO RG, 1977, BIOCHEMISTRY-US, V16, P698, DOI 10.1021/bi00623a022; DRAKE TA, 1989, AM J PATHOL, V134, P1087; DUGGLEBY RG, 1986, BIOCHEM J, V235, P613, DOI 10.1042/bj2350613; DURBIN J, 1951, BIOMETRIKA, V38, P159, DOI 10.1093/biomet/38.1-2.159; EVANS SA, 1982, J BIOL CHEM, V257, P3014; FORMAN SD, 1986, P NATL ACAD SCI USA, V83, P4675, DOI 10.1073/pnas.83.13.4675; GALVIN JB, 1987, J BIOL CHEM, V262, P2199; GREGORY SA, 1985, J CLIN INVEST, V76, P2440, DOI 10.1172/JCI112260; HIGGINS DL, 1983, J BIOL CHEM, V258, P6503; JACKSON CM, 1984, PROG HEMOST THROMB, V7, P55; JACKSON CM, 1975, THROMB DIATH HAEMOST, V34, P561; JENNY R, 1986, PREP BIOCHEM, V16, P227, DOI 10.1080/00327488608062468; KRISHNASWAMY S, 1988, J BIOL CHEM, V263, P5714; KRISHNASWAMY S, 1992, J BIOL CHEM, V267, P23696; KRISHNASWAMY S, 1988, J BIOL CHEM, V263, P3823; KRISHNASWAMY S, 1987, J BIOL CHEM, V262, P3291; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAWSON JH, 1992, J BIOL CHEM, V267, P4834; MACKMAN N, 1990, P NATL ACAD SCI USA, V87, P2254, DOI 10.1073/pnas.87.6.2254; MANN KG, 1981, METHOD ENZYMOL, V80, P286; MANN KG, 1988, ANNU REV BIOCHEM, V57, P915, DOI 10.1146/annurev.bi.57.070188.004411; MATHESON IBC, 1987, ANAL INSTRUM, V16, P345; MERTENS K, 1984, BIOCHEM J, V223, P599, DOI 10.1042/bj2230599; MONROE DM, 1988, ANAL BIOCHEM, V172, P427, DOI 10.1016/0003-2697(88)90465-4; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; MORRISSEY JH, 1987, CELL, V50, P129, DOI 10.1016/0092-8674(87)90669-6; MORRISSEY JH, 1988, THROMB RES, V50, P481, DOI 10.1016/0049-3848(88)90197-1; NAKAGAKI T, 1991, BIOCHEMISTRY-US, V30, P10819, DOI 10.1021/bi00109a001; NELSESTUEN GL, 1978, BIOCHEMISTRY-US, V17, P2134, DOI 10.1021/bi00604a017; NEMERSON Y, 1986, BIOCHEMISTRY-US, V25, P4020, DOI 10.1021/bi00362a006; NEMERSON Y, 1985, THROMB RES, V40, P351, DOI 10.1016/0049-3848(85)90270-1; NEMERSON Y, 1982, PROG HEMOST THROMB, V6, P237; NEMERSON Y, 1969, J CLIN INVEST, V48, P322, DOI 10.1172/JCI105988; NEMERSON Y, 1988, BLOOD, V71, P1; RAO LVM, 1988, P NATL ACAD SCI USA, V85, P6687, DOI 10.1073/pnas.85.18.6687; RICHTER PH, 1974, BIOPHYS CHEM, V2, P255, DOI 10.1016/0301-4622(74)80050-5; RUF W, 1991, J BIOL CHEM, V266, P2158; SILVERBERG SA, 1977, J BIOL CHEM, V252, P8481; VANDEWAART P, 1984, BIOCHEMISTRY-US, V23, P2838, DOI 10.1021/bi00307a047; VANDIEIJEN G, 1981, BIOCHEMISTRY-US, V20, P7096, DOI 10.1021/bi00528a007; ZAKIM D, 1989, METHOD ENZYMOL, V171, P253; ZUR M, 1982, J BIOL CHEM, V257, P5623; [No title captured]	56	135	145	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 25	1992	267	36					26110	26120						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KD073	1464622				2022-12-25	WOS:A1992KD07300079
J	LEAMON, CP; LOW, PS				LEAMON, CP; LOW, PS			CYTOTOXICITY OF MOMORDIN-FOLATE CONJUGATES IN CULTURED HUMAN-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBOSOME-INACTIVATING PROTEINS; RECEPTOR-MEDIATED ENDOCYTOSIS; THY 1.1 ANTIBODY; HUMAN KB-CELLS; BINDING-PROTEIN; DIPHTHERIA-TOXIN; MA104 CELLS; IMMUNOTOXINS; DELIVERY; INVITRO	We have shown previously that macromolecules can be nondestructively delivered into cultured cells via folate receptor-mediated endocytosis if the macromolecules are conjugated to folic acid prior to addition to receptor-bearing cells (Leamon, C.P., and Low, P. S. (1991) Proc. Natl. Acad. Sci. U.S.A. 88, 5572-5576). Although an intracellular destination of the folate-linked proteins could be easily documented, the spatial resolution of the earlier data was insufficient to evaluate whether any endocytosed material was delivered into the cytosol. To resolve this issue, a folate-toxin conjugate was constructed using the impermeable ribosome-inactivating protein, momordin. Diminution of [H-3]leucine incorporation into newly synthesized protein was then employed as a quantitative measure of the entry of the toxin into the cytosol. In studies with both HeLa and KB cells, cellular protein synthesis was found to be inhibited in a time- and concentration-dependent manner by the momordin-folate conjugate, but not by the underivatized toxin. IC50 values centered around 10(-9) M for the folate-linked samples. These observations provide direct evidence that folate conjugates not only reach the cytosol, but do so in a functionally active form.	PURDUE UNIV,DEPT CHEM,W LAFAYETTE,IN 47907	Purdue University System; Purdue University; Purdue University West Lafayette Campus				Low, Philip/0000-0001-9042-5528				ANTONY AC, 1985, J BIOL CHEM, V260, P4911; BARBIERI L, 1980, BIOCHEM J, V186, P443, DOI 10.1042/bj1860443; BASU SK, 1990, BIOCHEM PHARMACOL, V40, P1941, DOI 10.1016/0006-2952(90)90222-7; BLAKLEY RL, 1969, BIOCH FOLIC ACID REL, P760; HENDERSON GB, 1988, J MEMBRANE BIOL, V101, P247, DOI 10.1007/BF01872839; HUCKETT B, 1990, BIOCHEM PHARMACOL, V40, P253, DOI 10.1016/0006-2952(90)90686-F; HUDSON TH, 1991, J BIOL CHEM, V266, P18586; JANSEN G, 1989, CANCER RES, V49, P2455; KAMEN BA, 1989, J CLIN INVEST, V84, P1379, DOI 10.1172/JCI114310; KAMEN BA, 1988, J BIOL CHEM, V263, P13602; KANE MA, 1989, LAB INVEST, V60, P737; KANE MA, 1988, J CLIN INVEST, V81, P1398, DOI 10.1172/JCI113469; LEAMON CP, 1991, P NATL ACAD SCI USA, V88, P5572, DOI 10.1073/pnas.88.13.5572; MAGERSTADT M, 1991, ANTIBODY CONJUGATES; MCHUGH M, 1979, J BIOL CHEM, V254, P1312; MISKIMINS WK, 1979, BIOCHEM BIOPH RES CO, V91, P143, DOI 10.1016/0006-291X(79)90595-3; OELTMANN TN, 1979, J BIOL CHEM, V254, P1028; OLSNES S, 1989, IMMUNOL TODAY, V10, P291; Olsnes S., 1982, PHARMACOL THERAPEUT, V15, P355; POZNANSKY MJ, 1989, FASEB J, V3, P152, DOI 10.1096/fasebj.3.2.2644147; RASO V, 1984, RECEPTOR MEDIATED TA, P73; ROTHBERG KG, 1990, J CELL BIOL, V110, P637, DOI 10.1083/jcb.110.3.637; SAID HM, 1987, AM J PHYSIOL, V252, pG229, DOI 10.1152/ajpgi.1987.252.2.G229; Sambrook J, 1989, MOL CLONING LABORATO; SIEGALL CB, 1990, J BIOL CHEM, V265, P16318; SIMPSON DL, 1982, CELL, V29, P469, DOI 10.1016/0092-8674(82)90163-5; STIRPE F, 1988, NUCLEIC ACIDS RES, V16, P1349, DOI 10.1093/nar/16.4.1349; STIRPE F, 1986, FEBS LETT, V195, P1, DOI 10.1016/0014-5793(86)80118-1; STIRPE F, 1988, BRIT J CANCER, V58, P558, DOI 10.1038/bjc.1988.258; THORPE PE, 1985, J NATL CANCER I, V75, P151; THORPE PE, 1981, EUR J BIOCHEM, V116, P447, DOI 10.1111/j.1432-1033.1981.tb05356.x; WAGNER E, 1990, P NATL ACAD SCI USA, V87, P3410, DOI 10.1073/pnas.87.9.3410; WU GY, 1987, J BIOL CHEM, V262, P4429	33	130	164	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1992	267	35					24966	24971						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KB603	1460001				2022-12-25	WOS:A1992KB60300012
J	PEARSON, D; SASSE, J				PEARSON, D; SASSE, J			DIFFERENTIAL REGULATION OF BIGLYCAN AND DECORIN BY RETINOIC ACID IN BOVINE CHONDROCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DERMATAN SULFATE PROTEOGLYCANS; GROWTH-FACTOR-BETA; MESSENGER-RNA; ARTICULAR-CARTILAGE; TRANSCRIPTIONAL REPRESSION; NEGATIVE REGULATION; KIDNEY-CELLS; CORE PROTEIN; MATRIX; GENE	The small, leucine-rich proteoglycans, decorin and biglycan, are prominent components of many extracellular matrices and are differentially regulated in various tissues. We have examined the effects of retinoic acid (RA) on the expression of biglycan and decorin at the protein and mRNA levels in cultured bovine articular chondrocytes. Biglycan protein expression is rapidly turned off after 1-2 days of treatment with RA. In contrast, decorin protein expression is increased 12-18-fold following 3 days of RA treatment. The level of biglycan mRNA was also rapidly reduced upon RA treatment, mirroring the protein expression. The reduction was apparent by 6 h, and, by 4 days, the levels were nearly undetectable. In contrast, decorin mRNA was induced upon treatment with RA. The increase in decorin message levels was first apparent by 24 h, reaching maximum by 2 days, and remained constant through 4 days. The repression of biglycan mRNA displayed equal sensitivity to RA concentrations from 10(-5) to 10(-9) M. Decorin mRNA was induced in a dose-dependent fashion by RA. Retinoic acid at a concentration of 10(-5) M, the highest dose examined, resulted in maximal induction of the message, and control levels were obtained with 10(-8) M. The protein synthesis inhibitor cycloheximide inhibited the induction of decorin mRNA, indicating that the induction by RA was a secondary event. In contrast, the repression of biglycan by RA was not significantly altered by cycloheximide, showing that the repression was a direct effect. Actinomycin D inhibited the induction of decorin mRNA, indicating that transcription was required for the induction. Nuclear run-on assays confirmed that RA was regulating biglycan mRNA expression at the transcription level. A 24-h RA treatment decreased the level of transcription of the biglycan gene 5-fold. In contrast, no increase in transcription from the decorin gene could be detected by nuclear run-on assays. Therefore, the elevation in decorin mRNA levels observed after RA treatment was the result of a post-transcriptional event, most likely the consequence of stabilization of the message. This study demonstrates that the genes for these two similar proteoglycans are under very different forms of regulation by RA in chondrocytes. The pattern of differential expression of biglycan and decorin could serve as an additional marker for indicating changes of the cartilage phenotype.	UNIV S FLORIDA,SCH MED,DEPT BIOCHEM & MOLEC BIOL,TAMPA,FL 33620; SHRINERS HOSP CRIPPLED CHILDREN,TAMPA UNIT,TAMPA,FL 33612; UNIV S FLORIDA,INST BIOMOLEC SCI,TAMPA,FL 33620	State University System of Florida; University of South Florida; State University System of Florida; University of South Florida								ANDRUS L, 1988, J BIOL CHEM, V263, P6183; BASSOLS A, 1988, J BIOL CHEM, V263, P3039; BIANCO P, 1990, J HISTOCHEM CYTOCHEM, V38, P1549, DOI 10.1177/38.11.2212616; CHEAH KSE, 1985, P NATL ACAD SCI USA, V82, P2555, DOI 10.1073/pnas.82.9.2555; CHIU R, 1987, NATURE, V329, P648, DOI 10.1038/329648a0; CHOI HU, 1989, J BIOL CHEM, V264, P2876; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAY AA, 1987, BIOCHEM J, V248, P801, DOI 10.1042/bj2480801; FISHER LW, 1991, J BIOL CHEM, V266, P14371; FISHER LW, 1989, J BIOL CHEM, V264, P4571; GIGUERE V, 1989, NATURE, V337, P566, DOI 10.1038/337566a0; HORTON WE, 1987, DEV BIOL, V123, P508, DOI 10.1016/0012-1606(87)90409-X; JONES NC, 1988, GENE DEV, V2, P267, DOI 10.1101/gad.2.3.267; KAHARI VM, 1991, J BIOL CHEM, V266, P10608; KOCHHAR DM, 1967, ACTA PATHOL MIC SC, V70, P398; KOSHER RA, 1983, CARTILAGE, V1; KRUSIUS T, 1986, P NATL ACAD SCI USA, V83, P7683, DOI 10.1073/pnas.83.20.7683; KUETTNER KE, 1982, J CELL BIOL, V93, P743, DOI 10.1083/jcb.93.3.743; LEVINE M, 1989, CELL, V59, P405, DOI 10.1016/0092-8674(89)90024-X; Maniatis T., 1982, MOL CLONING; MENDLER M, 1989, J CELL BIOL, V108, P191, DOI 10.1083/jcb.108.1.191; MEYER ME, 1989, CELL, V57, P433, DOI 10.1016/0092-8674(89)90918-5; NAGAMINE Y, 1983, CELL, V32, P1181, DOI 10.1016/0092-8674(83)90301-X; NEAME PJ, 1989, J BIOL CHEM, V264, P8653; NICHOLSON RC, 1990, EMBO J, V9, P4443, DOI 10.1002/j.1460-2075.1990.tb07895.x; PENTTINEN RP, 1988, P NATL ACAD SCI USA, V85, P1105, DOI 10.1073/pnas.85.4.1105; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; RENKAWITZ R, 1990, TRENDS GENET, V6, P192, DOI 10.1016/0168-9525(90)90176-7; ROSENBERG LC, 1985, J BIOL CHEM, V260, P6304; RUOSLAHTI E, 1991, CELL, V64, P867, DOI 10.1016/0092-8674(91)90308-L; RUOSLAHTI E, 1988, ANNU REV CELL BIOL, V4, P229, DOI 10.1146/annurev.cb.04.110188.001305; SAMPAIO LD, 1988, BIOCHEM J, V254, P757; SAWHNEY RS, 1991, J BIOL CHEM, V266, P9230; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; TABIN CJ, 1991, CELL, V66, P199, DOI 10.1016/0092-8674(91)90612-3; VOGEL KG, 1984, BIOCHEM J, V223, P587, DOI 10.1042/bj2230587; YAMADA Y, 1990, ANN NY ACAD SCI, V580, P81, DOI 10.1111/j.1749-6632.1990.tb17920.x; YAMAGUCHI Y, 1988, NATURE, V336, P244, DOI 10.1038/336244a0; YAMAGUCHI Y, 1990, NATURE, V346, P281, DOI 10.1038/346281a0; ZELENT A, 1989, NATURE, V339, P714, DOI 10.1038/339714a0	40	37	40	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1992	267	35					25364	25370						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KB603	1460033				2022-12-25	WOS:A1992KB60300069
J	HEBERT, DN; CARRUTHERS, A				HEBERT, DN; CARRUTHERS, A			GLUCOSE TRANSPORTER OLIGOMERIC STRUCTURE DETERMINES TRANSPORTER FUNCTION - REVERSIBLE REDOX-DEPENDENT INTERCONVERSIONS OF TETRAMERIC AND DIMERIC GLUT1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ERYTHROCYTE SUGAR TRANSPORTER; CYTOCHALASIN-B BINDING; MONOSACCHARIDE TRANSPORTER; LIGAND-BINDING; KINETICS; CARRIER; PROTEIN; MEMBRANE; CELLS; SIZE	This study investigates the relationship between human erythrocyte glucose transport protein (GLUT1) oligomeric structure and glucose transporter function. Oligomeric structure was analyzed by hydrodynamic studies of cholate-solubilized GLUT1, by chemical cross-linking studies of membrane-resident GLUT1 and by using conformation-specific antibodies. Transporter function (substrate binding) was analyzed by equilibrium cytochalasin B and D-glucose binding measurements. Erythrocyte-resident glucose transporter is a GLUT1 homotetramer, binds 1 mol of cytochalasin B/2 mol of GLUT1, and presents at least two binding SiteS to D-glucose. Native structure and function appear to be stabilized by intramolecular disulfide bonds and are preserved during GLUT1 purification by the omission of reductant. Native structure is independent of in vitro and in vivo membrane GLUT1 density but is transformed to dimeric GLUT1 by alkaline reduction. Dimeric GLUT1 binds 1 mol of cytochalasin B/mol of GLUT1, presents a single population of binding sites to D-glucose, and is obtained upon GLUT1 purification in the presence of reductant. Native structure and function are restored by treatment of dimeric GLUT1 with glutathione-disulfide (K0.5, glutathione disulfide = 29 muM). We propose that native structure is established prior to transporter translocation to the plasma membrane and that intra-subunit disulfide bonds promote cooperative subunit interactions that stabilize transporter structure and function.	UNIV MASSACHUSETTS,MED CTR,DEPT BIOCHEM & MOLEC BIOL,373 PLANTAT ST,WORCESTER,MA 01605; UNIV MASSACHUSETTS,MED CTR,PROGRAM MOLEC MED,WORCESTER,MA 01605	University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester					NIDDK NIH HHS [DK 44888, DK 36081] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK036081, R01DK044888, R56DK036081] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		APPLEMAN JR, 1989, BIOCHEMISTRY-US, V28, P8221, DOI 10.1021/bi00446a038; BAKER GF, 1973, J PHYSIOL-LONDON, V231, P143, DOI 10.1113/jphysiol.1973.sp010225; BALDWIN SA, 1982, BIOCHEMISTRY-US, V21, P3836, DOI 10.1021/bi00259a018; CAIRNS MT, 1984, BIOCHEM J, V221, P179, DOI 10.1042/bj2210179; CAREY MC, 1970, AM J MED, V49, P590, DOI 10.1016/S0002-9343(70)80127-9; CARRUTHERS A, 1984, BIOCHEMISTRY-US, V23, P6901, DOI 10.1021/bi00321a096; CARRUTHERS A, 1991, BIOCHEMISTRY-US, V30, P3898, DOI 10.1021/bi00230a014; CARRUTHERS A, 1989, BIOCHEMISTRY-US, V28, P8337, DOI 10.1021/bi00447a011; CARRUTHERS A, 1986, BIOCHEMISTRY-US, V25, P3592, DOI 10.1021/bi00360a018; CARRUTHERS A, 1986, J BIOL CHEM, V261, P1028; CARRUTHERS A, 1991, BIOCHEMISTRY-US, V30, P3907, DOI 10.1021/bi00230a015; CARRUTHERS A, 1988, ADV MEMBRANE FLUDITY, V2, P201; CASEY JR, 1991, J BIOL CHEM, V266, P15726; CLARKE S, 1975, J BIOL CHEM, V250, P5459; CONNOLLY TJ, 1985, J BIOL CHEM, V260, P2617; GEISELMANN J, 1992, BIOCHEMISTRY-US, V31, P121, DOI 10.1021/bi00116a018; GEISELMANN J, 1992, BIOCHEMISTRY-US, V31, P111, DOI 10.1021/bi00116a017; GORGA FR, 1982, BIOCHEMISTRY-US, V21, P1905, DOI 10.1021/bi00537a031; HACKENBERG H, 1980, BIOCHEMISTRY-US, V19, P548, DOI 10.1021/bi00544a024; HARRISON SA, 1990, J BIOL CHEM, V265, P5793; HEBERT DN, 1991, BIOCHEMISTRY-US, V30, P4654, DOI 10.1021/bi00233a003; HELGERSON AL, 1987, J BIOL CHEM, V262, P5464; JANIAK MJ, 1976, BIOCHEMISTRY-US, V15, P4575, DOI 10.1021/bi00666a005; JARVIS SM, 1986, BIOCHIM BIOPHYS ACTA, V855, P312, DOI 10.1016/0005-2736(86)90179-3; JUNG CY, 1980, J BIOL CHEM, V255, P361; KONDO T, 1987, P NATL ACAD SCI USA, V84, P7373, DOI 10.1073/pnas.84.21.7373; LOWE AG, 1986, BIOCHIM BIOPHYS ACTA, V857, P146, DOI 10.1016/0005-2736(86)90342-1; LUNDAHL P, 1991, BIOCHIM BIOPHYS ACTA, V26, P177; MUECKLER M, 1985, SCIENCE, V229, P941, DOI 10.1126/science.3839598; NAFTALIN RJ, 1977, MEMBRANE TRANSPORT R, P257; PESSINO A, 1991, J BIOL CHEM, V26, P20213; RAO US, 1990, J BIOL CHEM, V265, P7227; SOGIN DC, 1980, BIOCHEMISTRY-US, V19, P5417, DOI 10.1021/bi00564a041; STITT BL, 1988, J BIOL CHEM, V263, P11130; WHEELER TJ, 1981, J BIOL CHEM, V256, P8907; WIDDAS WF, 1952, J PHYSIOL-LONDON, V118, P23, DOI 10.1113/jphysiol.1952.sp004770; ZOCCOLI MA, 1978, J BIOL CHEM, V253, P6923	37	135	136	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1992	267	33					23829	23838						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JZ239	1429721				2022-12-25	WOS:A1992JZ23900061
J	CONNOR, J; PAK, CH; ZWAAL, RFA; SCHROIT, AJ				CONNOR, J; PAK, CH; ZWAAL, RFA; SCHROIT, AJ			BIDIRECTIONAL TRANSBILAYER MOVEMENT OF PHOSPHOLIPID ANALOGS IN HUMAN RED-BLOOD-CELLS - EVIDENCE FOR AN ATP-DEPENDENT AND PROTEIN-MEDIATED PROCESS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-ERYTHROCYTE MEMBRANE; ASYMMETRIC DISTRIBUTION; PHOSPHATIDYLSERINE; TRANSLOCATION; PHOSPHATIDYLCHOLINE; MAINTENANCE; INVOLVEMENT; TRANSPORTER; SYSTEM; MODEL	The transbilayer movement of fluorescent and isotopically labeled analogs of phosphatidylserine (PS), phosphatidylethanolamine (PE), and phosphatidylcholine (PC) from the outer to the inner leaflet (flip) and from the inner to the outer leaflet (flop) of human red blood cells (RBC) was examined. The inward movement of 1-oleoyl-2-(N-4-nitrobenzo-2-oxa-1,3-diazole-aminocaproyl)-(C6-NBD-), 1-oleoyl-2-(N-(3-(3-[I-125]iodo-4-hydroxyphenyl)propionyl)aminoc aproyl)-(C6-I-125-), or 1-oleoyl-2-(N-(3-3-[I-125]iodo-4-azidophenyl) propionyl)aminocaproyl- (C6-I-125-Na-) analogs of PC and PE were relatively slow. In contrast, all analogs of PS and PE analogs containing aminododecanoic acid (C12 lipids) were rapidly transported to the cell's inner leaflet. Analysis of I-125-N3 lipids cross-linked to membrane proteins revealed labeling of 32-kDa Rh polypeptides that was dependent on the lipid's capacity to be transported to the inner leaflet but was independent of lipid species. To investigate whether lipids could also be transported from the inner to the outer leaflet, lipid probes residing exclusively in the inner leaflet were monitored for their appearance in the outer leaflet. Lipid movement could not be detected at 0-degrees-C. At 37-degrees-C, however, approximately 70% of the PC, 40% of the PE, and 15% of the PS redistributed to the cells outer leaflet, thereby attaining their normal asymmetric distribution. Continuous incubation in the presence of bovine serum albumin depleted the cells of the analogs (t1/2 approximately 1.5 h) in a manner that was independent of lipid species. Similar to the inward movement of aminophospholipids, the outward movement of PC, PE, and PS was ATP-dependent and could be blocked by oxidation of membrane sulfhydryls and by the histidine reagent bromophenacyl bromide. Evidence is presented which suggests that the outward movement of lipids is an intrinsic property of the cells unrelated to compensatory mechanisms due to an imbalance in lipid distribution.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT CELL BIOL,BOX 173,1515 HOLCOMBE BLVD,HOUSTON,TX 77030; UNIV LIMBURG,DEPT BIOCHEM,6200 MD MAASTRICHT,NETHERLANDS	University of Texas System; UTMD Anderson Cancer Center; Hasselt University; Maastricht University					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041714] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 41714] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDRICK C, 1991, BIOCHIM BIOPHYS ACTA, V1064, P235, DOI 10.1016/0005-2736(91)90307-T; BITBOL M, 1988, P NATL ACAD SCI USA, V85, P6783, DOI 10.1073/pnas.85.18.6783; BLOY C, 1988, MOL IMMUNOL, V25, P925, DOI 10.1016/0161-5890(88)90131-9; BUTIKOFER P, 1990, J BIOL CHEM, V265, P16035; CHATTOPADHYAY A, 1988, BIOCHIM BIOPHYS ACTA, V938, P24, DOI 10.1016/0005-2736(88)90118-6; COLLEAU M, 1991, CHEM PHYS LIPIDS, V57, P29, DOI 10.1016/0009-3084(91)90046-E; COMFURIUS P, 1990, J LIPID RES, V31, P1719; CONNOR J, 1990, BIOCHIM BIOPHYS ACTA, V1025, P82, DOI 10.1016/0005-2736(90)90193-R; CONNOR J, 1988, BIOCHEMISTRY-US, V27, P848, DOI 10.1021/bi00403a002; CONNOR J, 1991, BIOCHIM BIOPHYS ACTA, V1066, P37, DOI 10.1016/0005-2736(91)90247-6; CONNOR J, 1990, BIOCHEMISTRY-US, V29, P37, DOI 10.1021/bi00453a005; DALEKE DL, 1985, BIOCHEMISTRY-US, V24, P5406, DOI 10.1021/bi00341a019; DAO HNT, 1991, ANAL BIOCHEM, V196, P46; GORDESKY SE, 1975, J MEMBRANE BIOL, V20, P111, DOI 10.1007/BF01870631; HERRMANN A, 1986, BIOSCIENCE REP, V6, P185, DOI 10.1007/BF01115005; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWNDES JM, 1988, BIOCHIM BIOPHYS ACTA, V904, P154; MARTIN OC, 1987, J BIOL CHEM, V262, P5890; MIDDELKOOP E, 1986, BIOCHIM BIOPHYS ACTA, V855, P421, DOI 10.1016/0005-2736(86)90087-8; MORROT G, 1989, BIOCHEMISTRY-US, V28, P3456, DOI 10.1021/bi00434a046; SCHROIT AJ, 1987, BIOCHEMISTRY-US, V26, P1812, DOI 10.1021/bi00381a004; SCHROIT AJ, 1983, BIOCHEMISTRY-US, V22, P3617, DOI 10.1021/bi00284a012; SCHROIT AJ, 1990, BIOCHEMISTRY-US, V29, P10303, DOI 10.1021/bi00497a003; SEIGNEURET M, 1984, P NATL ACAD SCI-BIOL, V81, P3751, DOI 10.1073/pnas.81.12.3751; TILLEY L, 1986, FEBS LETT, V194, P21, DOI 10.1016/0014-5793(86)80044-8; VERKLEIJ AJ, 1973, BIOCHIM BIOPHYS ACTA, V323, P178, DOI 10.1016/0005-2736(73)90143-0; WILLIAMSON P, 1987, FEBS LETT, V219, P316, DOI 10.1016/0014-5793(87)80243-0; ZWAAL RFA, 1975, BIOCHIM BIOPHYS ACTA, V406, P83, DOI 10.1016/0005-2736(75)90044-9; [No title captured]	29	158	160	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1992	267	27					19412	19417						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JP593	1527061				2022-12-25	WOS:A1992JP59300061
J	ODOM, OW; HARDESTY, B				ODOM, OW; HARDESTY, B			USE OF 50 S-BINDING ANTIBIOTICS TO CHARACTERIZE THE RIBOSOMAL SITE TO WHICH PEPTIDYL-TRANSFER RNA IS BOUND	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI RIBOSOMES; SYNERGIMYCINS; ERYTHROMYCIN; MOVEMENT	Five antibiotics (puromycin, erythromycin, lincomycin, sparsomycin, and virginiamycin M1) that bind specifically to the 50 S ribosomal subunit near the peptidyl transferase center were used to compare and characterize the positions of bound AcylPhe-tRNA in the puromycin-reactive and -unreactive states. Binding of the antibiotics was quantitatively measured by their perturbation of fluorescence from probes attached to the alpha-amino group of Phe-tRNA. Derivatives of three probes with differing chemical characteristics and environmental sensitivities were used: a coumarin, an aminonaphthalenesulfonate, and a pyrene. The effects of the antibiotics on the fluorescence of labeled AcylPhe-tRNAs in the two states, while generally qualitatively similar, are nonetheless quantitatively distinct, as are the calculated binding constants for the antibiotics. Puromycin, as reported earlier, binds to both the puromycin-reactive and -unreactive states, but its dissociation constant is higher for the latter state. Erythromycin binds tightly to ribosomes bearing labeled AcylPhe-tRNA in either the puromycin-reactive or -unreactive state. Its effect on the fluorescence of the labeled tRNA is very similar in the two states, except with the pyrene probe, where it has a larger effect in the puromycin-reactive state. Lincomycin and sparsomycin bind to both ribosomal states, but both bind more tightly to the puromycin-reactive state, the extent of the difference varying with the identity of the fluorescent probe. Virginiamycin M1 binds to ribosomes with AcylPhe-tRNA in the puromycin-reactive site, but its binding could not be detected to ribosomes with AcylPhe-tRNA in the puromycin-unreactive site.	UNIV TEXAS, CLAYTON FDN BIOCHEM INST, DEPT CHEM & BIOCHEM, AUSTIN, TX 78712 USA	University of Texas System; University of Texas Austin								BARTA A, 1990, RIBOSOME, P358; COCITO C, 1971, BIOCHIMIE, V53, P763, DOI 10.1016/S0300-9084(71)80117-7; CONTRERAS A, 1977, EUR J BIOCHEM, V74, P539, DOI 10.1111/j.1432-1033.1977.tb11422.x; Cundliffe E., 1986, STRUCTURE FUNCTION G, P586; DIGIAMBATTISTA M, 1987, J BIOL CHEM, V262, P8591; DIGIAMBATTISTA M, 1989, J ANTIMICROB CHEMOTH, V24, P485; FERNANDEZMUNOZ R, 1971, EUR J BIOCHEM, V23, P185, DOI 10.1111/j.1432-1033.1971.tb01607.x; GOLDBERG IH, 1967, BIOCHEMISTRY-US, V6, P383, DOI 10.1021/bi00854a003; HARDESTY B, 1986, STRUCTURE FUNCTION G, P495; MOAZED D, 1989, NATURE, V342, P142, DOI 10.1038/342142a0; ODOM OW, 1987, BIOCHIMIE, V69, P925, DOI 10.1016/0300-9084(87)90226-4; ODOM OW, 1990, BIOCHEMISTRY-US, V29, P10734, DOI 10.1021/bi00500a004; ODOM OW, 1991, EUR J BIOCHEM, V198, P713, DOI 10.1111/j.1432-1033.1991.tb16071.x; ODOM OW, 1988, METHOD ENZYMOL, V164, P174; ODOM OW, 1984, BIOCHEMISTRY-US, V23, P5069, DOI 10.1021/bi00316a037; ODOM OW, 1980, BIOCHEMISTRY-US, V19, P5947, DOI 10.1021/bi00567a001; Ottenheijm H C, 1986, Prog Med Chem, V23, P219, DOI 10.1016/S0079-6468(08)70344-8; PESTKA S, 1974, ANTIMICROB AGENTS CH, V5, P255, DOI 10.1128/AAC.5.3.255; PESTKA S, 1972, J BIOL CHEM, V247, P4669; SKINNER R, 1983, J BIOL CHEM, V258, P2702; TAI PC, 1974, BIOCHEMISTRY-US, V13, P4653, DOI 10.1021/bi00719a029; WATSON JD, 1964, B SOC CHIM BIOL, V46, P1399	22	16	16	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 25	1992	267	27					19117	19122						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JP593	1527036				2022-12-25	WOS:A1992JP59300020
J	CLEGHON, V; KLESSIG, DF				CLEGHON, V; KLESSIG, DF			CHARACTERIZATION OF THE NUCLEIC-ACID BINDING REGION OF ADENOVIRUS DNA-BINDING PROTEIN BY PARTIAL PROTEOLYSIS AND PHOTOCHEMICAL CROSS-LINKING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-STRANDED-DNA; MESSENGER-RNA; FUNCTIONAL-CHARACTERIZATION; ULTRAVIOLET-IRRADIATION; NUCLEOTIDE-SEQUENCE; AROMATIC RESIDUES; BACTERIOPHAGE-FD; GENE-5 PROTEIN; CELLS; TYPE-5	The nucleic acid binding domain of the adenovirus type 2 (or type 5) DNA-binding protein (DBP) was characterized by using limited proteolysis and photochemical cross-linking. Three proteases were used to generate fragments of DBP which retained the ability to bind to single-stranded DNA. One fragment, a 35-kDa tryptic product, was partially sequenced and found to contain amino acid residues 153 to approximately 470. This fragment further defines the minimum region of the protein which is required for nucleic acid binding. The DNA binding pocket of DBP was defined by using ultraviolet irradiation to cross-link covalently the carboxyl-terminal portion of the protein to the oligonucleotide p(dT)14. Cross-linked complexes were digested with trypsin, and peptides which were associated with the oligonucleotide were isolated by anion-exchange and reverse-phase ion-pairing high performance liquid chromatography. Two DBP peptides comprised of residues 294-308 and 415-434 were isolated by this approach. Sequence analysis indicated that methionine 299 and phenylalanine 418 were probable sites of cross-linking between their respective peptides and the oligonucleotide; hence these residues may represent contact points between DBP and single-stranded DNA. Both residues are highly conserved and are near, but not identical to, regions of the protein implicated previously in DNA binding.	RUTGERS STATE UNIV,WAKSMAN INST MICROBIOL,PISCATAWAY,NJ 08855	Rutgers State University New Brunswick					NIAID NIH HHS [AI 23591] Funding Source: Medline; NIGMS NIH HHS [T32 GM 08339] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI023591] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008339] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAM SA, 1987, J VIROL, V61, P3276, DOI 10.1128/JVI.61.10.3276-3283.1987; ANDERSON CW, 1983, J VIROL, V48, P31, DOI 10.1128/JVI.48.1.31-39.1983; ANDERSON KP, 1984, P NATL ACAD SCI-BIOL, V81, P4023, DOI 10.1073/pnas.81.13.4023; ANDERSON RA, 1975, BIOCHEMISTRY-US, V14, P907, DOI 10.1021/bi00676a006; BABICH A, 1981, CELL, V26, P371, DOI 10.1016/0092-8674(81)90206-3; BERG JM, 1990, J BIOL CHEM, V265, P6513; BRAYER GD, 1983, J MOL BIOL, V169, P565, DOI 10.1016/S0022-2836(83)80065-5; BRAYER GD, 1984, BIOCHEMISTRY-US, V23, P340, DOI 10.1021/bi00297a025; BRUN F, 1975, BIOCHEMISTRY-US, V14, P558, DOI 10.1021/bi00674a015; CARTER TH, 1978, J VIROL, V25, P664, DOI 10.1128/JVI.25.2.664-674.1978; CARTER TH, 1978, J VIROL, V28, P450, DOI 10.1128/JVI.28.2.450-456.1978; CLEGHON VG, 1986, P NATL ACAD SCI USA, V83, P8947, DOI 10.1073/pnas.83.23.8947; EAGLE PA, 1992, VIROLOGY, V187, P777, DOI 10.1016/0042-6822(92)90479-9; FOWLKES DM, 1979, J MOL BIOL, V132, P163, DOI 10.1016/0022-2836(79)90389-9; FRIEFELD BR, 1983, VIROLOGY, V124, P380, DOI 10.1016/0042-6822(83)90354-9; HANDA H, 1983, NATURE, V302, P545, DOI 10.1038/302545a0; HAVRON A, 1977, BIOCHEMISTRY-US, V16, P5631, DOI 10.1021/bi00644a038; HORWITZ MS, 1978, P NATL ACAD SCI USA, V75, P4291, DOI 10.1073/pnas.75.9.4291; KITCHINGMAN GR, 1985, VIROLOGY, V146, P90, DOI 10.1016/0042-6822(85)90055-8; KLESSIG DF, 1980, J MOL BIOL, V139, P221, DOI 10.1016/0022-2836(80)90306-X; KLESSIG DF, 1979, CELL, V17, P957, DOI 10.1016/0092-8674(79)90335-0; KREVOLIN MD, 1987, VIROLOGY, V156, P167, DOI 10.1016/0042-6822(87)90448-X; KRUIJER W, 1983, VIROLOGY, V128, P140, DOI 10.1016/0042-6822(83)90325-2; KRUIJER W, 1982, NUCLEIC ACIDS RES, V10, P4493, DOI 10.1093/nar/10.15.4493; KRUIJER W, 1981, NUCLEIC ACIDS RES, V9, P4439, DOI 10.1093/nar/9.18.4439; KUIL ME, 1989, BIOCHEMISTRY-US, V28, P9795, DOI 10.1021/bi00451a038; LINNE T, 1980, EUR J BIOCHEM, V103, P259, DOI 10.1111/j.1432-1033.1980.tb04310.x; MALY P, 1980, BIOCHEMISTRY-US, V19, P4179, DOI 10.1021/bi00559a007; MERRILL BM, 1988, J BIOL CHEM, V263, P3307; MERRILL BM, 1984, J BIOL CHEM, V259, P850; MEYERS ML, 1990, J BIOL CHEM, V265, P5875; MOLLER K, 1978, J MOL BIOL, V126, P489, DOI 10.1016/0022-2836(78)90055-4; NEALE GAM, 1989, J BIOL CHEM, V264, P3153; NEALE GAM, 1990, J VIROL, V64, P630, DOI 10.1128/JVI.64.2.630-638.1990; NEVINS JR, 1980, P NATL ACAD SCI-BIOL, V77, P1893, DOI 10.1073/pnas.77.4.1893; NICOLAS JC, 1983, VIROLOGY, V126, P228, DOI 10.1016/0042-6822(83)90474-9; PARADISO PR, 1979, J BIOL CHEM, V254, P4739; PRELICH G, 1986, J VIROL, V57, P883, DOI 10.1128/JVI.57.3.883-892.1986; PRIGODICH RV, 1986, BIOCHEMISTRY-US, V25, P3666, DOI 10.1021/bi00360a029; Sambrook J, 1989, MOL CLONING LABORATO; SCHECHTER NM, 1980, BIOCHEMISTRY-US, V19, P2802, DOI 10.1021/bi00553a041; SHAMOO Y, 1988, PROTEINS, V4, P1, DOI 10.1002/prot.340040103; SMITH KC, 1969, BIOCHEM BIOPH RES CO, V34, P354, DOI 10.1016/0006-291X(69)90840-7; SPERLING J, 1976, BIOCHEMISTRY-US, V15, P1489, DOI 10.1021/bi00652a020; TSERNOGLOU D, 1985, FEBS LETT, V188, P248, DOI 10.1016/0014-5793(85)80381-1; VANDERVLIET PC, 1977, VIROLOGY, V80, P98, DOI 10.1016/0042-6822(77)90383-X; VANDERVLIET PC, 1975, VIROLOGY, V67, P415, DOI 10.1016/0042-6822(75)90443-2; VANDERVLIET PC, 1973, NATURE-NEW BIOL, V246, P170, DOI 10.1038/newbio246170a0; VANDERVLIET PC, 1975, J VIROL, V15, P348, DOI 10.1128/JVI.15.2.348-354.1975; VOS HL, 1988, VIROLOGY, V163, P1, DOI 10.1016/0042-6822(88)90227-9; WILLIAMS KR, 1979, J BIOL CHEM, V254, P11051; WILLIAMS KR, 1987, PROTEIN-STRUCT FUNCT, P45	52	15	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1992	267	25					17872	17881						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JM223	1517223				2022-12-25	WOS:A1992JM22300061
J	SHIMBARA, N; ORINO, E; SONE, S; OGURA, T; TAKASHINA, M; SHONO, M; TAMURA, T; YASUDA, H; TANAKA, K; ICHIHARA, A				SHIMBARA, N; ORINO, E; SONE, S; OGURA, T; TAKASHINA, M; SHONO, M; TAMURA, T; YASUDA, H; TANAKA, K; ICHIHARA, A			REGULATION OF GENE-EXPRESSION OF PROTEASOMES (MULTIPROTEASE COMPLEXES) DURING GROWTH AND DIFFERENTIATION OF HUMAN HEMATOPOIETIC-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTICATALYTIC PROTEINASE COMPLEXES; PROMYELOCYTIC LEUKEMIA-CELLS; MOLECULAR-CLONING; RAT-LIVER; MULTIPROTEASE COMPLEXES; SUBUNIT PATTERN; MAJOR SUBUNITS; HL-60 CELLS; HL60 CELLS; KINASE-C	We have reported that proteasomes are expressed at abnormally high levels in various hematopoietic tumor cells (Kumatori, A., Tanaka, K., Inamura, N., Sone, S., Ogura, T., Matsumoto, T., Tachikawa, T., Shin, S., and Ichihara, A. (1990) Proc. Natl. Acad. Sci. U. S. A. 87, 7071-7075). In the present study, we examined changes in the expressions of proteasomes during growth of peripheral T-lymphocytes from healthy adults and differentiation of human leukemic cell lines. Up-regulation of mRNAs encoding multiple proteasome subunits was observed during proliferation of resting T-cells induced by mitogens such as phytohemagglutinin and interleukin-2. In contrast, in vitro terminal differentiation into monocytic, granulocytic, and erythroid cells of various immature leukemic cell lines, such as HL-60 promyelocytic leukemia cells and K562 erythroleukemia cells, by various inducing agents caused rapid and marked down-regulation of proteasome expression, independently of the cell type, direction of differentiation, or type of signal. The syntheses of proteasome subunits of 21-31 kDa and their associated components of 35-110 kDa, measured by [S-35]methionine incorporation, were much higher in mitogen-activated T-cells and unstimulated HL-60 cells, which grow rapidly, than in resting and differentiated cells, indicating apparent correlations of the mRNA levels of proteasomes with their translational activities. However, immunochemically, no detectable difference in the cellular contents of proteasomes was found in these cells in induced and uninduced states for proliferation and differentiation, suggesting accelerated turnover of proteasomes in rapidly proliferating cells. Inhibition of proteasome expression by an antisense oligodeoxynucleotide for the largest proteasome subunit, C2, caused partial arrest of cell cycle progression of T-lymphocytes, suggesting that up-regulation of proteasomes is indispensable for proliferation of the cells. We also observed that the nuclear fraction of proteasomes increased in proliferating T-cells and that proteasomes moved rapidly between the nucleus and cytoplasm during differentiation of HL-60 cells.	UNIV TOKUSHIMA,SCH MED,MED RES LAB,TOKUSHIMA 770,JAPAN; BIOMAT RES INST,YOKOHAMA 244,JAPAN; UNIV TOKUSHIMA,SCH MED,INST ENZYME RES,TOKUSHIMA 770,JAPAN; KANAZAWA UNIV,FAC PHARMACEUT SCI,DIV BIOL,KANAZAWA,ISHIKAWA 920,JAPAN	Tokushima University; Tokushima University; Kanazawa University			Tamura, Tomohiro/M-4732-2018	Tamura, Tomohiro/0000-0003-2409-6556				AHN JY, 1991, J BIOL CHEM, V266, P15746; ARRIGO AP, 1988, NATURE, V331, P192, DOI 10.1038/331192a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREITMAN TR, 1980, P NATL ACAD SCI-BIOL, V77, P2936, DOI 10.1073/pnas.77.5.2936; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CIOE L, 1981, CANCER RES, V41, P237; COLLINS SJ, 1978, P NATL ACAD SCI USA, V75, P2458, DOI 10.1073/pnas.75.5.2458; DEMARS R, 1992, TRENDS CELL BIOL, V2, P80; DICOLA D, 1991, FEBS LETT, V280, P137, DOI 10.1016/0014-5793(91)80222-O; DRISCOLL J, 1992, CELL, V68, P823, DOI 10.1016/0092-8674(92)90024-7; EMORI Y, 1991, MOL CELL BIOL, V11, P344, DOI 10.1128/MCB.11.1.344; FUJIWARA T, 1990, J BIOL CHEM, V265, P16604; FUJIWARA T, 1989, BIOCHEMISTRY-US, V28, P7332, DOI 10.1021/bi00444a028; FURUKAWA Y, 1990, SCIENCE, V250, P805, DOI 10.1126/science.2237430; GOLDBERG AL, 1992, NATURE, V357, P375, DOI 10.1038/357375a0; GOLDBERG AL, 1992, EUR J BIOCHEM, V204, P9; HAASS C, 1989, EXP CELL RES, V180, P243, DOI 10.1016/0014-4827(89)90228-0; HAMADA S, 1983, HISTOCHEMISTRY, V79, P219, DOI 10.1007/BF00489783; HASHIMOT.Y, 1972, GANN, V63, P79; HEINEMEYER W, 1991, EMBO J, V10, P555, DOI 10.1002/j.1460-2075.1991.tb07982.x; HENDIL KB, 1988, BIOCHEM INT, V17, P471; HERSHKO A, 1991, TRENDS BIOCHEM SCI, V16, P265, DOI 10.1016/0968-0004(91)90101-Z; HIDAKA H, 1984, BIOCHEMISTRY-US, V23, P5036, DOI 10.1021/bi00316a032; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661; KANAYAMA H, 1991, CANCER RES, V51, P4467; KANAYAMA H, 1992, IN PRESS EUR J BIOCH; KLEIN U, 1990, J CELL BIOL, V111, P2275, DOI 10.1083/jcb.111.6.2275; KUMATORI A, 1990, P NATL ACAD SCI USA, V87, P7071, DOI 10.1073/pnas.87.18.7071; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE DH, 1992, BIOCHEM BIOPH RES CO, V182, P452, DOI 10.1016/0006-291X(92)91753-D; MCCARTHY DM, 1983, LEUKEMIA RES, V7, P51, DOI 10.1016/0145-2126(83)90057-7; MERRILL AH, 1986, J BIOL CHEM, V261, P2610; ORINO E, 1991, FEBS LETT, V284, P206, DOI 10.1016/0014-5793(91)80686-W; ORLOWSKI M, 1990, BIOCHEMISTRY-US, V29, P10289, DOI 10.1021/bi00497a001; PICKART CM, 1988, J BIOL CHEM, V263, P12028; RECHSTEINER M, 1991, CELL, V66, P615, DOI 10.1016/0092-8674(91)90104-7; RIVETT AJ, 1988, ARCH BIOCHEM BIOPHYS, V268, P1; ROBERTSON M, 1991, NATURE, V353, P300, DOI 10.1038/353300a0; ROVERA G, 1979, P NATL ACAD SCI USA, V76, P2779, DOI 10.1073/pnas.76.6.2779; SCHERRER K, 1990, MOL BIOL REP, V14, P1, DOI 10.1007/BF00422709; SIEBENLIST U, 1988, MOL CELL BIOL, V8, P867, DOI 10.1128/MCB.8.2.867; SIMPSON RU, 1989, J BIOL CHEM, V264, P19710; SPEISER S, 1982, J BIOL CHEM, V257, P4122; TAMURA T, 1991, BIOCHIM BIOPHYS ACTA, V1089, P95, DOI 10.1016/0167-4781(91)90090-9; TANAKA K, 1990, FEBS LETT, V271, P41, DOI 10.1016/0014-5793(90)80367-R; TANAKA K, 1989, BIOCHEM BIOPH RES CO, V159, P1309, DOI 10.1016/0006-291X(89)92253-5; TANAKA K, 1992, NEW BIOL, V4, P173; TANAKA K, 1988, J MOL BIOL, V203, P985, DOI 10.1016/0022-2836(88)90123-4; TANAKA K, 1988, J BIOL CHEM, V263, P16209; TANAKA K, 1989, J CELL PHYSIOL, V139, P34, DOI 10.1002/jcp.1041390107; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TSUKAHARA T, 1991, BIOCHIM BIOPHYS ACTA, V1079, P273, DOI 10.1016/0167-4838(91)90069-C; YASUDA H, 1990, BIOCHEM BIOPH RES CO, V172, P371, DOI 10.1016/0006-291X(90)90682-D	53	111	115	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1992	267	25					18100	18109						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JM223	1517242				2022-12-25	WOS:A1992JM22300095
J	TAYLOR, CG; BAUMAN, PF; SIKORSKI, B; BRAY, TM				TAYLOR, CG; BAUMAN, PF; SIKORSKI, B; BRAY, TM			ELEVATION OF LUNG GLUTATHIONE BY ORAL SUPPLEMENTATION OF L-2-OXOTHIAZOLIDINE-4-CARBOXYLATE PROTECTS AGAINST OXYGEN-TOXICITY IN PROTEIN-ENERGY MALNOURISHED RATS	FASEB JOURNAL			English	Article						GLUTATHIONE; L-2-OXOTHIAZOLIDINE-4-CARBOXYLATE; HYPEROXIA; MAGNETIC RESONANCE IMAGING; MALNUTRITION	HEPATIC GLUTATHIONE; INTRACELLULAR CYSTEINE; DIETARY-PROTEIN; DEFICIENCY; ACID; MALNUTRITION; KWASHIORKOR; INHIBITION; METABOLISM; PRODRUG	The objectives of this study were to investigate whether oral supplementation of L-2-oxothiazolidine-4-carboxylate (OTC) is effective for increasing tissue glutathione (GSH) concentrations in rats fed a diet very low (0.5%) in protein - a model of wasting malnutrition - and to determine the efficacy of OTC for protection against pulmonary oxygen toxicity. Weanling rats, fed a 0.5 or 15% protein diet for 2 wk, were given an oral supplement of OTC, and tissue GSH concentrations were measured over a 24 h period. OTC supplementation to rats fed 0.5% protein significantly increased GSH concentrations in liver and lung, but not in kidney and blood, when compared with the 0.5% protein unsupplemented group. The liver GSH concentration in the 0.5% protein OTC-supplemented group was higher than the 15% control group. Daily supplementation of OTC protected rats from pulmonary oxygen toxicity during 4 days of 85% oxygen exposure as determined by lung-to-body weight ratios and in vivo proton magnetic resonance imaging. Although hyperoxia exposure increased lung GSH concentrations in all groups, OTC supplementation was effective for increasing lung GSH concentration in rats fed the 0.5% protein diet. This study demonstrated that oral administration of OTC to wasting malnourished rats is an effective procedure to increase GSH concentration rapidly in target organs such as lung, and that daily supplementation of a low dose of OTC has a sustained effect to protect against pulmonary oxygen toxicity during 4 days of hyperoxia exposure.	UNIV GUELPH, COLL BIOL SCI, DEPT NUTR SCI, GUELPH N1G 2W1, ONTARIO, CANADA	University of Guelph				Taylor, Carla G./0000-0003-3358-6418				ANDERSON ME, 1985, METHOD ENZYMOL, V113, P548; BAUMAN PF, 1988, CAN J PHYSIOL PHARM, V66, P1048, DOI 10.1139/y88-171; BAUMAN PF, 1988, J NUTR, V118, P1048, DOI 10.1093/jn/118.8.1048; Bieri JG., 1980, J NUTR, V110, P1726, DOI [10.1093/jn/110.8.1726, DOI 10.1093/JN/110.8.1726]; BIRNBAUM SM, 1957, ARCH BIOCHEM BIOPHYS, V72, P428, DOI 10.1016/0003-9861(57)90218-7; BISTRIAN BR, 1974, JAMA-J AM MED ASSOC, V230, P858, DOI 10.1001/jama.230.6.858; BISTRIAN BR, 1976, JAMA-J AM MED ASSOC, V235, P1567, DOI 10.1001/jama.235.15.1567; BRODEUR J, 1987, CAN J PHYSIOL PHARM, V65, P816, DOI 10.1139/y87-131; BUHL R, 1990, P NATL ACAD SCI USA, V87, P4063, DOI 10.1073/pnas.87.11.4063; BUHL R, 1989, LANCET, V2, P1294; CHO ES, 1981, J NUTR, V111, P914, DOI 10.1093/jn/111.5.914; DAVIES MH, 1984, J PHARMACOL METHOD, V12, P191, DOI 10.1016/0160-5402(84)90059-7; DENEKE SM, 1985, J NUTR, V115, P726, DOI 10.1093/jn/115.6.726; DENEKE SM, 1983, J APPL PHYSIOL, V54, P147, DOI 10.1152/jappl.1983.54.1.147; FRAHM J, 1985, J MAGN RESON, V64, P81, DOI 10.1016/0022-2364(85)90033-2; FRANK L, 1988, AM REV RESPIR DIS, V138, P725, DOI 10.1164/ajrccm/138.3.725; GOLDEN MHN, 1987, P NUTR SOC, V46, P53, DOI 10.1079/PNS19870008; GRANOT J, 1986, J MAGN RESON, V70, P488, DOI 10.1016/0022-2364(86)90142-3; HAMILOS DL, 1985, J IMMUNOL, V135, P2740; HAZELTON GA, 1986, J PHARMACOL EXP THER, V237, P341; JACKSON AA, 1986, T ROY SOC TROP MED H, V80, P911, DOI 10.1016/0035-9203(86)90256-7; JAESCHKE H, 1985, BIOCHEM PHARMACOL, V34, P1029, DOI 10.1016/0006-2952(85)90606-9; KAPLOWITZ N, 1983, J PHARMACOL EXP THER, V224, P141; MARTENSSON J, 1989, P NATL ACAD SCI USA, V86, P5296, DOI 10.1073/pnas.86.14.5296; MCFARLANE H, 1970, BMJ-BRIT MED J, V4, P268, DOI 10.1136/bmj.4.5730.268; MEISTER A, 1986, J AM COLL NUTR, V5, P137; MEISTER A, 1983, ANNU REV BIOCHEM, V52, P711, DOI 10.1146/annurev.bi.52.070183.003431; MESINA JE, 1989, BRAIN RES, V478, P181, DOI 10.1016/0006-8993(89)91494-7; MITCHELL JR, 1973, J PHARMACOL EXP THER, V187, P211; MOORE WR, 1989, P NATL ACAD SCI USA, V86, P1461, DOI 10.1073/pnas.86.5.1461; NORTHWAY WH, 1990, ARCH DIS CHILD-FETAL, V65, P1076, DOI 10.1136/adc.65.10_Spec_No.1076; OLNEY JW, 1970, NATURE, V227, P609, DOI 10.1038/227609b0; PORTA P, 1991, J PHARMACOL EXP THER, V257, P331; RICHMAN PG, 1975, J BIOL CHEM, V250, P1422; TATEISHI N, 1974, J BIOCHEM, V75, P93, DOI 10.1093/oxfordjournals.jbchem.a130387; THURNHAM DI, 1990, P NUTR SOC, V49, P247, DOI 10.1079/PNS19900028; TIETZE F, 1969, ANAL BIOCHEM, V27, P502, DOI 10.1016/0003-2697(69)90064-5; TREMPER JC, 1981, AM REV RESPIR DIS, V123, pS118; USA American Institute of Nutrition, 1977, Journal of Nutrition, V107, P1340; VANDERWERF P, 1975, ADV ENZYMOL RAMB, V43, P519; WILLIAMSON JM, 1981, P NATL ACAD SCI-BIOL, V78, P936, DOI 10.1073/pnas.78.2.936; WILLIAMSON JM, 1982, P NATL ACAD SCI-BIOL, V79, P6246, DOI 10.1073/pnas.79.20.6246; WOODWARD B, 1990, ADV NUTR RES, V8, P11; ZLOTKIN SH, 1982, PEDIATR RES, V16, P65; 1985, SAS USERS GUIDE STAT	45	39	42	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	1992	6	12					3101	3107		10.1096/fasebj.6.12.1521740	http://dx.doi.org/10.1096/fasebj.6.12.1521740			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	JN505	1521740	Green Submitted			2022-12-25	WOS:A1992JN50500012
J	RIDGE, KD; BHATTACHARYA, S; NAKAYAMA, TA; KHORANA, HG				RIDGE, KD; BHATTACHARYA, S; NAKAYAMA, TA; KHORANA, HG			LIGHT-STABLE RHODOPSIN .2. AN OPSIN MUTANT (TRP-265 -] PHE) AND A RETINAL ANALOG WITH A NONISOMERIZABLE 11-CIS CONFIGURATION FORM A PHOTOSTABLE CHROMOPHORE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE RHODOPSIN; PHOTOACTIVATABLE ANALOG; CYSTEINE RESIDUE-110	In order to prepare a completely light-stable rhodopsin, we have synthesized an analog, II, of 11-cis retinal in which isomerization at the C-11-C-12 cis-double bond is blocked by formation of a cyclohexene ring from the C-10 to C-13-methyl. We used this analog to generate a rhodopsin-like pigment from opsin expressed in COS-1 cells and opsin from rod outer segments (Bhattacharya, S., Ridge, K. D., Knox, B. E., and Khorana, H. G. (1992) J. Biol. Chem. 267, 6763-6769). The pigment (lambda(max), 512 nm) formed from opsin and analog II (rhodopsin-II) showed ground state properties very similar to those of rhodopsin, but was not entirely stable to light. In the present work, 12 opsin mutants (Ala-117 --> Phe, Glu-122 --> Gln(Ala, Asp), Trp-126 --> Phe(Leu, Ala), Trp-265 --> Ala(Tyr, Phe), Tyr-268 --> Phe, and Ala-292 --> Asp), where the mutations were presumed to be in the retinal binding pocket, were reconstituted with analog II. While all mutants formed rhodopsin-like pigments with II, blue-shifted (12-30 nm) chromophores were obtained with Ala-117 --> Phe, Glu-122 --> Gln(Ala), Trp-126 --> Leu(Ala), and Trp-265 --> Ala(Tyr, Phe) opsins. The extent of chromophore formation was markedly reduced in the mutants Ala-117 --> Phe and Trp-126 --> Ala. Upon illumination, the reconstituted pigments showed varying degrees of light sensitivity; the mutants Trp-126 --> Phe(Leu) showed light sensitivity similar to wild-type. Continuous illumination of the mutants Glu-122 --> Asp, Trp-265 --> Ala, Tyr-268 --> Phe, and Ala-292 --> Asp resulted in hydrolysis of the retinyl Schiff base. Markedly reduced light sensitivity was observed with the mutant Trp-265 --> Tyr, while the mutant Trp-265 --> Phe was light-insensitive. Consistent with this result, the mutant Trp-265 --> Phe showed no detectable light-dependent activation of transducin or phosphorylation by rhodopsin kinase.	MIT, DEPT CHEM, CAMBRIDGE, MA 02139 USA	Massachusetts Institute of Technology (MIT)	RIDGE, KD (corresponding author), MIT, DEPT BIOL, CAMBRIDGE, MA 02139 USA.		Bhattacharya, Santanu/N-6531-2019; Bhattacharya, Santanu/GRS-4780-2022; BHATTACHARYA, SANTANU/E-9739-2010	Bhattacharya, Santanu/0000-0001-9040-8971; BHATTACHARYA, SANTANU/0000-0001-9040-8971	NEI NIH HHS [F53-EY06269] Funding Source: Medline; NIAID NIH HHS [AI 11479] Funding Source: Medline; NIGMS NIH HHS [GM 28289] Funding Source: Medline; NATIONAL EYE INSTITUTE [U10EY006269, U01EY006269] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI011479] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM028289, R01GM028289] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BHATTACHARYA S, 1992, J BIOL CHEM, V267, P6757; DEGRIP WJ, 1990, EUR J BIOCHEM, V191, P211; FUKADA Y, 1984, BIOCHEMISTRY-US, V23, P5826, DOI 10.1021/bi00319a023; FUKUDA MN, 1979, J BIOL CHEM, V254, P8201; HARGRAVE PA, 1977, J SUPRAMOL STR CELL, V6, P559, DOI 10.1002/jss.400060409; KARNIK SS, 1990, J BIOL CHEM, V265, P17520; KARNIK SS, 1988, P NATL ACAD SCI USA, V85, P8459, DOI 10.1073/pnas.85.22.8459; KITO Y, 1968, NATURE, V218, P955, DOI 10.1038/218955a0; NAKAYAMA TA, 1990, J BIOL CHEM, V265, P15762; NAKAYAMA TA, 1991, J BIOL CHEM, V266, P4269; NAKAYAMA TA, 1990, J ORG CHEM, V55, P4953, DOI 10.1021/jo00303a038; OPRIAN DD, 1987, P NATL ACAD SCI USA, V84, P8874, DOI 10.1073/pnas.84.24.8874; OVCHINNIKOV YA, 1988, FEBS LETT, V230, P1, DOI 10.1016/0014-5793(88)80628-8; SAKMAR TP, 1989, P NATL ACAD SCI USA, V86, P8309, DOI 10.1073/pnas.86.21.8309; TSUNASAWA S, 1980, BIOCHIM BIOPHYS ACTA, V624, P218, DOI 10.1016/0005-2795(80)90241-X; WALD G, 1953, J GEN PHYSIOL, V37, P189, DOI 10.1085/jgp.37.2.189; WANG JK, 1980, BIOCHEMISTRY-US, V19, P5111, DOI 10.1021/bi00563a027; ZHUKOVSKY EA, 1989, SCIENCE, V246, P928, DOI 10.1126/science.2573154	18	38	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 5	1992	267	10					6770	6775						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HM053	1532391				2022-12-25	WOS:A1992HM05300048
J	SPARKS, DL; PHILLIPS, MC; LUNDKATZ, S				SPARKS, DL; PHILLIPS, MC; LUNDKATZ, S			THE CONFORMATION OF APOLIPOPROTEIN-A-I IN DISCOIDAL AND SPHERICAL RECOMBINANT HIGH-DENSITY-LIPOPROTEIN PARTICLES - C-13 NMR-STUDIES OF LYSINE IONIZATION BEHAVIOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LECITHIN-CHOLESTEROL ACYLTRANSFERASE; GRADIENT GEL-ELECTROPHORESIS; CELL-DERIVED CHOLESTEROL; REDUCTIVE METHYLATION; PLASMA-LIPOPROTEINS; PROTEIN; COMPLEXES; BINDING; PHOSPHATIDYLCHOLINE; ESTERIFICATION	To elucidate the molecular details of how high density lipoprotein (HDL) microstructure affects the conformation of apolipoprotein (apo) A-I in various classes of HDL particles, apoA-I structure in homogeneous recombinant HDL (rHDL) complexes containing palmitoyl-oleoyl phosphatidylcholine (POPC) and cholesteryl oleate has been investigated by NMR spectroscopy of [C-13]lysine-labeled apoA-I. All Lys residues in rHDL apoA-I were labeled with C-13 by reductive methylation, and then their ionization behavior was characterized by C-13 NMR spectroscopy. Four discoidal particles were prepared to contain from 64 to 256 molecules of POPC and 2 molecules of apoA-1; their major diameters ranged from 9.3 to 12.1 nm. ((CH3)-C-13)2-Lys resonances from apoA-I in discoidal complexes exhibit six distinct chemical shifts at pH 10. The various Lys have pK(alpha) values ranging from 8.3 to 10.5, indicating that they exist in different microenvironments. More than 80% of the Lys residues in small (9.3 nm) discoidal particles titrate at a significantly lower pH than in the large (12.1 nm) discoidal particles. This indicates that apoA-I has a different conformation on the differently sized discs. Two spherical particles were prepared with POPC:cholesteryl oleate:apoA-I molar stoichiometries of 56:16:2 and 232:84:4 and diameters of 7.4 and 12.6 nm, respectively. On spherical rHDL, apoA-I ((CH3)-C-13)2-Lys resonances exhibit five distinct chemical shifts at pH 10. The titration behavior of apoA-I Lys residues is the same in small and large spherical particles, indicating that apoA-I conformation is similar on the two particles. The Lys microenvironments indicate that the conformation of apoA-I in discoidal complexes is dependent on particle size and that these conformations are substantially different from that of apoA-1 on spherical complexes. Lys microenvironments in discoidal complexes differ from that of spherical complexes by 4 to 5 lysines which titrate with relatively low pK(alpha) values on discs. This reflects apparent differences in conformation in the NH2-terminal one-third of apoA-I on discs and spheres.			SPARKS, DL (corresponding author), MED COLL PENN,DEPT BIOCHEM,PHILADELPHIA,PA 19129, USA.			Phillips, Michael/0000-0002-7147-8007	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL022633] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL22633] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDREWS AL, 1976, EUR J BIOCHEM, V64, P549, DOI 10.1111/j.1432-1033.1976.tb10335.x; ATKINSON D, 1986, ANNU REV BIOPHYS BIO, V15, P403; AVIRAM M, 1988, J BIOL CHEM, V263, P16842; BANKA CL, 1991, J BIOL CHEM, V266, P23886; BARTER PJ, 1985, ATHEROSCLEROSIS, V58, P97, DOI 10.1016/0021-9150(85)90058-9; BOGUSKI MS, 1986, J LIPID RES, V27, P1011; BONOMO EA, 1988, J LIPID RES, V29, P380; BRASSEUR R, 1990, BIOCHIM BIOPHYS ACTA, V1043, P245, DOI 10.1016/0005-2760(90)90023-Q; CASTRO GR, 1988, BIOCHEMISTRY-US, V27, P25, DOI 10.1021/bi00401a005; COLLET X, 1991, J BIOL CHEM, V266, P9145; DICK LR, 1988, J BIOL CHEM, V263, P18864; EISENBERG S, 1984, J LIPID RES, V25, P1017; FORTE TM, 1986, METHOD ENZYMOL, V128, P442; FRANCONE OL, 1989, J BIOL CHEM, V264, P7066; GERKEN TA, 1982, J BIOL CHEM, V257, P2894; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; JENTOFT JE, 1989, BIOCHEMISTRY-US, V28, P3250, DOI 10.1021/bi00434a020; JENTOFT JE, 1979, J BIOL CHEM, V254, P4366; JENTOFT N, 1979, J BIOL CHEM, V254, P4359; JENTOFT N, 1983, METHOD ENZYMOL, V91, P570; JONAS A, 1990, J BIOL CHEM, V265, P22123; JONAS A, 1989, J BIOL CHEM, V264, P4818; JONAS A, 1986, METHOD ENZYMOL, V128, P553; JONAS A, 1985, BIOCHEMISTRY-US, V24, P3508, DOI 10.1021/bi00335a018; JONAS A, 1987, PLASMA LIPOPROTEINS, P299; LEBLOND L, 1991, J BIOL CHEM, V266, P6058; LUNDKATZ S, 1988, J BIOL CHEM, V263, P13831; MARCEL YL, 1980, P NATL ACAD SCI-BIOL, V77, P2969, DOI 10.1073/pnas.77.5.2969; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; MITCHELL CD, 1980, J LIPID RES, V21, P625; NICHOLS AV, 1983, BIOCHIM BIOPHYS ACTA, V750, P353, DOI 10.1016/0005-2760(83)90040-1; NICHOLS AV, 1986, METHOD ENZYMOL, V128, P417; NICHOLS AV, 1987, J LIPID RES, V28, P719; PATSCH JR, 1987, J CLIN INVEST, V80, P341, DOI 10.1172/JCI113078; PITTMAN RC, 1987, J BIOL CHEM, V262, P2435; Prevelige P., 1989, PREDICTION PROTEIN S, P391; SCANU AM, 1971, ANAL BIOCHEM, V44, P576, DOI 10.1016/0003-2697(71)90247-8; SCHIFFER M, 1967, BIOPHYS J, V7, P121, DOI 10.1016/S0006-3495(67)86579-2; SEGREST JP, 1974, FEBS LETT, V38, P247, DOI 10.1016/0014-5793(74)80064-5; SEGREST JP, 1992, J LIPID RES, V33, P141; SHERRY AD, 1984, BIOCHEMISTRY-US, V23, P3181, DOI 10.1021/bi00309a011; SOKOLOFF L, 1974, P SOC EXP BIOL MED, V146, P1166; SPARKS DL, 1989, ATHEROSCLEROSIS, V77, P183, DOI 10.1016/0021-9150(89)90080-4; SPARKS DL, 1992, J BIOL CHEM, V267, P25839; SWANEY JB, 1986, METHOD ENZYMOL, V128, P613; TANFORD C, 1955, J AM CHEM SOC, V77, P6409, DOI 10.1021/ja01629a001; WALD JH, 1990, J BIOL CHEM, V265, P20037; WALD JH, 1990, J BIOL CHEM, V265, P20044; WEISWEILER P, 1987, CLIN CHIM ACTA, V169, P249, DOI 10.1016/0009-8981(87)90325-1	49	134	137	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1992	267	36					25830	25838						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KD073	1464597				2022-12-25	WOS:A1992KD07300040
J	SUBRAMANIAM, S; GREENHALGH, DA; KHORANA, HG				SUBRAMANIAM, S; GREENHALGH, DA; KHORANA, HG			ASPARTIC ACID-85 IN BACTERIORHODOPSIN FUNCTIONS BOTH AS PROTON ACCEPTOR AND NEGATIVE COUNTERION TO THE SCHIFF-BASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOMINANT RETINITIS-PIGMENTOSA; AMINO-ACIDS; TRANSLOCATION; PHOTOCYCLE; MUTANTS; SUBSTITUTIONS; SPECTROSCOPY; PHOTOREACTIONS; SPECTRA; RELEASE	In bacteriorhodopsin Asp85 has been proposed to function both as a negative counterion to the Schiff base and as proton acceptor in the early stages of the photocycle. To test this proposal further, we have replaced Asp85 by His. The rationale for this replacement is that although His can function as a proton acceptor, it cannot provide a negative charge at residue 85 to serve as a counterion to the protonated Schiff base. We show here that the absorption spectrum of the D85H mutant is highly sensitive to the pH of the external medium. From spectroscopic titrations, we have determined the apparent pK for deprotonation of the Schiff base to be 8.8 +/- 0.1 and the apparent pK for protonation of the His85 side chain to be approximately 3.5. Between pH 3.5 and 8.8, where the Schiff base is protonated, and the His side chain is deprotonated, the D85H mutant is completely inactive in proton transport. Time-resolved studies show that there is no detectable formation of an M-like intermediate in the photocycle of the D85H mutant. These experiments show that the presence of a neutral proton-accepting moiety at residue 85 is not sufficient for carrying out light-driven proton transport. The requirements at residue 85 are therefore for a group that serves both as a negatively charged counterion and as a proton acceptor.	MIT,DEPT BIOL,RM 18-511,77 MASSACHUSETTS AVE,CAMBRIDGE,MA 02139; MIT,DEPT CHEM,CAMBRIDGE,MA 02139	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)	KHORANA, HG (corresponding author), MIT,DEPT BIOL,RM 18-511,77 MASSACHUSETTS AVE,CAMBRIDGE,MA 02139, USA.			Subramaniam, Sriram/0000-0003-4231-4115				AMES JB, 1990, BIOCHEMISTRY-US, V29, P7181, DOI 10.1021/bi00483a005; BLATZ PE, 1972, BIOCHEMISTRY-US, V11, P848, DOI 10.1021/bi00755a026; BRAIMAN MS, 1988, BIOCHEMISTRY-US, V27, P8516, DOI 10.1021/bi00423a002; BRAIMAN MS, 1991, P NATL ACAD SCI USA, V88, P2388, DOI 10.1073/pnas.88.6.2388; CREIGHTON TE, 1985, PROTEINS STRUCTURES; DRUCKMANN S, 1982, BIOCHEMISTRY-US, V21, P4953, DOI 10.1021/bi00263a019; DRYJA TP, 1991, P NATL ACAD SCI USA, V88, P9370, DOI 10.1073/pnas.88.20.9370; DUNACH M, 1990, J BIOL CHEM, V265, P16978; GERWERT K, 1990, P NATL ACAD SCI USA, V87, P9774, DOI 10.1073/pnas.87.24.9774; GERWERT K, 1989, P NATL ACAD SCI USA, V86, P4943, DOI 10.1073/pnas.86.13.4943; GREENHALGH DA, 1992, J BIOL CHEM, V267, P25734; GREENHALGH DA, 1991, P NATL ACAD SCI USA, V88, P8626, DOI 10.1073/pnas.88.19.8626; GRZESIEK S, 1986, FEBS LETT, V208, P337, DOI 10.1016/0014-5793(86)81045-6; LANYI JK, 1992, BIOCHIM BIOPHYS ACTA, V1099, P102, DOI 10.1016/0167-4838(92)90458-P; LEWIS A, 1978, P NATL ACAD SCI USA, V75, P4642, DOI 10.1073/pnas.75.10.4642; LOZIER RH, 1975, BIOPHYS J, V15, P955, DOI 10.1016/S0006-3495(75)85875-9; MARTI T, 1991, J BIOL CHEM, V266, P18674; MOGI T, 1988, P NATL ACAD SCI USA, V85, P4148, DOI 10.1073/pnas.85.12.4148; MOGI T, 1989, J BIOL CHEM, V264, P14192; MOWERY PC, 1979, BIOCHEMISTRY-US, V18, P4100, DOI 10.1021/bi00586a007; OTTO H, 1989, P NATL ACAD SCI USA, V86, P9228, DOI 10.1073/pnas.86.23.9228; OTTO H, 1990, P NATL ACAD SCI USA, V87, P1018, DOI 10.1073/pnas.87.3.1018; SHEVES M, 1986, P NATL ACAD SCI USA, V83, P3262, DOI 10.1073/pnas.83.10.3262; STERN LJ, 1989, J BIOL CHEM, V264, P14202; STITES WE, 1991, J MOL BIOL, V221, P7, DOI 10.1016/0022-2836(91)90795-8; SUBRAMANIAM S, 1991, P NATL ACAD SCI USA, V88, P2583, DOI 10.1073/pnas.88.6.2583; SUBRAMANIAM S, 1991, P NATL ACAD SCI USA, V88, P6873, DOI 10.1073/pnas.88.15.6873; SUBRAMANIAM S, 1990, P NATL ACAD SCI USA, V87, P1013, DOI 10.1073/pnas.87.3.1013; SUNG CH, 1991, P NATL ACAD SCI USA, V88, P6481, DOI 10.1073/pnas.88.15.6481; SUNG CH, 1991, P NATL ACAD SCI USA, V88, P8840, DOI 10.1073/pnas.88.19.8840; VARO G, 1989, BIOPHYS J, V56, P1143, DOI 10.1016/S0006-3495(89)82761-4	32	45	52	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1992	267	36					25730	25733						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KD073	1464589				2022-12-25	WOS:A1992KD07300023
J	KAMITANI, T; MENON, AK; HALLAQ, Y; WARREN, CD; YEH, ETH				KAMITANI, T; MENON, AK; HALLAQ, Y; WARREN, CD; YEH, ETH			COMPLEXITY OF ETHANOLAMINE PHOSPHATE ADDITION IN THE BIOSYNTHESIS OF GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORS IN MAMMALIAN-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VARIANT SURFACE GLYCOPROTEINS; HUMAN-ERYTHROCYTE ACETYLCHOLINESTERASE; PHOSPHATIDYLINOSITOL MEMBRANE ANCHOR; PAROXYSMAL-NOCTURNAL HEMOGLOBINURIA; DECAY-ACCELERATING FACTOR; GLYCOSYL-PHOSPHATIDYLINOSITOL; STRUCTURAL CHARACTERIZATION; GLYCOLIPID PRECURSORS; RESISTANT GLYCOLIPIDS; THY-1 GLYCOPROTEIN	Biosynthetic intermediates for the mammalian glycosylphosphatidylinositol (GPI) anchor have been described. The earliest GPI anchor precursor is N-acetylglucosaminylphosphatidylinositol, which is deacetylated to give glucosaminylphosphatidylinositol. This is followed by fatty acylation of the inositol ring, sequential addition of mannose residues donated by dolichyl mannosyl phosphate, and finally addition of ethanolamine phosphate. Here, we show that the final steps of GPI anchor biosynthesis are more complex than we have previously reported. Six distinct GPI anchor precursors were found to contain at least 1 ethanolamine phosphate residue. The headgroups of these glycolipids were purified and analyzed by a combination of Bio-Gel P4 chromatography and high resolution thin-layer chromatography. The sizes of neutral glycans were determined following HF dephosphorylation. The position of the ethanolamine phosphate residue was inferred from results of alpha-mannosidase treatment. Finally, the number of negative charges on the headgroups were determined by Mono Q chromatography. Our results show that the addition of ethanolamine phosphate is controlled by at least two different genes. Thus, the class F mutant, though unable to add ethanolamine phosphate to the third mannose residue, does incorporate ethanolamine phosphate into the first and second mannose residues. Only the wild type cells are capable of incorporating ethanolamine phosphate into the third mannose residue. Furthermore, the GPI core contains up to 3 ethanolamine phosphate residues. These results should facilitate the elucidation of the biochemical defects in paroxysmal nocturnal hemoglobinuria.	ROCKEFELLER UNIV,MOLEC PARASITOL LAB,NEW YORK,NY 10021; HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,DEPT MED,BOSTON,MA 02114	Rockefeller University; Harvard University; Harvard Medical School; Massachusetts General Hospital			Kamitani, Tetsu/GSI-7613-2022	Menon, Anant Kumar/0000-0001-6924-2698; Kamitani, Tetsu/0000-0002-3257-9630	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045851] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR003564] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK040930] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-45851] Funding Source: Medline; NIAMS NIH HHS [AR-03564] Funding Source: Medline; NIDDK NIH HHS [DK-40930] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		CROSS GAM, 1990, ANNU REV CELL BIOL, V6, P1, DOI 10.1146/annurev.cb.06.110190.000245; DEEG MA, 1992, J BIOL CHEM, V267, P18573; Defaye J., 1970, ADV CARBOHYD CHEM BI, V25, P181; DEGASPERI R, 1990, SCIENCE, V250, P988, DOI 10.1126/science.1978413; FATEMI SH, 1987, J BIOL CHEM, V262, P4728; FERGUSON MAJ, 1988, SCIENCE, V239, P753, DOI 10.1126/science.3340856; FERGUSON MAJ, 1988, ANNU REV BIOCHEM, V57, P285; GUTHER MLS, 1992, J BIOL CHEM, V267, P6820; HAAS R, 1986, BIOCHEMISTRY-US, V25, P3098, DOI 10.1021/bi00359a005; HIROSE S, 1991, P NATL ACAD SCI USA, V88, P3762, DOI 10.1073/pnas.88.9.3762; HIROSE S, 1992, J BIOL CHEM, V267, P16998; HOMANS SW, 1988, NATURE, V333, P269, DOI 10.1038/333269a0; HYMAN R, 1988, TRENDS GENET, V4, P5, DOI 10.1016/0168-9525(88)90120-5; KODUKULA K, 1992, P NATL ACAD SCI USA, V89, P4982, DOI 10.1073/pnas.89.11.4982; KRAKOW JL, 1986, J BIOL CHEM, V261, P2147; LEMANSKY P, 1991, MOL CELL BIOL, V11, P3879, DOI 10.1128/MCB.11.8.3879; LOW MG, 1989, FASEB J, V3, P1600, DOI 10.1096/fasebj.3.5.2522071; LOW MG, 1988, SCIENCE, V239, P268, DOI 10.1126/science.3276003; MAHONEY JF, 1992, BLOOD, V79, P1400; MASTERSON WJ, 1989, CELL, V56, P793, DOI 10.1016/0092-8674(89)90684-3; MASTERSON WJ, 1990, CELL, V62, P73, DOI 10.1016/0092-8674(90)90241-6; MAYOR S, 1990, J BIOL CHEM, V265, P6164; MAYOR S, 1990, Methods (Orlando), V1, P297, DOI 10.1016/S1046-2023(05)80331-7; MAYOR S, 1990, J BIOL CHEM, V265, P6174; MEDOF ME, 1986, BIOCHEMISTRY-US, V25, P6740, DOI 10.1021/bi00370a003; MENON AK, 1992, J BIOL CHEM, V267, P15277; MENON AK, 1988, J BIOL CHEM, V263, P1970; MENON AK, 1990, J BIOL CHEM, V265, P9033; PUOTI A, 1991, J BIOL CHEM, V266, P21051; ROBERTS WL, 1988, J BIOL CHEM, V263, P18776; ROSSE WF, 1990, ANNU REV MED, V41, P431; SCHNEIDER P, 1990, J BIOL CHEM, V265, P16955; STAHL E, 1961, J CHROMATOGR, V5, P351, DOI 10.1016/S0021-9673(01)92868-7; STEVENS VL, 1991, J BIOL CHEM, V266, P10039; SUGIYAMA E, 1991, J BIOL CHEM, V266, P12119; THOMAS JR, 1990, BIOCHEMISTRY-US, V29, P5413, DOI 10.1021/bi00475a001; THOMAS LJ, 1992, J CLIN INVEST, V89, P1172, DOI 10.1172/JCI115700; TSE AGD, 1985, SCIENCE, V230, P1003, DOI 10.1126/science.2865810; URAKAZE M, 1992, J BIOL CHEM, V267, P6459; YEH ETH, 1988, CELL, V52, P665, DOI 10.1016/0092-8674(88)90404-7	40	75	75	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1992	267	34					24611	24619						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KA263	1447204				2022-12-25	WOS:A1992KA26300070
J	POGNONEC, P; KATO, H; ROEDER, RG				POGNONEC, P; KATO, H; ROEDER, RG			THE HELIX-LOOP-HELIX LEUCINE REPEAT TRANSCRIPTION FACTOR USF CAN BE FUNCTIONALLY REGULATED IN A REDOX-DEPENDENT MANNER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXIDATION-REDUCTION; BINDING-ACTIVITY; ACTIVATION; PROTEIN; PHOSPHORYLATION; INVITRO; HIV-1; FOS; JUN; DNA	We showed previously that the DNA-binding capacity of the helix-loop-helix/leucine repeat transcription factor USF43 is lowered dramatically under nonreducing conditions. This report defines the molecular basis of this effect by showing (i) that the only two USF43 cysteine residues, both present within the helix-loop-helix protein-protein interface domain, are required for this regulation, (ii) that the sulfhydryl groups of these cysteine residues are the actual targets of this regulation, (iii) that oxidation of these groups results in both intra- and intermolecular nonrandom covalent links, (iv) that this redox modulation of USF43 DNA-binding potential can translate in vitro into a specific modulation of its ability to activate transcription from a USF-responsive promoter. The implications of these modulations of USF43 function in response to redox changes are discussed with regard to the apparent paradox of USF strong activation potential and its ubiquitous distribution in all cell types tested.	ROCKEFELLER UNIV,1230 YORK AVE,NEW YORK,NY 10021	Rockefeller University					NATIONAL CANCER INSTITUTE [R35CA042567] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI027397] Funding Source: NIH RePORTER; NCI NIH HHS [CA42567] Funding Source: Medline; NIAID NIH HHS [AI27397] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; CLANCEY CJ, 1987, J BIOL CHEM, V262, P13545; DEMPLE B, 1991, CELL, V67, P837, DOI 10.1016/0092-8674(91)90355-3; GUTZMANBARRON ES, 1951, ADV ENZYMOL, V11, P201; HENTZE MW, 1989, SCIENCE, V244, P357, DOI 10.1126/science.2711187; JONES N, 1990, CELL, V61, P9, DOI 10.1016/0092-8674(90)90207-U; KATO H, 1991, SCIENCE, V251, P1476, DOI 10.1126/science.2006421; KAULEN H, 1991, MOL CELL BIOL, V11, P412, DOI 10.1128/MCB.11.1.412; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; OFIR R, 1990, NATURE, V348, P80, DOI 10.1038/348080a0; OMAHONY DJ, 1992, J BIOL CHEM, V267, P35; POGNONEC P, 1991, NUCLEIC ACIDS RES, V19, P6650, DOI 10.1093/nar/19.23.6650; POGNONEC P, 1991, MOL CELL BIOL, V11, P5125, DOI 10.1128/MCB.11.10.5125; ROEDER RG, 1991, TRENDS BIOCHEM SCI, V16, P402, DOI 10.1016/0968-0004(91)90164-Q; SAWADOGO M, 1988, J BIOL CHEM, V263, P11985; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; STORZ G, 1990, SCIENCE, V248, P189, DOI 10.1126/science.2183352; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TOLEDANO MB, 1991, P NATL ACAD SCI USA, V88, P4328, DOI 10.1073/pnas.88.10.4328; TSIEN RY, 1982, NATURE, V295, P68, DOI 10.1038/295068a0; XANTHOUDAKIS S, 1992, EMBO J, V11, P653, DOI 10.1002/j.1460-2075.1992.tb05097.x	22	114	117	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1992	267	34					24563	24567						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KA263	1447201				2022-12-25	WOS:A1992KA26300063
J	WHITE, TC; HARRIS, GS; ORMEJOHNSON, WH				WHITE, TC; HARRIS, GS; ORMEJOHNSON, WH			ELECTROPHORETIC STUDIES ON THE ASSEMBLY OF THE NITROGENASE MOLYBDENUM-IRON PROTEIN FROM THE KLEBSIELLA-PNEUMONIAE NIFD AND NIFK GENE-PRODUCTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOFE PROTEIN; AZOTOBACTER-VINELANDII; ESCHERICHIA-COLI; COMPLEMENTATION ANALYSIS; COFACTOR FEMOCO; FIXATION GENES; DEAE-CELLULOSE; CLUSTER; MUTANTS; PURIFICATION	The electrophoretic properties of the molybdenum-iron (MoFe) protein component of nitrogenase and an iron-molybdenum cofactor (FeMoco)-reactivatable apoMoFe protein from Klebsiella pneumoniae were examined under anaerobic ([O2] < 5 ppm), nondenaturing conditions. In wild type K. pneumoniae extracts, two immunoreactive species migrating more slowly than purified MoFe protein were detected using antiMoFe protein antibodies. The uppermost species co-migrates with the apoMoFe protein produced by a K. pneumoniae mutant unable to synthesize FeMoco (UN106) and by Escherichia coli harboring the plasmids pVL222+pVL15 (nifHDKTYUSWZM+A). In vitro FeMoco titration of the UN106 and pVL222+ pVL15 extracts increases the electrophoretic mobility of the apoMoFe protein to that of purified MoFe protein in a two-step process giving rise to a species of intermediate mobility between the apo- and holoMoFe proteins. Two-dimensional gel electrophoresis showed that a 20-kDa peptide is associated with the apoMoFe protein and with the intermediate species, but not with the holoMoFe protein. N-terminal sequencing identified this associated peptide as the nifY gene product, which we propose is acting as a temporary enforcer of the apoMoFe protein structure required for cofactor binding that is released upon FeMoco activation. This FeMoco-induced mobility shift was used to characterize the mutant apoMoFe proteins produced in E. coli as a result of deleting the various nitrogen fixation (nif) genes from the plasmid pVL222. E. coli extracts bearing plasmids deleted in nifH, nifS, nifTYUM, or nifWZM exhibit less than 10% of the apoMoFe protein activity of derepressed UN106 and contain an immunoreactive species whose electrophoretic mobility is increased upon addition of FeMoco from that of apoMoFe protein to that of holoMoFe protein in a single step. Anaerobic nondenaturing gel electrophoresis of Fe-55-labeled E. coli extracts followed by autoradiography showed that these inactive apoMoFe species do not contain iron, indicating that the P-clusters are absent. We therefore propose that NifH, S, U, W, Z, and M are all involved, to varying degrees, in P-cluster assembly. In addition, the presence of the P-clusters does appear to be necessary for the two-step FeMoco activation of the apoMoFe protein to occur.	MIT,DEPT CHEM,CAMBRIDGE,MA 02139	Massachusetts Institute of Technology (MIT)					NIGMS NIH HHS [GM30943] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030943] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARNOLD W, 1988, J MOL BIOL, V203, P715, DOI 10.1016/0022-2836(88)90205-7; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BACHMANN BJ, 1972, BACTERIOL REV, V36, P525, DOI 10.1128/MMBR.36.4.525-557.1972; BOLIN JT, 1990, NITROGEN FIXATION : ACHIEVEMENTS AND OBJECTIVES, P117; BRILL WJ, 1974, ANAL BIOCHEM, V60, P237, DOI 10.1016/0003-2697(74)90149-3; CHANG ACY, 1978, J BACTERIOL, V134, P1141, DOI 10.1128/JB.134.3.1141-1156.1978; DIXON R, 1977, MOL GEN GENET, V157, P189, DOI 10.1007/BF00267397; Eady R. R., 1980, Methods for evaluating biological nitrogen fixation., P213; Fazekas de St Groth S., 1963, BIOCHIM BIOPHYS ACTA, V71, P377; FILLER WA, 1986, EUR J BIOCHEM, V160, P371, DOI 10.1111/j.1432-1033.1986.tb09981.x; HARRIS GS, 1990, J BIOL CHEM, V265, P15909; HAWKES TR, 1983, BIOCHEM J, V209, P43, DOI 10.1042/bj2090043; HAWKES TR, 1984, BIOCHEM J, V217, P317, DOI 10.1042/bj2170317; HAWKES TR, 1984, BIOCHEM J, V223, P783, DOI 10.1042/bj2230783; HOLLAND D, 1987, J BIOL CHEM, V262, P8814; HOOVER TR, 1989, BIOCHEMISTRY-US, V28, P2768, DOI 10.1021/bi00433a004; HOWARD JB, 1989, J BIOL CHEM, V264, P11270; HOWARD KS, 1986, J BIOL CHEM, V261, P772; JACOBSON MR, 1989, J BACTERIOL, V171, P1017, DOI 10.1128/jb.171.2.1017-1027.1989; JACOBSON MR, 1986, J BACTERIOL, V167, P480, DOI 10.1128/jb.167.2.480-486.1986; JACOBSON MR, 1989, MOL GEN GENET, V219, P49, DOI 10.1007/BF00261156; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MACNEIL T, 1978, J BACTERIOL, V136, P253, DOI 10.1128/JB.136.1.253-266.1978; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MCKENNA CE, 1977, ANAL BIOCHEM, V82, P337; MCLEAN PA, 1987, J BIOL CHEM, V262, P12900; MCLEAN PA, 1989, BIOCHEMISTRY-US, V28, P9402, DOI 10.1021/bi00450a023; MEIRER W, 1963, HELV CHIM ACTA, V216, P1929; NEIDHARDT FC, 1974, J BACTERIOL, V119, P736, DOI 10.1128/JB.119.3.736-747.1974; NELSON MJ, 1983, P NATL ACAD SCI-BIOL, V80, P147, DOI 10.1073/pnas.80.1.147; ORMEJOHNSON WH, 1985, ANNU REV BIOPHYS BIO, V14, P419, DOI 10.1146/annurev.biophys.14.1.419; ORMEJOHNSON WH, 1980, CURRENT PERSPECTIVES, P79; PAUL W, 1989, EUR J BIOCHEM, V178, P675, DOI 10.1111/j.1432-1033.1989.tb14497.x; PAUSTIAN TD, 1990, BIOCHEMISTRY-US, V29, P3515, DOI 10.1021/bi00466a014; Puhler A., 1981, Bothe, H.; Trebst, A. : Biology of inorganic nitrogen and sulfur., P276; ROBERTS GP, 1978, J BACTERIOL, V136, P267, DOI 10.1128/JB.136.1.267-279.1978; ROBINSON AC, 1989, J BIOL CHEM, V264, P10088; ROBINSON AC, 1987, J BIOL CHEM, V262, P14327; SHAH VK, 1973, BIOCHIM BIOPHYS ACTA, V305, P445, DOI 10.1016/0005-2728(73)90190-4; SHAH VK, 1978, BIOCHEM BIOPH RES CO, V81, P232, DOI 10.1016/0006-291X(78)91654-6; SHAH VK, 1977, P NATL ACAD SCI USA, V74, P3249, DOI 10.1073/pnas.74.8.3249; Smith B. E., 1988, Nitrogen fixation: Hundred years after. Proceedings of the 7th International Congress on Nitrogen Fixation, Koln (Cologne), FRG, March 13-20, 1988., P91; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WALMSLEY J, 1990, NITROGEN FIXATION AC, P599; WINK DA, 1989, BIOCHEMISTRY-US, V28, P9407, DOI 10.1021/bi00450a024	45	36	36	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1992	267	33					24007	24016						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JZ239	1429737				2022-12-25	WOS:A1992JZ23900086
J	ALBINO, AP; SOZZI, G; NANUS, DM; JHANWAR, SC; HOUGHTON, AN				ALBINO, AP; SOZZI, G; NANUS, DM; JHANWAR, SC; HOUGHTON, AN			MALIGNANT TRANSFORMATION OF HUMAN MELANOCYTES - INDUCTION OF A COMPLETE MELANOMA PHENOTYPE AND GENOTYPE	ONCOGENE			English	Note							MOUSE MONOCLONAL-ANTIBODY; MURINE SARCOMA-VIRUS; SURFACE-ANTIGENS; CELL-LINES; TUMOR PROGRESSION; CYTOGENETIC ANALYSIS; METASTATIC MELANOMA; GROWTH-FACTOR; HUMAN HOMOLOG; RAS ONCOGENE	Human melanoma provides a model to study malignant transformation and tumor progression. Expression of ras oncogenes in cultured normal human diploid melanocytes has induced a subset of phenotypic traits that are characteristic of malignant melanoma cells, including altered morphology, anchorage independence, induction of class II MHC antigens, up-regulation of the ganglioside G(D3), and chromosomal abnormalities. However, other characteristics of melanoma, such as loss of expression of adenosine deaminase-binding protein and tumorigenicity, were not observed. We report here that melanocytes infected with a retrovirus containing the viral Ha-ras oncogene underwent complete transformation, acquiring all phenotypic characteristics of malignant melanomas observed in vivo. Transformation occurred in a sequential manner and was associated with spontaneous chromosomal instability. Cytogenetic analysis of transformed melanocytes indicated that the earliest structural chromosomal abnormalities were isochromosomes 6p and 9q followed by complete loss of chromosome 1p, all common karyotypic abnormalities described in human melanomas. The findings suggest that these chromosome regions which are deleted or relatively deficient may contain genes that are critical for the initiation and progression of the melanoma phenotype.	IST NAZL TUMORI,I-20133 MILAN,ITALY	Fondazione IRCCS Istituto Nazionale Tumori Milan	ALBINO, AP (corresponding author), MEM SLOAN KETTERING CANC CTR,1275 YORK AVE,NEW YORK,NY 10021, USA.		sozzi, gabriella/G-8259-2011	sozzi, gabriella/0000-0001-9360-6914	NCI NIH HHS [CA-33049, CA-37907] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA037907, P01CA033049] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBINO AP, 1981, J EXP MED, V154, P1764, DOI 10.1084/jem.154.6.1764; ALBINO AP, 1991, CANCER RES, V51, P4815; ALBINO AP, 1986, J EXP MED, V164, P1710, DOI 10.1084/jem.164.5.1710; ALBINO AP, 1991, J EXP MED, V51, P4815; ALBINO AP, 1988, PIGMENT CELL RES S, V1, P169; BALABAN GB, 1986, CANCER GENET CYTOGEN, V19, P113, DOI 10.1016/0165-4608(86)90378-X; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BECHER R, 1983, CANCER GENET CYTOGEN, V9, P173, DOI 10.1016/0165-4608(83)90038-9; CHATTOPADHYAY SK, 1981, J VIROL, V39, P777, DOI 10.1128/JVI.39.3.777-791.1981; CHERESH DA, 1984, P NATL ACAD SCI-BIOL, V81, P5767, DOI 10.1073/pnas.81.18.5767; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLARK WH, 1984, HUM PATHOL, V15, P1147, DOI 10.1016/S0046-8177(84)80310-X; COWAN JM, 1986, CANCER GENET CYTOGEN, V20, P255, DOI 10.1016/0165-4608(86)90081-6; COWAN JM, 1988, J NATL CANCER I, V80, P1159, DOI 10.1093/jnci/80.14.1159; CUYPERS HT, 1986, HUM GENET, V72, P262, DOI 10.1007/BF00291892; DONIGER J, 1983, SCIENCE, V222, P1144, DOI 10.1126/science.6648529; DRACOPOLI NC, 1987, CANCER RES, V47, P3995; DRACOPOLI NC, 1989, P NATL ACAD SCI USA, V86, P4614, DOI 10.1073/pnas.86.12.4614; EISINGER M, 1985, SCIENCE, V229, P984, DOI 10.1126/science.4023718; EISINGER M, 1982, P NATL ACAD SCI-BIOL, V79, P2018, DOI 10.1073/pnas.79.6.2018; ELDER DE, 1989, CANCER RES, V49, P5091; FOUNTAIN JW, 1990, CANCER SURV, V9, P645; GRIFFIN CA, 1988, CANCER GENET CYTOGEN, V32, P129, DOI 10.1016/0165-4608(88)90319-6; HALABAN R, 1988, ONCOGENE RES, V3, P177; Harnden DG, 1985, INT SYSTEM HUMAN CYT; HEIM S, 1987, CANCER CYTOGENETICS; HERLYN M, 1988, ANNU REV IMMUNOL, V6, P283; HOLZMANN B, 1985, J EXP MED, V161, P366, DOI 10.1084/jem.161.2.366; HOUGHTON AN, 1984, J EXP MED, V160, P255, DOI 10.1084/jem.160.1.255; HOUGHTON AN, 1988, J EXP MED, V167, P197, DOI 10.1084/jem.167.1.197; HOUGHTON AN, 1982, J EXP MED, V156, P1755, DOI 10.1084/jem.156.6.1755; HOUGHTON AN, 1987, J EXP MED, V164, P812; HUME CR, 1987, P NATL ACAD SCI USA, V84, P8603, DOI 10.1073/pnas.84.23.8603; ICHIKAWA T, 1990, CANCER RES, V50, P6349; JANSSEN JWG, 1986, CYTOGENET CELL GENET, V41, P129, DOI 10.1159/000132217; JHANWAR SC, 1992, HEREDITARY COLON CAN; MACPHERSON I, 1964, VIROLOGY, V23, P291, DOI 10.1016/0042-6822(64)90301-0; MATYAS GR, 1987, P NATL ACAD SCI USA, V84, P6065, DOI 10.1073/pnas.84.17.6065; MILLIKIN D, 1991, CANCER RES, V51, P5449; MUSCHEL RJ, 1986, CANCER RES, V46, P4104; NAGARAJAN L, 1986, P NATL ACAD SCI USA, V83, P6568, DOI 10.1073/pnas.83.17.6568; NAKAKUMA H, 1984, J BIOCHEM-TOKYO, V96, P1471, DOI 10.1093/oxfordjournals.jbchem.a134976; NAKAMURA Y, 1988, AM J HUM GENET, V16, P9369; ODELBERG SJ, 1989, GENOMICS, V5, P915, DOI 10.1016/0888-7543(89)90134-1; OFFIT K, 1991, GENE CHROMOSOME CANC, V3, P189, DOI 10.1002/gcc.2870030304; OHYASHIKI JH, 1986, CANCER GENET CYTOGEN, V23, P77, DOI 10.1016/0165-4608(86)90151-2; PATHAK S, 1983, CYTOGENET CELL GENET, V36, P573, DOI 10.1159/000131975; PEDERSEN MI, 1989, CANCER GENET CYTOGEN, V41, P185, DOI 10.1016/0165-4608(89)90245-8; PFEFFER LM, 1977, CELL, V10, P313, DOI 10.1016/0092-8674(77)90225-2; PRATT CI, 1992, CANCER RES, V52, P688; PRESTI JC, 1991, CANCER RES, V51, P1544; PUKEL CS, 1982, J EXP MED, V155, P1133, DOI 10.1084/jem.155.4.1133; RAPPOLEE DA, 1989, J CELL BIOCHEM, V39, P1, DOI 10.1002/jcb.240390102; REAL FX, 1985, CANCER RES, V45, P4401; REICHMANN A, 1984, CANCER GENET CYTOGEN, V13, P275, DOI 10.1016/0165-4608(84)90049-9; REY JA, 1985, CANCER GENET CYTOGEN, V16, P179, DOI 10.1016/0165-4608(85)90013-5; RICHMOND A, 1986, J INVEST DERMATOL, V86, P295, DOI 10.1111/1523-1747.ep12285452; RODRIGUEZ E, 1990, CANCER RES, V50, P6410; SAGER R, 1983, P NATL ACAD SCI-BIOL, V80, P7601, DOI 10.1073/pnas.80.24.7601; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; Sambrook J, 1989, MOL CLONING LABORATO; SEMBA K, 1986, P NATL ACAD SCI USA, V83, P5459, DOI 10.1073/pnas.83.15.5459; SEYFRIED TN, 1985, MOL CELL BIOCHEM, V68, P3; THOMSON TM, 1988, J INVEST DERMATOL, V90, P459, DOI 10.1111/1523-1747.ep12460906; THOMSON TM, 1985, J INVEST DERMATOL, V85, P169, DOI 10.1111/1523-1747.ep12276608; TRAYLOR TD, 1980, J NEUROCHEM, V34, P126, DOI 10.1111/j.1471-4159.1980.tb04630.x; TRENT JM, 1989, CANCER RES, V49, P420; TRENT JM, 1990, NEW ENGL J MED, V322, P1508, DOI 10.1056/NEJM199005243222107; TRENT JM, 1990, SCIENCE, V247, P568, DOI 10.1126/science.2300817; TRENT JM, 1983, CANCER GENET CYTOGEN, V9, P177, DOI 10.1016/0165-4608(83)90039-0; VIJAYASARADHI S, 1990, J EXP MED, V171, P1375, DOI 10.1084/jem.171.4.1375; YOAKUM GH, 1985, SCIENCE, V227, P1174, DOI 10.1126/science.3975607	72	60	62	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1992	7	11					2315	2321						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JW665	1437153				2022-12-25	WOS:A1992JW66500025
J	DIEZ, E; LOUISFLAMBERG, P; HALL, RH; MAYER, RJ				DIEZ, E; LOUISFLAMBERG, P; HALL, RH; MAYER, RJ			SUBSTRATE SPECIFICITIES AND PROPERTIES OF HUMAN PHOSPHOLIPASES-A2 IN A MIXED VESICLE MODEL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARACHIDONOYL-HYDROLYZING PHOSPHOLIPASE-A2; CA2+-SENSITIVE CYTOSOLIC PHOSPHOLIPASE-A2; MACROPHAGE CELL-LINE; INTERFACIAL CATALYSIS; PANCREATIC PHOSPHOLIPASE-A2; SYNOVIAL-FLUID; CALCIUM; PURIFICATION; ACTIVATION; EXPRESSION	Studies of the specificity of phospholipases A2 (PLA2S) for different substrates have usually been carried out in vesicles or mixed micelles, where differences in shape, size, or charge of vesicles formed with different phospholipids may give misleading results. Another factor is binding of the enzyme to the phospholipid surface, which has recently been addressed using vesicles of an anionic phospholipid, dimyristoyl-sn-glycero-3-phosphomethanol (DMPM) to which some extracellular PLA2S were shown to bind with a very high affinity (Jain, M. K., and Berg, 0. G. (1989) Biochem. Biophys. Acta 1002, 127-156). In the present report we have used a similar system to study the substrate preferences of two human PLA2S that are thought to be physiologically relevant in the metabolism of arachidonic acid: a recombinant form of the human synovial fluid (14 kDa) PLA2 and the cytosolic (85 kDa) PLA2 found in monocytic cells. It is shown that both human enzymes bind tightly to DMPM vesicles and follow the basic characteristics of processive hydrolysis in this model using analysis of progress curves and substrate competition experiments. Mixed vesicles containing DMPM with small amounts (3-5 mol %) of other phospholipids have been used to study the substrate selectivity of the two human isoenzymes. The synovial fluid PLA2 Shows a clear preference (approximately 7-fold) for sn-glycero-3-phosphoethanolamine over sn-glycero-3-phosphocholine. Within glycerophosphocholines, this enzyme displays little preference for the sn-2 fatty acyl group, and a slight preference for phospholipids with sn-1-acyl versus sn-1-alkyl substituents. In contrast, the cytosolic PLA2 shows a marked selectivity for arachidonoyl in the sn-2 position and only minor differences in selectivity for the polar head group in the sn-3 position. This enzyme does not distinguish between sn-1-acyl and sn-1-alkyl subclasses of glycerophosphocholines.	SMITHKLINE BEECHAM PHARMACEUT, DEPT MED CHEM, KING OF PRUSSIA, PA 19406 USA; SMITHKLINE BEECHAM PHARMACEUT, DIV BIOMOLEC, KING OF PRUSSIA, PA 19406 USA	GlaxoSmithKline; GlaxoSmithKline								CHANNON JY, 1990, J BIOL CHEM, V265, P5409; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; CLARK JD, 1990, P NATL ACAD SCI USA, V87, P7708, DOI 10.1073/pnas.87.19.7708; DIEZ E, 1990, J BIOL CHEM, V265, P14654; DIJKSTRA BW, 1981, J MOL BIOL, V147, P97, DOI 10.1016/0022-2836(81)90081-4; Eibl H, 1981, Methods Enzymol, V72, P632; FRANSON R, 1978, BIOCHEMISTRY-US, V17, P4029, DOI 10.1021/bi00612a024; GHOMASHCHI F, 1991, BIOCHEMISTRY-US, V30, P7318, DOI 10.1021/bi00243a037; GRONICH JH, 1990, BIOCHEM J, V271, P37, DOI 10.1042/bj2710037; HAZEN SL, 1990, J BIOL CHEM, V265, P10622; JAIN MK, 1991, BIOCHEMISTRY-US, V30, P7306, DOI 10.1021/bi00243a036; JAIN MK, 1989, BIOCHIM BIOPHYS ACTA, V1002, P127, DOI 10.1016/0005-2760(89)90281-6; JAIN MK, 1991, METHOD ENZYMOL, V197, P112; JAIN MK, 1989, BIOCHEMISTRY-US, V28, P4135, DOI 10.1021/bi00436a002; KRAMER RM, 1989, J BIOL CHEM, V264, P5768; KRAMER RM, 1991, J BIOL CHEM, V266, P5268; LESLIE CC, 1988, BIOCHIM BIOPHYS ACTA, V963, P476, DOI 10.1016/0005-2760(88)90316-5; LESLIE CC, 1991, J BIOL CHEM, V266, P11366; LOEB LA, 1986, J BIOL CHEM, V261, P467; MARSHALL LA, 1991, J RHEUMATOL, V18, P59; PERNAS P, 1991, BIOCHEM BIOPH RES CO, V178, P1298, DOI 10.1016/0006-291X(91)91035-B; RAMIREZ F, 1991, PROTEINS, V9, P229, DOI 10.1002/prot.340090402; SAMUELSSON B, 1983, SCIENCE, V220, P568, DOI 10.1126/science.6301011; SCOTT DL, 1991, SCIENCE, V254, P1007, DOI 10.1126/science.1948070; SCOTT DL, 1990, SCIENCE, V250, P1563, DOI 10.1126/science.2274788; SEILHAMER JJ, 1989, J BIOL CHEM, V264, P5335; SHARP JD, 1991, J BIOL CHEM, V266, P14850; SLOTBOOM AJ, 1981, REV PHYSL PHARM, V91, P359; VADAS P, 1985, LIFE SCI, V36, P579, DOI 10.1016/0024-3205(85)90640-X; WAITE M, 1987, HDB LIPID RES, V5, P1030	30	114	116	2	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	1992	267	26					18342	18348						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JN502	1526974				2022-12-25	WOS:A1992JN50200018
J	DUPREZ, V; FERRER, M; DAUTRYVARSAT, A				DUPREZ, V; FERRER, M; DAUTRYVARSAT, A			HIGH-AFFINITY INTERLEUKIN-2 RECEPTOR-ALPHA AND BETA CHAINS ARE INTERNALIZED AND REMAIN ASSOCIATED INSIDE THE CELLS AFTER INTERLEUKIN-2 ENDOCYTOSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DENATURING ZWITTERIONIC DETERGENT; IL-2 RECEPTOR; GROWTH-FACTOR; MEDIATED INTERNALIZATION; MONOCLONAL-ANTIBODIES; DIRECT IDENTIFICATION; BIOCHEMICAL-EVIDENCE; SIGNAL TRANSDUCTION; MOLECULAR-CLONING; BINDING-PROTEIN	High-affinity interleukin 2 (IL2) receptors on human T lymphocytes are multimeric complexes containing two IL2-binding polypeptides, alpha and beta-chains of 50-55 and 70-75 kDa, respectively, associated by noncovalent bonds. IL2 binds to high-affinity IL2 receptors on the surface of T lymphocytes, mediates cell growth, and is internalized. In this paper, we used a biochemical method to directly identify the receptors components internalized together with the ligand. I-125-IL2-receptor complexes were solubilized with the detergent 3-[(3-cholamidopropyl)dimethylammonio]-1-propane-sulfonate, and IL2-binding polypeptides were identified by cross-linking with disuccinimidyl suberate. Under such conditions, the noncovalent association between alpha and beta is maintained. After IL2 internalization, two complexes of about 70 and 90 kDa, IL2 cross-linked to alpha and beta, respectively, were found inside the cells. Both components were immunoprecipitated with either anti-alpha or anti-beta monoclonal antibodies. This shows that the alpha and beta-chains are found in an intracellular compartment after IL2 endocytosis, and remain associated as a ternary complex with IL2.			DUPREZ, V (corresponding author), INST PASTEUR,UNITE BIOL INTERACT CELLULAIRES,CNRS,URA 361,25 RUE DR ROUX,F-75724 PARIS 15,FRANCE.							ASAO H, 1990, J EXP MED, V171, P637, DOI 10.1084/jem.171.3.637; BICHTHUY LT, 1987, J IMMUNOL, V139, P1550; BIRD TA, 1988, J BIOL CHEM, V263, P12063; COLAMONICI OR, 1990, J IMMUNOL, V145, P155; DUKOVICH M, 1987, NATURE, V327, P518, DOI 10.1038/327518a0; DUPREZ V, 1988, J BIOL CHEM, V263, P12860; DUPREZ V, 1986, J BIOL CHEM, V261, P5450; DUPREZ V, 1991, J BIOL CHEM, V266, P1497; DUPREZ V, 1985, P NATL ACAD SCI USA, V82, P6932, DOI 10.1073/pnas.82.20.6932; FUJII M, 1986, J EXP MED, V163, P550, DOI 10.1084/jem.163.3.550; FUNG MR, 1988, J EXP MED, V168, P1923, DOI 10.1084/jem.168.5.1923; GREENE WC, 1986, IMMUNOL REV, V92, P29, DOI 10.1111/j.1600-065X.1986.tb01492.x; HATAKEYAMA M, 1989, CELL, V59, P837, DOI 10.1016/0092-8674(89)90607-7; HATAKEYAMA M, 1989, SCIENCE, V244, P551, DOI 10.1126/science.2785715; HEMAR A, 1990, EUR J IMMUNOL, V20, P2629, DOI 10.1002/eji.1830201216; HERRMANN T, 1987, IMMUNOBIOLOGY, V175, P145, DOI 10.1016/S0171-2985(87)80024-4; HJELMELAND LM, 1980, P NATL ACAD SCI-BIOL, V77, P6368, DOI 10.1073/pnas.77.11.6368; HORAK ID, 1991, P NATL ACAD SCI USA, V88, P1996, DOI 10.1073/pnas.88.5.1996; KINET JP, 1985, BIOCHEMISTRY-US, V24, P7342, DOI 10.1021/bi00346a048; LEONARD WJ, 1983, P NATL ACAD SCI-BIOL, V80, P6957, DOI 10.1073/pnas.80.22.6957; LEONARD WJ, 1984, NATURE, V311, P626, DOI 10.1038/311626a0; LEONARD WJ, 1982, NATURE, V300, P267, DOI 10.1038/300267a0; LISCIA DS, 1982, J BIOL CHEM, V257, P9401; LOWENTHAL JW, 1987, J EXP MED, V166, P1156, DOI 10.1084/jem.166.4.1156; NABHOLZ M, 1987, EUR J IMMUNOL, V17, P783, DOI 10.1002/eji.1830170608; NIKAIDO T, 1984, NATURE, V311, P631, DOI 10.1038/311631a0; OLIVE D, 1986, EUR J IMMUNOL, V16, P611, DOI 10.1002/eji.1830160605; PETERS DK, 1990, BLOOD, V76, P97; ROBB RJ, 1984, J EXP MED, V160, P1126, DOI 10.1084/jem.160.4.1126; ROBB RJ, 1987, P NATL ACAD SCI USA, V84, P2002, DOI 10.1073/pnas.84.7.2002; ROBB RJ, 1981, J EXP MED, V154, P1455, DOI 10.1084/jem.154.5.1455; ROBB RJ, 1987, J EXP MED, V165, P1201, DOI 10.1084/jem.165.4.1201; ROBB RJ, 1983, J EXP MED, V158, P1332, DOI 10.1084/jem.158.4.1332; SAITO Y, 1991, J BIOL CHEM, V266, P22186; SARAGOVI H, 1990, P NATL ACAD SCI USA, V87, P11, DOI 10.1073/pnas.87.1.11; SARAGOVI H, 1987, J IMMUNOL, V139, P1918; SARAGOVI H, 1988, J IMMUNOL, V141, P476; SHARON M, 1990, P NATL ACAD SCI USA, V87, P4869, DOI 10.1073/pnas.87.12.4869; SHARON M, 1986, SCIENCE, V234, P859, DOI 10.1126/science.3095922; SIEGEL JP, 1987, SCIENCE, V238, P75, DOI 10.1126/science.3116668; SIMONDS WF, 1980, P NATL ACAD SCI-BIOL, V77, P4623, DOI 10.1073/pnas.77.8.4623; SMITH KA, 1989, ANNU REV CELL BIOL, V5, P397; STALZMAN EM, 1990, J BIOL CHEM, V265, P10138; TAKESHITA T, 1990, INT IMMUNOL, V2, P477, DOI 10.1093/intimm/2.5.477; TANAKA T, 1988, J IMMUNOL, V140, P866; TANIGUCHI T, 1986, IMMUNOL REV, V92, P121, DOI 10.1111/j.1600-065X.1986.tb01497.x; TESHIGAWARA K, 1987, J EXP MED, V165, P223, DOI 10.1084/jem.165.1.223; TSUDO M, 1989, P NATL ACAD SCI USA, V86, P1982, DOI 10.1073/pnas.86.6.1982; TSUDO M, 1986, P NATL ACAD SCI USA, V83, P9694, DOI 10.1073/pnas.83.24.9694; TSUDO M, 1990, J IMMUNOL, V145, P599; TSUDO M, 1987, P NATL ACAD SCI USA, V84, P5394, DOI 10.1073/pnas.84.15.5394; WANG HM, 1987, J EXP MED, V166, P1055, DOI 10.1084/jem.166.4.1055; WEISSMAN AM, 1986, P NATL ACAD SCI USA, V83, P1463, DOI 10.1073/pnas.83.5.1463	53	26	26	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1992	267	26					18639	18643						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JN502	1526996				2022-12-25	WOS:A1992JN50200060
J	LIU, XF; ELASHVILI, I; GRALLA, EB; VALENTINE, JS; LAPINSKAS, P; CULOTTA, VC				LIU, XF; ELASHVILI, I; GRALLA, EB; VALENTINE, JS; LAPINSKAS, P; CULOTTA, VC			YEAST LACKING SUPEROXIDE-DISMUTASE - ISOLATION OF GENETIC SUPPRESSORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; ALPHA-AMINOADIPATE; RESPIRATORY-CHAIN; ESCHERICHIA-COLI; OXYGEN-TOXICITY; MUTANTS; PROTEIN; BIOSYNTHESIS; MITOCHONDRIA; DEHYDRATASE	Null mutants of superoxide dismutase (SOD) in Saccharomyces cerevisiae are associated with a number of biochemical defects. In addition to being hypersensitive to oxygen toxicity, strains containing deletions in both the SOD1 (encoding Cu/Zn-SOD) and SOD2 (encoding Mn-SOD) genes are defective in sporulation, are associated with a high mutation rate, and are unable to biosynthesize lysine and methionine. The sod-linked defect in lysine metabolism was explored in detail and was found to occur at an early step in lysine biosynthesis, evidently at the level of the alpha-amino adipate transaminase. To better understand the role of SOD in cell metabolism, our laboratory has isolated yeast suppressors that have bypassed the SOD defect ("bsd" strains), that is, S. cerevisiae cells lacking SOD, yet resistant to oxygen toxicity. Two nuclear bsd complementation groups have been identified, and both suppress a variety of biological defects associated with sod1 and sod2 null mutants. These results demonstrate that a single gene mutation can alleviate the requirement for SOD in cell growth. Both bsd complementation groups are unable to utilize many non-fermentable carbon sources, suggesting a possible suppressor-linked defect in electron transport.	UNIV CALIF LOS ANGELES, DEPT CHEM & BIOCHEM, LOS ANGELES, CA 90024 USA	University of California System; University of California Los Angeles	LIU, XF (corresponding author), JOHNS HOPKINS UNIV, SCH HYG & PUBL HLTH, DEPT ENVIRONM HLTH SCI, DIV TOXICOL SCI, BALTIMORE, MD 21205 USA.		Valentine, Joan S/B-6665-2008	Valentine, Joan S/0000-0002-7174-925X	NIEHS NIH HHS [ES 07141, P03 ES 03819] Funding Source: Medline; NIGMS NIH HHS [GM 28222] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES003819] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028222] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAKER KP, 1991, NATURE, V349, P205, DOI 10.1038/349205a0; BERMINGHAMMCDONOGH O, 1988, P NATL ACAD SCI USA, V85, P4789, DOI 10.1073/pnas.85.13.4789; BHATTACHARJEE JK, 1985, CRC CR REV MICROBIOL, V12, P131, DOI 10.3109/10408418509104427; BILINSKI T, 1985, BIOCHEM BIOPH RES CO, V130, P533, DOI 10.1016/0006-291X(85)90449-8; BILINSKI T, 1989, BIOCHIM BIOPHYS ACTA, V1001, P102, DOI 10.1016/0005-2760(89)90312-3; BOSTEK CC, 1989, J AM ASS NURSE ANES, V57, P213; BROWN OR, 1978, BIOCHEM BIOPH RES CO, V85, P1219, DOI 10.1016/0006-291X(78)90672-1; CARLIOZ A, 1986, EMBO J, V5, P623, DOI 10.1002/j.1460-2075.1986.tb04256.x; CERUTTI P, 1989, MUTAT RES, V214, P81, DOI 10.1016/0027-5107(89)90200-5; CHANG EC, 1990, J BACTERIOL, V172, P1840, DOI 10.1128/jb.172.4.1840-1845.1990; CHANG EC, 1989, J BIOL CHEM, V264, P12172; CHANG EC, 1991, J BIOL CHEM, V266, P4417; CHATTOO BB, 1979, GENETICS, V93, P51; DAVIES KJA, 1987, J BIOL CHEM, V262, P9895; DEVRIES S, 1987, BIOCHIM BIOPHYS ACTA, V895, P205, DOI 10.1016/S0304-4173(87)80003-4; Esposito R. E., 1981, MOL BIOL YEAST SACCH, V11, P211; EVANS H, 1989, J FREE RAD BIOL MED, V2, P369; GARDNER PR, 1991, J BIOL CHEM, V266, P19328; GRALLA EB, 1991, J BACTERIOL, V173, P5918, DOI 10.1128/jb.173.18.5918-5920.1991; HALLIWELL B, 1984, BIOCHEM J, V219, P1, DOI 10.1042/bj2190001; HALLIWELL B, 1987, FASEB J, V1, P358, DOI 10.1096/fasebj.1.5.2824268; HARMAN D, 1981, P NATL ACAD SCI-BIOL, V78, P7124, DOI 10.1073/pnas.78.11.7124; IMLAY JA, 1988, SCIENCE, V240, P1302, DOI 10.1126/science.3287616; JAMIESON D, 1989, FREE RADICAL BIO MED, V7, P87, DOI 10.1016/0891-5849(89)90103-2; Jones E. W., 1982, MOL BIOL YEAST SACCH, P181; KASSIR Y, 1991, METHOD ENZYMOL, V194, P94; KUO CF, 1987, J BIOL CHEM, V262, P4724; MARRES CAM, 1985, EUR J BIOCHEM, V147, P153, DOI 10.1111/j.1432-1033.1985.tb08731.x; MATSUDA M, 1969, J BIOL CHEM, V244, P3352; VANLOON APGM, 1986, P NATL ACAD SCI USA, V83, P3820; WESTERBEEKMARRES CAM, 1988, EUR J BIOCHEM, V174, P611, DOI 10.1111/j.1432-1033.1988.tb14142.x; WINSTON MK, 1982, J BACTERIOL, V152, P874; YE ZH, 1991, J BASIC MICROB, V31, P149, DOI 10.1002/jobm.3620310215	33	137	140	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	1992	267	26					18298	18302						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JN502	1526970				2022-12-25	WOS:A1992JN50200011
J	SOLEIMANI, M; HATTABAUGH, YJ; BIZAL, GL				SOLEIMANI, M; HATTABAUGH, YJ; BIZAL, GL			PH SENSITIVITY OF THE NA+-HCO3- COTRANSPORTER IN BASOLATERAL MEMBRANE-VESICLES ISOLATED FROM RABBIT KIDNEY CORTEX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SODIUM-BICARBONATE COTRANSPORT; ELECTROGENIC NA/HCO3 COTRANSPORTER; RENAL-CORTEX; PROXIMAL TUBULE; NA+/H+ EXCHANGE; RAT HEPATOCYTES; CELLS; TRANSPORT	HCO3- exit across the basolateral membrane of the kidney proximal tubule cell is mediated via an electrogenic Na+:HCO3- cotransporter. We have studied the effect of pH on the activity of this cotransport system in basolateral membrane vesicles isolated from rabbit renal cortex. At constant internal pH 6.0, increasing the external pH and [HCO3-] increased the rate of diisothiocyanostilbene-2,2'-disulfonic acid-sensitive 4,4'-Na-22+ influx into the vesicles. To determine the role of internal pH on the activity of the Na+:HCO3- cotransport system, the influx of Na-22+ via HCO3-dependent Na+-Ne exchange was measured in the absence of an initial pH and [HCO3-] gradient (pH(i) = pH(o), 5% CO2). Increasing the pH from 6.8 to 7.2 increased whereas, increasing the pH from 7.4 to 8.0 decreased the rate of Na22+ influx via this exchange. Increasing pH at constant [HCO3-] (pH(i) = pH(o) = 8.0, 1.5% CO2 versus pH(i) = pH(o) = 7.2, 10% CO2) reduced the influx of Na-22+ via HCO3-dependent Na+-Na+ exchange. Increasing pH at constant [CO32-](pH(i) = pH(o) = 8.0, 1.5% CO2 versus pH(i) = pH(o) = 7.2, 60% CO2) Was associated with reduced Na-22+ uptake. Decreasing the pH (pH(i) = pH(o) = 6.3, 60% CO2 versus pH(i) = pH(o) = 7.2, 5% CO2) Was associated with a reduced rate of HCO3--dependent Na+-Na+ exchange. We conclude that the Na+:HCO3- cotransporter displays a significant pH sensitivity profile with the cotransporter being more functional at pH 7.0-7.4 and less active at more acid or alkaline pH. In addition, the results suggest that the pH sensitivity arises at the inner surface of the basolateral membrane.	VET AFFAIRS MED CTR,INDIANAPOLIS,IN 46202	US Department of Veterans Affairs; Veterans Health Administration (VHA)	SOLEIMANI, M (corresponding author), INDIANA UNIV,MED CTR,DEPT MED,NEPHROL SECT,FESLER HALL 108,1120 S DR,INDIANAPOLIS,IN 46202, USA.			soleimani, m/0000-0002-3446-8870				AKIBA T, 1986, J CLIN INVEST, V78, P1472, DOI 10.1172/JCI112738; ALPERN RJ, 1990, PHYSIOL REV, V70, P79, DOI 10.1152/physrev.1990.70.1.79; ARONSON PS, 1982, NATURE, V299, P161, DOI 10.1038/299161a0; ARONSON PS, 1991, SEMIN NEPHROL, V11, P28; ASTION ML, 1989, J GEN PHYSIOL, V93, P731, DOI 10.1085/jgp.93.4.731; BORON WF, 1989, KIDNEY INT, V36, P392, DOI 10.1038/ki.1989.208; CURCI S, 1987, PFLUG ARCH EUR J PHY, V408, P497, DOI 10.1007/BF00585075; FITZ JG, 1989, AM J PHYSIOL, V256, pG491, DOI 10.1152/ajpgi.1989.256.3.G491; GRASSL SM, 1986, J BIOL CHEM, V261, P8778; HATTABAUGH Y, 1991, Journal of the American Society of Nephrology, V2, P701; JENTSCH TJ, 1985, J BIOL CHEM, V260, P795; JENTSCH TJ, 1986, J BIOL CHEM, V261, P673; KRAPF R, 1988, J CLIN INVEST, V81, P381, DOI 10.1172/JCI113330; KRAPF R, 1988, J CLIN INVEST, V82, P234, DOI 10.1172/JCI113576; PASSOW H, 1986, REV PHYSL BIOCH PHAR, V103, P62; PREISIG P A, 1989, American Journal of Physiology, V256, pF751; RENNER EL, 1989, J CLIN INVEST, V83, P1225, DOI 10.1172/JCI114005; SOLEIMANI M, 1989, J BIOL CHEM, V264, P18302; SOLEIMANI M, 1991, J BIOL CHEM, V266, P8706; SOLEIMANI M, 1987, J CLIN INVEST, V79, P1276, DOI 10.1172/JCI112948; SOLEIMANI M, 1989, J CLIN INVEST, V83, P945, DOI 10.1172/JCI113980; SOLEIMANI M, 1990, J CLIN INVEST, V86, P1076, DOI 10.1172/JCI114810; SOLEIMANI M, 1991, J CLIN INVEST, V88, P1076; YOSHITOMI K, 1985, PFLUG ARCH EUR J PHY, V405, P360, DOI 10.1007/BF00595689	24	8	8	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1992	267	26					18349	18355						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JN502	1526975				2022-12-25	WOS:A1992JN50200019
J	URANO, S; INOMORI, Y; SUGAWARA, T; KATO, Y; KITAHARA, M; HASEGAWA, Y; MATSUO, M; MUKAI, K				URANO, S; INOMORI, Y; SUGAWARA, T; KATO, Y; KITAHARA, M; HASEGAWA, Y; MATSUO, M; MUKAI, K			VITAMIN-E - INHIBITION OF RETINOL-INDUCED HEMOLYSIS AND MEMBRANE-STABILIZING BEHAVIOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-TOCOPHEROL; LIPID-PEROXIDATION; PHOSPHOLIPIDS; FLUORESCENCE; ANTIOXIDANT; LIPOSOMES; MONOLAYERS; DYNAMICS; FLUIDITY	For the elucidation of the mechanism of membrane stabilization by vitamin E, the effects of alpha-tocopherol and its model compounds on either retinol-induced hemolysis of rabbit erythrocytes or the permeability and fluidity of liposomal membranes have been studied. Retinol-induced rabbit erythrocyte hemolysis has been found not to be caused by the oxidative disruption of erythrocyte membrane lipids initiated by retinol oxidation, but rather to arise from physical damage of the membrane micelle induced by penetration of retinol molecules. In suppressing hemolysis, alpha-tocopherol was more effective than other naturally occurring tocopherols. Alpha-tocopheryl acetate, nicotinate, and 6-deoxy-alpha-tocopherol were more effective than alpha-tocopherol itself. The inhibitory effects of alpha-tocopherol model compounds having side chains with at least two isoprene units or a long straight chain instead of the isoprenoid side chain were similar to those of alpha-tocopherol. These data suggest that for protection of membranes against retinol-induced damage, the hydroxyl group of alpha-tocopherol is not critical, but rather the chroman ring, three methyl groups on the aromatic ring, and the long side chain are necessary. To verify the mechanism of the inhibitory effect on hemolysis, not only the effect of vitamin E and its model compounds on the membrane permeability and fluidity, but also the mobility of alpha-tocopherol molecule in membranes has been investigated using bilayer liposomes as the model membranes. Addition of alpha-tocopherol to membranes produced a greater decrease in the permeability and fluidity of rat liver phosphatidylcholine liposomes compared with egg yolk phosphatidylcholine liposomes. In dipalmitoylphosphatidylcholine liposomes, however, alpha-tocopherol was less effective, that is, the more unsaturated the lipids, the more they interact with alpha-tocopherol. 2,2,5,7,8-Pentamethyl-6-chromanol with no isoprenoid side chain and phytol without the chromanol moiety had no effect. The measurement of C-13 NMR relaxation times revealed that the mobility of methyl groups on the aromatic ring of alpha-tocopherol in membranes is significantly restricted. In contrast, the methyl groups at positions 4'a and 8'a on the isoprenoid side chain have high degrees of motional freedom in the lipid core of membranes. Furthermore, it was found that alpha-tocopherol in membranes interacts with chromate ions added as potassium chromate outside the membranes, resulting in an increase in membrane fluidity. These results are compatible with those of the inhibitory effect on retinol-induced erythrocyte hemolysis. On the basis of the results obtained here, a possible mechanism for membrane stabilization by vitamin E is proposed.	EHIME UNIV,FAC SCI,DEPT CHEM,MATSUYAMA,EHIME 790,JAPAN	Ehime University	URANO, S (corresponding author), TOKYO METROPOLITAN GERIATR HOSP & INST GERONTOL,35-2 SAKAE CHO,ITABASHI KU,TOKYO 173,JAPAN.							ARANDA FJ, 1989, BIOCHIM BIOPHYS ACTA, V985, P26, DOI 10.1016/0005-2736(89)90098-9; BANGHAM AD, 1964, BIOCHEM J, V90, P133, DOI 10.1042/bj0900133; BARCLAY LRC, 1985, CAN J CHEM, V63, P366, DOI 10.1139/v85-062; BURTON GW, 1986, ACCOUNTS CHEM RES, V19, P194, DOI 10.1021/ar00127a001; deDuve C, 1978, TOCOPHEROL OXYGEN BI; DEVAUX P, 1972, J AM CHEM SOC, V94, P4475, DOI 10.1021/ja00768a600; DINGLE JT, 1962, BIOCHEM J, V84, P611, DOI 10.1042/bj0840611; DIPLOCK AT, 1973, FEBS LETT, V29, P205, DOI 10.1016/0014-5793(73)80020-1; EGGERTON MT, 1951, PLAST RECONSTR SURG, V8, P224; EKIEL IH, 1988, BIOCHEMISTRY-US, V27, P1432, DOI 10.1021/bi00405a007; ERIN AN, 1986, BRAIN RES, V398, P85, DOI 10.1016/0006-8993(86)91253-9; ERIN AN, 1985, BIOCHIM BIOPHYS ACTA, V815, P209, DOI 10.1016/0005-2736(85)90291-3; FUKUZAWA K, 1977, CHEM PHYS LIPIDS, V18, P39, DOI 10.1016/0009-3084(77)90025-1; FUKUZAWA K, 1985, ARCH BIOCHEM BIOPHYS, V240, P117, DOI 10.1016/0003-9861(85)90013-X; GIASUDDIN ASM, 1981, ARCH BIOCHEM BIOPHYS, V210, P348, DOI 10.1016/0003-9861(81)90198-3; IMURA H, 1977, YAKUBUTSURYONO, V10, P79; KAGAN VE, 1988, EUR J BIOCHEM, V171, P661, DOI 10.1111/j.1432-1033.1988.tb13837.x; KAGAN VE, 1987, FREE RADICALS OXIDAN, P425; KORNBRUST DJ, 1980, LIPIDS, V15, P315, DOI 10.1007/BF02533546; LEUNG HW, 1981, BIOCHIM BIOPHYS ACTA, V664, P266; MACHLIN LJ, 1980, VITAMIN E, V1; MAGGIO B, 1977, BIOCHEM J, V161, P111, DOI 10.1042/bj1610111; MAIORINO M, 1989, LIPIDS, V24, P721, DOI 10.1007/BF02535211; MOURI H, 1984, J BIOCHEM-TOKYO, V95, P551; MUKAI K, 1989, J ORG CHEM, V54, P552, DOI 10.1021/jo00264a010; NIKI E, 1983, CHEM LETT, P631, DOI 10.1246/cl.1983.631; NIKI E, 1987, CHEM PHYS LIPIDS, V44, P227, DOI 10.1016/0009-3084(87)90052-1; SHINITZKY M, 1978, BIOCHIM BIOPHYS ACTA, V515, P367, DOI 10.1016/0304-4157(78)90010-2; STOYANOVSKY DA, 1989, BIOCHEM BIOPH RES CO, V160, P834, DOI 10.1016/0006-291X(89)92509-6; TAYLOR SL, 1976, LIPIDS, V11, P530, DOI 10.1007/BF02532898; URANO S, 1987, BIOCHEM BIOPH RES CO, V146, P1413, DOI 10.1016/0006-291X(87)90807-2; URANO S, 1980, CHEM PHARM BULL, V28, P1992; URANO S, 1988, BIOCHEM BIOPH RES CO, V150, P469, DOI 10.1016/0006-291X(88)90544-X; WASSALL SR, 1986, BIOCHEMISTRY-US, V25, P319, DOI 10.1021/bi00350a006; [No title captured]	35	56	60	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1992	267	26					18365	18370						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JN502	1526978				2022-12-25	WOS:A1992JN50200022
J	DEFAZIO, A; CHIEW, YE; DONOGHUE, C; LEE, CSL; SUTHERLAND, RL				DEFAZIO, A; CHIEW, YE; DONOGHUE, C; LEE, CSL; SUTHERLAND, RL			EFFECT OF SODIUM-BUTYRATE ON ESTROGEN-RECEPTOR AND EPIDERMAL GROWTH-FACTOR RECEPTOR GENE-EXPRESSION IN HUMAN BREAST-CANCER CELL-LINES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTIONAL REGULATION; PROGESTERONE-RECEPTOR; CARCINOMA CELLS; MESSENGER-RNAS; MCF-7; DIFFERENTIATION; SENSITIVITY; MILK; AMPLIFICATION; STIMULATION	Estrogen receptor (ER) binding has been shown to decrease in breast cancer cell lines exposed to sodium butyrate; however, the underlying mechanisms are unknown. In MCF-7 breast cancer cells, butyrate caused a rapid time- and concentration-dependent decrease in ER mRNA levels, apparent by 3 h at 3 mm butyrate. ER gene transcription rate was decreased and cycloheximide co-treatment did not relieve this inhibitory effect, suggesting that the butyrate effect was not dependent on ongoing protein synthesis. In both MCF-7 and T-47D cells the decrease in ER mRNA was mirrored by an increase in the level of epidermal growth factor receptor (EGF-R) mRNA. A marked inverse relationship exists between ER and EGF-R in human breast cancer biopsies and cell lines, and the reciprocal modulation of these genes by butyrate suggests that the expression of ER and EGF-R may be co-regulated. This relationship was further investigated in lines expressing only one or the other receptor. In the ER-positive EGF-R-negative line, MDA-MB-134-VI, butyrate exposure decreased ER mRNA levels, implying that the regulation of ER mRNA by butyrate is independent of EGF-R expression. However, butyrate decreased EGF-R mRNA in two ER-negative lines, MDA-MB-231 and HBL-100. As this effect differed from that in ER-positive lines, the regulation of EGF-R may depend on the expression of ER. The possibility that ER and EGF-R gene expression are closely linked has implications in the understanding of progression of human breast cancers to a hormone-independent phenotype and for the use of ER and EGF-R levels as independent prognostic indicators.			DEFAZIO, A (corresponding author), ST VINCENTS HOSP,GARVAN INST MED RES,DIV CANC BIOL,SYDNEY,NSW 2010,AUSTRALIA.		DeFazio, Anna/O-2385-2019; deFazio, Anna/D-3939-2013; Sutherland, Robert L/A-8378-2008	DeFazio, Anna/0000-0003-0057-4744; deFazio, Anna/0000-0003-0057-4744; 				ABE M, 1984, CANCER RES, V44, P4574; ABE M, 1986, J CELL PHYSIOL, V126, P126, DOI 10.1002/jcp.1041260117; BIRREN BW, 1987, MOL CELL BIOL, V7, P3863, DOI 10.1128/MCB.7.11.3863; BRESNICK EH, 1990, P NATL ACAD SCI USA, V87, P3977, DOI 10.1073/pnas.87.10.3977; CHAN YL, 1984, J BIOL CHEM, V259, P224; CLARKE CL, 1991, J BIOL CHEM, V266, P18969; COSGROVE DE, 1990, BIOCHIM BIOPHYS ACTA, V1087, P80, DOI 10.1016/0167-4781(90)90124-K; DAVIDSON NE, 1987, MOL ENDOCRINOL, V1, P216, DOI 10.1210/mend-1-3-216; DEFROMENTEL CC, 1985, EXP CELL RES, V160, P83, DOI 10.1016/0014-4827(85)90238-1; GLADHAUG IP, 1989, ANTICANCER RES, V9, P1587; GRAHAM KA, 1988, J CELL PHYSIOL, V136, P63, DOI 10.1002/jcp.1041360108; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; GUILBAUD NF, 1990, J CELL PHYSIOL, V145, P162, DOI 10.1002/jcp.1041450122; GUNNING P, 1983, MOL CELL BIOL, V3, P787, DOI 10.1128/MCB.3.5.787; HALL RE, 1990, INT J CANCER, V46, P1081, DOI 10.1002/ijc.2910460622; HORWITZ KB, 1982, CELL, V28, P633, DOI 10.1016/0092-8674(82)90218-5; KRUH J, 1982, MOL CELL BIOCHEM, V42, P65; Lee CSL, 1990, GROWTH FACTORS, V3, P97, DOI 10.3109/08977199009108272; LEE CSL, 1989, BIOCHEM BIOPH RES CO, V162, P415, DOI 10.1016/0006-291X(89)92013-5; LIBERMANN TA, 1985, NATURE, V313, P144, DOI 10.1038/313144a0; MALDEN LT, 1988, CANCER RES, V48, P2711; MILLER AA, 1987, EUR J CANCER CLIN ON, V23, P1283, DOI 10.1016/0277-5379(87)90109-X; NATHAN DF, 1990, EXP CELL RES, V190, P76, DOI 10.1016/0014-4827(90)90146-2; NOVOGRODSKY A, 1983, CANCER-AM CANCER SOC, V51, P9, DOI 10.1002/1097-0142(19830101)51:1<9::AID-CNCR2820510104>3.0.CO;2-4; PAN CJ, 1991, CANCER RES, V51, P2058; PEREZ R, 1984, BREAST CANCER RES TR, V4, P189, DOI 10.1007/BF01806484; PLANCHON P, 1991, INT J CANCER, V48, P443, DOI 10.1002/ijc.2910480323; REDDEL RR, 1985, CANCER RES, V45, P1525; SAINI K, 1990, BIOCHEM J, V272, P541, DOI 10.1042/bj2720541; SAINSBURY JRC, 1987, LANCET, V1, P1398; SAINSBURY JRC, 1985, LANCET, V1, P364; Sambrook J, 1989, MOL CLONING LABORATO; STEVENS MS, 1984, BIOCHEM BIOPH RES CO, V119, P132, DOI 10.1016/0006-291X(84)91628-0; TICHONICKY L, 1990, BIOL CELL, V69, P65, DOI 10.1016/0248-4900(90)90329-2; TOI M, 1990, CANCER, V65, P1980, DOI 10.1002/1097-0142(19900501)65:9<1980::AID-CNCR2820650917>3.0.CO;2-U; VALVERIUS EM, 1990, INT J CANCER, V46, P712, DOI 10.1002/ijc.2910460427; WALKERJONES D, 1989, CANCER RES, V49, P6407; WALTER P, 1985, P NATL ACAD SCI USA, V82, P7889, DOI 10.1073/pnas.82.23.7889	38	56	58	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1992	267	25					18008	18012						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JM223	1517234				2022-12-25	WOS:A1992JM22300081
J	TORMANEN, VT; PFEIFER, GP				TORMANEN, VT; PFEIFER, GP			MAPPING OF UV PHOTOPRODUCTS WITHIN RAS PROTOONCOGENES IN UV-IRRADIATED CELLS - CORRELATION WITH MUTATIONS IN HUMAN SKIN-CANCER	ONCOGENE			English	Article							LIGATION-MEDIATED PCR; N-RAS; PYRIMIDINE DIMERS; METHYLATION ANALYSIS; ESCHERICHIA-COLI; XERODERMA PIGMENTOSUM; 6-4 PHOTOPRODUCTS; POINT MUTATIONS; MAMMALIAN-CELLS; DNA DAMAGE	Mutations in ras proto-oncogenes have been found in human skin cancers. Since ultraviolet light is implicated in the development of skin cancers, we have investigated the formation of UV-induced photoproducts along exons 1 and 2 of the three ras proto-oncogenes, H-ras, K-ras, and N-ras, in UV-irradiated human cells. The two major types of DNA photoproducts, cyclobutane pyrimidine dimers and pyrimidine (6-4) pyrimidone photoproducts [(6-4) photoproducts], were mapped at the DNA sequence level by ligation-mediated polymerase chain reaction (LMPCR). No significant differences were seen between irradiated purified DNA and irradiated cells, implying that local chromatin structure does not influence the distribution of photoproducts along exons 1 and 2 of the three ras genes. We find that the transcribed strand near codon 61 in H-ras, K-ras and N-ras shows a high frequency of potentially mutagenic cyclobutane dimers and (6-4) photoproducts. Codon 12 of H-ras, K-ras and N-ras displays only barely detectable photoproducts at a CpC dinucleotide. In human skin cancers, mutations were most frequently detected at codon 12 of H-ras and K-ras. These results imply that the initial frequency distribution of a mutagenic DNA adduct may not correlate with mutation spectra in human tumors.	CITY HOPE NATL MED CTR,BECKMAN RES INT,DEPT BIOL,DUARTE,CA 91010	City of Hope; Beckman Research Institute of City of Hope								ALBINO AP, 1989, ONCOGENE, V4, P1363; ANANTHASWAMY HN, 1990, PHOTOCHEM PHOTOBIOL, V52, P1119, DOI 10.1111/j.1751-1097.1990.tb08452.x; ARMSTRONG JD, 1990, P NATL ACAD SCI USA, V87, P9005, DOI 10.1073/pnas.87.22.9005; BALMAIN A, 1988, ADV CANCER RES, V51, P147, DOI 10.1016/S0065-230X(08)60222-5; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BARBACID M, 1990, EUR J CLIN INVEST, V20, P225, DOI 10.1111/j.1365-2362.1990.tb01848.x; BECKER MM, 1984, NATURE, V309, P682, DOI 10.1038/309682a0; BOS JL, 1987, NATURE, V327, P293, DOI 10.1038/327293a0; BOURRE F, 1987, NUCLEIC ACIDS RES, V15, P8861, DOI 10.1093/nar/15.21.8861; BRASH DE, 1982, NATURE, V298, P189, DOI 10.1038/298189a0; BRASH DE, 1988, PHOTOCHEM PHOTOBIOL, V48, P59; BRASH DE, 1987, P NATL ACAD SCI USA, V84, P3782, DOI 10.1073/pnas.84.11.3782; BRASH DE, 1991, P NATL ACAD SCI USA, V88, P10124, DOI 10.1073/pnas.88.22.10124; BROWN R, 1984, EMBO J, V3, P1321, DOI 10.1002/j.1460-2075.1984.tb01970.x; CAPON DJ, 1983, NATURE, V302, P33, DOI 10.1038/302033a0; COLLINS SJ, 1988, ONCOGENE RES, V3, P117; COROMINAS M, 1989, P NATL ACAD SCI USA, V86, P6372, DOI 10.1073/pnas.86.16.6372; DROBETSKY EA, 1987, P NATL ACAD SCI USA, V84, P9103, DOI 10.1073/pnas.84.24.9103; FORRESTER K, 1987, NATURE, V327, P298, DOI 10.1038/327298a0; GALE JM, 1987, P NATL ACAD SCI USA, V84, P6644, DOI 10.1073/pnas.84.19.6644; GROSSMAN L, 1988, FASEB J, V2, P2696, DOI 10.1096/fasebj.2.11.3294078; HASELTINE WA, 1980, NATURE, V285, P634, DOI 10.1038/285634a0; KEIJZER W, 1989, CANCER RES, V49, P1229; KOEHLER DR, 1991, J BIOL CHEM, V266, P11766; LEON J, 1988, MOL CELL BIOL, V8, P786, DOI 10.1128/MCB.8.2.786; LIPPKE JA, 1981, P NATL ACAD SCI-BIOL, V78, P3388, DOI 10.1073/pnas.78.6.3388; LIU E, 1987, NATURE, V330, P186, DOI 10.1038/330186a0; LOEB LA, 1986, ANNU REV GENET, V20, P201, DOI 10.1146/annurev.ge.20.120186.001221; MCGRATH JP, 1983, NATURE, V304, P501, DOI 10.1038/304501a0; MELLON I, 1987, CELL, V51, P241, DOI 10.1016/0092-8674(87)90151-6; MEULLER PR, 1989, SCIENCE, V246, P780; MILLER JH, 1985, J MOL BIOL, V182, P45, DOI 10.1016/0022-2836(85)90026-9; MITCHELL DL, 1990, NUCLEIC ACIDS RES, V18, P963, DOI 10.1093/nar/18.4.963; MITCHELL DL, 1992, NUCLEIC ACIDS RES, V20, P225, DOI 10.1093/nar/20.2.225; MITCHELL DL, 1988, PHOTOCHEM PHOTOBIOL, V48, P51; MITCHELL DL, 1989, PHOTOCHEM PHOTOBIOL, V49, P805, DOI 10.1111/j.1751-1097.1989.tb05578.x; PADUA RA, 1985, MOL CELL BIOL, V5, P582, DOI 10.1128/MCB.5.3.582; PFEIFER GP, 1992, MOL CELL BIOL, V12, P1798, DOI 10.1128/MCB.12.4.1798; PFEIFER GP, 1991, P NATL ACAD SCI USA, V88, P1374, DOI 10.1073/pnas.88.4.1374; PFEIFER GP, 1989, SCIENCE, V246, P810, DOI 10.1126/science.2814502; PFEIFER GP, 1990, GENE DEV, V4, P1277, DOI 10.1101/gad.4.8.1277; PFEIFER GP, 1991, GENE DEV, V5, P1102, DOI 10.1101/gad.5.6.1102; PFEIFER GP, 1992, METHODS MOL BIOL PCR; PIERCEALL WE, 1991, MOL CARCINOGEN, V4, P196, DOI 10.1002/mc.2940040306; PIERCEALL WE, 1991, ONCOGENE, V6, P2085; PIERCEALL WE, 1991, MOL CARCINOGEN, V4, P445, DOI 10.1002/mc.2940040606; RYCHLIK W, 1989, NUCLEIC ACIDS RES, V17, P8543, DOI 10.1093/nar/17.21.8543; SANCAR A, 1984, J BIOL CHEM, V259, P6028; SARASIN A, 1991, 9TH P INT C RAD RES, P42; SCOTTO J, 1983, NIH832433 PUBL; SHUKLA VK, 1989, ONCOGENE RES, V5, P121; STEIGERWALD SD, 1990, NUCLEIC ACIDS RES, V18, P1435, DOI 10.1093/nar/18.6.1435; SUAREZ HG, 1989, CANCER RES, V49, P1223; THOMAS DC, 1989, J BIOL CHEM, V264, P18005; VANDERLUBBE JLM, 1988, ONCOGENE RES, V3, P9; VANDERSCHROEFF JG, 1990, J INVEST DERMATOL, V94, P423, DOI 10.1111/1523-1747.ep12874504; VANTVEER LJ, 1989, MOL CELL BIOL, V9, P3114, DOI 10.1128/MCB.9.7.3114; ZARBL H, 1985, NATURE, V315, P382, DOI 10.1038/315382a0	58	70	70	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1992	7	9					1729	1736						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JJ376	1501884				2022-12-25	WOS:A1992JJ37600008
J	TAL, M; LIANG, Y; NAJAFI, H; LODISH, HF; MATSCHINSKY, FM				TAL, M; LIANG, Y; NAJAFI, H; LODISH, HF; MATSCHINSKY, FM			EXPRESSION AND FUNCTION OF GLUT-1 AND GLUT-2 GLUCOSE TRANSPORTER ISOFORMS IN CELLS OF CULTURED RAT PANCREATIC-ISLETS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIABETIC RATS; BETA-CELLS; LIVER; GLUCOKINASE; LANGERHANS; INSULIN; MODULATION; SECRETION; GLUCAGON; PROTEINS	We have previously investigated glucose induction of glucokinase, glucose usage and insulin release in isolated cultured rat pancreatic islets (Liang, Y., Najafit, H., Smith, R. M., Zimmerman, E. C., Magnuson, M. A., Tal, M., and Mastchinsky, F. M. (1992) Diabetes (1992) 41, 792-806). Here we studied the expression and function of GLUT-1 and GLUT-2 glucose transporter isoforms, using the same system, i.e. isolated pancreatic rat islets immediately after isolation or cultured in the presence of 3 or 30 mm glucose for as long as 10 days. We found by immunofluorescence microscopy and Western and Northern blot analysis of islet extracts that GLUT-1 expression was induced in islet beta-cells in tissue culture both with low or high glucose present. The induction of GLUT-1 was specific to beta-cells but was not present in all beta-cells and was not detected in alpha-cells. GLUT-2 expression was also specific for beta-cells and was not observed in all beta-cells. Some beta-cells in culture coexpressed GLUT-1 and GLUT-2. The expression of the two glucose transporters was regulated in the opposite direction in response to glucose concentration in the culture medium. GLUT-1 was more effectively induced when glucose was low, and GLUT-2 expression was more pronounced when glucose was high in the culture media. Another difference between the two glucose transporters was that GLUT-2 expression was increased while GLUT-1 expression was decreased as culturing continued as long as 7 days. Thus, after 7 days of culture GLUT-2 expression in beta-cells was nearly the same at low and high glucose, whereas GLUT-1 was practically absent no matter what the glucose level was. In attempts to correlate GLUT-1 and GLUT-2 expression to beta-cell function glucose uptake and glucose-stimulated insulin release in fresh and cultured islets were measured. In freshly isolated islet glucose uptake was estimated to be 100-fold in excess of actual glucose use. Glucose uptake was reduced by 7-day culture to about one-third of that observed in freshly isolated islets no matter what the glucose concentration of the culture media. We conclude that in the present experimental system GLUT-1 and GLUT-2 expression and function are not closely associated with glucose usage rates or the secretory function of beta-cells.	UNIV PENN, DIABET RES CTR, 36TH & HAMILTON WALK, PHILADELPHIA, PA 19104 USA; UNIV PENN, DEPT BIOCHEM & BIOPHYS, PHILADELPHIA, PA 19104 USA; MIT, DEPT BIOL, CAMBRIDGE, MA 02139 USA; WHITEHEAD INST BIOMED RES, CAMBRIDGE, MA 02142 USA	University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Whitehead Institute					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL041484] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK022122, R37DK022122] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040916] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 41484] Funding Source: Medline; NIDDK NIH HHS [NIDDK 22122] Funding Source: Medline; NIGMS NIH HHS [GM 40916] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLARD WJ, 1987, BIOCHIM BIOPHYS ACTA, V929, P288, DOI 10.1016/0167-4889(87)90255-2; AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; BIRNBAUM MJ, 1986, P NATL ACAD SCI USA, V83, P5784, DOI 10.1073/pnas.83.16.5784; BURCH PT, 1984, J GERONTOL, V39, P2, DOI 10.1093/geronj/39.1.2; GERICH JE, 1976, ANNU REV PHYSIOL, V38, P353, DOI 10.1146/annurev.ph.38.030176.002033; JOHNSON JH, 1990, J BIOL CHEM, V265, P6548; LEHRACH H, 1977, BIOCHEMISTRY-US, V16, P4743, DOI 10.1021/bi00640a033; LIANG Y, 1991, DIABETES, V40, P327, DOI 10.2337/diabetes.40.3.327; LIANG Y, 1990, J BIOL CHEM, V265, P16863; LOWRY OH, 1972, FLEXIBLE SYSTEM ENZY, P147; MATSCHIN.FM, 1968, J BIOL CHEM, V243, P2730; MATSCHINSKY FM, 1976, J BIOL CHEM, V251, P6053; MATSCHINSKY FM, 1988, PATHOGENESIS NONINSU, P61; MATSCHINSKY FM, 1971, RECENT ADV QUANTITAT, P143; MCLEAN IW, 1974, J HISTOCHEM CYTOCHEM, V22, P1077, DOI 10.1177/22.12.1077; MEGLASSON M D, 1986, Diabetes Metabolism Reviews, V2, P163; MEGLASSON MD, 1983, P NATL ACAD SCI-BIOL, V80, P85, DOI 10.1073/pnas.80.1.85; NEWGARD CB, 1990, BIOCHEM SOC T, V18, P851, DOI 10.1042/bst0180851; PACE CS, 1975, DIABETES, V24, P476, DOI 10.2337/diabetes.24.5.476; PAGLIARA AS, 1974, J CLIN INVEST, V54, P819, DOI 10.1172/JCI107822; SMITH RM, 1991, P NATL ACAD SCI USA, V88, P6893, DOI 10.1073/pnas.88.15.6893; TAL M, 1990, J CLIN INVEST, V86, P986, DOI 10.1172/JCI114801; TAL M, 1992, MOL CELL BIOL, V12, P422, DOI 10.1128/MCB.12.1.422; THORENS B, 1990, DIABETES CARE, V13, P209, DOI 10.2337/diacare.13.3.209; THORENS B, 1988, CELL, V55, P281, DOI 10.1016/0092-8674(88)90051-7; THORENS B, 1990, AM J PHYSIOL, V259, pC286; THORENS B, 1990, P NATL ACAD SCI USA, V87, P6492, DOI 10.1073/pnas.87.17.6492; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; UNGER RH, 1991, SCIENCE, V251, P1200, DOI 10.1126/science.2006409; WERTHEIMER E, 1991, P NATL ACAD SCI USA, V88, P2525, DOI 10.1073/pnas.88.6.2525; WHEELER TJ, 1981, J BIOL CHEM, V256, P8907; YASUDA K, 1992, DIABETES, V41, P76, DOI 10.2337/diabetes.41.1.76; YIN L, 1992, DIABETES, V41, P792	33	79	80	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	1992	267	24					17241	17247						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JL053	1512261				2022-12-25	WOS:A1992JL05300078
J	PARENT, CA; LAGARDE, M; VENTON, DL; LEBRETON, GC				PARENT, CA; LAGARDE, M; VENTON, DL; LEBRETON, GC			SELECTIVE MODULATION OF THE HUMAN PLATELET THROMBOXANE-A(2) PROSTAGLANDIN-H2 RECEPTOR BY EICOSAPENTAENOIC AND DOCOSAHEXAENOIC ACIDS IN INTACT PLATELETS AND SOLUBILIZED PLATELET MEMBRANES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UNSATURATED FATTY-ACIDS; ALPHA-2-ADRENERGIC RECEPTOR; INVITRO INCORPORATION; ARACHIDONIC-ACID; BINDING; FLUIDITY; AGGREGATION; CHOLESTEROL; INHIBITION; METABOLISM	We previously demonstrated that nonesterified as well as esterified eicosapentaenoic acid (20:5n-3) and docosahexaenoic acid (22:6n-3) inhibit U46619-induced platelet aggregation and [H-3]U46619 specific binding to washed human platelets. It was also demonstrated that esterification of these fatty acids resulted in a decrease in the affinity of [H-3]U46619 for the thromboxane A2/prostaglandin H-2 (TXA2/PGH2) receptor. In order to investigate the specificity of this inhibition, the effects of 20:5n-3 and 22:6n-3 on the function and binding of the platelet alpha(2)-adrenergic receptor were studied. It was found that neither 20:5n-3 nor 22:6n-3 (nonesterified or esterified) altered epinephrine-induced aggregation or [H-3]yohimbine specific binding. Moreover, Scatchard analysis revealed that esterification with either 20:5n-3 or 22:6n-3 did not alter the dissociation constant for [H-3]yohimbine binding. Modulation of the TXA2/PGH2 receptor by 20:5n-3 and 22:6n-3 was next evaluated using CHAPS- and digitonin-solubilized platelet membranes. [H-3]SQ29,548 dissociation constants of 26.5 nM and 20.8 nM were measured for CHAPS and digitonin-solubilized membranes, respectively. Competitive binding experiments in these solubilized preparations revealed that 20:5n-3 or 22:6n-3 blocked [H-3]SQ29,548 binding with IC50 values in the range of 6-15-mu-M, while concentrations of these fatty acids of up to 100-mu-M showed no effect on [H-3]yohimbine binding. On the other hand, the IC50 values for inhibition of [H-3]SQ29,548 binding by linoleic acid (18:2n-6) and gamma-linolenic acid (18:3n-6) were in the range of 150-mu-M. Furthermore, 18:2n-6 and 18:3n-6 showed similar inhibitory effects on [H-3]yohimbine binding. Finally, competition binding studies performed in a partially purified TXA2/PGH2 receptor preparation also demonstrated inhibition of [H-3]SQ29,548 binding by 20:5n-3 and 22:6n-3. Collectively, these findings support the notion that 20:5n-3 and 22:6n-3 can selectively and directly modulate TXA2/PGH2 receptor function, and that this mechanism of action may contribute to the antiplatelet activity associated with diets rich in these fatty acids.	UNIV ILLINOIS,DEPT PHARMACOL,CHICAGO,IL 60612; INST NATL SCI APPL,INSERM,U205,F-69621 VILLEURBANNE,FRANCE	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National des Sciences Appliquees de Lyon - INSA Lyon					NHLBI NIH HHS [HL24530] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL024530] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BALLOU LR, 1985, P NATL ACAD SCI USA, V82, P371, DOI 10.1073/pnas.82.2.371; BORN GVR, 1962, NATURE, V194, P927, DOI 10.1038/194927b0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; COREY EJ, 1983, P NATL ACAD SCI-BIOL, V80, P3581, DOI 10.1073/pnas.80.12.3581; CROSET M, 1986, THROMB HAEMOSTASIS, V56, P57; FISCHER S, 1984, BIOCHEM BIOPH RES CO, V120, P907, DOI 10.1016/S0006-291X(84)80193-X; GIBNEY MJ, 1988, BRIT J NUTR, V60, P5, DOI 10.1079/BJN19880070; GORDON LM, 1980, J BIOL CHEM, V255, P4519; GRYGLEWSKI RJ, 1979, PROSTAGLANDINS, V18, P453, DOI 10.1016/S0090-6980(79)80063-5; HAJARINE M, 1986, BIOCHIM BIOPHYS ACTA, V877, P299, DOI 10.1016/0005-2760(86)90307-3; HATMI M, 1988, BIOCHEM PHARMACOL, V37, P481, DOI 10.1016/0006-2952(88)90218-3; HEDBERG A, 1988, J PHARMACOL EXP THER, V245, P786; HEEMSKERK JWM, 1989, BIOCHIM BIOPHYS ACTA, V1004, P252, DOI 10.1016/0005-2760(89)90275-0; HIRATA M, 1991, NATURE, V349, P617, DOI 10.1038/349617a0; HORNSTRA G, 1986, PROG LIPID RES, V25, P637, DOI 10.1016/0163-7827(86)90130-X; INSEL PA, 1978, BIOCHEMISTRY-US, V17, P5269, DOI 10.1021/bi00617a029; KIM S, 1991, IN PRESS BIOCH PHARM; KOBILKA BK, 1987, SCIENCE, V238, P650, DOI 10.1126/science.2823383; LAGARDE M, 1980, THROMB RES, V17, P581, DOI 10.1016/0049-3848(80)90098-5; LAGARDE M, 1985, BIOCHIM BIOPHYS ACTA, V833, P52, DOI 10.1016/0005-2760(85)90252-8; LEAF A, 1988, NEW ENGL J MED, V318, P549, DOI 10.1056/NEJM198803033180905; LIMBIRD LE, 1982, MOL PHARMACOL, V21, P609; MACINTYRE DE, 1984, BLOOD, V63, P848; MCPHERSON GA, 1983, COMPUT PROG BIOMED, V17, P107, DOI 10.1016/0010-468X(83)90031-4; MOTULSKY HJ, 1980, BIOCHEM BIOPH RES CO, V97, P1562, DOI 10.1016/S0006-291X(80)80044-1; NEEDLEMAN P, 1979, P NATL ACAD SCI USA, V76, P944, DOI 10.1073/pnas.76.2.944; NEEDLEMAN SW, 1982, PROSTAGLANDINS, V24, P607, DOI 10.1016/0090-6980(82)90031-4; RADOMSKI M, 1983, THROMB RES, V30, P383, DOI 10.1016/0049-3848(83)90230-X; ROSS R, 1986, NEW ENGL J MED, V314, P488, DOI 10.1056/NEJM198602203140806; SATO T, 1989, BIOCHIM BIOPHYS ACTA, V992, P168, DOI 10.1016/0304-4165(89)90006-8; SATO T, 1987, BIOCHIM BIOPHYS ACTA, V931, P157, DOI 10.1016/0167-4889(87)90201-1; SHATTIL SJ, 1975, J CLIN INVEST, V55, P636, DOI 10.1172/JCI107971; SWANN PG, 1989, FEBS LETT, V243, P244, DOI 10.1016/0014-5793(89)80137-1; SWANN PG, 1990, J BIOL CHEM, V265, P21692; TANDON N, 1983, J BIOL CHEM, V258, P1840; TOMIZUKA T, 1990, THROMB HAEMOSTASIS, V64, P594; VALLEE E, 1980, AGENTS ACTIONS, V10, P57, DOI 10.1007/BF02024179; VONSCHACKY C, 1987, ANN INTERN MED, V107, P890, DOI 10.7326/0003-4819-107-6-890	38	34	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1992	267	10					6541	6547						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HM053	1532390				2022-12-25	WOS:A1992HM05300017
J	LEE, JI; KUHN, A; DALBEY, RE				LEE, JI; KUHN, A; DALBEY, RE			DISTINCT DOMAINS OF AN OLIGOTOPIC MEMBRANE-PROTEIN ARE SEC-DEPENDENT AND SEC-INDEPENDENT FOR MEMBRANE INSERTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI LEADER PEPTIDASE; POSITIVELY CHARGED RESIDUES; SIGNAL-ANCHOR DOMAIN; MALTOSE-BINDING PROTEIN; ESCHERICHIA-COLI; ENDOPLASMIC-RETICULUM; CYTOPLASMIC MEMBRANE; HYDROPHOBIC DOMAIN; PLASMA-MEMBRANE; OUTER MEMBRANE	Leader peptidase of Escherichia coli spans the plasma membrane twice with its amino terminus on the periplasmic surface of the membrane and its large carboxyl-terminal domain protruding into the periplasm. To monitor the transfer of the amino terminus of leader peptidase to the periplasm, we have constructed a fusion protein between the 18-residue amino-terminal periplasmic domain of Pf3 bacteriophage coat protein and the beginning of leader peptidase. We find that neither the SecA or SecY proteins nor a transmembrane electrochemical potential is required for insertion of the amino terminus, while the transfer of the carboxyl-terminal domain of leader peptidase has these requirements. The first 35 residues of leader peptidase, which include the first hydrophobic domain and the carboxyl-terminal positively charged cluster, are sufficient to insert the amino terminus. When positively charged residues are introduced before the first transmembrane segment, translocation of the amino terminus is abolished. These studies in protein membrane topogenesis, showing that there are different requirements for amino and carboxyl termini insertion, indicate that multiple mechanisms exist even within the same protein.	UNIV KARLSRUHE, DEPT APPL MICROBIOL, W-7500 KARLSRUHE, GERMANY	Helmholtz Association; Karlsruhe Institute of Technology	LEE, JI (corresponding author), OHIO STATE UNIV, DEPT CHEM, COLUMBUS, OH 43210 USA.							ANDERSON DJ, 1983, P NATL ACAD SCI-BIOL, V80, P7249, DOI 10.1073/pnas.80.23.7249; BASSFORD PJ, 1979, J BACTERIOL, V139, P19, DOI 10.1128/JB.139.1.19-31.1979; BECKWITH J, 1986, CURR TOP MICROBIOL, V125, P5; BLOBEL G, 1980, P NATL ACAD SCI-BIOL, V77, P1496, DOI 10.1073/pnas.77.3.1496; CARLSON M, 1982, CELL, V28, P145, DOI 10.1016/0092-8674(82)90384-1; COHEN SN, 1973, P NATL ACAD SCI USA, V70, P3240, DOI 10.1073/pnas.70.11.3240; DALBEY RE, 1988, J BIOL CHEM, V263, P404; DALBEY RE, 1987, SCIENCE, V235, P783, DOI 10.1126/science.3544218; DALBEY RE, 1987, J BIOL CHEM, V262, P13241; DALBEY RE, 1986, J BIOL CHEM, V261, P3844; DALBEY RE, 1990, TRENDS BIOCHEM SCI, V15, P253, DOI 10.1016/0968-0004(90)90047-F; DALBEY RE, 1991, METHOD CELL BIOL, V34, P39; DAVIS NG, 1985, CELL, V41, P607, DOI 10.1016/S0092-8674(85)80033-7; DAVIS NG, 1985, J MOL BIOL, V181, P111, DOI 10.1016/0022-2836(85)90329-8; EMR SD, 1978, P NATL ACAD SCI USA, V75, P5802, DOI 10.1073/pnas.75.12.5802; HULL JD, 1988, J CELL BIOL, V106, P1489, DOI 10.1083/jcb.106.5.1489; ITO K, 1980, J BIOL CHEM, V255, P2123; JOHNSTON S, 1985, GENE, V34, P137, DOI 10.1016/0378-1119(85)90121-0; KUHN A, 1990, EMBO J, V9, P2385, DOI 10.1002/j.1460-2075.1990.tb07413.x; LAWS JK, 1989, EMBO J, V8, P2095, DOI 10.1002/j.1460-2075.1989.tb03618.x; Maniatis T., 1982, MOL CLONING; MANOIL C, 1986, SCIENCE, V233, P1403, DOI 10.1126/science.3529391; MICHAELIS S, 1982, ANNU REV MICROBIOL, V36, P435, DOI 10.1146/annurev.mi.36.100182.002251; MONIER S, 1988, J CELL BIOL, V107, P457, DOI 10.1083/jcb.107.2.457; MOORE KE, 1987, J BIOL CHEM, V262, P8806; NILSSON IM, 1990, CELL, V62, P1135, DOI 10.1016/0092-8674(90)90390-Z; OSBORN MJ, 1972, J BIOL CHEM, V247, P3962; RANDALL LL, 1986, CELL, V46, P921, DOI 10.1016/0092-8674(86)90074-7; ROHRER J, 1990, SCIENCE, V250, P1418, DOI 10.1126/science.2124001; SAIER MH, 1989, MICROBIOL REV, V53, P333, DOI 10.1128/MMBR.53.3.333-366.1989; SANMILLAN JL, 1989, J BACTERIOL, V171, P5536, DOI 10.1128/jb.171.10.5536-5541.1989; SPIESS M, 1987, EMBO J, V6, P2683, DOI 10.1002/j.1460-2075.1987.tb02560.x; VERNER K, 1988, SCIENCE, V241, P1307, DOI 10.1126/science.2842866; VONHEIJNE G, 1988, P NATL ACAD SCI USA, V85, P3363; VONHEIJNE G, 1988, EUR J BIOCHEM, V174, P671; VONHEIJNE G, 1989, NATURE, V341, P456, DOI 10.1038/341456a0; WICKNER WT, 1985, SCIENCE, V230, P400, DOI 10.1126/science.4048938; WOLFE PB, 1983, J BIOL CHEM, V258, P2073; WOLFE PB, 1984, CELL, V36, P1067, DOI 10.1016/0092-8674(84)90056-4; WOLFE PB, 1985, J BIOL CHEM, V260, P1836; WOLFE PB, 1982, J BIOL CHEM, V257, P7898; ZHU HY, 1989, J BIOL CHEM, V264, P11833; ZOLLER MJ, 1983, METHOD ENZYMOL, V100, P468	43	81	81	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 15	1992	267	2					938	943						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY960	1530939				2022-12-25	WOS:A1992GY96000042
J	DONNADIEU, E; BISMUTH, G; TRAUTMANN, A				DONNADIEU, E; BISMUTH, G; TRAUTMANN, A			CALCIUM FLUXES IN LYMPHOCYTES-T	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PAROTID ACINAR-CELLS; ENDOPLASMIC-RETICULUM; FURA-2-LOADED HEPATOCYTES; SARCOPLASMIC-RETICULUM; CA2+ INFLUX; OSCILLATIONS; CA-2+; MEMBRANE; THAPSIGARGIN; RELEASE	Mechanisms controlling Ca2+ fluxes through the plasma membrane of lymphocytes have been characterized in a human T-cell clone and in the Jurkat T-cell line. Due to endogenous buffers, about 1/125 of the Ca2+ ions that enter the cell are free. Ca2+ fluxes were estimated from the variations in intracellular Ca2+ concentration ([Ca2+]i) elicited by concentration jumps in extracellular Ca2+ ([Ca2+]o). Thapsigargin was used to inhibit Ca2+ uptake into intracellular stores and to stimulate Ca2+ entry. Ca2+ extrusion was strictly due to the activity of plasma membrane Ca2+-ATPases since there was no detectable Na+/Ca2+ exchange activity in these cells. The rate of Ca2+ extrusion was mainly influenced by [Ca2+]i and less by [Ca2+]o but was insensitive to cell depolarization. In depolarized cells, thapsigargin-induced Ca2+ influx was reduced to 10% of the value measured in normally polarized cells, suggesting that depolarization not only reduces the electrochemical gradient for Ca2+ ions, but also inhibits Ca2+ permeation. When Ca2+ ions enter the cell, they bind to a site inside the channel, with a K(d) of 3.3 mM. Stimulation of clonal T-cells with low concentrations of either anti-CD3 antibodies or thapsigargin elicited Ca2+ oscillations. Both the amplitude and the frequency of CD3-induced Ca" oscillations were sensitive to [Ca2+]o. These oscillations were immediately interrupted when extracellular Ca2+ was removed. The properties of Ca" oscillations in T lymphocytes suggest that they are mainly due to variations of Ca2+ influx, modulated by variations in [Ca2+]i.	GRP HOSP PITIE SALPETRIERE,CERVI,IMMUNOL CELLULAIRE & TISSULAIRE LAB,CNRS,URA 625,F-75634 PARIS 13,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite	DONNADIEU, E (corresponding author), ECOLE NORM SUPER,NEUROBIOL LAB,CNRS,URA 295,46 RUE ULM,F-75231 PARIS 05,FRANCE.		Donnadieu, Emmanuel/P-4566-2017					AMBUDKAR IS, 1988, J MEMBRANE BIOL, V102, P59, DOI 10.1007/BF01875353; BEZPROZVANNY I, 1991, NATURE, V351, P751, DOI 10.1038/351751a0; CAHALAN MD, 1987, MECHANISMS LYMPHOCYT, P85; CARBONE E, 1987, J PHYSIOL-LONDON, V386, P547, DOI 10.1113/jphysiol.1987.sp016551; CHAD JE, 1986, J PHYSIOL-LONDON, V378, P31, DOI 10.1113/jphysiol.1986.sp016206; DONNADIEU E, 1992, J IMMUNOL, V148, P2643; FINCH EA, 1991, SCIENCE, V252, P443, DOI 10.1126/science.2017683; FOSKETT JK, 1991, J BIOL CHEM, V266, P14535; GOUY H, 1990, EUR J IMMUNOL, V20, P2269, DOI 10.1002/eji.1830201016; GRAY PTA, 1988, J PHYSIOL-LONDON, V406, P35, DOI 10.1113/jphysiol.1988.sp017367; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; GURNEY AM, 1989, NATURE, V341, P65, DOI 10.1038/341065a0; HADLEY RW, 1991, J PHYSIOL-LONDON, V444, P257, DOI 10.1113/jphysiol.1991.sp018876; HAROOTUNIAN AT, 1991, SCIENCE, V251, P75, DOI 10.1126/science.1986413; Hille B, 1984, IONIC CHANNELS EXCIT; HODGKIN AL, 1949, J PHYSIOL-LONDON, V108, P37, DOI 10.1113/jphysiol.1949.sp004310; ISHIDA Y, 1988, J EXP MED, V168, P839, DOI 10.1084/jem.168.3.839; JAMESKRACKE MR, 1992, J GEN PHYSIOL, V99, P41, DOI 10.1085/jgp.99.1.41; KAWANISHI T, 1989, J BIOL CHEM, V264, P12859; LASKEY RE, 1992, P NATL ACAD SCI USA, V89, P1690, DOI 10.1073/pnas.89.5.1690; LEWIS RS, 1989, CELL REGUL, V1, P99, DOI 10.1091/mbc.1.1.99; LOESSBERG PA, 1991, J BIOL CHEM, V266, P1363; MATTHEWS G, 1989, J PHYSIOL-LONDON, V418, P105, DOI 10.1113/jphysiol.1989.sp017830; MELDOLESI J, 1991, TRENDS PHARMACOL SCI, V12, P289, DOI 10.1016/0165-6147(91)90577-F; MERRITT JE, 1988, J BIOL CHEM, V263, P6161; MERTZ LM, 1992, J MEMBRANE BIOL, V126, P183; MOUTIN MJ, 1988, J BIOL CHEM, V263, P4228; NEHER E, 1992, J PHYSIOL-LONDON, V450, P273, DOI 10.1113/jphysiol.1992.sp019127; OBRIEN PJ, 1990, MOL CELL BIOCHEM, V96, P88; RANDRIAMAMPITA C, 1991, CELL CALCIUM, V12, P313, DOI 10.1016/0143-4160(91)90005-Y; RANDRIAMAMPITA C, 1990, J BIOL CHEM, V265, P18059; RANDRIAMAMPITA C, 1989, FEBS LETT, V249, P199, DOI 10.1016/0014-5793(89)80624-6; REEVES JP, 1990, INTRACELLULAR CALCIU, P305; ROONEY TA, 1989, J BIOL CHEM, V264, P17131; SCHATZMANN HJ, 1989, ANNU REV PHYSIOL, V51, P473, DOI 10.1146/annurev.ph.51.030189.002353; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; TRIEBEL F, 1984, EUR J IMMUNOL, V14, P697, DOI 10.1002/eji.1830140805; TSIEN RY, 1982, NATURE, V295, P68, DOI 10.1038/295068a0; TSUNODA Y, 1991, NEW BIOL, V3, P3; VONTSCHARNER V, 1986, J BIOL CHEM, V261, P163; WEISS A, 1989, FUNDAMENTAL IMMUNOLO, P359; WILSON HA, 1985, J CELL PHYSIOL, V125, P72, DOI 10.1002/jcp.1041250110; ZAO H, 1990, J BIOL CHEM, V265, P20856; ZHANG BX, 1992, AM J PHYSIOL, V262, pC1125, DOI 10.1152/ajpcell.1992.262.5.C1125	44	128	128	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1992	267	36					25864	25872						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KD073	1464601				2022-12-25	WOS:A1992KD07300044
J	FREDENBURGH, JC; NESHEIM, ME				FREDENBURGH, JC; NESHEIM, ME			LYS-PLASMINOGEN IS A SIGNIFICANT INTERMEDIATE IN THE ACTIVATION OF GLU-PLASMINOGEN DURING FIBRINOLYSIS INVITRO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INHIBITOR COMPLEXES; MOLECULAR-FORMS; BINDING-SITES; TISSUE; UROKINASE; PLASMA; KINETICS; SYSTEM; ENHANCEMENT; MECHANISM	Plasminogen, the zymogen form of the fibrinolytic enzyme plasmin, is known to undergo plasmin-mediated modification in vitro. The modified form, Lys-plasminogen, is superior to the native Glu-plasminogen in fibrin binding and as a substrate for activation by tissue-type plasminogen activator (t-PA). The present study was undertaken to determine the existence and significance of the Glu- to Lys-plasminogen conversion during t-PA-mediated lysis of plasma clots in vitro. When human plasma was supplemented with exogenous Lys-plasminogen and clotted, a dose-dependent shortening of lysis time was observed. Formation of Lys-plasminogen in situ during fibrinolysis was determined using I-131-Glu-plasminogen-supplemented plasma. By the time of lysis, Lys-plasminogen had accumulated to about 20% of the initial concentration of Glu-plasminogen. Quantitation of activation of both Glu- and Lys-plasminogen as well as the conversion of Glu- to Lys-plasminogen in plasma supplemented with both I-131-Glu-plasminogen and I-125-Lys-plasminogen was accomplished by determining the flux of the isotopically labeled species along three pathways: Glu-plasminogen --> Glu-plasmin, Glu-plasminogen --> Lys-plasminogen, and Lys-plasminogen --> Lys-plasmin. After a brief lag, the Glu-plasminogen activation rate was constant until lysis was achieved, at which point activation ceased. The Lys-plasminogen activation rate also was essentially constant until lysis but was not characterized by a lag phase. The rate of conversion of Glu- to Lys-plasminogen was nonlinear and correlated directly with the rate of fibrinolysis. By the time lysis had occurred, Glu-plasminogen consumption had been distributed equally between direct activation to plasmin and conversion to Lys-plasminogen, and 45% of the plasmin which had been formed was derived from Lys-plasminogen. These results demonstrate both the formation and the subsequent activation of Lys-plasminogen during fibrinolysis. As a result of improved fibrin binding and activation of Lys-plasminogen compared to Glu-plasminogen, the formation of Lys-plasminogen within a clot constitutes a positive feedback mechanism that can further stimulate the activation of plasminogen by t-PA as fibrinolysis progresses.	QUEENS UNIV,DEPT MED,KINGSTON K7L 3N6,ONTARIO,CANADA; QUEENS UNIV,DEPT BIOCHEM,KINGSTON K7L 3N6,ONTARIO,CANADA	Queens University - Canada; Queens University - Canada	NESHEIM, ME (corresponding author), QUEENS UNIV,DEPT MED,KINGSTON K7L 3N6,ONTARIO,CANADA.							BACHMANN F, 1987, THROMB DIATH HAEMO, P227; BAJZAR L, 1990, J BIOL CHEM, V265, P16948; CASTELLINO FJ, 1981, METHOD ENZYMOL, V80, P365; CASTELLINO FJ, 1981, CHEM REV, V81, P431, DOI 10.1021/cr00045a001; DEVRIES C, 1990, J BIOL CHEM, V265, P13547; FREDENBURGH J C, 1990, Fibrinolysis, V4, P48; FRIBERGER P, 1982, SCAND J CLIN LAB INV, V42, P1; HARPEL PC, 1985, J BIOL CHEM, V260, P4432; HOLVOET P, 1985, J BIOL CHEM, V260, P2106; HOYLAERTS M, 1982, J BIOL CHEM, V257, P2912; JOHANNESSEN M, 1989, FIBRINOLYSIS, V3, P215, DOI 10.1016/0268-9499(89)90049-0; LIJNEN HR, 1989, FIBRINOLYSIS, V3, P67, DOI 10.1016/0268-9499(89)90034-9; LIJNEN HR, 1990, THROMB HAEMOSTASIS, V64, P61; LUCAS MA, 1983, J BIOL CHEM, V258, P2171; MULLERTZ S, 1984, BIOCHEM J, V223, P169; NESHEIM M, 1990, J BIOL CHEM, V265, P21541; NESHEIM M E, 1990, Fibrinolysis, V4, P108; NESHEIM ME, 1983, J BIOL CHEM, V258, P4708; NISHINO N, 1991, THROMB HAEMOSTASIS, V66, P672; NORRMAN B, 1985, EUR J BIOCHEM, V149, P193, DOI 10.1111/j.1432-1033.1985.tb08911.x; PANYIM S, 1969, ARCH BIOCHEM BIOPHYS, V130, P337, DOI 10.1016/0003-9861(69)90042-3; ROUY D, 1990, BIOCHEM J, V271, P51, DOI 10.1042/bj2710051; SAKATA Y, 1982, J CLIN INVEST, V69, P536, DOI 10.1172/JCI110479; SUENSON E, 1986, BIOCHIM BIOPHYS ACTA, V870, P510, DOI 10.1016/0167-4838(86)90260-8; SUENSON E, 1988, BIOCHEMISTRY-US, V27, P2435, DOI 10.1021/bi00407a029; SUENSON E, 1984, EUR J BIOCHEM, V140, P513, DOI 10.1111/j.1432-1033.1984.tb08132.x; SUENSON E, 1990, J BIOL CHEM, V265, P22228; TAKADA A, 1986, THROMB RES, V41, P819, DOI 10.1016/0049-3848(86)90380-4; THORSEN S, 1984, BIOCHEM J, V223, P179, DOI 10.1042/bj2230179; TRANTHANG C, 1986, EUR J BIOCHEM, V160, P599, DOI 10.1111/j.1432-1033.1986.tb10080.x; URANO S, 1989, P NATL ACAD SCI USA, V86, P2568, DOI 10.1073/pnas.86.8.2568; WATAHIKI Y, 1989, THROMB HAEMOSTASIS, V61, P502; WOHL RC, 1980, J BIOL CHEM, V255, P2005	33	52	62	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1992	267	36					26150	26156						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KD073	1464625				2022-12-25	WOS:A1992KD07300084
J	NGUYEN, M; FOLKMAN, J; BISCHOFF, J				NGUYEN, M; FOLKMAN, J; BISCHOFF, J			1-DEOXYMANNOJIRIMYCIN INHIBITS CAPILLARY-TUBE FORMATION INVITRO - ANALYSIS OF N-LINKED OLIGOSACCHARIDES IN BOVINE CAPILLARY ENDOTHELIAL-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANGIOGENESIS INVITRO; GLYCOPROTEIN-SYNTHESIS; CARBOHYDRATE LIGAND; ALPHA-MANNOSIDASES; SIALYL-LEX; ADHESION; ELAM-1; DIFFERENTIATION; CHROMATOGRAPHY; RECOGNITION	Capillary endothelial cells can be induced to form capillary-like structures in vitro by plating on fibronectin-coated dishes (Ingber, D. E., and Folkman, J. (1989) J. Cell Biol. 109, 317-330), thereby mimicking angiogenesis. To assess the role of glycoproteins bearing asparagine-linked oligosaccharides in this process, we tested the effect of oligosaccharide processing inhibitors on the formation of capillary tubes. Deoxymannojirimycin, a compound that prevents synthesis of hybrid and complex-type oligosaccharides, inhibited the formation of capillary tubes. In contrast, swainsonine, an inhibitor that blocks synthesis of complex- but not hybrid-type oligosaccharides, did not inhibit tube formation. Lectin affinity chromatography of 2-[H-3] mannose-labeled glycopeptides from endothelial cells induced to form tubes did not reveal a striking difference in the spectrum of oligosaccharides compared to uninduced cells. Since endothelial cells formed tubes normally in the presence of swainsonine, we analyzed glycopeptides from swainsonine-treated induced and uninduced cells. Cells induced to form tubes were enriched in monosialylated hybrid-type oligosaccharides sensitive to alpha-fucosidase, beta-galactosidase, and beta-N-acetylhexosaminidase, suggestive of sialyl Lewis-X determinants. We used an enzyme-linked immunoassay to measure sialyl Lewis-X epitopes on capillary endothelial cells and found that both induced and uninduced cells expressed sialyl Lewis-X epitopes. Deoxymannojirimycin and, to a lesser extent, swainsonine reduced the level of sialyl Lewis-X epitopes in cells induced to form capillary tubes, but neither compound affected the level of epitopes in cell monolayers. We conclude that synthesis of at least hybrid-type oligosaccharides is required for capillary tube formation in vitro and that an increase in monosialylated, fucosylated glycans on asparagine-linked oligosaccharides occurs during this process.	HARVARD UNIV,CHILDRENS HOSP,SCH MED,SURG RES LAB,BOSTON,MA 02115; HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT SURG,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT ANAT & CELL BIOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT CELLULAR & MOLEC PHYSIOL,BOSTON,MA 02115	Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	BISCHOFF, J (corresponding author), HARVARD UNIV,CHILDRENS HOSP,SCH MED,SURG RES LAB,BOSTON,MA 02115, USA.			Bischoff, Joyce/0000-0002-6367-1974	NCI NIH HHS [5 T32 CA 09535-06] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009535] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKIYAMA SK, 1989, J BIOL CHEM, V264, P18011; BERG EL, 1991, J BIOL CHEM, V266, P14869; BISCHOFF J, 1986, J BIOL CHEM, V261, P4766; BISCHOFF J, 1984, BIOCHEM BIOPH RES CO, V125, P324, DOI 10.1016/S0006-291X(84)80371-X; CAMPBELL C, 1984, J BIOL CHEM, V261, P13370; CUMMINGS RD, 1982, J BIOL CHEM, V257, P1235; ELBEIN AD, 1990, J BIOL CHEM, V265, P15599; FOLKMAN J, 1979, P NATL ACAD SCI USA, V76, P5217, DOI 10.1073/pnas.76.10.5217; FOLKMAN J, 1980, NATURE, V288, P551, DOI 10.1038/288551a0; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; FUHRMANN U, 1984, NATURE, V307, P755, DOI 10.1038/307755a0; FUHRMANN U, 1985, BIOCHIM BIOPHYS ACTA, V825, P95, DOI 10.1016/0167-4781(85)90095-8; FUKUDA M, 1984, J BIOL CHEM, V259, P925; HEIFETZ A, 1982, J BIOL CHEM, V257, P13581; Heusser C H, 1981, Methods Enzymol, V73, P406; INGBER DE, 1989, J CELL BIOL, V109, P317, DOI 10.1083/jcb.109.1.317; KLAGSBRUN M, 1990, HDB EXPT PHARM, V95; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KUBOTA Y, 1988, J CELL BIOL, V107, P1589, DOI 10.1083/jcb.107.4.1589; LONGMORE GD, 1982, CARBOHYD RES, V100, P365, DOI 10.1016/S0008-6215(00)81049-6; LOWE JB, 1990, CELL, V63, P475, DOI 10.1016/0092-8674(90)90444-J; MACHER B A, 1991, Glycobiology, V1, P577, DOI 10.1093/glycob/1.6.577; MACIAG T, 1982, J CELL BIOL, V94, P511, DOI 10.1083/jcb.94.3.511; MCEVER RP, 1991, THROMB HAEMOSTASIS, V66, P80; MELLIS SJ, 1981, ANAL BIOCHEM, V114, P276, DOI 10.1016/0003-2697(81)90480-2; MOLLICONE R, 1990, EUR J BIOCHEM, V191, P169, DOI 10.1111/j.1432-1033.1990.tb19107.x; MONTESANO R, 1985, CELL, V42, P469, DOI 10.1016/0092-8674(85)90104-7; NARASIMHAN S, 1982, J BIOL CHEM, V257, P235; PAULSON JC, 1989, TRENDS BIOCHEM SCI, V14, P272, DOI 10.1016/0968-0004(89)90062-5; PHILLIPS ML, 1990, SCIENCE, V250, P1130, DOI 10.1126/science.1701274; ROUX L, 1988, J BIOL CHEM, V263, P8879; SAITOH O, 1992, J BIOL CHEM, V267, P5700; STANLEY P, 1988, J BIOL CHEM, V263, P11374; TAKADA A, 1991, BIOCHEM BIOPH RES CO, V179, P713, DOI 10.1016/0006-291X(91)91875-D; TULSIANI DRP, 1982, J BIOL CHEM, V257, P7936; TYRRELL D, 1991, P NATL ACAD SCI USA, V88, P10372, DOI 10.1073/pnas.88.22.10372; VARKI A, 1983, J BIOL CHEM, V258, P2808; WALZ G, 1990, SCIENCE, V250, P1132, DOI 10.1126/science.1701275; ZHOU Q, 1991, J CELL BIOL, V115, P557, DOI 10.1083/jcb.115.2.557	39	61	62	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1992	267	36					26157	26165						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KD073	1464626				2022-12-25	WOS:A1992KD07300085
J	BASSILANA, M; ARKOWITZ, RA; WICKNER, W				BASSILANA, M; ARKOWITZ, RA; WICKNER, W			THE ROLE OF THE MATURE DOMAIN OF PROOMPA IN THE TRANSLOCATION ATPASE REACTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MALTOSE-BINDING PROTEIN; COLI PLASMA-MEMBRANE; ESCHERICHIA-COLI; PRECURSOR PROTEINS; TRIGGER FACTOR; M13 PROCOAT; CYTOPLASMIC MEMBRANE; SIGNAL PEPTIDASE; LEADER PEPTIDASE; COAT PROTEIN	The export of proOmpA, the precursor of outer membrane protein A from Escherichia coli, requires preprotein translocase, which is comprised of SecA, SecY/E, and acidic phospholipids. Previous studies of proOmpA translocation intermediates (Schiebel, E., Driessen, A. J. M., Hartl, F.-U., and Wickner, W. (1991) Cell 64, 927-939) suggested that the "slippage" of the translocating polypeptide chain and the high level of ATP hydrolysis, characteristic of the "translocation ATPase," were part of a futile cycle. To examine the role of the mature domain of proOmpA in its translocation-dependent ATP hydrolysis, we used chemical cleavage to generate NH2-terminal fragments of this preprotein. Each fragment contained the 21-residue leader region and either 53 or 228 residues of the mature domain (preproteins P74 and P249, respectively). As observed with full-length proOmpA, the translocation of each fragment requires ATP and both the SecA and SecY/E domains of translocase and is stimulated by the transmembrane proton electrochemical gradient. The apparent maximal velocities of P74 and proOmpA translocation are similar. While the translocation of P74 and of proOmpA show the same apparent K(m) for ATP, far less ATP is hydrolyzed during the translocation of P74. Thus, the mature carboxyl-terminal domain of proOmpA has a major role in supporting the translocation ATPase.	UNIV CALIF LOS ANGELES, DEPT BIOL CHEM, LOS ANGELES, CA 90024 USA; CEA, DEPT BIOL CELLULAIRE & MOLEC, LAB J MAETZ, F-06230 Villefranche Sur Mer, FRANCE	University of California System; University of California Los Angeles; CEA	BASSILANA, M (corresponding author), UNIV CALIF LOS ANGELES, INST MOLEC BIOL, LOS ANGELES, CA 90024 USA.		Bassilana, Martine/AAS-5814-2021; arkowitz, robert/ABC-1860-2021	arkowitz, robert/0000-0002-5216-5013; Bassilana, Martine/0000-0001-9965-567X				BIEKER KL, 1990, J BIOENERG BIOMEMBR, V22, P291, DOI 10.1007/BF00763169; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUNDAGE L, 1990, CELL, V62, P649, DOI 10.1016/0092-8674(90)90111-Q; BRUNDAGE L, 1992, J BIOL CHEM, V267, P4166; CHANG CN, 1978, P NATL ACAD SCI USA, V75, P361, DOI 10.1073/pnas.75.1.361; COLLIER DN, 1990, J BACTERIOL, V172, P6875, DOI 10.1128/jb.172.12.6875-6884.1990; CROOKE E, 1987, P NATL ACAD SCI USA, V84, P5216, DOI 10.1073/pnas.84.15.5216; CROOKE E, 1988, CELL, V54, P1003, DOI 10.1016/0092-8674(88)90115-8; CUNNINGHAM K, 1989, P NATL ACAD SCI USA, V86, P8630, DOI 10.1073/pnas.86.22.8630; CUNNINGHAM K, 1989, EMBO J, V8, P955, DOI 10.1002/j.1460-2075.1989.tb03457.x; DALBEY RE, 1985, J BIOL CHEM, V260, P5925; DRIESSEN AJM, 1991, P NATL ACAD SCI USA, V88, P2471, DOI 10.1073/pnas.88.6.2471; FREUDL R, 1989, J MOL BIOL, V205, P771, DOI 10.1016/0022-2836(89)90321-5; GELLER BL, 1989, J BIOL CHEM, V264, P16465; GIERASCH LM, 1989, BIOCHEMISTRY-US, V28, P923, DOI 10.1021/bi00429a001; HARTL FU, 1990, CELL, V63, P269, DOI 10.1016/0092-8674(90)90160-G; HENDRICK JP, 1991, J BIOL CHEM, V266, P24596; ITO K, 1980, J BIOL CHEM, V255, P2123; KATO M, 1992, J BIOL CHEM, V267, P413; KLIONSKY DJ, 1984, J BACTERIOL, V160, P1055, DOI 10.1128/JB.160.3.1055-1060.1984; KUHN A, 1986, EMBO J, V5, P3681, DOI 10.1002/j.1460-2075.1986.tb04699.x; KUHN A, 1986, NATURE, V322, P335, DOI 10.1038/322335a0; KUHN A, 1987, EMBO J, V6, P501, DOI 10.1002/j.1460-2075.1987.tb04781.x; KUMAMOTO CA, 1989, P NATL ACAD SCI USA, V86, P5320, DOI 10.1073/pnas.86.14.5320; KUPERSZTOCH YM, 1990, J BACTERIOL, V172, P2427, DOI 10.1128/jb.172.5.2427-2432.1990; LECKER S, 1989, EMBO J, V8, P2703, DOI 10.1002/j.1460-2075.1989.tb08411.x; LEE JI, 1992, J BIOL CHEM, V267, P938; LILL R, 1990, CELL, V60, P271, DOI 10.1016/0092-8674(90)90742-W; LILL R, 1989, EMBO J, V8, P961, DOI 10.1002/j.1460-2075.1989.tb03458.x; LIU GP, 1989, P NATL ACAD SCI USA, V86, P9213, DOI 10.1073/pnas.86.23.9213; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCGOVERN K, 1991, J BIOL CHEM, V266, P20870; RANDALL LL, 1989, SCIENCE, V243, P1156, DOI 10.1126/science.2646712; RANDALL LL, 1990, SCIENCE, V248, P860, DOI 10.1126/science.2188362; SCHATZ PJ, 1990, ANNU REV GENET, V24, P215, DOI 10.1146/annurev.ge.24.120190.001243; SCHIEBEL E, 1991, CELL, V64, P927, DOI 10.1016/0092-8674(91)90317-R; TANI K, 1989, J BIOL CHEM, V264, P18582; TANI K, 1990, J BIOL CHEM, V265, P17341; WEISS JB, 1988, P NATL ACAD SCI USA, V85, P8978, DOI 10.1073/pnas.85.23.8978; WICKNER W, 1991, ANNU REV BIOCHEM, V60, P101, DOI 10.1146/annurev.bi.60.070191.000533; WOLFE PB, 1985, J BIOL CHEM, V260, P1836; WOLFE PB, 1982, J BIOL CHEM, V257, P7898; YAMANE K, 1988, J BIOL CHEM, V263, P5368; ZWIZINSKI C, 1980, J BIOL CHEM, V255, P7973	44	18	18	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	1992	267	35					25246	25250						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KB603	1460025				2022-12-25	WOS:A1992KB60300052
J	KIHLBERG, BM; SJOBRING, U; KASTERN, W; BJORCK, L				KIHLBERG, BM; SJOBRING, U; KASTERN, W; BJORCK, L			PROTEIN LG - A HYBRID MOLECULE WITH UNIQUE IMMUNOGLOBULIN BINDING-PROPERTIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IGG-BINDING; GEL ELECTROPHORESIS; ESCHERICHIA-COLI; LIGHT CHAIN; STREPTOCOCCUS; EXPRESSION; AFFINITY; REGIONS; GENE	Immunoglobulin (Ig)-binding bacterial proteins have attracted theoretical interest for their role in molecular host-parasite interactions, and they are widely used as tools in immunology, biochemistry, medicine, and biotechnology. Protein L of the anaerobic bacterial species Peptostreptococcus magnus binds Ig light chains, whereas streptococcal protein G has affinity for the constant (Fc) region of IgG. In this report, Ig binding parts of protein L and protein G were combined to form a hybrid molecule, protein LG, which was found to bind a large majority of intact human Igs as well as Fc and Fab fragments, and Ig light chains. Binding to Ig was specific, and the affinity constants of the reactions between protein LG and human IgG, IgGFc fragments, and kappa light chains, determined by Scatchard plots, were 5.9 x 10(9), 2.2 x 10(9), and 2.0 x 10(9) M-1, respectively. The binding properties of protein LG were more complete as compared with previously described Ig-binding proteins when also tested against mouse and rat Igs. This hybrid protein thus represents a powerful tool for the binding, detection, and purification of antibodies and antibody fragments.	UNIV LUND,DEPT MED & PHYSIOL CHEM,POB 94,S-22100 LUND,SWEDEN; UNIV LUND,DEPT MED MICROBIOL,S-22100 LUND,SWEDEN; UNIV FLORIDA,DEPT PATHOL,GAINESVILLE,FL 32610	Lund University; Lund University; State University System of Florida; University of Florida								AKERSTROM B, 1989, J BIOL CHEM, V264, P19740; AKERSTROM B, 1987, J BIOL CHEM, V262, P13388; AKERSTROM B, 1985, J IMMUNOL, V135, P2589; AKERSTROM B, 1986, J BIOL CHEM, V261, P240; BJORCK L, 1988, J IMMUNOL, V140, P1194; BJORCK L, 1984, J IMMUNOL, V133, P969; BJORCK L, 1990, BACTERIAL IMMUNOGLOB, V2, P91; BJORCK L, 1990, BACTERIAL IMMUNOGLOB, V1, P267; BOLTON AE, 1973, BIOCHEM J, V133, P529, DOI 10.1042/bj1330529; BOYLE MDP, 1990, BACTERIAL IMMUNOGLOB, V1; DALBOGE H, 1989, GENE, V79, P325, DOI 10.1016/0378-1119(89)90214-X; ERNTELL M, 1988, MOL IMMUNOL, V25, P121, DOI 10.1016/0161-5890(88)90059-4; FAHNESTOCK SR, 1986, J BACTERIOL, V167, P870, DOI 10.1128/jb.167.3.870-880.1986; FORSGREN A, 1966, J IMMUNOL, V97, P822; GJORSTRUP P, 1990, TRANSFUS SCI, V11, P281, DOI 10.1016/0955-3886(90)90028-H; GRONENBORN AM, 1991, SCIENCE, V253, P657, DOI 10.1126/science.1871600; GUSS B, 1986, EMBO J, V5, P1567, DOI 10.1002/j.1460-2075.1986.tb04398.x; JOHANSSON BG, 1972, SCAND J CLIN LAB INV, V29, P7, DOI 10.3109/00365517209102747; KASTERN W, 1992, J BIOL CHEM, V267, P12820; KASTERN W, 1990, INFECT IMMUN, V58, P1217, DOI 10.1128/IAI.58.5.1217-1222.1990; MYHRE EB, 1985, MOL IMMUNOL, V22, P879, DOI 10.1016/0161-5890(85)90073-2; NEVILLE DM, 1971, J BIOL CHEM, V246, P6328; NILSON BHK, 1992, J BIOL CHEM, V267, P2234; PLUCKTHUN A, 1991, BIO-TECHNOL, V9, P545, DOI 10.1038/nbt0691-545; REIS KJ, 1984, J IMMUNOL, V132, P3091; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sambrook J, 1989, MOL CLONING LABORATO; SJOBRING U, 1991, J BIOL CHEM, V266, P399; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350	29	45	54	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1992	267	35					25583	25588						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KB603	1460053				2022-12-25	WOS:A1992KB60300100
J	LI, XY; YODER, BL; BURGERS, PMJ				LI, XY; YODER, BL; BURGERS, PMJ			A SACCHAROMYCES-CEREVISIAE DNA HELICASE ASSOCIATED WITH REPLICATION FACTOR-C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL NUCLEAR ANTIGEN; ESCHERICHIA-COLI; POLYACRYLAMIDE GELS; UNWINDING ACTIVITY; POLYMERASE-DELTA; BINDING-PROTEIN; CALF THYMUS; HELA-CELLS; PURIFICATION; COMPLEX	A novel DNA helicase has been isolated from Saccharomyces cerevisiae. This DNA helicase co-purified with replication factor C (RF-C) during chromatography on S-Sepharose, DEAE-silica gel high performance liquid chromatography (HPLC), Affi-Gel Blue-agarose, heparin-agarose, single-stranded DNA-cellulose, fast protein liquid chromatography MonoS, and hydroxyapatite HPLC. Surprisingly, the helicase could be separated from RF-C by sedimentation on a glycerol gradient in the presence of 200 mM NaCl. The helicase is probably a homodimer of a 60-kDa polypeptide, which by UV cross-linking has been shown to bind ATP. It has a single-stranded DNA-dependent ATPase activity, with a K(m) for ATP of 60 muM. The DNA helicase activity depends on the hydrolysis of NTP (dNTP), with ATP and dATP the most efficient cofactors, followed by CTP and dCTP. The DNA helicase has a 5' to 3' directionality and is only marginally stimulated by coating the single-stranded DNA with the yeast single-stranded DNA-binding protein RF-A.	WASHINGTON UNIV,SCH MED,DEPT BIOCHEM & MOLEC BIOPHYS,660 S EUCLID,BOX 8231,ST LOUIS,MO 63110	Washington University (WUSTL)			Burgers, Peter M/AAW-6621-2021		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032431] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM32431, R01 GM032431] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ACKERS GK, 1975, PROTEINS, V1, P2; BAUER GA, 1988, J BIOL CHEM, V263, P917; BISWAS SB, 1984, J BIOL CHEM, V259, P7990; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUCKNER RC, 1991, J BIOL CHEM, V266, P2669; BURGERS PMJ, 1991, J BIOL CHEM, V266, P22698; CHA TA, 1989, J BIOL CHEM, V264, P12220; CRUTE JJ, 1989, P NATL ACAD SCI USA, V86, P2186, DOI 10.1073/pnas.86.7.2186; DAILEY L, 1990, MOL CELL BIOL, V10, P6225, DOI 10.1128/MCB.10.12.6225; HAGER DA, 1980, ANAL BIOCHEM, V109, P76, DOI 10.1016/0003-2697(80)90013-5; HAROSH I, 1989, J BIOL CHEM, V264, P20532; KIM CS, 1992, MOL CELL BIOL, V12, P3050, DOI 10.1128/MCB.12.7.3050; KORNBERG A, 1991, DNA REPLICATION, P355; LASKEN RS, 1988, J BIOL CHEM, V263, P5512; LEBOWITZ JH, 1986, J BIOL CHEM, V261, P4738; LEE MS, 1987, P NATL ACAD SCI USA, V84, P8345, DOI 10.1073/pnas.84.23.8345; LEE SH, 1991, J BIOL CHEM, V266, P594; LI XY, 1992, BIOCHEMISTRY-US, V31, P3507, DOI 10.1021/bi00128a027; LOHMAN TM, 1992, MOL MICROBIOL, V6, P5, DOI 10.1111/j.1365-2958.1992.tb00831.x; MATSON SW, 1990, ANNU REV BIOCHEM, V59, P289, DOI 10.1146/annurev.bi.59.070190.001445; MATSON SW, 1983, J BIOL CHEM, V258, P4017; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; RICHARDSON RW, 1989, J BIOL CHEM, V264, P4725; RICHARDSON RW, 1989, J BIOL CHEM, V264, P4732; RUNYON GT, 1983, IN PRESS BIOCHEMISTR; SCOTT JF, 1977, P NATL ACAD SCI USA, V74, P193, DOI 10.1073/pnas.74.1.193; SEO YS, 1991, J BIOL CHEM, V266, P13161; SIEGAL S, 1992, J BIOL CHEM, V267, P13629; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; STAHL H, 1986, EMBO J, V5, P1939, DOI 10.1002/j.1460-2075.1986.tb04447.x; SUGINO A, 1986, J BIOL CHEM, V261, P1744; SUNG P, 1987, P NATL ACAD SCI USA, V84, P8951, DOI 10.1073/pnas.84.24.8951; THOMMES P, 1990, J BIOL CHEM, V265, P14347; THOMMES P, 1992, J BIOL CHEM, V267, P6063; TSURIMOTO T, 1991, J BIOL CHEM, V266, P1950; TUTEJA N, 1991, NUCLEIC ACIDS RES, V19, P3613, DOI 10.1093/nar/19.13.3613; WEINBERG DH, 1990, P NATL ACAD SCI USA, V87, P8692, DOI 10.1073/pnas.87.22.8692; WIEKOWSKI M, 1988, J BIOL CHEM, V263, P436; WONG I, 1992, SCIENCE, V256, P350, DOI 10.1126/science.256.5055.350; YANAGISAWA J, 1992, J BIOL CHEM, V267, P3644; YODER BL, 1991, J BIOL CHEM, V266, P22689; ZHANG SS, 1991, J BIOL CHEM, V266, P20483	42	22	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1992	267	35					25321	25327						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KB603	1460028				2022-12-25	WOS:A1992KB60300063
J	KUMAR, KA; MUNIYAPPA, K				KUMAR, KA; MUNIYAPPA, K			USE OF STRUCTURE-DIRECTED DNA LIGANDS TO PROBE THE BINDING OF RECA PROTEIN TO NARROW AND WIDE GROOVES OF DNA AND ON ITS ABILITY TO PROMOTE HOMOLOGOUS PAIRING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-STRANDED-DNA; LINEAR DUPLEX DNA; CLOSED CIRCULAR DNA; ESCHERICHIA-COLI; GENETIC-RECOMBINATION; NUCLEOPROTEIN FILAMENTS; NUCLEOSOME CORES; DOUBLE-HELIX; EXCHANGE; MECHANISM	We have used circular dichroism and structure-directed drugs to identify the role of structural features, wide and narrow grooves in particular, required for the cooperative polymerization, recognition of homologous sequences, and the formation of joint molecules promoted by recA protein. The path of cooperative polymerization of recA protein was deduced by its ability to cause quantitative displacement of distamycin from the narrow groove of duplex DNA. By contrast, methyl green bound to the wide groove was retained by the nucleoprotein filaments comprised of recA protein-DNA. Further, the mode of binding of these ligands and recA protein to DNA was confirmed by DNaseI digestion. More importantly, the formation of joint molecules was prevented by distamycin in the narrow groove while methyl green in the wide groove had no adverse effect. Intriguingly, distamycin interfered with the production of coaggregates between nucleoprotein filaments of recA protein-M13 ssDNA and naked linear M13 duplex DNA, but not with linear phiX174 duplex DNA. Thus, these data, in conjunction with molecular modeling, suggest that the narrow grooves of duplex DNA provide the fundamental framework required for the cooperative polymerization of recA protein and alignment of homologous sequences. These findings and their significance are discussed in relation to models of homologous pairing between two intertwined DNA molecules.	INDIAN INST SCI,DEPT BIOCHEM,BANGALORE 560012,KARNATAKA,INDIA; INDIAN INST SCI,CTR GENET ENGN,BANGALORE 560012,KARNATAKA,INDIA	Indian Institute of Science (IISC) - Bangalore; Indian Institute of Science (IISC) - Bangalore								AGGARWAL AK, 1988, SCIENCE, V242, P99; ARNOTT S, 1974, J MOL BIOL, V88, P523, DOI 10.1016/0022-2836(74)90499-9; BHATTACHARYYA A, 1991, J MOL BIOL, V221, P1191, DOI 10.1016/0022-2836(91)90928-Y; BRENNER SL, 1987, J BIOL CHEM, V262, P4011; BRYANT FR, 1985, P NATL ACAD SCI USA, V82, P297, DOI 10.1073/pnas.82.2.297; CHABBERT M, 1991, J BIOL CHEM, V266, P5395; COLL M, 1987, P NATL ACAD SCI USA, V84, P8385, DOI 10.1073/pnas.84.23.8385; COTTERILL SM, 1983, BIOCHEMISTRY-US, V22, P3525, DOI 10.1021/bi00283a034; COX MM, 1987, ANNU REV BIOCHEM, V56, P229, DOI 10.1146/annurev.bi.56.070187.001305; CUNNINGHAM RP, 1980, CELL, V20, P223, DOI 10.1016/0092-8674(80)90250-0; DASGUPTA D, 1987, BIOCHEMISTRY-US, V26, P6381, DOI 10.1021/bi00394a011; DICAPUA E, 1987, EMBO J, V6, P2493, DOI 10.1002/j.1460-2075.1987.tb02531.x; DOMBROSKI DF, 1983, NUCLEIC ACIDS RES, V11, P7487, DOI 10.1093/nar/11.21.7487; DREW HR, 1982, P NATL ACAD SCI-BIOL, V79, P4040, DOI 10.1073/pnas.79.13.4040; FEUGHELMAN M, 1955, NATURE, V175, P834, DOI 10.1038/175834a0; FLORY J, 1984, P NATL ACAD SCI-BIOL, V81, P7026, DOI 10.1073/pnas.81.22.7026; GRIFFITH J, 1985, BIOCHEMISTRY-US, V24, P158, DOI 10.1021/bi00322a022; GRIFFITH J, 1988, CRC CRIT REV BIOCH, V23, pS53; HOWARDFLANDERS P, 1984, NATURE, V309, P215, DOI 10.1038/309215a0; HSIEH P, 1990, GENE DEV, V4, P1951, DOI 10.1101/gad.4.11.1951; HUANG Y, 1991, J BIOL CHEM, V266, P17424; JAIN SK, 1992, J BIOL CHEM, V267, P4215; KOWALCZYKOWSKI SC, 1987, P NATL ACAD SCI USA, V84, P3127, DOI 10.1073/pnas.84.10.3127; KOWALCZYKOWSKI SC, 1991, ANNU REV BIOPHYS BIO, V20, P539, DOI 10.1146/annurev.bb.20.060191.002543; LAUDER SD, 1991, J BIOL CHEM, V266, P5450; LEAHY MC, 1986, J BIOL CHEM, V261, P6954; LEE JW, 1990, BIOCHEMISTRY-US, V29, P7677, DOI 10.1021/bi00485a017; LINDSLEY JE, 1989, J MOL BIOL, V205, P695, DOI 10.1016/0022-2836(89)90315-X; LOHMAN TM, 1986, BIOCHEMISTRY-US, V25, P21, DOI 10.1021/bi00349a004; MCGAVIN S, 1977, HEREDITY, V39, P15, DOI 10.1038/hdy.1977.39; MENDOZA R, 1990, BIOCHEMISTRY-US, V29, P5035, DOI 10.1021/bi00473a006; MENETSKI JP, 1985, J MOL BIOL, V181, P281, DOI 10.1016/0022-2836(85)90092-0; MORRICAL SW, 1985, BIOCHEMISTRY-US, V24, P760, DOI 10.1021/bi00324a034; MOSER HE, 1987, SCIENCE, V238, P645, DOI 10.1126/science.3118463; MUNIYAPPA K, 1984, P NATL ACAD SCI-BIOL, V81, P2757, DOI 10.1073/pnas.81.9.2757; MUNIYAPPA K, 1990, NUCLEIC ACIDS RES, V18, P3967, DOI 10.1093/nar/18.13.3967; MUNIYAPPA K, 1991, BIOCHIMIE, V73, P187, DOI 10.1016/0300-9084(91)90201-B; MUNIYAPPA K, 1991, NUCLEIC ACIDS RES, V73, P187; NORDEN B, 1977, CHEM PHYS LETT, V50, P508, DOI 10.1016/0009-2614(77)80379-5; OHTANI T, 1982, NATURE, V299, P86, DOI 10.1038/299086a0; PUGH BF, 1988, J MOL BIOL, V203, P479, DOI 10.1016/0022-2836(88)90014-9; PUGH BF, 1987, J BIOL CHEM, V262, P1337; RADDING CM, 1991, J BIOL CHEM, V266, P5355; RAMDAS J, 1989, J BIOL CHEM, V264, P17395; RAMDAS J, 1991, P NATL ACAD SCI USA, V88, P1344, DOI 10.1073/pnas.88.4.1344; RAO BJ, 1990, J MOL BIOL, V213, P789, DOI 10.1016/S0022-2836(05)80264-5; REGISTER JC, 1985, J BIOL CHEM, V260, P2308; ROULD E, 1992, J MOL BIOL, V226, P127, DOI 10.1016/0022-2836(92)90129-8; ROULD MA, 1989, SCIENCE, V246, P1135, DOI 10.1126/science.2479982; Stasiak A, 1988, GENETIC RECOMBINATIO, P265; SUCK D, 1988, NATURE, V332, P465; THRESHER RJ, 1990, P NATL ACAD SCI USA, V87, P5056, DOI 10.1073/pnas.87.13.5056; TSANG SS, 1985, J MOL BIOL, V185, P295, DOI 10.1016/0022-2836(85)90405-X; UMLAUF SW, 1990, J BIOL CHEM, V265, P16898; Vinter J G, 1987, J Comput Aided Mol Des, V1, P31, DOI 10.1007/BF01680556; WILKINS MHF, 1956, COLD SPRING HARB SYM, V21, P75, DOI 10.1101/SQB.1956.021.01.007; WILSON JH, 1979, P NATL ACAD SCI USA, V76, P3641, DOI 10.1073/pnas.76.8.3641; YONESAKI T, 1988, MOL GEN GENET, V213, P548, DOI 10.1007/BF00339630; ZIMMER C, 1986, PROG BIOPHYS MOL BIO, V47, P31, DOI 10.1016/0079-6107(86)90005-2	59	30	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1992	267	34					24824	24832						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KA263	1447220				2022-12-25	WOS:A1992KA26300100
J	FRENKEL, RA; JOHNSTON, JM				FRENKEL, RA; JOHNSTON, JM			METABOLIC CONVERSION OF PLATELET-ACTIVATING-FACTOR INTO ETHANOLAMINE PLASMALOGEN IN AN AMNION-DERIVED CELL-LINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACETYLGLYCERYL ETHER PHOSPHORYLCHOLINE; ARACHIDONIC-ACID; FACTOR PAF; FACTOR 1-0-ALKYL-2-ACETYL-SN-GLYCERO-3-PHOSPHOCHOLINE; INDEPENDENT TRANSACYLASE; MACROPHAGE MICROSOMES; ANIMAL-CELLS; RABBIT; LYSOPHOSPHOLIPIDS; GLYCOGENOLYSIS	Platelet-activating factor (1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine, PAF) labeled with H-3 in the alkyl side chain was taken up rapidly by amnion-derived WISH cells in culture. The radioactivity was found in a number of cellular metabolites, principally 1-O-alkyl-2-acyl-sn-glycero-3-phosphocholine (alkyl-acyl-GPC) which was labeled at a rapid rate. No intracellular accumulation of lyso-PAF was detected. At longer time periods, a substantial proportion of the radioactivity was found in association with the phosphatidylethanolamine fraction extracted from the cells. This fraction contained a high proportion of the corresponding 1',2'-alkenyl derivative (plasmalogen), as judged by the formation of long-chain fatty aldehyde after exposure to acid. The magnitude of the conversion of PAF into ethanolamine plasmalogen is suggestive of a correlation between plasmalogen content and exposure to PAF in some tissues. The exact sequence of reactions leading from alkyl-acyl-GPC to the ethanolamine derivatives is yet to be established.	UNIV TEXAS,SW MED CTR,DEPT BIOCHEM,5323 HARRY HINES BLVD,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT OBSTET GYNECOL,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,CECIL H & IDA GREEN CTR REPROD BIOL SCI,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas					NICHD NIH HHS [HD11149] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P01HD011149] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P50HD011149] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ABISOGUN AO, 1989, SCIENCE, V243, P381, DOI 10.1126/science.2911750; ANGLE MJ, 1990, UTERINE FUNCTION MOL, P471; BAKER RC, 1988, FASEB J, V3, pA1377; BENVENISTE J, 1979, CR ACAD SCI D NAT, V289, P1037; BILLAH MM, 1983, BIOCHEM BIOPH RES CO, V113, P51, DOI 10.1016/0006-291X(83)90430-8; BILLAH MM, 1985, PROSTAGLANDINS, V30, P841; BLANK ML, 1979, BIOCHEM BIOPH RES CO, V90, P523; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BUXTON DB, 1984, J BIOL CHEM, V259, P1468; DANIEL LW, 1986, J BIOL CHEM, V261, P9128; DEMOPOULOS CA, 1979, J BIOL CHEM, V254, P9355; FORD DA, 1989, P NATL ACAD SCI USA, V86, P3479, DOI 10.1073/pnas.86.10.3479; GROSS RW, 1984, BIOCHEMISTRY-US, V23, P158, DOI 10.1021/bi00296a026; HARRIS AN, 1988, AM J OBSTET GYNECOL, V159, P1385, DOI 10.1016/0002-9378(88)90561-3; HAYFLICK L, 1961, EXP CELL RES, V23, P14, DOI 10.1016/0014-4827(61)90059-3; HOFFMAN DR, 1986, BIOCHIM BIOPHYS ACTA, V879, P88, DOI 10.1016/0005-2760(86)90270-5; HOFFMAN DR, 1986, AM J OBSTET GYNECOL, V55, P50; Horrocks L. A., 1972, ETHER LIPIDS CHEM BI, P177, DOI [DOI 10.1016/B978-0-12-654150-2.50016-6, 10.1016/b978-0-12-654150-2.50016-6]; JOHNSTON JM, 1989, PAF HLTH DISEASE, P297; JOHNSTON JM, 1986, PLATELET ACTIVATING, P129; KRAMER RM, 1984, J BIOL CHEM, V259, P3316; Martonosi, 1985, ENZYMES BIOL MEMBR, V2, P1; MCMANUS LM, 1980, J IMMUNOL, V124, P2919; MONTRUCCHIO G, 1986, PROSTAGLANDINS, V32, P539, DOI 10.1016/0090-6980(86)90036-5; MORAND OH, 1988, J BIOL CHEM, V263, P11597; NISHIHIRA J, 1984, LIPIDS, V19, P907, DOI 10.1007/BF02534724; OKITA JR, 1982, J BIOL CHEM, V257, P4029; ONEILL C, 1987, FERTIL STERIL, V47, P969; PALTAUF F, 1974, J BIOL CHEM, V249, P2661; ROBINSON M, 1985, J BIOL CHEM, V260, P7889; SHUKLA SD, 1983, J BIOL CHEM, V258, P212; SPINKS NR, 1987, LANCET, V1, P106; STRUM JC, 1992, J BIOL CHEM, V267, P1576; SUGIURA T, 1985, BIOCHEM BIOPH RES CO, V127, P384, DOI 10.1016/S0006-291X(85)80171-6; SUGIURA T, 1987, J BIOL CHEM, V262, P1199; TETTA C, 1986, P SOC EXP BIOL MED, V183, P376; TIETZ A, 1964, J BIOL CHEM, V239, P4081; UEMURA Y, 1991, J BIOL CHEM, V266, P8268; VENABLE ME, 1991, J BIOL CHEM, V266, P18691; ZHU YP, 1992, AM J OBSTET GYNECOL, V166, P1222, DOI 10.1016/S0002-9378(11)90610-3; ZOELLER RA, 1988, J BIOL CHEM, V263, P11590	41	17	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1992	267	27					19186	19191						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JP593	1527040				2022-12-25	WOS:A1992JP59300029
J	MAWALDEWAN, M; SEN, PC; ABDELGHANY, M; SHALLOWAY, D; RACKER, E				MAWALDEWAN, M; SEN, PC; ABDELGHANY, M; SHALLOWAY, D; RACKER, E			PHOSPHORYLATION OF TAU-PROTEIN BY PURIFIED P34(CDC28) AND A RELATED PROTEIN-KINASE FROM NEUROFILAMENTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; PAIRED HELICAL FILAMENTS; MATURATION-PROMOTING FACTOR; CELL-CYCLE CONTROL; ALZHEIMERS-DISEASE; FACTOR RECEPTOR; DEPENDENT KINASE; HISTONE KINASE; CDC2 KINASE; PURIFICATION	It has been suggested that hyperphosphorylation of the tau protein in neurofibrillary tangles may be relevant to the etiology of Alzheimer's disease and that at least one of the hyperphosphorylated sites lies within a consensus sequence for the p34cdc2/cdc28 family of kinases. We describe a new method for large-scale purification of p34cdc28 kinase from Saccharomyces cerevisiae and show that the purified enzyme can phosphorylate bovine and human tau. Phosphorylation was greatly enhanced by the addition of basic and acidic substrate modulators. The effect of the substrate modulators differed both with the structures of the substrates and the modulators. Similar results were obtained with a kinase that could be purified from neurofilaments by p13suc1 affinity chromatography, a hallmark of p34cdc2/cdc28-type kinases. These results are consistent with the hypothesis that a kinase of this type is involved in tau phosphorylation in vivo and open the possibility that hyperphosphorylation in Alzheimer's disease may be controlled by substrate modulators.	CORNELL UNIV, BIOCHEM & MOLEC & CELL BIOL SECT, ITHACA, NY 14853 USA; BOSE INST, DEPT CHEM, Kolkata 700009, W BENGAL, INDIA	Cornell University; Department of Science & Technology (India); Bose Institute					NCI NIH HHS [CA 08964] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA008964] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABDELGHANY M, 1990, P NATL ACAD SCI USA, V87, P7061, DOI 10.1073/pnas.87.18.7061; ABDELGHANY M, 1987, P NATL ACAD SCI USA, V84, P8888, DOI 10.1073/pnas.84.24.8888; BAUDIER J, 1987, J BIOL CHEM, V262, P17577; BAUDIER J, 1987, J BIOL CHEM, V262, P17584; BIERNAT J, 1992, EMBO J, V11, P1593, DOI 10.1002/j.1460-2075.1992.tb05204.x; BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766; BRIZUELA L, 1987, EMBO J, V6, P3507, DOI 10.1002/j.1460-2075.1987.tb02676.x; BROEK D, 1991, NATURE, V349, P388, DOI 10.1038/349388a0; CHAMBERS TC, 1990, J BIOL CHEM, V265, P16940; CISEK LJ, 1991, METHOD ENZYMOL, V200, P301; CLARK EA, 1991, J NEUROCHEM, V57, P802, DOI 10.1111/j.1471-4159.1991.tb08222.x; DOSEMECI A, 1990, CELL MOL NEUROBIOL, V10, P369, DOI 10.1007/BF00711181; DRAETTA G, 1990, TRENDS BIOCHEM SCI, V15, P378, DOI 10.1016/0968-0004(90)90235-4; DREWES G, 1992, EMBO J, V11, P2131, DOI 10.1002/j.1460-2075.1992.tb05272.x; DRUBIN D, 1986, METHOD ENZYMOL, V134, P156; FAUCHER M, 1988, J BIOL CHEM, V263, P5319; FINCH CE, 1988, MOL BIOL ALZHEIMERS, P137; Futcher AB, 1990, CURR OPIN CELL BIOL, V2, P246, DOI 10.1016/0955-0674(90)90014-6; GOATE A, 1991, NATURE, V349, P704, DOI 10.1038/349704a0; GRUNDKEIQBAL I, 1986, P NATL ACAD SCI USA, V83, P4913, DOI 10.1073/pnas.83.13.4913; GRUNDKEIQBAL I, 1986, J BIOL CHEM, V261, P6084; HISANAGA S, 1991, J BIOL CHEM, V266, P21798; IGARASHI Y, 1990, J BIOL CHEM, V265, P5385; IGARASHI Y, 1989, BIOCHEMISTRY-US, V28, P6796, DOI 10.1021/bi00443a002; IQBAL K, 1989, P NATL ACAD SCI USA, V86, P5646, DOI 10.1073/pnas.86.14.5646; KIPREOS ET, 1990, SCIENCE, V248, P217, DOI 10.1126/science.2183353; Kosik KS, 1990, CURR OPIN CELL BIOL, V2, P101, DOI 10.1016/S0955-0674(05)80038-9; KSIEZAKREDING H, 1990, J NEUROSCI RES, V25, P420, DOI 10.1002/jnr.490250320; LANGAN TA, 1989, MOL CELL BIOL, V9, P3860, DOI 10.1128/MCB.9.9.3860; LEE MG, 1987, NATURE, V327, P31, DOI 10.1038/327031a0; LEE VMY, 1991, SCIENCE, V251, P675, DOI 10.1126/science.1899488; LIU WK, 1991, J BIOL CHEM, V266, P21723; LOHKA MJ, 1988, P NATL ACAD SCI USA, V85, P3009, DOI 10.1073/pnas.85.9.3009; MCVEY D, 1989, NATURE, V341, P503, DOI 10.1038/341503a0; MULLERHILL B, 1989, ANNU REV BIOCHEM, V58, P287; RACKER E, 1991, METHOD ENZYMOL, V200, P112; REVISGUPTA S, 1991, P NATL ACAD SCI USA, V88, P5954, DOI 10.1073/pnas.88.14.5954; Roden L., 1972, METHODS ENZYMOLOGY, V28, P73; SCHUBERT D, 1988, SCIENCE, V241, P223, DOI 10.1126/science.2968652; SHALLOWAY D, 1991, ADV CANCER RES, V57, P185; SHENOY S, 1989, CELL, V57, P763, DOI 10.1016/0092-8674(89)90791-5; SOLOMON MJ, 1990, CELL, V63, P1013, DOI 10.1016/0092-8674(90)90504-8; STEINER B, 1990, EMBO J, V9, P3539, DOI 10.1002/j.1460-2075.1990.tb07563.x; VINCENT IJ, 1990, BRAIN RES, V531, P127, DOI 10.1016/0006-8993(90)90765-4; VULLIET PR, 1989, J BIOL CHEM, V264, P16292; WEDEGAERTNER PB, 1989, J BIOL CHEM, V264, P11346; WIBLE BA, 1989, P NATL ACAD SCI USA, V86, P720, DOI 10.1073/pnas.86.2.720; 1979, AFFINITY CHROMATOGR, P15	48	66	67	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 25	1992	267	27					19705	19709						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JP593	1527090				2022-12-25	WOS:A1992JP59300102
J	NICOLAIDES, NC; CORREA, I; CASADEVALL, C; TRAVALI, S; SOPRANO, KJ; CALABRETTA, B				NICOLAIDES, NC; CORREA, I; CASADEVALL, C; TRAVALI, S; SOPRANO, KJ; CALABRETTA, B			THE JUN FAMILY MEMBERS, C-JUN AND JUND, TRANSACTIVATE THE HUMAN C-MYB PROMOTER VIA AN AP1-LIKE ELEMENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING ACTIVITY; AVIAN-MYELOBLASTOSIS VIRUS; NORMAL HUMAN HEMATOPOIESIS; CELL-CYCLE PROGRESSION; HUMAN LYMPHOCYTES-T; TRANSCRIPTIONAL ACTIVATION; ERYTHROLEUKEMIA DIFFERENTIATION; MOUSE FIBROBLASTS; ONCOGENE PRODUCT; GROWTH-FACTORS	The c-myb protooncogene, which is preferentially expressed in hematopoietic cells at the G1/S boundary of the cell cycle, encodes a transcriptional activator that functions via DNA binding. The regulatory mechanisms governing this specific pattern of expression are not fully understood, although human c-myb expression appears to be positively autoregulated via myb-binding sites in the 5'-flanking region of the c-myb gene (Nicolaides, N. C., Gualdi, R., Casadevall, C., Manzella, L., and Calabretta, B. (1991) Mol. Cell. Biol. 11, 6166-6176). To determine the contribution of other transcription regulators such as JUN family members in the control of c-myb expression, transient expression assays were carried out which revealed a 6- to a 15-fold enhancement by c-Jun and JunD, but not JunB, in chloramphenicol acetyltransferase reporter gene expression driven by different segments of the human c-myb 5'-flanking region. An Ap1-like element located at nucleotide -149 from the c-myb initiation site appears to be required for this transactivation upon binding to a nuclear protein complex containing c-Jun and JunD, since site-directed mutations of this Ap1-like element abolished c-Jun and JunD binding and transactivation. Exposure of phytohemagglutinin-stimulated peripheral blood mononuclear cells to c-jun and junD antisense oligodeoxynucleotides resulted in a 46 and 43% inhibition of T-lymphocyte proliferation that was accompanied by a decrease in c-myb mRNA levels as compared with sense-treated cultures. Because T-lymphocytes induced to proliferate express c-jun and junD before c-myb, these data suggest a mechanism whereby c-Jun and JunD contribute to the transcriptional activation of c-myb that, in turn, is maintained at the G1/S transition and during S phase by positive autoregulation.	TEMPLE UNIV,SCH MED,DEPT MICROBIOL,PHILADELPHIA,PA 19107; TEMPLE UNIV,SCH MED,FELS INST CANC RES & MOLEC BIOL,PHILADELPHIA,PA 19107	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	NICOLAIDES, NC (corresponding author), THOMAS JEFFERSON UNIV,JEFFERSON CANC INST,BLUEMLE LIFE SCI BLDG,PHILADELPHIA,PA 19140, USA.			Casadevall, Carme/0000-0001-6458-8972	NATIONAL CANCER INSTITUTE [P01CA056309, T32CA009644] Funding Source: NIH RePORTER; NCI NIH HHS [CA56309, CA09644] Funding Source: Medline; PHS HHS [46782] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ANFOSSI G, 1989, P NATL ACAD SCI USA, V86, P3379, DOI 10.1073/pnas.86.9.3379; ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; BIEDENKAPP H, 1988, NATURE, V335, P835, DOI 10.1038/335835a0; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BOYLE WJ, 1984, P NATL ACAD SCI-BIOL, V81, P4265, DOI 10.1073/pnas.81.14.4265; CALABRETTA B, 1991, CANCER RES, V51, P4505; CARACCIOLO D, 1990, J CLIN INVEST, V85, P55, DOI 10.1172/JCI114433; CLARKE MF, 1988, MOL CELL BIOL, V8, P884, DOI 10.1128/MCB.8.2.884; DASGUPTA P, 1990, P NATL ACAD SCI USA, V87, P8090, DOI 10.1073/pnas.87.20.8090; DUPREY SP, 1985, P NATL ACAD SCI USA, V82, P6937, DOI 10.1073/pnas.82.20.6937; FURUKAWA Y, 1990, SCIENCE, V250, P805, DOI 10.1126/science.2237430; GEWIRTZ AM, 1989, SCIENCE, V245, P180, DOI 10.1126/science.2665077; GEWIRTZ AM, 1988, SCIENCE, V242, P1303, DOI 10.1126/science.2461588; HALAZONETIS TD, 1988, CELL, V55, P917, DOI 10.1016/0092-8674(88)90147-X; HATTORI K, 1988, P NATL ACAD SCI USA, V85, P9148, DOI 10.1073/pnas.85.23.9148; HUTTNER KM, 1981, J CELL BIOL, V91, P153, DOI 10.1083/jcb.91.1.153; KENNEY SC, 1992, MOL CELL BIOL, V12, P136, DOI 10.1128/MCB.12.1.136; KLEMPNAUER KH, 1984, CELL, V37, P537, DOI 10.1016/0092-8674(84)90384-2; KLEMPNAUER KH, 1987, EMBO J, V6, P2719, DOI 10.1002/j.1460-2075.1987.tb02565.x; KOVARY K, 1991, MOL CELL BIOL, V11, P4466, DOI 10.1128/MCB.11.9.4466; KOVARY K, 1991, MOL CELL BIOL, V11, P2451, DOI 10.1128/MCB.11.5.2451; KREIG PA, 1987, METHOD ENZYMOL, V155, P397; LAMPH WW, 1988, NATURE, V334, P629, DOI 10.1038/334629a0; MCCLINTON D, 1990, MOL CELL BIOL, V10, P705, DOI 10.1128/MCB.10.2.705; MCMAHON J, 1988, ONCOGENE, V3, P717; MIZUGUCHI G, 1990, J BIOL CHEM, V265, P9280; MOELLING K, 1985, CELL, V40, P983, DOI 10.1016/0092-8674(85)90358-7; Moscovici C, 1975, Curr Top Microbiol Immunol, V71, P79; Moscovici C., 1982, ADV VIRAL ONCOL, V1, P83; MULLER HP, 1990, TRENDS GENET, V6, P300, DOI 10.1016/0168-9525(90)90236-Y; NAKABEPPU Y, 1988, CELL, V55, P907, DOI 10.1016/0092-8674(88)90146-8; NAKAGOSHI H, 1990, J BIOL CHEM, V265, P3479; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; NICOLAIDES NC, 1991, MOL CELL BIOL, V11, P6166, DOI 10.1128/MCB.11.12.6166; NOMURA N, 1988, NUCLEIC ACIDS RES, V16, P11075, DOI 10.1093/nar/16.23.11075; NOMURA N, 1990, NUCLEIC ACIDS RES, V18, P347; OGAS J, 1991, CELL, V66, P1015, DOI 10.1016/0092-8674(91)90445-5; PROCHOWNIK EV, 1990, BLOOD, V76, P1830; REISS K, 1991, J CELL PHYSIOL, V148, P338, DOI 10.1002/jcp.1041480303; RYDER K, 1988, P NATL ACAD SCI USA, V85, P8464, DOI 10.1073/pnas.85.22.8464; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; RYSECK RP, 1988, NATURE, V334, P535, DOI 10.1038/334535a0; RYSECK RP, 1991, ONCOGENE, V6, P533; SAKURA H, 1989, P NATL ACAD SCI USA, V86, P5758, DOI 10.1073/pnas.86.15.5758; Sambrook J, 1989, MOL CLONING LABORATO; STEIN B, 1989, MOL CELL BIOL, V9, P5169, DOI 10.1128/MCB.9.11.5169; TALAVERA A, 1977, J CELL PHYSIOL, V92, P425, DOI 10.1002/jcp.1040920310; TRAVALI S, 1991, MOL CELL BIOL, V11, P731, DOI 10.1128/MCB.11.2.731; VENTURELLI D, 1990, P NATL ACAD SCI USA, V87, P5963, DOI 10.1073/pnas.87.15.5963; WESTIN EH, 1982, P NATL ACAD SCI-BIOL, V79, P2194, DOI 10.1073/pnas.79.7.2194; WESTON K, 1989, CELL, V58, P85, DOI 10.1016/0092-8674(89)90405-4	52	48	56	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1992	267	27					19665	19672						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JP593	1527086				2022-12-25	WOS:A1992JP59300096
J	DYRKS, T; DYRKS, E; HARTMANN, T; MASTERS, C; BEYREUTHER, K				DYRKS, T; DYRKS, E; HARTMANN, T; MASTERS, C; BEYREUTHER, K			AMYLOIDOGENICITY OF BETA-A4 AND BETA-A4-BEARING AMYLOID PROTEIN-PRECURSOR FRAGMENTS BY METAL-CATALYZED OXIDATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALZHEIMERS-DISEASE; LIPID-PEROXIDATION; OXYGEN RADICALS; GLUTAMINE-SYNTHETASE; NERVOUS-SYSTEM; CLEAVAGE; BRAIN; IRON; IDENTIFICATION; INACTIVATION	Previously we have shown that the COOH-terminal 100 residues (A4CT) of the amyloid protein precursor (APP), which carry the sequence of the amyloid beta-A4 protein of Alzheimer's disease at N-terminal position, form highly insoluble aggregates if expressed in the rabbit reticulocyte lysate and analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (Dyrks, T., Weidemann, A., Multhaup, G., Salbaum, J. M., Lemaire, H.-G., Kang, J., Muller-Hill, B., Masters, C. L., and Beyreuther, K. (1988) EMBO J. 7, 949-957). Here we report that aggregation of this COOH-terminal APP fragment A4CT and also of beta-A4 itself depends on additional factors. In contrast to the reticulocyte expression system, expression of A4CT and beta-A4 in the wheat germ expression system resulted in only monomeric forms. We have identified the factors which are capable of transforming both soluble A4CT and beta-A4 into insoluble and aggregating molecules. Monomeric A4CT or beta-A4 expressed in the wheat germ lysate could be transformed into aggregating molecules by the addition of metal-catalyzed oxidation systems. The addition of radical scavengers such as ascorbic acid, trolox, and amino acids prevented the aggregation process induced by the radical initiators. Thus, the aggregation of amyloidogenic APP fragments if analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis requires amino acid oxidation and protein cross-linking induced by radical generation systems.	UNIV MELBOURNE,DEPT PATHOL,PARKVILLE,VIC 3052,AUSTRALIA	University of Melbourne	DYRKS, T (corresponding author), UNIV HEIDELBERG,CTR MOLEC BIOL HEIDELBERG,NEUENHEIMER FELD 282,W-6900 HEIDELBERG,GERMANY.		Hartmann, Tobias/AAB-8297-2022	Hartmann, Tobias/0000-0001-7481-6430				ANDERSON JP, 1991, NEUROSCI LETT, V128, P126, DOI 10.1016/0304-3940(91)90775-O; ARAI H, 1987, BIOCHEM INT, V14, P741; BEYREUTHER K, 1986, DISCUSSIONS NEUROSCI, V3, P68; BLEIJENB.BG, 1971, CLIN CHIM ACTA, V31, P277, DOI 10.1016/0009-8981(71)90387-1; BOSHART M, 1985, CELL, V41, P521, DOI 10.1016/S0092-8674(85)80025-8; BRAUGHLER JM, 1986, J BIOL CHEM, V261, P282; CERTA U, 1986, EMBO J, V5, P3051, DOI 10.1002/j.1460-2075.1986.tb04605.x; CONNOR JR, 1992, J NEUROSCI RES, V31, P75, DOI 10.1002/jnr.490310111; DAVIES KJA, 1987, J BIOL CHEM, V262, P9908; DOBA T, 1985, BIOCHIM BIOPHYS ACTA, V835, P298, DOI 10.1016/0005-2760(85)90285-1; DYRKS T, 1988, EMBO J, V7, P949, DOI 10.1002/j.1460-2075.1988.tb02900.x; ESCH FS, 1990, SCIENCE, V248, P1122, DOI 10.1126/science.2111583; ESTUS S, 1992, SCIENCE, V255, P726, DOI 10.1126/science.1738846; FUCCI L, 1983, P NATL ACAD SCI-BIOL, V80, P1521, DOI 10.1073/pnas.80.6.1521; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V122, P1131, DOI 10.1016/0006-291X(84)91209-9; GOLDE TE, 1992, SCIENCE, V255, P728, DOI 10.1126/science.1738847; GOLDGABER D, 1987, SCIENCE, V235, P877, DOI 10.1126/science.3810169; GUTTERIDGE JMC, 1982, LANCET, V2, P459; HALLIVELL B, 1988, METHOD ENZYMOL, V186, P1; HALLIWELL B, 1984, BIOCHEM J, V219, P1, DOI 10.1042/bj2190001; HALLIWELL B, 1985, TRENDS NEUROSCI, V8, P22, DOI 10.1016/0166-2236(85)90010-4; HILBICH C, 1991, J MOL BIOL, V218, P149, DOI 10.1016/0022-2836(91)90881-6; HUNKAPOILLER MW, 1983, METHOD ENZYMOL, V97, P227; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KATZMAN R, 1986, NEW ENGL J MED, V314, P964, DOI 10.1056/NEJM198604103141506; KITAGUCHI N, 1988, NATURE, V331, P530, DOI 10.1038/331530a0; KONARSKA MM, 1984, CELL, V38, P731, DOI 10.1016/0092-8674(84)90268-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVINE RL, 1981, P NATL ACAD SCI-BIOL, V78, P2120, DOI 10.1073/pnas.78.4.2120; MASTERS CL, 1985, EMBO J, V4, P2757, DOI 10.1002/j.1460-2075.1985.tb04000.x; MASTERS CL, 1985, P NATL ACAD SCI USA, V82, P4245, DOI 10.1073/pnas.82.12.4245; MASTERS CL, 1988, AGING BRAIN, V32, P183; MINOTTI G, 1987, J BIOL CHEM, V262, P1098; OLTERSDORF T, 1989, NATURE, V341, P144, DOI 10.1038/341144a0; PONTE P, 1988, NATURE, V331, P525, DOI 10.1038/331525a0; PRELLI F, 1988, J NEUROCHEM, V51, P648, DOI 10.1111/j.1471-4159.1988.tb01087.x; RIVETT AJ, 1990, ARCH BIOCHEM BIOPHYS, V278, P26, DOI 10.1016/0003-9861(90)90226-O; ROTH M, 1966, NATURE, V209, P109, DOI 10.1038/209109a0; Sambrook J, 1989, MOL CLONING LABORATO; SISODIA SS, 1990, SCIENCE, V248, P492, DOI 10.1126/science.1691865; SMITH CD, 1991, P NATL ACAD SCI USA, V88, P10540, DOI 10.1073/pnas.88.23.10540; SOLAR I, 1990, ARCH BIOCHEM BIOPHYS, V283, P81, DOI 10.1016/0003-9861(90)90615-6; STADTMAN ER, 1991, J BIOL CHEM, V266, P17201; TANZI RE, 1988, NATURE, V331, P528, DOI 10.1038/331528a0; VANDUINEN SG, 1987, P NATL ACAD SCI USA, V84, P5991; WEIDEMANN A, 1989, CELL, V57, P115, DOI 10.1016/0092-8674(89)90177-3; WINTERBOURN CC, 1990, METHOD ENZYMOL, V186, P265	48	336	341	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1992	267	25					18210	18217						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JM223	1517249				2022-12-25	WOS:A1992JM22300111
J	HIRAI, H; FUJISAWA, J; SUZUKI, T; UEDA, K; MURAMATSU, M; TSUBOI, A; ARAI, N; YOSHIDA, M				HIRAI, H; FUJISAWA, J; SUZUKI, T; UEDA, K; MURAMATSU, M; TSUBOI, A; ARAI, N; YOSHIDA, M			TRANSCRIPTIONAL ACTIVATOR TAX OF HTLV-1 BINDS TO THE NF-KAPPA-B PRECURSOR P105	ONCOGENE			English	Article							T-CELL LEUKEMIA; VIRUS TYPE-I; TROPICAL SPASTIC PARAPARESIS; LONG TERMINAL REPEATS; NECROSIS-FACTOR-ALPHA; DNA-BINDING; TRANS-ACTIVATION; NUCLEAR PROTEINS; GENE-EXPRESSION; REL ONCOGENE	Human T-cell leukemia virus type 1 (HTLV-1) induces adult T-cell leukemia and also a neurological disease, tropical spastic paraparesis. Tax protein (p40tax) of HTLV-1 activates in trans its own transcriptional enhancer in the long terminal repeat and also those in some cellular genes such as interleukin 2 receptor-alpha, granulocyte-macrophage colony-stimulating factor, Fos, Jun and MHC class I. Thus, Tax has been proposed to play a critical role in the pathogenesis induced by HTLV-1 infection. Here, we report formation of a complex of Tax protein with the precursor protein p105 of the NF-kappa-B p50 subunit. p105 was co-immunoprecipitated with Tax protein from cells infected with HTLV-1 from cells transfected with the Tax expression plasmid, but not from cells transfected with inactive mutants of Tax. Furthermore, a GST-p105 fusion protein produced in Escherichia coli bound to Tax protein. These results strongly suggest that the trans-activator Tax protein forms a complex with precursor NF-kappa-B p105 and plays a role in trans-activation of transcriptional initiation.	UNIV TOKYO,INST MED SCI,DEPT CELLULAR & MOLEC BIOL,4-6-1 SHIROKANEDAI,MINATO KU,TOKYO 108,JAPAN; UNIV TOKYO,INST MED SCI,DEPT MOLEC & DEV BIOL,TOKYO 108,JAPAN; DNAX RES INST MOLEC & CELLULAR BIOL INC,DEPT MOLEC BIOL,PALO ALTO,CA	University of Tokyo; University of Tokyo; Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.				Tsuboi, Akio/0000-0002-4790-4512				BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BLANK V, 1991, EMBO J, V10, P4159, DOI 10.1002/j.1460-2075.1991.tb04994.x; BOURS V, 1990, NATURE, V348, P76, DOI 10.1038/348076a0; CROSS SL, 1987, CELL, V49, P47, DOI 10.1016/0092-8674(87)90754-9; FAN CM, 1991, NATURE, V354, P395, DOI 10.1038/354395a0; FELBER BK, 1985, SCIENCE, V229, P675, DOI 10.1126/science.2992082; FUJII M, 1988, P NATL ACAD SCI USA, V85, P8526, DOI 10.1073/pnas.85.22.8526; FUJII M, 1991, ONCOGENE, V6, P1023; FUJISAWA J, 1985, P NATL ACAD SCI USA, V82, P2277, DOI 10.1073/pnas.82.8.2277; FUJISAWA J, 1986, EMBO J, V5, P713, DOI 10.1002/j.1460-2075.1986.tb04272.x; FUJISAWA JI, 1991, J VIROL, V65, P4525, DOI 10.1128/JVI.65.8.4525-4528.1991; GESSAIN A, 1985, LANCET, V2, P407; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; HIDAKA M, 1988, EMBO J, V7, P519, DOI 10.1002/j.1460-2075.1988.tb02840.x; HINUMA Y, 1981, P NATL ACAD SCI-BIOL, V78, P6476, DOI 10.1073/pnas.78.10.6476; HOHMANN HP, 1990, J BIOL CHEM, V265, P15183; INOUE J, 1986, EMBO J, V5, P2883, DOI 10.1002/j.1460-2075.1986.tb04583.x; INOUE J, 1987, P NATL ACAD SCI USA, V84, P3635; KALYANARAMAN VS, 1982, P NATL ACAD SCI-BIOL, V79, P1653, DOI 10.1073/pnas.79.5.1653; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; KIYOKAWA T, 1985, P NATL ACAD SCI USA, V82, P8359, DOI 10.1073/pnas.82.24.8359; KIYOKAWA T, 1984, GANN, V75, P747; LEUNG K, 1988, NATURE, V333, P776, DOI 10.1038/333776a0; LOWENTHAL JW, 1988, P NATL ACAD SCI USA, V85, P4468, DOI 10.1073/pnas.85.12.4468; MARUYAMA M, 1987, CELL, V48, P343, DOI 10.1016/0092-8674(87)90437-5; MEYER R, 1991, P NATL ACAD SCI USA, V88, P966, DOI 10.1073/pnas.88.3.966; MIYATAKE S, 1988, NUCLEIC ACIDS RES, V16, P6547, DOI 10.1093/nar/16.14.6547; MIYOSHI I, 1981, NATURE, V294, P770, DOI 10.1038/294770a0; NOLAN GP, 1991, CELL, V64, P961, DOI 10.1016/0092-8674(91)90320-X; OSAME M, 1987, ANN NEUROL, V21, P117, DOI 10.1002/ana.410210203; OSAME M, 1986, LANCET, V1, P1031; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; RODGERSJOHNSON P, 1985, LANCET, V2, P1247; SAWADA M, 1990, J VIROL, V64, P4002, DOI 10.1128/JVI.64.8.4002-4006.1990; SHIMOTOHNO K, 1986, P NATL ACAD SCI USA, V83, P8112, DOI 10.1073/pnas.83.21.8112; SIEKEVITZ M, 1987, P NATL ACAD SCI USA, V84, P5389, DOI 10.1073/pnas.84.15.5389; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SMITH MR, 1990, GENE DEV, V4, P1875, DOI 10.1101/gad.4.11.1875; SODROSKI JG, 1984, SCIENCE, V226, P177; WATANABE T, 1990, J EXP MED, V172, P759, DOI 10.1084/jem.172.3.759; YOSHIDA M, 1984, P NATL ACAD SCI-BIOL, V81, P2534, DOI 10.1073/pnas.81.8.2534; YOSHIDA M, 1982, P NATL ACAD SCI-BIOL, V79, P2031, DOI 10.1073/pnas.79.6.2031; YOSHIMURA T, 1990, EMBO J, V9, P2537, DOI 10.1002/j.1460-2075.1990.tb07434.x	45	149	150	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1992	7	9					1737	1742						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JJ376	1501885				2022-12-25	WOS:A1992JJ37600009
J	MCCONVILLE, MJ; HOMANS, SW				MCCONVILLE, MJ; HOMANS, SW			IDENTIFICATION OF THE DEFECT IN LIPOPHOSPHOGLYCAN BIOSYNTHESIS IN A NONPATHOGENIC STRAIN OF LEISHMANIA-MAJOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DONOVANI LIPOPHOSPHOGLYCAN; SURFACE GLYCOPROTEIN; MACROPHAGES; PROMASTIGOTES; RECEPTOR; FAMILY; GLYCOLIPIDS; SURVIVAL; MOIETY; BINDS	The major macromolecule on the surface of the protozoan parasite, Leishmania major, is a complex lipophosphoglycan (LPG), which is anchored to the plasma membrane by an inositol-containing phospholipid. A defect in LPG biosynthesis is thought to be responsible for the avirulence of the L. major strain LRC L119 in mice. In order to identify the nature of this defect we have characterized two truncated forms of LPG, which are accumulated in this strain, by one- and two-dimensional 500-MHz H-1 NMR spectroscopy, two-dimensional heteronuclear H-1-P-31 NMR spectroscopy, methylation analysis, and exoglycosidase digestions. The structures of these glycoinositolphospholipids, termed GIPL-4 and -6, are as follows: [GRAPHICS] The glycan moieties of GIPL-4 and -6 are identical to the anchor region of LPG, which is also substituted with a Glc-1-PO4 residue in approximately 60% of the structures. However, instead of being capped with chains of phosphorylated oligosaccharide repeat units, both glycan moieties terminate in Man-alpha-1-PO4, suggesting that the defect in LPG biosynthesis is in the transfer of galactose to this residue to form the disaccharide backbone of the first repeat unit. These results indicate that the phosphoglycan moiety of LPG is essential for intracellular survival of the parasite and have implications for LPG biosynthesis.			MCCONVILLE, MJ (corresponding author), UNIV DUNDEE,DEPT BIOCHEM,DUNDEE DD1 4HN,SCOTLAND.				Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		CARVER MA, 1991, J BIOL CHEM, V266, P10974; CHAN J, 1989, P NATL ACAD SCI USA, V86, P2453, DOI 10.1073/pnas.86.7.2453; DASILVA RP, 1989, J IMMUNOL, V143, P617; ELHAY MJ, 1990, MOL BIOCHEM PARASIT, V40, P151; ELON J, 1980, EXP PARASITOL, V49, P167, DOI 10.1016/0014-4894(80)90114-9; FERGUSON MAJ, 1988, SCIENCE, V239, P753, DOI 10.1126/science.3340856; HANDMAN E, 1986, J IMMUNOL, V137, P3608; HANDMAN E, 1985, EMBO J, V4, P329, DOI 10.1002/j.1460-2075.1985.tb03633.x; MCCONVILLE MJ, 1987, P NATL ACAD SCI USA, V84, P8941, DOI 10.1073/pnas.84.24.8941; MCCONVILLE MJ, 1990, J BIOL CHEM, V265, P7385; MCCONVILLE MJ, 1990, J BIOL CHEM, V265, P19611; MCCONVILLE MJ, 1989, J BIOL CHEM, V264, P757; MCCONVILLE MJ, 1990, MOL BIOCHEM PARASIT, V38, P57, DOI 10.1016/0166-6851(90)90205-Z; MCNEELY TB, 1990, J IMMUNOL, V144, P2745; MCNEELY TB, 1987, BIOCHEM BIOPH RES CO, V148, P653, DOI 10.1016/0006-291X(87)90926-0; NEUHAUS D, 1984, J MAGN RESON, V57, P164, DOI 10.1016/0022-2364(84)90250-6; ORLANDI PA, 1987, J BIOL CHEM, V262, P10384; PUENTES SM, 1990, J IMMUNOL, V145, P4311; RUSSELL DG, 1988, J EXP MED, V168, P279, DOI 10.1084/jem.168.1.279; SUTHERLAND IW, 1985, ANNU REV MICROBIOL, V39, P243; TALAMASROHANA P, 1990, J IMMUNOL, V144, P4817	21	36	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1992	267	9					5855	5861						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HK318	1532574				2022-12-25	WOS:A1992HK31800024
J	BECKER, K; GUIARD, B; RASSOW, J; SOLLNER, T; PFANNER, N				BECKER, K; GUIARD, B; RASSOW, J; SOLLNER, T; PFANNER, N			TARGETING OF A CHEMICALLY PURE PREPROTEIN TO MITOCHONDRIA DOES NOT REQUIRE THE ADDITION OF A CYTOSOLIC SIGNAL RECOGNITION FACTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ORNITHINE CARBAMOYLTRANSFERASE PRECURSOR; ESCHERICHIA-COLI; PROTEIN IMPORT; ENDOPLASMIC-RETICULUM; HEAT-SHOCK; PROCESSING PEPTIDASE; MICROSOMAL-MEMBRANES; INTERMEMBRANE SPACE; SECRETORY PROTEIN; ADP/ATP CARRIER	To analyze the role of cytosolic cofactors in mitochondrial protein targeting, we prepared a chemically pure mitochondrial preprotein. When diluted out of 7 M urea, this precursor protein was efficiently imported into mitochondria without the addition of cytosolic cofactors. Extensive prewashing of mitochondria (up to 2 M KCl) did not reduce its import. Import of the purified precursor showed the characteristics of authentic mitochondrial import including use of the receptor MOM19, requirement for a membrane potential, and proteolytic processing. When the precursor was preincubated at a low concentration of urea, cytosolic cofactors were needed to preserve its import competence. We conclude that targeting of this preprotein via the mitochondrial master receptor MOM19 does not require a cytosolic signal recognition factor; cytosolic cofactors apparently have chaperone-like functions in mitochondrial protein uptake. Moreover, we found that a cleavable presequence was sufficient to direct protein import via MOM19. Together with the cofactor-independent function of MOM19, it is thus conceivable that MOM19 functions as mitochondrial presequence receptor.	UNIV MUNICH, INST PHYSIOL CHEM, GOETHESTR 33, W-8000 MUNICH 2, GERMANY; UNIV PIERRE & MARIE CURIE, CNRS, PROPRE LAB, CTR GENET MOLEC, F-91190 GIF SUR YVETTE, FRANCE	University of Munich; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Saclay			Pfanner, Nikolaus/AAV-7878-2021					ALTIERI F, 1989, J BIOL CHEM, V264, P4782; ARGAN C, 1985, BIOCHEM BIOPH RES CO, V131, P289, DOI 10.1016/0006-291X(85)91801-7; ARGAN C, 1983, J BIOL CHEM, V258, P6667; BAKER KP, 1991, NATURE, V349, P205, DOI 10.1038/349205a0; CHAMBERLAIN JP, 1979, ANAL BIOCHEM, V98, P132, DOI 10.1016/0003-2697(79)90716-4; CHEN WJ, 1987, J BIOL CHEM, V262, P15598; CHEN WJ, 1987, CELL, V49, P651, DOI 10.1016/0092-8674(87)90541-1; CLARY DO, 1990, J BIOL CHEM, V265, P10109; CUNNINGHAM K, 1989, EMBO J, V8, P955, DOI 10.1002/j.1460-2075.1989.tb03457.x; DESHAIES RJ, 1988, NATURE, V332, P800, DOI 10.1038/332800a0; DOUGLAS MG, 1986, MICROBIOL REV, V50, P166, DOI 10.1128/MMBR.50.2.166-178.1986; EILERS M, 1988, EMBO J, V7, P1139, DOI 10.1002/j.1460-2075.1988.tb02923.x; EILERS M, 1986, NATURE, V322, P228, DOI 10.1038/322228a0; FIRGAIRA FA, 1984, SCIENCE, V226, P1319, DOI 10.1126/science.6209799; FURUYA S, 1991, EMBO J, V10, P1759, DOI 10.1002/j.1460-2075.1991.tb07700.x; GILMORE R, 1982, J CELL BIOL, V95, P470, DOI 10.1083/jcb.95.2.470; GUIARD B, 1975, NATURE, V255, P422, DOI 10.1038/255422a0; GUIARD B, 1985, EMBO J, V4, P3265, DOI 10.1002/j.1460-2075.1985.tb04076.x; HALPIN C, 1989, EMBO J, V8, P3917, DOI 10.1002/j.1460-2075.1989.tb08572.x; HARTL FU, 1987, CELL, V51, P1027, DOI 10.1016/0092-8674(87)90589-7; HARTL FU, 1990, SCIENCE, V247, P930, DOI 10.1126/science.2406905; HARTL FU, 1986, CELL, V47, P939, DOI 10.1016/0092-8674(86)90809-3; HARTL FU, 1989, BIOCHIM BIOPHYS ACTA, V988, P1, DOI 10.1016/0304-4157(89)90002-6; HAWLITSCHEK G, 1988, CELL, V53, P795, DOI 10.1016/0092-8674(88)90096-7; HIGH S, 1991, J CELL BIOL, V113, P229, DOI 10.1083/jcb.113.2.229; Horwich A, 1990, CURR OPIN CELL BIOL, V2, P625, DOI 10.1016/0955-0674(90)90103-L; HURT EC, 1987, NATURE, V325, P499, DOI 10.1038/325499a0; HURT EC, 1984, EMBO J, V3, P3149, DOI 10.1002/j.1460-2075.1984.tb02272.x; KEEGSTRA K, 1989, CELL, V56, P247, DOI 10.1016/0092-8674(89)90898-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LECKER S, 1989, EMBO J, V8, P2703, DOI 10.1002/j.1460-2075.1989.tb08411.x; MEYER DI, 1982, NATURE, V297, P647, DOI 10.1038/297647a0; MILLER BR, 1991, J CELL BIOL, V112, P833, DOI 10.1083/jcb.112.5.833; MIURA S, 1983, J BIOL CHEM, V258, P6671; MURAKAMI H, 1988, J CELL BIOL, V107, P2051, DOI 10.1083/jcb.107.6.2051; MURAKAMI K, 1988, J BIOL CHEM, V263, P18437; MURAKAMI K, 1990, EMBO J, V9, P3201, DOI 10.1002/j.1460-2075.1990.tb07518.x; NEUPERT W, 1990, CELL, V63, P447, DOI 10.1016/0092-8674(90)90437-J; OHTA S, 1984, EMBO J, V3, P651, DOI 10.1002/j.1460-2075.1984.tb01862.x; ONO H, 1988, J BIOL CHEM, V263, P3188; OSTERMANN J, 1989, NATURE, V341, P125, DOI 10.1038/341125a0; PAK YK, 1990, J BIOL CHEM, V265, P14298; PELHAM HRB, 1986, CELL, V46, P959, DOI 10.1016/0092-8674(86)90693-8; PFALLER R, 1988, J CELL BIOL, V107, P2483, DOI 10.1083/jcb.107.6.2483; PFALLER R, 1989, J BIOL CHEM, V264, P34; PFANNER N, 1987, EMBO J, V6, P3449, DOI 10.1002/j.1460-2075.1987.tb02668.x; PFANNER N, 1987, J BIOL CHEM, V262, P7528; PFANNER N, 1988, TRENDS BIOCHEM SCI, V13, P165, DOI 10.1016/0968-0004(88)90140-5; PFANNER N, 1991, TRENDS BIOCHEM SCI, V16, P63, DOI 10.1016/0968-0004(91)90026-R; PFANNER N, 1985, EMBO J, V4, P2819, DOI 10.1002/j.1460-2075.1985.tb04009.x; PORITZ MA, 1990, SCIENCE, V250, P1111, DOI 10.1126/science.1701272; RANDALL SK, 1989, FEBS LETT, V250, P561, DOI 10.1016/0014-5793(89)80796-3; RAPOPORT TA, 1990, TRENDS BIOCHEM SCI, V15, P355, DOI 10.1016/0968-0004(90)90076-N; RAPOPORT TA, 1991, NATURE, V349, P107, DOI 10.1038/349107a0; RASSOW J, 1990, FEBS LETT, V275, P190, DOI 10.1016/0014-5793(90)81469-5; RASSOW J, 1989, J CELL BIOL, V109, P1421, DOI 10.1083/jcb.109.4.1421; RASSOW J, 1990, NUCLEIC ACIDS RES, V18, P4922, DOI 10.1093/nar/18.16.4922; REID GA, 1982, J BIOL CHEM, V257, P3068; RIBES V, 1990, CELL, V63, P591, DOI 10.1016/0092-8674(90)90454-M; ROSENBERG LE, 1987, ANN NY ACAD SCI, V488, P99; ROTHMAN JE, 1989, CELL, V59, P591, DOI 10.1016/0092-8674(89)90005-6; SCHNEIDER A, 1991, EMBO J, V10, P247, DOI 10.1002/j.1460-2075.1991.tb07944.x; SCHNEIDER H, 1991, IN PRESS SCIENCE; SHEFFIELD WP, 1990, J BIOL CHEM, V265, P11069; SIEGEL V, 1988, TRENDS BIOCHEM SCI, V13, P314, DOI 10.1016/0968-0004(88)90127-2; SIMON SM, 1991, CELL, V65, P371, DOI 10.1016/0092-8674(91)90455-8; SMEEKENS S, 1986, CELL, V46, P365, DOI 10.1016/0092-8674(86)90657-4; SOLLNER T, 1989, CELL, V59, P1061, DOI 10.1016/0092-8674(89)90762-9; SOLLNER T, 1990, CELL, V62, P107, DOI 10.1016/0092-8674(90)90244-9; SOLLNER T, 1991, IN PRESS NATURE; SOLLNER T, 1991, METHOD CELL BIOL, V34, P345; STEGER HF, 1990, J CELL BIOL, V111, P2353, DOI 10.1083/jcb.111.6.2353; WALTER P, 1980, P NATL ACAD SCI-BIOL, V77, P7112, DOI 10.1073/pnas.77.12.7112; WALTER P, 1984, CELL, V38, P5, DOI 10.1016/0092-8674(84)90520-8; WALTER P, 1981, J CELL BIOL, V91, P551, DOI 10.1083/jcb.91.2.551; WARREN G, 1978, NATURE, V273, P569, DOI 10.1038/273569a0; WICKNER W, 1991, ANNU REV BIOCHEM, V60, P101, DOI 10.1146/annurev.bi.60.070191.000533; WICKNER WT, 1985, SCIENCE, V230, P400, DOI 10.1126/science.4048938; WIECH H, 1991, FEBS LETT, V285, P182, DOI 10.1016/0014-5793(91)80800-I; ZOPF D, 1990, EMBO J, V9, P4511, DOI 10.1002/j.1460-2075.1990.tb07902.x	80	41	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 15	1992	267	8					5637	5643						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HH747	1531985				2022-12-25	WOS:A1992HH74700095
J	FELDINGHABERMANN, B; RUGGERI, ZM; CHERESH, DA				FELDINGHABERMANN, B; RUGGERI, ZM; CHERESH, DA			DISTINCT BIOLOGICAL CONSEQUENCES OF INTEGRIN-ALPHA-V-BETA-3-MEDIATED MELANOMA CELL-ADHESION TO FIBRINOGEN AND ITS PLASMIC FRAGMENTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR RECOGNITION DOMAINS; ENDOTHELIAL-CELLS; GAMMA-CHAIN; ALPHA-CHAIN; PLATELET RECEPTOR; VONWILLEBRAND-FACTOR; ACID SEQUENCES; BINDING; VITRONECTIN; PEPTIDES	Fibrinogen/fibrin and its proteolytic fragments serve as potential adhesive substrates during thrombosis, wound healing, and cancer. In this report we examined the biological response of human melanoma cells exposed to fibrinogen and its naturally occurring plasmic breakdown products that are known constituents of the tumor stroma. Plasmin treatment of fibrinogen first results in fragment X, which is characterized by removal of the COOH-terminal portion of the a chain including an RGD sequence (A-alpha 572-575). Further digestion leads to fragment D comprising primarily an intact COOH-terminal stretch of the gamma-chain containing the platelet adhesion sequence HHLGGAKQAGDV. In a sensitive adhesion assay M21 human melanoma cells utilized integrin alpha-v-beta-3 to attach to all three of these ligands. However, only intact fibrinogen promoted significant cell spreading, while fragment X produced minimal spreading and fragment D promoted only adhesion. These results indicate that fibrinogen contains at least two alpha-v-beta-3-dependent adhesive sites and these promote distinct biological responses of human melanoma cells. The differential functional properties of these ligands directly correlate to their relative binding affinity for purified alpha-v-beta-3 as measured in a solid-phase receptor binding assay. These results provide evidence that a single integrin can promote distinct biological signals depending on the molecular nature of the ligand binding event.	Scripps Res Inst, RES INST, COMM VASC BIOL, LA JOLLA, CA 92037 USA; Scripps Res Inst, RES INST, DEPT IMMUNOL, LA JOLLA, CA 92037 USA; Scripps Res Inst, RES INST, DEPT MOLEC & EXPTL MED, LA JOLLA, CA 92037 USA	Scripps Research Institute; Scripps Research Institute; Scripps Research Institute					NATIONAL CANCER INSTITUTE [R37CA050286, R01CA045726, R01CA050286] Funding Source: NIH RePORTER; NCI NIH HHS [CA45726, CA50286] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBELDA SM, 1990, CANCER RES, V50, P6757; ANDRIEUX A, 1989, J BIOL CHEM, V264, P9258; BROCK TA, 1991, AM J PATHOL, V138, P213; BROWN LF, 1989, AM REV RESPIR DIS, V140, P1104, DOI 10.1164/ajrccm/140.4.1104; BUDZYNSK.AZ, 1974, J BIOL CHEM, V249, P2294; CHARO IF, 1990, J CELL BIOL, V111, P2795, DOI 10.1083/jcb.111.6.2795; CHEN CS, 1988, BIOCHEMISTRY-US, V27, P6121, DOI 10.1021/bi00416a044; CHERESH DA, 1989, CELL, V58, P945, DOI 10.1016/0092-8674(89)90946-X; CHERESH DA, 1987, P NATL ACAD SCI USA, V84, P6471, DOI 10.1073/pnas.84.18.6471; CHERESH DA, 1987, J BIOL CHEM, V262, P17703; COLMAN RW, 1987, HEMOSTASIS THROMBOSI, P3; DANO K, 1985, ADV CANCER RES, V44, P139, DOI 10.1016/S0065-230X(08)60028-7; DEJANA E, 1987, J CELL BIOL, V104, P1403, DOI 10.1083/jcb.104.5.1403; DOOLITTLE RF, 1984, ANNU REV BIOCHEM, V53, P195, DOI 10.1146/annurev.bi.53.070184.001211; DOOLITTLE RF, 1979, NATURE, V280, P464, DOI 10.1038/280464a0; DVORAK HF, 1990, PROG CLIN BIOL RES, V354, P317; DVORAK HF, 1983, CANCER METAST REV, V2, P41, DOI 10.1007/BF00046905; GUSTAFSON EJ, 1989, J CELL BIOL, V109, P377, DOI 10.1083/jcb.109.1.377; HAWIGER J, 1982, P NATL ACAD SCI-BIOL, V79, P2068, DOI 10.1073/pnas.79.6.2068; HAWIGER J, 1989, BIOCHEMISTRY-US, V28, P2909, DOI 10.1021/bi00433a024; KADISH JL, 1979, TISSUE CELL, V11, P99, DOI 10.1016/0040-8166(79)90010-7; KAZAL LA, 1963, P SOC EXP BIOL MED, V113, P989; KLOCZEWIAK M, 1989, BIOCHEMISTRY-US, V28, P2915, DOI 10.1021/bi00433a025; KLOCZEWIAK M, 1984, BIOCHEMISTRY-US, V23, P1767, DOI 10.1021/bi00303a028; LAM SCT, 1987, J BIOL CHEM, V262, P947; MARGUERIE GA, 1984, EUR J BIOCHEM, V139, P5, DOI 10.1111/j.1432-1033.1984.tb07968.x; MARGUERIE GA, 1979, J BIOL CHEM, V254, P5337; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MCLEAN JR, 1964, NATURE, V202, P605, DOI 10.1038/202605a0; MOOS M, 1988, J BIOL CHEM, V263, P6005; MOSESSON MW, 1974, J BIOL CHEM, V249, P4656; ORLANDO RA, 1991, J BIOL CHEM, V266, P19543; PLOW EF, 1987, BLOOD, V70, P110; PYTELA R, 1986, SCIENCE, V231, P1559, DOI 10.1126/science.2420006; RIBES JA, 1989, J CLIN INVEST, V84, P435, DOI 10.1172/JCI114184; SAVAGE B, 1991, J BIOL CHEM, V266, P11227; SHAFER JA, 1988, CRIT REV CL LAB SCI, V26, P1; SMITH JW, 1990, J BIOL CHEM, V265, P12267; SMITH JW, 1988, J BIOL CHEM, V263, P18726; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; STRICKLAND DK, 1982, BIOCHEMISTRY-US, V21, P721, DOI 10.1021/bi00533a021; TIMMONS S, 1989, BIOCHEMISTRY-US, V28, P2919, DOI 10.1021/bi00433a026; WAYNER EA, 1991, J CELL BIOL, V113, P919, DOI 10.1083/jcb.113.4.919; YATOHGO T, 1988, CELL STRUCT FUNCT, V13, P281, DOI 10.1247/csf1975.13.281	44	79	82	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1992	267	8					5070	5077						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HH747	1531979				2022-12-25	WOS:A1992HH74700013
J	TAZI, J; DAUGERON, MC; CATHALA, G; BRUNEL, C; JEANTEUR, P				TAZI, J; DAUGERON, MC; CATHALA, G; BRUNEL, C; JEANTEUR, P			ADENOSINE PHOSPHOROTHIOATES (ATP-ALPHA-S AND ATP-TAU-S) DIFFERENTIALLY AFFECT THE 2 STEPS OF MAMMALIAN PRE-MESSENGER-RNA SPLICING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMALL NUCLEAR RIBONUCLEOPROTEIN; U2 SNRNP; PROTEIN; YEAST; IDENTIFICATION; SITE; PURIFICATION; PARTICLES; COMPLEXES; INVITRO	We have investigated the function of ATP hydrolysis in mammalian pre-mRNA in vitro splicing using adenosine phosphorothioates (ATP-alpha-S and ATP-tau-S) known to affect the activity of a number of ATP-requiring enzymes. Spliceosome assembly, but neither one of the two transesterification reactions involved in splicing, occurs with ATP-alpha-S suggesting that at least two types of ATP-requiring factors are brought into play. ATP-alpha-S has no effect in the presence of normal ATP and, therefore, spliceosomes assembled in the presence of ATP-alpha-S remain competent for splicing when supplied with normal ATP. ATP-tau-S noticeably and irreversibly inhibits the second transesterification reaction, i.e. at a time when most of the analog has been hydrolyzed and regenerated to normal ATP by creatine phosphate. This indicates that the inhibition results from an earlier event, most likely the thiophosphorylation of spliceosomal proteins. Under this assumption, the inhibition could be due to the failure of the thiophosphorylated proteins to be dephosphorylated. Indeed, okadaic acid, a potent inhibitor of protein phosphatases, inhibits the second step of a reaction in the presence of normal ATP. We propose that some splicing factors undergo phosphorylation-dephosphorylation cycles during spliceosome assembly and splicing, while others that could be the mammalian equivalents of the RNA helicase-like proteins recently discovered in yeast most likely bind and hydrolyze ATP.	UNIV MONTPELLIER 2, BIOL MOLEC LAB, F-34095 MONTPELLIER 5, FRANCE	Universite de Montpellier	TAZI, J (corresponding author), CTR VAL DAURELLE PAUL LAMARQUE, BIOCHIM LAB, CNRS, UA 1191, F-34094 MONTPELLIER 5, FRANCE.			Tazi, Jamal/0000-0002-1949-8748				ALIBERT C, 1990, NUCLEIC ACIDS RES, V18, P235, DOI 10.1093/nar/18.2.235; BEHRENS SE, 1991, GENE DEV, V5, P1439, DOI 10.1101/gad.5.8.1439; Bindereif A, 1990, Genet Eng (N Y), V12, P201; BLACK DL, 1989, MOL CELL BIOL, V9, P3350, DOI 10.1128/MCB.9.8.3350; BLACK DL, 1985, CELL, V42, P737, DOI 10.1016/0092-8674(85)90270-3; BURGESS S, 1990, CELL, V60, P705, DOI 10.1016/0092-8674(90)90086-T; CHABOT B, 1985, SCIENCE, V230, P1344, DOI 10.1126/science.2933810; CHABOT B, 1987, MOL CELL BIOL, V7, P281, DOI 10.1128/MCB.7.1.281; CHENG SC, 1987, GENE DEV, V1, P1014, DOI 10.1101/gad.1.9.1014; CHOI YD, 1986, SCIENCE, V231, P1534, DOI 10.1126/science.3952495; COMPANY M, 1991, NATURE, V349, P487, DOI 10.1038/349487a0; DALBADIEMCFARLAND G, 1990, P NATL ACAD SCI USA, V87, P4236, DOI 10.1073/pnas.87.11.4236; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; ECKSTEIN F, 1985, ANNU REV BIOCHEM, V54, P367, DOI 10.1146/annurev.bi.54.070185.002055; ECKSTEIN F, 1976, BIOCHEMISTRY-US, V15, P1685, DOI 10.1021/bi00653a015; GARCIABLANCO MA, 1989, GENE DEV, V3, P1874, DOI 10.1101/gad.3.12a.1874; GERKE V, 1986, CELL, V47, P973, DOI 10.1016/0092-8674(86)90812-3; JAMIESON DJ, 1991, NATURE, V349, P715, DOI 10.1038/349715a0; KHELLIL S, 1991, NUCLEIC ACIDS RES, V19, P877, DOI 10.1093/nar/19.4.877; KONARSKA MM, 1987, CELL, V49, P763, DOI 10.1016/0092-8674(87)90614-3; KONARSKA MM, 1986, CELL, V46, P845, DOI 10.1016/0092-8674(86)90066-8; KRAINER AR, 1984, CELL, V36, P993, DOI 10.1016/0092-8674(84)90049-7; KRAMER A, 1988, GENE DEV, V2, P1155, DOI 10.1101/gad.2.9.1155; KRAMER A, 1984, CELL, V38, P299, DOI 10.1016/0092-8674(84)90551-8; LAMOND AI, 1990, NUCLEIC ACIDS MOL BI, P243; LI HC, 1988, METHOD ENZYMOL, V159, P346; LOSSKY M, 1987, CELL, V51, P1019, DOI 10.1016/0092-8674(87)90588-5; LUHRMANN R, 1990, BIOCHIM BIOPHYS ACTA, V1087, P265, DOI 10.1016/0167-4781(90)90001-I; MOUNT SM, 1983, CELL, V33, P509, DOI 10.1016/0092-8674(83)90432-4; PICK L, 1986, J BIOL CHEM, V261, P6684; PIKIELNY CW, 1986, NATURE, V324, P341, DOI 10.1038/324341a0; ROZEN F, 1990, MOL CELL BIOL, V10, P1134, DOI 10.1128/MCB.10.3.1134; RUBY SW, 1991, TRENDS GENET, V7, P79; RUSKIN B, 1985, CELL, V43, P131, DOI 10.1016/0092-8674(85)90018-2; RUSKIN B, 1988, CELL, V52, P207, DOI 10.1016/0092-8674(88)90509-0; SCHWER B, 1991, NATURE, V349, P494, DOI 10.1038/349494a0; SENTER P, 1983, BIOCHEMISTRY-US, V22, P5514, DOI 10.1021/bi00293a010; SERAPHIN B, 1989, CELL, V59, P349, DOI 10.1016/0092-8674(89)90296-1; SHENOLIKAR S, 1991, ADV 2ND MESSENGER PH, V23, P1; SONENBERG N, 1988, PROG NUCLEIC ACID RE, V35, P174; Steitz J. A., 1988, STRUCTURE FUNCTION M, P115; TAZI J, 1989, NUCLEIC ACIDS RES, V17, P5223, DOI 10.1093/nar/17.13.5223; TAZI J, 1986, CELL, V47, P755, DOI 10.1016/0092-8674(86)90518-0; WOOLEY JC, 1983, P NATL ACAD SCI-BIOL, V80, P5208, DOI 10.1073/pnas.80.17.5208; WOPPMANN A, 1990, NUCLEIC ACIDS RES, V18, P4427, DOI 10.1093/nar/18.15.4427; ZAMORE PD, 1989, P NATL ACAD SCI USA, V86, P9243, DOI 10.1073/pnas.86.23.9243	46	55	55	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	1992	267	7					4322	4326						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HF642	1531649				2022-12-25	WOS:A1992HF64200012
J	ZECHNER, EL; WU, CA; MARIANS, KJ				ZECHNER, EL; WU, CA; MARIANS, KJ			COORDINATED LEADING-STRAND AND LAGGING-STRAND SYNTHESIS AT THE ESCHERICHIA-COLI DNA-REPLICATION FORK .3. A POLYMERASE-PRIMASE INTERACTION GOVERNS PRIMER SIZE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3'->5' EXONUCLEASE ACTIVITY; III HOLOENZYME; SITE SELECTION; BETA-SUBUNIT; PROTEIN; COMPLEX; ALPHA; INITIATION; PRIMOSOME; MECHANISM	Studies with a rolling-circle DNA replication system reconstituted in vitro with a tailed form II DNA template, the DNA polymerase III holoenzyme (Pol III HE), the Escherichia coli single-stranded DNA binding protein, and the primosome, showed that within the context of a replication fork, the oligoribonucleotide primers that were formed were limited to a length in the range of 9 to 14 nucleotides, regardless of whether they were subsequently elongated by the lagging-strand DNA polymerase. This is in contrast to the 8-60-nucleotide-long primers synthesized by the primosome in the absence of DNA replication on a bacteriophage phi-X174 DNA template, although when primer synthesis and DNA replication were catalyzed concurrently in this system, the extent of RNA polymerization decreased. As described in this report, we therefore examined the effect of the DNA Pol III HE on the length of primers synthesized by primase in vitro in the absence of DNA replication. When primer synthesis was catalyzed either: i) by the primosome on a phi-X174 DNA template, ii) by primase on naked DNA with the aid of the DnaB protein (general priming), or iii) by primase alone at the bacteriophage G4 origin, the presence of the DNA Pol III HE in the reaction mixtures resulted in a universal reduction in the length of the heterogeneous RNA products to a uniform size of approximately 10 nucleotides. dNTPs were not required, and the addition of dGMP, an inhibitor of the 3' --> 5' exonuclease of the DNA Pol III HE, did not alter the effect; therefore, neither the 5' --> 3' DNA polymerase activity nor the 3' --> 5' exonuclease activity of the DNA Pol III HE was involved. E. coli DNA polymerase I, and the DNA polymerases of bacteriophages T4 and T7 could not substitute for the DNA Pol III HE. The Pol III core plays a crucial role in mediating this effect, although other subunits of the DNA Pol III HE are also required. These observations suggest that the association of primase with the DNA Pol III HE during primer synthesis regulates its catalytic activity and that this regulatory interaction occurs independently of, and prior to, formation of a preinitiation complex of the DNA Pol III HE on the primer terminus.	CORNELL UNIV, GRAD SCH MED SCI, GRAD PROGRAM MOLEC BIOL, NEW YORK, NY 10021 USA	Cornell University	ZECHNER, EL (corresponding author), MEM SLOAN KETTERING CANC CTR, SLOAN KETTERING INST, PROGRAM MOLEC BIOL, NEW YORK, NY 10021 USA.			Zechner, Ellen L./0000-0003-2035-1898	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM034557, R01GM034557] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 34557] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARAI K, 1979, P NATL ACAD SCI USA, V76, P4308, DOI 10.1073/pnas.76.9.4308; ARAI KI, 1981, P NATL ACAD SCI-BIOL, V78, P707, DOI 10.1073/pnas.78.2.707; BADARACCO G, 1986, EUR J BIOCHEM, V161, P435, DOI 10.1111/j.1432-1033.1986.tb10463.x; BENZ EW, 1980, J BIOL CHEM, V255, P1096; BOUCHE JP, 1978, J BIOL CHEM, V253, P765; BOUCHE JP, 1975, J BIOL CHEM, V250, P5995; CONAWAY RC, 1982, P NATL ACAD SCI-BIOL, V79, P2523, DOI 10.1073/pnas.79.8.2523; FAY PJ, 1981, J BIOL CHEM, V256, P976; FERSHT AR, 1983, J MOL BIOL, V165, P669, DOI 10.1016/S0022-2836(83)80273-3; GRIEP MA, 1990, BIOCHEMISTRY-US, V29, P9006, DOI 10.1021/bi00490a018; HU SZ, 1984, J BIOL CHEM, V259, P2602; JOHANSON KO, 1982, J BIOL CHEM, V257, P2310; KAGUNI J, 1979, J MOL BIOL, V135, P863, DOI 10.1016/0022-2836(79)90516-3; KITANI T, 1985, J MOL BIOL, V184, P45, DOI 10.1016/0022-2836(85)90042-7; LASKEN RS, 1987, J BIOL CHEM, V262, P1720; LEHMAN IR, 1989, J BIOL CHEM, V264, P4265; MCMACKEN R, 1978, J BIOL CHEM, V253, P3313; ODONNELL M, 1990, J BIOL CHEM, V265, P1179; ODONNELL ME, 1987, J BIOL CHEM, V262, P16558; OGAWA T, 1983, J BIOL CHEM, V258, P3353; ROWEN L, 1978, J BIOL CHEM, V253, P758; ROWEN L, 1978, J BIOL CHEM, V253, P770; SCHEUERMANN RH, 1984, P NATL ACAD SCI-BIOL, V81, P7747, DOI 10.1073/pnas.81.24.7747; SINGH H, 1984, J BIOL CHEM, V259, P7936; STAYTON MM, 1983, J BIOL CHEM, V258, P3205; STUDWELL P, 1990, ICN UCLA S MOL CELLU, V127, P153; TSENG BY, 1983, J BIOL CHEM, V258, P9845; WEINER JH, 1976, P NATL ACAD SCI USA, V73, P752, DOI 10.1073/pnas.73.3.752; WICKNER S, 1977, P NATL ACAD SCI USA, V74, P2815, DOI 10.1073/pnas.74.7.2815; WICKNER S, 1976, P NATL ACAD SCI USA, V73, P3511, DOI 10.1073/pnas.73.10.3511; WICKNER S, 1975, ICN UCLA S MOL CELLU, P227; WICKNER W, 1974, J BIOL CHEM, V249, P6244; WU CA, 1992, J BIOL CHEM, V267, P4030; WU CA, 1992, J BIOL CHEM, V267, P4064; WU CA, 1992, J BIOL CHEM, V267, P4074; ZECHEL K, 1975, J BIOL CHEM, V250, P4684; ZECHNER EL, 1992, J BIOL CHEM, V267, P4045	37	73	74	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1992	267	6					4054	4063						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HE607	1531480				2022-12-25	WOS:A1992HE60700075
J	WEBER, J; LEE, RSF; GRELL, E; WISE, JG; SENIOR, AE				WEBER, J; LEE, RSF; GRELL, E; WISE, JG; SENIOR, AE			ON THE LOCATION AND FUNCTION OF TYROSINE-BETA-331 IN THE CATALYTIC SITE OF ESCHERICHIA-COLI F1-ATPASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-BINDING-SITES; HEART MITOCHONDRIAL F1-ATPASE; DEFECTIVE PROTON-ATPASE; AMINO-ACID RESIDUES; UNCA MUTANT STRAINS; BETA-SUBUNIT; ADENOSINE-TRIPHOSPHATASE; DIRECTED MUTAGENESIS; OXIDATIVE-PHOSPHORYLATION; ADENINE-NUCLEOTIDES	1) Using a combination of site-directed mutagenesis and fluorescence spectroscopy we have studied the location and function of residue beta-Y331 in the catalytic site of Escherichia coli F1-ATPase. The fluorescent analog lin-benzo-ADP was used as a catalytic-site probe, and was found to bind to three sites in normal F1, with K(d1) = 0.20-mu-M and K(d2,3) = 5.5-mu-M. lin-Benzo-ATP was a good substrate for hydrolysis. 2) The mutants investigated were beta-Y331F, L, A and E. k(cat)/K(M) for ATP hydrolysis in purified F1 was reduced according to the series Y greater-than-or-equal-to F > L > A > E, with E being severely impaired; concomitant decreases in binding affinity for lin-benzo-ADP were seen. 3) Fluorescence properties of lin-benzo-ADP bound to F1 differed widely, depending on the residue present at position beta-331. Red shifts of excitation and emission spectra occurred with F and L residues, but not with Y, A, or E. There was strong quenching of fluorescence with wild-type (Y), partial quenching with A, and no quenching with F, L, or E. 4) We conclude that (a) the environment around the bound adenine moiety in the catalytic site is nonpolar, (b) residue beta-331 is part of the adenine-binding subdomain and when tyrosine is the residue, the phenolic hydroxyl makes direct interaction with the fluorophore, (c) an aromatic residue is not absolutely required at position beta-331 for catalytic function, but an increase in polarity leads to functional impairment, and (d) in terms of fluorescence response of bound lin-benzo-ADP all three catalytic sites behaved the same. 5) F1 from mutant beta-Y297F bound lin-benzo-ADP with the same fluorescence and binding characteristics as normal F1, and catalytic properties were similar to normal. Therefore, there was no reason to conclude that residue beta-Y297 is involved in binding the adenine moiety of ATP.	SUNY HLTH SCI CTR, DEPT BIOCHEM & MOLEC BIOL, SYRACUSE, NY 13210 USA; MAX PLANCK INST BIOPHYS, W-6000 FRANKFURT 70, GERMANY	State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center; Max Planck Society	WEBER, J (corresponding author), UNIV ROCHESTER, MED CTR, DEPT BIOCHEM, ROCHESTER, NY 14642 USA.			Wise, John/0000-0001-5398-8794	NIGMS NIH HHS [GM25349] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM025349, R37GM025349] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADMON A, 1987, BIOCHEMISTRY-US, V26, P3193, DOI 10.1021/bi00385a038; ALOISE P, 1991, J BIOL CHEM, V266, P10368; ANDREWS WW, 1984, J BIOL CHEM, V259, P8219; BOYER PD, 1987, BIOCHEMISTRY-US, V26, P8503, DOI 10.1021/bi00400a001; BOYER PD, 1989, FASEB J, V3, P2164, DOI 10.1096/fasebj.3.10.2526771; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROOKER LGS, 1965, J AM CHEM SOC, V87, P2443, DOI 10.1021/ja01089a025; BULLOUGH DA, 1988, J BIOL CHEM, V263, P14053; BULLOUGH DA, 1986, J BIOL CHEM, V261, P14171; CROSS RL, 1987, P NATL ACAD SCI USA, V84, P5715, DOI 10.1073/pnas.84.16.5715; DIMROTH K, 1963, LIEBIGS ANN CHEM, V661, P1; DUNCAN TM, 1985, J BIOL CHEM, V260, P4901; FUTAI M, 1989, ANNU REV BIOCHEM, V58, P111; GARIN J, 1989, BIOCHEMISTRY-US, V28, P1442, DOI 10.1021/bi00430a003; GARIN J, 1986, BIOCHEMISTRY-US, V25, P4431, DOI 10.1021/bi00363a039; HOLLEMANS M, 1983, J BIOL CHEM, V258, P9307; ISSARTEL JP, 1986, J BIOL CHEM, V261, P895; KAMLET MJ, 1977, J AM CHEM SOC, V99, P6027, DOI 10.1021/ja00460a031; KAUFFMAN RF, 1978, BIOCHEMISTRY-US, V17, P3686, DOI 10.1021/bi00611a002; KNAUER BR, 1976, J AM CHEM SOC, V98, P4395, DOI 10.1021/ja00431a010; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE RSF, 1991, BIOCHEMISTRY-US, V30, P6842, DOI 10.1021/bi00242a006; LEONARD NJ, 1978, BIOCHEMISTRY-US, V17, P3677, DOI 10.1021/bi00611a001; LEONARD NJ, 1976, J AM CHEM SOC, V98, P3987, DOI 10.1021/ja00429a040; LUNARDI J, 1987, J BIOL CHEM, V262, P15172; MILLER GL, 1959, ANAL CHEM, V31, P964, DOI 10.1021/ac60149a611; PARSONAGE D, 1987, J BIOL CHEM, V262, P8022; PENEFSKY HS, 1977, J BIOL CHEM, V252, P2891; PEREZ JA, 1986, FEBS LETT, V198, P113, DOI 10.1016/0014-5793(86)81195-4; PERLIN DS, 1983, J BIOL CHEM, V258, P9793; RAO R, 1988, J BIOL CHEM, V263, P5569; RAO R, 1988, J BIOL CHEM, V263, P15957; SENIOR AE, 1983, BIOCHEM J, V210, P395, DOI 10.1042/bj2100395; SENIOR AE, 1979, BIOCHEM J, V180, P111, DOI 10.1042/bj1800111; SENIOR AE, 1984, ARCH BIOCHEM BIOPHYS, V228, P49, DOI 10.1016/0003-9861(84)90045-6; SENIOR AE, 1988, PHYSIOL REV, V68, P177, DOI 10.1152/physrev.1988.68.1.177; SENIOR AE, 1983, J MEMBRANE BIOL, V73, P105, DOI 10.1007/BF01870434; SENIOR AE, 1979, BIOCHEM J, V180, P103, DOI 10.1042/bj1800103; SENIOR AE, 1990, ANNU REV BIOPHYS BIO, V19, P7; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SUTTON R, 1985, EUR J BIOCHEM, V148, P551, DOI 10.1111/j.1432-1033.1985.tb08875.x; VANDERLIJN P, 1978, P NATL ACAD SCI USA, V75, P4204, DOI 10.1073/pnas.75.9.4204; VANDEYAR MA, 1988, GENE, V65, P129, DOI 10.1016/0378-1119(88)90425-8; VANVELDHOVEN PP, 1987, ANAL BIOCHEM, V161, P45, DOI 10.1016/0003-2697(87)90649-X; WEBER J, 1990, J BIOL CHEM, V265, P10884; WISE JG, 1981, J BIOL CHEM, V256, P383; WISE JG, 1987, FEBS LETT, V223, P395, DOI 10.1016/0014-5793(87)80326-5; WISE JG, 1990, J BIOL CHEM, V265, P10403; WU JC, 1987, J BIOL CHEM, V262, P5145; [No title captured]	50	70	71	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 25	1992	267	3					1712	1718						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HA485	1530942				2022-12-25	WOS:A1992HA48500050
J	MATSUMOTO, K; TAJIMA, H; OKAZAKI, H; NAKAMURA, T				MATSUMOTO, K; TAJIMA, H; OKAZAKI, H; NAKAMURA, T			NEGATIVE REGULATION OF HEPATOCYTE GROWTH-FACTOR GENE-EXPRESSION IN HUMAN LUNG FIBROBLASTS AND LEUKEMIC-CELLS BY TRANSFORMING GROWTH FACTOR-BETA-1 AND GLUCOCORTICOIDS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							SCATTER FACTOR; FACTOR-BETA; EPITHELIAL-CELLS; RAT PLATELETS; MESSENGER-RNA; LIVER-REGENERATION; MOLECULAR-CLONING; HEPATOPOIETIN-A; DNA-SYNTHESIS; PURIFICATION	Hepatocyte growth factor (HGF), a mesenchymal-derived factor which regulates growth, motility, and morphogenesis of epithelial and endothelial cells, functions as a hepatotrophic and renotrophic factor for regeneration of the liver and kidney. We have now obtained evidence that transforming growth factor-beta1 (TGF-beta1) and glucocorticoids are negative regulators for HGF gene expression. When TGF-beta1 or dexamethasone was added to cultures of MRC-5 human embryonic lung fibroblasts and HL-60 human promyelocytic leukemic cells, the amount of HGF secreted into the culture medium was inhibited to 30-40% of that of control cultures by 10 ng/ml TGF-beta1 and to 40-50% by 10(-6) M dexamethasone. The inhibitory effect of TGF-beta1 and dexamethasone on HGF synthesis in MRC-5 cells was additive, thereby suggesting that TGF-beta1 and dexamethasone exert effects through distinct mechanisms. Hydrocortisone also inhibited HGF synthesis with the same potency as dexamethasone; however, testosterone, estriol, and beta-estradiol had no effect. The rate of HGF synthesis in MRC-5 cells, as measured by pulse labeling with [S-35]methionine and subsequent immunoprecipitation, was suppressed to 30-40% of the control with 10 ng/ml TGF-beta1, and to 30-45% by 10(-6) M dexamethasone. HGF mRNA levels in MRC-5 cells and HL-60 cells were dose-dependently suppressed by TGF-beta1 and dexamethasone; 10 ng/ml TGF-beta1 suppressed HGF mRNA levels to 32% and 35% of control culture, respectively, in MRC-5 cells and HL-60 cells, and 10(-6) M dexamethasone suppressed to 43% and 38%, respectively. Thus, TGF-beta1 and glucocorticoids seem to inhibit HGF synthesis by suppressing the expression of the HGF gene. We propose that a negative regulation of HGF gene expression by TGF-beta1 or glucocorticoids may be involved in physiological or pathological processes during tissue regeneration.	KYUSHU UNIV,FAC SCI,DEPT BIOL,FUKUOKA 812,JAPAN; PRESTO,RES DEV CORP JAPAN,CELL & INFORMAT GRP,KYOTO 600,JAPAN	Kyushu University; Japan Science & Technology Agency (JST)								ASAMI O, 1991, J BIOCHEM-TOKYO, V109, P8; BARNARD JA, 1990, BIOCHIM BIOPHYS ACTA, V1032, P79, DOI 10.1016/0304-419X(90)90013-Q; BOTTARO DP, 1991, SCIENCE, V254, P1382; BRAUN L, 1988, P NATL ACAD SCI USA, V85, P1539, DOI 10.1073/pnas.85.5.1539; BUCHER NLR, 1963, INT REV CYTOL, V15, P245, DOI 10.1016/S0074-7696(08)61119-5; CARR BI, 1986, CANCER RES, V46, P2330; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CZAJA MJ, 1989, J CELL BIOL, V108, P2477, DOI 10.1083/jcb.108.6.2477; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; FURLONG RA, 1991, J CELL SCI, V100, P173; GHERARDI E, 1991, CANCER CELL-MON REV, V3, P227; GHERARDI E, 1990, NATURE, V346, P228, DOI 10.1038/346228b0; GOHDA E, 1988, J CLIN INVEST, V81, P414, DOI 10.1172/JCI113334; GUMBINER BM, 1992, CELL, V69, P385, DOI 10.1016/0092-8674(92)90440-N; HIGASHIO K, 1990, BIOCHEM BIOPH RES CO, V170, P397, DOI 10.1016/0006-291X(90)91287-3; HIGUCHI O, 1992, FEBS LETT, V301, P282, DOI 10.1016/0014-5793(92)80257-H; IGAWA T, 1991, BIOCHEM BIOPH RES CO, V174, P831, DOI 10.1016/0006-291X(91)91493-V; IGNOTZ RA, 1987, J BIOL CHEM, V262, P6443; ISHIKI Y, 1992, IN PRESS HEPATOLOGY; KAMALATI T, 1991, J CELL SCI, V101, P323; KAN M, 1991, BIOCHEM BIOPH RES CO, V174, P331, DOI 10.1016/0006-291X(91)90524-B; KONISHI T, 1991, BIOCHEM BIOPH RES CO, V180, P765, DOI 10.1016/S0006-291X(05)81131-3; MATSUMOTO K, 1991, EXP CELL RES, V196, P114, DOI 10.1016/0014-4827(91)90462-4; MATSUMOTO K, 1992, P NATL ACAD SCI USA, V89, P3800, DOI 10.1073/pnas.89.9.3800; MATSUMOTO K, 1991, J GASTROEN HEPATOL, V6, P509, DOI 10.1111/j.1440-1746.1991.tb00897.x; MATSUMOTO K, 1992, IN PRESS BIOCH BIOPH; MATSUMOTO K, 1992, Critical Reviews in Oncogenesis, V3, P27; MCMAHON JB, 1986, CANCER RES, V46, P4665; MIYAZAWA K, 1989, BIOCHEM BIOPH RES CO, V163, P967, DOI 10.1016/0006-291X(89)92316-4; MONTESANO R, 1991, CELL, V66, P697, DOI 10.1016/0092-8674(91)90115-F; MONTESANO R, 1991, CELL, V67, P901, DOI 10.1016/0092-8674(91)90363-4; MORIMOTO A, 1991, BIOCHEM BIOPH RES CO, V179, P1042, DOI 10.1016/0006-291X(91)91924-2; NAGAIKE M, 1991, J BIOL CHEM, V266, P22781; NAKAMURA T, 1985, BIOCHEM BIOPH RES CO, V133, P1042, DOI 10.1016/0006-291X(85)91241-0; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; NAKAMURA T, 1986, P NATL ACAD SCI USA, V83, P6489, DOI 10.1073/pnas.83.17.6489; NAKAMURA T, 1991, Progress in Growth Factor Research, V3, P67, DOI 10.1016/0955-2235(91)90014-U; NAKAMURA T, 1987, FEBS LETT, V224, P311, DOI 10.1016/0014-5793(87)80475-1; NAKAMURA T, 1984, BIOCHEM BIOPH RES CO, V122, P1450, DOI 10.1016/0006-291X(84)91253-1; NALDINI L, 1991, ONCOGENE, V6, P501; NALDINI L, 1991, EMBO J, V10, P2867, DOI 10.1002/j.1460-2075.1991.tb07836.x; NOJI S, 1990, BIOCHEM BIOPH RES CO, V173, P42, DOI 10.1016/S0006-291X(05)81018-6; OKADA F, 1989, J BIOCHEM-TOKYO, V106, P304, DOI 10.1093/oxfordjournals.jbchem.a122849; ROBERTS AB, 1986, P NATL ACAD SCI USA, V83, P4167, DOI 10.1073/pnas.83.12.4167; RUBIN JS, 1991, P NATL ACAD SCI USA, V88, P415, DOI 10.1073/pnas.88.2.415; RUSSELL WE, 1984, J CELL PHYSIOL, V119, P183, DOI 10.1002/jcp.1041190207; RUSSELL WE, 1988, P NATL ACAD SCI USA, V85, P5126, DOI 10.1073/pnas.85.14.5126; SEKI T, 1990, BIOCHEM BIOPH RES CO, V172, P321, DOI 10.1016/S0006-291X(05)80212-8; SHIOTA G, 1992, P NATL ACAD SCI USA, V89, P373, DOI 10.1073/pnas.89.1.373; SHIPLEY GD, 1985, P NATL ACAD SCI USA, V82, P4147, DOI 10.1073/pnas.82.12.4147; SPORN MB, 1987, J CELL BIOL, V105, P1039, DOI 10.1083/jcb.105.3.1039; TAJIMA H, 1991, FEBS LETT, V291, P229, DOI 10.1016/0014-5793(91)81291-F; TASHIRO K, 1990, P NATL ACAD SCI USA, V87, P3200, DOI 10.1073/pnas.87.8.3200; WEIDNER KM, 1990, J CELL BIOL, V111, P2097, DOI 10.1083/jcb.111.5.2097; WEIDNER KM, 1991, P NATL ACAD SCI USA, V88, P7001, DOI 10.1073/pnas.88.16.7001; YANAGITA K, 1992, BIOCHEM BIOPH RES CO, V182, P802, DOI 10.1016/0006-291X(92)91803-X; ZARNEGAR R, 1989, CANCER RES, V49, P3314	57	158	162	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1992	267	35					24917	24920						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KB603	1459995				2022-12-25	WOS:A1992KB60300002
J	OSTHEIMER, GJ; STARKEY, JR; LAMBERT, CG; HELGERSON, SL; DRATZ, EA				OSTHEIMER, GJ; STARKEY, JR; LAMBERT, CG; HELGERSON, SL; DRATZ, EA			NMR CONSTRAINED SOLUTION STRUCTURES FOR LAMININ PEPTIDE-11 - ANALOGS DEFINE STRUCTURAL REQUIREMENTS FOR INHIBITION OF TUMOR-CELL INVASION OF BASEMENT-MEMBRANE MATRIX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SECONDARY STRUCTURE; HEPARIN-BINDING; WATER SOLUTION; ADHESION; SPECTROSCOPY; PENTAPEPTIDE; PROTEINS; FRAGMENTS; DOMAINS; CONFORMATIONS	Peptide 11, CDPGYIGSR-NH2, is a segment of laminin which blocks tumor cell invasion. A high affinity laminin receptor in tumor cells is thought to be blocked by the carboxyl-terminal YIGSR, and conformational energy calculations suggest that the glycine in YIGSR allows an important conformational bend. We replaced the YIGSR glycine residue in peptide 11 with either D-alanine or L-alanine to allow or disfavor the proposed glycine bend. We found the Gly7 --> D-Ala7 analog to be equal to peptide 11 in inhibiting tumor cell invasion of basement membrane matrix. The Gly7 --> L-Ala7 analog was much less capable of invasion inhibition. Two-dimensional H-1-H-1 NMR was used to study the solution conformations of the peptide 11 analogs. NOESY experiments revealed close NH-NH contacts in peptide 11 and the D-Ala7 analog, but not in the L-Ala7 analog. Molecular dynamics generated low energy structures with excellent NOE agreement for peptide 11 and its analogs. Both peptide 11 and the D-Ala7 analog, but not the less active L-Ala7 analog, were predicted to have similar bends around Gly7 or D-Ala7. These results suggest that a bend in the YIGSR region of peptide 11 may be important for the binding of laminin to its metastasis-associated receptor.	MONTANA STATE UNIV, DEPT CHEM & BIOCHEM, BOZEMAN, MT 59717 USA; MONTANA STATE UNIV, DEPT MICROBIOL, BOZEMAN, MT 59717 USA	Montana State University System; Montana State University Bozeman; Montana State University System; Montana State University Bozeman			Lambert, Christophe/AAH-4448-2021	Lambert, Christophe/0000-0003-1994-2893	NEI NIH HHS [R01 EY06913] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY006913] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		BASUS VJ, 1989, METHOD ENZYMOL, V177, P132; BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; BAX A, 1985, J MAGN RESON, V63, P207, DOI 10.1016/0022-2364(85)90171-4; BODENHAUSEN G, 1980, J MAGN RESON, V37, P93, DOI 10.1016/0022-2364(80)90096-7; BOTHNERBY AA, 1984, J AM CHEM SOC, V106, P811, DOI 10.1021/ja00315a069; BRANDTRAUF PW, 1989, J PROTEIN CHEM, V8, P149, DOI 10.1007/BF01025085; BUNDI A, 1979, BIOPOLYMERS, V18, P285, DOI 10.1002/bip.1979.360180206; BURKE C, 1991, J BIOL CHEM, V266, P19407; CHARONIS AS, 1988, J CELL BIOL, V107, P1253, DOI 10.1083/jcb.107.3.1253; DYSON HJ, 1988, J MOL BIOL, V201, P161, DOI 10.1016/0022-2836(88)90446-9; DYSON HJ, 1988, J MOL BIOL, V201, P201, DOI 10.1016/0022-2836(88)90447-0; GRAF J, 1987, BIOCHEMISTRY-US, V26, P6896, DOI 10.1021/bi00396a004; GRAF J, 1987, CELL, V48, P989, DOI 10.1016/0092-8674(87)90707-0; GRANT DS, 1989, CELL, V58, P933, DOI 10.1016/0092-8674(89)90945-8; GRATHWOHL C, 1981, BIOPOLYMERS, V20, P2623, DOI 10.1002/bip.1981.360201209; IWAMOTO Y, 1987, SCIENCE, V238, P1132, DOI 10.1126/science.2961059; JEENER J, 1979, J CHEM PHYS, V71, P4546, DOI 10.1063/1.438208; KLEINMAN HK, 1985, J CELL BIOCHEM, V27, P317, DOI 10.1002/jcb.240270402; KRAMER RH, 1991, CANCER METAST REV, V10, P49, DOI 10.1007/BF00046843; MARION D, 1989, J MAGN RESON, V84, P425, DOI 10.1016/0022-2364(89)90391-0; MARION D, 1988, J MAGN RESON, V79, P352, DOI 10.1016/0022-2364(88)90230-2; MAYO KH, 1991, BIOCHEMISTRY-US, V30, P8251, DOI 10.1021/bi00247a022; MCKELVEY DR, 1991, J PROTEIN CHEM, V10, P265, DOI 10.1007/BF01025625; MECHAM RP, 1991, FASEB J, V5, P2538, DOI 10.1096/fasebj.5.11.1651264; NI F, 1989, BIOCHEMISTRY-US, V28, P3082, DOI 10.1021/bi00433a052; PANAYOTOU G, 1989, CELL, V56, P93, DOI 10.1016/0092-8674(89)90987-2; PLATEAU P, 1982, J AM CHEM SOC, V104, P7310, DOI 10.1021/ja00389a067; POSTE G, 1980, CANCER RES, V40, P1636; RAMOS DM, 1991, INVAS METAST, V11, P125; REED J, 1988, EUR J BIOCHEM, V178, P141, DOI 10.1111/j.1432-1033.1988.tb14439.x; REPESH LA, 1989, INVAS METAST, V9, P192; SKUBITZ APN, 1988, J BIOL CHEM, V263, P4861; STARKEY JR, 1990, CANCER METAST REV, V9, P113, DOI 10.1007/BF00046338; WRIGHT PE, 1988, BIOCHEMISTRY-US, V27, P7167, DOI 10.1021/bi00419a001; WUTHRICK K, 1986, NMR PROTEINS NUCLEIC	35	21	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	1992	267	35					25120	25128						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KB603	1460013				2022-12-25	WOS:A1992KB60300034
J	SHANAFELT, AB; KASTELEIN, RA				SHANAFELT, AB; KASTELEIN, RA			HIGH-AFFINITY LIGAND-BINDING IS NOT ESSENTIAL FOR GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR RECEPTOR ACTIVATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GM-CSF RECEPTOR; HUMAN INTERLEUKIN-4; EXPRESSION CLONING; DELETION ANALYSIS; ESCHERICHIA-COLI; CRITICAL REGIONS; GROWTH-HORMONE; GENE FAMILY; IDENTIFICATION; SUBUNIT	The high affinity receptor of the cytokine granulocyte-macrophage colony-stimulating factor (GM-CSF) is a heterodimer composed of two members of the cytokine receptor superfamily. GM-CSF binds to the alpha-subunit (GM-Ralpha) with low affinity and to the receptor alphabeta complex (GM-Ralphabeta) with high affinity. The GM-CSF.GM-Ralphabeta complex is responsible for biological activity. Interactions of the N-terminal helix of mouse GM-CSF with mGM-Ralphabeta were examined by introducing single alanine substitutions of hydrophilic residues in this region of mGM-CSF. The consequences of these substitutions were evaluated by receptor binding and biological assays. Although all mutant proteins exhibited near wild-type biological activity, most were defective in high affinity receptor binding. In particular, substitution of Glu-21 with alanine abrogated high affinity binding leaving low affinity binding unaffected. Despite near wild-type biological activity, no detectable binding interaction of this mutant with mGM-Rbeta in the context of mGM-Ralphabeta was observed. Cross-linking studies showed an apparent interaction of this mutant protein with mGM-Ralphabeta. The deficient receptor binding characteristics and near wild-type biological activity of this mutant protein demonstrate that mGM-CSF receptor activation can occur independently of high affinity binding, suggesting that conformational changes in the receptor induced by mGM-CSF binding generate an active ligand-receptor complex.			SHANAFELT, AB (corresponding author), DNAX RES INST MOLEC & CELLULAR BIOL INC, DEPT MOLEC BIOL, 901 CALIF AVE, PALO ALTO, CA 94304 USA.							ABDELMEGUID SS, 1987, P NATL ACAD SCI USA, V84, P6434, DOI 10.1073/pnas.84.18.6434; ARIMA N, 1991, J IMMUNOL, V147, P3396; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; CUNNINGHAM BC, 1991, SCIENCE, V254, P821, DOI 10.1126/science.1948064; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; DIEDERICHS K, 1991, SCIENCE, V254, P1779, DOI 10.1126/science.1837174; GEARING DP, 1989, EMBO J, V8, P3667, DOI 10.1002/j.1460-2075.1989.tb08541.x; GORMAN DM, 1990, P NATL ACAD SCI USA, V87, P5459, DOI 10.1073/pnas.87.14.5459; GOUGH NM, 1985, EMBO J, V4, P645, DOI 10.1002/j.1460-2075.1985.tb03678.x; GREENBERG R, 1988, CURR MICROBIOL, V17, P321, DOI 10.1007/BF01570872; HAYASHIDA K, 1990, P NATL ACAD SCI USA, V87, P9655, DOI 10.1073/pnas.87.24.9655; HOWARDFLANDERS P, 1964, GENETICS, V49, P237; IDZERDA RL, 1990, J EXP MED, V171, P861, DOI 10.1084/jem.171.3.861; ITOH N, 1990, SCIENCE, V247, P324, DOI 10.1126/science.2404337; KITAMURA T, 1991, CELL, V66, P1165, DOI 10.1016/0092-8674(91)90039-2; KITAMURA T, 1991, P NATL ACAD SCI USA, V88, P5082, DOI 10.1073/pnas.88.12.5082; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOPEZ AF, 1992, EMBO J, V11, P909, DOI 10.1002/j.1460-2075.1992.tb05129.x; LUNDELL D, 1990, J IND MICROBIOL, V5, P215, DOI 10.1007/BF01569679; MEROPOL NJ, 1992, J BIOL CHEM, V267, P14266; MESSING J, 1983, METHOD ENZYMOL, V101, P20; METCALF D, 1986, BLOOD, V67, P257; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; MUNSON PJ, 1983, METHOD ENZYMOL, V92, P543; PARK LS, 1992, P NATL ACAD SCI USA, V89, P4295, DOI 10.1073/pnas.89.10.4295; REDFIELD C, 1991, BIOCHEMISTRY-US, V30, P11029, DOI 10.1021/bi00110a004; RENNICK D, 1987, P NATL ACAD SCI USA, V84, P6889, DOI 10.1073/pnas.84.19.6889; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEGEL IH, 1976, BIOCH CALCULATIONS, V334; SHANAFELT AB, 1991, J BIOL CHEM, V266, P13804; SHANAFELT AB, 1991, EMBO J, V10, P4105, DOI 10.1002/j.1460-2075.1991.tb04987.x; SHANAFELT AB, 1989, P NATL ACAD SCI USA, V86, P4872, DOI 10.1073/pnas.86.13.4872; SMITH LJ, 1992, J MOL BIOL, V224, P899, DOI 10.1016/0022-2836(92)90457-U; ZURAWSKI SM, 1988, EMBO J, V7, P1061, DOI 10.1002/j.1460-2075.1988.tb02914.x	35	45	47	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	1992	267	35					25466	25472						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KB603	1460041				2022-12-25	WOS:A1992KB60300084
J	GHOSN, CR; RAL, BBA; WINOKUR, ST; UNGER, TF; STEELE, RE				GHOSN, CR; RAL, BBA; WINOKUR, ST; UNGER, TF; STEELE, RE			STRUCTURAL ORGANIZATION OF A SRC GENE FROM XENOPUS-LAEVIS	ONCOGENE			English	Note							MURINE HCK GENE; C-SRC; NUCLEOTIDE-SEQUENCE; PROTO-ONCOGENE; CHLORAMPHENICOL ACETYLTRANSFERASE; EUKARYOTIC RIBOSOMES; SECONDARY STRUCTURE; MAMMALIAN-CELLS; MESSENGER-RNA; FYN GENES	By sequence analysis of genomic clones, the exon-intron structure of one of the two src genes from Xenopus laevis has been determined. The coding region of the gene is interrupted by 10 introns whose locations are identical to the introns in the coding regions of the src genes of human and chicken. The 5' untranslated region is contained on a separate exon with no sequence conservation relative to the corresponding region of the chicken gene. The 5' untranslated region of the Xenopus gene contains a G + C-rich stem-loop sequence and two ATG triplets. A 1.4-kb fragment containing the 5' untranslated region and sequences upstream of it acts as a promoter when introduced in the correct orientation into X. laevis cell lines. The DNA sequence of this fragment lacks the typical arrangement of TATA and CCAAT sequences but contains the ATGCAAAT octamer sequence and a (TA)39 sequence.	UNIV CALIF IRVINE,DEPT BIOL CHEM,IRVINE,CA 92717; UNIV CALIF IRVINE,CTR DEV BIOL,IRVINE,CA 92717	University of California System; University of California Irvine; University of California System; University of California Irvine								ANDERSON SK, 1985, MOL CELL BIOL, V5, P1122, DOI 10.1128/MCB.5.5.1122; BOSCH TCG, 1989, MOL CELL BIOL, V9, P4141, DOI 10.1128/MCB.9.10.4141; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; CHIEN YH, 1984, MOL CELL BIOL, V4, P507, DOI 10.1128/MCB.4.3.507; CHU G, 1987, NUCLEIC ACIDS RES, V15, P1311, DOI 10.1093/nar/15.3.1311; CILIBERTO G, 1985, EMBO J, V4, P1537, DOI 10.1002/j.1460-2075.1985.tb03814.x; COLLETT JW, 1992, IN PRESS DEV BIOL; Cooper J.A, 1990, PEPT PROT PHOSPH, P85; COTTON PC, 1983, MOL CELL BIOL, V3, P1157, DOI 10.1128/MCB.3.6.1157; CRABB DW, 1987, ANAL BIOCHEM, V163, P88, DOI 10.1016/0003-2697(87)90096-0; DORAI T, 1991, MOL CELL BIOL, V11, P4165, DOI 10.1128/MCB.11.8.4165; GARVIN AM, 1988, MOL CELL BIOL, V8, P3058, DOI 10.1128/MCB.8.8.3058; GONDA TJ, 1982, MOL CELL BIOL, V2, P617, DOI 10.1128/MCB.2.6.617; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GREAVES DR, 1985, EMBO J, V4, P2617, DOI 10.1002/j.1460-2075.1985.tb03979.x; GREAVES DR, 1985, J MOL BIOL, V185, P461, DOI 10.1016/0022-2836(85)90064-6; GROSS DS, 1988, ANNU REV BIOCHEM, V57, P159, DOI 10.1146/annurev.bi.57.070188.001111; GUTKIND JS, 1991, MOL CELL BIOL, V11, P1500, DOI 10.1128/MCB.11.3.1500; HANIFORD DB, 1985, NUCLEIC ACIDS RES, V13, P4343, DOI 10.1093/nar/13.12.4343; HANNIG G, 1991, ONCOGENE, V6, P361; HOFFMANN FM, 1983, CELL, V35, P393, DOI 10.1016/0092-8674(83)90172-1; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KOZAK M, 1987, MOL CELL BIOL, V7, P3438, DOI 10.1128/MCB.7.10.3438; KOZAK M, 1986, P NATL ACAD SCI USA, V83, P2850, DOI 10.1073/pnas.83.9.2850; LEVY JB, 1987, MOL CELL BIOL, V7, P4142, DOI 10.1128/MCB.7.11.4142; LOCK P, 1990, MOL CELL BIOL, V10, P4603, DOI 10.1128/MCB.10.9.4603; MARTINEZ R, 1987, SCIENCE, V237, P411, DOI 10.1126/science.2440106; MATSUZAWA Y, 1991, ONCOGENE, V6, P1561; MATTAJ IW, 1985, NATURE, V316, P163, DOI 10.1038/316163a0; MURPHY JT, 1982, CELL, V29, P265, DOI 10.1016/0092-8674(82)90111-8; NECKAMEYER WS, 1986, MOL CELL BIOL, V6, P1478, DOI 10.1128/MCB.6.5.1478; PATEL M, 1990, ONCOGENE, V5, P201; PYPER JM, 1989, J NEUROSCI RES, V24, P89, DOI 10.1002/jnr.490240113; RAFFERTY KA, 1969, BIOL AMPHIBIAN TUMOR, P52; RAULF F, 1989, J NEUROSCI RES, V24, P81, DOI 10.1002/jnr.490240112; SCHARTL M, 1989, ONCOGENE, V4, P1185; SIMON MA, 1985, CELL, V42, P831, DOI 10.1016/0092-8674(85)90279-X; SIVE HL, 1986, MOL CELL BIOL, V6, P3329, DOI 10.1128/MCB.6.10.3329; STEELE RE, 1985, NUCLEIC ACIDS RES, V13, P1747, DOI 10.1093/nar/13.5.1747; STEELE RE, 1989, J BIOL CHEM, V264, P10649; STEELE RE, 1989, ONCOGENE RES, V4, P223; STEELE RE, 1990, ONCOGENE, V5, P369; SUDOL M, 1986, MOL CELL BIOL, V6, P2839, DOI 10.1128/MCB.6.8.2839; TAKEYA T, 1983, CELL, V32, P881, DOI 10.1016/0092-8674(83)90073-9; TANAKA A, 1987, MOL CELL BIOL, V7, P1978, DOI 10.1128/MCB.7.5.1978; TINOCO I, 1973, NATURE-NEW BIOL, V246, P40, DOI 10.1038/newbio246040a0; VORONOVA AF, 1987, MOL CELL BIOL, V7, P4407, DOI 10.1128/MCB.7.12.4407; WIRTH T, 1987, NATURE, V329, P174, DOI 10.1038/329174a0; ZIEGLER SF, 1991, ONCOGENE, V6, P283	49	3	3	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1992	7	11					2345	2350						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JW665	1437158				2022-12-25	WOS:A1992JW66500030
J	WU, AM; LIN, SR; CHIN, LK; CHOW, LP; LIN, JY				WU, AM; LIN, SR; CHIN, LK; CHOW, LP; LIN, JY			DEFINING THE CARBOHYDRATE SPECIFICITIES OF ABRUS-PRECATORIUS AGGLUTININ AS T (GAL-BETA-1-]3GALNAC) GREATER-THAN I/II (GAL-BETA-1-]3/4GLCNAC)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA ALPHA-1-ACID GLYCOPROTEIN; 500-MHZ H-1-NMR SPECTROSCOPY; OVINE SUBMAXILLARY MUCINS; BLOOD-GROUP; PERMETHYLATION ANALYSIS; OLIGOSACCHARIDES; LECTINS; SUBSTANCE; FETUIN; UNITS	The combining site of the nontoxic carbohydrate binding protein (Abrus precatorius agglutinin, APA) purified from the needs of Abrus precatorius (Jequirity bean), was studied by quantitative precipitin and precipitin-inhibition assays. Of 26 glycoproteins and polysaccharides tested, all, except sialic acid-containing glycoproteins and desialized ovine salivary glycoproteins, reacted strongly with the lectin, and precipitated over 70% of the lectin added, indicating that APA has a broad range of affinity and recognizes (internal) Galbeta1 --> sequences of carbohydrate chains. The strong reaction with desialized porcine and rat salivary glycoproteins as well as pneumococcus type XIV polysaccharide suggests that APA has affinity for one or more of the following carbohydrate sequences: Thomsen-Friedenreich (T, Galbeta1-->3GalNAc), blood group precursor type I and/or type II (Galbeta1-->3/4GlcNAc) disaccharide determinants of complex carbohydrates. Among the oligosaccharides tested, the T structure was the best inhibitor; it was 2.4 and 3.2 times more active than type II and type I sequences, respectively. The blood group I Ma-active trisaccharide, Galbeta1-->1 4GlcNAcbeta1-->6Gal, was about as active as the corresponding disaccharide (II). From the above results, we conclude that the size of the combining site of the A. precatorius agglutinin is probably as large as a disaccharide and most strongly complementary to the Galbeta1-->3GalNAc (T determinant) sequence. The carbohydrate specificities of this lectin will be further investigated once the related oligosaccharide structures become available.	NATL TAIWAN UNIV, COLL MED, INST BIOCHEM, TAIPEI, TAIWAN	National Taiwan University	WU, AM (corresponding author), CHANG GUNG MED COLL, INST MOLEC & CELLULAR BIOL, GLYCOIMMUNOCHEM RES LAB, KWEI SAN, TAOYUAN 33332, TAIWAN.		Lin, Jung-Yaw/AGW-9336-2022	Lin, Jung-Yaw/0000-0002-6341-1160; CHOW, LU-PING/0000-0002-4420-211X				ALLEN PZ, 1959, J IMMUNOL, V82, P340; BEISER SM, 1952, J IMMUNOL, V68, P19; BERTOLINI M, 1970, CARBOHYD RES, V14, P53, DOI 10.1016/S0008-6215(00)80699-0; BRILES EB, 1977, J BIOL CHEM, V252, P1107; CARLSON DM, 1968, J BIOL CHEM, V243, P616; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; DEREVITSKAYA VA, 1978, EUR J BIOCHEM, V86, P423, DOI 10.1111/j.1432-1033.1978.tb12325.x; DEVRIES AL, 1970, J BIOL CHEM, V245, P2901; EDGE ASB, 1987, J BIOL CHEM, V262, P16135; FOURNET B, 1978, BIOCHEMISTRY-US, V17, P5206, DOI 10.1021/bi00617a021; GALLAGHER JT, 1984, BIOSCIENCE REP, V4, P621, DOI 10.1007/BF01121015; Goldstein I., 1986, LECTINS, DOI DOI 10.1016/B978-0-12-449945-4.50007-5; GRAHAM ERB, 1972, GLYCOPROTEINS, P717; Herp A., 1988, Advances in Experimental Medicine and Biology, V228, P395; HOWE C, 1959, J AM CHEM SOC, V80, P6656, DOI 10.1021/ja01557a049; Kabat E A, 1961, EXPT IMMUNOCHEMISTRY; KABAT EA, 1948, J EXP MED, V88, P43, DOI 10.1084/jem.88.1.43; KABAT EA, 1956, BLOOD GROUP SUBSTANC, P135; Kabat EA, 1976, STRUCTURAL CONCEPTS, V2nd; Kristiansen T, 1974, Methods Enzymol, V34, P331; LESKOWITZ S, 1954, J AM CHEM SOC, V76, P5060, DOI 10.1021/ja01649a015; LIN JY, 1970, CANCER RES, V30, P2431; LIN JY, 1981, TOXICON, V19, P41; LINDBERG B, 1977, CARBOHYD RES, V58, P177, DOI 10.1016/S0008-6215(00)83413-8; LIS H, 1986, ANNU REV BIOCHEM, V55, P35, DOI 10.1146/annurev.bi.55.070186.000343; Lis H., 1977, ANTIGENS, V4, P429; LLOYD KO, 1968, BIOCHEMISTRY-US, V7, P2976, DOI 10.1021/bi00848a039; LLOYD KO, 1968, P NATL ACAD SCI USA, V61, P1470, DOI 10.1073/pnas.61.4.1470; MAISONROUGEMCAULIFFE F, 1976, ARCH BIOCHEM BIOPHYS, V175, P81, DOI 10.1016/0003-9861(76)90487-2; MAISONROUGEMCAULIFFEF, 1976, ARCH BIOCHEM BIOPHYS, V175, P71; MAKELA O, 1957, ANN MED EXP BIOL FEN, V35, P7; MOSCHERA J, 1975, CARBOHYD RES, V40, P53, DOI 10.1016/S0008-6215(00)82668-3; MUTSAERS JHGM, 1986, EUR J BIOCHEM, V157, P139, DOI 10.1111/j.1432-1033.1986.tb09649.x; NICOLSON GL, 1974, INT REV CYTOL, V39, P89, DOI 10.1016/S0074-7696(08)60939-0; NILSSON B, 1979, J BIOL CHEM, V254, P4545; OLSNES S, METHOD ENZYMOL, V50, P323; PEREIRA M E A, 1979, Critical Reviews in Immunology, V1, P33; PEREIRA MEA, 1976, CARBOHYD RES, V51, P107; PEREIRA MEA, 1976, J EXP MED, V143, P422, DOI 10.1084/jem.143.2.422; PROKOP O, 1965, HUMAN BLOOD SERUM GR; Race RR., 1975, BLOOD GROUPS MAN; REISNER Y, 1979, P NATL ACAD SCI USA, V76, P447, DOI 10.1073/pnas.76.1.447; RICHARDS RL, 1979, P NATL ACAD SCI USA, V76, P1673, DOI 10.1073/pnas.76.4.1673; SARKAR M, 1981, ARCH BIOCHEM BIOPHYS, V209, P204, DOI 10.1016/0003-9861(81)90273-3; SAVAGE AV, 1986, EUR J BIOCHEM, V160, P123, DOI 10.1111/j.1432-1033.1986.tb09948.x; SCHIFFMAN G, 1964, BIOCHEMISTRY-US, V3, P113, DOI 10.1021/bi00889a018; SCHMID K, 1979, BIOCHIM BIOPHYS ACTA, V581, P356, DOI 10.1016/0005-2795(79)90255-1; SLOMIANY A, 1978, J BIOL CHEM, V253, P7301; SLOMIANY BL, 1973, J BIOL CHEM, V248, P2290; SMITH DF, 1989, METHOD ENZYMOL, V179, P30; SPIRO RG, 1974, J BIOL CHEM, V249, P5704; STANLEY P, 1980, BIOCH GLYCOPROTEINS, P161; STANLEY WS, 1979, P NATL ACAD SCI USA, V76, P303, DOI 10.1073/pnas.76.1.303; TETTAMANTI G, 1968, ARCH BIOCHEM BIOPHYS, V124, P41, DOI 10.1016/0003-9861(68)90301-9; TOWNSEND RR, 1986, BIOCHEMISTRY-US, V25, P5716, DOI 10.1021/bi00367a055; VANHALBEEK H, 1981, EUR J BIOCHEM, V118, P487; VANHALBEEK H, 1982, EUR J BIOCHEM, V127, P21; VICARI G, 1970, IMMUNOCHEMISTRY, V7, P829, DOI 10.1016/0019-2791(70)90059-5; Watkins W M, 1980, Adv Hum Genet, V10, P1; Watkins W. M, 1972, GLYCOPROTEINS, V5, P830; WEI CH, 1975, J BIOL CHEM, V250, P4790; Wu A M, 1988, Adv Exp Med Biol, V228, P205; Wu A M, 1988, Adv Exp Med Biol, V228, P351; WU AM, 1980, ARCH BIOCHEM BIOPHYS, V204, P622, DOI 10.1016/0003-9861(80)90074-0; WU AM, 1988, CARBOHYD RES, V178, P243, DOI 10.1016/0008-6215(88)80116-2; WU AM, 1991, CARBOHYD RES, V213, P127, DOI 10.1016/S0008-6215(00)90604-9; WU AM, 1984, MOL CELL BIOCHEM, V61, P131; WU AM, 1982, ARCH BIOCHEM BIOPHYS, V215, P390, DOI 10.1016/0003-9861(82)90099-6; WU AM, 1984, J BIOL CHEM, V259, P7178; YAMAMOTO K, 1981, BIOCHEM J, V195, P701, DOI 10.1042/bj1950701	71	65	65	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 25	1992	267	27					19130	19139						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JP593	1527037				2022-12-25	WOS:A1992JP59300022
J	KOIZUMI, S; SUZUKI, K; OTSUKA, F				KOIZUMI, S; SUZUKI, K; OTSUKA, F			A NUCLEAR FACTOR THAT RECOGNIZES THE METAL-RESPONSIVE ELEMENTS OF HUMAN METALLOTHIONEIN-IIA GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							I GENE; REGULATORY ELEMENTS; HEAVY-METALS; DEPENDENT BINDING; HELA-CELLS; RAT-LIVER; MOUSE; PROMOTER; SEQUENCES; TRANSCRIPTION	Expression of metallothionein (MT) genes is regulated by heavy metals mainly at the transcriptional level, via cis-acting elements called the metal-responsive elements (MREs). A HeLa cell nuclear factor that recognizes MREs of the human MTII(A) (hMTII(A)) gene, MREBP, was characterized. Mobility shift assay and DNase I footprinting experiments showed that MREBP binds specifically to several MREs present upstream of the hMTII(A) gene. Cadmium and zinc ions inhibited binding of MREBP to a MRE at high concentrations, suggesting a role of MREBP in the negative regulation of the hMTII(A) gene. MREBP was partially purified by passing the HeLa nuclear extract over heparin-agarose, Sephacryl S-300, and MRE-Sepharose affinity columns. Blotting experiments showed that a polypeptide with an M(r) of 112,000 is responsible for the MREBP activity.	TEIKYO UNIV,FAC PHARMACEUT SCI,DEPT ENVIRONM TOXICOL,SAGAMIKO,KANAGAWA 19901,JAPAN	Teikyo University	KOIZUMI, S (corresponding author), NATL INST IND HLTH SCI,DEPT EXPTL TOXICOL,6-21-1 NAGAO,TAMA KU,KAWASAKI 214,JAPAN.							ANDERSEN RD, 1987, MOL CELL BIOL, V7, P3574, DOI 10.1128/MCB.7.10.3574; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARTER AD, 1984, P NATL ACAD SCI-BIOL, V81, P7392, DOI 10.1073/pnas.81.23.7392; CULOTTA VC, 1989, MOL CELL BIOL, V9, P1376, DOI 10.1128/MCB.9.3.1376; DURNAM DM, 1981, J BIOL CHEM, V256, P5712; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; HAMER DH, 1986, ANNU REV BIOCHEM, V55, P913, DOI 10.1146/annurev.biochem.55.1.913; HIDALGO HA, 1978, BIOCHEM J, V170, P219, DOI 10.1042/bj1700219; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; IMBERT J, 1989, MOL CELL BIOL, V9, P5315, DOI 10.1128/MCB.9.12.5315; JOHNSON PF, 1989, ANNU REV BIOCHEM, V58, P799, DOI 10.1146/annurev.biochem.58.1.799; KADONAGA JT, 1986, P NATL ACAD SCI USA, V83, P5889, DOI 10.1073/pnas.83.16.5889; Kagi J.H.R., 1987, METALLOTHIONEIN, VII; Kagi J.H.R., 1979, METALLOTHIONEIN; KARIN M, 1983, P NATL ACAD SCI-BIOL, V80, P4040, DOI 10.1073/pnas.80.13.4040; KARIN M, 1984, CELL, V36, P371, DOI 10.1016/0092-8674(84)90230-7; KARIN M, 1982, NATURE, V299, P797, DOI 10.1038/299797a0; KARIN M, 1984, NATURE, V308, P513, DOI 10.1038/308513a0; KARIN M, 1981, EUR J BIOCHEM, V118, P527, DOI 10.1111/j.1432-1033.1981.tb05551.x; KOIZUMI S, 1985, J BIOL CHEM, V260, P3672; KOIZUMI S, 1991, CHEM-BIOL INTERACT, V80, P145, DOI 10.1016/0009-2797(91)90021-X; KOIZUMI S, 1985, J CELL PHYSIOL, V125, P223, DOI 10.1002/jcp.1041250208; KOIZUMI S, 1985, BIOCHEM J, V227, P879, DOI 10.1042/bj2270879; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE W, 1987, NATURE, V325, P368, DOI 10.1038/325368a0; MERRIL CR, 1981, SCIENCE, V211, P1437, DOI 10.1126/science.6162199; MUELLER PR, 1988, GENE DEV, V2, P412, DOI 10.1101/gad.2.4.412; PROBST GS, 1977, TOXICOL APPL PHARM, V39, P51, DOI 10.1016/0041-008X(77)90176-4; SCHOLER H, 1986, SCIENCE, V232, P76, DOI 10.1126/science.3006253; SEARLE PF, 1990, NUCLEIC ACIDS RES, V18, P4683, DOI 10.1093/nar/18.16.4683; SEARLE PF, 1985, MOL CELL BIOL, V5, P1480, DOI 10.1128/MCB.5.6.1480; SEGUIN C, 1984, NATURE, V312, P781, DOI 10.1038/312781a0; SEGUIN C, 1988, NUCLEIC ACIDS RES, V16, P10547, DOI 10.1093/nar/16.22.10547; SEGUIN C, 1987, SCIENCE, V235, P1383, DOI 10.1126/science.3103216; SEGUIN C, 1991, NUCLEIC ACIDS RES, V97, P295; STUART GW, 1984, P NATL ACAD SCI-BIOL, V81, P7318, DOI 10.1073/pnas.81.23.7318; STUART GW, 1985, NATURE, V317, P828, DOI 10.1038/317828a0; WESTIN G, 1988, EMBO J, V7, P3763, DOI 10.1002/j.1460-2075.1988.tb03260.x; WINGE DR, 1975, ARCH BIOCHEM BIOPHYS, V170, P242, DOI 10.1016/0003-9861(75)90115-0; YAGLE MK, 1985, MOL CELL BIOL, V5, P291, DOI 10.1128/MCB.5.2.291	41	38	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1992	267	26					18659	18664						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JN502	1526997				2022-12-25	WOS:A1992JN50200063
J	WINGROVE, JA; DISCIPIO, RG; CHEN, ZX; POTEMPA, J; TRAVIS, J; HUGLI, TE				WINGROVE, JA; DISCIPIO, RG; CHEN, ZX; POTEMPA, J; TRAVIS, J; HUGLI, TE			ACTIVATION OF COMPLEMENT COMPONENTS C3 AND C5 BY A CYSTEINE PROTEINASE (GINGIPAIN-1) FROM PORPHYROMONAS (BACTEROIDES) GINGIVALIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLACK-PIGMENTED BACTEROIDES; COLLAGENOLYTIC ACTIVITY; PURIFICATION; PROTEASE; PERIODONTITIS; ANAPHYLATOXIN; VIRULENT; STRAINS; SYSTEM	Complement components C3 and C5 are susceptible to limited proteolysis by an arginine-specific cysteine proteinase isolated from Porphyromonas gingivalis. This bacterium is an anaerobe commonly associated with severe periodontal disease. Infection by P. gingivalis is accompanied by an acute inflammatory response, complete with extensive neutrophil involvement. This prompted us to investigate a possible direct role for complement in peridontitis evoked by P. gingivalis. Exposure of C3 and C5 to the cysteine proteinase at molar ratios between 1:25 and 1:100 (enzyme to substrate ratios) resulted in a time-dependent, limited degradation of each component. C3 was converted in a stepwise manner to C3a-like and C3b-like fragments with evidence of extensive further degradation of the C3a-like portion of the molecule. We were unable to demonstrate C3a activity in the C3 digestion mixtures. C3 degradation appears to involve primarily the alpha-chain. Proteolysis of C5 also progresses in a stepwise manner producing an initial internal cleavage of the alpha-chain to generate 30- and 86-kDa fragments. Further digestion of the 86-kDa amino-terminal fragment of the alpha-chain leads to the release of C5a or a C5a-like fragment that is biologically active for neutrophil activation. The fact that a potent chemotactic factor, i.e. C5a, can be generated from C5 by a proteinase derived from P. gingivalis suggests a recruiting mechanism for attracting neutrophils to the gingival lesion site in periodontal disease.	INST SCRIPPS CLIN,DEPT IMMUNOL,LA JOLLA,CA 92037; JAGIELLONIAN UNIV,INST MOLEC BIOL,PL-31007 KRAKOW,POLAND; UNIV GEORGIA,DEPT BIOCHEM,ATHENS,GA 30602	Scripps Research Institute; Jagiellonian University; University System of Georgia; University of Georgia					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL025658, P01HL016411] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI017354] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL25658, HL16411] Funding Source: Medline; NIAID NIH HHS [AI17354] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BIRKEDALHANSEN H, 1988, J PERIODONTAL RES, V23, P258, DOI 10.1111/j.1600-0765.1988.tb01369.x; CHEN ZX, 1992, J BIOL CHEM, V267, P18896; CHENOWETH DE, 1980, MOL IMMUNOL, V17, P151, DOI 10.1016/0161-5890(80)90067-X; DAHINDEN C, 1983, J IMMUNOL, V130, P857; DISCIPIO RG, 1981, BIOCHEM J, V199, P485, DOI 10.1042/bj1990485; DISCIPIO RG, 1992, J BIOL CHEM, V267, P17087; EDMAN P, 1967, EUR J BIOCHEM, V1, P80, DOI 10.1111/j.1432-1033.1967.tb00047.x; EMBER JA, 1992, J IMMUNOL, V148, P3165; FEHR J, 1979, J CLIN INVEST, V64, P8, DOI 10.1172/JCI109466; FERNANDEZ HN, 1976, J IMMUNOL, V117, P1688; GRENIER D, 1987, J CLIN MICROBIOL, V25, P738, DOI 10.1128/JCM.25.4.738-740.1987; HASTON WS, 1985, J IMMUNOL METHODS, V81, P229, DOI 10.1016/0022-1759(85)90208-X; HAVILAND DL, 1991, J IMMUNOL, V146, P362; HUGLI T E, 1986, Complement, V3, P111; HUGLI TE, 1981, MOL CELL BIOCHEM, V41, P59; HUGLI TE, 1975, J BIOL CHEM, V250, P1472; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARSH PD, 1989, FEMS MICROBIOL LETT, V59, P181; MAYRAND D, 1988, MICROBIOL REV, V52, P134, DOI 10.1128/MMBR.52.1.134-152.1988; MERRIL CR, 1979, P NATL ACAD SCI USA, V76, P4335, DOI 10.1073/pnas.76.9.4335; MOORE WEC, 1982, INFECT IMMUN, V38, P1137, DOI 10.1128/IAI.38.3.1137-1148.1982; MORGAN EL, 1992, FASEB J, V6, pA1121; MULLEREBERHARD HJ, 1988, ANNU REV BIOCHEM, V57, P321, DOI 10.1146/annurev.biochem.57.1.321; OTSUKA M, 1987, J PERIODONTAL RES, V22, P491, DOI 10.1111/j.1600-0765.1987.tb02060.x; PARKES C, 1981, BIOCHEM J, V193, P963, DOI 10.1042/bj1930963; SCHENKEIN HA, 1988, J PERIODONTAL RES, V23, P187, DOI 10.1111/j.1600-0765.1988.tb01356.x; SLOTS J, 1986, J CLIN PERIODONTOL, V13, P570, DOI 10.1111/j.1600-051X.1986.tb00849.x; SMALLEY JW, 1989, ORAL MICROBIOL IMMUN, V4, P178, DOI 10.1111/j.1399-302X.1989.tb00249.x; SUNDQVIST G, 1985, J MED MICROBIOL, V19, P85, DOI 10.1099/00222615-19-1-85; SUNDQVIST G, 1987, J PERIODONTAL RES, V22, P300, DOI 10.1111/j.1600-0765.1987.tb01589.x; TACK BF, 1976, BIOCHEMISTRY-US, V15, P4513, DOI 10.1021/bi00665a028; TSUTSUI H, 1987, INFECT IMMUN, V55, P420, DOI 10.1128/IAI.55.2.420-427.1987; WHITE D, 1981, J PERIODONTAL RES, V16, P259, DOI 10.1111/j.1600-0765.1981.tb00974.x; YOSHIMURA F, 1984, ARCH ORAL BIOL, V29, P559, DOI 10.1016/0003-9969(84)90078-5; ZAMBON JJ, 1981, INFECT IMMUN, V32, P198, DOI 10.1128/IAI.32.1.198-203.1981	35	211	218	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1992	267	26					18902	18907						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JN502	1527018				2022-12-25	WOS:A1992JN50200098
J	HYDER, SM; STANCEL, GM; NAWAZ, Z; MCDONNELL, DP; LOOSEMITCHELL, DS				HYDER, SM; STANCEL, GM; NAWAZ, Z; MCDONNELL, DP; LOOSEMITCHELL, DS			IDENTIFICATION OF AN ESTROGEN RESPONSE ELEMENT IN THE 3'-FLANKING REGION OF THE MURINE C-FOS PROTOONCOGENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER RIBONUCLEIC-ACID; GROWTH-FACTOR RECEPTOR; SACCHAROMYCES-CEREVISIAE; CELL-PROLIFERATION; BREAST-CANCER; GENE; EXPRESSION; ONCOGENE; PROTEIN; BINDS	We have used transient transfection assays with reporter plasmids expressing chloramphenicol acetyltransferase, linked to regions of mouse c-fos, to identify a specific estrogen response element (ERE) in this protooncogene. This element is located in the untranslated 3'-flanking region of the c-fos gene, 5 kilobases (kb) downstream from the c-fos promoter and 1.5 kb downstream of the poly(A) signal. This element confers estrogen responsiveness to chloramphenicol acetyltransferase reporters linked to both the herpes simplex virus thymidine kinase promoter and the homologous c-fos promoter. Deletion analysis localized the response element to a 200-base pair fragment which contains the element GGTCACCACAGCC that resembles the consensus ERE sequence GGTCACAGTGACC originally identified in Xenopus vitellogenin A2 gene. A synthetic 36-base pair oligodeoxynucleotide containing this c-fos sequence conferred estrogen inducibility to the thymidine kinase promoter. The corresponding sequence also induced reporter activity when present in the c-fos gene fragment 3 kb from the thymidine kinase promoter. Gel-shift experiments demonstrated that synthetic oligonucleotides containing either the consensus ERE or the c-fos element bind human estrogen receptor obtained from a yeast expression system. However, the mobility of the shifted band is faster for the fos-ERE-complex than the consensus ERE complex suggesting that the three-dimensional structure of the protein-DNA complexes is different or that other factors are differentially involved in the two reactions. When the 5'-GGTCA sequence present in the c-fos ERE is mutated to 5'-TTTCA, transcriptional activation and receptor binding activities are both lost. Mutation of the CAGCC-3' element corresponding to the second half-site of the c-fos sequence also led to the loss of receptor binding activity, suggesting that both half-sites of this element are involved in this function. The estrogen induction mediated by either the c-fos or the consensus ERE was blunted by the antiestrogen tamoxifen. Based on these studies, we believe the 3'-fos ERE sequence we have identified may be a major cis-acting element involved in the physiologieal regulation of the gene by estrogens in vivo.	BAYLOR COLL MED,DEPT CELL BIOL,HOUSTON,TX 77030	Baylor College of Medicine	HYDER, SM (corresponding author), UNIV TEXAS,SCH MED,DEPT PHARMACOL,POB 20708,HOUSTON,TX 77225, USA.				NICHD NIH HHS [HD-08615] Funding Source: Medline	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BECK I, 1991, J BIOL CHEM, V266, P15563; BERRY M, 1989, P NATL ACAD SCI USA, V86, P1218, DOI 10.1073/pnas.86.4.1218; CHIAPPETTA C, 1992, J STEROID BIOCHEM, V41, P113, DOI 10.1016/0960-0760(92)90037-J; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; CURRAN T, 1982, J VIROL, V44, P674, DOI 10.1128/JVI.44.2.674-682.1982; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; DENTE L, 1983, NUCLEIC ACIDS RES, V11, P1645, DOI 10.1093/nar/11.6.1645; DICKSON RB, 1990, J STEROID BIOCHEM, V37, P305, DOI 10.1016/0960-0760(90)90479-5; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; GALAND P, 1971, J ENDOCRINOL, V49, P243, DOI 10.1677/joe.0.0490243; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HOLT JT, 1986, P NATL ACAD SCI USA, V83, P4794, DOI 10.1073/pnas.83.13.4794; HUGHES MJ, 1989, BIOCHEMISTRY-US, V28, P9137, DOI 10.1021/bi00449a027; HYDER SM, 1991, STEROIDS, V56, P498, DOI 10.1016/0039-128X(91)90114-B; HYDER SM, 1991, GENE, V105, P281, DOI 10.1016/0378-1119(91)90164-7; KATO S, 1992, CELL, V68, P731, DOI 10.1016/0092-8674(92)90148-6; KIRKLAND JL, 1992, ENDOCRINOLOGY, V130, P3223, DOI 10.1210/en.130.6.3223; KLEINHITPASS L, 1988, NUCLEIC ACIDS RES, V16, P647, DOI 10.1093/nar/16.2.647; KLEINHITPASS L, 1989, MOL CELL BIOL, V9, P42; KUMAR V, 1988, CELL, V55, P145, DOI 10.1016/0092-8674(88)90017-7; LAMB NJC, 1990, CELL, V61, P485, DOI 10.1016/0092-8674(90)90530-R; LINGHAM RB, 1988, MOL ENDOCRINOL, V2, P230, DOI 10.1210/mend-2-3-230; LOOSEMITCHELL DS, 1988, MOL ENDOCRINOL, V2, P946, DOI 10.1210/mend-2-10-946; LUCIBELLO FC, 1989, CELL, V59, P999, DOI 10.1016/0092-8674(89)90756-3; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MAK P, 1989, J BIOL CHEM, V264, P21613; Maniatis T., 1982, MOL CLONING; MAURER RA, 1987, MOL CELL BIOL, V7, P4247, DOI 10.1128/MCB.7.12.4247; MCDONNELL DP, 1991, J STEROID BIOCHEM, V39, P291, DOI 10.1016/0960-0760(91)90038-7; MILLER AD, 1984, CELL, V36, P51; MUELLER GC, 1958, RECENT PROG HORM RES, V14, P95; MUKKU VR, 1985, J BIOL CHEM, V260, P9820; MULLER R, 1984, NATURE, V311, P438, DOI 10.1038/311438a0; NISHIKURA K, 1987, MOL CELL BIOL, V7, P636; PHAM TA, 1991, P NATL ACAD SCI USA, V88, P3125, DOI 10.1073/pnas.88.8.3125; RICHARD S, 1990, J BIOL CHEM, V265, P6098; SASSONECORSI P, 1988, NATURE, V334, P314, DOI 10.1038/334314a0; SCHONTHAL A, 1988, CELL, V54, P325, DOI 10.1016/0092-8674(88)90195-X; SHYU AB, 1991, GENE DEV, V5, P221, DOI 10.1101/gad.5.2.221; VANDERBURG B, 1989, MOL CELL ENDOCRINOL, V64, P223, DOI 10.1016/0303-7207(89)90149-4; VERMA IM, 1987, ADV CANCER RES, V49, P29, DOI 10.1016/S0065-230X(08)60793-9; WANG ZQ, 1991, EMBO J, V10, P2437, DOI 10.1002/j.1460-2075.1991.tb07783.x; WEISZ A, 1986, BIOCHEM BIOPH RES CO, V139, P396, DOI 10.1016/S0006-291X(86)80004-3; WEISZ A, 1990, NUCLEIC ACIDS RES, V18, P5097, DOI 10.1093/nar/18.17.5097; WEISZ A, 1988, MOL ENDOCRINOL, V2, P816, DOI 10.1210/mend-2-9-816; WEISZ A, 1988, PROGR CANCER RES THE, V35, P122	47	105	108	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1992	267	25					18047	18054						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JM223	1517237				2022-12-25	WOS:A1992JM22300087
J	TVERBERG, LA; RUSSO, AF				TVERBERG, LA; RUSSO, AF			CELL-SPECIFIC GLUCOCORTICOID REPRESSION OF CALCITONIN CALCITONIN GENE-RELATED PEPTIDE TRANSCRIPTION - LOCALIZATION TO AN 18-BASE PAIR BASAL ENHANCER ELEMENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE AMINOTRANSFERASE GENE; RECEPTOR-BINDING; HORMONE GENE; C-JUN; DEXAMETHASONE; LINE; EXPRESSION; DNA; INHIBITION; PROMOTER	We have investigated the mechanisms underlying cell-specific glucocorticoid repression of calcitonin/calcitonin gene-related peptide (CGRP) gene expression. Treatment with the synthetic glucocorticoid dexamethasone has been shown to decrease mRNA levels in the 44-2C thyroid C cell line. Nuclear run-on assays showed that dexamethasone repressed transcription 2-3-fold in 44-2C cells. In contrast, dexamethasone stimulated calcitonin/CGRP transcription 4-6-fold in the CA77 thyroid C cell line. Transient transfection assays were used to map repression of reporter gene activity in 44-2C cells to a neuroendocrine cell-specific enhancer located between -920 and -1125 base pairs (bp). Within this region, an 18-bp element was found that conferred both full basal enhancer activity and dexamethasone-dependent repression in 44-2C cells. The 18-bp region contains possible binding sites for AP-1 and helix-loop- helix transcription factors as well as a glucocorticoid receptor half-site. Colocalization of repression and enhancer activity was then investigated in other cell lines. In CA77 cells, while the 920-1125 region strongly enhanced transcription, the 18-bp region conferred only partial activation and dexamethasone had little effect on reporter gene activity. Dexamethasone did not repress the calcitonin/CGRP activity in the heterologous HeLa and Rat1 fibroblast cell lines. These results suggest that glucocorticoids repress transcription of the calcitonin/CGRP gene by inhibiting cell-specific transcription factor activity.	UNIV IOWA, DEPT PHYSIOL & BIOPHYS, IOWA CITY, IA 52242 USA	University of Iowa				Russo, Andrew/0000-0002-8156-5649	NICHD NIH HHS [R01 HD25969] Funding Source: Medline; NIDDK NIH HHS [DK25295] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD025969] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK025295] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BESNARD P, 1989, FEBS LETT, V258, P293, DOI 10.1016/0014-5793(89)81677-1; BRASIER AR, 1989, BIOTECHNIQUES, V7, P1116; CELANO P, 1989, BIOTECHNIQUES, V7, P942; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COTE GJ, 1986, J BIOL CHEM, V261, P5524; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; FODOR E, 1991, BIOCHEMISTRY-US, V30, P8102, DOI 10.1021/bi00247a002; GABUZDA DH, 1989, MOL CELL BIOL, V9, P2728, DOI 10.1128/MCB.9.6.2728; GHYSEN A, 1988, GENE DEV, V2, P495, DOI 10.1101/gad.2.5.495; GLASS CK, 1990, CELL, V63, P729, DOI 10.1016/0092-8674(90)90139-6; GRANGE T, 1989, NUCLEIC ACIDS RES, V17, P8695, DOI 10.1093/nar/17.21.8695; GREENBERG ME, 1988, CURRENT PROTOCOLS MO; HU YF, 1990, GENE DEV, V4, P1741, DOI 10.1101/gad.4.10.1741; JANTZEN HM, 1987, CELL, V49, P29, DOI 10.1016/0092-8674(87)90752-5; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; KALINYAK JE, 1987, J BIOL CHEM, V262, P460; KARIN M, 1987, MOL CELL BIOL, V7, P606, DOI 10.1128/MCB.7.2.606; LO LC, 1991, GENE DEV, V5, P1524, DOI 10.1101/gad.5.9.1524; LU C, 1989, MOL ENDOCRINOL, V3, P2034, DOI 10.1210/mend-3-12-2034; MANZ B, 1983, J CLIN CHEM CLIN BIO, V21, P69; MCDERMOTT MT, 1987, ENDOCR REV, V8, P377, DOI 10.1210/edrv-8-4-377; MERMOD N, 1988, NATURE, V332, P557, DOI 10.1038/332557a0; MORDACQ JC, 1989, GENE DEV, V3, P760, DOI 10.1101/gad.3.6.760; MUSZYNSKI M, 1983, J BIOL CHEM, V258, P1678; NAVEHMANY T, 1988, J CLIN INVEST, V81, P270, DOI 10.1172/JCI113305; NECHUSHTAN H, 1987, NUCLEIC ACIDS RES, V15, P6405, DOI 10.1093/nar/15.16.6405; NELSON C, 1990, GENE DEV, V4, P1035, DOI 10.1101/gad.4.6.1035; PRESSLEY L, 1975, ENDOCRINOLOGY, V97, P588, DOI 10.1210/endo-97-3-588; RAY A, 1990, MOL CELL BIOL, V10, P5736, DOI 10.1128/MCB.10.11.5736; ROBINSON BG, 1988, P NATL ACAD SCI USA, V85, P5244, DOI 10.1073/pnas.85.14.5244; ROSENFELD MG, 1983, NATURE, V304, P129, DOI 10.1038/304129a0; RUSSO AF, 1992, MOL ENDOCRINOL, V6, P207, DOI 10.1210/me.6.2.207; RUSSO AF, 1988, J BIOL CHEM, V263, P5; Sambrook J, 1989, MOL CLONING LABORATO; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; SEED B, 1988, GENE, V67, P273; SLATER EP, 1985, MOL CELL BIOL, V5, P2984, DOI 10.1128/MCB.5.11.2984; STOLARSKYFREDMAN L, 1990, MOL ENDOCRINOL, V4, P497, DOI 10.1210/mend-4-3-497; TAVIANINI MA, 1989, MOL ENDOCRINOL, V3, P605, DOI 10.1210/mend-3-4-605; TONG Y, 1990, Molecular and Cellular Neuroscience, V1, P78; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V; ZEYTIN FN, 1987, ENDOCRINOLOGY, V121, P361, DOI 10.1210/endo-121-1-361	44	48	50	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 5	1992	267	25					17567	17573						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JM223	1517207				2022-12-25	WOS:A1992JM22300017
J	MARTI, T; OTTO, H; ROSSELET, SJ; HEYN, MP; KHORANA, HG				MARTI, T; OTTO, H; ROSSELET, SJ; HEYN, MP; KHORANA, HG			ANION BINDING TO THE SCHIFF-BASE OF THE BACTERIORHODOPSIN MUTANTS ASP-85-]ASN ASP-212-]ASN AND ARG-82-]GLN ASP-85-]ASN ASP-212-]ASN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTON PUMP; VIBRATIONAL SPECTROSCOPY; ACID SUBSTITUTIONS; ASPARTIC ACID-96; ESCHERICHIA-COLI; PURPLE MEMBRANE; BACTERIO-OPSIN; CHLORIDE PUMP; HALORHODOPSIN; CHROMOPHORE	Studies of bacteriorhodopsin have indicated that the charge environment of the protonated Schiff base consists of residues Asp-85, Asp-212, and Arg-82. As shown recently (Marti, T., Rosselet, S. J., Otto, H., Heyn, M. P., and Khorana, H. G. (1991) J. Biol. Chem. 266, 18674-18683), in the double mutant Asp-85 --> Asn/Asp-212 --> Asn chromophore formation is restored in the presence of salts, suggesting that exogenous anions function as counterions to the protonated Schiff base. To investigate the role of Arg-82 and of the Schiff base in anion binding, we have prepared the triple mutant Arg-82 --> Gln/Asp-85 --> Asn/Asp-212 --> Asn and compared its properties with those of the Asp-85 --> Asn/Asp-212 --> Asn double mutant. Regeneration of the chromophore with absorption maximum near 560 nm occurs in the triple mutant in the presence of millimolar salt, whereas in the double mutant molar salt concentrations are required. Spectrometric titrations reveal that the pK(a) of Schiff base deprotonation is markedly reduced from 11.3 for the wild type to 4.9 for the triple mutant in 1 mM NaCl and to 5.5 for the double mutant in 10 mM NaCl. In both mutants, increasing the chloride concentration promotes protonation of the chromophore and results in a continuous rise of the Schiff base pK(a), yielding a value of 8.4 and 7.6, respectively, in 4 M NaCl. The absorption maximum of the two mutants shows a progressive red shift, as the ionic radius of the halide increases in the sequence fluoride, chloride, bromide, and iodide. An identical spectral correlation in the presence of halides is observed for the acid-purple form of bacteriorhodopsin. We conclude, therefore, that upon neutralization of the two counterions Asp-85 and Asp-212 by mutation or by protonation at low pH, exogenous anions substitute as counterions by directly binding to the protonated Schiff base. This interaction may provide the basis for the proposed anion translocation by the acid-purple form of bacteriorhodopsin as well as by the related halorhodopsin.	MIT,DEPT BIOL,CAMBRIDGE,MA 02139; FREE UNIV BERLIN,BIOPHYS GRP,W-1000 BERLIN 33,GERMANY	Massachusetts Institute of Technology (MIT); Free University of Berlin					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI011479] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028289, R37GM028289] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 11479] Funding Source: Medline; NIGMS NIH HHS [GM 28289] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALEXIEV U, 1992, FASEB J, V6, pA529; BAMBERG E, 1984, BIOCHEMISTRY-US, V23, P6216, DOI 10.1021/bi00320a050; BLATZ PE, 1972, BIOCHEMISTRY-US, V11, P848, DOI 10.1021/bi00755a026; BOUSCHE O, 1991, J BIOL CHEM, V266, P11063; BRAIMAN MS, 1988, BIOCHEMISTRY-US, V27, P8516, DOI 10.1021/bi00423a002; BRAIMAN MS, 1987, J BIOL CHEM, V262, P9271; BUTT HJ, 1989, EMBO J, V8, P1657, DOI 10.1002/j.1460-2075.1989.tb03556.x; DEGROOT HJM, 1990, BIOCHEMISTRY-US, V29, P6873, DOI 10.1021/bi00481a017; DEGROOT HJM, 1989, BIOCHEMISTRY-US, V28, P3346, DOI 10.1021/bi00434a033; DER A, 1991, P NATL ACAD SCI USA, V88, P4751, DOI 10.1073/pnas.88.11.4751; EHRENBERG B, 1989, FEBS LETT, V250, P179, DOI 10.1016/0014-5793(89)80715-X; FISCHER U, 1979, BIOPHYS J, V28, P211, DOI 10.1016/S0006-3495(79)85172-3; GERWERT K, 1990, P NATL ACAD SCI USA, V87, P9774, DOI 10.1073/pnas.87.24.9774; HACKETT NR, 1987, J BIOL CHEM, V262, P9277; JONAS R, 1990, PHOTOCHEM PHOTOBIOL, V52, P1163, DOI 10.1111/j.1751-1097.1990.tb08455.x; LANYI JK, 1990, FEBS LETT, V265, P1, DOI 10.1016/0014-5793(90)80869-K; LONDON E, 1982, J BIOL CHEM, V257, P7003; MARTI T, 1991, J BIOL CHEM, V266, P6919; MARTI T, 1991, J BIOL CHEM, V266, P18674; MATHIES RA, 1991, ANNU REV BIOPHYS BIO, V20, P491, DOI 10.1146/annurev.bb.20.060191.002423; MOGI T, 1988, P NATL ACAD SCI USA, V85, P4148, DOI 10.1073/pnas.85.12.4148; NASSAL M, 1987, J BIOL CHEM, V262, P9264; NEEDLEMAN R, 1991, J BIOL CHEM, V266, P11478; OESTERHELT D, 1989, TRENDS BIOCHEM SCI, V14, P57, DOI 10.1016/0968-0004(89)90044-3; OTTO H, 1989, P NATL ACAD SCI USA, V86, P9228, DOI 10.1073/pnas.86.23.9228; OTTO H, 1990, P NATL ACAD SCI USA, V87, P1018, DOI 10.1073/pnas.87.3.1018; PANDE C, 1989, BIOPHYS J, V55, P425, DOI 10.1016/S0006-3495(89)82836-X; RATH P, 1992, FASEB J, V6, pA533; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHOBERT B, 1986, J BIOL CHEM, V261, P2690; STEINER M, 1984, J BIOL CHEM, V259, P2179; SUBRAMANIAM S, 1991, P NATL ACAD SCI USA, V88, P2583, DOI 10.1073/pnas.88.6.2583; TITTOR J, 1989, EMBO J, V8, P3477, DOI 10.1002/j.1460-2075.1989.tb08512.x	34	32	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1992	267	24					16922	16927						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JL053	1512233				2022-12-25	WOS:A1992JL05300032
J	ROEBROEK, AJM; CREEMERS, JWM; PAULI, IGL; KURZIKDUMKE, U; RENTROP, M; GATEFF, EAF; LEUNISSEN, JAM; VANDEVEN, WJM				ROEBROEK, AJM; CREEMERS, JWM; PAULI, IGL; KURZIKDUMKE, U; RENTROP, M; GATEFF, EAF; LEUNISSEN, JAM; VANDEVEN, WJM			CLONING AND FUNCTIONAL EXPRESSION OF DFURIN2, A SUBTILISIN-LIKE PROPROTEIN PROCESSING ENZYME OF DROSOPHILA-MELANOGASTER WITH MULTIPLE REPEATS OF A CYSTEINE MOTIF	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VONWILLEBRAND-FACTOR VWF; MAMMALIAN-CELLS; GENE-EXPRESSION; PROTO-ONCOGENE; MESSENGER-RNAS; CDNA SEQUENCE; YEAST KEX2; FURIN; PROHORMONE; PROTEASE	Production of a variety of regulatory eukaryotic proteins, such as growth factors and polypeptide hormones, often involves endoproteolytic processing of proproteins at cleavage sites consisting of paired basic residues. The first known mammalian proprotein processing enzyme with such specificity is the human fur gene product furin. Structurally and functionally, furin is related to the subtilisin-like serine endoprotease kexin (EC 3.4.21.61) of yeast Saccharomyces cerevisiae; unlike kexin, it contains a cysteine-rich region with an unknown function. Here, we describe cloning and sequencing of a 5.8-kbp cDNA of the Dfur2 gene, a fur-like gene of Drosophila melanogaster, which we found expressed during various stages of development. This Dfur2 cDNA has an open reading frame for a 1680-residue protein, called Dfurin2. Dfurin2 contains similar protein domains as mammalian furin, however, it has an extended amino-terminal region and its cysteine-rich region is much larger than that of mammalian furin. Because of this latter phenomenon, we were able to identify a particular cysteine motif that was repeated multiple times in Dfurin2 but present only twice in mammalian furin. Furthermore, we show that Dfur2 encodes an endoproteolytic enzyme with specificity for paired basic amino acid residues as, in cotransfection experiments, correct cleavage was demonstrated of the precursor of the von Willebrand factor but not of a cleavage mutant. Finally, Dfur2 was mapped to region 14C of the X chromosome of D. melanogaster.	CATHOLIC UNIV LEUVEN,CTR HUMAN GENET,MOLEC ONCOL LAB,HEREST 49,B-3000 LOUVAIN,BELGIUM; CATHOLIC UNIV NIJMEGEN,FAC SCI,CTR COMP ASSISTED ORGAN SYNTH COMP ASSISTED MOLEC MODELLING,6525 ED NIJMEGEN,NETHERLANDS; UNIV MAINZ,INST GENET,W-6500 MAINZ 1,GERMANY	KU Leuven; Radboud University Nijmegen; Johannes Gutenberg University of Mainz								AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; BAIROCH A, 1991, NUCLEIC ACIDS RES, V19, P2241, DOI 10.1093/nar/19.suppl.2241; BARR PJ, 1991, DNA CELL BIOL, V10, P319, DOI 10.1089/dna.1991.10.319; BATHURST IC, 1987, SCIENCE, V235, P348, DOI 10.1126/science.3541206; BENJANNET S, 1991, P NATL ACAD SCI USA, V88, P3564, DOI 10.1073/pnas.88.9.3564; BRESNAHAN PA, 1990, J CELL BIOL, V111, P2851, DOI 10.1083/jcb.111.6.2851; CHRETIEN M, 1967, CAN J BIOCHEM CELL B, V45, P1163, DOI 10.1139/o67-133; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CREEMERS JWM, 1992, FEBS LETT, V300, P82, DOI 10.1016/0014-5793(92)80169-H; DOCHERTY K, 1982, ANNU REV PHYSIOL, V44, P625, DOI 10.1146/annurev.ph.44.030182.003205; DOUGLASS J, 1984, ANNU REV BIOCHEM, V53, P665; FOSTER DC, 1990, BIOCHEMISTRY-US, V29, P347, DOI 10.1021/bi00454a007; FULLER RS, 1988, ANNU REV PHYSIOL, V50, P345, DOI 10.1146/annurev.ph.50.030188.002021; FULLER RS, 1989, SCIENCE, V246, P482, DOI 10.1126/science.2683070; FULLER RS, 1991, ADV LIFE SCI; HAKES DJ, 1991, ENDOCRINOLOGY, V129, P3053, DOI 10.1210/endo-129-6-3053; HATSUZAWA K, 1990, J BIOL CHEM, V265, P22075; HAYFLICK JS, 1992, J NEUROSCI, V12, P705; HUIJSER P, 1987, MOL GEN GENET, V206, P441, DOI 10.1007/BF00428884; KIEFER MC, 1991, DNA CELL BIOL, V10, P757, DOI 10.1089/dna.1991.10.757; KORNER J, 1991, P NATL ACAD SCI USA, V88, P11393, DOI 10.1073/pnas.88.24.11393; LASKOWSKI M, 1980, ANNU REV BIOCHEM, V49, P593, DOI 10.1146/annurev.bi.49.070180.003113; MARYNEN P, 1990, FEBS LETT, V262, P349, DOI 10.1016/0014-5793(90)80226-9; MISUMI Y, 1991, J BIOL CHEM, V266, P16954; MISUMI Y, 1990, NUCLEIC ACIDS RES, V18, P6719, DOI 10.1093/nar/18.22.6719; ROEBROEK AJM, 1986, EMBO J, V5, P2197, DOI 10.1002/j.1460-2075.1986.tb04484.x; ROEBROEK AJM, 1986, MOL BIOL REP, V11, P117, DOI 10.1007/BF00364823; ROEBROEK AJM, 1991, FEBS LETT, V289, P133, DOI 10.1016/0014-5793(91)81052-A; SCHALKEN JA, 1987, J CLIN INVEST, V80, P1545, DOI 10.1172/JCI113240; SEIDAH NG, 1991, MOL ENDOCRINOL, V5, P111, DOI 10.1210/mend-5-1-111; SEIDAH NG, 1990, DNA CELL BIOL, V9, P415, DOI 10.1089/dna.1990.9.415; SMEEKENS SP, 1991, P NATL ACAD SCI USA, V88, P340, DOI 10.1073/pnas.88.2.340; SMEEKENS SP, 1990, J BIOL CHEM, V265, P2997; SOSSIN WS, 1989, NEURON, V2, P1407, DOI 10.1016/0896-6273(89)90186-4; STEINER DF, 1967, P NATL ACAD SCI USA, V57, P145; TAMKUN JW, 1992, CELL, V68, P561, DOI 10.1016/0092-8674(92)90191-E; TASHIRO M, 1987, J BIOCHEM-TOKYO, V102, P297, DOI 10.1093/oxfordjournals.jbchem.a122054; THOMAS G, 1988, SCIENCE, V241, P226, DOI 10.1126/science.3291117; THOMAS L, 1991, P NATL ACAD SCI USA, V88, P5297, DOI 10.1073/pnas.88.12.5297; VANDENOUWELAND AMW, 1990, NUCLEIC ACIDS RES, V18, P664, DOI 10.1093/nar/18.3.664; VANDEVEN WJ, 1992, IN PRESS ENZYME; VANDEVEN WJM, 1990, MOL BIOL REP, V14, P265, DOI 10.1007/BF00429896; VANDUIJNHOVEN JLP, 1992, HYBRIDOMA, V11, P71; VERWEIJ CL, 1986, EMBO J, V5, P1839, DOI 10.1002/j.1460-2075.1986.tb04435.x; VOORBERG J, 1990, EMBO J, V9, P797, DOI 10.1002/j.1460-2075.1990.tb08176.x; WISE RJ, 1990, P NATL ACAD SCI USA, V87, P9378, DOI 10.1073/pnas.87.23.9378	46	83	87	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1992	267	24					17208	17215						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JL053	1512259				2022-12-25	WOS:A1992JL05300074
J	HIKITA, C; MIZUSHIMA, S				HIKITA, C; MIZUSHIMA, S			EFFECTS OF TOTAL HYDROPHOBICITY AND LENGTH OF THE HYDROPHOBIC DOMAIN OF A SIGNAL PEPTIDE ON INVITRO TRANSLOCATION EFFICIENCY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MALTOSE-BINDING-PROTEIN; PROTON MOTIVE FORCE; OUTER-MEMBRANE PROTEIN; AMINO-TERMINAL REGION; ESCHERICHIA-COLI; POSITIVE CHARGE; SECA PROTEIN; CYTOPLASMIC MEMBRANE; SECRETORY PROTEINS; LAMBDA-RECEPTOR	The hydrophobic domain of the signal peptide of OmpF-Lpp, a model secretory protein, was systematically engineered so as to be composed of different lengths of polyleucine residues or polymers with alternate leucine and alanine residues, and the effects of the length and nature of the hydrophobic stretch on the rate of in vitro translocation were studied using everted membrane vesicles of Escherichia coli. The translocation reaction exhibited high substrate specificity as to the number of hydrophobic residues. The results suggest that the hydrophobic domain is recognized specifically by a component(s) of the secretory machinery rather than nonspecifically by the hydrophobic region of the membrane. The in vitro translocation thus demonstrated required SecA and ATP and was markedly enhanced upon imposition of the proton motive force, as in the case of secretory proteins possessing a natural signal peptide. The highest translocation rate was obtained with the octamer in the case of polyleucine-containing signal peptides, whereas it was the decamer in the case of ones containing both leucine and alanine. These results suggest that the total hydrophobicity of the hydrophobic region of the signal peptides is an important determinant of the substrate specificity.	UNIV TOKYO,INST APPL MICROBIOL,BUNKYO KU,TOKYO 113,JAPAN	University of Tokyo								AKITA M, 1990, J BIOL CHEM, V265, P8164; BANKAITIS VA, 1984, CELL, V37, P243, DOI 10.1016/0092-8674(84)90320-9; BERNSTEIN HD, 1989, NATURE, V340, P482, DOI 10.1038/340482a0; BOSCH D, 1989, BIOCHIM BIOPHYS ACTA, V979, P69, DOI 10.1016/0005-2736(89)90524-5; BRIGGS MS, 1984, BIOCHEMISTRY-US, V23, P3111, DOI 10.1021/bi00309a001; CHOU MM, 1990, J BIOL CHEM, V265, P2873; COBET WWE, 1989, J BIOL CHEM, V264, P10169; COLLIER DN, 1988, CELL, V53, P273, DOI 10.1016/0092-8674(88)90389-3; CUNNINGHAM K, 1989, EMBO J, V8, P955, DOI 10.1002/j.1460-2075.1989.tb03457.x; EMR SD, 1983, P NATL ACAD SCI-BIOL, V80, P4599, DOI 10.1073/pnas.80.15.4599; EMR SD, 1980, NATURE, V285, P82, DOI 10.1038/285082a0; IINO T, 1987, J BIOL CHEM, V262, P7412; INOKUCHI K, 1982, NUCLEIC ACIDS RES, V21, P6958; INOUYE S, 1982, P NATL ACAD SCI-BIOL, V79, P3438, DOI 10.1073/pnas.79.11.3438; JOHNSON D, 1986, CELL, V47, P545, DOI 10.1016/0092-8674(86)90619-7; JONES JD, 1990, J BIOENERG BIOMEMBR, V22, P213, DOI 10.1007/BF00763166; KAM W, 1985, P NATL ACAD SCI USA, V82, P8715, DOI 10.1073/pnas.82.24.8715; KAWASAKI H, 1989, FEBS LETT, V242, P431, DOI 10.1016/0014-5793(89)80516-2; KENDALL DA, 1988, J BIOL CHEM, V263, P7261; KENDALL DA, 1986, NATURE, V321, P706, DOI 10.1038/321706a0; LILL R, 1989, EMBO J, V8, P961, DOI 10.1002/j.1460-2075.1989.tb03458.x; LOPEZ JA, 1987, P NATL ACAD SCI USA, V84, P5615, DOI 10.1073/pnas.84.16.5615; LU HM, 1991, J BIOL CHEM, V266, P9977; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MIZUSHIMA S, 1990, J BIOENERG BIOMEMBR, V22, P389, DOI 10.1007/BF00763174; OLIVER DB, 1981, CELL, V25, P765, DOI 10.1016/0092-8674(81)90184-7; OZAWA Y, 1987, J BACTERIOL, V169, P1331, DOI 10.1128/jb.169.3.1331-1334.1987; PINCUS MR, 1982, P NATL ACAD SCI-BIOL, V79, P3413, DOI 10.1073/pnas.79.11.3413; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SASAKI S, 1990, J BIOL CHEM, V265, P4358; SHIOZUKA K, 1990, J BIOL CHEM, V265, P18843; VLASUK GP, 1983, J BIOL CHEM, V258, P7141; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4; WALFE PB, 1985, J BIOL CHEM, V260, P1836; WEISS JB, 1988, P NATL ACAD SCI USA, V85, P8978, DOI 10.1073/pnas.85.23.8978; YAMADA H, 1989, J BIOL CHEM, V264, P1723; YAMAMOTO Y, 1987, BIOCHEM BIOPH RES CO, V149, P431, DOI 10.1016/0006-291X(87)90385-8; YAMANE K, 1987, J BIOL CHEM, V262, P2358; YAMANE K, 1988, J BIOL CHEM, V263, P5368; ZOPF D, 1990, EMBO J, V9, P4511, DOI 10.1002/j.1460-2075.1990.tb07902.x	40	53	64	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1992	267	7					4882	4888						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HF642	1531659				2022-12-25	WOS:A1992HF64200088
J	WILLIAMS, RT; CARBONAROHALL, DA; HALL, FL				WILLIAMS, RT; CARBONAROHALL, DA; HALL, FL			COPURIFICATION OF P34CDC2/P58CYCLIN-A PROLINE-DIRECTED PROTEIN-KINASE AND THE RETINOBLASTOMA TUMOR SUSCEPTIBILITY GENE-PRODUCT - INTERACTION OF AN ONCOGENIC SERINE THREONINE PROTEIN-KINASE WITH A TUMOR-SUPPRESSOR PROTEIN	ONCOGENE			English	Article							CELL-CYCLE CONTROL; HISTONE H-1 KINASE; M-PHASE; OSTEO-SARCOMA; CDC2 PROTEIN; DNA-REPLICATION; E1A PROTEINS; PHOSPHORYLATION; EXPRESSION; P53	Proline-directed protein kinase (PDPK) is characterized as a cytoplasmic oncogenic serine/theonine kinase that is activated by growth factor-mediated mechanisms and is proposed to function in mammalian somatic cells as an S phase promoting factor. The present study was undertaken to assess the hypothesis that p34cdc2/p58cyclin A PDPK is a physiologically relevant form of the p34cdc2 protein kinase that phosphorylates and inactivates the product of the retinoblastoma/osteosarcoma tumor susceptibility gene (Rb protein). In the course of these studies it was determined (fortuitously) that the p34cdc2/p58cyclin A PDPK purified from the cytosol of FM3A mouse mammary carcinoma cells was 'contaminated' by several high molecular weight substrate proteins that essentially co-purified with the protein kinase, one of which was identified as the Rb protein itself (p105Rb). High-resolution fast protein liquid chromatography (FPLC) revealed that the Rb protein co-purified with a particular subset of the PDPK heterodimer, i.e. with a single species of the 58 kDa cyclin A doublet. The subset of PDPK associated with the Rb protein exhibited somewhat lower specific enzyme activity, as judged by in vitro kinase assays and comparative Western blotting. Immunoprecipitation studies confirmed that p105Rb is physically associated with the p34cdc2/p58cyclin A PDPK. Further studies confirmed that the underphosphorylated Rb protein (p105Rb) present in G1 lysates of synchronized human MG63 osteosarcoma cells could be readily phosphorylated by purified PDPK in vitro, resulting in the characteristic shift in the apparent molecular mass (SDS-PAGE) of the Rb protein that is reported to accompany the hyperphosphorylation and functional inactivation of this protein. Moreover, the induction of the cyclin A subunit of PDPK in these synchronized MG63 cells was found to be closely correlated with the cell cycle-dependent phosphorylation of the Rb protein. From these studies it is concluded that the growth factor-sensitive PDPK is a physiological Rb kinase, which may function to inactivate the Rb protein in vivo.	CHILDRENS HOSP, DIV ORTHOPAED SURG, 4650 SUNSET BLVD, LOS ANGELES, CA 90054 USA; UNIV SO CALIF, SCH MED, DEPT MOLEC PHARMACOL & TOXICOL, LOS ANGELES, CA 90033 USA; UNIV SO CALIF, SCH PHARM, LOS ANGELES, CA 90089 USA	Children's Hospital Los Angeles; University of Southern California; University of Southern California								ADDISON C, 1990, ONCOGENE, V5, P423; ARION D, 1988, CELL, V55, P371, DOI 10.1016/0092-8674(88)90060-8; BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766; BOOHER R, 1986, MOL CELL BIOL, V6, P3523, DOI 10.1128/MCB.6.10.3523; Braun R K, 1989, Proc West Pharmacol Soc, V32, P15; BRIZUELA L, 1989, P NATL ACAD SCI USA, V86, P4362, DOI 10.1073/pnas.86.12.4362; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CHAMBERS TC, 1990, J BIOL CHEM, V265, P16940; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; COOPER JA, 1989, CELL, V58, P1009, DOI 10.1016/0092-8674(89)90495-9; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; Doree M, 1990, CURR OPIN CELL BIOL, V2, P269, DOI 10.1016/0955-0674(90)90018-A; DRAETTA G, 1990, TRENDS BIOCHEM SCI, V15, P378, DOI 10.1016/0968-0004(90)90235-4; DRAETTA G, 1988, CELL, V54, P17, DOI 10.1016/0092-8674(88)90175-4; DRAETTA G, 1989, CELL, V56, P829, DOI 10.1016/0092-8674(89)90687-9; DURSO G, 1990, SCIENCE, V250, P786, DOI 10.1126/science.2173140; EDELMAN AM, 1987, ANNU REV BIOCHEM, V56, P567, DOI 10.1146/annurev.biochem.56.1.567; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; GIORDANO A, 1991, ONCOGENE, V6, P481; GIORDANO A, 1989, CELL, V58, P981, DOI 10.1016/0092-8674(89)90949-5; Hall F L, 1989, Proc West Pharmacol Soc, V32, P1; HALL FL, 1990, J BIOL CHEM, V265, P6944; HALL FL, 1991, J BIOL CHEM, V266, P17430; HALL FL, 1991, J BONE JT SURG ORTHO, V15, P454; Hall FL, 1991, CURR OPIN CELL BIOL, V3, P176, DOI 10.1016/0955-0674(91)90136-M; HANSEN MF, 1985, P NATL ACAD SCI USA, V82, P6216, DOI 10.1073/pnas.82.18.6216; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; Kulp K S, 1990, Proc West Pharmacol Soc, V33, P219; LABBE JC, 1989, EMBO J, V8, P3053, DOI 10.1002/j.1460-2075.1989.tb08456.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; LANGAN TA, 1989, MOL CELL BIOL, V9, P3860, DOI 10.1128/MCB.9.9.3860; LANGAN TA, 1980, PROTEIN PHOSPHORYLAT, P70; LEE MG, 1987, NATURE, V327, P31, DOI 10.1038/327031a0; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; LEHNER CF, 1989, CELL, V56, P957, DOI 10.1016/0092-8674(89)90629-6; LEHNER CF, 1990, CELL, V61, P535, DOI 10.1016/0092-8674(90)90535-M; LEWIN B, 1990, CELL, V61, P743, DOI 10.1016/0092-8674(90)90181-D; LIN BTY, 1991, EMBO J, V10, P857, DOI 10.1002/j.1460-2075.1991.tb08018.x; LUDLOW JW, 1989, CELL, V56, P57, DOI 10.1016/0092-8674(89)90983-5; MATTHEWS HR, 1984, MOL CELL BIOCHEM, V59, P81; MCVEY D, 1989, NATURE, V341, P503, DOI 10.1038/341503a0; MEIJER L, 1989, EMBO J, V8, P2275, DOI 10.1002/j.1460-2075.1989.tb08353.x; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; MILLER CW, 1990, CANCER RES, V50, P7950; MINSHULL J, 1989, J CELL SCI, P77; MINSHULL J, 1990, EMBO J, V9, P2865, DOI 10.1002/j.1460-2075.1990.tb07476.x; MORENO S, 1990, CELL, V61, P549, DOI 10.1016/0092-8674(90)90463-O; MURPHREE AL, 1984, SCIENCE, V223, P1028, DOI 10.1126/science.6320372; MURRAY AW, 1989, SCIENCE, V246, P614, DOI 10.1126/science.2683077; MURRAY AW, 1989, NATURE, V339, P275, DOI 10.1038/339275a0; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PINES J, 1990, New Biologist, V2, P389; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; SAGER R, 1989, SCIENCE, V246, P1406, DOI 10.1126/science.2574499; SHAULSKY G, 1990, ONCOGENE, V5, P1707; SIMANIS V, 1986, CELL, V45, P261, DOI 10.1016/0092-8674(86)90390-9; TAYA Y, 1989, BIOCHEM BIOPH RES CO, V164, P580, DOI 10.1016/0006-291X(89)91759-2; TOGUCHIDA J, 1988, CANCER RES, V48, P3939; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VARLEY JM, 1989, ONCOGENE, V4, P725; Vulliet P R, 1988, Proc West Pharmacol Soc, V31, P255; VULLIET PR, 1989, J BIOL CHEM, V264, P16292; WANG J, 1990, NATURE, V343, P555, DOI 10.1038/343555a0; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; YOKOTA J, 1988, ONCOGENE, V3, P471	70	48	50	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	1992	7	3					423	432						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HK005	1532245				2022-12-25	WOS:A1992HK00500004
J	SAGARA, Y; WADE, JB; INESI, G				SAGARA, Y; WADE, JB; INESI, G			A CONFORMATIONAL MECHANISM FOR FORMATION OF A DEAD-END COMPLEX BY THE SARCOPLASMIC-RETICULUM ATPASE WITH THAPSIGARGIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; ADENOSINE-TRIPHOSPHATASE; FLUORESCEIN ISOTHIOCYANATE; INORGANIC-PHOSPHATE; CALCIUM-BINDING; TUMOR PROMOTER; CA-2+-ATPASE; CA-2+; PHOSPHORYLATION; INHIBITION	Thapsigargin (TG), a plant sesquiterpene lactone extract, interacts tightly with the sarcoplasmic reticulum (SR) Ca2+ transport ATPase yielding a 1:1 stoichiometric complex. In addition to inhibiting steady state enzyme activity, TG can be shown to inhibit two individual partial reactions of the ATPase cycle (i.e. Ca2+ binding in the absence of ATP and enzyme phosphorylation by P(i) in the absence of Ca2+) even when these reactions are studied separately without interdependence. As the two partial reactions occur at domains relatively distant from each other in the protein structure, it is apparent that the TG induced perturbation involves the entire enzyme. The rate of TG interaction with the ATPase, as estimated by the onset of functional inhibition and by the development of an intrinsic fluorescence signal, is relatively low in the presence of Ca2+. The interaction is much faster when Ca2+ is removed from the medium by the addition of EGTA or is dissociated from the enzyme by utilization of ATP. When the TG interaction with the ATPase is studied in the presence of Ca2+ as a function of temperature (15-35-degrees-C) and pH (6.0-8.0), two distinct kinetic components are observed: a fast component which is prevalent at high temperature and low pH, and a slow component which is prevalent at low temperature and high pH. This pattern suggests that the enzyme resides in two states, whose relatively slow equilibration is temperature- and pH-dependent. As only one state is reactive to TG, the enzyme population residing in this state reacts immediately with TG. On the other hand, the enzyme population residing in the alternate state must undergo slow conversion to the reactive state before being affected by TG. It can be also demonstrated that in the presence of Ca2+ TG shifts the ATPase from a refractory state to a state which is able to form bidimensional crystalline arrays stabilized by decavanadate. It is concluded that TG reacts specifically with the ATPase conformation which is prevalent in the absence of Ca2+, thereby forming a catalytically inactive dead-end complex.	UNIV MARYLAND, SCH MED, DEPT PHYSIOL, BALTIMORE, MD 21201 USA	University System of Maryland; University of Maryland Baltimore	SAGARA, Y (corresponding author), UNIV MARYLAND, SCH MED, DEPT BIOL CHEM, BALTIMORE, MD 21201 USA.							BIGELOW DJ, 1991, BIOCHEMISTRY-US, V30, P2113, DOI 10.1021/bi00222a016; BIRMACHU W, 1990, BIOCHEMISTRY-US, V29, P3904, DOI 10.1021/bi00468a017; BISHOP JE, 1988, BIOCHEMISTRY-US, V27, P5233, DOI 10.1021/bi00414a043; BUHLE EL, 1983, J ULTRA MOL STRUCT R, V85, P186, DOI 10.1016/S0022-5320(83)90106-5; CAMPBELL AM, 1991, J BIOL CHEM, V266, P16050; CASTELLANI L, 1985, J MOL BIOL, V185, P579, DOI 10.1016/0022-2836(85)90073-7; CLARKE DM, 1989, NATURE, V339, P476, DOI 10.1038/339476a0; COAN C, 1986, J BIOL CHEM, V261, P394; de Meis L, 1974, Biochemistry, V13, P2057, DOI 10.1021/bi00707a009; DEMEIS L, 1979, ANNU REV BIOCHEM, V48, P275; DUPONT Y, 1976, BIOCHEM BIOPH RES CO, V71, P544, DOI 10.1016/0006-291X(76)90821-4; DUX L, 1983, J BIOL CHEM, V258, P2599; ELETR S, 1972, BIOCHIM BIOPHYS ACTA, V282, P174, DOI 10.1016/0005-2736(72)90321-5; GREEN NM, 1986, CIBA F SYMP, V122, P93; GRYCZYNSKI I, 1989, BIOCHEMISTRY-US, V28, P3490, DOI 10.1021/bi00434a051; INESI G, 1976, BIOCHEMISTRY-US, V15, P5293, DOI 10.1021/bi00669a015; INESI G, 1980, J BIOL CHEM, V255, P3025; JACKSON TR, 1988, BIOCHEM J, V253, P81, DOI 10.1042/bj2530081; LACAPERE JJ, 1981, J BIOL CHEM, V256, P2302; LIN TI, 1977, ANAL BIOCHEM, V77, P10, DOI 10.1016/0003-2697(77)90284-6; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MACLENNAN DH, 1985, NATURE, V316, P696, DOI 10.1038/316696a0; MASUDA H, 1973, BIOCHEMISTRY-US, V12, P4581, DOI 10.1021/bi00747a006; MITCHINSON C, 1982, FEBS LETT, V146, P87, DOI 10.1016/0014-5793(82)80710-2; PICK U, 1981, FEBS LETT, V123, P127, DOI 10.1016/0014-5793(81)80035-X; SAGARA Y, 1991, J BIOL CHEM, V266, P13503; SCHARFF O, 1988, BIOCHIM BIOPHYS ACTA, V972, P257, DOI 10.1016/S0005-2728(88)80056-2; SUMBILLA C, 1991, J BIOL CHEM, V266, P12682; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; THASTRUP O, 1990, AGENTS ACTIONS, V29, P8, DOI 10.1007/BF01964706; WATANABE T, 1981, BIOCHEMISTRY-US, V20, P6617, DOI 10.1021/bi00526a015	31	120	123	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 15	1992	267	2					1286	1292						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY960	1530936				2022-12-25	WOS:A1992GY96000094
J	DELPINO, MMS; HAWKINS, RA; PETERSON, DR				DELPINO, MMS; HAWKINS, RA; PETERSON, DR			NEUTRAL AMINO-ACID-TRANSPORT BY THE BLOOD-BRAIN-BARRIER - MEMBRANE VESICLE STUDIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-GLUTAMYL-TRANSPEPTIDASE; PYROGLUTAMYL-HISTIDINE; ENDOTHELIAL-CELLS; RAT; MICROVESSELS; FRACTIONATION; KINETICS; RABBIT; CAPILLARIES; INNERVATION	Endothelial cell membranes, the site of the blood-brain barrier, were obtained from the capillaries of cow brain. The luminal and abluminal membranes were separated by centrifugation on a discontinuous Ficoll gradient. Electron microscopy revealed that the membrane preparations consisted almost entirely of sealed vesicles. The release of latent enzyme activity showed that both membrane preparations were primarily right side out. Radiolabeled L-phenylalanine uptake by luminal vesicles was proportional to membrane protein concentration, with less than 10% binding. Transport was by a high affinity carrier (K(m) 11.8 +/- 0.1 muM, asymptotic standard error) that showed little or no stereospecificity, and was independent of Na+ or H+ gradients. Transport was inhibited by L-tryptophan, L-leucine, 2-aminobicyclo[2,2,l]heptane-2-carboxylate and D-phenylalanine, but not by N-(methylamino)-isobutyrate. Abluminal membranes showed an additional component in which a Na+ gradient accelerated the transport of both phenylalanine and N-(methylamino)-isobutyrate. These studies demonstrate the utility of membrane vesicles as a model to characterize the transport properties of the distinct membranes of the polar endothelial cells that form the blood-brain barrier.	UNIV HLTH SCI CHICAGO MED SCH, DEPT PHYSIOL & BIOPHYS, 3333 GREEN BAY RD, N CHICAGO, IL 60064 USA	Chicago Medical School	PETERSON, DR (corresponding author), UNIV HLTH SCI CHICAGO MED SCH, DEPT PHYSIOL & BIOPHYS, 3333 GREEN BAY RD, N CHICAGO, IL 60064 USA.		del Pino, Manuel M. Sánchez/I-3977-2015	del Pino, Manuel M. Sánchez/0000-0001-9696-7600	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS031017] Funding Source: NIH RePORTER; NINDS NIH HHS [NS 31017-01] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AOYAGI M, 1988, J NEUROCHEM, V50, P1220, DOI 10.1111/j.1471-4159.1988.tb10596.x; BERTELOOT A, 1990, METHOD ENZYMOL, V192, P409; BETZ AL, 1980, BRAIN RES, V192, P17, DOI 10.1016/0006-8993(80)91004-5; BETZ AL, 1978, SCIENCE, V202, P225, DOI 10.1126/science.211586; BRADBURY M, 1979, CONCEPT BLOOD BRAIN, P60; Bradbury M.W., 1989, IMPLICATIONS BLOOD B, V1, P119; BRIGHTMA.MW, 1969, J CELL BIOL, V40, P648, DOI 10.1083/jcb.40.3.648; DELCASTILLO JR, 1982, BIOCHIM BIOPHYS ACTA, V688, P45, DOI 10.1016/0005-2736(82)90577-6; DERMIETZEL R, 1991, INT REV CYTOL, V127, P57; Fenstermacher JD, 1989, IMPLICATIONS BLOOD B, V1, P137; FOWLER S, 1977, J CELL BIOL, V75, P166, DOI 10.1083/jcb.75.1.166; FREY A, 1991, EUR J BIOCHEM, V202, P421, DOI 10.1111/j.1432-1033.1991.tb16391.x; FUJIWARA T, 1984, AM J ANAT, V170, P39, DOI 10.1002/aja.1001700104; GANAPATHY V, 1981, J BIOL CHEM, V256, P118; GHANDOUR MS, 1980, NEUROSCI LETT, V20, P125, DOI 10.1016/0304-3940(80)90133-0; GOLDSTEIN GW, 1986, SCI AM, V255, P74, DOI 10.1038/scientificamerican0986-74; GOLDSTEIN GW, 1975, J NEUROCHEM, V25, P715, DOI 10.1111/j.1471-4159.1975.tb04395.x; HANDLOGTEN ME, 1982, BIOCHEM BIOPH RES CO, V104, P307, DOI 10.1016/0006-291X(82)91975-1; HARGREAVES KM, 1988, J BIOL CHEM, V263, P19392; HARIK SI, 1986, P NATL ACAD SCI USA, V83, P4067, DOI 10.1073/pnas.83.11.4067; HEINZ E, 1984, BIOCHIM BIOPHYS ACTA, V776, P83, DOI 10.1016/0005-2736(84)90253-0; HERMAN IM, 1985, J CELL BIOL, V101, P43, DOI 10.1083/jcb.101.1.43; HJELLE JT, 1978, P NATL ACAD SCI USA, V75, P4544, DOI 10.1073/pnas.75.9.4544; HJELLE JT, 1981, KIDNEY INT, V20, P71, DOI 10.1038/ki.1981.106; JAFFE S, 1987, BIOCHIM BIOPHYS ACTA, V898, P37, DOI 10.1016/0005-2736(87)90107-6; JOO F, 1985, NEUROCHEM INT, V7, P1, DOI 10.1016/0197-0186(85)90002-6; KILBERG MS, 1981, J BIOL CHEM, V256, P3304; KNUDSEN GM, 1990, J CEREBR BLOOD F MET, V10, P698, DOI 10.1038/jcbfm.1990.123; KOEPPE RA, 1990, J CEREBR BLOOD F MET, V10, P727, DOI 10.1038/jcbfm.1990.126; LISY V, 1979, NEUROCHEM RES, V4, P747, DOI 10.1007/BF00964471; MAUNSBACH AB, 1966, J ULTRA MOL STRUCT R, V15, P242, DOI 10.1016/S0022-5320(66)80109-0; MURER H, 1980, J MEMBRANE BIOL, V55, P81, DOI 10.1007/BF01871151; NOVOGRODSKY A, 1976, P NATL ACAD SCI USA, V73, P2414, DOI 10.1073/pnas.73.7.2414; OLDENDORF WH, 1971, AM J PHYSIOL, V221, P1629, DOI 10.1152/ajplegacy.1971.221.6.1629; OLDENDORF WH, 1975, NERVOUS SYSTEM BASIC, P279; OXENDER DL, 1965, J BIOL CHEM, V240, P2976; PARDRIDGE WM, 1977, J NEUROCHEM, V28, P103, DOI 10.1111/j.1471-4159.1977.tb07714.x; PARDRIDGE WM, 1985, J NEUROCHEM, V44, P1178, DOI 10.1111/j.1471-4159.1985.tb08741.x; PARDRIDGE WM, 1983, PHYSIOL REV, V63, P1481, DOI 10.1152/physrev.1983.63.4.1481; PARDRIDGE WM, 1991, PEPTIDE DRUG DELIVER, P91; ROSTGAARD J, 1971, EXP CELL RES, V68, P356, DOI 10.1016/0014-4827(71)90161-3; SKOPICKI HA, 1989, AM J PHYSIOL, V257, pC971, DOI 10.1152/ajpcell.1989.257.5.C971; SKOPICKI HA, 1988, AM J PHYSIOL, V255, pC822, DOI 10.1152/ajpcell.1988.255.6.C822; SMITH QR, 1991, ADV EXP MED BIOL, V291, P55; SMITH QR, 1986, ANN NY ACAD SCI, V481, P186, DOI 10.1111/j.1749-6632.1986.tb27150.x; SMITH QR, 1987, J NEUROCHEM, V49, P1651, DOI 10.1111/j.1471-4159.1987.tb01039.x; TOVAR A, 1988, J NEUROCHEM, V51, P1285, DOI 10.1111/j.1471-4159.1988.tb03098.x; TRIGUERO D, 1990, J NEUROCHEM, V54, P1882, DOI 10.1111/j.1471-4159.1990.tb04886.x; TULKENS P, 1974, J CELL BIOL, V63, P383, DOI 10.1083/jcb.63.2.383; TURNER RJ, 1983, J MEMBRANE BIOL, V76, P1, DOI 10.1007/BF01871450; VADGAMA JV, 1985, J BIOL CHEM, V260, P2912; VORBRODT AW, 1988, PROG HISTOCHEM CYTOC, V18, P1	52	66	70	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 25	1992	267	36					25951	25957						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KD073	1464608				2022-12-25	WOS:A1992KD07300056
J	VILSEN, B; ANDERSEN, JP				VILSEN, B; ANDERSEN, JP			CRATP-INDUCED CA2+ OCCLUSION IN MUTANTS OF THE CA2+-ATPASE OF SARCOPLASMIC-RETICULUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTIONAL CONSEQUENCES; TRANSMEMBRANE DOMAIN; CA-2+-ATPASE; CALCIUM; CA-2+; TRANSPORT; ATPASE; PHOSPHORYLATION; MECHANISM; MUTATIONS	Use of the nonphosphorylating beta,gamma-bidentate chromium(III) complex of ATP to induce a stable Ca2+-occluded form of the sarcoplasmic reticulum Ca2+-ATPase was combined with molecular sieve high performance liquid chromatography of detergent-solubilized protein to examine the ability of the Ca2+-ATPase mutants Gly-233 --> Glu, Gly-233 --> Val, Glu-309 --> Gln, Gly-310 --> Pro, Pro-312 --> Ala, Ile-315 --> Arg, Leu-319 --> Arg, Asp-703 --> Ala, Gly-770 --> Ala, Glu-771 --> Gln, Asp-800 --> Asn, and Gly-801 --> Val to occlude Ca2+. This provided a new approach to identification of amino acid residues involved in Ca2+ binding and in the closure of the gates to the Ca2+ binding pocket of the Ca2+-ATPase. The "phosphorylation-negative" mutant Asp-703 --> Ala and mutants of ADP-sensitive phosphoenzyme intermediate type were fully capable of occluding Ca2+, as was the mutant Gly-770 --> Ala. Mutants in which carboxylic acid-containing residues in the putative transmembrane segments had been substituted ("Ca2+-site mutants") and mutant Gly-801 --> Val were unable to occlude either of the two calcium ions. In addition, the mutant Gly-310 --> Pro, previously classified as ADP-insensitive phosphoenzyme intermediate type (Andersen, J. P., Vilsen, B., and MacLennan, D. H. (1992). J. Biol. Chem. 267, 2767-2774), was unable to occlude Ca2+, even though Ca2+-activated phosphorylation from MgATP took place in this mutant.			VILSEN, B (corresponding author), AARHUS UNIV,INST PHYSIOL,DANISH BIOMEMBRANE RES CTR,DK-8000 AARHUS,DENMARK.			Vilsen, Bente/0000-0002-4727-9382; Andersen, Jens Peter/0000-0003-0654-4300				ANDERSEN JP, 1992, J BIOL CHEM, V267, P19383; ANDERSEN JP, 1989, BIOCHIM BIOPHYS ACTA, V988, P47, DOI 10.1016/0304-4157(89)90003-8; ANDERSEN JP, 1992, J BIOL CHEM, V267, P2767; ANDERSEN JP, 1989, J BIOL CHEM, V264, P21018; ANDERSEN JP, 1986, BIOCHEMISTRY-US, V25, P6439, DOI 10.1021/bi00369a015; CARVALHOALVES PC, 1983, J BIOL CHEM, V258, P3134; CLARKE DM, 1990, J BIOL CHEM, V265, P6262; CLARKE DM, 1989, NATURE, V339, P476, DOI 10.1038/339476a0; DEMEIS L, 1981, SARCOPLASMIC RETICUL; Forbush B 3rd, 1988, Prog Clin Biol Res, V268A, P229; GLYNN IM, 1990, ANNU REV BIOCHEM, V59, P171, DOI 10.1146/annurev.bi.59.070190.001131; GREEN NM, 1989, BIOCHEM SOC T, V17, P972, DOI 10.1042/bst0170972; INESI G, 1985, ANNU REV PHYSIOL, V47, P573, DOI 10.1146/annurev.ph.47.030185.003041; MARUYAMA K, 1988, P NATL ACAD SCI USA, V85, P3314, DOI 10.1073/pnas.85.10.3314; MCINTOSH DB, 1991, P NATL ACAD SCI USA, V88, P6437, DOI 10.1073/pnas.88.15.6437; ORLOWSKI S, 1991, BIOCHEMISTRY-US, V30, P352, DOI 10.1021/bi00216a007; SERPERSU EH, 1982, EUR J BIOCHEM, V122, P347, DOI 10.1111/j.1432-1033.1982.tb05887.x; TANFORD C, 1987, P NATL ACAD SCI USA, V84, P7094, DOI 10.1073/pnas.84.20.7094; VILSEN B, 1991, J BIOL CHEM, V266, P16157; VILSEN B, 1992, J BIOL CHEM, V267, P3539; VILSEN B, 1992, FEBS LETT, V306, P247, DOI 10.1016/0014-5793(92)81010-J; VILSEN B, 1987, BIOCHIM BIOPHYS ACTA, V898, P313, DOI 10.1016/0005-2736(87)90072-1; VILSEN B, 1986, BIOCHIM BIOPHYS ACTA, V855, P429, DOI 10.1016/0005-2736(86)90089-1; VILSEN B, 1991, J BIOL CHEM, V266, P18839; VILSEN B, 1989, J BIOL CHEM, V264, P21024	25	62	63	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1992	267	36					25739	25743						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KD073	1464590				2022-12-25	WOS:A1992KD07300025
J	ZILLIACUS, J; WRIGHT, APH; NORINDER, U; GUSTAFSSON, JA; CARLSTEDTDUKE, J				ZILLIACUS, J; WRIGHT, APH; NORINDER, U; GUSTAFSSON, JA; CARLSTEDTDUKE, J			DETERMINANTS FOR DNA-BINDING SITE RECOGNITION BY THE GLUCOCORTICOID RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEROID-HORMONE RECEPTORS; HIGH-LEVEL EXPRESSION; GENE-EXPRESSION; PROTEIN INTERACTIONS; RESPONSIVE ELEMENT; ESTROGEN-RECEPTOR; AMINO-ACIDS; DOMAIN; TRANSACTIVATION; SUPERFAMILY	The glucocorticoid receptor binds with high specificity to glucocorticoid response elements, discriminating them from other closely related binding sites. Three amino acids in the recognition alpha-helix of the DNA-binding domain of the receptor are primarily responsible for this specific DNA binding activity. In this study we analyze in detail how these residues determine the specific DNA binding by studying a series of mutant glucocorticoid receptor DNA-binding domains containing all combinations of glucocorticoid and estrogen receptor-specific residues at these positions. Statistical analysis of the results enables us to create models describing the association between amino acids and base pairs. Several strategies appear to be used in accomplishing discrimination between the glucocorticoid and estrogen response elements. Single residues (i.e., Val-443 in the glucocorticoid receptor and Glu-439 in the estrogen receptor) appear to form both positive contacts with specific base pairs in the cognate binding site and negative contacts in the non-cognate site. In the glucocorticoid receptor Ser-440 is pleiotropically negative for all sites tested but the negative effect is stronger for the estrogen response element thus contributing to binding site discrimination. Furthermore, combinations of amino acids appear to act synergistically, most often causing a reduction in binding to non-cognate sites.	KARO BIO AB,S-14104 HUDDINGE,SWEDEN		ZILLIACUS, J (corresponding author), KAROLINSKA INST,CTR BIOTECHNOL,NOVUM,S-14157 HUDDINGE,SWEDEN.		Wright, Anthony PH/J-8187-2015	Norinder, Ulf/0000-0003-3107-331X				ALROY I, 1992, NUCLEIC ACIDS RES, V20, P1045, DOI 10.1093/nar/20.5.1045; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; CARLSTEDTDUKE J, 1987, P NATL ACAD SCI USA, V84, P4437, DOI 10.1073/pnas.84.13.4437; DAHLMAN K, 1989, J BIOL CHEM, V264, P804; DAHLMANWRIGHT K, 1990, J BIOL CHEM, V265, P14030; DANIELSEN M, 1989, CELL, V57, P1131, DOI 10.1016/0092-8674(89)90050-0; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FREEDMAN LP, 1988, NATURE, V334, P543, DOI 10.1038/334543a0; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; GREEN JBA, 1988, MOL GEN GENET, V215, P100, DOI 10.1007/BF00331310; GREEN S, 1987, NATURE, V325, P75, DOI 10.1038/325075a0; GUSTAFSSON JA, 1987, ENDOCR REV, V8, P185, DOI 10.1210/edrv-8-2-185; HAM J, 1988, NUCLEIC ACIDS RES, V16, P5263, DOI 10.1093/nar/16.12.5263; HARD T, 1990, SCIENCE, V249, P157, DOI 10.1126/science.2115209; KLOCK G, 1987, NATURE, V329, P734, DOI 10.1038/329734a0; KUBINYI H, 1990, COMPREHENSIVE MED CH, V4, P589; LAUDET V, 1992, EMBO J, V11, P1003, DOI 10.1002/j.1460-2075.1992.tb05139.x; LUISI BF, 1991, NATURE, V352, P497, DOI 10.1038/352497a0; MADER S, 1989, NATURE, V338, P271, DOI 10.1038/338271a0; MARTINEZ E, 1987, EMBO J, V6, P3719, DOI 10.1002/j.1460-2075.1987.tb02706.x; NORINDER U, 1990, J COMPUT AID MOL DES, V4, P381, DOI 10.1007/BF00117403; OMALLEY B, 1990, MOL ENDOCRINOL, V4, P363, DOI 10.1210/mend-4-3-363; REMEROWSKI ML, 1991, BIOCHEMISTRY-US, V30, P11620, DOI 10.1021/bi00114a003; RUSCONI S, 1987, EMBO J, V6, P1309, DOI 10.1002/j.1460-2075.1987.tb02369.x; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHWABE JWR, 1990, NATURE, V348, P458, DOI 10.1038/348458a0; SHERMAN F, 1986, LABORATORY COURSE MA; STRAHLE U, 1987, P NATL ACAD SCI USA, V84, P7871, DOI 10.1073/pnas.84.22.7871; TRUSS M, 1990, P NATL ACAD SCI USA, V87, P7180, DOI 10.1073/pnas.87.18.7180; TRUSS M, 1991, MOL CELL BIOL, V11, P3247, DOI 10.1128/MCB.11.6.3247; TSAI SY, 1988, CELL, V55, P361, DOI 10.1016/0092-8674(88)90059-1; UMESONO K, 1989, CELL, V57, P1139, DOI 10.1016/0092-8674(89)90051-2; Wold S., 1984, CHEMOMETRICS MATH ST, P17, DOI DOI 10.1007/978-94-017-1026-8_2; WOLD S, 1979, TECHNOMETRICS, V20, P379; WRIGHT APH, 1991, P NATL ACAD SCI USA, V88, P8283, DOI 10.1073/pnas.88.19.8283; WRIGHT APH, 1990, J BIOL CHEM, V265, P14763; WRIGHT APH, 1991, MOL ENDOCRINOL, V5, P1366, DOI 10.1210/mend-5-10-1366; YAMAMOTO KR, 1985, ANNU REV GENET, V19, P209, DOI 10.1146/annurev.genet.19.1.209; ZILLIACUS J, 1991, J BIOL CHEM, V266, P3101	39	39	39	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1992	267	35					24941	24947						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KB603	1459998				2022-12-25	WOS:A1992KB60300008
J	GARFINKEL, S; HAINES, DS; BROWN, S; WESSENDORF, J; GILLESPIE, DH; MACIAG, T				GARFINKEL, S; HAINES, DS; BROWN, S; WESSENDORF, J; GILLESPIE, DH; MACIAG, T			INTERLEUKIN-1-ALPHA MEDIATES AN ALTERNATIVE PATHWAY FOR THE ANTIPROLIFERATIVE ACTION OF POLY(I.C) ON HUMAN ENDOTHELIAL-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRANDED-RNA; HUMAN-TUMOR CELLS; GROWTH-FACTOR; MESSENGER-RNA; SERIAL PROPAGATION; HUMAN INTERFERONS; VIRUS-INFECTION; IL-6 PRODUCTION; NECROSIS-FACTOR; EXPRESSION	The antiproliferative effect of double-stranded RNA (dsRNA) on human tumor and normal cells has been well established. However, the genes involved in the dsRNA-induced antiproliferative response and the molecular mechanisms by which this occurs remain less well defined. We have studied the ability of synthetic dsRNA, polyinosinic:polycytidylic acid (poly(I.C)) to modify human umbilical vein endothelial cell (HUVEC) growth and report that poly(I.C) induces a dose-dependent inhibition of HUVEC proliferation in vitro. In addition, the mRNA levels for the cytokines interleukin-1alpha (IL-1alpha) and interferon-beta1 are induced in poly(I.C)-treated cells. Moreover, the growth inhibitory effects of poly(I.C) are relieved when cells are grown in the presence of an IL-1alpha antisense oligonucleotide to the human IL-1alpha transcript. Thus, the effects of poly(I.C) appear to be mediated, in part, through the function of IL-1alpha, suggesting an alternative pathway for dsRNA-mediated inhibition of human endothelial cell growth.	AMER RED CROSS, HOLLAND LAB, DEPT MOLEC BIOL, 15601 CRABBS BRANCH WAY, ROCKVILLE, MD 20855 USA; HAHNEMANN UNIV, DEPT NEOPLAST DIS, PHILADELPHIA, PA 19102 USA	American Red Cross; Drexel University					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL035627] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL35627] Funding Source: Medline; NIA NIH HHS [AG07450] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BENDITT EP, 1983, P NATL ACAD SCI-BIOL, V80, P6386, DOI 10.1073/pnas.80.20.6386; CHAPEKAR MS, 1988, MOL PHARMACOL, V34, P461; CONTENT J, 1985, EUR J BIOCHEM, V152, P253, DOI 10.1111/j.1432-1033.1985.tb09191.x; COZZOLINO F, 1990, P NATL ACAD SCI USA, V87, P6487, DOI 10.1073/pnas.87.17.6487; CURVEN KD, 1980, LAB INVEST, V42, P366; DICK RS, 1987, J NEURO-ONCOL, V5, P331, DOI 10.1007/BF00148390; DINARELLO CA, 1984, REV INFECT DIS, V6, P51, DOI 10.1016/S1359-6101(97)00023-3; EINHORN S, 1985, J CELL PHYSIOL, V122, P200, DOI 10.1002/jcp.1041220206; ELIAS JA, 1990, J IMMUNOL, V145, P161; FORSBERG K, 1988, J CELL PHYSIOL, V136, P266, DOI 10.1002/jcp.1041360208; FRIEDMAN HM, 1981, J INFECT DIS, V143, P266, DOI 10.1093/infdis/143.2.266; FRIESEL R, 1987, J CELL BIOL, V104, P689, DOI 10.1083/jcb.104.3.689; GAY CG, 1990, J BIOL CHEM, V265, P3284; GHEZZI P, 1988, J IMMUNOL, V140, P4238; HAINES DS, 1991, J CELL BIOCHEM, V46, P9, DOI 10.1002/jcb.240460104; HAINES DS, 1992, BIOTECHNIQUES, V12, P736; HUBBELL HR, 1991, P NATL ACAD SCI USA, V88, P906, DOI 10.1073/pnas.88.3.906; HUBBELL HR, 1986, INT J CANCER, V37, P359, DOI 10.1002/ijc.2910370306; HUBBELL HR, 1984, CANCER RES, V44, P3252; JAMESON P, 1982, TEX REP BIOL MED, V41, P135; JIRIK FR, 1989, J IMMUNOL, V142, P144; LIN SL, 1982, NATURE, V297, P417, DOI 10.1038/297417a0; MACGREGOR RR, 1980, J CLIN INVEST, V65, P1469, DOI 10.1172/JCI109811; MACIAG T, 1981, J CELL BIOL, V91, P420, DOI 10.1083/jcb.91.2.420; MARCH CJ, 1985, NATURE, V315, P641, DOI 10.1038/315641a0; MINICK CR, 1979, AM J PATHOL, V96, P673; MONTESANO R, 1985, J CELL PHYSIOL, V122, P424, DOI 10.1002/jcp.1041220313; NORIOKA K, 1987, BIOCHEM BIOPH RES CO, V145, P969, DOI 10.1016/0006-291X(87)91060-6; RAY A, 1988, P NATL ACAD SCI USA, V85, P6701, DOI 10.1073/pnas.85.18.6701; ROSS R, 1976, NEW ENGL J MED, V295, P420, DOI 10.1056/NEJM197608192950805; ROSS R, 1976, NEW ENGL J MED, V295, P369, DOI 10.1056/NEJM197608122950707; Sambrook J, 1989, MOL CLONING LABORATO; SIRONI M, 1989, J IMMUNOL, V142, P549; TANIGUCHI T, 1989, J INTERFERON RES, V9, P633, DOI 10.1089/jir.1989.9.633; TORRENCE PF, 1977, PHARMACOL THER PT A, V2, P1, DOI 10.1016/0362-5478(77)90009-2; VANDAMME J, 1985, NATURE, V314, P266, DOI 10.1038/314266a0; VANDAMME J, 1987, J IMMUNOL, V139, P1867; VILCEK J, 1987, J CELL PHYSIOL, V130, P37, DOI 10.1002/jcp.1041300107; WARNER SJC, 1987, J IMMUNOL, V139, P1911; WILLIAMS BRG, 1980, TRENDS BIOCHEM SCI, V5, P138, DOI 10.1016/0968-0004(80)90057-2; WISDOM R, 1991, GENE DEV, V5, P232, DOI 10.1101/gad.5.2.232; ZILBERSTEIN A, 1986, EMBO J, V5, P2529, DOI 10.1002/j.1460-2075.1986.tb04531.x; ZULLO JN, 1985, CELL, V43, P793, DOI 10.1016/0092-8674(85)90252-1	43	34	34	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 5	1992	267	34					24375	24378						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KA263	1447187				2022-12-25	WOS:A1992KA26300038
J	SOMMER, A; PRENNER, E; GORGES, R; STUTZ, H; GRILLHOFER, H; KOSTNER, GM; PALTAUF, F; HERMETTER, A				SOMMER, A; PRENNER, E; GORGES, R; STUTZ, H; GRILLHOFER, H; KOSTNER, GM; PALTAUF, F; HERMETTER, A			ORGANIZATION OF PHOSPHATIDYLCHOLINE AND SPHINGOMYELIN IN THE SURFACE MONOLAYER OF LOW-DENSITY-LIPOPROTEIN AND LIPOPROTEIN(A) AS DETERMINED BY TIME-RESOLVED FLUOROMETRY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FLUORESCENCE LIFETIME DISTRIBUTIONS; EGG-YOLK PHOSPHATIDYLCHOLINE; NUCLEAR-MAGNETIC-RESONANCE; HUMAN-SERUM LIPOPROTEINS; HUMAN-PLASMA; APOLIPOPROTEIN-B; CHOLESTERYL ESTERS; PHASE-SEPARATION; LIPID BILAYERS; DIPHENYLHEXATRIENE	Fluorescent analogs of phosphatidylcholine (PC) and sphingomyelin (SM) labeled with diphenylhexatrienylpropionic acid (DPH) were prepared and incorporated into the surface layer of human low density lipoprotein (LDL) and lipoprotein(a) (Lp(a)). Fluorescence anisotropy measurements of DPH-PC and DPH-SM in both lipoprotein classes were carried out at different temperatures ranging from 20 to 37-degrees-C. DPH-PC as well as DPH-SM were shown to reside in more rigid domains in Lp(a) than in LDL according to higher anisotropy values in Lp(a). In both LDL and Lp(a), DPH-PC experienced a more rigid environment than DPH-SM, suggesting different environments of PC and SM in the surface shell of the lipoproteins. Fluorescence lifetimes of the labeled lipoproteins were determined by phase and modulation fluorometry. We found bimodal Lorentzian distributions for the decay times of DPH-PC and DPH-SM in LDL and Lp(a). Lifetime distribution centers for labeled lipids were very similar except for DPH-PC in Lp(a) which was shifted to longer lifetimes, suggesting a less polar environment of PC in Lp(a) than in LDL. The distributional width of DPH-PC in Lp(a) was broader than in LDL. Accordingly, phosphatidylcholine must be localized in a more homogeneous environment in LDL as compared with Lp(a). On the other hand, no difference in distributional widths was observed for DPH-SM in both lipoproteins, showing that SM organization in Lp(a) is unaffected by apo(a). From the obtained fluorescence data we propose that apoproteins discriminate between the choline phospholipids and preferentially associate with phosphatidylcholine. This effect is enhanced in Lp(a) due to the presence of apolipoprotein(a).	GRAZ TECH UNIV,INST BIOCHEM & LEBENSMITTELCHEM,A-8010 GRAZ,AUSTRIA; GRAZ UNIV,INST MED BIOCHEM,A-8010 GRAZ,AUSTRIA	Graz University of Technology; University of Graz			Prenner, Elmar J/E-5549-2011					ALCALA JR, 1987, BIOPHYS J, V51, P587, DOI 10.1016/S0006-3495(87)83383-0; ARMSTRONG VW, 1985, J LIPID RES, V26, P1314; ATKINSON D, 1977, P NATL ACAD SCI USA, V74, P1042, DOI 10.1073/pnas.74.3.1042; BATZRI S, 1973, BIOCHIM BIOPHYS ACTA, V298, P1015, DOI 10.1016/0005-2736(73)90408-2; BAUMSTARK MW, 1990, BIOCHIM BIOPHYS ACTA, V1037, P48, DOI 10.1016/0167-4838(90)90100-T; BERLIN E, 1983, ATHEROSCLEROSIS, V48, P15, DOI 10.1016/0021-9150(83)90014-X; BOGGS JM, 1987, BIOCHIM BIOPHYS ACTA, V906, P353, DOI 10.1016/0304-4157(87)90017-7; BROEKHUYSE RM, 1968, BIOCHIM BIOPHYS ACTA, V152, P307, DOI 10.1016/0005-2760(68)90038-6; CLADARAS C, 1986, EMBO J, V5, P3495, DOI 10.1002/j.1460-2075.1986.tb04675.x; COHEN R, 1984, CHEM PHYS LIPIDS, V35, P371, DOI 10.1016/0009-3084(84)90079-3; DECKELBAUM RJ, 1977, J BIOL CHEM, V252, P744; DECKELBAUM RJ, 1975, SCIENCE, V190, P392, DOI 10.1126/science.170681; DHAWAN S, 1983, BIOCHEMISTRY-US, V22, P3660, DOI 10.1021/bi00284a019; DOBRETSOV GE, 1982, BIOCHIM BIOPHYS ACTA, V710, P172, DOI 10.1016/0005-2760(82)90147-3; FENSKE DB, 1990, BIOCHEMISTRY-US, V29, P3973, DOI 10.1021/bi00468a026; FINER EG, 1975, BIOCHIM BIOPHYS ACTA, V380, P320, DOI 10.1016/0005-2760(75)90018-1; FIORINI RM, 1987, BIOCHEM BIOPH RES CO, V147, P460, DOI 10.1016/S0006-291X(87)80143-2; FLESS GM, 1986, J BIOL CHEM, V261, P8712; FOLCH J, 1957, J BIOL CHEM, V226, P497; GAUBATZ JW, 1983, J BIOL CHEM, V258, P4582; GRATTON E, 1983, BIOPHYS J, V44, P315, DOI 10.1016/S0006-3495(83)84305-7; GRIES A, 1988, J LIPID RES, V29, P1; GRONBERG L, 1991, BIOCHEMISTRY-US, V30, P10746, DOI 10.1021/bi00108a020; HANDA T, 1992, BIOCHEMISTRY-US, V31, P1415, DOI 10.1021/bi00120a018; HERMETTER A, 1989, CHEM PHYS LIPIDS, V50, P57, DOI 10.1016/0009-3084(89)90026-1; HOERRMANN W, 1991, VASA-J VASCULAR DIS, V20, P319; IBDAH JA, 1988, BIOCHEMISTRY-US, V27, P7155, DOI 10.1021/bi00418a073; JAMES DR, 1987, BIOCHEMISTRY-US, V26, P6272, DOI 10.1021/bi00393a047; JAMESON DM, 1983, NEW DIRECTIONS MOL L, P67; JONAS A, 1977, BIOCHIM BIOPHYS ACTA, V486, P10, DOI 10.1016/0005-2760(77)90065-0; KALB E, 1989, BIOPHYS J, V56, P1245, DOI 10.1016/S0006-3495(89)82771-7; KALLER H, 1961, BIOCHEM Z, V334, P451; KAN CC, 1991, BIOCHEMISTRY-US, V30, P7759, DOI 10.1021/bi00245a013; KARADI I, 1988, BIOCHIM BIOPHYS ACTA, V960, P91, DOI 10.1016/0005-2760(88)90013-6; KATES M, 1986, LAB TECHNIQUES BIOCH, V3, P186; KNIPPING G, 1986, BIOCHEMISTRY-US, V25, P5242, DOI 10.1021/bi00366a039; KNOTT TJ, 1986, NATURE, V323, P734, DOI 10.1038/323734a0; KREMER JMH, 1977, BIOCHEMISTRY-US, V16, P3932, DOI 10.1021/bi00636a033; KRIEGER M, 1978, J BIOL CHEM, V253, P4093; LAGGNER P, 1978, EUR J BIOCHEM, V84, P227, DOI 10.1111/j.1432-1033.1978.tb12160.x; LAGGNER P, 1981, J BIOL CHEM, V256, P1832; LAKOWICZ JR, 1981, J BIOCHEM BIOPH METH, V5, P131, DOI 10.1016/0165-022X(81)90012-9; LAURELL CB, 1966, ANAL BIOCHEM, V15, P45, DOI 10.1016/0003-2697(66)90246-6; LAW SW, 1986, P NATL ACAD SCI USA, V83, P8142, DOI 10.1073/pnas.83.21.8142; LENTZ BR, 1989, BIOPHYS J, V56, P723, DOI 10.1016/S0006-3495(89)82720-1; LENTZ BR, 1989, CHEM PHYS LIPIDS, V50, P171, DOI 10.1016/0009-3084(89)90049-2; LUNDKATZ S, 1986, BIOCHEMISTRY-US, V25, P1562, DOI 10.1021/bi00355a016; LUNDKATZ S, 1988, J BIOL CHEM, V263, P13831; LUNDKATZ S, 1990, J BIOL CHEM, V265, P12217; MCINTOSH TJ, 1992, BIOCHEMISTRY-US, V31, P2012, DOI 10.1021/bi00122a017; MOLOTKOVSKY JG, 1982, EUR J BIOCHEM, V122, P573; MULLER K, 1978, EUR J BIOCHEM, V82, P73, DOI 10.1111/j.1432-1033.1978.tb11998.x; MYHER JJ, 1989, LIPIDS, V24, P408, DOI 10.1007/BF02535148; OLOFSSON SO, 1987, ATHEROSCLEROSIS, V68, P1, DOI 10.1016/0021-9150(87)90088-8; PARASASSI T, 1984, J BIOL CHEM, V259, P4011; PARASASSI T, 1991, BIOPHYS J, V59, P466, DOI 10.1016/S0006-3495(91)82240-8; PARENTE RA, 1986, BIOCHEMISTRY-US, V25, P1021, DOI 10.1021/bi00353a011; POWNALL HJ, 1980, ATHEROSCLEROSIS, V36, P299, DOI 10.1016/0021-9150(80)90211-7; SATTLER W, 1991, BIOCHIM BIOPHYS ACTA, V1081, P65, DOI 10.1016/0005-2760(91)90251-C; SCANU AM, 1990, J CLIN INVEST, V85, P1709, DOI 10.1172/JCI114625; SCANU AM, 1991, CURR OPIN LIPIDOL, V2, P253; SKLAR LA, 1980, BIOCHEMISTRY-US, V19, P1294, DOI 10.1021/bi00548a005; SKLAR LA, 1981, J BIOL CHEM, V256, P4286; SMUTZER G, 1988, BIOCHIM BIOPHYS ACTA, V958, P323, DOI 10.1016/0005-2760(88)90217-2; SOMMER A, 1991, BIOCHEMISTRY-US, V30, P11245, DOI 10.1021/bi00111a008; SOUTAR A, 1978, NATURE, V1, P11; SPENCER RD, 1969, ANN NY ACAD SCI, V158, P361, DOI 10.1111/j.1749-6632.1969.tb56231.x; STEYRER E, 1990, J LIPID RES, V31, P1247; STRAUME M, 1987, BIOCHEMISTRY-US, V26, P5113, DOI 10.1021/bi00390a033; TRELEAVEN WD, 1986, BIOCHIM BIOPHYS ACTA, V877, P198, DOI 10.1016/0005-2760(86)90135-9; VANCE JE, 1990, BIOCHIM BIOPHYS ACTA, V1045, P128, DOI 10.1016/0005-2760(90)90141-J; VAUHKONEN M, 1989, BIOCHIM BIOPHYS ACTA, V984, P81, DOI 10.1016/0005-2736(89)90345-3; WATT RM, 1981, BIOCHEMISTRY-US, V20, P3897, DOI 10.1021/bi00516a036; WILLIAMS BW, 1988, BIOCHEMISTRY-US, V27, P7994, DOI 10.1021/bi00421a004; WILLIAMS BW, 1990, BIOCHEMISTRY-US, V29, P3248, DOI 10.1021/bi00465a016; YANG CY, 1986, NATURE, V323, P738, DOI 10.1038/323738a0; YEAGLE PL, 1977, BIOCHEMISTRY-US, V16, P3487, DOI 10.1021/bi00634a031; YEAGLE PL, 1982, BIOCHEMISTRY-US, V21, P1249, DOI 10.1021/bi00535a022; ZAWADZKI Z, 1988, BIOCHEMISTRY-US, V27, P8474, DOI 10.1021/bi00422a027	79	55	56	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1992	267	34					24217	24222						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KA263	1447171				2022-12-25	WOS:A1992KA26300014
J	FORESTA, C; ROSSATO, M; DIVIRGILIO, F				FORESTA, C; ROSSATO, M; DIVIRGILIO, F			EXTRACELLULAR ATP IS A TRIGGER FOR THE ACROSOME REACTION IN HUMAN SPERMATOZOA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-MEDIATED CYTOTOXICITY; EGG ZONA PELLUCIDA; BOVINE SPERMATOZOA; FOLLICULAR-FLUID; SPERM RECEPTOR; INDUCTION; IDENTIFICATION; FERTILIZATION; MEMBRANE; BINDING	We tested the effect of extracellular adenosine 5'-triphosphate (ATP(o)) on the activation of human spermatozoa. ATP(o), in a concentration range from 50-mu-M to 5 mM, induced the acrosome reaction, which, at the optimal concentration of 2.5 mM, was maximal (30-35% of spermatozoa activated) within 60 min of the addition of the nucleotide. At the end of this incubation in the presence of ATP. no decrease in cell motility and viability was observed. Among other purine/pyrimidine nucleotides only the ATP analogue adeny-5'-lyl imidodiphosphate was effective (70% of ATP); a weak (10% of ATP) effect was also observed with CTP and the ATP analogues adenosine 5'-(betagamma-methylene)triphosphate and adenosine 5'-O-(thiotriphosphate). ATP. did not cause Ca2+ release from intracellular stores, nor it caused Ca2+ influx from the extracellular milieu; on the contrary, it caused a clear, albeit slow, plasma membrane depolarization. ATP(o)-activated spermatozoa showed a nearly 100% success rate in the standard hamster egg fertilization test. Our results describe a new effect of ATP(o) in human spermatozoa with relevant potential applications in fertility studies.	UNIV FERRARA, INST GEN PATHOL, VIA BORSARI 46, I-44100 FERRARA, ITALY; UNIV PADUA, CATTEDRA PATOL MED 3, I-35121 PADUA, ITALY	University of Ferrara; University of Padua			rossato, marco/I-2093-2012; Di Virgilio, Francesco/J-3754-2018	rossato, marco/0000-0003-4327-2500; Di Virgilio, Francesco/0000-0003-3566-1362				Bean B P, 1990, Ion Channels, V2, P169; BIGGERS J. D., 1971, Methods in mammalian embryology, P86; BLEIL JD, 1988, DEV BIOL, V128, P376, DOI 10.1016/0012-1606(88)90299-0; BLEIL JD, 1988, P NATL ACAD SCI USA, V85, P6778, DOI 10.1073/pnas.85.18.6778; BYRD W, 1981, J EXP ZOOL, V215, P35, DOI 10.1002/jez.1402150105; CROZET N, 1984, GAMETE RES, V10, P241, DOI 10.1002/mrd.1120100304; CROZET N, 1984, GAMETE RES, V10, P97, DOI 10.1002/mrd.1120100202; DETOGNI P, 1984, BIOCHEM J, V224, P629, DOI 10.1042/bj2240629; DIVIRGILIO F, 1990, IMMUNOL TODAY, V11, P274, DOI 10.1016/0167-5699(90)90111-L; DIVIRGILIO F, 1987, J BIOL CHEM, V262, P9189; DUBYAK GR, 1991, AM J RESP CELL MOL, V4, P295, DOI 10.1165/ajrcmb/4.4.295; DUBYAK GR, 1990, ANN N Y ACAD SCI, V603; FAWCETT DW, 1975, DEV BIOL, V44, P394, DOI 10.1016/0012-1606(75)90411-X; FILIPPINI A, 1990, P NATL ACAD SCI USA, V87, P8267, DOI 10.1073/pnas.87.21.8267; GORDON JL, 1986, BIOCHEM J, V233, P309, DOI 10.1042/bj2330309; GREENBERG S, 1988, J BIOL CHEM, V263, P10337; HANDROW RR, 1982, BIOCHEM BIOPH RES CO, V107, P1326, DOI 10.1016/S0006-291X(82)80143-5; HYNE RV, 1979, P NATL ACAD SCI USA, V76, P5699, DOI 10.1073/pnas.76.11.5699; KARUHN RF, 1977, Patent No. 4036212; KINLOCH RA, 1988, P NATL ACAD SCI USA, V85, P6409, DOI 10.1073/pnas.85.17.6409; LI GD, 1991, J BIOL CHEM, V266, P3449; LUI CW, 1977, BIOL REPROD, V17, P34, DOI 10.1095/biolreprod17.1.34; NAZ RK, 1991, J CELL SCI, V99, P157; OSMAN RA, 1989, BIOCHEM BIOPH RES CO, V160, P828, DOI 10.1016/0006-291X(89)92508-4; RINGUETTE MJ, 1988, DEV BIOL, V127, P287, DOI 10.1016/0012-1606(88)90315-6; STEINBERG TH, 1991, CURR OPIN IMMUNOL, V3, P71, DOI 10.1016/0952-7915(91)90080-K; STEINBERG TH, 1989, METHOD CELL BIOL, V31, P45; SUAREZ SS, 1986, GAMETE RES, V14, P107, DOI 10.1002/mrd.1120140203; TALBOT P, 1981, J EXP ZOOL, V215, P201, DOI 10.1002/jez.1402150210; WASSARMAN PM, 1987, ANNU REV CELL BIOL, V3, P109, DOI 10.1146/annurev.cellbio.3.1.109; WOLF DP, 1985, BIOL REPROD, V32, P1157, DOI 10.1095/biolreprod32.5.1157; YANAGIMACHI R, 1976, BIOL REPROD, V15, P471, DOI 10.1095/biolreprod15.4.471; Yanagimachi R., 1988, P135	33	78	84	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 25	1992	267	27					19443	19447						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JP593	1527064				2022-12-25	WOS:A1992JP59300065
J	GOLDBERG, H; HELAAKOSKI, T; GARRETT, LA; KARSENTY, G; PELLEGRINO, A; LOZANO, G; MAITY, S; DECROMBRUGGHE, B				GOLDBERG, H; HELAAKOSKI, T; GARRETT, LA; KARSENTY, G; PELLEGRINO, A; LOZANO, G; MAITY, S; DECROMBRUGGHE, B			TISSUE-SPECIFIC EXPRESSION OF THE MOUSE ALPHA-2(I) COLLAGEN PROMOTER - STUDIES IN TRANSGENIC MICE AND IN TISSUE-CULTURE CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING FACTOR; NUCLEAR FACTOR-I; GROWTH-FACTOR-BETA; TRANSCRIPTION FACTOR; 1ST INTRON; REGULATORY FACTORS; SEQUENCE IDENTITY; MAMMALIAN-CELLS; GENE PROMOTER; ALPHA-1(I)	We sought to determine the cis-acting elements responsible for the pattern of tissue specific expression of the mouse alpha2(I) collagen gene. Using an RNase protection assay we first verified that expression of the alpha2(I) collagen gene is mainly confined to tendons, bone, and skin in mice. Both transgenic mice and DNA transfection of tissue culture cells were used as experimental approaches. Transgenic mice lines were generated harboring chloramphenicol acetyltransferase (CAT) chimeric genes that contained either (a) 2000 base pairs (bp) of 5'-flanking sequences of the mouse alpha2(I) collagen gene plus additional sequences between +418 and +1524 of the first intron of this gene or (b) the same promoter sequences without intron sequences or (c) the 350-bp proximal promoter sequences. Transgenic mice containing both types of 2000-bp promoters showed a pattern of CAT expression that was tissue specific. The presence of sequences of the first intron in the transgene did not increase the level of promoter activity. Transgenic mice harboring the 350-bp alpha2(I) collagen promoter also showed a pattern that was tissue-specific except that high level expression also occurred in the brain. This suggests that negative regulation is an important component of tissue-specific expression. In order to analyze the first 350 bases in detail, we performed transient expression experiments, using promoter fragments attached to the luciferase reporter gene. Fibroblasts, which show a high level expression of the endogenous alpha2(I) collagen gene, and B cells, in which the gene is silent, were transfected with a series of deletions and substitution mutations within the proximal 350-bp promotor. These experiments were unable to define unique cell-specific cis-acting elements. However, when the sequence between -315 and -284 was tandemly repeated upstream of a minimal alpha2(I) collagen promoter (-41 to +54), the activity of this construction was considerably higher in fibroblasts than in B cells when compared with the minimal promoter itself. In gel retardation assays, the levels of complexes that bind to this sequence were higher in fibroblast nuclear extracts than in myeloma nuclear extracts. Our results are consistent with the hypothesis that the -315 to -284 DNA sequence participates in the cell-specific control of the alpha2(I) collagen gene in fibroblasts.	UNIV TEXAS, MD ANDERSON CANC CTR, DEPT MOLEC GENET, HOUSTON, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center				Garrett-Sinha, Lee Ann/0000-0001-7806-4352	NHLBI NIH HHS [HL 41264] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL041264, R01HL141264] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BOAST S, 1990, J BIOL CHEM, V265, P13351; BORNSTEIN P, 1988, J BIOL CHEM, V263, P1603; BORNSTEIN P, 1989, PROG NUCLEIC ACID RE, V37, P67; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; FRAIN M, 1989, CELL, V59, P145, DOI 10.1016/0092-8674(89)90877-5; GIL G, 1988, P NATL ACAD SCI USA, V85, P8963, DOI 10.1073/pnas.85.23.8963; GILMAN M, 1987, CURRENT PROTOCOLS MO; HATAMOCHI A, 1986, J BIOL CHEM, V261, P1310; HATAMOCHI A, 1988, J BIOL CHEM, V263, P5940; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; INGRAHAM HA, 1988, CELL, V55, P519, DOI 10.1016/0092-8674(88)90038-4; INOUE T, 1990, J BIOL CHEM, V265, P19065; KAKUNAGA T, 1973, INT J CANCER, V12, P463, DOI 10.1002/ijc.2910120217; KARSENTY G, 1988, J BIOL CHEM, V263, P13909; KARSENTY G, 1990, J BIOL CHEM, V265, P9934; KARSENTY G, 1991, BIOCHEM BIOPH RES CO, V177, P538, DOI 10.1016/0006-291X(91)92017-E; KHILLAN JS, 1986, P NATL ACAD SCI USA, V83, P725, DOI 10.1073/pnas.83.3.725; LIAU G, 1986, J BIOL CHEM, V261, P1362; MACGREGOR GR, 1989, NUCLEIC ACIDS RES, V17, P2365, DOI 10.1093/nar/17.6.2365; MAITY SN, 1990, P NATL ACAD SCI USA, V87, P5378, DOI 10.1073/pnas.87.14.5378; MAITY SN, 1988, SCIENCE, V241, P582, DOI 10.1126/science.3399893; MAXWELL IH, 1989, BIOTECHNIQUES, V7, P276; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; OIKARINEN J, 1987, J BIOL CHEM, V262, P11064; OLSEN AS, 1991, J BIOL CHEM, V266, P1117; PAVLIN D, 1992, J CELL BIOL, V116, P227, DOI 10.1083/jcb.116.1.227; RITZENTHALER JD, 1991, BIOCHEM J, V280, P157, DOI 10.1042/bj2800157; ROSSI P, 1988, CELL, V52, P405, DOI 10.1016/S0092-8674(88)80033-3; ROSSI P, 1987, P NATL ACAD SCI USA, V84, P5590, DOI 10.1073/pnas.84.16.5590; ROSSOUW CMS, 1987, J BIOL CHEM, V262, P15151; RUPP RAW, 1990, NUCLEIC ACIDS RES, V18, P2607, DOI 10.1093/nar/18.9.2607; SANDMEYER S, 1981, J BIOL CHEM, V256, P5022; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; SCHMIDT A, 1985, NATURE, V314, P286, DOI 10.1038/314286a0; SCHMIDT A, 1986, MOL CELL BIOL, V6, P347, DOI 10.1128/MCB.6.2.347; SCHMIDT A, 1984, J BIOL CHEM, V259, P7411; SLACK JL, 1991, MOL CELL BIOL, V11, P2066, DOI 10.1128/MCB.11.4.2066; THOMPSON JP, 1991, J BIOL CHEM, V266, P2549; VUORIO T, 1990, J BIOL CHEM, V265, P22480; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; WOOD WM, 1989, J BIOL CHEM, V264, P14840	42	74	75	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 25	1992	267	27					19622	19630						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JP593	1527081				2022-12-25	WOS:A1992JP59300090
J	VIERECK, JC; BEINFELD, MC				VIERECK, JC; BEINFELD, MC			CHARACTERIZATION OF A CHOLECYSTOKININ-8-GENERATING ENDOPROTEASE PURIFIED FROM RAT-BRAIN SYNAPTOSOMES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONVERTING ENZYME; SECRETORY GRANULES; PREPROCHOLECYSTOKININ PRODUCTS; PROCESSING ENZYME; MONOBASIC SITES; CEREBRAL-CORTEX; CLEAVAGE; PEPTIDE; CELL; PROSOMATOSTATIN	An endoproteolytic activity that specifically cleaves CCK 33, producing CCK 8, has been purified from a rat brain synaptosome preparation. The purification, which included anion exchange, chromatofocusing, hydroxyapatite, and gel filtration chromatography, resulted in a greater than 3000-fold increase in specific activity. This neutral endoprotease (pH optimum 8) exists as a 90-kDa species, which can be dissociated into active 40-kDa species. The enzyme is a non-trypsin serine protease, which is inhibited by diisopropyl-fluorophosphate and p-aminobenzamidine but not by soybean trypsin inhibitor, phenylmethysulfonyl fluoride, aprotinin, or a number of thiol or metalloprotease inhibitors. It is highly substrate-specific and cleaves neither trypsin, enteropeptidase, kallikrein substrates, nor analogues of mono- or dibasic cleavage sites of prohormones other than pro-CCK. The endoprotease will not cleave CCK 12 desulfate or CCK (20-29), although these peptides contain common sequences with CCK-33. The protease does cleave [Glu27]CCK (20-29), a peptide in which the glutamate mimics the negative charge normally present on tyrosine sulfate. This suggests that the negative charge at position 27 is important in substrate recognition. The enzyme will also cleave CCK 33 and CCK (1-21) on the carboxyl-terminal side of a single lysine residue in position 11. The subcellular location and specificity of this endoprotease make it a good candidate for a CCK-processing protease.			VIERECK, JC (corresponding author), ST LOUIS UNIV,SCH MED,DEPT PHARMACOL & PHYSIOL SCI,1402 S GRAND BLVD,ST LOUIS,MO 63104, USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS018667] Funding Source: NIH RePORTER; NINDS NIH HHS [NS 18667] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALLARD LR, 1985, NEUROPEPTIDES, V6, P239, DOI 10.1016/0143-4179(85)90094-0; Atherton E., 1990, SOLID PHASE PEPTIDE; BEINFELD MC, 1989, J BIOL CHEM, V264, P4460; BEINFELD MC, 1981, NEUROPEPTIDES, V1, P203, DOI 10.1016/0143-4179(81)90015-9; BEINFELD MC, 1981, BRAIN RES, V212, P51, DOI 10.1016/0006-8993(81)90031-7; BEK E, 1990, BIOCHEMISTRY-US, V29, P178, DOI 10.1021/bi00453a024; BENOIT R, 1987, SCIENCE, V238, P1126, DOI 10.1126/science.2891188; BOURDAIS J, 1991, J BIOL CHEM, V266, P23386; CHAO J, 1983, J BIOL CHEM, V258, P5173; DAVIDSON HW, 1987, BIOCHEM J, V246, P279, DOI 10.1042/bj2460279; DAVIDSON HW, 1988, NATURE, V333, P93, DOI 10.1038/333093a0; DEVI L, 1991, FEBS LETT, V280, P189, DOI 10.1016/0014-5793(91)80290-J; DEVI L, 1984, P NATL ACAD SCI-BIOL, V81, P1892, DOI 10.1073/pnas.81.6.1892; DODD PR, 1981, BRAIN RES, V226, P107, DOI 10.1016/0006-8993(81)91086-6; DOUGLASS J, 1984, ANNU REV BIOCHEM, V53, P665; ENG J, 1983, P NATL ACAD SCI-BIOL, V80, P6381, DOI 10.1073/pnas.80.20.6381; FULLER RS, 1988, ANNU REV PHYSIOL, V50, P345, DOI 10.1146/annurev.ph.50.030188.002021; GLUSCHANKOF P, 1988, FEBS LETT, V234, P149, DOI 10.1016/0014-5793(88)81322-X; GLUSCHANKOF P, 1985, BIOCHEM BIOPH RES CO, V128, P1051, DOI 10.1016/0006-291X(85)91046-0; GOLTERMANN NR, 1980, J BIOL CHEM, V255, P6181; JULIUS D, 1984, CELL, V37, P1075, DOI 10.1016/0092-8674(84)90442-2; KAWABATA SI, 1988, EUR J BIOCHEM, V172, P17, DOI 10.1111/j.1432-1033.1988.tb13849.x; KORNER J, 1991, P NATL ACAD SCI USA, V88, P6834, DOI 10.1073/pnas.88.15.6834; KUKS P, 1991, J BIOL CHEM, V264, P14609; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOH YP, 1984, ANNU REV NEUROSCI, V7, P189, DOI 10.1146/annurev.ne.07.030184.001201; LOH YP, 1985, J BIOL CHEM, V260, P7194; LUGTENBERG B, 1975, FEBS LETT, V58, P254, DOI 10.1016/0014-5793(75)80272-9; MACKIN RB, 1991, ENDOCRINOLOGY, V129, P1951, DOI 10.1210/endo-129-4-1951; MALESCI A, 1980, P NATL ACAD SCI-BIOL, V77, P597, DOI 10.1073/pnas.77.1.597; MEEK JL, 1983, BRAIN RES, V276, P375, DOI 10.1016/0006-8993(83)90751-5; MIZUNO K, 1987, BIOCHEM BIOPH RES CO, V144, P807, DOI 10.1016/S0006-291X(87)80036-0; PLEVRAKIS I, 1989, BIOCHEMISTRY-US, V28, P2705, DOI 10.1021/bi00432a051; PORTER JG, 1989, J BIOL CHEM, V264, P6689; REHFELD JF, 1986, J BIOL CHEM, V261, P5832; REHFELD JF, 1986, J BIOL CHEM, V261, P5841; REHFELD JF, 1988, BIOCHIMIE, V70, P25, DOI 10.1016/0300-9084(88)90155-1; RHOLAM M, 1986, FEBS LETT, V207, P1, DOI 10.1016/0014-5793(86)80002-3; RYDER SW, 1980, P NATL ACAD SCI-BIOL, V77, P3669, DOI 10.1073/pnas.77.6.3669; SCHNEIDER LE, 1988, P NATL ACAD SCI USA, V85, P1993, DOI 10.1073/pnas.85.6.1993; SEIDAH NG, 1990, DNA CELL BIOL, V9, P415, DOI 10.1089/dna.1990.9.415; SMEEKENS SP, 1991, P NATL ACAD SCI USA, V88, P340, DOI 10.1073/pnas.88.2.340; STOCCHI V, 1989, ANAL BIOCHEM, V178, P107, DOI 10.1016/0003-2697(89)90364-3; STRAUS E, 1978, P NATL ACAD SCI USA, V75, P5711, DOI 10.1073/pnas.75.11.5711; VERHAGE M, 1991, J NEUROCHEM, V56, P1394, DOI 10.1111/j.1471-4159.1991.tb11437.x; WYPIJ DM, 1988, J BIOL CHEM, V263, P7079	46	25	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1992	267	27					19475	19481						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JP593	1527068				2022-12-25	WOS:A1992JP59300070
J	BAILEY, AD; STANHOPE, M; SLIGHTOM, JL; GOODMAN, M; SHEN, CC; SHEN, CKJ				BAILEY, AD; STANHOPE, M; SLIGHTOM, JL; GOODMAN, M; SHEN, CC; SHEN, CKJ			TANDEMLY DUPLICATED ALPHA GLOBIN GENES OF GIBBON	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-SEQUENCE; MOLECULAR EVOLUTION; THETA-1-GLOBIN GENE; CONCERTED EVOLUTION; HIGHER PRIMATES; GAMMA-GLOBIN; DNA; CONVERSIONS; RECOMBINATION; EXPRESSION	The alpha-globin gene locus of the common gibbon (Hylobates lar) was isolated, and it contains two closely linked alpha-globin genes that share the same arrangement as that found for the homologous genes of other catarrhine primates. The nucleotide sequences of the gibbon alpha-globin genes were determined and compared with the alpha-globin gene sequences from other primate species (human, chimpanzee, orangutan, baboon, and rhesus); the prosimian primate, galago, alpha-A and alpha-B globin genes provided the outgroup for this analysis. The degree of divergence for both synonymous and nonsynonymous substitutions among the alpha-globin genes are generally smaller for intraspecies than interspecies comparisons, which is indicative of concerted evolution between the paired alpha-globin genes of each catarrhine species. The pattern of differences is suggestive of gene conversions. This possibility is supported by both site-by-site and branch-swapping parsimony analyses. The site-by-site parsimony analysis was also used to determine the 3' boundary of each catarrhine species-specific conversion. These alpha-globin gene conversion events encompass most of the transcriptional region, including the promoter, exons, introns, and about one-half of the 3'-untranslated region. However, the paired gibbon alpha-globin genes show the highest degree of divergence, differing by five nucleotides in their coding regions, three of which encode amino acid replacement substitutions. It appears that the last convergence event between the paired gibbon alpha-globin genes is relatively ancient, having occurred approximately 11 million years ago. The remaining 3'-untranslated region and flanking DNAs show no evidence of involvement in any recent conversion event as the parsimony analysis of these sequences group all the alpha-1 globin genes of the different catarrhine species into one clade and all the alpha-2 globin gene of these species into a separate clade. The sequence comparison among the alpha-globin genes of different primate species also provides interesting implications regarding the evolution and functional domains of the 3'-untranslated regions.	UNIV CALIF DAVIS,DEPT GENET,DAVIS,CA 95616; WAYNE STATE UNIV,SCH MED,DEPT ANAT & CELL BIOL,DETROIT,MI 48201; UPJOHN CO,MOLEC BIOL UNIT 7242,KALAMAZOO,MI 49001	University of California System; University of California Davis; Wayne State University; Pfizer					NHLBI NIH HHS [HL-33940] Funding Source: Medline; NIDDK NIH HHS [DK-29800] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL033940] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK029800] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAILEY AD, 1991, THESIS U CALIFORNIA; BAILEY WJ, 1991, MOL BIOL EVOL, V8, P155; Bunn HF, 1986, HEMOGLOBIN MOL GENET; CHEN EY, 1985, DNA-J MOLEC CELL BIO, V4, P165, DOI 10.1089/dna.1985.4.165; CHENG JF, 1986, J BIOL CHEM, V261, P839; CLEGG JB, 1987, MOL BIOL EVOL, V4, P492; DODGSON JB, 1983, J BIOL CHEM, V258, P4623; DUNN IS, 1987, NUCLEIC ACIDS RES, V15, P2677; FITCH DHA, 1990, J BIOL CHEM, V265, P781; HALTINER M, 1985, NUCLEIC ACIDS RES, V13, P1015, DOI 10.1093/nar/13.3.1015; HESS JF, 1984, SCIENCE, V226, P67, DOI 10.1126/science.6474190; HESS JF, 1983, P NATL ACAD SCI-BIOL, V80, P5970, DOI 10.1073/pnas.80.19.5970; HSU SL, 1988, NATURE, V331, P94, DOI 10.1038/331094a0; KOOP BF, 1989, J BIOL CHEM, V264, P68; LAUER J, 1980, CELL, V20, P119, DOI 10.1016/0092-8674(80)90240-8; LEONG S, 1989, NUCLEIC ACIDS RES, V17, P8283; LIEBHABER SA, 1983, NUCLEIC ACIDS RES, V11, P8915, DOI 10.1093/nar/11.24.8915; LIEBHABER SA, 1981, NATURE, V290, P26, DOI 10.1038/290026a0; LIEBHABER SA, 1980, P NATL ACAD SCI-BIOL, V77, P7054, DOI 10.1073/pnas.77.12.7054; LIEBHABER SA, 1982, J BIOL CHEM, V257, P1852; MAHONEY WC, 1980, BIOCHEMISTRY-US, V19, P1529, DOI 10.1021/bi00548a041; Maniatis T., 1982, MOL CLONING; MARKS J, 1986, P NATL ACAD SCI USA, V83, P1413, DOI 10.1073/pnas.83.5.1413; MICHELSON AM, 1983, J BIOL CHEM, V258, P5245; NEI M, 1986, MOL BIOL EVOL, V3, P418; PROUDFOOT NJ, 1982, CELL, V31, P553, DOI 10.1016/0092-8674(82)90311-7; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAWADA I, 1986, J MOL BIOL, V192, P693, DOI 10.1016/0022-2836(86)90022-7; SCHON EA, 1982, J BIOL CHEM, V257, P6825; SHAW JP, 1987, NATURE, V326, P717, DOI 10.1038/326717a0; SHAW JP, 1989, P NATL ACAD SCI USA, V86, P1312, DOI 10.1073/pnas.86.4.1312; SHAW JP, 1987, DEV CONTROL GLOBIN G, P65; SLIGHTOM JL, 1980, CELL, V21, P627, DOI 10.1016/0092-8674(80)90426-2; SLIGHTOM JL, 1988, J BIOL CHEM, V263, P12427; SLIGHTOM JL, 1992, IN PRESS METHODS ENZ; Swofford David L., 1990, P411; Szalay F.S., 1979, EVOLUTIONARY HIST PR; WICKENS M, 1990, TRENDS BIOCHEM SCI, V15, P277, DOI 10.1016/0968-0004(90)90054-F; ZIMMER EA, 1980, P NATL ACAD SCI-BIOL, V77, P2158, DOI 10.1073/pnas.77.4.2158	39	4	6	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1992	267	26					18398	18406						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JN502	1526980				2022-12-25	WOS:A1992JN50200028
J	MAEGLEY, KA; GONZALEZ, L; SMITH, DW; REICH, NO				MAEGLEY, KA; GONZALEZ, L; SMITH, DW; REICH, NO			COFACTOR AND DNA INTERACTIONS IN ECORI DNA METHYLTRANSFERASE - FLUORESCENCE SPECTROSCOPY AND PHENYLALANINE REPLACEMENT FOR TRYPTOPHAN 183	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING; PROTEIN; IDENTIFICATION; METHYLASE; SEQUENCE; FORMS; SITE	EcoRI DNA methyltransferase contains tryptophans at positions 183 and 225. Tryptophan 225 is adjacent to residues previously implicated in S-adenosylmethionine (AdoMet) binding and to cysteine 223, previously shown to be the site of N-ethyl maleimide-mediated inactivation of the enzyme (Reich, N. O., and Everett, E. (1990) J. Biol. Chem. 265, 8929-8934; Everett, E. A., Falick, A. M., and Reich, N. 0. (1990) J. Biol. Chem. 265, 17713-17719). The fluorescence spectra of the wild-type enzyme is centered at 338 nm indicating partial tryptophan solvent accessibility. Substitution of tryptophan 183 with phenylalanine results in a 45% drop in fluorescence intensity, but no shift in lambda(max). DNA binding to the wild-type methyltransferase caused an increase in the fluorescence intensity, while binding to the tryptophan 183 mutant had a quenching effect, suggesting that DNA binding induces a conformational change near both tryptophans. Binding of AdoMet and various AdoMet analogs to the wild-type methyltransferase results in no change in the fluorescence spectrum when excitation occurs at 295 nm, suggesting that no conformational change occurs, and AdoMet does not interact with either tryptophan. In contrast, quenching was observed when excitation occurred at 280 nm, suggesting that AdoMet and its analogs may be quenching tyrosine to tryptophan energy transfer. Protein-ligand complexes were titrated with acrylamide, and the data also implicate conformational changes upon DNA binding but not upon AdoMet binding, consistent with previous limited proteolysis results (Reich, N. O., Maegley, K. A., Shoemaker, D. D., and Everett, E. (1991) Biochemistry 30, 2940-2946).	UNIV CALIF SANTA BARBARA, DEPT CHEM, SANTA BARBARA, CA 93106 USA	University of California System; University of California Santa Barbara			Gonzalez, Lino/E-4102-2012	Gonzalez, Lino/0000-0003-3817-6450				Adams R. L. P., 1985, MOL BIOL DNA METHYLA; BORCHARDT RT, 1978, J MED CHEM, V21, P1307, DOI 10.1021/jm00210a026; BORCHARDT RT, 1976, J MED CHEM, V19, P1104, DOI 10.1021/jm00231a005; BUJALOWSKI W, 1987, BIOCHEMISTRY-US, V26, P3099, DOI 10.1021/bi00385a023; BURNSTEIN EA, 1973, PHOTOCHEM PHOTOBIOL, V18, P263; Chandrasegaran S, 1988, STRUCTURE EXPRESSION, V1, P149; EVERETT EA, 1990, J BIOL CHEM, V265, P17713; GREENE PJ, 1978, NUCLEIC ACIDS RES, V5, P2373, DOI 10.1093/nar/5.7.2373; HANSEN D, 1987, J BIOL CHEM, V262, P12269; HARD T, 1989, BIOCHEMISTRY-US, V28, P396; INGROSSO D, 1989, J BIOL CHEM, V264, P20131; KAKOWICZ JR, 1983, PRINCIPLES FLUORESCE, P259; KELLY RC, 1976, J BIOL CHEM, V251, P7229; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LEHRER SS, 1971, BIOCHEMISTRY-US, V10, P3254, DOI 10.1021/bi00793a015; MCCUBBIN WD, 1988, J BIOL CHEM, V263, P17663; Modrich P., 1982, NUCLEASES, P109; Parker C. A., 1968, PHOTOLUMINESCENCE SO, P220; RAZIN A, 1984, DNA METHYLATION BIOC; REICH NO, 1991, BIOCHEMISTRY-US, V30, P2940, DOI 10.1021/bi00225a030; REICH NO, 1990, J BIOL CHEM, V265, P8929; REICH NO, 1991, BIOCHEMISTRY-US, V30, P2933, DOI 10.1021/bi00225a029; RUBIN RA, 1977, J BIOL CHEM, V252, P7265; SAMWORTH CM, 1988, EUR J BIOCHEM, V171, P81, DOI 10.1111/j.1432-1033.1988.tb13761.x; Stern O, 1919, PHYS Z, V20, P183; TSAO DHH, 1991, BIOCHEMISTRY-US, V30, P4565, DOI 10.1021/bi00232a029; WILSON GG, 1991, NUCLEIC ACIDS RES, V19, P2539, DOI 10.1093/nar/19.10.2539	27	10	10	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	1992	267	26					18527	18532						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JN502	1526989				2022-12-25	WOS:A1992JN50200046
J	DIMMELER, S; LOTTSPEICH, F; BRUNE, B				DIMMELER, S; LOTTSPEICH, F; BRUNE, B			NITRIC-OXIDE CAUSES ADP-RIBOSYLATION AND INHIBITION OF GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							L-ARGININE; DIPHTHERIA-TOXIN; RIBOSYLTRANSFERASE; PROTEINS; MACROPHAGES; BINDING; CELLS; NEUROTOXICITY; SYNTHASE	Nitric oxide and nitric oxide-generating agents like 3-morpholinosydnonimine (SIN-1) stimulate the mono-ADP-ribosylation of a cytosolic, 39-kDa protein in various tissues. This protein was purified from human platelet cytosol by conventional and fast protein liquid chromatography techniques. N-terminal sequence analysis identified the isolated protein as the glycolytic enzyme glyceraldehyde-3-phosphate dehydrogenase (GAPDH). Nitric oxide stimulates the auto-ADP-ribosylation of GAPDH in a time and concentration-dependent manner with maximal effects after about 60 min. Associated with ADP-ribosylation is a loss of enzymatic activity. NAD+-free enzyme is not inhibited by SIN-1, indicating the absolute requirement of NAD+ as the substrate of the ADP-ribosylation reaction. Inhibition of the glycolytic enzyme GAPDH may be relevant as a cytotoxic effect of NO complementary to its inhibitory actions on iron-sulfur enzymes like aconitase and electron transport proteins of the respiratory chain.	UNIV CONSTANCE,FAC BIOL,UNIV STR 8-10,POSTFACH 5560,W-7750 CONSTANCE,GERMANY; MAX PLANCK INST BIOCHEM,GENZENTRUM,W-8033 MARTINSRIED,GERMANY	University of Konstanz; Max Planck Society				Dimmeler, Stefanie/0000-0002-1045-2436				AKTORIES K, 1988, BIOCHEM BIOPH RES CO, V156, P361, DOI 10.1016/S0006-291X(88)80849-0; ALTHAUS FR, 1987, ADP RIBOSYLATION PRO; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; BRUNE B, 1989, J BIOL CHEM, V264, P8455; BRUNE B, 1990, ARCH BIOCHEM BIOPHYS, V279, P286, DOI 10.1016/0003-9861(90)90493-I; CURRAN RD, 1991, FASEB J, V5, P2085, DOI 10.1096/fasebj.5.7.1707021; DAWSON VL, 1991, P NATL ACAD SCI USA, V88, P6368, DOI 10.1073/pnas.88.14.6368; DIMMELER S, 1991, BIOCHEM BIOPH RES CO, V178, P848, DOI 10.1016/0006-291X(91)90968-D; DRAPIER JC, 1986, J CLIN INVEST, V78, P790, DOI 10.1172/JCI112642; DUMAN RS, 1991, J NEUROCHEM, V57, P2124, DOI 10.1111/j.1471-4159.1991.tb06431.x; FORSTERMANN U, 1991, BIOCHEM PHARMACOL, V42, P1849, DOI 10.1016/0006-2952(91)90581-O; FURCHGOTT RF, 1989, FASEB J, V3, P2007, DOI 10.1096/fasebj.3.9.2545495; GRANGER DL, 1988, J CLIN INVEST, V81, P1129, DOI 10.1172/JCI113427; HAYAISHI O, 1977, ANNU REV BIOCHEM, V46, P95, DOI 10.1146/annurev.bi.46.070177.000523; HIBBS JB, 1988, BIOCHEM BIOPH RES CO, V157, P87, DOI 10.1016/S0006-291X(88)80015-9; IGNARRO LJ, 1989, FASEB J, V3, P31, DOI 10.1096/fasebj.3.1.2642868; JACOBSON MK, 1990, J BIOL CHEM, V265, P10825; JACOBSON MK, 1989, ADP RIBOSE TRANSFER; JOHNSTON RF, 1990, ELECTROPHORESIS, V11, P355, DOI 10.1002/elps.1150110503; KOTS AY, 1992, FEBS LETT, V300, P9, DOI 10.1016/0014-5793(92)80153-8; KRONCKE KD, 1991, BIOCHEM BIOPH RES CO, V175, P752, DOI 10.1016/0006-291X(91)91630-U; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE H, 1984, P NATL ACAD SCI-BIOL, V81, P2703, DOI 10.1073/pnas.81.9.2703; MELDRUM B, 1990, TRENDS PHARMACOL SCI, V11, P379, DOI 10.1016/0165-6147(90)90184-A; MONCADA S, 1991, PHARMACOL REV, V43, P109; MOSS J, 1988, ADV ENZYMOL RAMB, V61, P303; MOSS J, 1984, METHOD ENZYMOL, V106, P430; PAPPENHEIMER AM, 1977, ANNU REV BIOCHEM, V46, P69, DOI 10.1146/annurev.bi.46.070177.000441; SLATER M, 1991, FEBS LETT, V291, P145; SNYDER SH, 1991, TRENDS PHARMACOL SCI, V12, P125, DOI 10.1016/0165-6147(91)90526-X; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P444, DOI 10.1073/pnas.89.1.444; TAKEMA M, 1991, J IMMUNOL, V146, P1928; TANUMA S, 1988, J BIOL CHEM, V263, P5485; TAYLOR JF, 1948, J BIOL CHEM, V173, P619; TORCHINSKY YM, 1981, SULFUR PROTEINS, P154; UI M, 1990, ADP RIBOSYLATING TOX, P45; VAUGHAN M, 1982, CURR TOP CELL REGUL, V20, P205; WALDMAN SA, 1987, PHARMACOL REV, V39, P163; WICK MJ, 1990, ADP RIBOSYLATING TOX, P31	40	269	273	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1992	267	24					16771	16774						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JL053	1512218				2022-12-25	WOS:A1992JL05300007
J	LE, AQ; FERRELL, GA; DISHON, DS; LE, QQA; SIFERS, RN				LE, AQ; FERRELL, GA; DISHON, DS; LE, QQA; SIFERS, RN			SOLUBLE AGGREGATES OF THE HUMAN PIZ ALPHA-1-ANTITRYPSIN VARIANT ARE DEGRADED WITHIN THE ENDOPLASMIC-RETICULUM BY A MECHANISM SENSITIVE TO INHIBITORS OF PROTEIN-SYNTHESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ALPHA-1-PROTEINASE INHIBITOR; HEPATOMA SECRETORY PROTEINS; TRANSGENIC MICE; INTRACELLULAR DEGRADATION; GOLGI STACK; BREFELDIN-A; PRE-GOLGI; TRANSPORT; COMPLEX; GENE	Greater than 85% of the transport-impaired PiZ variant of human alpha-1-antitrypsin is retained within transfected mouse hepatoma cells and is subjected to intracellular degradation (Le, A., Graham, K., and Sifers, R. N. (1990) J. Biol. Chem. 265, 14001-14007). The retained protein undergoes a discrete size reduction that results from the modification of its endoglycosidase H-sensitive oligosaccharides and is inhibited by 1-deoxymannojirimycin. Metabolic poisons and inhibitors of protein synthesis perturb the intracellular degradation of the retained protein but do not affect its size reduction. The ability of metabolic poisons to influence the degradation of the PiZ variant in cells treated with brefeldin A indicates that export of the macromolecule from the endoplasmic reticulum (ER) is not the energy-dependent component of its degradation. Subcellular fractionation experiments have verified that both the size reduction and degradation of the retained PiZ variant occur within the rough ER. Finally, sedimentation velocity centrifugation analysis of radiolabeled cell extracts has indicated that approximately 80% of the PiZ variant, consists as soluble aggregates immediately after its synthesis. An inability to detect more extensive aggregation during the retention period supports our previous conclusion that only a small fraction of the macromolecules actually form large insoluble aggregates (Graham, K. S., Le, A., and Sifers, R. N. (1990) J. Biol. Chem. 265, 20463-20468). Overall, these findings indicate that soluble aggregates of the PiZ variant are degraded within the ER by a mechanism sensitive to inhibitors of protein synthesis.	BAYLOR COLL MED,DEPT PATHOL,MOLEC PATHOBIOL SECT,1 BAYLOR PLAZA,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT CELL BIOL,HOUSTON,TX 77030	Baylor College of Medicine; Baylor College of Medicine			Sifers, Richard Norman/AGQ-7262-2022		NATIONAL CENTER FOR RESEARCH RESOURCES [S07RR005425] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK042806] Funding Source: NIH RePORTER; NCRR NIH HHS [SO7 RR05425] Funding Source: Medline; NIDDK NIH HHS [DK 42806] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AMARA JF, 1989, J CELL BIOL, V109, P3315, DOI 10.1083/jcb.109.6.3315; BALCH WE, 1986, J BIOL CHEM, V261, P4681; BECKERS CJM, 1989, J CELL BIOL, V108, P1245, DOI 10.1083/jcb.108.4.1245; BISCHOFF J, 1986, J BIOL CHEM, V261, P4768; BONAFACINO JS, 1990, CELL, V63, P503; BONIFACINO JS, 1990, SCIENCE, V247, P79, DOI 10.1126/science.2294595; BRANTLY M, 1988, AM J MED, V84, P13; CARLSON JA, 1988, J CLIN INVEST, V82, P26, DOI 10.1172/JCI113580; CARLSON JA, 1989, J CLIN INVEST, V83, P1183, DOI 10.1172/JCI113999; CARRELL RW, 1982, NATURE, V298, P329, DOI 10.1038/298329a0; COX DW, 1986, FEBS LETT, V205, P255, DOI 10.1016/0014-5793(86)80908-5; DEBRABANDER MJ, 1976, CANCER RES, V36, P905; DONALDSON JG, 1990, J CELL BIOL, V111, P2295, DOI 10.1083/jcb.111.6.2295; DUNPHY WG, 1985, CELL, V42, P13, DOI 10.1016/S0092-8674(85)80097-0; DYAICO MJ, 1988, SCIENCE, V242, P1409; GRAHAM KS, 1990, J BIOL CHEM, V265, P20463; IVESSA N E, 1989, Journal of Cell Biology, V109, p207A; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; LE A, 1990, J BIOL CHEM, V265, P14001; LIPPINCOTTSCHWARTZ J, 1990, CELL, V60, P821, DOI 10.1016/0092-8674(90)90096-W; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; LIPPINCOTTSCHWARTZ J, 1988, CELL, V54, P209, DOI 10.1016/0092-8674(88)90553-3; LODISH HF, 1987, J CELL BIOL, V104, P221, DOI 10.1083/jcb.104.2.221; LODISH HF, 1983, NATURE, V304, P80, DOI 10.1038/304080a0; LOEBERMANN H, 1984, J MOL BIOL, V177, P531, DOI 10.1016/0022-2836(84)90298-5; MARTIN RG, 1961, J BIOL CHEM, V236, P1372; MCCRACKEN AA, 1989, MOL CELL BIOL, V9, P1406, DOI 10.1128/MCB.9.4.1406; MILLER AL, 1981, LYSOSOMES LYSOSOMAL, P271; NUKIWA T, 1986, J BIOL CHEM, V261, P5989; PELHAM HRB, 1988, EMBO J, V7, P913, DOI 10.1002/j.1460-2075.1988.tb02896.x; PERLMUTTER DH, 1989, AM J PHYSIOL, V257, pL147, DOI 10.1152/ajplung.1989.257.4.L147; RIZZOLO LJ, 1988, J BIOL CHEM, V263, P9520; ROTHMAN JE, 1987, CELL, V50, P521, DOI 10.1016/0092-8674(87)90024-9; SAUNIER B, 1982, J BIOL CHEM, V257, P4155; SHARP HL, 1969, J LAB CLIN MED, V73, P934; SIFERS RN, 1987, NUCLEIC ACIDS RES, V15, P1459, DOI 10.1093/nar/15.4.1459; SIFERS RN, 1988, J BIOL CHEM, V263, P7330; WALTER P, 1984, CELL, V38, P5, DOI 10.1016/0092-8674(84)90520-8; WIELAND FT, 1987, CELL, V50, P289, DOI 10.1016/0092-8674(87)90224-8; WIKSTROM L, 1991, J CELL BIOL, V113, P997, DOI 10.1083/jcb.113.5.997; WILEMAN T, 1990, J CELL BIOL, V110, P973, DOI 10.1083/jcb.110.4.973	41	104	104	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 15	1992	267	2					1072	1080						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY960	1530934				2022-12-25	WOS:A1992GY96000064
J	ZIEGELHOFFER, T; YAU, P; CHANDRASEKHAR, GN; KOCHAN, J; GEORGOPOULOS, C; MURIALDO, H				ZIEGELHOFFER, T; YAU, P; CHANDRASEKHAR, GN; KOCHAN, J; GEORGOPOULOS, C; MURIALDO, H			THE PURIFICATION AND PROPERTIES OF THE SCAFFOLDING PROTEIN OF BACTERIOPHAGE-LAMBDA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBULOSE BISPHOSPHATE CARBOXYLASE; ESCHERICHIA-COLI; GENE-PRODUCTS; HEAD MORPHOGENESIS; ASSEMBLY INVITRO; GROEL; DNA; IDENTIFICATION; MITOCHONDRIA; MATURATION	The Nu3 gene of bacteriophage lambda-resides within a cluster of genes that specify structural components of the bacteriophage head. Previous experiments indicate that the Nu3 gene product (gpNu3) is associated with immature proheads but is not detectable in mature proheads or bacteriophage particles, hence its classification as a scaffolding protein. The Nu3 gene has been cloned and overexpressed, and its protein product has been purified. The purified protein is biologically active, as demonstrated by its ability to complement a gpNu3-deficient extract in an in vitro assembly reaction. The sequence of the amino terminus of the protein indicates that translation of Nu3 starts at nucleotide position 5,342 on the standard lambda-DNA sequence, yielding a protein with a calculated M(r) of 13,396. A combination of gel exclusion chromatography and velocity sedimentation gradient data indicates that gpNu3 possesses an unusually elongated shape.	UNIV UTAH,MED CTR,DEPT CELLULAR VIRAL & MOLEC BIOL,SALT LAKE CITY,UT 84132; UNIV TORONTO,FAC MED,DEPT MOLEC & MED GENET,TORONTO M5S 1A8,ONTARIO,CANADA	Utah System of Higher Education; University of Utah; University of Toronto					NIGMS NIH HHS [5T32GMO7464-13, GM23917] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007464, R37GM023917, R01GM023917] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BECKER A, 1988, J MOL BIOL, V199, P5987; Cantor C. R., 1980, BIOPHYSICAL CHEM 2, P549; CHANDRASEKHAR GN, 1986, J BIOL CHEM, V261, P2414; CHENG MY, 1989, NATURE, V337, P620, DOI 10.1038/337620a0; CHOW WY, 1988, P NATL ACAD SCI USA, V85, P6468, DOI 10.1073/pnas.85.17.6468; DANIELS DL, 1983, LAMBDA, V2, P519; EARNSHAW WC, 1979, J MOL BIOL, V134, P575, DOI 10.1016/0022-2836(79)90368-1; FAYET O, 1989, J BACTERIOL, V171, P1379, DOI 10.1128/JB.171.3.1379-1385.1989; FEISS M, 1983, LAMBDA, V2, P305; FERRUCCI F, 1981, BACTERIOPHAGE ASSEMB, P193; FRIEDMAN DI, 1984, MICROBIOL REV, V48, P299, DOI 10.1128/MMBR.48.4.299-325.1984; FULLER MT, 1982, J MOL BIOL, V156, P633, DOI 10.1016/0022-2836(82)90270-4; GEORGOPOULOS C, 1982, J BACTERIOL, V149, P1175, DOI 10.1128/JB.149.3.1175-1177.1982; Georgopoulos C., 1983, LAMBDA 2, P279; GEORGOPOULOS C P, 1974, Journal of Supramolecular Structure, V2, P349, DOI 10.1002/jss.400020224; GEORGOPOULOS CP, 1973, J MOL BIOL, V76, P45, DOI 10.1016/0022-2836(73)90080-6; GOLOUBINOFF P, 1989, NATURE, V342, P884, DOI 10.1038/342884a0; GOLOUBINOFF P, 1989, NATURE, V337, P44, DOI 10.1038/337044a0; HEMMINGSEN SM, 1988, NATURE, V333, P330, DOI 10.1038/333330a0; HENDRIX RW, 1974, P NATL ACAD SCI USA, V71, P1451, DOI 10.1073/pnas.71.4.1451; HENDRIX RW, 1975, J MOL BIOL, V91, P187, DOI 10.1016/0022-2836(75)90159-X; JARA L, 1975, VIROLOGY, V64, P264, DOI 10.1016/0042-6822(75)90097-5; KOCHAN J, 1984, J MOL BIOL, V174, P433, DOI 10.1016/0022-2836(84)90330-9; KOCHAN J, 1983, VIROLOGY, V131, P100, DOI 10.1016/0042-6822(83)90537-8; KUSUKAWA N, 1989, EMBO J, V8, P3517, DOI 10.1002/j.1460-2075.1989.tb08517.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMINET AA, 1990, EMBO J, V9, P2315, DOI 10.1002/j.1460-2075.1990.tb07403.x; LECKER S, 1989, EMBO J, V8, P2703, DOI 10.1002/j.1460-2075.1989.tb08411.x; MARTIN RG, 1961, J BIOL CHEM, V236, P1372; MCMULLIN TW, 1988, MOL CELL BIOL, V8, P371, DOI 10.1128/MCB.8.1.371; Morissey J. H., 1981, ANAL BIOCHEM, V117, P307; MURIALDO H, 1972, VIROLOGY, V48, P824, DOI 10.1016/0042-6822(72)90163-8; MURIALDO H, 1984, GENE, V30, P183, DOI 10.1016/0378-1119(84)90119-7; MURIALDO H, 1978, MICROBIOL REV, V42, P529, DOI 10.1128/MMBR.42.3.529-576.1978; MURIALDO H, 1979, VIROLOGY, V96, P341, DOI 10.1016/0042-6822(79)90094-1; MURIALDO H, 1978, J MOL BIOL, V125, P57, DOI 10.1016/0022-2836(78)90254-1; MURIALDO H, 1981, J MOL BIOL, V145, P375, DOI 10.1016/0022-2836(81)90211-4; MURIALDO H, 1972, VIROLOGY, V48, P785, DOI 10.1016/0042-6822(72)90162-6; NEIDHARDT FC, 1981, J BACTERIOL, V145, P513, DOI 10.1128/JB.145.1.513-520.1981; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; OSTERMANN J, 1989, NATURE, V341, P125, DOI 10.1038/341125a0; PHILLIPS GJ, 1990, NATURE, V344, P882, DOI 10.1038/344882a0; PREVELIGE PE, 1988, J MOL BIOL, V202, P743, DOI 10.1016/0022-2836(88)90555-4; RAY P, 1975, VIROLOGY, V64, P247, DOI 10.1016/0042-6822(75)90096-3; REYES O, 1979, VIROLOGY, V94, P400, DOI 10.1016/0042-6822(79)90470-7; ROBINSON NC, 1975, BIOCHEMISTRY-US, V14, P369, DOI 10.1021/bi00673a025; SANGER F, 1982, J MOL BIOL, V162, P729, DOI 10.1016/0022-2836(82)90546-0; SHAW JE, 1980, NATURE, V283, P30, DOI 10.1038/283030a0; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; SUSSMAN R, 1962, CR HEBD ACAD SCI, V254, P1517; TILLY K, 1983, J BACTERIOL, V154, P1505, DOI 10.1128/JB.154.3.1505-1507.1983; TILLY K, 1982, J BACTERIOL, V149, P1082, DOI 10.1128/JB.149.3.1082-1088.1982; ZYLICZ M, 1983, P NATL ACAD SCI-BIOL, V80, P6431, DOI 10.1073/pnas.80.21.6431	53	20	22	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1992	267	1					455	461						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY439	1530932				2022-12-25	WOS:A1992GY43900073
J	ANDO, S; KAIBUCHI, K; SASAKI, T; HIRAOKA, K; NISHIYAMA, T; MIZUNO, T; ASADA, M; NUNOI, H; MATSUDA, I; MATSUURA, Y; POLAKIS, P; MCCORMICK, F; TAKAI, Y				ANDO, S; KAIBUCHI, K; SASAKI, T; HIRAOKA, K; NISHIYAMA, T; MIZUNO, T; ASADA, M; NUNOI, H; MATSUDA, I; MATSUURA, Y; POLAKIS, P; MCCORMICK, F; TAKAI, Y			POSTTRANSLATIONAL PROCESSING OF RAC P21S IS IMPORTANT BOTH FOR THEIR INTERACTION WITH THE GDP GTP EXCHANGE PROTEINS AND FOR THEIR ACTIVATION OF NADPH OXIDASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHRONIC GRANULOMATOUS-DISEASE; BOVINE BRAIN CYTOSOL; C-TERMINAL REGION; SODIUM DODECYL-SULFATE; CELL-FREE SYSTEM; BINDING PROTEIN; MOLECULAR-CLONING; SUBSEQUENT BINDING; SMG P21S; PURIFICATION	rac1 and rac2 p21s are ras p21-like small GTP-binding proteins which are implicated in the NADPH oxidase-catalyzed superoxide generation in phagocytes. rac1 and rac2 p21s have a Cys-A-A-Leu (A = aliphatic amino acid) structure in their C-terminal region which may undergo post-translational processing including prenylation, proteolysis, and carboxyl methylation. We studied the function of this post-translational processing of rac p21s in their interaction with the stimulatory and inhibitory GDP/GTP exchange proteins for rac p21s, named smg GDS and rho GDI, and in their NADPH oxidase activation. We produced human recombinant rac1 and rac2 p21s in insect cells and purified them from the membrane and soluble fractions as the post-translationally processed and unprocessed forms, respectively. Post-translationally processed rac1 and rac2 p21s were sensitive to both smg GDS and rho GDI, but post-translationally unprocessed rac1 and rac2 p21s were insensitive to them. The GTP-gammaS (guanosine 5'-(3-O-thio)triphosphate)-bound form of post-translationally processed rac1 and rac2 p21s stimulated the NADPH oxidase activity, but post-translationally unprocessed rac1 and rac2 p21s were far less effective. These results indicate that both rac1 and rac2 p21s stimulate the NADPH oxidase activity and that their post-translational processing is important not only for their interaction with smg GDS and rho GDI but also for their NADPH oxidase activation.	KOBE UNIV,SCH MED,DEPT BIOCHEM,KOBE 650,JAPAN; EISAI & CO LTD,TSUKUBA RES LABS,TSUKUBA 30026,JAPAN; KUMAMOTO UNIV,SCH MED,DEPT PEDIAT,KUMAMOTO 860,JAPAN; NATL INST HLTH,DEPT VET SCI,TOKYO 141,JAPAN; CHIRON CORP,DEPT MOLEC BIOL,EMERYVILLE,CA 94608	Kobe University; Eisai Co Ltd; Kumamoto University; National Institute of Health Sciences - Japan; Novartis	TAKAI, Y (corresponding author), KOBE UNIV,SCH MED,DEPT BIOCHEM,KOBE 650,JAPAN.							ABO A, 1991, NATURE, V353, P668, DOI 10.1038/353668a0; AMBRUSO DR, 1990, J BIOL CHEM, V265, P924; ARAKI S, 1991, MOL CELL BIOL, V11, P1438, DOI 10.1128/MCB.11.3.1438; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BOKOCH GM, 1992, J CLIN INVEST, V89, P402, DOI 10.1172/JCI115599; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CLARK RA, 1990, J INFECT DIS, V161, P1140, DOI 10.1093/infdis/161.6.1140; DIDSBURY J, 1989, J BIOL CHEM, V264, P16378; FUJITA I, 1987, BIOCHIM BIOPHYS ACTA, V931, P41, DOI 10.1016/0167-4889(87)90048-6; FUKUMOTO Y, 1990, ONCOGENE, V5, P1321; GLOMSET JA, 1990, TRENDS BIOCHEM SCI, V15, P139, DOI 10.1016/0968-0004(90)90213-U; HIRAOKA K, 1992, BIOCHEM BIOPH RES CO, V182, P921, DOI 10.1016/0006-291X(92)91820-G; HIROYOSHI M, 1991, J BIOL CHEM, V266, P2962; HORI Y, 1991, ONCOGENE, V6, P515; KAIBUCHI K, 1991, MOL CELL BIOL, V11, P2873, DOI 10.1128/MCB.11.5.2873; KINSELLA BT, 1991, J BIOL CHEM, V266, P9786; KNAUS UG, 1991, SCIENCE, V254, P1512, DOI 10.1126/science.1660188; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LETO TL, 1990, SCIENCE, V248, P727, DOI 10.1126/science.1692159; LETO TL, 1991, J BIOL CHEM, V266, P19812; LOMAX KJ, 1989, SCIENCE, V245, P409, DOI 10.1126/science.2547247; LOWE PN, 1991, J BIOL CHEM, V266, P1672; LOWE PN, 1990, ONCOGENE, V5, P1045; MATSUI Y, 1990, MOL CELL BIOL, V10, P4116, DOI 10.1128/MCB.10.8.4116; MATSUURA Y, 1987, J GEN VIROL, V68, P1233, DOI 10.1099/0022-1317-68-5-1233; MIZUNO T, 1991, P NATL ACAD SCI USA, V88, P6442, DOI 10.1073/pnas.88.15.6442; MIZUNO T, 1992, J BIOL CHEM, V267, P10215; MUNEMITSU S, 1990, MOL CELL BIOL, V10, P5977, DOI 10.1128/MCB.10.11.5977; NUNOI H, 1988, SCIENCE, V242, P1298, DOI 10.1126/science.2848319; PICK E, 1989, J IMMUNOL, V143, P4180; RINE J, 1990, New Biologist, V2, P219; ROTROSEN D, 1992, SCIENCE, V256, P1459, DOI 10.1126/science.1318579; SASAKI T, 1990, J BIOL CHEM, V265, P2333; SEGAL AW, 1989, J CLIN INVEST, V83, P1785, DOI 10.1172/JCI114083; SHIRATAKI H, 1992, J BIOL CHEM, V267, P10946; SHPUNGIN S, 1989, J BIOL CHEM, V264, P9195; TAKAI Y, 1992, INT REV CYTOL, V133, P187, DOI 10.1016/S0074-7696(08)61861-6; UEDA T, 1990, J BIOL CHEM, V265, P9373; YAMAMOTO T, 1990, J BIOL CHEM, V265, P16626; YOSHIDA Y, 1991, BIOCHEM BIOPH RES CO, V175, P720, DOI 10.1016/0006-291X(91)91625-M	40	132	133	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1992	267	36					25709	25713						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KD073	1464587				2022-12-25	WOS:A1992KD07300020
J	CHEN, HJ; FLINT, SJ				CHEN, HJ; FLINT, SJ			MUTATIONAL ANALYSIS OF THE ADENOVIRUS-2 IV(A2) INITIATOR AND DOWNSTREAM ELEMENTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA POLYMERASE-II; MAJOR LATE PROMOTER; YEAST TATA ELEMENT; BETA-GLOBIN GENE; TRANSCRIPTION FACTOR; SEQUENCE REQUIREMENTS; BINDING PROTEIN; DNA-SEQUENCES; CAP SITE; ACTIVATES TRANSCRIPTION	The initiator element of the adenovirus type 2 IVa2 promoter is sufficient to direct accurate initiation by RNA polymerase II. Analysis of the effects of substitution of specific base pairs on initiator activity in in vitro transcription systems indicated that specific sequences between positions -4 and +5 were essential for initiator activity. Mutations that impaired or eliminated initiator activity altered both base pairs that are conserved in sequence-related initiators and non-conserved sequences. Neither the downstream TA-rich sequence of the IVa2 promoter, nor the adenovirus 2 major late TATA element placed at the same downstream site could overcome the severe inhibitory effects of initiator mutations, indicating that the initiator is the primary determinant of the specificity and direction of IVa2 transcription. By contrast, when the ML TATA element was placed 31 nucleotides upstream of the IVa2 initiator, the precise specificity, but neither the efficiency nor direction of transcription, depended on the presence of a functional initiator. Activity of the IVa2 promoter was relatively insensitive to changes in the orientation or nature of the TA-rich sequence. Furthermore, only a promoter containing the ML TATAAAA sequence downstream of the IVa2 initiator was competent to direct both IVa2 transcription and transcription from the opposite strand. The implications of this functional difference for recognition of the downstream element are discussed.	PRINCETON UNIV,DEPT MOLEC BIOL,PRINCETON,NJ 08544	Princeton University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037705] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM37705] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AYER DE, 1988, MOL CELL BIOL, V8, P2021, DOI 10.1128/MCB.8.5.2021; BAKER CC, 1981, J MOL BIOL, V149, P189, DOI 10.1016/0022-2836(81)90298-9; BEAUPAIN D, 1990, NUCLEIC ACIDS RES, V18, P6509, DOI 10.1093/nar/18.22.6509; BENOIST C, 1981, NATURE, V290, P304, DOI 10.1038/290304a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; BURATOWSKI S, 1988, NATURE, V334, P37, DOI 10.1038/334037a0; CARCAMO J, 1989, J BIOL CHEM, V264, P7704; CARCAMO J, 1991, P NATL ACAD SCI USA, V88, P8052, DOI 10.1073/pnas.88.18.8052; CARCAMO J, 1990, GENE DEV, V4, P1611, DOI 10.1101/gad.4.9.1611; CHATTERJEE PK, 1988, EMBO J, V7, P835, DOI 10.1002/j.1460-2075.1988.tb02882.x; COMAI L, 1992, CELL, V68, P965, DOI 10.1016/0092-8674(92)90039-F; CONAWAY JW, 1991, J BIOL CHEM, V266, P7804; CONCINO MF, 1984, NUCLEIC ACIDS RES, V12, P7423, DOI 10.1093/nar/12.19.7423; CORDEN J, 1980, SCIENCE, V209, P1405; CORMACK BP, 1992, CELL, V69, P685, DOI 10.1016/0092-8674(92)90232-2; DIERKS P, 1981, P NATL ACAD SCI-BIOL, V78, P1411, DOI 10.1073/pnas.78.3.1411; DIERKS P, 1983, CELL, V32, P695, DOI 10.1016/0092-8674(83)90055-7; ENGLER JA, 1982, GENE, V19, P71, DOI 10.1016/0378-1119(82)90190-1; GHOSH PK, 1981, P NATL ACAD SCI-BIOL, V78, P100, DOI 10.1073/pnas.78.1.100; GINGERAS TR, 1982, J BIOL CHEM, V257, P13475; GROSSCHEDL R, 1980, P NATL ACAD SCI-BIOL, V77, P1432, DOI 10.1073/pnas.77.3.1432; GROSSCHEDL R, 1981, NATURE, V294, P178, DOI 10.1038/294178a0; HAHN S, 1989, P NATL ACAD SCI USA, V86, P5718, DOI 10.1073/pnas.86.15.5718; HARIHARAN N, 1990, P NATL ACAD SCI USA, V87, P1526, DOI 10.1073/pnas.87.4.1526; HORIKOSHI M, 1988, CELL, V54, P665, DOI 10.1016/S0092-8674(88)80011-4; HU SL, 1981, P NATL ACAD SCI-BIOL, V78, P820, DOI 10.1073/pnas.78.2.820; HURST HC, 1987, GENE DEV, V1, P1132, DOI 10.1101/gad.1.10.1132; KASAI Y, 1992, MOL CELL BIOL, V12, P2884, DOI 10.1128/MCB.12.6.2884; LEE KAW, 1987, P NATL ACAD SCI USA, V84, P8355, DOI 10.1073/pnas.84.23.8355; LEONG K, 1984, J BIOL CHEM, V259, P1527; LOBO SM, 1991, GENE DEV, V5, P1477, DOI 10.1101/gad.5.8.1477; MANLEY JL, 1983, METHOD ENZYMOL, V101, P568; MEANS AL, 1990, MOL CELL BIOL, V10, P653, DOI 10.1128/MCB.10.2.653; OSHEAGREENFIELD A, 1992, J BIOL CHEM, V267, P1391; PAL SK, 1991, MOL CELL BIOL, V11, P5190, DOI 10.1128/MCB.11.10.5190; PUGH BF, 1991, GENE DEV, V5, P1935, DOI 10.1101/gad.5.11.1935; ROY AL, 1991, NATURE, V354, P245, DOI 10.1038/354245a0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAWADOGO M, 1990, ANNU REV BIOCHEM, V59, P711, DOI 10.1146/annurev.bi.59.070190.003431; SCHULTZ MC, 1992, CELL, V69, P697, DOI 10.1016/0092-8674(92)90233-3; SETO E, 1991, NATURE, V354, P241, DOI 10.1038/354241a0; SHAPIRO DJ, 1988, DNA-J MOLEC CELL BIO, V7, P47, DOI 10.1089/dna.1988.7.47; Shenk T, 1981, Curr Top Microbiol Immunol, V93, P25; SHU LM, 1986, GENE, V46, P187, DOI 10.1016/0378-1119(86)90403-8; SINGER VL, 1990, GENE DEV, V4, P636, DOI 10.1101/gad.4.4.636; SMALE ST, 1990, P NATL ACAD SCI USA, V87, P4509, DOI 10.1073/pnas.87.12.4509; SMALE ST, 1988, CELL, V57, P103; STARR DB, 1991, CELL, V67, P1231, DOI 10.1016/0092-8674(91)90299-E; STRUHL K, 1987, CELL, V50, P841, DOI 10.1016/0092-8674(87)90511-3; STRUHL K, 1989, ANNU REV BIOCHEM, V58, P1051, DOI 10.1146/annurev.bi.58.070189.005155; TALKINGTON CA, 1982, NATURE, V298, P192, DOI 10.1038/298192a0; TOKUNAGA K, 1984, NUCLEIC ACIDS RES, V12, P1543, DOI 10.1093/nar/12.3.1543; WALDSCHMIDT R, 1991, EMBO J, V10, P2595, DOI 10.1002/j.1460-2075.1991.tb07801.x; WHITE RJ, 1992, P NATL ACAD SCI USA, V89, P1949, DOI 10.1073/pnas.89.5.1949; WOBBE CR, 1990, MOL CELL BIOL, V10, P3859, DOI 10.1128/MCB.10.8.3859; XU LC, 1991, NUCLEIC ACIDS RES, V19, P6699, DOI 10.1093/nar/19.24.6699; YOO WD, 1991, J VIROL, V65, P5391, DOI 10.1128/JVI.65.10.5391-5400.1991	58	13	13	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1992	267	35					25457	25465						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KB603	1460040				2022-12-25	WOS:A1992KB60300083
J	SHERWOOD, AL; HOLMES, EH				SHERWOOD, AL; HOLMES, EH			BREFELDIN-A INDUCED-INHIBITION OF DENOVO GLOBO-SERIES AND NEOLACTO-SERIES GLYCOLIPID CORE CHAIN BIOSYNTHESIS IN HUMAN-CELLS - EVIDENCE FOR AN EFFECT ON BETA-1-]4GALACTOSYLTRANSFERASE ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN COLONIC ADENOCARCINOMA; TRANS-GOLGI CISTERNAE; ENDOPLASMIC-RETICULUM; GLYCOSYLTRANSFERASE ACTIVITIES; SUBCELLULAR ORGANIZATION; GANGLIOSIDE BIOSYNTHESIS; SECRETORY PROTEINS; HELA-CELLS; RAT-LIVER; 2 FORMS	De novo synthesis of neolacto-series glycolipids has been studied in human cell lines via metabolic labeling of ceramide with [H-3]serine. Intense labeling of ceramide mono- and dihexoside glycolipids occurred with labeling of progressively longer chain derivatives with increasing time. Most of the label was recovered in neutral glycolipids with about 5% of the total labeling in the ganglioside fraction. Experiments done using cell treatment with 2.5 mug/ml brefeldin A resulted in a stimulation in the total amount of labeling, accumulation of a neutral glycolipid identified as Lc3 due to inhibited transfer of the neolacto-series core chain terminal beta-Gal residue, and a corresponding inhibition of labeling of longer chain neutral glycolipids in all cell lines. Brefeldin A also blocked synthesis of the globo-series precursor, Gb3, longer chain sialylated structures such as IV3NeuAcnLc4, but not de novo G(M3) synthesis. Brefeldin A treatment had no effect on cellular beta1-->3N-acetylglucosaminyl-, beta1-->4galactosyl-, or alpha1-->3fucosyltransferase specific activities, nor was it inhibitory in beta1-->4galactosyltransferase assays in vitro. The results describe brefeldin A-induced blocks in globo- and neolacto-series glycolipid biosynthesis, consistent with differential localization of enzymes in intracellular membranes. In particular, the results suggest that the beta1-->4galactosyltransferase in these cells is either not redistributed by brefeldin A or is otherwise rendered nonfunctional.	PACIFIC NW RES FDN,720 BROADWAY,SEATTLE,WA 98122						NATIONAL CANCER INSTITUTE [K04CA001343, R01CA041521] Funding Source: NIH RePORTER; NCI NIH HHS [CA41521, K04 CA01343] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CHATTERJEE S, 1992, J BIOL CHEM, V267, P7148; CHEGE NW, 1990, J CELL BIOL, V111, P893, DOI 10.1083/jcb.111.3.893; CHIEN JL, 1978, J BIOL CHEM, V253, P4031; DOMS RW, 1989, J CELL BIOL, V109, P61, DOI 10.1083/jcb.109.1.61; DONALDSON JG, 1991, J CELL BIOL, V112, P579, DOI 10.1083/jcb.112.4.579; DONALDSON JG, 1991, SCIENCE, V254, P1197, DOI 10.1126/science.1957170; FARQUHAR MG, 1985, ANNU REV CELL BIOL, V1, P447, DOI 10.1146/annurev.cb.01.110185.002311; FUJIWARA T, 1988, J BIOL CHEM, V263, P18545; GINSBURG V, 1966, METHOD ENZYMOL, V8, P293; GOLDBERG DE, 1983, J BIOL CHEM, V258, P3159; HOLMES EH, 1990, J CELL BIOCHEM, V44, P93, DOI 10.1002/jcb.240440204; HOLMES EH, 1991, ARCH BIOCHEM BIOPHYS, V288, P87, DOI 10.1016/0003-9861(91)90168-I; HOLMES EH, 1987, J BIOL CHEM, V262, P15649; HOLMES EH, 1989, ARCH BIOCHEM BIOPHYS, V274, P14, DOI 10.1016/0003-9861(89)90410-4; HOLMES EH, 1989, ARCH BIOCHEM BIOPHYS, V270, P630, DOI 10.1016/0003-9861(89)90546-8; KANNAGI R, 1982, J BIOL CHEM, V257, P4865; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; LIPPINCOTTSCHWARTZ J, 1990, CELL, V60, P821, DOI 10.1016/0092-8674(90)90096-W; LOPEZ LC, 1991, J BIOL CHEM, V266, P15984; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAGNANI JL, 1980, ANAL BIOCHEM, V109, P399, DOI 10.1016/0003-2697(80)90667-3; MISUMI Y, 1986, J BIOL CHEM, V261, P1398; PFEFFER SR, 1987, ANNU REV BIOCHEM, V56, P829, DOI 10.1146/annurev.biochem.56.1.829; ROTH J, 1987, BIOCHIM BIOPHYS ACTA, V906, P405, DOI 10.1016/0304-4157(87)90018-9; ROTH J, 1982, J CELL BIOL, V93, P223, DOI 10.1083/jcb.93.1.223; RUSSO RN, 1990, J BIOL CHEM, V265, P3324; SAITO T, 1971, J LIPID RES, V12, P257; SAMPATH D, 1992, J BIOL CHEM, V267, P4440; SHAPER JH, 1988, BIOCHIMIE, V70, P1683, DOI 10.1016/0300-9084(88)90303-3; STROUS GJ, 1983, J CELL BIOL, V97, P723, DOI 10.1083/jcb.97.3.723; STROUS GJ, 1991, BIOL CELL, V71, P25, DOI 10.1016/0248-4900(91)90048-R; TRINCHERA M, 1990, J BIOL CHEM, V265, P18242; TRINCHERA M, 1989, J BIOL CHEM, V264, P15766; VANECHTEN G, 1990, EUR J CELL BIOL, V51, P135; YAMATO K, 1982, J BIOCHEM-TOKYO, V92, P1123, DOI 10.1093/oxfordjournals.jbchem.a134028; YOUNG WW, 1990, P NATL ACAD SCI USA, V87, P6838, DOI 10.1073/pnas.87.17.6838; YU RK, 1972, J LIPID RES, V13, P680; 1977, LIPIDS, V12, P455	39	29	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1992	267	35					25328	25336						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KB603	1460029				2022-12-25	WOS:A1992KB60300064
J	CHEN, Y; BAL, BS; GORSKI, JP				CHEN, Y; BAL, BS; GORSKI, JP			CALCIUM AND COLLAGEN BINDING-PROPERTIES OF OSTEOPONTIN, BONE SIALOPROTEIN, AND BONE ACIDIC GLYCOPROTEIN-75 FROM BONE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHORYLATED GLYCOPROTEIN; DEVELOPMENTAL EXPRESSION; SPARC OSTEONECTIN; SKELETAL-MUSCLE; CHICKEN BONE; RAT BONE; PROTEIN; PHOSPHOPROTEIN; MATRIX; TISSUES	Calcium binding properties of bone acidic glycoprotein-75, osteopontin, and bone sialoprotein were determined in 10 mM imidazole buffer (pH 6.8), containing either 60 mM KCl or 150 mM NaCl. Proteins assayed were first bound to nitrocellulose to mimic substrate-bound forms in vivo; retention of phosphoproteins was determined through use of radioiodinated tracers. Binding studies were carried out both as a function of calcium concentration and the amount of phosphoprotein. In the presence of 60 mM KCl, bone acidic glycoprotein-75 exhibited the largest calcium binding capacity (139 atoms/molecule at saturation), with bone sialoprotein intermediary (83 atoms/molecule) and osteopontin lowest (50 atoms/molecule). Sites detected for each phosphoprotein exhibited overall binding constants in the 0.5-1.0 mM extracellular range. In 150 mM NaCl and 1-2 mM total calcium, phosphoproteins bound between 72 and 19 mol of calcium/mol with the same relative order. Binding was proportional to amount of phosphoprotein in either salt condition. The presence of 5 mM calcium had a different effect on concentration-dependent binding to type I collagen for each phosphoprotein. Bone acidic glycoprotein-75 alone was found to undergo an unusual calcium-enhanced polymerization reaction, confirmed by light scattering measurements, wherein collagen binding was greatest with polymeric forms. These findings demonstrate that acidic phosphoproteins from bone bind calcium atoms with a range of capacities. Calcium appears to induce conformational changes in bone acidic glycoprotein-75 which influences its self-association and binding to different substrata.	UNIV MISSOURI, SCH BIOL SCI, DIV MOLEC BIOL & BIOCHEM, KANSAS CITY, MO 64110 USA; UNIV MISSOURI, SCH MED, DEPT ORTHOPED, KANSAS CITY, MO 64110 USA	University of Missouri System; University of Missouri Kansas City; University of Missouri System; University of Missouri Kansas City				Bal, B. Sonny/0000-0002-9615-8632	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R15AR040923] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR 40923] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Anderson HC, 1985, BONE MINERAL RES, V3, P109; AOKI T, 1987, BIOCHIM BIOPHYS ACTA, V911, P238, DOI 10.1016/0167-4838(87)90013-6; BIANCO P, 1991, CALCIFIED TISSUE INT, V49, P421, DOI 10.1007/BF02555854; BOYAN BD, 1989, CONNECT TISSUE RES, V22, P629, DOI 10.3109/03008208909114115; CHEN J, 1991, HISTOCHEM J, V23, P281, DOI 10.1007/BF01045047; CURLEYJOSEPH J, 1979, J DENT RES, V58, P1625, DOI 10.1177/00220345790580061201; FISHER LW, 1990, J BIOL CHEM, V265, P2347; FRANZEN A, 1985, BIOCHEM J, V232, P715, DOI 10.1042/bj2320715; FRANZEN A, 1985, CHEM BIOL MINERALIZE, P132; FRANZINIARMSTRONG C, 1987, J CELL BIOL, V105, P49, DOI 10.1083/jcb.105.1.49; FUJISAWA R, 1986, CALCIFIED TISSUE INT, V39, P248, DOI 10.1007/BF02555213; GLIMCHER MJ, 1989, ANAT REC, V224, P139, DOI 10.1002/ar.1092240205; GORSKI JP, 1992, CALCIFIED TISSUE INT, V50, P391, DOI 10.1007/BF00296767; GORSKI JP, 1990, J BIOL CHEM, V265, P14956; GORSKI JP, 1988, J BIOL CHEM, V263, P15938; GORSKI JP, 1987, DEV DISEASES CARTILA, P377; GORSKI JP, 1992, CONNECT TISSUE RES, V27, P112; GOTOH Y, 1990, BIOCHEM BIOPH RES CO, V173, P471, DOI 10.1016/S0006-291X(05)81082-4; GRIZZUTI K, 1973, BIOCHEMISTRY-US, V12, P4399, DOI 10.1021/bi00746a016; HALE JE, 1987, J BIOL CHEM, V262, P1916; HEDBOM E, 1989, J BIOL CHEM, V264, P6898; KELM RJ, 1991, J BIOL CHEM, V266, P9632; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDIS WJ, 1991, J STRUCT BIOL, V107, P116, DOI 10.1016/1047-8477(91)90015-O; LEVINE BA, 1983, BIOCHIM BIOPHYS ACTA, V726, P187, DOI 10.1016/0304-4173(83)90005-8; LOWNSTAM A, 1989, BIOMINERALISATION, P25; MARCHALONIS JJ, 1969, BIOCHEM J, V113, P299, DOI 10.1042/bj1130299; MARK MP, 1988, CELL TISSUE RES, V251, P23, DOI 10.1007/BF00215443; MARUYAMA K, 1984, J BIOCHEM-TOKYO, V95, P511, DOI 10.1093/oxfordjournals.jbchem.a134633; MAURER A, 1985, P NATL ACAD SCI USA, V82, P4036, DOI 10.1073/pnas.82.12.4036; MAYER U, 1991, EUR J BIOCHEM, V198, P141, DOI 10.1111/j.1432-1033.1991.tb15996.x; MCKEE MD, 1990, ANAT REC, V228, P77, DOI 10.1002/ar.1092280112; NOMURA S, 1988, J CELL BIOL, V106, P441, DOI 10.1083/jcb.106.2.441; OLDBERG A, 1986, P NATL ACAD SCI USA, V83, P8819, DOI 10.1073/pnas.83.23.8819; OLDBERG A, 1988, J BIOL CHEM, V263, P19430; OLDBERG A, 1988, J BIOL CHEM, V263, P19433; PARALKAR VM, 1990, J BIOL CHEM, V265, P17281; PRINCE CW, 1987, J BIOL CHEM, V262, P2900; REINHOLT FP, 1990, P NATL ACAD SCI USA, V87, P4473, DOI 10.1073/pnas.87.12.4473; SATO M, 1992, FASEB J, V6, P2966, DOI 10.1096/fasebj.6.11.1644260; Schmidt D. G., 1982, Developments in Dairy Chemistry, V1, P61; SOMERMAN MJ, 1988, CALCIFIED TISSUE INT, V43, P50, DOI 10.1007/BF02555169; STRYNADKA NCJ, 1989, ANNU REV BIOCHEM, V58, P951, DOI 10.1146/annurev.bi.58.070189.004511; YOON K, 1987, BIOCHEM BIOPH RES CO, V148, P1129, DOI 10.1016/S0006-291X(87)80250-4; ZANETTI M, 1981, EUR J BIOCHEM, V113, P541, DOI 10.1111/j.1432-1033.1981.tb05096.x; ZHANG R, 1990, J BIOL CHEM, V265, P15375	46	205	215	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 5	1992	267	34					24871	24878						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KA263	1447223				2022-12-25	WOS:A1992KA26300106
J	REISER, KM; AMIGABLE, MA; LAST, JA				REISER, KM; AMIGABLE, MA; LAST, JA			NONENZYMATIC GLYCATION OF TYPE-I COLLAGEN - THE EFFECTS OF AGING ON PREFERENTIAL GLYCATION SITES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NON-ENZYMATIC GLYCOSYLATION; PERFORMANCE LIQUID-CHROMATOGRAPHY; DIABETIC RATS; CROSS-LINKS; SKIN; DERIVATIZATION; COMPLICATIONS; PROTEIN	The present study was designed to investigate the effects of aging on preferential sites of glucose adduct formation on type I collagen chains. Two CNBr peptides, one from each type of chain in the type I tropocollagen molecule, were investigated in detail: alpha1(I)CB3 and alpha2CB3-5. Together these peptides comprise approximately 25% of the total tropocollagen molecule. The CNBr peptides were purified from rat tail tendon, obtained from animals aged 6, 18, and 36 months, by ion exchange chromatography, gel filtration, and high-performance liquid chromatography (HPLC). Sugar adducts were radiolabeled by reduction with (NaBH4)-H-3. Glycated tryptic peptides were prepared from tryptic digests of alpha2CB3-5 and alpha1(I)CB3 by boronate affinity chromatography and HPLC. Peptides were identified by sequencing and by compositional analysis. Preferential sites of glycation were observed in both CB3 and alpha2CB3-5. Of the 5 lysine residues in CB3, Lys-434 was the favored glycation site. Of the 18 lysine residues and 1 hydroxylysine residue in alpha2CB3-5, 3 residues (Lys-453, Lys-479, and Lys-924) contained more than 80% of the glucose adducts on the peptide. Preferential glycation sites were highly conserved with aging. In collagen that had been glycated in vitro, the relative distribution of glucose adducts in old animals differed from that of young animals. In vitro experiments suggest that primary structure is the major determinant of preferential glycation sites but that higher order structure may influence the relative distribution of glucose adducts among these preferred sites.	UNIV CALIF DAVIS,CALIF REG PRIMATE RES CTR,DAVIS,CA 95616	University of California System; University of California Davis	REISER, KM (corresponding author), UNIV CALIF DAVIS,SCH MED,DEPT INTERNAL MED,DAVIS,CA 95616, USA.				NCRR NIH HHS [RR00169] Funding Source: Medline; NIA NIH HHS [AGO5324, AGO7711] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P51RR000169] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG005324, R01AG007711] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Baynes J. W., 1989, MAILLARD REACTION AG, P43; Baynes JW, 1989, MAILLARD REACTION AG; BERNSTEIN RE, 1987, ADV CLIN CHEM, V26, P1, DOI 10.1016/S0065-2423(08)60321-2; BIDLINGMEYER BA, 1984, J CHROMATOGR, V336, P93, DOI 10.1016/S0378-4347(00)85133-6; BRENNAN M, 1989, J BIOL CHEM, V264, P20953; BROWNLEE M, 1983, DIABETES, V32, P680, DOI 10.2337/diabetes.32.7.680; BUCKINGHAM B, 1990, J CLIN INVEST, V86, P1046, DOI 10.1172/JCI114807; EINARSSON S, 1985, J CHROMATOGR, V348, P213, DOI 10.1016/S0021-9673(01)92455-0; FUJIMOTO D, 1988, CUTANEOUS AGING, P263; GALLOWAY D, 1982, COLLAGEN HLTH DISEAS, P528; GARLICK RL, 1983, J BIOL CHEM, V258, P6142; GERRIETS JE, 1989, FED PROC, V245, P1456; GLENNY RW, 1991, J APPL PHYSIOL, V70, P2351, DOI 10.1152/jappl.1991.70.6.2351; GONEN B, 1981, DIABETES, V30, P875, DOI 10.2337/diabetes.30.10.875; KOHN RR, 1989, AGING SKIN, P121; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAVKER RM, 1986, DERMATOL CLIN, V4, P379, DOI 10.1016/S0733-8635(18)30801-5; LEPAPE A, 1981, BIOCHEM BIOPH RES CO, V100, P1214, DOI 10.1016/0006-291X(81)91953-7; LIPSITZ LA, 1992, JAMA-J AM MED ASSOC, V267, P1806, DOI 10.1001/jama.267.13.1806; REISER IKM, 1991, FASEB J, V6, P2439; REISER KM, 1991, P SOC EXP BIOL MED, V196, P17; REISER KM, 1987, BIOCHIM BIOPHYS ACTA, V926, P339, DOI 10.1016/0304-4165(87)90220-0; REISER KM, 1980, ANAL BIOCHEM, V104, P87, DOI 10.1016/0003-2697(80)90280-8; REISER KM, 1983, CONNECT TISSUE RES, V12, P1, DOI 10.3109/03008208309005607; REISER KM, 1981, AM REV RESPIR DIS, V123, P58; REISER KM, 1983, LIQUID CHROMATOGR, V1, P498; REISER KM, 1990, DIABETES, V39, P28; Robins S.P., 1982, METHOD BIOCHEM ANAL, V28, P330; SHAKLAI N, 1984, J BIOL CHEM, V259, P3812; SHAPIRO R, 1980, J BIOL CHEM, V255, P3120; SMITH L, 1989, CUTIS, V43, P414; TANAKA S, 1988, J MOL BIOL, V203, P495, DOI 10.1016/0022-2836(88)90015-0; TARSIO JF, 1988, DIABETES, V37, P532, DOI 10.2337/diabetes.37.5.532; TSILIBARY EC, 1988, J BIOL CHEM, V263, P4302; VANDERREST M, 1982, EUR J BIOCHEM, V125, P491, DOI 10.1111/j.1432-1033.1982.tb06709.x; WATKINS NG, 1985, J BIOL CHEM, V260, P629; WOESSNER JF, 1961, ARCH BIOCHEM BIOPHYS, V93, P440, DOI 10.1016/0003-9861(61)90291-0; YAMAUCHI M, 1982, P NATL ACAD SCI-BIOL, V79, P7684, DOI 10.1073/pnas.79.24.7684; YUE DK, 1983, DIABETOLOGIA, V24, P282	39	77	78	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1992	267	34					24207	24216						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KA263	1447170				2022-12-25	WOS:A1992KA26300013
J	LEE, RT; GABIUS, HJ; LEE, YC				LEE, RT; GABIUS, HJ; LEE, YC			LIGAND-BINDING CHARACTERISTICS OF THE MAJOR MISTLETOE LECTIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VISCUM-ALBUM L; GALACTOSIDE-SPECIFIC LECTIN; TOXIC LECTIN; PROTEINS; CELLS; ACETYLGALACTOSAMINE; 1-THIOGLYCOSIDES; GLYCOSIDES; EXTRACT; ABRIN	Carbohydrate binding specificity of the galactose-specific, major lectin of mistletoe extract (ML-1) was studied by an inhibition assay using monosaccharides, monosaccharide derivatives, disaccharides, and compounds containing multiple galactosyl terminals. The results indicate that 1) both alpha- and beta-galactosyl residues are recognized equally well; 2) each of the hydroxyl groups of galactose contributes to varying degrees to the binding process, the 4-OH being the most important and the 6-OH the least important hydroxyl group; 3) disaccharide sequences of Galbeta2Gal and Galbeta3Gal have much higher affinity than galactose, whereas affinity of all other Gal-disaccharides is only slightly better than galactose; 4) macromolecular ligands having 10 or more terminal galactosyl residues have 500-fold higher affinity than Gal; and 5) a group on ML-1 with pK(alpha) of 4.8 appears to be involved in the binding of ligand.	JOHNS HOPKINS UNIV,MCCOLLUM PRATT INST,BALTIMORE,MD 21218; UNIV MARBURG,INST PHARMACEUT CHEM,DEPT GLYCOBIOCHEM & APPL TUMORLECTINOL,W-3550 MARBURG,GERMANY	Johns Hopkins University; Philipps University Marburg	LEE, RT (corresponding author), JOHNS HOPKINS UNIV,DEPT BIOL,BALTIMORE,MD 21218, USA.			Gabius, Hans-Joachim/0000-0003-3467-3900	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK009970, R37DK009970] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-09970] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BEUTH J, 1992, CLIN INVESTIGATOR, V70, P658; BEUTH J, 1991, IN VIVO, V5, P19; EIKLID K, 1980, EXP CELL RES, V126, P321, DOI 10.1016/0014-4827(80)90270-0; FRANZ H, 1985, PHARMAZIE, V40, P97; GABIUS HJ, 1992, ANTICANCER RES, V12, P669; GABIUS HJ, 1990, ANAL BIOCHEM, V189, P91, DOI 10.1016/0003-2697(90)90050-J; GREENWOOD FC, 1963, BIOCHEM J, V89, P114, DOI 10.1042/bj0890114; HAJTO T, 1989, CANCER RES, V49, P4803; HAJTO T, 1990, CANCER RES, V50, P3322; HAUSER SP, 1992, IN PRESS THERAPIEWOC; JANSEN EF, 1946, J AM CHEM SOC, V68, P1475, DOI 10.1021/ja01212a025; JOHNSON G, 1975, CARBOHYD RES, V39, P271, DOI 10.1016/S0008-6215(00)86137-6; JOSHI SS, 1991, LECTINS CANC, P207; KAJIKAWA T, 1986, LIFE SCI, V39, P1177, DOI 10.1016/0024-3205(86)90349-8; LEE RT, 1987, GLYCOCONJUGATE J, V4, P317, DOI 10.1007/BF01048365; LEE RT, 1982, CARBOHYD RES, V101, P39, DOI 10.1016/S0008-6215(00)80793-4; LEE RT, 1979, CARBOHYD RES, V77, P270, DOI 10.1016/S0008-6215(00)83818-5; LEE RT, 1990, J BIOL CHEM, V265, P7864; LEE RT, 1979, CARBOHYD RES, V77, P149, DOI 10.1016/S0008-6215(00)83801-X; LEE RT, 1974, CARBOHYD RES, V37, P193, DOI 10.1016/S0008-6215(00)87074-3; LEE RT, 1984, BIOCHEMISTRY-US, V23, P4255, DOI 10.1021/bi00313a037; LEE YC, 1976, BIOCHEMISTRY-US, V15, P3956, DOI 10.1021/bi00663a008; LEFFLER H, 1986, J BIOL CHEM, V261, P119; LIN JY, 1970, NATURE, V227, P292, DOI 10.1038/227292a0; Lis H, 1986, LECTINS PROPERTIES F, P266; LONGCHAMBON F, 1981, ACTA CRYSTALLOGR B, V37, P601, DOI 10.1107/S0567740881003658; LUTHER P, 1980, INT J BIOCHEM, V11, P429, DOI 10.1016/0020-711X(80)90314-6; OFFNER H, 1990, J NEUROIMMUNOL, V28, P177, DOI 10.1016/0165-5728(90)90032-I; OLSNES S, 1982, J BIOL CHEM, V257, P13263; OLSNES S, 1982, MOL ACTIONS TOXINS V, P5; Porath J, 1976, Methods Enzymol, V44, P19; QUIOCHO FA, 1986, ANNU REV BIOCHEM, V55, P287, DOI 10.1146/annurev.bi.55.070186.001443; RICE KG, 1990, ANAL BIOCHEM, V184, P249, DOI 10.1016/0003-2697(90)90676-Z; STIRPE F, 1982, J BIOL CHEM, V257, P13271; STULTS NL, 1983, ANAL BIOCHEM, V135, P392, DOI 10.1016/0003-2697(83)90701-7; VERNON J, 1980, CARBOHYD RES, V82, P59, DOI 10.1016/S0008-6215(00)85520-2; ZISKA P, 1981, EXPERIENTIA, V37, P219, DOI 10.1007/BF01991618	37	110	111	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1992	267	33					23722	23727						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JZ239	1429712				2022-12-25	WOS:A1992JZ23900046
J	JEFFERS, M; PELLICER, A				JEFFERS, M; PELLICER, A			MULTIPLE INTRAGENIC ELEMENTS REGULATE THE EXPRESSION OF THE MURINE N-RAS GENE	ONCOGENE			English	Article							ADENOSINE-DEAMINASE GENE; RNA POLYMERASE-II; C-MYC GENE; TRANSCRIPTIONAL ARREST; SEQUENCE REQUIREMENTS; PREMATURE TERMINATION; TRANSFORMING GENES; RIBONUCLEIC-ACID; MAMMALIAN-CELLS; SARCOMA-VIRUSES	We have identified two separate regions within the murine N-ras transcription unit which may participate in the regulation of N-ras gene expression. One of these regions, localized to the first half of intron 1, contains a site of premature transcriptional arrest. We propose that premature transcription termination, which has been identified as an important control mechanism for several genes, may also play a role in the regulation of the N-ras gene. In addition, we have identified a positively acting region within the N-ras transcription unit. This region, localized to the end of intron 1/beginning of exon 1, was found to greatly increase expression from the N-ras promoter.	NYU MED CTR,DEPT PATHOL,NEW YORK,NY 10016; NYU MED CTR,KAPLAN CANC CTR,NEW YORK,NY 10016	New York University; New York University			MARTINEZ, ANTONIO PELLICER/C-4832-2015	Pellicer, Angel/0000-0002-5062-0692	NATIONAL CANCER INSTITUTE [R37CA036327, R01CA036327, R01CA050434] Funding Source: NIH RePORTER; NCI NIH HHS [CA36327, CA50434] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARONOW B, 1989, GENE DEV, V3, P1384, DOI 10.1101/gad.3.9.1384; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BARSAGI D, 1985, CELL, V42, P841, DOI 10.1016/0092-8674(85)90280-6; BENTLEY DL, 1988, CELL, V53, P245, DOI 10.1016/0092-8674(88)90386-8; BENTLEY DL, 1991, J CELL BIOCH SG, V15, P268; BESMOND C, 1987, CURRENT PROTOCOLS MO, V1; CHANG EH, 1982, NATURE, V297, P479, DOI 10.1038/297479a0; CHANG HY, 1987, ONCOGENE RES, V1, P129; CHEN Z, 1990, MOL CELL BIOL, V10, P4555, DOI 10.1128/MCB.10.9.4555; CHEN Z, 1991, MOL CELL BIOL, V11, P6248, DOI 10.1128/MCB.11.12.6248; CHINSKY JM, 1989, J BIOL CHEM, V264, P14561; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOI T, 1991, MOL CELL BIOL, V11, P3070, DOI 10.1128/MCB.11.6.3070; CHUNG S, 1989, MOL CELL BIOL, V9, P2075, DOI 10.1128/MCB.9.5.2075; COHEN JB, 1988, NATURE, V334, P119, DOI 10.1038/334119a0; DER CJ, 1982, P NATL ACAD SCI-BIOL, V79, P3637, DOI 10.1073/pnas.79.11.3637; DONIGER J, 1988, NUCLEIC ACIDS RES, V16, P969, DOI 10.1093/nar/16.3.969; EICK D, 1986, NUCLEIC ACIDS RES, V14, P8331, DOI 10.1093/nar/14.21.8331; FARNHAM PJ, 1990, MOL CELL BIOL, V10, P1390, DOI 10.1128/MCB.10.4.1390; FERAMISCO JR, 1984, CELL, V38, P109, DOI 10.1016/0092-8674(84)90531-2; FUJITA J, 1985, P NATL ACAD SCI USA, V82, P3849, DOI 10.1073/pnas.82.11.3849; GEROSA MA, 1989, J NATL CANCER I, V81, P63, DOI 10.1093/jnci/81.1.63; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GREENBERG M, 1987, CURRENT PROTOCOLS MO, V1; GROSS DS, 1988, ANNU REV BIOCHEM, V57, P159, DOI 10.1146/annurev.bi.57.070188.001111; GUERRERO I, 1986, J CELL PHYSIOL, V129, P71, DOI 10.1002/jcp.1041290111; GUNNING P, 1983, MOL CELL BIOL, V3, P787, DOI 10.1128/MCB.3.5.787; HALL A, 1985, NUCLEIC ACIDS RES, V13, P5255, DOI 10.1093/nar/13.14.5255; HALL C V, 1983, Journal of Molecular and Applied Genetics, V2, P101; HAWLEY DK, 1985, J BIOL CHEM, V260, P8163; HONKAWA H, 1987, MOL CELL BIOL, V7, P2933, DOI 10.1128/MCB.7.8.2933; INGOLIA DE, 1986, MOL CELL BIOL, V6, P4458, DOI 10.1128/MCB.6.12.4458; INNIS JW, 1991, MOL CELL BIOL, V11, P5398, DOI 10.1128/MCB.11.11.5398; JEFFERS M, 1990, NUCLEIC ACIDS RES, V18, P4891; LATTIER DL, 1989, NUCLEIC ACIDS RES, V17, P1061, DOI 10.1093/nar/17.3.1061; LEE PC, 1973, DEV BIOL, V31, P227, DOI 10.1016/0012-1606(73)90259-5; LEON J, 1987, MOL CELL BIOL, V7, P1535, DOI 10.1128/MCB.7.4.1535; LONDON L, 1991, MOL CELL BIOL, V11, P4599, DOI 10.1128/MCB.11.9.4599; LOWNDES NF, 1989, MOL CELL BIOL, V9, P3758, DOI 10.1128/MCB.9.9.3758; MANGUES R, 1992, IN PRESS ONCOGENE; MCKAY IA, 1986, EMBO J, V5, P2617, DOI 10.1002/j.1460-2075.1986.tb04542.x; MECHTI N, 1991, MOL CELL BIOL, V11, P2832, DOI 10.1128/MCB.11.5.2832; MICOLAIEW N, 1991, ONCOGENE, V6, P721; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; NODA M, 1985, NATURE, V318, P73, DOI 10.1038/318073a0; PACIUCCI R, 1991, MOL CELL BIOL, V11, P1334, DOI 10.1128/MCB.11.3.1334; PROUDFOOT NJ, 1986, NATURE, V322, P562, DOI 10.1038/322562a0; PULCIANI S, 1985, MOL CELL BIOL, V5, P2836, DOI 10.1128/MCB.5.10.2836; RAMAMURTHY V, 1990, MOL CELL BIOL, V10, P1484, DOI 10.1128/MCB.10.4.1484; ROEDER RG, 1974, J BIOL CHEM, V249, P241; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANTOS E, 1982, NATURE, V298, P343, DOI 10.1038/298343a0; SCHWAB M, 1983, NATURE, V303, P497, DOI 10.1038/303497a0; SPENCER CA, 1990, ONCOGENE, V5, P777; SPENCER CA, 1990, GENE DEV, V4, P75, DOI 10.1101/gad.4.1.75; THORN JT, 1991, ONCOGENE, V65, P1843; WINTER E, 1986, MOL CELL BIOL, V6, P2562, DOI 10.1128/MCB.6.7.2562; YAMAMOTO F, 1988, ONCOGENE RES, V3, P125; YANG JQ, 1986, EMBO J, V5, P3553, DOI 10.1002/j.1460-2075.1986.tb04682.x	60	12	12	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1992	7	11					2115	2123						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JW665	1437142				2022-12-25	WOS:A1992JW66500003
J	LANZI, C; BORRELLO, MG; BONGARZONE, I; MIGLIAZZA, A; FUSCO, A; GRIECO, M; SANTORO, M; GAMBETTA, RA; ZUNINO, F; DELLAPORTA, G; PIEROTTI, MA				LANZI, C; BORRELLO, MG; BONGARZONE, I; MIGLIAZZA, A; FUSCO, A; GRIECO, M; SANTORO, M; GAMBETTA, RA; ZUNINO, F; DELLAPORTA, G; PIEROTTI, MA			IDENTIFICATION OF THE PRODUCT OF 2 ONCOGENIC REARRANGED FORMS OF THE RET PROTOONCOGENE IN PAPILLARY THYROID CARCINOMAS	ONCOGENE			English	Article							TYROSINE KINASE; AFFINITY-CHROMATOGRAPHY; PHOSPHORYLATION; NEUROBLASTOMA; ACTIVATION; PROTEINS; PTC; PROTOONCOGENE; EXPRESSION; RECEPTOR	In papillary thyroid carcinomas, we have identified two tumor-specific rearrangements of the RET protooncogene leading to the formation of different transforming fusion products sharing the tyrosine kinase (tk) domain of the proto-oncogene and designated ptc-1 and ptc-2. We have analysed ptc-1 and ptc-2 products by immunoprecipitation with specific anti-RET antibodies followed by immunoblotting with the same reagent or with antibodies specific for phosphotyrosine (P-tyr) residues. The anti-RET antibodies were reactive with 64-kDa (p64ptc-1) and 81-kDa (p81ptc-2) proteins from lysates of ptc-1 and ptc-2 transformed cells, respectively, and identified two proteins of 140 kDa and 160 kDa from extracts of SK-N-SH, a neuroblastoma cell line previously shown to express two differently glycosylated forms of the normal RET product. The anti P-tyr antibodies, while detecting the same p64ptc-1 and p81ptc-2 proteins from ptc-1 and ptc-2 extracts, did not show any specific band in the neuroblastoma lysates. An additional set of experiments led us to conclude that, whereas the normal product of the RET proto-oncogene is a membrane-associated receptor-like molecule not intrinsically phosphorylated on tyrosine, both oncogenic forms of RET, ptc-1 and ptc-2, are constitutively phosphorylated on tyrosine, display an 'in vitro' autophosphorylation activity, are translocated from the membrane to the cytoplasm and are apparently unaffected by protein kinase C modulation.	IST NAZL TUMORI, DIV ONCOL SPERIMENTALE B, VIA G VENEZIAN 1, I-20133 MILAN, ITALY; NAPLES UNIV, DIPARTIMENTO BIOL PATOL CELLULARE & MOLEC, CNR, I-80134 NAPLES, ITALY; IST NAZL TUMORI, DIV ONCOL SPERIMENTALE A, I-20133 MILAN, ITALY; UNIV REGGIO CALABRIA, FAC MED & CHIRURG CATANZARO, DIPARTIMENTO MED SPERIMENTALE & CLIN, CALABRIA, ITALY	Fondazione IRCCS Istituto Nazionale Tumori Milan; Consiglio Nazionale delle Ricerche (CNR); University of Naples Federico II; Fondazione IRCCS Istituto Nazionale Tumori Milan; Universita Mediterranea di Reggio Calabria			Borrello, Maria Grazia/C-3161-2017; Lanzi, Cinzia/J-6539-2016; Pierotti, Marco Alessandro/AAC-4728-2022; Bongarzone, Italia/B-9544-2017	Borrello, Maria Grazia/0000-0002-6854-2848; Lanzi, Cinzia/0000-0002-4480-9413; Pierotti, Marco Alessandro/0000-0002-7431-8332; Bongarzone, Italia/0000-0003-2530-9170; Fusco, Alfredo/0000-0003-3332-5197; Grieco, Michele/0000-0002-4212-7814				BARBACID M, 1981, J VIROL, V40, P812, DOI 10.1128/JVI.40.3.812-821.1981; BONGARZONE I, 1989, ONCOGENE, V4, P1457; CATHALA G, 1983, DNA-J MOLEC CELL BIO, V2, P329, DOI 10.1089/dna.1983.2.329; CIRILLO DM, 1986, MOL CELL BIOL, V6, P4641, DOI 10.1128/MCB.6.12.4641; DONGHI R, 1989, ONCOGENE, V4, P521; DUCLOS B, 1991, METHOD ENZYMOL, V201, P10; FUSCO A, 1987, NATURE, V328, P170, DOI 10.1038/328170a0; GANDINO L, 1990, ONCOGENE, V5, P721; GIORDANO S, 1989, ONCOGENE, V4, P1383; GRIECO M, 1990, CELL, V60, P557, DOI 10.1016/0092-8674(90)90659-3; IKEDA I, 1990, ONCOGENE, V5, P1291; ISHIZAKA Y, 1989, ONCOGENE, V4, P789; KAMPS MP, 1991, METHOD ENZYMOL, V201, P21; KODA T, 1988, Hokkaido Journal of Medical Science, V63, P913; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDT M, 1978, BIOCHEMISTRY-US, V17, P915, DOI 10.1021/bi00598a027; LAU KHW, 1989, BIOCHEM J, V257, P23, DOI 10.1042/bj2570023; MOLLOY CJ, 1989, NATURE, V342, P711, DOI 10.1038/342711a0; PIEROTTI MA, 1992, P NATL ACAD SCI USA, V89, P1616, DOI 10.1073/pnas.89.5.1616; ROSS AH, 1981, NATURE, V294, P654, DOI 10.1038/294654a0; SANTORO M, 1992, IN PRESS J CLIN INVE, V3; SIBLEY DR, 1987, CELL, V48, P913, DOI 10.1016/0092-8674(87)90700-8; SOZZI G, 1991, ONCOGENE, V6, P339; TAHIRA T, 1990, ONCOGENE, V5, P97; TAKAHASHI M, 1991, ONCOGENE, V6, P297; TAKAHASHI M, 1987, MOL CELL BIOL, V7, P1378, DOI 10.1128/MCB.7.4.1378; TAKAHASHI M, 1988, ONCOGENE, V3, P571; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VAUGHAN JM, 1989, METHOD ENZYMOL, V168, P588	29	77	81	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	1992	7	11					2189	2194						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JW665	1437145				2022-12-25	WOS:A1992JW66500011
J	OKUDA, T; CLEVELAND, JL; DOWNING, JR				OKUDA, T; CLEVELAND, JL; DOWNING, JR			PCTAIRE-1 AND PCTAIRE-3, 2 MEMBERS OF A NOVEL CDC2/CDC28-RELATED PROTEIN-KINASE GENE FAMILY	ONCOGENE			English	Review							CELL-CYCLE CONTROL; SEA-URCHIN EGGS; SACCHAROMYCES-CEREVISIAE; FISSION YEAST; TYROSINE PHOSPHORYLATION; SCHIZOSACCHAROMYCES-POMBE; M-PHASE; DIVISION CYCLE; CDC25 PROTEIN; MESSENGER-RNA	We have isolated two murine cDNAs designated PCTAIRE-1 and -3 which encode putative serine/threonine-specific protein kinases. The predicted products of PCTAIRE-1 and -3 are 65% homologous and are organized into a core 295-residue kinase domain flanked by unique 161 and 117 amino acid N-terminal and 40 and 39 amino acid C-terminal domains respectively. The kinase domains are approximately 50-55% homologous to members of the cdc2/CDC28 kinase gene family, and each contains a cysteine-for-serine substitution within the conserved PSTAIRE motif. PCTAIRE-1 was ubiquitously expressed as a predominant 3.0-kb transcript and a minor 2.2-kb mRNA resulting from differential polyadenylation. In contrast, PCTAIRE-3 exhibited a more restricted pattern of expression with a single 3.0-kb mRNA detected in brain, kidney and intestine. The PCTAIRE-1 and -3 products produced by in vitro transcription-translation failed to bind to p13suc1 but were precipitated by antibodies directed to Schizosaccharomyces pombe p34cdc2 or to the human PSTAIRE motif. Thus, PCTAIRE-1 and -3 are members of a novel subfamily of cdc2/CDC28-related protein kinases.	ST JUDE CHILDRENS RES HOSP, DEPT PATHOL, 575 ST JUDE PL, MEMPHIS, TN 38105 USA; ST JUDE CHILDRENS RES HOSP, DEPT BIOCHEM, MEMPHIS, TN 38105 USA; ST JUDE CHILDRENS RES HOSP, DEPT TUMOR CELL BIOL, MEMPHIS, TN 38105 USA	St Jude Children's Research Hospital; St Jude Children's Research Hospital; St Jude Children's Research Hospital			Downing, James R./N-8102-2018		NCI NIH HHS [CA-21765, CA-01429] Funding Source: Medline; NIDDK NIH HHS [DK-44158] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K08CA001429, P30CA021765] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044158] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSON SJ, 1984, J VIROL, V51, P730, DOI 10.1128/JVI.51.3.730-741.1984; BENDAVID Y, 1991, EMBO J, V10, P317, DOI 10.1002/j.1460-2075.1991.tb07952.x; BLENIS J, 1991, CANCER CELL-MON REV, V3, P445; BOULTON TG, 1990, SCIENCE, V249, P64, DOI 10.1126/science.2164259; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BRIZUELA L, 1987, EMBO J, V6, P3507, DOI 10.1002/j.1460-2075.1987.tb02676.x; BUNNELL BA, 1990, P NATL ACAD SCI USA, V87, P7467, DOI 10.1073/pnas.87.19.7467; BUSTOS JG, 1991, BIOCHIM BIOPHYS ACTA, V1071, P83; CAO L, 1992, NATURE, V355, P176, DOI 10.1038/355176a0; CHELSKY D, 1989, MOL CELL BIOL, V9, P2487, DOI 10.1128/MCB.9.6.2487; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; Cleveland J L, 1988, Oncogene Res, V3, P357; COURCHESNE WE, 1989, CELL, V58, P1107, DOI 10.1016/0092-8674(89)90509-6; CROSS FR, 1988, MOL CELL BIOL, V8, P4675, DOI 10.1128/MCB.8.11.4675; DRAETTA G, 1987, CELL, V50, P319, DOI 10.1016/0092-8674(87)90227-3; DRAETTA G, 1990, TRENDS BIOCHEM SCI, V15, P378, DOI 10.1016/0968-0004(90)90235-4; DRAETTA G, 1988, CELL, V54, P17, DOI 10.1016/0092-8674(88)90175-4; DUCOMMUN B, 1991, MOL CELL BIOL, V11, P6177, DOI 10.1128/MCB.11.12.6177; DUCOMMUN B, 1991, EMBO J, V10, P3311, DOI 10.1002/j.1460-2075.1991.tb04895.x; DUNPHY WG, 1991, CELL, V67, P189, DOI 10.1016/0092-8674(91)90582-J; DUNPHY WG, 1988, CELL, V54, P423, DOI 10.1016/0092-8674(88)90205-X; ELION EA, 1990, CELL, V60, P649, DOI 10.1016/0092-8674(90)90668-5; ELLEDGE SJ, 1991, EMBO J, V10, P2653, DOI 10.1002/j.1460-2075.1991.tb07808.x; ELLEDGE SJ, 1992, P NATL ACAD SCI USA, V89, P2907, DOI 10.1073/pnas.89.7.2907; EVANS T, 1983, CELL, V33, P389, DOI 10.1016/0092-8674(83)90420-8; FEATHERSTONE C, 1991, NATURE, V349, P808, DOI 10.1038/349808a0; FERAMISCO JR, 1980, J BIOL CHEM, V255, P4240; FERRELL JE, 1991, MOL CELL BIOL, V11, P1965, DOI 10.1128/MCB.11.4.1965; GALAKTIONOV K, 1991, CELL, V67, P1181, DOI 10.1016/0092-8674(91)90294-9; GAUTIER J, 1991, CELL, V67, P197, DOI 10.1016/0092-8674(91)90583-K; GHIARA JB, 1991, CELL, V65, P163, DOI 10.1016/0092-8674(91)90417-W; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; GOTOH Y, 1991, NATURE, V349, P251, DOI 10.1038/349251a0; GOTOH Y, 1991, EMBO J, V10, P2661, DOI 10.1002/j.1460-2075.1991.tb07809.x; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; GOULD KL, 1991, EMBO J, V10, P3297, DOI 10.1002/j.1460-2075.1991.tb04894.x; HADWIGER JA, 1989, P NATL ACAD SCI USA, V86, P6255, DOI 10.1073/pnas.86.16.6255; HADWIGER JA, 1989, MOL CELL BIOL, V9, P2034, DOI 10.1128/MCB.9.5.2034; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HANKS SK, 1987, P NATL ACAD SCI USA, V84, P388, DOI 10.1073/pnas.84.2.388; HARTWELL LH, 1974, SCIENCE, V183, P46, DOI 10.1126/science.183.4120.46; HAYLES J, 1986, MOL GEN GENET, V202, P291, DOI 10.1007/BF00331653; HAYLES J, 1986, EMBO J, V5, P3373, DOI 10.1002/j.1460-2075.1986.tb04653.x; HINDLEY J, 1987, MOL CELL BIOL, V7, P504, DOI 10.1128/MCB.7.1.504; Hunt T, 1989, CURR OPIN CELL BIOL, V1, P268, DOI 10.1016/0955-0674(89)90099-9; HUNTER T, 1991, CELL, V66, P1071, DOI 10.1016/0092-8674(91)90028-W; IGARASHI M, 1991, NATURE, V353, P80, DOI 10.1038/353080a0; JOHNSON KW, 1991, J BIOL CHEM, V266, P3402; KIDD VJ, 1991, CELL GROWTH DIFFER, V2, P85; KISHIMOTO A, 1985, J BIOL CHEM, V260, P2492; KOFF A, 1991, CELL, V66, P1217, DOI 10.1016/0092-8674(91)90044-Y; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KREK W, 1991, EMBO J, V10, P3331, DOI 10.1002/j.1460-2075.1991.tb04897.x; KREK W, 1991, EMBO J, V10, P305, DOI 10.1002/j.1460-2075.1991.tb07951.x; KUMAGAI A, 1991, CELL, V64, P903, DOI 10.1016/0092-8674(91)90315-P; LAPIDOTLIFSON Y, 1992, DEV BIOL, V89, P579; LEE MG, 1987, NATURE, V327, P31, DOI 10.1038/327031a0; LEOPOLD P, 1991, CELL, V66, P1207, DOI 10.1016/0092-8674(91)90043-X; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; LEWIN B, 1990, CELL, V61, P743, DOI 10.1016/0092-8674(90)90181-D; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; LORINCZ AT, 1984, NATURE, V307, P183, DOI 10.1038/307183a0; LUNDGREN K, 1991, CELL, V64, P1111, DOI 10.1016/0092-8674(91)90266-2; MATSUSHIME H, 1990, MOL CELL BIOL, V10, P2261, DOI 10.1128/MCB.10.5.2261; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MEYERSON M, 1992, EMBO J, V11, P2909, DOI 10.1002/j.1460-2075.1992.tb05360.x; MILLAR JBA, 1992, CELL, V68, P407, DOI 10.1016/0092-8674(92)90177-E; MINSHULL J, 1989, CELL, V56, P947, DOI 10.1016/0092-8674(89)90628-4; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; MURRAY AW, 1989, NATURE, V339, P280, DOI 10.1038/339280a0; MURRAY AW, 1989, SCIENCE, V246, P614, DOI 10.1126/science.2683077; MURRAY AW, 1989, NATURE, V339, P275, DOI 10.1038/339275a0; NASH R, 1988, EMBO J, V7, P4335, DOI 10.1002/j.1460-2075.1988.tb03332.x; NINOMIYATSUJI J, 1991, P NATL ACAD SCI USA, V88, P9006, DOI 10.1073/pnas.88.20.9006; NURSE P, 1981, NATURE, V292, P558, DOI 10.1038/292558a0; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; PAGANO M, 1992, SCIENCE, V255, P1144, DOI 10.1126/science.1312258; PARIS J, 1991, P NATL ACAD SCI USA, V88, P1039, DOI 10.1073/pnas.88.3.1039; PARKER LL, 1991, EMBO J, V10, P1255, DOI 10.1002/j.1460-2075.1991.tb08067.x; PARKER LL, 1992, P NATL ACAD SCI USA, V89, P2917, DOI 10.1073/pnas.89.7.2917; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; PINES J, 1987, EMBO J, V6, P2987, DOI 10.1002/j.1460-2075.1987.tb02604.x; PINES J, 1990, New Biologist, V2, P389; POSADA J, 1991, MOL CELL BIOL, V11, P2517, DOI 10.1128/MCB.11.5.2517; REED SI, 1980, GENETICS, V95, P561; REID BJ, 1977, J CELL BIOL, V75, P355, DOI 10.1083/jcb.75.2.355; RIABOWOL K, 1989, CELL, V57, P393, DOI 10.1016/0092-8674(89)90914-8; RICHARDSON HE, 1990, GENE DEV, V4, P1332, DOI 10.1101/gad.4.8.1332; RUSSELL P, 1987, CELL, V49, P559, DOI 10.1016/0092-8674(87)90458-2; SAMIEI M, 1991, J BIOL CHEM, V266, P14889; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHEETS MD, 1990, NUCLEIC ACIDS RES, V18, P5799, DOI 10.1093/nar/18.19.5799; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; SOLOMON MJ, 1990, CELL, V63, P1013, DOI 10.1016/0092-8674(90)90504-8; STANDART N, 1987, DEV BIOL, V124, P248, DOI 10.1016/0012-1606(87)90476-3; STRAUSFELD U, 1991, NATURE, V351, P242, DOI 10.1038/351242a0; STURGILL TW, 1991, BIOCHIM BIOPHYS ACTA, V1092, P350, DOI 10.1016/S0167-4889(97)90012-4; SUDBERY PE, 1980, NATURE, V288, P401, DOI 10.1038/288401a0; THNG JPH, 1990, CELL, V63, P313, DOI 10.1016/0092-8674(90)90164-A; THOMAS G, 1992, CELL, V68, P3, DOI 10.1016/0092-8674(92)90199-M; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; UESONO Y, 1987, NUCLEIC ACIDS RES, V15, P10299, DOI 10.1093/nar/15.24.10299; WITTENBERG C, 1990, CELL, V62, P225, DOI 10.1016/0092-8674(90)90361-H; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D	104	98	103	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	1992	7	11					2249	2258						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JW665	1437147				2022-12-25	WOS:A1992JW66500017
J	BIELAWSKA, A; LINARDIC, CM; HANNUN, YA				BIELAWSKA, A; LINARDIC, CM; HANNUN, YA			CERAMIDE-MEDIATED BIOLOGY - DETERMINATION OF STRUCTURAL AND STEREOSPECIFIC REQUIREMENTS THROUGH THE USE OF N-ACYL-PHENYLAMINOALCOHOL ANALOGS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; PROTEIN-KINASE-C; CELL-DIFFERENTIATION; SPHINGOMYELIN TURNOVER; SPHINGOLIPIDS; SPHINGOSINE; MODULATION	Ceramide is a postulated intracellular modulator of cell growth and differentiation (Okazaki, T., Bielawska, A., Bell, R. M., and Hannun, Y. A. (1990) J. Biol. Chem. 265, 15823-1583). In order to determine the structural and stereospecific requirements for ceramide effects on HL-60 cells, N-acyl-phenylaminoalcohol analogs were synthesized and evaluated for their ability to mimic the effects of ceramide on cell proliferation and differentiation. These compounds share with ceramide a similar polar headgroup that allows the investigation of the roles of the primary and secondary hydroxyls, the hydrophobicity of the molecule, and stereospecificity. N-Myristoyl derivatives of phenylamino alcohols showed optimal activity over other chain length analogs and were able to mimic the effects of C2-ceramide on cell growth and differentiation. Neither the primary nor the secondary alcohol was necessary for activity, but the amide-linked acyl chain was required. Stereospecificity of action was demonstrated with an enantiomeric pair: D-erythro-N-myristoyl-2-amino-1-phenyl-1-propanol (C14-D-e-APP-1) and L-erythro-N-myristoyl-2-amino-1-phenyl-1-propanol (C14-L-e-APP-1). The D stereoisomer was as effective as C2-ceramide in inhibiting HL-60 cell growth and in inducing cell differentiation, whereas the L enantiomer lacked activity in both assays. These results suggest stereospecific action of ceramide and strongly support a physiologic role for ceramide as an intracellular mediator with primary roles in regulation of cell growth and differentiation.	DUKE UNIV,MED CTR,DEPT MED,BOX 3355,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT CELL BIOL,DURHAM,NC 27710	Duke University; Duke University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043825, R37GM043825] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-43825] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARORA RC, 1972, J LIPID RES, V13, P86; DOBROWSKY RT, 1992, J BIOL CHEM, V267, P5048; GOODWIN BJ, 1982, J CLIN INVEST, V70, P699, DOI 10.1172/JCI110665; HAKOMORI S, 1990, J BIOL CHEM, V4265, P18713; HANNUN YA, 1986, J BIOL CHEM, V261, P2604; HANNUN YA, 1989, SCIENCE, V243, P500, DOI 10.1126/science.2643164; KIM MY, 1991, J BIOL CHEM, V266, P484; MATHIAS S, 1991, P NATL ACAD SCI USA, V88, P10009, DOI 10.1073/pnas.88.22.10009; MERRILL AH, 1989, BIOCHIM BIOPHYS ACTA, V1010, P131, DOI 10.1016/0167-4889(89)90152-3; OKAZAKI T, 1989, J BIOL CHEM, V264, P19076; OKAZAKI T, 1990, J BIOL CHEM, V265, P15823; PICK E, 1981, J IMMUNOL METHODS, V46, P211, DOI 10.1016/0022-1759(81)90138-1; SHAPIRO D, 1961, J AM CHEM SOC, V83, P3327, DOI 10.1021/ja01476a033	13	116	130	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1992	267	26					18493	18497						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JN502	1526986				2022-12-25	WOS:A1992JN50200041
J	MANOHARAN, TH; GULICK, AM; PUCHALSKI, RB; SERVAIS, AL; FAHL, WE				MANOHARAN, TH; GULICK, AM; PUCHALSKI, RB; SERVAIS, AL; FAHL, WE			STRUCTURAL STUDIES ON HUMAN GLUTATHIONE-S-TRANSFERASE-PI - SUBSTITUTION MUTATIONS TO DETERMINE AMINO-ACIDS NECESSARY FOR BINDING GLUTATHIONE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVE-SITE; MESSENGER-RNA; EXPRESSION; MUTAGENESIS; LIVER; GENE; YA; RESISTANCE; HISTIDINE; CLONING	In order to identify amino acids involved in binding the co-substrate glutathione to the human glutathione S-transferase (GST) pi-enzyme, we assembled three criteria to implicate amino acids whose role in binding and catalysis could be tested. Presence of a residue in the highly conserved exon 4 of the GST gene, positional conservation of a residue in 12 glutathione S-transferase amino acid sequences, and results from published chemical modification studies were used to implicate 14 residues. A bacterial expression vector (pUC120-pi), which enabled abundant production (2-26% of soluble Escherichia coli protein) of wild-type or mutant GST-pi, was constructed, and, following nonconservative substitution mutation of the 14 implicated residues, five mutants (R13S, D57K, Q64R, 168Y, L72F) showed a >95% decrease in specific activity. A quantitative assay was developed which rapidly measured the ability of wild-type or mutant glutathione S-transferase to bind to glutathione-agarose. Using this assay, each of the five loss of function mutants showed a >20-fold decrease in binding glutathione, an observation consistent with a recent crystal structure analysis showing that several of these residues help to form the glutathione-binding cleft.	UNIV WISCONSIN,MCARDLE LAB CANC RES,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison				Gulick, Andrew/0000-0003-4238-7453	NATIONAL CANCER INSTITUTE [P30CA007175] Funding Source: NIH RePORTER; NCI NIH HHS [P30-CA07175] Funding Source: Medline; PHS HHS [P01-22484] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ARMSTRONG RN, 1991, CHEM RES TOXICOL, V4, P131, DOI 10.1021/tx00020a001; AWASTHI YC, 1987, BIOCHEM BIOPH RES CO, V143, P965, DOI 10.1016/0006-291X(87)90345-7; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; Cleland W. W, 1970, ENZYMES, V2, P1; COWELL IG, 1988, BIOCHEM J, V255, P79, DOI 10.1042/bj2550079; FAHL WE, 1990, GLUTATHIONE S-TRANSFERASES AND DRUG RESISTANCE, P186; GRAMINSKI GF, 1989, BIOCHEMISTRY-US, V28, P3562, DOI 10.1021/bi00434a062; GULICK AM, 1992, J BIOL CHEM, V267, P18946; HABIG WH, 1974, J BIOL CHEM, V249, P7130; Hanes CS, 1932, BIOCHEM J, V26, P1406, DOI 10.1042/bj0261406; KANO T, 1987, CANCER RES, V47, P5626; KATUSZ RM, 1991, BIOCHEMISTRY-US, V30, P11230, DOI 10.1021/bi00111a006; KETTERER B, 1988, MUTAT RES, V202, P343, DOI 10.1016/0027-5107(88)90197-2; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAI HCJ, 1986, J BIOL CHEM, V261, P3793; LIU X, 1992, J BIOL CHEM, V267, P4296; MANNERVIK B, 1988, CRC CR REV BIOCH MOL, V23, P283, DOI 10.3109/10409238809088226; MANOHARAN TH, 1987, J BIOL CHEM, V262, P3739; MANOHARAN TH, 1992, IN PRESS J MOL BIOL; OKUDA A, 1987, J BIOL CHEM, V262, P3858; PICKETT CB, 1989, ANNU REV BIOCHEM, V58, P743, DOI 10.1146/annurev.bi.58.070189.003523; PICKETT CB, 1984, J BIOL CHEM, V259, P5182; PUCHALSKI RB, 1990, P NATL ACAD SCI USA, V87, P2443, DOI 10.1073/pnas.87.7.2443; REDDY KJ, 1987, CURRENT PROTOCOLS MO; REINEMER P, 1991, EMBO J, V10, P1997, DOI 10.1002/j.1460-2075.1991.tb07729.x; Sambrook J, 1989, MOL CLONING LABORATO; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STENBERG G, 1991, FEBS LETT, V293, P153, DOI 10.1016/0014-5793(91)81174-7; TOWNSEND A J, 1989, Cancer Bulletin (Houston), V41, P31; TU CPD, 1987, GLUTATHIONE S TRANSF, P87; VANOMMEN B, 1989, EUR J BIOCHEM, V181, P423; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; VORACHEK WR, 1991, P NATL ACAD SCI USA, V88, P4443, DOI 10.1073/pnas.88.10.4443; WANG RW, 1991, ARCH BIOCHEM BIOPHYS, V286, P574, DOI 10.1016/0003-9861(91)90082-T; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; ZHANG PH, 1991, J BIOL CHEM, V266, P19475	36	52	52	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1992	267	26					18940	18945						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JN502	1527021				2022-12-25	WOS:A1992JN50200103
J	PATINO, MM; WALDEN, WE				PATINO, MM; WALDEN, WE			CLONING OF A FUNCTIONAL CDNA FOR THE RABBIT FERRITIN MESSENGER-RNA REPRESSOR PROTEIN - DEMONSTRATION OF A TISSUE-SPECIFIC PATTERN OF EXPRESSION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRON-RESPONSIVE ELEMENT; 3' UNTRANSLATED REGION; BINDING-PROTEIN; TRANSFERRIN RECEPTOR; TRANSLATIONAL REPRESSION; AFFINITY PURIFICATION; GENE-EXPRESSION; IRE-BP; ACONITASE; IDENTIFICATION	Ferritin synthesis is controlled at the translational level in response to cellular iron status. A component of this regulatory system is the ferritin repressor protein (FRP) which binds to the iron-responsive element (IRE) located at the 5' end of all known ferritin mRNAs, thus inhibiting its translation. Antibodies against purified FRP were raised in mouse and used to isolate an FRP cDNA from a rabbit liver cDNA library cloned in the expression vector lambda-gt11. The FRP cDNA encodes a 98.5-kilodalton protein which shares greater than 90% identity with IRE-binding proteins from other species. The FRP cDNA was placed under the transcriptional direction of the yeast GAL1 promoter. Yeast transformed with this gene express IRE-specific binding activity, illustrating the potential utility of yeast for the study of FRP structure/function. Analysis of FRP distribution in rabbit tissues shows that it is present in a variety of tissues. The levels of FRP differ dramatically from tissue to tissue, however. An examination of FRP mRNA levels and comparison to FRP protein suggest that synthesis of FRP is regulated transcriptionally and post-transcriptionally.	UNIV ILLINOIS, DEPT MICROBIOL & IMMUNOL, CHICAGO, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital								AZIZ N, 1987, P NATL ACAD SCI USA, V84, P8478, DOI 10.1073/pnas.84.23.8478; BARTON HA, 1990, J BIOL CHEM, V265, P7000; BECKER DM, 1991, METHOD ENZYMOL, V194, P182; BEINERT H, 1989, EUR J BIOCHEM, V186, P5, DOI 10.1111/j.1432-1033.1989.tb15170.x; BRIDGES KR, 1984, J BIOL CHEM, V259, P2970; BROWN PH, 1989, J BIOL CHEM, V264, P13383; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CASEY JL, 1989, EMBO J, V8, P3693, DOI 10.1002/j.1460-2075.1989.tb08544.x; CASEY JL, 1988, SCIENCE, V240, P924, DOI 10.1126/science.2452485; CASEY JL, 1988, P NATL ACAD SCI USA, V85, P1787, DOI 10.1073/pnas.85.6.1787; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COX TC, 1991, EMBO J, V10, P1891, DOI 10.1002/j.1460-2075.1991.tb07715.x; DANDEKAR T, 1991, EMBO J, V10, P1903, DOI 10.1002/j.1460-2075.1991.tb07716.x; DRYSDALE JW, 1988, PROG NUCLEIC ACID RE, V35, P127, DOI 10.1016/S0079-6603(08)60612-1; GOOSSEN B, 1990, EMBO J, V9, P4127, DOI 10.1002/j.1460-2075.1990.tb07635.x; HAILE DJ, 1989, MOL CELL BIOL, V9, P5055, DOI 10.1128/MCB.9.11.5055; HAILE DJ, 1990, J BIOL CHEM, V265, P12786; HARRELL CM, 1991, P NATL ACAD SCI USA, V88, P4166, DOI 10.1073/pnas.88.10.4166; HENTZE MW, 1987, P NATL ACAD SCI USA, V84, P6730, DOI 10.1073/pnas.84.19.6730; HENTZE MW, 1987, SCIENCE, V238, P1570, DOI 10.1126/science.3685996; HENTZE MW, 1991, NUCLEIC ACIDS RES, V19, P1739, DOI 10.1093/nar/19.8.1739; HIRLING H, 1992, NUCLEIC ACIDS RES, V20, P33, DOI 10.1093/nar/20.1.33; JAEGER JA, 1989, P NATL ACAD SCI USA, V86, P7706, DOI 10.1073/pnas.86.20.7706; KAPTAIN S, 1991, P NATL ACAD SCI USA, V88, P10109, DOI 10.1073/pnas.88.22.10109; KENAN DJ, 1991, TRENDS BIOCHEM SCI, V16, P214, DOI 10.1016/0968-0004(91)90088-D; KLAUSNER RD, 1989, SCIENCE, V246, P870, DOI 10.1126/science.2683086; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; LEIBOLD EA, 1988, P NATL ACAD SCI USA, V85, P2171, DOI 10.1073/pnas.85.7.2171; LEIBOLD EA, 1990, NUCLEIC ACIDS RES, V18, P1819, DOI 10.1093/nar/18.7.1819; LIN JJ, 1991, P NATL ACAD SCI USA, V88, P6068, DOI 10.1073/pnas.88.14.6068; LIN JJ, 1990, SCIENCE, V247, P74, DOI 10.1126/science.2294594; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Maniatis T., 1982, MOL CLONING; MATTIA E, 1984, J BIOL CHEM, V259, P2689; MULLNER EW, 1988, CELL, V53, P815, DOI 10.1016/0092-8674(88)90098-0; MUNRO HN, 1978, PHYSIOL REV, V58, P317, DOI 10.1152/physrev.1978.58.2.317; NEUPERT B, 1990, NUCLEIC ACIDS RES, V18, P51, DOI 10.1093/nar/18.1.51; OWEN D, 1987, EMBO J, V6, P1287, DOI 10.1002/j.1460-2075.1987.tb02366.x; PHILPOTT CC, 1991, NUCLEIC ACIDS RES, V19, P6333, DOI 10.1093/nar/19.22.6333; PRODROMOU C, 1992, EUR J BIOCHEM, V204, P599, DOI 10.1111/j.1432-1033.1992.tb16673.x; ROBBINS AH, 1989, PROTEINS, V5, P289, DOI 10.1002/prot.340050406; ROTHENBERGER S, 1990, NUCLEIC ACIDS RES, V18, P1175, DOI 10.1093/nar/18.5.1175; ROUAULT TA, 1989, P NATL ACAD SCI USA, V86, P5768, DOI 10.1073/pnas.86.15.5768; ROUAULT TA, 1991, CELL, V64, P881, DOI 10.1016/0092-8674(91)90312-M; ROUAULT TA, 1990, P NATL ACAD SCI USA, V87, P7958, DOI 10.1073/pnas.87.20.7958; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHULL GE, 1982, J BIOL CHEM, V257, P4187; SWENSON GR, 1991, BIOL MET, V4, P48, DOI 10.1007/BF01135557; THEIL EC, 1990, J BIOL CHEM, V265, P4771; WALDEN WE, 1986, BIOCHEMISTRY-US, V25, P2033, DOI 10.1021/bi00356a030; WALDEN WE, 1988, P NATL ACAD SCI USA, V85, P9503, DOI 10.1073/pnas.85.24.9503; WALDEN WE, 1989, J BIOL CHEM, V264, P13765; WANG YH, 1990, NUCLEIC ACIDS RES, V18, P4463, DOI 10.1093/nar/18.15.4463; YOUNG RA, 1983, P NATL ACAD SCI-BIOL, V80, P1194, DOI 10.1073/pnas.80.5.1194; YU Y, 1992, J BIOL CHEM, V267, P19005; ZAHRINGER J, 1976, P NATL ACAD SCI USA, V73, P857, DOI 10.1073/pnas.73.3.857	56	48	48	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	1992	267	26					19011	19016						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JN502	1527028				2022-12-25	WOS:A1992JN50200113
J	TONINELLO, A; VIA, LD; SILIPRANDI, D; GARLID, KD				TONINELLO, A; VIA, LD; SILIPRANDI, D; GARLID, KD			EVIDENCE THAT SPERMINE, SPERMIDINE, AND PUTRESCINE ARE TRANSPORTED ELECTROPHORETICALLY IN MITOCHONDRIA BY A SPECIFIC POLYAMINE UNIPORTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER MITOCHONDRIA; ORNITHINE DECARBOXYLASE ACTIVITY; NEURO-BLASTOMA CELLS; CA-2+ TRANSPORT; METHYLGLYOXAL BIS(GUANYLHYDRAZONE); OXIDATIVE-PHOSPHORYLATION; HUMAN FIBROBLASTS; SYSTEM; LYMPHOCYTES; METABOLISM	We present evidence that polyamine uptake into rat liver mitochondria is mediated by a specific polyamine uniporter. Polyamine transport is not mediated by the ornithine, lysine, or Ca2+ transporters of mitochondria. Polyamine transport is a saturable process, with apparent K(m) values of 0.13 mM for spermine, 0.26 mM for spermidine, and 1 mM for putrescine. These substrates are mutually competitive inhibitors, indicating a common transport system. Polyamine transport is strictly dependent on membrane potential and insensitive to medium pH, showing that these polycations are transported electrophoretically. Spermine, spermidine, and putrescine are taken up by rat liver mitochondria at rates that increase with increasing valence of the transported species. The activation enthalpies for transport were 24, 32, and 59 kJ/mol for putrescine, spermidine, and spermine, respectively. These values, which amount to about 12 kJ/mol per charge transferred, may be compared to a value of 76 kJ/mol observed for monovalent tetraethylammonium cation. Flux-voltage analysis is consistent with the hypothesis that the mitochondrial polyamine transporter catalyzes transport via a channel mechanism.	MED COLL OHIO,DEPT PHARMACOL,TOLEDO,OH 43699		TONINELLO, A (corresponding author), UNIV PADUA,CNR,CTR STUDIO FISIOL MITOCONDRIALE,DIPARTIMENTO CHIM BIOL,I-35100 PADUA,ITALY.			DALLA VIA, LISA/0000-0002-9828-9388; Garlid, Keith/0000-0002-6777-1235	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031086] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-31086] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AFFOLTER H, 1979, ANAL BIOCHEM, V97, P315, DOI 10.1016/0003-2697(79)90078-2; ALHONENHONGISTO L, 1982, FEBS LETT, V145, P182, DOI 10.1016/0014-5793(82)80163-4; ALHONENHONGISTO L, 1980, BIOCHEM J, V192, P941, DOI 10.1042/bj1920941; BETHELL DR, 1981, J CELL PHYSIOL, V109, P461, DOI 10.1002/jcp.1041090312; BRAGADIN M, 1979, FEBS LETT, V104, P347, DOI 10.1016/0014-5793(79)80849-2; CHEN KY, 1981, BIOCHEM BIOPH RES CO, V101, P243, DOI 10.1016/S0006-291X(81)80037-X; CHEN KY, 1988, BIOCHEM BIOPH RES CO, V150, P185, DOI 10.1016/0006-291X(88)90503-7; COLOMBATTO S, 1990, INT J BIOCHEM, V22, P489, DOI 10.1016/0020-711X(90)90262-2; DAMUNI Z, 1987, J BIOL CHEM, V262, P5133; DEVIS RH, 1988, ARCH BIOCHEM BIOPHYS, V267, P479; DIPASQUALE A, 1978, EXP CELL RES, V116, P317, DOI 10.1016/0014-4827(78)90454-8; GARLID KD, 1989, BIOCHIM BIOPHYS ACTA, V976, P109, DOI 10.1016/S0005-2728(89)80219-1; GAWELTHOMPSON K, 1988, J CELL PHYSIOL, V136, P237, DOI 10.1002/jcp.1041360205; HEBY O, 1981, ADV POLYAMINE RES, V3, P357; HOMMES FA, 1983, BIOCHEM MED METAB B, V30, P313, DOI 10.1016/0006-2944(83)90022-4; JENSEN BD, 1986, ARCH BIOCHEM BIOPHYS, V248, P305, DOI 10.1016/0003-9861(86)90427-3; KAKINUMA Y, 1988, EUR J BIOCHEM, V176, P409, DOI 10.1111/j.1432-1033.1988.tb14297.x; KAMO N, 1979, J MEMBRANE BIOL, V49, P105, DOI 10.1007/BF01868720; KANO K, 1976, J BIOL CHEM, V251, P2795; KASHIWAGI K, 1986, J BACTERIOL, V165, P972, DOI 10.1128/jb.165.3.972-977.1986; LENZEN S, 1986, J BIOL CHEM, V261, P6478; MALKAWA S, 1989, BIOCHIM BIOPHYS ACTA, V993, P199; MANCON M, 1990, ITAL J BIOCHEM, V39, P278; MCCORMACK JG, 1989, BIOCHEM J, V264, P167, DOI 10.1042/bj2640167; MCGIVAN JD, 1977, BIOCHEM J, V162, P147, DOI 10.1042/bj1620147; MENDE P, 1982, EUR J BIOCHEM, V128, P91; Mitchell P., 1966, REGULATION METABOLIC, P65; MORENOSANCHEZ R, 1988, BIOCHEM J, V256, P403, DOI 10.1042/bj2560403; NICCHITTA CV, 1984, J BIOL CHEM, V259, P2978; Palmieri F, 1979, Methods Enzymol, V56, P279; PALMIERI F, 1978, BIOENERGETICS MITOCH, P5; PEGG AE, 1984, BIOCHEM J, V224, P29, DOI 10.1042/bj2240029; PHILLIPS JE, 1982, BIOCHEM BIOPH RES CO, V108, P174, DOI 10.1016/0006-291X(82)91847-2; PISTOCCHI R, 1989, PLANT PHYSIOL, V92, P690; POHJANPELTO P, 1976, J CELL BIOL, V68, P512, DOI 10.1083/jcb.68.3.512; RANNELS DE, 1987, AM J PHYSIOL, V252, pE96, DOI 10.1152/ajpendo.1987.252.1.E96; RINEHART CA, 1984, J BIOL CHEM, V259, P4750; ROTTENBERG H, 1990, BIOCHIM BIOPHYS ACTA, V1016, P77, DOI 10.1016/0005-2728(90)90009-S; SHAKIR S, 1989, BIOL CHEM H-S, V370, P1279; TABOR CW, 1984, ANNU REV BIOCHEM, V53, P749, DOI 10.1146/annurev.bi.53.070184.003533; TABOR CW, 1966, J BIOL CHEM, V241, P3714; TONINELLO A, 1988, J BIOL CHEM, V263, P19407; TONINELLO A, 1985, BIOCHIM BIOPHYS ACTA, V815, P399, DOI 10.1016/0005-2736(85)90366-9; TONINELLO A, CARDIOSCIENCE, V1, P287; TONINELLO A, 1988, EBEC REP, V5, P208; Toninello A, 1984, ADV POLYAMINES BIOME, P31; VERTINO PM, 1991, MOL PHARMACOL, V39, P487; VOTYAKOVA TV, 1990, FEBS LETT, V261, P139, DOI 10.1016/0014-5793(90)80655-3; YOSHINO M, 1991, BIOCHIM BIOPHYS ACTA, V1073, P200	49	88	88	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1992	267	26					18393	18397						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JN502	1526979				2022-12-25	WOS:A1992JN50200027
J	MATTS, RL; HURST, R				MATTS, RL; HURST, R			THE RELATIONSHIP BETWEEN PROTEIN-SYNTHESIS AND HEAT-SHOCK PROTEINS LEVELS IN RABBIT RETICULOCYTE LYSATES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INITIATION FACTOR-II; REGULATED EIF-2-ALPHA KINASE; STEROID-RECEPTOR COMPLEXES; PROGESTERONE-RECEPTOR; ALPHA-SUBUNIT; GLUCOCORTICOID RECEPTORS; 59-KILODALTON PROTEIN; MONOCLONAL-ANTIBODIES; REVERSING FACTOR; DNA-BINDING	Besides heme deficiency, protein synthesis in rabbit reticulocyte lysates becomes inhibited upon exposure to a variety of agents that mimic conditions which induce the heat shock response in cells. This inhibition has been demonstrated to be due primarily to the activation of the heme-regulated eIF-2-alpha kinase (HRI) which causes an arrest in the initiation of translation. In this report, the sensitivity of protein synthesis in hemin-supplemented lysates to inhibition by Hg2+, GSSG, methylene blue, and heat shock was examined in six different reticulocyte lysate preparations. The extent to which translation was inhibited in response to Hg2+, GSSG, methylene blue, and heat shock correlated inversely with the relative levels of the 70-kDa heat shock proteins (hsp 70) and a 56-kDa protein (p56) present in the lysates determined by Western blotting. The ability of hemin to restore protein synthesis upon addition to heme-deficient lysates was also examined. While the restoration of protein synthesis correlated roughly with the levels of hsp 90 present, the results also suggest that the heme regulation of HRI probably involves the interaction of HRI with several factors present in the lysate besides hsp 90. A comparison of two lysate preparations, which had a 2-fold difference in their protein synthesis rates, indicated that the slower translational rate of the one lysate could be accounted for by its low level of constitutive eIF-2-alpha phosphorylation, with its accompanying decrease in the eIF-2B activity and lower level of polyribosome loading. The present study supports the notion that the previously demonstrated interaction of HRI with hsp 90, hsp 70, and p56 in reticulocyte lysates may play a direct role in regulating HRI activation or activity. We hypothesize that the competition of denatured protein and HRI for the binding of hsp 70 may be a molecular signal that triggers the activation of HRI in reticulocyte lysates in response to stress. Possible functions for p56 in the regulation of HRI activity are also discussed.	OKLAHOMA STATE UNIV,OKLAHOMA AGR EXPT STN,STILLWATER,OK 74078	Oklahoma State University System; Oklahoma State University - Stillwater	MATTS, RL (corresponding author), OKLAHOMA STATE UNIV,DEPT BIOCHEM,454 PS 2,STILLWATER,OK 74078, USA.				NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES004299, R29ES004299] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES-04299] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ANG D, 1991, J BIOL CHEM, V266, P24233; BECKMANN RP, 1990, SCIENCE, V248, P850, DOI 10.1126/science.2188360; CHEN JJ, 1989, J BIOL CHEM, V264, P9559; CRAIG EA, 1991, TRENDS BIOCHEM SCI, V16, P135, DOI 10.1016/0968-0004(91)90055-Z; DALMAN FC, 1989, J BIOL CHEM, V264, P19815; DEBENEDETTI A, 1986, J BIOL CHEM, V261, P338; DIDOMENICO BJ, 1982, CELL, V31, P593, DOI 10.1016/0092-8674(82)90315-4; DUNCAN RF, 1989, J CELL BIOL, V109, P1467, DOI 10.1083/jcb.109.4.1467; ERNST V, 1978, J BIOL CHEM, V253, P7163; ERNST V, 1982, HEAT SHOCK BACTERIA, P215; ESTES PA, 1987, BIOCHEMISTRY-US, V26, P6250, DOI 10.1021/bi00393a045; GERNER EW, 1975, NATURE, V256, P500, DOI 10.1038/256500a0; HAHN GM, 1982, RADIAT RES, V92, P452, DOI 10.2307/3575917; HENLE KJ, 1976, RADIAT RES, V66, P505, DOI 10.2307/3574455; HERSHEY JWB, 1989, J BIOL CHEM, V264, P20823; HIGHTOWER LE, 1980, J CELL PHYSIOL, V102, P407, DOI 10.1002/jcp.1041020315; HOLMGREN A, 1985, ANNU REV BIOCHEM, V54, P237, DOI 10.1146/annurev.bi.54.070185.001321; HOLMGREN A, 1989, J BIOL CHEM, V264, P13963; HUNT T, 1983, EUR J BIOCHEM, V131, P303, DOI 10.1111/j.1432-1033.1983.tb07263.x; HUNT T, 1972, J MOL BIOL, V66, P471, DOI 10.1016/0022-2836(72)90427-5; HUNT T, 1979, WIN MIAM S GEN PROT, V16, P321; HURST R, 1987, J BIOL CHEM, V262, P15939; HURTLEY SM, 1989, J CELL BIOL, V108, P2117, DOI 10.1083/jcb.108.6.2117; JACKSON RJ, 1983, EUR J BIOCHEM, V131, P313, DOI 10.1111/j.1432-1033.1983.tb07264.x; Jackson RJ, 1991, TRANSLATION EUKARYOT, P193; KASSENBROCK CK, 1988, NATURE, V333, P90, DOI 10.1038/333090a0; KOST SL, 1989, MOL CELL BIOL, V9, P3829, DOI 10.1128/MCB.9.9.3829; LANDRY J, 1982, CANCER RES, V42, P2457; LANKS KW, 1986, EXP CELL RES, V165, P1, DOI 10.1016/0014-4827(86)90528-8; LASZLO A, 1988, EXP CELL RES, V178, P401, DOI 10.1016/0014-4827(88)90409-0; LEBEAU MC, 1992, J BIOL CHEM, V267, P4281; LI GC, 1983, J CELL PHYSIOL, V115, P116, DOI 10.1002/jcp.1041150203; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; Livingston D M, 1974, Methods Enzymol, V34, P723; LONDON IM, 1981, COLD SPRING HARBOR C, V8, P941; LONDON IM, 1985, CONTROL ANIMAL CELL, V1, P515; MACHAMER CE, 1990, J BIOL CHEM, V265, P6879; MATTS RL, 1984, J BIOL CHEM, V259, P6708; MATTS RL, 1992, J BIOL CHEM, V267, P18160; MATTS RL, 1989, J BIOL CHEM, V264, P15542; MATTS RL, 1991, J BIOL CHEM, V266, P12695; MATTS RL, 1988, FEBS LETT, V236, P179, DOI 10.1016/0014-5793(88)80310-7; MICHELSON AM, 1984, J BIOL CHEM, V259, P8529; MIZZEN LA, 1988, J CELL BIOL, V106, P1105, DOI 10.1083/jcb.106.4.1105; Morimoto RI, 1990, STRESS PROTEINS BIOL; MOSSER DD, 1990, P NATL ACAD SCI USA, V87, P3748, DOI 10.1073/pnas.87.10.3748; NOVER L, 1990, HEAT SHOCK RESPONSE; PAIN VM, 1991, TRANSLATION EUKARYOT, P293; PAL JK, 1991, BIOCHEMISTRY-US, V30, P2555, DOI 10.1021/bi00223a037; PERDEW GH, 1991, J BIOL CHEM, V266, P6708; PIGIET VP, 1986, P NATL ACAD SCI USA, V83, P7643, DOI 10.1073/pnas.83.20.7643; PREDEW GH, 1988, J BIOL CHEM, V263, P13802; RENOIR JM, 1990, J BIOL CHEM, V265, P10740; RIEHL RM, 1985, BIOCHEMISTRY-US, V24, P6586, DOI 10.1021/bi00344a042; SANCHEZ ER, 1990, BIOCHEMISTRY-US, V29, P5145, DOI 10.1021/bi00473a021; SANCHEZ ER, 1990, J BIOL CHEM, V265, P22067; SANCHEZ ER, 1990, J BIOL CHEM, V265, P20123; SCHERRER LC, 1990, J BIOL CHEM, V265, P21397; SCHLESINGER MJ, 1990, J BIOL CHEM, V265, P12111; SCHREIBER SL, 1991, SCIENCE, V251, P283, DOI 10.1126/science.1702904; SCORSONE KA, 1987, J BIOL CHEM, V262, P14538; SIEKIERKA J, 1984, P NATL ACAD SCI-BIOL, V81, P352, DOI 10.1073/pnas.81.2.352; SMITH DF, 1990, MOL ENDOCRINOL, V4, P1704, DOI 10.1210/mend-4-11-1704; SMITH DF, 1990, J BIOL CHEM, V265, P3996; SORGER PK, 1991, CELL, V65, P363, DOI 10.1016/0092-8674(91)90452-5; STONE DE, 1990, MOL CELL BIOL, V10, P1622, DOI 10.1128/MCB.10.4.1622; SZYSZKA R, 1989, BIOCHEMISTRY-US, V28, P1435, DOI 10.1021/bi00430a001; TAI PKK, 1986, BIOCHEMISTRY-US, V25, P5269, DOI 10.1021/bi00366a043; THOMAS NSB, 1985, J BIOL CHEM, V260, P9860; WELCH WJ, 1986, J CELL BIOL, V103, P2035, DOI 10.1083/jcb.103.5.2035; YEM AW, 1992, J BIOL CHEM, V267, P2868; [No title captured]	72	43	46	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1992	267	25					18168	18174						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JM223	1517246				2022-12-25	WOS:A1992JM22300105
J	LAUTENBERGER, JA; BURDETT, LA; GUNNELL, MA; QI, SM; WATSON, DK; OBRIEN, SJ; PAPAS, TS				LAUTENBERGER, JA; BURDETT, LA; GUNNELL, MA; QI, SM; WATSON, DK; OBRIEN, SJ; PAPAS, TS			GENOMIC DISPERSAL OF THE ETS GENE FAMILY DURING METAZOAN EVOLUTION	ONCOGENE			English	Article							PUTATIVE ONCOGENE SPI-1; PROTO-ONCOGENE; C-ETS; CHROMOSOMAL LOCALIZATION; TRANSCRIPTION FACTOR; DEVELOPMENTAL EXPRESSION; MOLECULAR-ORGANIZATION; C-ETS-1 PROTOONCOGENE; TRANSFORMING GENE; LEUKEMIA-VIRUS	Evolutionary homologs of the ets proto-oncogene have been discovered in the genomes of widely divergent eucaryote species from Drosophila to sea urchin to vertebrates. The prototype mammalian ets-1 and ets-2 genes are divided into three coding domains that differ in their rate of accumulation of sequence divergence. An analysis of sequence divergence of ets gene homologs in various species has produced a phylogenetic history of the ets gene family in the context of metazoan evolutionary radiation. A minimum of five duplication events of ets primordial genes were evident, namely (1) a duplication that separates primitive ets genes (Drosophila precursor of 74E, mouse PU.1 and human ELK1) from the ets-1, ets-2, erg ancestor; (2) and (3) two duplications that established separate ets, erg and elg/GABP-alpha lineages which occurred prior to invertebrate-vertebrate divergence; (4) divergence of ets-1 and ets-2 gene family also associated with vertebrate-invertebrate divergence; (5) duplication of ets-1 and ets-2 in Xenopus laevis to produce two ets-1 genes and two ets-2 genes during genomic tetraploidation in the recent ancestry of this species.	FREDERICK CANC RES & DEV CTR, PROGRAM RESOURCES INC, FREDERICK, MD 21702 USA; NCI, VIRAL CARCINOGENESIS LAB, FREDERICK, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	LAUTENBERGER, JA (corresponding author), NCI, MOLEC ONCOL LAB, FREDERICK, MD 21702 USA.		OBRIEN, STEPHEN/ABD-1346-2020	OBRIEN, STEPHEN/0000-0001-7857-0757				BAUD V, 1991, GENOMICS, V11, P223, DOI 10.1016/0888-7543(91)90124-W; BENDAVID Y, 1991, GENE DEV, V5, P908, DOI 10.1101/gad.5.6.908; BERGERON D, 1991, J VIROL, V65, P7, DOI 10.1128/JVI.65.1.7-15.1991; BOSSELUT R, 1990, EMBO J, V9, P3137, DOI 10.1002/j.1460-2075.1990.tb07511.x; BOULUKOS KE, 1988, EMBO J, V7, P697, DOI 10.1002/j.1460-2075.1988.tb02865.x; BURDETT LA, 1992, NUCLEIC ACIDS RES, V20, P371, DOI 10.1093/nar/20.2.371; BURTIS KC, 1990, CELL, V61, P85, DOI 10.1016/0092-8674(90)90217-3; CHEN JH, 1990, ONCOGENE RES, V5, P277; CHEN ZQ, 1988, DEV BIOL, V125, P432, DOI 10.1016/0012-1606(88)90224-2; DETAISNE C, 1984, NATURE, V310, P581, DOI 10.1038/310581a0; DEVEREAUX J, 1991, SEQUENCE ANAL SOFTWA; DUTERQUECOQUILLAUD M, 1988, ONCOGENE RES, V2, P335; FITCH WM, 1967, SCIENCE, V155, P279, DOI 10.1126/science.155.3760.279; GOEBL MG, 1990, CELL, V61, P1165, DOI 10.1016/0092-8674(90)90676-6; HO IC, 1990, SCIENCE, V250, P814, DOI 10.1126/science.2237431; JANKNECHT R, 1989, NUCLEIC ACIDS RES, V17, P4455, DOI 10.1093/nar/17.12.4455; JORCYK CL, 1991, ONCOGENE, V6, P523; JUNIEN C, 1990, CYTOGENET CELL GENET, V55, P153, DOI 10.1159/000133007; KARIM FD, 1990, GENE DEV, V4, P1451, DOI 10.1101/gad.4.9.1451; KINGSLEY DM, 1989, GENETICS, V123, P165; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; KOBEL HR, 1986, TRENDS GENET, V2, P310, DOI 10.1016/0168-9525(86)90286-6; LAMARCO K, 1991, SCIENCE, V253, P789, DOI 10.1126/science.1876836; LEPRINCE D, 1983, NATURE, V306, P395, DOI 10.1038/306395a0; LEPRINCE D, 1988, J VIROL, V62, P3233, DOI 10.1128/JVI.62.9.3233-3241.1988; LIPMAN DJ, 1989, P NATL ACAD SCI USA, V86, P4412, DOI 10.1073/pnas.86.12.4412; MOREAUGACHELIN F, 1989, ONCOGENE, V4, P1449; MOREAUGACHELIN F, 1990, ONCOGENE, V5, P941; MYERS G, 1991, HUMAN RETROVIRUSES A, P25; NEEDLEMAN SB, 1970, J MOL BIOL, V48, P443, DOI 10.1016/0022-2836(70)90057-4; NUNN MF, 1983, NATURE, V306, P391, DOI 10.1038/306391a0; PRIBYL LJ, 1991, ONCOGENE, V6, P1175; PRIBYL LJ, 1988, DEV BIOL, V127, P45, DOI 10.1016/0012-1606(88)90187-X; RAO VN, 1987, SCIENCE, V237, P635, DOI 10.1126/science.3299708; RAO VN, 1988, ONCOGENE, V3, P497; RAO VN, 1989, SCIENCE, V244, P66, DOI 10.1126/science.2539641; REDDY ESP, 1988, ONCOGENE RES, V3, P239; REDDY ESP, 1987, P NATL ACAD SCI USA, V84, P6131, DOI 10.1073/pnas.84.17.6131; REEVES RH, 1988, J VIROL, V62, P4372, DOI 10.1128/JVI.62.11.4372-4375.1988; REITZ MS, 1991, NATURE, V351, P358, DOI 10.1038/351358a0; SACCHI N, 1988, Genomics, V3, P110, DOI 10.1016/0888-7543(88)90140-1; Sneath P.H.A., 1973, NUMERICAL TAXONOMY P; STIEGLER P, 1990, NUCLEIC ACIDS RES, V18, P5298, DOI 10.1093/nar/18.17.5298; SWOFFORD DL, 1984, PHYLOGENETIC ANAL US; THOMPSON CC, 1991, SCIENCE, V253, P762, DOI 10.1126/science.1876833; VALENTINE JW, 1991, EVOLUTIONARY BIOL, V25, P279; VANCONG N, 1990, HUM GENET, V84, P542; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WASYLYK C, 1991, EMBO J, V10, P1127, DOI 10.1002/j.1460-2075.1991.tb08053.x; WATSON D K, 1990, Critical Reviews in Oncogenesis, V1, P409; WATSON DK, 1990, ADV AP BIOT, V6, P221; WATSON DK, 1988, VIROLOGY, V164, P99, DOI 10.1016/0042-6822(88)90624-1; WATSON DK, 1990, ONCOGENE, V5, P1521; WATSON DK, 1988, P NATL ACAD SCI USA, V85, P7862, DOI 10.1073/pnas.85.21.7862; WATSON DK, 1985, P NATL ACAD SCI USA, V82, P7294, DOI 10.1073/pnas.82.21.7294; WATSON DK, 1986, P NATL ACAD SCI USA, V83, P1792, DOI 10.1073/pnas.83.6.1792; WOLFF CM, 1991, CELL GROWTH DIFFER, V2, P447; [No title captured]	58	58	59	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	1992	7	9					1713	1719						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JJ376	1501883				2022-12-25	WOS:A1992JJ37600006
J	JACKSON, JA; HOLT, JT; PLEDGER, WJ				JACKSON, JA; HOLT, JT; PLEDGER, WJ			PLATELET-DERIVED GROWTH-FACTOR REGULATION OF FOS STABILITY CORRELATES WITH GROWTH INDUCTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERUM RESPONSE ELEMENT; C 3T3 CELLS; PROTO-ONCOGENE; DNA-SYNTHESIS; ANTISENSE RNA; JUN; TRANSCRIPTION; GENE; STIMULATION; EXPRESSION	A brief exposure of quiescent, density-arrested Balb/c 3T3 fibroblasts to platelet-derived growth factor (PDGF) results in expression of the proto-oncogene c-fos; furthermore, the translation product of c-fos, p55fos, was shown to have increased stability in cells upon continued exposure to PDGF. The induction of competence or growth initiation requires a longer exposure to PDGF than that necessary for the induction of the immediate-early, growth-related genes. The need for the continued presence of PDGF for growth initiation beyond the time required for the induction of immediate-early gene expression may be due, in part, to PDGF-dependent post-translational stabilizations of gene products. We speculate that a PDGF-mediated event increases p55fos stability, resulting in a continued elevated level of Fos protein, which in turn allows a continued Fos-mediated activity required by Balb/c 3T3 cells to become competent to enter the cell cycle.			JACKSON, JA (corresponding author), VANDERBILT UNIV,MED CTR,SCH MED,DEPT CELL BIOL,NASHVILLE,TN 37232, USA.		Jackson, Jon/AAC-5925-2019	Jackson, Jon/0000-0001-5709-2610	NATIONAL CANCER INSTITUTE [R01CA042713, R01CA051735, T32CA009592] Funding Source: NIH RePORTER; NCI NIH HHS [CA51735, T32-CA09592, CA42713] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; COATS SR, 1992, J CELL BIOCHEM, V48, P242, DOI 10.1002/jcb.240480304; COCHRAN BH, 1983, CELL, V33, P939, DOI 10.1016/0092-8674(83)90037-5; CURRAN T, 1987, ONCOGENE, V2, P79; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HALAZONETIS TD, 1988, CELL, V55, P917, DOI 10.1016/0092-8674(88)90147-X; HARRINGTON MA, 1987, METHOD ENZYMOL, V147, P400; HOLT JT, 1986, P NATL ACAD SCI USA, V83, P4794, DOI 10.1073/pnas.83.13.4794; KAMATA N, 1992, MOL CELL BIOL, V12, P876, DOI 10.1128/MCB.12.2.876; KOVARY K, 1991, MOL CELL BIOL, V11, P4466, DOI 10.1128/MCB.11.9.4466; KRUIJER W, 1984, NATURE, V312, P711, DOI 10.1038/312711a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAU LF, 1987, P NATL ACAD SCI USA, V84, P1182, DOI 10.1073/pnas.84.5.1182; LUCIBELLO FC, 1989, CELL, V59, P999, DOI 10.1016/0092-8674(89)90756-3; MORGAN CJ, 1989, J CELL PHYSIOL, V141, P535, DOI 10.1002/jcp.1041410312; MULLER R, 1984, NATURE, V312, P716, DOI 10.1038/312716a0; NAKABEPPU Y, 1988, CELL, V55, P907, DOI 10.1016/0092-8674(88)90146-8; NISHIKURA K, 1987, MOL CELL BIOL, V7, P639, DOI 10.1128/MCB.7.2.639; OSHEA EK, 1992, CELL, V68, P699, DOI 10.1016/0092-8674(92)90145-3; PLEDGER WJ, 1978, P NATL ACAD SCI USA, V75, P2839, DOI 10.1073/pnas.75.6.2839; PLEDGER WJ, 1977, P NATL ACAD SCI USA, V74, P4481, DOI 10.1073/pnas.74.10.4481; RAHM M, 1990, J CELL PHYSIOL, V143, P475, DOI 10.1002/jcp.1041430311; RAUSCHER FJ, 1988, GENE DEV, V2, P1687, DOI 10.1101/gad.2.12b.1687; RIABOWOL KT, 1988, MOL CELL BIOL, V8, P1670, DOI 10.1128/MCB.8.4.1670; RIVERA VM, 1990, GENE DEV, V4, P255, DOI 10.1101/gad.4.2.255; ROBINSONBENION C, 1991, ANTISENSE RES DEV, V1, P21, DOI 10.1089/ard.1991.1.21; ROUX P, 1990, CELL, V63, P341, DOI 10.1016/0092-8674(90)90167-D; SASSONECORSI P, 1988, NATURE, V334, P314, DOI 10.1038/334314a0; SASSONECORSI P, 1988, NATURE, V336, P692, DOI 10.1038/336692a0; SCHULE R, 1990, CELL, V61, P497, DOI 10.1016/0092-8674(90)90531-I; TRATNER I, 1992, MOL CELL BIOL, V12, P998, DOI 10.1128/MCB.12.3.998	33	9	9	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1992	267	24					17444	17448						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JL053	1512275				2022-12-25	WOS:A1992JL05300106
J	MORI, H; TAKIO, K; OGAWARA, M; SELKOE, D				MORI, H; TAKIO, K; OGAWARA, M; SELKOE, D			MASS-SPECTROMETRY OF PURIFIED AMYLOID-BETA PROTEIN IN ALZHEIMERS-DISEASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEREDITARY CEREBRAL-HEMORRHAGE; PLAQUE CORE PROTEIN; PRECURSOR PROTEIN; PREAMYLOID DEPOSITS; GENETIC-LINKAGE; DUTCH TYPE; MUTATION; PEPTIDES; BRAIN; CDNA	The amyloid beta-protein (A-beta) that is progressively deposited in Alzheimer's disease (AD) arises from proteolysis of the integral membrane protein, beta-amyloid precursor protein (beta-APP). Although A-beta formation appears to play a seminal role in AD, only a few studies have examined the chemical structure of A-beta purified from brain, and there are discrepancies among the findings. We describe a new method for the rapid extraction and purification of A-beta that minimizes artifactual proteolysis. A-beta purified by two-dimensional reverse-phase HPLC was analyzed by combined amino acid sequencing and mass spectrometry after digestion with a lysylendopeptidase. The major A-beta peptide in the cerebral cortex of all five AD brains examined was aspartic acid 1 to valine 40. A minor species beginning at glutamic acid 3 but blocked by conversion to pyroglutamate was also found in all cases. A species ending at threonine 43 was detected, varying from approximately 5 to 25% of total A-beta COOH-terminal fragments. Peptides ending with valine 39, isoleucine 41, or alanine 42 were not detected, except for one brain with a minor peptide ending at valine 39. Our findings suggest that A-beta1-40 is the major species of beta-protein in AD cerebral cortex. A-beta1-40 and A-beta1-43 peptides could arise independently from beta-APP, or A-beta1-43 Could be the initial excised fragment, followed by digestion to yield A-beta1-40. These analyses of native A-beta in AD brain recommend the use of synthetic A-beta1-40 peptide to model amyloid fibrillogenesis and toxicity in vitro.	RIKEN,CTR BIOMOLEC CHARACTERIZAT,SAITAMA 35101,JAPAN; HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,CTR NEUROL DIS,BOSTON,MA 02115; TOKYO METROPOLITAN GERIATR HOSP & INST GERONTOL,ITABASHI KU,TOKYO 173,JAPAN	RIKEN; Harvard University; Brigham & Women's Hospital; Harvard Medical School	MORI, H (corresponding author), UNIV TOKYO,INST BRAIN RES,DEPT NEUROPATHOL,7-3-1 HONGO,BUNKYO KU,TOKYO 113,JAPAN.							CHARTIERHARLIN MC, 1991, NATURE, V353, P844, DOI 10.1038/353844a0; CLINTON J, 1991, NEUROPATH APPL NEURO, V17, P69, DOI 10.1111/j.1365-2990.1991.tb00695.x; CORIA F, 1987, AM J PATHOL, V129, P422; GIACCONE G, 1989, NEUROSCI LETT, V97, P232, DOI 10.1016/0304-3940(89)90169-9; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V122, P1131, DOI 10.1016/0006-291X(84)91209-9; GOATE A, 1991, NATURE, V349, P704, DOI 10.1038/349704a0; GOLDGABER D, 1987, SCIENCE, V235, P877, DOI 10.1126/science.3810169; GOREVIC P, 1986, J NEUROPATHOL EXP NE, V46, P647; JOACHIM CL, 1988, BRAIN RES, V474, P100, DOI 10.1016/0006-8993(88)90673-7; JOACHIM CL, 1989, NATURE, V341, P226, DOI 10.1038/341226a0; JOACHIM CL, 1989, AM J PATHOL, V135, P309; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; LEMAIRE HG, 1989, NUCLEIC ACIDS RES, V17, P517, DOI 10.1093/nar/17.2.517; LEVY E, 1990, SCIENCE, V248, P1124, DOI 10.1126/science.2111584; LUCOTTE G, 1991, NATURE, V351, P530, DOI 10.1038/351530b0; MASAKI T, 1981, BIOCHIM BIOPHYS ACTA, V660, P51, DOI 10.1016/0005-2744(81)90107-8; MASTERS CL, 1985, P NATL ACAD SCI USA, V82, P4245, DOI 10.1073/pnas.82.12.4245; MILLER DL, 1990, J NEUROPATH EXP NEUR, V49, P267, DOI 10.1097/00005072-199005000-00024; MORI H, 1987, SCIENCE, V235, P1641, DOI 10.1126/science.3029875; MURRELL J, 1991, SCIENCE, V254, P97, DOI 10.1126/science.1925564; NARUSE S, 1991, LANCET, V337, P978, DOI 10.1016/0140-6736(91)91612-X; PRELLI F, 1988, J NEUROCHEM, V51, P648, DOI 10.1111/j.1471-4159.1988.tb01087.x; PRELLI F, 1988, BIOCHEM BIOPH RES CO, V151, P1150, DOI 10.1016/S0006-291X(88)80486-8; ROBAKIS NK, 1987, P NATL ACAD SCI USA, V84, P4190, DOI 10.1073/pnas.84.12.4190; ROHER A, 1986, P NATL ACAD SCI USA, V83, P2662, DOI 10.1073/pnas.83.8.2662; SELKOE DJ, 1986, J NEUROCHEM, V46, P1820; SELKOE DJ, 1991, NEURON, V6, P487, DOI 10.1016/0896-6273(91)90052-2; STGEORGEHYSLOP PH, 1990, NATURE, V347, P194, DOI 10.1038/347194a0; TAGLIAVINI F, 1988, NEUROSCI LETT, V93, P191, DOI 10.1016/0304-3940(88)90080-8; TANZI RE, 1987, SCIENCE, V235, P880, DOI 10.1126/science.2949367; VANDUINEN SG, 1987, P NATL ACAD SCI USA, V84, P5991; WISNIEWSKI T, 1991, BIOCHEM BIOPH RES CO, V179, P1247, DOI 10.1016/0006-291X(91)91706-I; YAMAGUCHI H, 1989, ACTA NEUROPATHOL, V77, P314, DOI 10.1007/BF00687584	34	436	461	0	23	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1992	267	24					17082	17086						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JL053	1512246				2022-12-25	WOS:A1992JL05300056
J	LACEY, ML; HAIMO, LT				LACEY, ML; HAIMO, LT			CYTOPLASMIC DYNEIN IS A VESICLE PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TERMINAL-SPECIFIC PHOSPHOPROTEIN; SMALL SYNAPTIC VESICLES; SYNAPSIN-I; MEMBRANOUS ORGANELLES; AXONAL-TRANSPORT; BINDING-SITES; HEAVY-CHAINS; MYOSIN-I; BRAIN; MICROTUBULES	Microtubule-based organelle transport is thought to be mediated by the force-generating proteins cytoplasmic dynein and kinesin. These motor proteins have been characterized based on their ability to associate with and translocate microtubules. We show here that cytoplasmic dynein is also present as a peripheral membrane protein of purified synaptic vesicles. The vesicle-associated cytoplasmic dynein is identified by its photo-induced cleavage in the presence of ATP and vanadate. Purified, soluble cytoplasmic dynein is competent to bind to vesicle membranes stripped of endogenous peripheral membrane proteins by alkaline pH. Dynein binding to membranes is saturable at a concentration of 1.00 +/- 0.15 pmol/mu-g vesicle protein and has a dissociation constant of 22.3 +/- 2.4 nM. The association of cytoplasmic dynein with the membrane cannot be reversed by incubation with ATP. Furthermore, following binding to membranes, dynein retains its ability to bind ATP and to be photo-cleaved in the presence of vanadate. The presence of cytoplasmic dynein on synaptic vesicles and its ability to bind to extracted membranes supports current models of microtubule-based organelle translocation.	UNIV CALIF RIVERSIDE,DEPT BIOL,RIVERSIDE,CA 92521	University of California System; University of California Riverside								ADAMS RJ, 1989, NATURE, V340, P565, DOI 10.1038/340565a0; BENFENATI F, 1989, J CELL BIOL, V108, P1863, DOI 10.1083/jcb.108.5.1863; BENFENATI F, 1989, J CELL BIOL, V108, P1851, DOI 10.1083/jcb.108.5.1851; BRADY ST, 1985, NATURE, V317, P73, DOI 10.1038/317073a0; DECAMILLI P, 1983, J CELL BIOL, V96, P1355, DOI 10.1083/jcb.96.5.1355; EUTENEUER U, 1988, NATURE, V332, P176, DOI 10.1038/332176a0; GIBBONS IR, 1987, J BIOL CHEM, V262, P2780; GILBERT SP, 1986, J CELL BIOL, V103, P947, DOI 10.1083/jcb.103.3.947; GILBERT SP, 1989, J CELL BIOL, V109, P2379, DOI 10.1083/jcb.109.5.2379; HAIMO LT, 1988, CELL MOTIL CYTOSKEL, V9, P129, DOI 10.1002/cm.970090205; HAYDEN SM, 1990, J CELL BIOL, V111, P443, DOI 10.1083/jcb.111.2.443; HELL JW, 1988, EMBO J, V7, P3023, DOI 10.1002/j.1460-2075.1988.tb03166.x; HIROKAWA N, 1990, J CELL BIOL, V111, P1027, DOI 10.1083/jcb.111.3.1027; HOLZBAUR ELF, 1991, NATURE, V351, P579, DOI 10.1038/351579a0; HUTTNER WB, 1983, J CELL BIOL, V96, P1374, DOI 10.1083/jcb.96.5.1374; JANETZKO A, 1989, NEUROSCIENCE, V32, P65, DOI 10.1016/0306-4522(89)90108-5; KELLY RB, 1988, NEURON, V1, P431, DOI 10.1016/0896-6273(88)90174-2; KOONCE MP, 1990, CELL MOTIL CYTOSKEL, V15, P52; LEEEIFORD A, 1986, J BIOL CHEM, V261, P2337; LYE RJ, 1987, CELL, V51, P309, DOI 10.1016/0092-8674(87)90157-7; MARCH PE, 1987, NEUROCHEM RES, V12, P635, DOI 10.1007/BF00971013; MILLER RH, 1985, J CELL BIOL, V101, P2181, DOI 10.1083/jcb.101.6.2181; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; NAVONE F, 1986, J CELL BIOL, V103, P2511, DOI 10.1083/jcb.103.6.2511; NEELY MD, 1988, J CELL BIOL, V107, P1767, DOI 10.1083/jcb.107.5.1767; OTTER T, 1987, ANAL BIOCHEM, V162, P370, DOI 10.1016/0003-2697(87)90406-4; PASCHAL BM, 1987, J CELL BIOL, V105, P1273, DOI 10.1083/jcb.105.3.1273; PASCHAL BM, 1989, NATURE, V342, P569, DOI 10.1038/342569a0; PASCHAL BM, 1987, NATURE, V330, P181, DOI 10.1038/330181a0; PFISTER KK, 1989, J CELL BIOL, V108, P1453, DOI 10.1083/jcb.108.4.1453; RODIONOV VI, 1990, J BIOL CHEM, V265, P5702; SCHIEBLER W, 1986, J BIOL CHEM, V261, P8383; SCHNAPP BJ, 1989, P NATL ACAD SCI USA, V86, P1548, DOI 10.1073/pnas.86.5.1548; SCHROER TA, 1988, J CELL BIOL, V107, P1785, DOI 10.1083/jcb.107.5.1785; SCHROER TA, 1989, CELL, V56, P937, DOI 10.1016/0092-8674(89)90627-2; SCHROER TA, 1991, ANNU REV PHYSIOL, V53, P629, DOI 10.1146/annurev.ph.53.030191.003213; STEBBINGS H, 1990, J CELL SCI, V95, P5; STECK T L, 1973, Journal of Supramolecular Structure, V1, P220, DOI 10.1002/jss.400010307; STEPHENS RE, 1986, BIOL CELL, V57, P95, DOI 10.1111/j.1768-322X.1986.tb00467.x; SUDHOF TC, 1991, NEURON, V6, P665, DOI 10.1016/0896-6273(91)90165-V; VALE RD, 1987, ANNU REV CELL BIOL, V3, P347, DOI 10.1146/annurev.cb.03.110187.002023; VALE RD, 1985, CELL, V42, P39, DOI 10.1016/S0092-8674(85)80099-4; VALLEE RB, 1988, NATURE, V332, P561, DOI 10.1038/332561a0; VERDE F, 1991, J CELL BIOL, V112, P1177, DOI 10.1083/jcb.112.6.1177; WALKER JH, 1987, BIOCHEM J, V247, P249, DOI 10.1042/bj2470249; WRIGHT BD, 1991, J CELL BIOL, V113, P817, DOI 10.1083/jcb.113.4.817; ZIMMERMANN H, 1989, CELL BIOL INT REP, V13, P993, DOI 10.1016/0309-1651(89)90015-5	47	60	60	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1992	267	7					4793	4798						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HF642	1531658				2022-12-25	WOS:A1992HF64200077
J	CONNOR, J; BARELI, M; GILLUM, KD; SCHROIT, AJ				CONNOR, J; BARELI, M; GILLUM, KD; SCHROIT, AJ			EVIDENCE FOR A STRUCTURALLY HOMOLOGOUS RH-LIKE POLYPEPTIDE IN RH(NULL) ERYTHROCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RED-CELL MEMBRANE; RHNULL HUMAN-ERYTHROCYTES; BLOOD-GROUP SYSTEM; RH(D) POLYPEPTIDE; ANTIGEN-ACTIVITY; RHO(D) ANTIGEN; PROTEIN; ANTIBODY; TRANSPORT; PHOSPHATIDYLSERINE	Human Rh(null) red blood cells fail to react with Rh antibodies, indicating that these cells are either devoid of Rh protein or, like other species, possess antigenically distinct variants. To determine whether Rh(null) cells possess an Rh-like polypeptide, 32-kDa proteins from D--, rr, and Rh(null) cells were labeled with the cysteine-specific probe, I-125-labeled pyridyldithioethylamine. Size comparisons of labeled proteins in Triton X-100-solubilized membranes from Rh-bearing and Rh(null) cells showed similar sedimentation coefficients and Stoke's radii. Immunoprecipitated Rh(D) from D-- cells, Rh(c) from rr cells, and purified 32-kDa proteins from Rh(null) cells were digested with alpha-chymotrypsin and examined by high-performance liquid chromatography and by two-dimensional iodopeptide mapping. Analysis of I-125-labeled chymotryptic fragments from immunoprecipitated Rh(D) and Rh(c) showed the labeled peptides from both phenotypes to be virtually identical. High-performance liquid chromatography profiles and iodopeptide maps of 32-kDa Rh(null) proteins yielded patterns identical to 32-kDa proteins isolated from D-- cells and rr cells with the exception of one missing I-125-labeled peptide. Further analysis of the Rh-related fragments from Rh(null) cells showed significant homology with immunoprecipitated Rh(D) and Rh(c). DNA sequence analysis of cysteine-encoding regions from Rh-bearing and Rh(null) cells showed complete identity. These data suggest that Rh(null) red blood cells, although serologically distinct, possess an Rh-like protein that is structurally very similar to Rh(D) and Rh(c).	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT CELL BIOL,BOX 173,1515 HOLCOMBE BLVD,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center	SCHROIT, AJ (corresponding author), UNIV TEXAS,MD ANDERSON CANC CTR,DEPT CELL BIOL,BOX 173,1515 HOLCOMBE BLVD,HOUSTON,TX 77030, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041714] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 41714] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABBOTT RE, 1976, J BIOL CHEM, V251, P7176; AGRE P, 1991, BLOOD, V78, P551, DOI 10.1182/blood.V78.3.551.bloodjournal783551; AVENT ND, 1990, BIOCHEM J, V271, P821, DOI 10.1042/bj2710821; AVENT ND, 1988, BIOCHEM J, V256, P1043, DOI 10.1042/bj2561043; BALLAS SK, 1984, BLOOD, V63, P1046; BARELI M, 1989, BRIT J HAEMATOL, V72, P36, DOI 10.1111/j.1365-2141.1989.tb07648.x; BARELI M, 1989, BLOOD, V73, P2281; BLANCHARD D, 1988, BLOOD, V72, P1424; BLOY C, 1990, J BIOL CHEM, V265, P21482; BLOY C, 1988, BLOOD, V72, P661; BLOY C, 1988, MOL IMMUNOL, V25, P925, DOI 10.1016/0161-5890(88)90131-9; BLOY C, 1987, BLOOD, V69, P1491; CHERIFZAHAR B, 1990, P NATL ACAD SCI USA, V87, P6243, DOI 10.1073/pnas.87.16.6243; CONNOR J, 1988, BIOCHEMISTRY-US, V27, P848, DOI 10.1021/bi00403a002; DEVETTEN MP, 1988, J BIOL CHEM, V263, P18193; ELDER JH, 1977, J BIOL CHEM, V252, P6510; GAHMBERG CG, 1983, EMBO J, V2, P223, DOI 10.1002/j.1460-2075.1983.tb01409.x; GAHMBERG CG, 1984, J IMMUNOL, V133, P334; GREEN FA, 1984, MOL IMMUNOL, V21, P433, DOI 10.1016/0161-5890(84)90058-0; GREEN FA, 1983, MOL IMMUNOL, V20, P769, DOI 10.1016/0161-5890(83)90055-X; GREEN FA, 1967, IMMUNOCHEMISTRY, V4, P247, DOI 10.1016/0019-2791(67)90186-3; GREEN FA, 1982, IMMUNOL COMMUN, V11, P25, DOI 10.3109/08820138209050721; GREEN FA, 1972, J BIOL CHEM, V247, P881; HARTELSCHENK S, 1992, J BIOL CHEM, V267, P5569; HUGHESJONES NC, 1988, MOL IMMUNOL, V25, P931, DOI 10.1016/0161-5890(88)90132-0; KENNEDY L, 1989, BIOCHEMISTRY-US, V28, P9153, DOI 10.1021/bi00449a029; KRAHMER M, 1987, FEBS LETT, V226, P105, DOI 10.1016/0014-5793(87)80560-4; KUYPERS F, 1984, BIOCHEM J, V221, P931, DOI 10.1042/bj2210931; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAUF PK, 1976, BLOOD, V48, P457; LEVANKIM C, 1992, BLOOD, V80, P1074; MOLLISON PL, 1987, BLOOD TRANSFUSION CL, P329; MOORE S, 1982, NATURE, V295, P529, DOI 10.1038/295529a0; MOORE S, 1987, BIOCHEM J, V244, P735, DOI 10.1042/bj2440735; NASH R, 1987, AM J HEMATOL, V24, P267, DOI 10.1002/ajh.2830240306; PARADIS G, 1986, J IMMUNOL, V137, P240; Petz LD, 1980, ACQUIRED IMMUNE HEMO; RIDGWELL K, 1984, FEBS LETT, V174, P7, DOI 10.1016/0014-5793(84)81066-2; RIDGWELL K, 1983, BIOCHEM J, V213, P267, DOI 10.1042/bj2130267; SABOORI AM, 1989, J CLIN INVEST, V83, P187, DOI 10.1172/JCI113857; SABOORI AM, 1988, P NATL ACAD SCI USA, V85, P4042, DOI 10.1073/pnas.85.11.4042; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SCHROIT AJ, 1990, BIOCHEMISTRY-US, V29, P10303, DOI 10.1021/bi00497a003; SMITH RE, 1990, BLOOD, V76, P1021; STURGEON P, 1970, BLOOD-J HEMATOL, V36, P310, DOI 10.1182/blood.V36.3.310.310; SUYAMA K, 1990, BLOOD, V75, P255; SUYAMA K, 1988, BLOOD, V72, P1622; SUYAMA K, 1992, BLOOD, V79, P808; VOS GH, 1961, LANCET, V1, P14	49	20	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1992	267	36					26050	26055						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KD073	1464615				2022-12-25	WOS:A1992KD07300070
J	XING, MZ; MATTERA, R				XING, MZ; MATTERA, R			PHOSPHORYLATION-DEPENDENT REGULATION OF PHOSPHOLIPASE-A(2) BY G-PROTEINS AND CA2+ IN HL-60 GRANULOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARACHIDONIC-ACID RELEASE; GTP-BINDING PROTEINS; CANINE KIDNEY-CELLS; KINASE-C; HUMAN-NEUTROPHILS; HL-60 CELLS; ELECTROPERMEABILIZED NEUTROPHILS; ALPHA-1-ADRENERGIC STIMULATION; TYROSINE PHOSPHORYLATION; MEMBRANE ASSOCIATION	We studied the regulation of arachidonic acid (AA) release by guanosine 5'-O-(3-thiotriphosphate (GTP-gammaS) and Ca2+ in electropermeabilized HL60 granulocytes. Stimulation of AA release by GTPgammaS and Ca2+ was mediated by phospholipase A2 (PLA2) and required the presence of MgATP (EC50: 100-250 muM). The nucleotide effects were Ca2+-dependent (maximal effects detected at 1 muM free cation). UTP and ATPgammaS, which stimulate AA release in intact HL60 granulocytes with potencies and efficacies similar to those of ATP, were ineffective in supporting the effects of GTPgammaS in electropermeabilized cells. Pretreatment with pertussis toxin affected stimulation of AA release by ATP in intact cell, without altering the nucleotide effects in permeabilized cells. We observed the protein kinase C-dependent phosphorylation of PLA2 in permeabilized HL60 granulocytes, together with a correlation between the effects of phorbol esters and staurosporine on this reaction and on AA release. ATP-independent activation of PLA2 by GTP-gammaS and/or Ca2+ was measured in subcellular fractions prepared from HL60 granulocytes. These data appear consistent with a model in which PLA2 activity in resting HL60 granulocytes is subjected to an inhibitory constraint that prevents its activation by Ca2+ and G-proteins. Removal of this constraint, either by the protein kinase C-dependent phosphorylation of the enzyme in vivo or physical disruption of the regulatory assembly (e.g. by N2 cavitation), allows its activation by Ca2+ and G-proteins.	CASE WESTERN RESERVE UNIV,SCH MED,DEPT PHYSIOL & BIOPHYS,2109 ADELBERT RD,CLEVELAND,OH 44106	Case Western Reserve University	MATTERA, R (corresponding author), CASE WESTERN RESERVE UNIV,SCH MED,DEPT PHYSIOL & BIOPHYS,2109 ADELBERT RD,CLEVELAND,OH 44106, USA.				NIGMS NIH HHS [GM 46552-01A1] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R55GM046552] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALEXXANDRINI A, 1992, P NATL ACAD SCI USA, V89, P8200; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOKOCH GM, 1984, CELL, V39, P301, DOI 10.1016/0092-8674(84)90008-4; BONVENTRE JV, 1990, J BIOL CHEM, V265, P4934; BROOKS RC, 1989, J BIOL CHEM, V264, P20147; BURCH RM, 1987, P NATL ACAD SCI USA, V84, P6374, DOI 10.1073/pnas.84.18.6374; BURCH RM, 1986, P NATL ACAD SCI USA, V83, P7201, DOI 10.1073/pnas.83.19.7201; CARLIN CR, 1984, J BIOL CHEM, V259, P7902; CHANNON JY, 1990, J BIOL CHEM, V265, P5409; CLARK JD, 1990, P NATL ACAD SCI USA, V87, P7708, DOI 10.1073/pnas.87.19.7708; COCKCROFT S, 1989, BIOCHEM J, V263, P715, DOI 10.1042/bj2630715; COCKCROFT S, 1991, BIOCHEM J, V275, P127, DOI 10.1042/bj2750127; COWEN DS, 1990, BIOCHIM BIOPHYS ACTA, V1053, P195, DOI 10.1016/0167-4889(90)90014-5; CURNUTTE JT, 1984, J BIOL CHEM, V259, P1851; DENNIS EA, 1991, FASEB J, V5, P2068, DOI 10.1096/fasebj.5.7.1901288; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; FELDER CC, 1990, J PHARMACOL EXP THER, V255, P1140; GODSON C, 1990, J BIOL CHEM, V265, P8369; GOMEZ N, 1991, NATURE, V353, P170, DOI 10.1038/353170a0; GOPALAKRISHNA R, 1986, J BIOL CHEM, V261, P6438; GRINSTEIN S, 1988, J BIOL CHEM, V263, P1779; GRINSTEIN S, 1989, BIOCHEM J, V261, P755, DOI 10.1042/bj2610755; GRONICH JH, 1990, BIOCHEM J, V271, P37, DOI 10.1042/bj2710037; HAZEN SL, 1991, J BIOL CHEM, V266, P14526; HAZEN SL, 1991, BIOCHEM J, V280, P581, DOI 10.1042/bj2800581; HENDERSON LM, 1989, BIOCHEM J, V264, P249, DOI 10.1042/bj2640249; HO AK, 1987, J BIOL CHEM, V262, P11764; KADIRI C, 1990, MOL PHARMACOL, V38, P418; KILEY S, 1990, J BIOL CHEM, V265, P15704; KNIGHT DE, 1986, BIOCHEM J, V234, P497, DOI 10.1042/bj2340497; KRISHNAMURTHI S, 1987, EUR J BIOCHEM, V167, P585, DOI 10.1111/j.1432-1033.1987.tb13376.x; LALLEMAIN G, 1991, MOL CELL BIOL, V11, P1002, DOI 10.1128/MCB.11.2.1002; LIN LL, 1992, P NATL ACAD SCI USA, V89, P6147, DOI 10.1073/pnas.89.13.6147; LU DJ, 1990, J BIOL CHEM, V265, P13721; MARTIN TFJ, 1987, METHOD ENZYMOL, V141, P111; MURAYAMA T, 1990, J BIOL CHEM, V265, P4290; NAKASHIMA S, 1989, BIOCHEM J, V259, P139, DOI 10.1042/bj2590139; NASMITH PE, 1989, BIOCHEM J, V257, P893, DOI 10.1042/bj2570893; NEL AE, 1991, J IMMUNOL, V147, P1933; NIELSON CP, 1991, BIOCHIM BIOPHYS ACTA, V1095, P83, DOI 10.1016/0167-4889(91)90048-3; OLSON SC, 1991, J BIOL CHEM, V266, P17236; REHFELDT W, 1991, BIOCHEM J, V276, P631, DOI 10.1042/bj2760631; SCOTT DL, 1990, SCIENCE, V250, P1541, DOI 10.1126/science.2274785; TAO W, 1989, BIOCHEM J, V257, P633, DOI 10.1042/bj2570633; TOUQUI L, 1986, NATURE, V321, P177, DOI 10.1038/321177a0; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; UHING RJ, 1987, J BIOL CHEM, V262, P15575; WEISS BA, 1991, J BIOL CHEM, V266, P2126; WIJKANDER J, 1991, EUR J BIOCHEM, V202, P873, DOI 10.1111/j.1432-1033.1991.tb16445.x; XIE MS, 1991, BIOCHEM J, V278, P81, DOI 10.1042/bj2780081; XING MZ, 1992, J BIOL CHEM, V267, P6602; YOUNT RG, 1975, ADV ENZYMOL RAMB, V43, P1	52	79	79	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1992	267	36					25966	25975						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KD073	1464609				2022-12-25	WOS:A1992KD07300058
J	OCONNELL, BC; HAGEN, FK; TABAK, LA				OCONNELL, BC; HAGEN, FK; TABAK, LA			THE INFLUENCE OF FLANKING SEQUENCE ON THE O-GLYCOSYLATION OF THREONINE INVITRO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; UDP-N-ACETYLGALACTOSAMINE; OVINE SUBMAXILLARY MUCIN; ERYTHROCYTE GLYCOPHORIN; ATTACHMENT SITES; PURIFICATION; TRANSFERASE; IDENTIFICATION; GLYCOPROTEINS; PROTEIN	To investigate the influence of flanking amino acid sequence on the O-glycosylation of a single threonine residue in vitro, we have examined a series of 52 related peptides. The substrates were based upon a sequence from human von Willebrand factor which is known to be glycosylated in vivo (-6PHMAQVTVGPGL+5). Each residue of the parent peptide was substituted, in turn, with isoleucine, alanine, proline, glutamic acid, or arginine. Peptides were glycosylated using a UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferase purified 15,000-fold from bovine colostrum by chromatography on DEAE-Sephacel, SP-Sephadex, Sephacryl S-300, Affi-Gel Blue, and 5-mercuri-UDP-GalNAc thiopropyl-Sepharose. Single amino acid changes in the sequences flanking the threonine could profoundly alter the glycosylation of the substrate peptides. Substitution of any amino acid tested at positions +3, -3, and -2 markedly decreased O-glycosylation, as did the presence of a charged residue at position -1. The substitution of amino acids at the other positions of the peptide substrate had little effect on the incorporation of GalNAc. Statistical analysis of sequences flanking known glycosylated threonine and serine residues suggests that they should be glycosylated with equal efficiency in the same sequence context (O'Connell et al., 1991). However, the bovine colostrum transferase failed to glycosylate a peptide derived from human erythropoietin which contains a serine that is glycosylated in vivo (-5PPDAASAAPLR+5). When a threonine was substituted for the serine in this peptide (-5PPDAATAAPLR+5), the substrate proved to be an excellent acceptor of GalNAc. These observations indicate that although flanking amino acid sequence is important for the O-glycosylation of specific hydroxyamino acids, discrete threonine- and serine-specific transferases may exist.	UNIV ROCHESTER, SCH MED & DENT, DEPT DENT RES, ROCHESTER, NY 14642 USA; UNIV ROCHESTER, SCH MED & DENT, DEPT BIOCHEM, ROCHESTER, NY 14642 USA	University of Rochester; University of Rochester				O'Connell, Brian/0000-0003-4529-7664	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R37DE008108, R01DE008108, K16DE000159] Funding Source: NIH RePORTER; NIDCR NIH HHS [DE-08108, DE-089511, K16 DE-00159] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		AUBERT JP, 1976, ARCH BIOCHEM BIOPHYS, V175, P410, DOI 10.1016/0003-9861(76)90528-2; BENDIAK B, 1987, J BIOL CHEM, V262, P5775; BRIAND JP, 1981, J BIOL CHEM, V256, P2205; COTTRELL JM, 1992, BIOCHEM J, V283, P299, DOI 10.1042/bj2830299; ECKHARDT AE, 1987, J BIOL CHEM, V262, P11339; ELHAMMER A, 1986, J BIOL CHEM, V261, P5249; FLYNN GC, 1991, NATURE, V353, P726, DOI 10.1038/353726a0; GERKEN TA, 1989, BIOCHEMISTRY-US, V28, P5536, DOI 10.1021/bi00439a030; GOOLEY AA, 1991, BIOCHEM BIOPH RES CO, V178, P1194, DOI 10.1016/0006-291X(91)91019-9; HAGOPIAN A, 1971, J BIOL CHEM, V246, P2519; HAGOPIAN A, 1969, ARCH BIOCHEM BIOPHYS, V129, P515, DOI 10.1016/0003-9861(69)90209-4; HILL HD, 1977, J BIOL CHEM, V252, P3799; HONMA K, 1980, J BIOCHEM-TOKYO, V88, P1679, DOI 10.1093/oxfordjournals.jbchem.a133143; HUGHES RC, 1988, CARBOHYD RES, V178, P259, DOI 10.1016/0008-6215(88)80117-4; LAI PH, 1986, J BIOL CHEM, V261, P3116; LAM KS, 1991, NATURE, V354, P82, DOI 10.1038/354082a0; MURAYAMA JI, 1982, J MEMBRANE BIOL, V64, P205, DOI 10.1007/BF01870887; OCONNELL B, 1991, BIOCHEM BIOPH RES CO, V180, P1024, DOI 10.1016/S0006-291X(05)81168-4; OPPENHEIM FG, 1985, J BIOL CHEM, V260, P671; PUTNAM FW, 1981, P NATL ACAD SCI-BIOL, V78, P6168, DOI 10.1073/pnas.78.10.6168; RALL SC, 1982, J BIOL CHEM, V257, P4171; SHOGREN R, 1989, BIOCHEMISTRY-US, V28, P5525, DOI 10.1021/bi00439a029; SMYTH DS, 1967, NATURE, V216, P332, DOI 10.1038/216332a0; SUGIURA M, 1982, J BIOL CHEM, V257, P9501; TITANI K, 1986, BIOCHEMISTRY-US, V25, P3171, DOI 10.1021/bi00359a015; TOMITA M, 1975, P NATL ACAD SCI USA, V72, P2964, DOI 10.1073/pnas.72.8.2964; WANG YC, 1992, J BIOL CHEM, V267, P2728; WILSON IBH, 1991, BIOCHEM J, V275, P529, DOI 10.1042/bj2750529; YOUNG JD, 1979, BIOCHEMISTRY-US, V18, P4444, DOI 10.1021/bi00587a026	29	106	108	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	1992	267	35					25010	25018						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KB603	1460004				2022-12-25	WOS:A1992KB60300018
J	CLARK, BJ; WATERMAN, MR				CLARK, BJ; WATERMAN, MR			FUNCTIONAL EXPRESSION OF BOVINE 17-ALPHA-HYDROXYLASE IN COS-1 CELLS IS DEPENDENT UPON THE PRESENCE OF AN AMINO-TERMINAL SIGNAL ANCHOR SEQUENCE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNTHESIZING SECRETORY PROTEIN; ENDOPLASMIC-RETICULUM; MICROSOMAL-MEMBRANES; INSERTION SIGNAL; CYTOCHROME-P-450; TRANSLOCATION; ORIENTATION; PEPTIDE; ENZYME; CDNA	Microsomal forms of eukaryotic cytochrome P450 proteins are integral membrane proteins of the endoplasmic reticulum (ER) membrane which are targeted to the ER via the signal recognition particle pathway. A hydrophobic amino terminus serves as a combined signal sequence and major membrane anchor (signal-anchor sequence) for the microsomal P450s. We have examined the insertion of bovine 17alpha-hydroxylase (P45017alpha) into the ER of COS 1 cells in order to evaluate the role of membrane insertion of the amino-terminal signal-anchor of microsomal P450s as a functional determinant for these enzymes. Previously, we have shown that deletion of the hydrophobic amino terminus from P45017alpha reduced membrane targeting and insertion by 5-fold compared with the wild-type protein, abolished enzymatic activity, and resulted in an aberrant CO difference spectrum. In the present study we have replaced the amino terminus of P45017alpha with two heterologous signal-anchor sequences, one that is similar and one that is very different from the P45017alpha sequence. The chimeric proteins were expressed in COS 1 cells. Immunoblot analysis of isolated microsomal membranes show that the heterologous signal-anchor sequences functioned to target the P45017alpha protein to the ER. Enzymatic assays in intact COS 1 cells indicate that both the chimeric proteins are efficient 17alpha-hydroxylase enzymes. The amino terminus of P45017alpha was also replaced with a sequence that is not a signal-anchor, and the expressed protein was neither targeted to the ER nor was functional in COS 1 cells. In conclusion, both the structure and catalytic activity of P45017alpha in COS 1 cells is dependent upon an amino-terminal sequence that functions as a signal-anchor sequence and not upon the precise sequence of the amino terminus.	VANDERBILT UNIV,MED CTR,SCH MED,DEPT BIOCHEM,NASHVILLE,TN 37232; UNIV TEXAS,HLTH SCI CTR,SW MED SCH,DEPT BIOCHEM,DALLAS,TX 75235; UNIV TEXAS,HLTH SCI CTR,SW MED SCH,DEPT OBSTET & GYNECOL,DALLAS,TX 75235; UNIV TEXAS,HLTH SCI CTR,SW MED SCH,CECIL H & IDA GREEN CTR REPROD BIOL SCI,DALLAS,TX 75235	Vanderbilt University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas				Clark, Barbara/0000-0003-1558-1904	NIGMS NIH HHS [GM 37429] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R15GM037429] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; CLARK BJ, 1991, J BIOL CHEM, V266, P5898; COATS WS, 1991, J BIOL CHEM, V266, P16113; ESTABROOK RW, 1988, OXIDASES RELATED RED, P525; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LARSON JR, 1991, P NATL ACAD SCI USA, V88, P9141, DOI 10.1073/pnas.88.20.9141; LI YC, 1991, J BIOL CHEM, V266, P19186; LORENCE MC, 1989, ARCH BIOCHEM BIOPHYS, V273, P79, DOI 10.1016/0003-9861(89)90164-1; MONIER S, 1988, J CELL BIOL, V107, P457, DOI 10.1083/jcb.107.2.457; NEBERT DW, 1991, DNA CELL BIOL, V10, P1, DOI 10.1089/dna.1991.10.1; NELSON DR, 1988, J BIOL CHEM, V263, P6038; OKADA Y, 1982, EUR J BIOCHEM, V122, P393, DOI 10.1111/j.1432-1033.1982.tb05894.x; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SAKAGUCHI M, 1984, P NATL ACAD SCI-BIOL, V81, P3361, DOI 10.1073/pnas.81.11.3361; SAKAGUCHI M, 1987, EMBO J, V6, P2425, DOI 10.1002/j.1460-2075.1987.tb02521.x; SAKAKI T, 1989, DNA-J MOLEC CELL BIO, V8, P409, DOI 10.1089/dna.1.1989.8.409; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SATO T, 1990, EMBO J, V9, P2391, DOI 10.1002/j.1460-2075.1990.tb07414.x; SZCZESNASKORUPA E, 1988, P NATL ACAD SCI USA, V85, P738, DOI 10.1073/pnas.85.3.738; VONHEIJNE G, 1988, BIOCHIM BIOPHYS ACTA, V947, P307, DOI 10.1016/0304-4157(88)90013-5; WALTER P, 1981, J CELL BIOL, V91, P551, DOI 10.1083/jcb.91.2.551; WALTER P, 1981, J CELL BIOL, V91, P557, DOI 10.1083/jcb.91.2.557; WALTER P, 1981, J CELL BIOL, V91, P545, DOI 10.1083/jcb.91.2.545; YABUSAKI Y, 1988, DNA-J MOLEC CELL BIO, V7, P701, DOI 10.1089/dna.1988.7.701	25	17	17	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1992	267	34					24568	24574						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KA263	1447202				2022-12-25	WOS:A1992KA26300064
J	JOHANSSON, C; BUTKOWSKI, R; WIESLANDER, J				JOHANSSON, C; BUTKOWSKI, R; WIESLANDER, J			THE STRUCTURAL ORGANIZATION OF TYPE-IV COLLAGEN - IDENTIFICATION OF 3 NC1 POPULATIONS IN THE GLOMERULAR-BASEMENT-MEMBRANE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GOODPASTURE ANTIGEN; GLOBULAR DOMAIN; NONCOLLAGENOUS DOMAIN; POLYACRYLAMIDE GELS; PROTEINS; CHAIN; LOCALIZATION; KIDNEY	Type IV collagen, which has long been assumed to contain two alpha1(IV) and one alpha2(IV) chains, also contains alpha3(IV), alpha4(IV), and alpha5(IV) chains. Stoichiometry of collagenous alpha(IV) chains differs among tissues, suggesting the existence of subclasses of type IV collagen, each with a unique chain composition. This study seeks to define, by characterization of subunit compositions of NC1 domain populations, the structural organization of type IV collagen from bovine glomerular basement membrane. NC1 hexamers from type IV collagen were separated on two affinity chromatography columns, one containing monoclonal antibodies to the alpha3 chain, and another, to the alpha1 chain. SDS-polyacrylamide gel electrophoresis, immunoblotting, reversed phase high-performance liquid chromatography, and enzyme-linked immunosorbent assay identified three NC1 hexamer populations: 1) a hexamer composed of (alpha1)2 and (alpha2)2 homodimers; 2) a hexamer composed of (alpha3)2 and (alpha4)2 homodimers; 3) a hexamer containing all four alpha chains connected in heterodimers, alpha1-alpha3 and alpha2-alpha4. Results suggest that there are two distinct type IV collagen molecules, one composed of alpha1(IV) and alpha2(IV) chains and another composed of alpha3(IV) and alpha4(IV) chains. Furthermore, polymerization occurs between molecules with the same chain composition and between molecules with different chain composition. Moreover, crosslinking between different alpha chains is restricted, thus limiting the number of possible macromolecular structures.	UNIV MINNESOTA,DEPT LAB MED & PATHOL,MINNEAPOLIS,MN 55455; STATE SERUM INST,DK-2300 COPENHAGEN,DENMARK	University of Minnesota System; University of Minnesota Twin Cities; Statens Serum Institut	JOHANSSON, C (corresponding author), UNIV LUND HOSP,DEPT NEPHROL,S-22185 LUND,SWEDEN.							BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; BUTKOWSKI RJ, 1987, J BIOL CHEM, V262, P7874; BUTKOWSKI RJ, 1989, KIDNEY INT, V35, P1195, DOI 10.1038/ki.1989.110; BUTKOWSKI RJ, 1985, J BIOL CHEM, V260, P3739; GUNWAR S, 1991, J BIOL CHEM, V266, P15318; HARLOW E, 1988, ANTIBODIES LABORATOR, P505; HOSTIKKA SL, 1990, P NATL ACAD SCI USA, V87, P1606, DOI 10.1073/pnas.87.4.1606; JOHANSSON C, 1991, CONNECT TISSUE RES, V25, P229, DOI 10.3109/03008209109029159; KLEPPEL MM, 1989, AM J PATHOL, V134, P813; KLEPPEL MM, 1987, J CLIN INVEST, V80, P263, DOI 10.1172/JCI113057; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGEVELD JPM, 1988, J BIOL CHEM, V263, P10481; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; SAUS J, 1988, J BIOL CHEM, V263, P13374; TIMPL R, 1981, EUR J BIOCHEM, V120, P203, DOI 10.1111/j.1432-1033.1981.tb05690.x; WIESLANDER J, 1984, P NATL ACAD SCI-BIOL, V81, P1544, DOI 10.1073/pnas.81.5.1544; WIESLANDER J, 1985, J BIOL CHEM, V260, P8564	17	58	60	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1992	267	34					24533	24537						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KA263	1447198				2022-12-25	WOS:A1992KA26300059
J	DIXON, KH; MULLIGAN, T; CHUNG, KN; ELWOOD, PC; COWAN, KH				DIXON, KH; MULLIGAN, T; CHUNG, KN; ELWOOD, PC; COWAN, KH			EFFECTS OF FOLATE RECEPTOR EXPRESSION FOLLOWING STABLE TRANSFECTION INTO WILD-TYPE AND METHOTREXATE TRANSPORT-DEFICIENT ZR-75-1 HUMAN BREAST-CANCER CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN KB-CELLS; PROBENECID-SENSITIVE CARRIER; AMINO-ACID-SEQUENCE; CCRF-CEM CELLS; BINDING-PROTEIN; L1210 CELLS; GLYCOSYL-PHOSPHATIDYLINOSITOL; LEUKEMIA-CELLS; OVARIAN-CANCER; HUMAN-PLACENTA	Two biochemically distinct systems, the high affinity folate receptor and the lower affinity reduced-folate carrier, have each been implicated in mediating the transport of folates and antifolates into cells. Previous studies from our laboratory have shown that methotrexate accumulation into wild type (WT) ZR-75-1 human breast cancer cells involves a system with characteristics of the reduced-folate carrier, that this system is deficient in methotrexate resistant (MTX(R)) ZR-75-1 cells in which methotrexate transport is undetectable and that neither breast cancer cell line expresses folate receptors. In this report we examined the possible interaction of the reduced-folate carrier with folate receptors by stably transfecting both WT ZR-75-1 and MTX(R) ZR-75-1 cells with an expression vector containing a folate receptor cDNA. Clones of stably transfected MTX(R) ZR-75-1 and WT ZR-75-1 cells expressing comparable levels of folate receptors were studied and compared to the nontransfected cell lines. Although nontransfected WT and MTX(R) ZR-751 cell lines require concentrations greater-than-or-equal-to 100 nM folic acid for growth, the expression of folate receptors in transfected WT and MTX(R) ZR-75-1 cells permitted the growth of both cell lines in low concentrations (1 nM) of folic acid. While the defect in the reduced-folate carrier system in MTX(R) ZR-75-1 cells inhibits their growth in medium containing low concentrations of folinic acid (less-than-or-equal-to 1 muM), MTX(R) ZR-75-1 cells expressing folate receptors display uninhibited growth in 1 nM folinic acid. The accumulation of folic acid, folinic acid, and methotrexate is enhanced in folate receptor-transfected WT ZR-75-1 cells and MTX(R) ZR-75-1 cells. Furthermore, the accumulation of folates and antifolate was similar in both transfected WT and MTX(R) ZR751 cell lines that expressed folate receptors. This suggests that alterations in the reduced-folate carrier do not affect folate receptor function. We also examined the effect of folate receptor expression on the sensitivity of WT and MTX(R) ZR-75-1 cells to methotrexate and to the lipophillic antifolate trimetrexate. Increased folate receptor expression decreased the sensitivity of WT ZR-75-1 cells toward the antifolate trimetrexate, presumably through increased uptake of reduced folates. Although the expression of the folate receptor enhanced the growth of both cell lines in low folate concentrations, it did not affect the sensitivity of either WT or MTX(R) ZR-75-1 cells to methotrexate.			DIXON, KH (corresponding author), NCI, MED BRANCH, BLDG 10, RM 12N226, 9000 ROCKVILLE PIKE, BETHESDA, MD 20892 USA.							ALBERTI S, 1990, BIOCHEM BIOPH RES CO, V171, P1051, DOI 10.1016/0006-291X(90)90790-T; ANTONY AC, 1985, J BIOL CHEM, V260, P4911; ANTONY AC, 1981, J BIOL CHEM, V256, P9684; ASSARAF YG, 1987, P NATL ACAD SCI USA, V84, P7154, DOI 10.1073/pnas.84.20.7154; BELL DR, 1985, J CLIN ONCOL, V3, P311, DOI 10.1200/JCO.1985.3.3.311; BRIGLE KE, 1991, J BIOL CHEM, V266, P17243; CAMPBELL IG, 1991, CANCER RES, V51, P5329; CHELLO PL, 1977, CANCER RES, V37, P4297; CONEY LR, 1991, CANCER RES, V51, P6125; COWAN KH, 1984, J BIOL CHEM, V259, P793; DEUTSCH JC, 1989, ARCH BIOCHEM BIOPHYS, V274, P327, DOI 10.1016/0003-9861(89)90446-3; DIXON KH, 1991, CANCER COMMUN-US, V3, P357, DOI 10.3727/095535491820873687; ELWOOD PC, 1986, J BIOL CHEM, V261, P5416; ELWOOD PC, 1989, J BIOL CHEM, V264, P14893; ELWOOD PC, 1991, J BIOL CHEM, V266, P2346; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FLINTOFF WF, 1983, ARCH BIOCHEM BIOPHYS, V223, P433, DOI 10.1016/0003-9861(83)90607-0; FREISHEIM JH, 1989, ADV ENZYME REGUL, V29, P13, DOI 10.1016/0065-2571(89)90091-5; GOLDMAN ID, 1985, PHARMACOL THERAPEUT, V28, P77, DOI 10.1016/0163-7258(85)90083-X; GOLDMAN ID, 1968, J BIOL CHEM, V243, P5007; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HENDERSON GB, 1990, ANNU REV NUTR, V10, P319, DOI [10.1146/annurev.nutr.10.1.319, 10.1146/annurev.nu.10.070190.001535]; HENDERSON GB, 1988, J MEMBRANE BIOL, V101, P247, DOI 10.1007/BF01872839; HENDERSON GB, 1984, J BIOL CHEM, V259, P4558; HENDERSON GB, 1990, CANCER RES, V50, P1709; HENDERSON GB, 1983, ARCH BIOCHEM BIOPHYS, V221, P438, DOI 10.1016/0003-9861(83)90162-5; HENDERSON GB, 1985, J MEMBRANE BIOL, V85, P263, DOI 10.1007/BF01871521; HOLM J, 1991, BIOCHEM J, V280, P267, DOI 10.1042/bj2800267; JANSEN G, 1989, CANCER RES, V49, P2455; KAMEN BA, 1989, J CLIN INVEST, V84, P1379, DOI 10.1172/JCI114310; KAMEN BA, 1986, P NATL ACAD SCI USA, V83, P5983, DOI 10.1073/pnas.83.16.5983; KAMEN BA, 1975, J BIOL CHEM, V250, P2203; KAMEN BA, 1988, J BIOL CHEM, V263, P13602; KAMEN BA, 1991, J CLIN INVEST, V87, P1442, DOI 10.1172/JCI115150; KAMEN BA, 1986, BIOCHEM PHARMACOL, V35, P2323, DOI 10.1016/0006-2952(86)90458-2; KNIGHT CB, 1989, ADV ENZYME REGUL, V29, P3, DOI 10.1016/0065-2571(89)90090-3; LACEY SW, 1989, J CLIN INVEST, V84, P715, DOI 10.1172/JCI114220; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUHRS CA, 1989, J BIOL CHEM, V264, P21446; MCHUGH M, 1979, J BIOL CHEM, V254, P1312; RATNAM M, 1989, BIOCHEMISTRY-US, V28, P8249, DOI 10.1021/bi00446a042; REISENAUER AM, 1990, BIOCHEM J, V267, P249, DOI 10.1042/bj2670249; ROTHBERG KG, 1990, J CELL BIOL, V110, P637, DOI 10.1083/jcb.110.3.637; SADASIVAN E, 1989, J BIOL CHEM, V264, P5806; Sambrook J, 1989, MOL CLONING LABORATO; SCHUETZ JD, 1988, J BIOL CHEM, V263, P9840; SIROTNAK FM, 1981, CANCER TREAT REP, V65, P19; SIROTNAK FM, 1981, CANCER RES, V41, P4447; SKEHAN P, 1990, J NATL CANCER I, V82, P1107, DOI 10.1093/jnci/82.13.1107; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SVENDSEN IB, 1984, CARLSBERG RES COMMUN, V49, P123, DOI 10.1007/BF02913971; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; TSO JY, 1985, NUCLEIC ACIDS RES, V13, P2485, DOI 10.1093/nar/13.7.2485; VANDERVEER LJ, 1989, LEUKEMIA RES, V13, P981, DOI 10.1016/0145-2126(89)90005-2; VERMA RS, 1991, J BIOL CHEM, V266, P12522; VERMA RS, 1992, J BIOL CHEM, V267, P4119; WESTERHOF GR, 1991, CANCER RES, V51, P5507	57	51	52	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	1992	267	33					24140	24147						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JZ239	1429743				2022-12-25	WOS:A1992JZ23900106
J	SUNDARAM, KS; LEV, M				SUNDARAM, KS; LEV, M			PURIFICATION AND ACTIVATION OF BRAIN SULFOTRANSFERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-BRAIN; GALACTOCEREBROSIDE SULFOTRANSFERASE; SULFATED GLYCOLIPIDS; ACTIVITY INVITRO; VITAMIN-K; ENZYME; BINDS; MODULATION; KINASE	Galactosylceramide sulfotransferase (EC 2.8.2.11) catalyzes the biosynthesis of sulfatide from galactocerebroside and adenosine 3'-phosphate 5'-phosphosulfate (PAPS). This enzyme is developmentally controlled, reaching a maximum activity in the brains of mice corresponding to that of maximum myelination. The product, sulfatide, is an important component of myelin. This transferase from mouse brain has been purified 2600-fold using a combination of pyridoxal 5'-phosphate- and ATP-ligated columns. The purified enzyme yielded a single band following SDS-polyacrylamide gel electrophoresis with an apparent M(r) of 31,000. The entire purification procedure can be completed in 1 day. The pH optimum for the enzyme is 7.0. The K(m) for PAPS is 1.2 x 10(-6) M, and the K(m) for cerebroside is 2.6 x 10(-5) M. Cerebroside concentrations >80 pmol/ml are inhibitory. Enzyme preparations were associated with several lipids. Vitamin K + P(i) activated purified preparations of the sulfotransferase and maintained enzyme activity during storage at -80-degrees-C.			SUNDARAM, KS (corresponding author), CUNY,SCH MED,SOPHIE DAVIS SCH BIOMED EDUC,DEPT MICROBIOL,NEW YORK,NY 10031, USA.				NCRR NIH HHS [RRO3060] Funding Source: Medline	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ARUFFO A, 1991, CELL, V67, P35, DOI 10.1016/0092-8674(91)90570-O; CHURCHICH JE, 1984, EUR J BIOCHEM, V138, P327, DOI 10.1111/j.1432-1033.1984.tb07918.x; FARRELL DF, 1971, J BIOL CHEM, V246, P4694; FRESSINAUD C, 1990, CR ACAD SCI III-VIE, V310, P303; FUJIKI H, 1986, BIOCHEM BIOPH RES CO, V138, P153, DOI 10.1016/0006-291X(86)90259-7; HOLT GD, 1990, J BIOL CHEM, V265, P2852; KOLODNY EH, 1989, METABOLIC BASIS INHE; LEV M, 1991, FASEB J, V5, pA457; LINGWOOD CA, 1986, BIOCHIM BIOPHYS ACTA, V877, P246, DOI 10.1016/0005-2760(86)90301-2; LINGWOOD CA, 1981, CAN J BIOCHEM, V57, P556; OTTERNESS DM, 1991, MOL PHARMACOL, V39, P34; ROBERTS DD, 1985, J BIOL CHEM, V260, P9405; ROBERTS DD, 1985, P NATL ACAD SCI USA, V82, P1306, DOI 10.1073/pnas.82.5.1306; SAKAC D, 1992, J BIOL CHEM, V267, P1655; SAKAC D, 1989, BIOCHEM J, V261, P423, DOI 10.1042/bj2610423; SARLIEVE LL, 1976, J NEUROCHEM, V26, P211; SIEGRIST HP, 1977, BIOCHIM BIOPHYS ACTA, V489, P58, DOI 10.1016/0005-2760(77)90231-4; SUNDARAM KS, 1990, ARCH BIOCHEM BIOPHYS, V277, P109, DOI 10.1016/0003-9861(90)90557-F; SUNDARAM KS, 1990, BIOCHEM BIOPH RES CO, V169, P927, DOI 10.1016/0006-291X(90)91982-X; SUNDARAM KS, 1988, J LIPID RES, V29, P1475; TAYLOR T, 1987, BIOCHIM BIOPHYS ACTA, V913, P131, DOI 10.1016/0167-4838(87)90321-9; TENNEKOON G, 1978, J NEUROCHEM, V31, P329, DOI 10.1111/j.1471-4159.1978.tb12466.x; TENNEKOON G, 1985, ARCH BIOCHEM BIOPHYS, V240, P932, DOI 10.1016/0003-9861(85)90102-X; TENNEKOON GI, 1981, J CELL BIOL, V91, P332, DOI 10.1083/jcb.91.2.332	24	25	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1992	267	33					24041	24044						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JZ239	1429739				2022-12-25	WOS:A1992JZ23900091
J	CAPPALONGA, AM; ALEXANDER, RS; CHRISTIANSON, DW				CAPPALONGA, AM; ALEXANDER, RS; CHRISTIANSON, DW			STRUCTURAL COMPARISON OF SULFODIIMINE AND SULFONAMIDE INHIBITORS IN THEIR COMPLEXES WITH ZINC ENZYMES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANGIOTENSIN-CONVERTING ENZYME; CARBONIC-ANHYDRASE INHIBITORS; CARBOXYPEPTIDASE-A; MACROMOLECULAR STRUCTURES; CRYSTAL-STRUCTURE; THERMOLYSIN; RECOGNITION; PHOSPHATE; MOLECULES; GLAUCOMA	The three-dimensional structure of (L(-)-2-carboxy-3-phenylpropyl) methylsulfodiimine in its complex with the zinc metalloenzyme carboxypeptidase A has been determined at 2.25-angstrom resolution by x-ray crystallographic methods. This is the first example of a sulfodiimine-containing inhibitor binding to a zinc enzyme, and the structure of the enzyme-inhibitor complex reveals that the tetrahedral sulfodiimine group coordinates to the active site zinc ion in unidentate fashion. The zinc-coordinated nitrogen atom of the sulfodiimine group is also within hydrogen bonding distance to active site base Glu-270; presumably, the sulfodiimine is ionized and accepts a hydrogen bond from protonated Glu-270. The other sulfodiimine nitrogen accepts a hydrogen bond from Arg-127, and the inhibitor binds as a possible analogue of the tetrahedral transition state (or intermediate) in a promoted water pathway for peptide hydrolysis. The unidentate sulfodiimine-zinc binding mode observed in this enzyme-inhibitor complex is reminiscent of that observed in sulfonamide complexes with the zinc metalloenzyme carbonic anhydrase II, and the structural features of sulfodiimine- and sulfonamide-zinc interactions exhibit important similarities among recently determined structures of enzyme-inhibitor complexes: ionized nitrogens bind to zinc in each structure, and these nitrogens are engaged in hydrogen bond interactions with neighboring enzyme residues.			CAPPALONGA, AM (corresponding author), UNIV PENN,DEPT CHEM,PHILADELPHIA,PA 19104, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045614, R29GM045614] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM45614] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALEXANDER RS, 1990, J AM CHEM SOC, V112, P933, DOI 10.1021/ja00159a004; ALLEN FH, 1983, ACCOUNTS CHEM RES, V16, P146, DOI 10.1021/ar00089a001; ALLEN FH, 1979, ACTA CRYSTALLOGR B, V35, P2331, DOI 10.1107/S0567740879009249; BALDWIN JJ, 1989, J MED CHEM, V32, P2510, DOI 10.1021/jm00132a003; BECKER B, 1954, AM J OPHTHALMOL, V37, P13, DOI 10.1016/0002-9394(54)92027-9; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BREININ GM, 1954, AMA ARCH OPHTHALMOL, V52, P333, DOI 10.1001/archopht.1954.00920050335001; CHRISTIANSON DW, 1989, ACCOUNTS CHEM RES, V22, P62, DOI 10.1021/ar00158a003; CHRISTIANSON DW, 1991, ADV PROTEIN CHEM, V42, P281; CHRISTIANSON DW, 1988, J AM CHEM SOC, V110, P5560, DOI 10.1021/ja00224a047; Coleman JE., 1986, ZINC ENZYMES, P49; CUSHMAN DW, 1977, BIOCHEMISTRY-US, V16, P5484, DOI 10.1021/bi00644a014; ERIKSSON AE, 1988, PROTEINS, V4, P283, DOI 10.1002/prot.340040407; Eriksson E. A., 1986, ZINC ENZYMES, P317; FRIEDENWALD JS, 1949, AM J OPHTHALMOL, V32, P9, DOI 10.1016/S0002-9394(14)78354-0; GRANT WM, 1954, AMA ARCH OPHTHALMOL, V51, P735; Hendrickson W. A., 1981, BIOMOLECULAR STRUCTU, V1, P43; HENDRICKSON WA, 1985, METHOD ENZYMOL, V115, P252; HOLDEN HM, 1987, BIOCHEMISTRY-US, V26, P8542, DOI 10.1021/bi00400a008; JONES TA, 1985, METHOD ENZYMOL, V115, P157; KANYO ZF, 1991, J BIOL CHEM, V266, P4264; KIM H, 1990, BIOCHEMISTRY-US, V29, P5546, DOI 10.1021/bi00475a019; KIM HD, 1991, BIOCHEMISTRY-US, V30, P8171, DOI 10.1021/bi00247a012; KINSEY VE, 1953, AMA ARCH OPHTHALMOL, V50, P401, DOI 10.1001/archopht.1953.00920030409001; KUTZELNIGG W, 1977, PURE APPL CHEM, V49, P981, DOI 10.1351/pac197749070981; LINDSKOG S, 1986, ZINC ENZYMES, P307; LUZZATI V, 1952, ACTA CRYSTALLOGR, V5, P802, DOI 10.1107/S0365110X52002161; Mann T., 1940, NATURE, V146, P164, DOI [10.1038/146164a0, DOI 10.1038/146164A0]; MAREN TH, 1987, DRUG DEVELOP RES, V10, P255, DOI 10.1002/ddr.430100407; MAREN TH, 1984, ANN NY ACAD SCI, V429, P49; MATTHEWS BW, 1988, ACCOUNTS CHEM RES, V21, P333, DOI 10.1021/ar00153a003; MAYCOCK AL, 1981, BIOCHEM BIOPH RES CO, V102, P963, DOI 10.1016/0006-291X(81)91632-6; MOCK WL, 1989, J AM CHEM SOC, V111, P4467, DOI 10.1021/ja00194a049; ONDETTI MA, 1977, SCIENCE, V196, P441, DOI 10.1126/science.191908; PATCHETT AA, 1980, NATURE, V288, P280, DOI 10.1038/288280a0; Pocker Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P149; PRUGH JD, 1991, J MED CHEM, V34, P1805, DOI 10.1021/jm00110a008; REES DC, 1983, J MOL BIOL, V168, P367, DOI 10.1016/S0022-2836(83)80024-2; SILVERMAN DN, 1988, ACCOUNTS CHEM RES, V21, P30, DOI 10.1021/ar00145a005; TENEYCK LF, 1973, ACTA CRYSTALLOGR A, VA 29, P183, DOI 10.1107/S0567739473000458; TENEYCK LF, 1977, ACTA CRYSTALLOGR A, V33, P486, DOI 10.1107/S0567739477001211; TRONRUD DE, 1987, SCIENCE, V235, P571, DOI 10.1126/science.3810156; VALLEE BL, 1990, BIOCHEMISTRY-US, V29, P5647, DOI 10.1021/bi00476a001; VALLEE BL, 1990, P NATL ACAD SCI USA, V87, P220, DOI 10.1073/pnas.87.1.220; VALLEE BL, 1984, ADV ENZYMOL RAMB, V56, P283; VIDGREN J, 1990, INT J BIOL MACROMOL, V12, P342, DOI 10.1016/0141-8130(90)90040-H; WALLMEIER H, 1979, J AM CHEM SOC, V101, P2804, DOI 10.1021/ja00505a002; WYCKOFF HW, 1967, J MOL BIOL, V27, P563, DOI 10.1016/0022-2836(67)90059-9	48	28	32	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1992	267	27					19192	19197						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JP593	1527041				2022-12-25	WOS:A1992JP59300030
J	KURODA, M; DEWAARD, S; MIZUSHIMA, K; TSUDA, M; POSTMA, P; TSUCHIYA, T				KURODA, M; DEWAARD, S; MIZUSHIMA, K; TSUDA, M; POSTMA, P; TSUCHIYA, T			RESISTANCE OF THE MELIBIOSE CARRIER TO INHIBITION BY THE PHOSPHOTRANSFERASE SYSTEM DUE TO SUBSTITUTIONS OF AMINO-ACID-RESIDUES IN THE CARRIER OF SALMONELLA-TYPHIMURIUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; INDUCER EXCLUSION; TRANSPORT-SYSTEM; MALTOSE TRANSPORT; MOLECULAR-CLONING; LACTOSE PERMEASE; SUGAR-TRANSPORT; ENZYME-III; PHOSPHOENOLPYRUVATE; SEQUENCE	The melibiose carrier of Salmonella typhimurium is under the control of the phosphoenolpyruvate:carbohydrate phosphotransferase system (PTS). We isolated mutants of the melibiose carrier that showed resistance to inhibition via the PTS. Growth of the mutants on melibiose was not inhibited by 2-deoxyglucose, a non-metabolizable substrate of the PTS, although growth of the parent strain was inhibited. Transport activity of the melibiose carrier in the mutants was fairly resistant to inhibition by 2-deoxyglucose, although the activity in the parent was sensitive to inhibition. We cloned the mutated melB gene that encodes the melibiose carrier, determined the nucleotide sequences, and identified replaced nucleotides. The mutations resulted in substitutions of Asp-438 with Tyr, Arg-441 with Ser, or Ile-445 with Asn. All of these residues are in the COOH-terminal region of the carrier. The secondary structure of this region is predicted to be an alpha-helix, and the mutated residues were on the same side of the helix. This region showed sequence similarity to a region of the MalK protein, in which substitution of amino acid residues also resulted in PTS-resistant mutants. Thus the COOH-terminal portion of the melibiose carrier is important for the interaction of dephosphorylated III(Glc), which is an entity causing reversible inactivation of the carrier.	OKAYAMA UNIV,FAC PHARMACEUT SCI,DEPT MICROBIOL,OKAYAMA 700,JAPAN; UNIV AMSTERDAM,EC SLATER INST BIOCHEM RES,AMSTERDAM,NETHERLANDS	Okayama University; University of Amsterdam				de Waard, Jacobus H./0000-0003-4118-1015				BERNS KI, 1965, J MOL BIOL, V11, P476, DOI 10.1016/S0022-2836(65)80004-3; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; BOTFIELD MC, 1988, J BIOL CHEM, V263, P12909; BOTFIELD MC, 1992, J BIOL CHEM, V267, P1818; BOTFIELD MC, 1989, J BIOL CHEM, V264, P11643; BUCHEL DE, 1980, NATURE, V283, P541, DOI 10.1038/283541a0; BURSTEIN C, 1971, BIOCHIM BIOPHYS ACTA, V230, P52, DOI 10.1016/0304-4165(71)90053-5; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; COMEAU DE, 1988, MOL GEN GENET, V213, P166, DOI 10.1007/BF00333415; DEAN DA, 1990, J BIOL CHEM, V265, P21005; FOSTER DL, 1983, J BIOL CHEM, V258, P31; HANATANI M, 1984, J BIOL CHEM, V259, P1807; HATTORI M, 1986, ANAL BIOCHEM, V152, P232, DOI 10.1016/0003-2697(86)90403-3; IDE M, 1969, BIOCHEM BIOPH RES CO, V36, P42, DOI 10.1016/0006-291X(69)90646-9; KUHNAU S, 1991, J BACTERIOL, V173, P2180; LENNOX ES, 1955, VIROLOGY, V1, P190, DOI 10.1016/0042-6822(55)90016-7; LOPILATO J, 1978, J BACTERIOL, V134, P147, DOI 10.1128/JB.134.1.147-156.1978; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAGASANIK B, 1961, COLD SPRING HARB SYM, V26, P249, DOI 10.1101/SQB.1961.026.01.031; Magasanik B, 1970, LACTOSE OPERON, P189; MISKO TP, 1987, J BIOL CHEM, V262, P16261; MIZUSHIMA K, 1992, IN PRESS MOL GEN GEN; MONOD J, 1947, GROWTH, V11, P223; Neidhardt F., 1987, ESCHERICHIA COLI SAL; NELSON SO, 1983, EMBO J, V2, P715, DOI 10.1002/j.1460-2075.1983.tb01490.x; NELSON SO, 1986, EUR J BIOCHEM, V154, P337, DOI 10.1111/j.1432-1033.1986.tb09402.x; NELSON SO, 1984, EMBO J, V3, P1587, DOI 10.1002/j.1460-2075.1984.tb02015.x; NELSON SO, 1982, J BACTERIOL, V15, P604; NIIYA S, 1980, J BACTERIOL, V144, P192, DOI 10.1128/JB.144.1.192-199.1980; OKADA T, 1981, J BACTERIOL, V146, P1030, DOI 10.1128/JB.146.3.1030-1037.1981; OSUMI T, 1982, P NATL ACAD SCI-BIOL, V79, P1457, DOI 10.1073/pnas.79.5.1457; PETERKOFSKY A, 1989, FEMS MICROBIOL REV, V63, P103; POLLARDKNIGHT D, 1990, ANAL BIOCHEM, V185, P84, DOI 10.1016/0003-2697(90)90259-C; POSTMA PW, 1985, MICROBIOL REV, V49, P232, DOI 10.1128/MMBR.49.3.232-269.1985; POSTMA PW, 1988, MOL BASIS BIOMEMBRAN, P43; SAFFEN DW, 1987, J BIOL CHEM, V262, P16241; SAIER MH, 1989, MICROBIOL REV, V53, P109, DOI 10.1128/MMBR.53.1.109-120.1989; SAIER MH, 1978, J BACTERIOL, V133, P1358, DOI 10.1128/JB.133.3.1358-1367.1978; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; TANAKA S, 1967, J BACTERIOL, V93, P642, DOI 10.1128/JB.93.2.642-648.1967; TAO M, 1969, P NATL ACAD SCI USA, V63, P86, DOI 10.1073/pnas.63.1.86; TSUCHIYA T, 1978, MEMBRANE BIOCHEM, V2, P63, DOI 10.3109/09687687809063858; WILSON TH, 1990, BIOCHIM BIOPHYS ACTA, V1029, P113, DOI 10.1016/0005-2736(90)90443-R; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; YAZYU H, 1984, J BIOL CHEM, V259, P4320	47	22	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1992	267	26					18336	18341						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JN502	1526973				2022-12-25	WOS:A1992JN50200017
J	KLEIBOEKER, SB; MILANICK, MA; HALE, CC				KLEIBOEKER, SB; MILANICK, MA; HALE, CC			INTERACTIONS OF THE EXCHANGE INHIBITORY PEPTIDE WITH NA-CA EXCHANGE IN BOVINE CARDIAC SARCOLEMMAL VESICLES AND FERRET RED-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-UPTAKE; SODIUM; IDENTIFICATION; PURIFICATION; CALMODULIN; PUMP	The Na-Ca exchange inhibitory peptide (XIP), which corresponds to residues 251-270 of the Na-Ca exchange protein, specifically inhibits exchange activity (Li, Z., Nicoll, D. A, Collins, A., Hilgemann, D. W., Filoteo, A. G., Penniston, J. T., Weiss, J. N., Tomich, J. M., and Philipson, K. D. (1991) J. Biol. Chem. 266, 1014-1020). We have found that XIP decreased Na+1-dependent Ca2+ uptake to 46 and 20% of control in mixed and inside-out bovine sarcolemmal (SL) vesicles, respectively, and to 22% of control in ferret red cell vesicles. XIP inhibited uptake in bovine SL vesicles after proteolytic digestion. XIP also inhibited Na+o-dependent Ca2+ efflux in bovine SL vesicles but did not inhibit Ca2+ uptake in reconstituted proteoliposomes. Extracellular XIP did not inhibit Ca2+ uptake into intact ferret red cells. Inhibition of uptake in bovine SL vesicles was reduced as the ionic strength was increased. I-125-labeled XIP (1-mu-M) was cross-linked to proteins of bovine SL vesicles, ferret red cell vesicles, and intact ferret red cells. Labeling of bands at approximately 75, 120, and 220 kDa (in bovine SL vesicles) and bands at 55 and 85 kDa (in ferret red cell vesicles) was detected. No cross-linking was detected in intact ferret red cells. We conclude that XIP inhibition is insensitive to proteolytic digestion and is partially dependent on charge association and conformation of the exchanger. XIP binds to and interacts with the intracellular side of the Na-Ca exchanger.	UNIV MISSOURI,DEPT VET BIOMED SCI,COLUMBIA,MO 65211; UNIV MISSOURI,JOHN M DALTON RES CTR,COLUMBIA,MO 65211; UNIV MISSOURI,DEPT MED PHYSIOL,COLUMBIA,MO 65211	University of Missouri System; University of Missouri Columbia; University of Missouri System; University of Missouri Columbia; University of Missouri System; University of Missouri Columbia					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037512, K04DK002006] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK02006, DK 37512] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		FAIRBANKS G, 1988, METHODS HEMATOL, V19, P17; FRANK JS, 1984, CIRC RES, V54, P414, DOI 10.1161/01.RES.54.4.414; HALE CC, 1984, P NATL ACAD SCI-BIOL, V81, P6569, DOI 10.1073/pnas.81.21.6569; KIMURA J, 1987, J PHYSIOL-LONDON, V384, P199, DOI 10.1113/jphysiol.1987.sp016450; KIMURA J, 1988, J MOL CELL CARDIO S4, V20, pS19; KUWAYAMA H, 1982, J BIOCHEM-TOKYO, V91, P1419, DOI 10.1093/oxfordjournals.jbchem.a133830; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI ZP, 1991, J BIOL CHEM, V266, P1014; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MILANICK MA, 1989, AM J PHYSIOL, V256, pC390, DOI 10.1152/ajpcell.1989.256.2.C390; MILANICK MA, 1992, FASEB J, V6, pA1760; NICOLL DA, 1990, SCIENCE, V250, P562, DOI 10.1126/science.1700476; PHILIPSON KD, 1985, BIOCHIM BIOPHYS ACTA, V821, P367, DOI 10.1016/0005-2736(85)90107-5; PHILIPSON KD, 1982, J BIOL CHEM, V257, P5111; REEVES JP, 1983, J BIOL CHEM, V258, P3178; REEVES JP, 1989, SODIUM CALCIUM EXCHA, P27; SARKADI B, 1980, CELL CALCIUM, V1, P287, DOI 10.1016/0143-4160(80)90031-7; SLAUGHTER RS, 1983, J BIOL CHEM, V258, P183; Steck T L, 1974, Methods Enzymol, V31, P172; VEMURI R, 1989, AM J PHYSIOL, V256, pC1273, DOI 10.1152/ajpcell.1989.256.6.C1273	20	24	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1992	267	25					17836	17841						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JM223	1517221				2022-12-25	WOS:A1992JM22300056
J	REGAZZI, R; KIKUCHI, A; TAKAI, Y; WOLLHEIM, CB				REGAZZI, R; KIKUCHI, A; TAKAI, Y; WOLLHEIM, CB			THE SMALL GTP-BINDING PROTEINS IN THE CYTOSOL OF INSULIN-SECRETING CELLS ARE COMPLEXED TO GDP DISSOCIATION INHIBITOR PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GDP/GTP EXCHANGE PROTEIN; ADP-RIBOSYLATION FACTOR; C-TERMINAL REGION; PERMEABILIZED RINM5F CELLS; BOVINE BRAIN CYTOSOL; SMG P25A; REGULATORY PROTEIN; MOLECULAR-CLONING; SUBCELLULAR DISTRIBUTIONS; COMPETITIVE INHIBITOR	Ras-related small GTP-binding proteins (SMGs) exist in a cytosolic and a membrane-bound pool. The mechanism regulating the intracellular distribution of SMGs remains to be elucidated. We have, therefore, investigated the properties of SMGs expressed in cells of the insulin-secreting lines RINm5F and HIT-T15. Phase-partitioning analysis revealed that smg25A/rab3A as well as all the SMGs in the 23-27 kDa range, labeled by radioactive GTP after blotting, were hydrophobic, regardless of their subcellular distribution. In contrast, the cytosolic forms of ADP ribosylation factor, rho, and CDC42 were hydrophilic. The cytosolic pool of the 23-27-kDa group, including smg25A/rab3A, sedimented in a sucrose density gradient as complexes with an apparent M(r) of about 80,000, whereas rho and CDC42 were recovered in 45-kDa complexes. ARF, however, was uncomplexed (M(r) close to 20,000). The 80-kDa aggregates were likely to be formed by 1:1 complexes with the regulatory protein smg25/GDP dissociation inhibitor (smg25/GDI). In fact, pure smg25/GDI by sucrose gradient exhibited a molecular mass of 55 kDa, but cosedimented with the 80-kDa complexes in cytosolic extracts of insulin-secreting cells. Moreover, purified smg25/GDI was able to extract the SMGs of the 23-27-kDa group from the membranes. Similarly, in cytosolic extracts, rho/GDI cosedimented with the 45-kDa aggregates. Blocking the synthesis of isoprenoid groups with lovastatin resulted in the appearance in the cytosol of SMGs that were hydrophilic. These SMGs were found to sediment with an apparent M(r) close to 25,000 and to be unable to form complexes with smg25/GDI. Lovastatin treatment also caused the accumulation of the noncomplexed form of CDC42 but not of rho proteins. We propose that 1) except for ARF, all the SMGs detected in the cytosol of insulin-secreting cells are associated in 1:1 complexes with their regulatory proteins; 2) the different SMGs can be subdivided into functional groups according to the regulatory protein bound to them; 3) the formation of the 80-kDa complexes with smg25/GDI and of the CDC42 complexes with rho/GDI necessitate the correct carboxyl-terminal post-translational modification of the SMGs.	KOBE UNIV,SCH MED,DEPT BIOCHEM,KOBE 650,JAPAN	Kobe University	REGAZZI, R (corresponding author), UNIV GENEVA,CTR MED,DEPT MED,DIV BIOCHIM CLIN,CH-1211 GENEVA 4,SWITZERLAND.							ABO A, 1991, NATURE, V353, P668, DOI 10.1038/353668a0; ADAMS AEM, 1990, J CELL BIOL, V111, P131, DOI 10.1083/jcb.111.1.131; AKTORIES K, 1988, EUR J BIOCHEM, V172, P445, DOI 10.1111/j.1432-1033.1988.tb13908.x; ALBERTS AW, 1980, P NATL ACAD SCI-BIOL, V77, P3957, DOI 10.1073/pnas.77.7.3957; ARAKI S, 1991, MOL CELL BIOL, V11, P1438, DOI 10.1128/MCB.11.3.1438; ARAKI S, 1990, J BIOL CHEM, V265, P13007; BHULLAR RP, 1987, BIOCHEM J, V245, P617, DOI 10.1042/bj2450617; BORDIER C, 1981, J BIOL CHEM, V256, P1604; BOURNE HR, 1988, CELL, V53, P669, DOI 10.1016/0092-8674(88)90081-5; CHARDIN P, 1988, NUCLEIC ACIDS RES, V16, P2717, DOI 10.1093/nar/16.6.2717; DOWNWARD J, 1990, TRENDS BIOCHEM SCI, V15, P469, DOI 10.1016/0968-0004(90)90300-Z; Evans T, 1991, CURR OPIN CELL BIOL, V3, P185, DOI 10.1016/0955-0674(91)90137-N; FARNSWORTH CC, 1991, P NATL ACAD SCI USA, V88, P6196, DOI 10.1073/pnas.88.14.6196; FUJIOKA H, 1990, BIOCHEM BIOPH RES CO, V168, P1244, DOI 10.1016/0006-291X(90)91162-L; FUKUMOTO Y, 1990, ONCOGENE, V5, P1321; GOUD B, 1988, CELL, V53, P753, DOI 10.1016/0092-8674(88)90093-1; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HART MJ, 1990, J BIOL CHEM, V265, P5990; HIGASHIJIMA T, 1991, J BIOL CHEM, V266, P3396; HIRAOKA K, 1992, BIOCHEM BIOPH RES CO, V182, P921, DOI 10.1016/0006-291X(92)91820-G; HIROYOSHI M, 1991, J BIOL CHEM, V266, P2962; HORI Y, 1991, ONCOGENE, V6, P515; ISOMURA M, 1991, ONCOGENE, V6, P119; JOHNSTON PA, 1991, NEURON, V7, P101, DOI 10.1016/0896-6273(91)90078-E; KAHN RA, 1988, J BIOL CHEM, V263, P8282; KAHN RA, 1986, J BIOL CHEM, V261, P7906; KATAYAMA M, 1991, J BIOL CHEM, V266, P12639; KAWATA M, 1990, P NATL ACAD SCI USA, V87, P8960, DOI 10.1073/pnas.87.22.8960; KIKUCHI A, 1988, J BIOL CHEM, V263, P2897; KINSELLA BT, 1991, J BIOL CHEM, V266, P8540; KITA T, 1980, J CLIN INVEST, V66, P1094, DOI 10.1172/JCI109938; LAPETINA EG, 1989, P NATL ACAD SCI USA, V86, P3131, DOI 10.1073/pnas.86.9.3131; MALTESE WA, 1990, J BIOL CHEM, V265, P17883; MATSUI Y, 1990, MOL CELL BIOL, V10, P4116, DOI 10.1128/MCB.10.8.4116; MATSUI Y, 1988, J BIOL CHEM, V263, P11071; MIZOGUCHI A, 1990, J BIOL CHEM, V265, P11872; MIZOGUCHI A, 1989, BIOCHEM BIOPH RES CO, V162, P1438, DOI 10.1016/0006-291X(89)90835-8; NONAKA H, 1991, BIOCHEM BIOPH RES CO, V174, P556, DOI 10.1016/0006-291X(91)91453-J; PATERSON HF, 1990, J CELL BIOL, V111, P1001, DOI 10.1083/jcb.111.3.1001; PRENTKI M, 1987, PHYSIOL REV, V67, P1185, DOI 10.1152/physrev.1987.67.4.1185; REGAZZI R, 1990, J BIOL CHEM, V265, P15003; REGAZZI R, 1989, J BIOL CHEM, V264, P9939; REGAZZI R, 1991, BIOCHEM J, V275, P639, DOI 10.1042/bj2750639; REGAZZI R, 1990, Diabetologia, V33, pA87; SASAKI T, 1991, MOL CELL BIOL, V11, P2909, DOI 10.1128/MCB.11.5.2909; SASAKI T, 1990, J BIOL CHEM, V265, P2333; SEGEV N, 1988, CELL, V52, P915, DOI 10.1016/0092-8674(88)90433-3; SERAFINI T, 1991, CELL, V67, P239, DOI 10.1016/0092-8674(91)90176-Y; SHIMIZU K, 1991, BIOCHEM BIOPH RES CO, V175, P199, DOI 10.1016/S0006-291X(05)81220-3; SHINJO K, 1990, P NATL ACAD SCI USA, V87, P9853, DOI 10.1073/pnas.87.24.9853; TAKAI Y, 1992, INT REV CYTOL, V133, P187, DOI 10.1016/S0074-7696(08)61861-6; UEDA T, 1990, J BIOL CHEM, V265, P9373; UEDA T, 1991, BIOCHEMISTRY-US, V30, P909, DOI 10.1021/bi00218a005; ULLRICH S, 1988, J BIOL CHEM, V263, P8615; VALLAR L, 1987, J BIOL CHEM, V262, P5049; WHITE TE, 1990, P NATL ACAD SCI USA, V87, P758, DOI 10.1073/pnas.87.2.758; YERAMIAN P, 1987, NUCLEIC ACIDS RES, V15, P1869, DOI 10.1093/nar/15.4.1869; ZAHRAOUI A, 1989, J BIOL CHEM, V264, P12394	59	162	163	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1992	267	25					17512	17519						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JM223	1517204				2022-12-25	WOS:A1992JM22300009
J	HIBINO, Y; KUMAR, CS; MARIANO, TM; LAI, D; PESTKA, S				HIBINO, Y; KUMAR, CS; MARIANO, TM; LAI, D; PESTKA, S			CHIMERIC INTERFERON-GAMMA RECEPTORS DEMONSTRATE THAT AN ACCESSORY FACTOR REQUIRED FOR ACTIVITY INTERACTS WITH THE EXTRACELLULAR DOMAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; PROTEIN KINASE-C; IMMUNE INTERFERON; TYROSINE KINASE; TRANSCRIPTIONAL ACTIVATION; MONOCLONAL-ANTIBODIES; INSULIN-RECEPTOR; GENETIC-ANALYSIS; EGF RECEPTOR; EXPRESSION	We determined the species specificity and function of structural domains of the interferon-gamma receptor (IFN-gamma-R) by construction of human/murine chimeric IFN-gamma-R cDNA clones and their expression in various cells. We demonstrate that we can reconstitute a biologically active IFN-gamma-R in eukaryotic cells with chimeric receptors as long as the extracellular domain and an accessory factor are from the same species. These results indicate that the extracellular domain of the receptor interacts directly or indirectly with the species-specific accessory factor.	UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,DEPT MOLEC GENET & MICROBIOL,PISCATAWAY,NJ 08854	Rutgers State University New Brunswick; Rutgers State University Medical Center			Kumar, Dr Suresh/HHZ-2615-2022; chitta, suresh kumar/N-1569-2016; KUMAR, P. SURESH/AAT-8951-2020	Kumar, Dr Suresh/0000-0002-2539-6553; KUMAR, P. SURESH/0000-0003-3222-2604	NCI NIH HHS [R01 CA46465] Funding Source: Medline; NIAID NIH HHS [UO1 AI25914] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA046465] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI025914] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AGUET M, 1988, CELL, V55, P273, DOI 10.1016/0092-8674(88)90050-5; BARNSTABLE CJ, 1978, CELL, V14, P9, DOI 10.1016/0092-8674(78)90296-9; BLANAR MA, 1988, P NATL ACAD SCI USA, V85, P4672, DOI 10.1073/pnas.85.13.4672; CARPENTER G, 1987, ANNU REV BIOCHEM, V56, P881, DOI 10.1146/annurev.biochem.56.1.881; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; COFANO F, 1990, J BIOL CHEM, V265, P4064; DIFIORE PP, 1990, SCIENCE, V248, P79, DOI 10.1126/science.2181668; DOBASHI K, 1989, DNA-J MOLEC CELL BIO, V8, P723, DOI 10.1089/dna.1989.8.723; ESCOBEDO JA, 1988, MOL CELL BIOL, V8, P5126, DOI 10.1128/MCB.8.12.5126; FAN XD, 1988, P NATL ACAD SCI USA, V85, P5122, DOI 10.1073/pnas.85.14.5122; FIELDS R, 1988, J INTERFERON RES, V8, P549, DOI 10.1089/jir.1988.8.549; FOUNTOULAKIS M, 1991, J BIOL CHEM, V266, P14970; FRIEDMAN JS, 1989, BIO-TECHNOL, V7, P359, DOI 10.1038/nbt0489-359; GARIGLIO M, 1988, J INTERFERON RES, V8, P463, DOI 10.1089/jir.1988.8.463; GAROTTA G, 1990, J BIOL CHEM, V265, P6908; GOVERMAN J, 1990, CELL, V60, P929, DOI 10.1016/0092-8674(90)90341-B; GRAY PW, 1989, P NATL ACAD SCI USA, V86, P8497, DOI 10.1073/pnas.86.21.8497; GYLLENSTEN UB, 1988, P NATL ACAD SCI USA, V85, P7652, DOI 10.1073/pnas.85.20.7652; HAMILTON TA, 1985, J BIOL CHEM, V260, P1378; HEMMI S, 1989, P NATL ACAD SCI USA, V86, P9901, DOI 10.1073/pnas.86.24.9901; HERSHEY GKK, 1989, J BIOL CHEM, V264, P11981; HIBI M, 1990, CELL, V63, P1149, DOI 10.1016/0092-8674(90)90411-7; HIBINO Y, 1991, J BIOL CHEM, V266, P6948; JUNG V, 1988, SOMAT CELL MOLEC GEN, V14, P583, DOI 10.1007/BF01535312; JUNG V, 1990, J BIOL CHEM, V265, P1827; JUNG V, 1987, P NATL ACAD SCI USA, V84, P4151, DOI 10.1073/pnas.84.12.4151; KASHLES O, 1988, P NATL ACAD SCI USA, V85, P9567, DOI 10.1073/pnas.85.24.9567; KOBILKA BK, 1988, SCIENCE, V240, P1310, DOI 10.1126/science.2836950; KOKAI Y, 1989, CELL, V58, P287, DOI 10.1016/0092-8674(89)90843-X; KOKAI Y, 1988, P NATL ACAD SCI USA, V85, P5389, DOI 10.1073/pnas.85.15.5389; KOZAK CA, 1980, J EXP MED, V152, P1419, DOI 10.1084/jem.152.5.1419; KUMAR CS, 1989, J BIOL CHEM, V264, P17939; KUNG HF, 1986, METHOD ENZYMOL, V119, P296; LAMMERS R, 1989, EMBO J, V8, P1369, DOI 10.1002/j.1460-2075.1989.tb03517.x; LANGER JA, 1988, IMMUNOL TODAY, V9, P393, DOI 10.1016/0167-5699(88)91241-8; LANGER JA, 1990, PHARM TECHNOL, V14, P46; LAROCHELLE WJ, 1990, SCIENCE, V248, P1541, DOI 10.1126/science.2163109; MARIANO TM, 1987, J BIOL CHEM, V262, P5812; MOE GR, 1989, P NATL ACAD SCI USA, V86, P5683, DOI 10.1073/pnas.86.15.5683; MUNRO S, 1989, P NATL ACAD SCI USA, V86, P9248, DOI 10.1073/pnas.86.23.9248; NADEAU JH, 1989, TRENDS GENET, V5, P82, DOI 10.1016/0168-9525(89)90031-0; NAGATA Y, 1984, J CELL BIOL, V98, P1342, DOI 10.1083/jcb.98.4.1342; OZATO K, 1985, P NATL ACAD SCI USA, V82, P2427, DOI 10.1073/pnas.82.8.2427; OZATO K, 1982, TRANSPLANTATION, V34, P113, DOI 10.1097/00007890-198209000-00001; PESTKA S, 1987, ANNU REV BIOCHEM, V56, P727, DOI 10.1146/annurev.biochem.56.1.727; PRPIC V, 1989, SCIENCE, V244, P469, DOI 10.1126/science.2541500; PUCK TT, 1985, MOL CELL GENET, V37, P37; RASHIDBAIGI A, 1986, P NATL ACAD SCI USA, V83, P384, DOI 10.1073/pnas.83.2.384; RASHIDBAIGI A, 1985, J BIOL CHEM, V260, P8514; RAZIUDDIN A, 1984, P NATL ACAD SCI-BIOL, V81, P5504, DOI 10.1073/pnas.81.17.5504; REHBERG E, 1982, J BIOL CHEM, V257, P1497; SCHNECK J, 1982, P NATL ACAD SCI-BIOL, V79, P1879, DOI 10.1073/pnas.79.6.1879; SMITH LL, 1988, J BIOL CHEM, V263, P7359; THREADGILL DS, 1991, P NATL ACAD SCI USA, V88, P154, DOI 10.1073/pnas.88.1.154; TRINCHIERI G, 1985, IMMUNOL TODAY, V6, P131, DOI 10.1016/0167-5699(85)90080-5; VANCAMP G, 1990, SOMAT CELL MOLEC GEN, V16, P241; WEINER DB, 1989, ONCOGENE, V4, P1175; WEINER DB, 1989, NATURE, V339, P230, DOI 10.1038/339230a0; YON J, 1989, NUCLEIC ACIDS RES, V17, P4895, DOI 10.1093/nar/17.12.4895	59	76	79	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1992	267	6					3741	3749						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HE607	1531478				2022-12-25	WOS:A1992HE60700033
J	JANSSEN, GG; NES, WD				JANSSEN, GG; NES, WD			STRUCTURAL REQUIREMENTS FOR TRANSFORMATION OF SUBSTRATES BY THE S-ADENOSYL-L-METHIONINE - DELTA-24(25)-STEROL METHYLTRANSFERASE - INHIBITION BY ANALOGS OF THE TRANSITION-STATE COORDINATE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GIBBERELLA-FUJIKUROI; STEROL BIOSYNTHESIS; METHYL TRANSFERASE; TISSUE-CULTURES; SIDE-CHAIN; ZEA-MAYS; 24(R,S),25-EPIMINOLANOSTEROL; 24-METHYLENECYCLOARTANOL; ISOFUCOSTEROL; LANOSTEROL	Microsomes from sunflower seedlings were used to investigate the transition state coordinate for the C-24 methylation reaction that mediates phytosterol biosynthesis. They were then used to study structurally related cationic and uncharged compounds of the natural sterol substrate, which were designed to interfere with the reaction progress. The hypothetical reaction course is described to proceed through an S(n)2 formation of an activated complex involving the initial production of a covalent structure with a dative bond (methyl from AdoMet attacks si-face of the 24,25-double bond of the sterol) and the secondary production of a series of high energy intermediates, the stabilization of which determines the final C-24 methylated product. Derivatives of lanosterol and cholesterol with a methyl, hydrogen, oxygen, or bromine atom introduced into the side chain and/or at C-3 in place of the natural nucleophile were studied as inhibitors that interfere with the formation of the hypothetical tertiary isopropylcarbinyl cation intermediate in the conversion of cycloartenol to 24(28)-methylene cycloartanol. The data indicate the most potent inhibitor is a sterol with an aziridine group attached to C-24(25), which mimics the bridged C-24(25) carbenium ion generated in the transition state, and the methyltransferase possesses two strategic sites: one that recognizes the proximal end of the sterol acting as a proton donor and the other that recognizes the distal end that acts as a proton acceptor. The best fit (binding/catalysis) involves a flat sterol (including substrate and inhibitor) with intact unsubstituted nucleophilic centers at C-3 and C-24 and a freely rotating side chain that can assume the pseudocyclic conformation.	RICHARD B RUSSELL RES CTR,MICROBIAL PROD RES UNIT,950 COLL STN RD,ATHENS,GA 30613		NES, WD (corresponding author), RICHARD B RUSSELL RES CTR,MICROBIAL PROD RES UNIT,950 COLL STN RD,ATHENS,GA 30613, USA.							AKHTAR M, 1967, BIOCHEM J, V103, P616, DOI 10.1042/bj1030616; Akihisa T., 1991, PHYSL BIOCH STEROLS, P172; Arigoni D., 1978, CIBA FDN S, P243; BACH TJ, 1986, LIPIDS, V21, P82, DOI 10.1007/BF02534307; BENVENISTE P, 1986, ANNU REV PLANT PHYS, V37, P275, DOI 10.1146/annurev.pp.37.060186.001423; BLOCH KE, 1983, CRC CR REV BIOCH MOL, V14, P47, DOI 10.3109/10409238309102790; DIXON M, 1953, BIOCHEM J, V55, P170, DOI 10.1042/bj0550170; Gaylor J. L., 1981, BIOISOPRENOID COMP, V1, P481; GILL HK, 1986, J CHEM SOC CHEM COMM, P1459, DOI 10.1039/c39860001459; GOAD LJ, 1974, LIPIDS, V9, P582, DOI 10.1007/BF02532508; GROSSMANN K, 1985, PLANTA, V164, P370, DOI 10.1007/BF00402948; IKEKAWA N, 1991, PHYSL BIOCH STEROLS, P346; MISSO NLA, 1983, PHYTOCHEMISTRY, V22, P2473, DOI 10.1016/0031-9422(83)80143-5; NES WD, 1989, ARCH BIOCHEM BIOPHYS, V272, P323, DOI 10.1016/0003-9861(89)90226-9; NES WD, 1991, BIOCHEM BIOPH RES CO, V177, P566, DOI 10.1016/0006-291X(91)92021-B; NES WD, 1990, BIOCHIM BIOPHYS ACTA, V1042, P119, DOI 10.1016/0005-2760(90)90065-6; NES WD, 1992, PHYTOCHEMISTRY, V31, P805, DOI 10.1016/0031-9422(92)80019-B; NES WD, 1990, RECENT ADV PHYTOCHEM, V24, P283; NES WD, 1991, J BIOL CHEM, V266, P15202; NICOTRA F, 1981, J CHEM SOC PERK T 1, P498, DOI 10.1039/p19810000498; OEHLSCHLAGER AC, 1984, BIOCHEMISTRY-US, V23, P3582, DOI 10.1021/bi00311a003; PARISH EJ, 1989, SYNTHETIC COMMUN, V18, P221; RAHIER A, 1984, J BIOL CHEM, V259, P5215; SCHEID F, 1982, PHYTOCHEMISTRY, V21, P1959, DOI 10.1016/0031-9422(82)83023-9; SEO S, 1988, J CHEM SOC PERK T 1, P2407, DOI 10.1039/p19880002407; SEO S, 1990, J CHEM SOC PERK T 1, P105, DOI 10.1039/p19900000105; SEO S, 1983, J AM CHEM SOC, V105, P6343, DOI 10.1021/ja00358a042; XU SH, 1988, J CHROMATOGR, V452, P377, DOI 10.1016/S0021-9673(01)81462-X	28	40	41	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1992	267	36					25856	25863						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KD073	1464600				2022-12-25	WOS:A1992KD07300043
J	LEE, SH; SOYOOLA, E; CHANMUGAM, P; HART, S; SUN, WQ; ZHONG, H; LIOU, S; SIMMONS, D; HWANG, D				LEE, SH; SOYOOLA, E; CHANMUGAM, P; HART, S; SUN, WQ; ZHONG, H; LIOU, S; SIMMONS, D; HWANG, D			SELECTIVE EXPRESSION OF MITOGEN-INDUCIBLE CYCLOOXYGENASE IN MACROPHAGES STIMULATED WITH LIPOPOLYSACCHARIDE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROSTAGLANDIN ENDOPEROXIDE SYNTHASE; HUMAN-ENDOTHELIAL-CELLS; COMPLEMENTARY-DNA; PHORBOL ESTER; MESSENGER-RNA; G/H SYNTHASE; SHOCK; GENE; RAT; MECHANISM	Two forms of cyclooxygenase are known to be present in eukaryotic organisms: a cyclooxygenase (COX-1) first purified from ram seminal vesicles encoded by a 2.8-kilobase mRNA, and a newly discovered mitogen-inducible cyclooxygenase (COX-2) encoded by a 4-kilobase mRNA. Expression of these two forms of the enzyme in rat alveolar macrophages stimulated with lipopolysaccharide was investigated by 1) determining the activity of newly synthesized enzyme after inactivating the endogenous enzyme with aspirin; 2) comparing levels of newly synthesized enzyme proteins in cells treated with or without lipopolysaccharide; and 3) assessing the expression of the mRNAs encoding COX-1 and COX-2. Levels of enzyme proteins were assessed by Western blot analysis and immunoprecipitation of S-35 labeled enzyme using two different antibodies, one specific for COX-2 and the other recognizing both forms of the enzyme but preferentially recognizing COX-1. We report here that the enhanced cyclooxygenase activity induced by the bacterial lipopolysaccharide in rat alveolar macrophages is caused by selective expression of the COX-2. Expression of COX-2 in macrophages stimulated by lipopolysaccharide was completely inhibited by dexamethasone, whereas COX-1 was unaffected. In resting unstimulated macrophages, only COX-1 but not COX-2 was detected. Levels of mRNA for the COX-2 in macrophages were increased, but those of the COX-1 were not affected by lipopolysaccharide as assessed by reverse transcription coupled with polymerase chain reaction. These results indicate that increased synthesis of prostaglandins and thromboxanes in lipopolysaccharide-stimulated macrophages results from selective expression of COX-2.	LOUISIANA STATE UNIV,PENNINGTON BIOMED RES CTR,6400 PERKINS RD,BATON ROUGE,LA 70808; BRIGHAM YOUNG UNIV,DEPT CHEM,PROVO,UT 84602	Louisiana State University System; Louisiana State University; Pennington Biomedical Research Center; Brigham Young University	HWANG, D (corresponding author), LOUISIANA STATE UNIV,PENNINGTON BIOMED RES CTR,6400 PERKINS RD,BATON ROUGE,LA 70808, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041868] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK 41868] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		CHANDLER DB, 1987, J IMMUNOL, V139, P893; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; COOK JA, 1980, J CLIN INVEST, V65, P227, DOI 10.1172/JCI109655; DEWITT DL, 1988, P NATL ACAD SCI USA, V85, P1412, DOI 10.1073/pnas.85.5.1412; DEWITT DL, 1990, J BIOL CHEM, V265, P5192; FU JY, 1990, J BIOL CHEM, V265, P16737; HARLOW E, 1988, ANTIBODIES LABORATOR, P84; HEMLER ME, 1980, J BIOL CHEM, V255, P6253; JONES DA, 1990, J BIOL CHEM, V265, P20166; KESSLER E, 1973, J LAB CLIN MED, V81, P85; KUJUBU DA, 1991, J BIOL CHEM, V266, P12866; KUJUBU DA, 1992, J BIOL CHEM, V267, P7991; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAIER JAM, 1990, J BIOL CHEM, V265, P10805; MASFERRER JL, 1992, P NATL ACAD SCI USA, V89, P3917, DOI 10.1073/pnas.89.9.3917; MERLIE JP, 1988, J BIOL CHEM, V263, P3550; OBANION MK, 1991, J BIOL CHEM, V266, P23261; OSULLIVAN MG, 1992, J BIOL CHEM, V267, P14547; Pace-Asciak CR, 1983, ENZYMES LIPID ENZYMO, VXVI, P543; SCHUMER W, 1981, CIRC SHOCK, V8, P667; Simmons D.L., 1991, PROSTAGLANDINS LEUKO, P67; TSO JY, 1985, NUCLEIC ACIDS RES, V13, P2485, DOI 10.1093/nar/13.7.2485; WU KK, 1988, J BIOL CHEM, V263, P19043; XIE WL, 1991, P NATL ACAD SCI USA, V88, P2692, DOI 10.1073/pnas.88.7.2692; YOKOYAMA C, 1988, FEBS LETT, V231, P347, DOI 10.1016/0014-5793(88)80847-0; YOKOYAMA C, 1989, BIOCHEM BIOPH RES CO, V165, P888, DOI 10.1016/S0006-291X(89)80049-X	27	787	807	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1992	267	36					25934	25938						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KD073	1464605				2022-12-25	WOS:A1992KD07300053
J	JIANG, HX; COOPER, B; ROBEY, FA; GEWURZ, H				JIANG, HX; COOPER, B; ROBEY, FA; GEWURZ, H			DNA BINDS AND ACTIVATES COMPLEMENT VIA RESIDUES 14-26 OF THE HUMAN C1Q A-CHAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCES; 1ST COMPONENT; SUBCOMPONENT C1Q; REGIONS PRESENT; CLQ; COMPLEXES; ANTIBODY; LOCATION; PROTEINS; GAMMA	The mechanism by which DNA activates the classical complement pathway was investigated, with emphasis upon the C1q binding sites involved. DNA bound to both the collagen-like and globular regions of C1q. Binding reactivity with DNA was retained after reduction/alkylation and sodium dodecyl sulfate treatment of C1q. DNA bound preferentially to the A chain of C1q. Binding sites for DNA were localized by using synthetic C1q A chain peptides to two cationic regions within residues 14-26 and 76-92, respectively. Peptides 14-26 and 76-92 avidly bound DNA in enzyme-linked immunosorbent and gel shift assays. Peptide 14-26 also precipitated with DNA and blocked its ability to bind C1q and activate C. Replacement of the two prolines with alanines or scrambling the order of the amino acids resulted in loss of ability of peptide 14-26 to inhibit C1q binding and complement activation by DNA; similar investigations showed a sequence specificity for peptide 76-92 as well. These experiments identify C1q A chain residues 14-26 as the major site, and residues 76-92 as a secondary site, through which DNA binds C1q and activates the classical complement pathway, and demonstrate that a peptide identical to residues 14-26 can modulate C1q binding and complement activation by DNA.	NIDR,CELLULAR DEV & ONCOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	JIANG, HX (corresponding author), RUSH MED COLL,DEPT IMMUNOL MICROBIOL,CHICAGO,IL 60612, USA.		Gewurz, Henry/P-8678-2019					AGNELLO V, 1969, FED PROC, V28, P696; AGNELLO V, 1970, IMMUNOLOGY, V19, P909; ALMEDA S, 1983, J BIOL CHEM, V258, P785; AUBERT B, 1985, BIOCHEM J, V232, P513, DOI 10.1042/bj2320513; BRISTOW CL, 1986, MOL IMMUNOL, V23, P1045, DOI 10.1016/0161-5890(86)90003-9; CLAUS DR, 1977, J IMMUNOL, V118, P83; Cooper N R, 1973, Contemp Top Mol Immunol, V2, P155; COOPER NR, 1985, ADV IMMUNOL, V37, P151, DOI 10.1016/S0065-2776(08)60340-5; ENTWISTLE RA, 1988, BIOCHEMISTRY-US, V27, P507, DOI 10.1021/bi00401a073; GAITHER TA, 1974, J IMMUNOL, V113, P574; GILMOUR S, 1980, NATURE, V285, P512, DOI 10.1038/285512a0; HOEKZEMA R, 1988, MOL IMMUNOL, V25, P485, DOI 10.1016/0161-5890(88)90169-1; HUGHESJONES NC, 1979, MOL IMMUNOL, V16, P697, DOI 10.1016/0161-5890(79)90010-5; JIANG H, 1992, J EXP MED, V175, P1373, DOI 10.1084/jem.175.5.1373; JIANG H, 1991, Complement and Inflammation, V8, P169; JIANG HX, 1991, J IMMUNOL, V146, P2324; KILCHHERR E, 1986, J IMMUNOL, V137, P255; KILCHHERR E, 1987, J IMMUNOL, V138, P849; KILCHHERR E, 1985, BIOCHEM BIOPH RES CO, V128, P785; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Mayer M.M., 1961, EXPT IMMUNOCHEMISTRY, P133; MENZEL J, 1981, BIOCHIM BIOPHYS ACTA, V670, P265; NELSON RA, 1966, IMMUNOCHEMISTRY, V3, P111, DOI 10.1016/0019-2791(66)90292-8; PAQUES EP, 1979, H-S Z PHYSIOL CHEM, V360, P177, DOI 10.1515/bchm2.1979.360.1.177; PELTIER AP, 1978, IMMUNOLOGY, V35, P779; PORTER RR, 1978, NATURE, V275, P699, DOI 10.1038/275699a0; REID KBM, 1979, BIOCHEM J, V179, P367, DOI 10.1042/bj1790367; REID KBM, 1982, BIOCHEM J, V203, P559, DOI 10.1042/bj2030559; REID KBM, 1977, BIOCHEM J, V161, P239, DOI 10.1042/bj1610239; REID KBM, 1984, ACTA PATH MICRO IM C, V92, P11; REID KBM, 1976, BIOCHEM J, V155, P5, DOI 10.1042/bj1550005; ROSENBERG AM, 1988, J RHEUMATOL, V15, P1091; SCHUMAKER VN, 1981, J MOL BIOL, V148, P191, DOI 10.1016/0022-2836(81)90511-8; SELLAR GC, 1991, BIOCHEM J, V274, P481, DOI 10.1042/bj2740481; SIEGEL J, 1974, J EXP MED, V140, P631, DOI 10.1084/jem.140.3.631; SIEGEL RC, 1983, MOL IMMUNOL, V20, P53, DOI 10.1016/0161-5890(83)90105-0; TENNER AJ, 1981, J IMMUNOL, V127, P648; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; UWATOKO S, 1990, J IMMUNOL, V144, P3484; VANSCHRAVENDIJK MR, 1982, MOL IMMUNOL, V19, P1179, DOI 10.1016/0161-5890(82)90328-5; WANTIER JL, 1977, IMMUNOCHEMISTRY, V14, P763; ZICCARDI RJ, 1982, J IMMUNOL, V128, P2505	42	93	101	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1992	267	35					25597	25601						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KB603	1460055				2022-12-25	WOS:A1992KB60300102
J	FOMINAYA, JM; HOFSTEENGE, J				FOMINAYA, JM; HOFSTEENGE, J			INACTIVATION OF RIBONUCLEASE INHIBITOR BY THIOL-DISULFIDE EXCHANGE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN PLACENTAL RIBONUCLEASE; ANGIOGENIN; OXIDATION; PROTEINS; CLEAVAGE; BINDING	Porcine ribonuclease inhibitor (RI) contains 30 1/2-cystinyl residues, all of which occur in the reduced form. Reaction of the native protein with 5,5'-dithiobis(2-nitrobenzoic acid) resulted in the release of 30 mol of the product 5-mercapto-2-nitrobenzoate, and the loss of the RNase inhibitory activity. A linear relationship between the degree of modification and inactivation was observed. The rate of modification was greatly increased in the presence of 6 M guanidinium HCl. Reaction with substoichiometric amounts of 5,5'-dithiobis(2-nitrobenzoic acid) was found to yield a mixture of fully reduced active molecules, and fully oxidized inactive ones, but no partially oxidized forms were detected. This suggests that an "all-or-none" type of modification and inactivation took place. All 1/2-cystinyl residues in the inactive, monomeric inhibitor had formed disulfide bridges, judged by the absence of either free thiol groups or mixed disulfides with 5-mercapto-2-nitrobenzoate. This fully disulfide-cross-linked molecule had an open conformation compared to the native one, as shown by gel filtration and limited proteolysis. Reaction of phenylarsinoxide with vicinal dithiols yields products that are much more stable than those with monothiols. Titration of RI with this reagent yielded complete inactivation at a reagent/thiol ratio of 0.5. Taken together, these observations suggest that the thiol groups in RI have a diminished reactivity due to three-dimensional constraints. After the initial modification of a small number of thiol groups, a conformational change occurs which causes an increase in reactivity of the remaining thiols. The thiol groups are situated close enough together to permit the formation of 15 disulfide bridges in the inactive molecule.	FRIEDRICH MIESCHER INST, POB 2543, CH-4002 BASEL, SWITZERLAND	Friedrich Miescher Institute for Biomedical Research								BATES DJ, 1985, NEUROCHEM RES, V10, P713, DOI 10.1007/BF00964409; BISHAY ES, 1973, ARCH BIOCHEM BIOPHYS, V158, P185, DOI 10.1016/0003-9861(73)90612-7; Blackburn P, 1982, ENZYMES, VXV, P317; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURTON LE, 1982, INT J PEPT PROT RES, V19, P372; CAVALLI L, 1979, OPHTHALMIC RES, V11, P416, DOI 10.1159/000265044; FOMINAYA JM, 1988, BIOCHIM BIOPHYS ACTA, V954, P216, DOI 10.1016/0167-4838(88)90074-X; FRIEDMAN M, 1975, CHEM BIOCH SULFHYDRY, P311; GILBERT HF, 1990, ADV ENZYMOL RAMB, V63, P69; GIRIJA NS, 1966, BIOCHEM J, V98, P562, DOI 10.1042/bj0980562; GREGORET LM, 1991, PROTEINS, V9, P99, DOI 10.1002/prot.340090204; HENTZE MW, 1989, SCIENCE, V244, P357, DOI 10.1126/science.2711187; HOFSTEENGE J, 1988, BIOCHEMISTRY-US, V27, P8537, DOI 10.1021/bi00423a006; JOCELYN PC, 1987, METHOD ENZYMOL, V143, P44; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE FS, 1988, BIOCHEMISTRY-US, V27, P8545, DOI 10.1021/bi00423a007; LEE FS, 1989, BIOCHEMISTRY-US, V28, P219, DOI 10.1021/bi00427a030; MIRABELLI F, 1988, ARCH BIOCHEM BIOPHYS, V264, P261, DOI 10.1016/0003-9861(88)90593-0; ROTH JS, 1956, BIOCHIM BIOPHYS ACTA, V21, P34, DOI 10.1016/0006-3002(56)90091-9; SCHNEIDER R, 1988, EMBO J, V7, P4151, DOI 10.1002/j.1460-2075.1988.tb03310.x; SHAPIRO R, 1991, BIOCHEMISTRY-US, V30, P2246, DOI 10.1021/bi00222a030; SHORTMAN K, 1962, BIOCHIM BIOPHYS ACTA, V55, P88; SPECTOR A, 1978, P NATL ACAD SCI USA, V75, P3244, DOI 10.1073/pnas.75.7.3244; SRIVASTAVA SK, 1973, EXP EYE RES, V17, P33, DOI 10.1016/0014-4835(73)90165-6; Torchinskii Y. M., 1974, SULFHYDRYL DISULFIDE, P7; TORCHINSKII YM, 1974, SULFHYDRYL DISULFIDE, P125; VICENTINI AM, 1990, BIOCHEMISTRY-US, V29, P8827, DOI 10.1021/bi00489a046; WOLFF SP, 1986, TRENDS BIOCHEM SCI, V11, P27, DOI 10.1016/0968-0004(86)90228-8	28	37	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 5	1992	267	34					24655	24660						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KA263	1447207				2022-12-25	WOS:A1992KA26300076
J	PREVIATO, JO; MENDONCAPREVIATO, L; JONES, C; WAIT, R; FOURNET, B				PREVIATO, JO; MENDONCAPREVIATO, L; JONES, C; WAIT, R; FOURNET, B			STRUCTURAL CHARACTERIZATION OF A NOVEL CLASS OF GLYCOPHOSPHOSPHINGOLIPIDS FROM THE PROTOZOAN LEPTOMONAS-SAMUELI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEISHMANIA-DONOVANI LIPOPHOSPHOGLYCAN; PHOSPHATIDYLINOSITOL MEMBRANE ANCHOR; NUCLEAR MAGNETIC-RESONANCE; GLYCOSYLATED-PHOSPHATIDYLINOSITOLS; KINETOPLASTID PARASITES; EVOLUTIONARY ASPECTS; GPI METABOLISM; C-13; MONOSACCHARIDES; SPHINGOLIPIDS	Aqueous phenol extraction of the lower trypanosomatid Leptomonas samueli released into the aqueous layer a chloroform/methanol/water-soluble glycophosphosphingolipid fraction. Alkaline degradation and purification by gel filtration chromatography resulted in a tetrasaccharide (phosphatidylinositol (PI)-oligosaccharide A), and a pentasaccharide (PI-oligosaccharide B), each containing 2 mol of 2-aminoethylphosphonate and 1 mol of phosphate. Nuclear magnetic resonance spectroscopy and fast atom bombardment-mass spectrometry suggested that the structure of PI-oligosaccharide A is [GRAPHICS] and that of PI-oligosaccharide B is as shown. [GRAPHICS] Both compounds contain an inositol unit linked to ceramide via a phosphodiester bridge. The major aliphatic components of the ceramide portion are stearic acid, lignoceric acid, and C20-phytosphingosine. These novel glycolipids fall within the glycosylated phosphatidylinositol (GPI) family, since they contain the core structure Manalpha(1-->4)GlcNH2alpha(1-->6)myo-inositol-1-PO4, which is also found in the glycoinositolphospholipids and lipophosphoglycan of Leishmania spp., the L. major promastigote surface protease, the glycosylphosphatidylinositol anchor of Trypanosoma brucei variant surface glycoprotein, and the lipopeptidophosphoglycan of Trypanosoma cruzi. The glycophosphosphingolipids of Leptomonas have features in common with the glycolipids of both Leishmania and T. cruzi, resembling the former by the alpha(1-->3) linkage of mannose to the GPI core, while the 2-aminoethylphosphonate substituent on O-6 of glucosamine and the presence of ceramide in place of glycerol lipids is more reminiscent of T. cruzi. Thus these data lend some support to the hypothesis that both T. cruzi and Leishmania evolved from a Leptomonas-like ancestor.	NATL INST BIOL STAND & CONTROLS,MOLEC STRUCT LAB,POTTERS BAR EN6 3QG,HERTS,ENGLAND; PUBL HLTH LAB SERV,CTR APPL MICROBIOL & RES,DIV PATHOL,SALISBURY SP4 0JG,WILTS,ENGLAND; UNIV LILLE 1,CHIM BIOL LAB,F-59655 VILLENEUVE DASCQ,FRANCE	National Institute for Biological Standards & Control; Universite de Lille - ISITE; Universite de Lille	PREVIATO, JO (corresponding author), UNIV FED RIO DE JANEIRO,INST MICROBIOL,DEPT MICROBIOL GERAL,RIO JANEIRO,BRAZIL.		Jones, Chris/AAF-4063-2021	Jones, Chris/0000-0001-7109-492X; Mendonca Previato, Lucia/0000-0003-3927-3244; Previato, Jose Osvaldo/0000-0002-9233-9954				Ames B. N., 1966, METHOD ENZYMOL, P115, DOI DOI 10.1016/0076-6879(66)08014-5; ARAKI S, 1987, J BIOL CHEM, V262, P14141; AUE WP, 1976, J CHEM PHYS, V64, P2229, DOI 10.1063/1.432450; BAKER JR, 1963, EXP PARASITOL, V13, P219, DOI 10.1016/0014-4894(63)90074-2; BARTLETT GR, 1959, J BIOL CHEM, V234, P466; BAX A, 1981, J MAGN RESON, V42, P501, DOI 10.1016/0022-2364(81)90272-9; BOCK K, 1983, ADV CARBOHYD CHEM BI, V41, P27, DOI 10.1016/S0065-2318(08)60055-4; CARTER HE, 1967, BIOCHEM BIOPH RES CO, V29, P886, DOI 10.1016/0006-291X(67)90304-X; DAVIES CR, 1990, PARASITOLOGY, V101, P337, DOI 10.1017/S0031182000060522; DOMON B, 1988, GLYCOCONJUGATE J, V5, P397, DOI 10.1007/BF01049915; DUBOIS M, 1956, ANAL CHEM, V28, P350, DOI 10.1021/ac60111a017; FERGUSON MAJ, 1991, CELL BIOL INT REP, V15, P991, DOI 10.1016/0309-1651(91)90052-K; FERGUSON MAJ, 1988, SCIENCE, V239, P753, DOI 10.1126/science.3340856; FERGUSON MAJ, 1988, ANNU REV BIOCHEM, V57, P285; FERGUSON MAJ, 1991, SCIENCE, V15, P991; GAVER RC, 1966, J AM CHEM SOC, V88, P3643, DOI 10.1021/ja00967a032; GERWIG GJ, 1978, CARBOHYD RES, V62, P349, DOI 10.1016/S0008-6215(00)80881-2; HOMANS SW, 1988, NATURE, V333, P269, DOI 10.1038/333269a0; HORIGUCHI M, 1984, BIOCH NATURAL C P CO, P8; LAINE RA, 1987, METHOD ENZYMOL, V138, P186; LAUTER CJ, 1962, J LIPID RES, V3, P136; LEDERKREMER RM, 1990, EUR J BIOCHEM, V192, P337; LEDERKREMER RM, 1991, J BIOL CHEM, V266, P23670; LOW MG, 1989, BIOCHIM BIOPHYS ACTA, V988, P427, DOI 10.1016/0304-4157(89)90014-2; MCCONVILLE MJ, 1987, P NATL ACAD SCI USA, V84, P8941, DOI 10.1073/pnas.84.24.8941; MCCONVILLE MJ, 1990, J BIOL CHEM, V265, P7385; MCCONVILLE MJ, 1991, J BIOL CHEM, V266, P15170; MCCONVILLE MJ, 1991, CELL BIOL INT REP, V15, P779, DOI 10.1016/0309-1651(91)90033-F; MCCONVILLE MJ, 1989, J BIOL CHEM, V264, P757; MCOCONVILLE MJ, 1990, J BIOL CHEM, V265, P19611; OCONNOR JV, 1979, BIOCHEMISTRY-US, V18, P500, DOI 10.1021/bi00570a020; ORLANDI PA, 1987, J BIOL CHEM, V262, P10384; PALATNIK CB, 1987, COMP BIOCHEM PHYS B, V86, P593, DOI 10.1016/0305-0491(87)90454-8; PREVIATO JO, 1990, J BIOL CHEM, V265, P2518; PUENTES SM, 1990, J IMMUNOL, V145, P4311; RITCHIE RGS, 1975, CAN J CHEM, V53, P1424, DOI 10.1139/v75-197; SCHNEIDER P, 1990, J BIOL CHEM, V265, P16955; SMITH SW, 1974, J BIOL CHEM, V249, P3395; SWEELEY CC, 1963, J AM CHEM SOC, V85, P2497, DOI 10.1021/ja00899a032; THOMAS JR, 1990, BIOCHEMISTRY-US, V29, P5413, DOI 10.1021/bi00475a001; THORPE SR, 1967, BIOCHEMISTRY-US, V6, P887, DOI 10.1021/bi00855a033; TURCO SJ, 1987, BIOCHEMISTRY-US, V26, P6233, DOI 10.1021/bi00393a042; TURCO SJ, 1989, J BIOL CHEM, V264, P6711; WALLACE FG, 1966, EXP PARASITOL, V18, P124, DOI 10.1016/0014-4894(66)90015-4; WALLACE FG, 1979, BIOL KINETOPLASTIDA, V2, P213	45	43	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1992	267	34					24279	24286						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KA263	1447177				2022-12-25	WOS:A1992KA26300024
J	BUTLER, JD; BLANCHETTEMACKIE, J; GOLDIN, E; ONEILL, RR; CARSTEA, G; ROFF, CF; PATTERSON, MC; PATEL, S; COMLY, ME; COONEY, A; VANIER, MT; BRADY, RO; PENTCHEV, PG				BUTLER, JD; BLANCHETTEMACKIE, J; GOLDIN, E; ONEILL, RR; CARSTEA, G; ROFF, CF; PATTERSON, MC; PATEL, S; COMLY, ME; COONEY, A; VANIER, MT; BRADY, RO; PENTCHEV, PG			PROGESTERONE BLOCKS CHOLESTEROL TRANSLOCATION FROM LYSOSOMES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY LIPOPROTEIN; NIEMANN-PICK DISEASE; ACYL-COENZYME-A; MACROPHAGE FOAM CELLS; HAMSTER OVARY CELLS; INTRACELLULAR-TRANSPORT; PLASMA-MEMBRANE; ENDOPLASMIC-RETICULUM; CULTURED FIBROBLASTS; REDUCTASE-ACTIVITY	Fluorescent microscopic examination of fibroblasts cultured with low density lipoprotein (LDL) and progesterone (10 mug/ml) for 24 h revealed extensive filipin-cholesterol staining of perinuclear lysosomes. Levels of unesterified cholesterol were 2-fold greater than in fibroblasts cultured with LDL alone. Progesterone strongly blocked cholesteryl ester synthesis. When cellular uptake of LDL was monitored in the presence of 58035, a specific inhibitor of acyl-CoA:cholesterol acyltransferase, excess unesterified cholesterol was not stored in lysosomes. Discontinuation of LDL uptake in conjunction with progesterone washout markedly reversed the filipin-cholesterol staining of lysosomes. Reversal of the lysosomal cholesterol lipidosis was associated with a rapid burst of cholesteryl ester synthesis and a normalization of the cellular levels of free and esterified cholesterol. In contrast to normal cells, progesterone removal from Niemann-Pick C fibroblasts did not reverse the lysosomal cholesterol accumulation of these mutant cultures. The metabolic precursor of progesterone, pregnenolone, also induced extensive accumulation of cholesterol in lysosomes. Other steroids induced less vacuolar cholesterol accumulation in the following decreasing order: corticosterone and testosterone, promegestone, RU 486. The relative inhibition of cellular cholesterol esterification by the steroids paralleled their respective abilities to sequester cholesterol in lysosomes rather than their inhibition of acyl-CoA:cholesterol acyltransferase activity in cell-free extracts. The progesterone-related inhibition and restoration of lysosomal cholesterol trafficking is a useful experimental means of studying intracellular cholesterol transport. A particularly important feature of its utility is the facile reversibility of the steroid-induced block. The lysosomal cholesterol lipidosis established with a hydrophobic amine, U18666A, was not as readily reversed.	NINCDS,DEV & METAB NEUROL BRANCH,BETHESDA,MD 20892; NICHHD,HUMAN GENET BRANCH,BETHESDA,MD 20892; NIDDKD,CELLULAR & DEV BIOL LAB,BETHESDA,MD 20892; VET ADM MED CTR,NEUROL SERV,NEWINGTON,CT 06111; FAC MED LYON SUD,BIOCHIM LAB,INSERM,U189,F-69921 OULLINS,FRANCE	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Connecticut Healthcare System; Institut National de la Sante et de la Recherche Medicale (Inserm)			Patterson, Marc/AAI-5056-2020; Patterson, Marc C./H-5331-2019	Patterson, Marc/0000-0002-1116-126X				AKERSTROM B, 1990, TRENDS BIOCHEM SCI, V15, P240, DOI 10.1016/0968-0004(90)90037-C; BALBIN M, 1990, BIOCHEM J, V271, P803, DOI 10.1042/bj2710803; BILLHEIMER JT, 1990, SUBCELLULAR BIOCH, P301; BLACKMORE PF, 1990, J BIOL CHEM, V265, P1376; BLANCHETTEMACKIE EJ, 1988, P NATL ACAD SCI USA, V85, P8022, DOI 10.1073/pnas.85.21.8022; BRASAEMLE DL, 1990, J LIPID RES, V31, P103; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; BROWN MS, 1980, J BIOL CHEM, V255, P9344; BYERS DM, 1992, BIOCHIM BIOPHYS ACTA, V1138, P20, DOI 10.1016/0925-4439(92)90146-E; DEGRELLA RF, 1982, J BIOL CHEM, V257, P4256; DILORENZO D, 1991, CANCER RES, V51, P4470; DRANGOVA R, 1980, J STEROID BIOCHEM, V13, P629, DOI 10.1016/0022-4731(80)90029-1; DUVAL D, 1983, BIOCHIM BIOPHYS ACTA, V737, P409, DOI 10.1016/0304-4157(83)90008-4; FLINT APF, 1973, BIOCHEM J, V132, P313, DOI 10.1042/bj1320313; GAL D, 1981, J CLIN ENDOCR METAB, V53, P29, DOI 10.1210/jcem-53-1-29; GAMBLE W, 1978, J LIPID RES, V19, P1068; GODOVAC-ZIMMERMANN J, 1988, TRENDS BIOCHEM SCI, V13, P64, DOI 10.1016/0968-0004(88)90031-X; GOLDSTEIN JL, 1978, P NATL ACAD SCI USA, V75, P1877, DOI 10.1073/pnas.75.4.1877; JOHNSON WJ, 1990, J BIOL CHEM, V265, P5546; JOHNSON WJ, 1991, BIOCHIM BIOPHYS ACTA, V1085, P273, DOI 10.1016/0005-2760(91)90132-2; KALIMI M, 1987, RECEPTOR MEDIATED AN, P121; KAPLAN MR, 1985, J CELL BIOL, V101, P446, DOI 10.1083/jcb.101.2.446; KODAVANTI UP, 1990, PHARMACOL REV, V42, P327; KRUTH HS, 1986, J BIOL CHEM, V261, P6769; KUTE T, 1976, BIOCHIM BIOPHYS ACTA, V420, P195, DOI 10.1016/0005-2795(76)90358-5; LAN NC, 1990, EUR J PHARM-MOLEC PH, V188, P403, DOI 10.1016/0922-4106(90)90201-8; LANGE Y, 1983, J BIOL CHEM, V258, P5130; LISCUM L, 1989, J CELL BIOL, V108, P1625, DOI 10.1083/jcb.108.5.1625; LISCUM L, 1990, BIOCHIM BIOPHYS ACTA, V1045, P40, DOI 10.1016/0005-2760(90)90201-8; LISCUM L, 1989, J BIOL CHEM, V264, P11796; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAHFOUDI A, 1991, MOL CELL ENDOCRINOL, V79, pR15, DOI 10.1016/0303-7207(91)90112-6; MARTYR R J, 1973, Biochemistry, V12, P2172, DOI 10.1021/bi00735a025; MCGOOKEY DJ, 1983, J CELL BIOL, V97, P1156, DOI 10.1083/jcb.97.4.1156; MIDDLETON B, 1987, BIOCHEM BIOPH RES CO, V145, P350, DOI 10.1016/0006-291X(87)91328-3; MOREAU M, 1980, DEV BIOL, V78, P201, DOI 10.1016/0012-1606(80)90329-2; NAGY L, 1990, ENDOCRINOLOGY, V126, P2267, DOI 10.1210/endo-126-5-2267; PANINI SR, 1987, J BIOL CHEM, V262, P14435; PENTCHEV PG, 1986, J BIOL CHEM, V261, P6775; PENTCHEV PG, 1986, J BIOL CHEM, V261, P2772; PENTCHEV PG, 1987, FASEB J, V1, P40, DOI 10.1096/fasebj.1.1.3609608; QIAN XD, 1990, J BIOL CHEM, V265, P18753; REINHART MP, 1990, EXPERIENTIA, V46, P599, DOI 10.1007/BF01939699; RODRIGUEZLAFRASSE C, 1990, BIOCHIM BIOPHYS ACTA, V1043, P123, DOI 10.1016/0005-2760(90)90284-5; ROFF CF, 1991, DEV NEUROSCI-BASEL, V13, P315, DOI 10.1159/000112179; ROSS AC, 1984, J BIOL CHEM, V259, P815; SEXTON R, 1986, J LIPID RES, V27, P567; SIMPSON ER, 1980, ARCH BIOCHEM BIOPHYS, V200, P79, DOI 10.1016/0003-9861(80)90333-1; SLOTTE JP, 1989, BIOCHIM BIOPHYS ACTA, V1005, P303, DOI 10.1016/0005-2760(89)90053-2; SLOTTE JP, 1987, BIOCHEM J, V248, P237, DOI 10.1042/bj2480237; SOKOL J, 1988, J BIOL CHEM, V263, P3411; TABAS I, 1988, J BIOL CHEM, V263, P1266; URBANI L, 1990, J BIOL CHEM, V265, P1919; WALTERS MR, 1979, ENDOCRINOLOGY, V105, P382, DOI 10.1210/endo-105-2-382; WASSERMAN WJ, 1980, P NATL ACAD SCI-BIOL, V77, P1534, DOI 10.1073/pnas.77.3.1534; WESTPHAL U, 1966, H-S Z PHYSIOL CHEM, V346, P243, DOI 10.1515/bchm2.1966.346.1-2.243; WILKIN DJ, 1992, J BIOL CHEM, V267, P2831; XU XX, 1991, J BIOL CHEM, V266, P17040	58	152	152	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1992	267	33					23797	23805						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JZ239	1429719				2022-12-25	WOS:A1992JZ23900057
J	BECKER, D; LEE, PL; RODECK, U; HERLYN, M				BECKER, D; LEE, PL; RODECK, U; HERLYN, M			INHIBITION OF THE FIBROBLAST GROWTH-FACTOR RECEPTOR 1 (FGFR-1) GENE IN HUMAN MELANOCYTES AND MALIGNANT MELANOMAS LEADS TO INHIBITION OF PROLIFERATION AND SIGNS INDICATIVE OF DIFFERENTIATION	ONCOGENE			English	Article							PROTEIN-TYROSINE KINASE; TUMOR-NECROSIS-FACTOR; STRUCTURAL ARRANGEMENT UNDERLIES; 3RD IMMUNOGLOBULIN DOMAIN; MOLECULAR-CLONING; ANTISENSE OLIGODEOXYNUCLEOTIDES; NUCLEOTIDE-SEQUENCE; MESSENGER-RNA; CELL-SURFACE; EXPRESSION	Fibroblast growth factor receptor (FGFR-1) is expressed as a single 3.5-kb mRNA transcript in normal human melanocytes and in malignant melanomas as determined upon Northern hybridization to a cDNA clone encoding the membrane-spanning form of the human FGFR-1. Polyclonal antisera directed against the chicken FGFR recognized a 145-kDa protein in primary and metastatic melanomas. Antisense oligodeoxynucleotides targeted against the translation start site and a splice donor-acceptor site of human FGFR-1, in addition to inhibiting the proliferation of normal human melanocytes and malignant melanomas, caused extensive dendrite formation and severe disruption of cell-cell contact - morphological changes that were not observed upon inhibition of the genes encoding basic fibroblast, growth factor (bFGF) and retinoic acid-alpha receptor. Thus, unlike in the case of the ligand bFGF, expression of the FGFR-1 may represent a requisite to prevent human melanocytes and malignant melanomas from undergoing (terminal) differentiation.	SCRIPPS CLIN & RES FDN,DIV BIOCHEM,LA JOLLA,CA 92037; WISTAR INST,PHILADELPHIA,PA 19104	Scripps Research Institute; The Wistar Institute	BECKER, D (corresponding author), UNIV PITTSBURGH,PITTSBURGH CANC INST,DEPT MED,BIOMED SCI TOWER,E1057,PITTSBURGH,PA 15261, USA.							ABRAHAM JA, 1986, EMBO J, V5, P2523, DOI 10.1002/j.1460-2075.1986.tb04530.x; BECKER D, 1984, MOL CELL BIOL, V4, P2247, DOI 10.1128/MCB.4.11.2247; BECKER D, 1989, GENOMICS, V4, P97, DOI 10.1016/0888-7543(89)90320-0; BECKER D, 1990, ONCOGENE, V5, P1133; BECKER D, 1989, EMBO J, V8, P3685, DOI 10.1002/j.1460-2075.1989.tb08543.x; BLAM SB, 1988, ONCOGENE, V3, P129; CATHALA G, 1983, DNA-J MOLEC CELL BIO, V2, P329, DOI 10.1089/dna.1983.2.329; COUSSENS L, 1986, NATURE, V320, P277, DOI 10.1038/320277a0; DIONNE CA, 1990, EMBO J, V9, P2685, DOI 10.1002/j.1460-2075.1990.tb07454.x; EISINGER M, 1982, P NATL ACAD SCI-BIOL, V79, P2018, DOI 10.1073/pnas.79.6.2018; FEIGE JJ, 1988, J BIOL CHEM, V263, P14023; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GIALLONGO A, 1986, P NATL ACAD SCI USA, V83, P6741, DOI 10.1073/pnas.83.18.6741; GIGUERE V, 1987, NATURE, V330, P624, DOI 10.1038/330624a0; HALABAN R, 1986, J INVEST DERMATOL, V87, P95, DOI 10.1111/1523-1747.ep12523594; HALABAN R, 1988, J CELL BIOL, V107, P1611, DOI 10.1083/jcb.107.4.1611; HALABAN R, 1987, IN VITRO CELL DEV B, V23, P47; HALABAN R, 1988, ONCOGENE RES, V3, P177; HATTORI Y, 1990, P NATL ACAD SCI USA, V87, P5983, DOI 10.1073/pnas.87.15.5983; HERLYN M, 1988, EXP CELL RES, V179, P322, DOI 10.1016/0014-4827(88)90271-6; HERLYN M, 1987, LAB INVEST, V56, P461; HOLT JT, 1988, MOL CELL BIOL, V8, P963, DOI 10.1128/MCB.8.2.963; HOU JZ, 1991, SCIENCE, V251, P665, DOI 10.1126/science.1846977; HOUSSAINT E, 1990, P NATL ACAD SCI USA, V87, P8180, DOI 10.1073/pnas.87.20.8180; JOHNSON DE, 1990, MOL CELL BIOL, V10, P4728, DOI 10.1128/MCB.10.9.4728; JOHNSON DE, 1991, MOL CELL BIOL, V11, P4627, DOI 10.1128/MCB.11.9.4627; KEEGAN K, 1991, P NATL ACAD SCI USA, V88, P1095, DOI 10.1073/pnas.88.4.1095; KOIKE S, 1990, EMBO J, V9, P3247; KORNBLUTH S, 1988, MOL CELL BIOL, V8, P5541, DOI 10.1128/MCB.8.12.5541; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE PL, 1989, SCIENCE, V245, P57, DOI 10.1126/science.2544996; LOETSCHER H, 1990, CELL, V61, P351, DOI 10.1016/0092-8674(90)90815-V; MANSUKHANI A, 1990, P NATL ACAD SCI USA, V87, P4378, DOI 10.1073/pnas.87.11.4378; MATSUI T, 1989, SCIENCE, V243, P800, DOI 10.1126/science.2536956; MOSLEY B, 1989, CELL, V59, P335, DOI 10.1016/0092-8674(89)90295-X; NOPHAR Y, 1990, EMBO J, V9, P3269, DOI 10.1002/j.1460-2075.1990.tb07526.x; PARTANEN J, 1991, EMBO J, V10, P1347, DOI 10.1002/j.1460-2075.1991.tb07654.x; PASQUALE EB, 1990, P NATL ACAD SCI USA, V87, P5812, DOI 10.1073/pnas.87.15.5812; PASQUALE EB, 1989, P NATL ACAD SCI USA, V86, P5449, DOI 10.1073/pnas.86.14.5449; REID HH, 1990, P NATL ACAD SCI USA, V87, P1596, DOI 10.1073/pnas.87.4.1596; RODECK U, 1991, J INVEST DERMATOL, V97, P20, DOI 10.1111/1523-1747.ep12477822; RODECK U, 1987, INT J CANCER, V40, P687, DOI 10.1002/ijc.2910400520; RUTA M, 1989, P NATL ACAD SCI USA, V86, P8722, DOI 10.1073/pnas.86.22.8722; RUTA M, 1988, ONCOGENE, V3, P9; SAFRAN A, 1990, ONCOGENE, V5, P635; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; SZCZYLIK C, 1991, SCIENCE, V253, P562, DOI 10.1126/science.1857987; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WRNER S, 1992, MOL CELL BIOL, V12, P82; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W	52	94	98	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1992	7	11					2303	2313						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JW665	1437152				2022-12-25	WOS:A1992JW66500024
J	GARCIARAMIREZ, M; DONG, F; AUSIO, J				GARCIARAMIREZ, M; DONG, F; AUSIO, J			ROLE OF THE HISTONE TAILS IN THE FOLDING OF OLIGONUCLEOSOMES DEPLETED OF HISTONE-H1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOSOME CORE PARTICLE; HIGHER-ORDER STRUCTURE; IONIC-STRENGTH; FLUORESCENCE ANISOTROPY; DNA TOPOLOGY; CHROMATIN; HYPERACETYLATION; INVITRO; RNA; RECONSTITUTION	An oligonucleosome 12-mer was reconstituted in the absence of linker histones, onto a DNA template consisting of 12 tandemly arranged 208-base pair fragments of the 5 S rRNA gene from the sea urchin Lytechinus variegatus (Simpson, R. T., Thoma, F. S., and Burbaker, J. M. (1985) Cell 42, 799-808). The ionic strength-dependent folding of this nucleohistone complex was compared with that of a native oligonucleosome fraction obtained from chicken erythrocyte chromatin, which had been carefully stripped of linker histones and fractionated in sucrose gradients. The DNA of this native fraction exhibited a narrow size distribution centered around the length of the 208-12 DNA template used in the reconstituted complex. These two complexes displayed very similar hydrodynamic behavior as judged by sedimentation velocity analysis. By combining these data with electron microscopy analysis, it was shown that the salt-dependent folding of oligonucleosomes in the absence of linker histones involves the bending of the linker DNA region connecting adjacent nucleosomes. It was also found that selective removal by trypsin of the N-terminal regions ("tails") of the core histones prevents the oligonucleosome chains from folding. Thus, in the absence of these histone domains, the bending of the linker DNA necessary to bring the nucleosomes in contact is completely abolished. In addition to the complete lack of folding, removal of the histone tails results in an unwinding at low salt of a 20-base pair region at each flanking side of the nucleosome core particle. The possible functional relevance of these results is discussed.	UNIV VICTORIA,DEPT BIOCHEM & MICROBIOL,VICTORIA V8W 3P6,BC,CANADA; UNIV POLITECN CATALUNYA,DEPT ENGN QUIM,E-08028 BARCELONA,SPAIN; OREGON STATE UNIV,DEPT BIOCHEM & BIOPHYS,CORVALLIS,OR 97331	University of Victoria; Universitat Politecnica de Catalunya; Oregon State University				Garcia-Ramirez, Marta/0000-0003-4249-7177				ALLAN J, 1982, J CELL BIOL, V93, P285, DOI 10.1083/jcb.93.2.285; ARENTS G, 1991, P NATL ACAD SCI USA, V88, P10148, DOI 10.1073/pnas.88.22.10148; AUSIO J, 1989, J MOL BIOL, V206, P451, DOI 10.1016/0022-2836(89)90493-2; AUSIO J, 1984, J MOL BIOL, V176, P77, DOI 10.1016/0022-2836(84)90383-8; AUSIO J, 1984, J MOL BIOL, V177, P373, DOI 10.1016/0022-2836(84)90291-2; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; BLOOMFIE.V, 1967, BIOPOLYMERS, V5, P135, DOI 10.1002/bip.1967.360050202; BOROCHOV N, 1984, NUCLEIC ACIDS RES, V12, P3089, DOI 10.1093/nar/12.7.3089; BROWN DW, 1991, BIOCHEMISTRY-US, V30, P5293, DOI 10.1021/bi00235a024; BUTLER PJG, 1980, J MOL BIOL, V140, P505, DOI 10.1016/0022-2836(80)90268-5; BUTTINELLI M, 1991, NUCLEIC ACIDS RES, V19, P4543, DOI 10.1093/nar/19.16.4543; CARY PD, 1978, EUR J BIOCHEM, V89, P475, DOI 10.1111/j.1432-1033.1978.tb12551.x; CHAMBERS SAM, 1984, J BIOL CHEM, V259, P3458; CHRISTENSEN ME, 1982, DEV BIOL, V93, P404, DOI 10.1016/0012-1606(82)90127-0; DAVIE JR, 1978, P NATL ACAD SCI USA, V75, P3574, DOI 10.1073/pnas.75.8.3574; DONG F, 1991, P NATL ACAD SCI USA, V88, P10596, DOI 10.1073/pnas.88.23.10596; DONG F, 1990, P NATL ACAD SCI USA, V87, P5724, DOI 10.1073/pnas.87.15.5724; DONG F, 1990, BIOCHEMISTRY-US, V29, P10710, DOI 10.1021/bi00499a020; GALE JM, 1988, BIOCHEMISTRY-US, V27, P7197, DOI 10.1021/bi00419a006; GONZALEZ PJ, 1989, J BIOL CHEM, V264, P18457; GRAZIANO V, 1988, J MOL BIOL, V203, P997, DOI 10.1016/0022-2836(88)90124-6; HANSEN JC, 1992, TRENDS BIOCHEM SCI, V17, P187, DOI 10.1016/0968-0004(92)90264-A; HANSEN JC, 1989, BIOCHEMISTRY-US, V28, P9129, DOI 10.1021/bi00449a026; HAYES JJ, 1991, P NATL ACAD SCI USA, V88, P6829, DOI 10.1073/pnas.88.15.6829; ILYIN YV, 1971, EUR J BIOCHEM, V22, P235, DOI 10.1111/j.1432-1033.1971.tb01537.x; KAYNE PS, 1988, CELL, V55, P27, DOI 10.1016/0092-8674(88)90006-2; KIRKWOOD JG, 1954, J POLYM SCI, V12, P1, DOI 10.1002/pol.1954.120120102; LABHART P, 1981, EUR J CELL BIOL, V24, P309; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIBERTINI LJ, 1982, BIOCHEMISTRY-US, V21, P3327, DOI 10.1021/bi00257a013; LIBERTINI LJ, 1988, BIOPHYS J, V53, P477, DOI 10.1016/S0006-3495(88)83126-6; LIBERTINI LJ, 1980, NUCLEIC ACIDS RES, V8, P3517, DOI 10.1093/nar/8.16.3517; Maniatis T., 1982, MOL CLONING; MEERSSEMAN G, 1991, J MOL BIOL, V220, P89, DOI 10.1016/0022-2836(91)90383-H; MEGEE PC, 1990, SCIENCE, V247, P841, DOI 10.1126/science.2106160; NORTON VG, 1989, CELL, V57, P449, DOI 10.1016/0092-8674(89)90920-3; POGO BGT, 1966, P NATL ACAD SCI USA, V55, P805, DOI 10.1073/pnas.55.4.805; RIEHM MR, 1989, BIOCHEMISTRY-US, V28, P5787, DOI 10.1021/bi00440a013; SCHUSTER T, 1986, CELL, V45, P445, DOI 10.1016/0092-8674(86)90330-2; SIMPSON RT, 1985, CELL, V42, P799, DOI 10.1016/0092-8674(85)90276-4; SIMPSON RT, 1983, P NATL ACAD SCI-BIOL, V80, P51, DOI 10.1073/pnas.80.1.51; SMITH S, 1991, EMBO J, V10, P971, DOI 10.1002/j.1460-2075.1991.tb08031.x; TATCHELL K, 1977, BIOCHEMISTRY-US, V16, P5295, DOI 10.1021/bi00643a021; THOMSEN B, 1991, EUR J BIOCHEM, V201, P107, DOI 10.1111/j.1432-1033.1991.tb16262.x; VANHOLDE KE, 1978, BIOPOLYMERS, V17, P1387, DOI 10.1002/bip.1978.360170602; VANHOLDE KE, 1975, PROTEINS, P225; WHITLOCK JP, 1978, J BIOL CHEM, V253, P3857; YAGER TD, 1984, J BIOL CHEM, V259, P4212; YAO J, 1991, BIOCHEMISTRY-US, V30, P8408, DOI 10.1021/bi00098a019; YAO J, 1990, P NATL ACAD SCI USA, V87, P7603, DOI 10.1073/pnas.87.19.7603	50	198	210	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1992	267	27					19587	19595						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JP593	1527076				2022-12-25	WOS:A1992JP59300085
J	HOROWITZ, PM; XU, RF				HOROWITZ, PM; XU, RF			ACID PH-INDUCED CONFORMATIONAL-CHANGES IN BOVINE LIVER RHODANESE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOMERIC MITOCHONDRIAL RHODANESE; UREA-DENATURED RHODANESE; CHAPERONINS FACILITATE; TRYPTOPHAN RESIDUES; PROTEINS; STATES; GROEL; SHOW	The enzyme rhodanese is greatly stabilized in the range pH 4-6, and samples at pH 5 are fully active after several days at 23-degrees-C. This is very different from results at pH > 7, where there is significant loss of activity within 1 h. A pH-dependent conformational change occurs below pH 4 in a transition centered around pH 3.25 that leads slowly to inactive rhodanese at pH 3 (t1/2 = 22 min at pH3). The inactive rhodanese can be reactivated by incubation under conditions required for detergent-assisted refolding of denatured rhodanese. The inactive enzyme at pH 3 has the maximum of its intrinsic fluorescence spectrum shifted to 345 nm from 335 nm, which is characteristic of native rhodanese at pH > 4. At pH 3, rhodanese shows increased exposure of organized hydrophobic surfaces as measured by 1,1'-bis(4-anilino)naphthalene-5,5'-disulfonic acid binding. The secondary structure is maintained over the entire pH range studied (pH 2-7). Fluorescence anisotropy measurements of the intrinsic fluorescence provide evidence suggesting that the pH transition produces a state that does not display greatly increased average flexibility at tryptophan residues. Pepsin digestibility of rhodanese follows the pH dependence of conformational changes reported by activity and physical methods. Rhodanese is resistant to proteolysis above pH 4 but becomes increasingly susceptible as the pH is lowered. The form of the enzyme at pH 3 is cleaved at discrete sites to produce a few large fragments. It appears that pepsin initially cleaves close to one end of the protein and then clips at additional sites to produce species of a size expected for the individual domains into which rhodanese is folded. Overall, it appears that in the pH range between pH 3 and 4, titration of groups on rhodanese leads to opening of the structure to produce a conformation resembling, but more rigid than, the molten globule state that is observed as an intermediate during reversible unfolding of rhodanese.			HOROWITZ, PM (corresponding author), UNIV TEXAS,HLTH SCI CTR,DEPT BIOCHEM,7703 FLOYD CURL DR,SAN ANTONIO,TX 78284, USA.				NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES005729] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM025177] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES05729] Funding Source: Medline; NIGMS NIH HHS [GM25177] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AIRD BA, 1988, J BIOL CHEM, V263, P15270; BURSTEIN EA, 1973, PHOTOCHEM PHOTOBIOL, V18, P263, DOI 10.1111/j.1751-1097.1973.tb06422.x; CANNELLA C, 1981, EUR J BIOCHEM, V119, P491, DOI 10.1111/j.1432-1033.1981.tb05634.x; CHOW SF, 1986, J BIOL CHEM, V261, P7264; CHOW SF, 1985, J BIOL CHEM, V260, P2763; DOLGIKH DA, 1981, FEBS LETT, V136, P311, DOI 10.1016/0014-5793(81)80642-4; FINK AL, 1991, CONFORMATIONS FORCES, P169; GOTO Y, 1990, BIOCHEMISTRY-US, V29, P3480, DOI 10.1021/bi00466a009; GOTO Y, 1990, P NATL ACAD SCI USA, V87, P573, DOI 10.1073/pnas.87.2.573; HARRINGTON WF, 1956, BIOCHEM J, V62, P569, DOI 10.1042/bj0620569; HOL WGJ, 1983, FUND APPL TOXICOL, V3, P370, DOI 10.1016/S0272-0590(83)80007-4; HOROWITZ PM, 1989, J BIOL CHEM, V264, P3311; HOROWITZ PM, 1978, ANAL BIOCHEM, V86, P751, DOI 10.1016/0003-2697(78)90803-5; HOROWITZ PM, 1990, J BIOL CHEM, V265, P2576; HOROWITZ PM, 1991, CONFORMATION FORCES, P185; LAKOWICZ JR, 1983, BIOCHEMISTRY-US, V22, P1741, DOI 10.1021/bi00277a001; LANDRY SJ, 1991, BIOCHEMISTRY-US, V30, P7359, DOI 10.1021/bi00244a001; LANDRY SJ, 1991, J CELL BIOCH SG, V15, P197; LEMIRE BD, 1989, J BIOL CHEM, V264, P20206; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; MENDOZA J, 1991, FASEB J, V5, pA432; MENDOZA JA, 1991, J BIOL CHEM, V266, P13587; MENDOZA JA, 1991, J BIOL CHEM, V266, P13044; MENDOZA JA, 1991, J BIOL CHEM, V266, P16973; MILLER DM, 1991, J BIOL CHEM, V266, P4686; OGATA K, 1989, J BIOL CHEM, V264, P2718; RINDERKNECHT H, 1968, CLIN CHIM ACTA, V21, P197, DOI 10.1016/0009-8981(68)90127-7; ROSEN CG, 1969, BIOCHEMISTRY-US, V8, P3915, DOI 10.1021/bi00838a006; RUSSELL J, 1978, J BIOL CHEM, V253, P8102; SORBO BH, 1953, ACTA CHEM SCAND, V7, P1129, DOI 10.3891/acta.chem.scand.07-1129; TANDON S, 1989, J BIOL CHEM, V264, P9859; TANDON S, 1986, J BIOL CHEM, V261, P5615; TEALE FWJ, 1970, BIOCHEM J, V116, P341, DOI 10.1042/bj1160341; WEBER G, 1952, BIOCHEM J, V51, P145, DOI 10.1042/bj0510145; WESTLEY J, 1973, ADV ENZYMOL RAMB, V39, P327	35	12	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1992	267	27					19464	19469						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JP593	1527067				2022-12-25	WOS:A1992JP59300068
J	KANG, S; WOHLRAB, F; WELLS, RD				KANG, S; WOHLRAB, F; WELLS, RD			GC-RICH FLANKING TRACTS DECREASE THE KINETICS OF INTRAMOLECULAR DNA TRIPLEX FORMATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIMPLEX VIRUS TYPE-1; HOMOPURINE-HOMOPYRIMIDINE SEQUENCES; SUPERCOILED DNA; CRUCIFORMS; STABILITY; PROMOTER; PLASMIDS; REGION; TRANSMISSION; TEMPERATURE	The effect of the base composition of flanking sequences on DNA intramolecular triplex formation was investigated in negatively supercoiled plasmids. The rates of triplex formation at two oligopurine.oligopyrimidine inserts with interrupting sequences in plasmids containing AT- or GC-rich flanking sequences were compared as a function of temperature, pH, and negative superhelical density. The kinetics of the transition of linear B-DNA to triplex (also called H-DNA) were influenced by all of these factors; triplexes were formed slower in a GC-rich background than in an AT-rich background. However, at equilibrium, the same amounts of the triplexes in AT- or GC-rich contexts were formed, and the conformations adopted by (GAA)4TTCGC(GAA), showed the canonical intramolecular triplex as mapped with chemical probes. We propose that the GC-rich segments caused this effect by thermodynamically clamping the DNA inserts, since the dependence of kinetics on base composition disappeared in tetraalkylammonium ions which eliminate the dependence of helix-coil transitions on base composition. The dependence of the kinetics of intramolecular triplex formation on flanking sequences further strengthens the concept of the role of DNA as a dynamic participant in cellular events.			KANG, S (corresponding author), TEXAS A&M UNIV SYST,INST BIOSCI & TECHNOL,HOUSTON,TX 77030, USA.				NCI NIH HHS [CA13148] Funding Source: Medline; NIGMS NIH HHS [GM30822] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA013148] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030822] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERNUES J, 1989, EMBO J, V8, P2087, DOI 10.1002/j.1460-2075.1989.tb03617.x; BURD JF, 1975, J BIOL CHEM, V250, P5109; DREW HR, 1985, NUCLEIC ACIDS RES, V13, P4445, DOI 10.1093/nar/13.12.4445; GOUGH GW, 1986, EMBO J, V5, P191, DOI 10.1002/j.1460-2075.1986.tb04195.x; HANVEY JC, 1988, J BIOL CHEM, V263, P7386; HOGAN M, 1979, NATURE, V278, P521, DOI 10.1038/278521a0; HTUN H, 1989, SCIENCE, V243, P1571, DOI 10.1126/science.2648571; KANG S, 1992, J BIOL CHEM, V267, P1259; KARLOVSKY P, 1990, FEBS LETT, V274, P39, DOI 10.1016/0014-5793(90)81324-H; KLEIN RD, 1982, J BIOL CHEM, V257, P2954; KOHWI Y, 1991, GENE DEV, V5, P2547, DOI 10.1101/gad.5.12b.2547; KOHWI Y, 1988, P NATL ACAD SCI USA, V85, P3781, DOI 10.1073/pnas.85.11.3781; KOHWI Y, 1992, J MOL BIOL, V223, P817, DOI 10.1016/0022-2836(92)90242-C; KOHWI Y, 1991, NUCLEIC ACIDS RES, V19, P4267; KOWALSKI D, 1989, EMBO J, V8, P4335, DOI 10.1002/j.1460-2075.1989.tb08620.x; MCGEOCH DJ, 1986, NUCLEIC ACIDS RES, V14, P1727, DOI 10.1093/nar/14.4.1727; MCGEOCH DJ, 1985, J MOL BIOL, V181, P1, DOI 10.1016/0022-2836(85)90320-1; MCKEON C, 1984, J BIOL CHEM, V259, P6636; MCLEAN MJ, 1987, NUCLEIC ACIDS RES, V15, P6917, DOI 10.1093/nar/15.17.6917; MCLEAN MJ, 1986, P NATL ACAD SCI USA, V83, P5884, DOI 10.1073/pnas.83.16.5884; MELCHIOR WB, 1973, P NATL ACAD SCI USA, V70, P298, DOI 10.1073/pnas.70.2.298; MIRKIN SM, 1987, NATURE, V330, P495, DOI 10.1038/330495a0; MULLER UR, 1987, J BIOL CHEM, V262, P3730; MYERS RM, 1985, NUCLEIC ACIDS RES, V13, P3111, DOI 10.1093/nar/13.9.3111; PALECEK E, 1991, CRIT REV BIOCHEM MOL, V26, P151, DOI 10.3109/10409239109081126; PANAYOTATOS N, 1981, NATURE, V289, P466, DOI 10.1038/289466a0; PANUTIN IG, 1992, J BIOL CHEM, V267, P5495; PATEL DJ, 1985, BIOCHEMISTRY-US, V24, P926, DOI 10.1021/bi00325a018; RAJAGOPALAN M, 1990, J BIOL CHEM, V265, P17294; RICH A, 1984, ANNU REV BIOCHEM, V53, P791, DOI 10.1146/annurev.bi.53.070184.004043; SASSEDWIGHT S, 1989, J BIOL CHEM, V264, P8074; SHIMIZU M, 1989, J BIOL CHEM, V264, P5944; SINDEN RR, 1984, J BIOL CHEM, V259, P6593; SINGLETON CK, 1983, J BIOL CHEM, V258, P7661; SINGLETON CK, 1982, ANAL BIOCHEM, V122, P253, DOI 10.1016/0003-2697(82)90277-9; SULLIVAN KM, 1986, CELL, V47, P817, DOI 10.1016/0092-8674(86)90524-6; SULLIVAN KM, 1988, J BIOL CHEM, V263, P13074; WELLS RD, 1988, FASEB J, V2, P2939, DOI 10.1096/fasebj.2.14.3053307; WELLS RD, 1990, BACTERIAL CHROMOSOME, V13, P187; Wells RD, 1987, UNUSUAL DNA STRUCTUR; WOHLRAB F, 1989, J BIOL CHEM, V264, P8207; WOHLRAB F, 1987, J BIOL CHEM, V262, P6407; ZIMMERMAN SB, 1982, ANNU REV BIOCHEM, V51, P395, DOI 10.1146/annurev.bi.51.070182.002143	43	22	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1992	267	27					19435	19442						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JP593	1527063				2022-12-25	WOS:A1992JP59300064
J	ERICSSON, J; APPELKVIST, EL; THELIN, A; CHOJNACKI, T; DALLNER, G				ERICSSON, J; APPELKVIST, EL; THELIN, A; CHOJNACKI, T; DALLNER, G			ISOPRENOID BIOSYNTHESIS IN RAT-LIVER PEROXISOMES - CHARACTERIZATION OF CIS-PRENYLTRANSFERASE AND SQUALENE SYNTHETASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEROL CARRIER PROTEIN-2; UNDECAPRENYL PYROPHOSPHATE SYNTHETASE; DOLICHYL PHOSPHATE BIOSYNTHESIS; RUBBER ELONGATION-FACTOR; COENZYME-A REDUCTASE; PRESQUALENE PYROPHOSPHATE; CHOLESTEROL-SYNTHESIS; MICROCOCCUS-LUTEUS; HEVEA-BRASILIENSIS; PURIFICATION	Isolated peroxisomes were able to utilize [H-3]isopentenyl diphosphate to synthesize farnesyl diphosphate, which then was utilized as substrate by both the peroxisomal squalene synthetase and cis-prenyltransferase. The specific activity of squalene synthetase in peroxisomes was as high as in microsomes, i.e. 160 pmol/mg of protein/min. If NADPH was omitted from the assay medium, presqualene diphosphate accumulated, which indicates that the reaction occurs in two steps, as in microsomes. In the presence of NADPH, incorporation from [H-3]farnesyl diphosphate was stimulated 3-fold, and the major products were squalene and cholesterol. The specific activity of cis-prenyltransferase in peroxisomes was 4-fold higher than in microsomes, i.e. 456 pmol of isopentenyl diphosphate incorporated/mg of protein/h. There were two major products formed from farnesyl diphosphate and [H-3] isopentenyl diphosphate, i.e. trans,trans,cis-geranyl-geranyl diphosphate and long chain polyprenyl diphosphates. The polyprenyl diphosphates had the same chain length distribution as that of dolichol derivatives in rat liver, with the dominating polyisoprenes being C90 and C95. In contrast to the microsomal enzyme, peroxisomal cis-prenyltransferase did not require detergents for optimal activity. The enzyme was associated primarily with the peroxisomal membrane after sonication of the peroxisomes.	KAROLINSKA INST,HUDDINGE HOSP,CLIN RES CTR,S-14186 HUDDINGE,SWEDEN; POLISH ACAD SCI,INST BIOCHEM & BIOPHYS,PL-02532 WARSAW,POLAND	Karolinska Institutet; Polish Academy of Sciences; Institute of Biochemistry & Biophysics - Polish Academy of Sciences	ERICSSON, J (corresponding author), UNIV STOCKHOLM,ARRHENIUS LABS NAT SCI,DEPT BIOCHEM,S-10691 STOCKHOLM,SWEDEN.							ADAIR WL, 1984, J BIOL CHEM, V259, P4441; ADAIR WL, 1982, J BIOL CHEM, V257, P8990; ADAIR WL, 1983, BIOCHIM BIOPHYS ACTA, V208, P532; AGNEW WS, 1978, J BIOL CHEM, V253, P4566; AGNEW WS, 1985, METHOD ENZYMOL, V110, P359; APPELKVIST EL, 1987, BIOSCIENCE REP, V7, P853, DOI 10.1007/BF01119476; APPELKVIST EL, 1989, EUR J BIOCHEM, V185, P503, DOI 10.1111/j.1432-1033.1989.tb15142.x; APPELKVIST EL, 1981, J BIOCHEM BIOPH METH, V5, P203, DOI 10.1016/0165-022X(81)90045-2; APPELKVIST EL, 1990, ARCH BIOCHEM BIOPHYS, V282, P318, DOI 10.1016/0003-9861(90)90123-G; BABA T, 1980, ARCH BIOCHEM BIOPHYS, V200, P474, DOI 10.1016/0003-9861(80)90379-3; BABA T, 1978, BIOCHEMISTRY-US, V17, P5598, DOI 10.1021/bi00619a003; BROWN MS, 1976, SCIENCE, V191, P150, DOI 10.1126/science.174194; BROWN MS, 1980, J LIPID RES, V21, P505; BRUENGER E, 1988, ANAL BIOCHEM, V173, P321, DOI 10.1016/0003-2697(88)90196-0; CHOJNACKI T, 1988, BIOCHEM J, V251, P1; CHOJNACKI T, 1984, ACTA BIOCHIM POL, V31, P115; CRICK DC, 1991, J NEUROCHEM, V57, P1354, DOI 10.1111/j.1471-4159.1991.tb08301.x; DALLNER G, 1981, MITOCHONDRIA MICROSO, P655; DENNIS MS, 1989, J BIOL CHEM, V264, P18618; DENNIS MS, 1989, J BIOL CHEM, V264, P18608; EPSTEIN WW, 1970, J BIOL CHEM, V245, P4597; ERICSSON J, 1991, J BIOL CHEM, V266, P10602; ERICSSON J, 1991, EUR J BIOCHEM, V209, P789; ERICSSON J, 1992, IN PRESS J BIOL CHEM; ERIKSSON LC, 1982, INT ENCY PHARM THERA, P9; FAUST JR, 1979, P NATL ACAD SCI USA, V76, P5018, DOI 10.1073/pnas.76.10.5018; GOLDSTEIN JL, 1977, ANNU REV BIOCHEM, V46, P897, DOI 10.1146/annurev.bi.46.070177.004341; HEMMING FW, 1983, BIOSYNTHESIS ISOPREN, V2, P305; HODGE VJ, 1991, BIOCHEM BIOPH RES CO, V181, P537, DOI 10.1016/0006-291X(91)91222-X; JAMES MJ, 1980, J BIOL CHEM, V255, P8618; JENNINGS SM, 1991, P NATL ACAD SCI USA, V88, P6038, DOI 10.1073/pnas.88.14.6038; KANDUTSCH AA, 1978, SCIENCE, V201, P498, DOI 10.1126/science.663671; KELLER GA, 1986, J CELL BIOL, V103, P875, DOI 10.1083/jcb.103.3.875; KELLER GA, 1989, J CELL BIOL, V108, P1353, DOI 10.1083/jcb.108.4.1353; KELLER GA, 1985, P NATL ACAD SCI USA, V82, P770, DOI 10.1073/pnas.82.3.770; KELLER RK, 1986, J BIOL CHEM, V261, P2053; KUSWIKRABIEGA G, 1987, J BIOL CHEM, V262, P1505; LEIGHTON F, 1968, J CELL BIOL, V37, P482, DOI 10.1083/jcb.37.2.482; LIGHT DR, 1989, J BIOL CHEM, V264, P18598; LIGHT DR, 1989, J BIOL CHEM, V264, P18589; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LYONS HT, 1991, ARCH BIOCHEM BIOPHYS, V285, P238, DOI 10.1016/0003-9861(91)90355-M; MUSCIO F, 1973, J BIOL CHEM, V249, P3746; Nes W. R., 1977, BIOCH STEROIDS OTHER; OHNUMA S, 1991, J BIOL CHEM, V266, P23706; POPJAK G, 1979, MOL CELL BIOCHEM, V27, P97; POPJAK G, 1962, J BIOL CHEM, V237, P56; POTTER JER, 1981, J BIOL CHEM, V256, P2371; POULTER DC, 1981, BIOSYNTHESIS ISOPREN, V1, P414; SAGAMI H, 1991, J BIOL CHEM, V266, P3458; SAGAMI H, 1989, BIOCHIM BIOPHYS ACTA, V266, P218; SASIAK K, 1988, ARCH BIOCHEM BIOPHYS, V260, P622, DOI 10.1016/0003-9861(88)90490-0; SCHROEPFER GJ, 1981, ANNU REV BIOCHEM, V50, P585, DOI 10.1146/annurev.bi.50.070181.003101; SCHROEPFER GJ, 1982, ANNU REV BIOCHEM, V51, P555, DOI 10.1146/annurev.bi.51.070182.003011; TAKAHASHI I, 1982, J BIOCHEM-TOKYO, V92, P1527, DOI 10.1093/oxfordjournals.jbchem.a134077; THOMPSON SL, 1987, J BIOL CHEM, V262, P17420; THOMPSON SL, 1990, J BIOL CHEM, V265, P5731; TOLLBOM O, 1988, J BIOL CHEM, V263, P1347; TSUNEOKA M, 1988, J BIOCHEM-TOKYO, V104, P560, DOI 10.1093/oxfordjournals.jbchem.a122510; VANDERKRIFT TP, 1985, BIOCHIM BIOPHYS ACTA, V812, P387, DOI 10.1016/0005-2736(85)90313-X; WONG TK, 1982, J BIOL CHEM, V257, P6619	61	53	53	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1992	267	26					18708	18714						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JN502	1527001				2022-12-25	WOS:A1992JN50200071
J	LEVYWILSON, B; PAULWEBER, B; NAGY, BP; LUDWIG, EH; BROOKS, AR				LEVYWILSON, B; PAULWEBER, B; NAGY, BP; LUDWIG, EH; BROOKS, AR			NUCLEASE-HYPERSENSITIVE SITES DEFINE A REGION WITH ENHANCER ACTIVITY IN THE 3RD INTRON OF THE HUMAN APOLIPOPROTEIN-B GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							5' END; INVITRO TRANSCRIPTION; PROMOTER; ELEMENTS; CELLS; ACTIVATION; ALBUMIN; ALPHA-1-ANTITRYPSIN; SEQUENCES; HEPG2	The positions of several DNase I-hypersensitive (DH) sites have been mapped in the second and third introns of the human apolipoprotein B gene. Two such DH sites, I and V, are present both in human hepatoma (HepG2) and colon carcinoma (CaCo-2) cells that express the gene but absent from HeLa cells that do not express the gene. These DH sites map near sequence elements that have been highly conserved between the human and mouse genes. A PvuII-EcoRI fragment (+1064 to +2977) from the hypersensitive region exhibited enhancer activity, which was further localized by means of deletion experiments to a 155-base pair segment located entirely within the third intron and flanked by two DH sites. Three DNase I footprints were observed within this core enhancer, one of which contains putative binding sites for three liver specific nuclear proteins. Experiments are presented that suggest that this enhancer operates by a similar mechanism as that described previously for the strong second intron enhancer, involving an interaction with the basal transcriptional machinery. Digestions with low levels of micrococcal nuclease were performed to ascertain whether nucleosomes were present in the DNase I sensitive enhancer region. Nine different micrococcal nuclease-hypersensitive (MH) sites were detected in HepG2 cells but not in HeLa cells; one MH site was common to both cell types, and HeLa cells exhibited three unique MH sites. The first six MH sites (I-VI) are spaced approximately 200 base pairs apart, suggesting the presence of positioned nucleosomes in that region. MH sites VI-X are more closely spaced, suggesting either additional cutting sites within the core particle or the absence of one or two nucleosomes in this segment of the third intron enhancer.	UNIV CALIF SAN FRANCISCO,DEPT PHARMACEUT CHEM,SAN FRANCISCO,CA 94141	University of California System; University of California San Francisco	LEVYWILSON, B (corresponding author), UNIV CALIF SAN FRANCISCO,GLADSTONE INST CARDIOVASC DIS,CARDIOVASC RES INST,POB 419100,SAN FRANCISCO,CA 94141, USA.				NHLBI NIH HHS [HL41633] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL041633] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BROOKS AR, 1991, J BIOL CHEM, V266, P7848; BROOKS AR, 1992, MOL CELL BIOL, V12, P1134, DOI 10.1128/MCB.12.3.1134; CORDINGLEY MG, 1987, CELL, V48, P261, DOI 10.1016/0092-8674(87)90429-6; COSTA RH, 1988, P NATL ACAD SCI USA, V85, P3840, DOI 10.1073/pnas.85.11.3840; EISENBERG JC, 1985, ANNU REV GENET, V19, P485; ELGIN SCR, 1988, J BIOL CHEM, V263, P19259; FELSENFELD G, 1992, NATURE, V355, P219, DOI 10.1038/355219a0; FLANAGAN PM, 1991, NATURE, V350, P436, DOI 10.1038/350436a0; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; GROSS DS, 1987, TRENDS BIOCHEM SCI, V12, P293, DOI 10.1016/0968-0004(87)90144-7; GRUNSTEIN M, 1990, ANNU REV CELL BIOL, V6, P643, DOI 10.1146/annurev.cellbio.6.1.643; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LEVYWILSON B, 1989, J BIOL CHEM, V264, P9891; LEVYWILSON B, 1988, MOL CELL BIOL, V8, P71, DOI 10.1128/MCB.8.1.71; LIN YS, 1990, NATURE, V345, P359, DOI 10.1038/345359a0; LUDWIG EH, 1991, DNA CELL BIOL, V10, P329, DOI 10.1089/dna.1991.10.329; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MONACI P, 1988, EMBO J, V7, P2075, DOI 10.1002/j.1460-2075.1988.tb03047.x; PAULWEBER B, 1991, J BIOL CHEM, V266, P21956; PAULWEBER B, 1991, J BIOL CHEM, V266, P24149; PAULWEBER B, 1991, J BIOL CHEM, V266, P24161; PETROPOULOS I, 1991, J BIOL CHEM, V266, P24220; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; PULLINGER CR, 1989, J LIPID RES, V30, P1065; SIMONET WS, 1991, J BIOL CHEM, V266, P8651	26	15	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1992	267	26					18735	18743						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JN502	1527004				2022-12-25	WOS:A1992JN50200075
J	OSBORNE, TF; BENNETT, M; RHEE, K				OSBORNE, TF; BENNETT, M; RHEE, K			RED 25, A PROTEIN THAT BINDS SPECIFICALLY TO THE STEROL REGULATORY REGION IN THE PROMOTER FOR 3-HYDROXY-3-METHYLGLUTARYL-COENZYME-A REDUCTASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; COENZYME-A REDUCTASE; RECEPTOR GENE; CHOLESTEROL-SYNTHESIS; RESPONSE ELEMENT; TRANSCRIPTION; PURIFICATION; SEQUENCE; IDENTIFICATION; EXPRESSION	A protein that binds to the sterol regulatory region of the hamster promoter for 3-hydroxy-3-methylglutaryl-coenzyme A reductase has been identified. All of the DNA bases crucial to the binding of this protein were previously shown to be essential for sterol regulation of the intact promoter in cultured cells. This low abundance protein, called Red 25, has been purified from nuclear extracts of hamster liver by a series of standard chromatographic techniques coupled with a DNA affinity step. Its size has been estimated as approximately 42 kDa by gel electrophoresis, size exclusion chromatography, and protein-DNA cross-linking studies. Furthermore, it binds to its target site with a K(d) = 6 X 10(-11) M. Red 25 does not bind to the sterol regulatory regions of the LDL receptor or 3-hydroxy-3-methylglutaryl-coenzyme A synthase. This is consistent with recent studies that show there is a unique site for sterol regulation in the reductase promoter. The identification and purification of this protein represents a significant step in the study of feedback regulation by cholesterol.			OSBORNE, TF (corresponding author), UNIV CALIF IRVINE,DEPT MOLEC BIOL & BIOCHEM,IRVINE,CA 92717, USA.							BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; DAWSON PA, 1988, J BIOL CHEM, V263, P3372; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; GIL G, 1988, P NATL ACAD SCI USA, V85, P8963, DOI 10.1073/pnas.85.23.8963; GIL G, 1988, J BIOL CHEM, V263, P19009; GOODBOURN S, 1988, P NATL ACAD SCI USA, V85, P1447, DOI 10.1073/pnas.85.5.1447; KADONAGA JT, 1986, P NATL ACAD SCI USA, V83, P5889, DOI 10.1073/pnas.83.16.5889; Maxam A M, 1980, Methods Enzymol, V65, P499; OAKLEY BR, 1980, ANAL BIOCHEM, V105, P361, DOI 10.1016/0003-2697(80)90470-4; OSBORNE TF, 1988, J BIOL CHEM, V263, P3380; OSBORNE TF, 1985, CELL, V42, P203, DOI 10.1016/S0092-8674(85)80116-1; OSBORNE TF, 1991, J BIOL CHEM, V266, P13947; OSBORNE TF, 1987, P NATL ACAD SCI USA, V84, P3614, DOI 10.1073/pnas.84.11.3614; PAONESSA G, 1988, EMBO J, V7, P3115, DOI 10.1002/j.1460-2075.1988.tb03178.x; RAJAVASHISTH T, 1989, SCIENCE, V24, P640; REAGAN JW, 1990, J BIOL CHEM, V265, P9381; RYAN WA, 1989, EMBO J, V8, P1785, DOI 10.1002/j.1460-2075.1989.tb03572.x; SANTORO C, 1988, NATURE, V334, P218, DOI 10.1038/334218a0; SCHULE R, 1990, CELL, V61, P497, DOI 10.1016/0092-8674(90)90531-I; SMITH JR, 1990, J BIOL CHEM, V265, P2306; SMITH JR, 1988, J BIOL CHEM, V263, P18480; SPADY DK, 1985, J LIPID RES, V26, P465; STANGE EF, 1983, P NATL ACAD SCI-BIOL, V80, P5739, DOI 10.1073/pnas.80.18.5739; STARK HC, 1992, P NATL ACAD SCI USA, V89, P2180, DOI 10.1073/pnas.89.6.2180; SUDHOF TC, 1987, CELL, V48, P1061, DOI 10.1016/0092-8674(87)90713-6; SUDHOF TC, 1987, J BIOL CHEM, V262, P10773	27	60	61	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1992	267	26					18973	18982						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JN502	1527023				2022-12-25	WOS:A1992JN50200108
J	PALCZEWSKI, K; BUCZYLKO, J; VANHOOSER, P; CARR, SA; HUDDLESTON, MJ; CRABB, JW				PALCZEWSKI, K; BUCZYLKO, J; VANHOOSER, P; CARR, SA; HUDDLESTON, MJ; CRABB, JW			IDENTIFICATION OF THE AUTOPHOSPHORYLATION SITES IN RHODOPSIN KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ROD OUTER SEGMENTS; ADRENERGIC-RECEPTOR KINASE; LIGHT-DEPENDENT PHOSPHORYLATION; RETINALDEHYDE-BINDING PROTEIN; PHOTORECEPTOR MEMBRANES; PHOTOEXCITED RHODOPSIN; MASS-SPECTROMETRY; ACTIVATION; PHOSPHODIESTERASE; PURIFICATION	Rhodopsin kinase (RK) is a second-messenger-independent protein kinase that is involved in deactivation of photolyzed rhodopsin (Rho*). We have developed a significantly improved method for isolation of RK based on the specific interactions of phosphorylated forms of the enzyme with heparin-Sepharose. Conversion of the dephosphorylated form of RK to the fully phosphorylated enzyme leads to specific elution of the kinase from the resin. Limited proteolysis of RK with endoproteinase Asp-N removes the phosphorylation sites. Peptides containing the autophosphorylation sites were isolated by reverse-phase high performance liquid chromatography and analyzed by Edman degradation and tandem mass spectrometry. The derived amino acid sequence of the peptide containing the major autophosphorylation site yielded the following sequence: DVGAFS488T489VKGVAFEK, where Ser488 and Thr489 are phosphorylated. Additionally, a minor autophosphorylation site was identified at Ser21. A 15-residue peptide (DVGAFSTVKGVAFEK) encompassing the major autophosphorylation site was synthesized and used for phosphorylation and inhibition studies. In contrast to many other protein kinases, the low catalytic activity of RK toward its autophosphorylation site peptide and the poor inhibitory properties of this peptide suggest unique properties of this member of the family of G protein-coupled receptor kinases.	GOOD SAMARITAN HOSP, RS DOW NEUROL SCI INST, PORTLAND, OR 97209 USA; UNIV WASHINGTON, DEPT OPHTHALMOL & PHARMACOL, SEATTLE, WA 98195 USA; SMITHKLINE BEECHAM PHARMACEUT, DEPT PHYS & STRUCT CHEM, KING OF PRUSSIA, PA 19406 USA; W ALTON JONES CELL SCI CTR, LAKE PLACID, NY 12946 USA	University of Washington; University of Washington Seattle; GlaxoSmithKline			Carr, Steven A./AAH-8366-2019		NCI NIH HHS [CA 37589] Funding Source: Medline; NEI NIH HHS [EY 08061] Funding Source: Medline; NIDDK NIH HHS [DK 38639] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA037589] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R29EY008061, R01EY008061] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK038639] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANANT JS, 1992, BIOCHEM BIOPH RES CO, V183, P468, DOI 10.1016/0006-291X(92)90505-F; BENOVIC JL, 1987, J BIOL CHEM, V262, P9026; BINDER BM, 1990, J BIOL CHEM, V265, P15333; BOWNDS D, 1972, NATURE-NEW BIOL, V237, P125, DOI 10.1038/newbio237125a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUCZYLKO J, 1991, P NATL ACAD SCI USA, V88, P2568, DOI 10.1073/pnas.88.6.2568; CARR SA, 1991, ANAL CHEM, V63, P2802, DOI 10.1021/ac00024a003; Covey T R, 1988, Rapid Commun Mass Spectrom, V2, P249, DOI 10.1002/rcm.1290021111; CRABB JW, 1988, J BIOL CHEM, V263, P18678; CRABB JW, 1986, BIOCHEMISTRY-US, V25, P4988, DOI 10.1021/bi00366a003; CRABB JW, 1991, J BIOL CHEM, V266, P16674; DRATZ EA, 1983, TRENDS BIOCHEM SCI, V8, P128, DOI 10.1016/0968-0004(83)90235-9; FOWLES C, 1988, FEBS LETT, V238, P56, DOI 10.1016/0014-5793(88)80224-2; FRANK RN, 1973, J BIOL CHEM, V248, P596; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HOUSE C, 1987, SCIENCE, V238, P1726, DOI 10.1126/science.3686012; INGLESE J, 1992, J BIOL CHEM, V267, P1422; KELLEHER DJ, 1990, J BIOL CHEM, V265, P2632; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; KUHN H, 1974, NATURE, V250, P588, DOI 10.1038/250588a0; KUHN H, 1972, FEBS LETT, V20, P1, DOI 10.1016/0014-5793(72)80002-4; KUHN H, 1978, BIOCHEMISTRY-US, V17, P4389; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE RH, 1982, BIOCHEMISTRY-US, V21, P3303, DOI 10.1021/bi00257a009; LOHSE MJ, 1990, SCIENCE, V248, P1547, DOI 10.1126/science.2163110; LORENZ W, 1991, P NATL ACAD SCI USA, V88, P8715, DOI 10.1073/pnas.88.19.8715; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MERRIFIELD RB, 1963, J AM CHEM SOC, V85, P2149, DOI 10.1021/ja00897a025; ONORATO JJ, 1991, BIOCHEMISTRY-US, V30, P5118, DOI 10.1021/bi00235a002; OVCHINNIKOV YA, 1988, FEBS LETT, V230, P1, DOI 10.1016/0014-5793(88)80628-8; PALCZEWSKI K, 1989, BIOCHEMISTRY-US, V28, P8764, DOI 10.1021/bi00448a013; PALCZEWSKI K, 1988, J BIOL CHEM, V263, P14067; PALCZEWSKI K, 1991, J BIOL CHEM, V266, P12949; PALCZEWSKI K, 1992, NEURON, V8, P117, DOI 10.1016/0896-6273(92)90113-R; PALCZEWSKI K, 1988, BIOCHEMISTRY-US, V27, P2306, DOI 10.1021/bi00407a010; PALCZEWSKI K, 1991, TRENDS BIOCHEM SCI, V16, P387, DOI 10.1016/0968-0004(91)90157-Q; PALCZEWSKI K, 1988, FASEB J, V2, pA994; PAPERMASTER DS, 1982, METHOD ENZYMOL, V81, P48; PEARSON RB, 1988, SCIENCE, V241, P970, DOI 10.1126/science.3406746; SITARAMAYYA A, 1986, BIOCHEMISTRY-US, V25, P5460, DOI 10.1021/bi00367a017; SMITH MK, 1990, J BIOL CHEM, V265, P1837; SMITH RD, 1990, ANAL CHEM, V62, P882, DOI 10.1021/ac00208a002; Speicher D.W., 1989, TECHNIQUES PROTEIN C, P24; SPIEGEL AM, 1991, TRENDS BIOCHEM SCI, V16, P338, DOI 10.1016/0968-0004(91)90139-M; TARR GE, 1983, ANAL BIOCHEM, V131, P99, DOI 10.1016/0003-2697(83)90140-9; THOMPSON P, 1984, BIOCHEM J, V220, P773, DOI 10.1042/bj2200773; WALD G, 1953, J GEN PHYSIOL, V37, P189, DOI 10.1085/jgp.37.2.189; WEST KA, 1992, CURRENT RES PROTEIN, P37; WILDEN U, 1986, P NATL ACAD SCI USA, V83, P1174, DOI 10.1073/pnas.83.5.1174	49	69	73	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	1992	267	26					18991	18998						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JN502	1527025				2022-12-25	WOS:A1992JN50200110
J	RUEGG, CL; RAJASEKAR, S; STEIN, BS; ENGLEMAN, EG				RUEGG, CL; RAJASEKAR, S; STEIN, BS; ENGLEMAN, EG			DEGRADATION OF CD4 FOLLOWING PHORBOL-INDUCED INTERNALIZATION IN HUMAN LYMPHOCYTES-T - EVIDENCE FOR DISTINCT ENDOCYTIC ROUTING OF CD4 AND CD3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN KINASE-C; RECEPTOR-MEDIATED ENDOCYTOSIS; GROWTH-FACTOR-RECEPTOR; DOWN-REGULATION; MONOCLONAL-ANTIBODY; MYRISTATE ACETATE; ANTIGEN RECEPTOR; HIV INFECTION; K562 CELLS; MODULATION	Exposure of T lymphocytes to phorbol esters induces endocytosis of CD4 and the CD3/T-cell receptor complex. We compared the pathway of CD4 internalization to that of CD3 following activation of human T lymphocytes with phorbol 12,13-dibutyrate (PDBu). Both CD3 and CD4 were rapidly internalized in response to PDBu, but only CD3, and not CD4, was recycled to the cell surface after removal of PDBu. In support of a degradative fate for internalized CD4, radioimmunoprecipitation studies revealed that the total amount of cellular CD4 was reduced by >90% after exposure to PDBu for 4 h, whereas total CD3 remained constant. PDBu induced CD4 capping and localization consistent with sequestration in intracellular vesicles, presumably lysosomes, prior to becoming degraded. Lysosomotropic agents, such as NH4Cl, chloroquine, and monensin inhibited CD4 degradation, consistent with a lysosomal fate for CD4. Internalization and degradation of CD4 was blocked by staurosporine, an inhibitor of protein kinase C suggestive of a role for protein kinase C in the endocytic fate of CD4. The results of this study demonstrate that CD3 and CD4 follow distinct endocytic pathways which may be relevant to their having distinct roles in T cell activation and function.	STANFORD UNIV,MED CTR,SCH MED,DEPT PATHOL,STANFORD,CA 94305	Stanford University	RUEGG, CL (corresponding author), STANFORD UNIV,SCH MED,CTR BLOOD,PALO ALTO,CA 94304, USA.				NATIONAL CANCER INSTITUTE [T32CA009151] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI025922, N01AI072657] Funding Source: NIH RePORTER; NCI NIH HHS [CA09151] Funding Source: Medline; NIAID NIH HHS [AI72657, AI25922] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ACRES RB, 1986, J BIOL CHEM, V261, P6210; ANDERSON P, 1988, J IMMUNOL, V140, P1732; BEGUINOT L, 1984, P NATL ACAD SCI-BIOL, V81, P2384, DOI 10.1073/pnas.81.8.2384; BIDDISON WE, 1989, IMMUNOL REV, V109, P5, DOI 10.1111/j.1600-065X.1989.tb00017.x; BIGBY M, 1990, J IMMUNOL, V144, P3111; BONIFACINO JS, 1990, SCIENCE, V247, P79, DOI 10.1126/science.2294595; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P51; CARLBERG K, 1991, EMBO J, V10, P877, DOI 10.1002/j.1460-2075.1991.tb08020.x; DAVIGNON JL, 1988, J IMMUNOL, V141, P1848; DEVRIES JE, 1989, IMMUNOL REV, V109, P119; ENGLEMAN EG, 1983, J IMMUNOL, V130, P2623; ENGLEMAN EG, 1981, J IMMUNOL, V127, P2124; ENGLEMAN EG, 1981, J EXP MED, V153, P193; GOLDSTEIN JL, 1985, ANNU REV CELL BIOL, V1, P1, DOI 10.1146/annurev.cb.01.110185.000245; HAMAMOTO Y, 1989, BIOCHEM BIOPH RES CO, V164, P339, DOI 10.1016/0006-291X(89)91723-3; Harlow E, 1988, ANTIBODIES LABORATOR, P359; HONEGGER AM, 1987, CELL, V51, P199, DOI 10.1016/0092-8674(87)90147-4; HOXIE JA, 1988, J IMMUNOL, V140, P786; HOXIE JA, 1986, J IMMUNOL, V137, P1194; Janeway C A Jr, 1991, Semin Immunol, V3, P153; JUNG LKL, 1988, CELL IMMUNOL, V117, P352, DOI 10.1016/0008-8749(88)90124-4; KRANGEL MS, 1987, J EXP MED, V165, P1141, DOI 10.1084/jem.165.4.1141; LIFSON JD, 1989, IMMUNOL REV, V109, P93, DOI 10.1111/j.1600-065X.1989.tb00021.x; MARSH M, 1990, BIOCHEM SOC T, V18, P139, DOI 10.1042/bst0180139; MINAMI Y, 1987, J BIOL CHEM, V262, P13342; Mishell B.B., 1980, SELECTED METHODS CEL; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; PEARSE BMF, 1988, EMBO J, V7, P3331, DOI 10.1002/j.1460-2075.1988.tb03204.x; PELCHENMATTHEWS A, 1991, J EXP MED, V173, P575, DOI 10.1084/jem.173.3.575; PELCHENMATTHEWS A, 1989, EMBO J, V8, P3641, DOI 10.1002/j.1460-2075.1989.tb08538.x; PERLMUTTER DH, 1990, J BIOL CHEM, V265, P16713; RIVAS A, 1988, J IMMUNOL, V140, P2912; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; SASAKI DT, 1987, CYTOMETRY, V8, P413, DOI 10.1002/cyto.990080411; SATTENTAU QJ, 1988, CELL, V52, P631, DOI 10.1016/0092-8674(88)90397-2; SHIN JY, 1991, J BIOL CHEM, V266, P10658; SORKIN A, 1991, J CELL BIOL, V112, P469, DOI 10.1083/jcb.112.3.469; SORKIN A, 1991, J CELL BIOL, V112, P55, DOI 10.1083/jcb.112.1.55; STEIN BS, 1984, J BIOL CHEM, V259, P4762; STEIN BS, 1990, J BIOL CHEM, V265, P2640; STEIN BS, 1986, J BIOL CHEM, V261, P319; STOSCHECK CM, 1984, J CELL BIOL, V98, P1048, DOI 10.1083/jcb.98.3.1048; TAMAOKI T, 1986, BIOCHEM BIOPH RES CO, V135, P397, DOI 10.1016/0006-291X(86)90008-2; THOMPSON JA, 1987, BIOCHEMISTRY-US, V26, P743, DOI 10.1021/bi00377a014; THUILLIER L, 1990, EUR J IMMUNOL, V20, P1197, DOI 10.1002/eji.1830200539; VANRENSWOUDE J, 1982, P NATL ACAD SCI-BIOL, V79, P6186	46	43	44	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1992	267	26					18837	18843						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JN502	1527011				2022-12-25	WOS:A1992JN50200089
J	ALLARD, JD; BERTRAND, KP				ALLARD, JD; BERTRAND, KP			MEMBRANE TOPOLOGY OF THE PBR322 TETRACYCLINE RESISTANCE PROTEIN - TETA-PHOA GENE FUSIONS AND IMPLICATIONS FOR THE MECHANISM OF TETA MEMBRANE INSERTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POSITIVELY CHARGED RESIDUES; ESCHERICHIA-COLI; ALKALINE-PHOSPHATASE; NUCLEOTIDE-SEQUENCE; INNER MEMBRANE; SIGNAL SEQUENCE; CLONING VECTORS; AMINO-ACIDS; PLASMID DNA; DETERMINANTS	The tetracycline resistance gene of pBR322 encodes a 41-kDa inner membrane protein (TetA) that acts as a tetracycline/H+ antiporter. Based on hydrophobicity profiles, we identified 12 potential transmembrane segments in TetA. We used oligonucleotide deletion mutagenesis to fuse alkaline phosphatase (PhoA) to the C-terminal edge of each of the predicted periplasmic and cytoplasmic segments of TetA. In general, the PhoA activities of the TetA-PhoA fusions support a TetA topology model consisting of 12 transmembrane segments with the N and C termini in the cytoplasm. However, several TetA-PhoA fusions have unexpected properties. One PhoA fusion to a predicted cytoplasmic segment (C6) has high activity. However, previous protease accessibility studies on the related Tn10 TetA protein indicated that C6 is cytoplasmically localized as predicted (Eckert, B., and Beck, C. F. (1989) J. Biol. Chem. 264, 11663-11670). PhoA fusions to three predicted periplasmic segments (P1, P2, and P5) have low to intermediate activity. In each case, the preceding transmembrane segment (TM1, TM3, and TM9) contains an aspartate (Asp17, Asp86, and Asp287). We show that these aspartates act like signal sequence mutations for PhoA export: (i) Asp-->Ala mutations increase the PhoA activity of fusions to P1, P2, and P5. (ii) The signal sequence mutation suppressor prlA402 increases the PhoA activity of these same fusions. We also show that the aspartates in TM1, TM3, and TM9 are critical for wild-type TetA function; they are conserved in related TetA proteins and Asp-->Ala mutations reduce or eliminate tetracycline resistance. The properties of the anomalous TetA-PhoA fusions suggest that TetA sequences C-terminal to some cytoplasmic and periplasmic segments are required for the proper localization of those segments, i.e. long range interactions may be more important in determining the membrane topology of TetA than suggested in some general models.	WASHINGTON STATE UNIV,DEPT BIOCHEM & BIOPHYS,PULLMAN,WA 99164	Washington State University					NIAID NIH HHS [AI16735] Funding Source: Medline; NIGMS NIH HHS [GM08336] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI016735] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AKIYAMA Y, 1989, J BIOL CHEM, V264, P437; BANKAITIS VA, 1985, J BACTERIOL, V161, P169, DOI 10.1128/JB.161.1.169-178.1985; BENSON SA, 1985, ANNU REV BIOCHEM, V54, P101; BLOBEL G, 1980, P NATL ACAD SCI-BIOL, V77, P1496, DOI 10.1073/pnas.77.3.1496; BOLIVAR F, 1977, GENE, V2, P95, DOI 10.1016/0378-1119(77)90000-2; BOYD D, 1990, CELL, V62, P1031, DOI 10.1016/0092-8674(90)90378-R; BOYD D, 1989, P NATL ACAD SCI USA, V86, P9446, DOI 10.1073/pnas.86.23.9446; BOYD D, 1987, P NATL ACAD SCI USA, V84, P8525, DOI 10.1073/pnas.84.23.8525; Boyd D, 1987, PHOSPHATE METABOLISM, P89; CALAMIA J, 1990, P NATL ACAD SCI USA, V87, P4937, DOI 10.1073/pnas.87.13.4937; CASADABAN MJ, 1976, J MOL BIOL, V104, P541, DOI 10.1016/0022-2836(76)90119-4; CHOTHIA C, 1986, EMBO J, V5, P823, DOI 10.1002/j.1460-2075.1986.tb04288.x; CRAIK CS, 1985, SCIENCE, V228, P291, DOI 10.1126/science.3838593; CURIALE MS, 1984, J BACTERIOL, V157, P211, DOI 10.1128/JB.157.1.211-217.1984; DEISENHOFER J, 1985, NATURE, V318, P618, DOI 10.1038/318618a0; DELSAL G, 1988, NUCLEIC ACIDS RES, V16, P9878; DERMAN AI, 1991, J BACTERIOL, V173, P7719, DOI 10.1128/jb.173.23.7719-7722.1991; ECKERT B, 1989, J BIOL CHEM, V264, P11663; EISENBERG D, 1984, J MOL BIOL, V179, P125, DOI 10.1016/0022-2836(84)90309-7; ENGELMAN DM, 1986, ANNU REV BIOPHYS BIO, V15, P321, DOI 10.1146/annurev.bb.15.060186.001541; ENGELMAN DM, 1981, CELL, V23, P411, DOI 10.1016/0092-8674(81)90136-7; FRIEDLANDER M, 1985, NATURE, V318, P338, DOI 10.1038/318338a0; Gibson T.J., 1984, THESIS CAMBRIDGE U U; HENDERSON PJF, 1990, PHILOS T ROY SOC B, V326, P391, DOI 10.1098/rstb.1990.0020; HENGGE R, 1985, J BACTERIOL, V162, P972, DOI 10.1128/JB.162.3.972-978.1985; HICKMAN RK, 1988, J BACTERIOL, V170, P1715, DOI 10.1128/jb.170.4.1715-1720.1988; HILLEN W, 1983, NUCLEIC ACIDS RES, V11, P525, DOI 10.1093/nar/11.2.525; HILLEN W, 1989, PROTEIN NUCLEIC ACID, P143; HOFFMAN CS, 1987, PHOSPHATE METABOLISM, P78; ITO K, 1981, CELL, V24, P707, DOI 10.1016/0092-8674(81)90097-0; JORGENSEN RA, 1979, J BACTERIOL, V161, P326; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASKEY RA, 1975, EUR J BIOCHEM, V56, P335, DOI 10.1111/j.1432-1033.1975.tb02238.x; LEVINSON A, 1984, Journal of Molecular and Applied Genetics, V2, P507; MANOIL C, 1986, SCIENCE, V233, P1403, DOI 10.1126/science.3529391; MANOIL C, 1985, P NATL ACAD SCI USA, V82, P8129, DOI 10.1073/pnas.82.23.8129; MANOIL C, 1990, J BACTERIOL, V172, P515, DOI 10.1128/jb.172.2.515-518.1990; MARSHALL B, 1986, GENE, V50, P111, DOI 10.1016/0378-1119(86)90315-X; MCMURRY L, 1980, P NATL ACAD SCI-BIOL, V77, P3974, DOI 10.1073/pnas.77.7.3974; MENDEZ B, 1980, PLASMID, V3, P99, DOI 10.1016/0147-619X(80)90101-8; MICHAELIS S, 1983, J BACTERIOL, V154, P366, DOI 10.1128/JB.154.1.366-374.1983; Miller J.H., 1972, EXPT MOL GENETICS; MOYED HS, 1983, J BACTERIOL, V155, P549, DOI 10.1128/JB.155.2.549-556.1983; NGUYEN TT, 1983, GENE, V25, P83, DOI 10.1016/0378-1119(83)90170-1; NGUYEN TT, 1987, THESIS U CALIFORNIA; NILSSON IM, 1990, CELL, V62, P1135, DOI 10.1016/0092-8674(90)90390-Z; NOEL D, 1979, BIOCHEMISTRY-US, V18, P4159, DOI 10.1021/bi00586a017; PEDAN KWC, 1983, GENE AMST, V22, P277; POPOT JL, 1990, BIOCHEMISTRY-US, V29, P4031, DOI 10.1021/bi00469a001; RUBIN RA, 1990, GENE, V87, P7, DOI 10.1016/0378-1119(90)90489-E; RUSSEL M, 1986, GENE, V45, P333, DOI 10.1016/0378-1119(86)90032-6; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANMILLAN JL, 1989, J BACTERIOL, V171, P5536, DOI 10.1128/jb.171.10.5536-5541.1989; SUTCLIFFE JG, 1979, COLD SPRING HARB SYM, V43, P77, DOI 10.1101/SQB.1979.043.01.013; TWIGG AJ, 1980, NATURE, V283, P216, DOI 10.1038/283216a0; UNGER B, 1984, NUCLEIC ACIDS RES, V12, P7693, DOI 10.1093/nar/12.20.7693; VONHEIJNE G, 1988, EUR J BIOCHEM, V174, P671; VONHEIJNE G, 1986, EMBO J, V5, P3021, DOI 10.1002/j.1460-2075.1986.tb04601.x; VONHEIJNE G, 1989, NATURE, V341, P456, DOI 10.1038/341456a0; WATERS SH, 1983, NUCLEIC ACIDS RES, V11, P6089, DOI 10.1093/nar/11.17.6089; YAMAGUCHI A, 1990, J BIOL CHEM, V265, P4809; YAMAGUCHI A, 1991, J BIOL CHEM, V266, P6045; YAMAGUCHI A, 1990, FEBS LETT, V265, P17, DOI 10.1016/0014-5793(90)80872-G; YAMAGUCHI A, 1990, J BIOL CHEM, V265, P15525; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; ZAGURSKY RJ, 1984, GENE, V27, P183, DOI 10.1016/0378-1119(84)90139-2; [No title captured]	70	100	102	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1992	267	25					17809	17819						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JM223	1517220				2022-12-25	WOS:A1992JM22300053
J	CHEN, XR; AZIZKHAN, JC; LEE, DC				CHEN, XR; AZIZKHAN, JC; LEE, DC			THE BINDING OF TRANSCRIPTION FACTOR SP1 TO MULTIPLE SITES IS REQUIRED FOR MAXIMAL EXPRESSION FROM THE RAT TRANSFORMING GROWTH-FACTOR ALPHA-PROMOTER	ONCOGENE			English	Article							SPECIFICALLY STIMULATES TRANSCRIPTION; REDUCTASE GENE PROMOTER; EPITHELIAL-CELL LINE; FACTOR RECEPTOR GENE; RNA POLYMERASE-II; C-FOS GENE; TGF-ALPHA; TRANSGENIC MICE; MESSENGER-RNA; HEPATOCELLULAR-CARCINOMA	Transcription from the rat transforming growth factor-alpha (TGF-alpha) promoter initiates at multiple sites within a 200-bp G+C-rich region that lacks TATA and CAAT motifs but contains multiple potential binding sites for the transcription factor Sp1. In the present study, we used deletion analysis to establish the 5' boundary of sequences required for efficient transcription from the predominant - 58 start site. We then examined the functional activity of several putative Spl binding sites that occur within the transcriptionally important region downstream from - 155. In the presence of either crude HeLa cell extract or purified Sp1 protein, two double-stranded oligonucleotides from this region, each of which contains three Spl elements, both displayed gel mobility shifts that were specifically inhibited in the presence of excess bona fide Spl-binding sequence from the hamster dihydrofolate reductase (DHFR) gene. Methylation interference analysis of the major gel-shift complex produced with one of these oligonucleotides revealed a series of critical guanine residues located in, or adjacent to, one of the putative Sp1 recognition elements. rhe functional importance of Sp1 binding was confirmed by these findings that transcription in vitro from the - 58 start site was inhibited in the presence of excess consensus Sp1-binding sequence and that coexpression of Spl dramatically induced TGF-alpha promoter-directed chloramphenicol acetyl transferase (CAT) expression in transfected Drostophila Schneider cells that otherwise lack functional Sp1. Additionally, the introduction of mutations into any of several putative Spl elements inhibited transcription in vitro from the - 58 site, with the most proximal element tested having the largest effect. Sequential mutation of more distal elements produced a synergistic inhibition of transcription, suggesting that cooperative interactions between Spl sites are necessary for full expression from the TGF-alpha promoter.	UNIV N CAROLINA, DEPT MICROBIOL & IMMUNOL, CHAPEL HILL, NC 27599 USA; UNIV N CAROLINA, DEPT PEDIAT, CHAPEL HILL, NC 27599 USA; UNIV N CAROLINA, DEPT PHARMACOL, CHAPEL HILL, NC 27599 USA; UNIV N CAROLINA, LINEBERGER COMPREHENS CANC CTR, CHAPEL HILL, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill					NCI NIH HHS [CA-43793] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA043793] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARTEAGA CL, 1988, CANCER RES, V48, P5023; AZIZKHAN JC, 1986, BIOCHEMISTRY-US, V25, P6228, DOI 10.1021/bi00368a059; BARRANDON Y, 1987, CELL, V50, P1131, DOI 10.1016/0092-8674(87)90179-6; BLAKE MC, 1989, MOL CELL BIOL, V9, P4994, DOI 10.1128/MCB.9.11.4994; BLAKE MC, 1990, MOL CELL BIOL, V10, P6632, DOI 10.1128/MCB.10.12.6632; BLASBAND AJ, 1990, ONCOGENE, V5, P1213; BLASBAND AJ, 1990, MOL CELL BIOL, V10, P2111, DOI 10.1128/MCB.10.5.2111; BRACHMANN R, 1989, CELL, V56, P691, DOI 10.1016/0092-8674(89)90591-6; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; BRINGMAN TS, 1987, CELL, V48, P429, DOI 10.1016/0092-8674(87)90194-2; CARTHEW RW, 1985, CELL, V43, P439, DOI 10.1016/0092-8674(85)90174-6; COFFEY RJ, 1987, NATURE, V328, P817, DOI 10.1038/328817a0; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; DELARCO JE, 1978, P NATL ACAD SCI USA, V75, P4001; DERYNCK R, 1984, CELL, V38, P287, DOI 10.1016/0092-8674(84)90550-6; DERYNCK R, 1987, CANCER RES, V47, P707; DERYNCK R, 1986, J CELL BIOCHEM, V32, P293, DOI 10.1002/jcb.240320406; DICKSON RB, 1986, CANCER RES, V46, P1707; DICKSON RB, 1987, P NATL ACAD SCI USA, V84, P837, DOI 10.1073/pnas.84.3.837; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DINOCERA PP, 1983, P NATL ACAD SCI-BIOL, V80, P7095; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; GIDONI D, 1984, NATURE, V312, P409, DOI 10.1038/312409a0; GIDONI D, 1985, SCIENCE, V230, P511, DOI 10.1126/science.2996137; GODWIN AK, 1990, ONCOGENE, V5, P1231; HAN VKM, 1987, MOL CELL BIOL, V7, P2335, DOI 10.1128/MCB.7.7.2335; HENDRICKSON W, 1985, P NATL ACAD SCI USA, V82, P3129, DOI 10.1073/pnas.82.10.3129; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HENNINGHAUSEN L, 1987, METHOD ENZYMOL, V152, P725; HIGASHIYAMA S, 1991, SCIENCE, V251, P936, DOI 10.1126/science.1840698; IGNOTZ RA, 1986, P NATL ACAD SCI USA, V83, P6307, DOI 10.1073/pnas.83.17.6307; JACKSON SP, 1988, CELL, V55, P125, DOI 10.1016/0092-8674(88)90015-3; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; JAKOBOVITS EB, 1988, MOL CELL BIOL, V8, P5549, DOI 10.1128/MCB.8.12.5549; JHAPPAN C, 1990, CELL, V61, P1137, DOI 10.1016/0092-8674(90)90076-Q; JONES KA, 1986, SCIENCE, V232, P755, DOI 10.1126/science.3008338; KADONAGA JT, 1987, NEW FRONTIERS STUDY, P87; KAGEYAMA R, 1988, P NATL ACAD SCI USA, V85, P5016, DOI 10.1073/pnas.85.14.5016; KAGEYAMA R, 1988, J BIOL CHEM, V263, P6329; KAGEYAMA R, 1989, J BIOL CHEM, V264, P15508; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KINGSTON RE, 1989, CURRENT PROTOCOLS MO, P481; KRUIJER W, 1984, NATURE, V312, P711, DOI 10.1038/312711a0; KUDLOW JE, 1989, J BIOL CHEM, V264, P3880; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LEE DC, 1985, NATURE, V313, P489, DOI 10.1038/313489a0; LIU C, 1988, CANCER RES, V48, P850; LIU SC, 1987, MOL ENDOCRINOL, V1, P683, DOI 10.1210/mend-1-10-683; LOBB DK, 1989, BIOL REPROD, V40, P1087, DOI 10.1095/biolreprod40.5.1087; LUETTEKE NC, 1988, BIOCHEMISTRY-US, V27, P6487, DOI 10.1021/bi00417a043; MADTES DK, 1988, CELL, V53, P285, DOI 10.1016/0092-8674(88)90390-X; MARCO ED, 1989, ONCOGENE, V4, P831; MASSAGUE J, 1983, J BIOL CHEM, V258, P3614; MATSUI Y, 1990, CELL, V61, P1147, DOI 10.1016/0092-8674(90)90077-R; Maxam A M, 1980, Methods Enzymol, V65, P499; MITCHELL PJ, 1986, MOL CELL BIOL, V6, P425, DOI 10.1128/MCB.6.2.425; MUELLER SG, 1989, MOL ENDOCRINOL, V3, P976, DOI 10.1210/mend-3-6-976; MULLER R, 1984, NATURE, V312, P716, DOI 10.1038/312716a0; OZANNE B, 1980, J CELL PHYSIOL, V105, P163, DOI 10.1002/jcp.1041050118; PITTELKOW MR, 1989, J BIOL CHEM, V264, P5164; RAJA RH, 1991, MOL ENDOCRINOL, V5, P514, DOI 10.1210/mend-5-4-514; RAYMOND VW, 1989, CANCER RES, V49, P3608; ROSENTHAL A, 1986, CELL, V46, P301, DOI 10.1016/0092-8674(86)90747-6; SALOMON DS, 1987, J CELL PHYSIOL, V130, P397, DOI 10.1002/jcp.1041300313; SAMSOONDAR J, 1986, J BIOL CHEM, V261, P4408; SANDGREN EP, 1990, CELL, V61, P1121, DOI 10.1016/0092-8674(90)90075-P; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHAUFELE F, 1990, J BIOL CHEM, V265, P17189; SCHNEIDER I, 1972, J EMBRYOL EXP MORPH, V27, P353; SHOYAB M, 1989, SCIENCE, V243, P1074, DOI 10.1126/science.2466334; SKINNER MK, 1989, ENDOCRINOLOGY, V124, P845, DOI 10.1210/endo-124-2-845; SWICK AG, 1989, NUCLEIC ACIDS RES, V17, P9291, DOI 10.1093/nar/17.22.9291; TEIXIDO J, 1988, J BIOL CHEM, V263, P3924; TSAO MS, 1984, EXP CELL RES, V154, P38, DOI 10.1016/0014-4827(84)90666-9; VASSAR R, 1991, GENE DEV, V5, P714, DOI 10.1101/gad.5.5.714; WILCOX JN, 1988, J NEUROSCI, V8, P1901; WONG ST, 1989, CELL, V56, P495, DOI 10.1016/0092-8674(89)90252-3; YEH YC, 1987, CANCER RES, V47, P896; ZOLLER MJ, 1983, METHOD ENZYMOL, V100, P468	79	65	65	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	1992	7	9					1805	1815						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JJ376	1501890				2022-12-25	WOS:A1992JJ37600017
J	GODBOUT, R; MIYAKOSHI, J; DOBLER, KD; ANDISON, R; MATSUO, K; ALLALUNISTURNER, MJ; TAKEBE, H; DAY, RS				GODBOUT, R; MIYAKOSHI, J; DOBLER, KD; ANDISON, R; MATSUO, K; ALLALUNISTURNER, MJ; TAKEBE, H; DAY, RS			LACK OF EXPRESSION OF TUMOR-SUPPRESSOR GENES IN HUMAN-MALIGNANT GLIOMA CELL-LINES	ONCOGENE			English	Article							RETINOBLASTOMA-SUSCEPTIBILITY GENE; HUMAN O-6-METHYLGUANINE-DNA METHYLTRANSFERASE; SV40 LARGE-T; SV40-TRANSFORMED CELLS; HUMAN FIBROBLASTS; ESCHERICHIA-COLI; CARCINOMA-CELLS; MESSENGER-RNA; P53 MUTATIONS; RB1 GENE	Human malignant gliomas (glioblastomas and anaplastic astrocytomas) are the most frequent brain tumors and are associated with a variety of genetic alterations including retinoblastoma (RB) and p53 gene mutations, loss of interferon-alpha and beta (IFNA, IFNB) genes and lack of O6-methylguanine-DNA methyltransferase (MGMT) expression. Yet, in the studies performed to date, the relationship between these alterations has not been addressed. In this report, we have studied gene expression in 29 malignant glioma cell lines and have determined that, although loss of the interferon genes and loss of RB, p53 and MGMT mRNAs are frequent events, combinations of genetic alterations involving these four proven or putative tumor-suppressor genes are relatively infrequent. The exception was loss of RB mRNA, which may be associated with lack of MGMT mRNA.	CROSS CANC INST,DEPT MED,MOLEC GENET & CARCINOGENESIS LAB,11560 UNIV AVE,EDMONTON T6G 1Z2,ALBERTA,CANADA; CROSS CANC INST,DEPT RADIAT ONCOL,RADIOBIOL LAB,EDMONTON T6G 1Z2,ALBERTA,CANADA; KYOTO UNIV,FAC MED,DEPT ANGEW PHYS,KYOTO 606,JAPAN	University of Alberta; University of Alberta; Kyoto University			Godbout, Roseline/I-4639-2016	Godbout, Roseline/0000-0002-4779-9265				AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BIGNER SH, 1988, CANCER RES, V48, P405; BOOKSTEIN R, 1990, SCIENCE, V247, P712, DOI 10.1126/science.2300823; DAY RS, 1979, NATURE, V279, P797, DOI 10.1038/279797a0; DAY RS, 1980, NATURE, V288, P724, DOI 10.1038/288724a0; DAY RS, 1974, CANCER RES, V34, P1965; DAY RS, 1991, MUTAT RES, V254, P153, DOI 10.1016/0921-8777(91)90006-B; DUNN JM, 1989, MOL CELL BIOL, V9, P4596, DOI 10.1128/MCB.9.11.4596; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FORNACE AJ, 1990, CANCER RES, V50, P7908; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; FULTS D, 1989, CANCER RES, V49, P6572; FUNG YKT, 1987, SCIENCE, V236, P1657, DOI 10.1126/science.2885916; GARDNER E, 1991, GENOMICS, V11, P475, DOI 10.1016/0888-7543(91)90162-8; GIARD DJ, 1973, J NATL CANCER I, V51, P1417, DOI 10.1093/jnci/51.5.1417; GODDARD AD, 1988, MOL CELL BIOL, V8, P2082, DOI 10.1128/MCB.8.5.2082; GOEDDEL DV, 1980, NATURE, V287, P411, DOI 10.1038/287411a0; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HOROWITZ JM, 1989, SCIENCE, V243, P937, DOI 10.1126/science.2521957; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; JAMES CD, 1988, CANCER RES, V48, P5546; JAMES CD, 1991, CANCER RES, V51, P1684; KIM SJ, 1991, P NATL ACAD SCI USA, V88, P3052, DOI 10.1073/pnas.88.8.3052; KOIKE G, 1990, J BIOL CHEM, V265, P14754; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LEE EYHP, 1988, SCIENCE, V241, P218, DOI 10.1126/science.3388033; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LI FP, 1988, CANCER RES, V48, P5358; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; LUDLOW JW, 1989, CELL, V56, P57, DOI 10.1016/0092-8674(89)90983-5; LUDLOW JW, 1990, CELL, V60, P387, DOI 10.1016/0092-8674(90)90590-B; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MINTY AJ, 1981, J BIOL CHEM, V256, P1008; MIYAKOSHI J, 1990, CANCER RES, V50, P278; MIYAKOSHI J, 1991, MUTAT RES, V254, P55, DOI 10.1016/0921-8777(91)90040-V; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; PIEPER RO, 1991, CANCER COMMUN, V3, P241, DOI 10.3727/095535491820873092; PIEPER RO, 1990, CANCER COMMUN, V2, P13, DOI 10.3727/095535490820874812; Ponten J, 1975, HUMAN TUMOR CELLS IN, P175, DOI [10.1007/9781-47571647-4_7, DOI 10.1007/9781-47571647-4_7]; RYDBERG B, 1990, J BIOL CHEM, V265, P9563; SARIBAN E, 1987, CANCER RES, V47, P3988; SCUDIERO DA, 1984, CANCER RES, V44, P961; Shew J.-Y., 1989, ONCOGENE RES, V1, P205; SHRIVASTAVA S, 1990, NATURE, V348, P747; TANG A, 1988, SCIENCE, V242, P263, DOI 10.1126/science.3175651; TANO K, 1990, P NATL ACAD SCI USA, V87, P686, DOI 10.1073/pnas.87.2.686; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; TOGUCHIDA J, 1988, CANCER RES, V48, P3939; VENTER DJ, 1991, ONCOGENE, V6, P445; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; WAHL GM, 1979, P NATL ACAD SCI USA, V76, P3863; WEICHSELBAUM RR, 1988, P NATL ACAD SCI USA, V85, P2106, DOI 10.1073/pnas.85.7.2106; YOKOTA J, 1988, ONCOGENE, V3, P471; ZAKUTHOURI R, 1985, EMBO J, V4, P1251, DOI 10.1002/j.1460-2075.1985.tb03768.x	57	35	35	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1992	7	9					1879	1884						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JJ376	1501894				2022-12-25	WOS:A1992JJ37600026
J	POLLARD, HB; DHARIWAL, K; ADEYEMO, OM; MARKEY, CJ; CAOHUY, H; LEVINE, M; MARKEY, S; YOUDIM, MBH				POLLARD, HB; DHARIWAL, K; ADEYEMO, OM; MARKEY, CJ; CAOHUY, H; LEVINE, M; MARKEY, S; YOUDIM, MBH			A PARKINSONIAN SYNDROME INDUCED IN THE GOLDFISH BY THE NEUROTOXIN MPTP	FASEB JOURNAL			English	Article						CATECHOLAMINES; MPP+; BRAIN; NEURONS; REGENERATION	1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE MPTP; MONOAMINE-OXIDASE; DOPAMINERGIC NEUROTOXICITY; TYROSINE-HYDROXYLASE; PRIMATE MODEL; OPTIC-NERVE; BRAIN; NEURONS; DISEASE; N-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE	Parkinson's disease has been modeled in humans, lower primates, and to a lesser extent in some other vertebrates by administration of the potent neurotoxin MPTP (1-methyl-4-phenyl-1,2,3,6 tetra-hydropyridine). The MPTP model has thus drawn considerable attention as a system to search for anti-Parkinson's disease drugs, although the cost and scarcity of primates has limited extensive applications. We now report that a parkinsonian syndrome can be elicited in the common goldfish (Carassius auratus) by a single dose of MPTP. The syndrome is characterized by profound bradykinesia (slow movement), the full extent of which is reached 3 days after MPTP administration. The reduction in movement is paralleled by loss of dopamine and norepinephrine from the forebrain and mid-brain and in other brain regions as well. The toxic oxidative product of MPTP, MPP+, is also accumulated predominantly in forebrain and midbrain, and pretreatment with the monoamine oxidase blocker tranylcypromine substantially reduces accumulation of the toxic metabolite. A barely perceptible coarseness in balance adjustment also occurs in treated animals. The MPTP-treated goldfish recover normal movement and normal brain monoamine levels within 10-13 days after administration of the drug. We interpret these and other data to indicate that MPTP can induce a Parkinson's disease-like syndrome in the goldfish that is similar in many aspects to the syndrome induced by MPTP in humans and other primates. This remarkable parallel may permit the goldfish to supplement expensive and scarce primates for the purpose of searching and screening neuroprotective drugs with specific relevance to Parkinson's disease.	UNIFORMED SERV UNIV HLTH SCI, DEPT PHARMACOL, BETHESDA, MD 20892 USA; NIMH, CLIN SCI LAB, BETHESDA, MD 20892 USA; UNIFORMED SERV UNIV HLTH SCI, DEPT NEUROL, BETHESDA, MD 20892 USA	Uniformed Services University of the Health Sciences - USA; National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH); Uniformed Services University of the Health Sciences - USA	POLLARD, HB (corresponding author), NIDDKD, CELL BIOL & GENET LAB, BETHESDA, MD 20892 USA.							ADEYEMO OM, 1991, TOXICOL APPL PHARM, V108, P489, DOI 10.1016/0041-008X(91)90095-V; AMBRE JJ, 1988, CLIN PHARMACOL THER, V44, P1, DOI 10.1038/clpt.1988.104; ATTARDI DG, 1963, EXP NEUROL, V7, P46, DOI 10.1016/0014-4886(63)90093-1; BARBEAU A, 1986, MPTP NEUROTOXIN PROD; BENOWITZ LI, 1981, J NEUROSCI, V1, P300; BERNHEIM.H, 1965, KLIN WOCHENSCHR, V43, P711, DOI 10.1007/BF01707066; BIRKMAYER W, 1985, J NEURAL TRANSM, V64, P113, DOI 10.1007/BF01245973; Birkmayer W, 1983, Mod Probl Pharmacopsychiatry, V19, P170; BOYCE S, 1984, BIOCHEM PHARMACOL, V33, P1747, DOI 10.1016/0006-2952(84)90344-7; BRADBURY M, 1979, CONCEPT BLOOD BRAIN, P301; Bullock Theodore H., 1977, INTRO NERVOUS SYSTEM; BURNS RS, 1983, P NATL ACAD SCI-BIOL, V80, P4546, DOI 10.1073/pnas.80.14.4546; CHIBA K, 1984, BIOCHEM BIOPH RES CO, V120, P574, DOI 10.1016/0006-291X(84)91293-2; CHIUEH CC, 1984, PSYCHOPHARMACOL BULL, V20, P548; COHEN G, 1984, EUR J PHARMACOL, V106, P209, DOI 10.1016/0014-2999(84)90700-3; DOLI A, 1990, BRAIN RES, V534, P45; FRITZ RR, 1985, FEBS LETT, V186, P224, DOI 10.1016/0014-5793(85)80713-4; HALLMAN H, 1985, J NEUROCHEM, V44, P117, DOI 10.1111/j.1471-4159.1985.tb07120.x; HEIKKILA RE, 1985, J NEUROCHEM, V44, P310, DOI 10.1111/j.1471-4159.1985.tb07146.x; HEIKKILA RE, 1984, SCIENCE, V224, P1451, DOI 10.1126/science.6610213; HEIKKILA RE, 1984, NATURE, V311, P467, DOI 10.1038/311467a0; HEIKKILA RE, 1987, HDB PARKINSONS DISEA, P267; HESS A, 1984, ABSTR SOC NEUROSCI, V10, P705; HORNBY PJ, 1987, J COMP NEUROL, V261, P1, DOI 10.1002/cne.902610102; HORNYKIEWICZ O., 1963, WIENER KLIN WOCHENSCHR, V75, P309; IKEDA H, 1992, IN PRESS BRAIN RES; JARVIS MF, 1990, SYNAPSE, V5, P104, DOI 10.1002/syn.890050204; JAVITCH JA, 1985, P NATL ACAD SCI USA, V82, P2173, DOI 10.1073/pnas.82.7.2173; JENNER P, 1984, NEUROSCI LETT, V50, P85, DOI 10.1016/0304-3940(84)90467-1; JENNER P, 1990, SEMIN NEUROSCI, V2, P117; JOHANNESSEN J N, 1985, Society for Neuroscience Abstracts, V11, P631; KAPPERS CUA, 1936, COMP ANATOMY NERVOUS, V2; KINEMUCHI H, 1987, NEUROCHEM INT, V11, P359, DOI 10.1016/0197-0186(87)90024-6; KOPP N, 1982, ACTA NEUROPATHOL, V56, P17, DOI 10.1007/BF00691177; LANGSTON JW, 1983, SCIENCE, V219, P979, DOI 10.1126/science.6823561; LANGSTON JW, 1984, BRAIN RES, V292, P390; LENT CM, 1986, MPTP NEUROTOXIN PROD; LEVINE M, 1988, J BIOL CHEM, V263, P19353; LEVINE RL, 1983, DEV BRAIN RES, V9, P416, DOI 10.1016/0165-3806(83)90043-3; LLOYD KG, 1975, J PHARMACOL EXP THER, V195, P453; MARKEY SP, 1986, MED RES REV, V6, P389, DOI 10.1002/med.2610060402; MEFFORD IN, 1980, ANAL BIOCHEM, V104, P469, DOI 10.1016/0003-2697(80)90101-3; MITCHELL IJ, 1985, NEUROSCI LETT, V61, P195, DOI 10.1016/0304-3940(85)90424-0; MOORE RY, 1979, ANNU REV NEUROSCI, V2, P113, DOI 10.1146/annurev.ne.02.030179.000553; MURRAY M, 1969, EXP NEUROL, V23, P544, DOI 10.1016/0014-4886(69)90124-1; NAGATSU I, 1984, ACTA HISTOCHEM CYTOC, V17, P151, DOI 10.1267/ahc.17.151; PARISI JE, 1986, MPTP NEUROTOXIN PROD, P141; PIFL C, 1991, NEUROSCIENCE, V44, P591, DOI 10.1016/0306-4522(91)90080-8; PILEBLAD E, 1988, PHARMACOL TOXICOL, V62, P213, DOI 10.1111/j.1600-0773.1988.tb01875.x; Price K S, 1978, Adv Biochem Psychopharmacol, V19, P293; SCATTON B, 1983, BRAIN RES, V275, P321, DOI 10.1016/0006-8993(83)90993-9; SCHERER SS, 1984, J NEUROCYTOL, V13, P519, DOI 10.1007/BF01148079; SCHNEIDER JS, 1986, BRAIN RES, V373, P258, DOI 10.1016/0006-8993(86)90340-9; SPERRY RW, 1974, Q REV BIOL S, V2, P311; SPRINGER AD, 1977, BRAIN RES, V128, P405, DOI 10.1016/0006-8993(77)90167-6; SUN CJ, 1988, J NEURAL TRANSM, V74, P75, DOI 10.1007/BF01245141; TETRUD JW, 1989, ACTA NEUROL SCAND, V80, P35, DOI 10.1111/j.1600-0404.1989.tb01780.x; WOOTEN GF, 1987, HDB PARKINSONS DISEA, P237; YOON MG, 1976, J PHYSIOL-LONDON, V257, P621, DOI 10.1113/jphysiol.1976.sp011388; YOUDIM MBH, 1992, NEUROCHEM INT, V20, pS275; YOUDIM MBH, 1988, CATECHOLAMINE 2, V90; ZAMIR N, 1984, BRAIN RES, V322, P356, DOI 10.1016/0006-8993(84)90133-1; 1990, OTABA436 OFF TECHN A, P361	63	51	54	1	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	1992	6	12					3108	3116		10.1096/fasebj.6.12.1521741	http://dx.doi.org/10.1096/fasebj.6.12.1521741			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	JN505	1521741				2022-12-25	WOS:A1992JN50500013
J	HENNEMANN, H; DAHL, E; WHITE, JB; SCHWARZ, HJ; LALLEY, PA; CHANG, S; NICHOLSON, BJ; WILLECKE, K				HENNEMANN, H; DAHL, E; WHITE, JB; SCHWARZ, HJ; LALLEY, PA; CHANG, S; NICHOLSON, BJ; WILLECKE, K			2 GAP JUNCTION GENES, CONNEXIN 31.1 AND 30.3, ARE CLOSELY LINKED ON MOUSE CHROMOSOME-4 AND PREFERENTIALLY EXPRESSED IN SKIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTIONAL EXPRESSION; MOLECULAR-CLONING; SEQUENCE-ANALYSIS; MESSENGER-RNAS; PROTEINS; LIVER; FAMILY; CELLS; VOLTAGE; CHANNEL	Two new gap junction genes isolated from the mouse genome code for connexin homologues of 271 and 266 amino acids, designated here Cx31.1 and Cx30.3, respectively. The two open reading frames, oriented in the same direction, are only 3.4 kb apart on mouse chromosome 4. Within the connexin family, these two proteins are most closely related to one another (70% amino acid sequence identity) and to Cx31 (65 and 68% identity, respectively). Comparison of the Cx31.1 mouse gene with a Cx31.1 cDNA showed a similar genomic organization to that found with other members of the connexin gene family, i.e. the coding and 3'-untranslated regions are contained within a single exon, which is preceded by an intron, less than 25 bases upstream of the ATG start codon. Northern blot hybridization revealed highly tissue-specific coexpression of the 1.6-kb Cx31.1 mRNA and two Cx30.3 transcripts of 1.9- and 3.2-kb size, predominantly in skin and two related mouse keratinocyte cell lines. Minor levels of Cx31.1 mRNA were detected in testis. Microinjection of Cx30.3, but not Cx31.1 cRNA, into Xenopus oocyte pairs induced formation of functional gap junction channels with unique voltage-gated parameters compared to other connexins expressed similarly.	UNIV BONN,INST GENET,MOLEK GENET ABT,ROMERSTR 164,W-5300 BONN 1,GERMANY; SUNY BUFFALO,DEPT BIOL SCI,BUFFALO,NY 14260; WAYNE STATE UNIV,CTR MOLEC BIOL,DETROIT,MI 48201	University of Bonn; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; Wayne State University				Nicholson, Bruce/0000-0003-1649-7173	NCI NIH HHS [CA-48049] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA048049] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABKEN H, 1986, J CELL BIOL, V103, P795, DOI 10.1083/jcb.103.3.795; BARRIO LC, 1991, P NATL ACAD SCI USA, V88, P8410, DOI 10.1073/pnas.88.19.8410; BENNETT MVL, 1991, NEURON, V6, P305, DOI 10.1016/0896-6273(91)90241-Q; BEYER EC, 1990, J MEMBRANE BIOL, V116, P187, DOI 10.1007/BF01868459; BRISSETTE JL, 1991, MOL CELL BIOL, V11, P5364, DOI 10.1128/MCB.11.10.5364; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DASH P, 1987, P NATL ACAD SCI USA, V84, P7896, DOI 10.1073/pnas.84.22.7896; FALLON RF, 1981, J CELL BIOL, V90, P521, DOI 10.1083/jcb.90.2.521; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FISHMAN GI, 1990, J CELL BIOL, V111, P589, DOI 10.1083/jcb.111.2.589; FISHMAN GI, 1991, GENOMICS, V10, P250, DOI 10.1016/0888-7543(91)90507-B; FRANCKE U, 1977, CYTOGENET CELL GENET, V19, P57, DOI 10.1159/000130799; Fusenig N E, 1985, Carcinog Compr Surv, V9, P293; FUSENIG NE, 1983, J INVEST DERMATOL, V91, P1685; GIMLICH RL, 1990, J CELL BIOL, V110, P597, DOI 10.1083/jcb.110.3.597; HAEFLIGER JA, 1992, J BIOL CHEM, V267, P2057; HENNEMANN H, 1992, EUR J CELL BIOL, V57, P51; HENNEMANN H, 1992, J CELL BIOL, V117, P1299, DOI 10.1083/jcb.117.6.1299; HENNEMANN H, 1992, IN PRESS EUR J CELL; HERTZBERG EL, 1988, J BIOL CHEM, V263, P19105; HOH JH, 1991, J BIOL CHEM, V266, P6524; HSIEH CL, 1991, SOMAT CELL MOLEC GEN, V17, P191, DOI 10.1007/BF01232976; HYNES NE, 1981, P NATL ACAD SCI-BIOL, V78, P2038, DOI 10.1073/pnas.78.4.2038; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; LALLEY PA, 1978, P NATL ACAD SCI USA, V75, P2382, DOI 10.1073/pnas.75.5.2382; LOEWENSTEIN W, 1988, CELL, V48, P725; MILKS LC, 1988, EMBO J, V7, P2967, DOI 10.1002/j.1460-2075.1988.tb03159.x; MILLER T, 1988, BIOSCIENCE REP, V8, P455, DOI 10.1007/BF01121644; MINNA JD, 1978, SOMAT CELL GENET, V4, P241, DOI 10.1007/BF01538988; QUEEN C, 1984, NUCLEIC ACIDS RES, V12, P581, DOI 10.1093/nar/12.1Part2.581; Sambrook J, 1989, J SAMBROOK MOL CLONI; SHAPIRO MB, 1987, NUCLEIC ACIDS RES, V15, P7155, DOI 10.1093/nar/15.17.7155; SHORT JM, 1988, NUCLEIC ACIDS RES, V16, P7583, DOI 10.1093/nar/16.15.7583; SPRAY DC, 1981, J GEN PHYSIOL, V77, P77, DOI 10.1085/jgp.77.1.77; SWENSON KI, 1989, CELL, V57, P145, DOI 10.1016/0092-8674(89)90180-3; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; TRAUB O, 1989, J CELL BIOL, V108, P1039, DOI 10.1083/jcb.108.3.1039; UNWIN N, 1989, NEURON, V3, P665, DOI 10.1016/0896-6273(89)90235-3; WILLECKE K, 1991, EUR J CELL BIOL, V56, P1; WILLECKE K, 1991, J CELL BIOL, V114, P1049, DOI 10.1083/jcb.114.5.1049; WILLS RBH, 1990, J SCI FOOD AGR, V53, P275, DOI 10.1002/jsfa.2740530216; YANCEY SB, 1989, J CELL BIOL, V108, P2241, DOI 10.1083/jcb.108.6.2241; YANCEY SB, 1981, J SUPRAMOL STR CELL, V16, P221, DOI 10.1002/jsscb.1981.380160303; ZHANG JT, 1989, J CELL BIOL, V109, P3391, DOI 10.1083/jcb.109.6.3391; ZIMMER DB, 1987, J BIOL CHEM, V262, P7751	48	85	89	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1992	267	24					17225	17233						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JL053	1512260				2022-12-25	WOS:A1992JL05300076
J	HURLBURT, BK; YANOFSKY, C				HURLBURT, BK; YANOFSKY, C			TRP REPRESSOR/TRP OPERATOR INTERACTION - EQUILIBRIUM AND KINETIC-ANALYSIS OF COMPLEX-FORMATION AND STABILITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI K-12; STRUCTURAL GENE; L-TRYPTOPHAN; DNA-BINDING; NUCLEOTIDE-SEQUENCE; CRYSTAL-STRUCTURE; APOREPRESSOR; AROH; ASSIGNMENTS; EXPRESSION	The trp repressor of Escherichia coli regulates transcription initiation in the trp operon by binding at an operator located within the trp promoter region. We have used a filter binding assay to analyze the interaction between purified trp repressor and a synthetic 43-base pair DNA fragment containing the natural trp promoter-operator region. In equilibrium binding experiments, the K(D) of high affinity binding of trp repressor to this DNA fragment was determined to be 2 x 10(-10) M. Low affinity binding was observed at repressor concentrations above 10 nM. In kinetic experiments with various input ratios of repressor to operator, trp repressor-operator complexes dissociated with equivalent, first-order kinetics. Instantaneous reduction of the tryptophan concentration resulted in increased rates of complex dissociation, indicating that loss of one or both tryptophan molecules from the repressor-operator complex destabilizes the complex. A heterodimeric repressor with a single tryptophan binding site was constructed and its affinity for operator was compared with that of ligand free aporepressor and tryptophan saturated repressor. The heterodimeric repressor had a 20-25-fold higher affinity for operator than did the aporepressor, and it had a 20-25-fold lower affinity for operator than did the tryptophan-saturated repressor.			HURLBURT, BK (corresponding author), STANFORD UNIV,DEPT BIOL SCI,STANFORD,CA 94305, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM011980] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM11980] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARROWSMITH C, 1991, EUR J BIOCHEM, V202, P53, DOI 10.1111/j.1432-1033.1991.tb16344.x; ARROWSMITH CH, 1990, BIOCHEMISTRY-US, V29, P6332, DOI 10.1021/bi00479a002; ARROWSMITH CH, 1989, BIOCHEMISTRY-US, V28, P3875, DOI 10.1021/bi00435a037; ARVIDSON DN, 1986, J BIOL CHEM, V261, P238; BENNETT GN, 1978, J MOL BIOL, V121, P179, DOI 10.1016/S0022-2836(78)80004-7; CAREY J, 1989, J BIOL CHEM, V264, P1941; CAREY J, 1991, J BIOL CHEM, V266, P24509; CAREY J, 1988, P NATL ACAD SCI USA, V85, P975, DOI 10.1073/pnas.85.4.975; CHOU WY, 1989, J BIOL CHEM, V264, P18309; GRADDIS TJ, 1988, PROTEINS, V4, P173, DOI 10.1002/prot.340040304; GUNSALUS RP, 1980, P NATL ACAD SCI-BIOL, V77, P7117, DOI 10.1073/pnas.77.12.7117; HARRISON SC, 1990, ANNU REV BIOCHEM, V59, P933, DOI 10.1146/annurev.bi.59.070190.004441; HE JJ, 1990, J BIOL CHEM, V265, P731; HEATWOLE VM, 1991, J BACTERIOL, V173, P108, DOI 10.1128/jb.173.1.108-115.1991; HURLBURT BK, 1992, NUCLEIC ACIDS RES, V20, P337, DOI 10.1093/nar/20.2.337; HURLBURT BK, 1990, J BIOL CHEM, V265, P7853; JOACHIMIAK A, 1983, P NATL ACAD SCI-BIOL, V80, P668, DOI 10.1073/pnas.80.3.668; KELLEY RL, 1985, P NATL ACAD SCI USA, V82, P483, DOI 10.1073/pnas.82.2.483; KLIG LS, 1988, J MOL BIOL, V202, P769, DOI 10.1016/0022-2836(88)90557-8; KLIG LS, 1987, NUCLEIC ACIDS RES, V15, P5339, DOI 10.1093/nar/15.13.5339; KUMAMOTO AA, 1987, GENE DEV, V1, P556, DOI 10.1101/gad.1.6.556; LAWSON CL, 1988, PROTEINS, V3, P18, DOI 10.1002/prot.340030103; MAJORS J, 1975, NATURE, V256, P672, DOI 10.1038/256672a0; MARMORSTEIN RQ, 1987, J BIOL CHEM, V262, P4922; MARMORSTEIN RQ, 1989, J BIOL CHEM, V264, P9149; OTWINOWSKI Z, 1988, NATURE, V335, P321, DOI 10.1038/335321a0; PALUH JL, 1986, NUCLEIC ACIDS RES, V14, P7851, DOI 10.1093/nar/14.20.7851; SARSERO JP, 1991, J BACTERIOL, V173, P4133, DOI 10.1128/jb.173.13.4133-4143.1991; SCHEVITZ RW, 1985, NATURE, V317, P782, DOI 10.1038/317782a0; SQUIRES CL, 1975, J MOL BIOL, V92, P93, DOI 10.1016/0022-2836(75)90093-5; STAACKE D, 1990, EMBO J, V9, P1963, DOI 10.1002/j.1460-2075.1990.tb08324.x; TAKEDA Y, 1977, J BIOL CHEM, V252, P6177; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; ZHANG RG, 1987, NATURE, V327, P591, DOI 10.1038/327591a0; ZURAWSKI G, 1981, J MOL BIOL, V145, P47, DOI 10.1016/0022-2836(81)90334-X	35	21	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1992	267	24					16783	16789						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JL053	1512220				2022-12-25	WOS:A1992JL05300010
J	PHILLIPS, WJ; WONG, SC; CERIONE, RA				PHILLIPS, WJ; WONG, SC; CERIONE, RA			RHODOPSIN TRANSDUCIN INTERACTIONS .2. INFLUENCE OF THE TRANSDUCIN-BETA-GAMMA SUBUNIT COMPLEX ON THE COUPLING OF THE TRANSDUCIN-ALPHA SUBUNIT TO RHODOPSIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ROD OUTER SEGMENTS; NUCLEOTIDE-BINDING PROTEINS; PHOSPHOLIPID-VESICLES; PERTUSSIS TOXIN; BOVINE BRAIN; KINASE-C; PHOSPHORYLATION; RECEPTOR; PHOTOTRANSDUCTION; RECONSTITUTION	In these studies we have investigated the role of the beta-gamma(T) subunit complex in promoting the rhodopsin-stimulated guanine nucleotide exchange reaction (i.e. the activation event) of the alpha(T) subunit. The results of these studies demonstrate that although the beta-gamma(T) subunit complex increases the association of the alpha(T) subunit with lipid vesicles that lack the photoreceptor, the beta-gamma(T) complex is not necessary for the binding of alpha(T) to lipid vesicles containing rhodopsin, provided sufficient amounts of rhodopsin are present. The rhodopsin-promoted GDP/guanosine 5'-O-(3-thiotriphosphate) (GTP-gamma-S) exchange reaction, within the rhodopsin-alpha(T) complex, then results in the dissociation of the alpha(T)GTP-gamma-S species from the rhodopsin-containing phospholipid vesicles. A second line of evidence for the occurrence of rhodopsin/alpha(T) interactions, in the absence of beta-gamma(T), comes from phosphorylation studies using the beta-1 isoform of protein kinase C. The phosphorylation of the alpha(T) subunit by protein kinase C is inhibited by beta-gamma(T), both in the absence and in the presence of rhodopsin, but is enhanced by rhodopsin in the absence of beta-gamma(T). These rhodopsin-alpha(T) complexes also appear to be capable of undergoing a rhodopsin-stimulated guanine nucleotide exchange event. When the guanine nucleotide exchange is allowed to occur prior to the addition of protein kinase C, the phosphorylation of the alpha(T) subunit is inhibited. Although beta-gamma(T) is not absolutely required for the rhodopsin/alpha(T) interaction, it appears to increase the apparent affinity of the alpha(T) subunit for rhodopsin, both when rhodopsin was inserted into phosphatidylcholine vesicles and when soluble lipid-free preparations of rhodopsin were used. This results in a significant kinetic advantage for the rhodopsin-stimulated guanine nucleotide exchange event, such that the addition of beta-gamma(T) causes a 10-fold promotion of the rhodopsin-stimulation [S-35]GTP-gamma-S binding to alpha(T) after 1 min but provides less than a 20% promotion of the rhodopsin-stimulated binding after 1 h. The ability of beta-gamma(T) to increase the association of alpha(T) with the lipid vesicle surface does not appear to contribute significantly to the ability of rhodopsin to couple functionally to alpha(T) subunits, and there appears to be no requirement for beta-gamma(T) in the alpha(T) activation event, once the rhodopsin-alpha(T) complex has formed.	CORNELL UNIV, COLL VET MED, DEPT PHARMACOL, SCHURMAN HALL, ITHACA, NY 14853 USA	Cornell University					NATIONAL EYE INSTITUTE [R01EY006429] Funding Source: NIH RePORTER; NEI NIH HHS [EY06429] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CASEY PJ, 1989, BIOCHEMISTRY-US, V28, P611, DOI 10.1021/bi00428a029; CERIONE RA, 1991, METHOD ENZYMOL, V195, P329; CERIONE RA, 1991, BIOCHIM BIOPHYS ACTA, V71, P473; CHABRE M, 1985, ANNU REV BIOPHYS BIO, V14, P331, DOI 10.1146/annurev.biophys.14.1.331; DERETIC D, 1987, J BIOL CHEM, V262, P10839; ERICKSON JW, 1991, BIOCHEMISTRY-US, V30, P7112, DOI 10.1021/bi00243a011; FRANKE RR, 1988, J BIOL CHEM, V263, P2119; FUNG BKK, 1983, J BIOL CHEM, V258, P503; FUNG BKK, 1983, J BIOL CHEM, V258, P495; FUNG BKK, 1985, MOL MECHANISMS TRANS, P183; GUY PM, 1990, BIOCHEMISTRY-US, V29, P6954, DOI 10.1021/bi00482a003; HINGORANI VN, 1987, FEBS LETT, V4220, P15; HO YK, 1984, J BIOL CHEM, V259, P6694; HUFF RM, 1986, J BIOL CHEM, V261, P1105; KATADA T, 1986, J BIOL CHEM, V261, P8182; KATADA T, 1985, EUR J BIOCHEM, V151, P431, DOI 10.1111/j.1432-1033.1985.tb09120.x; KELLEHER DJ, 1988, MOL PHARMACOL, V34, P452; KHORANA HG, 1992, J BIOL CHEM, V267, P1; KNOPF JL, 1986, CELL, V46, P491, DOI 10.1016/0092-8674(86)90874-3; KOBILKA BK, 1988, SCIENCE, V240, P1310, DOI 10.1126/science.2836950; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOUNSBURY KM, 1991, J BIOL CHEM, V266, P22051; ODOWD BF, 1988, J BIOL CHEM, V263, P15985; PHILLIPS WJ, 1992, J BIOL CHEM, V267, P17032; PHILLIPS WJ, 1991, J BIOL CHEM, V266, P11017; STERNWEIS PC, 1986, J BIOL CHEM, V261, P631; STRYER L, 1991, J BIOL CHEM, V266, P10711; WEISS ER, 1988, J BIOL CHEM, V263, P6150; WEISS ER, 1988, FASEB J, V2, P2841, DOI 10.1096/fasebj.2.13.3139484; ZICK Y, 1986, P NATL ACAD SCI USA, V83, P9294, DOI 10.1073/pnas.83.24.9294	31	69	70	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	1992	267	24					17040	17046						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JL053	1512243				2022-12-25	WOS:A1992JL05300049
J	SHEPPARD, D; COHEN, DS; WANG, A; BUSK, M				SHEPPARD, D; COHEN, DS; WANG, A; BUSK, M			TRANSFORMING GROWTH-FACTOR-BETA DIFFERENTIALLY REGULATES EXPRESSION OF INTEGRIN SUBUNITS IN GUINEA-PIG AIRWAY EPITHELIAL-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-V SUBUNIT; FIBRONECTIN RECEPTOR; VITRONECTIN RECEPTOR; ADHESION RECEPTORS; FIBROBLASTS; ASSOCIATION; SEQUENCE; CHAINS	The integrin family is composed of a large number of heterodimers, each one mediating distinct interactions with extracellular matrix and/or cell surface ligands. The expression of integrins appears to be tightly regulated in vivo, but the mechanisms by which cells control the formation and surface expression of specific pairs of subunits have not been well characterized. Two integrin subunits, the alpha-subunit alpha(v), and the beta-subunit beta-1, could pose special problems in regulation because of their capacity to associate with multiple partners. In the present study, we have examined the effects of the cytokine transforming growth factor beta-1 (TGF-beta-1) on the expression of alpha(v)- and beta-1-containing integrins in primary cultures of guinea pig airway epithelial cells, e.g. cells that we have previously found to express multiple potential partners for both alpha(v) and beta-1. TGF-beta-1 increased the surface expression of both alpha(v)- and beta-1-containing heterodimers after periods of stimulation from 24 to 72 h. These increases in surface expression were associated with significant increases in the concentrations of mRNA encoding each of the partners of alpha(v) and beta-1, but with only minimal increases in mRNA encoding alpha(v) and beta-1 themselves. Airway epithelial cells metabolically labeled with [S-35]methionine during stimulation with TGF-beta-1 demonstrated only a minimal increase in the synthesis of new alpha(v) protein at a time when synthesis of alpha(v)'s beta-subunit partners and surface expression of alpha(v)-containing heterodimers were dramatically increased. These data suggest that, at least in some cells, promiscuous integrin subunits (both alpha and beta) may normally be synthesized in excess. Thus, the surface expression of specific integrin heterodimers can be regulated primarily through regulation of the synthesis of the specific partners of these subunits.	UNIV CALIF SAN FRANCISCO,CTR OCCUPAT & ENVIRONM HLTH,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,CARDIOVASC RES INST,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	SHEPPARD, D (corresponding author), UNIV CALIF SAN FRANCISCO,CTR LUNG BIOL,SAN FRANCISCO,CA 94143, USA.				NHLBI NIH HHS [HL 19155, HL-AI33259, HL 47412] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL019155, R01HL047412, R01HL033259] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADLER KB, 1987, BIOTECHNIQUES, V5, P462; AKIYAMA SK, 1987, J BIOL CHEM, V262, P17536; BATES RC, 1991, J BIOL CHEM, V266, P18593; BODARY SC, 1990, J BIOL CHEM, V265, P5938; BOSSY B, 1990, BIOCHEMISTRY-US, V29, P10191, DOI 10.1021/bi00496a006; BUSK M, 1992, J BIOL CHEM, V267, P5790; CHERESH DA, 1989, CELL, V57, P59, DOI 10.1016/0092-8674(89)90172-4; CHERESH DA, 1987, P NATL ACAD SCI USA, V84, P6471, DOI 10.1073/pnas.84.18.6471; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; HEINO J, 1989, J BIOL CHEM, V264, P380; HOLZMANN B, 1989, EMBO J, V8, P1735, DOI 10.1002/j.1460-2075.1989.tb03566.x; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; IGNOTZ RA, 1989, J BIOL CHEM, V264, P389; MOYLE M, 1991, J BIOL CHEM, V266, P19650; NEUGEBAUER KM, 1991, NEURON, V6, P345, DOI 10.1016/0896-6273(91)90244-T; PYTELA R, 1985, P NATL ACAD SCI USA, V82, P5766, DOI 10.1073/pnas.82.17.5766; ROBERTS CJ, 1988, J BIOL CHEM, V263, P4586; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; SHEPPARD D, 1990, J BIOL CHEM, V265, P11502; SMITH JW, 1990, J BIOL CHEM, V265, P11008; TAMURA RN, 1990, J CELL BIOL, V111, P1593, DOI 10.1083/jcb.111.4.1593; VOGEL BE, 1990, J BIOL CHEM, V265, P5934; WANG A, 1991, J BIOL CHEM, V266, P15598; WERB Z, 1989, J CELL BIOL, V109, P877, DOI 10.1083/jcb.109.2.877	24	111	114	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1992	267	24					17409	17414						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JL053	1512272				2022-12-25	WOS:A1992JL05300101
J	SUZU, S; OHTSUKI, T; YANAI, N; TAKATSU, Z; KAWASHIMA, T; TAKAKU, F; NAGATA, N; MOTOYOSHI, K				SUZU, S; OHTSUKI, T; YANAI, N; TAKATSU, Z; KAWASHIMA, T; TAKAKU, F; NAGATA, N; MOTOYOSHI, K			IDENTIFICATION OF A HIGH-MOLECULAR-WEIGHT MACROPHAGE COLONY-STIMULATING FACTOR AS A GLYCOSAMINOGLYCAN-CONTAINING SPECIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARAN-SULFATE PROTEOGLYCAN; FIBROBLAST GROWTH-FACTOR; MONOCYTE TUMORICIDAL ACTIVITY; CARTILAGE PROTEOGLYCAN; RABBIT THROMBOMODULIN; CELL-ADHESION; CDNA CLONES; BONE; SEQUENCE; CLONING	Chinese hamster ovary cells transfected with a 4.0-kilobase macrophage colony-stimulating factor (M-CSF) cDNA express two different M-CSF species; one has an apparent molecular weight of 85,000 and is identified as a homodimer of a 43-kDa subunit, and the other has an indeterminate structure greater than 200 kDa. In this study, we investigated the structure of the high molecular weight M-CSF by immunochemical procedures. The high molecular weight M-CSF was easily purified, since it bound tightly to DEAE-Sephacel and eluted at a characteristically high salt concentration. The high molecular weight M-CSF migrated as a diffuse band of over than 200,000 on nonreducing sodium dodecyl sulfate-polyacrylamide gels. Analysis of the same samples under reducing conditions revealed that the larger species consisted of a heteromer of the 43- and 150-200-kDa M-CSF subunits. Digestion of the 150-200-kDa M-CSF subunit with chondroitinase, which degrades the chondroitin sulfate glycosaminoglycan chain, yielded a 100 kDa band. This species was secreted instead of 150-200-kDa species when the cells were cultured in the presence of beta-D-xyloside, which inhibits the elongation of the chondroitin sulfate glycosaminoglycan chain in proteoglycans, providing additional evidence for the existence of a chondroitin sulfate chain in the 150-200-kDa M-CSF subunit. Removal of O- and N-linked carbohydrate from the 150-200-kDa subunit yielded a polypeptide chain with a larger molecular mass (approximately 45 kDa) than that of the 43-kDa subunit (approximately 25 kDa). Collectively, these results indicate that the 150-200-kDa M-CSF subunit is a proteoglycan with a core protein that may be an alternatively processed form of M-CSF.	NATL DEF MED COLL,DEPT INTERNAL MED 3,3-2 NAMIKI,TOKOROZAWA,SAITAMA 359,JAPAN; MORINAGA MILK IND CO LTD,BIOCHEM RES LAB,ZAMA,KANAGAWA 228,JAPAN; NATL MED CTR,TOKYO,TOKYO 162,JAPAN	National Defense Medical College - Japan; Morinaga Milk Industry Company, Ltd			Ohtsuki, Tomoaki/D-7179-2014; Suzu, Shinya/F-5786-2013	Suzu, Shinya/0000-0003-2531-4770				BOURIN MC, 1989, THROMB RES, V54, P27; BOURIN MC, 1988, J BIOL CHEM, V263, P8044; BOURIN MC, 1986, P NATL ACAD SCI USA, V83, P5924, DOI 10.1073/pnas.83.16.5924; BUREGESS WH, 1989, ANN REV BIOCH, V58, P575; CHOPRA RK, 1985, BIOCHEM J, V232, P277, DOI 10.1042/bj2320277; CLARK SC, 1987, SCIENCE, V236, P1229, DOI 10.1126/science.3296190; COLE GJ, 1989, NEURON, V2, P1157, DOI 10.1016/0896-6273(89)90182-7; DAY AA, 1987, BIOCHEM J, V248, P801, DOI 10.1042/bj2480801; DOEGE K, 1987, J BIOL CHEM, V262, P17757; FISHER LW, 1989, J BIOL CHEM, V264, P4571; GOSPODAROWICZ D, 1987, ENDOCR REV, V8, P95, DOI 10.1210/edrv-8-2-95; HATAKE K, 1985, J CHROMATOGR, V344, P339, DOI 10.1016/S0378-4347(00)82037-X; ISHAIMICHAELI R, 1990, CELL REGUL, V1, P833, DOI 10.1091/mbc.1.11.833; KAESBERG PR, 1989, J CLIN INVEST, V83, P994, DOI 10.1172/JCI113986; KATO M, 1985, ANAL BIOCHEM, V148, P479, DOI 10.1016/0003-2697(85)90255-6; KLEBE RJ, 1982, J CELL PHYSIOL, V112, P5, DOI 10.1002/jcp.1041120103; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MANOS MM, 1988, MOL CELL BIOL, V8, P5035, DOI 10.1128/MCB.8.11.5035; MCCORMICK D, 1987, P NATL ACAD SCI USA, V84, P4044, DOI 10.1073/pnas.84.12.4044; MOTOYOSHI K, 1982, BLOOD, V60, P1378; MOTOYOSHI K, 1978, BLOOD, V52, P1012; NAWA K, 1990, BIOCHEM BIOPH RES CO, V171, P729, DOI 10.1016/0006-291X(90)91207-9; NOONAN DM, 1988, J BIOL CHEM, V263, P16379; OIKE Y, 1980, BIOCHEM J, V191, P193, DOI 10.1042/bj1910193; OKAYAMA M, 1973, J BIOCHEM-TOKYO, V74, P1069; OLDBERG A, 1987, BIOCHEM J, V243, P255, DOI 10.1042/bj2430255; PRESSNER KT, 1990, J BIOL CHEM, V265, P4915; RALPH P, 1987, CELL IMMUNOL, V105, P270, DOI 10.1016/0008-8749(87)90076-1; RETTENMIER CW, 1988, MOL CELL BIOL, V8, P5026, DOI 10.1128/MCB.8.11.5026; ROBINSON J, 1984, J CELL BIOL, V98, P946, DOI 10.1083/jcb.98.3.946; ROBINSON JA, 1981, BIOCHEM J, V194, P839, DOI 10.1042/bj1940839; RUOSLAHTI E, 1988, ANNU REV BIOCHEM, V57, P375, DOI 10.1146/annurev.bi.57.070188.002111; RUOSLAHTI E, 1991, CELL, V64, P867, DOI 10.1016/0092-8674(91)90308-L; RUOSLAHTI E, 1988, ANNU REV CELL BIOL, V4, P229, DOI 10.1146/annurev.cb.04.110188.001305; RUOSLAHTI E, 1980, BIOCHIM BIOPHYS ACTA, V631, P350, DOI 10.1016/0304-4165(80)90308-6; RUOSLAHTI E, 1989, J BIOL CHEM, V264, P13369; SAKSELA O, 1990, J CELL BIOL, V110, P767, DOI 10.1083/jcb.110.3.767; SAMPSONJOHANNES A, 1988, J IMMUNOL, V141, P3680; SAUNDERS S, 1989, J CELL BIOL, V108, P1547, DOI 10.1083/jcb.108.4.1547; SPOONCER E, 1983, J CELL BIOL, V96, P510, DOI 10.1083/jcb.96.2.510; SUZU S, 1991, BLOOD, V77, P2160; SUZU S, 1989, CANCER RES, V49, P5913; WONG GG, 1987, SCIENCE, V235, P1504, DOI 10.1126/science.3493529; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W	44	60	62	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1992	267	7					4345	4348						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HF642	1531650				2022-12-25	WOS:A1992HF64200016
J	BLYSTONE, SD; KAPLAN, JE				BLYSTONE, SD; KAPLAN, JE			ISOLATION OF AN AMINO-TERMINAL FIBRONECTIN-BINDING PROTEIN ON HUMAN U937 CELLS AND RAT PERITONEAL-MACROPHAGES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA FIBRONECTIN; HUMAN-MONOCYTES; MATRIX; RECEPTORS; FRAGMENTS; STIMULATION; SECRETION; PARTICLES; COLLAGEN; FIBRIN	Several cell-mediated activities for the amino terminus of fibronectin have been documented. In the present study we describe a macrophage surface protein with binding activity directed to the amino terminus of the fibronectin molecule. The binding of a 29-kDa amino-terminal fibronectin fragment to macrophages reached steady state by 30 min and was half-maximal at approximately 2 x 10(-8) M. This binding was specifically inhibited by excess unlabeled 29-kDa fragment or intact fibronectin but not by a 180-kDa fibronectin fragment which lacks the amino terminus. Competitive binding studies of the 70-kDa amino-terminal fibronectin fragment to macrophages revealed a single binding site with K(D) = 7.14 x 10(-8) M and approximately 8 x 10(4) binding sites/cell. Radiolabeled surface proteins extracted from rat peritoneal macrophages and from the human U937 cell line were applied to an affinity column comprised of the 70-kDa amino-terminal fragment of fibronectin coupled to a solid support. A single trypsin-sensitive radiolabeled protein of 67 kDa, from either cell type, was eluted from this column with urea. This protein showed no immunologic identity with fibronectin, fibrin(ogen), or albumin. The 67-kDa protein exhibited identical apparent molecular weight under reducing and nonreducing conditions, as assessed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis analysis. We have localized the fibronectin binding activity of this protein to within the 29-kDa amino-terminal domain of fibronectin. The 67-kDa protein eluted from the 70-kDa column failed to bind to a column comprised of the 45-kDa gelatin-binding fragment of fibronectin. Additionally, the 67-kDa protein was specifically eluted from the 70-kDa column by the 29-kDa amino-terminal fragment but not by the 45-kDa gelatin-binding fragment. These data suggest that this 67-kDa protein is a macrophage cell surface binding protein for the amino terminus of fibronectin.	UNION UNIV,DEPT PHYSIOL & CELL BIOL,A-134,ALBANY,NY 12208	Union College					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007194] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM040761] Funding Source: NIH RePORTER; NHLBI NIH HHS [T32-HL-07194] Funding Source: Medline; NIGMS NIH HHS [P01 GM40761] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BEEZHOLD DH, 1987, IMMUNOL INVEST, V16, P437, DOI 10.3109/08820138709087097; BEVILACQUA MP, 1981, J EXP MED, V153, P42, DOI 10.1084/jem.153.1.42; Blumenstock F A, 1979, Adv Shock Res, V2, P55; BLYSTONE SD, 1991, BLOOD, V178, P2900; BROWN EJ, 1988, J EXP MED, V167, P777, DOI 10.1084/jem.167.3.777; CARDARELLI PM, 1990, J LEUKOCYTE BIOL, V48, P426, DOI 10.1002/jlb.48.5.426; CLARK RAF, 1988, J BIOL CHEM, V263, P12115; ENGVALL E, 1977, INT J CANCER, V20, P1, DOI 10.1002/ijc.2910200102; FROMAN G, 1987, J BIOL CHEM, V262, P6564; GUAN JL, 1990, CELL, V60, P53, DOI 10.1016/0092-8674(90)90715-Q; GUDEWICZ PW, 1980, J CELL BIOL, V87, P427, DOI 10.1083/jcb.87.2.427; HOMANDBERG GA, 1991, FASEB J, V5, pA1558; HORMANN H, 1987, THROMB RES, V46, P39, DOI 10.1016/0049-3848(87)90205-2; HORMANN H, 1985, THROMB RES, V38, P183; KAPLAN JE, 1989, J LAB CLIN MED, V113, P168; KOWALCZYK AP, 1990, BLOOD, V75, P2335; LACELLE P, 1990, BLOOD, V75, P470; LIMPER AH, 1991, J BIOL CHEM, V266, P9697; LOHR KM, 1990, BLOOD, V76, P2117; MARTIN BM, 1983, AM J PATHOL, V111, P367; MCDONALD JA, 1987, J BIOL CHEM, V262, P2957; MCDONALD JA, 1988, ANNU REV CELL BIOL, V4, P183, DOI 10.1146/annurev.cb.04.110188.001151; MCGAVIN MJ, 1991, J BIOL CHEM, V266, P8343; MCKEOWNLONGO PJ, 1985, J CELL BIOL, V100, P364, DOI 10.1083/jcb.100.2.364; MCKEOWNLONGO PJ, 1987, J CELL BIOL, V104, P601, DOI 10.1083/jcb.104.3.601; MCKEOWNLONGO PJ, 1987, REV INFECT DIS, V9, P322; MCKEOWNLONGO PJ, 1987, J CELL BIOL, V105, P44; MEYERS R, 1991, FASEB J, V5, P425; MORRISON M, 1970, BIOCHEMISTRY-US, V9, P2995, DOI 10.1021/bi00817a010; ROURKE FJ, 1984, J IMMUNOL, V132, P1931; RUOSLAHTI E, 1991, J CLIN INVEST, V87, P1, DOI 10.1172/JCI114957; TAKADA Y, 1988, J CELL BIOCHEM, V37, P385, DOI 10.1002/jcb.240370406	32	21	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1992	267	6					3968	3975						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HE607	1531479				2022-12-25	WOS:A1992HE60700065
J	EPPS, DE; YEM, AW; FISHER, JF; MCGEE, JE; PASLAY, JW; DEIBEL, MR				EPPS, DE; YEM, AW; FISHER, JF; MCGEE, JE; PASLAY, JW; DEIBEL, MR			SPECTRAL CHARACTERIZATION OF ENVIRONMENT-SENSITIVE ADDUCTS OF INTERLEUKIN-1-BETA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECOMBINANT HUMAN INTERLEUKIN-1-BETA; FLUORESCENT-PROBE; CRYSTAL-STRUCTURE; ACRYLODAN	We have determined the fluorescence properties of two covalently attached acrylodan derivatives of recombinant human interleukin-1-beta, namely the Cys-8 and Lys-103 adducts. The emission and excitation maxima indicated the presence of two operationally distinct conformers for each probe. The iodide quenching and the kinetics of fluorescence changes associated with guanidinium chloride-induced denaturation show that each covalent adduct exists both in hydrated and dehydrated environments. Furthermore, fluorescence changes associated with the binding of the adducts to a recombinant soluble murine receptor indicated that only the conformers with the label in the hydrophobic environment are competent toward the soluble murine interleukin receptor and that the hydrated and dehydrated conformers are in a dynamic equilibrium on the time scale of the binding experiments.			EPPS, DE (corresponding author), UPJOHN CO,UPJOHN LABS,301 HENRIETTA ST,KALAMAZOO,MI 49001, USA.			Fisher, Jed/0000-0002-7174-4352				ALCALA JR, 1985, ANAL INSTRUM, V14, P225; CARTER DB, 1988, PROTEINS, V3, P121, DOI 10.1002/prot.340030207; CRAIG S, 1987, BIOCHEMISTRY-US, V26, P3570, DOI 10.1021/bi00386a048; DUSZYNSKI J, 1988, BIOCHEMISTRY-US, V27, P6288, DOI 10.1021/bi00417a014; FINZEL BC, 1989, J MOL BIOL, V209, P779, DOI 10.1016/0022-2836(89)90606-2; ILICH P, 1989, J PHYS CHEM-US, V93, P4441, DOI 10.1021/j100348a014; KAISER ET, 1984, SCIENCE, V223, P249, DOI 10.1126/science.6322295; Lackowicz J. R., 1983, PRINCIPLES FLUORESCE, P112; LEHRER SS, 1988, BIOCHEMISTRY-US, V27, P5899, DOI 10.1021/bi00416a012; MCGREGOR RB, 1981, ANN NY ACAD SCI, V366, P140; PISTON DW, 1989, REV SCI INSTRUM, V60, P2596, DOI 10.1063/1.1140677; PRENDERGAST FG, 1983, J BIOL CHEM, V258, P7541; PRIESTLE JP, 1988, EMBO J, V7, P339, DOI 10.1002/j.1460-2075.1988.tb02818.x; SIMS JE, 1988, SCIENCE, V241, P585, DOI 10.1126/science.2969618; WEBER G, 1979, BIOCHEMISTRY-US, V18, P3075, DOI 10.1021/bi00581a025; YEM AW, 1992, J BIOL CHEM, V267, P3122	16	11	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 15	1992	267	5					3129	3135						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HD154	1531338				2022-12-25	WOS:A1992HD15400049
J	VILSEN, B; ANDERSEN, JP				VILSEN, B; ANDERSEN, JP			INTERDEPENDENCE OF CA2+ OCCLUSION SITES IN THE UNPHOSPHORYLATED SARCOPLASMIC-RETICULUM CA2+-ATPASE COMPLEX WITH CRATP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM ADENOSINE-TRIPHOSPHATASE; CONFORMATIONAL TRANSITIONS; TRANSPORTING ATPASES; NUCLEOTIDE-BINDING; PUMP MECHANISM; CA-2+ BINDING; ACTIVE-SITE; CA-2+-ATPASE; PHOSPHORYLATION; TRANSLOCATION	The beta,gamma-bidentate chromium(III) complex of ATP (CrATP) was used as a substrate analog to stabilize a form of the Ca2+-ATPase of the sarcoplasmic reticulum containing both of the bound calcium ions in an occluded state without enzyme phosphorylation. The kinetics of dissociation of Ca2+ from the occlusion sites in the CrATP-enzyme complex were consistent with the existence of two nonequivalent and interdependent Ca2+ occlusion sites, both in the membranous Ca2+-ATPase and in a detergent-solubilized monomeric Ca2+-ATPase preparation. The rate constant for release of the first calcium ion was k1 = 0.99 h-1, whereas the second calcium ion was released with a rate constant of k2 = 0.25 h-1 when the first site was empty and with a rate constant of k3 = 0.13 h-1 when the first site was occupied by Ca2+. Ca2+ binding at the first site occurred with a rate constant of k-1 = 0.96-mu-M-1 h-1 (apparent K(d) = 1.0-mu-M). The Ca2+-occluded state was further stabilized by ADP, binding in exchange with ATP with an apparent K(d) of 8.6-mu-M. Two kinetic classes of CrATP-binding sites were observed, each with a stoichiometry of 3-4 nmol/mg of protein; but only the fast phase of CrATP binding was associated with Ca2+ occlusion. Derivatization of the Ca2+-ATPase with N-cyclohexyl-N'-4-dimethylamino-1-naphthyl)carbodiimide resulted in inactivation of phosphorylation of the enzyme from MgATP, whereas the ability to occlude Ca2+ in the presence of CrATP was retained, albeit with a reduced apparent affinity for Ca2+.			VILSEN, B (corresponding author), AARHUS UNIV, INST PHYSIOL, DANISH BIOMEMBRANE RES CTR, DK-8000 AARHUS, DENMARK.			Vilsen, Bente/0000-0002-4727-9382; Andersen, Jens Peter/0000-0003-0654-4300				Andersen JP, 1990, CURR OPIN CELL BIOL, V2, P722, DOI 10.1016/0955-0674(90)90116-V; ANDERSEN JP, 1982, J BIOL CHEM, V257, P8300; ANDERSEN JP, 1989, BIOCHIM BIOPHYS ACTA, V988, P47, DOI 10.1016/0304-4157(89)90003-8; ANDERSEN JP, 1985, J MEMBRANE BIOL, V88, P187, DOI 10.1007/BF01868432; ANDERSEN JP, 1986, J MEMBRANE BIOL, V93, P85, DOI 10.1007/BF01871021; ANDERSEN JP, 1986, BIOCHEMISTRY-US, V25, P6439, DOI 10.1021/bi00369a015; ANDERSEN JP, 1985, J BIOL CHEM, V260, P371; BARRABIN H, 1984, BIOCHEMISTRY-US, V23, P1542, DOI 10.1021/bi00302a031; CHADWICK CC, 1984, BIOCHIM BIOPHYS ACTA, V769, P291, DOI 10.1016/0005-2736(84)90309-2; CHADWICK CC, 1983, BIOCHIM BIOPHYS ACTA, V730, P201, DOI 10.1016/0005-2736(83)90334-6; CHEN ZD, 1991, J BIOL CHEM, V266, P12386; CLARKE DM, 1989, NATURE, V339, P476, DOI 10.1038/339476a0; DEMEIS L, 1981, TRANSPORT LIFE SCI, V2; DUPONT Y, 1982, BIOCHIM BIOPHYS ACTA, V688, P75, DOI 10.1016/0005-2736(82)90580-6; DUPONT Y, 1980, EUR J BIOCHEM, V109, P231, DOI 10.1111/j.1432-1033.1980.tb04788.x; Forbush B 3rd, 1988, Prog Clin Biol Res, V268A, P229; GAFNI A, 1984, BIOCHEMISTRY-US, V23, P4362, DOI 10.1021/bi00314a018; GLYNN IM, 1990, ANNU REV BIOCHEM, V59, P171, DOI 10.1146/annurev.bi.59.070190.001131; GREEN NM, 1986, CIBA F SYMP, V122, P93; HASSELBACH W, 1961, BIOCHEM Z, V333, P518; IKEMOTO N, 1981, J BIOL CHEM, V256, P8593; INESI G, 1989, J BIOL CHEM, V264, P5929; INESI G, 1990, PHYSIOL REV, V70, P749, DOI 10.1152/physrev.1990.70.3.749; INESI G, 1987, J BIOL CHEM, V262, P16338; INESI G, 1985, ANNU REV PHYSIOL, V47, P573, DOI 10.1146/annurev.ph.47.030185.003041; INESI G, 1980, J BIOL CHEM, V255, P3025; Inesi G, 1978, Ann N Y Acad Sci, V307, P224, DOI 10.1111/j.1749-6632.1978.tb41947.x; JENCKS WP, 1989, J BIOL CHEM, V264, P18855; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MITCHINSON C, 1982, FEBS LETT, V146, P87, DOI 10.1016/0014-5793(82)80710-2; MOLLER JV, 1980, J BIOL CHEM, V255, P1912; NAKAMURA J, 1986, BIOCHIM BIOPHYS ACTA, V870, P495, DOI 10.1016/0167-4838(86)90258-X; ORLOWSKI S, 1991, BIOCHEMISTRY-US, V30, P352, DOI 10.1021/bi00216a007; PETITHORY JR, 1988, BIOCHEMISTRY-US, V27, P8626, DOI 10.1021/bi00423a018; PETITHORY JR, 1988, BIOCHEMISTRY-US, V27, P5553, DOI 10.1021/bi00415a025; PICK U, 1985, EUR J BIOCHEM, V152, P83, DOI 10.1111/j.1432-1033.1985.tb09166.x; ROSS DC, 1987, J BIOL CHEM, V262, P12977; SCOTT TL, 1988, MOL CELL BIOCHEM, V82, P51; SERPERSU EH, 1982, EUR J BIOCHEM, V122, P347, DOI 10.1111/j.1432-1033.1982.tb05887.x; SHULL GE, 1988, J BIOL CHEM, V263, P8646; SUMBILLA C, 1991, J BIOL CHEM, V266, P12682; SUMIDA M, 1974, J BIOCHEM-TOKYO, V75, P283, DOI 10.1093/oxfordjournals.jbchem.a130396; TAKISAWA H, 1981, NATURE, V290, P271, DOI 10.1038/290271a0; TANFORD C, 1984, CRC CR REV BIOCH MOL, V17, P123, DOI 10.3109/10409238409113603; TANFORD C, 1987, P NATL ACAD SCI USA, V84, P7094, DOI 10.1073/pnas.84.20.7094; TAYLOR WR, 1989, EUR J BIOCHEM, V179, P241, DOI 10.1111/j.1432-1033.1989.tb14547.x; VILSEN B, 1991, J BIOL CHEM, V266, P16157; VILSEN B, 1987, J BIOL CHEM, V262, P10511; VILSEN B, 1987, BIOCHIM BIOPHYS ACTA, V898, P313, DOI 10.1016/0005-2736(87)90072-1; VILSEN B, 1986, BIOCHIM BIOPHYS ACTA, V855, P429, DOI 10.1016/0005-2736(86)90089-1; VILSEN B, 1989, J BIOL CHEM, V264, P21024; WEBER K, 1969, J BIOL CHEM, V244, P4406; ZUBRZYCKAGAARN E, 1984, J BIOENERG BIOMEMBR, V16, P441, DOI 10.1007/BF00743238	53	42	43	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 15	1992	267	5					3539	3550						12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HD154	1531342				2022-12-25	WOS:A1992HD15400108
J	FANG, WJ; HARTMANN, N; CHOW, DT; RIEGEL, AT; WELLSTEIN, A				FANG, WJ; HARTMANN, N; CHOW, DT; RIEGEL, AT; WELLSTEIN, A			PLEIOTROPHIN STIMULATES FIBROBLASTS AND ENDOTHELIAL AND EPITHELIAL-CELLS AND IS EXPRESSED IN HUMAN CANCER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARIN-BINDING PROTEIN; AMINO-ACID-SEQUENCE; GROWTH-FACTOR; DEVELOPING BRAIN; TUMOR-GROWTH; PURIFICATION; BOVINE; RAT; DISTINCT; AFFINITY	Previously we reported the purification of the heparin-binding growth factor pleiotrophin (PTN) from supernatants of the human breast cancer cell line MDA-MB-231. To investigate further the biological activities of PTN and its potential role in cancer, we cloned a PTN cDNA and expressed the gene in a human kidney and in a human adrenal carcinoma cell line (SW-13). The supernatants harvested from cells transfected with PTN contained a heparin-binding specific protein of an apparent molecular mass of 18 kDa. These supernatants stimulated the proliferation of endothelial cells as well as the anchorage-independent growth of SW-13 cells and of normal rat kidney fibroblasts. Furthermore, SW-13 cells transfected with PTN acquired autonomous growth in soft agar and were tumorigenic in athymic nude mice. In contrast to these results with PTN from human cells, PTN obtained from insect cells (Sf9) using recombinant baculovirus as a vector was biologically inactive. We detected high levels of PTN mRNA in 16 of 27 primary human breast cancer samples (62%) as well as in 8 of 8 carcinogen-induced rat mammary tumors. Furthermore, 9 of 34 human tumor cell lines of different origin showed detectable PTN mRNA. We conclude that PTN may function as a tumor growth and angiogenesis factor in addition to its role during embryonic development.	GEORGETOWN UNIV, MED CTR, VINCENT T LOMBARDI CANC RES CTR, 3800 RESERVOIR RD NW, WASHINGTON, DC 20007 USA; GEORGETOWN UNIV, DEPT PHARMACOL, WASHINGTON, DC 20007 USA	Georgetown University; Georgetown University	WELLSTEIN, A (corresponding author), GEORGETOWN UNIV, MED CTR, VINCENT T LOMBARDI CANC RES CTR, 3800 RESERVOIR RD NW, WASHINGTON, DC 20007 USA.			Wellstein, Anton/0000-0002-0570-4950	NATIONAL CANCER INSTITUTE [U01CA051908] Funding Source: NIH RePORTER; NCI NIH HHS [U01 CA51908] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bohlen P, 1991, GROWTH FACTORS, V4, P97, DOI 10.3109/08977199109000261; BOHLEN P, 1991, Progress in Growth Factor Research, V3, P143, DOI 10.1016/S0955-2235(05)80005-5; CHRISTENSEN K, 1991, MOL ENDOCRINOL, V5, P1755, DOI 10.1210/mend-5-11-1755; COURTY J, 1991, BIOCHEM BIOPH RES CO, V180, P145, DOI 10.1016/S0006-291X(05)81267-7; COURTY J, 1991, J CELL BIOCH F S, V15, P221; CROSS M, 1991, CELL, V64, P271, DOI 10.1016/0092-8674(91)90638-F; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; HAMPTON BS, 1992, MOL BIOL CELL, V3, P85, DOI 10.1091/mbc.3.1.85; HERLYN M, 1991, LAB INVEST, V65, P262; HUBER D, 1990, NEUROCHEM RES, V15, P435, DOI 10.1007/BF00969930; JORDAN VC, 1983, BREAST CANCER RES TR, V3, pS73, DOI 10.1007/BF01855131; KAIDOH T, 1991, VIRCHOWS ARCH A, V418, P111, DOI 10.1007/BF01600286; KANDEL J, 1991, CELL, V66, P1095, DOI 10.1016/0092-8674(91)90033-U; KLAGSBRUN M, 1987, METHOD ENZYMOL, V147, P95; KOHNO T, 1990, METHOD ENZYMOL, V185, P187; KOVESDI I, 1990, BIOCHEM BIOPH RES CO, V172, P850, DOI 10.1016/0006-291X(90)90753-A; KUO MD, 1990, J BIOL CHEM, V265, P18749; LI YS, 1990, SCIENCE, V250, P1690, DOI 10.1126/science.2270483; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; LIPPMAN ME, 1989, RECENT PROG HORM RES, V45, P383; MATSUURA Y, 1991, DEV BIOLOGICALS, V73, P79; MERENMIES J, 1990, J BIOL CHEM, V265, P16721; MILNER PG, 1989, BIOCHEM BIOPH RES CO, V165, P1096, DOI 10.1016/0006-291X(89)92715-0; RAULO E, 1992, J BIOL CHEM, V267, P11408; RAUVALA H, 1989, EMBO J, V8, P2933, DOI 10.1002/j.1460-2075.1989.tb08443.x; RODECK U, 1991, J INVEST DERMATOL, V97, P20, DOI 10.1111/1523-1747.ep12477822; ROSE DP, 1985, ANTICANCER RES, V5, P397; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARKADI B, 1992, J BIOL CHEM, V267, P2087; SIOW YL, 1992, BIOCHEMISTRY-US, V31, P4268, DOI 10.1021/bi00132a017; TAKAGI Y, 1992, BIOCHEM BIOPH RES CO, V184, P471, DOI 10.1016/0006-291X(92)91218-F; TAKAMATSU H, 1992, BIOCHEM BIOPH RES CO, V185, P224, DOI 10.1016/S0006-291X(05)80979-9; TEZUKA K, 1990, BIOCHEM BIOPH RES CO, V173, P246, DOI 10.1016/S0006-291X(05)81048-4; WELLSTEIN A, 1990, CELL GROWTH DIFFER, V1, P63; WELLSTEIN A, 1991, JNCI-J NATL CANCER I, V83, P716, DOI 10.1093/jnci/83.10.716; WELLSTEIN A, 1992, J BIOL CHEM, V267, P2582; WELLSTEIN A, 1991, J BIOL CHEM, V266, P12234; WELSCH CW, 1985, CANCER RES, V45, P3415; XIE YB, 1992, J BIOL CHEM, V267, P4939	39	214	224	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 25	1992	267	36					25889	25897						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KD073	1464602				2022-12-25	WOS:A1992KD07300047
J	WERNER, PK; SAIER, MH; MULLER, M				WERNER, PK; SAIER, MH; MULLER, M			MEMBRANE INSERTION OF THE MANNITOL PERMEASE OF ESCHERICHIA-COLI OCCURS UNDER CONDITIONS OF IMPAIRED SECA FUNCTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POSITIVELY CHARGED RESIDUES; BACTERIAL PHOSPHOTRANSFERASE SYSTEM; PROTEIN EXPORT; PLASMA-MEMBRANE; M13 PROCOAT; ENZYME-II; CYTOPLASMIC MEMBRANE; LEADER PEPTIDASE; LACTOSE PERMEASE; SECY24 DEFECT	The membrane insertion of the mannitol permease (MtlA protein) of Escherichia coli, a polytopic cytoplasmic membrane protein possessing an uncleaved amphiphilic signal sequence, was studied using a cell-free protein synthesis system. The MtlA protein synthesized in the presence of inside-out cytoplasmic membrane vesicles was shown to insert into the membranes based on the following criteria: (a) co-sedimentation of the majority of the MtlA protein with the vesicles; (b) selective extraction of the membrane-associated MtlA by deoxycholate but not by urea treatment; and (c) protease resistance of a defined MtlA fragment observed exclusively in the presence of membranes. Post-translational addition of membrane vesicles allowed membrane association of MtlA but did not allow efficient integration. In cell-free systems having reduced levels of the export factors SecA and SecB and exhibiting defective translocation of preOmpA and preLamB, insertion of the in vitro synthesized MtlA apparently occurred normally. In contrast, when membranes from the secY24ts mutant or trypsin-treated membranes were used, insertion of MtlA was reduced. In vivo experiments monitoring the permease activity of MtlA in the secA and secY mutants supported the conclusions of the in vitro results. Thus, the insertion of MtlA is essentially SecA- and SecB-independent but may be dependent on SecY and/or an as yet unidentified membrane protein. The requirements for the insertion of the mannitol permease are therefore clearly different from those for the translocation of most proteins having a cleavable hydrophobic signal sequence.	UNIV FREIBURG, INST BIOCHEM, W-7800 FREIBURG, GERMANY; UNIV CALIF SAN DIEGO, DEPT BIOL, LA JOLLA, CA 92093 USA	University of Freiburg; University of California System; University of California San Diego					NIAID NIH HHS [5 RO1 AI 21702] Funding Source: Medline; PHS HHS [2 ROI 14176] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI021702] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AHREM B, 1989, J CELL BIOL, V108, P1637, DOI 10.1083/jcb.108.5.1637; AKIYAMA Y, 1989, J BIOL CHEM, V264, P437; AKIYAMA Y, 1987, EMBO J, V6, P3465, DOI 10.1002/j.1460-2075.1987.tb02670.x; BIEKER KL, 1990, J BIOENERG BIOMEMBR, V22, P291, DOI 10.1007/BF00763169; BLOBEL G, 1980, P NATL ACAD SCI-BIOL, V77, P1496, DOI 10.1073/pnas.77.3.1496; CABELLI RJ, 1988, CELL, V55, P683, DOI 10.1016/0092-8674(88)90227-9; CALAMIA J, 1990, P NATL ACAD SCI USA, V87, P4937, DOI 10.1073/pnas.87.13.4937; CUNNINGHAM K, 1989, EMBO J, V8, P955, DOI 10.1002/j.1460-2075.1989.tb03457.x; DALBEY RE, 1987, J BIOL CHEM, V262, P13241; DALBEY RE, 1990, TRENDS BIOCHEM SCI, V15, P253, DOI 10.1016/0968-0004(90)90047-F; DECOCK H, 1989, BIOCHIM BIOPHYS ACTA, V985, P313, DOI 10.1016/0005-2736(89)90418-5; FANDL J, 1990, J BIOENERG BIOMEMBR, V22, P369, DOI 10.1007/BF00763173; FANDL JP, 1987, P NATL ACAD SCI USA, V84, P7448, DOI 10.1073/pnas.84.21.7448; FANDL JP, 1988, P NATL ACAD SCI USA, V85, P8953, DOI 10.1073/pnas.85.23.8953; FREUDL R, 1985, EMBO J, V4, P3593, DOI 10.1002/j.1460-2075.1985.tb04122.x; FROSHAUER S, 1988, J MOL BIOL, V200, P501, DOI 10.1016/0022-2836(88)90539-6; GEBERT JF, 1988, J BIOL CHEM, V263, P16652; GELLER BL, 1985, J BIOL CHEM, V260, P3281; GILMORE R, 1985, CELL, V42, P497, DOI 10.1016/0092-8674(85)90107-2; GRISAFI PL, 1989, J BACTERIOL, V171, P2719, DOI 10.1128/jb.171.5.2719-2727.1989; HARTL FU, 1990, CELL, V63, P269, DOI 10.1016/0092-8674(90)90160-G; ITO K, 1991, MOL MICROBIOL, V5, P2243, DOI 10.1111/j.1365-2958.1991.tb02154.x; ITO K, 1990, J BIOENERG BIOMEMBR, V22, P353, DOI 10.1007/BF00763172; JACOBSON GR, 1983, J BIOL CHEM, V258, P2955; JACOBSON GR, 1983, J BIOL CHEM, V258, P748; KUHN A, 1990, EMBO J, V9, P2385, DOI 10.1002/j.1460-2075.1990.tb07413.x; KUHN A, 1986, NATURE, V322, P335, DOI 10.1038/322335a0; KUMAMOTO CA, 1985, J BACTERIOL, V163, P267, DOI 10.1128/JB.163.1.267-274.1985; LEE CA, 1981, P NATL ACAD SCI-BIOL, V78, P7336, DOI 10.1073/pnas.78.12.7336; LEE CA, 1983, J BACTERIOL, V153, P685, DOI 10.1128/JB.153.2.685-692.1983; LEE CA, 1983, J BIOL CHEM, V258, P761; LILL R, 1990, CELL, V60, P271, DOI 10.1016/0092-8674(90)90742-W; MACINTYRE S, 1989, FEBS LETT, V247, P396, DOI 10.1016/0014-5793(89)81378-X; MCGOVERN K, 1991, J BIOL CHEM, V266, P20870; MULLER M, 1984, P NATL ACAD SCI-BIOL, V81, P7421, DOI 10.1073/pnas.81.23.7421; MULLER M, 1984, P NATL ACAD SCI-BIOL, V81, P7737, DOI 10.1073/pnas.81.24.7737; OLIVER DB, 1982, CELL, V30, P311, DOI 10.1016/0092-8674(82)90037-X; OLIVER DB, 1990, J BIOENERG BIOMEMBR, V22, P311, DOI 10.1007/BF00763170; SAIER MH, 1992, J BACTERIOL, V174, P1433, DOI 10.1128/jb.174.5.1433-1438.1992; SAIER MH, 1976, J BIOL CHEM, V251, P6584; SAIER MH, 1988, BIOCHIMIE, V70, P1743, DOI 10.1016/0300-9084(88)90033-8; SAIER MH, 1989, MICROBIOL REV, V53, P333, DOI 10.1128/MMBR.53.3.333-366.1989; SAIER MH, 1988, FASEB J, V2, P199, DOI 10.1096/fasebj.2.3.2832233; SCHIEBEL E, 1991, CELL, V64, P927, DOI 10.1016/0092-8674(91)90317-R; SHIBA K, 1984, EMBO J, V3, P631, DOI 10.1002/j.1460-2075.1984.tb01859.x; SINGER SJ, 1990, TRENDS BIOCHEM SCI, V15, P369, DOI 10.1016/0968-0004(90)90230-9; STEPHAN MM, 1986, BIOCHEMISTRY-US, V25, P8230, DOI 10.1021/bi00373a016; STOCHAJ U, 1988, J BACTERIOL, V170, P2639, DOI 10.1128/jb.170.6.2639-2645.1988; STOCHAJ U, 1987, EUR J BIOCHEM, V163, P653, DOI 10.1111/j.1432-1033.1987.tb10914.x; STOSCHECK CM, 1990, METHOD ENZYMOL, V182, P50; STRAUCH KL, 1986, J BACTERIOL, V166, P505, DOI 10.1128/jb.166.2.505-512.1986; SWIDERSKY UE, 1990, EMBO J, V9, P1777, DOI 10.1002/j.1460-2075.1990.tb08302.x; THOME BM, 1991, MOL MICROBIOL, V5, P2815, DOI 10.1111/j.1365-2958.1991.tb01990.x; TROSCHEL D, 1990, J CELL BIOL, V111, P87, DOI 10.1083/jcb.111.1.87; VOGEL HJ, 1956, J BIOL CHEM, V218, P97; VONHEIJNE G, 1986, EMBO J, V5, P3021, DOI 10.1002/j.1460-2075.1986.tb04601.x; VONHEIJNE G, 1989, NATURE, V341, P456, DOI 10.1038/341456a0; WATANABE M, 1989, CELL, V58, P695, DOI 10.1016/0092-8674(89)90104-9; WICKNER W, 1991, ANNU REV BIOCHEM, V60, P101, DOI 10.1146/annurev.bi.60.070191.000533; WOLFE PB, 1985, J BIOL CHEM, V260, P1836; YAMADA Y, 1991, J BIOL CHEM, V266, P17863; YAMATO I, 1992, J BIOCHEM-TOKYO, V111, P444, DOI 10.1093/oxfordjournals.jbchem.a123777; ZHU HY, 1989, J BIOL CHEM, V264, P11833	63	42	42	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 5	1992	267	34					24523	24532						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KA263	1447197				2022-12-25	WOS:A1992KA26300058
J	NISHIZAKI, T; WALENT, JH; KOWALCHYK, JA; MARTIN, TFJ				NISHIZAKI, T; WALENT, JH; KOWALCHYK, JA; MARTIN, TFJ			A KEY ROLE FOR A 145-KDA CYTOSOLIC PROTEIN IN THE STIMULATION OF CA2+-DEPENDENT SECRETION BY PROTEIN-KINASE-C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADRENAL CHROMAFFIN CELLS; THYROTROPIN-RELEASING-HORMONE; GH3 PITUITARY-CELLS; CALCIUM-DEPENDENT EXOCYTOSIS; PERMEABILIZED PC12 CELLS; PHORBOL ESTER TPA; RAT MAST-CELLS; GTP-GAMMA-S; CATECHOLAMINE RELEASE; TRANSMITTER RELEASE	Cytoplasmic Ca2+ is a major regulator of exocytosis in secretory cells; however, the Ca2+-dependent mechanisms that trigger secretion have not been elucidated. Protein kinase C (PKC) has been proposed to be an important Ca2+-dependent component of this regulation; however, the effects of this enzyme on the exocytotic apparatus have not been identified. We developed a PKC-deficient, semi-intact PC12 cell system in which direct stimulatory effects of purified PKC on Ca2+-dependent norepinephrine secretion were studied. The reconstitution of optimal Ca2+-activated norepinephrine secretion by semi-intact PC12 cells required the addition of MgATP and cytosolic proteins. PKC-deficient cytosol exhibited reduced reconstituting activity that was fully restored by the addition of purified PKC. The restoration of Ca2+-dependent norepinephrine secretion by PKC required the presence of other proteins in the cytosol, in particular, a high molecular weight protein. The high molecular weight protein was identified as p145, a recently characterized 145-kDa brain protein. The addition of PKC enhanced phosphorylation of p145 under conditions of fully reconstituted Ca2+-activated norepinephrine secretion. The results indicate that 1) PKC is neither necessary nor sufficient for Ca2+-activated secretion, whereas other cytosolic proteins are required; and 2) the stimulation of Ca2+-activated secretion by PKC is dependent upon cytosolic proteins such as p145 and may be largely mediated through the phosphorylation of p145.	UNIV WISCONSIN, DEPT ZOOL, ZOOL RES BLDG, 1117 W JOHNSON ST, MADISON, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK025861, R37DK025861, R01DK040428] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 40428, DK 25861] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AGNER PD, 1990, J BIOL CHEM, V265, P10352; AHNERTHILGER G, 1987, BIOCHEMISTRY-US, V26, P7842, DOI 10.1021/bi00398a046; ALI SM, 1989, NATURE, V340, P313, DOI 10.1038/340313a0; ALI SM, 1990, CELL SIGNAL, V2, P265, DOI 10.1016/0898-6568(90)90054-E; AUGUSTINE GJ, 1987, ANNU REV NEUROSCI, V10, P633, DOI 10.1146/annurev.ne.10.030187.003221; BENSHLOMO H, 1991, BIOCHEM J, V280, P65, DOI 10.1042/bj2800065; BITTNER MA, 1990, J NEUROCHEM, V54, P205, DOI 10.1111/j.1471-4159.1990.tb13302.x; BROCKLEHURST KW, 1985, FEBS LETT, V183, P107, DOI 10.1016/0014-5793(85)80964-9; BURGOYNE RD, 1984, BIOCHIM BIOPHYS ACTA, V779, P201, DOI 10.1016/0304-4157(84)90009-1; BURGOYNE RD, 1988, FEBS LETT, V238, P151, DOI 10.1016/0014-5793(88)80246-1; BURGOYNE RD, 1989, CELL SIGNAL, V1, P323, DOI 10.1016/0898-6568(89)90051-X; CHURCHER Y, 1990, CELL REGUL, V1, P337, DOI 10.1091/mbc.1.4.337; CHURCHER Y, 1990, CELL REGUL, V1, P523, DOI 10.1091/mbc.1.7.523; CONN PM, 1985, BIOCHEM BIOPH RES CO, V126, P532, DOI 10.1016/0006-291X(85)90638-2; DELISLE RC, 1986, ANNU REV PHYSIOL, V48, P225; DERIEMER SA, 1985, NATURE, V313, P313, DOI 10.1038/313313a0; DEVIRGILIO F, 1984, NATURE, V310, P691; DRUST DS, 1984, J BIOL CHEM, V259, P4520; DUFY B, 1987, ENDOCRINOLOGY, V121, P793, DOI 10.1210/endo-121-2-793; HARLOW E, 1988, ANTIBODIES LABORATOR; HAY JC, 1992, J CELL BIOL, V119, P139, DOI 10.1083/jcb.119.1.139; HOLZ RW, 1989, J BIOL CHEM, V264, P5412; HOWELL TW, 1989, CELL SIGNAL, V1, P157, DOI 10.1016/0898-6568(89)90005-3; HUTTON JC, 1986, CELL CALCIUM, V7, P339, DOI 10.1016/0143-4160(86)90037-0; JAKEN S, 1987, P NATL ACAD SCI USA, V84, P4418, DOI 10.1073/pnas.84.13.4418; KNIGHT DE, 1988, J MEMBRANE BIOL, V104, P21, DOI 10.1007/BF01871899; KNIGHT DE, 1983, FEBS LETT, V160, P98, DOI 10.1016/0014-5793(83)80944-2; KOFFER A, 1989, J CELL SCI, V94, P585; KOOPMANN WR, 1990, BIOCHEM J, V265, P365, DOI 10.1042/bj2650365; LOMNETH R, 1991, J NEUROCHEM, V57, P1413, DOI 10.1111/j.1471-4159.1991.tb08308.x; MARTIN TFJ, 1984, ENDOCRINOLOGY, V115, P1517, DOI 10.1210/endo-115-4-1517; MARTIN TFJ, 1990, J BIOL CHEM, V265, P7623; MARTIN TFJ, 1989, J BIOL CHEM, V264, P10299; MARTIN TFJ, 1989, METHOD ENZYMOL, V168, P225; MATTHIES HJG, 1988, FEBS LETT, V229, P238, DOI 10.1016/0014-5793(88)81132-3; MATTHIES HJG, 1987, J NEUROSCI, V7, P1198; MORGAN A, 1992, NATURE, V355, P833, DOI 10.1038/355833a0; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; POCOTTE SL, 1985, P NATL ACAD SCI USA, V82, P930, DOI 10.1073/pnas.82.3.930; POZZAN T, 1984, J CELL BIOL, V99, P628, DOI 10.1083/jcb.99.2.628; RONNING SA, 1986, J BIOL CHEM, V261, P7840; SARAFIAN T, 1991, J CELL BIOL, V114, P1135, DOI 10.1083/jcb.114.6.1135; SARAFIAN T, 1987, J BIOL CHEM, V262, P16671; SHAPIRA R, 1987, NATURE, V325, P58, DOI 10.1038/325058a0; TERBUSH DR, 1990, J BIOL CHEM, V265, P21179; TERBUSH DR, 1986, J BIOL CHEM, V261, P7099; VANDERMERWE PA, 1990, BIOCHEM J, V268, P493, DOI 10.1042/bj2680493; WALENT JH, 1992, CELL, V70, P765, DOI 10.1016/0092-8674(92)90310-9; WALKER JH, 1987, BIOCHEM J, V247, P249, DOI 10.1042/bj2470249; WILSON SP, 1990, J BIOL CHEM, V265, P648	50	57	57	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	1992	267	33					23972	23981						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JZ239	1429734				2022-12-25	WOS:A1992JZ23900081
J	SATOYOSHITAKE, R; YORIFUJI, H; INAGAKI, M; HIROKAWA, N				SATOYOSHITAKE, R; YORIFUJI, H; INAGAKI, M; HIROKAWA, N			THE PHOSPHORYLATION OF KINESIN REGULATES ITS BINDING TO SYNAPTIC VESICLES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE BRAIN KINESIN; MEMBRANOUS ORGANELLES INVIVO; FAST AXONAL-TRANSPORT; MICROTUBULES INVITRO; MONOCLONAL-ANTIBODY; SINGLE MICROTUBULES; PROTEIN-KINASES; SQUID AXOPLASM; HEAVY-CHAIN; IDENTIFICATION	Membrane organella are transported bidirectionally in cells, and the axonal transport system has provided an ideal model system for studying this bidirectional transport. Kinesin and cytoplasmic dynein were identified as candidates for the motor molecules of fast axonal transport, which transport organella along microtubules anterogradely and retrogradely. However, the mechanism that controls this bidirectional transport is unknown. Our previous work revealed that kinesin in axons was associated abundantly with anterogradely transported membranous organella, most of which are believed to be precursors of synaptic vesicles and axonal plasma membranes, while the fractions bound to retrogradely transported ones were very small (Hirokawa, N., Sato-Yoshitake, R., Kobayashi, N., Pfister, K. K., Bloom, G. S., and Brady, S. T. (1991) J. Cell Biol. 114, 295-302). Here we demonstrated in vitro that the binding of kinesin to synaptic vesicles was concentration-dependent and saturable and could be released by high salt concentration. When kinesin was phosphorylated by cAMP-dependent protein kinase, its binding to synaptic vesicles was significantly reduced. By motility assay and by statistical analysis using electron microscopy, we further revealed that synaptic vesicles preincubated with phosphorylated kinesin associated less frequently with microtubules than synaptic vesicles preincubated with unphosphorylated kinesin. The phosphorylation of kinesin should therefore play an essential role in regulating the direction of fast axonal transport by inhibiting its binding to membrane organella, thus releasing it from membrane organella at nerve terminals.	UNIV TOKYO, SCH MED, DEPT ANAT & CELL BIOL, TOKYO 113, JAPAN; TOKYO METROPOLITAN GERIATR HOSP & INST GERONTOL, NEUROPHYSIOL LAB, ITABASHI KU, TOKYO 173, JAPAN	University of Tokyo			Inagaki, Masaki/B-9920-2016					ALLEN RD, 1981, CELL MOTIL CYTOSKEL, V1, P291, DOI 10.1002/cm.970010303; Beavo J A, 1974, Methods Enzymol, V38, P299; BLOOM GS, 1988, BIOCHEMISTRY-US, V27, P3409, DOI 10.1021/bi00409a043; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRADY ST, 1990, P NATL ACAD SCI USA, V87, P1061, DOI 10.1073/pnas.87.3.1061; BRADY ST, 1985, NATURE, V317, P73, DOI 10.1038/317073a0; BREUER AC, 1975, J CELL BIOL, V65, P562, DOI 10.1083/jcb.65.3.562; BUSTER D, 1990, J CELL BIOL, V111, P418; DUNKLEY PR, 1988, J NEUROCHEM, V51, P57, DOI 10.1111/j.1471-4159.1988.tb04835.x; EDSTROM A, 1977, J NEUROBIOL, V8, P371, DOI 10.1002/neu.480080408; GRAFSTEIN B, 1980, PHYSIOL REV, V60, P1167, DOI 10.1152/physrev.1980.60.4.1167; HERZOG W, 1978, EUR J BIOCHEM, V92, P1, DOI 10.1111/j.1432-1033.1978.tb12716.x; HIROKAWA N, 1991, J CELL BIOL, V114, P295, DOI 10.1083/jcb.114.2.295; HIROKAWA N, 1990, J CELL BIOL, V111, P1027, DOI 10.1083/jcb.111.3.1027; HIROKAWA N, 1989, CELL, V56, P867, DOI 10.1016/0092-8674(89)90691-0; HOLLENBECK PJ, 1986, J CELL BIOL, V103, P1539, DOI 10.1083/jcb.103.4.1539; INAGAKI M, 1990, J BIOL CHEM, V265, P4722; KUZNETSOV SA, 1988, EMBO J, V7, P353, DOI 10.1002/j.1460-2075.1988.tb02820.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASEK RJ, 1984, J CELL BIOL, V99, pS212, DOI 10.1083/jcb.99.1.212s; LESLIE RJ, 1987, P NATL ACAD SCI USA, V84, P2771, DOI 10.1073/pnas.84.9.2771; LYE RJ, 1987, CELL, V51, P309, DOI 10.1016/0092-8674(87)90157-7; MUROFUSHI H, 1988, J BIOL CHEM, V263, P12744; MURPHY DB, 1989, J CELL BIOL, V109, P80; NAIRN AC, 1985, ANNU REV BIOCHEM, V54, P931, DOI 10.1146/annurev.bi.54.070185.004435; NESTLER EJ, 1989, BASIC NEUROCHEMISTRY, P373; PASCHAL BM, 1987, J CELL BIOL, V105, P1273, DOI 10.1083/jcb.105.3.1273; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCHNAPP BJ, 1986, METHOD ENZYMOL, V134, P561; SCHNAPP BJ, 1985, CELL, V40, P455, DOI 10.1016/0092-8674(85)90160-6; SCHNAPP BJ, 1989, P NATL ACAD SCI USA, V86, P1548, DOI 10.1073/pnas.86.5.1548; SCHOLEY JM, 1985, NATURE, V318, P483, DOI 10.1038/318483a0; SCHOLEY JM, 1989, NATURE, V338, P355, DOI 10.1038/338355a0; SCHROER TA, 1988, J CELL BIOL, V107, P1785, DOI 10.1083/jcb.107.5.1785; SCHROER TA, 1989, CELL, V56, P937, DOI 10.1016/0092-8674(89)90627-2; SCHWARTZ JH, 1979, ANNU REV NEUROSCI, V2, P467, DOI 10.1146/annurev.ne.02.030179.002343; SCHWYTER DH, 1990, J CELL BIOL, V111, P465, DOI 10.1083/jcb.111.2.465; SHELANSKI ML, 1973, P NATL ACAD SCI USA, V76, P4350; SMITH RS, 1980, J NEUROCYTOL, V9, P39, DOI 10.1007/BF01205226; TSUKITA S, 1980, J CELL BIOL, V84, P513, DOI 10.1083/jcb.84.3.513; UEDA T, 1979, J CELL BIOL, V83, P308, DOI 10.1083/jcb.83.2.308; VALE RD, 1985, CELL, V42, P39, DOI 10.1016/S0092-8674(85)80099-4; VALE RD, 1985, CELL, V43, P623, DOI 10.1016/0092-8674(85)90234-X; WAGNER MC, 1989, CELL MOTIL CYTOSKEL, V12, P195, DOI 10.1002/cm.970120403; WALTER U, 1978, J BIOL CHEM, V253, P6275; WRIGHT BD, 1991, J CELL BIOL, V113, P817, DOI 10.1083/jcb.113.4.817; YANG JT, 1989, CELL, V56, P879, DOI 10.1016/0092-8674(89)90692-2	47	132	134	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	1992	267	33					23930	23936						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JZ239	1429730				2022-12-25	WOS:A1992JZ23900075
J	PANTERNE, B; HATZFELD, J; BLANCHARD, JM; LEVESQUE, JP; BERTHIER, R; GINSBOURG, M; HATZFELD, A				PANTERNE, B; HATZFELD, J; BLANCHARD, JM; LEVESQUE, JP; BERTHIER, R; GINSBOURG, M; HATZFELD, A			C-FOS MESSENGER-RNA CONSTITUTIVE EXPRESSION BY MATURE HUMAN MEGAKARYOCYTES	ONCOGENE			English	Note							INSITU HYBRIDIZATION; GENE-EXPRESSION; HUMAN-MONOCYTES; PROTO-ONCOGENE; 3T3 CELLS; GROWTH; TRANSCRIPTION; MACROPHAGES; PROTOONCOGENE; GRANULOCYTES	By in situ hybridization with a c-fos probe, we have shown that human bone marrow megakaryocytes cultured in the presence of 20% aplastic anemia plasma constitutively express c-fos mRNA. At day 0, megakaryocytes are mostly immature and only 3% of them are labeled. The number of labeled cells reached 23% after 12 days of culture. Interleukin 3 (IL-3) and IL-6 added together at day 10 further increased this number to 31% 2 days later. Mature labeled megakaryocytes were more numerous and more strongly labeled than immature ones. These results suggest that c-fos could play a role in megakaryocytic terminal differentiation, either in the polyploidization or in the thrombopoietic function unique to these cells.	HOP PAUL BROUSSE,ICIG,BIOL CELLULAIRE & MOLEC FACTEURS CROISSANCE LAB,CNRS,F-94804 VILLEJUIF,FRANCE; CEN,DEPT HEMATOL,F-38041 GRENOBLE,FRANCE; UNIV MONTPELLIER 2,BIOCHIM LAB,CNRS,UA 1191,F-34060 MONTPELLIER,FRANCE; UNIV MONTPELLIER 2,BIOL MOLEC LAB,CNRS,UA 1191,F-34060 MONTPELLIER,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Paul-Brousse - APHP; Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier			Levesque, Jean-Pierre/C-5426-2011; HATZFELD, Antoinette/I-2341-2013; HATZFELD, Jacques A/I-2346-2013	Levesque, Jean-Pierre/0000-0002-7299-6025; HATZFELD, Antoinette/0000-0002-9147-533X; HATZFELD, Jacques A/0000-0002-3468-6659				ANGERER LM, 1987, METHOD ENZYMOL, V152, P649; BERNAUDIN JF, 1988, J IMMUNOL, V140, P3822; BERTHIER R, 1987, EXP HEMATOL, V15, P750; CAUBET JF, 1989, BLOOD, V74, P947; COCHRAN BH, 1984, SCIENCE, V226, P1080, DOI 10.1126/science.6093261; COLLART MA, 1987, J IMMUNOL, V139, P949; COLLART MA, 1991, MOL CELL BIOL, V11, P2826, DOI 10.1128/MCB.11.5.2826; COLOTTA F, 1987, J EXP MED, V165, P1224, DOI 10.1084/jem.165.4.1224; COX KH, 1984, DEV BIOL, V101, P485, DOI 10.1016/0012-1606(84)90162-3; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; Curran T, 1988, ONCOGENE HDB, P307; DEBILI N, 1991, BLOOD, V77, P2326; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HATZFELD J, 1991, J EXP MED, V174, P925, DOI 10.1084/jem.174.4.925; Hayhoe FG, 1982, COLOUR ATLAS HAEMATO; KREIPE H, 1987, J HISTOCHEM CYTOCHEM, V35, P837, DOI 10.1177/35.8.3298425; LAU LF, 1987, P NATL ACAD SCI USA, V84, P1182, DOI 10.1073/pnas.84.5.1182; LEE J, 1987, BLOOD, V69, P1542; MCCUNE JM, 1990, SCIENCE, V217, P864; MESSNER HA, 1987, P NATL ACAD SCI USA, V84, P6765, DOI 10.1073/pnas.84.19.6765; MESSNER HA, 1984, METHODS HEMATOLOGY, V2, P73; SARIBAN E, 1988, MOL CELL BIOL, V8, P340, DOI 10.1128/MCB.8.1.340	22	13	13	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1992	7	11					2341	2344						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JW665	1437157				2022-12-25	WOS:A1992JW66500029
J	SAMUEL, M; PIXLEY, RA; VILLANUEVA, MA; COLMAN, RW; VILLANUEVA, GB				SAMUEL, M; PIXLEY, RA; VILLANUEVA, MA; COLMAN, RW; VILLANUEVA, GB			HUMAN FACTOR-XII (HAGEMAN-FACTOR) AUTOACTIVATION BY DEXTRAN SULFATE - CIRCULAR-DICHROISM, FLUORESCENCE, AND ULTRAVIOLET DIFFERENCE SPECTROSCOPIC STUDIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COAGULATION FACTOR-XII; BLOOD-COAGULATION; CONTACT ACTIVATION; PLASMA KALLIKREIN; SURFACE; SYSTEM; PROTEINS; BINDING; HEPARIN; ACID	The first event leading to the activation of the plasma kallikrein-kinin system is the surface-dependent conversion of factor XII to an active enzyme. Factor XII autoactivation was investigated using dextran sulfate as a soluble activating surface, and the significance of aggregation and the nature of the conformational change were examined by ultraviolet difference spectroscopy, fluorescence and circular dichroism. Results indicate that DS500 (500-kDa dextran sulfate) induces aggregation of factor XII. Analysis of the binding data suggests that 165-192 factor XII molecules can bind to one DS500 chain, while a 1:1 stoichiometry is observed with 5-kDa dextran sulfate. The interaction of factor XII and dextran sulfate is a biphasic process. It is initiated by a fast contraction of the molecule upon binding, as revealed by an apparent increase in organized secondary structures, and then followed by a slow relaxation process during cleavage and subsequent activation. Overall, the results are consistent with a model in which factor XII undergoes conformational changes upon binding to the activating surface. The rapidity of autoactivation in the presence of DS500, as opposed to 5-kDa dextran sulfate, implies that aggregation provides a special mechanism whereby proteolytic cleavage is accomplished efficiently when factor XII molecules are bound side by side on the DS500 molecule.	NEW YORK MED COLL,DEPT BIOCHEM & MOLEC BIOL,VALHALLA,NY 10595; TEMPLE UNIV,CTR THROMBOSIS RES,PHILADELPHIA,PA 19140	New York Medical College; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL043252, P50HL045486] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 43252, HL45486] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDREWS LJ, 1972, BIOCHEMISTRY-US, V11, P1875, DOI 10.1021/bi00760a023; BOCK PE, 1981, BIOCHEMISTRY-US, V20, P7258, DOI 10.1021/bi00528a032; BOUMA BN, 1977, J BIOL CHEM, V252, P6432; CHEN YH, 1974, BIOCHEMISTRY-US, V13, P3350, DOI 10.1021/bi00713a027; COGAN U, 1976, EUR J BIOCHEM, V65, P71, DOI 10.1111/j.1432-1033.1976.tb10390.x; COLMAN RW, 1984, J CLIN INVEST, V73, P1249, DOI 10.1172/JCI111326; DONALDSO.VH, 1965, SCIENCE, V150, P754, DOI 10.1126/science.150.3697.754; Donovan J W, 1973, Methods Enzymol, V27, P497; Dorman B P, 1973, Methods Enzymol, V27, P767; FUJIKAWA K, 1980, BIOCHEMISTRY-US, V19, P1322, DOI 10.1021/bi00548a010; GREENFIE.N, 1969, BIOCHEMISTRY-US, V8, P4108, DOI 10.1021/bi00838a031; GRIEP MA, 1986, BIOCHEMISTRY-US, V25, P6688, DOI 10.1021/bi00369a054; GRIEP MA, 1985, BIOCHEMISTRY-US, V24, P4124, DOI 10.1021/bi00336a047; GRIFFIN JH, 1978, P NATL ACAD SCI USA, V75, P1998, DOI 10.1073/pnas.75.4.1998; GRIFFIN JH, 1979, SEMIN THROMB HEMOST, V5, P254; HARPEL PC, 1972, J CLIN INVEST, V51, P1813, DOI 10.1172/JCI106983; HEIMARK RL, 1980, NATURE, V286, P456, DOI 10.1038/286456a0; Kaplan A P, 1978, Prog Hemost Thromb, V4, P127; KOENIG JM, 1991, J LAB CLIN MED, V117, P523; LEACH SJ, 1960, J BIOL CHEM, V235, P2827; MARGOLIS J, 1958, J PHYSIOL-LONDON, V144, P1; MARGOLIS J, 1963, ANN NY ACAD SCI, V104, P133, DOI 10.1111/j.1749-6632.1963.tb17659.x; MCMILLIN CR, 1974, J CLIN INVEST, V54, P1312, DOI 10.1172/JCI107877; NOSSEL HL, 1964, CONTACT PHASE BLOOD, P19; PIXLEY RA, 1987, J BIOL CHEM, V262, P10140; PIXLEY RA, 1991, THROMB HAEMOSTASIS, V66, P540; Ratnoff O D, 1979, Curr Top Hematol, V2, P1; REICH C, 1980, BIOCHEMISTRY-US, V19, P5208, DOI 10.1021/bi00564a009; SHORE JD, 1987, BIOCHEMISTRY-US, V26, P2250, DOI 10.1021/bi00382a027; SILVERBERG M, 1987, BIOCHEM J, V248, P715, DOI 10.1042/bj2480715; TANKERSLEY DL, 1984, BIOCHEMISTRY-US, V23, P273, DOI 10.1021/bi00297a016; THOMPSON RE, 1977, J CLIN INVEST, V60, P1376, DOI 10.1172/JCI108898; VILLANUE.GB, 1971, BIOCHEMISTRY-US, V10, P3358, DOI 10.1021/bi00794a007; VROMAN L, 1965, NATURE, V205, P496, DOI 10.1038/205496a0; WILNER GD, 1968, J CLIN INVEST, V47, P2608, DOI 10.1172/JCI105943; YANARI S, 1960, J BIOL CHEM, V235, P2818	36	121	122	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1992	267	27					19691	19697						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JP593	1527088				2022-12-25	WOS:A1992JP59300100
J	SELANDERSUNNERHAGEN, M; ULLNER, M; PERSSON, E; TELEMAN, O; STENFLO, J; DRAKENBERG, T				SELANDERSUNNERHAGEN, M; ULLNER, M; PERSSON, E; TELEMAN, O; STENFLO, J; DRAKENBERG, T			HOW AN EPIDERMAL GROWTH-FACTOR (EGF)-LIKE DOMAIN BINDS CALCIUM - HIGH-RESOLUTION NMR STRUCTURE OF THE CALCIUM FORM OF THE NH2-TERMINAL EGF-LIKE DOMAIN IN COAGULATION FACTOR-X	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-MAGNETIC-RESONANCE; BETA-HYDROXYASPARTIC ACID; DEPENDENT PROTEIN-S; HUMAN FACTOR-IX; MARFAN-SYNDROME; HEMOPHILIA-B; FACTOR-ALPHA; DROSOPHILA-MELANOGASTER; TRANSMEMBRANE PROTEIN; THROMBIN BINDING	Domains homologous to the epidermal growth factor (EGF) are important building blocks for extracellular proteins. Proteins containing these domains have been shown to function in such diverse biological processes as blood coagulation, complement activation, and the developmental determination of embryonic cell fates. Many of these proteins require calcium for their biological function. In the case of coagulation factors IX and X and anticoagulants proteins C and S, calcium has been found to bind to the EGF-like domains. We have now determined the three-dimensional structure of the calcium-bound form of the NH2-terminal EGF-like domain in coagulation factor X by two-dimensional NMR and simulated folding. Ligands to the calcium ion are the two backbone carbonyls in Gly-47 and Gly-64, as well as the side chains in Gln-49, erythro-beta-hydroxyaspartic acid (Hya) 63, and possibly Asp-46. The conserved Asp-48 is not a ligand in our present structures. The remaining ligands are assumed to be solvent molecules or, in the intact protein, ligands from neighboring domains. Other proteins interacting in a calcium-dependent manner may also contribute ligands. A comparison with the calcium-free form shows that calcium binding induces strictly local structural changes in the domain. Residues corresponding to the side chain ligands in factor X are conserved in many other proteins, such as the integral membrane protein TAN-1 of human lymphocytes and its developmentally important homolog, Notch, in Drosophila. Calcium binding to EGF-like domains may be crucial for numerous protein-protein interactions involving EGF-like domains in coagulation factors, plasma proteins, and membrane proteins. Therefore, there is reason to believe that this novel calcium site plays an important role in the biochemistry of extracellular proteins.	UNIV LUND,MALMO GEN HOSP,DEPT CLIN CHEM,S-21401 MALMO,SWEDEN; TECH RES CTR FINLAND,BIOTECH LABS,SF-02151 ESPOO,FINLAND; TECH RES CTR FINLAND,CHEM LABS,SF-02151 ESPOO,FINLAND	Lund University; VTT Technical Research Center Finland; VTT Technical Research Center Finland	SELANDERSUNNERHAGEN, M (corresponding author), UNIV LUND,DEPT PHYS CHEM 2,POB 124,S-22100 LUND,SWEDEN.			Ullner, Magnus/0000-0002-4248-466X; Persson, Egon/0000-0003-3005-4926				ADLER M, 1991, J MAGN RESON, V91, P450, DOI 10.1016/0022-2364(91)90212-C; AKKE M, 1991, J MOL BIOL, V220, P173, DOI 10.1016/0022-2836(91)90389-N; APPELLA E, 1987, J BIOL CHEM, V262, P4437; APPELLA E, 1988, FEBS LETT, V231, P1, DOI 10.1016/0014-5793(88)80690-2; ASTERMARK J, 1992, J BIOL CHEM, V267, P3249; BARON M, 1991, TRENDS BIOCHEM SCI, V16, P13, DOI 10.1016/0968-0004(91)90009-K; BARON M, 1992, PROTEIN SCI, V1, P81; BAX A, 1989, ANNU REV BIOCHEM, V58, P223; CARPENTER G, 1990, HDB EXPT PHARM, V95, P69; CLORE GM, 1991, SCIENCE, V252, P1390, DOI 10.1126/science.2047852; COOKE RM, 1987, NATURE, V327, P339, DOI 10.1038/327339a0; COTTMAN C, 1990, SCIENCE, V249, P1438; DAHLBACK B, 1990, J BIOL CHEM, V265, P18481; DAHLBACK B, 1990, J BIOL CHEM, V265, P16082; DAVIS LM, 1987, BLOOD, V69, P140; DIETZ HC, 1991, NATURE, V352, P337, DOI 10.1038/352337a0; DRAKENBERG T, 1983, P NATL ACAD SCI-BIOL, V80, P1802, DOI 10.1073/pnas.80.7.1802; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; ENGEL J, 1989, FEBS LETT, V251, P1, DOI 10.1016/0014-5793(89)81417-6; FEHON RG, 1990, CELL, V61, P523, DOI 10.1016/0092-8674(90)90534-L; FLEMING RJ, 1990, GENE DEV, V4, P2188, DOI 10.1101/gad.4.12a.2188; FURIE B, 1988, CELL, V53, P505, DOI 10.1016/0092-8674(88)90567-3; GREEN PM, 1989, EMBO J, V8, P1067, DOI 10.1002/j.1460-2075.1989.tb03474.x; GRONKE RS, 1989, P NATL ACAD SCI USA, V86, P3609, DOI 10.1073/pnas.86.10.3609; HANDFORD PA, 1990, EMBO J, V9, P475, DOI 10.1002/j.1460-2075.1990.tb08133.x; HANDFORD PA, 1991, NATURE, V351, P164, DOI 10.1038/351164a0; HARVEY TS, 1991, EUR J BIOCHEM, V198, P555, DOI 10.1111/j.1432-1033.1991.tb16050.x; HOGG PJ, 1992, J BIOL CHEM, V267, P703; KELLEY MR, 1987, CELL, V51, P539, DOI 10.1016/0092-8674(87)90123-1; KLINE TP, 1990, BIOCHEMISTRY-US, V29, P7805, DOI 10.1021/bi00486a005; KONING TMG, 1990, J MAGN RESON, V90, P111, DOI 10.1016/0022-2364(90)90369-K; KORDEL J, 1991, THESIS LUND U; KUMAR A, 1981, J AM CHEM SOC, V103, P3654, DOI 10.1021/ja00403a008; KUROSAWA S, 1988, J BIOL CHEM, V263, P5993; LEE B, 1991, NATURE, V352, P330, DOI 10.1038/352330a0; LINSE S, 1990, BIOCHEMISTRY-US, V29, P5925, DOI 10.1021/bi00477a007; LINSE S, 1991, NATURE, V351, P164; LOZIER JN, 1990, BLOOD, V75, P1097; MASLEN CL, 1991, NATURE, V352, P334, DOI 10.1038/352334a0; MCCORD DM, 1990, J BIOL CHEM, V265, P10250; MONTELIONE GT, 1992, BIOCHEMISTRY-US, V31, P236, DOI 10.1021/bi00116a033; OHLIN AK, 1988, J BIOL CHEM, V263, P7411; OHLIN AK, 1988, J BIOL CHEM, V263, P19240; Patthy L, 1991, CURR OPIN STRUC BIOL, V1, P351, DOI 10.1016/0959-440X(91)90033-P; PERSSON E, 1989, J BIOL CHEM, V264, P16897; PERSSON E, 1991, J BIOL CHEM, V266, P2444; REBAY I, 1991, CELL, V67, P687, DOI 10.1016/0092-8674(91)90064-6; REES DJG, 1988, EMBO J, V7, P2053, DOI 10.1002/j.1460-2075.1988.tb03045.x; RICHARDSSON JS, 1981, ANN REV BIOCH, V54, P459; SCOTT DL, 1990, SCIENCE, V250, P1541, DOI 10.1126/science.2274785; SELANDER M, 1990, BIOCHEMISTRY-US, V29, P811; STENFLO J, 1991, BLOOD, V78, P1637; STENFLO J, 1987, P NATL ACAD SCI USA, V84, P368, DOI 10.1073/pnas.84.2.368; STRYNADKA NCJ, 1989, ANNU REV BIOCHEM, V58, P951, DOI 10.1146/annurev.bi.58.070189.004511; SUZUKI K, 1989, J BIOL CHEM, V264, P4872; TAPPIN MJ, 1989, EUR J BIOCHEM, V179, P629, DOI 10.1111/j.1432-1033.1989.tb14594.x; ULLNER M, 1992, BIOCHEMISTRY-US, V31, P5974, DOI 10.1021/bi00141a004; VASSIN H, 1987, EMBO J, V6, P3431, DOI 10.1002/j.1460-2075.1987.tb02666.x; WAGNER G, 1987, J MOL BIOL, V196, P611, DOI 10.1016/0022-2836(87)90037-4; WHARTON KA, 1985, CELL, V43, P567, DOI 10.1016/0092-8674(85)90229-6; WINSHIP PR, 1991, BRIT J HAEMATOL, V77, P102, DOI 10.1111/j.1365-2141.1991.tb07955.x; WUTHRICH K, 1983, J MOL BIOL, V169, P949, DOI 10.1016/S0022-2836(83)80144-2; Wuthrich K., 1986, NMR PROTEINS NUCL AC; YIP PF, 1990, J MAGN RESON, V90, P382, DOI 10.1016/0022-2364(90)90146-Z	64	168	177	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1992	267	27					19642	19649						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JP593	1527084				2022-12-25	WOS:A1992JP59300093
J	DEDHAR, S; JEWELL, K; ROJIANI, M; GRAY, V				DEDHAR, S; JEWELL, K; ROJIANI, M; GRAY, V			THE RECEPTOR FOR THE BASEMENT-MEMBRANE GLYCOPROTEIN ENTACTIN IS THE INTEGRIN ALPHA-3 BETA-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; EMBRYONAL CARCINOMA-CELLS; OSTEO-SARCOMA CELLS; FIBRONECTIN RECEPTOR; RETINOIC ACID; SIGNAL TRANSDUCTION; ADHESION RECEPTORS; DIVALENT-CATIONS; LAMININ-BINDING; CYCLIC-AMP	Entactin is a glycoprotein found in basement membranes in complex with laminin, and purified entactin can promote the attachment and spreading of cells. We report here the isolation and identification of the plasma membrane receptor for entactin from PC-3 human prostate carcinoma cells which attach and spread on entactin. The receptor was isolated by affinity chromatography on mouse recombinant entactin-Sepharose of I-125 surface-labeled octyl glucoside cell extracts. The receptor, which consisted of two polypeptides of relative molecular masses of 150 and 116 kDa, bound to the entactin-Sepharose matrix in the presence of CaCl2, MgCl2, and MnCl2, and was eluted with EDTA, but not with Arg-Gly-Asp-containing peptides. Utilizing anti-integrin antibodies, the heterodimeric receptor was identified as the integrin alpha-3-beta-1. Purified alpha-3-beta-1 bound to entactin Sepharose in a divalent cation-dependent manner and liposomes prepared with fractions eluted from the entactin-Sepharose matrix, as well as purified alpha-3-beta-1 also bound to entactin. Liposomes prepared with other integrins such as alpha-2-beta-1 did not bind to entactin. Antibody inhibition assays demonstrated that an anti-alpha-3 antibody (P1B5) inhibited the attachment of PC-3 cells to entactin whereas this antibody did not inhibit the attachment of these cells to laminin. Attachment to laminin was, however, blocked by anti-alpha-6 antibody (G0H3). These data demonstrate that the cell surface receptor for entactin on these prostate carcinoma cells is the integrin alpha-3-beta-1 and that these cells utilize alpha-6-beta-1 the receptor for laminin.	UNIV BRITISH COLUMBIA, DEPT PATHOL, VANCOUVER V6T 1Z3, BC, CANADA; SUNNYBROOK HLTH SCI CTR, DIV CANC RES, TORONTO M4N 3M5, ONTARIO, CANADA	University of British Columbia; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center	DEDHAR, S (corresponding author), BRITISH COLUMBIA CANC AGCY, DEPT ADV THERAPEUT, 600 W 10TH AVE, VANCOUVER V5Z 4E6, BC, CANADA.			Dedhar, Shoukat/0000-0003-4355-1657				ALSTADT SP, 1987, J INVEST DERMATOL, V88, P55, DOI 10.1111/1523-1747.ep12465007; ARATANI Y, 1988, J BIOL CHEM, V263, P16153; CARLIN B, 1981, J BIOL CHEM, V256, P5209; CARLIN BE, 1983, J BIOL CHEM, V258, P7729; CARTER WG, 1991, CELL, V65, P599, DOI 10.1016/0092-8674(91)90092-D; CHAKRAVARTI S, 1990, J BIOL CHEM, V265, P10597; CHUNG AE, 1990, AM J RESP CELL MOL, V3, P275, DOI 10.1165/ajrcmb/3.4.275; CHUNG AE, 1979, CELL, V16, P277, DOI 10.1016/0092-8674(79)90005-9; CHUNG AE, 1977, BIOCHEM BIOPH RES CO, V79, P859, DOI 10.1016/0006-291X(77)91190-1; COOPER AR, 1983, DEV BIOL, V99, P510, DOI 10.1016/0012-1606(83)90300-7; DEDHAR S, 1989, EXP CELL RES, V183, P207, DOI 10.1016/0014-4827(89)90430-8; DEDHAR S, 1987, J CELL BIOL, V105, P1175, DOI 10.1083/jcb.105.3.1175; DEDHAR S, 1987, J CELL BIOL, V104, P585, DOI 10.1083/jcb.104.3.585; DEDHAR S, 1989, J BIOL CHEM, V264, P4832; DEDHAR S, 1991, J BIOL CHEM, V266, P21846; DURKIN ME, 1988, J CELL BIOL, V107, P2749, DOI 10.1083/jcb.107.6.2749; ELICES MJ, 1991, J CELL BIOL, V112, P169, DOI 10.1083/jcb.112.1.169; GAILIT J, 1988, J BIOL CHEM, V263, P12927; GEHLSEN KR, 1992, J CELL BIOL, V117, P449, DOI 10.1083/jcb.117.2.449; GEHLSEN KR, 1989, J BIOL CHEM, V264, P19034; GRAY J, 1987, CELL, V48, P989; HALL DE, 1990, J CELL BIOL, V110, P2175, DOI 10.1083/jcb.110.6.2175; HEMLER ME, 1988, IMMUNOL TODAY, V9, P109, DOI 10.1016/0167-5699(88)91280-7; HEMLER ME, 1990, ANNU REV IMMUNOL, V8, P365, DOI 10.1146/annurev.iy.08.040190.002053; HORWITZ A, 1986, NATURE, V320, P531, DOI 10.1038/320531a0; KIRCHHOFER D, 1991, J BIOL CHEM, V266, P4471; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGUINO LR, 1989, J CELL BIOL, V109, P2455, DOI 10.1083/jcb.109.5.2455; LEBIEN TW, 1982, J IMMUNOL, V129, P2287; MANN K, 1988, EUR J BIOCHEM, V178, P71, DOI 10.1111/j.1432-1033.1988.tb14430.x; MANN K, 1989, EMBO J, V8, P65, DOI 10.1002/j.1460-2075.1989.tb03349.x; MARTIN GR, 1987, ANNU REV CELL BIOL, V3, P57, DOI 10.1146/annurev.cellbio.3.1.57; NAGAYOSHI T, 1989, DNA-J MOLEC CELL BIO, V8, P581, DOI 10.1089/dna.1989.8.581; OTEY CA, 1990, J CELL BIOL, V111, P721, DOI 10.1083/jcb.111.2.721; PYTELA R, 1985, CELL, V40, P191, DOI 10.1016/0092-8674(85)90322-8; ROJIANI MV, 1991, BIOCHEMISTRY-US, V30, P9859, DOI 10.1021/bi00105a008; RUOSLAHTI E, 1982, METHOD ENZYMOL, V82, P803; SASAKI M, 1988, J BIOL CHEM, V263, P16536; SONNENBERG A, 1991, EXP CELL RES, V197, P234, DOI 10.1016/0014-4827(91)90428-W; SONNENBERG A, 1988, NATURE, V336, P487, DOI 10.1038/336487a0; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; TIMPL R, 1983, EUR J BIOCHEM, V137, P455, DOI 10.1111/j.1432-1033.1983.tb07849.x; TIMPL R, 1989, EUR J BIOCHEM, V180, P487, DOI 10.1111/j.1432-1033.1989.tb14673.x; TSAO T, 1990, J BIOL CHEM, V265, P5188; WAYNER EA, 1988, J CELL BIOL, V107, P1881, DOI 10.1083/jcb.107.5.1881; WAYNER EA, 1987, J CELL BIOL, V105, P1873, DOI 10.1083/jcb.105.4.1873; WERB Z, 1989, J CELL BIOL, V109, P877, DOI 10.1083/jcb.109.2.877; YURCHENCO PD, 1990, FASEB J, V4, P1577, DOI 10.1096/fasebj.4.6.2180767	48	133	134	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	1992	267	26					18908	18914						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JN502	1527019				2022-12-25	WOS:A1992JN50200099
J	DEVIVO, M; CHEN, JH; CODINA, J; IYENGAR, R				DEVIVO, M; CHEN, JH; CODINA, J; IYENGAR, R			ENHANCED PHOSPHOLIPASE-C STIMULATION AND TRANSFORMATION IN NIH-3T3 CELLS EXPRESSING Q209LGQ-ALPHA-SUBUNITS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							ALPHA-SUBUNITS; G-PROTEINS; RECEPTOR; ACTIVATION; MECHANISM; PROLIFERATION	NIH-3T3 cells were transfected with cDNA encoding the native alpha-subunit of the G protein G(q)(alpha(q)) or a mutant (Q209L) form of alpha(q). Cells expressing Q209L-alpha(q) showed greatly enhanced basal phospholipase C activity. Stimulation of phospholipase C activity by prostaglandin F2-alpha or fetal calf serum was increased up to 10-fold in Q209L-alpha(q)-transfected cells. Continuous expression of Q209L-alpha(q) or overexpression of alpha(q) in NIH-3T3 cells resulted in formation of foci after 3 weeks. The number of foci was proportional to the number of transfected cells and was greater in cells expressing the Q209L-alpha(q) than in cells that overexpressed the wild type alpha(q). Q209L-alpha(q)-transfected NIH-3T3 cells also formed colonies in soft agar indicating their capacity to grow in an anchorage-independent manner. Expression of Q209L-alpha(q) in Rat-1 cells resulted in enhanced basal and fetal calf serum-stimulated phospholipase C activity, but these cells were not transformed as assessed by either the focus formation or the soft agar colony formation assays. These results indicate that expression of continuously activated G(q)-alpha can result in transformation in a cell type-specific manner.	BAYLOR COLL MED,DEPT CELL BIOL,HOUSTON,TX 77030	Baylor College of Medicine	DEVIVO, M (corresponding author), CUNY MT SINAI SCH MED,DEPT PHARMACOL,NEW YORK,NY 10029, USA.				NCI NIH HHS [CA 44998] Funding Source: Medline; NIDDK NIH HHS [DK 387612] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA044998] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALLEN LF, 1991, P NATL ACAD SCI USA, V88, P11354, DOI 10.1073/pnas.88.24.11354; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BERNSTEIN G, 1992, J BIOL CHEM, V267, P8081; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; CASSEL D, 1978, P NATL ACAD SCI USA, V75, P4155, DOI 10.1073/pnas.75.9.4155; CASSEL D, 1978, P NATL ACAD SCI USA, V75, P2669, DOI 10.1073/pnas.75.6.2669; CONKLIN BR, 1992, J BIOL CHEM, V267, P31; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GRAZIANO MP, 1989, J BIOL CHEM, V264, P15475; GUPTA SK, 1992, MOL CELL BIOL, V12, P190, DOI 10.1128/MCB.12.1.190; GUTKIND JS, 1991, P NATL ACAD SCI USA, V88, P4703, DOI 10.1073/pnas.88.11.4703; GUTOWSKI S, 1991, J BIOL CHEM, V266, P20519; HERMOUET S, 1991, P NATL ACAD SCI USA, V88, P10455, DOI 10.1073/pnas.88.23.10455; HOECK W, 1989, J BIOL CHEM, V264, P14396; IMAI A, 1987, METHOD ENZYMOL, V141, P100; JULIUS D, 1989, SCIENCE, V244, P1057, DOI 10.1126/science.2727693; Kriegler M., 1990, GENE TRANSFER EXPRES; KROLL SD, 1992, IN PRESS J BIOL CHEM, V267; LOWNDES JM, 1991, J BIOL CHEM, V266, P14193; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; RHEE SG, 1992, J BIOL CHEM, V267, P12393; SMITH MR, 1989, P NATL ACAD SCI USA, V86, P3659, DOI 10.1073/pnas.86.10.3659; TAYLOR SJ, 1991, NATURE, V350, P516, DOI 10.1038/350516a0; WU DQ, 1992, J BIOL CHEM, V267, P1811	26	92	92	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1992	267	26					18263	18266						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JN502	1526966				2022-12-25	WOS:A1992JN50200004
J	SOIFER, NE; DEE, KE; INSOGNA, KL; BURTIS, WJ; MATOVCIK, LM; WU, TL; MILSTONE, LM; BROADUS, AE; PHILBRICK, WM; STEWART, AF				SOIFER, NE; DEE, KE; INSOGNA, KL; BURTIS, WJ; MATOVCIK, LM; WU, TL; MILSTONE, LM; BROADUS, AE; PHILBRICK, WM; STEWART, AF			PARATHYROID HORMONE-RELATED PROTEIN - EVIDENCE FOR SECRETION OF A NOVEL MID-REGION FRAGMENT BY 3 DIFFERENT CELL-TYPES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLASE-STIMULATING ACTIVITY; HUMORAL HYPERCALCEMIA; BONE-RESORPTION; MALIGNANCY; IDENTIFICATION; TUMORS; CANCER; PEPTIDE	The cDNA-predicted amino acid sequence of parathyroid hormone-related protein (PTHrP) contains multiple basic amino acid motifs, suggesting that PTHrP undergoes extensive post-translational processing prior to secretion. The secretory forms of the peptide are currently unknown. To identify these secretory forms, medium was harvested from three cell types: human renal carcinoma (SKRC-1) cells, human keratinocytes, and rat insulinoma cells stably transfected with the cDNA for PTHrP(1-141) (RIN-141 cells). Amino-terminal species were immunopurified using an anti-PTHrP(1-36) column, and mid-region species using an anti-PTHrP(37-74) column. PTHrP peptides in medium and in cell extracts were further resolved by reverse phase high performance liquid chromatography (RP-HPLC) and identified using region-specific immunoassays. SKRC-1 and RIN-141 cells secreted three distinct amino-terminal species and a novel, non-amino-terminal, mid-region fragment. Sequence and sodium dodecyl sulfate-polyacrylamide gel electrophoresis analysis indicated that the RIN-141 cell mid-region fragment begins at amino acid 38 of the cDNA-predicted sequence and is approximately 70 amino acids in length. Comparison of RP-HPLC elution patterns suggests that SKRC-1 cells and keratinocytes secrete a similar or identical mid-region fragment. Immunofluorescence studies revealed a Golgi pattern for the amino-terminal species and a secretory granule pattern for the mid-region fragment. These studies indicate that 1) multiple PTHrP species are secreted, including a novel mid-region fragment; 2) Arg37 serves as a cleavage site in at least three cell types; 3) PTHrP(1-36) is likely to be an authentic secretory form of PTHrP; and 4) the mid-region fragment appears to be packaged into secretory granules. The marked interspecies conservation of this mid-region PTHrP suggests that it will have important biological functions.	W HAVEN VET AFFAIRS MED CTR,DIV NEPHROL,W HAVEN,CT 06510; W HAVEN VET AFFAIRS MED CTR,DIV DERMATOL,W HAVEN,CT 06510; YALE UNIV,SCH MED,NEW HAVEN,CT 06510	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Connecticut Healthcare System; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Connecticut Healthcare System; Yale University	SOIFER, NE (corresponding author), W HAVEN VET AFFAIRS MED CTR,DIV ENDOCRINOL,RES 151,950 CAMPBELL AVE,W HAVEN,CT 06516, USA.			Insogna, Karl/0000-0001-6973-5679	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R37AR030102, R01AR030102, R01AR039571] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007276] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR-39571, AR-30102] Funding Source: Medline; NIDDK NIH HHS [5T32DKO7276-14] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARON MD, 1990, J BIOL CHEM, V265, P19928; BRANDT DW, 1991, ENDOCRINOLOGY, V129, P2466, DOI 10.1210/endo-129-5-2466; BURTIS WJ, 1990, NEW ENGL J MED, V322, P1106, DOI 10.1056/NEJM199004193221603; BURTIS WJ, 1987, J BIOL CHEM, V262, P7151; BURTIS WJ, 1991, J BONE MINER RES  S1, V6, P229; CARE AD, 1990, EXP PHYSIOL, V75, P605, DOI 10.1113/expphysiol.1990.sp003437; FENTON AJ, 1991, ENDOCRINOLOGY, V129, P3424, DOI 10.1210/endo-129-6-3424; HALLORAN BP, 1991, PARATHYROID HORMONE, P93; HAMMONDS RG, 1989, J BIOL CHEM, V264, P14806; HORMAN AJ, 1987, P NATL ACAD SCI USA, V84, P2150; MANGIN M, 1988, P NATL ACAD SCI USA, V85, P597, DOI 10.1073/pnas.85.2.597; MOSELEY JM, 1987, P NATL ACAD SCI USA, V84, P5048, DOI 10.1073/pnas.84.14.5048; PANDIAN MR, 1992, CLIN CHEM, V38, P282; SEVARINO KA, 1987, J BIOL CHEM, V262, P4987; STEWART AF, 1986, J BONE MINER RES, V1, P267; STEWART AF, 1983, P NATL ACAD SCI-BIOL, V80, P1454, DOI 10.1073/pnas.80.5.1454; STEWART AF, 1987, J BONE MINER RES, V2, P587; STEWART AF, 1988, J CLIN INVEST, V81, P596, DOI 10.1172/JCI113358; STEWART AF, 1990, J CLIN ENDOCR METAB, V71, P1410, DOI 10.1210/jcem-71-6-1410; STEWART AF, 1990, ADV ENDOCRINOLOGY, P1; STREWLER GJ, 1983, J CLIN INVEST, V71, P769, DOI 10.1172/JCI110825; WEIR EC, 1988, J CLIN INVEST, V81, P818, DOI 10.1172/JCI113389; WU TL, 1991, J CLIN ENDOCR METAB, V73, P1002, DOI 10.1210/jcem-73-5-1002	23	111	111	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1992	267	25					18236	18243						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JM223	1517251				2022-12-25	WOS:A1992JM22300115
J	THELER, JM; MOLLARD, P; GUERINEAU, N; VACHER, P; PRALONG, WF; SCHLEGEL, W; WOLLHEIM, CB				THELER, JM; MOLLARD, P; GUERINEAU, N; VACHER, P; PRALONG, WF; SCHLEGEL, W; WOLLHEIM, CB			VIDEO IMAGING OF CYTOSOLIC CA2+ IN PANCREATIC BETA-CELLS STIMULATED BY GLUCOSE, CARBACHOL, AND ATP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BURSTING ELECTRICAL-ACTIVITY; ADRENAL CHROMAFFIN CELLS; INDUCED INSULIN RELEASE; B-CELLS; CYTOPLASMIC CA-2+; INDUCED OSCILLATIONS; INTRACELLULAR CALCIUM; PITUITARY-CELLS; MOUSE ISLETS; IONIC FLUXES	In order to define the differences in the distribution of cytosolic free Ca2+ ([Ca2+]i) in pancreatic beta-cells stimulated with the fuel secretagogue glucose or the Ca2+-mobilizing agents carbachol and ATP, we applied digital video imaging to beta-cells loaded with fura-2.83% of the cells responded to glucose with an increase in [Ca2+]i after a latency of 117 +/- 24 s (mean +/- S.E., 85 cells). Of these cells, 16% showed slow wave oscillations (frequency 0.35/min). In order to assess the relationship between membrane potential and the distribution of the [Ca2+]i rise, digital image analysis and perforated patch-clamp methods were applied simultaneously. The system used allowed sufficient temporal resolution to visualize a subplasmalemmal Ca2+ transient due to a single glucose-induced action potential. Glucose could also elicit a slow depolarization which did not cause Ca2+ influx until the appearance of the first of a train of action potentials. [Ca2+]i rose progressively during spike firing. Inhibition of Ca2+ influx by EGTA abolished the glucose-induced rise in [Ca2+]i. In contrast, the peak amplitude of the [Ca2+]i response to carbachol was not significantly different in normal or in Ca2+-deprived medium. Occasionally, the increase of the [Ca2+]i rise was polarized to one area of the cell different from the subplasmalemmal rise caused by glucose. The amplitude of the response and the number of responding cells were significantly increased when carbachol was applied after the addition of high glucose (11.2 mM). ATP also raised [Ca2+]i and promoted both Ca2+ mobilization and Ca2+ influx. The intracellular distribution of [Ca2+]i was homogeneous during the onset of the response. A polarity in the [Ca2+]i distribution could be detected either in the descending phase of the peak or in subsequent peaks during [Ca2+]i oscillations caused by ATP. In the absence of extracellular Ca2+, the sequential application of ATP and carbachol revealed that carbachol was still able to raise [Ca2+]i after exhaustion of the ATP response. This may be due to desensitization to the former agonist, since the response occurred in the same area of the cell. These results reveal subtle differences in [Ca2+]i distribution following membrane depolarization with glucose or the application of Ca2+ mobilizing agonists.	UNIV GENEVA, DEPT MED, FDN RECH MED, CH-1211 GENEVA 4, SWITZERLAND; UNIV BORDEAUX 2, CNRS, URA 1200, NEUROPHYSIOL LAB, F-33076 BORDEAUX, FRANCE	University of Geneva; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite de Bordeaux	THELER, JM (corresponding author), UNIV GENEVA, CTR MED, DIV BIOCHIM CLIN, CH-1211 GENEVA 4, SWITZERLAND.		Vacher, Pierre/N-2243-2018	VACHER, Pierre/0000-0003-3503-7981; Guerineau, Nathalie/0000-0003-2517-4210				AMMALA C, 1991, NATURE, V353, P849, DOI 10.1038/353849a0; ASHCROFT FM, 1984, NATURE, V312, P446, DOI 10.1038/312446a0; ASHCROFT FM, 1989, PROG BIOPHYS MOL BIO, V54, P87, DOI 10.1016/0079-6107(89)90013-8; BIDEN TJ, 1987, J BIOL CHEM, V262, P3567; BLACHIER F, 1988, BIOCHIM BIOPHYS ACTA, V970, P222, DOI 10.1016/0167-4889(88)90182-6; CARROLL PB, 1990, EUR BIOPHYS J, V18, P71, DOI 10.1007/BF00183265; CHEEK TR, 1989, J CELL BIOL, V109, P1219, DOI 10.1083/jcb.109.3.1219; COOK DL, 1984, NATURE, V311, P271, DOI 10.1038/311271a0; FALKE LC, 1989, FEBS LETT, V251, P167, DOI 10.1016/0014-5793(89)81448-6; GARCIA MC, 1988, BIOCHEM J, V254, P211, DOI 10.1042/bj2540211; GESCHWIND JF, 1989, BIOCHIM BIOPHYS ACTA, V1012, P107, DOI 10.1016/0167-4889(89)90018-9; GRAPENGIESSER E, 1988, BIOCHEM BIOPH RES CO, V150, P419, DOI 10.1016/0006-291X(88)90537-2; GRAPENGIESSER E, 1988, BIOCHEM BIOPH RES CO, V151, P1299, DOI 10.1016/S0006-291X(88)80503-5; GROHOVAZ F, 1991, J CELL BIOL, V113, P1341, DOI 10.1083/jcb.113.6.1341; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; GYLFE E, 1991, CELL CALCIUM, V12, P229, DOI 10.1016/0143-4160(91)90023-8; GYLFE E, 1987, BRIT J PHARMACOL, V92, P281, DOI 10.1111/j.1476-5381.1987.tb11322.x; GYLFE E, 1988, J BIOL CHEM, V263, P5044; HENQUIN JC, 1984, EXPERIENTIA, V40, P1043, DOI 10.1007/BF01971450; HERCHUELZ A, 1991, CELL CALCIUM, V12, P577, DOI 10.1016/0143-4160(91)90076-Q; HORN R, 1988, J GEN PHYSIOL, V92, P145, DOI 10.1085/jgp.92.2.145; JOHANSSON H, 1989, CELL CALCIUM, V10, P205, DOI 10.1016/0143-4160(89)90003-1; LEONG DA, 1989, METHOD ENZYMOL, V168, P263; LI GD, 1991, J BIOL CHEM, V266, P3449; LONGO EA, 1991, J BIOL CHEM, V266, P9314; MACDONALD MJ, 1991, J BIOL CHEM, V266, P22392; MARKS PW, 1990, CELL CALCIUM, V11, P18, DOI 10.1016/0143-4160(90)90069-7; MEDA P, 1984, Q J EXP PHYSIOL CMS, V69, P719; NILSSON T, 1988, BIOCHEM BIOPH RES CO, V153, P984, DOI 10.1016/S0006-291X(88)81325-1; OSULLIVAN AJ, 1989, EMBO J, V8, P401, DOI 10.1002/j.1460-2075.1989.tb03391.x; PETERRIESCH B, 1988, J CLIN INVEST, V81, P1154, DOI 10.1172/JCI113430; PETERSEN OH, 1987, PHYSIOL REV, V67, P1054, DOI 10.1152/physrev.1987.67.3.1054; PIPELEERS D, 1987, DIABETOLOGIA, V30, P277, DOI 10.1007/BF00299019; PRALONG WF, 1990, EMBO J, V9, P53, DOI 10.1002/j.1460-2075.1990.tb08079.x; PRALONG WF, 1991, DIABETES S1, V40, pA80; PRENTKI M, 1987, PHYSIOL REV, V67, P1185, DOI 10.1152/physrev.1987.67.4.1185; RANA RS, 1985, J BIOL CHEM, V260, P7861; RASMUSSEN H, 1990, DIABETES CARE, V13, P655, DOI 10.2337/diacare.13.6.655; RAWLINGS SR, 1991, J BIOL CHEM, V266, P22755; ROSARIO LM, 1986, BIOPHYSICS PANCREATI, P413; SALA F, 1990, BIOPHYS J, V57, P313, DOI 10.1016/S0006-3495(90)82533-9; SALOMON D, 1986, EXP CELL RES, V162, P507, DOI 10.1016/0014-4827(86)90354-X; SANTOS RM, 1991, PFLUG ARCH EUR J PHY, V418, P417, DOI 10.1007/BF00550880; SCHLEGEL W, 1987, NATURE, V329, P719, DOI 10.1038/329719a0; SCHUIT FC, 1988, P NATL ACAD SCI USA, V85, P3865, DOI 10.1073/pnas.85.11.3865; SENER A, 1990, BIOCHIM BIOPHYS ACTA, V1019, P42, DOI 10.1016/0005-2728(90)90122-K; SMITH PA, 1990, FEBS LETT, V261, P187, DOI 10.1016/0014-5793(90)80667-8; SORIA B, 1991, DIABETES, V40, P1069, DOI 10.2337/diabetes.40.8.1069; STEFAN Y, 1987, J CLIN INVEST, V80, P175, DOI 10.1172/JCI113045; SWANDULLA D, 1991, NEURON, V7, P915, DOI 10.1016/0896-6273(91)90337-Y; TAKAMATSU T, 1990, CELL CALCIUM, V11, P111, DOI 10.1016/0143-4160(90)90064-2; THELER JM, 1991, J RECEPTOR RES, V11, P627, DOI 10.3109/10799899109066431; TSIEN RY, 1990, CELL CALCIUM, V11, P93, DOI 10.1016/0143-4160(90)90063-Z; TSIEN RY, 1985, CELL CALCIUM, V6, P145, DOI 10.1016/0143-4160(85)90041-7; TSIEN RY, 1986, TRENDS BIOCHEM SCI, V11, P450, DOI 10.1016/0968-0004(86)90245-8; VALDEOLMILLOS M, 1989, FEBS LETT, V259, P19, DOI 10.1016/0014-5793(89)81484-X; VALLAR L, 1987, J BIOL CHEM, V262, P5049; WANG JL, 1990, BIOCHEM BIOPH RES CO, V166, P813, DOI 10.1016/0006-291X(90)90882-N; WILLIAMS DA, 1985, NATURE, V318, P558, DOI 10.1038/318558a0; WOLLHEIM CB, 1984, FEBS LETT, V177, P17, DOI 10.1016/0014-5793(84)80972-2; WOLLHEIM CB, 1986, ANN NY ACAD SCI, V488, P317; WOLLHEIM CB, 1990, FEBS LETT, V268, P376, DOI 10.1016/0014-5793(90)81289-Z; WOLLHEIM CB, 1981, PHYSIOL REV, V61, P914, DOI 10.1152/physrev.1981.61.4.914; WOLLHEIM CB, 1980, ENDOCRINOLOGY, V107, P924, DOI 10.1210/endo-107-4-924; YADA T, 1992, CELL CALCIUM, V13, P69, DOI 10.1016/0143-4160(92)90031-M	65	119	121	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 5	1992	267	25					18110	18117						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JM223	1517243				2022-12-25	WOS:A1992JM22300096
J	LITTLEWOOD, TD; AMATI, B; LAND, H; EVAN, GI				LITTLEWOOD, TD; AMATI, B; LAND, H; EVAN, GI			MAX AND C-MYC MAX DNA-BINDING ACTIVITIES IN CELL-EXTRACTS	ONCOGENE			English	Article							LEUCINE ZIPPER; MONOCLONAL-ANTIBODIES; PROTEIN; DIMERIZATION; OLIGOMERIZATION; TRANSFORMATION; TRANSCRIPTION; LOCALIZATION; REGIONS; DOMAINS	We have examined the interactions and DNA-binding activities of the c-Myc oncoprotein and its partner Max. In cell extracts virtually all c-Mvc molecules are associated with Max in heterodimeric complexes. Moreover, DNA-binding studies with in vitro-translated protein and cell extracts show that both Max alone and c-Myc/Max bind the same DNA sequence. Conversely, c-Myc is unable to bind this sequence in the absence of Max. These findings suggest that c-Myc may function via obligate complex formation with Max.	IMPERIAL CANC RES FUND,GROWTH CONTROL & DEV LAB,LONDON WC2A 3PX,ENGLAND	Cancer Research UK	LITTLEWOOD, TD (corresponding author), IMPERIAL CANC RES FUND,BIOCHEM CELL NUCLEUS LAB,44 LINCOLNS INN FIELDS,LONDON WC2A 3PX,ENGLAND.		Amati, Bruno/AAM-3418-2020	Amati, Bruno/0000-0002-2958-1799				ALITALO K, 1983, P NATL ACAD SCI-BIOL, V80, P1707, DOI 10.1073/pnas.80.6.1707; BADER JP, 1985, J VIROL, V53, P509, DOI 10.1128/JVI.53.2.509-514.1985; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; DANG CV, 1991, MOL CELL BIOL, V11, P954, DOI 10.1128/MCB.11.2.954; DANG CV, 1989, NATURE, V337, P664, DOI 10.1038/337664a0; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; EVAN GI, 1984, J IMMUNOL METHODS, V73, P427, DOI 10.1016/0022-1759(84)90417-4; EVAN GI, 1986, CURR TOP MICROBIOL, V132, P362; GREGOR PD, 1990, GENE DEV, V4, P1730, DOI 10.1101/gad.4.10.1730; HALAZONETIS TD, 1991, P NATL ACAD SCI USA, V88, P6162, DOI 10.1073/pnas.88.14.6162; HANN SR, 1988, CELL, V52, P185, DOI 10.1016/0092-8674(88)90507-7; JONES N, 1990, CELL, V61, P9, DOI 10.1016/0092-8674(90)90207-U; KATO GJ, 1990, MOL CELL BIOL, V10, P5914, DOI 10.1128/MCB.10.11.5914; KERKHOFF E, 1991, ONCOGENE, V6, P93; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; MCKAY RDG, 1981, J MOL BIOL, V145, P471, DOI 10.1016/0022-2836(81)90540-4; MOORE JP, 1987, ONCOGENE RES, V2, P65; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; NAGAI K, 1987, METHOD ENZYMOL, V153, P461; PENN LJZ, 1990, MOL CELL BIOL, V10, P4961, DOI 10.1128/MCB.10.9.4961; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; STONE J, 1987, MOL CELL BIOL, V7, P1697, DOI 10.1128/MCB.7.5.1697; WATERS C, 1991, ONCOGENE, V6, P101; WATT RA, 1985, MOL CELL BIOL, V5, P448, DOI 10.1128/MCB.5.3.448; WENZEL A, 1991, EMBO J, V10, P3703, DOI 10.1002/j.1460-2075.1991.tb04938.x	27	102	102	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1992	7	9					1783	1792						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JJ376	1501888				2022-12-25	WOS:A1992JJ37600015
J	XU, Q; BRICKER, TM				XU, Q; BRICKER, TM			STRUCTURAL ORGANIZATION OF PROTEINS ON THE OXIDIZING SIDE OF PHOTOSYSTEM-II - 2 MOLECULES OF THE 33-KDA MANGANESE-STABILIZING PROTEINS PER REACTION CENTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOTOSYNTHETIC OXYGEN-EVOLUTION; REACTION CENTER COMPLEX; EVOLVING COMPLEX; MONOCLONAL-ANTIBODY; CORE PREPARATION; BINDING PROTEIN; POLYPEPTIDE; SPINACH; PARTICLES; CYTOCHROME-B-559	The 33-kDa manganese-stabilizing protein stabilizes the manganese cluster in the oxygen-evolving complex. There has been, however, a considerable amount of controversy concerning the stoichiometry of this photosystem II (PS II) component. In this paper, we have verified the extinction coefficient of the manganese-stabilizing protein by amino acid analysis, determined the manganese content of oxygen-evolving photosystem II membranes and reaction center complex using inductively coupled plasma spectrometry, and determined immunologically the amount of the manganese-stabilizing protein associated with photosystem II. Oxygen-evolving photosystem II membranes and reaction center complex preparations contained 258 +/- 11 and 67 +/- 3 chlorophyll, respectively, per tetranuclear manganese cluster. Immunoquantification of the manganese-stabilizing protein using mouse polyclonal antibodies on "Western blots" demonstrated the presence of 2.1 +/- 0.2 and 2.0 +/- 0.3 molecules of the manganese-stabilizing protein/tetranuclear manganese cluster in oxygen-evolving PS II membranes and highly purified PS II reaction center complex, respectively. Since the manganese-stabilizing protein co-migrated with the D2 protein in our electrophoretic system, accurate immunoquantification required the inclusion of CaCl2-washed PS II membrane proteins or reaction center complex proteins in the manganese-stabilizing protein standards to compensate for the possible masking effect of the D2 protein on the binding of the manganese-stabilizing protein to Immobilon-P membranes. Failure to include these additional protein components in the manganese-stabilizing protein standards leads to a marked underestimation of the amount of the manganese-stabilizing protein associated with these photosystem II preparations.	LOUISIANA STATE UNIV, DEPT BOT, BATON ROUGE, LA 70803 USA	Louisiana State University System; Louisiana State University	BRICKER, TM (corresponding author), LOUISIANA STATE UNIV, DEPT BOT, BATON ROUGE, LA 70803 USA.							ANDERSSON B, 1984, BIOCHIM BIOPHYS ACTA, V766, P21, DOI 10.1016/0005-2728(84)90212-3; ANDERSSON B., 1991, CURR TOP BIOENERG, V16, P1; ARNON DI, 1949, PLANT PHYSIOL, V24, P1, DOI 10.1104/pp.24.1.1; BABCOCK GT, 1989, BIOCHEMISTRY-US, V28, P9557, DOI 10.1021/bi00451a001; BABCOCK GT, 1983, BIOCHIM BIOPHYS ACTA, V723, P276, DOI 10.1016/0005-2728(83)90127-5; BERTHOLD DA, 1981, FEBS LETT, V134, P231, DOI 10.1016/0014-5793(81)80608-4; BRICKER TM, 1987, ARCH BIOCHEM BIOPHYS, V256, P295, DOI 10.1016/0003-9861(87)90449-8; BRICKER TM, 1988, FEBS LETT, V231, P111, DOI 10.1016/0014-5793(88)80713-0; BRICKER TM, 1990, PHOTOSYNTH RES, V24, P1, DOI 10.1007/BF00032639; BRICKER TM, 1985, ARCH BIOCHEM BIOPHYS, V237, P170, DOI 10.1016/0003-9861(85)90266-8; BRICKER TM, 1992, BIOCHEMISTRY-US, V31, P4623, DOI 10.1021/bi00134a012; BURNAP RL, 1991, BIOCHEMISTRY-US, V30, P440, DOI 10.1021/bi00216a020; CAMM EL, 1987, PHOTOSYNTH RES, V13, P69, DOI 10.1007/BF00032266; CRAMER WA, 1986, PHOTOSYNTH RES, V10, P393, DOI 10.1007/BF00118305; DEISENHOFER J, 1985, NATURE, V318, P618, DOI 10.1038/318618a0; DEKKER JP, 1989, FEBS LETT, V254, P150, DOI 10.1016/0014-5793(89)81028-2; DEVITRY C, 1984, BIOCHIM BIOPHYS ACTA, V767, P415, DOI 10.1016/0005-2728(84)90039-2; ENAMI I, 1991, BIOCHIM BIOPHYS ACTA, V1060, P224, DOI 10.1016/S0005-2728(09)91010-6; ENAMI I, 1992, PLANT CELL PHYSIOL, V33, P291, DOI 10.1093/oxfordjournals.pcp.a078253; FASSEL VA, 1974, ANAL CHEM, V46, P1110, DOI 10.1021/ac60349a722; FRANZEN LG, 1986, PHOTOBIOCH PHOTOBIOP, V13, P15; GHANOTAKIS DF, 1990, ANNU REV PLANT PHYS, V41, P255, DOI 10.1146/annurev.pp.41.060190.001351; GHANOTAKIS DF, 1989, BIOCHIM BIOPHYS ACTA, V974, P44, DOI 10.1016/S0005-2728(89)80164-1; GHANOTAKIS DF, 1984, BIOCHIM BIOPHYS ACTA, V765, P388, DOI 10.1016/0005-2728(84)90180-4; GHANOTAKIS DF, 1987, BIOCHIM BIOPHYS ACTA, V891, P15, DOI 10.1016/0005-2728(87)90078-8; GHANOTAKIS DF, 1983, FEBS LETT, V153, P231, DOI 10.1016/0014-5793(83)80154-9; IKEUCHI M, 1986, ARCH BIOCHEM BIOPHYS, V247, P97, DOI 10.1016/0003-9861(86)90538-2; IKEUCHI M, 1988, FEBS LETT, V241, P99, DOI 10.1016/0014-5793(88)81039-1; ISOGAI Y, 1985, FEBS LETT, V187, P240, DOI 10.1016/0014-5793(85)81250-3; KASHINO Y, 1986, FEBS LETT, V205, P150, DOI 10.1016/0014-5793(86)80884-5; KLOTZ AV, 1991, ARCH BIOCHEM BIOPHYS, V291, P113, DOI 10.1016/0003-9861(91)90112-V; KUWABARA T, 1985, BIOCHIM BIOPHYS ACTA, V806, P283, DOI 10.1016/0005-2728(85)90107-0; KUWABARA T, 1984, ADV PHOTOSYNTHESIS R, V1, P371; MAVANKAL G, 1986, FEBS LETT, V202, P235, DOI 10.1016/0014-5793(86)80693-7; MEI R, 1989, BIOCHEMISTRY-US, V28, P5560, DOI 10.1021/bi00439a033; MICHEL H, 1988, BIOCHEMISTRY-US, V27, P1, DOI 10.1021/bi00401a001; MILLNER PA, 1987, PHOTOSYNTH RES, V13, P185, DOI 10.1007/BF00035240; MIYAO M, 1984, FEBS LETT, V170, P350, DOI 10.1016/0014-5793(84)81342-3; MURATA N, 1984, BIOCHIM BIOPHYS ACTA, V765, P363, DOI 10.1016/0005-2728(84)90177-4; NAKATANI HY, 1984, BIOCHIM BIOPHYS ACTA, V765, P347, DOI 10.1016/0005-2728(84)90175-0; NANBA O, 1987, P NATL ACAD SCI USA, V84, P109, DOI 10.1073/pnas.84.1.109; ODOM WR, 1992, BIOCHEMISTRY-US, V31, P5616, DOI 10.1021/bi00139a027; ODOM WR, 1990, PHOTOSYNTHETICA, V24, P46; OHOKA H, 1986, FEBS LETT, V197, P63, DOI 10.1016/0014-5793(86)80299-X; SEIBERT M, 1989, BIOCHIM BIOPHYS ACTA, V974, P185, DOI 10.1016/S0005-2728(89)80371-8; STEWART AC, 1985, BIOCHIM BIOPHYS ACTA, V808, P353, DOI 10.1016/0005-2728(85)90145-8; TAMURA N, 1989, BIOCHIM BIOPHYS ACTA, V973, P281, DOI 10.1016/S0005-2728(89)80433-5; WALES R, 1989, PLANT MOL BIOL, V12, P439, DOI 10.1007/BF00017583	48	77	80	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 25	1992	267	36					25816	25821						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KD073	1464595				2022-12-25	WOS:A1992KD07300038
J	DESCHAMPS, BJ; LAWLESS, DE; CARR, FE; WONG, NCW				DESCHAMPS, BJ; LAWLESS, DE; CARR, FE; WONG, NCW			RAT HEPATONUCLEAR FACTOR PS-1 REGULATES TISSUE-SPECIFIC ACTIVITY OF THE S14 PROMOTER INVITRO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATIC GENE-EXPRESSION; HORMONE-RESPONSIVE GENE; THYROID-HORMONE; MESSENGER-RNA; ALBUMIN PROMOTER; BINDING PROTEINS; TRANSCRIPTION; LIVER; DNA; BOX	We have previously identified a rat hepatonuclear factor, PS-1 that binds to the thyroid hormone responsive gene, S14. To determine whether PS-1 is involved in regulating tissue-specific expression of the S14 gene, we have correlated the DNA binding activity of PS-1 with mRNA-S14 expression in a variety of tissues. Gel retardation analysis revealed a pattern of binding to the recognition site that was characteristic of tissues with high levels of mRNA-S14, a different pattern was found in tissues which do not express the gene. Competition studies using mutant oligonucleotides showed that the first 4 nucleotides and the CAAT motif contained within the PS-1 recognition sequence are essential for protein binding. C/EBP, a CCAAT-transcription factor binds to the PS-1 recognition site thus raising the possibility that both C/EBP and PS-1 may belong to the same family of proteins. Next we used a cell-free transcription assay to measure activity of a template, pS14-GFC(-72), that contained the PS-1 sequence. The pS14-GFC(-72) template was active in hepatonuclear extracts but deletion of or competition with the PS-1 binding sequence rendered the construct inactive. A template containing three PS-1 binding sequences increased S14 promoter activity by 12- to 13-fold. In nuclear extracts from spleen and testis, relative S14 promoter activity was only 2% of that in the liver, this observation mimicked closely in vivo expression of the gene. Mixing together extracts from liver and spleen in varying proportions, prior to incubation with S14 template, yielded a linear increase in S14 promoter activity that correlated with the amount of liver extract in the reaction. This finding is consistent with the absence of an essential factor or factors in spleen that is/are required for S14 promoter activity in vitro. In summary, PS-1 binds to a DNA sequence that contains a CAAT motif and appears to play a critical role in determining tissue-specific activity of the S14 promoter in vitro.	UNIV CALGARY,HLTH SCI CTR,FAC MED,DEPT MED,3330 HOSP DR NW,CALGARY T2N 4N1,ALBERTA,CANADA; WALTER REED ARMY MED CTR,KYLE METAB UNIT,WASHINGTON,DC 20307; UNIV CALGARY,DEPT MED BIOCHEM,CALGARY T2N 4N1,ALBERTA,CANADA	University of Calgary; University of Manitoba; Children's Hospital Research Institute of Manitoba; United States Department of Defense; United States Army; Walter Reed National Military Medical Center; University of Calgary								CARR FE, 1983, J CLIN INVEST, V72, P154, DOI 10.1172/JCI110953; CHODOSH LA, 1988, CELL, V53, P11, DOI 10.1016/0092-8674(88)90483-7; DORN A, 1987, CELL, V50, P863, DOI 10.1016/0092-8674(87)90513-7; FREAKE HC, 1987, P NATL ACAD SCI USA, V84, P3070, DOI 10.1073/pnas.84.9.3070; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; GRAVES BJ, 1986, CELL, V44, P565, DOI 10.1016/0092-8674(86)90266-7; HATAMOCHI A, 1986, J BIOL CHEM, V261, P1310; JOHNSON PF, 1989, ANNU REV BIOCHEM, V58, P799, DOI 10.1146/annurev.biochem.58.1.799; JONES KA, 1985, CELL, V42, P559, DOI 10.1016/0092-8674(85)90113-8; JONES KA, 1987, CELL, V48, P79, DOI 10.1016/0092-8674(87)90358-8; JUMP DB, 1984, J BIOL CHEM, V259, P2789; JUMP DB, 1988, J BIOL CHEM, V263, P7254; JUMP DB, 1987, J BIOL CHEM, V262, P778; JUMP DB, 1989, J BIOL CHEM, V264, P4698; KINLAW WB, 1987, ENDOCRINOLOGY, V120, P1563, DOI 10.1210/endo-120-4-1563; LANDSCHULZ WH, 1988, GENE DEV, V2, P786, DOI 10.1101/gad.2.7.786; LIAW C, 1983, BIOCHEMISTRY-US, V22, P213, DOI 10.1021/bi00270a031; LIAW CW, 1984, J BIOL CHEM, V259, P7253; LUM LSY, 1990, MOL CELL BIOL, V10, P6709, DOI 10.1128/MCB.10.12.6709; Maniatis T., 1982, MOL CLONING; MARIASH CN, 1982, ANAL BIOCHEM, V121, P388, DOI 10.1016/0003-2697(82)90498-5; NARAYAN P, 1985, MOL CELL BIOL, V5, P2642, DOI 10.1128/MCB.5.10.2642; OPPENHEIMER JH, 1987, ENDOCR REV, V8, P288, DOI 10.1210/edrv-8-3-288; PEREZCASTILLO A, 1987, AM J PHYSIOL, V253, pE530; POELLINGER L, 1989, NATURE, V337, P573, DOI 10.1038/337573a0; RYFFEL GU, 1989, NUCLEIC ACIDS RES, V17, P939, DOI 10.1093/nar/17.3.939; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SAKURAI A, 1990, MOL ENDOCRINOL, V4, P1988, DOI 10.1210/mend-4-12-1988; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAWADOGO M, 1985, P NATL ACAD SCI USA, V82, P4394, DOI 10.1073/pnas.82.13.4394; SEELIG S, 1981, P NATL ACAD SCI-BIOL, V78, P4733, DOI 10.1073/pnas.78.8.4733; WANKE IE, 1991, J BIOL CHEM, V266, P6068; WEINBERGER J, 1986, NATURE, V322, P846, DOI 10.1038/322846a0; WONG NCW, 1990, J BIOL CHEM, V265, P8775; WONG NCW, 1989, J BIOL CHEM, V264, P4466	35	7	7	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1992	267	35					25167	25171						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KB603	1460016				2022-12-25	WOS:A1992KB60300040
J	PASCALE, MC; ERRA, MC; MALAGOLINI, N; SERAFINICESSI, F; LEONE, A; BONATTI, S				PASCALE, MC; ERRA, MC; MALAGOLINI, N; SERAFINICESSI, F; LEONE, A; BONATTI, S			POSTTRANSLATIONAL PROCESSING OF AN O-GLYCOSYLATED PROTEIN, THE HUMAN CD8 GLYCOPROTEIN, DURING THE INTRACELLULAR-TRANSPORT TO THE PLASMA-MEMBRANE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ROUGH ENDOPLASMIC-RETICULUM; DENSITY-LIPOPROTEIN RECEPTOR; CELL-SURFACE SIALOMUCIN; LINKED OLIGOSACCHARIDES; TEMPORAL ASPECTS; GOLGI-APPARATUS; N-GLYCOSYLATION; BREFELDIN-A; BIOSYNTHESIS; OLIGOMERIZATION	The biosynthesis of human CD8 glycoprotein in transfected rat epithelial cells produces an unglycosylated precursor, an intermediate species only initially O-glycosylated, and a doublet mature form carrying neutral and sialylated O-linked oligosaccharides with the core-2 structure (Pascale, M. C., Malagolini, N., Serafini-Cessi, F., Migliaccio, G., Leone, A., and Bonatti, S. (1992) J. Biol. Chem. 267, 9940-9947). In this study the most relevant post-translational events: dimerization, addition of the first O-linked GalNAc, fulfillment of O-linked chains, as well as expression of involved glycosyltransferases, have been examined and correlated with the localization and transit rate of CD8 through the exocytic pathway. The glycosyltransferase activities measured in rat epithelial cells transfected with human CD8 DNA are entirely consistent with the primary structure assigned to CD8 oligosaccharides. The half-time of appearance of the initially O-glycosylated precursor and mature form was estimated to be 4 and 14 min, respectively, and the half-time for delivery of mature CD8 to the cell surface was found to be about 30 min, indicating a very fast routing. Pulse experiments with [S-35]cysteine at 37-degrees-C followed by chase-periods at low temperatures showed that folding/dimerization occurs before routing to the Golgi apparatus, whereas the addiction of O-linked GalNAc appears to take place later, very likely in cis-Golgi cisternae. Treatment of cells with monensin accumulated the intermediate CD8 form carrying non-elongated O-linked GalNAc, whereas brefeldin A treatment produced a sialylated glycoprotein species with a mobility faster than the mature CD8. These results indicate that the two drugs affect assembly of O-linked chains at different time of their processing.	NAPLES UNIV, DEPT BIOCHEM & MED BIOTECHNOL, I-80131 NAPLES, ITALY	University of Naples Federico II			Pascale, Maria/B-4273-2012					BONATTI S, 1989, J BIOL CHEM, V264, P12590; CARLSSON SR, 1986, J BIOL CHEM, V261, P2787; COPELAND CS, 1988, CELL, V53, P197, DOI 10.1016/0092-8674(88)90381-9; CUMMINGS RD, 1983, J BIOL CHEM, V258, P5261; DALLOLIO F, 1992, BIOCHEM BIOPH RES CO, V184, P1405, DOI 10.1016/S0006-291X(05)80039-7; DEKKER J, 1990, J BIOL CHEM, V265, P18116; ELHAMMER A, 1984, J CELL BIOL, V99, P327, DOI 10.1083/jcb.99.1.327; FUKUDA M, 1991, Glycobiology, V1, P347, DOI 10.1093/glycob/1.4.347; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; HANOVER JA, 1982, J BIOL CHEM, V257, P172; HILKENS J, 1988, J BIOL CHEM, V263, P4215; HIRSCHBERG CB, 1987, ANNU REV BIOCHEM, V56, P63, DOI 10.1146/annurev.bi.56.070187.000431; HSU VW, 1991, NATURE, V352, P441, DOI 10.1038/352441a0; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; Huttner WB, 1988, MODERN CELL BIOL, V6, P97; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; LEAHY DJ, 1992, CELL, V68, P1145, DOI 10.1016/0092-8674(92)90085-Q; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; LODISH HF, 1988, J BIOL CHEM, V263, P2107; LOTTI LV, 1992, J CELL BIOL, V118, P43, DOI 10.1083/jcb.118.1.43; MATLIN KS, 1983, CELL, V34, P233, DOI 10.1016/0092-8674(83)90154-X; MELLMAN I, 1992, CELL, V68, P829, DOI 10.1016/0092-8674(92)90027-A; MIGLIACCIO G, 1990, EUR J CELL BIOL, V52, P291; MORROW B, 1987, J BIOL CHEM, V262, P13812; NIEMANN H, 1982, EMBO J, V1, P1499, DOI 10.1002/j.1460-2075.1982.tb01346.x; NITSCH L, 1985, EUR J CELL BIOL, V38, P57; PARNES JR, 1989, ADV IMMUNOL, V44, P265; PASCALE MC, 1992, J BIOL CHEM, V267, P9940; PEREZVILAR J, 1991, J BIOL CHEM, V266, P23967; PILLER F, 1991, J EXP MED, V173, P1501, DOI 10.1084/jem.173.6.1501; PILLER F, 1988, J BIOL CHEM, V263, P15146; PILLER V, 1990, J BIOL CHEM, V265, P9264; PILLER V, 1989, EUR J BIOCHEM, V183, P123, DOI 10.1111/j.1432-1033.1989.tb14904.x; ROTH J, 1987, BIOCHIM BIOPHYS ACTA, V906, P405, DOI 10.1016/0304-4157(87)90018-9; ROTHMAN JE, 1992, NATURE, V355, P409, DOI 10.1038/355409a0; Sadler J. E., 1984, BIOL CARBOHYDRATES, V2, P199; SARASTE J, 1984, CELL, V38, P535, DOI 10.1016/0092-8674(84)90508-7; SCHWEIZER A, 1990, EUR J CELL BIOL, V53, P185; SERAFINICESSI F, 1989, BIOCHEM J, V262, P479, DOI 10.1042/bj2620479; SERAFINICESSI F, 1985, ARCH BIOCHEM BIOPHYS, V240, P866, DOI 10.1016/0003-9861(85)90097-9; SERAFINICESSI F, 1977, BIOCHEM J, V166, P381, DOI 10.1042/bj1660381; SHITE S, 1990, J BIOL CHEM, V265, P17385; SNOW PM, 1983, J BIOL CHEM, V258, P4675; SPIELMAN J, 1987, J BIOL CHEM, V262, P269; SPIELMAN J, 1988, J BIOL CHEM, V263, P9621; SPIRO RG, 1974, J BIOL CHEM, V249, P5704; TAN A, 1992, J CELL BIOL, V116, P1357, DOI 10.1083/jcb.116.6.1357; TOOZE SA, 1988, J CELL BIOL, V106, P1475, DOI 10.1083/jcb.106.5.1475; WILSON IBH, 1991, BIOCHEM J, V275, P529, DOI 10.1042/bj2750529	50	38	39	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	1992	267	35					25196	25201						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KB603	1460019				2022-12-25	WOS:A1992KB60300044
J	ANDERSON, L; DENNY, JB				ANDERSON, L; DENNY, JB			PROTEIN TRANSLOCATION IN THE ENDOPLASMIC-RETICULUM - ULTRAVIOLET-LIGHT INDUCES THE NONCOVALENT ASSOCIATION OF NASCENT PEPTIDES WITH TRANSLOCON PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL RECOGNITION PARTICLE; SYNTHESIZING SECRETORY PROTEIN; RIBOSOME-MEMBRANE JUNCTION; GTP-BINDING PROTEIN; MICROSOMAL-MEMBRANES; SEQUENCE RECEPTOR; ESCHERICHIA-COLI; PREPROLACTIN; COMPLEX; PARTICIPATION	We have photolyzed cell-free translation systems synthesizing beta-lactamase with 254-nm ultraviolet light. In the presence of canine rough microsomes (RM), incomplete chains of beta-lactamase became enriched relative to the full-length molecule in pellet fractions obtained following photolysis and alkaline carbonate extraction. In addition, high molecular weight aggregates were present on SDS-polyacrylamide gels and occurred only when translocation-competent microsomal membranes were used in translation mixtures. The incomplete chains and high molecular weight aggregates were not obtained when RM were inactivated by reaction with N-ethylmaleimide. The incomplete chains did not bind to concanavalin A-Sepharose, indicating that they had not sedimented as a result of being covalently cross-linked to membrane glycoproteins. Both photolysis and alkaline carbonate extraction were required to produce the results. Nascent peptides that were not exposed to alkaline carbonate following photolysis did not appear as high molecular weight bands on SDS-polyacrylamide gels. The high molecular weight aggregates therefore represent denatured protein complexes that contain nascent peptides and microsomal translocon proteins. The results suggest that the translocon is a large proteinaceous complex and that at least a portion of it, when denatured, migrates at a molecular mass of approximately 205 kDa.	UNIV TEXAS, DIV LIFE SCI, 6900 LOOP 1604 NW, SAN ANTONIO, TX 78249 USA	University of Texas System								BERNSTEIN HD, 1989, NATURE, V340, P482, DOI 10.1038/340482a0; BLOBEL G, 1980, P NATL ACAD SCI-BIOL, V77, P1496, DOI 10.1073/pnas.77.3.1496; BLOBEL G, 1975, J CELL BIOL, V67, P835, DOI 10.1083/jcb.67.3.835; BRIGGS MS, 1986, ADV PROTEIN CHEM, V38, P109, DOI 10.1016/S0065-3233(08)60527-6; CONNOLLY T, 1989, J CELL BIOL, V108, P299, DOI 10.1083/jcb.108.2.299; CONNOLLY T, 1991, SCIENCE, V252, P1171, DOI 10.1126/science.252.5009.1171; CONNOLLY T, 1986, J CELL BIOL, V103, P2253, DOI 10.1083/jcb.103.6.2253; ENGELMAN DM, 1981, CELL, V23, P411, DOI 10.1016/0092-8674(81)90136-7; EVANS EA, 1986, P NATL ACAD SCI USA, V83, P581, DOI 10.1073/pnas.83.3.581; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; GILMORE R, 1983, CELL, V35, P677, DOI 10.1016/0092-8674(83)90100-9; GILMORE R, 1982, J CELL BIOL, V95, P463, DOI 10.1083/jcb.95.2.463; GILMORE R, 1985, CELL, V42, P497, DOI 10.1016/0092-8674(85)90107-2; GORLICH D, 1990, J CELL BIOL, V111, P2283, DOI 10.1083/jcb.111.6.2283; GORLICH D, 1992, NATURE, V357, P47, DOI 10.1038/357047a0; HANSEN W, 1986, CELL, V45, P397, DOI 10.1016/0092-8674(86)90325-9; HARTMANN E, 1989, EMBO J, V8, P2225, DOI 10.1002/j.1460-2075.1989.tb08346.x; HOFFMAN KE, 1988, J BIOL CHEM, V263, P4381; IWANIJ V, 1985, P NATL ACAD SCI USA, V82, P325, DOI 10.1073/pnas.82.2.325; KELLARIS KV, 1991, J CELL BIOL, V114, P21, DOI 10.1083/jcb.114.1.21; KRIEG UC, 1986, P NATL ACAD SCI USA, V83, P8604, DOI 10.1073/pnas.83.22.8604; KRIEG UC, 1989, J CELL BIOL, V109, P2033, DOI 10.1083/jcb.109.5.2033; KURZCHALIA TV, 1986, NATURE, V320, P634, DOI 10.1038/320634a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MEYER DI, 1982, NATURE, V297, P647, DOI 10.1038/297647a0; MIGLIACCIO G, 1992, J CELL BIOL, V117, P15, DOI 10.1083/jcb.117.1.15; NICCHITTA CV, 1991, CELL, V65, P587, DOI 10.1016/0092-8674(91)90091-C; NICCHITTA CV, 1990, CELL, V60, P259, DOI 10.1016/0092-8674(90)90741-V; NICCHITTA CV, 1989, J CELL BIOL, V108, P789, DOI 10.1083/jcb.108.3.789; OSWALD RE, 1982, FEBS LETT, V139, P225, DOI 10.1016/0014-5793(82)80857-0; POLLITT S, 1983, J BACTERIOL, V153, P27, DOI 10.1128/JB.153.1.27-32.1983; RAPOPORT TA, 1990, TRENDS BIOCHEM SCI, V15, P355, DOI 10.1016/0968-0004(90)90076-N; SANDERS SL, 1992, J BIOL CHEM, V267, P13791; SIMON SM, 1989, P NATL ACAD SCI USA, V86, P6176, DOI 10.1073/pnas.86.16.6176; SIMON SM, 1991, CELL, V65, P371, DOI 10.1016/0092-8674(91)90455-8; SINGER SJ, 1987, P NATL ACAD SCI USA, V84, P1015, DOI 10.1073/pnas.84.4.1015; SUTCLIFFE JG, 1978, P NATL ACAD SCI USA, V75, P3737, DOI 10.1073/pnas.75.8.3737; SVOBODA M, 1982, REGUL PEPTIDES, V4, P163, DOI 10.1016/0167-0115(82)90084-2; UMBREIT JN, 1973, J BIOL CHEM, V248, P6759; WALTER P, 1980, P NATL ACAD SCI-BIOL, V77, P7112, DOI 10.1073/pnas.77.12.7112; WALTER P, 1983, METHOD ENZYMOL, V96, P84; WALTER P, 1981, J CELL BIOL, V91, P551, DOI 10.1083/jcb.91.2.551; WALTER P, 1981, J CELL BIOL, V91, P557, DOI 10.1083/jcb.91.2.557; WALTER P, 1981, J CELL BIOL, V91, P545, DOI 10.1083/jcb.91.2.545; WALTER P, 1986, ANNU REV CELL BIOL, V2, P499, DOI 10.1146/annurev.cellbio.2.1.499; WALTER P, 1982, NATURE, V299, P691, DOI 10.1038/299691a0; WICKNER W, 1979, ANNU REV BIOCHEM, V48, P23, DOI 10.1146/annurev.bi.48.070179.000323; WIEDMANN M, 1987, NATURE, V328, P830, DOI 10.1038/328830a0; WOLIN SL, 1989, J CELL BIOL, V109, P2617, DOI 10.1083/jcb.109.6.2617	49	4	4	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	1992	267	33					23916	23921						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JZ239	1429729				2022-12-25	WOS:A1992JZ23900073
J	BACKLUND, PS				BACKLUND, PS			GTP-STIMULATED CARBOXYL METHYLATION OF A SOLUBLE FORM OF THE GTP-BINDING PROTEIN G25K IN BRAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-TERMINAL CYSTEINE; GAMMA SUBUNITS CONTAIN; MEMBRANE-BINDING; BOVINE BRAIN; SACCHAROMYCES-CEREVISIAE; MOLECULAR-CLONING; HUMAN HOMOLOG; LAMIN-B; GENE; IDENTIFICATION	The GTP-stimulated carboxyl methylation of an M(r) 23,000 protein was investigated in brain homogenates. An M(r) 23,000 methylation substrate was purified from brain homogenates, using an assay for protein methyl-acceptor activity in the presence of a membrane-bound methyltransferase. The M(r) 23,000 methyl-acceptor protein was identified as a soluble form of the GTP-binding protein G25K, based on antibody reactivity and amino acid sequences of tryptic peptides. Two forms of methylated G25K, differing in isoelectric points, were isolated. The soluble G25K could be methylated with a stoichiometry approaching 1 mol of methyl group per mol of G25K, and guanosine 5'-O-3(thio)triphosphate stimulated the methylation by decreasing the K(m) for G25K from 0.79 to 0.17-mu-m. After methylation, the G25K was associated with the membrane fraction. The soluble G25K was isolated as a heterodimer of G25K and an M(r) 28,000 protein. The G25K and M(r) 28,000 protein complex was dissociated with 3-[(3-cholamidopropyl)-dimethylammonio]-1-propanesulfonate detergent, and the subunits were separated by Mono-Q chromatography. The association of the M(r) 28,000 protein with G25K decreased the methylation of G25K and altered the guanine nucleotide specificity, indicating that the M(r) 28,000 protein may regulate the methylation of G25K.			BACKLUND, PS (corresponding author), NIMH,GEN & COMPARAT BIOCHEM LAB,BLDG 36,RM 3D-06,9000 ROCKVILLE PIKE,BETHESDA,MD 20892, USA.							AKBAR H, 1991, Journal of Biological Chemistry, V266, P4387; BACKLUND PS, 1990, J BIOL CHEM, V265, P15572; BACKLUND PS, 1988, J BIOL CHEM, V263, P15864; BACKLUND PS, 1988, BIOCHEMISTRY-US, V27, P2040, DOI 10.1021/bi00406a034; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CASEY PJ, 1989, P NATL ACAD SCI USA, V86, P8323, DOI 10.1073/pnas.86.21.8323; CHELSKY D, 1984, ANAL BIOCHEM, V141, P143, DOI 10.1016/0003-2697(84)90437-8; CHELSKY D, 1987, J BIOL CHEM, V262, P4303; CLARKE S, 1988, P NATL ACAD SCI USA, V85, P4643, DOI 10.1073/pnas.85.13.4643; EVANS T, 1986, J BIOL CHEM, V261, P7052; FARNSWORTH CC, 1989, J BIOL CHEM, V264, P20422; FUKADA Y, 1990, NATURE, V346, P658, DOI 10.1038/346658a0; FUNG BKK, 1990, FEBS LETT, V260, P313, DOI 10.1016/0014-5793(90)80132-3; GLOMSET JA, 1990, TRENDS BIOCHEM SCI, V15, P139, DOI 10.1016/0968-0004(90)90213-U; GUTIERREZ L, 1989, EMBO J, V8, P1093, DOI 10.1002/j.1460-2075.1989.tb03478.x; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HANCOCK JF, 1991, EMBO J, V10, P641, DOI 10.1002/j.1460-2075.1991.tb07992.x; HART MJ, 1990, J BIOL CHEM, V265, P5990; HRYCYNA CA, 1990, MOL CELL BIOL, V10, P5071, DOI 10.1128/MCB.10.10.5071; ISOMURA M, 1990, BIOCHEM BIOPH RES CO, V169, P652, DOI 10.1016/0006-291X(90)90380-6; JOHNSON DI, 1990, J CELL BIOL, V111, P143, DOI 10.1083/jcb.111.1.143; KAWATA M, 1990, P NATL ACAD SCI USA, V87, P8960, DOI 10.1073/pnas.87.22.8960; KIKUCHI A, 1988, J BIOL CHEM, V263, P2897; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MALTESE WA, 1990, J BIOL CHEM, V265, P17883; MARR RS, 1990, J BIOL CHEM, V265, P20057; MUMBY SM, 1990, P NATL ACAD SCI USA, V87, P5873, DOI 10.1073/pnas.87.15.5873; MUNEMITSU S, 1990, MOL CELL BIOL, V10, P5977, DOI 10.1128/MCB.10.11.5977; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; OHGA N, 1989, BIOCHEM BIOPH RES CO, V163, P1523, DOI 10.1016/0006-291X(89)91153-4; ONG OC, 1989, P NATL ACAD SCI USA, V86, P9238, DOI 10.1073/pnas.86.23.9238; POLAKIS PG, 1989, BIOCHEM BIOPH RES CO, V160, P25, DOI 10.1016/0006-291X(89)91615-X; REISS Y, 1990, CELL, V62, P81, DOI 10.1016/0092-8674(90)90242-7; SHINJO K, 1990, P NATL ACAD SCI USA, V87, P9853, DOI 10.1073/pnas.87.24.9853; STEPHENSON RC, 1990, J BIOL CHEM, V265, P16248; TAMIR A, 1990, BIOCHEMISTRY-US, V29, P6947, DOI 10.1021/bi00482a002; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; VALENCIA A, 1991, BIOCHEMISTRY-US, V30, P4637, DOI 10.1021/bi00233a001; VOLKER C, 1991, J BIOL CHEM, V266, P21515; WALDO GL, 1987, BIOCHEM J, V246, P431, DOI 10.1042/bj2460431; YAMANE HK, 1990, P NATL ACAD SCI USA, V87, P5868, DOI 10.1073/pnas.87.15.5868; YAMANE HK, 1991, P NATL ACAD SCI USA, V88, P286, DOI 10.1073/pnas.88.1.286; YAMANE HK, 1989, J BIOL CHEM, V264, P20100; YOKOYAMA K, 1991, P NATL ACAD SCI USA, V88, P5302, DOI 10.1073/pnas.88.12.5302	46	41	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1992	267	26					18432	18439						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JN502	1526984				2022-12-25	WOS:A1992JN50200033
J	FISHER, RJ; KOIZUMI, S; KONDOH, A; MARIANO, JM; MAVROTHALASSITIS, G; BHAT, NK; PAPAS, TS				FISHER, RJ; KOIZUMI, S; KONDOH, A; MARIANO, JM; MAVROTHALASSITIS, G; BHAT, NK; PAPAS, TS			HUMAN ETS1-ONCOPROTEIN - PURIFICATION, ISOFORMS, SH MODIFICATION, AND DNA SEQUENCE-SPECIFIC BINDING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG TERMINAL REPEAT; TRANSCRIPTION FACTOR; CHLOROMETHYL KETONE; ACTIVITY INVITRO; LEUKEMIA-VIRUS; PROTO-ONCOGENE; ETS ONCOGENE; PROTEINS; GENE; ACTIVATION	The human ETS1 proto-oncogene proteins have been isolated from the T-cell leukemia line, CEM, by immunoaffinity chromatography and their identity confirmed by NH2-terminal amino acid sequencing. Incubation of CEM cells with N(alpha)-P-tosyl-L-lysine chloromethyl ketone (TLCK) indicates that ETS proteins can be modified in their cellular context and that pretreatment of the cells with N-ethylmaleimide (NEM) protects ETS1 proteins from TLCK modification. These data show that ETS1 proteins can exist in at least two different states, -SH-available and -SH-protected. Renatured human ETS1 has DNA sequence-specific binding to the PEA3 (CAGGAAGT) motif. The ETS1.PEA3 complex can be observed by electrophoretic mobility shift assays (EMSA). Purified ETS1 retards a band which is exactly the same size as a complex that is retarded from nuclear extracts prepared from CEM cells. Reduced ETS1 is required to form the ETS1.PEA3 complex, however; modification of the ETS1 -SH groups by either NEM or by TLCK does not inhibit formation of the complex. The ETS1.PEA3 complex formed with TLCK-modified ETS1 has a slower mobility than the complex formed with unmodified ETS1. Zone sedimentation analysis of purified ETS1 indicates that it is the monomer of ETS1 which binds to the PEA3 oligonucleotide.	NCI,MOLEC ONCOL LAB,FREDERICK,MD 21702	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	FISHER, RJ (corresponding author), NCI,FREDERICK CANC RES & DEV CTR,DYNCORP,PROGRAM RESOURCES INC,CELLULAR BIOCHEM LAB,FREDERICK,MD 21702, USA.		Fisher, Robert/B-1431-2009		NCI NIH HHS [N01-CO-74102] Funding Source: Medline; OFFICE OF THE DIRECTOR, NCI [N01CO074102] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; ANDERSON WF, 1981, NATURE, V290, P754, DOI 10.1038/290754a0; AUSUBEL FM, 1991, PROTOCOLS MOL BIOL; BAIRD BA, 1976, J BIOL CHEM, V252, P6953; BENDAVID Y, 1991, GENE DEV, V5, P908, DOI 10.1101/gad.5.6.908; BOSSELUT R, 1990, EMBO J, V9, P3137, DOI 10.1002/j.1460-2075.1990.tb07511.x; BOULUKOS KE, 1989, MOL CELL BIOL, V9, P5718, DOI 10.1128/MCB.9.12.5718; BURTIS KC, 1990, CELL, V61, P85, DOI 10.1016/0092-8674(90)90217-3; CHODOSH LA, 1986, MOL CELL BIOL, V6, P4723, DOI 10.1128/MCB.6.12.4723; FAIRALL L, 1986, J MOL BIOL, V192, P577, DOI 10.1016/0022-2836(86)90278-0; FISHER RJ, 1991, ONCOGENE, V6, P2249; FUJIWARA S, 1988, ONCOGENE, V2, P99; FUJIWARA S, 1988, MOL CELL BIOL, V8, P4700, DOI 10.1128/MCB.8.11.4700; GUNTHER CV, 1990, GENE DEV, V4, P667, DOI 10.1101/gad.4.4.667; HO IC, 1990, SCIENCE, V250, P814, DOI 10.1126/science.2237431; JORCYK CL, 1991, ONCOGENE, V6, P523; KANEIISHII C, 1990, J BIOL CHEM, V265, P19990; KARIM FD, 1990, GENE DEV, V4, P1451, DOI 10.1101/gad.4.9.1451; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; KOIZUMI S, 1990, ONCOGENE, V5, P675; KUPFER A, 1979, P NATL ACAD SCI USA, V76, P3073, DOI 10.1073/pnas.76.7.3073; LABARCA C, 1980, ANAL BIOCHEM, V100, P188; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDSCHULZ WH, 1989, SCIENCE, V243, P1681, DOI 10.1126/science.2494700; LIANG AM, 1983, J BIOL CHEM, V258, P4788; MALLERY SR, 1991, J CELL BIOCHEM, V45, P82, DOI 10.1002/jcb.240450115; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; Powers J C, 1977, Methods Enzymol, V46, P197; RAO VN, 1987, SCIENCE, V237, P635, DOI 10.1126/science.3299708; RAO VN, 1989, SCIENCE, V244, P66, DOI 10.1126/science.2539641; REDDY ESP, 1988, ONCOGENE RES, V3, P239; RICHERT N, 1979, CELL, V18, P369, DOI 10.1016/0092-8674(79)90056-4; SCHNEIDER C, 1982, J BIOL CHEM, V257, P766; SETH A, 1992, CELL GROWTH DIFFER, V3, P327; STAAL FJT, 1990, P NATL ACAD SCI USA, V87, P9943, DOI 10.1073/pnas.87.24.9943; STECK TL, 1972, J MOL BIOL, V66, P295, DOI 10.1016/0022-2836(72)90481-0; TROLL W, 1970, SCIENCE, V169, P1211, DOI 10.1126/science.169.3951.1211; WANG K, 1974, J BIOL CHEM, V249, P6953; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WASYLYK C, 1991, EMBO J, V10, P1127, DOI 10.1002/j.1460-2075.1991.tb08053.x; WATSON DK, 1988, P NATL ACAD SCI USA, V85, P7862, DOI 10.1073/pnas.85.21.7862; WCHSLER ST, 1982, VIROLOGY, V121, P204	43	44	45	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1992	267	25					17957	17965						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JM223	1517230				2022-12-25	WOS:A1992JM22300073
J	NATHANSON, MH; PADFIELD, PJ; OSULLIVAN, AJ; BURGSTAHLER, AD; JAMIESON, JD				NATHANSON, MH; PADFIELD, PJ; OSULLIVAN, AJ; BURGSTAHLER, AD; JAMIESON, JD			MECHANISM OF CA2+ WAVE-PROPAGATION IN PANCREATIC ACINAR-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INOSITOL 1,4,5-TRISPHOSPHATE; ENDOPLASMIC-RETICULUM; CALCIUM OSCILLATIONS; EXOCRINE PANCREAS; CHROMAFFIN CELLS; SECRETION; TRISPHOSPHATE; RELEASE; CA-2+; <CA-2+>I	An increase in cytosolic Ca2+ often begins as a Ca2+ wave, and this wave is thought to result from sequential activation of Ca2+-sensitive Ca2+ stores across the cell. We tested that hypothesis in pancreatic acinar cells, and since Ca2+ waves may regulate acinar Cl- secretion, we examined whether such waves also are important for amylase secretion. Ca2+ wave speed and direction was determined in individual cells within rat pancreatic acini using confocal line scanning microscopy. Both acetylcholine (ACh) and cholecystokinin-8 induced rapid Ca2+ waves which usually travelled in an apical-to-basal direction. Both caffeine and ryanodine, at concentrations that inhibit Ca2+-induced Ca2+ release (CICR), markedly slowed the speed of these waves. Amylase secretion was increased over 3-fold in response to ACh stimulation, and this increase was preserved in the presence of ryanodine. These results indicate that 1) stimulation of either muscarinic or cholecystokinin-8 receptors induces apical-to-basal Ca2+ waves in pancreatic acinar cells, 2) the speed of such waves is dependent upon mobilization of caffeine- and ryanodine-sensitive Ca2+ stores, and 3) ACh-induced amylase secretion is not inhibited by ryanodine. These observations provide direct evidence that Ca2+-induced Ca2+ release is important for propagation of cytosolic Ca2+ waves in pancreatic acinar cells.	YALE UNIV,SCH MED,DEPT CELL BIOL,NEW HAVEN,CT 06510	Yale University	NATHANSON, MH (corresponding author), YALE UNIV,SCH MED,DEPT MED,LIVER STUDY UNIT,1080 LMP,NEW HAVEN,CT 06510, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK034989, R37DK017389] Funding Source: NIH RePORTER; NIDDK NIH HHS [P30 DK34989, R37 DK17389] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AFIFI AA, 1979, STATISTICAL ANAL COM; AMSTERDA.A, 1974, J CELL BIOL, V63, P1037, DOI 10.1083/jcb.63.3.1037; BACKX PH, 1989, J GEN PHYSIOL, V93, P963, DOI 10.1085/jgp.93.5.963; BERNFELD P, 1955, METHOD ENZYMOL, V1, P149, DOI 10.1016/0076-6879(55)01021-5; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BERRIDGE MJ, 1990, J BIOL CHEM, V265, P9583; BRUZZONE R, 1985, BIOCHEM J, V226, P621, DOI 10.1042/bj2260621; BRUZZONE R, 1990, GASTROENTEROLOGY, V99, P1157, DOI 10.1016/0016-5085(90)90640-M; BURGOYNE RD, 1989, NATURE, V342, P72, DOI 10.1038/342072a0; CHANSON M, 1991, AM J PHYSIOL, V261, pG28, DOI 10.1152/ajpgi.1991.261.1.G28; GILKEY JC, 1978, J CELL BIOL, V76, P448, DOI 10.1083/jcb.76.2.448; HERNANDEZCRUZ A, 1990, SCIENCE, V247, P858, DOI 10.1126/science.2154851; HODGKIN AL, 1957, J PHYSIOL-LONDON, V138, P253, DOI 10.1113/jphysiol.1957.sp005850; JAFFE LF, 1991, P NATL ACAD SCI USA, V88, P9883, DOI 10.1073/pnas.88.21.9883; KAO JPY, 1989, J BIOL CHEM, V264, P8179; KASAI H, 1990, NATURE, V348, P735, DOI 10.1038/348735a0; KUSHMERICK MJ, 1969, SCIENCE, V166, P1297, DOI 10.1126/science.166.3910.1297; MALGAROLI A, 1990, J BIOL CHEM, V265, P3005; MARUYAMA Y, 1988, J PHYSIOL-LONDON, V406, P299, DOI 10.1113/jphysiol.1988.sp017381; MEDA P, 1987, P NATL ACAD SCI USA, V84, P4901, DOI 10.1073/pnas.84.14.4901; NATHANSON MH, 1992, MOL BIOL CELL, V3, P113, DOI 10.1091/mbc.3.1.113; NATHANSON MH, 1992, CELL CALCIUM, V13, P89, DOI 10.1016/0143-4160(92)90002-A; PADFIELD PJ, 1991, BIOCHEM BIOPH RES CO, V174, P536, DOI 10.1016/0006-291X(91)91450-Q; PRALONG WF, 1988, FEBS LETT, V242, P79, DOI 10.1016/0014-5793(88)80989-X; RANDRIAMAMPITA C, 1991, CELL REGUL, V2, P513, DOI 10.1091/mbc.2.7.513; SAEZ JC, 1989, P NATL ACAD SCI USA, V86, P2708, DOI 10.1073/pnas.86.8.2708; SALUJA AK, 1992, J BIOL CHEM, V267, P11202; SCHMID A, 1990, NATURE, V346, P374, DOI 10.1038/346374a0; SHEARS SB, 1988, BIOCHEM J, V256, P363, DOI 10.1042/bj2560363; SHOSHANBARMATZ V, 1990, BIOCHEM J, V268, P699, DOI 10.1042/bj2680699; SHOSHANBARMATZ V, 1990, FEBS LETT, V263, P317, DOI 10.1016/0014-5793(90)81403-B; SPEKSNIJDER JE, 1990, DEV BIOL, V142, P246, DOI 10.1016/0012-1606(90)90168-I; WAKUI M, 1990, CELL, V63, P1025, DOI 10.1016/0092-8674(90)90505-9; WIER WG, 1987, SCIENCE, V235, P325, DOI 10.1126/science.3798114	34	169	169	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1992	267	25					18118	18121						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JM223	1517244				2022-12-25	WOS:A1992JM22300097
J	SUGIURA, N; HAGIWARA, H; HIROSE, S				SUGIURA, N; HAGIWARA, H; HIROSE, S			MOLECULAR-CLONING OF PORCINE SOLUBLE ANGIOTENSIN-BINDING PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							II RECEPTORS; RABBIT LIVER; REPETITIVE SEQUENCES; SIMILARITY SEARCHES; GENE-EXPRESSION; MESSENGER-RNAS; DNA; GROWTH; CELLS; SYSTEM	Soluble angiotensin-binding protein (sABP) is a 75-kDa cytosolic protein that binds angiotensins and its analogues with high affinity. In this study, the primary structure of porcine sABP is determined by cDNA cloning. Based on the partial amino acid sequences of sABP tryptic fragments, fully degenerate oligonucleotides were synthesized, and used as primers for polymerase chain reactions to amplify the corresponding sABP cDNA fragment from porcine liver first-strand cDNA. By using initially the polymerase chain reaction product and later partial cDNA clones as probes, porcine heart and liver cDNA libraries were screened, and several positive clones were obtained including one covering the entire coding region. From the cDNA sequence, an open reading frame that encodes sABP as a 704-amino acid protein with molecular mass of 80,800 daltons is predicted. No significant homology was seen between sABP and other proteins in GenBank and NBRF data bases, including the angiotensin-related proteins such as angiotensin converting enzyme, renin, and AT1 angiotensin II receptor. Northern blot analysis of poly(A)+ RNA revealed that the mRNA for sABP is expressed as 5.3- and 2.8-3.2-kilobase transcripts. These transcripts are generated by the use of alternative polyadenylation signals. Within the 3'-untranslated region of the cDNA sequence downstream from the polyadenylation signals for smaller transcripts, a porcine short interspersed repetitive element (SINE) was found; only the longer 5.3-kilobase transcript had the SINE sequence.			SUGIURA, N (corresponding author), TOKYO INST TECHNOL,DEPT BIOL SCI,MEGURO KU,TOKYO 152,JAPAN.							ACETO JF, 1990, AM J PHYSIOL, V258, pH806, DOI 10.1152/ajpheart.1990.258.3.H806; ADENIYIJONES S, 1985, NATURE, V317, P81, DOI 10.1038/317081a0; ARIGA H, 1984, MOL CELL BIOL, V4, P1476, DOI 10.1128/MCB.4.8.1476; BANDYOPADHYAY SK, 1988, ARCH BIOCHEM BIOPHYS, V263, P272, DOI 10.1016/0003-9861(88)90636-4; CAMPBELL DJ, 1987, J CLIN INVEST, V79, P1, DOI 10.1172/JCI112768; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CLEMENS MJ, 1987, CELL, V49, P157, DOI 10.1016/0092-8674(87)90553-8; CLEVENGER CV, 1990, ENDOCRINOLOGY, V127, P3151, DOI 10.1210/endo-127-6-3151; CROSS M, 1990, EMBO J, V9, P1283, DOI 10.1002/j.1460-2075.1990.tb08237.x; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FISHMAN MC, 1981, SCIENCE, V214, P921, DOI 10.1126/science.6272392; FRENGEN E, 1991, GENOMICS, V10, P949, DOI 10.1016/0888-7543(91)90184-G; GARRISON JC, 1982, J BIOL CHEM, V257, P3135; GEISTERFER AAT, 1988, CIRC RES, V62, P749, DOI 10.1161/01.RES.62.4.749; GLAICHENHAUS N, 1987, CELL, V50, P1081, DOI 10.1016/0092-8674(87)90174-7; HAGIWARA H, 1989, EUR J BIOCHEM, V185, P405, DOI 10.1111/j.1432-1033.1989.tb15129.x; HARADA F, 1980, BIOCHEM INT, V1, P539; HATTORI M, 1986, ANAL BIOCHEM, V152, P232, DOI 10.1016/0003-2697(86)90403-3; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HERGET T, 1986, EMBO J, V5, P659, DOI 10.1002/j.1460-2075.1986.tb04264.x; HOWARD B H, 1990, New Biologist, V2, P759; JACKSON TR, 1988, NATURE, V335, P437, DOI 10.1038/335437a0; JAMES R, 1984, ANNU REV BIOCHEM, V53, P259; JELINEK WR, 1980, P NATL ACAD SCI-BIOL, V77, P1398, DOI 10.1073/pnas.77.3.1398; KANEHISA M, 1982, NUCLEIC ACIDS RES, V10, P183, DOI 10.1093/nar/10.1.183; KIRON MAR, 1989, J BIOL CHEM, V264, P4138; KOGA Y, 1988, P NATL ACAD SCI USA, V85, P4521, DOI 10.1073/pnas.85.12.4521; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KOZAK M, 1991, J BIOL CHEM, V266, P19867; KRESS M, 1984, SCIENCE, V226, P974, DOI 10.1126/science.6095445; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LEE CC, 1988, SCIENCE, V239, P1288, DOI 10.1126/science.3344434; LIPMAN DJ, 1985, SCIENCE, V227, P1435, DOI 10.1126/science.2983426; LOBIE PE, 1991, J BIOL CHEM, V266, P22645; MASON AJ, 1985, NATURE, V318, P659, DOI 10.1038/318659a0; MCKINNON RD, 1986, P NATL ACAD SCI USA, V83, P3751, DOI 10.1073/pnas.83.11.3751; MENDELSOHN FAO, 1985, J HYPERTENS, V3, P307, DOI 10.1097/00004872-198508000-00002; MILLAN MA, 1991, P NATL ACAD SCI USA, V88, P11440, DOI 10.1073/pnas.88.24.11440; MILLAN MA, 1989, SCIENCE, V244, P1340, DOI 10.1126/science.2734613; MURPHY D, 1983, CELL, V35, P865, DOI 10.1016/0092-8674(83)90119-8; MURPHY TJ, 1991, NATURE, V351, P233, DOI 10.1038/351233a0; OKADA N, 1991, TRENDS ECOL EVOL, V6, P358, DOI 10.1016/0169-5347(91)90226-N; OKAMURA T, 1981, P NATL ACAD SCI-BIOL, V78, P6940, DOI 10.1073/pnas.78.11.6940; PEACH MJ, 1990, J CARDIOVASC PHARM, V16, pS25, DOI 10.1097/00005344-199016004-00007; PEACH MJ, 1977, PHYSIOL REV, V57, P313, DOI 10.1152/physrev.1977.57.2.313; PHILLIPS MI, 1987, ANNU REV PHYSIOL, V49, P413, DOI 10.1146/annurev.physiol.49.1.413; PILKIS SJ, 1988, ANNU REV BIOCHEM, V57, P755, DOI 10.1146/annurev.bi.57.070188.003543; PUCELL AG, 1987, J BIOL CHEM, V262, P7076; RE RN, 1984, BIOCHEM BIOPH RES CO, V119, P220, DOI 10.1016/0006-291X(84)91641-3; RE RN, 1981, CLIN SCI, V61, pS245, DOI 10.1042/cs061245s; ROBERTSON AL, 1971, SCIENCE, V172, P1138, DOI 10.1126/science.172.3988.1138; ROSENBERG E, 1988, BIOCHEM BIOPH RES CO, V156, P1230, DOI 10.1016/S0006-291X(88)80764-2; ROSENBERG E, 1988, BIOCHEM BIOPH RES CO, V151, P466, DOI 10.1016/0006-291X(88)90616-X; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SASAKI K, 1991, NATURE, V351, P230, DOI 10.1038/351230a0; SCHELLING P, 1991, J HYPERTENS, V9, P3; SHARMA RK, 1991, BIOCHEM BIOPH RES CO, V179, P85, DOI 10.1016/0006-291X(91)91337-C; SHEETS MD, 1990, NUCLEIC ACIDS RES, V18, P5799, DOI 10.1093/nar/18.19.5799; SINGER DS, 1987, NUCLEIC ACIDS RES, V15, P2780, DOI 10.1093/nar/15.6.2780; SOFFER RL, 1986, J HYPERTENS, V4, pS17; STIRLING D, 1990, J BIOL CHEM, V265, P5; SUGIURA N, 1991, PEPTIDE REGULATION C, P157; TAKANO E, 1988, BIOCHEMISTRY-US, V27, P1964, DOI 10.1021/bi00406a024; TIMMERMANS PBMWM, 1991, TRENDS PHARMACOL SCI, V12, P55, DOI 10.1016/0165-6147(91)90498-H; VALLOTTON MB, 1987, TRENDS PHARMACOL SCI, V8, P69, DOI 10.1016/0165-6147(87)90013-7; VASSEUR M, 1985, EMBO J, V4, P1749, DOI 10.1002/j.1460-2075.1985.tb03846.x; VISWANATHAN M, 1991, BIOCHEM BIOPH RES CO, V179, P1361, DOI 10.1016/0006-291X(91)91723-P; WEINER AM, 1986, ANNU REV BIOCHEM, V55, P631, DOI 10.1146/annurev.bi.55.070186.003215; WILBUR WJ, 1983, P NATL ACAD SCI-BIOL, V80, P726, DOI 10.1073/pnas.80.3.726	71	46	51	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1992	267	25					18067	18072						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JM223	1517239				2022-12-25	WOS:A1992JM22300090
J	THEUER, CP; FITZGERALD, D; PASTAN, I				THEUER, CP; FITZGERALD, D; PASTAN, I			A RECOMBINANT FORM OF PSEUDOMONAS EXOTOXIN DIRECTED AT THE EPIDERMAL GROWTH-FACTOR RECEPTOR THAT IS CYTOTOXIC WITHOUT REQUIRING PROTEOLYTIC PROCESSING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIPHTHERIA-TOXIN; DOMAIN-II; ESCHERICHIA-COLI; FUSION PROTEIN; LOW PH; TRANSLOCATION; SEQUENCE; TERMINUS; BINDING; GENE	Pseudomonas exotoxin A is composed of three structural domains that mediate cell recognition (I), membrane translocation (II), and ADP-ribosylation (III). Within the cell, the toxin is cleaved within domain II to produce a 37-kDa carboxyl-terminal fragment, containing amino acids 280-613, which is translocated to the cytosol and causes cell death. In this study, we constructed a mutant protein (PE37), composed of amino acids 280-613 of Pseudomonas exotoxin A, which does not require proteolysis to translocate. PE37 was targeted specifically to cells with epidermal growth factor receptors by inserting transforming growth factor-alpha (TGF-alpha) after amino acid 607 near the carboxyl terminus of Pseudomonas exotoxin A. PE37/TGF-alpha was very cytotoxic to cells with epidermal growth factor receptors. It was severalfold more cytotoxic than a derivative of full-length Pseudomonas exotoxin A containing TGF-alpha in the same position, probably because the latter requires intracellular proteolytic processing to exhibit its cytotoxicity, and proteolytic processing is not 100% efficient. Deletion of 2, 4, or 7 amino acids from the amino terminus of PE37/TGF-alpha greatly diminished cytotoxic activity, indicating the need for a proper amino-terminal sequence. In addition, a mutant containing an internal deletion of amino acids 314-380 was minimally active, indicating that other regions of domain II are also required for the cytotoxic activity of Pseudomonas exotoxin A.	NCI,DIV CANC BIOL DIAGNOSIS & CTR,MOLEC BIOL LAB,9000 ROCKVILLE PIKE,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			pastan, ira/P-9319-2019	pastan, ira/0000-0002-9223-0270				BIRD P, 1990, J BIOL CHEM, V265, P8420; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHAUDHARY VK, 1988, P NATL ACAD SCI USA, V85, P2939, DOI 10.1073/pnas.85.9.2939; CHAUDHARY VK, 1991, BIOCHEM BIOPH RES CO, V180, P545, DOI 10.1016/S0006-291X(05)81099-X; CHAUDHARY VK, 1990, P NATL ACAD SCI USA, V87, P308, DOI 10.1073/pnas.87.1.308; CHAUDHARY VK, 1987, P NATL ACAD SCI USA, V84, P4538, DOI 10.1073/pnas.84.13.4538; COLLIER RJ, 1971, J BIOL CHEM, V246, P1496; DEBINSKI W, 1992, IN PRESS J CLIN INVE; HARTL F, 1990, SCIENCE, V747, P930; HWANG J, 1987, CELL, V48, P129, DOI 10.1016/0092-8674(87)90363-1; IDZIOREK T, 1990, INFECT IMMUN, V58, P1415, DOI 10.1128/IAI.58.5.1415-1420.1990; JIANG JX, 1991, J BIOL CHEM, V266, P24003; JINNO Y, 1989, J BIOL CHEM, V264, P15953; KAPUT J, 1982, J BIOL CHEM, V257, P5054; KONDO T, 1988, J BIOL CHEM, V263, P9470; KREITMAN RJ, 1992, BIOCONJUGATE CHEM, V3, P58, DOI 10.1021/bc00013a009; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; OGATA M, 1990, J BIOL CHEM, V265, P20678; PASTAN I, 1991, SCIENCE, V254, P1173, DOI 10.1126/science.1683495; PASTAN I, 1992, ANNU REV BIOCHEM, V61, P331, DOI 10.1146/annurev.bi.61.070192.001555; PRIOR TI, 1992, BIOCHEMISTRY-US, V31, P3555, DOI 10.1021/bi00129a001; PRIOR TI, 1991, CELL, V64, P1017, DOI 10.1016/0092-8674(91)90325-S; RAPOPORT TA, 1987, J MOL BIOL, V195, P621, DOI 10.1016/0022-2836(87)90186-0; SANDVIG K, 1987, BIOCHEM J, V245, P899, DOI 10.1042/bj2450899; SANGER F, 1977, P NATL ACAD SCI USA, V75, P2659; SEETHARAM S, 1991, J BIOL CHEM, V266, P17376; SIEGALL CB, 1988, P NATL ACAD SCI USA, V85, P9738, DOI 10.1073/pnas.85.24.9738; SIEGALL CB, 1989, J BIOL CHEM, V264, P14256; SIEGALL CB, 1991, TRANSLOC BIOCH, V30, P7154; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; VIEBROCK A, 1982, EMBO J, V1, P565, DOI 10.1002/j.1460-2075.1982.tb01209.x; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4	32	37	51	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1992	267	24					16872	16877						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JL053	1512230				2022-12-25	WOS:A1992JL05300025
J	KOMATSUTAKAKI, M				KOMATSUTAKAKI, M			ENERGY-DEPENDENT CHANGES IN CONFORMATION AND CATALYTIC ACTIVITY OF THE CHLOROPLAST ATP SYNTHASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COUPLING FACTOR-I; TIGHTLY BOUND NUCLEOTIDES; SPINACH-CHLOROPLASTS; EPSILON-SUBUNIT; COMPLEX CF0.CF1; BINDING-SITES; BETA-SUBUNIT; CF1; SEQUENCE; EXCHANGE	Energy-dependent activation of the chloroplast ATP synthase (CF0CF1) has been elucidated by investigating the conformational changes, the ADP effect, and the catalytic cooperativity of ATP hydrolysis. Conformational change was observed by measuring the reactivity of Lys-109 of the epsilon-subunit of chloroplast coupling factor 1 with pyridoxal 5'-phosphate. In the postillumination dark, the Lys-109 reactivity decreased biphasically with half-times of < 1 and 17 s. NH4Cl accelerated the slow phase decrease. Addition of ADP (0.2-mu-M) in the postillumination dark inactivated CF0CF1 (0.05-mu-M) with a half-time of 12 s. At high concentration of CF0CF1 (1.2-mu-M), inactivation occurred without exogenously added ADP with a half-time of 12 s. Accompanying the inactivation, the positive catalytic cooperativity of ATP hydrolysis decreased. Addition of 10 mM NH4Cl before ADP (0.2-mu-M) decelerated the ADP-induced inactivation to a half-time of 64 s. Throughout this inactivation, the positive catalytic cooperativity was maintained at a high level. These results suggest three distinct conformations of CF0CF1, E(H), E(M), and E(L), and their ADP binding forms E(M)-ADP and E(L)-ADP. E(H), E(M), and E(L) have a low affinity for ADP, a high affinity for ADP, and low accessibility to ADP, respectively. E(M) and E(L) exhibit highly cooperative ATP hydrolysis. ATP hydrolysis catalyzed by E(M)-ADP exhibits no cooperativity. E(L)-ADP is inactive.			KOMATSUTAKAKI, M (corresponding author), TEIKYO UNIV,FAC PHARMACEUT SCI,DEPT CHEM,SAGAMIKO,KANAGAWA 19901,JAPAN.							ADMON A, 1987, BIOCHEMISTRY-US, V26, P3193, DOI 10.1021/bi00385a038; AKEY CW, 1983, EMBO J, V2, P1409, DOI 10.1002/j.1460-2075.1983.tb01599.x; ANDRALOJC PJ, 1990, BIOCHIM BIOPHYS ACTA, V1016, P55, DOI 10.1016/0005-2728(90)90006-P; BARZVI D, 1980, FEBS LETT, V119, P68, DOI 10.1016/0014-5793(80)80999-9; CARMELI C, 1972, BIOCHIM BIOPHYS ACTA, V267, P86, DOI 10.1016/0005-2728(72)90140-5; CERIONE RA, 1983, BIOCHEMISTRY-US, V22, P769, DOI 10.1021/bi00273a010; DU ZY, 1989, BIOCHEMISTRY-US, V28, P873, DOI 10.1021/bi00428a070; FRASCH WD, 1980, FEBS LETT, V122, P125, DOI 10.1016/0014-5793(80)80417-0; FROMME P, 1990, BIOCHIM BIOPHYS ACTA, V1016, P29, DOI 10.1016/0005-2728(90)90003-M; HARRIS DA, 1975, BIOCHIM BIOPHYS ACTA, V387, P335, DOI 10.1016/0005-2728(75)90114-0; HERMANS J, 1988, PLANT MOL BIOL, V10, P323, DOI 10.1007/BF00029882; HUDSON GS, 1987, J MOL BIOL, V196, P283, DOI 10.1016/0022-2836(87)90690-5; KOMATSUTAKAKI M, 1989, J BIOL CHEM, V264, P17750; KOMATSUTAKAKI M, 1987, J BIOL CHEM, V262, P8202; KOMATSUTAKAKI M, 1986, J BIOL CHEM, V261, P9805; MCCARTY RE, 1987, TRENDS BIOCHEM SCI, V12, P234, DOI 10.1016/0968-0004(87)90116-2; MCCARTY RE, 1985, ENZYMES BIOL MEMBR, P383; MIKI J, 1988, FEBS LETT, V232, P221, DOI 10.1016/0014-5793(88)80421-6; MORONEY JV, 1983, FEBS LETT, V158, P58, DOI 10.1016/0014-5793(83)80676-0; RICHTER ML, 1985, BIOCHEMISTRY-US, V24, P5755, DOI 10.1021/bi00342a011; ROOS P, 1983, Z NATURFORSCH C, V38, P799; SCHUMANN J, 1984, BIOCHIM BIOPHYS ACTA, V766, P334, DOI 10.1016/0005-2728(84)90249-4; SCHUMANN J, 1981, PHOTOSYNTHESIS, V2, P881; SHOSHAN V, 1979, J BIOL CHEM, V254, P8801; SNYDER B, 1984, BIOCHEMISTRY-US, V23, P5787, DOI 10.1021/bi00319a018; STROTMANN H, 1973, BIOCHIM BIOPHYS ACTA, V314, P202, DOI 10.1016/0005-2728(73)90135-7; STROTMANN H, 1977, BIOCHIM BIOPHYS ACTA, V460, P126, DOI 10.1016/0005-2728(77)90158-X; TIEDGE H, 1985, P NATL ACAD SCI USA, V82, P7874, DOI 10.1073/pnas.82.23.7874; XUE ZX, 1987, BIOCHEMISTRY-US, V26, P3749, DOI 10.1021/bi00387a001; XUE ZX, 1987, FEBS LETT, V223, P391, DOI 10.1016/0014-5793(87)80325-3; ZURAWSKI G, 1982, P NATL ACAD SCI-BIOL, V79, P6260, DOI 10.1073/pnas.79.20.6260	31	17	17	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1992	267	4					2360	2363						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HB532	1531139				2022-12-25	WOS:A1992HB53200039
J	KANE, PM; KUEHN, MC; HOWALDSTEVENSON, I; STEVENS, TH				KANE, PM; KUEHN, MC; HOWALDSTEVENSON, I; STEVENS, TH			ASSEMBLY AND TARGETING OF PERIPHERAL AND INTEGRAL MEMBRANE SUBUNITS OF THE YEAST VACUOLAR H+-ATPASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VESICLE PROTON PUMP; TRANSLOCATING ADENOSINE-TRIPHOSPHATASE; SACCHAROMYCES-CEREVISIAE; ENDOPLASMIC-RETICULUM; CDNA SEQUENCE; BETA-SUBUNIT; GENE-PRODUCT; ACIDIFICATION; POLYPEPTIDE; DISRUPTION	Previous purification and characterization of the yeast vacuolar proton-translocating ATPase (H+-ATPase) have indicated that it is a multisubunit complex consisting of both integral and peripheral membrane subunits (Uchida, E., Ohsumi, Y., and Anraku, Y. (1985) J. Biol. Chem. 260, 1090-1095; Kane, P. M., Yamashiro, C. T., and Stevens, T. H. (1989) J. Biol. Chem. 264, 19236-19244). We have obtained monoclonal antibodies recognizing the 42- and 100-kDa polypeptides that were co-purified with vacuolar ATPase activity. Using these antibodies we provide further evidence that the 42-kDa polypeptide, a peripheral membrane protein, and the 100-kDa polypeptide, an integral membrane protein, are genuine subunits of the yeast vacuolar H+-ATPase. The synthesis, assembly, and targeting of three of the peripheral subunits (the 69-, 60-, and 42-kDa subunits) and two of the integral membrane subunits (the 100- and 17-kDa subunits) were examined in mutant yeast cells containing chromosomal deletions in the TFP1, VAT2, or VMA3 genes, which encode the 69-, 60-, and 17-kDa subunits, respectively. The steady-state levels of the various subunits in whole cell lysates and purified vacuolar membranes were assessed by Western blotting, and the intracellular localization of the 60- and 100-kDa subunits was also examined by immunofluorescence microscopy. The results suggest that the assembly and/or the vacuolar targeting of the peripheral subunits of the yeast vacuolar H+-ATPase depend on the presence of all three of the 69-, 60-, and 17-kDa subunits. The 100-kDa subunit can be transported to the vacuole independently of the peripheral membrane subunits as long as the 17-kDa subunit is present; but in the absence of the 17-kDa subunit, the 100-kDa subunit appears to be both unstable and incompetent for transport to the vacuole.	UNIV OREGON, INST MOLEC BIOL, EUGENE, OR 97403 USA	University of Oregon				Stevens, Tom/0000-0001-6427-6848	NIGMS NIH HHS [GM 38006] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038006] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADACHI I, 1990, J BIOL CHEM, V265, P960; ARAI H, 1988, J BIOL CHEM, V263, P8796; BOTSTEIN D, 1979, GENE, V8, P16; BOWMAN BJ, 1988, J BIOL CHEM, V263, P14002; BOWMAN BJ, 1989, J BIOL CHEM, V264, P15606; BOWMAN EJ, 1988, J BIOL CHEM, V263, P13994; DENDA K, 1988, J BIOL CHEM, V263, P17251; FORGAC M, 1989, PHYSIOL REV, V69, P765, DOI 10.1152/physrev.1989.69.3.765; FOURY F, 1990, J BIOL CHEM, V265, P18554; GOGARTEN JP, 1989, P NATL ACAD SCI USA, V86, P6661, DOI 10.1073/pnas.86.17.6661; HIRATA R, 1990, J BIOL CHEM, V265, P6726; HIRSCH S, 1988, P NATL ACAD SCI USA, V85, P3004, DOI 10.1073/pnas.85.9.3004; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; INATOMI KI, 1989, J BIOL CHEM, V264, P10954; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JOLLEY ME, 1984, J IMMUNOL METHODS, V67, P21, DOI 10.1016/0022-1759(84)90082-6; JONES EW, 1991, METHOD ENZYMOL, V194, P428; KANE PM, 1990, SCIENCE, V250, P651, DOI 10.1126/science.2146742; KANE PM, 1989, J BIOL CHEM, V264, P19236; KLAUSNER RD, 1990, CELL, V62, P611, DOI 10.1016/0092-8674(90)90104-M; KLIONSKY DJ, 1989, EMBO J, V8, P2241, DOI 10.1002/j.1460-2075.1989.tb08348.x; KLIONSKY DJ, 1990, MICROBIOL REV, V54, P266, DOI 10.1128/MMBR.54.3.266-292.1990; LOTSCHER HR, 1984, BIOCHEMISTRY-US, V23, P4128, DOI 10.1021/bi00313a018; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MANOLSON MF, 1988, J BIOL CHEM, V263, P17987; MORIYAMA Y, 1989, J BIOL CHEM, V264, P18445; MORIYAMA Y, 1989, J BIOL CHEM, V264, P3577; NELSON H, 1989, J BIOL CHEM, V264, P5313; NELSON H, 1989, FEBS LETT, V247, P147, DOI 10.1016/0014-5793(89)81259-1; NELSON H, 1989, J BIOL CHEM, V264, P1775; NELSON H, 1990, P NATL ACAD SCI USA, V87, P3503, DOI 10.1073/pnas.87.9.3503; NELSON N, 1989, TRENDS BIOCHEM SCI, V14, P113, DOI 10.1016/0968-0004(89)90134-5; NOBREGA MP, 1990, J BIOL CHEM, V265, P14220; NOUMI T, 1991, P NATL ACAD SCI USA, V88, P1938, DOI 10.1073/pnas.88.5.1938; PUOPOLO K, 1990, J BIOL CHEM, V265, P14836; RAYMOND CK, 1990, J CELL BIOL, V111, P877, DOI 10.1083/jcb.111.3.877; ROBERTS CJ, 1991, METHOD ENZYMOL, V194, P644; ROTHMAN JH, 1989, J CELL BIOL, V109, P93, DOI 10.1083/jcb.109.1.93; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; Sambrook J, 1989, MOL CLONING LABORATO; Sherman F., 1982, METHODS YEAST GENETI; SUDHOF TC, 1989, P NATL ACAD SCI USA, V86, P6067, DOI 10.1073/pnas.86.16.6067; UCHIDA E, 1985, J BIOL CHEM, V260, P1090; UMEMOTO N, 1990, J BIOL CHEM, V265, P18447; WRAY W, 1981, ANAL BIOCHEM, V118, P97; YAMASHIRO CT, 1990, MOL CELL BIOL, V10, P3737, DOI 10.1128/MCB.10.7.3737; ZIMNIAK L, 1988, J BIOL CHEM, V263, P9102	47	164	167	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	1992	267	1					447	454						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY439	1530931				2022-12-25	WOS:A1992GY43900072
